__label__noRel	The overall remission rate was 87% with 31% complete remissions.	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.
__label__noRel	The overall remission rate was 87% with 31% complete remissions.	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.
__label__noRel	The overall remission rate was 87% with 31% complete remissions.	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.
__label__noRel	The overall remission rate was 87% with 31% complete remissions.	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).
__label__noRel	The overall remission rate was 87% with 31% complete remissions.	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.
__label__noRel	The overall remission rate was 87% with 31% complete remissions.	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.
__label__Support	The overall remission rate was 87% with 31% complete remissions.	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.
__label__noRel	The overall remission rate was 87% with 31% complete remissions.	patients with early alternating chemotherapy achieve a better subjective adjustment,
__label__noRel	The overall remission rate was 87% with 31% complete remissions.	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.
__label__noRel	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.	The overall remission rate was 87% with 31% complete remissions.
__label__noRel	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.
__label__noRel	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.
__label__noRel	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).
__label__noRel	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.
__label__noRel	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.
__label__Support	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.
__label__noRel	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.	patients with early alternating chemotherapy achieve a better subjective adjustment,
__label__noRel	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.
__label__noRel	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.	The overall remission rate was 87% with 31% complete remissions.
__label__noRel	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.
__label__noRel	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.
__label__noRel	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).
__label__noRel	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.
__label__noRel	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.
__label__Support	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.
__label__noRel	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.	patients with early alternating chemotherapy achieve a better subjective adjustment,
__label__noRel	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.
__label__noRel	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.	The overall remission rate was 87% with 31% complete remissions.
__label__noRel	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.
__label__noRel	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.
__label__noRel	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).
__label__noRel	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.
__label__noRel	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.
__label__noRel	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.
__label__noRel	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.	patients with early alternating chemotherapy achieve a better subjective adjustment,
__label__Support	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.
__label__noRel	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).	The overall remission rate was 87% with 31% complete remissions.
__label__noRel	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.
__label__noRel	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.
__label__noRel	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.
__label__noRel	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.
__label__noRel	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.
__label__noRel	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.
__label__noRel	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).	patients with early alternating chemotherapy achieve a better subjective adjustment,
__label__Support	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.
__label__noRel	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.	The overall remission rate was 87% with 31% complete remissions.
__label__noRel	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.
__label__noRel	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.
__label__noRel	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.
__label__noRel	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).
__label__noRel	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.
__label__noRel	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.
__label__noRel	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.	patients with early alternating chemotherapy achieve a better subjective adjustment,
__label__Support	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.
__label__noRel	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.	The overall remission rate was 87% with 31% complete remissions.
__label__noRel	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.
__label__noRel	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.
__label__noRel	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.
__label__noRel	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).
__label__noRel	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.
__label__noRel	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.
__label__Support	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.	patients with early alternating chemotherapy achieve a better subjective adjustment,
__label__noRel	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.
__label__noRel	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.	The overall remission rate was 87% with 31% complete remissions.
__label__noRel	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.
__label__noRel	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.
__label__noRel	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.
__label__noRel	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).
__label__noRel	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.
__label__noRel	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.
__label__noRel	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.	patients with early alternating chemotherapy achieve a better subjective adjustment,
__label__noRel	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.
__label__noRel	patients with early alternating chemotherapy achieve a better subjective adjustment,	The overall remission rate was 87% with 31% complete remissions.
__label__noRel	patients with early alternating chemotherapy achieve a better subjective adjustment,	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.
__label__noRel	patients with early alternating chemotherapy achieve a better subjective adjustment,	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.
__label__noRel	patients with early alternating chemotherapy achieve a better subjective adjustment,	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.
__label__noRel	patients with early alternating chemotherapy achieve a better subjective adjustment,	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).
__label__noRel	patients with early alternating chemotherapy achieve a better subjective adjustment,	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.
__label__noRel	patients with early alternating chemotherapy achieve a better subjective adjustment,	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.
__label__noRel	patients with early alternating chemotherapy achieve a better subjective adjustment,	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.
__label__noRel	patients with early alternating chemotherapy achieve a better subjective adjustment,	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.
__label__noRel	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.	The overall remission rate was 87% with 31% complete remissions.
__label__noRel	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.
__label__noRel	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.
__label__noRel	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.
__label__noRel	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).
__label__noRel	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.
__label__noRel	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.
__label__noRel	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.
__label__noRel	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.	patients with early alternating chemotherapy achieve a better subjective adjustment,
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	CP resulted in more anastomotic leaks.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	CP resulted in more anastomotic leaks.
__label__Support	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	CP resulted in more anastomotic leaks.
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__Support	there were no differences in the bowel function, continence score, and quality of life at 1 year.	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	CP resulted in more anastomotic leaks.
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	CP resulted in more anastomotic leaks.
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	CP resulted in more anastomotic leaks.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	CP resulted in more anastomotic leaks.
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	CP resulted in more anastomotic leaks.
__label__noRel	CP resulted in more anastomotic leaks.	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	CP resulted in more anastomotic leaks.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	CP resulted in more anastomotic leaks.	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	CP resulted in more anastomotic leaks.	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	CP resulted in more anastomotic leaks.	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__Support	CP resulted in more anastomotic leaks.	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	CP resulted in more anastomotic leaks.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	CP resulted in more anastomotic leaks.	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).	Median survival with GC and PE was 8.0 and 8.1 months, respectively.
__label__noRel	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.
__label__noRel	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),
__label__noRel	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).	but these were not associated with increased hospital admissions, infections or fatalities.
__label__noRel	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.
__label__noRel	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).
__label__Support	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.
__label__noRel	Median survival with GC and PE was 8.0 and 8.1 months, respectively.	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).
__label__noRel	Median survival with GC and PE was 8.0 and 8.1 months, respectively.	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.
__label__noRel	Median survival with GC and PE was 8.0 and 8.1 months, respectively.	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),
__label__noRel	Median survival with GC and PE was 8.0 and 8.1 months, respectively.	but these were not associated with increased hospital admissions, infections or fatalities.
__label__noRel	Median survival with GC and PE was 8.0 and 8.1 months, respectively.	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.
__label__noRel	Median survival with GC and PE was 8.0 and 8.1 months, respectively.	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).
__label__Support	Median survival with GC and PE was 8.0 and 8.1 months, respectively.	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.
__label__noRel	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).
__label__noRel	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.	Median survival with GC and PE was 8.0 and 8.1 months, respectively.
__label__noRel	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),
__label__noRel	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.	but these were not associated with increased hospital admissions, infections or fatalities.
__label__noRel	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.
__label__noRel	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).
__label__Support	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.
__label__noRel	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).
__label__noRel	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),	Median survival with GC and PE was 8.0 and 8.1 months, respectively.
__label__noRel	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.
__label__noRel	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),	but these were not associated with increased hospital admissions, infections or fatalities.
__label__noRel	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.
__label__noRel	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).
__label__Attack	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.
__label__noRel	but these were not associated with increased hospital admissions, infections or fatalities.	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).
__label__noRel	but these were not associated with increased hospital admissions, infections or fatalities.	Median survival with GC and PE was 8.0 and 8.1 months, respectively.
__label__noRel	but these were not associated with increased hospital admissions, infections or fatalities.	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.
__label__Attack	but these were not associated with increased hospital admissions, infections or fatalities.	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),
__label__noRel	but these were not associated with increased hospital admissions, infections or fatalities.	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.
__label__noRel	but these were not associated with increased hospital admissions, infections or fatalities.	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).
__label__noRel	but these were not associated with increased hospital admissions, infections or fatalities.	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.
__label__noRel	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).
__label__noRel	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.	Median survival with GC and PE was 8.0 and 8.1 months, respectively.
__label__noRel	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.
__label__noRel	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),
__label__noRel	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.	but these were not associated with increased hospital admissions, infections or fatalities.
__label__noRel	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).
__label__Support	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.
__label__noRel	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).
__label__noRel	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).	Median survival with GC and PE was 8.0 and 8.1 months, respectively.
__label__noRel	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.
__label__noRel	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),
__label__noRel	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).	but these were not associated with increased hospital admissions, infections or fatalities.
__label__noRel	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.
__label__Support	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.
__label__noRel	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).
__label__noRel	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.	Median survival with GC and PE was 8.0 and 8.1 months, respectively.
__label__noRel	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.
__label__noRel	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),
__label__noRel	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.	but these were not associated with increased hospital admissions, infections or fatalities.
__label__noRel	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.
__label__noRel	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).
__label__noRel	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.
__label__noRel	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).
__label__noRel	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).
__label__noRel	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).
__label__noRel	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.
__label__noRel	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.
__label__noRel	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).
__label__noRel	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).
__label__noRel	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).
__label__noRel	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.
__label__noRel	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.
__label__Support	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.
__label__noRel	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.
__label__noRel	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).
__label__noRel	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).
__label__noRel	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.
__label__noRel	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.
__label__noRel	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.
__label__noRel	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).
__label__noRel	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).
__label__noRel	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.
__label__noRel	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.
__label__noRel	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.
__label__noRel	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).
__label__noRel	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).
__label__noRel	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).
__label__noRel	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.
__label__noRel	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.
__label__noRel	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).
__label__noRel	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).
__label__noRel	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).
__label__noRel	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.
__label__noRel	Pilates exercises are effective and safe in female breast cancer patients.	When the two exercise groups were compared, there were significant differences in 6MWT in pilates-exercise group (P<0.05).
__label__noRel	Pilates exercises are effective and safe in female breast cancer patients.	After the exercise program, improvements were observed in Group 1 in 6-minute walk test, BDI, EORTC QLQ-C30 functional, and EORTC QLQ-C30 BR23 functional scores (P<0.05).
__label__noRel	Pilates exercises are effective and safe in female breast cancer patients.	no significant improvement was observed in Group 2 after the exercise program in any of parameters in comparison to the pre-exercise period (P>0.05).
__label__noRel	Pilates exercises are effective and safe in female breast cancer patients.	There is a need for further studies so that its effect can be confirmed.
__label__Support	When the two exercise groups were compared, there were significant differences in 6MWT in pilates-exercise group (P<0.05).	Pilates exercises are effective and safe in female breast cancer patients.
__label__noRel	When the two exercise groups were compared, there were significant differences in 6MWT in pilates-exercise group (P<0.05).	After the exercise program, improvements were observed in Group 1 in 6-minute walk test, BDI, EORTC QLQ-C30 functional, and EORTC QLQ-C30 BR23 functional scores (P<0.05).
__label__noRel	When the two exercise groups were compared, there were significant differences in 6MWT in pilates-exercise group (P<0.05).	no significant improvement was observed in Group 2 after the exercise program in any of parameters in comparison to the pre-exercise period (P>0.05).
__label__noRel	When the two exercise groups were compared, there were significant differences in 6MWT in pilates-exercise group (P<0.05).	There is a need for further studies so that its effect can be confirmed.
__label__Support	After the exercise program, improvements were observed in Group 1 in 6-minute walk test, BDI, EORTC QLQ-C30 functional, and EORTC QLQ-C30 BR23 functional scores (P<0.05).	Pilates exercises are effective and safe in female breast cancer patients.
__label__noRel	After the exercise program, improvements were observed in Group 1 in 6-minute walk test, BDI, EORTC QLQ-C30 functional, and EORTC QLQ-C30 BR23 functional scores (P<0.05).	When the two exercise groups were compared, there were significant differences in 6MWT in pilates-exercise group (P<0.05).
__label__noRel	After the exercise program, improvements were observed in Group 1 in 6-minute walk test, BDI, EORTC QLQ-C30 functional, and EORTC QLQ-C30 BR23 functional scores (P<0.05).	no significant improvement was observed in Group 2 after the exercise program in any of parameters in comparison to the pre-exercise period (P>0.05).
__label__noRel	After the exercise program, improvements were observed in Group 1 in 6-minute walk test, BDI, EORTC QLQ-C30 functional, and EORTC QLQ-C30 BR23 functional scores (P<0.05).	There is a need for further studies so that its effect can be confirmed.
__label__Support	no significant improvement was observed in Group 2 after the exercise program in any of parameters in comparison to the pre-exercise period (P>0.05).	Pilates exercises are effective and safe in female breast cancer patients.
__label__noRel	no significant improvement was observed in Group 2 after the exercise program in any of parameters in comparison to the pre-exercise period (P>0.05).	When the two exercise groups were compared, there were significant differences in 6MWT in pilates-exercise group (P<0.05).
__label__noRel	no significant improvement was observed in Group 2 after the exercise program in any of parameters in comparison to the pre-exercise period (P>0.05).	After the exercise program, improvements were observed in Group 1 in 6-minute walk test, BDI, EORTC QLQ-C30 functional, and EORTC QLQ-C30 BR23 functional scores (P<0.05).
__label__noRel	no significant improvement was observed in Group 2 after the exercise program in any of parameters in comparison to the pre-exercise period (P>0.05).	There is a need for further studies so that its effect can be confirmed.
__label__Attack	There is a need for further studies so that its effect can be confirmed.	Pilates exercises are effective and safe in female breast cancer patients.
__label__noRel	There is a need for further studies so that its effect can be confirmed.	When the two exercise groups were compared, there were significant differences in 6MWT in pilates-exercise group (P<0.05).
__label__noRel	There is a need for further studies so that its effect can be confirmed.	After the exercise program, improvements were observed in Group 1 in 6-minute walk test, BDI, EORTC QLQ-C30 functional, and EORTC QLQ-C30 BR23 functional scores (P<0.05).
__label__noRel	There is a need for further studies so that its effect can be confirmed.	no significant improvement was observed in Group 2 after the exercise program in any of parameters in comparison to the pre-exercise period (P>0.05).
__label__noRel	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.
__label__noRel	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.
__label__noRel	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.
__label__Support	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.
__label__noRel	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.
__label__noRel	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.
__label__noRel	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.
__label__Support	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.
__label__noRel	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.
__label__noRel	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.
__label__noRel	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.
__label__Support	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.
__label__noRel	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.
__label__noRel	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.
__label__noRel	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.
__label__Support	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.
__label__noRel	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.
__label__noRel	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.
__label__noRel	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.
__label__noRel	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.
__label__noRel	Difference between groups (p=0.007) for BMD at femur was significant.	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).
__label__noRel	Difference between groups (p=0.007) for BMD at femur was significant.	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.
__label__noRel	Difference between groups (p=0.007) for BMD at femur was significant.	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.
__label__noRel	Difference between groups (p=0.007) for BMD at femur was significant.	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).
__label__noRel	Difference between groups (p=0.007) for BMD at femur was significant.	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,
__label__noRel	Difference between groups (p=0.007) for BMD at femur was significant.	but there were positive changes in group A patients.
__label__noRel	Difference between groups (p=0.007) for BMD at femur was significant.	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.
__label__noRel	Difference between groups (p=0.007) for BMD at femur was significant.	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women
__label__noRel	Difference between groups (p=0.007) for BMD at femur was significant.	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.
__label__noRel	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).	Difference between groups (p=0.007) for BMD at femur was significant.
__label__noRel	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.
__label__noRel	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.
__label__noRel	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).
__label__noRel	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,
__label__noRel	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).	but there were positive changes in group A patients.
__label__noRel	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.
__label__noRel	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women
__label__noRel	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.
__label__noRel	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.	Difference between groups (p=0.007) for BMD at femur was significant.
__label__noRel	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).
__label__noRel	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.
__label__noRel	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).
__label__noRel	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,
__label__noRel	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.	but there were positive changes in group A patients.
__label__noRel	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.
__label__noRel	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women
__label__noRel	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.
__label__noRel	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.	Difference between groups (p=0.007) for BMD at femur was significant.
__label__noRel	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).
__label__noRel	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.
__label__noRel	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).
__label__noRel	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,
__label__noRel	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.	but there were positive changes in group A patients.
__label__noRel	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.
__label__noRel	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women
__label__noRel	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.
__label__noRel	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).	Difference between groups (p=0.007) for BMD at femur was significant.
__label__noRel	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).
__label__noRel	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.
__label__noRel	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.
__label__noRel	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,
__label__noRel	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).	but there were positive changes in group A patients.
__label__noRel	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.
__label__noRel	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women
__label__noRel	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.
__label__noRel	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,	Difference between groups (p=0.007) for BMD at femur was significant.
__label__noRel	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).
__label__noRel	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.
__label__noRel	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.
__label__noRel	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).
__label__noRel	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,	but there were positive changes in group A patients.
__label__noRel	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.
__label__noRel	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women
__label__noRel	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.
__label__noRel	but there were positive changes in group A patients.	Difference between groups (p=0.007) for BMD at femur was significant.
__label__noRel	but there were positive changes in group A patients.	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).
__label__noRel	but there were positive changes in group A patients.	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.
__label__noRel	but there were positive changes in group A patients.	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.
__label__noRel	but there were positive changes in group A patients.	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).
__label__noRel	but there were positive changes in group A patients.	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,
__label__noRel	but there were positive changes in group A patients.	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.
__label__noRel	but there were positive changes in group A patients.	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women
__label__noRel	but there were positive changes in group A patients.	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.
__label__noRel	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.	Difference between groups (p=0.007) for BMD at femur was significant.
__label__noRel	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).
__label__noRel	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.
__label__noRel	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.
__label__noRel	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).
__label__noRel	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,
__label__noRel	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.	but there were positive changes in group A patients.
__label__noRel	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women
__label__noRel	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.
__label__noRel	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women	Difference between groups (p=0.007) for BMD at femur was significant.
__label__noRel	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).
__label__noRel	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.
__label__noRel	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.
__label__noRel	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).
__label__noRel	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,
__label__noRel	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women	but there were positive changes in group A patients.
__label__noRel	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.
__label__noRel	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.
__label__noRel	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.	Difference between groups (p=0.007) for BMD at femur was significant.
__label__noRel	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).
__label__noRel	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.
__label__noRel	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.
__label__noRel	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).
__label__noRel	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,
__label__noRel	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.	but there were positive changes in group A patients.
__label__noRel	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.
__label__noRel	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women
__label__noRel	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;
__label__noRel	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.	the between-group difference was statistically significant (P<0.01).
__label__noRel	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;
__label__noRel	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.	the between-group difference was statistically significant (P<0.05).
__label__noRel	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),
__label__noRel	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.
__label__noRel	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.
__label__noRel	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.
__label__noRel	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;	the between-group difference was statistically significant (P<0.01).
__label__noRel	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;
__label__noRel	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;	the between-group difference was statistically significant (P<0.05).
__label__noRel	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),
__label__noRel	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.
__label__Support	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.
__label__noRel	the between-group difference was statistically significant (P<0.01).	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.
__label__Support	the between-group difference was statistically significant (P<0.01).	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;
__label__noRel	the between-group difference was statistically significant (P<0.01).	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;
__label__noRel	the between-group difference was statistically significant (P<0.01).	the between-group difference was statistically significant (P<0.05).
__label__noRel	the between-group difference was statistically significant (P<0.01).	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),
__label__noRel	the between-group difference was statistically significant (P<0.01).	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.
__label__noRel	the between-group difference was statistically significant (P<0.01).	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.
__label__noRel	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.
__label__noRel	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;
__label__noRel	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;	the between-group difference was statistically significant (P<0.01).
__label__noRel	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;	the between-group difference was statistically significant (P<0.05).
__label__noRel	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),
__label__noRel	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.
__label__Support	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.
__label__noRel	the between-group difference was statistically significant (P<0.05).	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.
__label__noRel	the between-group difference was statistically significant (P<0.05).	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;
__label__noRel	the between-group difference was statistically significant (P<0.05).	the between-group difference was statistically significant (P<0.01).
__label__Support	the between-group difference was statistically significant (P<0.05).	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;
__label__noRel	the between-group difference was statistically significant (P<0.05).	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),
__label__noRel	the between-group difference was statistically significant (P<0.05).	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.
__label__noRel	the between-group difference was statistically significant (P<0.05).	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.
__label__noRel	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.
__label__noRel	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;
__label__noRel	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),	the between-group difference was statistically significant (P<0.01).
__label__noRel	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;
__label__noRel	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),	the between-group difference was statistically significant (P<0.05).
__label__noRel	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.
__label__Support	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.
__label__noRel	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.
__label__noRel	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;
__label__noRel	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.	the between-group difference was statistically significant (P<0.01).
__label__noRel	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;
__label__noRel	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.	the between-group difference was statistically significant (P<0.05).
__label__noRel	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),
__label__Support	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.
__label__noRel	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.
__label__noRel	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;
__label__noRel	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.	the between-group difference was statistically significant (P<0.01).
__label__noRel	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;
__label__noRel	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.	the between-group difference was statistically significant (P<0.05).
__label__noRel	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),
__label__noRel	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.
__label__noRel	Most patients with advanced ovarian cancer develop recurrent disease.	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;
__label__noRel	Most patients with advanced ovarian cancer develop recurrent disease.	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation
__label__noRel	Most patients with advanced ovarian cancer develop recurrent disease.	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).
__label__noRel	Most patients with advanced ovarian cancer develop recurrent disease.	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).
__label__noRel	Most patients with advanced ovarian cancer develop recurrent disease.	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).
__label__noRel	Most patients with advanced ovarian cancer develop recurrent disease.	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.
__label__noRel	Most patients with advanced ovarian cancer develop recurrent disease.	No statistically significant differences in quality of life scores between arms were noted.
__label__noRel	Most patients with advanced ovarian cancer develop recurrent disease.	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	Most patients with advanced ovarian cancer develop recurrent disease.	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.
__label__noRel	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;	Most patients with advanced ovarian cancer develop recurrent disease.
__label__noRel	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation
__label__noRel	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).
__label__noRel	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).
__label__noRel	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).
__label__noRel	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.
__label__noRel	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;	No statistically significant differences in quality of life scores between arms were noted.
__label__noRel	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.
__label__noRel	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation	Most patients with advanced ovarian cancer develop recurrent disease.
__label__Attack	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;
__label__noRel	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).
__label__noRel	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).
__label__noRel	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).
__label__noRel	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.
__label__noRel	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation	No statistically significant differences in quality of life scores between arms were noted.
__label__noRel	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.
__label__noRel	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).	Most patients with advanced ovarian cancer develop recurrent disease.
__label__noRel	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;
__label__noRel	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation
__label__noRel	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).
__label__noRel	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).
__label__noRel	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.
__label__noRel	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).	No statistically significant differences in quality of life scores between arms were noted.
__label__Support	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.
__label__noRel	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).	Most patients with advanced ovarian cancer develop recurrent disease.
__label__noRel	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;
__label__noRel	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation
__label__noRel	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).
__label__noRel	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).
__label__noRel	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.
__label__noRel	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).	No statistically significant differences in quality of life scores between arms were noted.
__label__Support	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.
__label__noRel	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).	Most patients with advanced ovarian cancer develop recurrent disease.
__label__noRel	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;
__label__noRel	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation
__label__noRel	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).
__label__noRel	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).
__label__noRel	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.
__label__noRel	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).	No statistically significant differences in quality of life scores between arms were noted.
__label__Support	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.
__label__noRel	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.	Most patients with advanced ovarian cancer develop recurrent disease.
__label__noRel	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;
__label__noRel	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation
__label__noRel	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).
__label__noRel	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).
__label__noRel	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).
__label__noRel	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.	No statistically significant differences in quality of life scores between arms were noted.
__label__noRel	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.
__label__noRel	No statistically significant differences in quality of life scores between arms were noted.	Most patients with advanced ovarian cancer develop recurrent disease.
__label__noRel	No statistically significant differences in quality of life scores between arms were noted.	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;
__label__noRel	No statistically significant differences in quality of life scores between arms were noted.	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation
__label__noRel	No statistically significant differences in quality of life scores between arms were noted.	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).
__label__noRel	No statistically significant differences in quality of life scores between arms were noted.	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).
__label__noRel	No statistically significant differences in quality of life scores between arms were noted.	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).
__label__noRel	No statistically significant differences in quality of life scores between arms were noted.	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.
__label__Support	No statistically significant differences in quality of life scores between arms were noted.	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	No statistically significant differences in quality of life scores between arms were noted.	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.
__label__noRel	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.	Most patients with advanced ovarian cancer develop recurrent disease.
__label__noRel	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;
__label__noRel	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation
__label__noRel	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).
__label__noRel	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).
__label__noRel	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).
__label__noRel	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.
__label__noRel	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.	No statistically significant differences in quality of life scores between arms were noted.
__label__noRel	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.	Most patients with advanced ovarian cancer develop recurrent disease.
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.	No statistically significant differences in quality of life scores between arms were noted.
__label__Support	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	Hormone replacement therapy is often either undesirable or contraindicated.	Safe, effective non-hormonal treatments are needed.
__label__noRel	Hormone replacement therapy is often either undesirable or contraindicated.	Group CBT significantly reduced HFNS problem rating at 9 weeks after randomisation compared with usual care (mean difference -167, 95% CI -243 to -091; p<00001) and improvements were maintained at 26 weeks (mean difference -176, -254 to -099; p<00001).
__label__noRel	Hormone replacement therapy is often either undesirable or contraindicated.	We recorded no CBT-related adverse events.
__label__noRel	Hormone replacement therapy is often either undesirable or contraindicated.	Group CBT seems to be a safe and effective treatment for women who have problematic HFNS after breast cancer treatment with additional benefits to mood, sleep, and quality of life.
__label__noRel	Safe, effective non-hormonal treatments are needed.	Hormone replacement therapy is often either undesirable or contraindicated.
__label__noRel	Safe, effective non-hormonal treatments are needed.	Group CBT significantly reduced HFNS problem rating at 9 weeks after randomisation compared with usual care (mean difference -167, 95% CI -243 to -091; p<00001) and improvements were maintained at 26 weeks (mean difference -176, -254 to -099; p<00001).
__label__noRel	Safe, effective non-hormonal treatments are needed.	We recorded no CBT-related adverse events.
__label__noRel	Safe, effective non-hormonal treatments are needed.	Group CBT seems to be a safe and effective treatment for women who have problematic HFNS after breast cancer treatment with additional benefits to mood, sleep, and quality of life.
__label__noRel	Group CBT significantly reduced HFNS problem rating at 9 weeks after randomisation compared with usual care (mean difference -167, 95% CI -243 to -091; p<00001) and improvements were maintained at 26 weeks (mean difference -176, -254 to -099; p<00001).	Hormone replacement therapy is often either undesirable or contraindicated.
__label__noRel	Group CBT significantly reduced HFNS problem rating at 9 weeks after randomisation compared with usual care (mean difference -167, 95% CI -243 to -091; p<00001) and improvements were maintained at 26 weeks (mean difference -176, -254 to -099; p<00001).	Safe, effective non-hormonal treatments are needed.
__label__noRel	Group CBT significantly reduced HFNS problem rating at 9 weeks after randomisation compared with usual care (mean difference -167, 95% CI -243 to -091; p<00001) and improvements were maintained at 26 weeks (mean difference -176, -254 to -099; p<00001).	We recorded no CBT-related adverse events.
__label__Support	Group CBT significantly reduced HFNS problem rating at 9 weeks after randomisation compared with usual care (mean difference -167, 95% CI -243 to -091; p<00001) and improvements were maintained at 26 weeks (mean difference -176, -254 to -099; p<00001).	Group CBT seems to be a safe and effective treatment for women who have problematic HFNS after breast cancer treatment with additional benefits to mood, sleep, and quality of life.
__label__noRel	We recorded no CBT-related adverse events.	Hormone replacement therapy is often either undesirable or contraindicated.
__label__noRel	We recorded no CBT-related adverse events.	Safe, effective non-hormonal treatments are needed.
__label__noRel	We recorded no CBT-related adverse events.	Group CBT significantly reduced HFNS problem rating at 9 weeks after randomisation compared with usual care (mean difference -167, 95% CI -243 to -091; p<00001) and improvements were maintained at 26 weeks (mean difference -176, -254 to -099; p<00001).
__label__Support	We recorded no CBT-related adverse events.	Group CBT seems to be a safe and effective treatment for women who have problematic HFNS after breast cancer treatment with additional benefits to mood, sleep, and quality of life.
__label__noRel	Group CBT seems to be a safe and effective treatment for women who have problematic HFNS after breast cancer treatment with additional benefits to mood, sleep, and quality of life.	Hormone replacement therapy is often either undesirable or contraindicated.
__label__noRel	Group CBT seems to be a safe and effective treatment for women who have problematic HFNS after breast cancer treatment with additional benefits to mood, sleep, and quality of life.	Safe, effective non-hormonal treatments are needed.
__label__noRel	Group CBT seems to be a safe and effective treatment for women who have problematic HFNS after breast cancer treatment with additional benefits to mood, sleep, and quality of life.	Group CBT significantly reduced HFNS problem rating at 9 weeks after randomisation compared with usual care (mean difference -167, 95% CI -243 to -091; p<00001) and improvements were maintained at 26 weeks (mean difference -176, -254 to -099; p<00001).
__label__noRel	Group CBT seems to be a safe and effective treatment for women who have problematic HFNS after breast cancer treatment with additional benefits to mood, sleep, and quality of life.	We recorded no CBT-related adverse events.
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	The quality of life was almost the same between the arms
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	The quality of life was almost the same between the arms
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	The quality of life was almost the same between the arms
__label__Support	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__noRel	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	The quality of life was almost the same between the arms
__label__noRel	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__Support	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	Grades 3/4 toxicities occurred infrequently in both arms.	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	Grades 3/4 toxicities occurred infrequently in both arms.	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	Grades 3/4 toxicities occurred infrequently in both arms.	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	Grades 3/4 toxicities occurred infrequently in both arms.	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	Grades 3/4 toxicities occurred infrequently in both arms.	The quality of life was almost the same between the arms
__label__Support	Grades 3/4 toxicities occurred infrequently in both arms.	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__noRel	Grades 3/4 toxicities occurred infrequently in both arms.	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	The quality of life was almost the same between the arms	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	The quality of life was almost the same between the arms	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	The quality of life was almost the same between the arms	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	The quality of life was almost the same between the arms	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	The quality of life was almost the same between the arms	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	The quality of life was almost the same between the arms	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__noRel	The quality of life was almost the same between the arms	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	The quality of life was almost the same between the arms
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	The quality of life was almost the same between the arms
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__noRel	At the post-treatment assessment, IMCP participants demonstrated significantly greater improvement than the control condition for the primary outcomes of spiritual well-being (b = 0.39; P <.001, including both components of spiritual well-being (sense of meaning: b = 0.34; P = .003 and faith: b = 0.42; P = .03), and quality of life (b = 0.76; P = .013).	Significantly greater improvements for IMCP patients were also observed for the secondary outcomes of symptom burden (b = -6.56; P < .001) and symptom-related distress (b = -0.47; P < .001) but not for anxiety, depression, or hopelessness.
__label__noRel	At the post-treatment assessment, IMCP participants demonstrated significantly greater improvement than the control condition for the primary outcomes of spiritual well-being (b = 0.39; P <.001, including both components of spiritual well-being (sense of meaning: b = 0.34; P = .003 and faith: b = 0.42; P = .03), and quality of life (b = 0.76; P = .013).	At the 2-month follow-up assessment, the improvements observed for the IMCP group were no longer significantly greater than those observed for the TM group.
__label__Support	At the post-treatment assessment, IMCP participants demonstrated significantly greater improvement than the control condition for the primary outcomes of spiritual well-being (b = 0.39; P <.001, including both components of spiritual well-being (sense of meaning: b = 0.34; P = .003 and faith: b = 0.42; P = .03), and quality of life (b = 0.76; P = .013).	IMCP has clear short-term benefits for spiritual suffering and quality of life in patients with advanced cancer.
__label__noRel	Significantly greater improvements for IMCP patients were also observed for the secondary outcomes of symptom burden (b = -6.56; P < .001) and symptom-related distress (b = -0.47; P < .001) but not for anxiety, depression, or hopelessness.	At the post-treatment assessment, IMCP participants demonstrated significantly greater improvement than the control condition for the primary outcomes of spiritual well-being (b = 0.39; P <.001, including both components of spiritual well-being (sense of meaning: b = 0.34; P = .003 and faith: b = 0.42; P = .03), and quality of life (b = 0.76; P = .013).
__label__noRel	Significantly greater improvements for IMCP patients were also observed for the secondary outcomes of symptom burden (b = -6.56; P < .001) and symptom-related distress (b = -0.47; P < .001) but not for anxiety, depression, or hopelessness.	At the 2-month follow-up assessment, the improvements observed for the IMCP group were no longer significantly greater than those observed for the TM group.
__label__Support	Significantly greater improvements for IMCP patients were also observed for the secondary outcomes of symptom burden (b = -6.56; P < .001) and symptom-related distress (b = -0.47; P < .001) but not for anxiety, depression, or hopelessness.	IMCP has clear short-term benefits for spiritual suffering and quality of life in patients with advanced cancer.
__label__Attack	At the 2-month follow-up assessment, the improvements observed for the IMCP group were no longer significantly greater than those observed for the TM group.	At the post-treatment assessment, IMCP participants demonstrated significantly greater improvement than the control condition for the primary outcomes of spiritual well-being (b = 0.39; P <.001, including both components of spiritual well-being (sense of meaning: b = 0.34; P = .003 and faith: b = 0.42; P = .03), and quality of life (b = 0.76; P = .013).
__label__noRel	At the 2-month follow-up assessment, the improvements observed for the IMCP group were no longer significantly greater than those observed for the TM group.	Significantly greater improvements for IMCP patients were also observed for the secondary outcomes of symptom burden (b = -6.56; P < .001) and symptom-related distress (b = -0.47; P < .001) but not for anxiety, depression, or hopelessness.
__label__noRel	At the 2-month follow-up assessment, the improvements observed for the IMCP group were no longer significantly greater than those observed for the TM group.	IMCP has clear short-term benefits for spiritual suffering and quality of life in patients with advanced cancer.
__label__noRel	IMCP has clear short-term benefits for spiritual suffering and quality of life in patients with advanced cancer.	At the post-treatment assessment, IMCP participants demonstrated significantly greater improvement than the control condition for the primary outcomes of spiritual well-being (b = 0.39; P <.001, including both components of spiritual well-being (sense of meaning: b = 0.34; P = .003 and faith: b = 0.42; P = .03), and quality of life (b = 0.76; P = .013).
__label__noRel	IMCP has clear short-term benefits for spiritual suffering and quality of life in patients with advanced cancer.	Significantly greater improvements for IMCP patients were also observed for the secondary outcomes of symptom burden (b = -6.56; P < .001) and symptom-related distress (b = -0.47; P < .001) but not for anxiety, depression, or hopelessness.
__label__noRel	IMCP has clear short-term benefits for spiritual suffering and quality of life in patients with advanced cancer.	At the 2-month follow-up assessment, the improvements observed for the IMCP group were no longer significantly greater than those observed for the TM group.
__label__noRel	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.	The intervention demonstrated a trend toward improved CRF,
__label__noRel	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.	although this effect was reduced once confounders had been controlled statistically.
__label__noRel	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.
__label__noRel	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.	No decrease in fatigue-related distress was detected.
__label__noRel	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.
__label__noRel	The intervention demonstrated a trend toward improved CRF,	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.
__label__noRel	The intervention demonstrated a trend toward improved CRF,	although this effect was reduced once confounders had been controlled statistically.
__label__noRel	The intervention demonstrated a trend toward improved CRF,	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.
__label__noRel	The intervention demonstrated a trend toward improved CRF,	No decrease in fatigue-related distress was detected.
__label__Support	The intervention demonstrated a trend toward improved CRF,	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.
__label__noRel	although this effect was reduced once confounders had been controlled statistically.	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.
__label__Attack	although this effect was reduced once confounders had been controlled statistically.	The intervention demonstrated a trend toward improved CRF,
__label__noRel	although this effect was reduced once confounders had been controlled statistically.	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.
__label__noRel	although this effect was reduced once confounders had been controlled statistically.	No decrease in fatigue-related distress was detected.
__label__noRel	although this effect was reduced once confounders had been controlled statistically.	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.
__label__noRel	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.
__label__noRel	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.	The intervention demonstrated a trend toward improved CRF,
__label__noRel	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.	although this effect was reduced once confounders had been controlled statistically.
__label__noRel	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.	No decrease in fatigue-related distress was detected.
__label__Support	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.
__label__noRel	No decrease in fatigue-related distress was detected.	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.
__label__noRel	No decrease in fatigue-related distress was detected.	The intervention demonstrated a trend toward improved CRF,
__label__noRel	No decrease in fatigue-related distress was detected.	although this effect was reduced once confounders had been controlled statistically.
__label__noRel	No decrease in fatigue-related distress was detected.	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.
__label__Support	No decrease in fatigue-related distress was detected.	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.
__label__noRel	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.
__label__noRel	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.	The intervention demonstrated a trend toward improved CRF,
__label__noRel	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.	although this effect was reduced once confounders had been controlled statistically.
__label__noRel	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.
__label__noRel	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.	No decrease in fatigue-related distress was detected.
__label__noRel	This research study indicates that live music therapy using patient-preferred music can be beneficial in improving quality of life indicators such as anxiety, perception of the hospitalization or procedure, relaxation, and stress in patients undergoing surgical procedures of the brain.	Results indicated statistically significant differences for 4 of the 6 quality of life measures: anxiety (p = .03), perception of hospitalization (p = .03), relaxation (p = .001), and stress (p = .001).
__label__noRel	This research study indicates that live music therapy using patient-preferred music can be beneficial in improving quality of life indicators such as anxiety, perception of the hospitalization or procedure, relaxation, and stress in patients undergoing surgical procedures of the brain.	No statistically significant differences were found for mood (p > .05) or pain (p > .05) levels.
__label__Support	Results indicated statistically significant differences for 4 of the 6 quality of life measures: anxiety (p = .03), perception of hospitalization (p = .03), relaxation (p = .001), and stress (p = .001).	This research study indicates that live music therapy using patient-preferred music can be beneficial in improving quality of life indicators such as anxiety, perception of the hospitalization or procedure, relaxation, and stress in patients undergoing surgical procedures of the brain.
__label__noRel	Results indicated statistically significant differences for 4 of the 6 quality of life measures: anxiety (p = .03), perception of hospitalization (p = .03), relaxation (p = .001), and stress (p = .001).	No statistically significant differences were found for mood (p > .05) or pain (p > .05) levels.
__label__Support	No statistically significant differences were found for mood (p > .05) or pain (p > .05) levels.	This research study indicates that live music therapy using patient-preferred music can be beneficial in improving quality of life indicators such as anxiety, perception of the hospitalization or procedure, relaxation, and stress in patients undergoing surgical procedures of the brain.
__label__noRel	No statistically significant differences were found for mood (p > .05) or pain (p > .05) levels.	Results indicated statistically significant differences for 4 of the 6 quality of life measures: anxiety (p = .03), perception of hospitalization (p = .03), relaxation (p = .001), and stress (p = .001).
__label__noRel	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).
__label__noRel	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).
__label__noRel	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,
__label__noRel	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).
__label__noRel	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).
__label__noRel	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.
__label__noRel	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.
__label__noRel	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.
__label__noRel	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).
__label__noRel	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,
__label__noRel	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).
__label__noRel	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).
__label__Support	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.
__label__noRel	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.
__label__noRel	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.
__label__noRel	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).
__label__noRel	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,
__label__noRel	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).
__label__noRel	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).
__label__Support	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.
__label__noRel	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.
__label__noRel	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.
__label__noRel	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).
__label__noRel	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).
__label__noRel	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).
__label__noRel	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).
__label__Support	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.
__label__noRel	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.
__label__noRel	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.
__label__noRel	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).
__label__noRel	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).
__label__Attack	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,
__label__noRel	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).
__label__noRel	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.
__label__noRel	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.
__label__noRel	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.
__label__noRel	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).
__label__noRel	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).
__label__noRel	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,
__label__noRel	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).
__label__Support	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.
__label__noRel	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.
__label__noRel	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.
__label__noRel	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).
__label__noRel	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).
__label__noRel	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,
__label__noRel	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).
__label__noRel	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).
__label__Support	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.
__label__noRel	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.
__label__noRel	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).
__label__noRel	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).
__label__noRel	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,
__label__noRel	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).
__label__noRel	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).
__label__noRel	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.
__label__noRel	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).
__label__noRel	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);
__label__noRel	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.	at no point was any significant difference apparent on this end point.
__label__noRel	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.	Both treatments led to an improvement, over time, in dyspnoea.
__label__noRel	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.
__label__noRel	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.
__label__noRel	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.
__label__noRel	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.
__label__noRel	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);
__label__noRel	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).	at no point was any significant difference apparent on this end point.
__label__noRel	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).	Both treatments led to an improvement, over time, in dyspnoea.
__label__Support	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.
__label__noRel	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.
__label__noRel	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.
__label__noRel	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.
__label__noRel	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).
__label__noRel	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);	at no point was any significant difference apparent on this end point.
__label__noRel	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);	Both treatments led to an improvement, over time, in dyspnoea.
__label__Support	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.
__label__noRel	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.
__label__noRel	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.
__label__noRel	at no point was any significant difference apparent on this end point.	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.
__label__noRel	at no point was any significant difference apparent on this end point.	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).
__label__Support	at no point was any significant difference apparent on this end point.	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);
__label__noRel	at no point was any significant difference apparent on this end point.	Both treatments led to an improvement, over time, in dyspnoea.
__label__noRel	at no point was any significant difference apparent on this end point.	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.
__label__noRel	at no point was any significant difference apparent on this end point.	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.
__label__noRel	at no point was any significant difference apparent on this end point.	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.
__label__noRel	Both treatments led to an improvement, over time, in dyspnoea.	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.
__label__noRel	Both treatments led to an improvement, over time, in dyspnoea.	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).
__label__noRel	Both treatments led to an improvement, over time, in dyspnoea.	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);
__label__noRel	Both treatments led to an improvement, over time, in dyspnoea.	at no point was any significant difference apparent on this end point.
__label__Support	Both treatments led to an improvement, over time, in dyspnoea.	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.
__label__noRel	Both treatments led to an improvement, over time, in dyspnoea.	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.
__label__noRel	Both treatments led to an improvement, over time, in dyspnoea.	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.
__label__noRel	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.
__label__noRel	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).
__label__noRel	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);
__label__noRel	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.	at no point was any significant difference apparent on this end point.
__label__noRel	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.	Both treatments led to an improvement, over time, in dyspnoea.
__label__noRel	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.
__label__Support	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.
__label__noRel	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.
__label__noRel	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).
__label__noRel	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);
__label__noRel	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.	at no point was any significant difference apparent on this end point.
__label__noRel	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.	Both treatments led to an improvement, over time, in dyspnoea.
__label__Attack	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.
__label__noRel	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.
__label__noRel	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.
__label__noRel	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).
__label__noRel	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);
__label__noRel	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.	at no point was any significant difference apparent on this end point.
__label__noRel	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.	Both treatments led to an improvement, over time, in dyspnoea.
__label__noRel	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.
__label__noRel	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.
__label__noRel	No adverse events or skeletal complications occurred during the supervised exercise sessions.	The exercise program was well tolerated as evidenced by high attendance (83%) and compliance rates (93%), and the ability of the participants to exercise at an intensity within the target range for cancer survivors (rating of perceived exertion =13.81.5).
__label__noRel	No adverse events or skeletal complications occurred during the supervised exercise sessions.	The change in physical function (muscle strength 11%; submaximal aerobic exercise capacity 5% and ambulation 12%), physical activity level (24%) and lean mass (3%) differed significantly between groups following the intervention, with favorable changes in the exercise group compared with the usual care group.
__label__noRel	No adverse events or skeletal complications occurred during the supervised exercise sessions.	No significant between-group differences were observed for fatigue, quality of life or psychological distress.
__label__Support	No adverse events or skeletal complications occurred during the supervised exercise sessions.	This initial evidence involving a small sample size suggests that appropriately designed and supervised resistance exercise may be safe and well tolerated by prostate cancer patients with bone metastatic disease and can lead to improvements in physical function, physical activity levels and lean mass.
__label__noRel	No adverse events or skeletal complications occurred during the supervised exercise sessions.	Future trials involving larger sample sizes are required to expand these preliminary findings.
__label__noRel	The exercise program was well tolerated as evidenced by high attendance (83%) and compliance rates (93%), and the ability of the participants to exercise at an intensity within the target range for cancer survivors (rating of perceived exertion =13.81.5).	No adverse events or skeletal complications occurred during the supervised exercise sessions.
__label__noRel	The exercise program was well tolerated as evidenced by high attendance (83%) and compliance rates (93%), and the ability of the participants to exercise at an intensity within the target range for cancer survivors (rating of perceived exertion =13.81.5).	The change in physical function (muscle strength 11%; submaximal aerobic exercise capacity 5% and ambulation 12%), physical activity level (24%) and lean mass (3%) differed significantly between groups following the intervention, with favorable changes in the exercise group compared with the usual care group.
__label__noRel	The exercise program was well tolerated as evidenced by high attendance (83%) and compliance rates (93%), and the ability of the participants to exercise at an intensity within the target range for cancer survivors (rating of perceived exertion =13.81.5).	No significant between-group differences were observed for fatigue, quality of life or psychological distress.
__label__Support	The exercise program was well tolerated as evidenced by high attendance (83%) and compliance rates (93%), and the ability of the participants to exercise at an intensity within the target range for cancer survivors (rating of perceived exertion =13.81.5).	This initial evidence involving a small sample size suggests that appropriately designed and supervised resistance exercise may be safe and well tolerated by prostate cancer patients with bone metastatic disease and can lead to improvements in physical function, physical activity levels and lean mass.
__label__noRel	The exercise program was well tolerated as evidenced by high attendance (83%) and compliance rates (93%), and the ability of the participants to exercise at an intensity within the target range for cancer survivors (rating of perceived exertion =13.81.5).	Future trials involving larger sample sizes are required to expand these preliminary findings.
__label__noRel	The change in physical function (muscle strength 11%; submaximal aerobic exercise capacity 5% and ambulation 12%), physical activity level (24%) and lean mass (3%) differed significantly between groups following the intervention, with favorable changes in the exercise group compared with the usual care group.	No adverse events or skeletal complications occurred during the supervised exercise sessions.
__label__noRel	The change in physical function (muscle strength 11%; submaximal aerobic exercise capacity 5% and ambulation 12%), physical activity level (24%) and lean mass (3%) differed significantly between groups following the intervention, with favorable changes in the exercise group compared with the usual care group.	The exercise program was well tolerated as evidenced by high attendance (83%) and compliance rates (93%), and the ability of the participants to exercise at an intensity within the target range for cancer survivors (rating of perceived exertion =13.81.5).
__label__noRel	The change in physical function (muscle strength 11%; submaximal aerobic exercise capacity 5% and ambulation 12%), physical activity level (24%) and lean mass (3%) differed significantly between groups following the intervention, with favorable changes in the exercise group compared with the usual care group.	No significant between-group differences were observed for fatigue, quality of life or psychological distress.
__label__Support	The change in physical function (muscle strength 11%; submaximal aerobic exercise capacity 5% and ambulation 12%), physical activity level (24%) and lean mass (3%) differed significantly between groups following the intervention, with favorable changes in the exercise group compared with the usual care group.	This initial evidence involving a small sample size suggests that appropriately designed and supervised resistance exercise may be safe and well tolerated by prostate cancer patients with bone metastatic disease and can lead to improvements in physical function, physical activity levels and lean mass.
__label__noRel	The change in physical function (muscle strength 11%; submaximal aerobic exercise capacity 5% and ambulation 12%), physical activity level (24%) and lean mass (3%) differed significantly between groups following the intervention, with favorable changes in the exercise group compared with the usual care group.	Future trials involving larger sample sizes are required to expand these preliminary findings.
__label__noRel	No significant between-group differences were observed for fatigue, quality of life or psychological distress.	No adverse events or skeletal complications occurred during the supervised exercise sessions.
__label__noRel	No significant between-group differences were observed for fatigue, quality of life or psychological distress.	The exercise program was well tolerated as evidenced by high attendance (83%) and compliance rates (93%), and the ability of the participants to exercise at an intensity within the target range for cancer survivors (rating of perceived exertion =13.81.5).
__label__noRel	No significant between-group differences were observed for fatigue, quality of life or psychological distress.	The change in physical function (muscle strength 11%; submaximal aerobic exercise capacity 5% and ambulation 12%), physical activity level (24%) and lean mass (3%) differed significantly between groups following the intervention, with favorable changes in the exercise group compared with the usual care group.
__label__Support	No significant between-group differences were observed for fatigue, quality of life or psychological distress.	This initial evidence involving a small sample size suggests that appropriately designed and supervised resistance exercise may be safe and well tolerated by prostate cancer patients with bone metastatic disease and can lead to improvements in physical function, physical activity levels and lean mass.
__label__noRel	No significant between-group differences were observed for fatigue, quality of life or psychological distress.	Future trials involving larger sample sizes are required to expand these preliminary findings.
__label__noRel	This initial evidence involving a small sample size suggests that appropriately designed and supervised resistance exercise may be safe and well tolerated by prostate cancer patients with bone metastatic disease and can lead to improvements in physical function, physical activity levels and lean mass.	No adverse events or skeletal complications occurred during the supervised exercise sessions.
__label__noRel	This initial evidence involving a small sample size suggests that appropriately designed and supervised resistance exercise may be safe and well tolerated by prostate cancer patients with bone metastatic disease and can lead to improvements in physical function, physical activity levels and lean mass.	The exercise program was well tolerated as evidenced by high attendance (83%) and compliance rates (93%), and the ability of the participants to exercise at an intensity within the target range for cancer survivors (rating of perceived exertion =13.81.5).
__label__noRel	This initial evidence involving a small sample size suggests that appropriately designed and supervised resistance exercise may be safe and well tolerated by prostate cancer patients with bone metastatic disease and can lead to improvements in physical function, physical activity levels and lean mass.	The change in physical function (muscle strength 11%; submaximal aerobic exercise capacity 5% and ambulation 12%), physical activity level (24%) and lean mass (3%) differed significantly between groups following the intervention, with favorable changes in the exercise group compared with the usual care group.
__label__noRel	This initial evidence involving a small sample size suggests that appropriately designed and supervised resistance exercise may be safe and well tolerated by prostate cancer patients with bone metastatic disease and can lead to improvements in physical function, physical activity levels and lean mass.	No significant between-group differences were observed for fatigue, quality of life or psychological distress.
__label__noRel	This initial evidence involving a small sample size suggests that appropriately designed and supervised resistance exercise may be safe and well tolerated by prostate cancer patients with bone metastatic disease and can lead to improvements in physical function, physical activity levels and lean mass.	Future trials involving larger sample sizes are required to expand these preliminary findings.
__label__noRel	Future trials involving larger sample sizes are required to expand these preliminary findings.	No adverse events or skeletal complications occurred during the supervised exercise sessions.
__label__noRel	Future trials involving larger sample sizes are required to expand these preliminary findings.	The exercise program was well tolerated as evidenced by high attendance (83%) and compliance rates (93%), and the ability of the participants to exercise at an intensity within the target range for cancer survivors (rating of perceived exertion =13.81.5).
__label__noRel	Future trials involving larger sample sizes are required to expand these preliminary findings.	The change in physical function (muscle strength 11%; submaximal aerobic exercise capacity 5% and ambulation 12%), physical activity level (24%) and lean mass (3%) differed significantly between groups following the intervention, with favorable changes in the exercise group compared with the usual care group.
__label__noRel	Future trials involving larger sample sizes are required to expand these preliminary findings.	No significant between-group differences were observed for fatigue, quality of life or psychological distress.
__label__Attack	Future trials involving larger sample sizes are required to expand these preliminary findings.	This initial evidence involving a small sample size suggests that appropriately designed and supervised resistance exercise may be safe and well tolerated by prostate cancer patients with bone metastatic disease and can lead to improvements in physical function, physical activity levels and lean mass.
__label__noRel	No late arising QOL issues were observed.	Regardless of treatment arm, participants reported high levels of QOL with few exceptions.
__label__noRel	No late arising QOL issues were observed.	cryoablation was associated with more acute urinary dysfunction (mean PCI urinary function cryoablation=69.4; mean EBRT=90.7; P<.001), which resolved over time.
__label__noRel	No late arising QOL issues were observed.	Both EBRT and cryoablation participants reported decreases in sexual function at 3 months with the cryoablation patients reporting poorer functioning (mean cryoablation=7.2: mean EBRT=32.9; P<.001).
__label__noRel	No late arising QOL issues were observed.	Mean sexual function score was 15 points lower at 3 years for the cryoablation group and 13% more of the cryoablation men said that sexuality was a moderate or big problem.
__label__Support	No late arising QOL issues were observed.	In this randomized trial, no long-term QOL advantage for either treatment was apparent
__label__noRel	No late arising QOL issues were observed.	with the exception of poorer sexual function reported by those treated with cryoablation.
__label__noRel	Regardless of treatment arm, participants reported high levels of QOL with few exceptions.	No late arising QOL issues were observed.
__label__noRel	Regardless of treatment arm, participants reported high levels of QOL with few exceptions.	cryoablation was associated with more acute urinary dysfunction (mean PCI urinary function cryoablation=69.4; mean EBRT=90.7; P<.001), which resolved over time.
__label__noRel	Regardless of treatment arm, participants reported high levels of QOL with few exceptions.	Both EBRT and cryoablation participants reported decreases in sexual function at 3 months with the cryoablation patients reporting poorer functioning (mean cryoablation=7.2: mean EBRT=32.9; P<.001).
__label__noRel	Regardless of treatment arm, participants reported high levels of QOL with few exceptions.	Mean sexual function score was 15 points lower at 3 years for the cryoablation group and 13% more of the cryoablation men said that sexuality was a moderate or big problem.
__label__Support	Regardless of treatment arm, participants reported high levels of QOL with few exceptions.	In this randomized trial, no long-term QOL advantage for either treatment was apparent
__label__noRel	Regardless of treatment arm, participants reported high levels of QOL with few exceptions.	with the exception of poorer sexual function reported by those treated with cryoablation.
__label__noRel	cryoablation was associated with more acute urinary dysfunction (mean PCI urinary function cryoablation=69.4; mean EBRT=90.7; P<.001), which resolved over time.	No late arising QOL issues were observed.
__label__noRel	cryoablation was associated with more acute urinary dysfunction (mean PCI urinary function cryoablation=69.4; mean EBRT=90.7; P<.001), which resolved over time.	Regardless of treatment arm, participants reported high levels of QOL with few exceptions.
__label__noRel	cryoablation was associated with more acute urinary dysfunction (mean PCI urinary function cryoablation=69.4; mean EBRT=90.7; P<.001), which resolved over time.	Both EBRT and cryoablation participants reported decreases in sexual function at 3 months with the cryoablation patients reporting poorer functioning (mean cryoablation=7.2: mean EBRT=32.9; P<.001).
__label__noRel	cryoablation was associated with more acute urinary dysfunction (mean PCI urinary function cryoablation=69.4; mean EBRT=90.7; P<.001), which resolved over time.	Mean sexual function score was 15 points lower at 3 years for the cryoablation group and 13% more of the cryoablation men said that sexuality was a moderate or big problem.
__label__Support	cryoablation was associated with more acute urinary dysfunction (mean PCI urinary function cryoablation=69.4; mean EBRT=90.7; P<.001), which resolved over time.	In this randomized trial, no long-term QOL advantage for either treatment was apparent
__label__noRel	cryoablation was associated with more acute urinary dysfunction (mean PCI urinary function cryoablation=69.4; mean EBRT=90.7; P<.001), which resolved over time.	with the exception of poorer sexual function reported by those treated with cryoablation.
__label__noRel	Both EBRT and cryoablation participants reported decreases in sexual function at 3 months with the cryoablation patients reporting poorer functioning (mean cryoablation=7.2: mean EBRT=32.9; P<.001).	No late arising QOL issues were observed.
__label__noRel	Both EBRT and cryoablation participants reported decreases in sexual function at 3 months with the cryoablation patients reporting poorer functioning (mean cryoablation=7.2: mean EBRT=32.9; P<.001).	Regardless of treatment arm, participants reported high levels of QOL with few exceptions.
__label__noRel	Both EBRT and cryoablation participants reported decreases in sexual function at 3 months with the cryoablation patients reporting poorer functioning (mean cryoablation=7.2: mean EBRT=32.9; P<.001).	cryoablation was associated with more acute urinary dysfunction (mean PCI urinary function cryoablation=69.4; mean EBRT=90.7; P<.001), which resolved over time.
__label__noRel	Both EBRT and cryoablation participants reported decreases in sexual function at 3 months with the cryoablation patients reporting poorer functioning (mean cryoablation=7.2: mean EBRT=32.9; P<.001).	Mean sexual function score was 15 points lower at 3 years for the cryoablation group and 13% more of the cryoablation men said that sexuality was a moderate or big problem.
__label__noRel	Both EBRT and cryoablation participants reported decreases in sexual function at 3 months with the cryoablation patients reporting poorer functioning (mean cryoablation=7.2: mean EBRT=32.9; P<.001).	In this randomized trial, no long-term QOL advantage for either treatment was apparent
__label__Support	Both EBRT and cryoablation participants reported decreases in sexual function at 3 months with the cryoablation patients reporting poorer functioning (mean cryoablation=7.2: mean EBRT=32.9; P<.001).	with the exception of poorer sexual function reported by those treated with cryoablation.
__label__noRel	Mean sexual function score was 15 points lower at 3 years for the cryoablation group and 13% more of the cryoablation men said that sexuality was a moderate or big problem.	No late arising QOL issues were observed.
__label__noRel	Mean sexual function score was 15 points lower at 3 years for the cryoablation group and 13% more of the cryoablation men said that sexuality was a moderate or big problem.	Regardless of treatment arm, participants reported high levels of QOL with few exceptions.
__label__noRel	Mean sexual function score was 15 points lower at 3 years for the cryoablation group and 13% more of the cryoablation men said that sexuality was a moderate or big problem.	cryoablation was associated with more acute urinary dysfunction (mean PCI urinary function cryoablation=69.4; mean EBRT=90.7; P<.001), which resolved over time.
__label__noRel	Mean sexual function score was 15 points lower at 3 years for the cryoablation group and 13% more of the cryoablation men said that sexuality was a moderate or big problem.	Both EBRT and cryoablation participants reported decreases in sexual function at 3 months with the cryoablation patients reporting poorer functioning (mean cryoablation=7.2: mean EBRT=32.9; P<.001).
__label__noRel	Mean sexual function score was 15 points lower at 3 years for the cryoablation group and 13% more of the cryoablation men said that sexuality was a moderate or big problem.	In this randomized trial, no long-term QOL advantage for either treatment was apparent
__label__Support	Mean sexual function score was 15 points lower at 3 years for the cryoablation group and 13% more of the cryoablation men said that sexuality was a moderate or big problem.	with the exception of poorer sexual function reported by those treated with cryoablation.
__label__noRel	In this randomized trial, no long-term QOL advantage for either treatment was apparent	No late arising QOL issues were observed.
__label__noRel	In this randomized trial, no long-term QOL advantage for either treatment was apparent	Regardless of treatment arm, participants reported high levels of QOL with few exceptions.
__label__noRel	In this randomized trial, no long-term QOL advantage for either treatment was apparent	cryoablation was associated with more acute urinary dysfunction (mean PCI urinary function cryoablation=69.4; mean EBRT=90.7; P<.001), which resolved over time.
__label__noRel	In this randomized trial, no long-term QOL advantage for either treatment was apparent	Both EBRT and cryoablation participants reported decreases in sexual function at 3 months with the cryoablation patients reporting poorer functioning (mean cryoablation=7.2: mean EBRT=32.9; P<.001).
__label__noRel	In this randomized trial, no long-term QOL advantage for either treatment was apparent	Mean sexual function score was 15 points lower at 3 years for the cryoablation group and 13% more of the cryoablation men said that sexuality was a moderate or big problem.
__label__noRel	In this randomized trial, no long-term QOL advantage for either treatment was apparent	with the exception of poorer sexual function reported by those treated with cryoablation.
__label__noRel	with the exception of poorer sexual function reported by those treated with cryoablation.	No late arising QOL issues were observed.
__label__noRel	with the exception of poorer sexual function reported by those treated with cryoablation.	Regardless of treatment arm, participants reported high levels of QOL with few exceptions.
__label__noRel	with the exception of poorer sexual function reported by those treated with cryoablation.	cryoablation was associated with more acute urinary dysfunction (mean PCI urinary function cryoablation=69.4; mean EBRT=90.7; P<.001), which resolved over time.
__label__noRel	with the exception of poorer sexual function reported by those treated with cryoablation.	Both EBRT and cryoablation participants reported decreases in sexual function at 3 months with the cryoablation patients reporting poorer functioning (mean cryoablation=7.2: mean EBRT=32.9; P<.001).
__label__noRel	with the exception of poorer sexual function reported by those treated with cryoablation.	Mean sexual function score was 15 points lower at 3 years for the cryoablation group and 13% more of the cryoablation men said that sexuality was a moderate or big problem.
__label__Attack	with the exception of poorer sexual function reported by those treated with cryoablation.	In this randomized trial, no long-term QOL advantage for either treatment was apparent
__label__noRel	LLLT was effective in improving the patient's subjective experience of OM and QOL in HNC patients receiving CRT.	a significant reduction (p<0.001) in incidence of severe OM, need for opioid analgesics, and total parenteral nutrition was observed.
__label__noRel	LLLT was effective in improving the patient's subjective experience of OM and QOL in HNC patients receiving CRT.	Results analysis revealed that OMWQ-HN (F=12.199, df =6,1314, p<0.001) and FACT-HN (p<0.05) scores were significantly lower in LLLT than placebo group patients.
__label__Support	a significant reduction (p<0.001) in incidence of severe OM, need for opioid analgesics, and total parenteral nutrition was observed.	LLLT was effective in improving the patient's subjective experience of OM and QOL in HNC patients receiving CRT.
__label__noRel	a significant reduction (p<0.001) in incidence of severe OM, need for opioid analgesics, and total parenteral nutrition was observed.	Results analysis revealed that OMWQ-HN (F=12.199, df =6,1314, p<0.001) and FACT-HN (p<0.05) scores were significantly lower in LLLT than placebo group patients.
__label__Support	Results analysis revealed that OMWQ-HN (F=12.199, df =6,1314, p<0.001) and FACT-HN (p<0.05) scores were significantly lower in LLLT than placebo group patients.	LLLT was effective in improving the patient's subjective experience of OM and QOL in HNC patients receiving CRT.
__label__noRel	Results analysis revealed that OMWQ-HN (F=12.199, df =6,1314, p<0.001) and FACT-HN (p<0.05) scores were significantly lower in LLLT than placebo group patients.	a significant reduction (p<0.001) in incidence of severe OM, need for opioid analgesics, and total parenteral nutrition was observed.
__label__noRel	Cisplatin reduces plasma ghrelin levels through the 5-hydroxytryptamine (5-HT) receptor.	Food intake and appetite VAS scores were significantly higher in the ghrelin group than in the placebo group (18.2  5.2 kcal/kg/day vs 12.7  3.4 kcal/kg/day [P = .001] and 6.2  0.9 vs 4.1  0.9 [P < .0001], respectively).
__label__noRel	Cisplatin reduces plasma ghrelin levels through the 5-hydroxytryptamine (5-HT) receptor.	Patients in the ghrelin group had fewer adverse events during chemotherapy related to anorexia and nausea than patients in the control group.
__label__noRel	Cisplatin reduces plasma ghrelin levels through the 5-hydroxytryptamine (5-HT) receptor.	Significant deterioration was noted after chemotherapy in the placebo group in QoL scores, appetite, nausea and vomiting, and global health status.
__label__noRel	Cisplatin reduces plasma ghrelin levels through the 5-hydroxytryptamine (5-HT) receptor.	Short-term administration of exogenous ghrelin at the start of cisplatin-based chemotherapy stimulated food intake and minimized adverse events.
__label__noRel	Food intake and appetite VAS scores were significantly higher in the ghrelin group than in the placebo group (18.2  5.2 kcal/kg/day vs 12.7  3.4 kcal/kg/day [P = .001] and 6.2  0.9 vs 4.1  0.9 [P < .0001], respectively).	Cisplatin reduces plasma ghrelin levels through the 5-hydroxytryptamine (5-HT) receptor.
__label__noRel	Food intake and appetite VAS scores were significantly higher in the ghrelin group than in the placebo group (18.2  5.2 kcal/kg/day vs 12.7  3.4 kcal/kg/day [P = .001] and 6.2  0.9 vs 4.1  0.9 [P < .0001], respectively).	Patients in the ghrelin group had fewer adverse events during chemotherapy related to anorexia and nausea than patients in the control group.
__label__noRel	Food intake and appetite VAS scores were significantly higher in the ghrelin group than in the placebo group (18.2  5.2 kcal/kg/day vs 12.7  3.4 kcal/kg/day [P = .001] and 6.2  0.9 vs 4.1  0.9 [P < .0001], respectively).	Significant deterioration was noted after chemotherapy in the placebo group in QoL scores, appetite, nausea and vomiting, and global health status.
__label__Support	Food intake and appetite VAS scores were significantly higher in the ghrelin group than in the placebo group (18.2  5.2 kcal/kg/day vs 12.7  3.4 kcal/kg/day [P = .001] and 6.2  0.9 vs 4.1  0.9 [P < .0001], respectively).	Short-term administration of exogenous ghrelin at the start of cisplatin-based chemotherapy stimulated food intake and minimized adverse events.
__label__noRel	Patients in the ghrelin group had fewer adverse events during chemotherapy related to anorexia and nausea than patients in the control group.	Cisplatin reduces plasma ghrelin levels through the 5-hydroxytryptamine (5-HT) receptor.
__label__noRel	Patients in the ghrelin group had fewer adverse events during chemotherapy related to anorexia and nausea than patients in the control group.	Food intake and appetite VAS scores were significantly higher in the ghrelin group than in the placebo group (18.2  5.2 kcal/kg/day vs 12.7  3.4 kcal/kg/day [P = .001] and 6.2  0.9 vs 4.1  0.9 [P < .0001], respectively).
__label__noRel	Patients in the ghrelin group had fewer adverse events during chemotherapy related to anorexia and nausea than patients in the control group.	Significant deterioration was noted after chemotherapy in the placebo group in QoL scores, appetite, nausea and vomiting, and global health status.
__label__Support	Patients in the ghrelin group had fewer adverse events during chemotherapy related to anorexia and nausea than patients in the control group.	Short-term administration of exogenous ghrelin at the start of cisplatin-based chemotherapy stimulated food intake and minimized adverse events.
__label__noRel	Significant deterioration was noted after chemotherapy in the placebo group in QoL scores, appetite, nausea and vomiting, and global health status.	Cisplatin reduces plasma ghrelin levels through the 5-hydroxytryptamine (5-HT) receptor.
__label__noRel	Significant deterioration was noted after chemotherapy in the placebo group in QoL scores, appetite, nausea and vomiting, and global health status.	Food intake and appetite VAS scores were significantly higher in the ghrelin group than in the placebo group (18.2  5.2 kcal/kg/day vs 12.7  3.4 kcal/kg/day [P = .001] and 6.2  0.9 vs 4.1  0.9 [P < .0001], respectively).
__label__noRel	Significant deterioration was noted after chemotherapy in the placebo group in QoL scores, appetite, nausea and vomiting, and global health status.	Patients in the ghrelin group had fewer adverse events during chemotherapy related to anorexia and nausea than patients in the control group.
__label__Support	Significant deterioration was noted after chemotherapy in the placebo group in QoL scores, appetite, nausea and vomiting, and global health status.	Short-term administration of exogenous ghrelin at the start of cisplatin-based chemotherapy stimulated food intake and minimized adverse events.
__label__noRel	Short-term administration of exogenous ghrelin at the start of cisplatin-based chemotherapy stimulated food intake and minimized adverse events.	Cisplatin reduces plasma ghrelin levels through the 5-hydroxytryptamine (5-HT) receptor.
__label__noRel	Short-term administration of exogenous ghrelin at the start of cisplatin-based chemotherapy stimulated food intake and minimized adverse events.	Food intake and appetite VAS scores were significantly higher in the ghrelin group than in the placebo group (18.2  5.2 kcal/kg/day vs 12.7  3.4 kcal/kg/day [P = .001] and 6.2  0.9 vs 4.1  0.9 [P < .0001], respectively).
__label__noRel	Short-term administration of exogenous ghrelin at the start of cisplatin-based chemotherapy stimulated food intake and minimized adverse events.	Patients in the ghrelin group had fewer adverse events during chemotherapy related to anorexia and nausea than patients in the control group.
__label__noRel	Short-term administration of exogenous ghrelin at the start of cisplatin-based chemotherapy stimulated food intake and minimized adverse events.	Significant deterioration was noted after chemotherapy in the placebo group in QoL scores, appetite, nausea and vomiting, and global health status.
__label__noRel	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.	Climacteric symptoms remained significantly below baseline values after dosage reduction;
__label__noRel	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.	some symptoms recurred after discontinuation of ccHRT.
__label__noRel	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.
__label__noRel	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.
__label__noRel	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.	They deteriorated during follow-up in women not continuing ccHRT.
__label__Support	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.
__label__noRel	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.
__label__noRel	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.	This supports the need for an individualized approach to therapy recommendations.
__label__noRel	Climacteric symptoms remained significantly below baseline values after dosage reduction;	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.
__label__noRel	Climacteric symptoms remained significantly below baseline values after dosage reduction;	some symptoms recurred after discontinuation of ccHRT.
__label__noRel	Climacteric symptoms remained significantly below baseline values after dosage reduction;	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.
__label__noRel	Climacteric symptoms remained significantly below baseline values after dosage reduction;	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.
__label__noRel	Climacteric symptoms remained significantly below baseline values after dosage reduction;	They deteriorated during follow-up in women not continuing ccHRT.
__label__Support	Climacteric symptoms remained significantly below baseline values after dosage reduction;	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.
__label__noRel	Climacteric symptoms remained significantly below baseline values after dosage reduction;	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.
__label__noRel	Climacteric symptoms remained significantly below baseline values after dosage reduction;	This supports the need for an individualized approach to therapy recommendations.
__label__noRel	some symptoms recurred after discontinuation of ccHRT.	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.
__label__noRel	some symptoms recurred after discontinuation of ccHRT.	Climacteric symptoms remained significantly below baseline values after dosage reduction;
__label__noRel	some symptoms recurred after discontinuation of ccHRT.	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.
__label__noRel	some symptoms recurred after discontinuation of ccHRT.	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.
__label__noRel	some symptoms recurred after discontinuation of ccHRT.	They deteriorated during follow-up in women not continuing ccHRT.
__label__noRel	some symptoms recurred after discontinuation of ccHRT.	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.
__label__noRel	some symptoms recurred after discontinuation of ccHRT.	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.
__label__noRel	some symptoms recurred after discontinuation of ccHRT.	This supports the need for an individualized approach to therapy recommendations.
__label__noRel	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.
__label__noRel	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.	Climacteric symptoms remained significantly below baseline values after dosage reduction;
__label__noRel	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.	some symptoms recurred after discontinuation of ccHRT.
__label__noRel	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.
__label__noRel	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.	They deteriorated during follow-up in women not continuing ccHRT.
__label__Support	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.
__label__noRel	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.
__label__noRel	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.	This supports the need for an individualized approach to therapy recommendations.
__label__noRel	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.
__label__noRel	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.	Climacteric symptoms remained significantly below baseline values after dosage reduction;
__label__noRel	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.	some symptoms recurred after discontinuation of ccHRT.
__label__noRel	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.
__label__noRel	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.	They deteriorated during follow-up in women not continuing ccHRT.
__label__Support	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.
__label__noRel	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.
__label__noRel	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.	This supports the need for an individualized approach to therapy recommendations.
__label__noRel	They deteriorated during follow-up in women not continuing ccHRT.	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.
__label__noRel	They deteriorated during follow-up in women not continuing ccHRT.	Climacteric symptoms remained significantly below baseline values after dosage reduction;
__label__noRel	They deteriorated during follow-up in women not continuing ccHRT.	some symptoms recurred after discontinuation of ccHRT.
__label__noRel	They deteriorated during follow-up in women not continuing ccHRT.	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.
__label__noRel	They deteriorated during follow-up in women not continuing ccHRT.	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.
__label__noRel	They deteriorated during follow-up in women not continuing ccHRT.	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.
__label__noRel	They deteriorated during follow-up in women not continuing ccHRT.	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.
__label__noRel	They deteriorated during follow-up in women not continuing ccHRT.	This supports the need for an individualized approach to therapy recommendations.
__label__noRel	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.
__label__noRel	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.	Climacteric symptoms remained significantly below baseline values after dosage reduction;
__label__noRel	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.	some symptoms recurred after discontinuation of ccHRT.
__label__noRel	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.
__label__noRel	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.
__label__noRel	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.	They deteriorated during follow-up in women not continuing ccHRT.
__label__noRel	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.
__label__Support	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.	This supports the need for an individualized approach to therapy recommendations.
__label__noRel	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.
__label__noRel	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.	Climacteric symptoms remained significantly below baseline values after dosage reduction;
__label__noRel	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.	some symptoms recurred after discontinuation of ccHRT.
__label__noRel	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.
__label__noRel	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.
__label__noRel	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.	They deteriorated during follow-up in women not continuing ccHRT.
__label__noRel	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.
__label__noRel	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.	This supports the need for an individualized approach to therapy recommendations.
__label__noRel	This supports the need for an individualized approach to therapy recommendations.	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.
__label__noRel	This supports the need for an individualized approach to therapy recommendations.	Climacteric symptoms remained significantly below baseline values after dosage reduction;
__label__noRel	This supports the need for an individualized approach to therapy recommendations.	some symptoms recurred after discontinuation of ccHRT.
__label__noRel	This supports the need for an individualized approach to therapy recommendations.	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.
__label__noRel	This supports the need for an individualized approach to therapy recommendations.	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.
__label__noRel	This supports the need for an individualized approach to therapy recommendations.	They deteriorated during follow-up in women not continuing ccHRT.
__label__noRel	This supports the need for an individualized approach to therapy recommendations.	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.
__label__noRel	This supports the need for an individualized approach to therapy recommendations.	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.
__label__noRel	HRQOL and symptom relief were equivalent in the treatment arms.	No significant difference in survival among arms A, B, and C was found, with median survival 8.2, 7.0, and 6.8 months, respectively.
__label__Support	HRQOL and symptom relief were equivalent in the treatment arms.	Our data indicate that protracted palliative TRT renders no improvement in symptom relief, HRQOL, or survival when compared with short-term hypofractionated treatment in advanced NSCLC.
__label__noRel	No significant difference in survival among arms A, B, and C was found, with median survival 8.2, 7.0, and 6.8 months, respectively.	HRQOL and symptom relief were equivalent in the treatment arms.
__label__Support	No significant difference in survival among arms A, B, and C was found, with median survival 8.2, 7.0, and 6.8 months, respectively.	Our data indicate that protracted palliative TRT renders no improvement in symptom relief, HRQOL, or survival when compared with short-term hypofractionated treatment in advanced NSCLC.
__label__noRel	Our data indicate that protracted palliative TRT renders no improvement in symptom relief, HRQOL, or survival when compared with short-term hypofractionated treatment in advanced NSCLC.	HRQOL and symptom relief were equivalent in the treatment arms.
__label__noRel	Our data indicate that protracted palliative TRT renders no improvement in symptom relief, HRQOL, or survival when compared with short-term hypofractionated treatment in advanced NSCLC.	No significant difference in survival among arms A, B, and C was found, with median survival 8.2, 7.0, and 6.8 months, respectively.
__label__noRel	There were no significant survival differences between the 244 interferon-alfa-treated patients and 248 noninterferon-alfa patients (hazard ratio, 1.00; 95% CI, 0.81-1.24) or between the 247 interleukin-2 and 245 noninterleukin-2-treated patients (hazard ratio, 1.07; 95% CI, 0.87-1.33; log rank, 0.99 and 0.52, respectively).	Grade 3-4 toxicities were significantly more frequent in cytokine-treated patients than in medroxyprogesterone-treated patients.
__label__Support	There were no significant survival differences between the 244 interferon-alfa-treated patients and 248 noninterferon-alfa patients (hazard ratio, 1.00; 95% CI, 0.81-1.24) or between the 247 interleukin-2 and 245 noninterleukin-2-treated patients (hazard ratio, 1.07; 95% CI, 0.87-1.33; log rank, 0.99 and 0.52, respectively).	Subcutaneous interleukin-2 and/or interferon-alfa provide no survival benefit in metastatic renal cancers of intermediate prognosis, and they induce a significant risk of toxicity.
__label__noRel	There were no significant survival differences between the 244 interferon-alfa-treated patients and 248 noninterferon-alfa patients (hazard ratio, 1.00; 95% CI, 0.81-1.24) or between the 247 interleukin-2 and 245 noninterleukin-2-treated patients (hazard ratio, 1.07; 95% CI, 0.87-1.33; log rank, 0.99 and 0.52, respectively).	Newly available angiogenesis inhibitors should be preferred for these patients.
__label__noRel	Grade 3-4 toxicities were significantly more frequent in cytokine-treated patients than in medroxyprogesterone-treated patients.	There were no significant survival differences between the 244 interferon-alfa-treated patients and 248 noninterferon-alfa patients (hazard ratio, 1.00; 95% CI, 0.81-1.24) or between the 247 interleukin-2 and 245 noninterleukin-2-treated patients (hazard ratio, 1.07; 95% CI, 0.87-1.33; log rank, 0.99 and 0.52, respectively).
__label__Support	Grade 3-4 toxicities were significantly more frequent in cytokine-treated patients than in medroxyprogesterone-treated patients.	Subcutaneous interleukin-2 and/or interferon-alfa provide no survival benefit in metastatic renal cancers of intermediate prognosis, and they induce a significant risk of toxicity.
__label__noRel	Grade 3-4 toxicities were significantly more frequent in cytokine-treated patients than in medroxyprogesterone-treated patients.	Newly available angiogenesis inhibitors should be preferred for these patients.
__label__noRel	Subcutaneous interleukin-2 and/or interferon-alfa provide no survival benefit in metastatic renal cancers of intermediate prognosis, and they induce a significant risk of toxicity.	There were no significant survival differences between the 244 interferon-alfa-treated patients and 248 noninterferon-alfa patients (hazard ratio, 1.00; 95% CI, 0.81-1.24) or between the 247 interleukin-2 and 245 noninterleukin-2-treated patients (hazard ratio, 1.07; 95% CI, 0.87-1.33; log rank, 0.99 and 0.52, respectively).
__label__noRel	Subcutaneous interleukin-2 and/or interferon-alfa provide no survival benefit in metastatic renal cancers of intermediate prognosis, and they induce a significant risk of toxicity.	Grade 3-4 toxicities were significantly more frequent in cytokine-treated patients than in medroxyprogesterone-treated patients.
__label__Support	Subcutaneous interleukin-2 and/or interferon-alfa provide no survival benefit in metastatic renal cancers of intermediate prognosis, and they induce a significant risk of toxicity.	Newly available angiogenesis inhibitors should be preferred for these patients.
__label__noRel	Newly available angiogenesis inhibitors should be preferred for these patients.	There were no significant survival differences between the 244 interferon-alfa-treated patients and 248 noninterferon-alfa patients (hazard ratio, 1.00; 95% CI, 0.81-1.24) or between the 247 interleukin-2 and 245 noninterleukin-2-treated patients (hazard ratio, 1.07; 95% CI, 0.87-1.33; log rank, 0.99 and 0.52, respectively).
__label__noRel	Newly available angiogenesis inhibitors should be preferred for these patients.	Grade 3-4 toxicities were significantly more frequent in cytokine-treated patients than in medroxyprogesterone-treated patients.
__label__noRel	Newly available angiogenesis inhibitors should be preferred for these patients.	Subcutaneous interleukin-2 and/or interferon-alfa provide no survival benefit in metastatic renal cancers of intermediate prognosis, and they induce a significant risk of toxicity.
__label__noRel	Patients in the VBT group reported better social functioning (P < .002) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms (P < .001).	Patients who received EBRT reported significantly higher levels of diarrhea and bowel symptoms.
__label__Support	Patients in the VBT group reported better social functioning (P < .002) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms (P < .001).	Vaginal brachytherapy provides a better QOL, and should be the preferred treatment from a QOL perspective.
__label__noRel	Patients in the VBT group reported better social functioning (P < .002) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms (P < .001).	Sexual functioning and symptoms did not differ between the treatment groups.
__label__noRel	Patients who received EBRT reported significantly higher levels of diarrhea and bowel symptoms.	Patients in the VBT group reported better social functioning (P < .002) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms (P < .001).
__label__Support	Patients who received EBRT reported significantly higher levels of diarrhea and bowel symptoms.	Vaginal brachytherapy provides a better QOL, and should be the preferred treatment from a QOL perspective.
__label__noRel	Patients who received EBRT reported significantly higher levels of diarrhea and bowel symptoms.	Sexual functioning and symptoms did not differ between the treatment groups.
__label__noRel	Vaginal brachytherapy provides a better QOL, and should be the preferred treatment from a QOL perspective.	Patients in the VBT group reported better social functioning (P < .002) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms (P < .001).
__label__noRel	Vaginal brachytherapy provides a better QOL, and should be the preferred treatment from a QOL perspective.	Patients who received EBRT reported significantly higher levels of diarrhea and bowel symptoms.
__label__noRel	Vaginal brachytherapy provides a better QOL, and should be the preferred treatment from a QOL perspective.	Sexual functioning and symptoms did not differ between the treatment groups.
__label__noRel	Sexual functioning and symptoms did not differ between the treatment groups.	Patients in the VBT group reported better social functioning (P < .002) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms (P < .001).
__label__noRel	Sexual functioning and symptoms did not differ between the treatment groups.	Patients who received EBRT reported significantly higher levels of diarrhea and bowel symptoms.
__label__Support	Sexual functioning and symptoms did not differ between the treatment groups.	Vaginal brachytherapy provides a better QOL, and should be the preferred treatment from a QOL perspective.
__label__noRel	Baseline characteristics were comparable for both groups,	except that more patients with ADPKD were assigned to the placebo group (P = .03).
__label__noRel	Baseline characteristics were comparable for both groups,	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.
__label__noRel	Baseline characteristics were comparable for both groups,	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).
__label__noRel	Baseline characteristics were comparable for both groups,	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).
__label__noRel	Baseline characteristics were comparable for both groups,	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.
__label__Attack	except that more patients with ADPKD were assigned to the placebo group (P = .03).	Baseline characteristics were comparable for both groups,
__label__noRel	except that more patients with ADPKD were assigned to the placebo group (P = .03).	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.
__label__noRel	except that more patients with ADPKD were assigned to the placebo group (P = .03).	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).
__label__noRel	except that more patients with ADPKD were assigned to the placebo group (P = .03).	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).
__label__noRel	except that more patients with ADPKD were assigned to the placebo group (P = .03).	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.
__label__noRel	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.	Baseline characteristics were comparable for both groups,
__label__noRel	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.	except that more patients with ADPKD were assigned to the placebo group (P = .03).
__label__noRel	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).
__label__noRel	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).
__label__Support	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.
__label__noRel	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).	Baseline characteristics were comparable for both groups,
__label__noRel	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).	except that more patients with ADPKD were assigned to the placebo group (P = .03).
__label__noRel	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.
__label__noRel	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).
__label__Support	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.
__label__noRel	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).	Baseline characteristics were comparable for both groups,
__label__noRel	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).	except that more patients with ADPKD were assigned to the placebo group (P = .03).
__label__noRel	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.
__label__noRel	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).
__label__Support	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.
__label__noRel	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.	Baseline characteristics were comparable for both groups,
__label__noRel	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.	except that more patients with ADPKD were assigned to the placebo group (P = .03).
__label__noRel	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.
__label__noRel	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).
__label__noRel	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).
__label__noRel	A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer.	At 6 weeks, both groups showed improvement in several HQL domains,
__label__noRel	A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer.	only physical functioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group.
__label__noRel	A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer.	After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P =.009), four functioning domains, and nine symptoms (.001 < P <. 01),
__label__noRel	A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer.	the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P <.05).
__label__noRel	A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer.	The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P <.003).
__label__noRel	A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer.	Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone.
__label__noRel	At 6 weeks, both groups showed improvement in several HQL domains,	A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer.
__label__noRel	At 6 weeks, both groups showed improvement in several HQL domains,	only physical functioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group.
__label__noRel	At 6 weeks, both groups showed improvement in several HQL domains,	After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P =.009), four functioning domains, and nine symptoms (.001 < P <. 01),
__label__noRel	At 6 weeks, both groups showed improvement in several HQL domains,	the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P <.05).
__label__noRel	At 6 weeks, both groups showed improvement in several HQL domains,	The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P <.003).
__label__Support	At 6 weeks, both groups showed improvement in several HQL domains,	Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone.
__label__noRel	only physical functioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group.	A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer.
__label__noRel	only physical functioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group.	At 6 weeks, both groups showed improvement in several HQL domains,
__label__noRel	only physical functioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group.	After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P =.009), four functioning domains, and nine symptoms (.001 < P <. 01),
__label__noRel	only physical functioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group.	the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P <.05).
__label__noRel	only physical functioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group.	The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P <.003).
__label__Support	only physical functioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group.	Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone.
__label__noRel	After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P =.009), four functioning domains, and nine symptoms (.001 < P <. 01),	A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer.
__label__noRel	After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P =.009), four functioning domains, and nine symptoms (.001 < P <. 01),	At 6 weeks, both groups showed improvement in several HQL domains,
__label__noRel	After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P =.009), four functioning domains, and nine symptoms (.001 < P <. 01),	only physical functioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group.
__label__noRel	After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P =.009), four functioning domains, and nine symptoms (.001 < P <. 01),	the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P <.05).
__label__noRel	After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P =.009), four functioning domains, and nine symptoms (.001 < P <. 01),	The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P <.003).
__label__Support	After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P =.009), four functioning domains, and nine symptoms (.001 < P <. 01),	Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone.
__label__noRel	the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P <.05).	A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer.
__label__noRel	the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P <.05).	At 6 weeks, both groups showed improvement in several HQL domains,
__label__noRel	the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P <.05).	only physical functioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group.
__label__noRel	the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P <.05).	After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P =.009), four functioning domains, and nine symptoms (.001 < P <. 01),
__label__noRel	the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P <.05).	The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P <.003).
__label__Support	the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P <.05).	Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone.
__label__Support	The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P <.003).	A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer.
__label__noRel	The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P <.003).	At 6 weeks, both groups showed improvement in several HQL domains,
__label__noRel	The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P <.003).	only physical functioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group.
__label__noRel	The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P <.003).	After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P =.009), four functioning domains, and nine symptoms (.001 < P <. 01),
__label__noRel	The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P <.003).	the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P <.05).
__label__noRel	The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P <.003).	Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone.
__label__Support	Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone.	A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer.
__label__noRel	Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone.	At 6 weeks, both groups showed improvement in several HQL domains,
__label__noRel	Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone.	only physical functioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group.
__label__noRel	Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone.	After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P =.009), four functioning domains, and nine symptoms (.001 < P <. 01),
__label__noRel	Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone.	the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P <.05).
__label__noRel	Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone.	The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P <.003).
__label__noRel	In endocrine therapy trials in advanced breast cancer, patients with response (complete response/partial response [CR/PR]) and patients with stable disease for at least 6 months (SD(6m)) have shown similar survival and therefore are often defined as a population with clinical benefit (patients with CR/PR or SD(6m)).	responders indicated better physical well-being (P =. 004) and mood (P =.02) at month 3.
__label__noRel	In endocrine therapy trials in advanced breast cancer, patients with response (complete response/partial response [CR/PR]) and patients with stable disease for at least 6 months (SD(6m)) have shown similar survival and therefore are often defined as a population with clinical benefit (patients with CR/PR or SD(6m)).	Compared only with patients with SD(6m), responders showed no significant difference in baseline QL and time to treatment failure (328.5 v 340 days).
__label__noRel	In endocrine therapy trials in advanced breast cancer, patients with response (complete response/partial response [CR/PR]) and patients with stable disease for at least 6 months (SD(6m)) have shown similar survival and therefore are often defined as a population with clinical benefit (patients with CR/PR or SD(6m)).	While under treatment, responders reported significantly better physical well-being (months 3 to 11), mood (months 5 to 11), coping (months 5 to 9), and appetite (months 7 to 11) and less dizziness (month 9) than patients with SD(6m).
__label__noRel	In endocrine therapy trials in advanced breast cancer, patients with response (complete response/partial response [CR/PR]) and patients with stable disease for at least 6 months (SD(6m)) have shown similar survival and therefore are often defined as a population with clinical benefit (patients with CR/PR or SD(6m)).	The changes between baseline and months 5 and 7, respectively, indicated improvement in responders but heterogeneous patterns in patients with SD(6m).
__label__noRel	In endocrine therapy trials in advanced breast cancer, patients with response (complete response/partial response [CR/PR]) and patients with stable disease for at least 6 months (SD(6m)) have shown similar survival and therefore are often defined as a population with clinical benefit (patients with CR/PR or SD(6m)).	Although the CR/PR and SD(6m) groups had similar times to treatment failure,
__label__noRel	In endocrine therapy trials in advanced breast cancer, patients with response (complete response/partial response [CR/PR]) and patients with stable disease for at least 6 months (SD(6m)) have shown similar survival and therefore are often defined as a population with clinical benefit (patients with CR/PR or SD(6m)).	patients with CR/PR reported better QL, suggesting more beneficial response to second-line endocrine treatment.
__label__noRel	responders indicated better physical well-being (P =. 004) and mood (P =.02) at month 3.	In endocrine therapy trials in advanced breast cancer, patients with response (complete response/partial response [CR/PR]) and patients with stable disease for at least 6 months (SD(6m)) have shown similar survival and therefore are often defined as a population with clinical benefit (patients with CR/PR or SD(6m)).
__label__noRel	responders indicated better physical well-being (P =. 004) and mood (P =.02) at month 3.	Compared only with patients with SD(6m), responders showed no significant difference in baseline QL and time to treatment failure (328.5 v 340 days).
__label__noRel	responders indicated better physical well-being (P =. 004) and mood (P =.02) at month 3.	While under treatment, responders reported significantly better physical well-being (months 3 to 11), mood (months 5 to 11), coping (months 5 to 9), and appetite (months 7 to 11) and less dizziness (month 9) than patients with SD(6m).
__label__noRel	responders indicated better physical well-being (P =. 004) and mood (P =.02) at month 3.	The changes between baseline and months 5 and 7, respectively, indicated improvement in responders but heterogeneous patterns in patients with SD(6m).
__label__noRel	responders indicated better physical well-being (P =. 004) and mood (P =.02) at month 3.	Although the CR/PR and SD(6m) groups had similar times to treatment failure,
__label__Support	responders indicated better physical well-being (P =. 004) and mood (P =.02) at month 3.	patients with CR/PR reported better QL, suggesting more beneficial response to second-line endocrine treatment.
__label__noRel	Compared only with patients with SD(6m), responders showed no significant difference in baseline QL and time to treatment failure (328.5 v 340 days).	In endocrine therapy trials in advanced breast cancer, patients with response (complete response/partial response [CR/PR]) and patients with stable disease for at least 6 months (SD(6m)) have shown similar survival and therefore are often defined as a population with clinical benefit (patients with CR/PR or SD(6m)).
__label__noRel	Compared only with patients with SD(6m), responders showed no significant difference in baseline QL and time to treatment failure (328.5 v 340 days).	responders indicated better physical well-being (P =. 004) and mood (P =.02) at month 3.
__label__noRel	Compared only with patients with SD(6m), responders showed no significant difference in baseline QL and time to treatment failure (328.5 v 340 days).	While under treatment, responders reported significantly better physical well-being (months 3 to 11), mood (months 5 to 11), coping (months 5 to 9), and appetite (months 7 to 11) and less dizziness (month 9) than patients with SD(6m).
__label__noRel	Compared only with patients with SD(6m), responders showed no significant difference in baseline QL and time to treatment failure (328.5 v 340 days).	The changes between baseline and months 5 and 7, respectively, indicated improvement in responders but heterogeneous patterns in patients with SD(6m).
__label__noRel	Compared only with patients with SD(6m), responders showed no significant difference in baseline QL and time to treatment failure (328.5 v 340 days).	Although the CR/PR and SD(6m) groups had similar times to treatment failure,
__label__Support	Compared only with patients with SD(6m), responders showed no significant difference in baseline QL and time to treatment failure (328.5 v 340 days).	patients with CR/PR reported better QL, suggesting more beneficial response to second-line endocrine treatment.
__label__noRel	While under treatment, responders reported significantly better physical well-being (months 3 to 11), mood (months 5 to 11), coping (months 5 to 9), and appetite (months 7 to 11) and less dizziness (month 9) than patients with SD(6m).	In endocrine therapy trials in advanced breast cancer, patients with response (complete response/partial response [CR/PR]) and patients with stable disease for at least 6 months (SD(6m)) have shown similar survival and therefore are often defined as a population with clinical benefit (patients with CR/PR or SD(6m)).
__label__noRel	While under treatment, responders reported significantly better physical well-being (months 3 to 11), mood (months 5 to 11), coping (months 5 to 9), and appetite (months 7 to 11) and less dizziness (month 9) than patients with SD(6m).	responders indicated better physical well-being (P =. 004) and mood (P =.02) at month 3.
__label__noRel	While under treatment, responders reported significantly better physical well-being (months 3 to 11), mood (months 5 to 11), coping (months 5 to 9), and appetite (months 7 to 11) and less dizziness (month 9) than patients with SD(6m).	Compared only with patients with SD(6m), responders showed no significant difference in baseline QL and time to treatment failure (328.5 v 340 days).
__label__noRel	While under treatment, responders reported significantly better physical well-being (months 3 to 11), mood (months 5 to 11), coping (months 5 to 9), and appetite (months 7 to 11) and less dizziness (month 9) than patients with SD(6m).	The changes between baseline and months 5 and 7, respectively, indicated improvement in responders but heterogeneous patterns in patients with SD(6m).
__label__noRel	While under treatment, responders reported significantly better physical well-being (months 3 to 11), mood (months 5 to 11), coping (months 5 to 9), and appetite (months 7 to 11) and less dizziness (month 9) than patients with SD(6m).	Although the CR/PR and SD(6m) groups had similar times to treatment failure,
__label__Support	While under treatment, responders reported significantly better physical well-being (months 3 to 11), mood (months 5 to 11), coping (months 5 to 9), and appetite (months 7 to 11) and less dizziness (month 9) than patients with SD(6m).	patients with CR/PR reported better QL, suggesting more beneficial response to second-line endocrine treatment.
__label__noRel	The changes between baseline and months 5 and 7, respectively, indicated improvement in responders but heterogeneous patterns in patients with SD(6m).	In endocrine therapy trials in advanced breast cancer, patients with response (complete response/partial response [CR/PR]) and patients with stable disease for at least 6 months (SD(6m)) have shown similar survival and therefore are often defined as a population with clinical benefit (patients with CR/PR or SD(6m)).
__label__noRel	The changes between baseline and months 5 and 7, respectively, indicated improvement in responders but heterogeneous patterns in patients with SD(6m).	responders indicated better physical well-being (P =. 004) and mood (P =.02) at month 3.
__label__noRel	The changes between baseline and months 5 and 7, respectively, indicated improvement in responders but heterogeneous patterns in patients with SD(6m).	Compared only with patients with SD(6m), responders showed no significant difference in baseline QL and time to treatment failure (328.5 v 340 days).
__label__noRel	The changes between baseline and months 5 and 7, respectively, indicated improvement in responders but heterogeneous patterns in patients with SD(6m).	While under treatment, responders reported significantly better physical well-being (months 3 to 11), mood (months 5 to 11), coping (months 5 to 9), and appetite (months 7 to 11) and less dizziness (month 9) than patients with SD(6m).
__label__noRel	The changes between baseline and months 5 and 7, respectively, indicated improvement in responders but heterogeneous patterns in patients with SD(6m).	Although the CR/PR and SD(6m) groups had similar times to treatment failure,
__label__Attack	The changes between baseline and months 5 and 7, respectively, indicated improvement in responders but heterogeneous patterns in patients with SD(6m).	patients with CR/PR reported better QL, suggesting more beneficial response to second-line endocrine treatment.
__label__noRel	Although the CR/PR and SD(6m) groups had similar times to treatment failure,	In endocrine therapy trials in advanced breast cancer, patients with response (complete response/partial response [CR/PR]) and patients with stable disease for at least 6 months (SD(6m)) have shown similar survival and therefore are often defined as a population with clinical benefit (patients with CR/PR or SD(6m)).
__label__noRel	Although the CR/PR and SD(6m) groups had similar times to treatment failure,	responders indicated better physical well-being (P =. 004) and mood (P =.02) at month 3.
__label__noRel	Although the CR/PR and SD(6m) groups had similar times to treatment failure,	Compared only with patients with SD(6m), responders showed no significant difference in baseline QL and time to treatment failure (328.5 v 340 days).
__label__noRel	Although the CR/PR and SD(6m) groups had similar times to treatment failure,	While under treatment, responders reported significantly better physical well-being (months 3 to 11), mood (months 5 to 11), coping (months 5 to 9), and appetite (months 7 to 11) and less dizziness (month 9) than patients with SD(6m).
__label__noRel	Although the CR/PR and SD(6m) groups had similar times to treatment failure,	The changes between baseline and months 5 and 7, respectively, indicated improvement in responders but heterogeneous patterns in patients with SD(6m).
__label__Attack	Although the CR/PR and SD(6m) groups had similar times to treatment failure,	patients with CR/PR reported better QL, suggesting more beneficial response to second-line endocrine treatment.
__label__noRel	patients with CR/PR reported better QL, suggesting more beneficial response to second-line endocrine treatment.	In endocrine therapy trials in advanced breast cancer, patients with response (complete response/partial response [CR/PR]) and patients with stable disease for at least 6 months (SD(6m)) have shown similar survival and therefore are often defined as a population with clinical benefit (patients with CR/PR or SD(6m)).
__label__noRel	patients with CR/PR reported better QL, suggesting more beneficial response to second-line endocrine treatment.	responders indicated better physical well-being (P =. 004) and mood (P =.02) at month 3.
__label__noRel	patients with CR/PR reported better QL, suggesting more beneficial response to second-line endocrine treatment.	Compared only with patients with SD(6m), responders showed no significant difference in baseline QL and time to treatment failure (328.5 v 340 days).
__label__noRel	patients with CR/PR reported better QL, suggesting more beneficial response to second-line endocrine treatment.	While under treatment, responders reported significantly better physical well-being (months 3 to 11), mood (months 5 to 11), coping (months 5 to 9), and appetite (months 7 to 11) and less dizziness (month 9) than patients with SD(6m).
__label__noRel	patients with CR/PR reported better QL, suggesting more beneficial response to second-line endocrine treatment.	The changes between baseline and months 5 and 7, respectively, indicated improvement in responders but heterogeneous patterns in patients with SD(6m).
__label__noRel	patients with CR/PR reported better QL, suggesting more beneficial response to second-line endocrine treatment.	Although the CR/PR and SD(6m) groups had similar times to treatment failure,
__label__noRel	Erlotinib was superior to placebo for survival, progression-free survival, and tumor response rate.	Exploratory analyses indicate that epidermal growth factor receptor status may be an important predictor of the erlotinib survival effect.
__label__noRel	Erlotinib was superior to placebo for survival, progression-free survival, and tumor response rate.	Rash (75% versus 17%) and diarrhea (54% versus 18%) in the erlotnib and placebo group respectively were the most common adverse events.
__label__noRel	Erlotinib was superior to placebo for survival, progression-free survival, and tumor response rate.	Severe rash occurred in 9% and severe diarrhea in 6% of erlotinib-treated patients and each resulted in study discontinuation in 1% of patients.
__label__noRel	Erlotinib was superior to placebo for survival, progression-free survival, and tumor response rate.	Dose reductions were required for 10% of patients with rash and 4% of patients with diarrhea.
__label__noRel	Exploratory analyses indicate that epidermal growth factor receptor status may be an important predictor of the erlotinib survival effect.	Erlotinib was superior to placebo for survival, progression-free survival, and tumor response rate.
__label__noRel	Exploratory analyses indicate that epidermal growth factor receptor status may be an important predictor of the erlotinib survival effect.	Rash (75% versus 17%) and diarrhea (54% versus 18%) in the erlotnib and placebo group respectively were the most common adverse events.
__label__noRel	Exploratory analyses indicate that epidermal growth factor receptor status may be an important predictor of the erlotinib survival effect.	Severe rash occurred in 9% and severe diarrhea in 6% of erlotinib-treated patients and each resulted in study discontinuation in 1% of patients.
__label__noRel	Exploratory analyses indicate that epidermal growth factor receptor status may be an important predictor of the erlotinib survival effect.	Dose reductions were required for 10% of patients with rash and 4% of patients with diarrhea.
__label__noRel	Rash (75% versus 17%) and diarrhea (54% versus 18%) in the erlotnib and placebo group respectively were the most common adverse events.	Erlotinib was superior to placebo for survival, progression-free survival, and tumor response rate.
__label__noRel	Rash (75% versus 17%) and diarrhea (54% versus 18%) in the erlotnib and placebo group respectively were the most common adverse events.	Exploratory analyses indicate that epidermal growth factor receptor status may be an important predictor of the erlotinib survival effect.
__label__noRel	Rash (75% versus 17%) and diarrhea (54% versus 18%) in the erlotnib and placebo group respectively were the most common adverse events.	Severe rash occurred in 9% and severe diarrhea in 6% of erlotinib-treated patients and each resulted in study discontinuation in 1% of patients.
__label__noRel	Rash (75% versus 17%) and diarrhea (54% versus 18%) in the erlotnib and placebo group respectively were the most common adverse events.	Dose reductions were required for 10% of patients with rash and 4% of patients with diarrhea.
__label__noRel	Severe rash occurred in 9% and severe diarrhea in 6% of erlotinib-treated patients and each resulted in study discontinuation in 1% of patients.	Erlotinib was superior to placebo for survival, progression-free survival, and tumor response rate.
__label__noRel	Severe rash occurred in 9% and severe diarrhea in 6% of erlotinib-treated patients and each resulted in study discontinuation in 1% of patients.	Exploratory analyses indicate that epidermal growth factor receptor status may be an important predictor of the erlotinib survival effect.
__label__noRel	Severe rash occurred in 9% and severe diarrhea in 6% of erlotinib-treated patients and each resulted in study discontinuation in 1% of patients.	Rash (75% versus 17%) and diarrhea (54% versus 18%) in the erlotnib and placebo group respectively were the most common adverse events.
__label__noRel	Severe rash occurred in 9% and severe diarrhea in 6% of erlotinib-treated patients and each resulted in study discontinuation in 1% of patients.	Dose reductions were required for 10% of patients with rash and 4% of patients with diarrhea.
__label__noRel	Dose reductions were required for 10% of patients with rash and 4% of patients with diarrhea.	Erlotinib was superior to placebo for survival, progression-free survival, and tumor response rate.
__label__noRel	Dose reductions were required for 10% of patients with rash and 4% of patients with diarrhea.	Exploratory analyses indicate that epidermal growth factor receptor status may be an important predictor of the erlotinib survival effect.
__label__noRel	Dose reductions were required for 10% of patients with rash and 4% of patients with diarrhea.	Rash (75% versus 17%) and diarrhea (54% versus 18%) in the erlotnib and placebo group respectively were the most common adverse events.
__label__noRel	Dose reductions were required for 10% of patients with rash and 4% of patients with diarrhea.	Severe rash occurred in 9% and severe diarrhea in 6% of erlotinib-treated patients and each resulted in study discontinuation in 1% of patients.
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ,	but long-term relief of obstructive symptoms was better after GJJ.
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ,	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ,	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ,	We found no difference in follow-up costs.
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ,	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ,	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.
__label__Support	Food intake improved more rapidly after stent placement than after GJJ,	Medical effects were better after GJJ
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ,	although GJJ had higher total costs.
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ,	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ,	Since the cost difference between the two treatments was only small,
__label__Attack	but long-term relief of obstructive symptoms was better after GJJ.	Food intake improved more rapidly after stent placement than after GJJ,
__label__noRel	but long-term relief of obstructive symptoms was better after GJJ.	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.
__label__noRel	but long-term relief of obstructive symptoms was better after GJJ.	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).
__label__noRel	but long-term relief of obstructive symptoms was better after GJJ.	We found no difference in follow-up costs.
__label__noRel	but long-term relief of obstructive symptoms was better after GJJ.	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).
__label__noRel	but long-term relief of obstructive symptoms was better after GJJ.	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.
__label__noRel	but long-term relief of obstructive symptoms was better after GJJ.	Medical effects were better after GJJ
__label__noRel	but long-term relief of obstructive symptoms was better after GJJ.	although GJJ had higher total costs.
__label__noRel	but long-term relief of obstructive symptoms was better after GJJ.	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.
__label__noRel	but long-term relief of obstructive symptoms was better after GJJ.	Since the cost difference between the two treatments was only small,
__label__noRel	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.	Food intake improved more rapidly after stent placement than after GJJ,
__label__noRel	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.	but long-term relief of obstructive symptoms was better after GJJ.
__label__noRel	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).
__label__noRel	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.	We found no difference in follow-up costs.
__label__noRel	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).
__label__noRel	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.
__label__Support	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.	Medical effects were better after GJJ
__label__noRel	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.	although GJJ had higher total costs.
__label__noRel	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.
__label__noRel	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.	Since the cost difference between the two treatments was only small,
__label__noRel	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).	Food intake improved more rapidly after stent placement than after GJJ,
__label__noRel	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).	but long-term relief of obstructive symptoms was better after GJJ.
__label__noRel	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.
__label__noRel	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).	We found no difference in follow-up costs.
__label__noRel	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).
__label__noRel	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.
__label__noRel	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).	Medical effects were better after GJJ
__label__Support	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).	although GJJ had higher total costs.
__label__noRel	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.
__label__noRel	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).	Since the cost difference between the two treatments was only small,
__label__noRel	We found no difference in follow-up costs.	Food intake improved more rapidly after stent placement than after GJJ,
__label__noRel	We found no difference in follow-up costs.	but long-term relief of obstructive symptoms was better after GJJ.
__label__noRel	We found no difference in follow-up costs.	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.
__label__noRel	We found no difference in follow-up costs.	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).
__label__noRel	We found no difference in follow-up costs.	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).
__label__noRel	We found no difference in follow-up costs.	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.
__label__noRel	We found no difference in follow-up costs.	Medical effects were better after GJJ
__label__Support	We found no difference in follow-up costs.	although GJJ had higher total costs.
__label__noRel	We found no difference in follow-up costs.	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.
__label__noRel	We found no difference in follow-up costs.	Since the cost difference between the two treatments was only small,
__label__noRel	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).	Food intake improved more rapidly after stent placement than after GJJ,
__label__noRel	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).	but long-term relief of obstructive symptoms was better after GJJ.
__label__noRel	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.
__label__noRel	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).
__label__noRel	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).	We found no difference in follow-up costs.
__label__noRel	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.
__label__noRel	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).	Medical effects were better after GJJ
__label__Support	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).	although GJJ had higher total costs.
__label__noRel	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.
__label__noRel	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).	Since the cost difference between the two treatments was only small,
__label__noRel	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.	Food intake improved more rapidly after stent placement than after GJJ,
__label__noRel	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.	but long-term relief of obstructive symptoms was better after GJJ.
__label__noRel	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.
__label__noRel	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).
__label__noRel	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.	We found no difference in follow-up costs.
__label__noRel	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).
__label__noRel	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.	Medical effects were better after GJJ
__label__Support	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.	although GJJ had higher total costs.
__label__noRel	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.
__label__noRel	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.	Since the cost difference between the two treatments was only small,
__label__noRel	Medical effects were better after GJJ	Food intake improved more rapidly after stent placement than after GJJ,
__label__noRel	Medical effects were better after GJJ	but long-term relief of obstructive symptoms was better after GJJ.
__label__noRel	Medical effects were better after GJJ	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.
__label__noRel	Medical effects were better after GJJ	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).
__label__noRel	Medical effects were better after GJJ	We found no difference in follow-up costs.
__label__noRel	Medical effects were better after GJJ	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).
__label__noRel	Medical effects were better after GJJ	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.
__label__noRel	Medical effects were better after GJJ	although GJJ had higher total costs.
__label__noRel	Medical effects were better after GJJ	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.
__label__noRel	Medical effects were better after GJJ	Since the cost difference between the two treatments was only small,
__label__noRel	although GJJ had higher total costs.	Food intake improved more rapidly after stent placement than after GJJ,
__label__noRel	although GJJ had higher total costs.	but long-term relief of obstructive symptoms was better after GJJ.
__label__noRel	although GJJ had higher total costs.	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.
__label__noRel	although GJJ had higher total costs.	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).
__label__noRel	although GJJ had higher total costs.	We found no difference in follow-up costs.
__label__noRel	although GJJ had higher total costs.	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).
__label__noRel	although GJJ had higher total costs.	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.
__label__noRel	although GJJ had higher total costs.	Medical effects were better after GJJ
__label__noRel	although GJJ had higher total costs.	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.
__label__noRel	although GJJ had higher total costs.	Since the cost difference between the two treatments was only small,
__label__noRel	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.	Food intake improved more rapidly after stent placement than after GJJ,
__label__noRel	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.	but long-term relief of obstructive symptoms was better after GJJ.
__label__noRel	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.
__label__noRel	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).
__label__noRel	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.	We found no difference in follow-up costs.
__label__noRel	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).
__label__noRel	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.
__label__noRel	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.	Medical effects were better after GJJ
__label__noRel	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.	although GJJ had higher total costs.
__label__noRel	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.	Since the cost difference between the two treatments was only small,
__label__noRel	Since the cost difference between the two treatments was only small,	Food intake improved more rapidly after stent placement than after GJJ,
__label__noRel	Since the cost difference between the two treatments was only small,	but long-term relief of obstructive symptoms was better after GJJ.
__label__noRel	Since the cost difference between the two treatments was only small,	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.
__label__noRel	Since the cost difference between the two treatments was only small,	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).
__label__noRel	Since the cost difference between the two treatments was only small,	We found no difference in follow-up costs.
__label__noRel	Since the cost difference between the two treatments was only small,	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).
__label__noRel	Since the cost difference between the two treatments was only small,	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.
__label__noRel	Since the cost difference between the two treatments was only small,	Medical effects were better after GJJ
__label__noRel	Since the cost difference between the two treatments was only small,	although GJJ had higher total costs.
__label__Support	Since the cost difference between the two treatments was only small,	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.
__label__noRel	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).
__label__noRel	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).
__label__noRel	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).
__label__noRel	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).	There was no significant difference in grade III/IV adverse events between the two groups.
__label__noRel	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).	All procedures were well tolerated by the patients.
__label__Support	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.
__label__noRel	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.
__label__noRel	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).
__label__noRel	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.
__label__noRel	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).
__label__noRel	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).
__label__noRel	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).
__label__noRel	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).	There was no significant difference in grade III/IV adverse events between the two groups.
__label__noRel	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).	All procedures were well tolerated by the patients.
__label__noRel	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.
__label__noRel	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.
__label__noRel	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).
__label__noRel	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.
__label__noRel	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).
__label__noRel	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).
__label__noRel	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).
__label__noRel	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).	There was no significant difference in grade III/IV adverse events between the two groups.
__label__noRel	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).	All procedures were well tolerated by the patients.
__label__noRel	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.
__label__noRel	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.
__label__noRel	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).
__label__noRel	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.
__label__noRel	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).
__label__noRel	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).
__label__noRel	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).
__label__noRel	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).	There was no significant difference in grade III/IV adverse events between the two groups.
__label__noRel	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).	All procedures were well tolerated by the patients.
__label__Support	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.
__label__noRel	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.
__label__noRel	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).
__label__noRel	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.
__label__noRel	There was no significant difference in grade III/IV adverse events between the two groups.	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).
__label__noRel	There was no significant difference in grade III/IV adverse events between the two groups.	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).
__label__noRel	There was no significant difference in grade III/IV adverse events between the two groups.	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).
__label__noRel	There was no significant difference in grade III/IV adverse events between the two groups.	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).
__label__noRel	There was no significant difference in grade III/IV adverse events between the two groups.	All procedures were well tolerated by the patients.
__label__Support	There was no significant difference in grade III/IV adverse events between the two groups.	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.
__label__noRel	There was no significant difference in grade III/IV adverse events between the two groups.	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.
__label__noRel	There was no significant difference in grade III/IV adverse events between the two groups.	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).
__label__noRel	There was no significant difference in grade III/IV adverse events between the two groups.	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.
__label__noRel	All procedures were well tolerated by the patients.	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).
__label__noRel	All procedures were well tolerated by the patients.	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).
__label__noRel	All procedures were well tolerated by the patients.	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).
__label__noRel	All procedures were well tolerated by the patients.	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).
__label__noRel	All procedures were well tolerated by the patients.	There was no significant difference in grade III/IV adverse events between the two groups.
__label__Support	All procedures were well tolerated by the patients.	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.
__label__noRel	All procedures were well tolerated by the patients.	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.
__label__noRel	All procedures were well tolerated by the patients.	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).
__label__noRel	All procedures were well tolerated by the patients.	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.
__label__noRel	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).
__label__noRel	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).
__label__noRel	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).
__label__noRel	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).
__label__noRel	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.	There was no significant difference in grade III/IV adverse events between the two groups.
__label__noRel	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.	All procedures were well tolerated by the patients.
__label__Support	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.
__label__noRel	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).
__label__noRel	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.
__label__noRel	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).
__label__noRel	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).
__label__noRel	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).
__label__noRel	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).
__label__noRel	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.	There was no significant difference in grade III/IV adverse events between the two groups.
__label__noRel	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.	All procedures were well tolerated by the patients.
__label__noRel	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.
__label__noRel	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).
__label__noRel	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.
__label__noRel	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).
__label__noRel	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).
__label__noRel	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).
__label__noRel	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).
__label__noRel	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).	There was no significant difference in grade III/IV adverse events between the two groups.
__label__noRel	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).	All procedures were well tolerated by the patients.
__label__noRel	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.
__label__noRel	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.
__label__noRel	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.
__label__noRel	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).
__label__noRel	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).
__label__noRel	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).
__label__noRel	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).
__label__noRel	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.	There was no significant difference in grade III/IV adverse events between the two groups.
__label__noRel	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.	All procedures were well tolerated by the patients.
__label__noRel	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.
__label__noRel	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.
__label__noRel	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).
__label__noRel	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.	Trends observed for the treatment groups were similar.
__label__noRel	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.
__label__noRel	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.
__label__noRel	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.	Although improvements in the UC group occurred by 12-months post-surgery,
__label__noRel	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.	the change did not meet the clinically relevant threshold.
__label__noRel	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.	There were no differences in other treatment-related side effects between groups.
__label__Support	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.
__label__noRel	Trends observed for the treatment groups were similar.	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.
__label__noRel	Trends observed for the treatment groups were similar.	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.
__label__noRel	Trends observed for the treatment groups were similar.	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.
__label__noRel	Trends observed for the treatment groups were similar.	Although improvements in the UC group occurred by 12-months post-surgery,
__label__noRel	Trends observed for the treatment groups were similar.	the change did not meet the clinically relevant threshold.
__label__noRel	Trends observed for the treatment groups were similar.	There were no differences in other treatment-related side effects between groups.
__label__noRel	Trends observed for the treatment groups were similar.	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.
__label__noRel	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.
__label__noRel	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.	Trends observed for the treatment groups were similar.
__label__noRel	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.
__label__noRel	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.	Although improvements in the UC group occurred by 12-months post-surgery,
__label__noRel	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.	the change did not meet the clinically relevant threshold.
__label__noRel	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.	There were no differences in other treatment-related side effects between groups.
__label__Support	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.
__label__noRel	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.
__label__noRel	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.	Trends observed for the treatment groups were similar.
__label__noRel	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.
__label__noRel	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.	Although improvements in the UC group occurred by 12-months post-surgery,
__label__noRel	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.	the change did not meet the clinically relevant threshold.
__label__noRel	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.	There were no differences in other treatment-related side effects between groups.
__label__noRel	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.
__label__noRel	Although improvements in the UC group occurred by 12-months post-surgery,	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.
__label__noRel	Although improvements in the UC group occurred by 12-months post-surgery,	Trends observed for the treatment groups were similar.
__label__noRel	Although improvements in the UC group occurred by 12-months post-surgery,	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.
__label__noRel	Although improvements in the UC group occurred by 12-months post-surgery,	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.
__label__noRel	Although improvements in the UC group occurred by 12-months post-surgery,	the change did not meet the clinically relevant threshold.
__label__noRel	Although improvements in the UC group occurred by 12-months post-surgery,	There were no differences in other treatment-related side effects between groups.
__label__noRel	Although improvements in the UC group occurred by 12-months post-surgery,	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.
__label__noRel	the change did not meet the clinically relevant threshold.	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.
__label__noRel	the change did not meet the clinically relevant threshold.	Trends observed for the treatment groups were similar.
__label__noRel	the change did not meet the clinically relevant threshold.	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.
__label__noRel	the change did not meet the clinically relevant threshold.	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.
__label__Attack	the change did not meet the clinically relevant threshold.	Although improvements in the UC group occurred by 12-months post-surgery,
__label__noRel	the change did not meet the clinically relevant threshold.	There were no differences in other treatment-related side effects between groups.
__label__noRel	the change did not meet the clinically relevant threshold.	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.
__label__noRel	There were no differences in other treatment-related side effects between groups.	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.
__label__noRel	There were no differences in other treatment-related side effects between groups.	Trends observed for the treatment groups were similar.
__label__noRel	There were no differences in other treatment-related side effects between groups.	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.
__label__noRel	There were no differences in other treatment-related side effects between groups.	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.
__label__noRel	There were no differences in other treatment-related side effects between groups.	Although improvements in the UC group occurred by 12-months post-surgery,
__label__noRel	There were no differences in other treatment-related side effects between groups.	the change did not meet the clinically relevant threshold.
__label__noRel	There were no differences in other treatment-related side effects between groups.	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.
__label__noRel	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.
__label__noRel	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.	Trends observed for the treatment groups were similar.
__label__noRel	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.
__label__noRel	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.
__label__noRel	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.	Although improvements in the UC group occurred by 12-months post-surgery,
__label__noRel	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.	the change did not meet the clinically relevant threshold.
__label__noRel	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.	There were no differences in other treatment-related side effects between groups.
__label__noRel	CRF was significantly reduced in the intervention group, corresponding to a Fatigue score reduction of 3.04 (effect size of 0.44, 95% CI 0.17-0.72) (P = .002), the FACT-An score by 5.40 (P = .015), the FACT-An Toi score by 5.22 (P = .009) and the Anaemia-ANS by 3.76 (P = .002).	There was no statistically significant effect on the General Quality of Life score (FACT-G) or on any of the individual wellbeing scores; Physical (P = .13), Emotional (P = .87), Social (P = .83) and Functional (P = .26).
__label__Support	CRF was significantly reduced in the intervention group, corresponding to a Fatigue score reduction of 3.04 (effect size of 0.44, 95% CI 0.17-0.72) (P = .002), the FACT-An score by 5.40 (P = .015), the FACT-An Toi score by 5.22 (P = .009) and the Anaemia-ANS by 3.76 (P = .002).	In summary, this six-week supervised multimodal exercise intervention can lead to significant reduction in self-reported CRF in cancer patients undergoing chemotherapy.
__label__noRel	There was no statistically significant effect on the General Quality of Life score (FACT-G) or on any of the individual wellbeing scores; Physical (P = .13), Emotional (P = .87), Social (P = .83) and Functional (P = .26).	CRF was significantly reduced in the intervention group, corresponding to a Fatigue score reduction of 3.04 (effect size of 0.44, 95% CI 0.17-0.72) (P = .002), the FACT-An score by 5.40 (P = .015), the FACT-An Toi score by 5.22 (P = .009) and the Anaemia-ANS by 3.76 (P = .002).
__label__noRel	There was no statistically significant effect on the General Quality of Life score (FACT-G) or on any of the individual wellbeing scores; Physical (P = .13), Emotional (P = .87), Social (P = .83) and Functional (P = .26).	In summary, this six-week supervised multimodal exercise intervention can lead to significant reduction in self-reported CRF in cancer patients undergoing chemotherapy.
__label__noRel	In summary, this six-week supervised multimodal exercise intervention can lead to significant reduction in self-reported CRF in cancer patients undergoing chemotherapy.	CRF was significantly reduced in the intervention group, corresponding to a Fatigue score reduction of 3.04 (effect size of 0.44, 95% CI 0.17-0.72) (P = .002), the FACT-An score by 5.40 (P = .015), the FACT-An Toi score by 5.22 (P = .009) and the Anaemia-ANS by 3.76 (P = .002).
__label__noRel	In summary, this six-week supervised multimodal exercise intervention can lead to significant reduction in self-reported CRF in cancer patients undergoing chemotherapy.	There was no statistically significant effect on the General Quality of Life score (FACT-G) or on any of the individual wellbeing scores; Physical (P = .13), Emotional (P = .87), Social (P = .83) and Functional (P = .26).
__label__noRel	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.	This difference was not statistically significant (log-rank test, p=0.818).
__label__noRel	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.
__label__noRel	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).
__label__noRel	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.
__label__noRel	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.
__label__noRel	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.
__label__noRel	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.
__label__noRel	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.
__label__noRel	This difference was not statistically significant (log-rank test, p=0.818).	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.
__label__Attack	This difference was not statistically significant (log-rank test, p=0.818).	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.
__label__noRel	This difference was not statistically significant (log-rank test, p=0.818).	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).
__label__noRel	This difference was not statistically significant (log-rank test, p=0.818).	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.
__label__noRel	This difference was not statistically significant (log-rank test, p=0.818).	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.
__label__noRel	This difference was not statistically significant (log-rank test, p=0.818).	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.
__label__noRel	This difference was not statistically significant (log-rank test, p=0.818).	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.
__label__noRel	This difference was not statistically significant (log-rank test, p=0.818).	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.
__label__noRel	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.
__label__noRel	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.	This difference was not statistically significant (log-rank test, p=0.818).
__label__noRel	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).
__label__noRel	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.
__label__noRel	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.
__label__noRel	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.
__label__noRel	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.
__label__Support	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.
__label__noRel	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.
__label__noRel	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).	This difference was not statistically significant (log-rank test, p=0.818).
__label__noRel	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.
__label__noRel	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.
__label__noRel	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.
__label__noRel	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.
__label__noRel	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.
__label__Support	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.
__label__noRel	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.
__label__noRel	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.	This difference was not statistically significant (log-rank test, p=0.818).
__label__noRel	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.
__label__noRel	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).
__label__noRel	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.
__label__noRel	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.
__label__noRel	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.
__label__Support	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.
__label__noRel	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.
__label__noRel	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.	This difference was not statistically significant (log-rank test, p=0.818).
__label__noRel	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.
__label__noRel	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).
__label__noRel	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.
__label__noRel	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.
__label__Support	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.
__label__noRel	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.
__label__noRel	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.
__label__noRel	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.	This difference was not statistically significant (log-rank test, p=0.818).
__label__noRel	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.
__label__noRel	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).
__label__noRel	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.
__label__noRel	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.
__label__noRel	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.
__label__noRel	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.
__label__Support	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.
__label__noRel	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.	This difference was not statistically significant (log-rank test, p=0.818).
__label__noRel	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.
__label__noRel	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).
__label__noRel	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.
__label__noRel	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.
__label__noRel	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.
__label__noRel	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.
__label__Support	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.
__label__noRel	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.	This difference was not statistically significant (log-rank test, p=0.818).
__label__noRel	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.
__label__noRel	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).
__label__noRel	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.
__label__noRel	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.
__label__noRel	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.
__label__noRel	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.
__label__noRel	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).
__label__noRel	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,
__label__noRel	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.	although myelosuppression did not influence dose delivery or patient safety.
__label__noRel	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.	Global quality of life was similar in both arms,
__label__noRel	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.	but substantive differences in many symptom scores favored docetaxel.
__label__Support	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,
__label__noRel	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.	although longer follow-up is required for a definitive statement on survival.
__label__noRel	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.
__label__noRel	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.
__label__noRel	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,
__label__noRel	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).	although myelosuppression did not influence dose delivery or patient safety.
__label__noRel	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).	Global quality of life was similar in both arms,
__label__Support	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).	but substantive differences in many symptom scores favored docetaxel.
__label__noRel	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,
__label__noRel	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).	although longer follow-up is required for a definitive statement on survival.
__label__noRel	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.
__label__noRel	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.
__label__noRel	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).
__label__noRel	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,	although myelosuppression did not influence dose delivery or patient safety.
__label__noRel	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,	Global quality of life was similar in both arms,
__label__noRel	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,	but substantive differences in many symptom scores favored docetaxel.
__label__noRel	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,
__label__noRel	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,	although longer follow-up is required for a definitive statement on survival.
__label__noRel	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.
__label__noRel	although myelosuppression did not influence dose delivery or patient safety.	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.
__label__noRel	although myelosuppression did not influence dose delivery or patient safety.	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).
__label__Attack	although myelosuppression did not influence dose delivery or patient safety.	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,
__label__noRel	although myelosuppression did not influence dose delivery or patient safety.	Global quality of life was similar in both arms,
__label__noRel	although myelosuppression did not influence dose delivery or patient safety.	but substantive differences in many symptom scores favored docetaxel.
__label__noRel	although myelosuppression did not influence dose delivery or patient safety.	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,
__label__noRel	although myelosuppression did not influence dose delivery or patient safety.	although longer follow-up is required for a definitive statement on survival.
__label__noRel	although myelosuppression did not influence dose delivery or patient safety.	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.
__label__noRel	Global quality of life was similar in both arms,	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.
__label__noRel	Global quality of life was similar in both arms,	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).
__label__noRel	Global quality of life was similar in both arms,	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,
__label__noRel	Global quality of life was similar in both arms,	although myelosuppression did not influence dose delivery or patient safety.
__label__noRel	Global quality of life was similar in both arms,	but substantive differences in many symptom scores favored docetaxel.
__label__noRel	Global quality of life was similar in both arms,	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,
__label__noRel	Global quality of life was similar in both arms,	although longer follow-up is required for a definitive statement on survival.
__label__noRel	Global quality of life was similar in both arms,	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.
__label__noRel	but substantive differences in many symptom scores favored docetaxel.	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.
__label__noRel	but substantive differences in many symptom scores favored docetaxel.	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).
__label__noRel	but substantive differences in many symptom scores favored docetaxel.	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,
__label__noRel	but substantive differences in many symptom scores favored docetaxel.	although myelosuppression did not influence dose delivery or patient safety.
__label__Attack	but substantive differences in many symptom scores favored docetaxel.	Global quality of life was similar in both arms,
__label__noRel	but substantive differences in many symptom scores favored docetaxel.	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,
__label__noRel	but substantive differences in many symptom scores favored docetaxel.	although longer follow-up is required for a definitive statement on survival.
__label__noRel	but substantive differences in many symptom scores favored docetaxel.	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.
__label__noRel	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.
__label__noRel	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).
__label__noRel	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,
__label__noRel	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,	although myelosuppression did not influence dose delivery or patient safety.
__label__noRel	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,	Global quality of life was similar in both arms,
__label__noRel	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,	but substantive differences in many symptom scores favored docetaxel.
__label__noRel	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,	although longer follow-up is required for a definitive statement on survival.
__label__Support	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.
__label__noRel	although longer follow-up is required for a definitive statement on survival.	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.
__label__noRel	although longer follow-up is required for a definitive statement on survival.	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).
__label__noRel	although longer follow-up is required for a definitive statement on survival.	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,
__label__noRel	although longer follow-up is required for a definitive statement on survival.	although myelosuppression did not influence dose delivery or patient safety.
__label__noRel	although longer follow-up is required for a definitive statement on survival.	Global quality of life was similar in both arms,
__label__noRel	although longer follow-up is required for a definitive statement on survival.	but substantive differences in many symptom scores favored docetaxel.
__label__Attack	although longer follow-up is required for a definitive statement on survival.	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,
__label__noRel	although longer follow-up is required for a definitive statement on survival.	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.
__label__noRel	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.
__label__noRel	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).
__label__noRel	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,
__label__noRel	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.	although myelosuppression did not influence dose delivery or patient safety.
__label__noRel	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.	Global quality of life was similar in both arms,
__label__noRel	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.	but substantive differences in many symptom scores favored docetaxel.
__label__noRel	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,
__label__noRel	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.	although longer follow-up is required for a definitive statement on survival.
__label__noRel	No interactions were found between other domains of quality of life, functioning, psychological distress and CBT.	Fatigue at T2 was predicted by a significant interaction between self-reported cognitive functioning and CBT.
__label__noRel	No interactions were found between other domains of quality of life, functioning, psychological distress and CBT.	At T3, no significant difference on fatigue was found between CBT and usual care.
__label__noRel	No interactions were found between other domains of quality of life, functioning, psychological distress and CBT.	Exploratory analyses showed that the difference nearly reached significance until 7months postintervention.
__label__noRel	No interactions were found between other domains of quality of life, functioning, psychological distress and CBT.	Patients who experienced more concentration and memory problems at T1 benefited more from CBT for fatigue and are indicators.
__label__noRel	No interactions were found between other domains of quality of life, functioning, psychological distress and CBT.	After a year of follow-up, the effect of CBT for fatigue was no longer observed, and the effect on fatigue seemed to be diminished 7months postintervention.
__label__noRel	No interactions were found between other domains of quality of life, functioning, psychological distress and CBT.	The implication is that CBT for fatigue should be offered to patients with cancer with the highest chance to benefit.
__label__noRel	Fatigue at T2 was predicted by a significant interaction between self-reported cognitive functioning and CBT.	No interactions were found between other domains of quality of life, functioning, psychological distress and CBT.
__label__noRel	Fatigue at T2 was predicted by a significant interaction between self-reported cognitive functioning and CBT.	At T3, no significant difference on fatigue was found between CBT and usual care.
__label__noRel	Fatigue at T2 was predicted by a significant interaction between self-reported cognitive functioning and CBT.	Exploratory analyses showed that the difference nearly reached significance until 7months postintervention.
__label__noRel	Fatigue at T2 was predicted by a significant interaction between self-reported cognitive functioning and CBT.	Patients who experienced more concentration and memory problems at T1 benefited more from CBT for fatigue and are indicators.
__label__noRel	Fatigue at T2 was predicted by a significant interaction between self-reported cognitive functioning and CBT.	After a year of follow-up, the effect of CBT for fatigue was no longer observed, and the effect on fatigue seemed to be diminished 7months postintervention.
__label__Support	Fatigue at T2 was predicted by a significant interaction between self-reported cognitive functioning and CBT.	The implication is that CBT for fatigue should be offered to patients with cancer with the highest chance to benefit.
__label__noRel	At T3, no significant difference on fatigue was found between CBT and usual care.	No interactions were found between other domains of quality of life, functioning, psychological distress and CBT.
__label__noRel	At T3, no significant difference on fatigue was found between CBT and usual care.	Fatigue at T2 was predicted by a significant interaction between self-reported cognitive functioning and CBT.
__label__noRel	At T3, no significant difference on fatigue was found between CBT and usual care.	Exploratory analyses showed that the difference nearly reached significance until 7months postintervention.
__label__noRel	At T3, no significant difference on fatigue was found between CBT and usual care.	Patients who experienced more concentration and memory problems at T1 benefited more from CBT for fatigue and are indicators.
__label__noRel	At T3, no significant difference on fatigue was found between CBT and usual care.	After a year of follow-up, the effect of CBT for fatigue was no longer observed, and the effect on fatigue seemed to be diminished 7months postintervention.
__label__Support	At T3, no significant difference on fatigue was found between CBT and usual care.	The implication is that CBT for fatigue should be offered to patients with cancer with the highest chance to benefit.
__label__noRel	Exploratory analyses showed that the difference nearly reached significance until 7months postintervention.	No interactions were found between other domains of quality of life, functioning, psychological distress and CBT.
__label__noRel	Exploratory analyses showed that the difference nearly reached significance until 7months postintervention.	Fatigue at T2 was predicted by a significant interaction between self-reported cognitive functioning and CBT.
__label__noRel	Exploratory analyses showed that the difference nearly reached significance until 7months postintervention.	At T3, no significant difference on fatigue was found between CBT and usual care.
__label__noRel	Exploratory analyses showed that the difference nearly reached significance until 7months postintervention.	Patients who experienced more concentration and memory problems at T1 benefited more from CBT for fatigue and are indicators.
__label__noRel	Exploratory analyses showed that the difference nearly reached significance until 7months postintervention.	After a year of follow-up, the effect of CBT for fatigue was no longer observed, and the effect on fatigue seemed to be diminished 7months postintervention.
__label__noRel	Exploratory analyses showed that the difference nearly reached significance until 7months postintervention.	The implication is that CBT for fatigue should be offered to patients with cancer with the highest chance to benefit.
__label__noRel	Patients who experienced more concentration and memory problems at T1 benefited more from CBT for fatigue and are indicators.	No interactions were found between other domains of quality of life, functioning, psychological distress and CBT.
__label__noRel	Patients who experienced more concentration and memory problems at T1 benefited more from CBT for fatigue and are indicators.	Fatigue at T2 was predicted by a significant interaction between self-reported cognitive functioning and CBT.
__label__noRel	Patients who experienced more concentration and memory problems at T1 benefited more from CBT for fatigue and are indicators.	At T3, no significant difference on fatigue was found between CBT and usual care.
__label__noRel	Patients who experienced more concentration and memory problems at T1 benefited more from CBT for fatigue and are indicators.	Exploratory analyses showed that the difference nearly reached significance until 7months postintervention.
__label__noRel	Patients who experienced more concentration and memory problems at T1 benefited more from CBT for fatigue and are indicators.	After a year of follow-up, the effect of CBT for fatigue was no longer observed, and the effect on fatigue seemed to be diminished 7months postintervention.
__label__Support	Patients who experienced more concentration and memory problems at T1 benefited more from CBT for fatigue and are indicators.	The implication is that CBT for fatigue should be offered to patients with cancer with the highest chance to benefit.
__label__noRel	After a year of follow-up, the effect of CBT for fatigue was no longer observed, and the effect on fatigue seemed to be diminished 7months postintervention.	No interactions were found between other domains of quality of life, functioning, psychological distress and CBT.
__label__noRel	After a year of follow-up, the effect of CBT for fatigue was no longer observed, and the effect on fatigue seemed to be diminished 7months postintervention.	Fatigue at T2 was predicted by a significant interaction between self-reported cognitive functioning and CBT.
__label__noRel	After a year of follow-up, the effect of CBT for fatigue was no longer observed, and the effect on fatigue seemed to be diminished 7months postintervention.	At T3, no significant difference on fatigue was found between CBT and usual care.
__label__noRel	After a year of follow-up, the effect of CBT for fatigue was no longer observed, and the effect on fatigue seemed to be diminished 7months postintervention.	Exploratory analyses showed that the difference nearly reached significance until 7months postintervention.
__label__noRel	After a year of follow-up, the effect of CBT for fatigue was no longer observed, and the effect on fatigue seemed to be diminished 7months postintervention.	Patients who experienced more concentration and memory problems at T1 benefited more from CBT for fatigue and are indicators.
__label__Attack	After a year of follow-up, the effect of CBT for fatigue was no longer observed, and the effect on fatigue seemed to be diminished 7months postintervention.	The implication is that CBT for fatigue should be offered to patients with cancer with the highest chance to benefit.
__label__noRel	The implication is that CBT for fatigue should be offered to patients with cancer with the highest chance to benefit.	No interactions were found between other domains of quality of life, functioning, psychological distress and CBT.
__label__noRel	The implication is that CBT for fatigue should be offered to patients with cancer with the highest chance to benefit.	Fatigue at T2 was predicted by a significant interaction between self-reported cognitive functioning and CBT.
__label__noRel	The implication is that CBT for fatigue should be offered to patients with cancer with the highest chance to benefit.	At T3, no significant difference on fatigue was found between CBT and usual care.
__label__noRel	The implication is that CBT for fatigue should be offered to patients with cancer with the highest chance to benefit.	Exploratory analyses showed that the difference nearly reached significance until 7months postintervention.
__label__noRel	The implication is that CBT for fatigue should be offered to patients with cancer with the highest chance to benefit.	Patients who experienced more concentration and memory problems at T1 benefited more from CBT for fatigue and are indicators.
__label__noRel	The implication is that CBT for fatigue should be offered to patients with cancer with the highest chance to benefit.	After a year of follow-up, the effect of CBT for fatigue was no longer observed, and the effect on fatigue seemed to be diminished 7months postintervention.
__label__noRel	There was a trend towards improved global HRQOL during the treatment period.	At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm,
__label__noRel	There was a trend towards improved global HRQOL during the treatment period.	but the low compliance does not allow to draw definitive conclusions.
__label__noRel	There was a trend towards improved global HRQOL during the treatment period.	Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2,
__label__noRel	There was a trend towards improved global HRQOL during the treatment period.	but to a limited extent.
__label__Support	There was a trend towards improved global HRQOL during the treatment period.	Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner.
__label__noRel	At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm,	There was a trend towards improved global HRQOL during the treatment period.
__label__noRel	At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm,	but the low compliance does not allow to draw definitive conclusions.
__label__noRel	At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm,	Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2,
__label__noRel	At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm,	but to a limited extent.
__label__Support	At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm,	Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner.
__label__noRel	but the low compliance does not allow to draw definitive conclusions.	There was a trend towards improved global HRQOL during the treatment period.
__label__Attack	but the low compliance does not allow to draw definitive conclusions.	At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm,
__label__noRel	but the low compliance does not allow to draw definitive conclusions.	Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2,
__label__noRel	but the low compliance does not allow to draw definitive conclusions.	but to a limited extent.
__label__noRel	but the low compliance does not allow to draw definitive conclusions.	Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner.
__label__noRel	Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2,	There was a trend towards improved global HRQOL during the treatment period.
__label__noRel	Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2,	At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm,
__label__noRel	Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2,	but the low compliance does not allow to draw definitive conclusions.
__label__noRel	Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2,	but to a limited extent.
__label__Support	Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2,	Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner.
__label__noRel	but to a limited extent.	There was a trend towards improved global HRQOL during the treatment period.
__label__noRel	but to a limited extent.	At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm,
__label__noRel	but to a limited extent.	but the low compliance does not allow to draw definitive conclusions.
__label__Attack	but to a limited extent.	Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2,
__label__noRel	but to a limited extent.	Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner.
__label__noRel	Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner.	There was a trend towards improved global HRQOL during the treatment period.
__label__noRel	Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner.	At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm,
__label__noRel	Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner.	but the low compliance does not allow to draw definitive conclusions.
__label__noRel	Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner.	Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2,
__label__noRel	Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner.	but to a limited extent.
__label__noRel	During the last decade, survival rates for breast cancer have increased as a result of earlier detection and increased use of adjuvant therapy.	Among all treatment groups, patients who had a mastectomy had the poorest physical functioning at registration (P<.001) and at enrollment (P=.05).
__label__noRel	During the last decade, survival rates for breast cancer have increased as a result of earlier detection and increased use of adjuvant therapy.	At enrollment, mood and emotional functioning were similar among all patients, with no differences by type of treatment received.
__label__noRel	During the last decade, survival rates for breast cancer have increased as a result of earlier detection and increased use of adjuvant therapy.	At enrollment, symptoms, including muscle stiffness, breast sensitivity, aches and pains, tendency to take naps, and difficulty concentrating, were common among patients in all groups and were statistically significantly associated with poor physical functioning and emotional well-being.
__label__noRel	During the last decade, survival rates for breast cancer have increased as a result of earlier detection and increased use of adjuvant therapy.	Sexual functioning was worse for women who received chemotherapy than for those who did not, regardless of type of surgery (P<.001).
__label__noRel	During the last decade, survival rates for breast cancer have increased as a result of earlier detection and increased use of adjuvant therapy.	At the end of primary treatment for breast cancer, women in all treatment groups report good emotional functioning but report decreased physical functioning, particularly among women who have a mastectomy or receive chemotherapy.
__label__noRel	During the last decade, survival rates for breast cancer have increased as a result of earlier detection and increased use of adjuvant therapy.	Clinical interventions to address common symptoms associated with treatment should be considered to improve physical and emotional functioning at the end of primary treatment for breast cancer.
__label__noRel	Among all treatment groups, patients who had a mastectomy had the poorest physical functioning at registration (P<.001) and at enrollment (P=.05).	During the last decade, survival rates for breast cancer have increased as a result of earlier detection and increased use of adjuvant therapy.
__label__noRel	Among all treatment groups, patients who had a mastectomy had the poorest physical functioning at registration (P<.001) and at enrollment (P=.05).	At enrollment, mood and emotional functioning were similar among all patients, with no differences by type of treatment received.
__label__noRel	Among all treatment groups, patients who had a mastectomy had the poorest physical functioning at registration (P<.001) and at enrollment (P=.05).	At enrollment, symptoms, including muscle stiffness, breast sensitivity, aches and pains, tendency to take naps, and difficulty concentrating, were common among patients in all groups and were statistically significantly associated with poor physical functioning and emotional well-being.
__label__noRel	Among all treatment groups, patients who had a mastectomy had the poorest physical functioning at registration (P<.001) and at enrollment (P=.05).	Sexual functioning was worse for women who received chemotherapy than for those who did not, regardless of type of surgery (P<.001).
__label__Support	Among all treatment groups, patients who had a mastectomy had the poorest physical functioning at registration (P<.001) and at enrollment (P=.05).	At the end of primary treatment for breast cancer, women in all treatment groups report good emotional functioning but report decreased physical functioning, particularly among women who have a mastectomy or receive chemotherapy.
__label__noRel	Among all treatment groups, patients who had a mastectomy had the poorest physical functioning at registration (P<.001) and at enrollment (P=.05).	Clinical interventions to address common symptoms associated with treatment should be considered to improve physical and emotional functioning at the end of primary treatment for breast cancer.
__label__noRel	At enrollment, mood and emotional functioning were similar among all patients, with no differences by type of treatment received.	During the last decade, survival rates for breast cancer have increased as a result of earlier detection and increased use of adjuvant therapy.
__label__noRel	At enrollment, mood and emotional functioning were similar among all patients, with no differences by type of treatment received.	Among all treatment groups, patients who had a mastectomy had the poorest physical functioning at registration (P<.001) and at enrollment (P=.05).
__label__noRel	At enrollment, mood and emotional functioning were similar among all patients, with no differences by type of treatment received.	At enrollment, symptoms, including muscle stiffness, breast sensitivity, aches and pains, tendency to take naps, and difficulty concentrating, were common among patients in all groups and were statistically significantly associated with poor physical functioning and emotional well-being.
__label__noRel	At enrollment, mood and emotional functioning were similar among all patients, with no differences by type of treatment received.	Sexual functioning was worse for women who received chemotherapy than for those who did not, regardless of type of surgery (P<.001).
__label__Support	At enrollment, mood and emotional functioning were similar among all patients, with no differences by type of treatment received.	At the end of primary treatment for breast cancer, women in all treatment groups report good emotional functioning but report decreased physical functioning, particularly among women who have a mastectomy or receive chemotherapy.
__label__noRel	At enrollment, mood and emotional functioning were similar among all patients, with no differences by type of treatment received.	Clinical interventions to address common symptoms associated with treatment should be considered to improve physical and emotional functioning at the end of primary treatment for breast cancer.
__label__noRel	At enrollment, symptoms, including muscle stiffness, breast sensitivity, aches and pains, tendency to take naps, and difficulty concentrating, were common among patients in all groups and were statistically significantly associated with poor physical functioning and emotional well-being.	During the last decade, survival rates for breast cancer have increased as a result of earlier detection and increased use of adjuvant therapy.
__label__noRel	At enrollment, symptoms, including muscle stiffness, breast sensitivity, aches and pains, tendency to take naps, and difficulty concentrating, were common among patients in all groups and were statistically significantly associated with poor physical functioning and emotional well-being.	Among all treatment groups, patients who had a mastectomy had the poorest physical functioning at registration (P<.001) and at enrollment (P=.05).
__label__noRel	At enrollment, symptoms, including muscle stiffness, breast sensitivity, aches and pains, tendency to take naps, and difficulty concentrating, were common among patients in all groups and were statistically significantly associated with poor physical functioning and emotional well-being.	At enrollment, mood and emotional functioning were similar among all patients, with no differences by type of treatment received.
__label__noRel	At enrollment, symptoms, including muscle stiffness, breast sensitivity, aches and pains, tendency to take naps, and difficulty concentrating, were common among patients in all groups and were statistically significantly associated with poor physical functioning and emotional well-being.	Sexual functioning was worse for women who received chemotherapy than for those who did not, regardless of type of surgery (P<.001).
__label__Support	At enrollment, symptoms, including muscle stiffness, breast sensitivity, aches and pains, tendency to take naps, and difficulty concentrating, were common among patients in all groups and were statistically significantly associated with poor physical functioning and emotional well-being.	At the end of primary treatment for breast cancer, women in all treatment groups report good emotional functioning but report decreased physical functioning, particularly among women who have a mastectomy or receive chemotherapy.
__label__noRel	At enrollment, symptoms, including muscle stiffness, breast sensitivity, aches and pains, tendency to take naps, and difficulty concentrating, were common among patients in all groups and were statistically significantly associated with poor physical functioning and emotional well-being.	Clinical interventions to address common symptoms associated with treatment should be considered to improve physical and emotional functioning at the end of primary treatment for breast cancer.
__label__noRel	Sexual functioning was worse for women who received chemotherapy than for those who did not, regardless of type of surgery (P<.001).	During the last decade, survival rates for breast cancer have increased as a result of earlier detection and increased use of adjuvant therapy.
__label__noRel	Sexual functioning was worse for women who received chemotherapy than for those who did not, regardless of type of surgery (P<.001).	Among all treatment groups, patients who had a mastectomy had the poorest physical functioning at registration (P<.001) and at enrollment (P=.05).
__label__noRel	Sexual functioning was worse for women who received chemotherapy than for those who did not, regardless of type of surgery (P<.001).	At enrollment, mood and emotional functioning were similar among all patients, with no differences by type of treatment received.
__label__noRel	Sexual functioning was worse for women who received chemotherapy than for those who did not, regardless of type of surgery (P<.001).	At enrollment, symptoms, including muscle stiffness, breast sensitivity, aches and pains, tendency to take naps, and difficulty concentrating, were common among patients in all groups and were statistically significantly associated with poor physical functioning and emotional well-being.
__label__noRel	Sexual functioning was worse for women who received chemotherapy than for those who did not, regardless of type of surgery (P<.001).	At the end of primary treatment for breast cancer, women in all treatment groups report good emotional functioning but report decreased physical functioning, particularly among women who have a mastectomy or receive chemotherapy.
__label__noRel	Sexual functioning was worse for women who received chemotherapy than for those who did not, regardless of type of surgery (P<.001).	Clinical interventions to address common symptoms associated with treatment should be considered to improve physical and emotional functioning at the end of primary treatment for breast cancer.
__label__noRel	At the end of primary treatment for breast cancer, women in all treatment groups report good emotional functioning but report decreased physical functioning, particularly among women who have a mastectomy or receive chemotherapy.	During the last decade, survival rates for breast cancer have increased as a result of earlier detection and increased use of adjuvant therapy.
__label__noRel	At the end of primary treatment for breast cancer, women in all treatment groups report good emotional functioning but report decreased physical functioning, particularly among women who have a mastectomy or receive chemotherapy.	Among all treatment groups, patients who had a mastectomy had the poorest physical functioning at registration (P<.001) and at enrollment (P=.05).
__label__noRel	At the end of primary treatment for breast cancer, women in all treatment groups report good emotional functioning but report decreased physical functioning, particularly among women who have a mastectomy or receive chemotherapy.	At enrollment, mood and emotional functioning were similar among all patients, with no differences by type of treatment received.
__label__noRel	At the end of primary treatment for breast cancer, women in all treatment groups report good emotional functioning but report decreased physical functioning, particularly among women who have a mastectomy or receive chemotherapy.	At enrollment, symptoms, including muscle stiffness, breast sensitivity, aches and pains, tendency to take naps, and difficulty concentrating, were common among patients in all groups and were statistically significantly associated with poor physical functioning and emotional well-being.
__label__noRel	At the end of primary treatment for breast cancer, women in all treatment groups report good emotional functioning but report decreased physical functioning, particularly among women who have a mastectomy or receive chemotherapy.	Sexual functioning was worse for women who received chemotherapy than for those who did not, regardless of type of surgery (P<.001).
__label__noRel	At the end of primary treatment for breast cancer, women in all treatment groups report good emotional functioning but report decreased physical functioning, particularly among women who have a mastectomy or receive chemotherapy.	Clinical interventions to address common symptoms associated with treatment should be considered to improve physical and emotional functioning at the end of primary treatment for breast cancer.
__label__noRel	Clinical interventions to address common symptoms associated with treatment should be considered to improve physical and emotional functioning at the end of primary treatment for breast cancer.	During the last decade, survival rates for breast cancer have increased as a result of earlier detection and increased use of adjuvant therapy.
__label__noRel	Clinical interventions to address common symptoms associated with treatment should be considered to improve physical and emotional functioning at the end of primary treatment for breast cancer.	Among all treatment groups, patients who had a mastectomy had the poorest physical functioning at registration (P<.001) and at enrollment (P=.05).
__label__noRel	Clinical interventions to address common symptoms associated with treatment should be considered to improve physical and emotional functioning at the end of primary treatment for breast cancer.	At enrollment, mood and emotional functioning were similar among all patients, with no differences by type of treatment received.
__label__noRel	Clinical interventions to address common symptoms associated with treatment should be considered to improve physical and emotional functioning at the end of primary treatment for breast cancer.	At enrollment, symptoms, including muscle stiffness, breast sensitivity, aches and pains, tendency to take naps, and difficulty concentrating, were common among patients in all groups and were statistically significantly associated with poor physical functioning and emotional well-being.
__label__noRel	Clinical interventions to address common symptoms associated with treatment should be considered to improve physical and emotional functioning at the end of primary treatment for breast cancer.	Sexual functioning was worse for women who received chemotherapy than for those who did not, regardless of type of surgery (P<.001).
__label__noRel	Clinical interventions to address common symptoms associated with treatment should be considered to improve physical and emotional functioning at the end of primary treatment for breast cancer.	At the end of primary treatment for breast cancer, women in all treatment groups report good emotional functioning but report decreased physical functioning, particularly among women who have a mastectomy or receive chemotherapy.
__label__noRel	In a multinational trial of anaemic patients with cancer receiving nonplatinum-containing chemotherapy, epoetin-alfa effectively increased haemoglobin levels, reduced red blood cell transfusion requirements, and improved QOL.	a survival trend was noted favouring epoetin-alfa compared with placebo (median survival 17 vs 11 months [p = 0.126]).
__label__noRel	In a multinational trial of anaemic patients with cancer receiving nonplatinum-containing chemotherapy, epoetin-alfa effectively increased haemoglobin levels, reduced red blood cell transfusion requirements, and improved QOL.	The ICUR for epoetin-alfa treatment was pounds 8,851 per QALY, with a 99% probability of a positive net benefit in QALYs (net benefit = 0.4805 years of perfect life) and a 94% probability of being acceptable using a threshold ICUR of pounds 30,000/QALY.
__label__noRel	In a multinational trial of anaemic patients with cancer receiving nonplatinum-containing chemotherapy, epoetin-alfa effectively increased haemoglobin levels, reduced red blood cell transfusion requirements, and improved QOL.	The main cost drivers distinguishing epoetin-alfa from placebo were the costs of drug and patient care due to increased survival.
__label__noRel	In a multinational trial of anaemic patients with cancer receiving nonplatinum-containing chemotherapy, epoetin-alfa effectively increased haemoglobin levels, reduced red blood cell transfusion requirements, and improved QOL.	The available data suggest a high probability of favourable cost-utility outcomes with epoetin-alfa treatment for anaemia in patients with stage IV breast cancer receiving nonplatinum-containing chemotherapy.
__label__noRel	In a multinational trial of anaemic patients with cancer receiving nonplatinum-containing chemotherapy, epoetin-alfa effectively increased haemoglobin levels, reduced red blood cell transfusion requirements, and improved QOL.	Additional studies are warranted.
__label__noRel	a survival trend was noted favouring epoetin-alfa compared with placebo (median survival 17 vs 11 months [p = 0.126]).	In a multinational trial of anaemic patients with cancer receiving nonplatinum-containing chemotherapy, epoetin-alfa effectively increased haemoglobin levels, reduced red blood cell transfusion requirements, and improved QOL.
__label__noRel	a survival trend was noted favouring epoetin-alfa compared with placebo (median survival 17 vs 11 months [p = 0.126]).	The ICUR for epoetin-alfa treatment was pounds 8,851 per QALY, with a 99% probability of a positive net benefit in QALYs (net benefit = 0.4805 years of perfect life) and a 94% probability of being acceptable using a threshold ICUR of pounds 30,000/QALY.
__label__noRel	a survival trend was noted favouring epoetin-alfa compared with placebo (median survival 17 vs 11 months [p = 0.126]).	The main cost drivers distinguishing epoetin-alfa from placebo were the costs of drug and patient care due to increased survival.
__label__noRel	a survival trend was noted favouring epoetin-alfa compared with placebo (median survival 17 vs 11 months [p = 0.126]).	The available data suggest a high probability of favourable cost-utility outcomes with epoetin-alfa treatment for anaemia in patients with stage IV breast cancer receiving nonplatinum-containing chemotherapy.
__label__noRel	a survival trend was noted favouring epoetin-alfa compared with placebo (median survival 17 vs 11 months [p = 0.126]).	Additional studies are warranted.
__label__noRel	The ICUR for epoetin-alfa treatment was pounds 8,851 per QALY, with a 99% probability of a positive net benefit in QALYs (net benefit = 0.4805 years of perfect life) and a 94% probability of being acceptable using a threshold ICUR of pounds 30,000/QALY.	In a multinational trial of anaemic patients with cancer receiving nonplatinum-containing chemotherapy, epoetin-alfa effectively increased haemoglobin levels, reduced red blood cell transfusion requirements, and improved QOL.
__label__noRel	The ICUR for epoetin-alfa treatment was pounds 8,851 per QALY, with a 99% probability of a positive net benefit in QALYs (net benefit = 0.4805 years of perfect life) and a 94% probability of being acceptable using a threshold ICUR of pounds 30,000/QALY.	a survival trend was noted favouring epoetin-alfa compared with placebo (median survival 17 vs 11 months [p = 0.126]).
__label__noRel	The ICUR for epoetin-alfa treatment was pounds 8,851 per QALY, with a 99% probability of a positive net benefit in QALYs (net benefit = 0.4805 years of perfect life) and a 94% probability of being acceptable using a threshold ICUR of pounds 30,000/QALY.	The main cost drivers distinguishing epoetin-alfa from placebo were the costs of drug and patient care due to increased survival.
__label__Support	The ICUR for epoetin-alfa treatment was pounds 8,851 per QALY, with a 99% probability of a positive net benefit in QALYs (net benefit = 0.4805 years of perfect life) and a 94% probability of being acceptable using a threshold ICUR of pounds 30,000/QALY.	The available data suggest a high probability of favourable cost-utility outcomes with epoetin-alfa treatment for anaemia in patients with stage IV breast cancer receiving nonplatinum-containing chemotherapy.
__label__noRel	The ICUR for epoetin-alfa treatment was pounds 8,851 per QALY, with a 99% probability of a positive net benefit in QALYs (net benefit = 0.4805 years of perfect life) and a 94% probability of being acceptable using a threshold ICUR of pounds 30,000/QALY.	Additional studies are warranted.
__label__noRel	The main cost drivers distinguishing epoetin-alfa from placebo were the costs of drug and patient care due to increased survival.	In a multinational trial of anaemic patients with cancer receiving nonplatinum-containing chemotherapy, epoetin-alfa effectively increased haemoglobin levels, reduced red blood cell transfusion requirements, and improved QOL.
__label__noRel	The main cost drivers distinguishing epoetin-alfa from placebo were the costs of drug and patient care due to increased survival.	a survival trend was noted favouring epoetin-alfa compared with placebo (median survival 17 vs 11 months [p = 0.126]).
__label__noRel	The main cost drivers distinguishing epoetin-alfa from placebo were the costs of drug and patient care due to increased survival.	The ICUR for epoetin-alfa treatment was pounds 8,851 per QALY, with a 99% probability of a positive net benefit in QALYs (net benefit = 0.4805 years of perfect life) and a 94% probability of being acceptable using a threshold ICUR of pounds 30,000/QALY.
__label__noRel	The main cost drivers distinguishing epoetin-alfa from placebo were the costs of drug and patient care due to increased survival.	The available data suggest a high probability of favourable cost-utility outcomes with epoetin-alfa treatment for anaemia in patients with stage IV breast cancer receiving nonplatinum-containing chemotherapy.
__label__noRel	The main cost drivers distinguishing epoetin-alfa from placebo were the costs of drug and patient care due to increased survival.	Additional studies are warranted.
__label__noRel	The available data suggest a high probability of favourable cost-utility outcomes with epoetin-alfa treatment for anaemia in patients with stage IV breast cancer receiving nonplatinum-containing chemotherapy.	In a multinational trial of anaemic patients with cancer receiving nonplatinum-containing chemotherapy, epoetin-alfa effectively increased haemoglobin levels, reduced red blood cell transfusion requirements, and improved QOL.
__label__noRel	The available data suggest a high probability of favourable cost-utility outcomes with epoetin-alfa treatment for anaemia in patients with stage IV breast cancer receiving nonplatinum-containing chemotherapy.	a survival trend was noted favouring epoetin-alfa compared with placebo (median survival 17 vs 11 months [p = 0.126]).
__label__noRel	The available data suggest a high probability of favourable cost-utility outcomes with epoetin-alfa treatment for anaemia in patients with stage IV breast cancer receiving nonplatinum-containing chemotherapy.	The ICUR for epoetin-alfa treatment was pounds 8,851 per QALY, with a 99% probability of a positive net benefit in QALYs (net benefit = 0.4805 years of perfect life) and a 94% probability of being acceptable using a threshold ICUR of pounds 30,000/QALY.
__label__noRel	The available data suggest a high probability of favourable cost-utility outcomes with epoetin-alfa treatment for anaemia in patients with stage IV breast cancer receiving nonplatinum-containing chemotherapy.	The main cost drivers distinguishing epoetin-alfa from placebo were the costs of drug and patient care due to increased survival.
__label__Support	The available data suggest a high probability of favourable cost-utility outcomes with epoetin-alfa treatment for anaemia in patients with stage IV breast cancer receiving nonplatinum-containing chemotherapy.	Additional studies are warranted.
__label__noRel	Additional studies are warranted.	In a multinational trial of anaemic patients with cancer receiving nonplatinum-containing chemotherapy, epoetin-alfa effectively increased haemoglobin levels, reduced red blood cell transfusion requirements, and improved QOL.
__label__noRel	Additional studies are warranted.	a survival trend was noted favouring epoetin-alfa compared with placebo (median survival 17 vs 11 months [p = 0.126]).
__label__noRel	Additional studies are warranted.	The ICUR for epoetin-alfa treatment was pounds 8,851 per QALY, with a 99% probability of a positive net benefit in QALYs (net benefit = 0.4805 years of perfect life) and a 94% probability of being acceptable using a threshold ICUR of pounds 30,000/QALY.
__label__noRel	Additional studies are warranted.	The main cost drivers distinguishing epoetin-alfa from placebo were the costs of drug and patient care due to increased survival.
__label__noRel	Additional studies are warranted.	The available data suggest a high probability of favourable cost-utility outcomes with epoetin-alfa treatment for anaemia in patients with stage IV breast cancer receiving nonplatinum-containing chemotherapy.
__label__noRel	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.
__label__noRel	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).
__label__noRel	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.
__label__noRel	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).	Peripheral neuropathy and alopecia were more common with CVP.
__label__noRel	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).	Patients receiving fludarabine had higher scores for social function (P =.008);
__label__noRel	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).	no other differences in QoL were detected.
__label__noRel	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.
__label__noRel	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).
__label__noRel	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).
__label__noRel	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.
__label__noRel	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.	Peripheral neuropathy and alopecia were more common with CVP.
__label__noRel	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.	Patients receiving fludarabine had higher scores for social function (P =.008);
__label__noRel	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.	no other differences in QoL were detected.
__label__Support	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.
__label__noRel	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).
__label__noRel	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.
__label__noRel	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.
__label__noRel	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).	Peripheral neuropathy and alopecia were more common with CVP.
__label__noRel	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).	Patients receiving fludarabine had higher scores for social function (P =.008);
__label__noRel	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).	no other differences in QoL were detected.
__label__Support	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.
__label__noRel	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).
__label__noRel	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.
__label__noRel	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).
__label__noRel	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.	Peripheral neuropathy and alopecia were more common with CVP.
__label__noRel	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.	Patients receiving fludarabine had higher scores for social function (P =.008);
__label__noRel	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.	no other differences in QoL were detected.
__label__Support	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.
__label__noRel	Peripheral neuropathy and alopecia were more common with CVP.	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).
__label__noRel	Peripheral neuropathy and alopecia were more common with CVP.	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.
__label__noRel	Peripheral neuropathy and alopecia were more common with CVP.	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).
__label__noRel	Peripheral neuropathy and alopecia were more common with CVP.	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.
__label__noRel	Peripheral neuropathy and alopecia were more common with CVP.	Patients receiving fludarabine had higher scores for social function (P =.008);
__label__noRel	Peripheral neuropathy and alopecia were more common with CVP.	no other differences in QoL were detected.
__label__noRel	Peripheral neuropathy and alopecia were more common with CVP.	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.
__label__noRel	Patients receiving fludarabine had higher scores for social function (P =.008);	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).
__label__noRel	Patients receiving fludarabine had higher scores for social function (P =.008);	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.
__label__noRel	Patients receiving fludarabine had higher scores for social function (P =.008);	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).
__label__noRel	Patients receiving fludarabine had higher scores for social function (P =.008);	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.
__label__noRel	Patients receiving fludarabine had higher scores for social function (P =.008);	Peripheral neuropathy and alopecia were more common with CVP.
__label__noRel	Patients receiving fludarabine had higher scores for social function (P =.008);	no other differences in QoL were detected.
__label__Support	Patients receiving fludarabine had higher scores for social function (P =.008);	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.
__label__noRel	no other differences in QoL were detected.	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).
__label__noRel	no other differences in QoL were detected.	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.
__label__noRel	no other differences in QoL were detected.	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).
__label__noRel	no other differences in QoL were detected.	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.
__label__noRel	no other differences in QoL were detected.	Peripheral neuropathy and alopecia were more common with CVP.
__label__noRel	no other differences in QoL were detected.	Patients receiving fludarabine had higher scores for social function (P =.008);
__label__noRel	no other differences in QoL were detected.	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.
__label__noRel	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).
__label__noRel	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.
__label__noRel	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).
__label__noRel	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.
__label__noRel	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.	Peripheral neuropathy and alopecia were more common with CVP.
__label__noRel	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.	Patients receiving fludarabine had higher scores for social function (P =.008);
__label__noRel	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.	no other differences in QoL were detected.
__label__noRel	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.
__label__noRel	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.
__label__noRel	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.
__label__noRel	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.
__label__noRel	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,
__label__noRel	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).	but the remaining QL data showed no differences.
__label__Support	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.
__label__noRel	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.
__label__noRel	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).
__label__noRel	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.
__label__noRel	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.
__label__noRel	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.
__label__noRel	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,
__label__noRel	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.	but the remaining QL data showed no differences.
__label__Support	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.
__label__noRel	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.
__label__noRel	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).
__label__noRel	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.
__label__noRel	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.
__label__noRel	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.
__label__noRel	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,
__label__noRel	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.	but the remaining QL data showed no differences.
__label__Support	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.
__label__noRel	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.
__label__noRel	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).
__label__noRel	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.
__label__noRel	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.
__label__noRel	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.
__label__noRel	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,
__label__noRel	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.	but the remaining QL data showed no differences.
__label__Attack	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.
__label__noRel	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.
__label__noRel	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).
__label__noRel	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.
__label__noRel	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.
__label__Support	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.
__label__noRel	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,
__label__noRel	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.	but the remaining QL data showed no differences.
__label__noRel	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.
__label__noRel	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.
__label__noRel	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).
__label__noRel	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.
__label__noRel	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.
__label__noRel	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.
__label__noRel	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.
__label__noRel	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,	but the remaining QL data showed no differences.
__label__Support	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.
__label__noRel	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.
__label__noRel	but the remaining QL data showed no differences.	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).
__label__noRel	but the remaining QL data showed no differences.	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.
__label__noRel	but the remaining QL data showed no differences.	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.
__label__noRel	but the remaining QL data showed no differences.	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.
__label__noRel	but the remaining QL data showed no differences.	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.
__label__Attack	but the remaining QL data showed no differences.	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,
__label__noRel	but the remaining QL data showed no differences.	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.
__label__noRel	but the remaining QL data showed no differences.	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.
__label__noRel	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).
__label__noRel	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.
__label__noRel	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.
__label__noRel	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.
__label__noRel	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.
__label__noRel	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,
__label__noRel	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.	but the remaining QL data showed no differences.
__label__noRel	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.
__label__noRel	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).
__label__noRel	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.
__label__noRel	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.
__label__noRel	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.
__label__noRel	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.
__label__noRel	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,
__label__noRel	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.	but the remaining QL data showed no differences.
__label__noRel	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.
__label__noRel	Epoetin alfa administered at 40,000 U once weekly (qw) to anemic cancer patients receiving chemotherapy increases hemoglobin levels, improves quality of life (QOL), and reduces transfusions.	At week 12, Functional Assessment of Cancer Therapy-Anemia (FACT-An; mean, 2.16 +/- 12.84 for epoetin alfa v -4.43 +/- 13.42 for SOC) and FACT-An fatigue (mean, 1.85 +/- 10.52 for epoetin alfa v -3.55 +/- 11.14 for SOC) change scores were significantly higher in the epoetin alfa group (P < .0001).
__label__noRel	Epoetin alfa administered at 40,000 U once weekly (qw) to anemic cancer patients receiving chemotherapy increases hemoglobin levels, improves quality of life (QOL), and reduces transfusions.	Hemoglobin responses defined as mean hemoglobin > or = 12 g/dL or a > or = 2 g/dL increase compared with baseline were significantly higher in the epoetin alfa group versus SOC: 52.0% v 5.1% and 65.7% v 6.3%, respectively (P < .0001 for both comparisons).
__label__noRel	Epoetin alfa administered at 40,000 U once weekly (qw) to anemic cancer patients receiving chemotherapy increases hemoglobin levels, improves quality of life (QOL), and reduces transfusions.	Percentage transfused was significantly lower in the epoetin alfa group compared with SOC (8.6% v 22.9%).
__label__noRel	Epoetin alfa administered at 40,000 U once weekly (qw) to anemic cancer patients receiving chemotherapy increases hemoglobin levels, improves quality of life (QOL), and reduces transfusions.	More than 90% of patients did not require a dose increase and 28.7% had a dose reduction.
__label__noRel	Epoetin alfa administered at 40,000 U once weekly (qw) to anemic cancer patients receiving chemotherapy increases hemoglobin levels, improves quality of life (QOL), and reduces transfusions.	Epoetin alfa administered at 40,000 U qw is effective in improving QOL, maintaining hemoglobin level, and reducing transfusion requirements in breast cancer patients.
__label__noRel	Epoetin alfa administered at 40,000 U once weekly (qw) to anemic cancer patients receiving chemotherapy increases hemoglobin levels, improves quality of life (QOL), and reduces transfusions.	The high effectiveness observed could be attributed in part to early treatment with epoetin alfa.
__label__noRel	At week 12, Functional Assessment of Cancer Therapy-Anemia (FACT-An; mean, 2.16 +/- 12.84 for epoetin alfa v -4.43 +/- 13.42 for SOC) and FACT-An fatigue (mean, 1.85 +/- 10.52 for epoetin alfa v -3.55 +/- 11.14 for SOC) change scores were significantly higher in the epoetin alfa group (P < .0001).	Epoetin alfa administered at 40,000 U once weekly (qw) to anemic cancer patients receiving chemotherapy increases hemoglobin levels, improves quality of life (QOL), and reduces transfusions.
__label__noRel	At week 12, Functional Assessment of Cancer Therapy-Anemia (FACT-An; mean, 2.16 +/- 12.84 for epoetin alfa v -4.43 +/- 13.42 for SOC) and FACT-An fatigue (mean, 1.85 +/- 10.52 for epoetin alfa v -3.55 +/- 11.14 for SOC) change scores were significantly higher in the epoetin alfa group (P < .0001).	Hemoglobin responses defined as mean hemoglobin > or = 12 g/dL or a > or = 2 g/dL increase compared with baseline were significantly higher in the epoetin alfa group versus SOC: 52.0% v 5.1% and 65.7% v 6.3%, respectively (P < .0001 for both comparisons).
__label__noRel	At week 12, Functional Assessment of Cancer Therapy-Anemia (FACT-An; mean, 2.16 +/- 12.84 for epoetin alfa v -4.43 +/- 13.42 for SOC) and FACT-An fatigue (mean, 1.85 +/- 10.52 for epoetin alfa v -3.55 +/- 11.14 for SOC) change scores were significantly higher in the epoetin alfa group (P < .0001).	Percentage transfused was significantly lower in the epoetin alfa group compared with SOC (8.6% v 22.9%).
__label__noRel	At week 12, Functional Assessment of Cancer Therapy-Anemia (FACT-An; mean, 2.16 +/- 12.84 for epoetin alfa v -4.43 +/- 13.42 for SOC) and FACT-An fatigue (mean, 1.85 +/- 10.52 for epoetin alfa v -3.55 +/- 11.14 for SOC) change scores were significantly higher in the epoetin alfa group (P < .0001).	More than 90% of patients did not require a dose increase and 28.7% had a dose reduction.
__label__Support	At week 12, Functional Assessment of Cancer Therapy-Anemia (FACT-An; mean, 2.16 +/- 12.84 for epoetin alfa v -4.43 +/- 13.42 for SOC) and FACT-An fatigue (mean, 1.85 +/- 10.52 for epoetin alfa v -3.55 +/- 11.14 for SOC) change scores were significantly higher in the epoetin alfa group (P < .0001).	Epoetin alfa administered at 40,000 U qw is effective in improving QOL, maintaining hemoglobin level, and reducing transfusion requirements in breast cancer patients.
__label__noRel	At week 12, Functional Assessment of Cancer Therapy-Anemia (FACT-An; mean, 2.16 +/- 12.84 for epoetin alfa v -4.43 +/- 13.42 for SOC) and FACT-An fatigue (mean, 1.85 +/- 10.52 for epoetin alfa v -3.55 +/- 11.14 for SOC) change scores were significantly higher in the epoetin alfa group (P < .0001).	The high effectiveness observed could be attributed in part to early treatment with epoetin alfa.
__label__noRel	Hemoglobin responses defined as mean hemoglobin > or = 12 g/dL or a > or = 2 g/dL increase compared with baseline were significantly higher in the epoetin alfa group versus SOC: 52.0% v 5.1% and 65.7% v 6.3%, respectively (P < .0001 for both comparisons).	Epoetin alfa administered at 40,000 U once weekly (qw) to anemic cancer patients receiving chemotherapy increases hemoglobin levels, improves quality of life (QOL), and reduces transfusions.
__label__noRel	Hemoglobin responses defined as mean hemoglobin > or = 12 g/dL or a > or = 2 g/dL increase compared with baseline were significantly higher in the epoetin alfa group versus SOC: 52.0% v 5.1% and 65.7% v 6.3%, respectively (P < .0001 for both comparisons).	At week 12, Functional Assessment of Cancer Therapy-Anemia (FACT-An; mean, 2.16 +/- 12.84 for epoetin alfa v -4.43 +/- 13.42 for SOC) and FACT-An fatigue (mean, 1.85 +/- 10.52 for epoetin alfa v -3.55 +/- 11.14 for SOC) change scores were significantly higher in the epoetin alfa group (P < .0001).
__label__noRel	Hemoglobin responses defined as mean hemoglobin > or = 12 g/dL or a > or = 2 g/dL increase compared with baseline were significantly higher in the epoetin alfa group versus SOC: 52.0% v 5.1% and 65.7% v 6.3%, respectively (P < .0001 for both comparisons).	Percentage transfused was significantly lower in the epoetin alfa group compared with SOC (8.6% v 22.9%).
__label__noRel	Hemoglobin responses defined as mean hemoglobin > or = 12 g/dL or a > or = 2 g/dL increase compared with baseline were significantly higher in the epoetin alfa group versus SOC: 52.0% v 5.1% and 65.7% v 6.3%, respectively (P < .0001 for both comparisons).	More than 90% of patients did not require a dose increase and 28.7% had a dose reduction.
__label__Support	Hemoglobin responses defined as mean hemoglobin > or = 12 g/dL or a > or = 2 g/dL increase compared with baseline were significantly higher in the epoetin alfa group versus SOC: 52.0% v 5.1% and 65.7% v 6.3%, respectively (P < .0001 for both comparisons).	Epoetin alfa administered at 40,000 U qw is effective in improving QOL, maintaining hemoglobin level, and reducing transfusion requirements in breast cancer patients.
__label__noRel	Hemoglobin responses defined as mean hemoglobin > or = 12 g/dL or a > or = 2 g/dL increase compared with baseline were significantly higher in the epoetin alfa group versus SOC: 52.0% v 5.1% and 65.7% v 6.3%, respectively (P < .0001 for both comparisons).	The high effectiveness observed could be attributed in part to early treatment with epoetin alfa.
__label__noRel	Percentage transfused was significantly lower in the epoetin alfa group compared with SOC (8.6% v 22.9%).	Epoetin alfa administered at 40,000 U once weekly (qw) to anemic cancer patients receiving chemotherapy increases hemoglobin levels, improves quality of life (QOL), and reduces transfusions.
__label__noRel	Percentage transfused was significantly lower in the epoetin alfa group compared with SOC (8.6% v 22.9%).	At week 12, Functional Assessment of Cancer Therapy-Anemia (FACT-An; mean, 2.16 +/- 12.84 for epoetin alfa v -4.43 +/- 13.42 for SOC) and FACT-An fatigue (mean, 1.85 +/- 10.52 for epoetin alfa v -3.55 +/- 11.14 for SOC) change scores were significantly higher in the epoetin alfa group (P < .0001).
__label__noRel	Percentage transfused was significantly lower in the epoetin alfa group compared with SOC (8.6% v 22.9%).	Hemoglobin responses defined as mean hemoglobin > or = 12 g/dL or a > or = 2 g/dL increase compared with baseline were significantly higher in the epoetin alfa group versus SOC: 52.0% v 5.1% and 65.7% v 6.3%, respectively (P < .0001 for both comparisons).
__label__noRel	Percentage transfused was significantly lower in the epoetin alfa group compared with SOC (8.6% v 22.9%).	More than 90% of patients did not require a dose increase and 28.7% had a dose reduction.
__label__Support	Percentage transfused was significantly lower in the epoetin alfa group compared with SOC (8.6% v 22.9%).	Epoetin alfa administered at 40,000 U qw is effective in improving QOL, maintaining hemoglobin level, and reducing transfusion requirements in breast cancer patients.
__label__noRel	Percentage transfused was significantly lower in the epoetin alfa group compared with SOC (8.6% v 22.9%).	The high effectiveness observed could be attributed in part to early treatment with epoetin alfa.
__label__noRel	More than 90% of patients did not require a dose increase and 28.7% had a dose reduction.	Epoetin alfa administered at 40,000 U once weekly (qw) to anemic cancer patients receiving chemotherapy increases hemoglobin levels, improves quality of life (QOL), and reduces transfusions.
__label__noRel	More than 90% of patients did not require a dose increase and 28.7% had a dose reduction.	At week 12, Functional Assessment of Cancer Therapy-Anemia (FACT-An; mean, 2.16 +/- 12.84 for epoetin alfa v -4.43 +/- 13.42 for SOC) and FACT-An fatigue (mean, 1.85 +/- 10.52 for epoetin alfa v -3.55 +/- 11.14 for SOC) change scores were significantly higher in the epoetin alfa group (P < .0001).
__label__noRel	More than 90% of patients did not require a dose increase and 28.7% had a dose reduction.	Hemoglobin responses defined as mean hemoglobin > or = 12 g/dL or a > or = 2 g/dL increase compared with baseline were significantly higher in the epoetin alfa group versus SOC: 52.0% v 5.1% and 65.7% v 6.3%, respectively (P < .0001 for both comparisons).
__label__noRel	More than 90% of patients did not require a dose increase and 28.7% had a dose reduction.	Percentage transfused was significantly lower in the epoetin alfa group compared with SOC (8.6% v 22.9%).
__label__Support	More than 90% of patients did not require a dose increase and 28.7% had a dose reduction.	Epoetin alfa administered at 40,000 U qw is effective in improving QOL, maintaining hemoglobin level, and reducing transfusion requirements in breast cancer patients.
__label__noRel	More than 90% of patients did not require a dose increase and 28.7% had a dose reduction.	The high effectiveness observed could be attributed in part to early treatment with epoetin alfa.
__label__noRel	Epoetin alfa administered at 40,000 U qw is effective in improving QOL, maintaining hemoglobin level, and reducing transfusion requirements in breast cancer patients.	Epoetin alfa administered at 40,000 U once weekly (qw) to anemic cancer patients receiving chemotherapy increases hemoglobin levels, improves quality of life (QOL), and reduces transfusions.
__label__noRel	Epoetin alfa administered at 40,000 U qw is effective in improving QOL, maintaining hemoglobin level, and reducing transfusion requirements in breast cancer patients.	At week 12, Functional Assessment of Cancer Therapy-Anemia (FACT-An; mean, 2.16 +/- 12.84 for epoetin alfa v -4.43 +/- 13.42 for SOC) and FACT-An fatigue (mean, 1.85 +/- 10.52 for epoetin alfa v -3.55 +/- 11.14 for SOC) change scores were significantly higher in the epoetin alfa group (P < .0001).
__label__noRel	Epoetin alfa administered at 40,000 U qw is effective in improving QOL, maintaining hemoglobin level, and reducing transfusion requirements in breast cancer patients.	Hemoglobin responses defined as mean hemoglobin > or = 12 g/dL or a > or = 2 g/dL increase compared with baseline were significantly higher in the epoetin alfa group versus SOC: 52.0% v 5.1% and 65.7% v 6.3%, respectively (P < .0001 for both comparisons).
__label__noRel	Epoetin alfa administered at 40,000 U qw is effective in improving QOL, maintaining hemoglobin level, and reducing transfusion requirements in breast cancer patients.	Percentage transfused was significantly lower in the epoetin alfa group compared with SOC (8.6% v 22.9%).
__label__noRel	Epoetin alfa administered at 40,000 U qw is effective in improving QOL, maintaining hemoglobin level, and reducing transfusion requirements in breast cancer patients.	More than 90% of patients did not require a dose increase and 28.7% had a dose reduction.
__label__noRel	Epoetin alfa administered at 40,000 U qw is effective in improving QOL, maintaining hemoglobin level, and reducing transfusion requirements in breast cancer patients.	The high effectiveness observed could be attributed in part to early treatment with epoetin alfa.
__label__noRel	The high effectiveness observed could be attributed in part to early treatment with epoetin alfa.	Epoetin alfa administered at 40,000 U once weekly (qw) to anemic cancer patients receiving chemotherapy increases hemoglobin levels, improves quality of life (QOL), and reduces transfusions.
__label__noRel	The high effectiveness observed could be attributed in part to early treatment with epoetin alfa.	At week 12, Functional Assessment of Cancer Therapy-Anemia (FACT-An; mean, 2.16 +/- 12.84 for epoetin alfa v -4.43 +/- 13.42 for SOC) and FACT-An fatigue (mean, 1.85 +/- 10.52 for epoetin alfa v -3.55 +/- 11.14 for SOC) change scores were significantly higher in the epoetin alfa group (P < .0001).
__label__noRel	The high effectiveness observed could be attributed in part to early treatment with epoetin alfa.	Hemoglobin responses defined as mean hemoglobin > or = 12 g/dL or a > or = 2 g/dL increase compared with baseline were significantly higher in the epoetin alfa group versus SOC: 52.0% v 5.1% and 65.7% v 6.3%, respectively (P < .0001 for both comparisons).
__label__noRel	The high effectiveness observed could be attributed in part to early treatment with epoetin alfa.	Percentage transfused was significantly lower in the epoetin alfa group compared with SOC (8.6% v 22.9%).
__label__noRel	The high effectiveness observed could be attributed in part to early treatment with epoetin alfa.	More than 90% of patients did not require a dose increase and 28.7% had a dose reduction.
__label__Attack	The high effectiveness observed could be attributed in part to early treatment with epoetin alfa.	Epoetin alfa administered at 40,000 U qw is effective in improving QOL, maintaining hemoglobin level, and reducing transfusion requirements in breast cancer patients.
__label__noRel	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).
__label__noRel	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.
__label__noRel	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.
__label__noRel	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).
__label__noRel	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.
__label__noRel	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.
__label__noRel	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.
__label__Support	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.
__label__noRel	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.
__label__noRel	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.
__label__noRel	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).
__label__noRel	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.
__label__noRel	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.
__label__noRel	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.
__label__Support	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.
__label__noRel	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).
__label__noRel	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.
__label__noRel	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).
__label__noRel	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.
__label__noRel	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.
__label__noRel	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.
__label__noRel	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.
__label__noRel	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).
__label__noRel	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.
__label__noRel	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).
__label__noRel	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.
__label__noRel	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.
__label__Support	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.
__label__noRel	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.
__label__noRel	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).
__label__noRel	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.
__label__noRel	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.
__label__noRel	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.
__label__noRel	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.
__label__Support	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.
__label__noRel	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.
__label__noRel	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).
__label__noRel	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.
__label__noRel	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.
__label__noRel	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).
__label__noRel	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.
__label__Support	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.
__label__noRel	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.
__label__noRel	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).
__label__noRel	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.
__label__noRel	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.
__label__noRel	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).
__label__noRel	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.
__label__Support	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.
__label__noRel	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.
__label__noRel	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).
__label__noRel	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.
__label__noRel	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.
__label__noRel	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).
__label__noRel	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.
__label__noRel	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.
__label__noRel	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.
__label__noRel	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.
__label__noRel	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.
__label__noRel	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.
__label__noRel	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.	The results were statistically significant.
__label__noRel	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.
__label__noRel	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.	The results were statistically significant.
__label__Attack	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,
__label__noRel	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.
__label__noRel	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.
__label__noRel	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.
__label__noRel	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.
__label__noRel	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.
__label__noRel	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.
__label__noRel	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.	The results were statistically significant.
__label__noRel	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.
__label__noRel	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.	The results were statistically significant.
__label__Attack	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,
__label__noRel	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.
__label__noRel	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.
__label__noRel	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.
__label__noRel	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.
__label__noRel	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.
__label__noRel	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.
__label__noRel	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.	The results were statistically significant.
__label__noRel	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.
__label__noRel	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.	The results were statistically significant.
__label__Support	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,
__label__noRel	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.
__label__noRel	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.
__label__noRel	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.
__label__noRel	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.
__label__noRel	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.
__label__noRel	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.
__label__noRel	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.	The results were statistically significant.
__label__noRel	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.
__label__noRel	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.	The results were statistically significant.
__label__Support	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,
__label__noRel	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.
__label__noRel	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.
__label__noRel	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.
__label__noRel	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.
__label__noRel	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.
__label__noRel	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.
__label__noRel	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.	The results were statistically significant.
__label__noRel	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.
__label__noRel	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.	The results were statistically significant.
__label__Attack	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,
__label__noRel	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.
__label__noRel	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.
__label__noRel	The results were statistically significant.	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.
__label__noRel	The results were statistically significant.	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.
__label__noRel	The results were statistically significant.	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.
__label__noRel	The results were statistically significant.	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.
__label__Support	The results were statistically significant.	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.
__label__noRel	The results were statistically significant.	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.
__label__noRel	The results were statistically significant.	The results were statistically significant.
__label__noRel	The results were statistically significant.	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,
__label__noRel	The results were statistically significant.	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.
__label__noRel	The results were statistically significant.	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.
__label__noRel	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.
__label__noRel	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.
__label__noRel	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.
__label__noRel	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.
__label__noRel	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.
__label__noRel	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.	The results were statistically significant.
__label__noRel	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.	The results were statistically significant.
__label__noRel	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,
__label__Support	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.
__label__noRel	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.
__label__noRel	The results were statistically significant.	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.
__label__noRel	The results were statistically significant.	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.
__label__noRel	The results were statistically significant.	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.
__label__noRel	The results were statistically significant.	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.
__label__noRel	The results were statistically significant.	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.
__label__noRel	The results were statistically significant.	The results were statistically significant.
__label__Support	The results were statistically significant.	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.
__label__noRel	The results were statistically significant.	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,
__label__noRel	The results were statistically significant.	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.
__label__noRel	The results were statistically significant.	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.
__label__noRel	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.
__label__noRel	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.
__label__noRel	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.
__label__noRel	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.
__label__noRel	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.
__label__noRel	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,	The results were statistically significant.
__label__noRel	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.
__label__noRel	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,	The results were statistically significant.
__label__noRel	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.
__label__Support	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.
__label__noRel	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.
__label__noRel	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.
__label__noRel	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.
__label__noRel	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.
__label__noRel	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.
__label__noRel	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.	The results were statistically significant.
__label__noRel	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.
__label__noRel	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.	The results were statistically significant.
__label__Attack	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,
__label__noRel	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.
__label__noRel	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.
__label__noRel	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.
__label__noRel	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.
__label__noRel	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.
__label__noRel	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.
__label__noRel	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.	The results were statistically significant.
__label__noRel	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.
__label__noRel	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.	The results were statistically significant.
__label__noRel	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,
__label__noRel	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.
__label__noRel	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).	Other grade 3/4 toxic effects were rare (<5%).
__label__noRel	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.
__label__noRel	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.
__label__noRel	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.
__label__Support	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,
__label__noRel	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).	but the study was not designed to detect differences in these parameters.
__label__noRel	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).	tumor response was shown to have a beneficial effect on QoL indicators.
__label__noRel	Other grade 3/4 toxic effects were rare (<5%).	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).
__label__noRel	Other grade 3/4 toxic effects were rare (<5%).	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.
__label__noRel	Other grade 3/4 toxic effects were rare (<5%).	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.
__label__noRel	Other grade 3/4 toxic effects were rare (<5%).	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.
__label__Support	Other grade 3/4 toxic effects were rare (<5%).	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,
__label__noRel	Other grade 3/4 toxic effects were rare (<5%).	but the study was not designed to detect differences in these parameters.
__label__noRel	Other grade 3/4 toxic effects were rare (<5%).	tumor response was shown to have a beneficial effect on QoL indicators.
__label__noRel	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).
__label__noRel	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.	Other grade 3/4 toxic effects were rare (<5%).
__label__noRel	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.
__label__noRel	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.
__label__noRel	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,
__label__noRel	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.	but the study was not designed to detect differences in these parameters.
__label__noRel	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.	tumor response was shown to have a beneficial effect on QoL indicators.
__label__noRel	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).
__label__noRel	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.	Other grade 3/4 toxic effects were rare (<5%).
__label__noRel	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.
__label__noRel	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.
__label__Support	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,
__label__noRel	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.	but the study was not designed to detect differences in these parameters.
__label__noRel	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.	tumor response was shown to have a beneficial effect on QoL indicators.
__label__noRel	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).
__label__noRel	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.	Other grade 3/4 toxic effects were rare (<5%).
__label__noRel	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.
__label__noRel	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.
__label__noRel	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,
__label__noRel	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.	but the study was not designed to detect differences in these parameters.
__label__Support	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.	tumor response was shown to have a beneficial effect on QoL indicators.
__label__noRel	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).
__label__noRel	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,	Other grade 3/4 toxic effects were rare (<5%).
__label__noRel	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.
__label__noRel	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.
__label__noRel	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.
__label__noRel	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,	but the study was not designed to detect differences in these parameters.
__label__noRel	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,	tumor response was shown to have a beneficial effect on QoL indicators.
__label__noRel	but the study was not designed to detect differences in these parameters.	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).
__label__noRel	but the study was not designed to detect differences in these parameters.	Other grade 3/4 toxic effects were rare (<5%).
__label__noRel	but the study was not designed to detect differences in these parameters.	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.
__label__noRel	but the study was not designed to detect differences in these parameters.	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.
__label__noRel	but the study was not designed to detect differences in these parameters.	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.
__label__Attack	but the study was not designed to detect differences in these parameters.	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,
__label__noRel	but the study was not designed to detect differences in these parameters.	tumor response was shown to have a beneficial effect on QoL indicators.
__label__noRel	tumor response was shown to have a beneficial effect on QoL indicators.	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).
__label__noRel	tumor response was shown to have a beneficial effect on QoL indicators.	Other grade 3/4 toxic effects were rare (<5%).
__label__noRel	tumor response was shown to have a beneficial effect on QoL indicators.	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.
__label__noRel	tumor response was shown to have a beneficial effect on QoL indicators.	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.
__label__noRel	tumor response was shown to have a beneficial effect on QoL indicators.	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.
__label__noRel	tumor response was shown to have a beneficial effect on QoL indicators.	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,
__label__noRel	tumor response was shown to have a beneficial effect on QoL indicators.	but the study was not designed to detect differences in these parameters.
__label__noRel	There were no significant group differences in global QoL, pain or fatigue up to 26 weeks.	The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks (P<0.05),
__label__noRel	There were no significant group differences in global QoL, pain or fatigue up to 26 weeks.	but this finding was inconsistent across different methods of analysis.
__label__noRel	There were no significant group differences in global QoL, pain or fatigue up to 26 weeks.	Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P=0.75, HR 1.04, 95% CI 0.82-1.31).
__label__noRel	There were no significant group differences in global QoL, pain or fatigue up to 26 weeks.	One- and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively.
__label__noRel	There were no significant group differences in global QoL, pain or fatigue up to 26 weeks.	Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively (P=0.21, HR 0.86, 95% CI 0.68-1.08).
__label__Support	There were no significant group differences in global QoL, pain or fatigue up to 26 weeks.	In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.
__label__noRel	The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks (P<0.05),	There were no significant group differences in global QoL, pain or fatigue up to 26 weeks.
__label__noRel	The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks (P<0.05),	but this finding was inconsistent across different methods of analysis.
__label__noRel	The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks (P<0.05),	Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P=0.75, HR 1.04, 95% CI 0.82-1.31).
__label__noRel	The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks (P<0.05),	One- and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively.
__label__noRel	The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks (P<0.05),	Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively (P=0.21, HR 0.86, 95% CI 0.68-1.08).
__label__Support	The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks (P<0.05),	In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.
__label__noRel	but this finding was inconsistent across different methods of analysis.	There were no significant group differences in global QoL, pain or fatigue up to 26 weeks.
__label__Attack	but this finding was inconsistent across different methods of analysis.	The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks (P<0.05),
__label__noRel	but this finding was inconsistent across different methods of analysis.	Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P=0.75, HR 1.04, 95% CI 0.82-1.31).
__label__noRel	but this finding was inconsistent across different methods of analysis.	One- and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively.
__label__noRel	but this finding was inconsistent across different methods of analysis.	Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively (P=0.21, HR 0.86, 95% CI 0.68-1.08).
__label__noRel	but this finding was inconsistent across different methods of analysis.	In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.
__label__noRel	Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P=0.75, HR 1.04, 95% CI 0.82-1.31).	There were no significant group differences in global QoL, pain or fatigue up to 26 weeks.
__label__noRel	Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P=0.75, HR 1.04, 95% CI 0.82-1.31).	The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks (P<0.05),
__label__noRel	Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P=0.75, HR 1.04, 95% CI 0.82-1.31).	but this finding was inconsistent across different methods of analysis.
__label__noRel	Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P=0.75, HR 1.04, 95% CI 0.82-1.31).	One- and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively.
__label__noRel	Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P=0.75, HR 1.04, 95% CI 0.82-1.31).	Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively (P=0.21, HR 0.86, 95% CI 0.68-1.08).
__label__Support	Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P=0.75, HR 1.04, 95% CI 0.82-1.31).	In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.
__label__noRel	One- and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively.	There were no significant group differences in global QoL, pain or fatigue up to 26 weeks.
__label__noRel	One- and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively.	The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks (P<0.05),
__label__noRel	One- and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively.	but this finding was inconsistent across different methods of analysis.
__label__noRel	One- and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively.	Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P=0.75, HR 1.04, 95% CI 0.82-1.31).
__label__noRel	One- and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively.	Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively (P=0.21, HR 0.86, 95% CI 0.68-1.08).
__label__Support	One- and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively.	In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.
__label__noRel	Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively (P=0.21, HR 0.86, 95% CI 0.68-1.08).	There were no significant group differences in global QoL, pain or fatigue up to 26 weeks.
__label__noRel	Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively (P=0.21, HR 0.86, 95% CI 0.68-1.08).	The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks (P<0.05),
__label__noRel	Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively (P=0.21, HR 0.86, 95% CI 0.68-1.08).	but this finding was inconsistent across different methods of analysis.
__label__noRel	Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively (P=0.21, HR 0.86, 95% CI 0.68-1.08).	Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P=0.75, HR 1.04, 95% CI 0.82-1.31).
__label__noRel	Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively (P=0.21, HR 0.86, 95% CI 0.68-1.08).	One- and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively.
__label__Support	Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively (P=0.21, HR 0.86, 95% CI 0.68-1.08).	In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.
__label__noRel	In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.	There were no significant group differences in global QoL, pain or fatigue up to 26 weeks.
__label__noRel	In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.	The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks (P<0.05),
__label__noRel	In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.	but this finding was inconsistent across different methods of analysis.
__label__noRel	In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.	Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P=0.75, HR 1.04, 95% CI 0.82-1.31).
__label__noRel	In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.	One- and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively.
__label__noRel	In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.	Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively (P=0.21, HR 0.86, 95% CI 0.68-1.08).
__label__noRel	Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy.	Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.
__label__noRel	Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy.	At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).
__label__noRel	Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy.	At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.
__label__noRel	Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy.	There were no opportunistic infections.
__label__noRel	Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.	Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy.
__label__noRel	Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.	At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).
__label__noRel	Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.	At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.
__label__noRel	Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.	There were no opportunistic infections.
__label__noRel	At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).	Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy.
__label__Support	At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).	Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.
__label__noRel	At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).	At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.
__label__noRel	At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).	There were no opportunistic infections.
__label__noRel	At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.	Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy.
__label__Support	At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.	Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.
__label__noRel	At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.	At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).
__label__noRel	At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.	There were no opportunistic infections.
__label__Support	There were no opportunistic infections.	Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy.
__label__noRel	There were no opportunistic infections.	Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.
__label__noRel	There were no opportunistic infections.	At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).
__label__noRel	There were no opportunistic infections.	At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.
__label__noRel	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).
__label__noRel	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).
__label__noRel	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.
__label__noRel	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.
__label__noRel	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).
__label__noRel	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.
__label__Support	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.
__label__noRel	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.
__label__noRel	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).
__label__noRel	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.
__label__noRel	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.
__label__noRel	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).
__label__noRel	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.
__label__Support	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.
__label__noRel	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.
__label__noRel	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).
__label__noRel	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.
__label__noRel	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.
__label__noRel	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).
__label__noRel	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.
__label__Support	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.
__label__noRel	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.
__label__noRel	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).
__label__noRel	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).
__label__noRel	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.
__label__noRel	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).
__label__Support	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.
__label__noRel	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.
__label__noRel	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.
__label__noRel	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).
__label__noRel	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).
__label__noRel	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.
__label__noRel	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).
__label__noRel	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.
__label__Support	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.
__label__noRel	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.
__label__noRel	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).
__label__noRel	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).
__label__noRel	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.
__label__noRel	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.
__label__noRel	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.
__label__Support	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.
__label__noRel	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.
__label__noRel	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).
__label__noRel	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).
__label__noRel	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.
__label__noRel	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.
__label__noRel	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).
__label__noRel	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.
__label__noRel	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.
__label__noRel	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).
__label__noRel	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).
__label__noRel	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.
__label__noRel	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.
__label__noRel	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).
__label__noRel	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.
__label__noRel	Based on the results of the area under the curve (AUC) analysis, patients receiving HMB/Arg/Gln had a strong trend higher LBM throughout the study as measured by both bioimpedance (p = 0.08) and skin-fold measurements (p = 0.08).	Among the subset of patients receiving concurrent chemotherapy, there were again no significant differences in the endpoints.
__label__noRel	Based on the results of the area under the curve (AUC) analysis, patients receiving HMB/Arg/Gln had a strong trend higher LBM throughout the study as measured by both bioimpedance (p = 0.08) and skin-fold measurements (p = 0.08).	This trial was unable to adequately test the ability of beta-hydroxy beta-methylbutyrate, glutamine, and arginine to reverse or prevent lean body mass wasting among cancer patients.
__label__noRel	Based on the results of the area under the curve (AUC) analysis, patients receiving HMB/Arg/Gln had a strong trend higher LBM throughout the study as measured by both bioimpedance (p = 0.08) and skin-fold measurements (p = 0.08).	The secondary endpoints were also not significantly different between the arms.
__label__noRel	Among the subset of patients receiving concurrent chemotherapy, there were again no significant differences in the endpoints.	Based on the results of the area under the curve (AUC) analysis, patients receiving HMB/Arg/Gln had a strong trend higher LBM throughout the study as measured by both bioimpedance (p = 0.08) and skin-fold measurements (p = 0.08).
__label__Support	Among the subset of patients receiving concurrent chemotherapy, there were again no significant differences in the endpoints.	This trial was unable to adequately test the ability of beta-hydroxy beta-methylbutyrate, glutamine, and arginine to reverse or prevent lean body mass wasting among cancer patients.
__label__noRel	Among the subset of patients receiving concurrent chemotherapy, there were again no significant differences in the endpoints.	The secondary endpoints were also not significantly different between the arms.
__label__noRel	This trial was unable to adequately test the ability of beta-hydroxy beta-methylbutyrate, glutamine, and arginine to reverse or prevent lean body mass wasting among cancer patients.	Based on the results of the area under the curve (AUC) analysis, patients receiving HMB/Arg/Gln had a strong trend higher LBM throughout the study as measured by both bioimpedance (p = 0.08) and skin-fold measurements (p = 0.08).
__label__noRel	This trial was unable to adequately test the ability of beta-hydroxy beta-methylbutyrate, glutamine, and arginine to reverse or prevent lean body mass wasting among cancer patients.	Among the subset of patients receiving concurrent chemotherapy, there were again no significant differences in the endpoints.
__label__noRel	This trial was unable to adequately test the ability of beta-hydroxy beta-methylbutyrate, glutamine, and arginine to reverse or prevent lean body mass wasting among cancer patients.	The secondary endpoints were also not significantly different between the arms.
__label__noRel	The secondary endpoints were also not significantly different between the arms.	Based on the results of the area under the curve (AUC) analysis, patients receiving HMB/Arg/Gln had a strong trend higher LBM throughout the study as measured by both bioimpedance (p = 0.08) and skin-fold measurements (p = 0.08).
__label__noRel	The secondary endpoints were also not significantly different between the arms.	Among the subset of patients receiving concurrent chemotherapy, there were again no significant differences in the endpoints.
__label__Support	The secondary endpoints were also not significantly different between the arms.	This trial was unable to adequately test the ability of beta-hydroxy beta-methylbutyrate, glutamine, and arginine to reverse or prevent lean body mass wasting among cancer patients.
__label__noRel	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.
__label__noRel	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).	Le(y) is an attractive target since it is expressed by most NSCLC.
__label__noRel	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.
__label__noRel	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively
__label__noRel	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).	Toxicity was mild in both arms.
__label__noRel	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).	QOL analyses favored Arm A.
__label__noRel	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients
__label__noRel	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).
__label__noRel	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.	Le(y) is an attractive target since it is expressed by most NSCLC.
__label__noRel	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.
__label__noRel	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively
__label__noRel	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.	Toxicity was mild in both arms.
__label__noRel	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.	QOL analyses favored Arm A.
__label__noRel	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients
__label__noRel	Le(y) is an attractive target since it is expressed by most NSCLC.	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).
__label__noRel	Le(y) is an attractive target since it is expressed by most NSCLC.	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.
__label__noRel	Le(y) is an attractive target since it is expressed by most NSCLC.	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.
__label__noRel	Le(y) is an attractive target since it is expressed by most NSCLC.	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively
__label__noRel	Le(y) is an attractive target since it is expressed by most NSCLC.	Toxicity was mild in both arms.
__label__noRel	Le(y) is an attractive target since it is expressed by most NSCLC.	QOL analyses favored Arm A.
__label__noRel	Le(y) is an attractive target since it is expressed by most NSCLC.	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients
__label__noRel	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).
__label__noRel	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.
__label__noRel	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.	Le(y) is an attractive target since it is expressed by most NSCLC.
__label__noRel	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively
__label__noRel	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.	Toxicity was mild in both arms.
__label__noRel	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.	QOL analyses favored Arm A.
__label__Support	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients
__label__noRel	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).
__label__noRel	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.
__label__noRel	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively	Le(y) is an attractive target since it is expressed by most NSCLC.
__label__noRel	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.
__label__noRel	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively	Toxicity was mild in both arms.
__label__noRel	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively	QOL analyses favored Arm A.
__label__Support	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients
__label__noRel	Toxicity was mild in both arms.	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).
__label__noRel	Toxicity was mild in both arms.	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.
__label__noRel	Toxicity was mild in both arms.	Le(y) is an attractive target since it is expressed by most NSCLC.
__label__noRel	Toxicity was mild in both arms.	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.
__label__noRel	Toxicity was mild in both arms.	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively
__label__noRel	Toxicity was mild in both arms.	QOL analyses favored Arm A.
__label__Support	Toxicity was mild in both arms.	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients
__label__noRel	QOL analyses favored Arm A.	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).
__label__noRel	QOL analyses favored Arm A.	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.
__label__noRel	QOL analyses favored Arm A.	Le(y) is an attractive target since it is expressed by most NSCLC.
__label__noRel	QOL analyses favored Arm A.	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.
__label__noRel	QOL analyses favored Arm A.	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively
__label__noRel	QOL analyses favored Arm A.	Toxicity was mild in both arms.
__label__Support	QOL analyses favored Arm A.	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients
__label__noRel	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).
__label__noRel	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.
__label__noRel	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients	Le(y) is an attractive target since it is expressed by most NSCLC.
__label__noRel	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.
__label__noRel	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively
__label__noRel	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients	Toxicity was mild in both arms.
__label__noRel	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients	QOL analyses favored Arm A.
__label__noRel	Adverse events in both groups included fatigue, diminished sexual function, and hot flushes.	The combination of radiotherapy plus 6 months of androgen suppression provides inferior survival as compared with radiotherapy plus 3 years of androgen suppression in the treatment of locally advanced prostate cancer.
__label__noRel	Adverse events in both groups included fatigue, diminished sexual function, and hot flushes.	After a median follow-up of 6.4 years, 132 patients in the short-term group and 98 in the long-term group had died;
__label__noRel	Adverse events in both groups included fatigue, diminished sexual function, and hot flushes.	the number of deaths due to prostate cancer was 47 in the short-term group and 29 in the long-term group.
__label__noRel	Adverse events in both groups included fatigue, diminished sexual function, and hot flushes.	The 5-year overall mortality for short-term and long-term suppression was 19.0% and 15.2%, respectively;
__label__noRel	The combination of radiotherapy plus 6 months of androgen suppression provides inferior survival as compared with radiotherapy plus 3 years of androgen suppression in the treatment of locally advanced prostate cancer.	Adverse events in both groups included fatigue, diminished sexual function, and hot flushes.
__label__noRel	The combination of radiotherapy plus 6 months of androgen suppression provides inferior survival as compared with radiotherapy plus 3 years of androgen suppression in the treatment of locally advanced prostate cancer.	After a median follow-up of 6.4 years, 132 patients in the short-term group and 98 in the long-term group had died;
__label__noRel	The combination of radiotherapy plus 6 months of androgen suppression provides inferior survival as compared with radiotherapy plus 3 years of androgen suppression in the treatment of locally advanced prostate cancer.	the number of deaths due to prostate cancer was 47 in the short-term group and 29 in the long-term group.
__label__noRel	The combination of radiotherapy plus 6 months of androgen suppression provides inferior survival as compared with radiotherapy plus 3 years of androgen suppression in the treatment of locally advanced prostate cancer.	The 5-year overall mortality for short-term and long-term suppression was 19.0% and 15.2%, respectively;
__label__noRel	After a median follow-up of 6.4 years, 132 patients in the short-term group and 98 in the long-term group had died;	Adverse events in both groups included fatigue, diminished sexual function, and hot flushes.
__label__Support	After a median follow-up of 6.4 years, 132 patients in the short-term group and 98 in the long-term group had died;	The combination of radiotherapy plus 6 months of androgen suppression provides inferior survival as compared with radiotherapy plus 3 years of androgen suppression in the treatment of locally advanced prostate cancer.
__label__noRel	After a median follow-up of 6.4 years, 132 patients in the short-term group and 98 in the long-term group had died;	the number of deaths due to prostate cancer was 47 in the short-term group and 29 in the long-term group.
__label__noRel	After a median follow-up of 6.4 years, 132 patients in the short-term group and 98 in the long-term group had died;	The 5-year overall mortality for short-term and long-term suppression was 19.0% and 15.2%, respectively;
__label__noRel	the number of deaths due to prostate cancer was 47 in the short-term group and 29 in the long-term group.	Adverse events in both groups included fatigue, diminished sexual function, and hot flushes.
__label__Support	the number of deaths due to prostate cancer was 47 in the short-term group and 29 in the long-term group.	The combination of radiotherapy plus 6 months of androgen suppression provides inferior survival as compared with radiotherapy plus 3 years of androgen suppression in the treatment of locally advanced prostate cancer.
__label__noRel	the number of deaths due to prostate cancer was 47 in the short-term group and 29 in the long-term group.	After a median follow-up of 6.4 years, 132 patients in the short-term group and 98 in the long-term group had died;
__label__noRel	the number of deaths due to prostate cancer was 47 in the short-term group and 29 in the long-term group.	The 5-year overall mortality for short-term and long-term suppression was 19.0% and 15.2%, respectively;
__label__noRel	The 5-year overall mortality for short-term and long-term suppression was 19.0% and 15.2%, respectively;	Adverse events in both groups included fatigue, diminished sexual function, and hot flushes.
__label__Support	The 5-year overall mortality for short-term and long-term suppression was 19.0% and 15.2%, respectively;	The combination of radiotherapy plus 6 months of androgen suppression provides inferior survival as compared with radiotherapy plus 3 years of androgen suppression in the treatment of locally advanced prostate cancer.
__label__noRel	The 5-year overall mortality for short-term and long-term suppression was 19.0% and 15.2%, respectively;	After a median follow-up of 6.4 years, 132 patients in the short-term group and 98 in the long-term group had died;
__label__noRel	The 5-year overall mortality for short-term and long-term suppression was 19.0% and 15.2%, respectively;	the number of deaths due to prostate cancer was 47 in the short-term group and 29 in the long-term group.
__label__noRel	The QLQ-C30 subscales physical function (P=0.044) and constipation (P<0.001) showed an improvement during induction in favour of the MP arm.	During thalidomide maintenance, the scores for the QLQ-MY24 paraesthesia became significantly higher in the MPT arm (P<0.001).
__label__noRel	The QLQ-C30 subscales physical function (P=0.044) and constipation (P<0.001) showed an improvement during induction in favour of the MP arm.	The QLQ-C30 subscales pain (P=0.12), insomnia (P=0.068), appetite loss (P=0.074) and the QLQ-MY24 item sick (P=0.086) scored marginally better during thalidomide maintenance.
__label__noRel	The QLQ-C30 subscales physical function (P=0.044) and constipation (P<0.001) showed an improvement during induction in favour of the MP arm.	The overall QoL-scale QLQ-C30-HRQoL showed a significant time trend towards more favourable mean values during protocol treatment without differences between MP and MPT.
__label__Support	The QLQ-C30 subscales physical function (P=0.044) and constipation (P<0.001) showed an improvement during induction in favour of the MP arm.	This study shows that the higher frequency of toxicity associated with MPT does not translate into a negative effect on HRQoL and that MPT holds a better patient perspective.
__label__noRel	The QLQ-C30 subscales physical function (P=0.044) and constipation (P<0.001) showed an improvement during induction in favour of the MP arm.	For the QLQ-C30 subscales emotional function and future perspectives, difference in favour of the MPT arm from the start of treatment was observed (P=0.018 and P=0.045, respectively) with no significant 'time  arm' interaction, indicating a persistent better patient perspective with MPT treatment.
__label__noRel	During thalidomide maintenance, the scores for the QLQ-MY24 paraesthesia became significantly higher in the MPT arm (P<0.001).	The QLQ-C30 subscales physical function (P=0.044) and constipation (P<0.001) showed an improvement during induction in favour of the MP arm.
__label__noRel	During thalidomide maintenance, the scores for the QLQ-MY24 paraesthesia became significantly higher in the MPT arm (P<0.001).	The QLQ-C30 subscales pain (P=0.12), insomnia (P=0.068), appetite loss (P=0.074) and the QLQ-MY24 item sick (P=0.086) scored marginally better during thalidomide maintenance.
__label__noRel	During thalidomide maintenance, the scores for the QLQ-MY24 paraesthesia became significantly higher in the MPT arm (P<0.001).	The overall QoL-scale QLQ-C30-HRQoL showed a significant time trend towards more favourable mean values during protocol treatment without differences between MP and MPT.
__label__Support	During thalidomide maintenance, the scores for the QLQ-MY24 paraesthesia became significantly higher in the MPT arm (P<0.001).	This study shows that the higher frequency of toxicity associated with MPT does not translate into a negative effect on HRQoL and that MPT holds a better patient perspective.
__label__noRel	During thalidomide maintenance, the scores for the QLQ-MY24 paraesthesia became significantly higher in the MPT arm (P<0.001).	For the QLQ-C30 subscales emotional function and future perspectives, difference in favour of the MPT arm from the start of treatment was observed (P=0.018 and P=0.045, respectively) with no significant 'time  arm' interaction, indicating a persistent better patient perspective with MPT treatment.
__label__noRel	The QLQ-C30 subscales pain (P=0.12), insomnia (P=0.068), appetite loss (P=0.074) and the QLQ-MY24 item sick (P=0.086) scored marginally better during thalidomide maintenance.	The QLQ-C30 subscales physical function (P=0.044) and constipation (P<0.001) showed an improvement during induction in favour of the MP arm.
__label__noRel	The QLQ-C30 subscales pain (P=0.12), insomnia (P=0.068), appetite loss (P=0.074) and the QLQ-MY24 item sick (P=0.086) scored marginally better during thalidomide maintenance.	During thalidomide maintenance, the scores for the QLQ-MY24 paraesthesia became significantly higher in the MPT arm (P<0.001).
__label__noRel	The QLQ-C30 subscales pain (P=0.12), insomnia (P=0.068), appetite loss (P=0.074) and the QLQ-MY24 item sick (P=0.086) scored marginally better during thalidomide maintenance.	The overall QoL-scale QLQ-C30-HRQoL showed a significant time trend towards more favourable mean values during protocol treatment without differences between MP and MPT.
__label__Support	The QLQ-C30 subscales pain (P=0.12), insomnia (P=0.068), appetite loss (P=0.074) and the QLQ-MY24 item sick (P=0.086) scored marginally better during thalidomide maintenance.	This study shows that the higher frequency of toxicity associated with MPT does not translate into a negative effect on HRQoL and that MPT holds a better patient perspective.
__label__noRel	The QLQ-C30 subscales pain (P=0.12), insomnia (P=0.068), appetite loss (P=0.074) and the QLQ-MY24 item sick (P=0.086) scored marginally better during thalidomide maintenance.	For the QLQ-C30 subscales emotional function and future perspectives, difference in favour of the MPT arm from the start of treatment was observed (P=0.018 and P=0.045, respectively) with no significant 'time  arm' interaction, indicating a persistent better patient perspective with MPT treatment.
__label__noRel	The overall QoL-scale QLQ-C30-HRQoL showed a significant time trend towards more favourable mean values during protocol treatment without differences between MP and MPT.	The QLQ-C30 subscales physical function (P=0.044) and constipation (P<0.001) showed an improvement during induction in favour of the MP arm.
__label__noRel	The overall QoL-scale QLQ-C30-HRQoL showed a significant time trend towards more favourable mean values during protocol treatment without differences between MP and MPT.	During thalidomide maintenance, the scores for the QLQ-MY24 paraesthesia became significantly higher in the MPT arm (P<0.001).
__label__noRel	The overall QoL-scale QLQ-C30-HRQoL showed a significant time trend towards more favourable mean values during protocol treatment without differences between MP and MPT.	The QLQ-C30 subscales pain (P=0.12), insomnia (P=0.068), appetite loss (P=0.074) and the QLQ-MY24 item sick (P=0.086) scored marginally better during thalidomide maintenance.
__label__Support	The overall QoL-scale QLQ-C30-HRQoL showed a significant time trend towards more favourable mean values during protocol treatment without differences between MP and MPT.	This study shows that the higher frequency of toxicity associated with MPT does not translate into a negative effect on HRQoL and that MPT holds a better patient perspective.
__label__noRel	The overall QoL-scale QLQ-C30-HRQoL showed a significant time trend towards more favourable mean values during protocol treatment without differences between MP and MPT.	For the QLQ-C30 subscales emotional function and future perspectives, difference in favour of the MPT arm from the start of treatment was observed (P=0.018 and P=0.045, respectively) with no significant 'time  arm' interaction, indicating a persistent better patient perspective with MPT treatment.
__label__noRel	This study shows that the higher frequency of toxicity associated with MPT does not translate into a negative effect on HRQoL and that MPT holds a better patient perspective.	The QLQ-C30 subscales physical function (P=0.044) and constipation (P<0.001) showed an improvement during induction in favour of the MP arm.
__label__noRel	This study shows that the higher frequency of toxicity associated with MPT does not translate into a negative effect on HRQoL and that MPT holds a better patient perspective.	During thalidomide maintenance, the scores for the QLQ-MY24 paraesthesia became significantly higher in the MPT arm (P<0.001).
__label__noRel	This study shows that the higher frequency of toxicity associated with MPT does not translate into a negative effect on HRQoL and that MPT holds a better patient perspective.	The QLQ-C30 subscales pain (P=0.12), insomnia (P=0.068), appetite loss (P=0.074) and the QLQ-MY24 item sick (P=0.086) scored marginally better during thalidomide maintenance.
__label__noRel	This study shows that the higher frequency of toxicity associated with MPT does not translate into a negative effect on HRQoL and that MPT holds a better patient perspective.	The overall QoL-scale QLQ-C30-HRQoL showed a significant time trend towards more favourable mean values during protocol treatment without differences between MP and MPT.
__label__noRel	This study shows that the higher frequency of toxicity associated with MPT does not translate into a negative effect on HRQoL and that MPT holds a better patient perspective.	For the QLQ-C30 subscales emotional function and future perspectives, difference in favour of the MPT arm from the start of treatment was observed (P=0.018 and P=0.045, respectively) with no significant 'time  arm' interaction, indicating a persistent better patient perspective with MPT treatment.
__label__noRel	For the QLQ-C30 subscales emotional function and future perspectives, difference in favour of the MPT arm from the start of treatment was observed (P=0.018 and P=0.045, respectively) with no significant 'time  arm' interaction, indicating a persistent better patient perspective with MPT treatment.	The QLQ-C30 subscales physical function (P=0.044) and constipation (P<0.001) showed an improvement during induction in favour of the MP arm.
__label__noRel	For the QLQ-C30 subscales emotional function and future perspectives, difference in favour of the MPT arm from the start of treatment was observed (P=0.018 and P=0.045, respectively) with no significant 'time  arm' interaction, indicating a persistent better patient perspective with MPT treatment.	During thalidomide maintenance, the scores for the QLQ-MY24 paraesthesia became significantly higher in the MPT arm (P<0.001).
__label__noRel	For the QLQ-C30 subscales emotional function and future perspectives, difference in favour of the MPT arm from the start of treatment was observed (P=0.018 and P=0.045, respectively) with no significant 'time  arm' interaction, indicating a persistent better patient perspective with MPT treatment.	The QLQ-C30 subscales pain (P=0.12), insomnia (P=0.068), appetite loss (P=0.074) and the QLQ-MY24 item sick (P=0.086) scored marginally better during thalidomide maintenance.
__label__noRel	For the QLQ-C30 subscales emotional function and future perspectives, difference in favour of the MPT arm from the start of treatment was observed (P=0.018 and P=0.045, respectively) with no significant 'time  arm' interaction, indicating a persistent better patient perspective with MPT treatment.	The overall QoL-scale QLQ-C30-HRQoL showed a significant time trend towards more favourable mean values during protocol treatment without differences between MP and MPT.
__label__Support	For the QLQ-C30 subscales emotional function and future perspectives, difference in favour of the MPT arm from the start of treatment was observed (P=0.018 and P=0.045, respectively) with no significant 'time  arm' interaction, indicating a persistent better patient perspective with MPT treatment.	This study shows that the higher frequency of toxicity associated with MPT does not translate into a negative effect on HRQoL and that MPT holds a better patient perspective.
__label__noRel	There was no differences in acute toxicities between the 2 groups.	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.
__label__noRel	There was no differences in acute toxicities between the 2 groups.	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.
__label__noRel	There was no differences in acute toxicities between the 2 groups.	The rhDNase group showed no change in OPS-DNA concentration,
__label__noRel	There was no differences in acute toxicities between the 2 groups.	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).
__label__noRel	There was no differences in acute toxicities between the 2 groups.	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).
__label__noRel	There was no differences in acute toxicities between the 2 groups.	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.
__label__noRel	There was no differences in acute toxicities between the 2 groups.	Both groups showed an increase in symptom and interference scores,
__label__noRel	There was no differences in acute toxicities between the 2 groups.	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.
__label__noRel	There was no differences in acute toxicities between the 2 groups.	There were no statistically significant differences in patients' QOL outcomes over the study period.
__label__noRel	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.	There was no differences in acute toxicities between the 2 groups.
__label__noRel	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.
__label__noRel	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.	The rhDNase group showed no change in OPS-DNA concentration,
__label__noRel	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).
__label__noRel	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).
__label__noRel	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.
__label__noRel	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.	Both groups showed an increase in symptom and interference scores,
__label__noRel	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.
__label__noRel	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.	There were no statistically significant differences in patients' QOL outcomes over the study period.
__label__noRel	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.	There was no differences in acute toxicities between the 2 groups.
__label__noRel	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.
__label__noRel	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.	The rhDNase group showed no change in OPS-DNA concentration,
__label__noRel	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).
__label__noRel	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).
__label__noRel	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.
__label__noRel	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.	Both groups showed an increase in symptom and interference scores,
__label__noRel	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.
__label__noRel	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.	There were no statistically significant differences in patients' QOL outcomes over the study period.
__label__noRel	The rhDNase group showed no change in OPS-DNA concentration,	There was no differences in acute toxicities between the 2 groups.
__label__noRel	The rhDNase group showed no change in OPS-DNA concentration,	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.
__label__Support	The rhDNase group showed no change in OPS-DNA concentration,	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.
__label__noRel	The rhDNase group showed no change in OPS-DNA concentration,	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).
__label__noRel	The rhDNase group showed no change in OPS-DNA concentration,	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).
__label__noRel	The rhDNase group showed no change in OPS-DNA concentration,	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.
__label__noRel	The rhDNase group showed no change in OPS-DNA concentration,	Both groups showed an increase in symptom and interference scores,
__label__noRel	The rhDNase group showed no change in OPS-DNA concentration,	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.
__label__noRel	The rhDNase group showed no change in OPS-DNA concentration,	There were no statistically significant differences in patients' QOL outcomes over the study period.
__label__noRel	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).	There was no differences in acute toxicities between the 2 groups.
__label__noRel	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.
__label__Support	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.
__label__noRel	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).	The rhDNase group showed no change in OPS-DNA concentration,
__label__noRel	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).
__label__noRel	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.
__label__noRel	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).	Both groups showed an increase in symptom and interference scores,
__label__noRel	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.
__label__noRel	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).	There were no statistically significant differences in patients' QOL outcomes over the study period.
__label__noRel	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).	There was no differences in acute toxicities between the 2 groups.
__label__noRel	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.
__label__Support	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.
__label__noRel	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).	The rhDNase group showed no change in OPS-DNA concentration,
__label__noRel	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).
__label__noRel	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.
__label__noRel	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).	Both groups showed an increase in symptom and interference scores,
__label__noRel	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.
__label__noRel	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).	There were no statistically significant differences in patients' QOL outcomes over the study period.
__label__noRel	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.	There was no differences in acute toxicities between the 2 groups.
__label__noRel	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.
__label__noRel	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.
__label__noRel	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.	The rhDNase group showed no change in OPS-DNA concentration,
__label__noRel	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).
__label__noRel	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).
__label__noRel	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.	Both groups showed an increase in symptom and interference scores,
__label__noRel	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.
__label__noRel	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.	There were no statistically significant differences in patients' QOL outcomes over the study period.
__label__noRel	Both groups showed an increase in symptom and interference scores,	There was no differences in acute toxicities between the 2 groups.
__label__noRel	Both groups showed an increase in symptom and interference scores,	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.
__label__noRel	Both groups showed an increase in symptom and interference scores,	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.
__label__noRel	Both groups showed an increase in symptom and interference scores,	The rhDNase group showed no change in OPS-DNA concentration,
__label__noRel	Both groups showed an increase in symptom and interference scores,	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).
__label__noRel	Both groups showed an increase in symptom and interference scores,	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).
__label__noRel	Both groups showed an increase in symptom and interference scores,	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.
__label__noRel	Both groups showed an increase in symptom and interference scores,	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.
__label__noRel	Both groups showed an increase in symptom and interference scores,	There were no statistically significant differences in patients' QOL outcomes over the study period.
__label__noRel	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.	There was no differences in acute toxicities between the 2 groups.
__label__noRel	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.
__label__noRel	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.
__label__noRel	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.	The rhDNase group showed no change in OPS-DNA concentration,
__label__noRel	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).
__label__noRel	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).
__label__noRel	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.
__label__Attack	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.	Both groups showed an increase in symptom and interference scores,
__label__noRel	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.	There were no statistically significant differences in patients' QOL outcomes over the study period.
__label__noRel	There were no statistically significant differences in patients' QOL outcomes over the study period.	There was no differences in acute toxicities between the 2 groups.
__label__Support	There were no statistically significant differences in patients' QOL outcomes over the study period.	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.
__label__noRel	There were no statistically significant differences in patients' QOL outcomes over the study period.	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.
__label__noRel	There were no statistically significant differences in patients' QOL outcomes over the study period.	The rhDNase group showed no change in OPS-DNA concentration,
__label__noRel	There were no statistically significant differences in patients' QOL outcomes over the study period.	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).
__label__noRel	There were no statistically significant differences in patients' QOL outcomes over the study period.	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).
__label__noRel	There were no statistically significant differences in patients' QOL outcomes over the study period.	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.
__label__noRel	There were no statistically significant differences in patients' QOL outcomes over the study period.	Both groups showed an increase in symptom and interference scores,
__label__noRel	There were no statistically significant differences in patients' QOL outcomes over the study period.	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.
__label__noRel	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.
__label__noRel	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.
__label__noRel	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).
__label__noRel	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.
__label__noRel	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.
__label__Support	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.
__label__noRel	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.
__label__noRel	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.
__label__noRel	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.
__label__noRel	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).
__label__noRel	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.
__label__noRel	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.
__label__Support	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.
__label__noRel	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.
__label__noRel	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.
__label__noRel	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.
__label__noRel	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).
__label__noRel	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.
__label__noRel	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.
__label__Support	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.
__label__noRel	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.
__label__noRel	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.
__label__noRel	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.
__label__noRel	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.
__label__noRel	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.
__label__noRel	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.
__label__Support	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.
__label__noRel	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.
__label__noRel	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.
__label__noRel	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.
__label__noRel	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.
__label__noRel	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).
__label__Support	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.
__label__noRel	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.
__label__noRel	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.
__label__noRel	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.
__label__noRel	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.
__label__noRel	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.
__label__noRel	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).
__label__noRel	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.
__label__noRel	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.
__label__noRel	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.
__label__noRel	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.
__label__noRel	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.
__label__noRel	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.
__label__noRel	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).
__label__noRel	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.
__label__noRel	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.
__label__noRel	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.
__label__noRel	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.
__label__noRel	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.
__label__noRel	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.
__label__noRel	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).
__label__noRel	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.
__label__noRel	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.
__label__Attack	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.
__label__noRel	Treatment was associated with significant improvements in pain (P=.024) and swelling (P<.001).	Of the 36 patients who reported that pain interfered with their normal work or activities at baseline, 25 (69%) improved.
__label__noRel	Treatment was associated with significant improvements in pain (P=.024) and swelling (P<.001).	Of the 41 patients who reported swelling at baseline, 38 (93%) improved.
__label__noRel	Treatment was associated with significant improvements in pain (P=.024) and swelling (P<.001).	Comparing the paclitaxel and PLD arms revealed comparable response rates (56% vs 46%; P=.49), median progression-free survival (17.5 months vs 12.2 months; P=.66), and 2-year survival rates (79% vs 78%; P=.75),
__label__noRel	Treatment was associated with significant improvements in pain (P=.024) and swelling (P<.001).	but somewhat more grade 3 to 5 toxicity for paclitaxel (84% vs 66%; P=.077).
__label__Support	Treatment was associated with significant improvements in pain (P=.024) and swelling (P<.001).	Treatment with either paclitaxel or PLD appears to produce significant improvements in pain and swelling in patients with advanced, symptomatic, HIV-associated KS treated in the HAART era.
__label__noRel	Of the 36 patients who reported that pain interfered with their normal work or activities at baseline, 25 (69%) improved.	Treatment was associated with significant improvements in pain (P=.024) and swelling (P<.001).
__label__noRel	Of the 36 patients who reported that pain interfered with their normal work or activities at baseline, 25 (69%) improved.	Of the 41 patients who reported swelling at baseline, 38 (93%) improved.
__label__noRel	Of the 36 patients who reported that pain interfered with their normal work or activities at baseline, 25 (69%) improved.	Comparing the paclitaxel and PLD arms revealed comparable response rates (56% vs 46%; P=.49), median progression-free survival (17.5 months vs 12.2 months; P=.66), and 2-year survival rates (79% vs 78%; P=.75),
__label__noRel	Of the 36 patients who reported that pain interfered with their normal work or activities at baseline, 25 (69%) improved.	but somewhat more grade 3 to 5 toxicity for paclitaxel (84% vs 66%; P=.077).
__label__Support	Of the 36 patients who reported that pain interfered with their normal work or activities at baseline, 25 (69%) improved.	Treatment with either paclitaxel or PLD appears to produce significant improvements in pain and swelling in patients with advanced, symptomatic, HIV-associated KS treated in the HAART era.
__label__noRel	Of the 41 patients who reported swelling at baseline, 38 (93%) improved.	Treatment was associated with significant improvements in pain (P=.024) and swelling (P<.001).
__label__noRel	Of the 41 patients who reported swelling at baseline, 38 (93%) improved.	Of the 36 patients who reported that pain interfered with their normal work or activities at baseline, 25 (69%) improved.
__label__noRel	Of the 41 patients who reported swelling at baseline, 38 (93%) improved.	Comparing the paclitaxel and PLD arms revealed comparable response rates (56% vs 46%; P=.49), median progression-free survival (17.5 months vs 12.2 months; P=.66), and 2-year survival rates (79% vs 78%; P=.75),
__label__noRel	Of the 41 patients who reported swelling at baseline, 38 (93%) improved.	but somewhat more grade 3 to 5 toxicity for paclitaxel (84% vs 66%; P=.077).
__label__Support	Of the 41 patients who reported swelling at baseline, 38 (93%) improved.	Treatment with either paclitaxel or PLD appears to produce significant improvements in pain and swelling in patients with advanced, symptomatic, HIV-associated KS treated in the HAART era.
__label__noRel	Comparing the paclitaxel and PLD arms revealed comparable response rates (56% vs 46%; P=.49), median progression-free survival (17.5 months vs 12.2 months; P=.66), and 2-year survival rates (79% vs 78%; P=.75),	Treatment was associated with significant improvements in pain (P=.024) and swelling (P<.001).
__label__noRel	Comparing the paclitaxel and PLD arms revealed comparable response rates (56% vs 46%; P=.49), median progression-free survival (17.5 months vs 12.2 months; P=.66), and 2-year survival rates (79% vs 78%; P=.75),	Of the 36 patients who reported that pain interfered with their normal work or activities at baseline, 25 (69%) improved.
__label__noRel	Comparing the paclitaxel and PLD arms revealed comparable response rates (56% vs 46%; P=.49), median progression-free survival (17.5 months vs 12.2 months; P=.66), and 2-year survival rates (79% vs 78%; P=.75),	Of the 41 patients who reported swelling at baseline, 38 (93%) improved.
__label__noRel	Comparing the paclitaxel and PLD arms revealed comparable response rates (56% vs 46%; P=.49), median progression-free survival (17.5 months vs 12.2 months; P=.66), and 2-year survival rates (79% vs 78%; P=.75),	but somewhat more grade 3 to 5 toxicity for paclitaxel (84% vs 66%; P=.077).
__label__Support	Comparing the paclitaxel and PLD arms revealed comparable response rates (56% vs 46%; P=.49), median progression-free survival (17.5 months vs 12.2 months; P=.66), and 2-year survival rates (79% vs 78%; P=.75),	Treatment with either paclitaxel or PLD appears to produce significant improvements in pain and swelling in patients with advanced, symptomatic, HIV-associated KS treated in the HAART era.
__label__noRel	but somewhat more grade 3 to 5 toxicity for paclitaxel (84% vs 66%; P=.077).	Treatment was associated with significant improvements in pain (P=.024) and swelling (P<.001).
__label__noRel	but somewhat more grade 3 to 5 toxicity for paclitaxel (84% vs 66%; P=.077).	Of the 36 patients who reported that pain interfered with their normal work or activities at baseline, 25 (69%) improved.
__label__noRel	but somewhat more grade 3 to 5 toxicity for paclitaxel (84% vs 66%; P=.077).	Of the 41 patients who reported swelling at baseline, 38 (93%) improved.
__label__noRel	but somewhat more grade 3 to 5 toxicity for paclitaxel (84% vs 66%; P=.077).	Comparing the paclitaxel and PLD arms revealed comparable response rates (56% vs 46%; P=.49), median progression-free survival (17.5 months vs 12.2 months; P=.66), and 2-year survival rates (79% vs 78%; P=.75),
__label__noRel	but somewhat more grade 3 to 5 toxicity for paclitaxel (84% vs 66%; P=.077).	Treatment with either paclitaxel or PLD appears to produce significant improvements in pain and swelling in patients with advanced, symptomatic, HIV-associated KS treated in the HAART era.
__label__noRel	Treatment with either paclitaxel or PLD appears to produce significant improvements in pain and swelling in patients with advanced, symptomatic, HIV-associated KS treated in the HAART era.	Treatment was associated with significant improvements in pain (P=.024) and swelling (P<.001).
__label__noRel	Treatment with either paclitaxel or PLD appears to produce significant improvements in pain and swelling in patients with advanced, symptomatic, HIV-associated KS treated in the HAART era.	Of the 36 patients who reported that pain interfered with their normal work or activities at baseline, 25 (69%) improved.
__label__noRel	Treatment with either paclitaxel or PLD appears to produce significant improvements in pain and swelling in patients with advanced, symptomatic, HIV-associated KS treated in the HAART era.	Of the 41 patients who reported swelling at baseline, 38 (93%) improved.
__label__noRel	Treatment with either paclitaxel or PLD appears to produce significant improvements in pain and swelling in patients with advanced, symptomatic, HIV-associated KS treated in the HAART era.	Comparing the paclitaxel and PLD arms revealed comparable response rates (56% vs 46%; P=.49), median progression-free survival (17.5 months vs 12.2 months; P=.66), and 2-year survival rates (79% vs 78%; P=.75),
__label__noRel	Treatment with either paclitaxel or PLD appears to produce significant improvements in pain and swelling in patients with advanced, symptomatic, HIV-associated KS treated in the HAART era.	but somewhat more grade 3 to 5 toxicity for paclitaxel (84% vs 66%; P=.077).
__label__noRel	Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy.	VC, GC, and TC are not superior to PC in terms of overall survival (OS).
__label__noRel	Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy.	However, the trend in RR, PFS, and OS favors PC.
__label__noRel	Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy.	The arms were comparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia.
__label__noRel	Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy.	Response rates (RRs) for PC, VC, GC, and TC were 29.1%, 25.9%, 22.3%, and 23.4%, respectively.
__label__noRel	Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy.	The hazard ratios for progression-free survival (PFS) were 1.36 (95% CI, 0.97 to 1.90) for VC, 1.39 (95% CI, 0.99 to 1.96) for GC, and 1.27 (95% CI, 0.90 to 1.78) for TC.
__label__noRel	Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy.	The experimental-to-PC hazard ratios of death were 1.15 (95% CI, 0.79 to 1.67) for VC, 1.32 (95% CI, 0.91 to 1.92) for GC, and 1.26 (95% CI, 0.86 to 1.82) for TC.
__label__noRel	VC, GC, and TC are not superior to PC in terms of overall survival (OS).	Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy.
__label__noRel	VC, GC, and TC are not superior to PC in terms of overall survival (OS).	However, the trend in RR, PFS, and OS favors PC.
__label__noRel	VC, GC, and TC are not superior to PC in terms of overall survival (OS).	The arms were comparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia.
__label__noRel	VC, GC, and TC are not superior to PC in terms of overall survival (OS).	Response rates (RRs) for PC, VC, GC, and TC were 29.1%, 25.9%, 22.3%, and 23.4%, respectively.
__label__noRel	VC, GC, and TC are not superior to PC in terms of overall survival (OS).	The hazard ratios for progression-free survival (PFS) were 1.36 (95% CI, 0.97 to 1.90) for VC, 1.39 (95% CI, 0.99 to 1.96) for GC, and 1.27 (95% CI, 0.90 to 1.78) for TC.
__label__noRel	VC, GC, and TC are not superior to PC in terms of overall survival (OS).	The experimental-to-PC hazard ratios of death were 1.15 (95% CI, 0.79 to 1.67) for VC, 1.32 (95% CI, 0.91 to 1.92) for GC, and 1.26 (95% CI, 0.86 to 1.82) for TC.
__label__noRel	However, the trend in RR, PFS, and OS favors PC.	Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy.
__label__Attack	However, the trend in RR, PFS, and OS favors PC.	VC, GC, and TC are not superior to PC in terms of overall survival (OS).
__label__noRel	However, the trend in RR, PFS, and OS favors PC.	The arms were comparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia.
__label__noRel	However, the trend in RR, PFS, and OS favors PC.	Response rates (RRs) for PC, VC, GC, and TC were 29.1%, 25.9%, 22.3%, and 23.4%, respectively.
__label__noRel	However, the trend in RR, PFS, and OS favors PC.	The hazard ratios for progression-free survival (PFS) were 1.36 (95% CI, 0.97 to 1.90) for VC, 1.39 (95% CI, 0.99 to 1.96) for GC, and 1.27 (95% CI, 0.90 to 1.78) for TC.
__label__noRel	However, the trend in RR, PFS, and OS favors PC.	The experimental-to-PC hazard ratios of death were 1.15 (95% CI, 0.79 to 1.67) for VC, 1.32 (95% CI, 0.91 to 1.92) for GC, and 1.26 (95% CI, 0.86 to 1.82) for TC.
__label__noRel	The arms were comparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia.	Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy.
__label__Support	The arms were comparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia.	VC, GC, and TC are not superior to PC in terms of overall survival (OS).
__label__noRel	The arms were comparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia.	However, the trend in RR, PFS, and OS favors PC.
__label__noRel	The arms were comparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia.	Response rates (RRs) for PC, VC, GC, and TC were 29.1%, 25.9%, 22.3%, and 23.4%, respectively.
__label__noRel	The arms were comparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia.	The hazard ratios for progression-free survival (PFS) were 1.36 (95% CI, 0.97 to 1.90) for VC, 1.39 (95% CI, 0.99 to 1.96) for GC, and 1.27 (95% CI, 0.90 to 1.78) for TC.
__label__noRel	The arms were comparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia.	The experimental-to-PC hazard ratios of death were 1.15 (95% CI, 0.79 to 1.67) for VC, 1.32 (95% CI, 0.91 to 1.92) for GC, and 1.26 (95% CI, 0.86 to 1.82) for TC.
__label__noRel	Response rates (RRs) for PC, VC, GC, and TC were 29.1%, 25.9%, 22.3%, and 23.4%, respectively.	Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy.
__label__Support	Response rates (RRs) for PC, VC, GC, and TC were 29.1%, 25.9%, 22.3%, and 23.4%, respectively.	VC, GC, and TC are not superior to PC in terms of overall survival (OS).
__label__noRel	Response rates (RRs) for PC, VC, GC, and TC were 29.1%, 25.9%, 22.3%, and 23.4%, respectively.	However, the trend in RR, PFS, and OS favors PC.
__label__noRel	Response rates (RRs) for PC, VC, GC, and TC were 29.1%, 25.9%, 22.3%, and 23.4%, respectively.	The arms were comparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia.
__label__noRel	Response rates (RRs) for PC, VC, GC, and TC were 29.1%, 25.9%, 22.3%, and 23.4%, respectively.	The hazard ratios for progression-free survival (PFS) were 1.36 (95% CI, 0.97 to 1.90) for VC, 1.39 (95% CI, 0.99 to 1.96) for GC, and 1.27 (95% CI, 0.90 to 1.78) for TC.
__label__noRel	Response rates (RRs) for PC, VC, GC, and TC were 29.1%, 25.9%, 22.3%, and 23.4%, respectively.	The experimental-to-PC hazard ratios of death were 1.15 (95% CI, 0.79 to 1.67) for VC, 1.32 (95% CI, 0.91 to 1.92) for GC, and 1.26 (95% CI, 0.86 to 1.82) for TC.
__label__noRel	The hazard ratios for progression-free survival (PFS) were 1.36 (95% CI, 0.97 to 1.90) for VC, 1.39 (95% CI, 0.99 to 1.96) for GC, and 1.27 (95% CI, 0.90 to 1.78) for TC.	Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy.
__label__Support	The hazard ratios for progression-free survival (PFS) were 1.36 (95% CI, 0.97 to 1.90) for VC, 1.39 (95% CI, 0.99 to 1.96) for GC, and 1.27 (95% CI, 0.90 to 1.78) for TC.	VC, GC, and TC are not superior to PC in terms of overall survival (OS).
__label__noRel	The hazard ratios for progression-free survival (PFS) were 1.36 (95% CI, 0.97 to 1.90) for VC, 1.39 (95% CI, 0.99 to 1.96) for GC, and 1.27 (95% CI, 0.90 to 1.78) for TC.	However, the trend in RR, PFS, and OS favors PC.
__label__noRel	The hazard ratios for progression-free survival (PFS) were 1.36 (95% CI, 0.97 to 1.90) for VC, 1.39 (95% CI, 0.99 to 1.96) for GC, and 1.27 (95% CI, 0.90 to 1.78) for TC.	The arms were comparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia.
__label__noRel	The hazard ratios for progression-free survival (PFS) were 1.36 (95% CI, 0.97 to 1.90) for VC, 1.39 (95% CI, 0.99 to 1.96) for GC, and 1.27 (95% CI, 0.90 to 1.78) for TC.	Response rates (RRs) for PC, VC, GC, and TC were 29.1%, 25.9%, 22.3%, and 23.4%, respectively.
__label__noRel	The hazard ratios for progression-free survival (PFS) were 1.36 (95% CI, 0.97 to 1.90) for VC, 1.39 (95% CI, 0.99 to 1.96) for GC, and 1.27 (95% CI, 0.90 to 1.78) for TC.	The experimental-to-PC hazard ratios of death were 1.15 (95% CI, 0.79 to 1.67) for VC, 1.32 (95% CI, 0.91 to 1.92) for GC, and 1.26 (95% CI, 0.86 to 1.82) for TC.
__label__noRel	The experimental-to-PC hazard ratios of death were 1.15 (95% CI, 0.79 to 1.67) for VC, 1.32 (95% CI, 0.91 to 1.92) for GC, and 1.26 (95% CI, 0.86 to 1.82) for TC.	Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy.
__label__Support	The experimental-to-PC hazard ratios of death were 1.15 (95% CI, 0.79 to 1.67) for VC, 1.32 (95% CI, 0.91 to 1.92) for GC, and 1.26 (95% CI, 0.86 to 1.82) for TC.	VC, GC, and TC are not superior to PC in terms of overall survival (OS).
__label__noRel	The experimental-to-PC hazard ratios of death were 1.15 (95% CI, 0.79 to 1.67) for VC, 1.32 (95% CI, 0.91 to 1.92) for GC, and 1.26 (95% CI, 0.86 to 1.82) for TC.	However, the trend in RR, PFS, and OS favors PC.
__label__noRel	The experimental-to-PC hazard ratios of death were 1.15 (95% CI, 0.79 to 1.67) for VC, 1.32 (95% CI, 0.91 to 1.92) for GC, and 1.26 (95% CI, 0.86 to 1.82) for TC.	The arms were comparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia.
__label__noRel	The experimental-to-PC hazard ratios of death were 1.15 (95% CI, 0.79 to 1.67) for VC, 1.32 (95% CI, 0.91 to 1.92) for GC, and 1.26 (95% CI, 0.86 to 1.82) for TC.	Response rates (RRs) for PC, VC, GC, and TC were 29.1%, 25.9%, 22.3%, and 23.4%, respectively.
__label__noRel	The experimental-to-PC hazard ratios of death were 1.15 (95% CI, 0.79 to 1.67) for VC, 1.32 (95% CI, 0.91 to 1.92) for GC, and 1.26 (95% CI, 0.86 to 1.82) for TC.	The hazard ratios for progression-free survival (PFS) were 1.36 (95% CI, 0.97 to 1.90) for VC, 1.39 (95% CI, 0.99 to 1.96) for GC, and 1.27 (95% CI, 0.90 to 1.78) for TC.
__label__noRel	In the UAE group, mean  standard deviation uterine volume was 670  503, 422  353, and 292  287 mL at baseline, 6 months, and 5 years, respectively.	Mean dominant fibroid diameter was 7.6  3.0, 5.8  2.9, and 5  2.9 cm at baseline, 6 months, and 5 years.
__label__noRel	In the UAE group, mean  standard deviation uterine volume was 670  503, 422  353, and 292  287 mL at baseline, 6 months, and 5 years, respectively.	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.
__label__noRel	In the UAE group, mean  standard deviation uterine volume was 670  503, 422  353, and 292  287 mL at baseline, 6 months, and 5 years, respectively.	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).
__label__noRel	In the UAE group, mean  standard deviation uterine volume was 670  503, 422  353, and 292  287 mL at baseline, 6 months, and 5 years, respectively.	No myomectomy cases had further intervention.
__label__noRel	In the UAE group, mean  standard deviation uterine volume was 670  503, 422  353, and 292  287 mL at baseline, 6 months, and 5 years, respectively.	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).
__label__noRel	In the UAE group, mean  standard deviation uterine volume was 670  503, 422  353, and 292  287 mL at baseline, 6 months, and 5 years, respectively.	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.
__label__noRel	In the UAE group, mean  standard deviation uterine volume was 670  503, 422  353, and 292  287 mL at baseline, 6 months, and 5 years, respectively.	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.
__label__noRel	In the UAE group, mean  standard deviation uterine volume was 670  503, 422  353, and 292  287 mL at baseline, 6 months, and 5 years, respectively.	New fibroid formation is significantly higher after myomectomy.
__label__noRel	Mean dominant fibroid diameter was 7.6  3.0, 5.8  2.9, and 5  2.9 cm at baseline, 6 months, and 5 years.	In the UAE group, mean  standard deviation uterine volume was 670  503, 422  353, and 292  287 mL at baseline, 6 months, and 5 years, respectively.
__label__noRel	Mean dominant fibroid diameter was 7.6  3.0, 5.8  2.9, and 5  2.9 cm at baseline, 6 months, and 5 years.	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.
__label__noRel	Mean dominant fibroid diameter was 7.6  3.0, 5.8  2.9, and 5  2.9 cm at baseline, 6 months, and 5 years.	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).
__label__noRel	Mean dominant fibroid diameter was 7.6  3.0, 5.8  2.9, and 5  2.9 cm at baseline, 6 months, and 5 years.	No myomectomy cases had further intervention.
__label__noRel	Mean dominant fibroid diameter was 7.6  3.0, 5.8  2.9, and 5  2.9 cm at baseline, 6 months, and 5 years.	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).
__label__noRel	Mean dominant fibroid diameter was 7.6  3.0, 5.8  2.9, and 5  2.9 cm at baseline, 6 months, and 5 years.	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.
__label__noRel	Mean dominant fibroid diameter was 7.6  3.0, 5.8  2.9, and 5  2.9 cm at baseline, 6 months, and 5 years.	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.
__label__noRel	Mean dominant fibroid diameter was 7.6  3.0, 5.8  2.9, and 5  2.9 cm at baseline, 6 months, and 5 years.	New fibroid formation is significantly higher after myomectomy.
__label__noRel	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.	In the UAE group, mean  standard deviation uterine volume was 670  503, 422  353, and 292  287 mL at baseline, 6 months, and 5 years, respectively.
__label__noRel	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.	Mean dominant fibroid diameter was 7.6  3.0, 5.8  2.9, and 5  2.9 cm at baseline, 6 months, and 5 years.
__label__noRel	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).
__label__noRel	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.	No myomectomy cases had further intervention.
__label__noRel	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).
__label__noRel	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.
__label__Support	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.
__label__noRel	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.	New fibroid formation is significantly higher after myomectomy.
__label__noRel	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).	In the UAE group, mean  standard deviation uterine volume was 670  503, 422  353, and 292  287 mL at baseline, 6 months, and 5 years, respectively.
__label__noRel	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).	Mean dominant fibroid diameter was 7.6  3.0, 5.8  2.9, and 5  2.9 cm at baseline, 6 months, and 5 years.
__label__noRel	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.
__label__noRel	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).	No myomectomy cases had further intervention.
__label__noRel	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).
__label__noRel	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.
__label__Support	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.
__label__noRel	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).	New fibroid formation is significantly higher after myomectomy.
__label__noRel	No myomectomy cases had further intervention.	In the UAE group, mean  standard deviation uterine volume was 670  503, 422  353, and 292  287 mL at baseline, 6 months, and 5 years, respectively.
__label__noRel	No myomectomy cases had further intervention.	Mean dominant fibroid diameter was 7.6  3.0, 5.8  2.9, and 5  2.9 cm at baseline, 6 months, and 5 years.
__label__noRel	No myomectomy cases had further intervention.	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.
__label__noRel	No myomectomy cases had further intervention.	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).
__label__noRel	No myomectomy cases had further intervention.	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).
__label__noRel	No myomectomy cases had further intervention.	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.
__label__noRel	No myomectomy cases had further intervention.	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.
__label__noRel	No myomectomy cases had further intervention.	New fibroid formation is significantly higher after myomectomy.
__label__noRel	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).	In the UAE group, mean  standard deviation uterine volume was 670  503, 422  353, and 292  287 mL at baseline, 6 months, and 5 years, respectively.
__label__noRel	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).	Mean dominant fibroid diameter was 7.6  3.0, 5.8  2.9, and 5  2.9 cm at baseline, 6 months, and 5 years.
__label__noRel	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.
__label__noRel	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).
__label__noRel	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).	No myomectomy cases had further intervention.
__label__noRel	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.
__label__noRel	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.
__label__Support	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).	New fibroid formation is significantly higher after myomectomy.
__label__noRel	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.	In the UAE group, mean  standard deviation uterine volume was 670  503, 422  353, and 292  287 mL at baseline, 6 months, and 5 years, respectively.
__label__noRel	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.	Mean dominant fibroid diameter was 7.6  3.0, 5.8  2.9, and 5  2.9 cm at baseline, 6 months, and 5 years.
__label__noRel	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.
__label__noRel	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).
__label__noRel	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.	No myomectomy cases had further intervention.
__label__noRel	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).
__label__noRel	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.
__label__noRel	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.	New fibroid formation is significantly higher after myomectomy.
__label__noRel	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.	In the UAE group, mean  standard deviation uterine volume was 670  503, 422  353, and 292  287 mL at baseline, 6 months, and 5 years, respectively.
__label__noRel	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.	Mean dominant fibroid diameter was 7.6  3.0, 5.8  2.9, and 5  2.9 cm at baseline, 6 months, and 5 years.
__label__noRel	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.
__label__noRel	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).
__label__noRel	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.	No myomectomy cases had further intervention.
__label__noRel	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).
__label__noRel	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.
__label__noRel	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.	New fibroid formation is significantly higher after myomectomy.
__label__noRel	New fibroid formation is significantly higher after myomectomy.	In the UAE group, mean  standard deviation uterine volume was 670  503, 422  353, and 292  287 mL at baseline, 6 months, and 5 years, respectively.
__label__noRel	New fibroid formation is significantly higher after myomectomy.	Mean dominant fibroid diameter was 7.6  3.0, 5.8  2.9, and 5  2.9 cm at baseline, 6 months, and 5 years.
__label__noRel	New fibroid formation is significantly higher after myomectomy.	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.
__label__noRel	New fibroid formation is significantly higher after myomectomy.	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).
__label__noRel	New fibroid formation is significantly higher after myomectomy.	No myomectomy cases had further intervention.
__label__noRel	New fibroid formation is significantly higher after myomectomy.	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).
__label__noRel	New fibroid formation is significantly higher after myomectomy.	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.
__label__noRel	New fibroid formation is significantly higher after myomectomy.	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.
__label__noRel	After the rehabilitation program, cancer survivors (n=63) displayed statistically significant improvements on health-related quality of life with effect sizes (ES) varying from 0.38 to 0.99 (RAND-36) and from -0.34 to -0.57 (RSCL), most persistent at 3-month follow-up.	Furthermore, statistically significant improvements in exercise capacity and muscle force of upper and lower extremities were displayed after rehabilitation.
__label__Support	After the rehabilitation program, cancer survivors (n=63) displayed statistically significant improvements on health-related quality of life with effect sizes (ES) varying from 0.38 to 0.99 (RAND-36) and from -0.34 to -0.57 (RSCL), most persistent at 3-month follow-up.	A multidimensional rehabilitation program has statistically and clinically relevant beneficial effects on health-related quality of life, exercise capacity, and muscle force in cancer patients with different diagnoses.
__label__noRel	After the rehabilitation program, cancer survivors (n=63) displayed statistically significant improvements on health-related quality of life with effect sizes (ES) varying from 0.38 to 0.99 (RAND-36) and from -0.34 to -0.57 (RSCL), most persistent at 3-month follow-up.	if offered the choice, the majority of cancer survivors seem to prefer multidimensional programs to programs with only one component.
__label__noRel	After the rehabilitation program, cancer survivors (n=63) displayed statistically significant improvements on health-related quality of life with effect sizes (ES) varying from 0.38 to 0.99 (RAND-36) and from -0.34 to -0.57 (RSCL), most persistent at 3-month follow-up.	If offered a choice, 80% of the patients prior to start and 58% of the patients after completion of the program indicated that they preferred the entire multidimensional program.
__label__noRel	Furthermore, statistically significant improvements in exercise capacity and muscle force of upper and lower extremities were displayed after rehabilitation.	After the rehabilitation program, cancer survivors (n=63) displayed statistically significant improvements on health-related quality of life with effect sizes (ES) varying from 0.38 to 0.99 (RAND-36) and from -0.34 to -0.57 (RSCL), most persistent at 3-month follow-up.
__label__Support	Furthermore, statistically significant improvements in exercise capacity and muscle force of upper and lower extremities were displayed after rehabilitation.	A multidimensional rehabilitation program has statistically and clinically relevant beneficial effects on health-related quality of life, exercise capacity, and muscle force in cancer patients with different diagnoses.
__label__noRel	Furthermore, statistically significant improvements in exercise capacity and muscle force of upper and lower extremities were displayed after rehabilitation.	if offered the choice, the majority of cancer survivors seem to prefer multidimensional programs to programs with only one component.
__label__noRel	Furthermore, statistically significant improvements in exercise capacity and muscle force of upper and lower extremities were displayed after rehabilitation.	If offered a choice, 80% of the patients prior to start and 58% of the patients after completion of the program indicated that they preferred the entire multidimensional program.
__label__noRel	A multidimensional rehabilitation program has statistically and clinically relevant beneficial effects on health-related quality of life, exercise capacity, and muscle force in cancer patients with different diagnoses.	After the rehabilitation program, cancer survivors (n=63) displayed statistically significant improvements on health-related quality of life with effect sizes (ES) varying from 0.38 to 0.99 (RAND-36) and from -0.34 to -0.57 (RSCL), most persistent at 3-month follow-up.
__label__noRel	A multidimensional rehabilitation program has statistically and clinically relevant beneficial effects on health-related quality of life, exercise capacity, and muscle force in cancer patients with different diagnoses.	Furthermore, statistically significant improvements in exercise capacity and muscle force of upper and lower extremities were displayed after rehabilitation.
__label__noRel	A multidimensional rehabilitation program has statistically and clinically relevant beneficial effects on health-related quality of life, exercise capacity, and muscle force in cancer patients with different diagnoses.	if offered the choice, the majority of cancer survivors seem to prefer multidimensional programs to programs with only one component.
__label__noRel	A multidimensional rehabilitation program has statistically and clinically relevant beneficial effects on health-related quality of life, exercise capacity, and muscle force in cancer patients with different diagnoses.	If offered a choice, 80% of the patients prior to start and 58% of the patients after completion of the program indicated that they preferred the entire multidimensional program.
__label__noRel	if offered the choice, the majority of cancer survivors seem to prefer multidimensional programs to programs with only one component.	After the rehabilitation program, cancer survivors (n=63) displayed statistically significant improvements on health-related quality of life with effect sizes (ES) varying from 0.38 to 0.99 (RAND-36) and from -0.34 to -0.57 (RSCL), most persistent at 3-month follow-up.
__label__noRel	if offered the choice, the majority of cancer survivors seem to prefer multidimensional programs to programs with only one component.	Furthermore, statistically significant improvements in exercise capacity and muscle force of upper and lower extremities were displayed after rehabilitation.
__label__noRel	if offered the choice, the majority of cancer survivors seem to prefer multidimensional programs to programs with only one component.	A multidimensional rehabilitation program has statistically and clinically relevant beneficial effects on health-related quality of life, exercise capacity, and muscle force in cancer patients with different diagnoses.
__label__noRel	if offered the choice, the majority of cancer survivors seem to prefer multidimensional programs to programs with only one component.	If offered a choice, 80% of the patients prior to start and 58% of the patients after completion of the program indicated that they preferred the entire multidimensional program.
__label__noRel	If offered a choice, 80% of the patients prior to start and 58% of the patients after completion of the program indicated that they preferred the entire multidimensional program.	After the rehabilitation program, cancer survivors (n=63) displayed statistically significant improvements on health-related quality of life with effect sizes (ES) varying from 0.38 to 0.99 (RAND-36) and from -0.34 to -0.57 (RSCL), most persistent at 3-month follow-up.
__label__noRel	If offered a choice, 80% of the patients prior to start and 58% of the patients after completion of the program indicated that they preferred the entire multidimensional program.	Furthermore, statistically significant improvements in exercise capacity and muscle force of upper and lower extremities were displayed after rehabilitation.
__label__noRel	If offered a choice, 80% of the patients prior to start and 58% of the patients after completion of the program indicated that they preferred the entire multidimensional program.	A multidimensional rehabilitation program has statistically and clinically relevant beneficial effects on health-related quality of life, exercise capacity, and muscle force in cancer patients with different diagnoses.
__label__Support	If offered a choice, 80% of the patients prior to start and 58% of the patients after completion of the program indicated that they preferred the entire multidimensional program.	if offered the choice, the majority of cancer survivors seem to prefer multidimensional programs to programs with only one component.
__label__noRel	For BT versus RP, there was no difference in bowel or hormonal domains,	men treated with BT scored better in urinary (91.8 v 88.1; P = .02) and sexual (52.5 v 39.2; P = .001) domains, and in patient satisfaction (93.6 v 76.9; P < .001).
__label__Support	For BT versus RP, there was no difference in bowel or hormonal domains,	HRQOL evaluated 3.2 to 6.5 years after treatment showed an advantage for BT in urinary and sexual domains and in patient satisfaction.
__label__noRel	men treated with BT scored better in urinary (91.8 v 88.1; P = .02) and sexual (52.5 v 39.2; P = .001) domains, and in patient satisfaction (93.6 v 76.9; P < .001).	For BT versus RP, there was no difference in bowel or hormonal domains,
__label__Support	men treated with BT scored better in urinary (91.8 v 88.1; P = .02) and sexual (52.5 v 39.2; P = .001) domains, and in patient satisfaction (93.6 v 76.9; P < .001).	HRQOL evaluated 3.2 to 6.5 years after treatment showed an advantage for BT in urinary and sexual domains and in patient satisfaction.
__label__noRel	HRQOL evaluated 3.2 to 6.5 years after treatment showed an advantage for BT in urinary and sexual domains and in patient satisfaction.	For BT versus RP, there was no difference in bowel or hormonal domains,
__label__noRel	HRQOL evaluated 3.2 to 6.5 years after treatment showed an advantage for BT in urinary and sexual domains and in patient satisfaction.	men treated with BT scored better in urinary (91.8 v 88.1; P = .02) and sexual (52.5 v 39.2; P = .001) domains, and in patient satisfaction (93.6 v 76.9; P < .001).
__label__noRel	For treatment of advanced breast cancer, SFI can alleviate the bone marrow inhibition caused by chemotherapy, improve clinical symptoms and quality of life and prolong the survival period by regulating cellular immune function of patients, so as to enhance the therapeutic effect of chemotherapy.	The level of CD3+ CD4+ and CD4+/CD8+ ratio increased (P < 0.05) and CD8+ decreased in the treatment group (P < 0.01), while they showed insignificant change in the control group.
__label__noRel	For treatment of advanced breast cancer, SFI can alleviate the bone marrow inhibition caused by chemotherapy, improve clinical symptoms and quality of life and prolong the survival period by regulating cellular immune function of patients, so as to enhance the therapeutic effect of chemotherapy.	The occurrence of adverse reaction in the treatment group was lower than that in the control group (P < 0.05).
__label__noRel	For treatment of advanced breast cancer, SFI can alleviate the bone marrow inhibition caused by chemotherapy, improve clinical symptoms and quality of life and prolong the survival period by regulating cellular immune function of patients, so as to enhance the therapeutic effect of chemotherapy.	The total short-term remission rate, the improvement rate of clinical syndrome and quality of life was 50.0%, 70.0% and 76.7% in the treatment group, and 43.3%, 46.7% and 50.0% in the control group, respectively, showing significant difference between the two groups (all P < 0.05).
__label__Support	The level of CD3+ CD4+ and CD4+/CD8+ ratio increased (P < 0.05) and CD8+ decreased in the treatment group (P < 0.01), while they showed insignificant change in the control group.	For treatment of advanced breast cancer, SFI can alleviate the bone marrow inhibition caused by chemotherapy, improve clinical symptoms and quality of life and prolong the survival period by regulating cellular immune function of patients, so as to enhance the therapeutic effect of chemotherapy.
__label__noRel	The level of CD3+ CD4+ and CD4+/CD8+ ratio increased (P < 0.05) and CD8+ decreased in the treatment group (P < 0.01), while they showed insignificant change in the control group.	The occurrence of adverse reaction in the treatment group was lower than that in the control group (P < 0.05).
__label__noRel	The level of CD3+ CD4+ and CD4+/CD8+ ratio increased (P < 0.05) and CD8+ decreased in the treatment group (P < 0.01), while they showed insignificant change in the control group.	The total short-term remission rate, the improvement rate of clinical syndrome and quality of life was 50.0%, 70.0% and 76.7% in the treatment group, and 43.3%, 46.7% and 50.0% in the control group, respectively, showing significant difference between the two groups (all P < 0.05).
__label__Support	The occurrence of adverse reaction in the treatment group was lower than that in the control group (P < 0.05).	For treatment of advanced breast cancer, SFI can alleviate the bone marrow inhibition caused by chemotherapy, improve clinical symptoms and quality of life and prolong the survival period by regulating cellular immune function of patients, so as to enhance the therapeutic effect of chemotherapy.
__label__noRel	The occurrence of adverse reaction in the treatment group was lower than that in the control group (P < 0.05).	The level of CD3+ CD4+ and CD4+/CD8+ ratio increased (P < 0.05) and CD8+ decreased in the treatment group (P < 0.01), while they showed insignificant change in the control group.
__label__noRel	The occurrence of adverse reaction in the treatment group was lower than that in the control group (P < 0.05).	The total short-term remission rate, the improvement rate of clinical syndrome and quality of life was 50.0%, 70.0% and 76.7% in the treatment group, and 43.3%, 46.7% and 50.0% in the control group, respectively, showing significant difference between the two groups (all P < 0.05).
__label__Support	The total short-term remission rate, the improvement rate of clinical syndrome and quality of life was 50.0%, 70.0% and 76.7% in the treatment group, and 43.3%, 46.7% and 50.0% in the control group, respectively, showing significant difference between the two groups (all P < 0.05).	For treatment of advanced breast cancer, SFI can alleviate the bone marrow inhibition caused by chemotherapy, improve clinical symptoms and quality of life and prolong the survival period by regulating cellular immune function of patients, so as to enhance the therapeutic effect of chemotherapy.
__label__noRel	The total short-term remission rate, the improvement rate of clinical syndrome and quality of life was 50.0%, 70.0% and 76.7% in the treatment group, and 43.3%, 46.7% and 50.0% in the control group, respectively, showing significant difference between the two groups (all P < 0.05).	The level of CD3+ CD4+ and CD4+/CD8+ ratio increased (P < 0.05) and CD8+ decreased in the treatment group (P < 0.01), while they showed insignificant change in the control group.
__label__noRel	The total short-term remission rate, the improvement rate of clinical syndrome and quality of life was 50.0%, 70.0% and 76.7% in the treatment group, and 43.3%, 46.7% and 50.0% in the control group, respectively, showing significant difference between the two groups (all P < 0.05).	The occurrence of adverse reaction in the treatment group was lower than that in the control group (P < 0.05).
__label__noRel	Significant group by time interactions showed that there was an improvement in dyads' coping (p < 0.05), self-efficacy (p < 0.05), and social QOL (p < 0.01) and in caregivers' emotional QOL (p < 0.05).	Risk for distress accounted for very few moderation effects.
__label__noRel	Significant group by time interactions showed that there was an improvement in dyads' coping (p < 0.05), self-efficacy (p < 0.05), and social QOL (p < 0.01) and in caregivers' emotional QOL (p < 0.05).	Both brief and extensive programs had positive outcomes for patient-caregiver dyads,
__label__noRel	Significant group by time interactions showed that there was an improvement in dyads' coping (p < 0.05), self-efficacy (p < 0.05), and social QOL (p < 0.01) and in caregivers' emotional QOL (p < 0.05).	but few sustained effects.
__label__Support	Significant group by time interactions showed that there was an improvement in dyads' coping (p < 0.05), self-efficacy (p < 0.05), and social QOL (p < 0.01) and in caregivers' emotional QOL (p < 0.05).	Patient-caregiver dyads benefit when viewed as the 'unit of care'.
__label__noRel	Risk for distress accounted for very few moderation effects.	Significant group by time interactions showed that there was an improvement in dyads' coping (p < 0.05), self-efficacy (p < 0.05), and social QOL (p < 0.01) and in caregivers' emotional QOL (p < 0.05).
__label__noRel	Risk for distress accounted for very few moderation effects.	Both brief and extensive programs had positive outcomes for patient-caregiver dyads,
__label__noRel	Risk for distress accounted for very few moderation effects.	but few sustained effects.
__label__noRel	Risk for distress accounted for very few moderation effects.	Patient-caregiver dyads benefit when viewed as the 'unit of care'.
__label__noRel	Both brief and extensive programs had positive outcomes for patient-caregiver dyads,	Significant group by time interactions showed that there was an improvement in dyads' coping (p < 0.05), self-efficacy (p < 0.05), and social QOL (p < 0.01) and in caregivers' emotional QOL (p < 0.05).
__label__noRel	Both brief and extensive programs had positive outcomes for patient-caregiver dyads,	Risk for distress accounted for very few moderation effects.
__label__noRel	Both brief and extensive programs had positive outcomes for patient-caregiver dyads,	but few sustained effects.
__label__Support	Both brief and extensive programs had positive outcomes for patient-caregiver dyads,	Patient-caregiver dyads benefit when viewed as the 'unit of care'.
__label__noRel	but few sustained effects.	Significant group by time interactions showed that there was an improvement in dyads' coping (p < 0.05), self-efficacy (p < 0.05), and social QOL (p < 0.01) and in caregivers' emotional QOL (p < 0.05).
__label__noRel	but few sustained effects.	Risk for distress accounted for very few moderation effects.
__label__Attack	but few sustained effects.	Both brief and extensive programs had positive outcomes for patient-caregiver dyads,
__label__noRel	but few sustained effects.	Patient-caregiver dyads benefit when viewed as the 'unit of care'.
__label__noRel	Patient-caregiver dyads benefit when viewed as the 'unit of care'.	Significant group by time interactions showed that there was an improvement in dyads' coping (p < 0.05), self-efficacy (p < 0.05), and social QOL (p < 0.01) and in caregivers' emotional QOL (p < 0.05).
__label__noRel	Patient-caregiver dyads benefit when viewed as the 'unit of care'.	Risk for distress accounted for very few moderation effects.
__label__noRel	Patient-caregiver dyads benefit when viewed as the 'unit of care'.	Both brief and extensive programs had positive outcomes for patient-caregiver dyads,
__label__noRel	Patient-caregiver dyads benefit when viewed as the 'unit of care'.	but few sustained effects.
__label__noRel	With a mixed modeling approach, total FACIT F scores for the entire sample declined at a significant rate (p = 0.003) beginning with cycle 3	but at a slower rate for the experimental group (p = 0.02).
__label__noRel	With a mixed modeling approach, total FACIT F scores for the entire sample declined at a significant rate (p = 0.003) beginning with cycle 3	Fatigue scores indicated less increase and physical well-being subscale scores showed less decline for the experimental group (p = 0.008 and p = 0.02, respectively).
__label__noRel	With a mixed modeling approach, total FACIT F scores for the entire sample declined at a significant rate (p = 0.003) beginning with cycle 3	Women with advanced breast cancer randomized to the seated exercise intervention had a slower decline in total and physical well-being and less increase in fatigue scores starting with the third cycle of chemotherapy.
__label__Support	With a mixed modeling approach, total FACIT F scores for the entire sample declined at a significant rate (p = 0.003) beginning with cycle 3	Seated exercise may be a feasible exercise program for women with advanced cancer for controlling fatigue and improving physical well-being.
__label__Attack	but at a slower rate for the experimental group (p = 0.02).	With a mixed modeling approach, total FACIT F scores for the entire sample declined at a significant rate (p = 0.003) beginning with cycle 3
__label__noRel	but at a slower rate for the experimental group (p = 0.02).	Fatigue scores indicated less increase and physical well-being subscale scores showed less decline for the experimental group (p = 0.008 and p = 0.02, respectively).
__label__noRel	but at a slower rate for the experimental group (p = 0.02).	Women with advanced breast cancer randomized to the seated exercise intervention had a slower decline in total and physical well-being and less increase in fatigue scores starting with the third cycle of chemotherapy.
__label__noRel	but at a slower rate for the experimental group (p = 0.02).	Seated exercise may be a feasible exercise program for women with advanced cancer for controlling fatigue and improving physical well-being.
__label__noRel	Fatigue scores indicated less increase and physical well-being subscale scores showed less decline for the experimental group (p = 0.008 and p = 0.02, respectively).	With a mixed modeling approach, total FACIT F scores for the entire sample declined at a significant rate (p = 0.003) beginning with cycle 3
__label__noRel	Fatigue scores indicated less increase and physical well-being subscale scores showed less decline for the experimental group (p = 0.008 and p = 0.02, respectively).	but at a slower rate for the experimental group (p = 0.02).
__label__noRel	Fatigue scores indicated less increase and physical well-being subscale scores showed less decline for the experimental group (p = 0.008 and p = 0.02, respectively).	Women with advanced breast cancer randomized to the seated exercise intervention had a slower decline in total and physical well-being and less increase in fatigue scores starting with the third cycle of chemotherapy.
__label__Support	Fatigue scores indicated less increase and physical well-being subscale scores showed less decline for the experimental group (p = 0.008 and p = 0.02, respectively).	Seated exercise may be a feasible exercise program for women with advanced cancer for controlling fatigue and improving physical well-being.
__label__noRel	Women with advanced breast cancer randomized to the seated exercise intervention had a slower decline in total and physical well-being and less increase in fatigue scores starting with the third cycle of chemotherapy.	With a mixed modeling approach, total FACIT F scores for the entire sample declined at a significant rate (p = 0.003) beginning with cycle 3
__label__noRel	Women with advanced breast cancer randomized to the seated exercise intervention had a slower decline in total and physical well-being and less increase in fatigue scores starting with the third cycle of chemotherapy.	but at a slower rate for the experimental group (p = 0.02).
__label__noRel	Women with advanced breast cancer randomized to the seated exercise intervention had a slower decline in total and physical well-being and less increase in fatigue scores starting with the third cycle of chemotherapy.	Fatigue scores indicated less increase and physical well-being subscale scores showed less decline for the experimental group (p = 0.008 and p = 0.02, respectively).
__label__Support	Women with advanced breast cancer randomized to the seated exercise intervention had a slower decline in total and physical well-being and less increase in fatigue scores starting with the third cycle of chemotherapy.	Seated exercise may be a feasible exercise program for women with advanced cancer for controlling fatigue and improving physical well-being.
__label__noRel	Seated exercise may be a feasible exercise program for women with advanced cancer for controlling fatigue and improving physical well-being.	With a mixed modeling approach, total FACIT F scores for the entire sample declined at a significant rate (p = 0.003) beginning with cycle 3
__label__noRel	Seated exercise may be a feasible exercise program for women with advanced cancer for controlling fatigue and improving physical well-being.	but at a slower rate for the experimental group (p = 0.02).
__label__noRel	Seated exercise may be a feasible exercise program for women with advanced cancer for controlling fatigue and improving physical well-being.	Fatigue scores indicated less increase and physical well-being subscale scores showed less decline for the experimental group (p = 0.008 and p = 0.02, respectively).
__label__noRel	Seated exercise may be a feasible exercise program for women with advanced cancer for controlling fatigue and improving physical well-being.	Women with advanced breast cancer randomized to the seated exercise intervention had a slower decline in total and physical well-being and less increase in fatigue scores starting with the third cycle of chemotherapy.
__label__Support	In the oxycodone/paracetamol group, 67% rated GI as good, very good, or excellent.	Patients with bone-cancer pain, already on opioids, obtain clinically important, additional pain-control, with regular oxycodone/paracetamol dosing.
__label__noRel	In the oxycodone/paracetamol group, 67% rated GI as good, very good, or excellent.	PIDs were 09 and 03 in the oxycodone/paracetamol and placebo groups respectively, on day 1 (P < 0001), and 15 and 03 respectively on day 3 (P < 0001).
__label__noRel	In the oxycodone/paracetamol group, 67% rated GI as good, very good, or excellent.	Thirty-eight patients in the treatment group, and 58 in the placebo group, suffered breakthrough pain on day 3 (P < 0001).
__label__noRel	In the oxycodone/paracetamol group, 67% rated GI as good, very good, or excellent.	The SF-6D score decreased to 212  25 in the oxycodone/paracetamol group at the end of the phase (P = 0001).
__label__noRel	Patients with bone-cancer pain, already on opioids, obtain clinically important, additional pain-control, with regular oxycodone/paracetamol dosing.	In the oxycodone/paracetamol group, 67% rated GI as good, very good, or excellent.
__label__noRel	Patients with bone-cancer pain, already on opioids, obtain clinically important, additional pain-control, with regular oxycodone/paracetamol dosing.	PIDs were 09 and 03 in the oxycodone/paracetamol and placebo groups respectively, on day 1 (P < 0001), and 15 and 03 respectively on day 3 (P < 0001).
__label__noRel	Patients with bone-cancer pain, already on opioids, obtain clinically important, additional pain-control, with regular oxycodone/paracetamol dosing.	Thirty-eight patients in the treatment group, and 58 in the placebo group, suffered breakthrough pain on day 3 (P < 0001).
__label__noRel	Patients with bone-cancer pain, already on opioids, obtain clinically important, additional pain-control, with regular oxycodone/paracetamol dosing.	The SF-6D score decreased to 212  25 in the oxycodone/paracetamol group at the end of the phase (P = 0001).
__label__noRel	PIDs were 09 and 03 in the oxycodone/paracetamol and placebo groups respectively, on day 1 (P < 0001), and 15 and 03 respectively on day 3 (P < 0001).	In the oxycodone/paracetamol group, 67% rated GI as good, very good, or excellent.
__label__Support	PIDs were 09 and 03 in the oxycodone/paracetamol and placebo groups respectively, on day 1 (P < 0001), and 15 and 03 respectively on day 3 (P < 0001).	Patients with bone-cancer pain, already on opioids, obtain clinically important, additional pain-control, with regular oxycodone/paracetamol dosing.
__label__noRel	PIDs were 09 and 03 in the oxycodone/paracetamol and placebo groups respectively, on day 1 (P < 0001), and 15 and 03 respectively on day 3 (P < 0001).	Thirty-eight patients in the treatment group, and 58 in the placebo group, suffered breakthrough pain on day 3 (P < 0001).
__label__noRel	PIDs were 09 and 03 in the oxycodone/paracetamol and placebo groups respectively, on day 1 (P < 0001), and 15 and 03 respectively on day 3 (P < 0001).	The SF-6D score decreased to 212  25 in the oxycodone/paracetamol group at the end of the phase (P = 0001).
__label__noRel	Thirty-eight patients in the treatment group, and 58 in the placebo group, suffered breakthrough pain on day 3 (P < 0001).	In the oxycodone/paracetamol group, 67% rated GI as good, very good, or excellent.
__label__Attack	Thirty-eight patients in the treatment group, and 58 in the placebo group, suffered breakthrough pain on day 3 (P < 0001).	Patients with bone-cancer pain, already on opioids, obtain clinically important, additional pain-control, with regular oxycodone/paracetamol dosing.
__label__noRel	Thirty-eight patients in the treatment group, and 58 in the placebo group, suffered breakthrough pain on day 3 (P < 0001).	PIDs were 09 and 03 in the oxycodone/paracetamol and placebo groups respectively, on day 1 (P < 0001), and 15 and 03 respectively on day 3 (P < 0001).
__label__noRel	Thirty-eight patients in the treatment group, and 58 in the placebo group, suffered breakthrough pain on day 3 (P < 0001).	The SF-6D score decreased to 212  25 in the oxycodone/paracetamol group at the end of the phase (P = 0001).
__label__noRel	The SF-6D score decreased to 212  25 in the oxycodone/paracetamol group at the end of the phase (P = 0001).	In the oxycodone/paracetamol group, 67% rated GI as good, very good, or excellent.
__label__Support	The SF-6D score decreased to 212  25 in the oxycodone/paracetamol group at the end of the phase (P = 0001).	Patients with bone-cancer pain, already on opioids, obtain clinically important, additional pain-control, with regular oxycodone/paracetamol dosing.
__label__noRel	The SF-6D score decreased to 212  25 in the oxycodone/paracetamol group at the end of the phase (P = 0001).	PIDs were 09 and 03 in the oxycodone/paracetamol and placebo groups respectively, on day 1 (P < 0001), and 15 and 03 respectively on day 3 (P < 0001).
__label__noRel	The SF-6D score decreased to 212  25 in the oxycodone/paracetamol group at the end of the phase (P = 0001).	Thirty-eight patients in the treatment group, and 58 in the placebo group, suffered breakthrough pain on day 3 (P < 0001).
__label__noRel	The incidence and type of adverse events were consistent between the double-blind and cumulative (double-blind plus long-term extension) periods.	Rates of serious adverse events were 25.6 and 23.4 per 100 patient-years in the double-blind versus cumulative period.
__label__noRel	The incidence and type of adverse events were consistent between the double-blind and cumulative (double-blind plus long-term extension) periods.	At 6 months and 2 years, using non-responder analyses, ACR responses in abatacept-treated patients were: ACR 20, 59.4% and 56.2%; ACR 50, 23.5% and 33.2%; ACR 70, 11.5% and 16.1%; HAQ-DI responses were 54.4% and 47.9%.
__label__noRel	The incidence and type of adverse events were consistent between the double-blind and cumulative (double-blind plus long-term extension) periods.	At 6 months and 2 years, using post-hoc as-observed analyses, the percentage of patients (95% confidence interval) achieving DAS28 (C-reactive protein) low disease activity score (< or = 3.2) and DAS28 (C-reactive protein)-defined remission (< 2.6) increased from 18.3% (13.0, 23.5) to 32.0% (24.6, 39.4) and 11.1% (6.8, 15.3) to 20.3% (13.9, 26.6).
__label__noRel	The incidence and type of adverse events were consistent between the double-blind and cumulative (double-blind plus long-term extension) periods.	Clinically meaningful improvements in SF-36, pain, fatigue and sleep problems were also maintained throughout the 2 years of abatacept treatment.
__label__noRel	The incidence and type of adverse events were consistent between the double-blind and cumulative (double-blind plus long-term extension) periods.	No unique safety observations were reported during open-label exposure.
__label__noRel	The incidence and type of adverse events were consistent between the double-blind and cumulative (double-blind plus long-term extension) periods.	Improvements in the signs and symptoms of rheumatoid arthritis, physical function and health-related quality of life observed after 6 months, were maintained throughout the 2 years in this population with difficult-to-treat disease.
__label__noRel	Rates of serious adverse events were 25.6 and 23.4 per 100 patient-years in the double-blind versus cumulative period.	The incidence and type of adverse events were consistent between the double-blind and cumulative (double-blind plus long-term extension) periods.
__label__noRel	Rates of serious adverse events were 25.6 and 23.4 per 100 patient-years in the double-blind versus cumulative period.	At 6 months and 2 years, using non-responder analyses, ACR responses in abatacept-treated patients were: ACR 20, 59.4% and 56.2%; ACR 50, 23.5% and 33.2%; ACR 70, 11.5% and 16.1%; HAQ-DI responses were 54.4% and 47.9%.
__label__noRel	Rates of serious adverse events were 25.6 and 23.4 per 100 patient-years in the double-blind versus cumulative period.	At 6 months and 2 years, using post-hoc as-observed analyses, the percentage of patients (95% confidence interval) achieving DAS28 (C-reactive protein) low disease activity score (< or = 3.2) and DAS28 (C-reactive protein)-defined remission (< 2.6) increased from 18.3% (13.0, 23.5) to 32.0% (24.6, 39.4) and 11.1% (6.8, 15.3) to 20.3% (13.9, 26.6).
__label__noRel	Rates of serious adverse events were 25.6 and 23.4 per 100 patient-years in the double-blind versus cumulative period.	Clinically meaningful improvements in SF-36, pain, fatigue and sleep problems were also maintained throughout the 2 years of abatacept treatment.
__label__noRel	Rates of serious adverse events were 25.6 and 23.4 per 100 patient-years in the double-blind versus cumulative period.	No unique safety observations were reported during open-label exposure.
__label__noRel	Rates of serious adverse events were 25.6 and 23.4 per 100 patient-years in the double-blind versus cumulative period.	Improvements in the signs and symptoms of rheumatoid arthritis, physical function and health-related quality of life observed after 6 months, were maintained throughout the 2 years in this population with difficult-to-treat disease.
__label__noRel	At 6 months and 2 years, using non-responder analyses, ACR responses in abatacept-treated patients were: ACR 20, 59.4% and 56.2%; ACR 50, 23.5% and 33.2%; ACR 70, 11.5% and 16.1%; HAQ-DI responses were 54.4% and 47.9%.	The incidence and type of adverse events were consistent between the double-blind and cumulative (double-blind plus long-term extension) periods.
__label__noRel	At 6 months and 2 years, using non-responder analyses, ACR responses in abatacept-treated patients were: ACR 20, 59.4% and 56.2%; ACR 50, 23.5% and 33.2%; ACR 70, 11.5% and 16.1%; HAQ-DI responses were 54.4% and 47.9%.	Rates of serious adverse events were 25.6 and 23.4 per 100 patient-years in the double-blind versus cumulative period.
__label__noRel	At 6 months and 2 years, using non-responder analyses, ACR responses in abatacept-treated patients were: ACR 20, 59.4% and 56.2%; ACR 50, 23.5% and 33.2%; ACR 70, 11.5% and 16.1%; HAQ-DI responses were 54.4% and 47.9%.	At 6 months and 2 years, using post-hoc as-observed analyses, the percentage of patients (95% confidence interval) achieving DAS28 (C-reactive protein) low disease activity score (< or = 3.2) and DAS28 (C-reactive protein)-defined remission (< 2.6) increased from 18.3% (13.0, 23.5) to 32.0% (24.6, 39.4) and 11.1% (6.8, 15.3) to 20.3% (13.9, 26.6).
__label__noRel	At 6 months and 2 years, using non-responder analyses, ACR responses in abatacept-treated patients were: ACR 20, 59.4% and 56.2%; ACR 50, 23.5% and 33.2%; ACR 70, 11.5% and 16.1%; HAQ-DI responses were 54.4% and 47.9%.	Clinically meaningful improvements in SF-36, pain, fatigue and sleep problems were also maintained throughout the 2 years of abatacept treatment.
__label__noRel	At 6 months and 2 years, using non-responder analyses, ACR responses in abatacept-treated patients were: ACR 20, 59.4% and 56.2%; ACR 50, 23.5% and 33.2%; ACR 70, 11.5% and 16.1%; HAQ-DI responses were 54.4% and 47.9%.	No unique safety observations were reported during open-label exposure.
__label__noRel	At 6 months and 2 years, using non-responder analyses, ACR responses in abatacept-treated patients were: ACR 20, 59.4% and 56.2%; ACR 50, 23.5% and 33.2%; ACR 70, 11.5% and 16.1%; HAQ-DI responses were 54.4% and 47.9%.	Improvements in the signs and symptoms of rheumatoid arthritis, physical function and health-related quality of life observed after 6 months, were maintained throughout the 2 years in this population with difficult-to-treat disease.
__label__noRel	At 6 months and 2 years, using post-hoc as-observed analyses, the percentage of patients (95% confidence interval) achieving DAS28 (C-reactive protein) low disease activity score (< or = 3.2) and DAS28 (C-reactive protein)-defined remission (< 2.6) increased from 18.3% (13.0, 23.5) to 32.0% (24.6, 39.4) and 11.1% (6.8, 15.3) to 20.3% (13.9, 26.6).	The incidence and type of adverse events were consistent between the double-blind and cumulative (double-blind plus long-term extension) periods.
__label__noRel	At 6 months and 2 years, using post-hoc as-observed analyses, the percentage of patients (95% confidence interval) achieving DAS28 (C-reactive protein) low disease activity score (< or = 3.2) and DAS28 (C-reactive protein)-defined remission (< 2.6) increased from 18.3% (13.0, 23.5) to 32.0% (24.6, 39.4) and 11.1% (6.8, 15.3) to 20.3% (13.9, 26.6).	Rates of serious adverse events were 25.6 and 23.4 per 100 patient-years in the double-blind versus cumulative period.
__label__noRel	At 6 months and 2 years, using post-hoc as-observed analyses, the percentage of patients (95% confidence interval) achieving DAS28 (C-reactive protein) low disease activity score (< or = 3.2) and DAS28 (C-reactive protein)-defined remission (< 2.6) increased from 18.3% (13.0, 23.5) to 32.0% (24.6, 39.4) and 11.1% (6.8, 15.3) to 20.3% (13.9, 26.6).	At 6 months and 2 years, using non-responder analyses, ACR responses in abatacept-treated patients were: ACR 20, 59.4% and 56.2%; ACR 50, 23.5% and 33.2%; ACR 70, 11.5% and 16.1%; HAQ-DI responses were 54.4% and 47.9%.
__label__noRel	At 6 months and 2 years, using post-hoc as-observed analyses, the percentage of patients (95% confidence interval) achieving DAS28 (C-reactive protein) low disease activity score (< or = 3.2) and DAS28 (C-reactive protein)-defined remission (< 2.6) increased from 18.3% (13.0, 23.5) to 32.0% (24.6, 39.4) and 11.1% (6.8, 15.3) to 20.3% (13.9, 26.6).	Clinically meaningful improvements in SF-36, pain, fatigue and sleep problems were also maintained throughout the 2 years of abatacept treatment.
__label__noRel	At 6 months and 2 years, using post-hoc as-observed analyses, the percentage of patients (95% confidence interval) achieving DAS28 (C-reactive protein) low disease activity score (< or = 3.2) and DAS28 (C-reactive protein)-defined remission (< 2.6) increased from 18.3% (13.0, 23.5) to 32.0% (24.6, 39.4) and 11.1% (6.8, 15.3) to 20.3% (13.9, 26.6).	No unique safety observations were reported during open-label exposure.
__label__noRel	At 6 months and 2 years, using post-hoc as-observed analyses, the percentage of patients (95% confidence interval) achieving DAS28 (C-reactive protein) low disease activity score (< or = 3.2) and DAS28 (C-reactive protein)-defined remission (< 2.6) increased from 18.3% (13.0, 23.5) to 32.0% (24.6, 39.4) and 11.1% (6.8, 15.3) to 20.3% (13.9, 26.6).	Improvements in the signs and symptoms of rheumatoid arthritis, physical function and health-related quality of life observed after 6 months, were maintained throughout the 2 years in this population with difficult-to-treat disease.
__label__noRel	Clinically meaningful improvements in SF-36, pain, fatigue and sleep problems were also maintained throughout the 2 years of abatacept treatment.	The incidence and type of adverse events were consistent between the double-blind and cumulative (double-blind plus long-term extension) periods.
__label__noRel	Clinically meaningful improvements in SF-36, pain, fatigue and sleep problems were also maintained throughout the 2 years of abatacept treatment.	Rates of serious adverse events were 25.6 and 23.4 per 100 patient-years in the double-blind versus cumulative period.
__label__noRel	Clinically meaningful improvements in SF-36, pain, fatigue and sleep problems were also maintained throughout the 2 years of abatacept treatment.	At 6 months and 2 years, using non-responder analyses, ACR responses in abatacept-treated patients were: ACR 20, 59.4% and 56.2%; ACR 50, 23.5% and 33.2%; ACR 70, 11.5% and 16.1%; HAQ-DI responses were 54.4% and 47.9%.
__label__noRel	Clinically meaningful improvements in SF-36, pain, fatigue and sleep problems were also maintained throughout the 2 years of abatacept treatment.	At 6 months and 2 years, using post-hoc as-observed analyses, the percentage of patients (95% confidence interval) achieving DAS28 (C-reactive protein) low disease activity score (< or = 3.2) and DAS28 (C-reactive protein)-defined remission (< 2.6) increased from 18.3% (13.0, 23.5) to 32.0% (24.6, 39.4) and 11.1% (6.8, 15.3) to 20.3% (13.9, 26.6).
__label__noRel	Clinically meaningful improvements in SF-36, pain, fatigue and sleep problems were also maintained throughout the 2 years of abatacept treatment.	No unique safety observations were reported during open-label exposure.
__label__noRel	Clinically meaningful improvements in SF-36, pain, fatigue and sleep problems were also maintained throughout the 2 years of abatacept treatment.	Improvements in the signs and symptoms of rheumatoid arthritis, physical function and health-related quality of life observed after 6 months, were maintained throughout the 2 years in this population with difficult-to-treat disease.
__label__noRel	No unique safety observations were reported during open-label exposure.	The incidence and type of adverse events were consistent between the double-blind and cumulative (double-blind plus long-term extension) periods.
__label__noRel	No unique safety observations were reported during open-label exposure.	Rates of serious adverse events were 25.6 and 23.4 per 100 patient-years in the double-blind versus cumulative period.
__label__noRel	No unique safety observations were reported during open-label exposure.	At 6 months and 2 years, using non-responder analyses, ACR responses in abatacept-treated patients were: ACR 20, 59.4% and 56.2%; ACR 50, 23.5% and 33.2%; ACR 70, 11.5% and 16.1%; HAQ-DI responses were 54.4% and 47.9%.
__label__noRel	No unique safety observations were reported during open-label exposure.	At 6 months and 2 years, using post-hoc as-observed analyses, the percentage of patients (95% confidence interval) achieving DAS28 (C-reactive protein) low disease activity score (< or = 3.2) and DAS28 (C-reactive protein)-defined remission (< 2.6) increased from 18.3% (13.0, 23.5) to 32.0% (24.6, 39.4) and 11.1% (6.8, 15.3) to 20.3% (13.9, 26.6).
__label__noRel	No unique safety observations were reported during open-label exposure.	Clinically meaningful improvements in SF-36, pain, fatigue and sleep problems were also maintained throughout the 2 years of abatacept treatment.
__label__noRel	No unique safety observations were reported during open-label exposure.	Improvements in the signs and symptoms of rheumatoid arthritis, physical function and health-related quality of life observed after 6 months, were maintained throughout the 2 years in this population with difficult-to-treat disease.
__label__noRel	Improvements in the signs and symptoms of rheumatoid arthritis, physical function and health-related quality of life observed after 6 months, were maintained throughout the 2 years in this population with difficult-to-treat disease.	The incidence and type of adverse events were consistent between the double-blind and cumulative (double-blind plus long-term extension) periods.
__label__noRel	Improvements in the signs and symptoms of rheumatoid arthritis, physical function and health-related quality of life observed after 6 months, were maintained throughout the 2 years in this population with difficult-to-treat disease.	Rates of serious adverse events were 25.6 and 23.4 per 100 patient-years in the double-blind versus cumulative period.
__label__noRel	Improvements in the signs and symptoms of rheumatoid arthritis, physical function and health-related quality of life observed after 6 months, were maintained throughout the 2 years in this population with difficult-to-treat disease.	At 6 months and 2 years, using non-responder analyses, ACR responses in abatacept-treated patients were: ACR 20, 59.4% and 56.2%; ACR 50, 23.5% and 33.2%; ACR 70, 11.5% and 16.1%; HAQ-DI responses were 54.4% and 47.9%.
__label__noRel	Improvements in the signs and symptoms of rheumatoid arthritis, physical function and health-related quality of life observed after 6 months, were maintained throughout the 2 years in this population with difficult-to-treat disease.	At 6 months and 2 years, using post-hoc as-observed analyses, the percentage of patients (95% confidence interval) achieving DAS28 (C-reactive protein) low disease activity score (< or = 3.2) and DAS28 (C-reactive protein)-defined remission (< 2.6) increased from 18.3% (13.0, 23.5) to 32.0% (24.6, 39.4) and 11.1% (6.8, 15.3) to 20.3% (13.9, 26.6).
__label__noRel	Improvements in the signs and symptoms of rheumatoid arthritis, physical function and health-related quality of life observed after 6 months, were maintained throughout the 2 years in this population with difficult-to-treat disease.	Clinically meaningful improvements in SF-36, pain, fatigue and sleep problems were also maintained throughout the 2 years of abatacept treatment.
__label__noRel	Improvements in the signs and symptoms of rheumatoid arthritis, physical function and health-related quality of life observed after 6 months, were maintained throughout the 2 years in this population with difficult-to-treat disease.	No unique safety observations were reported during open-label exposure.
__label__noRel	A small decline in visual analogue scale scores was observed (70.7 vs. 68.2, P=0.026).	Mean index scores remained stable (0.78 at baseline [n=267], 0.79 at eight weeks [n=186], P=0.34, Wilcoxon signed rank test), attributable to a modest deterioration of physical function domain scores coincident with small improvements in pain and anxiety/depression scores.
__label__noRel	A small decline in visual analogue scale scores was observed (70.7 vs. 68.2, P=0.026).	HRQOL changes within chemotherapy response strata revealed stable index scores
__label__noRel	A small decline in visual analogue scale scores was observed (70.7 vs. 68.2, P=0.026).	but a trend of worsened physical function among patients with disease progression compared with those with stable or improved disease.
__label__noRel	A small decline in visual analogue scale scores was observed (70.7 vs. 68.2, P=0.026).	Visual analogue scale scores trended downward over time irrespective of chemotherapy response status, with a statistically meaningful deterioration in patients who progressed (68.9 vs. 64.4, P=0.029).
__label__Support	A small decline in visual analogue scale scores was observed (70.7 vs. 68.2, P=0.026).	Response to gemcitabine treatment in APC is not associated with appreciable improvement of global HRQOL.
__label__noRel	A small decline in visual analogue scale scores was observed (70.7 vs. 68.2, P=0.026).	Those who respond to gemcitabine may experience a slight slowing of functional deterioration.
__label__noRel	Mean index scores remained stable (0.78 at baseline [n=267], 0.79 at eight weeks [n=186], P=0.34, Wilcoxon signed rank test), attributable to a modest deterioration of physical function domain scores coincident with small improvements in pain and anxiety/depression scores.	A small decline in visual analogue scale scores was observed (70.7 vs. 68.2, P=0.026).
__label__noRel	Mean index scores remained stable (0.78 at baseline [n=267], 0.79 at eight weeks [n=186], P=0.34, Wilcoxon signed rank test), attributable to a modest deterioration of physical function domain scores coincident with small improvements in pain and anxiety/depression scores.	HRQOL changes within chemotherapy response strata revealed stable index scores
__label__noRel	Mean index scores remained stable (0.78 at baseline [n=267], 0.79 at eight weeks [n=186], P=0.34, Wilcoxon signed rank test), attributable to a modest deterioration of physical function domain scores coincident with small improvements in pain and anxiety/depression scores.	but a trend of worsened physical function among patients with disease progression compared with those with stable or improved disease.
__label__noRel	Mean index scores remained stable (0.78 at baseline [n=267], 0.79 at eight weeks [n=186], P=0.34, Wilcoxon signed rank test), attributable to a modest deterioration of physical function domain scores coincident with small improvements in pain and anxiety/depression scores.	Visual analogue scale scores trended downward over time irrespective of chemotherapy response status, with a statistically meaningful deterioration in patients who progressed (68.9 vs. 64.4, P=0.029).
__label__Support	Mean index scores remained stable (0.78 at baseline [n=267], 0.79 at eight weeks [n=186], P=0.34, Wilcoxon signed rank test), attributable to a modest deterioration of physical function domain scores coincident with small improvements in pain and anxiety/depression scores.	Response to gemcitabine treatment in APC is not associated with appreciable improvement of global HRQOL.
__label__noRel	Mean index scores remained stable (0.78 at baseline [n=267], 0.79 at eight weeks [n=186], P=0.34, Wilcoxon signed rank test), attributable to a modest deterioration of physical function domain scores coincident with small improvements in pain and anxiety/depression scores.	Those who respond to gemcitabine may experience a slight slowing of functional deterioration.
__label__noRel	HRQOL changes within chemotherapy response strata revealed stable index scores	A small decline in visual analogue scale scores was observed (70.7 vs. 68.2, P=0.026).
__label__noRel	HRQOL changes within chemotherapy response strata revealed stable index scores	Mean index scores remained stable (0.78 at baseline [n=267], 0.79 at eight weeks [n=186], P=0.34, Wilcoxon signed rank test), attributable to a modest deterioration of physical function domain scores coincident with small improvements in pain and anxiety/depression scores.
__label__noRel	HRQOL changes within chemotherapy response strata revealed stable index scores	but a trend of worsened physical function among patients with disease progression compared with those with stable or improved disease.
__label__noRel	HRQOL changes within chemotherapy response strata revealed stable index scores	Visual analogue scale scores trended downward over time irrespective of chemotherapy response status, with a statistically meaningful deterioration in patients who progressed (68.9 vs. 64.4, P=0.029).
__label__Support	HRQOL changes within chemotherapy response strata revealed stable index scores	Response to gemcitabine treatment in APC is not associated with appreciable improvement of global HRQOL.
__label__noRel	HRQOL changes within chemotherapy response strata revealed stable index scores	Those who respond to gemcitabine may experience a slight slowing of functional deterioration.
__label__noRel	but a trend of worsened physical function among patients with disease progression compared with those with stable or improved disease.	A small decline in visual analogue scale scores was observed (70.7 vs. 68.2, P=0.026).
__label__noRel	but a trend of worsened physical function among patients with disease progression compared with those with stable or improved disease.	Mean index scores remained stable (0.78 at baseline [n=267], 0.79 at eight weeks [n=186], P=0.34, Wilcoxon signed rank test), attributable to a modest deterioration of physical function domain scores coincident with small improvements in pain and anxiety/depression scores.
__label__Attack	but a trend of worsened physical function among patients with disease progression compared with those with stable or improved disease.	HRQOL changes within chemotherapy response strata revealed stable index scores
__label__noRel	but a trend of worsened physical function among patients with disease progression compared with those with stable or improved disease.	Visual analogue scale scores trended downward over time irrespective of chemotherapy response status, with a statistically meaningful deterioration in patients who progressed (68.9 vs. 64.4, P=0.029).
__label__noRel	but a trend of worsened physical function among patients with disease progression compared with those with stable or improved disease.	Response to gemcitabine treatment in APC is not associated with appreciable improvement of global HRQOL.
__label__noRel	but a trend of worsened physical function among patients with disease progression compared with those with stable or improved disease.	Those who respond to gemcitabine may experience a slight slowing of functional deterioration.
__label__noRel	Visual analogue scale scores trended downward over time irrespective of chemotherapy response status, with a statistically meaningful deterioration in patients who progressed (68.9 vs. 64.4, P=0.029).	A small decline in visual analogue scale scores was observed (70.7 vs. 68.2, P=0.026).
__label__noRel	Visual analogue scale scores trended downward over time irrespective of chemotherapy response status, with a statistically meaningful deterioration in patients who progressed (68.9 vs. 64.4, P=0.029).	Mean index scores remained stable (0.78 at baseline [n=267], 0.79 at eight weeks [n=186], P=0.34, Wilcoxon signed rank test), attributable to a modest deterioration of physical function domain scores coincident with small improvements in pain and anxiety/depression scores.
__label__noRel	Visual analogue scale scores trended downward over time irrespective of chemotherapy response status, with a statistically meaningful deterioration in patients who progressed (68.9 vs. 64.4, P=0.029).	HRQOL changes within chemotherapy response strata revealed stable index scores
__label__noRel	Visual analogue scale scores trended downward over time irrespective of chemotherapy response status, with a statistically meaningful deterioration in patients who progressed (68.9 vs. 64.4, P=0.029).	but a trend of worsened physical function among patients with disease progression compared with those with stable or improved disease.
__label__noRel	Visual analogue scale scores trended downward over time irrespective of chemotherapy response status, with a statistically meaningful deterioration in patients who progressed (68.9 vs. 64.4, P=0.029).	Response to gemcitabine treatment in APC is not associated with appreciable improvement of global HRQOL.
__label__Support	Visual analogue scale scores trended downward over time irrespective of chemotherapy response status, with a statistically meaningful deterioration in patients who progressed (68.9 vs. 64.4, P=0.029).	Those who respond to gemcitabine may experience a slight slowing of functional deterioration.
__label__noRel	Response to gemcitabine treatment in APC is not associated with appreciable improvement of global HRQOL.	A small decline in visual analogue scale scores was observed (70.7 vs. 68.2, P=0.026).
__label__noRel	Response to gemcitabine treatment in APC is not associated with appreciable improvement of global HRQOL.	Mean index scores remained stable (0.78 at baseline [n=267], 0.79 at eight weeks [n=186], P=0.34, Wilcoxon signed rank test), attributable to a modest deterioration of physical function domain scores coincident with small improvements in pain and anxiety/depression scores.
__label__noRel	Response to gemcitabine treatment in APC is not associated with appreciable improvement of global HRQOL.	HRQOL changes within chemotherapy response strata revealed stable index scores
__label__noRel	Response to gemcitabine treatment in APC is not associated with appreciable improvement of global HRQOL.	but a trend of worsened physical function among patients with disease progression compared with those with stable or improved disease.
__label__noRel	Response to gemcitabine treatment in APC is not associated with appreciable improvement of global HRQOL.	Visual analogue scale scores trended downward over time irrespective of chemotherapy response status, with a statistically meaningful deterioration in patients who progressed (68.9 vs. 64.4, P=0.029).
__label__noRel	Response to gemcitabine treatment in APC is not associated with appreciable improvement of global HRQOL.	Those who respond to gemcitabine may experience a slight slowing of functional deterioration.
__label__noRel	Those who respond to gemcitabine may experience a slight slowing of functional deterioration.	A small decline in visual analogue scale scores was observed (70.7 vs. 68.2, P=0.026).
__label__noRel	Those who respond to gemcitabine may experience a slight slowing of functional deterioration.	Mean index scores remained stable (0.78 at baseline [n=267], 0.79 at eight weeks [n=186], P=0.34, Wilcoxon signed rank test), attributable to a modest deterioration of physical function domain scores coincident with small improvements in pain and anxiety/depression scores.
__label__noRel	Those who respond to gemcitabine may experience a slight slowing of functional deterioration.	HRQOL changes within chemotherapy response strata revealed stable index scores
__label__noRel	Those who respond to gemcitabine may experience a slight slowing of functional deterioration.	but a trend of worsened physical function among patients with disease progression compared with those with stable or improved disease.
__label__noRel	Those who respond to gemcitabine may experience a slight slowing of functional deterioration.	Visual analogue scale scores trended downward over time irrespective of chemotherapy response status, with a statistically meaningful deterioration in patients who progressed (68.9 vs. 64.4, P=0.029).
__label__noRel	Those who respond to gemcitabine may experience a slight slowing of functional deterioration.	Response to gemcitabine treatment in APC is not associated with appreciable improvement of global HRQOL.
__label__noRel	PFS was significantly prolonged in the erlotinib treatment arm, both overall (hazard ratio [HR]: 0.57; p=0.0067) and in patients with EGFR IHC-positive disease (HR=0.50; p=0.0057).	There was a trend towards an increase in OS, which reached statistical significance in the EGFR IHC-positive subgroup (p=0.0233).
__label__noRel	PFS was significantly prolonged in the erlotinib treatment arm, both overall (hazard ratio [HR]: 0.57; p=0.0067) and in patients with EGFR IHC-positive disease (HR=0.50; p=0.0057).	The overall response rate was significantly higher with erlotinib compared with placebo (24% versus 5%; p=0.0025).
__label__noRel	PFS was significantly prolonged in the erlotinib treatment arm, both overall (hazard ratio [HR]: 0.57; p=0.0067) and in patients with EGFR IHC-positive disease (HR=0.50; p=0.0057).	Erlotinib was generally well tolerated and had no negative impact on QoL in this subpopulation.
__label__noRel	PFS was significantly prolonged in the erlotinib treatment arm, both overall (hazard ratio [HR]: 0.57; p=0.0067) and in patients with EGFR IHC-positive disease (HR=0.50; p=0.0057).	The most common treatment-related adverse events were rash, diarrhea and pruritus.
__label__Support	PFS was significantly prolonged in the erlotinib treatment arm, both overall (hazard ratio [HR]: 0.57; p=0.0067) and in patients with EGFR IHC-positive disease (HR=0.50; p=0.0057).	Erlotinib was effective and well tolerated in Asian patients, producing benefits consistent with those observed in the overall SATURN population.
__label__noRel	PFS was significantly prolonged in the erlotinib treatment arm, both overall (hazard ratio [HR]: 0.57; p=0.0067) and in patients with EGFR IHC-positive disease (HR=0.50; p=0.0057).	Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy.
__label__noRel	There was a trend towards an increase in OS, which reached statistical significance in the EGFR IHC-positive subgroup (p=0.0233).	PFS was significantly prolonged in the erlotinib treatment arm, both overall (hazard ratio [HR]: 0.57; p=0.0067) and in patients with EGFR IHC-positive disease (HR=0.50; p=0.0057).
__label__noRel	There was a trend towards an increase in OS, which reached statistical significance in the EGFR IHC-positive subgroup (p=0.0233).	The overall response rate was significantly higher with erlotinib compared with placebo (24% versus 5%; p=0.0025).
__label__noRel	There was a trend towards an increase in OS, which reached statistical significance in the EGFR IHC-positive subgroup (p=0.0233).	Erlotinib was generally well tolerated and had no negative impact on QoL in this subpopulation.
__label__noRel	There was a trend towards an increase in OS, which reached statistical significance in the EGFR IHC-positive subgroup (p=0.0233).	The most common treatment-related adverse events were rash, diarrhea and pruritus.
__label__Support	There was a trend towards an increase in OS, which reached statistical significance in the EGFR IHC-positive subgroup (p=0.0233).	Erlotinib was effective and well tolerated in Asian patients, producing benefits consistent with those observed in the overall SATURN population.
__label__noRel	There was a trend towards an increase in OS, which reached statistical significance in the EGFR IHC-positive subgroup (p=0.0233).	Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy.
__label__noRel	The overall response rate was significantly higher with erlotinib compared with placebo (24% versus 5%; p=0.0025).	PFS was significantly prolonged in the erlotinib treatment arm, both overall (hazard ratio [HR]: 0.57; p=0.0067) and in patients with EGFR IHC-positive disease (HR=0.50; p=0.0057).
__label__noRel	The overall response rate was significantly higher with erlotinib compared with placebo (24% versus 5%; p=0.0025).	There was a trend towards an increase in OS, which reached statistical significance in the EGFR IHC-positive subgroup (p=0.0233).
__label__noRel	The overall response rate was significantly higher with erlotinib compared with placebo (24% versus 5%; p=0.0025).	Erlotinib was generally well tolerated and had no negative impact on QoL in this subpopulation.
__label__noRel	The overall response rate was significantly higher with erlotinib compared with placebo (24% versus 5%; p=0.0025).	The most common treatment-related adverse events were rash, diarrhea and pruritus.
__label__Support	The overall response rate was significantly higher with erlotinib compared with placebo (24% versus 5%; p=0.0025).	Erlotinib was effective and well tolerated in Asian patients, producing benefits consistent with those observed in the overall SATURN population.
__label__noRel	The overall response rate was significantly higher with erlotinib compared with placebo (24% versus 5%; p=0.0025).	Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy.
__label__noRel	Erlotinib was generally well tolerated and had no negative impact on QoL in this subpopulation.	PFS was significantly prolonged in the erlotinib treatment arm, both overall (hazard ratio [HR]: 0.57; p=0.0067) and in patients with EGFR IHC-positive disease (HR=0.50; p=0.0057).
__label__noRel	Erlotinib was generally well tolerated and had no negative impact on QoL in this subpopulation.	There was a trend towards an increase in OS, which reached statistical significance in the EGFR IHC-positive subgroup (p=0.0233).
__label__noRel	Erlotinib was generally well tolerated and had no negative impact on QoL in this subpopulation.	The overall response rate was significantly higher with erlotinib compared with placebo (24% versus 5%; p=0.0025).
__label__noRel	Erlotinib was generally well tolerated and had no negative impact on QoL in this subpopulation.	The most common treatment-related adverse events were rash, diarrhea and pruritus.
__label__Support	Erlotinib was generally well tolerated and had no negative impact on QoL in this subpopulation.	Erlotinib was effective and well tolerated in Asian patients, producing benefits consistent with those observed in the overall SATURN population.
__label__noRel	Erlotinib was generally well tolerated and had no negative impact on QoL in this subpopulation.	Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy.
__label__noRel	The most common treatment-related adverse events were rash, diarrhea and pruritus.	PFS was significantly prolonged in the erlotinib treatment arm, both overall (hazard ratio [HR]: 0.57; p=0.0067) and in patients with EGFR IHC-positive disease (HR=0.50; p=0.0057).
__label__noRel	The most common treatment-related adverse events were rash, diarrhea and pruritus.	There was a trend towards an increase in OS, which reached statistical significance in the EGFR IHC-positive subgroup (p=0.0233).
__label__noRel	The most common treatment-related adverse events were rash, diarrhea and pruritus.	The overall response rate was significantly higher with erlotinib compared with placebo (24% versus 5%; p=0.0025).
__label__Support	The most common treatment-related adverse events were rash, diarrhea and pruritus.	Erlotinib was generally well tolerated and had no negative impact on QoL in this subpopulation.
__label__noRel	The most common treatment-related adverse events were rash, diarrhea and pruritus.	Erlotinib was effective and well tolerated in Asian patients, producing benefits consistent with those observed in the overall SATURN population.
__label__noRel	The most common treatment-related adverse events were rash, diarrhea and pruritus.	Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy.
__label__noRel	Erlotinib was effective and well tolerated in Asian patients, producing benefits consistent with those observed in the overall SATURN population.	PFS was significantly prolonged in the erlotinib treatment arm, both overall (hazard ratio [HR]: 0.57; p=0.0067) and in patients with EGFR IHC-positive disease (HR=0.50; p=0.0057).
__label__noRel	Erlotinib was effective and well tolerated in Asian patients, producing benefits consistent with those observed in the overall SATURN population.	There was a trend towards an increase in OS, which reached statistical significance in the EGFR IHC-positive subgroup (p=0.0233).
__label__noRel	Erlotinib was effective and well tolerated in Asian patients, producing benefits consistent with those observed in the overall SATURN population.	The overall response rate was significantly higher with erlotinib compared with placebo (24% versus 5%; p=0.0025).
__label__noRel	Erlotinib was effective and well tolerated in Asian patients, producing benefits consistent with those observed in the overall SATURN population.	Erlotinib was generally well tolerated and had no negative impact on QoL in this subpopulation.
__label__noRel	Erlotinib was effective and well tolerated in Asian patients, producing benefits consistent with those observed in the overall SATURN population.	The most common treatment-related adverse events were rash, diarrhea and pruritus.
__label__Support	Erlotinib was effective and well tolerated in Asian patients, producing benefits consistent with those observed in the overall SATURN population.	Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy.
__label__noRel	Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy.	PFS was significantly prolonged in the erlotinib treatment arm, both overall (hazard ratio [HR]: 0.57; p=0.0067) and in patients with EGFR IHC-positive disease (HR=0.50; p=0.0057).
__label__noRel	Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy.	There was a trend towards an increase in OS, which reached statistical significance in the EGFR IHC-positive subgroup (p=0.0233).
__label__noRel	Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy.	The overall response rate was significantly higher with erlotinib compared with placebo (24% versus 5%; p=0.0025).
__label__noRel	Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy.	Erlotinib was generally well tolerated and had no negative impact on QoL in this subpopulation.
__label__noRel	Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy.	The most common treatment-related adverse events were rash, diarrhea and pruritus.
__label__noRel	Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy.	Erlotinib was effective and well tolerated in Asian patients, producing benefits consistent with those observed in the overall SATURN population.
__label__noRel	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).
__label__noRel	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.
__label__noRel	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.
__label__noRel	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.
__label__Support	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.
__label__noRel	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,
__label__noRel	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.	although the regimen generally was well tolerated.
__label__noRel	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.
__label__noRel	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.
__label__noRel	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.
__label__noRel	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.
__label__noRel	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.
__label__noRel	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,
__label__noRel	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).	although the regimen generally was well tolerated.
__label__noRel	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.
__label__Support	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).
__label__noRel	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.
__label__noRel	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.
__label__noRel	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.
__label__noRel	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,
__label__noRel	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.	although the regimen generally was well tolerated.
__label__noRel	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.
__label__noRel	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).
__label__noRel	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.
__label__noRel	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.
__label__noRel	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.
__label__Support	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,
__label__noRel	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.	although the regimen generally was well tolerated.
__label__noRel	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.
__label__noRel	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).
__label__noRel	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.
__label__noRel	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.
__label__noRel	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.
__label__noRel	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,
__label__noRel	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.	although the regimen generally was well tolerated.
__label__noRel	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.
__label__noRel	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).
__label__noRel	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.
__label__noRel	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.
__label__noRel	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.
__label__noRel	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,
__label__noRel	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.	although the regimen generally was well tolerated.
__label__noRel	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.
__label__noRel	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).
__label__noRel	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.
__label__noRel	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.
__label__noRel	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.
__label__noRel	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.
__label__noRel	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,	although the regimen generally was well tolerated.
__label__noRel	although the regimen generally was well tolerated.	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.
__label__noRel	although the regimen generally was well tolerated.	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).
__label__noRel	although the regimen generally was well tolerated.	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.
__label__noRel	although the regimen generally was well tolerated.	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.
__label__noRel	although the regimen generally was well tolerated.	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.
__label__noRel	although the regimen generally was well tolerated.	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.
__label__Attack	although the regimen generally was well tolerated.	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,
__label__noRel	The use of prophylactic tamsulosin resulted in a statistically lower dysuria severity score (difference of 2.7 vs 4.2, P < 0.005) at 1 month, with no discernible differences at 3, 6, 12 and 18 months.	Patients with dysuria had a statistically higher IPSS.
__label__noRel	The use of prophylactic tamsulosin resulted in a statistically lower dysuria severity score (difference of 2.7 vs 4.2, P < 0.005) at 1 month, with no discernible differences at 3, 6, 12 and 18 months.	The dysuria resolved faster in patients implanted with 103Pd
__label__noRel	The use of prophylactic tamsulosin resulted in a statistically lower dysuria severity score (difference of 2.7 vs 4.2, P < 0.005) at 1 month, with no discernible differences at 3, 6, 12 and 18 months.	In multivariate analysis, prophylactic alpha-blockers resulted in statistically lower maximum dysuria scores,
__label__noRel	The use of prophylactic tamsulosin resulted in a statistically lower dysuria severity score (difference of 2.7 vs 4.2, P < 0.005) at 1 month, with no discernible differences at 3, 6, 12 and 18 months.	while the maximum IPSS after implantation and isotope type (but only at 6 months) were the best predictors of the resolution of dysuria.
__label__noRel	The use of prophylactic tamsulosin resulted in a statistically lower dysuria severity score (difference of 2.7 vs 4.2, P < 0.005) at 1 month, with no discernible differences at 3, 6, 12 and 18 months.	Dysuria is common after brachytherapy but is typically mild.
__label__noRel	The use of prophylactic tamsulosin resulted in a statistically lower dysuria severity score (difference of 2.7 vs 4.2, P < 0.005) at 1 month, with no discernible differences at 3, 6, 12 and 18 months.	Prophylactic alpha-blockers gave significantly lower maximum dysuria scores
__label__noRel	The use of prophylactic tamsulosin resulted in a statistically lower dysuria severity score (difference of 2.7 vs 4.2, P < 0.005) at 1 month, with no discernible differences at 3, 6, 12 and 18 months.	but did not affect the time to the resolution of dysuria.
__label__noRel	The use of prophylactic tamsulosin resulted in a statistically lower dysuria severity score (difference of 2.7 vs 4.2, P < 0.005) at 1 month, with no discernible differences at 3, 6, 12 and 18 months.	The maximum IPSS after the implant was the best predictor of the resolution of dysuria.
__label__noRel	The use of prophylactic tamsulosin resulted in a statistically lower dysuria severity score (difference of 2.7 vs 4.2, P < 0.005) at 1 month, with no discernible differences at 3, 6, 12 and 18 months.	but was unaffected by the use of supplemental radiotherapy and/or androgen deprivation therapy.
__label__noRel	Patients with dysuria had a statistically higher IPSS.	The use of prophylactic tamsulosin resulted in a statistically lower dysuria severity score (difference of 2.7 vs 4.2, P < 0.005) at 1 month, with no discernible differences at 3, 6, 12 and 18 months.
__label__noRel	Patients with dysuria had a statistically higher IPSS.	The dysuria resolved faster in patients implanted with 103Pd
__label__noRel	Patients with dysuria had a statistically higher IPSS.	In multivariate analysis, prophylactic alpha-blockers resulted in statistically lower maximum dysuria scores,
__label__noRel	Patients with dysuria had a statistically higher IPSS.	while the maximum IPSS after implantation and isotope type (but only at 6 months) were the best predictors of the resolution of dysuria.
__label__noRel	Patients with dysuria had a statistically higher IPSS.	Dysuria is common after brachytherapy but is typically mild.
__label__noRel	Patients with dysuria had a statistically higher IPSS.	Prophylactic alpha-blockers gave significantly lower maximum dysuria scores
__label__noRel	Patients with dysuria had a statistically higher IPSS.	but did not affect the time to the resolution of dysuria.
__label__Support	Patients with dysuria had a statistically higher IPSS.	The maximum IPSS after the implant was the best predictor of the resolution of dysuria.
__label__noRel	Patients with dysuria had a statistically higher IPSS.	but was unaffected by the use of supplemental radiotherapy and/or androgen deprivation therapy.
__label__noRel	The dysuria resolved faster in patients implanted with 103Pd	The use of prophylactic tamsulosin resulted in a statistically lower dysuria severity score (difference of 2.7 vs 4.2, P < 0.005) at 1 month, with no discernible differences at 3, 6, 12 and 18 months.
__label__noRel	The dysuria resolved faster in patients implanted with 103Pd	Patients with dysuria had a statistically higher IPSS.
__label__noRel	The dysuria resolved faster in patients implanted with 103Pd	In multivariate analysis, prophylactic alpha-blockers resulted in statistically lower maximum dysuria scores,
__label__noRel	The dysuria resolved faster in patients implanted with 103Pd	while the maximum IPSS after implantation and isotope type (but only at 6 months) were the best predictors of the resolution of dysuria.
__label__noRel	The dysuria resolved faster in patients implanted with 103Pd	Dysuria is common after brachytherapy but is typically mild.
__label__Support	The dysuria resolved faster in patients implanted with 103Pd	Prophylactic alpha-blockers gave significantly lower maximum dysuria scores
__label__noRel	The dysuria resolved faster in patients implanted with 103Pd	but did not affect the time to the resolution of dysuria.
__label__noRel	The dysuria resolved faster in patients implanted with 103Pd	The maximum IPSS after the implant was the best predictor of the resolution of dysuria.
__label__noRel	The dysuria resolved faster in patients implanted with 103Pd	but was unaffected by the use of supplemental radiotherapy and/or androgen deprivation therapy.
__label__noRel	In multivariate analysis, prophylactic alpha-blockers resulted in statistically lower maximum dysuria scores,	The use of prophylactic tamsulosin resulted in a statistically lower dysuria severity score (difference of 2.7 vs 4.2, P < 0.005) at 1 month, with no discernible differences at 3, 6, 12 and 18 months.
__label__noRel	In multivariate analysis, prophylactic alpha-blockers resulted in statistically lower maximum dysuria scores,	Patients with dysuria had a statistically higher IPSS.
__label__noRel	In multivariate analysis, prophylactic alpha-blockers resulted in statistically lower maximum dysuria scores,	The dysuria resolved faster in patients implanted with 103Pd
__label__noRel	In multivariate analysis, prophylactic alpha-blockers resulted in statistically lower maximum dysuria scores,	while the maximum IPSS after implantation and isotope type (but only at 6 months) were the best predictors of the resolution of dysuria.
__label__noRel	In multivariate analysis, prophylactic alpha-blockers resulted in statistically lower maximum dysuria scores,	Dysuria is common after brachytherapy but is typically mild.
__label__Support	In multivariate analysis, prophylactic alpha-blockers resulted in statistically lower maximum dysuria scores,	Prophylactic alpha-blockers gave significantly lower maximum dysuria scores
__label__noRel	In multivariate analysis, prophylactic alpha-blockers resulted in statistically lower maximum dysuria scores,	but did not affect the time to the resolution of dysuria.
__label__noRel	In multivariate analysis, prophylactic alpha-blockers resulted in statistically lower maximum dysuria scores,	The maximum IPSS after the implant was the best predictor of the resolution of dysuria.
__label__noRel	In multivariate analysis, prophylactic alpha-blockers resulted in statistically lower maximum dysuria scores,	but was unaffected by the use of supplemental radiotherapy and/or androgen deprivation therapy.
__label__noRel	while the maximum IPSS after implantation and isotope type (but only at 6 months) were the best predictors of the resolution of dysuria.	The use of prophylactic tamsulosin resulted in a statistically lower dysuria severity score (difference of 2.7 vs 4.2, P < 0.005) at 1 month, with no discernible differences at 3, 6, 12 and 18 months.
__label__noRel	while the maximum IPSS after implantation and isotope type (but only at 6 months) were the best predictors of the resolution of dysuria.	Patients with dysuria had a statistically higher IPSS.
__label__noRel	while the maximum IPSS after implantation and isotope type (but only at 6 months) were the best predictors of the resolution of dysuria.	The dysuria resolved faster in patients implanted with 103Pd
__label__noRel	while the maximum IPSS after implantation and isotope type (but only at 6 months) were the best predictors of the resolution of dysuria.	In multivariate analysis, prophylactic alpha-blockers resulted in statistically lower maximum dysuria scores,
__label__noRel	while the maximum IPSS after implantation and isotope type (but only at 6 months) were the best predictors of the resolution of dysuria.	Dysuria is common after brachytherapy but is typically mild.
__label__noRel	while the maximum IPSS after implantation and isotope type (but only at 6 months) were the best predictors of the resolution of dysuria.	Prophylactic alpha-blockers gave significantly lower maximum dysuria scores
__label__noRel	while the maximum IPSS after implantation and isotope type (but only at 6 months) were the best predictors of the resolution of dysuria.	but did not affect the time to the resolution of dysuria.
__label__Support	while the maximum IPSS after implantation and isotope type (but only at 6 months) were the best predictors of the resolution of dysuria.	The maximum IPSS after the implant was the best predictor of the resolution of dysuria.
__label__noRel	while the maximum IPSS after implantation and isotope type (but only at 6 months) were the best predictors of the resolution of dysuria.	but was unaffected by the use of supplemental radiotherapy and/or androgen deprivation therapy.
__label__noRel	Dysuria is common after brachytherapy but is typically mild.	The use of prophylactic tamsulosin resulted in a statistically lower dysuria severity score (difference of 2.7 vs 4.2, P < 0.005) at 1 month, with no discernible differences at 3, 6, 12 and 18 months.
__label__noRel	Dysuria is common after brachytherapy but is typically mild.	Patients with dysuria had a statistically higher IPSS.
__label__noRel	Dysuria is common after brachytherapy but is typically mild.	The dysuria resolved faster in patients implanted with 103Pd
__label__noRel	Dysuria is common after brachytherapy but is typically mild.	In multivariate analysis, prophylactic alpha-blockers resulted in statistically lower maximum dysuria scores,
__label__noRel	Dysuria is common after brachytherapy but is typically mild.	while the maximum IPSS after implantation and isotope type (but only at 6 months) were the best predictors of the resolution of dysuria.
__label__noRel	Dysuria is common after brachytherapy but is typically mild.	Prophylactic alpha-blockers gave significantly lower maximum dysuria scores
__label__noRel	Dysuria is common after brachytherapy but is typically mild.	but did not affect the time to the resolution of dysuria.
__label__noRel	Dysuria is common after brachytherapy but is typically mild.	The maximum IPSS after the implant was the best predictor of the resolution of dysuria.
__label__noRel	Dysuria is common after brachytherapy but is typically mild.	but was unaffected by the use of supplemental radiotherapy and/or androgen deprivation therapy.
__label__noRel	Prophylactic alpha-blockers gave significantly lower maximum dysuria scores	The use of prophylactic tamsulosin resulted in a statistically lower dysuria severity score (difference of 2.7 vs 4.2, P < 0.005) at 1 month, with no discernible differences at 3, 6, 12 and 18 months.
__label__noRel	Prophylactic alpha-blockers gave significantly lower maximum dysuria scores	Patients with dysuria had a statistically higher IPSS.
__label__noRel	Prophylactic alpha-blockers gave significantly lower maximum dysuria scores	The dysuria resolved faster in patients implanted with 103Pd
__label__noRel	Prophylactic alpha-blockers gave significantly lower maximum dysuria scores	In multivariate analysis, prophylactic alpha-blockers resulted in statistically lower maximum dysuria scores,
__label__noRel	Prophylactic alpha-blockers gave significantly lower maximum dysuria scores	while the maximum IPSS after implantation and isotope type (but only at 6 months) were the best predictors of the resolution of dysuria.
__label__noRel	Prophylactic alpha-blockers gave significantly lower maximum dysuria scores	Dysuria is common after brachytherapy but is typically mild.
__label__noRel	Prophylactic alpha-blockers gave significantly lower maximum dysuria scores	but did not affect the time to the resolution of dysuria.
__label__noRel	Prophylactic alpha-blockers gave significantly lower maximum dysuria scores	The maximum IPSS after the implant was the best predictor of the resolution of dysuria.
__label__noRel	Prophylactic alpha-blockers gave significantly lower maximum dysuria scores	but was unaffected by the use of supplemental radiotherapy and/or androgen deprivation therapy.
__label__noRel	but did not affect the time to the resolution of dysuria.	The use of prophylactic tamsulosin resulted in a statistically lower dysuria severity score (difference of 2.7 vs 4.2, P < 0.005) at 1 month, with no discernible differences at 3, 6, 12 and 18 months.
__label__noRel	but did not affect the time to the resolution of dysuria.	Patients with dysuria had a statistically higher IPSS.
__label__noRel	but did not affect the time to the resolution of dysuria.	The dysuria resolved faster in patients implanted with 103Pd
__label__noRel	but did not affect the time to the resolution of dysuria.	In multivariate analysis, prophylactic alpha-blockers resulted in statistically lower maximum dysuria scores,
__label__noRel	but did not affect the time to the resolution of dysuria.	while the maximum IPSS after implantation and isotope type (but only at 6 months) were the best predictors of the resolution of dysuria.
__label__noRel	but did not affect the time to the resolution of dysuria.	Dysuria is common after brachytherapy but is typically mild.
__label__Attack	but did not affect the time to the resolution of dysuria.	Prophylactic alpha-blockers gave significantly lower maximum dysuria scores
__label__noRel	but did not affect the time to the resolution of dysuria.	The maximum IPSS after the implant was the best predictor of the resolution of dysuria.
__label__noRel	but did not affect the time to the resolution of dysuria.	but was unaffected by the use of supplemental radiotherapy and/or androgen deprivation therapy.
__label__noRel	The maximum IPSS after the implant was the best predictor of the resolution of dysuria.	The use of prophylactic tamsulosin resulted in a statistically lower dysuria severity score (difference of 2.7 vs 4.2, P < 0.005) at 1 month, with no discernible differences at 3, 6, 12 and 18 months.
__label__noRel	The maximum IPSS after the implant was the best predictor of the resolution of dysuria.	Patients with dysuria had a statistically higher IPSS.
__label__noRel	The maximum IPSS after the implant was the best predictor of the resolution of dysuria.	The dysuria resolved faster in patients implanted with 103Pd
__label__noRel	The maximum IPSS after the implant was the best predictor of the resolution of dysuria.	In multivariate analysis, prophylactic alpha-blockers resulted in statistically lower maximum dysuria scores,
__label__noRel	The maximum IPSS after the implant was the best predictor of the resolution of dysuria.	while the maximum IPSS after implantation and isotope type (but only at 6 months) were the best predictors of the resolution of dysuria.
__label__noRel	The maximum IPSS after the implant was the best predictor of the resolution of dysuria.	Dysuria is common after brachytherapy but is typically mild.
__label__noRel	The maximum IPSS after the implant was the best predictor of the resolution of dysuria.	Prophylactic alpha-blockers gave significantly lower maximum dysuria scores
__label__noRel	The maximum IPSS after the implant was the best predictor of the resolution of dysuria.	but did not affect the time to the resolution of dysuria.
__label__noRel	The maximum IPSS after the implant was the best predictor of the resolution of dysuria.	but was unaffected by the use of supplemental radiotherapy and/or androgen deprivation therapy.
__label__noRel	but was unaffected by the use of supplemental radiotherapy and/or androgen deprivation therapy.	The use of prophylactic tamsulosin resulted in a statistically lower dysuria severity score (difference of 2.7 vs 4.2, P < 0.005) at 1 month, with no discernible differences at 3, 6, 12 and 18 months.
__label__noRel	but was unaffected by the use of supplemental radiotherapy and/or androgen deprivation therapy.	Patients with dysuria had a statistically higher IPSS.
__label__Attack	but was unaffected by the use of supplemental radiotherapy and/or androgen deprivation therapy.	The dysuria resolved faster in patients implanted with 103Pd
__label__noRel	but was unaffected by the use of supplemental radiotherapy and/or androgen deprivation therapy.	In multivariate analysis, prophylactic alpha-blockers resulted in statistically lower maximum dysuria scores,
__label__noRel	but was unaffected by the use of supplemental radiotherapy and/or androgen deprivation therapy.	while the maximum IPSS after implantation and isotope type (but only at 6 months) were the best predictors of the resolution of dysuria.
__label__noRel	but was unaffected by the use of supplemental radiotherapy and/or androgen deprivation therapy.	Dysuria is common after brachytherapy but is typically mild.
__label__noRel	but was unaffected by the use of supplemental radiotherapy and/or androgen deprivation therapy.	Prophylactic alpha-blockers gave significantly lower maximum dysuria scores
__label__noRel	but was unaffected by the use of supplemental radiotherapy and/or androgen deprivation therapy.	but did not affect the time to the resolution of dysuria.
__label__noRel	but was unaffected by the use of supplemental radiotherapy and/or androgen deprivation therapy.	The maximum IPSS after the implant was the best predictor of the resolution of dysuria.
__label__noRel	Vinorelbine prolongs survival and improves quality of life in elderly patients with advanced non-small-cell lung cancer (NSCLC).	Some studies have also suggested that gemcitabine is well tolerated and effective in such patients.
__label__noRel	Vinorelbine prolongs survival and improves quality of life in elderly patients with advanced non-small-cell lung cancer (NSCLC).	Compared with each single drug, the combination treatment did not improve survival.
__label__noRel	Vinorelbine prolongs survival and improves quality of life in elderly patients with advanced non-small-cell lung cancer (NSCLC).	The hazard ratio of death for patients receiving the combination treatment was 1.17 (95% confidence interval [CI] = 0.95 to 1.44) that of patients receiving vinorelbine and 1.06 (95% CI = 0.86 to 1.29) that of patients receiving gemcitabine.
__label__noRel	Vinorelbine prolongs survival and improves quality of life in elderly patients with advanced non-small-cell lung cancer (NSCLC).	Although quality of life was similar across the three treatment arms,
__label__noRel	Vinorelbine prolongs survival and improves quality of life in elderly patients with advanced non-small-cell lung cancer (NSCLC).	the combination treatment was more toxic than the two drugs given singly.
__label__noRel	Vinorelbine prolongs survival and improves quality of life in elderly patients with advanced non-small-cell lung cancer (NSCLC).	The combination of vinorelbine plus gemcitabine is not more effective than single-agent vinorelbine or gemcitabine in the treatment of elderly patients with advanced NSCLC.
__label__noRel	Some studies have also suggested that gemcitabine is well tolerated and effective in such patients.	Vinorelbine prolongs survival and improves quality of life in elderly patients with advanced non-small-cell lung cancer (NSCLC).
__label__noRel	Some studies have also suggested that gemcitabine is well tolerated and effective in such patients.	Compared with each single drug, the combination treatment did not improve survival.
__label__noRel	Some studies have also suggested that gemcitabine is well tolerated and effective in such patients.	The hazard ratio of death for patients receiving the combination treatment was 1.17 (95% confidence interval [CI] = 0.95 to 1.44) that of patients receiving vinorelbine and 1.06 (95% CI = 0.86 to 1.29) that of patients receiving gemcitabine.
__label__noRel	Some studies have also suggested that gemcitabine is well tolerated and effective in such patients.	Although quality of life was similar across the three treatment arms,
__label__noRel	Some studies have also suggested that gemcitabine is well tolerated and effective in such patients.	the combination treatment was more toxic than the two drugs given singly.
__label__noRel	Some studies have also suggested that gemcitabine is well tolerated and effective in such patients.	The combination of vinorelbine plus gemcitabine is not more effective than single-agent vinorelbine or gemcitabine in the treatment of elderly patients with advanced NSCLC.
__label__noRel	Compared with each single drug, the combination treatment did not improve survival.	Vinorelbine prolongs survival and improves quality of life in elderly patients with advanced non-small-cell lung cancer (NSCLC).
__label__noRel	Compared with each single drug, the combination treatment did not improve survival.	Some studies have also suggested that gemcitabine is well tolerated and effective in such patients.
__label__noRel	Compared with each single drug, the combination treatment did not improve survival.	The hazard ratio of death for patients receiving the combination treatment was 1.17 (95% confidence interval [CI] = 0.95 to 1.44) that of patients receiving vinorelbine and 1.06 (95% CI = 0.86 to 1.29) that of patients receiving gemcitabine.
__label__noRel	Compared with each single drug, the combination treatment did not improve survival.	Although quality of life was similar across the three treatment arms,
__label__noRel	Compared with each single drug, the combination treatment did not improve survival.	the combination treatment was more toxic than the two drugs given singly.
__label__Support	Compared with each single drug, the combination treatment did not improve survival.	The combination of vinorelbine plus gemcitabine is not more effective than single-agent vinorelbine or gemcitabine in the treatment of elderly patients with advanced NSCLC.
__label__noRel	The hazard ratio of death for patients receiving the combination treatment was 1.17 (95% confidence interval [CI] = 0.95 to 1.44) that of patients receiving vinorelbine and 1.06 (95% CI = 0.86 to 1.29) that of patients receiving gemcitabine.	Vinorelbine prolongs survival and improves quality of life in elderly patients with advanced non-small-cell lung cancer (NSCLC).
__label__noRel	The hazard ratio of death for patients receiving the combination treatment was 1.17 (95% confidence interval [CI] = 0.95 to 1.44) that of patients receiving vinorelbine and 1.06 (95% CI = 0.86 to 1.29) that of patients receiving gemcitabine.	Some studies have also suggested that gemcitabine is well tolerated and effective in such patients.
__label__noRel	The hazard ratio of death for patients receiving the combination treatment was 1.17 (95% confidence interval [CI] = 0.95 to 1.44) that of patients receiving vinorelbine and 1.06 (95% CI = 0.86 to 1.29) that of patients receiving gemcitabine.	Compared with each single drug, the combination treatment did not improve survival.
__label__noRel	The hazard ratio of death for patients receiving the combination treatment was 1.17 (95% confidence interval [CI] = 0.95 to 1.44) that of patients receiving vinorelbine and 1.06 (95% CI = 0.86 to 1.29) that of patients receiving gemcitabine.	Although quality of life was similar across the three treatment arms,
__label__noRel	The hazard ratio of death for patients receiving the combination treatment was 1.17 (95% confidence interval [CI] = 0.95 to 1.44) that of patients receiving vinorelbine and 1.06 (95% CI = 0.86 to 1.29) that of patients receiving gemcitabine.	the combination treatment was more toxic than the two drugs given singly.
__label__Support	The hazard ratio of death for patients receiving the combination treatment was 1.17 (95% confidence interval [CI] = 0.95 to 1.44) that of patients receiving vinorelbine and 1.06 (95% CI = 0.86 to 1.29) that of patients receiving gemcitabine.	The combination of vinorelbine plus gemcitabine is not more effective than single-agent vinorelbine or gemcitabine in the treatment of elderly patients with advanced NSCLC.
__label__noRel	Although quality of life was similar across the three treatment arms,	Vinorelbine prolongs survival and improves quality of life in elderly patients with advanced non-small-cell lung cancer (NSCLC).
__label__noRel	Although quality of life was similar across the three treatment arms,	Some studies have also suggested that gemcitabine is well tolerated and effective in such patients.
__label__noRel	Although quality of life was similar across the three treatment arms,	Compared with each single drug, the combination treatment did not improve survival.
__label__noRel	Although quality of life was similar across the three treatment arms,	The hazard ratio of death for patients receiving the combination treatment was 1.17 (95% confidence interval [CI] = 0.95 to 1.44) that of patients receiving vinorelbine and 1.06 (95% CI = 0.86 to 1.29) that of patients receiving gemcitabine.
__label__Attack	Although quality of life was similar across the three treatment arms,	the combination treatment was more toxic than the two drugs given singly.
__label__noRel	Although quality of life was similar across the three treatment arms,	The combination of vinorelbine plus gemcitabine is not more effective than single-agent vinorelbine or gemcitabine in the treatment of elderly patients with advanced NSCLC.
__label__noRel	the combination treatment was more toxic than the two drugs given singly.	Vinorelbine prolongs survival and improves quality of life in elderly patients with advanced non-small-cell lung cancer (NSCLC).
__label__noRel	the combination treatment was more toxic than the two drugs given singly.	Some studies have also suggested that gemcitabine is well tolerated and effective in such patients.
__label__noRel	the combination treatment was more toxic than the two drugs given singly.	Compared with each single drug, the combination treatment did not improve survival.
__label__noRel	the combination treatment was more toxic than the two drugs given singly.	The hazard ratio of death for patients receiving the combination treatment was 1.17 (95% confidence interval [CI] = 0.95 to 1.44) that of patients receiving vinorelbine and 1.06 (95% CI = 0.86 to 1.29) that of patients receiving gemcitabine.
__label__noRel	the combination treatment was more toxic than the two drugs given singly.	Although quality of life was similar across the three treatment arms,
__label__Support	the combination treatment was more toxic than the two drugs given singly.	The combination of vinorelbine plus gemcitabine is not more effective than single-agent vinorelbine or gemcitabine in the treatment of elderly patients with advanced NSCLC.
__label__noRel	The combination of vinorelbine plus gemcitabine is not more effective than single-agent vinorelbine or gemcitabine in the treatment of elderly patients with advanced NSCLC.	Vinorelbine prolongs survival and improves quality of life in elderly patients with advanced non-small-cell lung cancer (NSCLC).
__label__noRel	The combination of vinorelbine plus gemcitabine is not more effective than single-agent vinorelbine or gemcitabine in the treatment of elderly patients with advanced NSCLC.	Some studies have also suggested that gemcitabine is well tolerated and effective in such patients.
__label__noRel	The combination of vinorelbine plus gemcitabine is not more effective than single-agent vinorelbine or gemcitabine in the treatment of elderly patients with advanced NSCLC.	Compared with each single drug, the combination treatment did not improve survival.
__label__noRel	The combination of vinorelbine plus gemcitabine is not more effective than single-agent vinorelbine or gemcitabine in the treatment of elderly patients with advanced NSCLC.	The hazard ratio of death for patients receiving the combination treatment was 1.17 (95% confidence interval [CI] = 0.95 to 1.44) that of patients receiving vinorelbine and 1.06 (95% CI = 0.86 to 1.29) that of patients receiving gemcitabine.
__label__noRel	The combination of vinorelbine plus gemcitabine is not more effective than single-agent vinorelbine or gemcitabine in the treatment of elderly patients with advanced NSCLC.	Although quality of life was similar across the three treatment arms,
__label__noRel	The combination of vinorelbine plus gemcitabine is not more effective than single-agent vinorelbine or gemcitabine in the treatment of elderly patients with advanced NSCLC.	the combination treatment was more toxic than the two drugs given singly.
__label__noRel	Compared with the intervention group, mean difference scores between the baseline (T1) and immediate after the test (T2) assessments increased significantly more for the control group for worst and average fatigue, Functional Assessment of Cancer Therapy-Fatigue, and Piper fatigue severity and interference measures.	These differences were not observed between baseline and T3 and T4 assessments.
__label__noRel	Compared with the intervention group, mean difference scores between the baseline (T1) and immediate after the test (T2) assessments increased significantly more for the control group for worst and average fatigue, Functional Assessment of Cancer Therapy-Fatigue, and Piper fatigue severity and interference measures.	No significant differences were identified for any pre- or post-test change scores for confidence with managing fatigue, cancer self-efficacy, anxiety, depression, or quality of life.
__label__Support	Compared with the intervention group, mean difference scores between the baseline (T1) and immediate after the test (T2) assessments increased significantly more for the control group for worst and average fatigue, Functional Assessment of Cancer Therapy-Fatigue, and Piper fatigue severity and interference measures.	Preparatory education and support has the potential to assist women to cope with cancer-related fatigue in the short term.
__label__noRel	Compared with the intervention group, mean difference scores between the baseline (T1) and immediate after the test (T2) assessments increased significantly more for the control group for worst and average fatigue, Functional Assessment of Cancer Therapy-Fatigue, and Piper fatigue severity and interference measures.	However, further research is needed to identify ways to improve the potency and sustainability of psychoeducational interventions for managing cancer-related fatigue.
__label__noRel	These differences were not observed between baseline and T3 and T4 assessments.	Compared with the intervention group, mean difference scores between the baseline (T1) and immediate after the test (T2) assessments increased significantly more for the control group for worst and average fatigue, Functional Assessment of Cancer Therapy-Fatigue, and Piper fatigue severity and interference measures.
__label__noRel	These differences were not observed between baseline and T3 and T4 assessments.	No significant differences were identified for any pre- or post-test change scores for confidence with managing fatigue, cancer self-efficacy, anxiety, depression, or quality of life.
__label__Support	These differences were not observed between baseline and T3 and T4 assessments.	Preparatory education and support has the potential to assist women to cope with cancer-related fatigue in the short term.
__label__noRel	These differences were not observed between baseline and T3 and T4 assessments.	However, further research is needed to identify ways to improve the potency and sustainability of psychoeducational interventions for managing cancer-related fatigue.
__label__noRel	No significant differences were identified for any pre- or post-test change scores for confidence with managing fatigue, cancer self-efficacy, anxiety, depression, or quality of life.	Compared with the intervention group, mean difference scores between the baseline (T1) and immediate after the test (T2) assessments increased significantly more for the control group for worst and average fatigue, Functional Assessment of Cancer Therapy-Fatigue, and Piper fatigue severity and interference measures.
__label__noRel	No significant differences were identified for any pre- or post-test change scores for confidence with managing fatigue, cancer self-efficacy, anxiety, depression, or quality of life.	These differences were not observed between baseline and T3 and T4 assessments.
__label__Support	No significant differences were identified for any pre- or post-test change scores for confidence with managing fatigue, cancer self-efficacy, anxiety, depression, or quality of life.	Preparatory education and support has the potential to assist women to cope with cancer-related fatigue in the short term.
__label__noRel	No significant differences were identified for any pre- or post-test change scores for confidence with managing fatigue, cancer self-efficacy, anxiety, depression, or quality of life.	However, further research is needed to identify ways to improve the potency and sustainability of psychoeducational interventions for managing cancer-related fatigue.
__label__noRel	Preparatory education and support has the potential to assist women to cope with cancer-related fatigue in the short term.	Compared with the intervention group, mean difference scores between the baseline (T1) and immediate after the test (T2) assessments increased significantly more for the control group for worst and average fatigue, Functional Assessment of Cancer Therapy-Fatigue, and Piper fatigue severity and interference measures.
__label__noRel	Preparatory education and support has the potential to assist women to cope with cancer-related fatigue in the short term.	These differences were not observed between baseline and T3 and T4 assessments.
__label__noRel	Preparatory education and support has the potential to assist women to cope with cancer-related fatigue in the short term.	No significant differences were identified for any pre- or post-test change scores for confidence with managing fatigue, cancer self-efficacy, anxiety, depression, or quality of life.
__label__noRel	Preparatory education and support has the potential to assist women to cope with cancer-related fatigue in the short term.	However, further research is needed to identify ways to improve the potency and sustainability of psychoeducational interventions for managing cancer-related fatigue.
__label__noRel	However, further research is needed to identify ways to improve the potency and sustainability of psychoeducational interventions for managing cancer-related fatigue.	Compared with the intervention group, mean difference scores between the baseline (T1) and immediate after the test (T2) assessments increased significantly more for the control group for worst and average fatigue, Functional Assessment of Cancer Therapy-Fatigue, and Piper fatigue severity and interference measures.
__label__noRel	However, further research is needed to identify ways to improve the potency and sustainability of psychoeducational interventions for managing cancer-related fatigue.	These differences were not observed between baseline and T3 and T4 assessments.
__label__noRel	However, further research is needed to identify ways to improve the potency and sustainability of psychoeducational interventions for managing cancer-related fatigue.	No significant differences were identified for any pre- or post-test change scores for confidence with managing fatigue, cancer self-efficacy, anxiety, depression, or quality of life.
__label__Attack	However, further research is needed to identify ways to improve the potency and sustainability of psychoeducational interventions for managing cancer-related fatigue.	Preparatory education and support has the potential to assist women to cope with cancer-related fatigue in the short term.
__label__noRel	Combining bevacizumab with docetaxel and trastuzumab did not significantly improve investigator-assessed PFS.	High baseline plasma vascular endothelial growth factor A (VEGF-A) concentrations were associated with greater bevacizumab benefit (not statistically significant).
__label__noRel	Combining bevacizumab with docetaxel and trastuzumab did not significantly improve investigator-assessed PFS.	Grade  3 febrile neutropenia and hypertension were more common with bevacizumab-containing therapy.
__label__noRel	Combining bevacizumab with docetaxel and trastuzumab did not significantly improve investigator-assessed PFS.	The RR was 70% versus 74%, respectively (P = .3492).
__label__noRel	Combining bevacizumab with docetaxel and trastuzumab did not significantly improve investigator-assessed PFS.	The hazard ratio for investigator-assessed PFS was 0.82 (95% CI, 0.65 to 1.02; P = .0775; median PFS, 13.7 v 16.5 months in the non-bevacizumab and bevacizumab arms, respectively; PFS events in 72%).
__label__noRel	Combining bevacizumab with docetaxel and trastuzumab did not significantly improve investigator-assessed PFS.	The Independent Review Committee-assessed PFS hazard ratio was 0.72 (95% CI, 0.54 to 0.94; P = .0162; median PFS, 13.9 v 16.8 months, respectively; PFS events in 53%).
__label__noRel	High baseline plasma vascular endothelial growth factor A (VEGF-A) concentrations were associated with greater bevacizumab benefit (not statistically significant).	Combining bevacizumab with docetaxel and trastuzumab did not significantly improve investigator-assessed PFS.
__label__noRel	High baseline plasma vascular endothelial growth factor A (VEGF-A) concentrations were associated with greater bevacizumab benefit (not statistically significant).	Grade  3 febrile neutropenia and hypertension were more common with bevacizumab-containing therapy.
__label__noRel	High baseline plasma vascular endothelial growth factor A (VEGF-A) concentrations were associated with greater bevacizumab benefit (not statistically significant).	The RR was 70% versus 74%, respectively (P = .3492).
__label__noRel	High baseline plasma vascular endothelial growth factor A (VEGF-A) concentrations were associated with greater bevacizumab benefit (not statistically significant).	The hazard ratio for investigator-assessed PFS was 0.82 (95% CI, 0.65 to 1.02; P = .0775; median PFS, 13.7 v 16.5 months in the non-bevacizumab and bevacizumab arms, respectively; PFS events in 72%).
__label__noRel	High baseline plasma vascular endothelial growth factor A (VEGF-A) concentrations were associated with greater bevacizumab benefit (not statistically significant).	The Independent Review Committee-assessed PFS hazard ratio was 0.72 (95% CI, 0.54 to 0.94; P = .0162; median PFS, 13.9 v 16.8 months, respectively; PFS events in 53%).
__label__noRel	Grade  3 febrile neutropenia and hypertension were more common with bevacizumab-containing therapy.	Combining bevacizumab with docetaxel and trastuzumab did not significantly improve investigator-assessed PFS.
__label__noRel	Grade  3 febrile neutropenia and hypertension were more common with bevacizumab-containing therapy.	High baseline plasma vascular endothelial growth factor A (VEGF-A) concentrations were associated with greater bevacizumab benefit (not statistically significant).
__label__noRel	Grade  3 febrile neutropenia and hypertension were more common with bevacizumab-containing therapy.	The RR was 70% versus 74%, respectively (P = .3492).
__label__noRel	Grade  3 febrile neutropenia and hypertension were more common with bevacizumab-containing therapy.	The hazard ratio for investigator-assessed PFS was 0.82 (95% CI, 0.65 to 1.02; P = .0775; median PFS, 13.7 v 16.5 months in the non-bevacizumab and bevacizumab arms, respectively; PFS events in 72%).
__label__noRel	Grade  3 febrile neutropenia and hypertension were more common with bevacizumab-containing therapy.	The Independent Review Committee-assessed PFS hazard ratio was 0.72 (95% CI, 0.54 to 0.94; P = .0162; median PFS, 13.9 v 16.8 months, respectively; PFS events in 53%).
__label__noRel	The RR was 70% versus 74%, respectively (P = .3492).	Combining bevacizumab with docetaxel and trastuzumab did not significantly improve investigator-assessed PFS.
__label__noRel	The RR was 70% versus 74%, respectively (P = .3492).	High baseline plasma vascular endothelial growth factor A (VEGF-A) concentrations were associated with greater bevacizumab benefit (not statistically significant).
__label__noRel	The RR was 70% versus 74%, respectively (P = .3492).	Grade  3 febrile neutropenia and hypertension were more common with bevacizumab-containing therapy.
__label__noRel	The RR was 70% versus 74%, respectively (P = .3492).	The hazard ratio for investigator-assessed PFS was 0.82 (95% CI, 0.65 to 1.02; P = .0775; median PFS, 13.7 v 16.5 months in the non-bevacizumab and bevacizumab arms, respectively; PFS events in 72%).
__label__noRel	The RR was 70% versus 74%, respectively (P = .3492).	The Independent Review Committee-assessed PFS hazard ratio was 0.72 (95% CI, 0.54 to 0.94; P = .0162; median PFS, 13.9 v 16.8 months, respectively; PFS events in 53%).
__label__Support	The hazard ratio for investigator-assessed PFS was 0.82 (95% CI, 0.65 to 1.02; P = .0775; median PFS, 13.7 v 16.5 months in the non-bevacizumab and bevacizumab arms, respectively; PFS events in 72%).	Combining bevacizumab with docetaxel and trastuzumab did not significantly improve investigator-assessed PFS.
__label__noRel	The hazard ratio for investigator-assessed PFS was 0.82 (95% CI, 0.65 to 1.02; P = .0775; median PFS, 13.7 v 16.5 months in the non-bevacizumab and bevacizumab arms, respectively; PFS events in 72%).	High baseline plasma vascular endothelial growth factor A (VEGF-A) concentrations were associated with greater bevacizumab benefit (not statistically significant).
__label__noRel	The hazard ratio for investigator-assessed PFS was 0.82 (95% CI, 0.65 to 1.02; P = .0775; median PFS, 13.7 v 16.5 months in the non-bevacizumab and bevacizumab arms, respectively; PFS events in 72%).	Grade  3 febrile neutropenia and hypertension were more common with bevacizumab-containing therapy.
__label__noRel	The hazard ratio for investigator-assessed PFS was 0.82 (95% CI, 0.65 to 1.02; P = .0775; median PFS, 13.7 v 16.5 months in the non-bevacizumab and bevacizumab arms, respectively; PFS events in 72%).	The RR was 70% versus 74%, respectively (P = .3492).
__label__noRel	The hazard ratio for investigator-assessed PFS was 0.82 (95% CI, 0.65 to 1.02; P = .0775; median PFS, 13.7 v 16.5 months in the non-bevacizumab and bevacizumab arms, respectively; PFS events in 72%).	The Independent Review Committee-assessed PFS hazard ratio was 0.72 (95% CI, 0.54 to 0.94; P = .0162; median PFS, 13.9 v 16.8 months, respectively; PFS events in 53%).
__label__Support	The Independent Review Committee-assessed PFS hazard ratio was 0.72 (95% CI, 0.54 to 0.94; P = .0162; median PFS, 13.9 v 16.8 months, respectively; PFS events in 53%).	Combining bevacizumab with docetaxel and trastuzumab did not significantly improve investigator-assessed PFS.
__label__noRel	The Independent Review Committee-assessed PFS hazard ratio was 0.72 (95% CI, 0.54 to 0.94; P = .0162; median PFS, 13.9 v 16.8 months, respectively; PFS events in 53%).	High baseline plasma vascular endothelial growth factor A (VEGF-A) concentrations were associated with greater bevacizumab benefit (not statistically significant).
__label__noRel	The Independent Review Committee-assessed PFS hazard ratio was 0.72 (95% CI, 0.54 to 0.94; P = .0162; median PFS, 13.9 v 16.8 months, respectively; PFS events in 53%).	Grade  3 febrile neutropenia and hypertension were more common with bevacizumab-containing therapy.
__label__noRel	The Independent Review Committee-assessed PFS hazard ratio was 0.72 (95% CI, 0.54 to 0.94; P = .0162; median PFS, 13.9 v 16.8 months, respectively; PFS events in 53%).	The RR was 70% versus 74%, respectively (P = .3492).
__label__noRel	The Independent Review Committee-assessed PFS hazard ratio was 0.72 (95% CI, 0.54 to 0.94; P = .0162; median PFS, 13.9 v 16.8 months, respectively; PFS events in 53%).	The hazard ratio for investigator-assessed PFS was 0.82 (95% CI, 0.65 to 1.02; P = .0775; median PFS, 13.7 v 16.5 months in the non-bevacizumab and bevacizumab arms, respectively; PFS events in 72%).
__label__noRel	The KPS score in the treated group after treatment was improved in 13 patients (23.6%), stabilized in 27 (49.6%) and declined in 15 (27.3%), while in the control group, it was improved in 7 (13.2%), stabilized in 21 (39.6%) and declined in 25 (47.2%), the difference between the two groups was significant (P < 0.05).	The results from evaluation with QLQ-C30 questionnaire and LC30 scale in the treated group was also superior to those in the control group (P < 0.05), respectively.
__label__noRel	The KPS score in the treated group after treatment was improved in 13 patients (23.6%), stabilized in 27 (49.6%) and declined in 15 (27.3%), while in the control group, it was improved in 7 (13.2%), stabilized in 21 (39.6%) and declined in 25 (47.2%), the difference between the two groups was significant (P < 0.05).	The scores of TCM efficacy (24.52 +/- 8.98 vs 29.76 +/- 7.09, P < 0.05) and the 6-min walking distance (233.4 +/- 29.2 m vs 205.8 +/- 31.9 m, P < 0.05) were better in the treated group.
__label__noRel	The KPS score in the treated group after treatment was improved in 13 patients (23.6%), stabilized in 27 (49.6%) and declined in 15 (27.3%), while in the control group, it was improved in 7 (13.2%), stabilized in 21 (39.6%) and declined in 25 (47.2%), the difference between the two groups was significant (P < 0.05).	After treatment in the treated group, the body weight was increased in 11 patients (20.0%), stabilized in 28 (50.9%) and decreased in 16 (29.1%), while in the control group it was increased in 5 (9.4%), stabilized in 26 (49.1%) and decreased in 22 (41.5%), difference between the two groups was significant, too (P < 0.05).
__label__Support	The KPS score in the treated group after treatment was improved in 13 patients (23.6%), stabilized in 27 (49.6%) and declined in 15 (27.3%), while in the control group, it was improved in 7 (13.2%), stabilized in 21 (39.6%) and declined in 25 (47.2%), the difference between the two groups was significant (P < 0.05).	TCM therapy for removing toxic substance and unblocking meridians can improve the post-radiation QOL of patients with lung cancer to some extent.
__label__noRel	The results from evaluation with QLQ-C30 questionnaire and LC30 scale in the treated group was also superior to those in the control group (P < 0.05), respectively.	The KPS score in the treated group after treatment was improved in 13 patients (23.6%), stabilized in 27 (49.6%) and declined in 15 (27.3%), while in the control group, it was improved in 7 (13.2%), stabilized in 21 (39.6%) and declined in 25 (47.2%), the difference between the two groups was significant (P < 0.05).
__label__noRel	The results from evaluation with QLQ-C30 questionnaire and LC30 scale in the treated group was also superior to those in the control group (P < 0.05), respectively.	The scores of TCM efficacy (24.52 +/- 8.98 vs 29.76 +/- 7.09, P < 0.05) and the 6-min walking distance (233.4 +/- 29.2 m vs 205.8 +/- 31.9 m, P < 0.05) were better in the treated group.
__label__noRel	The results from evaluation with QLQ-C30 questionnaire and LC30 scale in the treated group was also superior to those in the control group (P < 0.05), respectively.	After treatment in the treated group, the body weight was increased in 11 patients (20.0%), stabilized in 28 (50.9%) and decreased in 16 (29.1%), while in the control group it was increased in 5 (9.4%), stabilized in 26 (49.1%) and decreased in 22 (41.5%), difference between the two groups was significant, too (P < 0.05).
__label__Support	The results from evaluation with QLQ-C30 questionnaire and LC30 scale in the treated group was also superior to those in the control group (P < 0.05), respectively.	TCM therapy for removing toxic substance and unblocking meridians can improve the post-radiation QOL of patients with lung cancer to some extent.
__label__noRel	The scores of TCM efficacy (24.52 +/- 8.98 vs 29.76 +/- 7.09, P < 0.05) and the 6-min walking distance (233.4 +/- 29.2 m vs 205.8 +/- 31.9 m, P < 0.05) were better in the treated group.	The KPS score in the treated group after treatment was improved in 13 patients (23.6%), stabilized in 27 (49.6%) and declined in 15 (27.3%), while in the control group, it was improved in 7 (13.2%), stabilized in 21 (39.6%) and declined in 25 (47.2%), the difference between the two groups was significant (P < 0.05).
__label__noRel	The scores of TCM efficacy (24.52 +/- 8.98 vs 29.76 +/- 7.09, P < 0.05) and the 6-min walking distance (233.4 +/- 29.2 m vs 205.8 +/- 31.9 m, P < 0.05) were better in the treated group.	The results from evaluation with QLQ-C30 questionnaire and LC30 scale in the treated group was also superior to those in the control group (P < 0.05), respectively.
__label__noRel	The scores of TCM efficacy (24.52 +/- 8.98 vs 29.76 +/- 7.09, P < 0.05) and the 6-min walking distance (233.4 +/- 29.2 m vs 205.8 +/- 31.9 m, P < 0.05) were better in the treated group.	After treatment in the treated group, the body weight was increased in 11 patients (20.0%), stabilized in 28 (50.9%) and decreased in 16 (29.1%), while in the control group it was increased in 5 (9.4%), stabilized in 26 (49.1%) and decreased in 22 (41.5%), difference between the two groups was significant, too (P < 0.05).
__label__Support	The scores of TCM efficacy (24.52 +/- 8.98 vs 29.76 +/- 7.09, P < 0.05) and the 6-min walking distance (233.4 +/- 29.2 m vs 205.8 +/- 31.9 m, P < 0.05) were better in the treated group.	TCM therapy for removing toxic substance and unblocking meridians can improve the post-radiation QOL of patients with lung cancer to some extent.
__label__noRel	After treatment in the treated group, the body weight was increased in 11 patients (20.0%), stabilized in 28 (50.9%) and decreased in 16 (29.1%), while in the control group it was increased in 5 (9.4%), stabilized in 26 (49.1%) and decreased in 22 (41.5%), difference between the two groups was significant, too (P < 0.05).	The KPS score in the treated group after treatment was improved in 13 patients (23.6%), stabilized in 27 (49.6%) and declined in 15 (27.3%), while in the control group, it was improved in 7 (13.2%), stabilized in 21 (39.6%) and declined in 25 (47.2%), the difference between the two groups was significant (P < 0.05).
__label__noRel	After treatment in the treated group, the body weight was increased in 11 patients (20.0%), stabilized in 28 (50.9%) and decreased in 16 (29.1%), while in the control group it was increased in 5 (9.4%), stabilized in 26 (49.1%) and decreased in 22 (41.5%), difference between the two groups was significant, too (P < 0.05).	The results from evaluation with QLQ-C30 questionnaire and LC30 scale in the treated group was also superior to those in the control group (P < 0.05), respectively.
__label__noRel	After treatment in the treated group, the body weight was increased in 11 patients (20.0%), stabilized in 28 (50.9%) and decreased in 16 (29.1%), while in the control group it was increased in 5 (9.4%), stabilized in 26 (49.1%) and decreased in 22 (41.5%), difference between the two groups was significant, too (P < 0.05).	The scores of TCM efficacy (24.52 +/- 8.98 vs 29.76 +/- 7.09, P < 0.05) and the 6-min walking distance (233.4 +/- 29.2 m vs 205.8 +/- 31.9 m, P < 0.05) were better in the treated group.
__label__Support	After treatment in the treated group, the body weight was increased in 11 patients (20.0%), stabilized in 28 (50.9%) and decreased in 16 (29.1%), while in the control group it was increased in 5 (9.4%), stabilized in 26 (49.1%) and decreased in 22 (41.5%), difference between the two groups was significant, too (P < 0.05).	TCM therapy for removing toxic substance and unblocking meridians can improve the post-radiation QOL of patients with lung cancer to some extent.
__label__noRel	TCM therapy for removing toxic substance and unblocking meridians can improve the post-radiation QOL of patients with lung cancer to some extent.	The KPS score in the treated group after treatment was improved in 13 patients (23.6%), stabilized in 27 (49.6%) and declined in 15 (27.3%), while in the control group, it was improved in 7 (13.2%), stabilized in 21 (39.6%) and declined in 25 (47.2%), the difference between the two groups was significant (P < 0.05).
__label__noRel	TCM therapy for removing toxic substance and unblocking meridians can improve the post-radiation QOL of patients with lung cancer to some extent.	The results from evaluation with QLQ-C30 questionnaire and LC30 scale in the treated group was also superior to those in the control group (P < 0.05), respectively.
__label__noRel	TCM therapy for removing toxic substance and unblocking meridians can improve the post-radiation QOL of patients with lung cancer to some extent.	The scores of TCM efficacy (24.52 +/- 8.98 vs 29.76 +/- 7.09, P < 0.05) and the 6-min walking distance (233.4 +/- 29.2 m vs 205.8 +/- 31.9 m, P < 0.05) were better in the treated group.
__label__noRel	TCM therapy for removing toxic substance and unblocking meridians can improve the post-radiation QOL of patients with lung cancer to some extent.	After treatment in the treated group, the body weight was increased in 11 patients (20.0%), stabilized in 28 (50.9%) and decreased in 16 (29.1%), while in the control group it was increased in 5 (9.4%), stabilized in 26 (49.1%) and decreased in 22 (41.5%), difference between the two groups was significant, too (P < 0.05).
__label__noRel	Facial hirsutism is one of the characteristic features of polycystic ovary syndrome (PCOS), and this can lead to high levels of depression and anxiety.	Self-reported severity of facial hair in the intervention group (n = 51) fell from 7.3 to 3.6 over the 6-month study period; for the control group (n = 37) the corresponding scores were 7.1 and 6.1.
__label__noRel	Facial hirsutism is one of the characteristic features of polycystic ovary syndrome (PCOS), and this can lead to high levels of depression and anxiety.	The change was significantly greater in the intervention group [ancova F((1,83)) = 24.5, P < 0.05].
__label__noRel	Facial hirsutism is one of the characteristic features of polycystic ovary syndrome (PCOS), and this can lead to high levels of depression and anxiety.	Self-reported time spent on hair removal declined from 112 to 21 min per week in the intervention group and from 92 to 56 min in the control group [F((1,80)) = 10.2, P </= 0.05].
__label__noRel	Facial hirsutism is one of the characteristic features of polycystic ovary syndrome (PCOS), and this can lead to high levels of depression and anxiety.	Mean depression scores fell from 6.7 to 3.6 in the intervention group, compared with 6.1 to 5.4 in the control group [F((1,83)) = 14.7, P < 0.05].
__label__noRel	Facial hirsutism is one of the characteristic features of polycystic ovary syndrome (PCOS), and this can lead to high levels of depression and anxiety.	A similar change was seen for mean anxiety scores: intervention 11.1 to 8.2, control 9.6 to 9.3 [F((1,84)) = 17.8, P < 0.05].
__label__noRel	Facial hirsutism is one of the characteristic features of polycystic ovary syndrome (PCOS), and this can lead to high levels of depression and anxiety.	Psychological quality of life also improved more in the intervention group, from 49.6 to 61.2 vs. 50.1 to 51.5 in the control group [F((1,84)) = 10.9, P < 0.05].
__label__noRel	Facial hirsutism is one of the characteristic features of polycystic ovary syndrome (PCOS), and this can lead to high levels of depression and anxiety.	Laser treatment appeared to reduce the severity of facial hair and time spent on hair removal as well as alleviating depression and anxiety in women with PCOS.
__label__noRel	Facial hirsutism is one of the characteristic features of polycystic ovary syndrome (PCOS), and this can lead to high levels of depression and anxiety.	These findings suggest that ways of making this method of hair removal more widely available to women with facial hirsutism should be considered.
__label__noRel	Self-reported severity of facial hair in the intervention group (n = 51) fell from 7.3 to 3.6 over the 6-month study period; for the control group (n = 37) the corresponding scores were 7.1 and 6.1.	Facial hirsutism is one of the characteristic features of polycystic ovary syndrome (PCOS), and this can lead to high levels of depression and anxiety.
__label__noRel	Self-reported severity of facial hair in the intervention group (n = 51) fell from 7.3 to 3.6 over the 6-month study period; for the control group (n = 37) the corresponding scores were 7.1 and 6.1.	The change was significantly greater in the intervention group [ancova F((1,83)) = 24.5, P < 0.05].
__label__noRel	Self-reported severity of facial hair in the intervention group (n = 51) fell from 7.3 to 3.6 over the 6-month study period; for the control group (n = 37) the corresponding scores were 7.1 and 6.1.	Self-reported time spent on hair removal declined from 112 to 21 min per week in the intervention group and from 92 to 56 min in the control group [F((1,80)) = 10.2, P </= 0.05].
__label__noRel	Self-reported severity of facial hair in the intervention group (n = 51) fell from 7.3 to 3.6 over the 6-month study period; for the control group (n = 37) the corresponding scores were 7.1 and 6.1.	Mean depression scores fell from 6.7 to 3.6 in the intervention group, compared with 6.1 to 5.4 in the control group [F((1,83)) = 14.7, P < 0.05].
__label__noRel	Self-reported severity of facial hair in the intervention group (n = 51) fell from 7.3 to 3.6 over the 6-month study period; for the control group (n = 37) the corresponding scores were 7.1 and 6.1.	A similar change was seen for mean anxiety scores: intervention 11.1 to 8.2, control 9.6 to 9.3 [F((1,84)) = 17.8, P < 0.05].
__label__noRel	Self-reported severity of facial hair in the intervention group (n = 51) fell from 7.3 to 3.6 over the 6-month study period; for the control group (n = 37) the corresponding scores were 7.1 and 6.1.	Psychological quality of life also improved more in the intervention group, from 49.6 to 61.2 vs. 50.1 to 51.5 in the control group [F((1,84)) = 10.9, P < 0.05].
__label__Attack	Self-reported severity of facial hair in the intervention group (n = 51) fell from 7.3 to 3.6 over the 6-month study period; for the control group (n = 37) the corresponding scores were 7.1 and 6.1.	Laser treatment appeared to reduce the severity of facial hair and time spent on hair removal as well as alleviating depression and anxiety in women with PCOS.
__label__noRel	Self-reported severity of facial hair in the intervention group (n = 51) fell from 7.3 to 3.6 over the 6-month study period; for the control group (n = 37) the corresponding scores were 7.1 and 6.1.	These findings suggest that ways of making this method of hair removal more widely available to women with facial hirsutism should be considered.
__label__noRel	The change was significantly greater in the intervention group [ancova F((1,83)) = 24.5, P < 0.05].	Facial hirsutism is one of the characteristic features of polycystic ovary syndrome (PCOS), and this can lead to high levels of depression and anxiety.
__label__Attack	The change was significantly greater in the intervention group [ancova F((1,83)) = 24.5, P < 0.05].	Self-reported severity of facial hair in the intervention group (n = 51) fell from 7.3 to 3.6 over the 6-month study period; for the control group (n = 37) the corresponding scores were 7.1 and 6.1.
__label__noRel	The change was significantly greater in the intervention group [ancova F((1,83)) = 24.5, P < 0.05].	Self-reported time spent on hair removal declined from 112 to 21 min per week in the intervention group and from 92 to 56 min in the control group [F((1,80)) = 10.2, P </= 0.05].
__label__noRel	The change was significantly greater in the intervention group [ancova F((1,83)) = 24.5, P < 0.05].	Mean depression scores fell from 6.7 to 3.6 in the intervention group, compared with 6.1 to 5.4 in the control group [F((1,83)) = 14.7, P < 0.05].
__label__noRel	The change was significantly greater in the intervention group [ancova F((1,83)) = 24.5, P < 0.05].	A similar change was seen for mean anxiety scores: intervention 11.1 to 8.2, control 9.6 to 9.3 [F((1,84)) = 17.8, P < 0.05].
__label__noRel	The change was significantly greater in the intervention group [ancova F((1,83)) = 24.5, P < 0.05].	Psychological quality of life also improved more in the intervention group, from 49.6 to 61.2 vs. 50.1 to 51.5 in the control group [F((1,84)) = 10.9, P < 0.05].
__label__noRel	The change was significantly greater in the intervention group [ancova F((1,83)) = 24.5, P < 0.05].	Laser treatment appeared to reduce the severity of facial hair and time spent on hair removal as well as alleviating depression and anxiety in women with PCOS.
__label__noRel	The change was significantly greater in the intervention group [ancova F((1,83)) = 24.5, P < 0.05].	These findings suggest that ways of making this method of hair removal more widely available to women with facial hirsutism should be considered.
__label__noRel	Self-reported time spent on hair removal declined from 112 to 21 min per week in the intervention group and from 92 to 56 min in the control group [F((1,80)) = 10.2, P </= 0.05].	Facial hirsutism is one of the characteristic features of polycystic ovary syndrome (PCOS), and this can lead to high levels of depression and anxiety.
__label__noRel	Self-reported time spent on hair removal declined from 112 to 21 min per week in the intervention group and from 92 to 56 min in the control group [F((1,80)) = 10.2, P </= 0.05].	Self-reported severity of facial hair in the intervention group (n = 51) fell from 7.3 to 3.6 over the 6-month study period; for the control group (n = 37) the corresponding scores were 7.1 and 6.1.
__label__noRel	Self-reported time spent on hair removal declined from 112 to 21 min per week in the intervention group and from 92 to 56 min in the control group [F((1,80)) = 10.2, P </= 0.05].	The change was significantly greater in the intervention group [ancova F((1,83)) = 24.5, P < 0.05].
__label__noRel	Self-reported time spent on hair removal declined from 112 to 21 min per week in the intervention group and from 92 to 56 min in the control group [F((1,80)) = 10.2, P </= 0.05].	Mean depression scores fell from 6.7 to 3.6 in the intervention group, compared with 6.1 to 5.4 in the control group [F((1,83)) = 14.7, P < 0.05].
__label__noRel	Self-reported time spent on hair removal declined from 112 to 21 min per week in the intervention group and from 92 to 56 min in the control group [F((1,80)) = 10.2, P </= 0.05].	A similar change was seen for mean anxiety scores: intervention 11.1 to 8.2, control 9.6 to 9.3 [F((1,84)) = 17.8, P < 0.05].
__label__noRel	Self-reported time spent on hair removal declined from 112 to 21 min per week in the intervention group and from 92 to 56 min in the control group [F((1,80)) = 10.2, P </= 0.05].	Psychological quality of life also improved more in the intervention group, from 49.6 to 61.2 vs. 50.1 to 51.5 in the control group [F((1,84)) = 10.9, P < 0.05].
__label__Support	Self-reported time spent on hair removal declined from 112 to 21 min per week in the intervention group and from 92 to 56 min in the control group [F((1,80)) = 10.2, P </= 0.05].	Laser treatment appeared to reduce the severity of facial hair and time spent on hair removal as well as alleviating depression and anxiety in women with PCOS.
__label__noRel	Self-reported time spent on hair removal declined from 112 to 21 min per week in the intervention group and from 92 to 56 min in the control group [F((1,80)) = 10.2, P </= 0.05].	These findings suggest that ways of making this method of hair removal more widely available to women with facial hirsutism should be considered.
__label__noRel	Mean depression scores fell from 6.7 to 3.6 in the intervention group, compared with 6.1 to 5.4 in the control group [F((1,83)) = 14.7, P < 0.05].	Facial hirsutism is one of the characteristic features of polycystic ovary syndrome (PCOS), and this can lead to high levels of depression and anxiety.
__label__noRel	Mean depression scores fell from 6.7 to 3.6 in the intervention group, compared with 6.1 to 5.4 in the control group [F((1,83)) = 14.7, P < 0.05].	Self-reported severity of facial hair in the intervention group (n = 51) fell from 7.3 to 3.6 over the 6-month study period; for the control group (n = 37) the corresponding scores were 7.1 and 6.1.
__label__noRel	Mean depression scores fell from 6.7 to 3.6 in the intervention group, compared with 6.1 to 5.4 in the control group [F((1,83)) = 14.7, P < 0.05].	The change was significantly greater in the intervention group [ancova F((1,83)) = 24.5, P < 0.05].
__label__noRel	Mean depression scores fell from 6.7 to 3.6 in the intervention group, compared with 6.1 to 5.4 in the control group [F((1,83)) = 14.7, P < 0.05].	Self-reported time spent on hair removal declined from 112 to 21 min per week in the intervention group and from 92 to 56 min in the control group [F((1,80)) = 10.2, P </= 0.05].
__label__noRel	Mean depression scores fell from 6.7 to 3.6 in the intervention group, compared with 6.1 to 5.4 in the control group [F((1,83)) = 14.7, P < 0.05].	A similar change was seen for mean anxiety scores: intervention 11.1 to 8.2, control 9.6 to 9.3 [F((1,84)) = 17.8, P < 0.05].
__label__noRel	Mean depression scores fell from 6.7 to 3.6 in the intervention group, compared with 6.1 to 5.4 in the control group [F((1,83)) = 14.7, P < 0.05].	Psychological quality of life also improved more in the intervention group, from 49.6 to 61.2 vs. 50.1 to 51.5 in the control group [F((1,84)) = 10.9, P < 0.05].
__label__Support	Mean depression scores fell from 6.7 to 3.6 in the intervention group, compared with 6.1 to 5.4 in the control group [F((1,83)) = 14.7, P < 0.05].	Laser treatment appeared to reduce the severity of facial hair and time spent on hair removal as well as alleviating depression and anxiety in women with PCOS.
__label__noRel	Mean depression scores fell from 6.7 to 3.6 in the intervention group, compared with 6.1 to 5.4 in the control group [F((1,83)) = 14.7, P < 0.05].	These findings suggest that ways of making this method of hair removal more widely available to women with facial hirsutism should be considered.
__label__noRel	A similar change was seen for mean anxiety scores: intervention 11.1 to 8.2, control 9.6 to 9.3 [F((1,84)) = 17.8, P < 0.05].	Facial hirsutism is one of the characteristic features of polycystic ovary syndrome (PCOS), and this can lead to high levels of depression and anxiety.
__label__noRel	A similar change was seen for mean anxiety scores: intervention 11.1 to 8.2, control 9.6 to 9.3 [F((1,84)) = 17.8, P < 0.05].	Self-reported severity of facial hair in the intervention group (n = 51) fell from 7.3 to 3.6 over the 6-month study period; for the control group (n = 37) the corresponding scores were 7.1 and 6.1.
__label__noRel	A similar change was seen for mean anxiety scores: intervention 11.1 to 8.2, control 9.6 to 9.3 [F((1,84)) = 17.8, P < 0.05].	The change was significantly greater in the intervention group [ancova F((1,83)) = 24.5, P < 0.05].
__label__noRel	A similar change was seen for mean anxiety scores: intervention 11.1 to 8.2, control 9.6 to 9.3 [F((1,84)) = 17.8, P < 0.05].	Self-reported time spent on hair removal declined from 112 to 21 min per week in the intervention group and from 92 to 56 min in the control group [F((1,80)) = 10.2, P </= 0.05].
__label__noRel	A similar change was seen for mean anxiety scores: intervention 11.1 to 8.2, control 9.6 to 9.3 [F((1,84)) = 17.8, P < 0.05].	Mean depression scores fell from 6.7 to 3.6 in the intervention group, compared with 6.1 to 5.4 in the control group [F((1,83)) = 14.7, P < 0.05].
__label__noRel	A similar change was seen for mean anxiety scores: intervention 11.1 to 8.2, control 9.6 to 9.3 [F((1,84)) = 17.8, P < 0.05].	Psychological quality of life also improved more in the intervention group, from 49.6 to 61.2 vs. 50.1 to 51.5 in the control group [F((1,84)) = 10.9, P < 0.05].
__label__Support	A similar change was seen for mean anxiety scores: intervention 11.1 to 8.2, control 9.6 to 9.3 [F((1,84)) = 17.8, P < 0.05].	Laser treatment appeared to reduce the severity of facial hair and time spent on hair removal as well as alleviating depression and anxiety in women with PCOS.
__label__noRel	A similar change was seen for mean anxiety scores: intervention 11.1 to 8.2, control 9.6 to 9.3 [F((1,84)) = 17.8, P < 0.05].	These findings suggest that ways of making this method of hair removal more widely available to women with facial hirsutism should be considered.
__label__noRel	Psychological quality of life also improved more in the intervention group, from 49.6 to 61.2 vs. 50.1 to 51.5 in the control group [F((1,84)) = 10.9, P < 0.05].	Facial hirsutism is one of the characteristic features of polycystic ovary syndrome (PCOS), and this can lead to high levels of depression and anxiety.
__label__noRel	Psychological quality of life also improved more in the intervention group, from 49.6 to 61.2 vs. 50.1 to 51.5 in the control group [F((1,84)) = 10.9, P < 0.05].	Self-reported severity of facial hair in the intervention group (n = 51) fell from 7.3 to 3.6 over the 6-month study period; for the control group (n = 37) the corresponding scores were 7.1 and 6.1.
__label__noRel	Psychological quality of life also improved more in the intervention group, from 49.6 to 61.2 vs. 50.1 to 51.5 in the control group [F((1,84)) = 10.9, P < 0.05].	The change was significantly greater in the intervention group [ancova F((1,83)) = 24.5, P < 0.05].
__label__noRel	Psychological quality of life also improved more in the intervention group, from 49.6 to 61.2 vs. 50.1 to 51.5 in the control group [F((1,84)) = 10.9, P < 0.05].	Self-reported time spent on hair removal declined from 112 to 21 min per week in the intervention group and from 92 to 56 min in the control group [F((1,80)) = 10.2, P </= 0.05].
__label__noRel	Psychological quality of life also improved more in the intervention group, from 49.6 to 61.2 vs. 50.1 to 51.5 in the control group [F((1,84)) = 10.9, P < 0.05].	Mean depression scores fell from 6.7 to 3.6 in the intervention group, compared with 6.1 to 5.4 in the control group [F((1,83)) = 14.7, P < 0.05].
__label__noRel	Psychological quality of life also improved more in the intervention group, from 49.6 to 61.2 vs. 50.1 to 51.5 in the control group [F((1,84)) = 10.9, P < 0.05].	A similar change was seen for mean anxiety scores: intervention 11.1 to 8.2, control 9.6 to 9.3 [F((1,84)) = 17.8, P < 0.05].
__label__Support	Psychological quality of life also improved more in the intervention group, from 49.6 to 61.2 vs. 50.1 to 51.5 in the control group [F((1,84)) = 10.9, P < 0.05].	Laser treatment appeared to reduce the severity of facial hair and time spent on hair removal as well as alleviating depression and anxiety in women with PCOS.
__label__noRel	Psychological quality of life also improved more in the intervention group, from 49.6 to 61.2 vs. 50.1 to 51.5 in the control group [F((1,84)) = 10.9, P < 0.05].	These findings suggest that ways of making this method of hair removal more widely available to women with facial hirsutism should be considered.
__label__noRel	Laser treatment appeared to reduce the severity of facial hair and time spent on hair removal as well as alleviating depression and anxiety in women with PCOS.	Facial hirsutism is one of the characteristic features of polycystic ovary syndrome (PCOS), and this can lead to high levels of depression and anxiety.
__label__noRel	Laser treatment appeared to reduce the severity of facial hair and time spent on hair removal as well as alleviating depression and anxiety in women with PCOS.	Self-reported severity of facial hair in the intervention group (n = 51) fell from 7.3 to 3.6 over the 6-month study period; for the control group (n = 37) the corresponding scores were 7.1 and 6.1.
__label__noRel	Laser treatment appeared to reduce the severity of facial hair and time spent on hair removal as well as alleviating depression and anxiety in women with PCOS.	The change was significantly greater in the intervention group [ancova F((1,83)) = 24.5, P < 0.05].
__label__noRel	Laser treatment appeared to reduce the severity of facial hair and time spent on hair removal as well as alleviating depression and anxiety in women with PCOS.	Self-reported time spent on hair removal declined from 112 to 21 min per week in the intervention group and from 92 to 56 min in the control group [F((1,80)) = 10.2, P </= 0.05].
__label__noRel	Laser treatment appeared to reduce the severity of facial hair and time spent on hair removal as well as alleviating depression and anxiety in women with PCOS.	Mean depression scores fell from 6.7 to 3.6 in the intervention group, compared with 6.1 to 5.4 in the control group [F((1,83)) = 14.7, P < 0.05].
__label__noRel	Laser treatment appeared to reduce the severity of facial hair and time spent on hair removal as well as alleviating depression and anxiety in women with PCOS.	A similar change was seen for mean anxiety scores: intervention 11.1 to 8.2, control 9.6 to 9.3 [F((1,84)) = 17.8, P < 0.05].
__label__noRel	Laser treatment appeared to reduce the severity of facial hair and time spent on hair removal as well as alleviating depression and anxiety in women with PCOS.	Psychological quality of life also improved more in the intervention group, from 49.6 to 61.2 vs. 50.1 to 51.5 in the control group [F((1,84)) = 10.9, P < 0.05].
__label__Support	Laser treatment appeared to reduce the severity of facial hair and time spent on hair removal as well as alleviating depression and anxiety in women with PCOS.	These findings suggest that ways of making this method of hair removal more widely available to women with facial hirsutism should be considered.
__label__noRel	These findings suggest that ways of making this method of hair removal more widely available to women with facial hirsutism should be considered.	Facial hirsutism is one of the characteristic features of polycystic ovary syndrome (PCOS), and this can lead to high levels of depression and anxiety.
__label__noRel	These findings suggest that ways of making this method of hair removal more widely available to women with facial hirsutism should be considered.	Self-reported severity of facial hair in the intervention group (n = 51) fell from 7.3 to 3.6 over the 6-month study period; for the control group (n = 37) the corresponding scores were 7.1 and 6.1.
__label__noRel	These findings suggest that ways of making this method of hair removal more widely available to women with facial hirsutism should be considered.	The change was significantly greater in the intervention group [ancova F((1,83)) = 24.5, P < 0.05].
__label__noRel	These findings suggest that ways of making this method of hair removal more widely available to women with facial hirsutism should be considered.	Self-reported time spent on hair removal declined from 112 to 21 min per week in the intervention group and from 92 to 56 min in the control group [F((1,80)) = 10.2, P </= 0.05].
__label__noRel	These findings suggest that ways of making this method of hair removal more widely available to women with facial hirsutism should be considered.	Mean depression scores fell from 6.7 to 3.6 in the intervention group, compared with 6.1 to 5.4 in the control group [F((1,83)) = 14.7, P < 0.05].
__label__noRel	These findings suggest that ways of making this method of hair removal more widely available to women with facial hirsutism should be considered.	A similar change was seen for mean anxiety scores: intervention 11.1 to 8.2, control 9.6 to 9.3 [F((1,84)) = 17.8, P < 0.05].
__label__noRel	These findings suggest that ways of making this method of hair removal more widely available to women with facial hirsutism should be considered.	Psychological quality of life also improved more in the intervention group, from 49.6 to 61.2 vs. 50.1 to 51.5 in the control group [F((1,84)) = 10.9, P < 0.05].
__label__noRel	These findings suggest that ways of making this method of hair removal more widely available to women with facial hirsutism should be considered.	Laser treatment appeared to reduce the severity of facial hair and time spent on hair removal as well as alleviating depression and anxiety in women with PCOS.
__label__noRel	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).
__label__noRel	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;
__label__noRel	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).
__label__noRel	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.	The TC regimen was associated with a higher frequency of hematologic toxicity,
__label__noRel	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.
__label__noRel	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).
__label__noRel	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.
__label__noRel	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.
__label__noRel	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;
__label__noRel	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).
__label__noRel	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).	The TC regimen was associated with a higher frequency of hematologic toxicity,
__label__noRel	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.
__label__noRel	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).
__label__Support	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.
__label__noRel	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.
__label__noRel	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).
__label__noRel	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).
__label__noRel	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;	The TC regimen was associated with a higher frequency of hematologic toxicity,
__label__noRel	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.
__label__noRel	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).
__label__Support	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.
__label__noRel	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.
__label__noRel	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).
__label__noRel	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;
__label__noRel	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).	The TC regimen was associated with a higher frequency of hematologic toxicity,
__label__noRel	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.
__label__noRel	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).
__label__Support	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.
__label__noRel	The TC regimen was associated with a higher frequency of hematologic toxicity,	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.
__label__noRel	The TC regimen was associated with a higher frequency of hematologic toxicity,	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).
__label__noRel	The TC regimen was associated with a higher frequency of hematologic toxicity,	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;
__label__noRel	The TC regimen was associated with a higher frequency of hematologic toxicity,	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).
__label__noRel	The TC regimen was associated with a higher frequency of hematologic toxicity,	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.
__label__noRel	The TC regimen was associated with a higher frequency of hematologic toxicity,	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).
__label__Support	The TC regimen was associated with a higher frequency of hematologic toxicity,	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.
__label__noRel	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.
__label__noRel	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).
__label__noRel	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;
__label__noRel	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).
__label__Attack	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.	The TC regimen was associated with a higher frequency of hematologic toxicity,
__label__noRel	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).
__label__noRel	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.
__label__noRel	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.
__label__noRel	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).
__label__noRel	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;
__label__noRel	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).
__label__noRel	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).	The TC regimen was associated with a higher frequency of hematologic toxicity,
__label__noRel	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.
__label__Support	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.
__label__noRel	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.
__label__noRel	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).
__label__noRel	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;
__label__noRel	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).
__label__noRel	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.	The TC regimen was associated with a higher frequency of hematologic toxicity,
__label__noRel	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.
__label__noRel	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).
__label__noRel	No significant longitudinal changes were detected in the global health status in both groups upon available follow-up.	Surgery was associated with worsened physical functioning and fatigue symptoms up to 6 months after treatment (P < 0.001 and P = 0.021, respectively) and these scales improved at 2 years.
__label__noRel	No significant longitudinal changes were detected in the global health status in both groups upon available follow-up.	In terms of pulmonary function, dyspnoic and coughing symptoms were significantly worsened 3 months after surgery (P = 0.024 and P = 0.036, respectively) whereas symptoms in the CRT group progressively deteriorated over time.
__label__noRel	No significant longitudinal changes were detected in the global health status in both groups upon available follow-up.	Concerning the eating function, both groups had improvements in dysphagia but there were frequent need for endoscopic intervention.
__label__noRel	No significant longitudinal changes were detected in the global health status in both groups upon available follow-up.	Neither surgery nor definitive CRT significantly impaired the global health status of patients.
__label__noRel	No significant longitudinal changes were detected in the global health status in both groups upon available follow-up.	Surgery was associated with a short-term negative impact in some aspects of health related quality of life assessments
__label__Support	No significant longitudinal changes were detected in the global health status in both groups upon available follow-up.	but these changes became insignificant 2 years after treatment.
__label__noRel	No significant longitudinal changes were detected in the global health status in both groups upon available follow-up.	CRT was associated with progressive deteriorations in pulmonary function in the longer term.
__label__noRel	Surgery was associated with worsened physical functioning and fatigue symptoms up to 6 months after treatment (P < 0.001 and P = 0.021, respectively) and these scales improved at 2 years.	No significant longitudinal changes were detected in the global health status in both groups upon available follow-up.
__label__noRel	Surgery was associated with worsened physical functioning and fatigue symptoms up to 6 months after treatment (P < 0.001 and P = 0.021, respectively) and these scales improved at 2 years.	In terms of pulmonary function, dyspnoic and coughing symptoms were significantly worsened 3 months after surgery (P = 0.024 and P = 0.036, respectively) whereas symptoms in the CRT group progressively deteriorated over time.
__label__noRel	Surgery was associated with worsened physical functioning and fatigue symptoms up to 6 months after treatment (P < 0.001 and P = 0.021, respectively) and these scales improved at 2 years.	Concerning the eating function, both groups had improvements in dysphagia but there were frequent need for endoscopic intervention.
__label__noRel	Surgery was associated with worsened physical functioning and fatigue symptoms up to 6 months after treatment (P < 0.001 and P = 0.021, respectively) and these scales improved at 2 years.	Neither surgery nor definitive CRT significantly impaired the global health status of patients.
__label__Support	Surgery was associated with worsened physical functioning and fatigue symptoms up to 6 months after treatment (P < 0.001 and P = 0.021, respectively) and these scales improved at 2 years.	Surgery was associated with a short-term negative impact in some aspects of health related quality of life assessments
__label__noRel	Surgery was associated with worsened physical functioning and fatigue symptoms up to 6 months after treatment (P < 0.001 and P = 0.021, respectively) and these scales improved at 2 years.	but these changes became insignificant 2 years after treatment.
__label__noRel	Surgery was associated with worsened physical functioning and fatigue symptoms up to 6 months after treatment (P < 0.001 and P = 0.021, respectively) and these scales improved at 2 years.	CRT was associated with progressive deteriorations in pulmonary function in the longer term.
__label__noRel	In terms of pulmonary function, dyspnoic and coughing symptoms were significantly worsened 3 months after surgery (P = 0.024 and P = 0.036, respectively) whereas symptoms in the CRT group progressively deteriorated over time.	No significant longitudinal changes were detected in the global health status in both groups upon available follow-up.
__label__noRel	In terms of pulmonary function, dyspnoic and coughing symptoms were significantly worsened 3 months after surgery (P = 0.024 and P = 0.036, respectively) whereas symptoms in the CRT group progressively deteriorated over time.	Surgery was associated with worsened physical functioning and fatigue symptoms up to 6 months after treatment (P < 0.001 and P = 0.021, respectively) and these scales improved at 2 years.
__label__noRel	In terms of pulmonary function, dyspnoic and coughing symptoms were significantly worsened 3 months after surgery (P = 0.024 and P = 0.036, respectively) whereas symptoms in the CRT group progressively deteriorated over time.	Concerning the eating function, both groups had improvements in dysphagia but there were frequent need for endoscopic intervention.
__label__noRel	In terms of pulmonary function, dyspnoic and coughing symptoms were significantly worsened 3 months after surgery (P = 0.024 and P = 0.036, respectively) whereas symptoms in the CRT group progressively deteriorated over time.	Neither surgery nor definitive CRT significantly impaired the global health status of patients.
__label__Support	In terms of pulmonary function, dyspnoic and coughing symptoms were significantly worsened 3 months after surgery (P = 0.024 and P = 0.036, respectively) whereas symptoms in the CRT group progressively deteriorated over time.	Surgery was associated with a short-term negative impact in some aspects of health related quality of life assessments
__label__noRel	In terms of pulmonary function, dyspnoic and coughing symptoms were significantly worsened 3 months after surgery (P = 0.024 and P = 0.036, respectively) whereas symptoms in the CRT group progressively deteriorated over time.	but these changes became insignificant 2 years after treatment.
__label__noRel	In terms of pulmonary function, dyspnoic and coughing symptoms were significantly worsened 3 months after surgery (P = 0.024 and P = 0.036, respectively) whereas symptoms in the CRT group progressively deteriorated over time.	CRT was associated with progressive deteriorations in pulmonary function in the longer term.
__label__noRel	Concerning the eating function, both groups had improvements in dysphagia but there were frequent need for endoscopic intervention.	No significant longitudinal changes were detected in the global health status in both groups upon available follow-up.
__label__noRel	Concerning the eating function, both groups had improvements in dysphagia but there were frequent need for endoscopic intervention.	Surgery was associated with worsened physical functioning and fatigue symptoms up to 6 months after treatment (P < 0.001 and P = 0.021, respectively) and these scales improved at 2 years.
__label__noRel	Concerning the eating function, both groups had improvements in dysphagia but there were frequent need for endoscopic intervention.	In terms of pulmonary function, dyspnoic and coughing symptoms were significantly worsened 3 months after surgery (P = 0.024 and P = 0.036, respectively) whereas symptoms in the CRT group progressively deteriorated over time.
__label__noRel	Concerning the eating function, both groups had improvements in dysphagia but there were frequent need for endoscopic intervention.	Neither surgery nor definitive CRT significantly impaired the global health status of patients.
__label__noRel	Concerning the eating function, both groups had improvements in dysphagia but there were frequent need for endoscopic intervention.	Surgery was associated with a short-term negative impact in some aspects of health related quality of life assessments
__label__noRel	Concerning the eating function, both groups had improvements in dysphagia but there were frequent need for endoscopic intervention.	but these changes became insignificant 2 years after treatment.
__label__noRel	Concerning the eating function, both groups had improvements in dysphagia but there were frequent need for endoscopic intervention.	CRT was associated with progressive deteriorations in pulmonary function in the longer term.
__label__noRel	Neither surgery nor definitive CRT significantly impaired the global health status of patients.	No significant longitudinal changes were detected in the global health status in both groups upon available follow-up.
__label__noRel	Neither surgery nor definitive CRT significantly impaired the global health status of patients.	Surgery was associated with worsened physical functioning and fatigue symptoms up to 6 months after treatment (P < 0.001 and P = 0.021, respectively) and these scales improved at 2 years.
__label__noRel	Neither surgery nor definitive CRT significantly impaired the global health status of patients.	In terms of pulmonary function, dyspnoic and coughing symptoms were significantly worsened 3 months after surgery (P = 0.024 and P = 0.036, respectively) whereas symptoms in the CRT group progressively deteriorated over time.
__label__noRel	Neither surgery nor definitive CRT significantly impaired the global health status of patients.	Concerning the eating function, both groups had improvements in dysphagia but there were frequent need for endoscopic intervention.
__label__Attack	Neither surgery nor definitive CRT significantly impaired the global health status of patients.	Surgery was associated with a short-term negative impact in some aspects of health related quality of life assessments
__label__noRel	Neither surgery nor definitive CRT significantly impaired the global health status of patients.	but these changes became insignificant 2 years after treatment.
__label__noRel	Neither surgery nor definitive CRT significantly impaired the global health status of patients.	CRT was associated with progressive deteriorations in pulmonary function in the longer term.
__label__noRel	Surgery was associated with a short-term negative impact in some aspects of health related quality of life assessments	No significant longitudinal changes were detected in the global health status in both groups upon available follow-up.
__label__noRel	Surgery was associated with a short-term negative impact in some aspects of health related quality of life assessments	Surgery was associated with worsened physical functioning and fatigue symptoms up to 6 months after treatment (P < 0.001 and P = 0.021, respectively) and these scales improved at 2 years.
__label__noRel	Surgery was associated with a short-term negative impact in some aspects of health related quality of life assessments	In terms of pulmonary function, dyspnoic and coughing symptoms were significantly worsened 3 months after surgery (P = 0.024 and P = 0.036, respectively) whereas symptoms in the CRT group progressively deteriorated over time.
__label__noRel	Surgery was associated with a short-term negative impact in some aspects of health related quality of life assessments	Concerning the eating function, both groups had improvements in dysphagia but there were frequent need for endoscopic intervention.
__label__noRel	Surgery was associated with a short-term negative impact in some aspects of health related quality of life assessments	Neither surgery nor definitive CRT significantly impaired the global health status of patients.
__label__noRel	Surgery was associated with a short-term negative impact in some aspects of health related quality of life assessments	but these changes became insignificant 2 years after treatment.
__label__noRel	Surgery was associated with a short-term negative impact in some aspects of health related quality of life assessments	CRT was associated with progressive deteriorations in pulmonary function in the longer term.
__label__noRel	but these changes became insignificant 2 years after treatment.	No significant longitudinal changes were detected in the global health status in both groups upon available follow-up.
__label__noRel	but these changes became insignificant 2 years after treatment.	Surgery was associated with worsened physical functioning and fatigue symptoms up to 6 months after treatment (P < 0.001 and P = 0.021, respectively) and these scales improved at 2 years.
__label__noRel	but these changes became insignificant 2 years after treatment.	In terms of pulmonary function, dyspnoic and coughing symptoms were significantly worsened 3 months after surgery (P = 0.024 and P = 0.036, respectively) whereas symptoms in the CRT group progressively deteriorated over time.
__label__noRel	but these changes became insignificant 2 years after treatment.	Concerning the eating function, both groups had improvements in dysphagia but there were frequent need for endoscopic intervention.
__label__noRel	but these changes became insignificant 2 years after treatment.	Neither surgery nor definitive CRT significantly impaired the global health status of patients.
__label__Attack	but these changes became insignificant 2 years after treatment.	Surgery was associated with a short-term negative impact in some aspects of health related quality of life assessments
__label__noRel	but these changes became insignificant 2 years after treatment.	CRT was associated with progressive deteriorations in pulmonary function in the longer term.
__label__noRel	CRT was associated with progressive deteriorations in pulmonary function in the longer term.	No significant longitudinal changes were detected in the global health status in both groups upon available follow-up.
__label__noRel	CRT was associated with progressive deteriorations in pulmonary function in the longer term.	Surgery was associated with worsened physical functioning and fatigue symptoms up to 6 months after treatment (P < 0.001 and P = 0.021, respectively) and these scales improved at 2 years.
__label__noRel	CRT was associated with progressive deteriorations in pulmonary function in the longer term.	In terms of pulmonary function, dyspnoic and coughing symptoms were significantly worsened 3 months after surgery (P = 0.024 and P = 0.036, respectively) whereas symptoms in the CRT group progressively deteriorated over time.
__label__noRel	CRT was associated with progressive deteriorations in pulmonary function in the longer term.	Concerning the eating function, both groups had improvements in dysphagia but there were frequent need for endoscopic intervention.
__label__noRel	CRT was associated with progressive deteriorations in pulmonary function in the longer term.	Neither surgery nor definitive CRT significantly impaired the global health status of patients.
__label__noRel	CRT was associated with progressive deteriorations in pulmonary function in the longer term.	Surgery was associated with a short-term negative impact in some aspects of health related quality of life assessments
__label__noRel	CRT was associated with progressive deteriorations in pulmonary function in the longer term.	but these changes became insignificant 2 years after treatment.
__label__noRel	Seventeen of 25 HBO-treated patients (68%) improved versus 8 of 21 controls (38.1%; P = .043, (2) test).	Mean time to improvement was 39.7 weeks (95% confidence interval [CI], 22.4 to 57.0 weeks) for HBO-treated patients versus 67.9 weeks (95 CI, 48.4 to 87.5 weeks) for controls (P = .03, log-rank test).
__label__noRel	Seventeen of 25 HBO-treated patients (68%) improved versus 8 of 21 controls (38.1%; P = .043, (2) test).	However, complete gingival healing occurred in only 14 of 25 HBO-treated patients (52%) versus 7 of 21 controls (33.3%; P = .203, (2) test), and time to healing was 59 weeks (95% CI, 42.8% to 75.8%) for HBO-treated patients versus 70 weeks (95 CI, 52.2% to 88.36%) for controls (P = .32, log-rank test).
__label__noRel	Seventeen of 25 HBO-treated patients (68%) improved versus 8 of 21 controls (38.1%; P = .043, (2) test).	Pain decreased faster for HBO-treated subjects (P < .01, linear regression).
__label__noRel	Seventeen of 25 HBO-treated patients (68%) improved versus 8 of 21 controls (38.1%; P = .043, (2) test).	Quality-of-life scores for physical health (P = .002) and perceived health (P = .043) decreased at 6 months for control group but for not the HBO group.
__label__noRel	Seventeen of 25 HBO-treated patients (68%) improved versus 8 of 21 controls (38.1%; P = .043, (2) test).	ONJ is multifactorial and no single treatment modality is likely to reverse it;
__label__noRel	Seventeen of 25 HBO-treated patients (68%) improved versus 8 of 21 controls (38.1%; P = .043, (2) test).	however, it is treatable and even advanced presentations can improve with intensive multimodal therapy.
__label__Support	Seventeen of 25 HBO-treated patients (68%) improved versus 8 of 21 controls (38.1%; P = .043, (2) test).	Clinically, HBO appears to be a useful adjunct to ONJ treatment, particularly for more severe cases, although this study was underpowered to fully support this claim.
__label__noRel	Mean time to improvement was 39.7 weeks (95% confidence interval [CI], 22.4 to 57.0 weeks) for HBO-treated patients versus 67.9 weeks (95 CI, 48.4 to 87.5 weeks) for controls (P = .03, log-rank test).	Seventeen of 25 HBO-treated patients (68%) improved versus 8 of 21 controls (38.1%; P = .043, (2) test).
__label__noRel	Mean time to improvement was 39.7 weeks (95% confidence interval [CI], 22.4 to 57.0 weeks) for HBO-treated patients versus 67.9 weeks (95 CI, 48.4 to 87.5 weeks) for controls (P = .03, log-rank test).	However, complete gingival healing occurred in only 14 of 25 HBO-treated patients (52%) versus 7 of 21 controls (33.3%; P = .203, (2) test), and time to healing was 59 weeks (95% CI, 42.8% to 75.8%) for HBO-treated patients versus 70 weeks (95 CI, 52.2% to 88.36%) for controls (P = .32, log-rank test).
__label__noRel	Mean time to improvement was 39.7 weeks (95% confidence interval [CI], 22.4 to 57.0 weeks) for HBO-treated patients versus 67.9 weeks (95 CI, 48.4 to 87.5 weeks) for controls (P = .03, log-rank test).	Pain decreased faster for HBO-treated subjects (P < .01, linear regression).
__label__noRel	Mean time to improvement was 39.7 weeks (95% confidence interval [CI], 22.4 to 57.0 weeks) for HBO-treated patients versus 67.9 weeks (95 CI, 48.4 to 87.5 weeks) for controls (P = .03, log-rank test).	Quality-of-life scores for physical health (P = .002) and perceived health (P = .043) decreased at 6 months for control group but for not the HBO group.
__label__noRel	Mean time to improvement was 39.7 weeks (95% confidence interval [CI], 22.4 to 57.0 weeks) for HBO-treated patients versus 67.9 weeks (95 CI, 48.4 to 87.5 weeks) for controls (P = .03, log-rank test).	ONJ is multifactorial and no single treatment modality is likely to reverse it;
__label__noRel	Mean time to improvement was 39.7 weeks (95% confidence interval [CI], 22.4 to 57.0 weeks) for HBO-treated patients versus 67.9 weeks (95 CI, 48.4 to 87.5 weeks) for controls (P = .03, log-rank test).	however, it is treatable and even advanced presentations can improve with intensive multimodal therapy.
__label__Support	Mean time to improvement was 39.7 weeks (95% confidence interval [CI], 22.4 to 57.0 weeks) for HBO-treated patients versus 67.9 weeks (95 CI, 48.4 to 87.5 weeks) for controls (P = .03, log-rank test).	Clinically, HBO appears to be a useful adjunct to ONJ treatment, particularly for more severe cases, although this study was underpowered to fully support this claim.
__label__noRel	However, complete gingival healing occurred in only 14 of 25 HBO-treated patients (52%) versus 7 of 21 controls (33.3%; P = .203, (2) test), and time to healing was 59 weeks (95% CI, 42.8% to 75.8%) for HBO-treated patients versus 70 weeks (95 CI, 52.2% to 88.36%) for controls (P = .32, log-rank test).	Seventeen of 25 HBO-treated patients (68%) improved versus 8 of 21 controls (38.1%; P = .043, (2) test).
__label__noRel	However, complete gingival healing occurred in only 14 of 25 HBO-treated patients (52%) versus 7 of 21 controls (33.3%; P = .203, (2) test), and time to healing was 59 weeks (95% CI, 42.8% to 75.8%) for HBO-treated patients versus 70 weeks (95 CI, 52.2% to 88.36%) for controls (P = .32, log-rank test).	Mean time to improvement was 39.7 weeks (95% confidence interval [CI], 22.4 to 57.0 weeks) for HBO-treated patients versus 67.9 weeks (95 CI, 48.4 to 87.5 weeks) for controls (P = .03, log-rank test).
__label__noRel	However, complete gingival healing occurred in only 14 of 25 HBO-treated patients (52%) versus 7 of 21 controls (33.3%; P = .203, (2) test), and time to healing was 59 weeks (95% CI, 42.8% to 75.8%) for HBO-treated patients versus 70 weeks (95 CI, 52.2% to 88.36%) for controls (P = .32, log-rank test).	Pain decreased faster for HBO-treated subjects (P < .01, linear regression).
__label__noRel	However, complete gingival healing occurred in only 14 of 25 HBO-treated patients (52%) versus 7 of 21 controls (33.3%; P = .203, (2) test), and time to healing was 59 weeks (95% CI, 42.8% to 75.8%) for HBO-treated patients versus 70 weeks (95 CI, 52.2% to 88.36%) for controls (P = .32, log-rank test).	Quality-of-life scores for physical health (P = .002) and perceived health (P = .043) decreased at 6 months for control group but for not the HBO group.
__label__noRel	However, complete gingival healing occurred in only 14 of 25 HBO-treated patients (52%) versus 7 of 21 controls (33.3%; P = .203, (2) test), and time to healing was 59 weeks (95% CI, 42.8% to 75.8%) for HBO-treated patients versus 70 weeks (95 CI, 52.2% to 88.36%) for controls (P = .32, log-rank test).	ONJ is multifactorial and no single treatment modality is likely to reverse it;
__label__noRel	However, complete gingival healing occurred in only 14 of 25 HBO-treated patients (52%) versus 7 of 21 controls (33.3%; P = .203, (2) test), and time to healing was 59 weeks (95% CI, 42.8% to 75.8%) for HBO-treated patients versus 70 weeks (95 CI, 52.2% to 88.36%) for controls (P = .32, log-rank test).	however, it is treatable and even advanced presentations can improve with intensive multimodal therapy.
__label__Support	However, complete gingival healing occurred in only 14 of 25 HBO-treated patients (52%) versus 7 of 21 controls (33.3%; P = .203, (2) test), and time to healing was 59 weeks (95% CI, 42.8% to 75.8%) for HBO-treated patients versus 70 weeks (95 CI, 52.2% to 88.36%) for controls (P = .32, log-rank test).	Clinically, HBO appears to be a useful adjunct to ONJ treatment, particularly for more severe cases, although this study was underpowered to fully support this claim.
__label__noRel	Pain decreased faster for HBO-treated subjects (P < .01, linear regression).	Seventeen of 25 HBO-treated patients (68%) improved versus 8 of 21 controls (38.1%; P = .043, (2) test).
__label__noRel	Pain decreased faster for HBO-treated subjects (P < .01, linear regression).	Mean time to improvement was 39.7 weeks (95% confidence interval [CI], 22.4 to 57.0 weeks) for HBO-treated patients versus 67.9 weeks (95 CI, 48.4 to 87.5 weeks) for controls (P = .03, log-rank test).
__label__noRel	Pain decreased faster for HBO-treated subjects (P < .01, linear regression).	However, complete gingival healing occurred in only 14 of 25 HBO-treated patients (52%) versus 7 of 21 controls (33.3%; P = .203, (2) test), and time to healing was 59 weeks (95% CI, 42.8% to 75.8%) for HBO-treated patients versus 70 weeks (95 CI, 52.2% to 88.36%) for controls (P = .32, log-rank test).
__label__noRel	Pain decreased faster for HBO-treated subjects (P < .01, linear regression).	Quality-of-life scores for physical health (P = .002) and perceived health (P = .043) decreased at 6 months for control group but for not the HBO group.
__label__noRel	Pain decreased faster for HBO-treated subjects (P < .01, linear regression).	ONJ is multifactorial and no single treatment modality is likely to reverse it;
__label__noRel	Pain decreased faster for HBO-treated subjects (P < .01, linear regression).	however, it is treatable and even advanced presentations can improve with intensive multimodal therapy.
__label__Support	Pain decreased faster for HBO-treated subjects (P < .01, linear regression).	Clinically, HBO appears to be a useful adjunct to ONJ treatment, particularly for more severe cases, although this study was underpowered to fully support this claim.
__label__noRel	Quality-of-life scores for physical health (P = .002) and perceived health (P = .043) decreased at 6 months for control group but for not the HBO group.	Seventeen of 25 HBO-treated patients (68%) improved versus 8 of 21 controls (38.1%; P = .043, (2) test).
__label__noRel	Quality-of-life scores for physical health (P = .002) and perceived health (P = .043) decreased at 6 months for control group but for not the HBO group.	Mean time to improvement was 39.7 weeks (95% confidence interval [CI], 22.4 to 57.0 weeks) for HBO-treated patients versus 67.9 weeks (95 CI, 48.4 to 87.5 weeks) for controls (P = .03, log-rank test).
__label__noRel	Quality-of-life scores for physical health (P = .002) and perceived health (P = .043) decreased at 6 months for control group but for not the HBO group.	However, complete gingival healing occurred in only 14 of 25 HBO-treated patients (52%) versus 7 of 21 controls (33.3%; P = .203, (2) test), and time to healing was 59 weeks (95% CI, 42.8% to 75.8%) for HBO-treated patients versus 70 weeks (95 CI, 52.2% to 88.36%) for controls (P = .32, log-rank test).
__label__noRel	Quality-of-life scores for physical health (P = .002) and perceived health (P = .043) decreased at 6 months for control group but for not the HBO group.	Pain decreased faster for HBO-treated subjects (P < .01, linear regression).
__label__noRel	Quality-of-life scores for physical health (P = .002) and perceived health (P = .043) decreased at 6 months for control group but for not the HBO group.	ONJ is multifactorial and no single treatment modality is likely to reverse it;
__label__noRel	Quality-of-life scores for physical health (P = .002) and perceived health (P = .043) decreased at 6 months for control group but for not the HBO group.	however, it is treatable and even advanced presentations can improve with intensive multimodal therapy.
__label__Support	Quality-of-life scores for physical health (P = .002) and perceived health (P = .043) decreased at 6 months for control group but for not the HBO group.	Clinically, HBO appears to be a useful adjunct to ONJ treatment, particularly for more severe cases, although this study was underpowered to fully support this claim.
__label__noRel	ONJ is multifactorial and no single treatment modality is likely to reverse it;	Seventeen of 25 HBO-treated patients (68%) improved versus 8 of 21 controls (38.1%; P = .043, (2) test).
__label__noRel	ONJ is multifactorial and no single treatment modality is likely to reverse it;	Mean time to improvement was 39.7 weeks (95% confidence interval [CI], 22.4 to 57.0 weeks) for HBO-treated patients versus 67.9 weeks (95 CI, 48.4 to 87.5 weeks) for controls (P = .03, log-rank test).
__label__noRel	ONJ is multifactorial and no single treatment modality is likely to reverse it;	However, complete gingival healing occurred in only 14 of 25 HBO-treated patients (52%) versus 7 of 21 controls (33.3%; P = .203, (2) test), and time to healing was 59 weeks (95% CI, 42.8% to 75.8%) for HBO-treated patients versus 70 weeks (95 CI, 52.2% to 88.36%) for controls (P = .32, log-rank test).
__label__noRel	ONJ is multifactorial and no single treatment modality is likely to reverse it;	Pain decreased faster for HBO-treated subjects (P < .01, linear regression).
__label__noRel	ONJ is multifactorial and no single treatment modality is likely to reverse it;	Quality-of-life scores for physical health (P = .002) and perceived health (P = .043) decreased at 6 months for control group but for not the HBO group.
__label__noRel	ONJ is multifactorial and no single treatment modality is likely to reverse it;	however, it is treatable and even advanced presentations can improve with intensive multimodal therapy.
__label__noRel	ONJ is multifactorial and no single treatment modality is likely to reverse it;	Clinically, HBO appears to be a useful adjunct to ONJ treatment, particularly for more severe cases, although this study was underpowered to fully support this claim.
__label__noRel	however, it is treatable and even advanced presentations can improve with intensive multimodal therapy.	Seventeen of 25 HBO-treated patients (68%) improved versus 8 of 21 controls (38.1%; P = .043, (2) test).
__label__noRel	however, it is treatable and even advanced presentations can improve with intensive multimodal therapy.	Mean time to improvement was 39.7 weeks (95% confidence interval [CI], 22.4 to 57.0 weeks) for HBO-treated patients versus 67.9 weeks (95 CI, 48.4 to 87.5 weeks) for controls (P = .03, log-rank test).
__label__noRel	however, it is treatable and even advanced presentations can improve with intensive multimodal therapy.	However, complete gingival healing occurred in only 14 of 25 HBO-treated patients (52%) versus 7 of 21 controls (33.3%; P = .203, (2) test), and time to healing was 59 weeks (95% CI, 42.8% to 75.8%) for HBO-treated patients versus 70 weeks (95 CI, 52.2% to 88.36%) for controls (P = .32, log-rank test).
__label__noRel	however, it is treatable and even advanced presentations can improve with intensive multimodal therapy.	Pain decreased faster for HBO-treated subjects (P < .01, linear regression).
__label__noRel	however, it is treatable and even advanced presentations can improve with intensive multimodal therapy.	Quality-of-life scores for physical health (P = .002) and perceived health (P = .043) decreased at 6 months for control group but for not the HBO group.
__label__noRel	however, it is treatable and even advanced presentations can improve with intensive multimodal therapy.	ONJ is multifactorial and no single treatment modality is likely to reverse it;
__label__noRel	however, it is treatable and even advanced presentations can improve with intensive multimodal therapy.	Clinically, HBO appears to be a useful adjunct to ONJ treatment, particularly for more severe cases, although this study was underpowered to fully support this claim.
__label__noRel	Clinically, HBO appears to be a useful adjunct to ONJ treatment, particularly for more severe cases, although this study was underpowered to fully support this claim.	Seventeen of 25 HBO-treated patients (68%) improved versus 8 of 21 controls (38.1%; P = .043, (2) test).
__label__noRel	Clinically, HBO appears to be a useful adjunct to ONJ treatment, particularly for more severe cases, although this study was underpowered to fully support this claim.	Mean time to improvement was 39.7 weeks (95% confidence interval [CI], 22.4 to 57.0 weeks) for HBO-treated patients versus 67.9 weeks (95 CI, 48.4 to 87.5 weeks) for controls (P = .03, log-rank test).
__label__noRel	Clinically, HBO appears to be a useful adjunct to ONJ treatment, particularly for more severe cases, although this study was underpowered to fully support this claim.	However, complete gingival healing occurred in only 14 of 25 HBO-treated patients (52%) versus 7 of 21 controls (33.3%; P = .203, (2) test), and time to healing was 59 weeks (95% CI, 42.8% to 75.8%) for HBO-treated patients versus 70 weeks (95 CI, 52.2% to 88.36%) for controls (P = .32, log-rank test).
__label__noRel	Clinically, HBO appears to be a useful adjunct to ONJ treatment, particularly for more severe cases, although this study was underpowered to fully support this claim.	Pain decreased faster for HBO-treated subjects (P < .01, linear regression).
__label__noRel	Clinically, HBO appears to be a useful adjunct to ONJ treatment, particularly for more severe cases, although this study was underpowered to fully support this claim.	Quality-of-life scores for physical health (P = .002) and perceived health (P = .043) decreased at 6 months for control group but for not the HBO group.
__label__noRel	Clinically, HBO appears to be a useful adjunct to ONJ treatment, particularly for more severe cases, although this study was underpowered to fully support this claim.	ONJ is multifactorial and no single treatment modality is likely to reverse it;
__label__noRel	Clinically, HBO appears to be a useful adjunct to ONJ treatment, particularly for more severe cases, although this study was underpowered to fully support this claim.	however, it is treatable and even advanced presentations can improve with intensive multimodal therapy.
__label__noRel	EW was associated with a higher level of satisfaction with emotional support compared with controls.	it seems feasible to suggest that EW may be a cost effective accessible treatment that could be incorporated into the ongoing care of women.
__label__noRel	EW was associated with a higher level of satisfaction with emotional support compared with controls.	Most participants found writing valuable and did not report any long-term negative effects.
__label__noRel	EW was associated with a higher level of satisfaction with emotional support compared with controls.	There were no significant effects of the intervention on mood, QOL or healthcare utilisation.
__label__noRel	EW was associated with a higher level of satisfaction with emotional support compared with controls.	There was a significant effect of group on women's perceptions of social support with those in the intervention group being more satisfied with the emotional support they received (p<0.05).
__label__noRel	EW was associated with a higher level of satisfaction with emotional support compared with controls.	Satisfaction with emotional support was negatively correlated with depression/dejection (p<0.05) and anger/hostility (p<0.05) and positively correlated with social and family well-being (p<0.001) 6 months post intervention.
__label__noRel	it seems feasible to suggest that EW may be a cost effective accessible treatment that could be incorporated into the ongoing care of women.	EW was associated with a higher level of satisfaction with emotional support compared with controls.
__label__noRel	it seems feasible to suggest that EW may be a cost effective accessible treatment that could be incorporated into the ongoing care of women.	Most participants found writing valuable and did not report any long-term negative effects.
__label__noRel	it seems feasible to suggest that EW may be a cost effective accessible treatment that could be incorporated into the ongoing care of women.	There were no significant effects of the intervention on mood, QOL or healthcare utilisation.
__label__noRel	it seems feasible to suggest that EW may be a cost effective accessible treatment that could be incorporated into the ongoing care of women.	There was a significant effect of group on women's perceptions of social support with those in the intervention group being more satisfied with the emotional support they received (p<0.05).
__label__noRel	it seems feasible to suggest that EW may be a cost effective accessible treatment that could be incorporated into the ongoing care of women.	Satisfaction with emotional support was negatively correlated with depression/dejection (p<0.05) and anger/hostility (p<0.05) and positively correlated with social and family well-being (p<0.001) 6 months post intervention.
__label__Support	Most participants found writing valuable and did not report any long-term negative effects.	EW was associated with a higher level of satisfaction with emotional support compared with controls.
__label__noRel	Most participants found writing valuable and did not report any long-term negative effects.	it seems feasible to suggest that EW may be a cost effective accessible treatment that could be incorporated into the ongoing care of women.
__label__noRel	Most participants found writing valuable and did not report any long-term negative effects.	There were no significant effects of the intervention on mood, QOL or healthcare utilisation.
__label__noRel	Most participants found writing valuable and did not report any long-term negative effects.	There was a significant effect of group on women's perceptions of social support with those in the intervention group being more satisfied with the emotional support they received (p<0.05).
__label__noRel	Most participants found writing valuable and did not report any long-term negative effects.	Satisfaction with emotional support was negatively correlated with depression/dejection (p<0.05) and anger/hostility (p<0.05) and positively correlated with social and family well-being (p<0.001) 6 months post intervention.
__label__Support	There were no significant effects of the intervention on mood, QOL or healthcare utilisation.	EW was associated with a higher level of satisfaction with emotional support compared with controls.
__label__noRel	There were no significant effects of the intervention on mood, QOL or healthcare utilisation.	it seems feasible to suggest that EW may be a cost effective accessible treatment that could be incorporated into the ongoing care of women.
__label__noRel	There were no significant effects of the intervention on mood, QOL or healthcare utilisation.	Most participants found writing valuable and did not report any long-term negative effects.
__label__noRel	There were no significant effects of the intervention on mood, QOL or healthcare utilisation.	There was a significant effect of group on women's perceptions of social support with those in the intervention group being more satisfied with the emotional support they received (p<0.05).
__label__noRel	There were no significant effects of the intervention on mood, QOL or healthcare utilisation.	Satisfaction with emotional support was negatively correlated with depression/dejection (p<0.05) and anger/hostility (p<0.05) and positively correlated with social and family well-being (p<0.001) 6 months post intervention.
__label__Support	There was a significant effect of group on women's perceptions of social support with those in the intervention group being more satisfied with the emotional support they received (p<0.05).	EW was associated with a higher level of satisfaction with emotional support compared with controls.
__label__noRel	There was a significant effect of group on women's perceptions of social support with those in the intervention group being more satisfied with the emotional support they received (p<0.05).	it seems feasible to suggest that EW may be a cost effective accessible treatment that could be incorporated into the ongoing care of women.
__label__noRel	There was a significant effect of group on women's perceptions of social support with those in the intervention group being more satisfied with the emotional support they received (p<0.05).	Most participants found writing valuable and did not report any long-term negative effects.
__label__noRel	There was a significant effect of group on women's perceptions of social support with those in the intervention group being more satisfied with the emotional support they received (p<0.05).	There were no significant effects of the intervention on mood, QOL or healthcare utilisation.
__label__noRel	There was a significant effect of group on women's perceptions of social support with those in the intervention group being more satisfied with the emotional support they received (p<0.05).	Satisfaction with emotional support was negatively correlated with depression/dejection (p<0.05) and anger/hostility (p<0.05) and positively correlated with social and family well-being (p<0.001) 6 months post intervention.
__label__Support	Satisfaction with emotional support was negatively correlated with depression/dejection (p<0.05) and anger/hostility (p<0.05) and positively correlated with social and family well-being (p<0.001) 6 months post intervention.	EW was associated with a higher level of satisfaction with emotional support compared with controls.
__label__noRel	Satisfaction with emotional support was negatively correlated with depression/dejection (p<0.05) and anger/hostility (p<0.05) and positively correlated with social and family well-being (p<0.001) 6 months post intervention.	it seems feasible to suggest that EW may be a cost effective accessible treatment that could be incorporated into the ongoing care of women.
__label__noRel	Satisfaction with emotional support was negatively correlated with depression/dejection (p<0.05) and anger/hostility (p<0.05) and positively correlated with social and family well-being (p<0.001) 6 months post intervention.	Most participants found writing valuable and did not report any long-term negative effects.
__label__noRel	Satisfaction with emotional support was negatively correlated with depression/dejection (p<0.05) and anger/hostility (p<0.05) and positively correlated with social and family well-being (p<0.001) 6 months post intervention.	There were no significant effects of the intervention on mood, QOL or healthcare utilisation.
__label__noRel	Satisfaction with emotional support was negatively correlated with depression/dejection (p<0.05) and anger/hostility (p<0.05) and positively correlated with social and family well-being (p<0.001) 6 months post intervention.	There was a significant effect of group on women's perceptions of social support with those in the intervention group being more satisfied with the emotional support they received (p<0.05).
__label__noRel	there is no standard therapy for patients with advanced gastric carcinoma.	The superiority of combination therapy over monochemotherapy has not been demonstrated convincingly.
__label__noRel	there is no standard therapy for patients with advanced gastric carcinoma.	The median duration of response was 8.8 and 8.3 months, respectively, in Study A and Study B.
__label__noRel	there is no standard therapy for patients with advanced gastric carcinoma.	The median survival reached 8 months in Study A and 9 months in Study B.
__label__noRel	there is no standard therapy for patients with advanced gastric carcinoma.	In the whole population of patients survival was significantly higher in patients with a PS of 0-1 (P < 0.05).
__label__noRel	there is no standard therapy for patients with advanced gastric carcinoma.	Patients with a PS of 0-1 and a resected tumor had the significantly longest survival both in EEP-L treated patients and in all evaluable patients in the two studies.
__label__noRel	there is no standard therapy for patients with advanced gastric carcinoma.	The most frequent World Health Organization Grade 3-4 toxic effects were gastrointestinal in Study A and hematologic in Study B.
__label__noRel	there is no standard therapy for patients with advanced gastric carcinoma.	No treatment-related death was observed.
__label__noRel	there is no standard therapy for patients with advanced gastric carcinoma.	The efficacy of 5-FU, modulated with 6S-LV, is moderate in patients with advanced gastric carcinoma, similar to cisplatin-containing regimens.
__label__noRel	there is no standard therapy for patients with advanced gastric carcinoma.	PS and other prognostic factors could influence the response rate, which does not appear to be a reliable parameter for evaluating the outcome of chemotherapy trials.
__label__Support	The superiority of combination therapy over monochemotherapy has not been demonstrated convincingly.	there is no standard therapy for patients with advanced gastric carcinoma.
__label__noRel	The superiority of combination therapy over monochemotherapy has not been demonstrated convincingly.	The median duration of response was 8.8 and 8.3 months, respectively, in Study A and Study B.
__label__noRel	The superiority of combination therapy over monochemotherapy has not been demonstrated convincingly.	The median survival reached 8 months in Study A and 9 months in Study B.
__label__noRel	The superiority of combination therapy over monochemotherapy has not been demonstrated convincingly.	In the whole population of patients survival was significantly higher in patients with a PS of 0-1 (P < 0.05).
__label__noRel	The superiority of combination therapy over monochemotherapy has not been demonstrated convincingly.	Patients with a PS of 0-1 and a resected tumor had the significantly longest survival both in EEP-L treated patients and in all evaluable patients in the two studies.
__label__noRel	The superiority of combination therapy over monochemotherapy has not been demonstrated convincingly.	The most frequent World Health Organization Grade 3-4 toxic effects were gastrointestinal in Study A and hematologic in Study B.
__label__noRel	The superiority of combination therapy over monochemotherapy has not been demonstrated convincingly.	No treatment-related death was observed.
__label__noRel	The superiority of combination therapy over monochemotherapy has not been demonstrated convincingly.	The efficacy of 5-FU, modulated with 6S-LV, is moderate in patients with advanced gastric carcinoma, similar to cisplatin-containing regimens.
__label__noRel	The superiority of combination therapy over monochemotherapy has not been demonstrated convincingly.	PS and other prognostic factors could influence the response rate, which does not appear to be a reliable parameter for evaluating the outcome of chemotherapy trials.
__label__noRel	The median duration of response was 8.8 and 8.3 months, respectively, in Study A and Study B.	there is no standard therapy for patients with advanced gastric carcinoma.
__label__noRel	The median duration of response was 8.8 and 8.3 months, respectively, in Study A and Study B.	The superiority of combination therapy over monochemotherapy has not been demonstrated convincingly.
__label__noRel	The median duration of response was 8.8 and 8.3 months, respectively, in Study A and Study B.	The median survival reached 8 months in Study A and 9 months in Study B.
__label__noRel	The median duration of response was 8.8 and 8.3 months, respectively, in Study A and Study B.	In the whole population of patients survival was significantly higher in patients with a PS of 0-1 (P < 0.05).
__label__noRel	The median duration of response was 8.8 and 8.3 months, respectively, in Study A and Study B.	Patients with a PS of 0-1 and a resected tumor had the significantly longest survival both in EEP-L treated patients and in all evaluable patients in the two studies.
__label__noRel	The median duration of response was 8.8 and 8.3 months, respectively, in Study A and Study B.	The most frequent World Health Organization Grade 3-4 toxic effects were gastrointestinal in Study A and hematologic in Study B.
__label__noRel	The median duration of response was 8.8 and 8.3 months, respectively, in Study A and Study B.	No treatment-related death was observed.
__label__Support	The median duration of response was 8.8 and 8.3 months, respectively, in Study A and Study B.	The efficacy of 5-FU, modulated with 6S-LV, is moderate in patients with advanced gastric carcinoma, similar to cisplatin-containing regimens.
__label__noRel	The median duration of response was 8.8 and 8.3 months, respectively, in Study A and Study B.	PS and other prognostic factors could influence the response rate, which does not appear to be a reliable parameter for evaluating the outcome of chemotherapy trials.
__label__noRel	The median survival reached 8 months in Study A and 9 months in Study B.	there is no standard therapy for patients with advanced gastric carcinoma.
__label__noRel	The median survival reached 8 months in Study A and 9 months in Study B.	The superiority of combination therapy over monochemotherapy has not been demonstrated convincingly.
__label__noRel	The median survival reached 8 months in Study A and 9 months in Study B.	The median duration of response was 8.8 and 8.3 months, respectively, in Study A and Study B.
__label__noRel	The median survival reached 8 months in Study A and 9 months in Study B.	In the whole population of patients survival was significantly higher in patients with a PS of 0-1 (P < 0.05).
__label__noRel	The median survival reached 8 months in Study A and 9 months in Study B.	Patients with a PS of 0-1 and a resected tumor had the significantly longest survival both in EEP-L treated patients and in all evaluable patients in the two studies.
__label__noRel	The median survival reached 8 months in Study A and 9 months in Study B.	The most frequent World Health Organization Grade 3-4 toxic effects were gastrointestinal in Study A and hematologic in Study B.
__label__noRel	The median survival reached 8 months in Study A and 9 months in Study B.	No treatment-related death was observed.
__label__Support	The median survival reached 8 months in Study A and 9 months in Study B.	The efficacy of 5-FU, modulated with 6S-LV, is moderate in patients with advanced gastric carcinoma, similar to cisplatin-containing regimens.
__label__noRel	The median survival reached 8 months in Study A and 9 months in Study B.	PS and other prognostic factors could influence the response rate, which does not appear to be a reliable parameter for evaluating the outcome of chemotherapy trials.
__label__noRel	In the whole population of patients survival was significantly higher in patients with a PS of 0-1 (P < 0.05).	there is no standard therapy for patients with advanced gastric carcinoma.
__label__noRel	In the whole population of patients survival was significantly higher in patients with a PS of 0-1 (P < 0.05).	The superiority of combination therapy over monochemotherapy has not been demonstrated convincingly.
__label__noRel	In the whole population of patients survival was significantly higher in patients with a PS of 0-1 (P < 0.05).	The median duration of response was 8.8 and 8.3 months, respectively, in Study A and Study B.
__label__noRel	In the whole population of patients survival was significantly higher in patients with a PS of 0-1 (P < 0.05).	The median survival reached 8 months in Study A and 9 months in Study B.
__label__noRel	In the whole population of patients survival was significantly higher in patients with a PS of 0-1 (P < 0.05).	Patients with a PS of 0-1 and a resected tumor had the significantly longest survival both in EEP-L treated patients and in all evaluable patients in the two studies.
__label__noRel	In the whole population of patients survival was significantly higher in patients with a PS of 0-1 (P < 0.05).	The most frequent World Health Organization Grade 3-4 toxic effects were gastrointestinal in Study A and hematologic in Study B.
__label__noRel	In the whole population of patients survival was significantly higher in patients with a PS of 0-1 (P < 0.05).	No treatment-related death was observed.
__label__noRel	In the whole population of patients survival was significantly higher in patients with a PS of 0-1 (P < 0.05).	The efficacy of 5-FU, modulated with 6S-LV, is moderate in patients with advanced gastric carcinoma, similar to cisplatin-containing regimens.
__label__Support	In the whole population of patients survival was significantly higher in patients with a PS of 0-1 (P < 0.05).	PS and other prognostic factors could influence the response rate, which does not appear to be a reliable parameter for evaluating the outcome of chemotherapy trials.
__label__noRel	Patients with a PS of 0-1 and a resected tumor had the significantly longest survival both in EEP-L treated patients and in all evaluable patients in the two studies.	there is no standard therapy for patients with advanced gastric carcinoma.
__label__noRel	Patients with a PS of 0-1 and a resected tumor had the significantly longest survival both in EEP-L treated patients and in all evaluable patients in the two studies.	The superiority of combination therapy over monochemotherapy has not been demonstrated convincingly.
__label__noRel	Patients with a PS of 0-1 and a resected tumor had the significantly longest survival both in EEP-L treated patients and in all evaluable patients in the two studies.	The median duration of response was 8.8 and 8.3 months, respectively, in Study A and Study B.
__label__noRel	Patients with a PS of 0-1 and a resected tumor had the significantly longest survival both in EEP-L treated patients and in all evaluable patients in the two studies.	The median survival reached 8 months in Study A and 9 months in Study B.
__label__noRel	Patients with a PS of 0-1 and a resected tumor had the significantly longest survival both in EEP-L treated patients and in all evaluable patients in the two studies.	In the whole population of patients survival was significantly higher in patients with a PS of 0-1 (P < 0.05).
__label__noRel	Patients with a PS of 0-1 and a resected tumor had the significantly longest survival both in EEP-L treated patients and in all evaluable patients in the two studies.	The most frequent World Health Organization Grade 3-4 toxic effects were gastrointestinal in Study A and hematologic in Study B.
__label__noRel	Patients with a PS of 0-1 and a resected tumor had the significantly longest survival both in EEP-L treated patients and in all evaluable patients in the two studies.	No treatment-related death was observed.
__label__noRel	Patients with a PS of 0-1 and a resected tumor had the significantly longest survival both in EEP-L treated patients and in all evaluable patients in the two studies.	The efficacy of 5-FU, modulated with 6S-LV, is moderate in patients with advanced gastric carcinoma, similar to cisplatin-containing regimens.
__label__Support	Patients with a PS of 0-1 and a resected tumor had the significantly longest survival both in EEP-L treated patients and in all evaluable patients in the two studies.	PS and other prognostic factors could influence the response rate, which does not appear to be a reliable parameter for evaluating the outcome of chemotherapy trials.
__label__noRel	The most frequent World Health Organization Grade 3-4 toxic effects were gastrointestinal in Study A and hematologic in Study B.	there is no standard therapy for patients with advanced gastric carcinoma.
__label__noRel	The most frequent World Health Organization Grade 3-4 toxic effects were gastrointestinal in Study A and hematologic in Study B.	The superiority of combination therapy over monochemotherapy has not been demonstrated convincingly.
__label__noRel	The most frequent World Health Organization Grade 3-4 toxic effects were gastrointestinal in Study A and hematologic in Study B.	The median duration of response was 8.8 and 8.3 months, respectively, in Study A and Study B.
__label__noRel	The most frequent World Health Organization Grade 3-4 toxic effects were gastrointestinal in Study A and hematologic in Study B.	The median survival reached 8 months in Study A and 9 months in Study B.
__label__noRel	The most frequent World Health Organization Grade 3-4 toxic effects were gastrointestinal in Study A and hematologic in Study B.	In the whole population of patients survival was significantly higher in patients with a PS of 0-1 (P < 0.05).
__label__noRel	The most frequent World Health Organization Grade 3-4 toxic effects were gastrointestinal in Study A and hematologic in Study B.	Patients with a PS of 0-1 and a resected tumor had the significantly longest survival both in EEP-L treated patients and in all evaluable patients in the two studies.
__label__noRel	The most frequent World Health Organization Grade 3-4 toxic effects were gastrointestinal in Study A and hematologic in Study B.	No treatment-related death was observed.
__label__Support	The most frequent World Health Organization Grade 3-4 toxic effects were gastrointestinal in Study A and hematologic in Study B.	The efficacy of 5-FU, modulated with 6S-LV, is moderate in patients with advanced gastric carcinoma, similar to cisplatin-containing regimens.
__label__noRel	The most frequent World Health Organization Grade 3-4 toxic effects were gastrointestinal in Study A and hematologic in Study B.	PS and other prognostic factors could influence the response rate, which does not appear to be a reliable parameter for evaluating the outcome of chemotherapy trials.
__label__noRel	No treatment-related death was observed.	there is no standard therapy for patients with advanced gastric carcinoma.
__label__noRel	No treatment-related death was observed.	The superiority of combination therapy over monochemotherapy has not been demonstrated convincingly.
__label__noRel	No treatment-related death was observed.	The median duration of response was 8.8 and 8.3 months, respectively, in Study A and Study B.
__label__noRel	No treatment-related death was observed.	The median survival reached 8 months in Study A and 9 months in Study B.
__label__noRel	No treatment-related death was observed.	In the whole population of patients survival was significantly higher in patients with a PS of 0-1 (P < 0.05).
__label__noRel	No treatment-related death was observed.	Patients with a PS of 0-1 and a resected tumor had the significantly longest survival both in EEP-L treated patients and in all evaluable patients in the two studies.
__label__noRel	No treatment-related death was observed.	The most frequent World Health Organization Grade 3-4 toxic effects were gastrointestinal in Study A and hematologic in Study B.
__label__Support	No treatment-related death was observed.	The efficacy of 5-FU, modulated with 6S-LV, is moderate in patients with advanced gastric carcinoma, similar to cisplatin-containing regimens.
__label__noRel	No treatment-related death was observed.	PS and other prognostic factors could influence the response rate, which does not appear to be a reliable parameter for evaluating the outcome of chemotherapy trials.
__label__noRel	The efficacy of 5-FU, modulated with 6S-LV, is moderate in patients with advanced gastric carcinoma, similar to cisplatin-containing regimens.	there is no standard therapy for patients with advanced gastric carcinoma.
__label__noRel	The efficacy of 5-FU, modulated with 6S-LV, is moderate in patients with advanced gastric carcinoma, similar to cisplatin-containing regimens.	The superiority of combination therapy over monochemotherapy has not been demonstrated convincingly.
__label__noRel	The efficacy of 5-FU, modulated with 6S-LV, is moderate in patients with advanced gastric carcinoma, similar to cisplatin-containing regimens.	The median duration of response was 8.8 and 8.3 months, respectively, in Study A and Study B.
__label__noRel	The efficacy of 5-FU, modulated with 6S-LV, is moderate in patients with advanced gastric carcinoma, similar to cisplatin-containing regimens.	The median survival reached 8 months in Study A and 9 months in Study B.
__label__noRel	The efficacy of 5-FU, modulated with 6S-LV, is moderate in patients with advanced gastric carcinoma, similar to cisplatin-containing regimens.	In the whole population of patients survival was significantly higher in patients with a PS of 0-1 (P < 0.05).
__label__noRel	The efficacy of 5-FU, modulated with 6S-LV, is moderate in patients with advanced gastric carcinoma, similar to cisplatin-containing regimens.	Patients with a PS of 0-1 and a resected tumor had the significantly longest survival both in EEP-L treated patients and in all evaluable patients in the two studies.
__label__noRel	The efficacy of 5-FU, modulated with 6S-LV, is moderate in patients with advanced gastric carcinoma, similar to cisplatin-containing regimens.	The most frequent World Health Organization Grade 3-4 toxic effects were gastrointestinal in Study A and hematologic in Study B.
__label__noRel	The efficacy of 5-FU, modulated with 6S-LV, is moderate in patients with advanced gastric carcinoma, similar to cisplatin-containing regimens.	No treatment-related death was observed.
__label__noRel	The efficacy of 5-FU, modulated with 6S-LV, is moderate in patients with advanced gastric carcinoma, similar to cisplatin-containing regimens.	PS and other prognostic factors could influence the response rate, which does not appear to be a reliable parameter for evaluating the outcome of chemotherapy trials.
__label__noRel	PS and other prognostic factors could influence the response rate, which does not appear to be a reliable parameter for evaluating the outcome of chemotherapy trials.	there is no standard therapy for patients with advanced gastric carcinoma.
__label__noRel	PS and other prognostic factors could influence the response rate, which does not appear to be a reliable parameter for evaluating the outcome of chemotherapy trials.	The superiority of combination therapy over monochemotherapy has not been demonstrated convincingly.
__label__noRel	PS and other prognostic factors could influence the response rate, which does not appear to be a reliable parameter for evaluating the outcome of chemotherapy trials.	The median duration of response was 8.8 and 8.3 months, respectively, in Study A and Study B.
__label__noRel	PS and other prognostic factors could influence the response rate, which does not appear to be a reliable parameter for evaluating the outcome of chemotherapy trials.	The median survival reached 8 months in Study A and 9 months in Study B.
__label__noRel	PS and other prognostic factors could influence the response rate, which does not appear to be a reliable parameter for evaluating the outcome of chemotherapy trials.	In the whole population of patients survival was significantly higher in patients with a PS of 0-1 (P < 0.05).
__label__noRel	PS and other prognostic factors could influence the response rate, which does not appear to be a reliable parameter for evaluating the outcome of chemotherapy trials.	Patients with a PS of 0-1 and a resected tumor had the significantly longest survival both in EEP-L treated patients and in all evaluable patients in the two studies.
__label__noRel	PS and other prognostic factors could influence the response rate, which does not appear to be a reliable parameter for evaluating the outcome of chemotherapy trials.	The most frequent World Health Organization Grade 3-4 toxic effects were gastrointestinal in Study A and hematologic in Study B.
__label__noRel	PS and other prognostic factors could influence the response rate, which does not appear to be a reliable parameter for evaluating the outcome of chemotherapy trials.	No treatment-related death was observed.
__label__noRel	PS and other prognostic factors could influence the response rate, which does not appear to be a reliable parameter for evaluating the outcome of chemotherapy trials.	The efficacy of 5-FU, modulated with 6S-LV, is moderate in patients with advanced gastric carcinoma, similar to cisplatin-containing regimens.
__label__noRel	The combination of etoposide plus cisplatin (EP) is considered to be standard therapy for small-cell lung cancer (SCLC).	Patients in the PCDE arm had a statistically significant higher frequency of combined complete plus partial responses compared with those in the EP arm (21% plus 55% versus 13% plus 48%, respectively; P =.02 for difference in combined objective responses).
__label__noRel	The combination of etoposide plus cisplatin (EP) is considered to be standard therapy for small-cell lung cancer (SCLC).	Patients in the PCDE arm survived longer than those in the EP arm (1-year survival rate: 40% and 29%, respectively; median survival: 10.5 and 9.3 months, respectively; log-rank P =.0067).
__label__noRel	The combination of etoposide plus cisplatin (EP) is considered to be standard therapy for small-cell lung cancer (SCLC).	In the Cox model, the relative risk of death for patients in the PCDE arm compared with those in the EP arm was 0.70 (95% confidence interval = 0.51 to 0.95);
__label__noRel	The combination of etoposide plus cisplatin (EP) is considered to be standard therapy for small-cell lung cancer (SCLC).	the disease also progressed more slowly in patients in the PCDE arm.
__label__noRel	The combination of etoposide plus cisplatin (EP) is considered to be standard therapy for small-cell lung cancer (SCLC).	Hematologic toxicity was higher in the PCDE arm (22% with documented infections compared with 8% in the EP arm; P =.0038),
__label__noRel	The combination of etoposide plus cisplatin (EP) is considered to be standard therapy for small-cell lung cancer (SCLC).	the toxicity-related death rate was 9% in the PCDE arm versus 5.5% in the EP arm (P =.22).
__label__noRel	The combination of etoposide plus cisplatin (EP) is considered to be standard therapy for small-cell lung cancer (SCLC).	The global health status showed similar improvement in both arms during treatment.
__label__noRel	The combination of etoposide plus cisplatin (EP) is considered to be standard therapy for small-cell lung cancer (SCLC).	Compared with the EP regimen, the PCDE regimen yielded higher response rates and better survival rates in patients with extensive SCLC without affecting the quality of life of the patients during chemotherapy.
__label__noRel	Patients in the PCDE arm had a statistically significant higher frequency of combined complete plus partial responses compared with those in the EP arm (21% plus 55% versus 13% plus 48%, respectively; P =.02 for difference in combined objective responses).	The combination of etoposide plus cisplatin (EP) is considered to be standard therapy for small-cell lung cancer (SCLC).
__label__noRel	Patients in the PCDE arm had a statistically significant higher frequency of combined complete plus partial responses compared with those in the EP arm (21% plus 55% versus 13% plus 48%, respectively; P =.02 for difference in combined objective responses).	Patients in the PCDE arm survived longer than those in the EP arm (1-year survival rate: 40% and 29%, respectively; median survival: 10.5 and 9.3 months, respectively; log-rank P =.0067).
__label__noRel	Patients in the PCDE arm had a statistically significant higher frequency of combined complete plus partial responses compared with those in the EP arm (21% plus 55% versus 13% plus 48%, respectively; P =.02 for difference in combined objective responses).	In the Cox model, the relative risk of death for patients in the PCDE arm compared with those in the EP arm was 0.70 (95% confidence interval = 0.51 to 0.95);
__label__noRel	Patients in the PCDE arm had a statistically significant higher frequency of combined complete plus partial responses compared with those in the EP arm (21% plus 55% versus 13% plus 48%, respectively; P =.02 for difference in combined objective responses).	the disease also progressed more slowly in patients in the PCDE arm.
__label__noRel	Patients in the PCDE arm had a statistically significant higher frequency of combined complete plus partial responses compared with those in the EP arm (21% plus 55% versus 13% plus 48%, respectively; P =.02 for difference in combined objective responses).	Hematologic toxicity was higher in the PCDE arm (22% with documented infections compared with 8% in the EP arm; P =.0038),
__label__noRel	Patients in the PCDE arm had a statistically significant higher frequency of combined complete plus partial responses compared with those in the EP arm (21% plus 55% versus 13% plus 48%, respectively; P =.02 for difference in combined objective responses).	the toxicity-related death rate was 9% in the PCDE arm versus 5.5% in the EP arm (P =.22).
__label__noRel	Patients in the PCDE arm had a statistically significant higher frequency of combined complete plus partial responses compared with those in the EP arm (21% plus 55% versus 13% plus 48%, respectively; P =.02 for difference in combined objective responses).	The global health status showed similar improvement in both arms during treatment.
__label__Support	Patients in the PCDE arm had a statistically significant higher frequency of combined complete plus partial responses compared with those in the EP arm (21% plus 55% versus 13% plus 48%, respectively; P =.02 for difference in combined objective responses).	Compared with the EP regimen, the PCDE regimen yielded higher response rates and better survival rates in patients with extensive SCLC without affecting the quality of life of the patients during chemotherapy.
__label__noRel	Patients in the PCDE arm survived longer than those in the EP arm (1-year survival rate: 40% and 29%, respectively; median survival: 10.5 and 9.3 months, respectively; log-rank P =.0067).	The combination of etoposide plus cisplatin (EP) is considered to be standard therapy for small-cell lung cancer (SCLC).
__label__noRel	Patients in the PCDE arm survived longer than those in the EP arm (1-year survival rate: 40% and 29%, respectively; median survival: 10.5 and 9.3 months, respectively; log-rank P =.0067).	Patients in the PCDE arm had a statistically significant higher frequency of combined complete plus partial responses compared with those in the EP arm (21% plus 55% versus 13% plus 48%, respectively; P =.02 for difference in combined objective responses).
__label__noRel	Patients in the PCDE arm survived longer than those in the EP arm (1-year survival rate: 40% and 29%, respectively; median survival: 10.5 and 9.3 months, respectively; log-rank P =.0067).	In the Cox model, the relative risk of death for patients in the PCDE arm compared with those in the EP arm was 0.70 (95% confidence interval = 0.51 to 0.95);
__label__noRel	Patients in the PCDE arm survived longer than those in the EP arm (1-year survival rate: 40% and 29%, respectively; median survival: 10.5 and 9.3 months, respectively; log-rank P =.0067).	the disease also progressed more slowly in patients in the PCDE arm.
__label__noRel	Patients in the PCDE arm survived longer than those in the EP arm (1-year survival rate: 40% and 29%, respectively; median survival: 10.5 and 9.3 months, respectively; log-rank P =.0067).	Hematologic toxicity was higher in the PCDE arm (22% with documented infections compared with 8% in the EP arm; P =.0038),
__label__noRel	Patients in the PCDE arm survived longer than those in the EP arm (1-year survival rate: 40% and 29%, respectively; median survival: 10.5 and 9.3 months, respectively; log-rank P =.0067).	the toxicity-related death rate was 9% in the PCDE arm versus 5.5% in the EP arm (P =.22).
__label__noRel	Patients in the PCDE arm survived longer than those in the EP arm (1-year survival rate: 40% and 29%, respectively; median survival: 10.5 and 9.3 months, respectively; log-rank P =.0067).	The global health status showed similar improvement in both arms during treatment.
__label__Support	Patients in the PCDE arm survived longer than those in the EP arm (1-year survival rate: 40% and 29%, respectively; median survival: 10.5 and 9.3 months, respectively; log-rank P =.0067).	Compared with the EP regimen, the PCDE regimen yielded higher response rates and better survival rates in patients with extensive SCLC without affecting the quality of life of the patients during chemotherapy.
__label__noRel	In the Cox model, the relative risk of death for patients in the PCDE arm compared with those in the EP arm was 0.70 (95% confidence interval = 0.51 to 0.95);	The combination of etoposide plus cisplatin (EP) is considered to be standard therapy for small-cell lung cancer (SCLC).
__label__noRel	In the Cox model, the relative risk of death for patients in the PCDE arm compared with those in the EP arm was 0.70 (95% confidence interval = 0.51 to 0.95);	Patients in the PCDE arm had a statistically significant higher frequency of combined complete plus partial responses compared with those in the EP arm (21% plus 55% versus 13% plus 48%, respectively; P =.02 for difference in combined objective responses).
__label__noRel	In the Cox model, the relative risk of death for patients in the PCDE arm compared with those in the EP arm was 0.70 (95% confidence interval = 0.51 to 0.95);	Patients in the PCDE arm survived longer than those in the EP arm (1-year survival rate: 40% and 29%, respectively; median survival: 10.5 and 9.3 months, respectively; log-rank P =.0067).
__label__noRel	In the Cox model, the relative risk of death for patients in the PCDE arm compared with those in the EP arm was 0.70 (95% confidence interval = 0.51 to 0.95);	the disease also progressed more slowly in patients in the PCDE arm.
__label__noRel	In the Cox model, the relative risk of death for patients in the PCDE arm compared with those in the EP arm was 0.70 (95% confidence interval = 0.51 to 0.95);	Hematologic toxicity was higher in the PCDE arm (22% with documented infections compared with 8% in the EP arm; P =.0038),
__label__noRel	In the Cox model, the relative risk of death for patients in the PCDE arm compared with those in the EP arm was 0.70 (95% confidence interval = 0.51 to 0.95);	the toxicity-related death rate was 9% in the PCDE arm versus 5.5% in the EP arm (P =.22).
__label__noRel	In the Cox model, the relative risk of death for patients in the PCDE arm compared with those in the EP arm was 0.70 (95% confidence interval = 0.51 to 0.95);	The global health status showed similar improvement in both arms during treatment.
__label__noRel	In the Cox model, the relative risk of death for patients in the PCDE arm compared with those in the EP arm was 0.70 (95% confidence interval = 0.51 to 0.95);	Compared with the EP regimen, the PCDE regimen yielded higher response rates and better survival rates in patients with extensive SCLC without affecting the quality of life of the patients during chemotherapy.
__label__noRel	the disease also progressed more slowly in patients in the PCDE arm.	The combination of etoposide plus cisplatin (EP) is considered to be standard therapy for small-cell lung cancer (SCLC).
__label__noRel	the disease also progressed more slowly in patients in the PCDE arm.	Patients in the PCDE arm had a statistically significant higher frequency of combined complete plus partial responses compared with those in the EP arm (21% plus 55% versus 13% plus 48%, respectively; P =.02 for difference in combined objective responses).
__label__noRel	the disease also progressed more slowly in patients in the PCDE arm.	Patients in the PCDE arm survived longer than those in the EP arm (1-year survival rate: 40% and 29%, respectively; median survival: 10.5 and 9.3 months, respectively; log-rank P =.0067).
__label__noRel	the disease also progressed more slowly in patients in the PCDE arm.	In the Cox model, the relative risk of death for patients in the PCDE arm compared with those in the EP arm was 0.70 (95% confidence interval = 0.51 to 0.95);
__label__noRel	the disease also progressed more slowly in patients in the PCDE arm.	Hematologic toxicity was higher in the PCDE arm (22% with documented infections compared with 8% in the EP arm; P =.0038),
__label__noRel	the disease also progressed more slowly in patients in the PCDE arm.	the toxicity-related death rate was 9% in the PCDE arm versus 5.5% in the EP arm (P =.22).
__label__noRel	the disease also progressed more slowly in patients in the PCDE arm.	The global health status showed similar improvement in both arms during treatment.
__label__noRel	the disease also progressed more slowly in patients in the PCDE arm.	Compared with the EP regimen, the PCDE regimen yielded higher response rates and better survival rates in patients with extensive SCLC without affecting the quality of life of the patients during chemotherapy.
__label__noRel	Hematologic toxicity was higher in the PCDE arm (22% with documented infections compared with 8% in the EP arm; P =.0038),	The combination of etoposide plus cisplatin (EP) is considered to be standard therapy for small-cell lung cancer (SCLC).
__label__noRel	Hematologic toxicity was higher in the PCDE arm (22% with documented infections compared with 8% in the EP arm; P =.0038),	Patients in the PCDE arm had a statistically significant higher frequency of combined complete plus partial responses compared with those in the EP arm (21% plus 55% versus 13% plus 48%, respectively; P =.02 for difference in combined objective responses).
__label__noRel	Hematologic toxicity was higher in the PCDE arm (22% with documented infections compared with 8% in the EP arm; P =.0038),	Patients in the PCDE arm survived longer than those in the EP arm (1-year survival rate: 40% and 29%, respectively; median survival: 10.5 and 9.3 months, respectively; log-rank P =.0067).
__label__noRel	Hematologic toxicity was higher in the PCDE arm (22% with documented infections compared with 8% in the EP arm; P =.0038),	In the Cox model, the relative risk of death for patients in the PCDE arm compared with those in the EP arm was 0.70 (95% confidence interval = 0.51 to 0.95);
__label__noRel	Hematologic toxicity was higher in the PCDE arm (22% with documented infections compared with 8% in the EP arm; P =.0038),	the disease also progressed more slowly in patients in the PCDE arm.
__label__noRel	Hematologic toxicity was higher in the PCDE arm (22% with documented infections compared with 8% in the EP arm; P =.0038),	the toxicity-related death rate was 9% in the PCDE arm versus 5.5% in the EP arm (P =.22).
__label__noRel	Hematologic toxicity was higher in the PCDE arm (22% with documented infections compared with 8% in the EP arm; P =.0038),	The global health status showed similar improvement in both arms during treatment.
__label__noRel	Hematologic toxicity was higher in the PCDE arm (22% with documented infections compared with 8% in the EP arm; P =.0038),	Compared with the EP regimen, the PCDE regimen yielded higher response rates and better survival rates in patients with extensive SCLC without affecting the quality of life of the patients during chemotherapy.
__label__noRel	the toxicity-related death rate was 9% in the PCDE arm versus 5.5% in the EP arm (P =.22).	The combination of etoposide plus cisplatin (EP) is considered to be standard therapy for small-cell lung cancer (SCLC).
__label__noRel	the toxicity-related death rate was 9% in the PCDE arm versus 5.5% in the EP arm (P =.22).	Patients in the PCDE arm had a statistically significant higher frequency of combined complete plus partial responses compared with those in the EP arm (21% plus 55% versus 13% plus 48%, respectively; P =.02 for difference in combined objective responses).
__label__noRel	the toxicity-related death rate was 9% in the PCDE arm versus 5.5% in the EP arm (P =.22).	Patients in the PCDE arm survived longer than those in the EP arm (1-year survival rate: 40% and 29%, respectively; median survival: 10.5 and 9.3 months, respectively; log-rank P =.0067).
__label__noRel	the toxicity-related death rate was 9% in the PCDE arm versus 5.5% in the EP arm (P =.22).	In the Cox model, the relative risk of death for patients in the PCDE arm compared with those in the EP arm was 0.70 (95% confidence interval = 0.51 to 0.95);
__label__noRel	the toxicity-related death rate was 9% in the PCDE arm versus 5.5% in the EP arm (P =.22).	the disease also progressed more slowly in patients in the PCDE arm.
__label__noRel	the toxicity-related death rate was 9% in the PCDE arm versus 5.5% in the EP arm (P =.22).	Hematologic toxicity was higher in the PCDE arm (22% with documented infections compared with 8% in the EP arm; P =.0038),
__label__noRel	the toxicity-related death rate was 9% in the PCDE arm versus 5.5% in the EP arm (P =.22).	The global health status showed similar improvement in both arms during treatment.
__label__noRel	the toxicity-related death rate was 9% in the PCDE arm versus 5.5% in the EP arm (P =.22).	Compared with the EP regimen, the PCDE regimen yielded higher response rates and better survival rates in patients with extensive SCLC without affecting the quality of life of the patients during chemotherapy.
__label__noRel	The global health status showed similar improvement in both arms during treatment.	The combination of etoposide plus cisplatin (EP) is considered to be standard therapy for small-cell lung cancer (SCLC).
__label__noRel	The global health status showed similar improvement in both arms during treatment.	Patients in the PCDE arm had a statistically significant higher frequency of combined complete plus partial responses compared with those in the EP arm (21% plus 55% versus 13% plus 48%, respectively; P =.02 for difference in combined objective responses).
__label__noRel	The global health status showed similar improvement in both arms during treatment.	Patients in the PCDE arm survived longer than those in the EP arm (1-year survival rate: 40% and 29%, respectively; median survival: 10.5 and 9.3 months, respectively; log-rank P =.0067).
__label__noRel	The global health status showed similar improvement in both arms during treatment.	In the Cox model, the relative risk of death for patients in the PCDE arm compared with those in the EP arm was 0.70 (95% confidence interval = 0.51 to 0.95);
__label__noRel	The global health status showed similar improvement in both arms during treatment.	the disease also progressed more slowly in patients in the PCDE arm.
__label__noRel	The global health status showed similar improvement in both arms during treatment.	Hematologic toxicity was higher in the PCDE arm (22% with documented infections compared with 8% in the EP arm; P =.0038),
__label__noRel	The global health status showed similar improvement in both arms during treatment.	the toxicity-related death rate was 9% in the PCDE arm versus 5.5% in the EP arm (P =.22).
__label__noRel	The global health status showed similar improvement in both arms during treatment.	Compared with the EP regimen, the PCDE regimen yielded higher response rates and better survival rates in patients with extensive SCLC without affecting the quality of life of the patients during chemotherapy.
__label__noRel	Compared with the EP regimen, the PCDE regimen yielded higher response rates and better survival rates in patients with extensive SCLC without affecting the quality of life of the patients during chemotherapy.	The combination of etoposide plus cisplatin (EP) is considered to be standard therapy for small-cell lung cancer (SCLC).
__label__noRel	Compared with the EP regimen, the PCDE regimen yielded higher response rates and better survival rates in patients with extensive SCLC without affecting the quality of life of the patients during chemotherapy.	Patients in the PCDE arm had a statistically significant higher frequency of combined complete plus partial responses compared with those in the EP arm (21% plus 55% versus 13% plus 48%, respectively; P =.02 for difference in combined objective responses).
__label__noRel	Compared with the EP regimen, the PCDE regimen yielded higher response rates and better survival rates in patients with extensive SCLC without affecting the quality of life of the patients during chemotherapy.	Patients in the PCDE arm survived longer than those in the EP arm (1-year survival rate: 40% and 29%, respectively; median survival: 10.5 and 9.3 months, respectively; log-rank P =.0067).
__label__noRel	Compared with the EP regimen, the PCDE regimen yielded higher response rates and better survival rates in patients with extensive SCLC without affecting the quality of life of the patients during chemotherapy.	In the Cox model, the relative risk of death for patients in the PCDE arm compared with those in the EP arm was 0.70 (95% confidence interval = 0.51 to 0.95);
__label__noRel	Compared with the EP regimen, the PCDE regimen yielded higher response rates and better survival rates in patients with extensive SCLC without affecting the quality of life of the patients during chemotherapy.	the disease also progressed more slowly in patients in the PCDE arm.
__label__noRel	Compared with the EP regimen, the PCDE regimen yielded higher response rates and better survival rates in patients with extensive SCLC without affecting the quality of life of the patients during chemotherapy.	Hematologic toxicity was higher in the PCDE arm (22% with documented infections compared with 8% in the EP arm; P =.0038),
__label__noRel	Compared with the EP regimen, the PCDE regimen yielded higher response rates and better survival rates in patients with extensive SCLC without affecting the quality of life of the patients during chemotherapy.	the toxicity-related death rate was 9% in the PCDE arm versus 5.5% in the EP arm (P =.22).
__label__noRel	Compared with the EP regimen, the PCDE regimen yielded higher response rates and better survival rates in patients with extensive SCLC without affecting the quality of life of the patients during chemotherapy.	The global health status showed similar improvement in both arms during treatment.
__label__noRel	A model measuring effectiveness of CCSP on QOL (total and subscale) at 1-year follow-up showed that the CCSP group (n = 38) had significant improvement in overall QOL (p < 0.01), health and functioning (p < 0.05), and socioeconomic (p < 0.05) and psychological/spiritual well-being (p < 0.01) compared with the control group (n = 35).	The CCSP patients frequently used the CCSP to manage psychological (51%) and sleep problems (60%).
__label__noRel	A model measuring effectiveness of CCSP on QOL (total and subscale) at 1-year follow-up showed that the CCSP group (n = 38) had significant improvement in overall QOL (p < 0.01), health and functioning (p < 0.05), and socioeconomic (p < 0.05) and psychological/spiritual well-being (p < 0.01) compared with the control group (n = 35).	The CCSP improved QOL for patients at 1-year follow-up.
__label__noRel	A model measuring effectiveness of CCSP on QOL (total and subscale) at 1-year follow-up showed that the CCSP group (n = 38) had significant improvement in overall QOL (p < 0.01), health and functioning (p < 0.05), and socioeconomic (p < 0.05) and psychological/spiritual well-being (p < 0.01) compared with the control group (n = 35).	Patients overwhelmingly reported that CCSP was beneficial.
__label__Support	A model measuring effectiveness of CCSP on QOL (total and subscale) at 1-year follow-up showed that the CCSP group (n = 38) had significant improvement in overall QOL (p < 0.01), health and functioning (p < 0.05), and socioeconomic (p < 0.05) and psychological/spiritual well-being (p < 0.01) compared with the control group (n = 35).	The CCSP as an effective coping intervention has potential as a self-management program for breast cancer survivors.
__label__noRel	The CCSP patients frequently used the CCSP to manage psychological (51%) and sleep problems (60%).	A model measuring effectiveness of CCSP on QOL (total and subscale) at 1-year follow-up showed that the CCSP group (n = 38) had significant improvement in overall QOL (p < 0.01), health and functioning (p < 0.05), and socioeconomic (p < 0.05) and psychological/spiritual well-being (p < 0.01) compared with the control group (n = 35).
__label__noRel	The CCSP patients frequently used the CCSP to manage psychological (51%) and sleep problems (60%).	The CCSP improved QOL for patients at 1-year follow-up.
__label__noRel	The CCSP patients frequently used the CCSP to manage psychological (51%) and sleep problems (60%).	Patients overwhelmingly reported that CCSP was beneficial.
__label__Support	The CCSP patients frequently used the CCSP to manage psychological (51%) and sleep problems (60%).	The CCSP as an effective coping intervention has potential as a self-management program for breast cancer survivors.
__label__noRel	The CCSP improved QOL for patients at 1-year follow-up.	A model measuring effectiveness of CCSP on QOL (total and subscale) at 1-year follow-up showed that the CCSP group (n = 38) had significant improvement in overall QOL (p < 0.01), health and functioning (p < 0.05), and socioeconomic (p < 0.05) and psychological/spiritual well-being (p < 0.01) compared with the control group (n = 35).
__label__noRel	The CCSP improved QOL for patients at 1-year follow-up.	The CCSP patients frequently used the CCSP to manage psychological (51%) and sleep problems (60%).
__label__noRel	The CCSP improved QOL for patients at 1-year follow-up.	Patients overwhelmingly reported that CCSP was beneficial.
__label__Support	The CCSP improved QOL for patients at 1-year follow-up.	The CCSP as an effective coping intervention has potential as a self-management program for breast cancer survivors.
__label__noRel	Patients overwhelmingly reported that CCSP was beneficial.	A model measuring effectiveness of CCSP on QOL (total and subscale) at 1-year follow-up showed that the CCSP group (n = 38) had significant improvement in overall QOL (p < 0.01), health and functioning (p < 0.05), and socioeconomic (p < 0.05) and psychological/spiritual well-being (p < 0.01) compared with the control group (n = 35).
__label__noRel	Patients overwhelmingly reported that CCSP was beneficial.	The CCSP patients frequently used the CCSP to manage psychological (51%) and sleep problems (60%).
__label__noRel	Patients overwhelmingly reported that CCSP was beneficial.	The CCSP improved QOL for patients at 1-year follow-up.
__label__Support	Patients overwhelmingly reported that CCSP was beneficial.	The CCSP as an effective coping intervention has potential as a self-management program for breast cancer survivors.
__label__noRel	The CCSP as an effective coping intervention has potential as a self-management program for breast cancer survivors.	A model measuring effectiveness of CCSP on QOL (total and subscale) at 1-year follow-up showed that the CCSP group (n = 38) had significant improvement in overall QOL (p < 0.01), health and functioning (p < 0.05), and socioeconomic (p < 0.05) and psychological/spiritual well-being (p < 0.01) compared with the control group (n = 35).
__label__noRel	The CCSP as an effective coping intervention has potential as a self-management program for breast cancer survivors.	The CCSP patients frequently used the CCSP to manage psychological (51%) and sleep problems (60%).
__label__noRel	The CCSP as an effective coping intervention has potential as a self-management program for breast cancer survivors.	The CCSP improved QOL for patients at 1-year follow-up.
__label__noRel	The CCSP as an effective coping intervention has potential as a self-management program for breast cancer survivors.	Patients overwhelmingly reported that CCSP was beneficial.
__label__noRel	Systematic assessment is vital to palliative care	Results showed improved patient depression (P < .001) as a result of the intervention and improvement in both groups in patients' quality of life (P < .001).
__label__noRel	Systematic assessment is vital to palliative care	No other patient outcomes (symptom distress, spiritual needs) or caregiver outcomes (depression, support, spiritual needs) were significantly different.
__label__noRel	Systematic assessment is vital to palliative care	Hospice care was so good during the study that overall quality of life improved as a result of standard care and left little room for improvement in other variables.
__label__noRel	Systematic assessment is vital to palliative care	Systematic assessment of depression is needed in hospice patients.
__label__noRel	Results showed improved patient depression (P < .001) as a result of the intervention and improvement in both groups in patients' quality of life (P < .001).	Systematic assessment is vital to palliative care
__label__noRel	Results showed improved patient depression (P < .001) as a result of the intervention and improvement in both groups in patients' quality of life (P < .001).	No other patient outcomes (symptom distress, spiritual needs) or caregiver outcomes (depression, support, spiritual needs) were significantly different.
__label__noRel	Results showed improved patient depression (P < .001) as a result of the intervention and improvement in both groups in patients' quality of life (P < .001).	Hospice care was so good during the study that overall quality of life improved as a result of standard care and left little room for improvement in other variables.
__label__noRel	Results showed improved patient depression (P < .001) as a result of the intervention and improvement in both groups in patients' quality of life (P < .001).	Systematic assessment of depression is needed in hospice patients.
__label__noRel	No other patient outcomes (symptom distress, spiritual needs) or caregiver outcomes (depression, support, spiritual needs) were significantly different.	Systematic assessment is vital to palliative care
__label__noRel	No other patient outcomes (symptom distress, spiritual needs) or caregiver outcomes (depression, support, spiritual needs) were significantly different.	Results showed improved patient depression (P < .001) as a result of the intervention and improvement in both groups in patients' quality of life (P < .001).
__label__noRel	No other patient outcomes (symptom distress, spiritual needs) or caregiver outcomes (depression, support, spiritual needs) were significantly different.	Hospice care was so good during the study that overall quality of life improved as a result of standard care and left little room for improvement in other variables.
__label__noRel	No other patient outcomes (symptom distress, spiritual needs) or caregiver outcomes (depression, support, spiritual needs) were significantly different.	Systematic assessment of depression is needed in hospice patients.
__label__noRel	Hospice care was so good during the study that overall quality of life improved as a result of standard care and left little room for improvement in other variables.	Systematic assessment is vital to palliative care
__label__noRel	Hospice care was so good during the study that overall quality of life improved as a result of standard care and left little room for improvement in other variables.	Results showed improved patient depression (P < .001) as a result of the intervention and improvement in both groups in patients' quality of life (P < .001).
__label__noRel	Hospice care was so good during the study that overall quality of life improved as a result of standard care and left little room for improvement in other variables.	No other patient outcomes (symptom distress, spiritual needs) or caregiver outcomes (depression, support, spiritual needs) were significantly different.
__label__Support	Hospice care was so good during the study that overall quality of life improved as a result of standard care and left little room for improvement in other variables.	Systematic assessment of depression is needed in hospice patients.
__label__noRel	Systematic assessment of depression is needed in hospice patients.	Systematic assessment is vital to palliative care
__label__noRel	Systematic assessment of depression is needed in hospice patients.	Results showed improved patient depression (P < .001) as a result of the intervention and improvement in both groups in patients' quality of life (P < .001).
__label__noRel	Systematic assessment of depression is needed in hospice patients.	No other patient outcomes (symptom distress, spiritual needs) or caregiver outcomes (depression, support, spiritual needs) were significantly different.
__label__noRel	Systematic assessment of depression is needed in hospice patients.	Hospice care was so good during the study that overall quality of life improved as a result of standard care and left little room for improvement in other variables.
__label__noRel	Median survival was 16.9 months (95% confidence interval [CI], 10.5 to 21.2 months) in the TEE arm and 23.4 months (95% CI, 12.9 to 30.6 months) for patients treated with KA/VE.	Many patients (24%) failed to complete at least 6 weeks of therapy, including five (8%) treatment-related early deaths.
__label__noRel	Median survival was 16.9 months (95% confidence interval [CI], 10.5 to 21.2 months) in the TEE arm and 23.4 months (95% CI, 12.9 to 30.6 months) for patients treated with KA/VE.	Each of these regimens produced clinically significant responses,
__label__Support	Median survival was 16.9 months (95% confidence interval [CI], 10.5 to 21.2 months) in the TEE arm and 23.4 months (95% CI, 12.9 to 30.6 months) for patients treated with KA/VE.	the observed median survival (18.9 months for all 71 patients) compares favorably with previously published results, especially in the community setting.
__label__noRel	Median survival was 16.9 months (95% confidence interval [CI], 10.5 to 21.2 months) in the TEE arm and 23.4 months (95% CI, 12.9 to 30.6 months) for patients treated with KA/VE.	Nonetheless, it is apparent that these first-generation regimens must be applied judiciously,
__label__noRel	Median survival was 16.9 months (95% confidence interval [CI], 10.5 to 21.2 months) in the TEE arm and 23.4 months (95% CI, 12.9 to 30.6 months) for patients treated with KA/VE.	thus we view efforts at better patient selection and the development of more tolerable therapies as higher priorities than carrying either of these regimens to phase III evaluation in the cooperative group setting.
__label__noRel	Many patients (24%) failed to complete at least 6 weeks of therapy, including five (8%) treatment-related early deaths.	Median survival was 16.9 months (95% confidence interval [CI], 10.5 to 21.2 months) in the TEE arm and 23.4 months (95% CI, 12.9 to 30.6 months) for patients treated with KA/VE.
__label__noRel	Many patients (24%) failed to complete at least 6 weeks of therapy, including five (8%) treatment-related early deaths.	Each of these regimens produced clinically significant responses,
__label__noRel	Many patients (24%) failed to complete at least 6 weeks of therapy, including five (8%) treatment-related early deaths.	the observed median survival (18.9 months for all 71 patients) compares favorably with previously published results, especially in the community setting.
__label__noRel	Many patients (24%) failed to complete at least 6 weeks of therapy, including five (8%) treatment-related early deaths.	Nonetheless, it is apparent that these first-generation regimens must be applied judiciously,
__label__noRel	Many patients (24%) failed to complete at least 6 weeks of therapy, including five (8%) treatment-related early deaths.	thus we view efforts at better patient selection and the development of more tolerable therapies as higher priorities than carrying either of these regimens to phase III evaluation in the cooperative group setting.
__label__noRel	Each of these regimens produced clinically significant responses,	Median survival was 16.9 months (95% confidence interval [CI], 10.5 to 21.2 months) in the TEE arm and 23.4 months (95% CI, 12.9 to 30.6 months) for patients treated with KA/VE.
__label__noRel	Each of these regimens produced clinically significant responses,	Many patients (24%) failed to complete at least 6 weeks of therapy, including five (8%) treatment-related early deaths.
__label__Support	Each of these regimens produced clinically significant responses,	the observed median survival (18.9 months for all 71 patients) compares favorably with previously published results, especially in the community setting.
__label__noRel	Each of these regimens produced clinically significant responses,	Nonetheless, it is apparent that these first-generation regimens must be applied judiciously,
__label__noRel	Each of these regimens produced clinically significant responses,	thus we view efforts at better patient selection and the development of more tolerable therapies as higher priorities than carrying either of these regimens to phase III evaluation in the cooperative group setting.
__label__noRel	the observed median survival (18.9 months for all 71 patients) compares favorably with previously published results, especially in the community setting.	Median survival was 16.9 months (95% confidence interval [CI], 10.5 to 21.2 months) in the TEE arm and 23.4 months (95% CI, 12.9 to 30.6 months) for patients treated with KA/VE.
__label__noRel	the observed median survival (18.9 months for all 71 patients) compares favorably with previously published results, especially in the community setting.	Many patients (24%) failed to complete at least 6 weeks of therapy, including five (8%) treatment-related early deaths.
__label__noRel	the observed median survival (18.9 months for all 71 patients) compares favorably with previously published results, especially in the community setting.	Each of these regimens produced clinically significant responses,
__label__noRel	the observed median survival (18.9 months for all 71 patients) compares favorably with previously published results, especially in the community setting.	Nonetheless, it is apparent that these first-generation regimens must be applied judiciously,
__label__noRel	the observed median survival (18.9 months for all 71 patients) compares favorably with previously published results, especially in the community setting.	thus we view efforts at better patient selection and the development of more tolerable therapies as higher priorities than carrying either of these regimens to phase III evaluation in the cooperative group setting.
__label__noRel	Nonetheless, it is apparent that these first-generation regimens must be applied judiciously,	Median survival was 16.9 months (95% confidence interval [CI], 10.5 to 21.2 months) in the TEE arm and 23.4 months (95% CI, 12.9 to 30.6 months) for patients treated with KA/VE.
__label__noRel	Nonetheless, it is apparent that these first-generation regimens must be applied judiciously,	Many patients (24%) failed to complete at least 6 weeks of therapy, including five (8%) treatment-related early deaths.
__label__noRel	Nonetheless, it is apparent that these first-generation regimens must be applied judiciously,	Each of these regimens produced clinically significant responses,
__label__noRel	Nonetheless, it is apparent that these first-generation regimens must be applied judiciously,	the observed median survival (18.9 months for all 71 patients) compares favorably with previously published results, especially in the community setting.
__label__Support	Nonetheless, it is apparent that these first-generation regimens must be applied judiciously,	thus we view efforts at better patient selection and the development of more tolerable therapies as higher priorities than carrying either of these regimens to phase III evaluation in the cooperative group setting.
__label__noRel	thus we view efforts at better patient selection and the development of more tolerable therapies as higher priorities than carrying either of these regimens to phase III evaluation in the cooperative group setting.	Median survival was 16.9 months (95% confidence interval [CI], 10.5 to 21.2 months) in the TEE arm and 23.4 months (95% CI, 12.9 to 30.6 months) for patients treated with KA/VE.
__label__noRel	thus we view efforts at better patient selection and the development of more tolerable therapies as higher priorities than carrying either of these regimens to phase III evaluation in the cooperative group setting.	Many patients (24%) failed to complete at least 6 weeks of therapy, including five (8%) treatment-related early deaths.
__label__noRel	thus we view efforts at better patient selection and the development of more tolerable therapies as higher priorities than carrying either of these regimens to phase III evaluation in the cooperative group setting.	Each of these regimens produced clinically significant responses,
__label__noRel	thus we view efforts at better patient selection and the development of more tolerable therapies as higher priorities than carrying either of these regimens to phase III evaluation in the cooperative group setting.	the observed median survival (18.9 months for all 71 patients) compares favorably with previously published results, especially in the community setting.
__label__noRel	thus we view efforts at better patient selection and the development of more tolerable therapies as higher priorities than carrying either of these regimens to phase III evaluation in the cooperative group setting.	Nonetheless, it is apparent that these first-generation regimens must be applied judiciously,
__label__noRel	According to the Radiation Therapy Oncology Group scale, the Grade 2 or greater rectal toxicity rate was 14% and 19.5% for the 70- and 80-Gy arms (p = .22), respectively.	The Grade 2 or greater urinary toxicity was 10% at 70 Gy and 17.5% at 80 Gy (p = .046).
__label__noRel	According to the Radiation Therapy Oncology Group scale, the Grade 2 or greater rectal toxicity rate was 14% and 19.5% for the 70- and 80-Gy arms (p = .22), respectively.	Bladder toxicity was more frequent at 80 Gy than at 70 Gy (p = .039).
__label__noRel	According to the Radiation Therapy Oncology Group scale, the Grade 2 or greater rectal toxicity rate was 14% and 19.5% for the 70- and 80-Gy arms (p = .22), respectively.	Similar results were observed using the LENT-SOMA scale.
__label__noRel	According to the Radiation Therapy Oncology Group scale, the Grade 2 or greater rectal toxicity rate was 14% and 19.5% for the 70- and 80-Gy arms (p = .22), respectively.	The quality-of-life questionnaire results before and 5 years after treatment were available for 103 patients with no differences found between the 70- and 80-Gy arms.
__label__Support	According to the Radiation Therapy Oncology Group scale, the Grade 2 or greater rectal toxicity rate was 14% and 19.5% for the 70- and 80-Gy arms (p = .22), respectively.	High-dose radiotherapy provided a better 5-year biochemical outcome with slightly greater toxicity.
__label__noRel	The Grade 2 or greater urinary toxicity was 10% at 70 Gy and 17.5% at 80 Gy (p = .046).	According to the Radiation Therapy Oncology Group scale, the Grade 2 or greater rectal toxicity rate was 14% and 19.5% for the 70- and 80-Gy arms (p = .22), respectively.
__label__noRel	The Grade 2 or greater urinary toxicity was 10% at 70 Gy and 17.5% at 80 Gy (p = .046).	Bladder toxicity was more frequent at 80 Gy than at 70 Gy (p = .039).
__label__noRel	The Grade 2 or greater urinary toxicity was 10% at 70 Gy and 17.5% at 80 Gy (p = .046).	Similar results were observed using the LENT-SOMA scale.
__label__noRel	The Grade 2 or greater urinary toxicity was 10% at 70 Gy and 17.5% at 80 Gy (p = .046).	The quality-of-life questionnaire results before and 5 years after treatment were available for 103 patients with no differences found between the 70- and 80-Gy arms.
__label__Attack	The Grade 2 or greater urinary toxicity was 10% at 70 Gy and 17.5% at 80 Gy (p = .046).	High-dose radiotherapy provided a better 5-year biochemical outcome with slightly greater toxicity.
__label__noRel	Bladder toxicity was more frequent at 80 Gy than at 70 Gy (p = .039).	According to the Radiation Therapy Oncology Group scale, the Grade 2 or greater rectal toxicity rate was 14% and 19.5% for the 70- and 80-Gy arms (p = .22), respectively.
__label__noRel	Bladder toxicity was more frequent at 80 Gy than at 70 Gy (p = .039).	The Grade 2 or greater urinary toxicity was 10% at 70 Gy and 17.5% at 80 Gy (p = .046).
__label__noRel	Bladder toxicity was more frequent at 80 Gy than at 70 Gy (p = .039).	Similar results were observed using the LENT-SOMA scale.
__label__noRel	Bladder toxicity was more frequent at 80 Gy than at 70 Gy (p = .039).	The quality-of-life questionnaire results before and 5 years after treatment were available for 103 patients with no differences found between the 70- and 80-Gy arms.
__label__Support	Bladder toxicity was more frequent at 80 Gy than at 70 Gy (p = .039).	High-dose radiotherapy provided a better 5-year biochemical outcome with slightly greater toxicity.
__label__noRel	Similar results were observed using the LENT-SOMA scale.	According to the Radiation Therapy Oncology Group scale, the Grade 2 or greater rectal toxicity rate was 14% and 19.5% for the 70- and 80-Gy arms (p = .22), respectively.
__label__noRel	Similar results were observed using the LENT-SOMA scale.	The Grade 2 or greater urinary toxicity was 10% at 70 Gy and 17.5% at 80 Gy (p = .046).
__label__noRel	Similar results were observed using the LENT-SOMA scale.	Bladder toxicity was more frequent at 80 Gy than at 70 Gy (p = .039).
__label__noRel	Similar results were observed using the LENT-SOMA scale.	The quality-of-life questionnaire results before and 5 years after treatment were available for 103 patients with no differences found between the 70- and 80-Gy arms.
__label__noRel	Similar results were observed using the LENT-SOMA scale.	High-dose radiotherapy provided a better 5-year biochemical outcome with slightly greater toxicity.
__label__noRel	The quality-of-life questionnaire results before and 5 years after treatment were available for 103 patients with no differences found between the 70- and 80-Gy arms.	According to the Radiation Therapy Oncology Group scale, the Grade 2 or greater rectal toxicity rate was 14% and 19.5% for the 70- and 80-Gy arms (p = .22), respectively.
__label__noRel	The quality-of-life questionnaire results before and 5 years after treatment were available for 103 patients with no differences found between the 70- and 80-Gy arms.	The Grade 2 or greater urinary toxicity was 10% at 70 Gy and 17.5% at 80 Gy (p = .046).
__label__noRel	The quality-of-life questionnaire results before and 5 years after treatment were available for 103 patients with no differences found between the 70- and 80-Gy arms.	Bladder toxicity was more frequent at 80 Gy than at 70 Gy (p = .039).
__label__noRel	The quality-of-life questionnaire results before and 5 years after treatment were available for 103 patients with no differences found between the 70- and 80-Gy arms.	Similar results were observed using the LENT-SOMA scale.
__label__noRel	The quality-of-life questionnaire results before and 5 years after treatment were available for 103 patients with no differences found between the 70- and 80-Gy arms.	High-dose radiotherapy provided a better 5-year biochemical outcome with slightly greater toxicity.
__label__noRel	High-dose radiotherapy provided a better 5-year biochemical outcome with slightly greater toxicity.	According to the Radiation Therapy Oncology Group scale, the Grade 2 or greater rectal toxicity rate was 14% and 19.5% for the 70- and 80-Gy arms (p = .22), respectively.
__label__noRel	High-dose radiotherapy provided a better 5-year biochemical outcome with slightly greater toxicity.	The Grade 2 or greater urinary toxicity was 10% at 70 Gy and 17.5% at 80 Gy (p = .046).
__label__noRel	High-dose radiotherapy provided a better 5-year biochemical outcome with slightly greater toxicity.	Bladder toxicity was more frequent at 80 Gy than at 70 Gy (p = .039).
__label__noRel	High-dose radiotherapy provided a better 5-year biochemical outcome with slightly greater toxicity.	Similar results were observed using the LENT-SOMA scale.
__label__noRel	High-dose radiotherapy provided a better 5-year biochemical outcome with slightly greater toxicity.	The quality-of-life questionnaire results before and 5 years after treatment were available for 103 patients with no differences found between the 70- and 80-Gy arms.
__label__noRel	There was a significant survival advantage for GCa compared with MIC (hazard ratio, 0.76; 95% CI, 0.61 to 0. 93; P = .008).	Median survival was 10 months with GCa and 7.6 months with MIC (difference, 2.4 months; 95% CI, 1.0 to 4.0), and 1-year survival was 40% with GCa and 30% with MIC (difference, 10%; 95% CI, 3% to 18%).
__label__noRel	There was a significant survival advantage for GCa compared with MIC (hazard ratio, 0.76; 95% CI, 0.61 to 0. 93; P = .008).	Overall response rates were similar (42% for GCa v 41% for MIC; P = .84).
__label__noRel	There was a significant survival advantage for GCa compared with MIC (hazard ratio, 0.76; 95% CI, 0.61 to 0. 93; P = .008).	More thrombocytopenia occurred with GCa (P = .03),
__label__noRel	There was a significant survival advantage for GCa compared with MIC (hazard ratio, 0.76; 95% CI, 0.61 to 0. 93; P = .008).	but this was not associated with increased hospital admission or fatality.
__label__noRel	There was a significant survival advantage for GCa compared with MIC (hazard ratio, 0.76; 95% CI, 0.61 to 0. 93; P = .008).	GCa caused less nausea, vomiting, constipation, and alopecia and was associated with fewer admissions for administration and better quality of life.
__label__Support	There was a significant survival advantage for GCa compared with MIC (hazard ratio, 0.76; 95% CI, 0.61 to 0. 93; P = .008).	In patients with advanced NSCLC, GCa chemotherapy was shown to be a better-tolerated treatment that conferred a survival advantage over MIC.
__label__noRel	Median survival was 10 months with GCa and 7.6 months with MIC (difference, 2.4 months; 95% CI, 1.0 to 4.0), and 1-year survival was 40% with GCa and 30% with MIC (difference, 10%; 95% CI, 3% to 18%).	There was a significant survival advantage for GCa compared with MIC (hazard ratio, 0.76; 95% CI, 0.61 to 0. 93; P = .008).
__label__noRel	Median survival was 10 months with GCa and 7.6 months with MIC (difference, 2.4 months; 95% CI, 1.0 to 4.0), and 1-year survival was 40% with GCa and 30% with MIC (difference, 10%; 95% CI, 3% to 18%).	Overall response rates were similar (42% for GCa v 41% for MIC; P = .84).
__label__noRel	Median survival was 10 months with GCa and 7.6 months with MIC (difference, 2.4 months; 95% CI, 1.0 to 4.0), and 1-year survival was 40% with GCa and 30% with MIC (difference, 10%; 95% CI, 3% to 18%).	More thrombocytopenia occurred with GCa (P = .03),
__label__noRel	Median survival was 10 months with GCa and 7.6 months with MIC (difference, 2.4 months; 95% CI, 1.0 to 4.0), and 1-year survival was 40% with GCa and 30% with MIC (difference, 10%; 95% CI, 3% to 18%).	but this was not associated with increased hospital admission or fatality.
__label__noRel	Median survival was 10 months with GCa and 7.6 months with MIC (difference, 2.4 months; 95% CI, 1.0 to 4.0), and 1-year survival was 40% with GCa and 30% with MIC (difference, 10%; 95% CI, 3% to 18%).	GCa caused less nausea, vomiting, constipation, and alopecia and was associated with fewer admissions for administration and better quality of life.
__label__Support	Median survival was 10 months with GCa and 7.6 months with MIC (difference, 2.4 months; 95% CI, 1.0 to 4.0), and 1-year survival was 40% with GCa and 30% with MIC (difference, 10%; 95% CI, 3% to 18%).	In patients with advanced NSCLC, GCa chemotherapy was shown to be a better-tolerated treatment that conferred a survival advantage over MIC.
__label__noRel	Overall response rates were similar (42% for GCa v 41% for MIC; P = .84).	There was a significant survival advantage for GCa compared with MIC (hazard ratio, 0.76; 95% CI, 0.61 to 0. 93; P = .008).
__label__noRel	Overall response rates were similar (42% for GCa v 41% for MIC; P = .84).	Median survival was 10 months with GCa and 7.6 months with MIC (difference, 2.4 months; 95% CI, 1.0 to 4.0), and 1-year survival was 40% with GCa and 30% with MIC (difference, 10%; 95% CI, 3% to 18%).
__label__noRel	Overall response rates were similar (42% for GCa v 41% for MIC; P = .84).	More thrombocytopenia occurred with GCa (P = .03),
__label__noRel	Overall response rates were similar (42% for GCa v 41% for MIC; P = .84).	but this was not associated with increased hospital admission or fatality.
__label__noRel	Overall response rates were similar (42% for GCa v 41% for MIC; P = .84).	GCa caused less nausea, vomiting, constipation, and alopecia and was associated with fewer admissions for administration and better quality of life.
__label__noRel	Overall response rates were similar (42% for GCa v 41% for MIC; P = .84).	In patients with advanced NSCLC, GCa chemotherapy was shown to be a better-tolerated treatment that conferred a survival advantage over MIC.
__label__noRel	More thrombocytopenia occurred with GCa (P = .03),	There was a significant survival advantage for GCa compared with MIC (hazard ratio, 0.76; 95% CI, 0.61 to 0. 93; P = .008).
__label__noRel	More thrombocytopenia occurred with GCa (P = .03),	Median survival was 10 months with GCa and 7.6 months with MIC (difference, 2.4 months; 95% CI, 1.0 to 4.0), and 1-year survival was 40% with GCa and 30% with MIC (difference, 10%; 95% CI, 3% to 18%).
__label__noRel	More thrombocytopenia occurred with GCa (P = .03),	Overall response rates were similar (42% for GCa v 41% for MIC; P = .84).
__label__noRel	More thrombocytopenia occurred with GCa (P = .03),	but this was not associated with increased hospital admission or fatality.
__label__noRel	More thrombocytopenia occurred with GCa (P = .03),	GCa caused less nausea, vomiting, constipation, and alopecia and was associated with fewer admissions for administration and better quality of life.
__label__noRel	More thrombocytopenia occurred with GCa (P = .03),	In patients with advanced NSCLC, GCa chemotherapy was shown to be a better-tolerated treatment that conferred a survival advantage over MIC.
__label__noRel	but this was not associated with increased hospital admission or fatality.	There was a significant survival advantage for GCa compared with MIC (hazard ratio, 0.76; 95% CI, 0.61 to 0. 93; P = .008).
__label__noRel	but this was not associated with increased hospital admission or fatality.	Median survival was 10 months with GCa and 7.6 months with MIC (difference, 2.4 months; 95% CI, 1.0 to 4.0), and 1-year survival was 40% with GCa and 30% with MIC (difference, 10%; 95% CI, 3% to 18%).
__label__noRel	but this was not associated with increased hospital admission or fatality.	Overall response rates were similar (42% for GCa v 41% for MIC; P = .84).
__label__Attack	but this was not associated with increased hospital admission or fatality.	More thrombocytopenia occurred with GCa (P = .03),
__label__noRel	but this was not associated with increased hospital admission or fatality.	GCa caused less nausea, vomiting, constipation, and alopecia and was associated with fewer admissions for administration and better quality of life.
__label__noRel	but this was not associated with increased hospital admission or fatality.	In patients with advanced NSCLC, GCa chemotherapy was shown to be a better-tolerated treatment that conferred a survival advantage over MIC.
__label__noRel	GCa caused less nausea, vomiting, constipation, and alopecia and was associated with fewer admissions for administration and better quality of life.	There was a significant survival advantage for GCa compared with MIC (hazard ratio, 0.76; 95% CI, 0.61 to 0. 93; P = .008).
__label__noRel	GCa caused less nausea, vomiting, constipation, and alopecia and was associated with fewer admissions for administration and better quality of life.	Median survival was 10 months with GCa and 7.6 months with MIC (difference, 2.4 months; 95% CI, 1.0 to 4.0), and 1-year survival was 40% with GCa and 30% with MIC (difference, 10%; 95% CI, 3% to 18%).
__label__noRel	GCa caused less nausea, vomiting, constipation, and alopecia and was associated with fewer admissions for administration and better quality of life.	Overall response rates were similar (42% for GCa v 41% for MIC; P = .84).
__label__noRel	GCa caused less nausea, vomiting, constipation, and alopecia and was associated with fewer admissions for administration and better quality of life.	More thrombocytopenia occurred with GCa (P = .03),
__label__noRel	GCa caused less nausea, vomiting, constipation, and alopecia and was associated with fewer admissions for administration and better quality of life.	but this was not associated with increased hospital admission or fatality.
__label__Support	GCa caused less nausea, vomiting, constipation, and alopecia and was associated with fewer admissions for administration and better quality of life.	In patients with advanced NSCLC, GCa chemotherapy was shown to be a better-tolerated treatment that conferred a survival advantage over MIC.
__label__noRel	In patients with advanced NSCLC, GCa chemotherapy was shown to be a better-tolerated treatment that conferred a survival advantage over MIC.	There was a significant survival advantage for GCa compared with MIC (hazard ratio, 0.76; 95% CI, 0.61 to 0. 93; P = .008).
__label__noRel	In patients with advanced NSCLC, GCa chemotherapy was shown to be a better-tolerated treatment that conferred a survival advantage over MIC.	Median survival was 10 months with GCa and 7.6 months with MIC (difference, 2.4 months; 95% CI, 1.0 to 4.0), and 1-year survival was 40% with GCa and 30% with MIC (difference, 10%; 95% CI, 3% to 18%).
__label__noRel	In patients with advanced NSCLC, GCa chemotherapy was shown to be a better-tolerated treatment that conferred a survival advantage over MIC.	Overall response rates were similar (42% for GCa v 41% for MIC; P = .84).
__label__noRel	In patients with advanced NSCLC, GCa chemotherapy was shown to be a better-tolerated treatment that conferred a survival advantage over MIC.	More thrombocytopenia occurred with GCa (P = .03),
__label__noRel	In patients with advanced NSCLC, GCa chemotherapy was shown to be a better-tolerated treatment that conferred a survival advantage over MIC.	but this was not associated with increased hospital admission or fatality.
__label__noRel	In patients with advanced NSCLC, GCa chemotherapy was shown to be a better-tolerated treatment that conferred a survival advantage over MIC.	GCa caused less nausea, vomiting, constipation, and alopecia and was associated with fewer admissions for administration and better quality of life.
__label__noRel	Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy,	oral 5-FU derivatives have been shown a comparable antitumor activity.
__label__noRel	Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy,	Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate.
__label__noRel	Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy,	Mean numbers of chemotherapy cycles were 6.5+/-3.7 (IV arm) vs. 7.2+/-4.3 (oral arm), respectively.
__label__noRel	Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy,	The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5 %) in the oral arm, respectively (P = .937).
__label__noRel	Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy,	Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II; 1.1%) in the oral arm, respectively.
__label__noRel	Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy,	Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively.
__label__noRel	Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy,	The most common site of systemic recurrence was the liver.
__label__noRel	Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy,	Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm.
__label__noRel	Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy,	Diarrhea was more common in the oral arm.
__label__noRel	Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy,	Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy.
__label__noRel	Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy,	Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P<.05).
__label__noRel	Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy,	Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy.
__label__noRel	Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy,	The oral regimen also can be safely given with appropriate toxicity and tolerability.
__label__noRel	oral 5-FU derivatives have been shown a comparable antitumor activity.	Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy,
__label__noRel	oral 5-FU derivatives have been shown a comparable antitumor activity.	Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate.
__label__noRel	oral 5-FU derivatives have been shown a comparable antitumor activity.	Mean numbers of chemotherapy cycles were 6.5+/-3.7 (IV arm) vs. 7.2+/-4.3 (oral arm), respectively.
__label__noRel	oral 5-FU derivatives have been shown a comparable antitumor activity.	The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5 %) in the oral arm, respectively (P = .937).
__label__noRel	oral 5-FU derivatives have been shown a comparable antitumor activity.	Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II; 1.1%) in the oral arm, respectively.
__label__noRel	oral 5-FU derivatives have been shown a comparable antitumor activity.	Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively.
__label__noRel	oral 5-FU derivatives have been shown a comparable antitumor activity.	The most common site of systemic recurrence was the liver.
__label__noRel	oral 5-FU derivatives have been shown a comparable antitumor activity.	Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm.
__label__noRel	oral 5-FU derivatives have been shown a comparable antitumor activity.	Diarrhea was more common in the oral arm.
__label__noRel	oral 5-FU derivatives have been shown a comparable antitumor activity.	Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy.
__label__noRel	oral 5-FU derivatives have been shown a comparable antitumor activity.	Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P<.05).
__label__noRel	oral 5-FU derivatives have been shown a comparable antitumor activity.	Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy.
__label__noRel	oral 5-FU derivatives have been shown a comparable antitumor activity.	The oral regimen also can be safely given with appropriate toxicity and tolerability.
__label__noRel	Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate.	Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy,
__label__noRel	Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate.	oral 5-FU derivatives have been shown a comparable antitumor activity.
__label__noRel	Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate.	Mean numbers of chemotherapy cycles were 6.5+/-3.7 (IV arm) vs. 7.2+/-4.3 (oral arm), respectively.
__label__noRel	Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate.	The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5 %) in the oral arm, respectively (P = .937).
__label__noRel	Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate.	Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II; 1.1%) in the oral arm, respectively.
__label__noRel	Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate.	Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively.
__label__noRel	Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate.	The most common site of systemic recurrence was the liver.
__label__noRel	Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate.	Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm.
__label__noRel	Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate.	Diarrhea was more common in the oral arm.
__label__noRel	Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate.	Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy.
__label__noRel	Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate.	Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P<.05).
__label__noRel	Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate.	Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy.
__label__noRel	Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate.	The oral regimen also can be safely given with appropriate toxicity and tolerability.
__label__noRel	Mean numbers of chemotherapy cycles were 6.5+/-3.7 (IV arm) vs. 7.2+/-4.3 (oral arm), respectively.	Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy,
__label__noRel	Mean numbers of chemotherapy cycles were 6.5+/-3.7 (IV arm) vs. 7.2+/-4.3 (oral arm), respectively.	oral 5-FU derivatives have been shown a comparable antitumor activity.
__label__noRel	Mean numbers of chemotherapy cycles were 6.5+/-3.7 (IV arm) vs. 7.2+/-4.3 (oral arm), respectively.	Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate.
__label__noRel	Mean numbers of chemotherapy cycles were 6.5+/-3.7 (IV arm) vs. 7.2+/-4.3 (oral arm), respectively.	The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5 %) in the oral arm, respectively (P = .937).
__label__noRel	Mean numbers of chemotherapy cycles were 6.5+/-3.7 (IV arm) vs. 7.2+/-4.3 (oral arm), respectively.	Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II; 1.1%) in the oral arm, respectively.
__label__noRel	Mean numbers of chemotherapy cycles were 6.5+/-3.7 (IV arm) vs. 7.2+/-4.3 (oral arm), respectively.	Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively.
__label__noRel	Mean numbers of chemotherapy cycles were 6.5+/-3.7 (IV arm) vs. 7.2+/-4.3 (oral arm), respectively.	The most common site of systemic recurrence was the liver.
__label__noRel	Mean numbers of chemotherapy cycles were 6.5+/-3.7 (IV arm) vs. 7.2+/-4.3 (oral arm), respectively.	Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm.
__label__noRel	Mean numbers of chemotherapy cycles were 6.5+/-3.7 (IV arm) vs. 7.2+/-4.3 (oral arm), respectively.	Diarrhea was more common in the oral arm.
__label__noRel	Mean numbers of chemotherapy cycles were 6.5+/-3.7 (IV arm) vs. 7.2+/-4.3 (oral arm), respectively.	Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy.
__label__noRel	Mean numbers of chemotherapy cycles were 6.5+/-3.7 (IV arm) vs. 7.2+/-4.3 (oral arm), respectively.	Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P<.05).
__label__Support	Mean numbers of chemotherapy cycles were 6.5+/-3.7 (IV arm) vs. 7.2+/-4.3 (oral arm), respectively.	Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy.
__label__noRel	Mean numbers of chemotherapy cycles were 6.5+/-3.7 (IV arm) vs. 7.2+/-4.3 (oral arm), respectively.	The oral regimen also can be safely given with appropriate toxicity and tolerability.
__label__noRel	The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5 %) in the oral arm, respectively (P = .937).	Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy,
__label__noRel	The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5 %) in the oral arm, respectively (P = .937).	oral 5-FU derivatives have been shown a comparable antitumor activity.
__label__noRel	The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5 %) in the oral arm, respectively (P = .937).	Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate.
__label__noRel	The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5 %) in the oral arm, respectively (P = .937).	Mean numbers of chemotherapy cycles were 6.5+/-3.7 (IV arm) vs. 7.2+/-4.3 (oral arm), respectively.
__label__noRel	The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5 %) in the oral arm, respectively (P = .937).	Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II; 1.1%) in the oral arm, respectively.
__label__noRel	The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5 %) in the oral arm, respectively (P = .937).	Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively.
__label__noRel	The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5 %) in the oral arm, respectively (P = .937).	The most common site of systemic recurrence was the liver.
__label__noRel	The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5 %) in the oral arm, respectively (P = .937).	Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm.
__label__noRel	The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5 %) in the oral arm, respectively (P = .937).	Diarrhea was more common in the oral arm.
__label__noRel	The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5 %) in the oral arm, respectively (P = .937).	Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy.
__label__noRel	The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5 %) in the oral arm, respectively (P = .937).	Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P<.05).
__label__Support	The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5 %) in the oral arm, respectively (P = .937).	Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy.
__label__noRel	The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5 %) in the oral arm, respectively (P = .937).	The oral regimen also can be safely given with appropriate toxicity and tolerability.
__label__noRel	Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II; 1.1%) in the oral arm, respectively.	Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy,
__label__noRel	Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II; 1.1%) in the oral arm, respectively.	oral 5-FU derivatives have been shown a comparable antitumor activity.
__label__noRel	Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II; 1.1%) in the oral arm, respectively.	Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate.
__label__noRel	Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II; 1.1%) in the oral arm, respectively.	Mean numbers of chemotherapy cycles were 6.5+/-3.7 (IV arm) vs. 7.2+/-4.3 (oral arm), respectively.
__label__noRel	Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II; 1.1%) in the oral arm, respectively.	The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5 %) in the oral arm, respectively (P = .937).
__label__noRel	Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II; 1.1%) in the oral arm, respectively.	Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively.
__label__noRel	Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II; 1.1%) in the oral arm, respectively.	The most common site of systemic recurrence was the liver.
__label__noRel	Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II; 1.1%) in the oral arm, respectively.	Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm.
__label__noRel	Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II; 1.1%) in the oral arm, respectively.	Diarrhea was more common in the oral arm.
__label__noRel	Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II; 1.1%) in the oral arm, respectively.	Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy.
__label__noRel	Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II; 1.1%) in the oral arm, respectively.	Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P<.05).
__label__Support	Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II; 1.1%) in the oral arm, respectively.	Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy.
__label__noRel	Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II; 1.1%) in the oral arm, respectively.	The oral regimen also can be safely given with appropriate toxicity and tolerability.
__label__noRel	Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively.	Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy,
__label__noRel	Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively.	oral 5-FU derivatives have been shown a comparable antitumor activity.
__label__noRel	Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively.	Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate.
__label__noRel	Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively.	Mean numbers of chemotherapy cycles were 6.5+/-3.7 (IV arm) vs. 7.2+/-4.3 (oral arm), respectively.
__label__noRel	Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively.	The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5 %) in the oral arm, respectively (P = .937).
__label__noRel	Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively.	Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II; 1.1%) in the oral arm, respectively.
__label__noRel	Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively.	The most common site of systemic recurrence was the liver.
__label__noRel	Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively.	Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm.
__label__noRel	Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively.	Diarrhea was more common in the oral arm.
__label__noRel	Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively.	Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy.
__label__noRel	Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively.	Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P<.05).
__label__Support	Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively.	Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy.
__label__noRel	Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively.	The oral regimen also can be safely given with appropriate toxicity and tolerability.
__label__noRel	The most common site of systemic recurrence was the liver.	Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy,
__label__noRel	The most common site of systemic recurrence was the liver.	oral 5-FU derivatives have been shown a comparable antitumor activity.
__label__noRel	The most common site of systemic recurrence was the liver.	Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate.
__label__noRel	The most common site of systemic recurrence was the liver.	Mean numbers of chemotherapy cycles were 6.5+/-3.7 (IV arm) vs. 7.2+/-4.3 (oral arm), respectively.
__label__noRel	The most common site of systemic recurrence was the liver.	The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5 %) in the oral arm, respectively (P = .937).
__label__noRel	The most common site of systemic recurrence was the liver.	Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II; 1.1%) in the oral arm, respectively.
__label__noRel	The most common site of systemic recurrence was the liver.	Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively.
__label__noRel	The most common site of systemic recurrence was the liver.	Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm.
__label__noRel	The most common site of systemic recurrence was the liver.	Diarrhea was more common in the oral arm.
__label__noRel	The most common site of systemic recurrence was the liver.	Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy.
__label__noRel	The most common site of systemic recurrence was the liver.	Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P<.05).
__label__noRel	The most common site of systemic recurrence was the liver.	Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy.
__label__noRel	The most common site of systemic recurrence was the liver.	The oral regimen also can be safely given with appropriate toxicity and tolerability.
__label__noRel	Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm.	Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy,
__label__noRel	Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm.	oral 5-FU derivatives have been shown a comparable antitumor activity.
__label__noRel	Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm.	Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate.
__label__noRel	Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm.	Mean numbers of chemotherapy cycles were 6.5+/-3.7 (IV arm) vs. 7.2+/-4.3 (oral arm), respectively.
__label__noRel	Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm.	The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5 %) in the oral arm, respectively (P = .937).
__label__noRel	Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm.	Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II; 1.1%) in the oral arm, respectively.
__label__noRel	Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm.	Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively.
__label__noRel	Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm.	The most common site of systemic recurrence was the liver.
__label__noRel	Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm.	Diarrhea was more common in the oral arm.
__label__noRel	Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm.	Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy.
__label__noRel	Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm.	Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P<.05).
__label__noRel	Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm.	Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy.
__label__Support	Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm.	The oral regimen also can be safely given with appropriate toxicity and tolerability.
__label__noRel	Diarrhea was more common in the oral arm.	Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy,
__label__noRel	Diarrhea was more common in the oral arm.	oral 5-FU derivatives have been shown a comparable antitumor activity.
__label__noRel	Diarrhea was more common in the oral arm.	Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate.
__label__noRel	Diarrhea was more common in the oral arm.	Mean numbers of chemotherapy cycles were 6.5+/-3.7 (IV arm) vs. 7.2+/-4.3 (oral arm), respectively.
__label__noRel	Diarrhea was more common in the oral arm.	The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5 %) in the oral arm, respectively (P = .937).
__label__noRel	Diarrhea was more common in the oral arm.	Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II; 1.1%) in the oral arm, respectively.
__label__noRel	Diarrhea was more common in the oral arm.	Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively.
__label__noRel	Diarrhea was more common in the oral arm.	The most common site of systemic recurrence was the liver.
__label__noRel	Diarrhea was more common in the oral arm.	Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm.
__label__noRel	Diarrhea was more common in the oral arm.	Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy.
__label__noRel	Diarrhea was more common in the oral arm.	Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P<.05).
__label__noRel	Diarrhea was more common in the oral arm.	Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy.
__label__Support	Diarrhea was more common in the oral arm.	The oral regimen also can be safely given with appropriate toxicity and tolerability.
__label__noRel	Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy.	Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy,
__label__noRel	Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy.	oral 5-FU derivatives have been shown a comparable antitumor activity.
__label__noRel	Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy.	Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate.
__label__noRel	Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy.	Mean numbers of chemotherapy cycles were 6.5+/-3.7 (IV arm) vs. 7.2+/-4.3 (oral arm), respectively.
__label__noRel	Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy.	The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5 %) in the oral arm, respectively (P = .937).
__label__noRel	Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy.	Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II; 1.1%) in the oral arm, respectively.
__label__noRel	Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy.	Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively.
__label__noRel	Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy.	The most common site of systemic recurrence was the liver.
__label__noRel	Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy.	Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm.
__label__noRel	Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy.	Diarrhea was more common in the oral arm.
__label__noRel	Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy.	Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P<.05).
__label__Support	Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy.	Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy.
__label__noRel	Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy.	The oral regimen also can be safely given with appropriate toxicity and tolerability.
__label__noRel	Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P<.05).	Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy,
__label__noRel	Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P<.05).	oral 5-FU derivatives have been shown a comparable antitumor activity.
__label__noRel	Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P<.05).	Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate.
__label__noRel	Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P<.05).	Mean numbers of chemotherapy cycles were 6.5+/-3.7 (IV arm) vs. 7.2+/-4.3 (oral arm), respectively.
__label__noRel	Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P<.05).	The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5 %) in the oral arm, respectively (P = .937).
__label__noRel	Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P<.05).	Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II; 1.1%) in the oral arm, respectively.
__label__noRel	Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P<.05).	Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively.
__label__noRel	Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P<.05).	The most common site of systemic recurrence was the liver.
__label__noRel	Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P<.05).	Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm.
__label__noRel	Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P<.05).	Diarrhea was more common in the oral arm.
__label__noRel	Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P<.05).	Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy.
__label__Support	Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P<.05).	Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy.
__label__noRel	Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P<.05).	The oral regimen also can be safely given with appropriate toxicity and tolerability.
__label__noRel	Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy.	Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy,
__label__noRel	Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy.	oral 5-FU derivatives have been shown a comparable antitumor activity.
__label__noRel	Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy.	Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate.
__label__noRel	Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy.	Mean numbers of chemotherapy cycles were 6.5+/-3.7 (IV arm) vs. 7.2+/-4.3 (oral arm), respectively.
__label__noRel	Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy.	The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5 %) in the oral arm, respectively (P = .937).
__label__noRel	Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy.	Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II; 1.1%) in the oral arm, respectively.
__label__noRel	Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy.	Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively.
__label__noRel	Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy.	The most common site of systemic recurrence was the liver.
__label__noRel	Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy.	Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm.
__label__noRel	Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy.	Diarrhea was more common in the oral arm.
__label__noRel	Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy.	Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy.
__label__noRel	Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy.	Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P<.05).
__label__Support	Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy.	The oral regimen also can be safely given with appropriate toxicity and tolerability.
__label__noRel	The oral regimen also can be safely given with appropriate toxicity and tolerability.	Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy,
__label__noRel	The oral regimen also can be safely given with appropriate toxicity and tolerability.	oral 5-FU derivatives have been shown a comparable antitumor activity.
__label__noRel	The oral regimen also can be safely given with appropriate toxicity and tolerability.	Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate.
__label__noRel	The oral regimen also can be safely given with appropriate toxicity and tolerability.	Mean numbers of chemotherapy cycles were 6.5+/-3.7 (IV arm) vs. 7.2+/-4.3 (oral arm), respectively.
__label__noRel	The oral regimen also can be safely given with appropriate toxicity and tolerability.	The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5 %) in the oral arm, respectively (P = .937).
__label__noRel	The oral regimen also can be safely given with appropriate toxicity and tolerability.	Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II; 1.1%) in the oral arm, respectively.
__label__noRel	The oral regimen also can be safely given with appropriate toxicity and tolerability.	Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively.
__label__noRel	The oral regimen also can be safely given with appropriate toxicity and tolerability.	The most common site of systemic recurrence was the liver.
__label__noRel	The oral regimen also can be safely given with appropriate toxicity and tolerability.	Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm.
__label__noRel	The oral regimen also can be safely given with appropriate toxicity and tolerability.	Diarrhea was more common in the oral arm.
__label__noRel	The oral regimen also can be safely given with appropriate toxicity and tolerability.	Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy.
__label__noRel	The oral regimen also can be safely given with appropriate toxicity and tolerability.	Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P<.05).
__label__noRel	The oral regimen also can be safely given with appropriate toxicity and tolerability.	Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy.
__label__noRel	These results provide further support for the efficacy of abiraterone in this population.	Abiraterone acetate plus prednisone significantly improves radiographic progression-free survival in asymptomatic or mildly symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer compared with prednisone alone.
__label__noRel	These results provide further support for the efficacy of abiraterone in this population.	Abiraterone plus prednisone delays patient-reported pain progression and HRQoL deterioration in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
__label__noRel	These results provide further support for the efficacy of abiraterone in this population.	Median time to HRQoL deterioration was longer in patients assigned to abiraterone plus prednisone than in those assigned to placebo plus prednisone as assessed by the FACT-P total score (127 months [95% CI 111-140] vs 83 months [74-106]; HR 078, 95% CI 066-092; p=0003) and by the score on its prostate-cancer-specific subscale (111 months [86-138] vs 58 months [55-83]; HR 070, 95% CI 060-083; p<00001).
__label__noRel	These results provide further support for the efficacy of abiraterone in this population.	Median time to progression of worst pain was also longer with abiraterone plus prednisone (267 months [95% CI 194-not estimable]) than with placebo plus prednisone (194 months [166-not estimable]), but the difference was not significant (HR 085, 95% CI 069-104; p=0109).
__label__noRel	These results provide further support for the efficacy of abiraterone in this population.	Median time to progression of mean pain intensity was longer in patients assigned to abiraterone plus prednisone (267 months [95% CI 193-not estimable]) than in those assigned to placebo plus prednisone (184 months [149-not estimable]; hazard ratio [HR] 082, 95% CI 067-100; p=00490), as was median time to progression of pain interference with daily activities (103 months [95% CI 93-130] vs 74 months [64-86]; HR 079, 95% CI 067-093; p=0005).
__label__noRel	Abiraterone acetate plus prednisone significantly improves radiographic progression-free survival in asymptomatic or mildly symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer compared with prednisone alone.	These results provide further support for the efficacy of abiraterone in this population.
__label__noRel	Abiraterone acetate plus prednisone significantly improves radiographic progression-free survival in asymptomatic or mildly symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer compared with prednisone alone.	Abiraterone plus prednisone delays patient-reported pain progression and HRQoL deterioration in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
__label__noRel	Abiraterone acetate plus prednisone significantly improves radiographic progression-free survival in asymptomatic or mildly symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer compared with prednisone alone.	Median time to HRQoL deterioration was longer in patients assigned to abiraterone plus prednisone than in those assigned to placebo plus prednisone as assessed by the FACT-P total score (127 months [95% CI 111-140] vs 83 months [74-106]; HR 078, 95% CI 066-092; p=0003) and by the score on its prostate-cancer-specific subscale (111 months [86-138] vs 58 months [55-83]; HR 070, 95% CI 060-083; p<00001).
__label__noRel	Abiraterone acetate plus prednisone significantly improves radiographic progression-free survival in asymptomatic or mildly symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer compared with prednisone alone.	Median time to progression of worst pain was also longer with abiraterone plus prednisone (267 months [95% CI 194-not estimable]) than with placebo plus prednisone (194 months [166-not estimable]), but the difference was not significant (HR 085, 95% CI 069-104; p=0109).
__label__noRel	Abiraterone acetate plus prednisone significantly improves radiographic progression-free survival in asymptomatic or mildly symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer compared with prednisone alone.	Median time to progression of mean pain intensity was longer in patients assigned to abiraterone plus prednisone (267 months [95% CI 193-not estimable]) than in those assigned to placebo plus prednisone (184 months [149-not estimable]; hazard ratio [HR] 082, 95% CI 067-100; p=00490), as was median time to progression of pain interference with daily activities (103 months [95% CI 93-130] vs 74 months [64-86]; HR 079, 95% CI 067-093; p=0005).
__label__Support	Abiraterone plus prednisone delays patient-reported pain progression and HRQoL deterioration in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.	These results provide further support for the efficacy of abiraterone in this population.
__label__noRel	Abiraterone plus prednisone delays patient-reported pain progression and HRQoL deterioration in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.	Abiraterone acetate plus prednisone significantly improves radiographic progression-free survival in asymptomatic or mildly symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer compared with prednisone alone.
__label__noRel	Abiraterone plus prednisone delays patient-reported pain progression and HRQoL deterioration in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.	Median time to HRQoL deterioration was longer in patients assigned to abiraterone plus prednisone than in those assigned to placebo plus prednisone as assessed by the FACT-P total score (127 months [95% CI 111-140] vs 83 months [74-106]; HR 078, 95% CI 066-092; p=0003) and by the score on its prostate-cancer-specific subscale (111 months [86-138] vs 58 months [55-83]; HR 070, 95% CI 060-083; p<00001).
__label__noRel	Abiraterone plus prednisone delays patient-reported pain progression and HRQoL deterioration in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.	Median time to progression of worst pain was also longer with abiraterone plus prednisone (267 months [95% CI 194-not estimable]) than with placebo plus prednisone (194 months [166-not estimable]), but the difference was not significant (HR 085, 95% CI 069-104; p=0109).
__label__noRel	Abiraterone plus prednisone delays patient-reported pain progression and HRQoL deterioration in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.	Median time to progression of mean pain intensity was longer in patients assigned to abiraterone plus prednisone (267 months [95% CI 193-not estimable]) than in those assigned to placebo plus prednisone (184 months [149-not estimable]; hazard ratio [HR] 082, 95% CI 067-100; p=00490), as was median time to progression of pain interference with daily activities (103 months [95% CI 93-130] vs 74 months [64-86]; HR 079, 95% CI 067-093; p=0005).
__label__noRel	Median time to HRQoL deterioration was longer in patients assigned to abiraterone plus prednisone than in those assigned to placebo plus prednisone as assessed by the FACT-P total score (127 months [95% CI 111-140] vs 83 months [74-106]; HR 078, 95% CI 066-092; p=0003) and by the score on its prostate-cancer-specific subscale (111 months [86-138] vs 58 months [55-83]; HR 070, 95% CI 060-083; p<00001).	These results provide further support for the efficacy of abiraterone in this population.
__label__noRel	Median time to HRQoL deterioration was longer in patients assigned to abiraterone plus prednisone than in those assigned to placebo plus prednisone as assessed by the FACT-P total score (127 months [95% CI 111-140] vs 83 months [74-106]; HR 078, 95% CI 066-092; p=0003) and by the score on its prostate-cancer-specific subscale (111 months [86-138] vs 58 months [55-83]; HR 070, 95% CI 060-083; p<00001).	Abiraterone acetate plus prednisone significantly improves radiographic progression-free survival in asymptomatic or mildly symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer compared with prednisone alone.
__label__Support	Median time to HRQoL deterioration was longer in patients assigned to abiraterone plus prednisone than in those assigned to placebo plus prednisone as assessed by the FACT-P total score (127 months [95% CI 111-140] vs 83 months [74-106]; HR 078, 95% CI 066-092; p=0003) and by the score on its prostate-cancer-specific subscale (111 months [86-138] vs 58 months [55-83]; HR 070, 95% CI 060-083; p<00001).	Abiraterone plus prednisone delays patient-reported pain progression and HRQoL deterioration in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
__label__noRel	Median time to HRQoL deterioration was longer in patients assigned to abiraterone plus prednisone than in those assigned to placebo plus prednisone as assessed by the FACT-P total score (127 months [95% CI 111-140] vs 83 months [74-106]; HR 078, 95% CI 066-092; p=0003) and by the score on its prostate-cancer-specific subscale (111 months [86-138] vs 58 months [55-83]; HR 070, 95% CI 060-083; p<00001).	Median time to progression of worst pain was also longer with abiraterone plus prednisone (267 months [95% CI 194-not estimable]) than with placebo plus prednisone (194 months [166-not estimable]), but the difference was not significant (HR 085, 95% CI 069-104; p=0109).
__label__noRel	Median time to HRQoL deterioration was longer in patients assigned to abiraterone plus prednisone than in those assigned to placebo plus prednisone as assessed by the FACT-P total score (127 months [95% CI 111-140] vs 83 months [74-106]; HR 078, 95% CI 066-092; p=0003) and by the score on its prostate-cancer-specific subscale (111 months [86-138] vs 58 months [55-83]; HR 070, 95% CI 060-083; p<00001).	Median time to progression of mean pain intensity was longer in patients assigned to abiraterone plus prednisone (267 months [95% CI 193-not estimable]) than in those assigned to placebo plus prednisone (184 months [149-not estimable]; hazard ratio [HR] 082, 95% CI 067-100; p=00490), as was median time to progression of pain interference with daily activities (103 months [95% CI 93-130] vs 74 months [64-86]; HR 079, 95% CI 067-093; p=0005).
__label__noRel	Median time to progression of worst pain was also longer with abiraterone plus prednisone (267 months [95% CI 194-not estimable]) than with placebo plus prednisone (194 months [166-not estimable]), but the difference was not significant (HR 085, 95% CI 069-104; p=0109).	These results provide further support for the efficacy of abiraterone in this population.
__label__noRel	Median time to progression of worst pain was also longer with abiraterone plus prednisone (267 months [95% CI 194-not estimable]) than with placebo plus prednisone (194 months [166-not estimable]), but the difference was not significant (HR 085, 95% CI 069-104; p=0109).	Abiraterone acetate plus prednisone significantly improves radiographic progression-free survival in asymptomatic or mildly symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer compared with prednisone alone.
__label__Support	Median time to progression of worst pain was also longer with abiraterone plus prednisone (267 months [95% CI 194-not estimable]) than with placebo plus prednisone (194 months [166-not estimable]), but the difference was not significant (HR 085, 95% CI 069-104; p=0109).	Abiraterone plus prednisone delays patient-reported pain progression and HRQoL deterioration in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
__label__noRel	Median time to progression of worst pain was also longer with abiraterone plus prednisone (267 months [95% CI 194-not estimable]) than with placebo plus prednisone (194 months [166-not estimable]), but the difference was not significant (HR 085, 95% CI 069-104; p=0109).	Median time to HRQoL deterioration was longer in patients assigned to abiraterone plus prednisone than in those assigned to placebo plus prednisone as assessed by the FACT-P total score (127 months [95% CI 111-140] vs 83 months [74-106]; HR 078, 95% CI 066-092; p=0003) and by the score on its prostate-cancer-specific subscale (111 months [86-138] vs 58 months [55-83]; HR 070, 95% CI 060-083; p<00001).
__label__noRel	Median time to progression of worst pain was also longer with abiraterone plus prednisone (267 months [95% CI 194-not estimable]) than with placebo plus prednisone (194 months [166-not estimable]), but the difference was not significant (HR 085, 95% CI 069-104; p=0109).	Median time to progression of mean pain intensity was longer in patients assigned to abiraterone plus prednisone (267 months [95% CI 193-not estimable]) than in those assigned to placebo plus prednisone (184 months [149-not estimable]; hazard ratio [HR] 082, 95% CI 067-100; p=00490), as was median time to progression of pain interference with daily activities (103 months [95% CI 93-130] vs 74 months [64-86]; HR 079, 95% CI 067-093; p=0005).
__label__noRel	Median time to progression of mean pain intensity was longer in patients assigned to abiraterone plus prednisone (267 months [95% CI 193-not estimable]) than in those assigned to placebo plus prednisone (184 months [149-not estimable]; hazard ratio [HR] 082, 95% CI 067-100; p=00490), as was median time to progression of pain interference with daily activities (103 months [95% CI 93-130] vs 74 months [64-86]; HR 079, 95% CI 067-093; p=0005).	These results provide further support for the efficacy of abiraterone in this population.
__label__noRel	Median time to progression of mean pain intensity was longer in patients assigned to abiraterone plus prednisone (267 months [95% CI 193-not estimable]) than in those assigned to placebo plus prednisone (184 months [149-not estimable]; hazard ratio [HR] 082, 95% CI 067-100; p=00490), as was median time to progression of pain interference with daily activities (103 months [95% CI 93-130] vs 74 months [64-86]; HR 079, 95% CI 067-093; p=0005).	Abiraterone acetate plus prednisone significantly improves radiographic progression-free survival in asymptomatic or mildly symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer compared with prednisone alone.
__label__Support	Median time to progression of mean pain intensity was longer in patients assigned to abiraterone plus prednisone (267 months [95% CI 193-not estimable]) than in those assigned to placebo plus prednisone (184 months [149-not estimable]; hazard ratio [HR] 082, 95% CI 067-100; p=00490), as was median time to progression of pain interference with daily activities (103 months [95% CI 93-130] vs 74 months [64-86]; HR 079, 95% CI 067-093; p=0005).	Abiraterone plus prednisone delays patient-reported pain progression and HRQoL deterioration in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
__label__noRel	Median time to progression of mean pain intensity was longer in patients assigned to abiraterone plus prednisone (267 months [95% CI 193-not estimable]) than in those assigned to placebo plus prednisone (184 months [149-not estimable]; hazard ratio [HR] 082, 95% CI 067-100; p=00490), as was median time to progression of pain interference with daily activities (103 months [95% CI 93-130] vs 74 months [64-86]; HR 079, 95% CI 067-093; p=0005).	Median time to HRQoL deterioration was longer in patients assigned to abiraterone plus prednisone than in those assigned to placebo plus prednisone as assessed by the FACT-P total score (127 months [95% CI 111-140] vs 83 months [74-106]; HR 078, 95% CI 066-092; p=0003) and by the score on its prostate-cancer-specific subscale (111 months [86-138] vs 58 months [55-83]; HR 070, 95% CI 060-083; p<00001).
__label__noRel	Median time to progression of mean pain intensity was longer in patients assigned to abiraterone plus prednisone (267 months [95% CI 193-not estimable]) than in those assigned to placebo plus prednisone (184 months [149-not estimable]; hazard ratio [HR] 082, 95% CI 067-100; p=00490), as was median time to progression of pain interference with daily activities (103 months [95% CI 93-130] vs 74 months [64-86]; HR 079, 95% CI 067-093; p=0005).	Median time to progression of worst pain was also longer with abiraterone plus prednisone (267 months [95% CI 194-not estimable]) than with placebo plus prednisone (194 months [166-not estimable]), but the difference was not significant (HR 085, 95% CI 069-104; p=0109).
__label__noRel	Combination treatment in the GemCis arm was associated with a prolonged median progression-free survival (5.3 months v 3.1 months; hazard ratio [HR] = 0.75; P = .053).	Also, median overall survival was superior for patients treated in the GemCis arm as compared with the Gem arm (7.5 v 6.0 months),
__label__noRel	Combination treatment in the GemCis arm was associated with a prolonged median progression-free survival (5.3 months v 3.1 months; hazard ratio [HR] = 0.75; P = .053).	an advantage which did not, however, reach statistical significance (HR = 0.80; P = .15).
__label__noRel	Combination treatment in the GemCis arm was associated with a prolonged median progression-free survival (5.3 months v 3.1 months; hazard ratio [HR] = 0.75; P = .053).	Tumor response rates were comparable between treatment arms (10.2% v 8.2%).
__label__noRel	Combination treatment in the GemCis arm was associated with a prolonged median progression-free survival (5.3 months v 3.1 months; hazard ratio [HR] = 0.75; P = .053).	The rate of stable disease was, however, greater in the combination arm (60.2% v 40.2%; P < .001)
__label__noRel	Combination treatment in the GemCis arm was associated with a prolonged median progression-free survival (5.3 months v 3.1 months; hazard ratio [HR] = 0.75; P = .053).	Grade 3 to 4 hematologic toxicity did not exceed 15% in both treatment arms.
__label__noRel	Combination treatment in the GemCis arm was associated with a prolonged median progression-free survival (5.3 months v 3.1 months; hazard ratio [HR] = 0.75; P = .053).	These results support the efficacy and safety of an every-2-weeks treatment with gemcitabine plus cisplatin.
__label__Support	Combination treatment in the GemCis arm was associated with a prolonged median progression-free survival (5.3 months v 3.1 months; hazard ratio [HR] = 0.75; P = .053).	Median overall survival and progression-free survival were more favorable in the combination arm as compared with gemcitabine alone,
__label__noRel	Combination treatment in the GemCis arm was associated with a prolonged median progression-free survival (5.3 months v 3.1 months; hazard ratio [HR] = 0.75; P = .053).	although the difference did not attain statistical significance.
__label__noRel	Also, median overall survival was superior for patients treated in the GemCis arm as compared with the Gem arm (7.5 v 6.0 months),	Combination treatment in the GemCis arm was associated with a prolonged median progression-free survival (5.3 months v 3.1 months; hazard ratio [HR] = 0.75; P = .053).
__label__noRel	Also, median overall survival was superior for patients treated in the GemCis arm as compared with the Gem arm (7.5 v 6.0 months),	an advantage which did not, however, reach statistical significance (HR = 0.80; P = .15).
__label__noRel	Also, median overall survival was superior for patients treated in the GemCis arm as compared with the Gem arm (7.5 v 6.0 months),	Tumor response rates were comparable between treatment arms (10.2% v 8.2%).
__label__noRel	Also, median overall survival was superior for patients treated in the GemCis arm as compared with the Gem arm (7.5 v 6.0 months),	The rate of stable disease was, however, greater in the combination arm (60.2% v 40.2%; P < .001)
__label__noRel	Also, median overall survival was superior for patients treated in the GemCis arm as compared with the Gem arm (7.5 v 6.0 months),	Grade 3 to 4 hematologic toxicity did not exceed 15% in both treatment arms.
__label__noRel	Also, median overall survival was superior for patients treated in the GemCis arm as compared with the Gem arm (7.5 v 6.0 months),	These results support the efficacy and safety of an every-2-weeks treatment with gemcitabine plus cisplatin.
__label__Support	Also, median overall survival was superior for patients treated in the GemCis arm as compared with the Gem arm (7.5 v 6.0 months),	Median overall survival and progression-free survival were more favorable in the combination arm as compared with gemcitabine alone,
__label__noRel	Also, median overall survival was superior for patients treated in the GemCis arm as compared with the Gem arm (7.5 v 6.0 months),	although the difference did not attain statistical significance.
__label__noRel	an advantage which did not, however, reach statistical significance (HR = 0.80; P = .15).	Combination treatment in the GemCis arm was associated with a prolonged median progression-free survival (5.3 months v 3.1 months; hazard ratio [HR] = 0.75; P = .053).
__label__Attack	an advantage which did not, however, reach statistical significance (HR = 0.80; P = .15).	Also, median overall survival was superior for patients treated in the GemCis arm as compared with the Gem arm (7.5 v 6.0 months),
__label__noRel	an advantage which did not, however, reach statistical significance (HR = 0.80; P = .15).	Tumor response rates were comparable between treatment arms (10.2% v 8.2%).
__label__noRel	an advantage which did not, however, reach statistical significance (HR = 0.80; P = .15).	The rate of stable disease was, however, greater in the combination arm (60.2% v 40.2%; P < .001)
__label__noRel	an advantage which did not, however, reach statistical significance (HR = 0.80; P = .15).	Grade 3 to 4 hematologic toxicity did not exceed 15% in both treatment arms.
__label__noRel	an advantage which did not, however, reach statistical significance (HR = 0.80; P = .15).	These results support the efficacy and safety of an every-2-weeks treatment with gemcitabine plus cisplatin.
__label__noRel	an advantage which did not, however, reach statistical significance (HR = 0.80; P = .15).	Median overall survival and progression-free survival were more favorable in the combination arm as compared with gemcitabine alone,
__label__noRel	an advantage which did not, however, reach statistical significance (HR = 0.80; P = .15).	although the difference did not attain statistical significance.
__label__noRel	Tumor response rates were comparable between treatment arms (10.2% v 8.2%).	Combination treatment in the GemCis arm was associated with a prolonged median progression-free survival (5.3 months v 3.1 months; hazard ratio [HR] = 0.75; P = .053).
__label__noRel	Tumor response rates were comparable between treatment arms (10.2% v 8.2%).	Also, median overall survival was superior for patients treated in the GemCis arm as compared with the Gem arm (7.5 v 6.0 months),
__label__noRel	Tumor response rates were comparable between treatment arms (10.2% v 8.2%).	an advantage which did not, however, reach statistical significance (HR = 0.80; P = .15).
__label__noRel	Tumor response rates were comparable between treatment arms (10.2% v 8.2%).	The rate of stable disease was, however, greater in the combination arm (60.2% v 40.2%; P < .001)
__label__noRel	Tumor response rates were comparable between treatment arms (10.2% v 8.2%).	Grade 3 to 4 hematologic toxicity did not exceed 15% in both treatment arms.
__label__Support	Tumor response rates were comparable between treatment arms (10.2% v 8.2%).	These results support the efficacy and safety of an every-2-weeks treatment with gemcitabine plus cisplatin.
__label__noRel	Tumor response rates were comparable between treatment arms (10.2% v 8.2%).	Median overall survival and progression-free survival were more favorable in the combination arm as compared with gemcitabine alone,
__label__noRel	Tumor response rates were comparable between treatment arms (10.2% v 8.2%).	although the difference did not attain statistical significance.
__label__noRel	The rate of stable disease was, however, greater in the combination arm (60.2% v 40.2%; P < .001)	Combination treatment in the GemCis arm was associated with a prolonged median progression-free survival (5.3 months v 3.1 months; hazard ratio [HR] = 0.75; P = .053).
__label__noRel	The rate of stable disease was, however, greater in the combination arm (60.2% v 40.2%; P < .001)	Also, median overall survival was superior for patients treated in the GemCis arm as compared with the Gem arm (7.5 v 6.0 months),
__label__noRel	The rate of stable disease was, however, greater in the combination arm (60.2% v 40.2%; P < .001)	an advantage which did not, however, reach statistical significance (HR = 0.80; P = .15).
__label__noRel	The rate of stable disease was, however, greater in the combination arm (60.2% v 40.2%; P < .001)	Tumor response rates were comparable between treatment arms (10.2% v 8.2%).
__label__noRel	The rate of stable disease was, however, greater in the combination arm (60.2% v 40.2%; P < .001)	Grade 3 to 4 hematologic toxicity did not exceed 15% in both treatment arms.
__label__Support	The rate of stable disease was, however, greater in the combination arm (60.2% v 40.2%; P < .001)	These results support the efficacy and safety of an every-2-weeks treatment with gemcitabine plus cisplatin.
__label__noRel	The rate of stable disease was, however, greater in the combination arm (60.2% v 40.2%; P < .001)	Median overall survival and progression-free survival were more favorable in the combination arm as compared with gemcitabine alone,
__label__noRel	The rate of stable disease was, however, greater in the combination arm (60.2% v 40.2%; P < .001)	although the difference did not attain statistical significance.
__label__noRel	Grade 3 to 4 hematologic toxicity did not exceed 15% in both treatment arms.	Combination treatment in the GemCis arm was associated with a prolonged median progression-free survival (5.3 months v 3.1 months; hazard ratio [HR] = 0.75; P = .053).
__label__noRel	Grade 3 to 4 hematologic toxicity did not exceed 15% in both treatment arms.	Also, median overall survival was superior for patients treated in the GemCis arm as compared with the Gem arm (7.5 v 6.0 months),
__label__noRel	Grade 3 to 4 hematologic toxicity did not exceed 15% in both treatment arms.	an advantage which did not, however, reach statistical significance (HR = 0.80; P = .15).
__label__noRel	Grade 3 to 4 hematologic toxicity did not exceed 15% in both treatment arms.	Tumor response rates were comparable between treatment arms (10.2% v 8.2%).
__label__noRel	Grade 3 to 4 hematologic toxicity did not exceed 15% in both treatment arms.	The rate of stable disease was, however, greater in the combination arm (60.2% v 40.2%; P < .001)
__label__Support	Grade 3 to 4 hematologic toxicity did not exceed 15% in both treatment arms.	These results support the efficacy and safety of an every-2-weeks treatment with gemcitabine plus cisplatin.
__label__noRel	Grade 3 to 4 hematologic toxicity did not exceed 15% in both treatment arms.	Median overall survival and progression-free survival were more favorable in the combination arm as compared with gemcitabine alone,
__label__noRel	Grade 3 to 4 hematologic toxicity did not exceed 15% in both treatment arms.	although the difference did not attain statistical significance.
__label__noRel	These results support the efficacy and safety of an every-2-weeks treatment with gemcitabine plus cisplatin.	Combination treatment in the GemCis arm was associated with a prolonged median progression-free survival (5.3 months v 3.1 months; hazard ratio [HR] = 0.75; P = .053).
__label__noRel	These results support the efficacy and safety of an every-2-weeks treatment with gemcitabine plus cisplatin.	Also, median overall survival was superior for patients treated in the GemCis arm as compared with the Gem arm (7.5 v 6.0 months),
__label__noRel	These results support the efficacy and safety of an every-2-weeks treatment with gemcitabine plus cisplatin.	an advantage which did not, however, reach statistical significance (HR = 0.80; P = .15).
__label__noRel	These results support the efficacy and safety of an every-2-weeks treatment with gemcitabine plus cisplatin.	Tumor response rates were comparable between treatment arms (10.2% v 8.2%).
__label__noRel	These results support the efficacy and safety of an every-2-weeks treatment with gemcitabine plus cisplatin.	The rate of stable disease was, however, greater in the combination arm (60.2% v 40.2%; P < .001)
__label__noRel	These results support the efficacy and safety of an every-2-weeks treatment with gemcitabine plus cisplatin.	Grade 3 to 4 hematologic toxicity did not exceed 15% in both treatment arms.
__label__noRel	These results support the efficacy and safety of an every-2-weeks treatment with gemcitabine plus cisplatin.	Median overall survival and progression-free survival were more favorable in the combination arm as compared with gemcitabine alone,
__label__noRel	These results support the efficacy and safety of an every-2-weeks treatment with gemcitabine plus cisplatin.	although the difference did not attain statistical significance.
__label__noRel	Median overall survival and progression-free survival were more favorable in the combination arm as compared with gemcitabine alone,	Combination treatment in the GemCis arm was associated with a prolonged median progression-free survival (5.3 months v 3.1 months; hazard ratio [HR] = 0.75; P = .053).
__label__noRel	Median overall survival and progression-free survival were more favorable in the combination arm as compared with gemcitabine alone,	Also, median overall survival was superior for patients treated in the GemCis arm as compared with the Gem arm (7.5 v 6.0 months),
__label__noRel	Median overall survival and progression-free survival were more favorable in the combination arm as compared with gemcitabine alone,	an advantage which did not, however, reach statistical significance (HR = 0.80; P = .15).
__label__noRel	Median overall survival and progression-free survival were more favorable in the combination arm as compared with gemcitabine alone,	Tumor response rates were comparable between treatment arms (10.2% v 8.2%).
__label__noRel	Median overall survival and progression-free survival were more favorable in the combination arm as compared with gemcitabine alone,	The rate of stable disease was, however, greater in the combination arm (60.2% v 40.2%; P < .001)
__label__noRel	Median overall survival and progression-free survival were more favorable in the combination arm as compared with gemcitabine alone,	Grade 3 to 4 hematologic toxicity did not exceed 15% in both treatment arms.
__label__Support	Median overall survival and progression-free survival were more favorable in the combination arm as compared with gemcitabine alone,	These results support the efficacy and safety of an every-2-weeks treatment with gemcitabine plus cisplatin.
__label__noRel	Median overall survival and progression-free survival were more favorable in the combination arm as compared with gemcitabine alone,	although the difference did not attain statistical significance.
__label__noRel	although the difference did not attain statistical significance.	Combination treatment in the GemCis arm was associated with a prolonged median progression-free survival (5.3 months v 3.1 months; hazard ratio [HR] = 0.75; P = .053).
__label__noRel	although the difference did not attain statistical significance.	Also, median overall survival was superior for patients treated in the GemCis arm as compared with the Gem arm (7.5 v 6.0 months),
__label__noRel	although the difference did not attain statistical significance.	an advantage which did not, however, reach statistical significance (HR = 0.80; P = .15).
__label__noRel	although the difference did not attain statistical significance.	Tumor response rates were comparable between treatment arms (10.2% v 8.2%).
__label__noRel	although the difference did not attain statistical significance.	The rate of stable disease was, however, greater in the combination arm (60.2% v 40.2%; P < .001)
__label__noRel	although the difference did not attain statistical significance.	Grade 3 to 4 hematologic toxicity did not exceed 15% in both treatment arms.
__label__noRel	although the difference did not attain statistical significance.	These results support the efficacy and safety of an every-2-weeks treatment with gemcitabine plus cisplatin.
__label__Attack	although the difference did not attain statistical significance.	Median overall survival and progression-free survival were more favorable in the combination arm as compared with gemcitabine alone,
__label__noRel	In nonrandomized studies involving patients with different tumor types including non-small-cell lung cancer (NSCLC), ATP infusion appeared to inhibit loss of weight and deterioration of quality of life (QOL) and performance status.	Mean weight changes per 4-week period were -1.0 kg (95% confidence interval [CI] = -1.5 to -0.5) in the control group and 0.2 kg (95% CI = -0.2 to +0.6) in the ATP group (P =.002).
__label__noRel	In nonrandomized studies involving patients with different tumor types including non-small-cell lung cancer (NSCLC), ATP infusion appeared to inhibit loss of weight and deterioration of quality of life (QOL) and performance status.	Serum albumin concentration declined by -1.2 g/L (95% CI= -2.0 to -0.4) per 4 weeks in the control group but remained stable (0.0 g/L; 95% CI = -0.3 to +0.3) in the ATP group (P =.006).
__label__noRel	In nonrandomized studies involving patients with different tumor types including non-small-cell lung cancer (NSCLC), ATP infusion appeared to inhibit loss of weight and deterioration of quality of life (QOL) and performance status.	Elbow flexor muscle strength declined by -5.5% (95% CI = -9.6% to -1. 4%) per 4 weeks in the control group but remained stable (0.0%; 95% CI= -1.4% to +1.4%) in the ATP group (P =.01).
__label__noRel	In nonrandomized studies involving patients with different tumor types including non-small-cell lung cancer (NSCLC), ATP infusion appeared to inhibit loss of weight and deterioration of quality of life (QOL) and performance status.	A similar pattern was observed for knee extensor muscles (P =.02).
__label__noRel	In nonrandomized studies involving patients with different tumor types including non-small-cell lung cancer (NSCLC), ATP infusion appeared to inhibit loss of weight and deterioration of quality of life (QOL) and performance status.	The effects of ATP on body weight, muscle strength, and albumin concentration were especially marked in cachectic patients (P =.0002, P =.0001, and P =. 0001, respectively, for ATP versus no ATP).
__label__noRel	In nonrandomized studies involving patients with different tumor types including non-small-cell lung cancer (NSCLC), ATP infusion appeared to inhibit loss of weight and deterioration of quality of life (QOL) and performance status.	QOL score changes per 4-week period in the ATP group showed overall less deterioration than in the control group-physical scores (-0.2% versus -2.4%; P =. 0002); functional scores (+0.4% versus -5.5%; P =.02); psychologic scores (-0.7% versus -2.4%; P =.11); overall QOL score (+0.1% versus -3.5%; P =.0001).
__label__noRel	In nonrandomized studies involving patients with different tumor types including non-small-cell lung cancer (NSCLC), ATP infusion appeared to inhibit loss of weight and deterioration of quality of life (QOL) and performance status.	ATP has beneficial effects on weight, muscle strength, and QOL in patients with advanced NSCLC.
__label__noRel	Mean weight changes per 4-week period were -1.0 kg (95% confidence interval [CI] = -1.5 to -0.5) in the control group and 0.2 kg (95% CI = -0.2 to +0.6) in the ATP group (P =.002).	In nonrandomized studies involving patients with different tumor types including non-small-cell lung cancer (NSCLC), ATP infusion appeared to inhibit loss of weight and deterioration of quality of life (QOL) and performance status.
__label__noRel	Mean weight changes per 4-week period were -1.0 kg (95% confidence interval [CI] = -1.5 to -0.5) in the control group and 0.2 kg (95% CI = -0.2 to +0.6) in the ATP group (P =.002).	Serum albumin concentration declined by -1.2 g/L (95% CI= -2.0 to -0.4) per 4 weeks in the control group but remained stable (0.0 g/L; 95% CI = -0.3 to +0.3) in the ATP group (P =.006).
__label__noRel	Mean weight changes per 4-week period were -1.0 kg (95% confidence interval [CI] = -1.5 to -0.5) in the control group and 0.2 kg (95% CI = -0.2 to +0.6) in the ATP group (P =.002).	Elbow flexor muscle strength declined by -5.5% (95% CI = -9.6% to -1. 4%) per 4 weeks in the control group but remained stable (0.0%; 95% CI= -1.4% to +1.4%) in the ATP group (P =.01).
__label__noRel	Mean weight changes per 4-week period were -1.0 kg (95% confidence interval [CI] = -1.5 to -0.5) in the control group and 0.2 kg (95% CI = -0.2 to +0.6) in the ATP group (P =.002).	A similar pattern was observed for knee extensor muscles (P =.02).
__label__noRel	Mean weight changes per 4-week period were -1.0 kg (95% confidence interval [CI] = -1.5 to -0.5) in the control group and 0.2 kg (95% CI = -0.2 to +0.6) in the ATP group (P =.002).	The effects of ATP on body weight, muscle strength, and albumin concentration were especially marked in cachectic patients (P =.0002, P =.0001, and P =. 0001, respectively, for ATP versus no ATP).
__label__noRel	Mean weight changes per 4-week period were -1.0 kg (95% confidence interval [CI] = -1.5 to -0.5) in the control group and 0.2 kg (95% CI = -0.2 to +0.6) in the ATP group (P =.002).	QOL score changes per 4-week period in the ATP group showed overall less deterioration than in the control group-physical scores (-0.2% versus -2.4%; P =. 0002); functional scores (+0.4% versus -5.5%; P =.02); psychologic scores (-0.7% versus -2.4%; P =.11); overall QOL score (+0.1% versus -3.5%; P =.0001).
__label__Support	Mean weight changes per 4-week period were -1.0 kg (95% confidence interval [CI] = -1.5 to -0.5) in the control group and 0.2 kg (95% CI = -0.2 to +0.6) in the ATP group (P =.002).	ATP has beneficial effects on weight, muscle strength, and QOL in patients with advanced NSCLC.
__label__noRel	Serum albumin concentration declined by -1.2 g/L (95% CI= -2.0 to -0.4) per 4 weeks in the control group but remained stable (0.0 g/L; 95% CI = -0.3 to +0.3) in the ATP group (P =.006).	In nonrandomized studies involving patients with different tumor types including non-small-cell lung cancer (NSCLC), ATP infusion appeared to inhibit loss of weight and deterioration of quality of life (QOL) and performance status.
__label__noRel	Serum albumin concentration declined by -1.2 g/L (95% CI= -2.0 to -0.4) per 4 weeks in the control group but remained stable (0.0 g/L; 95% CI = -0.3 to +0.3) in the ATP group (P =.006).	Mean weight changes per 4-week period were -1.0 kg (95% confidence interval [CI] = -1.5 to -0.5) in the control group and 0.2 kg (95% CI = -0.2 to +0.6) in the ATP group (P =.002).
__label__noRel	Serum albumin concentration declined by -1.2 g/L (95% CI= -2.0 to -0.4) per 4 weeks in the control group but remained stable (0.0 g/L; 95% CI = -0.3 to +0.3) in the ATP group (P =.006).	Elbow flexor muscle strength declined by -5.5% (95% CI = -9.6% to -1. 4%) per 4 weeks in the control group but remained stable (0.0%; 95% CI= -1.4% to +1.4%) in the ATP group (P =.01).
__label__noRel	Serum albumin concentration declined by -1.2 g/L (95% CI= -2.0 to -0.4) per 4 weeks in the control group but remained stable (0.0 g/L; 95% CI = -0.3 to +0.3) in the ATP group (P =.006).	A similar pattern was observed for knee extensor muscles (P =.02).
__label__noRel	Serum albumin concentration declined by -1.2 g/L (95% CI= -2.0 to -0.4) per 4 weeks in the control group but remained stable (0.0 g/L; 95% CI = -0.3 to +0.3) in the ATP group (P =.006).	The effects of ATP on body weight, muscle strength, and albumin concentration were especially marked in cachectic patients (P =.0002, P =.0001, and P =. 0001, respectively, for ATP versus no ATP).
__label__noRel	Serum albumin concentration declined by -1.2 g/L (95% CI= -2.0 to -0.4) per 4 weeks in the control group but remained stable (0.0 g/L; 95% CI = -0.3 to +0.3) in the ATP group (P =.006).	QOL score changes per 4-week period in the ATP group showed overall less deterioration than in the control group-physical scores (-0.2% versus -2.4%; P =. 0002); functional scores (+0.4% versus -5.5%; P =.02); psychologic scores (-0.7% versus -2.4%; P =.11); overall QOL score (+0.1% versus -3.5%; P =.0001).
__label__noRel	Serum albumin concentration declined by -1.2 g/L (95% CI= -2.0 to -0.4) per 4 weeks in the control group but remained stable (0.0 g/L; 95% CI = -0.3 to +0.3) in the ATP group (P =.006).	ATP has beneficial effects on weight, muscle strength, and QOL in patients with advanced NSCLC.
__label__noRel	Elbow flexor muscle strength declined by -5.5% (95% CI = -9.6% to -1. 4%) per 4 weeks in the control group but remained stable (0.0%; 95% CI= -1.4% to +1.4%) in the ATP group (P =.01).	In nonrandomized studies involving patients with different tumor types including non-small-cell lung cancer (NSCLC), ATP infusion appeared to inhibit loss of weight and deterioration of quality of life (QOL) and performance status.
__label__noRel	Elbow flexor muscle strength declined by -5.5% (95% CI = -9.6% to -1. 4%) per 4 weeks in the control group but remained stable (0.0%; 95% CI= -1.4% to +1.4%) in the ATP group (P =.01).	Mean weight changes per 4-week period were -1.0 kg (95% confidence interval [CI] = -1.5 to -0.5) in the control group and 0.2 kg (95% CI = -0.2 to +0.6) in the ATP group (P =.002).
__label__noRel	Elbow flexor muscle strength declined by -5.5% (95% CI = -9.6% to -1. 4%) per 4 weeks in the control group but remained stable (0.0%; 95% CI= -1.4% to +1.4%) in the ATP group (P =.01).	Serum albumin concentration declined by -1.2 g/L (95% CI= -2.0 to -0.4) per 4 weeks in the control group but remained stable (0.0 g/L; 95% CI = -0.3 to +0.3) in the ATP group (P =.006).
__label__noRel	Elbow flexor muscle strength declined by -5.5% (95% CI = -9.6% to -1. 4%) per 4 weeks in the control group but remained stable (0.0%; 95% CI= -1.4% to +1.4%) in the ATP group (P =.01).	A similar pattern was observed for knee extensor muscles (P =.02).
__label__noRel	Elbow flexor muscle strength declined by -5.5% (95% CI = -9.6% to -1. 4%) per 4 weeks in the control group but remained stable (0.0%; 95% CI= -1.4% to +1.4%) in the ATP group (P =.01).	The effects of ATP on body weight, muscle strength, and albumin concentration were especially marked in cachectic patients (P =.0002, P =.0001, and P =. 0001, respectively, for ATP versus no ATP).
__label__noRel	Elbow flexor muscle strength declined by -5.5% (95% CI = -9.6% to -1. 4%) per 4 weeks in the control group but remained stable (0.0%; 95% CI= -1.4% to +1.4%) in the ATP group (P =.01).	QOL score changes per 4-week period in the ATP group showed overall less deterioration than in the control group-physical scores (-0.2% versus -2.4%; P =. 0002); functional scores (+0.4% versus -5.5%; P =.02); psychologic scores (-0.7% versus -2.4%; P =.11); overall QOL score (+0.1% versus -3.5%; P =.0001).
__label__Support	Elbow flexor muscle strength declined by -5.5% (95% CI = -9.6% to -1. 4%) per 4 weeks in the control group but remained stable (0.0%; 95% CI= -1.4% to +1.4%) in the ATP group (P =.01).	ATP has beneficial effects on weight, muscle strength, and QOL in patients with advanced NSCLC.
__label__noRel	A similar pattern was observed for knee extensor muscles (P =.02).	In nonrandomized studies involving patients with different tumor types including non-small-cell lung cancer (NSCLC), ATP infusion appeared to inhibit loss of weight and deterioration of quality of life (QOL) and performance status.
__label__noRel	A similar pattern was observed for knee extensor muscles (P =.02).	Mean weight changes per 4-week period were -1.0 kg (95% confidence interval [CI] = -1.5 to -0.5) in the control group and 0.2 kg (95% CI = -0.2 to +0.6) in the ATP group (P =.002).
__label__noRel	A similar pattern was observed for knee extensor muscles (P =.02).	Serum albumin concentration declined by -1.2 g/L (95% CI= -2.0 to -0.4) per 4 weeks in the control group but remained stable (0.0 g/L; 95% CI = -0.3 to +0.3) in the ATP group (P =.006).
__label__noRel	A similar pattern was observed for knee extensor muscles (P =.02).	Elbow flexor muscle strength declined by -5.5% (95% CI = -9.6% to -1. 4%) per 4 weeks in the control group but remained stable (0.0%; 95% CI= -1.4% to +1.4%) in the ATP group (P =.01).
__label__noRel	A similar pattern was observed for knee extensor muscles (P =.02).	The effects of ATP on body weight, muscle strength, and albumin concentration were especially marked in cachectic patients (P =.0002, P =.0001, and P =. 0001, respectively, for ATP versus no ATP).
__label__noRel	A similar pattern was observed for knee extensor muscles (P =.02).	QOL score changes per 4-week period in the ATP group showed overall less deterioration than in the control group-physical scores (-0.2% versus -2.4%; P =. 0002); functional scores (+0.4% versus -5.5%; P =.02); psychologic scores (-0.7% versus -2.4%; P =.11); overall QOL score (+0.1% versus -3.5%; P =.0001).
__label__Support	A similar pattern was observed for knee extensor muscles (P =.02).	ATP has beneficial effects on weight, muscle strength, and QOL in patients with advanced NSCLC.
__label__noRel	The effects of ATP on body weight, muscle strength, and albumin concentration were especially marked in cachectic patients (P =.0002, P =.0001, and P =. 0001, respectively, for ATP versus no ATP).	In nonrandomized studies involving patients with different tumor types including non-small-cell lung cancer (NSCLC), ATP infusion appeared to inhibit loss of weight and deterioration of quality of life (QOL) and performance status.
__label__noRel	The effects of ATP on body weight, muscle strength, and albumin concentration were especially marked in cachectic patients (P =.0002, P =.0001, and P =. 0001, respectively, for ATP versus no ATP).	Mean weight changes per 4-week period were -1.0 kg (95% confidence interval [CI] = -1.5 to -0.5) in the control group and 0.2 kg (95% CI = -0.2 to +0.6) in the ATP group (P =.002).
__label__noRel	The effects of ATP on body weight, muscle strength, and albumin concentration were especially marked in cachectic patients (P =.0002, P =.0001, and P =. 0001, respectively, for ATP versus no ATP).	Serum albumin concentration declined by -1.2 g/L (95% CI= -2.0 to -0.4) per 4 weeks in the control group but remained stable (0.0 g/L; 95% CI = -0.3 to +0.3) in the ATP group (P =.006).
__label__noRel	The effects of ATP on body weight, muscle strength, and albumin concentration were especially marked in cachectic patients (P =.0002, P =.0001, and P =. 0001, respectively, for ATP versus no ATP).	Elbow flexor muscle strength declined by -5.5% (95% CI = -9.6% to -1. 4%) per 4 weeks in the control group but remained stable (0.0%; 95% CI= -1.4% to +1.4%) in the ATP group (P =.01).
__label__noRel	The effects of ATP on body weight, muscle strength, and albumin concentration were especially marked in cachectic patients (P =.0002, P =.0001, and P =. 0001, respectively, for ATP versus no ATP).	A similar pattern was observed for knee extensor muscles (P =.02).
__label__noRel	The effects of ATP on body weight, muscle strength, and albumin concentration were especially marked in cachectic patients (P =.0002, P =.0001, and P =. 0001, respectively, for ATP versus no ATP).	QOL score changes per 4-week period in the ATP group showed overall less deterioration than in the control group-physical scores (-0.2% versus -2.4%; P =. 0002); functional scores (+0.4% versus -5.5%; P =.02); psychologic scores (-0.7% versus -2.4%; P =.11); overall QOL score (+0.1% versus -3.5%; P =.0001).
__label__Support	The effects of ATP on body weight, muscle strength, and albumin concentration were especially marked in cachectic patients (P =.0002, P =.0001, and P =. 0001, respectively, for ATP versus no ATP).	ATP has beneficial effects on weight, muscle strength, and QOL in patients with advanced NSCLC.
__label__noRel	QOL score changes per 4-week period in the ATP group showed overall less deterioration than in the control group-physical scores (-0.2% versus -2.4%; P =. 0002); functional scores (+0.4% versus -5.5%; P =.02); psychologic scores (-0.7% versus -2.4%; P =.11); overall QOL score (+0.1% versus -3.5%; P =.0001).	In nonrandomized studies involving patients with different tumor types including non-small-cell lung cancer (NSCLC), ATP infusion appeared to inhibit loss of weight and deterioration of quality of life (QOL) and performance status.
__label__noRel	QOL score changes per 4-week period in the ATP group showed overall less deterioration than in the control group-physical scores (-0.2% versus -2.4%; P =. 0002); functional scores (+0.4% versus -5.5%; P =.02); psychologic scores (-0.7% versus -2.4%; P =.11); overall QOL score (+0.1% versus -3.5%; P =.0001).	Mean weight changes per 4-week period were -1.0 kg (95% confidence interval [CI] = -1.5 to -0.5) in the control group and 0.2 kg (95% CI = -0.2 to +0.6) in the ATP group (P =.002).
__label__noRel	QOL score changes per 4-week period in the ATP group showed overall less deterioration than in the control group-physical scores (-0.2% versus -2.4%; P =. 0002); functional scores (+0.4% versus -5.5%; P =.02); psychologic scores (-0.7% versus -2.4%; P =.11); overall QOL score (+0.1% versus -3.5%; P =.0001).	Serum albumin concentration declined by -1.2 g/L (95% CI= -2.0 to -0.4) per 4 weeks in the control group but remained stable (0.0 g/L; 95% CI = -0.3 to +0.3) in the ATP group (P =.006).
__label__noRel	QOL score changes per 4-week period in the ATP group showed overall less deterioration than in the control group-physical scores (-0.2% versus -2.4%; P =. 0002); functional scores (+0.4% versus -5.5%; P =.02); psychologic scores (-0.7% versus -2.4%; P =.11); overall QOL score (+0.1% versus -3.5%; P =.0001).	Elbow flexor muscle strength declined by -5.5% (95% CI = -9.6% to -1. 4%) per 4 weeks in the control group but remained stable (0.0%; 95% CI= -1.4% to +1.4%) in the ATP group (P =.01).
__label__noRel	QOL score changes per 4-week period in the ATP group showed overall less deterioration than in the control group-physical scores (-0.2% versus -2.4%; P =. 0002); functional scores (+0.4% versus -5.5%; P =.02); psychologic scores (-0.7% versus -2.4%; P =.11); overall QOL score (+0.1% versus -3.5%; P =.0001).	A similar pattern was observed for knee extensor muscles (P =.02).
__label__noRel	QOL score changes per 4-week period in the ATP group showed overall less deterioration than in the control group-physical scores (-0.2% versus -2.4%; P =. 0002); functional scores (+0.4% versus -5.5%; P =.02); psychologic scores (-0.7% versus -2.4%; P =.11); overall QOL score (+0.1% versus -3.5%; P =.0001).	The effects of ATP on body weight, muscle strength, and albumin concentration were especially marked in cachectic patients (P =.0002, P =.0001, and P =. 0001, respectively, for ATP versus no ATP).
__label__Support	QOL score changes per 4-week period in the ATP group showed overall less deterioration than in the control group-physical scores (-0.2% versus -2.4%; P =. 0002); functional scores (+0.4% versus -5.5%; P =.02); psychologic scores (-0.7% versus -2.4%; P =.11); overall QOL score (+0.1% versus -3.5%; P =.0001).	ATP has beneficial effects on weight, muscle strength, and QOL in patients with advanced NSCLC.
__label__noRel	ATP has beneficial effects on weight, muscle strength, and QOL in patients with advanced NSCLC.	In nonrandomized studies involving patients with different tumor types including non-small-cell lung cancer (NSCLC), ATP infusion appeared to inhibit loss of weight and deterioration of quality of life (QOL) and performance status.
__label__noRel	ATP has beneficial effects on weight, muscle strength, and QOL in patients with advanced NSCLC.	Mean weight changes per 4-week period were -1.0 kg (95% confidence interval [CI] = -1.5 to -0.5) in the control group and 0.2 kg (95% CI = -0.2 to +0.6) in the ATP group (P =.002).
__label__noRel	ATP has beneficial effects on weight, muscle strength, and QOL in patients with advanced NSCLC.	Serum albumin concentration declined by -1.2 g/L (95% CI= -2.0 to -0.4) per 4 weeks in the control group but remained stable (0.0 g/L; 95% CI = -0.3 to +0.3) in the ATP group (P =.006).
__label__noRel	ATP has beneficial effects on weight, muscle strength, and QOL in patients with advanced NSCLC.	Elbow flexor muscle strength declined by -5.5% (95% CI = -9.6% to -1. 4%) per 4 weeks in the control group but remained stable (0.0%; 95% CI= -1.4% to +1.4%) in the ATP group (P =.01).
__label__noRel	ATP has beneficial effects on weight, muscle strength, and QOL in patients with advanced NSCLC.	A similar pattern was observed for knee extensor muscles (P =.02).
__label__noRel	ATP has beneficial effects on weight, muscle strength, and QOL in patients with advanced NSCLC.	The effects of ATP on body weight, muscle strength, and albumin concentration were especially marked in cachectic patients (P =.0002, P =.0001, and P =. 0001, respectively, for ATP versus no ATP).
__label__noRel	ATP has beneficial effects on weight, muscle strength, and QOL in patients with advanced NSCLC.	QOL score changes per 4-week period in the ATP group showed overall less deterioration than in the control group-physical scores (-0.2% versus -2.4%; P =. 0002); functional scores (+0.4% versus -5.5%; P =.02); psychologic scores (-0.7% versus -2.4%; P =.11); overall QOL score (+0.1% versus -3.5%; P =.0001).
__label__noRel	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.	Differences were most apparent shortly after the time of completion of radiotherapy.
__label__noRel	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.
__label__noRel	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.
__label__noRel	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.
__label__noRel	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.	Functionality was not greatly affected by treatment.
__label__noRel	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.
__label__noRel	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.	Results from the non-randomised patients did not confirm this effect, however.
__label__noRel	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.	Cosmetic results were better in those not receiving radiotherapy
__label__noRel	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.	but this did not appear to be an important issue to the patients.
__label__noRel	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.
__label__noRel	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.
__label__noRel	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.
__label__noRel	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.
__label__noRel	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.	the eventual cost-effectiveness will only become clear after long-term follow-up.
__label__noRel	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.
__label__noRel	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.
__label__noRel	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.	early postoperative outcome does not give a complete answer
__label__noRel	Differences were most apparent shortly after the time of completion of radiotherapy.	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.
__label__Support	Differences were most apparent shortly after the time of completion of radiotherapy.	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.
__label__noRel	Differences were most apparent shortly after the time of completion of radiotherapy.	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.
__label__noRel	Differences were most apparent shortly after the time of completion of radiotherapy.	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.
__label__noRel	Differences were most apparent shortly after the time of completion of radiotherapy.	Functionality was not greatly affected by treatment.
__label__noRel	Differences were most apparent shortly after the time of completion of radiotherapy.	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.
__label__noRel	Differences were most apparent shortly after the time of completion of radiotherapy.	Results from the non-randomised patients did not confirm this effect, however.
__label__noRel	Differences were most apparent shortly after the time of completion of radiotherapy.	Cosmetic results were better in those not receiving radiotherapy
__label__noRel	Differences were most apparent shortly after the time of completion of radiotherapy.	but this did not appear to be an important issue to the patients.
__label__noRel	Differences were most apparent shortly after the time of completion of radiotherapy.	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.
__label__noRel	Differences were most apparent shortly after the time of completion of radiotherapy.	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.
__label__noRel	Differences were most apparent shortly after the time of completion of radiotherapy.	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.
__label__noRel	Differences were most apparent shortly after the time of completion of radiotherapy.	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.
__label__noRel	Differences were most apparent shortly after the time of completion of radiotherapy.	the eventual cost-effectiveness will only become clear after long-term follow-up.
__label__noRel	Differences were most apparent shortly after the time of completion of radiotherapy.	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.
__label__noRel	Differences were most apparent shortly after the time of completion of radiotherapy.	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.
__label__noRel	Differences were most apparent shortly after the time of completion of radiotherapy.	early postoperative outcome does not give a complete answer
__label__noRel	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.
__label__noRel	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.	Differences were most apparent shortly after the time of completion of radiotherapy.
__label__noRel	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.
__label__noRel	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.
__label__noRel	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.	Functionality was not greatly affected by treatment.
__label__noRel	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.
__label__noRel	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.	Results from the non-randomised patients did not confirm this effect, however.
__label__noRel	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.	Cosmetic results were better in those not receiving radiotherapy
__label__noRel	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.	but this did not appear to be an important issue to the patients.
__label__noRel	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.
__label__noRel	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.
__label__noRel	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.
__label__noRel	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.
__label__noRel	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.	the eventual cost-effectiveness will only become clear after long-term follow-up.
__label__noRel	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.
__label__noRel	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.
__label__noRel	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.	early postoperative outcome does not give a complete answer
__label__noRel	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.
__label__noRel	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.	Differences were most apparent shortly after the time of completion of radiotherapy.
__label__noRel	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.
__label__noRel	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.
__label__noRel	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.	Functionality was not greatly affected by treatment.
__label__noRel	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.
__label__noRel	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.	Results from the non-randomised patients did not confirm this effect, however.
__label__noRel	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.	Cosmetic results were better in those not receiving radiotherapy
__label__noRel	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.	but this did not appear to be an important issue to the patients.
__label__noRel	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.
__label__noRel	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.
__label__noRel	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.
__label__noRel	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.
__label__noRel	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.	the eventual cost-effectiveness will only become clear after long-term follow-up.
__label__noRel	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.
__label__noRel	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.
__label__noRel	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.	early postoperative outcome does not give a complete answer
__label__noRel	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.
__label__noRel	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.	Differences were most apparent shortly after the time of completion of radiotherapy.
__label__noRel	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.
__label__noRel	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.
__label__noRel	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.	Functionality was not greatly affected by treatment.
__label__noRel	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.
__label__noRel	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.	Results from the non-randomised patients did not confirm this effect, however.
__label__noRel	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.	Cosmetic results were better in those not receiving radiotherapy
__label__noRel	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.	but this did not appear to be an important issue to the patients.
__label__noRel	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.
__label__noRel	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.
__label__noRel	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.
__label__noRel	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.
__label__noRel	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.	the eventual cost-effectiveness will only become clear after long-term follow-up.
__label__noRel	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.
__label__noRel	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.
__label__noRel	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.	early postoperative outcome does not give a complete answer
__label__noRel	Functionality was not greatly affected by treatment.	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.
__label__noRel	Functionality was not greatly affected by treatment.	Differences were most apparent shortly after the time of completion of radiotherapy.
__label__noRel	Functionality was not greatly affected by treatment.	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.
__label__noRel	Functionality was not greatly affected by treatment.	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.
__label__noRel	Functionality was not greatly affected by treatment.	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.
__label__noRel	Functionality was not greatly affected by treatment.	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.
__label__noRel	Functionality was not greatly affected by treatment.	Results from the non-randomised patients did not confirm this effect, however.
__label__noRel	Functionality was not greatly affected by treatment.	Cosmetic results were better in those not receiving radiotherapy
__label__noRel	Functionality was not greatly affected by treatment.	but this did not appear to be an important issue to the patients.
__label__noRel	Functionality was not greatly affected by treatment.	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.
__label__noRel	Functionality was not greatly affected by treatment.	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.
__label__noRel	Functionality was not greatly affected by treatment.	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.
__label__noRel	Functionality was not greatly affected by treatment.	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.
__label__noRel	Functionality was not greatly affected by treatment.	the eventual cost-effectiveness will only become clear after long-term follow-up.
__label__noRel	Functionality was not greatly affected by treatment.	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.
__label__noRel	Functionality was not greatly affected by treatment.	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.
__label__Support	Functionality was not greatly affected by treatment.	early postoperative outcome does not give a complete answer
__label__noRel	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.
__label__noRel	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.	Differences were most apparent shortly after the time of completion of radiotherapy.
__label__noRel	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.
__label__noRel	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.
__label__noRel	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.
__label__noRel	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.	Functionality was not greatly affected by treatment.
__label__noRel	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.	Results from the non-randomised patients did not confirm this effect, however.
__label__noRel	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.	Cosmetic results were better in those not receiving radiotherapy
__label__noRel	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.	but this did not appear to be an important issue to the patients.
__label__noRel	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.
__label__noRel	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.
__label__noRel	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.
__label__noRel	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.
__label__noRel	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.	the eventual cost-effectiveness will only become clear after long-term follow-up.
__label__noRel	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.
__label__noRel	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.
__label__noRel	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.	early postoperative outcome does not give a complete answer
__label__noRel	Results from the non-randomised patients did not confirm this effect, however.	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.
__label__noRel	Results from the non-randomised patients did not confirm this effect, however.	Differences were most apparent shortly after the time of completion of radiotherapy.
__label__noRel	Results from the non-randomised patients did not confirm this effect, however.	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.
__label__noRel	Results from the non-randomised patients did not confirm this effect, however.	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.
__label__noRel	Results from the non-randomised patients did not confirm this effect, however.	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.
__label__noRel	Results from the non-randomised patients did not confirm this effect, however.	Functionality was not greatly affected by treatment.
__label__Attack	Results from the non-randomised patients did not confirm this effect, however.	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.
__label__noRel	Results from the non-randomised patients did not confirm this effect, however.	Cosmetic results were better in those not receiving radiotherapy
__label__noRel	Results from the non-randomised patients did not confirm this effect, however.	but this did not appear to be an important issue to the patients.
__label__noRel	Results from the non-randomised patients did not confirm this effect, however.	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.
__label__noRel	Results from the non-randomised patients did not confirm this effect, however.	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.
__label__noRel	Results from the non-randomised patients did not confirm this effect, however.	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.
__label__noRel	Results from the non-randomised patients did not confirm this effect, however.	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.
__label__noRel	Results from the non-randomised patients did not confirm this effect, however.	the eventual cost-effectiveness will only become clear after long-term follow-up.
__label__noRel	Results from the non-randomised patients did not confirm this effect, however.	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.
__label__noRel	Results from the non-randomised patients did not confirm this effect, however.	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.
__label__noRel	Results from the non-randomised patients did not confirm this effect, however.	early postoperative outcome does not give a complete answer
__label__noRel	Cosmetic results were better in those not receiving radiotherapy	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.
__label__noRel	Cosmetic results were better in those not receiving radiotherapy	Differences were most apparent shortly after the time of completion of radiotherapy.
__label__noRel	Cosmetic results were better in those not receiving radiotherapy	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.
__label__noRel	Cosmetic results were better in those not receiving radiotherapy	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.
__label__noRel	Cosmetic results were better in those not receiving radiotherapy	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.
__label__noRel	Cosmetic results were better in those not receiving radiotherapy	Functionality was not greatly affected by treatment.
__label__noRel	Cosmetic results were better in those not receiving radiotherapy	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.
__label__noRel	Cosmetic results were better in those not receiving radiotherapy	Results from the non-randomised patients did not confirm this effect, however.
__label__noRel	Cosmetic results were better in those not receiving radiotherapy	but this did not appear to be an important issue to the patients.
__label__noRel	Cosmetic results were better in those not receiving radiotherapy	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.
__label__noRel	Cosmetic results were better in those not receiving radiotherapy	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.
__label__noRel	Cosmetic results were better in those not receiving radiotherapy	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.
__label__noRel	Cosmetic results were better in those not receiving radiotherapy	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.
__label__noRel	Cosmetic results were better in those not receiving radiotherapy	the eventual cost-effectiveness will only become clear after long-term follow-up.
__label__noRel	Cosmetic results were better in those not receiving radiotherapy	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.
__label__noRel	Cosmetic results were better in those not receiving radiotherapy	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.
__label__noRel	Cosmetic results were better in those not receiving radiotherapy	early postoperative outcome does not give a complete answer
__label__noRel	but this did not appear to be an important issue to the patients.	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.
__label__noRel	but this did not appear to be an important issue to the patients.	Differences were most apparent shortly after the time of completion of radiotherapy.
__label__noRel	but this did not appear to be an important issue to the patients.	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.
__label__noRel	but this did not appear to be an important issue to the patients.	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.
__label__noRel	but this did not appear to be an important issue to the patients.	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.
__label__noRel	but this did not appear to be an important issue to the patients.	Functionality was not greatly affected by treatment.
__label__noRel	but this did not appear to be an important issue to the patients.	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.
__label__noRel	but this did not appear to be an important issue to the patients.	Results from the non-randomised patients did not confirm this effect, however.
__label__Attack	but this did not appear to be an important issue to the patients.	Cosmetic results were better in those not receiving radiotherapy
__label__noRel	but this did not appear to be an important issue to the patients.	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.
__label__noRel	but this did not appear to be an important issue to the patients.	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.
__label__noRel	but this did not appear to be an important issue to the patients.	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.
__label__noRel	but this did not appear to be an important issue to the patients.	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.
__label__noRel	but this did not appear to be an important issue to the patients.	the eventual cost-effectiveness will only become clear after long-term follow-up.
__label__noRel	but this did not appear to be an important issue to the patients.	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.
__label__noRel	but this did not appear to be an important issue to the patients.	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.
__label__noRel	but this did not appear to be an important issue to the patients.	early postoperative outcome does not give a complete answer
__label__noRel	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.
__label__noRel	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.	Differences were most apparent shortly after the time of completion of radiotherapy.
__label__noRel	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.
__label__noRel	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.
__label__noRel	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.
__label__noRel	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.	Functionality was not greatly affected by treatment.
__label__noRel	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.
__label__noRel	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.	Results from the non-randomised patients did not confirm this effect, however.
__label__noRel	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.	Cosmetic results were better in those not receiving radiotherapy
__label__noRel	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.	but this did not appear to be an important issue to the patients.
__label__noRel	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.
__label__noRel	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.
__label__noRel	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.
__label__noRel	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.	the eventual cost-effectiveness will only become clear after long-term follow-up.
__label__noRel	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.
__label__noRel	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.
__label__noRel	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.	early postoperative outcome does not give a complete answer
__label__noRel	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.
__label__noRel	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.	Differences were most apparent shortly after the time of completion of radiotherapy.
__label__noRel	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.
__label__noRel	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.
__label__noRel	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.
__label__noRel	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.	Functionality was not greatly affected by treatment.
__label__noRel	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.
__label__noRel	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.	Results from the non-randomised patients did not confirm this effect, however.
__label__noRel	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.	Cosmetic results were better in those not receiving radiotherapy
__label__noRel	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.	but this did not appear to be an important issue to the patients.
__label__noRel	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.
__label__noRel	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.
__label__noRel	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.
__label__noRel	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.	the eventual cost-effectiveness will only become clear after long-term follow-up.
__label__noRel	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.
__label__noRel	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.
__label__Support	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.	early postoperative outcome does not give a complete answer
__label__noRel	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.
__label__noRel	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.	Differences were most apparent shortly after the time of completion of radiotherapy.
__label__noRel	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.
__label__noRel	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.
__label__noRel	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.
__label__noRel	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.	Functionality was not greatly affected by treatment.
__label__noRel	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.
__label__noRel	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.	Results from the non-randomised patients did not confirm this effect, however.
__label__noRel	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.	Cosmetic results were better in those not receiving radiotherapy
__label__noRel	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.	but this did not appear to be an important issue to the patients.
__label__noRel	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.
__label__noRel	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.
__label__noRel	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.
__label__noRel	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.	the eventual cost-effectiveness will only become clear after long-term follow-up.
__label__noRel	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.
__label__noRel	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.
__label__Support	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.	early postoperative outcome does not give a complete answer
__label__noRel	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.
__label__noRel	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.	Differences were most apparent shortly after the time of completion of radiotherapy.
__label__noRel	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.
__label__noRel	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.
__label__noRel	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.
__label__noRel	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.	Functionality was not greatly affected by treatment.
__label__noRel	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.
__label__noRel	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.	Results from the non-randomised patients did not confirm this effect, however.
__label__noRel	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.	Cosmetic results were better in those not receiving radiotherapy
__label__noRel	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.	but this did not appear to be an important issue to the patients.
__label__noRel	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.
__label__noRel	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.
__label__noRel	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.
__label__noRel	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.	the eventual cost-effectiveness will only become clear after long-term follow-up.
__label__Support	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.
__label__noRel	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.
__label__noRel	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.	early postoperative outcome does not give a complete answer
__label__noRel	the eventual cost-effectiveness will only become clear after long-term follow-up.	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.
__label__noRel	the eventual cost-effectiveness will only become clear after long-term follow-up.	Differences were most apparent shortly after the time of completion of radiotherapy.
__label__noRel	the eventual cost-effectiveness will only become clear after long-term follow-up.	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.
__label__noRel	the eventual cost-effectiveness will only become clear after long-term follow-up.	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.
__label__noRel	the eventual cost-effectiveness will only become clear after long-term follow-up.	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.
__label__noRel	the eventual cost-effectiveness will only become clear after long-term follow-up.	Functionality was not greatly affected by treatment.
__label__noRel	the eventual cost-effectiveness will only become clear after long-term follow-up.	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.
__label__noRel	the eventual cost-effectiveness will only become clear after long-term follow-up.	Results from the non-randomised patients did not confirm this effect, however.
__label__noRel	the eventual cost-effectiveness will only become clear after long-term follow-up.	Cosmetic results were better in those not receiving radiotherapy
__label__noRel	the eventual cost-effectiveness will only become clear after long-term follow-up.	but this did not appear to be an important issue to the patients.
__label__noRel	the eventual cost-effectiveness will only become clear after long-term follow-up.	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.
__label__noRel	the eventual cost-effectiveness will only become clear after long-term follow-up.	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.
__label__noRel	the eventual cost-effectiveness will only become clear after long-term follow-up.	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.
__label__noRel	the eventual cost-effectiveness will only become clear after long-term follow-up.	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.
__label__Attack	the eventual cost-effectiveness will only become clear after long-term follow-up.	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.
__label__noRel	the eventual cost-effectiveness will only become clear after long-term follow-up.	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.
__label__noRel	the eventual cost-effectiveness will only become clear after long-term follow-up.	early postoperative outcome does not give a complete answer
__label__noRel	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.
__label__noRel	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.	Differences were most apparent shortly after the time of completion of radiotherapy.
__label__noRel	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.
__label__noRel	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.
__label__noRel	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.
__label__noRel	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.	Functionality was not greatly affected by treatment.
__label__noRel	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.
__label__noRel	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.	Results from the non-randomised patients did not confirm this effect, however.
__label__noRel	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.	Cosmetic results were better in those not receiving radiotherapy
__label__noRel	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.	but this did not appear to be an important issue to the patients.
__label__noRel	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.
__label__noRel	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.
__label__noRel	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.
__label__noRel	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.
__label__noRel	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.	the eventual cost-effectiveness will only become clear after long-term follow-up.
__label__noRel	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.
__label__noRel	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.	early postoperative outcome does not give a complete answer
__label__noRel	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.
__label__noRel	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.	Differences were most apparent shortly after the time of completion of radiotherapy.
__label__noRel	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.
__label__noRel	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.
__label__noRel	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.
__label__noRel	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.	Functionality was not greatly affected by treatment.
__label__noRel	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.
__label__noRel	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.	Results from the non-randomised patients did not confirm this effect, however.
__label__noRel	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.	Cosmetic results were better in those not receiving radiotherapy
__label__noRel	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.	but this did not appear to be an important issue to the patients.
__label__noRel	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.
__label__noRel	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.
__label__noRel	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.
__label__noRel	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.
__label__noRel	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.	the eventual cost-effectiveness will only become clear after long-term follow-up.
__label__Attack	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.
__label__noRel	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.	early postoperative outcome does not give a complete answer
__label__noRel	early postoperative outcome does not give a complete answer	The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales.
__label__noRel	early postoperative outcome does not give a complete answer	Differences were most apparent shortly after the time of completion of radiotherapy.
__label__noRel	early postoperative outcome does not give a complete answer	Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects.
__label__noRel	early postoperative outcome does not give a complete answer	Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy.
__label__noRel	early postoperative outcome does not give a complete answer	By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy.
__label__noRel	early postoperative outcome does not give a complete answer	Functionality was not greatly affected by treatment.
__label__noRel	early postoperative outcome does not give a complete answer	Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial.
__label__noRel	early postoperative outcome does not give a complete answer	Results from the non-randomised patients did not confirm this effect, however.
__label__noRel	early postoperative outcome does not give a complete answer	Cosmetic results were better in those not receiving radiotherapy
__label__noRel	early postoperative outcome does not give a complete answer	but this did not appear to be an important issue to the patients.
__label__noRel	early postoperative outcome does not give a complete answer	The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data.
__label__noRel	early postoperative outcome does not give a complete answer	In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical.
__label__noRel	early postoperative outcome does not give a complete answer	Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation.
__label__noRel	early postoperative outcome does not give a complete answer	Over the first 15 months, radiotherapy for this population is not a cost-effective treatment.
__label__noRel	early postoperative outcome does not give a complete answer	the eventual cost-effectiveness will only become clear after long-term follow-up.
__label__noRel	early postoperative outcome does not give a complete answer	Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy.
__label__Support	early postoperative outcome does not give a complete answer	Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy.
__label__noRel	Participants in the Internet group showed significant improvements at post-assessment compared with those in the control group in overall insomnia severity (F(1,26) = 22.8; p<0.001), sleep efficiency (F(1,24) = 11.45; P = 0.002), sleep onset latency (F(1,24) = 5.18; P = 0.03), soundness of sleep (F(1,24) = 9.34; P = 0.005), restored feeling upon awakening (F(1,24) = 11.95; P = 0.002), and general fatigue (F(1,26) = 13.88; P = 0.001).	Although other group  time interactions were not significant, overall adjusted effect sizes for all sleep variables as well as for fatigue, depression, anxiety, and quality of life ranged from small to large.
__label__Support	Participants in the Internet group showed significant improvements at post-assessment compared with those in the control group in overall insomnia severity (F(1,26) = 22.8; p<0.001), sleep efficiency (F(1,24) = 11.45; P = 0.002), sleep onset latency (F(1,24) = 5.18; P = 0.03), soundness of sleep (F(1,24) = 9.34; P = 0.005), restored feeling upon awakening (F(1,24) = 11.95; P = 0.002), and general fatigue (F(1,26) = 13.88; P = 0.001).	CBT-I delivered through an interactive, individually tailored Internet intervention may be a viable treatment option for cancer survivors experiencing insomnia.
__label__noRel	Participants in the Internet group showed significant improvements at post-assessment compared with those in the control group in overall insomnia severity (F(1,26) = 22.8; p<0.001), sleep efficiency (F(1,24) = 11.45; P = 0.002), sleep onset latency (F(1,24) = 5.18; P = 0.03), soundness of sleep (F(1,24) = 9.34; P = 0.005), restored feeling upon awakening (F(1,24) = 11.95; P = 0.002), and general fatigue (F(1,26) = 13.88; P = 0.001).	Insomnia is a common complaint among cancer survivors.
__label__noRel	Although other group  time interactions were not significant, overall adjusted effect sizes for all sleep variables as well as for fatigue, depression, anxiety, and quality of life ranged from small to large.	Participants in the Internet group showed significant improvements at post-assessment compared with those in the control group in overall insomnia severity (F(1,26) = 22.8; p<0.001), sleep efficiency (F(1,24) = 11.45; P = 0.002), sleep onset latency (F(1,24) = 5.18; P = 0.03), soundness of sleep (F(1,24) = 9.34; P = 0.005), restored feeling upon awakening (F(1,24) = 11.95; P = 0.002), and general fatigue (F(1,26) = 13.88; P = 0.001).
__label__Support	Although other group  time interactions were not significant, overall adjusted effect sizes for all sleep variables as well as for fatigue, depression, anxiety, and quality of life ranged from small to large.	CBT-I delivered through an interactive, individually tailored Internet intervention may be a viable treatment option for cancer survivors experiencing insomnia.
__label__noRel	Although other group  time interactions were not significant, overall adjusted effect sizes for all sleep variables as well as for fatigue, depression, anxiety, and quality of life ranged from small to large.	Insomnia is a common complaint among cancer survivors.
__label__noRel	CBT-I delivered through an interactive, individually tailored Internet intervention may be a viable treatment option for cancer survivors experiencing insomnia.	Participants in the Internet group showed significant improvements at post-assessment compared with those in the control group in overall insomnia severity (F(1,26) = 22.8; p<0.001), sleep efficiency (F(1,24) = 11.45; P = 0.002), sleep onset latency (F(1,24) = 5.18; P = 0.03), soundness of sleep (F(1,24) = 9.34; P = 0.005), restored feeling upon awakening (F(1,24) = 11.95; P = 0.002), and general fatigue (F(1,26) = 13.88; P = 0.001).
__label__noRel	CBT-I delivered through an interactive, individually tailored Internet intervention may be a viable treatment option for cancer survivors experiencing insomnia.	Although other group  time interactions were not significant, overall adjusted effect sizes for all sleep variables as well as for fatigue, depression, anxiety, and quality of life ranged from small to large.
__label__noRel	CBT-I delivered through an interactive, individually tailored Internet intervention may be a viable treatment option for cancer survivors experiencing insomnia.	Insomnia is a common complaint among cancer survivors.
__label__noRel	Insomnia is a common complaint among cancer survivors.	Participants in the Internet group showed significant improvements at post-assessment compared with those in the control group in overall insomnia severity (F(1,26) = 22.8; p<0.001), sleep efficiency (F(1,24) = 11.45; P = 0.002), sleep onset latency (F(1,24) = 5.18; P = 0.03), soundness of sleep (F(1,24) = 9.34; P = 0.005), restored feeling upon awakening (F(1,24) = 11.95; P = 0.002), and general fatigue (F(1,26) = 13.88; P = 0.001).
__label__noRel	Insomnia is a common complaint among cancer survivors.	Although other group  time interactions were not significant, overall adjusted effect sizes for all sleep variables as well as for fatigue, depression, anxiety, and quality of life ranged from small to large.
__label__noRel	Insomnia is a common complaint among cancer survivors.	CBT-I delivered through an interactive, individually tailored Internet intervention may be a viable treatment option for cancer survivors experiencing insomnia.
__label__noRel	Hospital stay for patients who received EOF (n=71) was 4.7 vs. 5.8 days for the TOF group (n=72) (P=0.006).	The mean level of postoperative satisfaction was significantly higher in the EOF group (82.8 vs. 71.7 mm, P B 0.001).
__label__Support	Hospital stay for patients who received EOF (n=71) was 4.7 vs. 5.8 days for the TOF group (n=72) (P=0.006).	On the basis of these findings, the policy of EOF should be used after a complex gynecologic oncologic laparotomy.
__label__noRel	Hospital stay for patients who received EOF (n=71) was 4.7 vs. 5.8 days for the TOF group (n=72) (P=0.006).	Variables such as nausea and vomiting, analgesic and antiemetic requirement as well as level of pain and quality of life were not different between groups.
__label__noRel	Hospital stay for patients who received EOF (n=71) was 4.7 vs. 5.8 days for the TOF group (n=72) (P=0.006).	Patients who received the TOF scheme had significantly higher overall postoperative complications (39 vs. 17% in EOF group, P=0.003) and infective complications (14% in TOF group vs. 3% in EOF group, P=0.017).
__label__noRel	The mean level of postoperative satisfaction was significantly higher in the EOF group (82.8 vs. 71.7 mm, P B 0.001).	Hospital stay for patients who received EOF (n=71) was 4.7 vs. 5.8 days for the TOF group (n=72) (P=0.006).
__label__Support	The mean level of postoperative satisfaction was significantly higher in the EOF group (82.8 vs. 71.7 mm, P B 0.001).	On the basis of these findings, the policy of EOF should be used after a complex gynecologic oncologic laparotomy.
__label__noRel	The mean level of postoperative satisfaction was significantly higher in the EOF group (82.8 vs. 71.7 mm, P B 0.001).	Variables such as nausea and vomiting, analgesic and antiemetic requirement as well as level of pain and quality of life were not different between groups.
__label__noRel	The mean level of postoperative satisfaction was significantly higher in the EOF group (82.8 vs. 71.7 mm, P B 0.001).	Patients who received the TOF scheme had significantly higher overall postoperative complications (39 vs. 17% in EOF group, P=0.003) and infective complications (14% in TOF group vs. 3% in EOF group, P=0.017).
__label__noRel	On the basis of these findings, the policy of EOF should be used after a complex gynecologic oncologic laparotomy.	Hospital stay for patients who received EOF (n=71) was 4.7 vs. 5.8 days for the TOF group (n=72) (P=0.006).
__label__noRel	On the basis of these findings, the policy of EOF should be used after a complex gynecologic oncologic laparotomy.	The mean level of postoperative satisfaction was significantly higher in the EOF group (82.8 vs. 71.7 mm, P B 0.001).
__label__noRel	On the basis of these findings, the policy of EOF should be used after a complex gynecologic oncologic laparotomy.	Variables such as nausea and vomiting, analgesic and antiemetic requirement as well as level of pain and quality of life were not different between groups.
__label__noRel	On the basis of these findings, the policy of EOF should be used after a complex gynecologic oncologic laparotomy.	Patients who received the TOF scheme had significantly higher overall postoperative complications (39 vs. 17% in EOF group, P=0.003) and infective complications (14% in TOF group vs. 3% in EOF group, P=0.017).
__label__noRel	Variables such as nausea and vomiting, analgesic and antiemetic requirement as well as level of pain and quality of life were not different between groups.	Hospital stay for patients who received EOF (n=71) was 4.7 vs. 5.8 days for the TOF group (n=72) (P=0.006).
__label__noRel	Variables such as nausea and vomiting, analgesic and antiemetic requirement as well as level of pain and quality of life were not different between groups.	The mean level of postoperative satisfaction was significantly higher in the EOF group (82.8 vs. 71.7 mm, P B 0.001).
__label__Support	Variables such as nausea and vomiting, analgesic and antiemetic requirement as well as level of pain and quality of life were not different between groups.	On the basis of these findings, the policy of EOF should be used after a complex gynecologic oncologic laparotomy.
__label__noRel	Variables such as nausea and vomiting, analgesic and antiemetic requirement as well as level of pain and quality of life were not different between groups.	Patients who received the TOF scheme had significantly higher overall postoperative complications (39 vs. 17% in EOF group, P=0.003) and infective complications (14% in TOF group vs. 3% in EOF group, P=0.017).
__label__noRel	Patients who received the TOF scheme had significantly higher overall postoperative complications (39 vs. 17% in EOF group, P=0.003) and infective complications (14% in TOF group vs. 3% in EOF group, P=0.017).	Hospital stay for patients who received EOF (n=71) was 4.7 vs. 5.8 days for the TOF group (n=72) (P=0.006).
__label__noRel	Patients who received the TOF scheme had significantly higher overall postoperative complications (39 vs. 17% in EOF group, P=0.003) and infective complications (14% in TOF group vs. 3% in EOF group, P=0.017).	The mean level of postoperative satisfaction was significantly higher in the EOF group (82.8 vs. 71.7 mm, P B 0.001).
__label__Support	Patients who received the TOF scheme had significantly higher overall postoperative complications (39 vs. 17% in EOF group, P=0.003) and infective complications (14% in TOF group vs. 3% in EOF group, P=0.017).	On the basis of these findings, the policy of EOF should be used after a complex gynecologic oncologic laparotomy.
__label__noRel	Patients who received the TOF scheme had significantly higher overall postoperative complications (39 vs. 17% in EOF group, P=0.003) and infective complications (14% in TOF group vs. 3% in EOF group, P=0.017).	Variables such as nausea and vomiting, analgesic and antiemetic requirement as well as level of pain and quality of life were not different between groups.
__label__noRel	At week 12, changes in TPV for degarelix and goserelin were similar (-37.2% vs -39.0%) and met the predefined non-inferiority criterion.	Decreases in IPSS were greater in degarelix than in goserelin-treated patients, differences being statistically significant in patients with baseline IPSS > 13 (-6.7  1.8 vs -4.0  1.0; P = 0.02).
__label__noRel	At week 12, changes in TPV for degarelix and goserelin were similar (-37.2% vs -39.0%) and met the predefined non-inferiority criterion.	The number of patients with an IPSS change of  3 over baseline was also significantly higher in patients treated with degarelix (61.0 vs 44.3%, P = 0.02).
__label__noRel	At week 12, changes in TPV for degarelix and goserelin were similar (-37.2% vs -39.0%) and met the predefined non-inferiority criterion.	Both treatments were safe and well tolerated.
__label__noRel	At week 12, changes in TPV for degarelix and goserelin were similar (-37.2% vs -39.0%) and met the predefined non-inferiority criterion.	Medical castration reduces TPV and could also improve LUTS in patients with PCa.
__label__Support	At week 12, changes in TPV for degarelix and goserelin were similar (-37.2% vs -39.0%) and met the predefined non-inferiority criterion.	the short-term efficacy of degarelix and goserelin + bicalutamide was the same in terms of TPV reduction,
__label__noRel	At week 12, changes in TPV for degarelix and goserelin were similar (-37.2% vs -39.0%) and met the predefined non-inferiority criterion.	degarelix showed superiority in LUTS relief in symptomatic patients, which could highlight the different actions of these drugs on extrapituitary gonadotrophin-releasing hormone (GnRH) receptors in the bladder and/or the prostate.
__label__noRel	Decreases in IPSS were greater in degarelix than in goserelin-treated patients, differences being statistically significant in patients with baseline IPSS > 13 (-6.7  1.8 vs -4.0  1.0; P = 0.02).	At week 12, changes in TPV for degarelix and goserelin were similar (-37.2% vs -39.0%) and met the predefined non-inferiority criterion.
__label__noRel	Decreases in IPSS were greater in degarelix than in goserelin-treated patients, differences being statistically significant in patients with baseline IPSS > 13 (-6.7  1.8 vs -4.0  1.0; P = 0.02).	The number of patients with an IPSS change of  3 over baseline was also significantly higher in patients treated with degarelix (61.0 vs 44.3%, P = 0.02).
__label__noRel	Decreases in IPSS were greater in degarelix than in goserelin-treated patients, differences being statistically significant in patients with baseline IPSS > 13 (-6.7  1.8 vs -4.0  1.0; P = 0.02).	Both treatments were safe and well tolerated.
__label__noRel	Decreases in IPSS were greater in degarelix than in goserelin-treated patients, differences being statistically significant in patients with baseline IPSS > 13 (-6.7  1.8 vs -4.0  1.0; P = 0.02).	Medical castration reduces TPV and could also improve LUTS in patients with PCa.
__label__noRel	Decreases in IPSS were greater in degarelix than in goserelin-treated patients, differences being statistically significant in patients with baseline IPSS > 13 (-6.7  1.8 vs -4.0  1.0; P = 0.02).	the short-term efficacy of degarelix and goserelin + bicalutamide was the same in terms of TPV reduction,
__label__Support	Decreases in IPSS were greater in degarelix than in goserelin-treated patients, differences being statistically significant in patients with baseline IPSS > 13 (-6.7  1.8 vs -4.0  1.0; P = 0.02).	degarelix showed superiority in LUTS relief in symptomatic patients, which could highlight the different actions of these drugs on extrapituitary gonadotrophin-releasing hormone (GnRH) receptors in the bladder and/or the prostate.
__label__noRel	The number of patients with an IPSS change of  3 over baseline was also significantly higher in patients treated with degarelix (61.0 vs 44.3%, P = 0.02).	At week 12, changes in TPV for degarelix and goserelin were similar (-37.2% vs -39.0%) and met the predefined non-inferiority criterion.
__label__noRel	The number of patients with an IPSS change of  3 over baseline was also significantly higher in patients treated with degarelix (61.0 vs 44.3%, P = 0.02).	Decreases in IPSS were greater in degarelix than in goserelin-treated patients, differences being statistically significant in patients with baseline IPSS > 13 (-6.7  1.8 vs -4.0  1.0; P = 0.02).
__label__noRel	The number of patients with an IPSS change of  3 over baseline was also significantly higher in patients treated with degarelix (61.0 vs 44.3%, P = 0.02).	Both treatments were safe and well tolerated.
__label__noRel	The number of patients with an IPSS change of  3 over baseline was also significantly higher in patients treated with degarelix (61.0 vs 44.3%, P = 0.02).	Medical castration reduces TPV and could also improve LUTS in patients with PCa.
__label__noRel	The number of patients with an IPSS change of  3 over baseline was also significantly higher in patients treated with degarelix (61.0 vs 44.3%, P = 0.02).	the short-term efficacy of degarelix and goserelin + bicalutamide was the same in terms of TPV reduction,
__label__Support	The number of patients with an IPSS change of  3 over baseline was also significantly higher in patients treated with degarelix (61.0 vs 44.3%, P = 0.02).	degarelix showed superiority in LUTS relief in symptomatic patients, which could highlight the different actions of these drugs on extrapituitary gonadotrophin-releasing hormone (GnRH) receptors in the bladder and/or the prostate.
__label__noRel	Both treatments were safe and well tolerated.	At week 12, changes in TPV for degarelix and goserelin were similar (-37.2% vs -39.0%) and met the predefined non-inferiority criterion.
__label__noRel	Both treatments were safe and well tolerated.	Decreases in IPSS were greater in degarelix than in goserelin-treated patients, differences being statistically significant in patients with baseline IPSS > 13 (-6.7  1.8 vs -4.0  1.0; P = 0.02).
__label__noRel	Both treatments were safe and well tolerated.	The number of patients with an IPSS change of  3 over baseline was also significantly higher in patients treated with degarelix (61.0 vs 44.3%, P = 0.02).
__label__noRel	Both treatments were safe and well tolerated.	Medical castration reduces TPV and could also improve LUTS in patients with PCa.
__label__noRel	Both treatments were safe and well tolerated.	the short-term efficacy of degarelix and goserelin + bicalutamide was the same in terms of TPV reduction,
__label__noRel	Both treatments were safe and well tolerated.	degarelix showed superiority in LUTS relief in symptomatic patients, which could highlight the different actions of these drugs on extrapituitary gonadotrophin-releasing hormone (GnRH) receptors in the bladder and/or the prostate.
__label__noRel	Medical castration reduces TPV and could also improve LUTS in patients with PCa.	At week 12, changes in TPV for degarelix and goserelin were similar (-37.2% vs -39.0%) and met the predefined non-inferiority criterion.
__label__noRel	Medical castration reduces TPV and could also improve LUTS in patients with PCa.	Decreases in IPSS were greater in degarelix than in goserelin-treated patients, differences being statistically significant in patients with baseline IPSS > 13 (-6.7  1.8 vs -4.0  1.0; P = 0.02).
__label__noRel	Medical castration reduces TPV and could also improve LUTS in patients with PCa.	The number of patients with an IPSS change of  3 over baseline was also significantly higher in patients treated with degarelix (61.0 vs 44.3%, P = 0.02).
__label__noRel	Medical castration reduces TPV and could also improve LUTS in patients with PCa.	Both treatments were safe and well tolerated.
__label__noRel	Medical castration reduces TPV and could also improve LUTS in patients with PCa.	the short-term efficacy of degarelix and goserelin + bicalutamide was the same in terms of TPV reduction,
__label__noRel	Medical castration reduces TPV and could also improve LUTS in patients with PCa.	degarelix showed superiority in LUTS relief in symptomatic patients, which could highlight the different actions of these drugs on extrapituitary gonadotrophin-releasing hormone (GnRH) receptors in the bladder and/or the prostate.
__label__noRel	the short-term efficacy of degarelix and goserelin + bicalutamide was the same in terms of TPV reduction,	At week 12, changes in TPV for degarelix and goserelin were similar (-37.2% vs -39.0%) and met the predefined non-inferiority criterion.
__label__noRel	the short-term efficacy of degarelix and goserelin + bicalutamide was the same in terms of TPV reduction,	Decreases in IPSS were greater in degarelix than in goserelin-treated patients, differences being statistically significant in patients with baseline IPSS > 13 (-6.7  1.8 vs -4.0  1.0; P = 0.02).
__label__noRel	the short-term efficacy of degarelix and goserelin + bicalutamide was the same in terms of TPV reduction,	The number of patients with an IPSS change of  3 over baseline was also significantly higher in patients treated with degarelix (61.0 vs 44.3%, P = 0.02).
__label__noRel	the short-term efficacy of degarelix and goserelin + bicalutamide was the same in terms of TPV reduction,	Both treatments were safe and well tolerated.
__label__noRel	the short-term efficacy of degarelix and goserelin + bicalutamide was the same in terms of TPV reduction,	Medical castration reduces TPV and could also improve LUTS in patients with PCa.
__label__noRel	the short-term efficacy of degarelix and goserelin + bicalutamide was the same in terms of TPV reduction,	degarelix showed superiority in LUTS relief in symptomatic patients, which could highlight the different actions of these drugs on extrapituitary gonadotrophin-releasing hormone (GnRH) receptors in the bladder and/or the prostate.
__label__noRel	degarelix showed superiority in LUTS relief in symptomatic patients, which could highlight the different actions of these drugs on extrapituitary gonadotrophin-releasing hormone (GnRH) receptors in the bladder and/or the prostate.	At week 12, changes in TPV for degarelix and goserelin were similar (-37.2% vs -39.0%) and met the predefined non-inferiority criterion.
__label__noRel	degarelix showed superiority in LUTS relief in symptomatic patients, which could highlight the different actions of these drugs on extrapituitary gonadotrophin-releasing hormone (GnRH) receptors in the bladder and/or the prostate.	Decreases in IPSS were greater in degarelix than in goserelin-treated patients, differences being statistically significant in patients with baseline IPSS > 13 (-6.7  1.8 vs -4.0  1.0; P = 0.02).
__label__noRel	degarelix showed superiority in LUTS relief in symptomatic patients, which could highlight the different actions of these drugs on extrapituitary gonadotrophin-releasing hormone (GnRH) receptors in the bladder and/or the prostate.	The number of patients with an IPSS change of  3 over baseline was also significantly higher in patients treated with degarelix (61.0 vs 44.3%, P = 0.02).
__label__noRel	degarelix showed superiority in LUTS relief in symptomatic patients, which could highlight the different actions of these drugs on extrapituitary gonadotrophin-releasing hormone (GnRH) receptors in the bladder and/or the prostate.	Both treatments were safe and well tolerated.
__label__noRel	degarelix showed superiority in LUTS relief in symptomatic patients, which could highlight the different actions of these drugs on extrapituitary gonadotrophin-releasing hormone (GnRH) receptors in the bladder and/or the prostate.	Medical castration reduces TPV and could also improve LUTS in patients with PCa.
__label__noRel	degarelix showed superiority in LUTS relief in symptomatic patients, which could highlight the different actions of these drugs on extrapituitary gonadotrophin-releasing hormone (GnRH) receptors in the bladder and/or the prostate.	the short-term efficacy of degarelix and goserelin + bicalutamide was the same in terms of TPV reduction,
__label__noRel	At 3 months, women treated with 160 mg/d reported less severe side effects (P < .0005), better physical functioning (FLS, P < .0005), less psychologic distress (MHI, P = .008), and an improvement in overall quality of life (FLIC, P = .003) from the time of study entry as compared with those treated with 1,600 mg/d.	Patients who received the 800-mg/d dose fell between the low- and high-dose arms in reported intensity of drug side effects,
__label__noRel	At 3 months, women treated with 160 mg/d reported less severe side effects (P < .0005), better physical functioning (FLS, P < .0005), less psychologic distress (MHI, P = .008), and an improvement in overall quality of life (FLIC, P = .003) from the time of study entry as compared with those treated with 1,600 mg/d.	but responded similarly to those in the 160-mg/d group in terms of physical functioning, psychologic distress, and overall quality of life.
__label__Support	At 3 months, women treated with 160 mg/d reported less severe side effects (P < .0005), better physical functioning (FLS, P < .0005), less psychologic distress (MHI, P = .008), and an improvement in overall quality of life (FLIC, P = .003) from the time of study entry as compared with those treated with 1,600 mg/d.	Unless additional follow-up data demonstrate a survival advantage at higher doses, the 160-mg/d dose is optimal, achieving maximal treatment effect with the fewest side effects and better quality of life.
__label__noRel	Patients who received the 800-mg/d dose fell between the low- and high-dose arms in reported intensity of drug side effects,	At 3 months, women treated with 160 mg/d reported less severe side effects (P < .0005), better physical functioning (FLS, P < .0005), less psychologic distress (MHI, P = .008), and an improvement in overall quality of life (FLIC, P = .003) from the time of study entry as compared with those treated with 1,600 mg/d.
__label__noRel	Patients who received the 800-mg/d dose fell between the low- and high-dose arms in reported intensity of drug side effects,	but responded similarly to those in the 160-mg/d group in terms of physical functioning, psychologic distress, and overall quality of life.
__label__Attack	Patients who received the 800-mg/d dose fell between the low- and high-dose arms in reported intensity of drug side effects,	Unless additional follow-up data demonstrate a survival advantage at higher doses, the 160-mg/d dose is optimal, achieving maximal treatment effect with the fewest side effects and better quality of life.
__label__noRel	but responded similarly to those in the 160-mg/d group in terms of physical functioning, psychologic distress, and overall quality of life.	At 3 months, women treated with 160 mg/d reported less severe side effects (P < .0005), better physical functioning (FLS, P < .0005), less psychologic distress (MHI, P = .008), and an improvement in overall quality of life (FLIC, P = .003) from the time of study entry as compared with those treated with 1,600 mg/d.
__label__Attack	but responded similarly to those in the 160-mg/d group in terms of physical functioning, psychologic distress, and overall quality of life.	Patients who received the 800-mg/d dose fell between the low- and high-dose arms in reported intensity of drug side effects,
__label__noRel	but responded similarly to those in the 160-mg/d group in terms of physical functioning, psychologic distress, and overall quality of life.	Unless additional follow-up data demonstrate a survival advantage at higher doses, the 160-mg/d dose is optimal, achieving maximal treatment effect with the fewest side effects and better quality of life.
__label__noRel	Unless additional follow-up data demonstrate a survival advantage at higher doses, the 160-mg/d dose is optimal, achieving maximal treatment effect with the fewest side effects and better quality of life.	At 3 months, women treated with 160 mg/d reported less severe side effects (P < .0005), better physical functioning (FLS, P < .0005), less psychologic distress (MHI, P = .008), and an improvement in overall quality of life (FLIC, P = .003) from the time of study entry as compared with those treated with 1,600 mg/d.
__label__noRel	Unless additional follow-up data demonstrate a survival advantage at higher doses, the 160-mg/d dose is optimal, achieving maximal treatment effect with the fewest side effects and better quality of life.	Patients who received the 800-mg/d dose fell between the low- and high-dose arms in reported intensity of drug side effects,
__label__noRel	Unless additional follow-up data demonstrate a survival advantage at higher doses, the 160-mg/d dose is optimal, achieving maximal treatment effect with the fewest side effects and better quality of life.	but responded similarly to those in the 160-mg/d group in terms of physical functioning, psychologic distress, and overall quality of life.
__label__noRel	AM was associated with higher rates of acute nausea (P = .03), vomiting (P = .007), cardiovascular toxicity (P = .0001), and infection or febrile neutropenia (P = .03).	The rate of >/= grade 3 esophagitis was 30% with AM versus 34% without AM (P = .9).
__label__noRel	AM was associated with higher rates of acute nausea (P = .03), vomiting (P = .007), cardiovascular toxicity (P = .0001), and infection or febrile neutropenia (P = .03).	Patient diaries demonstrated lower swallowing dysfunction AUC with amifostine (z test P = .025).
__label__noRel	AM was associated with higher rates of acute nausea (P = .03), vomiting (P = .007), cardiovascular toxicity (P = .0001), and infection or febrile neutropenia (P = .03).	QOL was not significantly different between the two arms, except for pain, which showed more clinically meaningful improvement and less deterioration at 6 weeks follow-up (v pretreatment) in the AM arm (P = .003).
__label__noRel	AM was associated with higher rates of acute nausea (P = .03), vomiting (P = .007), cardiovascular toxicity (P = .0001), and infection or febrile neutropenia (P = .03).	The median survival rates for both arms were comparable (AM, 17.3 v no AM, 17.9 months; P = .87).
__label__noRel	AM was associated with higher rates of acute nausea (P = .03), vomiting (P = .007), cardiovascular toxicity (P = .0001), and infection or febrile neutropenia (P = .03).	AM did not significantly reduce esophagitis >/= grade 3 in patients receiving hyperfractionated radiation and chemotherapy.
__label__noRel	AM was associated with higher rates of acute nausea (P = .03), vomiting (P = .007), cardiovascular toxicity (P = .0001), and infection or febrile neutropenia (P = .03).	However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies.
__label__noRel	The rate of >/= grade 3 esophagitis was 30% with AM versus 34% without AM (P = .9).	AM was associated with higher rates of acute nausea (P = .03), vomiting (P = .007), cardiovascular toxicity (P = .0001), and infection or febrile neutropenia (P = .03).
__label__noRel	The rate of >/= grade 3 esophagitis was 30% with AM versus 34% without AM (P = .9).	Patient diaries demonstrated lower swallowing dysfunction AUC with amifostine (z test P = .025).
__label__noRel	The rate of >/= grade 3 esophagitis was 30% with AM versus 34% without AM (P = .9).	QOL was not significantly different between the two arms, except for pain, which showed more clinically meaningful improvement and less deterioration at 6 weeks follow-up (v pretreatment) in the AM arm (P = .003).
__label__noRel	The rate of >/= grade 3 esophagitis was 30% with AM versus 34% without AM (P = .9).	The median survival rates for both arms were comparable (AM, 17.3 v no AM, 17.9 months; P = .87).
__label__Support	The rate of >/= grade 3 esophagitis was 30% with AM versus 34% without AM (P = .9).	AM did not significantly reduce esophagitis >/= grade 3 in patients receiving hyperfractionated radiation and chemotherapy.
__label__noRel	The rate of >/= grade 3 esophagitis was 30% with AM versus 34% without AM (P = .9).	However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies.
__label__noRel	Patient diaries demonstrated lower swallowing dysfunction AUC with amifostine (z test P = .025).	AM was associated with higher rates of acute nausea (P = .03), vomiting (P = .007), cardiovascular toxicity (P = .0001), and infection or febrile neutropenia (P = .03).
__label__noRel	Patient diaries demonstrated lower swallowing dysfunction AUC with amifostine (z test P = .025).	The rate of >/= grade 3 esophagitis was 30% with AM versus 34% without AM (P = .9).
__label__noRel	Patient diaries demonstrated lower swallowing dysfunction AUC with amifostine (z test P = .025).	QOL was not significantly different between the two arms, except for pain, which showed more clinically meaningful improvement and less deterioration at 6 weeks follow-up (v pretreatment) in the AM arm (P = .003).
__label__noRel	Patient diaries demonstrated lower swallowing dysfunction AUC with amifostine (z test P = .025).	The median survival rates for both arms were comparable (AM, 17.3 v no AM, 17.9 months; P = .87).
__label__noRel	Patient diaries demonstrated lower swallowing dysfunction AUC with amifostine (z test P = .025).	AM did not significantly reduce esophagitis >/= grade 3 in patients receiving hyperfractionated radiation and chemotherapy.
__label__noRel	Patient diaries demonstrated lower swallowing dysfunction AUC with amifostine (z test P = .025).	However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies.
__label__noRel	QOL was not significantly different between the two arms, except for pain, which showed more clinically meaningful improvement and less deterioration at 6 weeks follow-up (v pretreatment) in the AM arm (P = .003).	AM was associated with higher rates of acute nausea (P = .03), vomiting (P = .007), cardiovascular toxicity (P = .0001), and infection or febrile neutropenia (P = .03).
__label__noRel	QOL was not significantly different between the two arms, except for pain, which showed more clinically meaningful improvement and less deterioration at 6 weeks follow-up (v pretreatment) in the AM arm (P = .003).	The rate of >/= grade 3 esophagitis was 30% with AM versus 34% without AM (P = .9).
__label__noRel	QOL was not significantly different between the two arms, except for pain, which showed more clinically meaningful improvement and less deterioration at 6 weeks follow-up (v pretreatment) in the AM arm (P = .003).	Patient diaries demonstrated lower swallowing dysfunction AUC with amifostine (z test P = .025).
__label__noRel	QOL was not significantly different between the two arms, except for pain, which showed more clinically meaningful improvement and less deterioration at 6 weeks follow-up (v pretreatment) in the AM arm (P = .003).	The median survival rates for both arms were comparable (AM, 17.3 v no AM, 17.9 months; P = .87).
__label__noRel	QOL was not significantly different between the two arms, except for pain, which showed more clinically meaningful improvement and less deterioration at 6 weeks follow-up (v pretreatment) in the AM arm (P = .003).	AM did not significantly reduce esophagitis >/= grade 3 in patients receiving hyperfractionated radiation and chemotherapy.
__label__Support	QOL was not significantly different between the two arms, except for pain, which showed more clinically meaningful improvement and less deterioration at 6 weeks follow-up (v pretreatment) in the AM arm (P = .003).	However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies.
__label__noRel	The median survival rates for both arms were comparable (AM, 17.3 v no AM, 17.9 months; P = .87).	AM was associated with higher rates of acute nausea (P = .03), vomiting (P = .007), cardiovascular toxicity (P = .0001), and infection or febrile neutropenia (P = .03).
__label__noRel	The median survival rates for both arms were comparable (AM, 17.3 v no AM, 17.9 months; P = .87).	The rate of >/= grade 3 esophagitis was 30% with AM versus 34% without AM (P = .9).
__label__noRel	The median survival rates for both arms were comparable (AM, 17.3 v no AM, 17.9 months; P = .87).	Patient diaries demonstrated lower swallowing dysfunction AUC with amifostine (z test P = .025).
__label__noRel	The median survival rates for both arms were comparable (AM, 17.3 v no AM, 17.9 months; P = .87).	QOL was not significantly different between the two arms, except for pain, which showed more clinically meaningful improvement and less deterioration at 6 weeks follow-up (v pretreatment) in the AM arm (P = .003).
__label__noRel	The median survival rates for both arms were comparable (AM, 17.3 v no AM, 17.9 months; P = .87).	AM did not significantly reduce esophagitis >/= grade 3 in patients receiving hyperfractionated radiation and chemotherapy.
__label__noRel	The median survival rates for both arms were comparable (AM, 17.3 v no AM, 17.9 months; P = .87).	However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies.
__label__noRel	AM did not significantly reduce esophagitis >/= grade 3 in patients receiving hyperfractionated radiation and chemotherapy.	AM was associated with higher rates of acute nausea (P = .03), vomiting (P = .007), cardiovascular toxicity (P = .0001), and infection or febrile neutropenia (P = .03).
__label__noRel	AM did not significantly reduce esophagitis >/= grade 3 in patients receiving hyperfractionated radiation and chemotherapy.	The rate of >/= grade 3 esophagitis was 30% with AM versus 34% without AM (P = .9).
__label__noRel	AM did not significantly reduce esophagitis >/= grade 3 in patients receiving hyperfractionated radiation and chemotherapy.	Patient diaries demonstrated lower swallowing dysfunction AUC with amifostine (z test P = .025).
__label__noRel	AM did not significantly reduce esophagitis >/= grade 3 in patients receiving hyperfractionated radiation and chemotherapy.	QOL was not significantly different between the two arms, except for pain, which showed more clinically meaningful improvement and less deterioration at 6 weeks follow-up (v pretreatment) in the AM arm (P = .003).
__label__noRel	AM did not significantly reduce esophagitis >/= grade 3 in patients receiving hyperfractionated radiation and chemotherapy.	The median survival rates for both arms were comparable (AM, 17.3 v no AM, 17.9 months; P = .87).
__label__noRel	AM did not significantly reduce esophagitis >/= grade 3 in patients receiving hyperfractionated radiation and chemotherapy.	However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies.
__label__noRel	However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies.	AM was associated with higher rates of acute nausea (P = .03), vomiting (P = .007), cardiovascular toxicity (P = .0001), and infection or febrile neutropenia (P = .03).
__label__noRel	However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies.	The rate of >/= grade 3 esophagitis was 30% with AM versus 34% without AM (P = .9).
__label__noRel	However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies.	Patient diaries demonstrated lower swallowing dysfunction AUC with amifostine (z test P = .025).
__label__noRel	However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies.	QOL was not significantly different between the two arms, except for pain, which showed more clinically meaningful improvement and less deterioration at 6 weeks follow-up (v pretreatment) in the AM arm (P = .003).
__label__noRel	However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies.	The median survival rates for both arms were comparable (AM, 17.3 v no AM, 17.9 months; P = .87).
__label__Attack	However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies.	AM did not significantly reduce esophagitis >/= grade 3 in patients receiving hyperfractionated radiation and chemotherapy.
__label__noRel	The mean amount of residual tumor tissue was 28.9% for standard surgery (SS) and 13.8% for surgery involving neuronavigation (SN).	The corresponding mean amounts of residual contrast-enhancing tumor tissue were 29.2 and 24.4%, respectively.
__label__noRel	The mean amount of residual tumor tissue was 28.9% for standard surgery (SS) and 13.8% for surgery involving neuronavigation (SN).	These differences were not significant.
__label__noRel	The mean amount of residual tumor tissue was 28.9% for standard surgery (SS) and 13.8% for surgery involving neuronavigation (SN).	Gross-total removal (GTR) was achieved in five patients who underwent SS and in three who underwent SN.
__label__noRel	The mean amount of residual tumor tissue was 28.9% for standard surgery (SS) and 13.8% for surgery involving neuronavigation (SN).	Median survival was significantly shorter in the SN group (5.6 months compared with 9 months, unadjusted hazard ratio = 1.6);
__label__noRel	The mean amount of residual tumor tissue was 28.9% for standard surgery (SS) and 13.8% for surgery involving neuronavigation (SN).	however, this difference may be attributable to the coincidental early death of three patients in the SN group.
__label__noRel	The mean amount of residual tumor tissue was 28.9% for standard surgery (SS) and 13.8% for surgery involving neuronavigation (SN).	No discernible important effect on the patients' 3-month postoperative course was identified.
__label__noRel	The mean amount of residual tumor tissue was 28.9% for standard surgery (SS) and 13.8% for surgery involving neuronavigation (SN).	There is no rationale for the routine use of neuronavigation to improve the extent of tumor resection and prognosis in patients harboring a solitary enhancing intracerebral lesion when neuronavigation is not already deemed advantageous because of the size or location of the lesion.
__label__noRel	The corresponding mean amounts of residual contrast-enhancing tumor tissue were 29.2 and 24.4%, respectively.	The mean amount of residual tumor tissue was 28.9% for standard surgery (SS) and 13.8% for surgery involving neuronavigation (SN).
__label__noRel	The corresponding mean amounts of residual contrast-enhancing tumor tissue were 29.2 and 24.4%, respectively.	These differences were not significant.
__label__noRel	The corresponding mean amounts of residual contrast-enhancing tumor tissue were 29.2 and 24.4%, respectively.	Gross-total removal (GTR) was achieved in five patients who underwent SS and in three who underwent SN.
__label__noRel	The corresponding mean amounts of residual contrast-enhancing tumor tissue were 29.2 and 24.4%, respectively.	Median survival was significantly shorter in the SN group (5.6 months compared with 9 months, unadjusted hazard ratio = 1.6);
__label__noRel	The corresponding mean amounts of residual contrast-enhancing tumor tissue were 29.2 and 24.4%, respectively.	however, this difference may be attributable to the coincidental early death of three patients in the SN group.
__label__noRel	The corresponding mean amounts of residual contrast-enhancing tumor tissue were 29.2 and 24.4%, respectively.	No discernible important effect on the patients' 3-month postoperative course was identified.
__label__noRel	The corresponding mean amounts of residual contrast-enhancing tumor tissue were 29.2 and 24.4%, respectively.	There is no rationale for the routine use of neuronavigation to improve the extent of tumor resection and prognosis in patients harboring a solitary enhancing intracerebral lesion when neuronavigation is not already deemed advantageous because of the size or location of the lesion.
__label__noRel	These differences were not significant.	The mean amount of residual tumor tissue was 28.9% for standard surgery (SS) and 13.8% for surgery involving neuronavigation (SN).
__label__Attack	These differences were not significant.	The corresponding mean amounts of residual contrast-enhancing tumor tissue were 29.2 and 24.4%, respectively.
__label__noRel	These differences were not significant.	Gross-total removal (GTR) was achieved in five patients who underwent SS and in three who underwent SN.
__label__noRel	These differences were not significant.	Median survival was significantly shorter in the SN group (5.6 months compared with 9 months, unadjusted hazard ratio = 1.6);
__label__noRel	These differences were not significant.	however, this difference may be attributable to the coincidental early death of three patients in the SN group.
__label__noRel	These differences were not significant.	No discernible important effect on the patients' 3-month postoperative course was identified.
__label__noRel	These differences were not significant.	There is no rationale for the routine use of neuronavigation to improve the extent of tumor resection and prognosis in patients harboring a solitary enhancing intracerebral lesion when neuronavigation is not already deemed advantageous because of the size or location of the lesion.
__label__noRel	Gross-total removal (GTR) was achieved in five patients who underwent SS and in three who underwent SN.	The mean amount of residual tumor tissue was 28.9% for standard surgery (SS) and 13.8% for surgery involving neuronavigation (SN).
__label__noRel	Gross-total removal (GTR) was achieved in five patients who underwent SS and in three who underwent SN.	The corresponding mean amounts of residual contrast-enhancing tumor tissue were 29.2 and 24.4%, respectively.
__label__noRel	Gross-total removal (GTR) was achieved in five patients who underwent SS and in three who underwent SN.	These differences were not significant.
__label__noRel	Gross-total removal (GTR) was achieved in five patients who underwent SS and in three who underwent SN.	Median survival was significantly shorter in the SN group (5.6 months compared with 9 months, unadjusted hazard ratio = 1.6);
__label__noRel	Gross-total removal (GTR) was achieved in five patients who underwent SS and in three who underwent SN.	however, this difference may be attributable to the coincidental early death of three patients in the SN group.
__label__noRel	Gross-total removal (GTR) was achieved in five patients who underwent SS and in three who underwent SN.	No discernible important effect on the patients' 3-month postoperative course was identified.
__label__noRel	Gross-total removal (GTR) was achieved in five patients who underwent SS and in three who underwent SN.	There is no rationale for the routine use of neuronavigation to improve the extent of tumor resection and prognosis in patients harboring a solitary enhancing intracerebral lesion when neuronavigation is not already deemed advantageous because of the size or location of the lesion.
__label__noRel	Median survival was significantly shorter in the SN group (5.6 months compared with 9 months, unadjusted hazard ratio = 1.6);	The mean amount of residual tumor tissue was 28.9% for standard surgery (SS) and 13.8% for surgery involving neuronavigation (SN).
__label__noRel	Median survival was significantly shorter in the SN group (5.6 months compared with 9 months, unadjusted hazard ratio = 1.6);	The corresponding mean amounts of residual contrast-enhancing tumor tissue were 29.2 and 24.4%, respectively.
__label__noRel	Median survival was significantly shorter in the SN group (5.6 months compared with 9 months, unadjusted hazard ratio = 1.6);	These differences were not significant.
__label__noRel	Median survival was significantly shorter in the SN group (5.6 months compared with 9 months, unadjusted hazard ratio = 1.6);	Gross-total removal (GTR) was achieved in five patients who underwent SS and in three who underwent SN.
__label__noRel	Median survival was significantly shorter in the SN group (5.6 months compared with 9 months, unadjusted hazard ratio = 1.6);	however, this difference may be attributable to the coincidental early death of three patients in the SN group.
__label__noRel	Median survival was significantly shorter in the SN group (5.6 months compared with 9 months, unadjusted hazard ratio = 1.6);	No discernible important effect on the patients' 3-month postoperative course was identified.
__label__noRel	Median survival was significantly shorter in the SN group (5.6 months compared with 9 months, unadjusted hazard ratio = 1.6);	There is no rationale for the routine use of neuronavigation to improve the extent of tumor resection and prognosis in patients harboring a solitary enhancing intracerebral lesion when neuronavigation is not already deemed advantageous because of the size or location of the lesion.
__label__noRel	however, this difference may be attributable to the coincidental early death of three patients in the SN group.	The mean amount of residual tumor tissue was 28.9% for standard surgery (SS) and 13.8% for surgery involving neuronavigation (SN).
__label__noRel	however, this difference may be attributable to the coincidental early death of three patients in the SN group.	The corresponding mean amounts of residual contrast-enhancing tumor tissue were 29.2 and 24.4%, respectively.
__label__noRel	however, this difference may be attributable to the coincidental early death of three patients in the SN group.	These differences were not significant.
__label__noRel	however, this difference may be attributable to the coincidental early death of three patients in the SN group.	Gross-total removal (GTR) was achieved in five patients who underwent SS and in three who underwent SN.
__label__Attack	however, this difference may be attributable to the coincidental early death of three patients in the SN group.	Median survival was significantly shorter in the SN group (5.6 months compared with 9 months, unadjusted hazard ratio = 1.6);
__label__noRel	however, this difference may be attributable to the coincidental early death of three patients in the SN group.	No discernible important effect on the patients' 3-month postoperative course was identified.
__label__noRel	however, this difference may be attributable to the coincidental early death of three patients in the SN group.	There is no rationale for the routine use of neuronavigation to improve the extent of tumor resection and prognosis in patients harboring a solitary enhancing intracerebral lesion when neuronavigation is not already deemed advantageous because of the size or location of the lesion.
__label__noRel	No discernible important effect on the patients' 3-month postoperative course was identified.	The mean amount of residual tumor tissue was 28.9% for standard surgery (SS) and 13.8% for surgery involving neuronavigation (SN).
__label__noRel	No discernible important effect on the patients' 3-month postoperative course was identified.	The corresponding mean amounts of residual contrast-enhancing tumor tissue were 29.2 and 24.4%, respectively.
__label__noRel	No discernible important effect on the patients' 3-month postoperative course was identified.	These differences were not significant.
__label__noRel	No discernible important effect on the patients' 3-month postoperative course was identified.	Gross-total removal (GTR) was achieved in five patients who underwent SS and in three who underwent SN.
__label__noRel	No discernible important effect on the patients' 3-month postoperative course was identified.	Median survival was significantly shorter in the SN group (5.6 months compared with 9 months, unadjusted hazard ratio = 1.6);
__label__noRel	No discernible important effect on the patients' 3-month postoperative course was identified.	however, this difference may be attributable to the coincidental early death of three patients in the SN group.
__label__noRel	No discernible important effect on the patients' 3-month postoperative course was identified.	There is no rationale for the routine use of neuronavigation to improve the extent of tumor resection and prognosis in patients harboring a solitary enhancing intracerebral lesion when neuronavigation is not already deemed advantageous because of the size or location of the lesion.
__label__noRel	There is no rationale for the routine use of neuronavigation to improve the extent of tumor resection and prognosis in patients harboring a solitary enhancing intracerebral lesion when neuronavigation is not already deemed advantageous because of the size or location of the lesion.	The mean amount of residual tumor tissue was 28.9% for standard surgery (SS) and 13.8% for surgery involving neuronavigation (SN).
__label__noRel	There is no rationale for the routine use of neuronavigation to improve the extent of tumor resection and prognosis in patients harboring a solitary enhancing intracerebral lesion when neuronavigation is not already deemed advantageous because of the size or location of the lesion.	The corresponding mean amounts of residual contrast-enhancing tumor tissue were 29.2 and 24.4%, respectively.
__label__noRel	There is no rationale for the routine use of neuronavigation to improve the extent of tumor resection and prognosis in patients harboring a solitary enhancing intracerebral lesion when neuronavigation is not already deemed advantageous because of the size or location of the lesion.	These differences were not significant.
__label__noRel	There is no rationale for the routine use of neuronavigation to improve the extent of tumor resection and prognosis in patients harboring a solitary enhancing intracerebral lesion when neuronavigation is not already deemed advantageous because of the size or location of the lesion.	Gross-total removal (GTR) was achieved in five patients who underwent SS and in three who underwent SN.
__label__noRel	There is no rationale for the routine use of neuronavigation to improve the extent of tumor resection and prognosis in patients harboring a solitary enhancing intracerebral lesion when neuronavigation is not already deemed advantageous because of the size or location of the lesion.	Median survival was significantly shorter in the SN group (5.6 months compared with 9 months, unadjusted hazard ratio = 1.6);
__label__noRel	There is no rationale for the routine use of neuronavigation to improve the extent of tumor resection and prognosis in patients harboring a solitary enhancing intracerebral lesion when neuronavigation is not already deemed advantageous because of the size or location of the lesion.	however, this difference may be attributable to the coincidental early death of three patients in the SN group.
__label__noRel	There is no rationale for the routine use of neuronavigation to improve the extent of tumor resection and prognosis in patients harboring a solitary enhancing intracerebral lesion when neuronavigation is not already deemed advantageous because of the size or location of the lesion.	No discernible important effect on the patients' 3-month postoperative course was identified.
__label__noRel	There was no difference in any outcome between groups.	Breast symptoms increased for both groups during radiotherapy, without loss of strength or range of movement.
__label__noRel	There was no difference in any outcome between groups.	The incidence of lymphedema during the study was low for both groups and did not differ between groups.
__label__noRel	There was no difference in any outcome between groups.	The pectoral stretching program did not influence the outcomes measured because the symptoms reported by patients were not a consequence of contracture.
__label__noRel	There was no difference in any outcome between groups.	Stretching is an effective technique for increasing range of motion,
__label__noRel	Breast symptoms increased for both groups during radiotherapy, without loss of strength or range of movement.	There was no difference in any outcome between groups.
__label__noRel	Breast symptoms increased for both groups during radiotherapy, without loss of strength or range of movement.	The incidence of lymphedema during the study was low for both groups and did not differ between groups.
__label__noRel	Breast symptoms increased for both groups during radiotherapy, without loss of strength or range of movement.	The pectoral stretching program did not influence the outcomes measured because the symptoms reported by patients were not a consequence of contracture.
__label__noRel	Breast symptoms increased for both groups during radiotherapy, without loss of strength or range of movement.	Stretching is an effective technique for increasing range of motion,
__label__noRel	The incidence of lymphedema during the study was low for both groups and did not differ between groups.	There was no difference in any outcome between groups.
__label__noRel	The incidence of lymphedema during the study was low for both groups and did not differ between groups.	Breast symptoms increased for both groups during radiotherapy, without loss of strength or range of movement.
__label__noRel	The incidence of lymphedema during the study was low for both groups and did not differ between groups.	The pectoral stretching program did not influence the outcomes measured because the symptoms reported by patients were not a consequence of contracture.
__label__noRel	The incidence of lymphedema during the study was low for both groups and did not differ between groups.	Stretching is an effective technique for increasing range of motion,
__label__noRel	The pectoral stretching program did not influence the outcomes measured because the symptoms reported by patients were not a consequence of contracture.	There was no difference in any outcome between groups.
__label__noRel	The pectoral stretching program did not influence the outcomes measured because the symptoms reported by patients were not a consequence of contracture.	Breast symptoms increased for both groups during radiotherapy, without loss of strength or range of movement.
__label__noRel	The pectoral stretching program did not influence the outcomes measured because the symptoms reported by patients were not a consequence of contracture.	The incidence of lymphedema during the study was low for both groups and did not differ between groups.
__label__noRel	The pectoral stretching program did not influence the outcomes measured because the symptoms reported by patients were not a consequence of contracture.	Stretching is an effective technique for increasing range of motion,
__label__noRel	Stretching is an effective technique for increasing range of motion,	There was no difference in any outcome between groups.
__label__noRel	Stretching is an effective technique for increasing range of motion,	Breast symptoms increased for both groups during radiotherapy, without loss of strength or range of movement.
__label__noRel	Stretching is an effective technique for increasing range of motion,	The incidence of lymphedema during the study was low for both groups and did not differ between groups.
__label__noRel	Stretching is an effective technique for increasing range of motion,	The pectoral stretching program did not influence the outcomes measured because the symptoms reported by patients were not a consequence of contracture.
__label__noRel	Subdomain analysis revealed a clinically moderate improvement from baseline for LAC in total QOL index at 18months (P=0.02) as well as other small symptomatic improvements.	Eighteen months after surgery, any differences in quality of life between patients randomized to LAC or open colectomy favored LAC.
__label__noRel	Subdomain analysis revealed a clinically moderate improvement from baseline for LAC in total QOL index at 18months (P=0.02) as well as other small symptomatic improvements.	However, the magnitude of the benefits was small.
__label__noRel	Subdomain analysis revealed a clinically moderate improvement from baseline for LAC in total QOL index at 18months (P=0.02) as well as other small symptomatic improvements.	Patients with poor preoperative QOL appear to be at higher risk for difficult postoperative courses, and may be candidates for enhanced ancillary services to address their particular needs.
__label__Support	Subdomain analysis revealed a clinically moderate improvement from baseline for LAC in total QOL index at 18months (P=0.02) as well as other small symptomatic improvements.	Postoperative outcomes of patients undergoing laparoscopic-assisted colectomy (LAC) have shown modest improvements in recovery but only minimal differences in quality of life (QOL) compared with open colectomy.
__label__noRel	Eighteen months after surgery, any differences in quality of life between patients randomized to LAC or open colectomy favored LAC.	Subdomain analysis revealed a clinically moderate improvement from baseline for LAC in total QOL index at 18months (P=0.02) as well as other small symptomatic improvements.
__label__noRel	Eighteen months after surgery, any differences in quality of life between patients randomized to LAC or open colectomy favored LAC.	However, the magnitude of the benefits was small.
__label__noRel	Eighteen months after surgery, any differences in quality of life between patients randomized to LAC or open colectomy favored LAC.	Patients with poor preoperative QOL appear to be at higher risk for difficult postoperative courses, and may be candidates for enhanced ancillary services to address their particular needs.
__label__Support	Eighteen months after surgery, any differences in quality of life between patients randomized to LAC or open colectomy favored LAC.	Postoperative outcomes of patients undergoing laparoscopic-assisted colectomy (LAC) have shown modest improvements in recovery but only minimal differences in quality of life (QOL) compared with open colectomy.
__label__noRel	However, the magnitude of the benefits was small.	Subdomain analysis revealed a clinically moderate improvement from baseline for LAC in total QOL index at 18months (P=0.02) as well as other small symptomatic improvements.
__label__Attack	However, the magnitude of the benefits was small.	Eighteen months after surgery, any differences in quality of life between patients randomized to LAC or open colectomy favored LAC.
__label__noRel	However, the magnitude of the benefits was small.	Patients with poor preoperative QOL appear to be at higher risk for difficult postoperative courses, and may be candidates for enhanced ancillary services to address their particular needs.
__label__noRel	However, the magnitude of the benefits was small.	Postoperative outcomes of patients undergoing laparoscopic-assisted colectomy (LAC) have shown modest improvements in recovery but only minimal differences in quality of life (QOL) compared with open colectomy.
__label__noRel	Patients with poor preoperative QOL appear to be at higher risk for difficult postoperative courses, and may be candidates for enhanced ancillary services to address their particular needs.	Subdomain analysis revealed a clinically moderate improvement from baseline for LAC in total QOL index at 18months (P=0.02) as well as other small symptomatic improvements.
__label__noRel	Patients with poor preoperative QOL appear to be at higher risk for difficult postoperative courses, and may be candidates for enhanced ancillary services to address their particular needs.	Eighteen months after surgery, any differences in quality of life between patients randomized to LAC or open colectomy favored LAC.
__label__noRel	Patients with poor preoperative QOL appear to be at higher risk for difficult postoperative courses, and may be candidates for enhanced ancillary services to address their particular needs.	However, the magnitude of the benefits was small.
__label__noRel	Patients with poor preoperative QOL appear to be at higher risk for difficult postoperative courses, and may be candidates for enhanced ancillary services to address their particular needs.	Postoperative outcomes of patients undergoing laparoscopic-assisted colectomy (LAC) have shown modest improvements in recovery but only minimal differences in quality of life (QOL) compared with open colectomy.
__label__noRel	Postoperative outcomes of patients undergoing laparoscopic-assisted colectomy (LAC) have shown modest improvements in recovery but only minimal differences in quality of life (QOL) compared with open colectomy.	Subdomain analysis revealed a clinically moderate improvement from baseline for LAC in total QOL index at 18months (P=0.02) as well as other small symptomatic improvements.
__label__noRel	Postoperative outcomes of patients undergoing laparoscopic-assisted colectomy (LAC) have shown modest improvements in recovery but only minimal differences in quality of life (QOL) compared with open colectomy.	Eighteen months after surgery, any differences in quality of life between patients randomized to LAC or open colectomy favored LAC.
__label__noRel	Postoperative outcomes of patients undergoing laparoscopic-assisted colectomy (LAC) have shown modest improvements in recovery but only minimal differences in quality of life (QOL) compared with open colectomy.	However, the magnitude of the benefits was small.
__label__noRel	Postoperative outcomes of patients undergoing laparoscopic-assisted colectomy (LAC) have shown modest improvements in recovery but only minimal differences in quality of life (QOL) compared with open colectomy.	Patients with poor preoperative QOL appear to be at higher risk for difficult postoperative courses, and may be candidates for enhanced ancillary services to address their particular needs.
__label__noRel	Compared with the control group, the intervention group had an improvement in fatigue as shown by a significantly greater decrease in BFI global score (-0.66 points; 95% CI -1.04 to -0.27) and FSS total score (-0.49; 95% CI, -0.78 to -0.21).	In secondary outcomes, the intervention group experienced a significantly greater decrease in HADS anxiety score (-0.90; 95% CI, -1.51 to -0.29) as well as global quality of life (5.22; 95% CI, 0.93 to 9.50) and several functioning scores of the EORTC QLQ-C30.
__label__noRel	Compared with the control group, the intervention group had an improvement in fatigue as shown by a significantly greater decrease in BFI global score (-0.66 points; 95% CI -1.04 to -0.27) and FSS total score (-0.49; 95% CI, -0.78 to -0.21).	An Internet-based education program based on NCCN guidelines and TTM may help patients manage CRF.
__label__Support	Compared with the control group, the intervention group had an improvement in fatigue as shown by a significantly greater decrease in BFI global score (-0.66 points; 95% CI -1.04 to -0.27) and FSS total score (-0.49; 95% CI, -0.78 to -0.21).	Internet-based tailored education program is effective for disease-free cancer survivors with cancer-related fatigue (CRF).
__label__noRel	In secondary outcomes, the intervention group experienced a significantly greater decrease in HADS anxiety score (-0.90; 95% CI, -1.51 to -0.29) as well as global quality of life (5.22; 95% CI, 0.93 to 9.50) and several functioning scores of the EORTC QLQ-C30.	Compared with the control group, the intervention group had an improvement in fatigue as shown by a significantly greater decrease in BFI global score (-0.66 points; 95% CI -1.04 to -0.27) and FSS total score (-0.49; 95% CI, -0.78 to -0.21).
__label__noRel	In secondary outcomes, the intervention group experienced a significantly greater decrease in HADS anxiety score (-0.90; 95% CI, -1.51 to -0.29) as well as global quality of life (5.22; 95% CI, 0.93 to 9.50) and several functioning scores of the EORTC QLQ-C30.	An Internet-based education program based on NCCN guidelines and TTM may help patients manage CRF.
__label__Support	In secondary outcomes, the intervention group experienced a significantly greater decrease in HADS anxiety score (-0.90; 95% CI, -1.51 to -0.29) as well as global quality of life (5.22; 95% CI, 0.93 to 9.50) and several functioning scores of the EORTC QLQ-C30.	Internet-based tailored education program is effective for disease-free cancer survivors with cancer-related fatigue (CRF).
__label__noRel	An Internet-based education program based on NCCN guidelines and TTM may help patients manage CRF.	Compared with the control group, the intervention group had an improvement in fatigue as shown by a significantly greater decrease in BFI global score (-0.66 points; 95% CI -1.04 to -0.27) and FSS total score (-0.49; 95% CI, -0.78 to -0.21).
__label__noRel	An Internet-based education program based on NCCN guidelines and TTM may help patients manage CRF.	In secondary outcomes, the intervention group experienced a significantly greater decrease in HADS anxiety score (-0.90; 95% CI, -1.51 to -0.29) as well as global quality of life (5.22; 95% CI, 0.93 to 9.50) and several functioning scores of the EORTC QLQ-C30.
__label__noRel	An Internet-based education program based on NCCN guidelines and TTM may help patients manage CRF.	Internet-based tailored education program is effective for disease-free cancer survivors with cancer-related fatigue (CRF).
__label__noRel	Internet-based tailored education program is effective for disease-free cancer survivors with cancer-related fatigue (CRF).	Compared with the control group, the intervention group had an improvement in fatigue as shown by a significantly greater decrease in BFI global score (-0.66 points; 95% CI -1.04 to -0.27) and FSS total score (-0.49; 95% CI, -0.78 to -0.21).
__label__noRel	Internet-based tailored education program is effective for disease-free cancer survivors with cancer-related fatigue (CRF).	In secondary outcomes, the intervention group experienced a significantly greater decrease in HADS anxiety score (-0.90; 95% CI, -1.51 to -0.29) as well as global quality of life (5.22; 95% CI, 0.93 to 9.50) and several functioning scores of the EORTC QLQ-C30.
__label__noRel	Internet-based tailored education program is effective for disease-free cancer survivors with cancer-related fatigue (CRF).	An Internet-based education program based on NCCN guidelines and TTM may help patients manage CRF.
__label__noRel	This negative impact tended to last longer in the HDC group, as for most of the QLQ-C30 scales, the QOL scores of HDC patients tend to improve at a slower rate than that of patients receiving standard chemotherapy.	physical functioning remains deteriorated 1 year after inclusion for HDC patients comparatively to conventional chemotherapy patients (85.99 vs. 76.65, P = 0.021)
__label__noRel	This negative impact tended to last longer in the HDC group, as for most of the QLQ-C30 scales, the QOL scores of HDC patients tend to improve at a slower rate than that of patients receiving standard chemotherapy.	and the pain score was still higher in the HDC group at that time (28.32 vs. 15.97, P = 0.004).
__label__noRel	This negative impact tended to last longer in the HDC group, as for most of the QLQ-C30 scales, the QOL scores of HDC patients tend to improve at a slower rate than that of patients receiving standard chemotherapy.	HDC has a negative impact on QOL even after treatment phase.
__label__Support	This negative impact tended to last longer in the HDC group, as for most of the QLQ-C30 scales, the QOL scores of HDC patients tend to improve at a slower rate than that of patients receiving standard chemotherapy.	Toxicity of HDC has a strong negative impact on patients' QOL during the treatment phase.
__label__noRel	physical functioning remains deteriorated 1 year after inclusion for HDC patients comparatively to conventional chemotherapy patients (85.99 vs. 76.65, P = 0.021)	This negative impact tended to last longer in the HDC group, as for most of the QLQ-C30 scales, the QOL scores of HDC patients tend to improve at a slower rate than that of patients receiving standard chemotherapy.
__label__noRel	physical functioning remains deteriorated 1 year after inclusion for HDC patients comparatively to conventional chemotherapy patients (85.99 vs. 76.65, P = 0.021)	and the pain score was still higher in the HDC group at that time (28.32 vs. 15.97, P = 0.004).
__label__Support	physical functioning remains deteriorated 1 year after inclusion for HDC patients comparatively to conventional chemotherapy patients (85.99 vs. 76.65, P = 0.021)	HDC has a negative impact on QOL even after treatment phase.
__label__noRel	physical functioning remains deteriorated 1 year after inclusion for HDC patients comparatively to conventional chemotherapy patients (85.99 vs. 76.65, P = 0.021)	Toxicity of HDC has a strong negative impact on patients' QOL during the treatment phase.
__label__noRel	and the pain score was still higher in the HDC group at that time (28.32 vs. 15.97, P = 0.004).	This negative impact tended to last longer in the HDC group, as for most of the QLQ-C30 scales, the QOL scores of HDC patients tend to improve at a slower rate than that of patients receiving standard chemotherapy.
__label__noRel	and the pain score was still higher in the HDC group at that time (28.32 vs. 15.97, P = 0.004).	physical functioning remains deteriorated 1 year after inclusion for HDC patients comparatively to conventional chemotherapy patients (85.99 vs. 76.65, P = 0.021)
__label__Support	and the pain score was still higher in the HDC group at that time (28.32 vs. 15.97, P = 0.004).	HDC has a negative impact on QOL even after treatment phase.
__label__noRel	and the pain score was still higher in the HDC group at that time (28.32 vs. 15.97, P = 0.004).	Toxicity of HDC has a strong negative impact on patients' QOL during the treatment phase.
__label__noRel	HDC has a negative impact on QOL even after treatment phase.	This negative impact tended to last longer in the HDC group, as for most of the QLQ-C30 scales, the QOL scores of HDC patients tend to improve at a slower rate than that of patients receiving standard chemotherapy.
__label__noRel	HDC has a negative impact on QOL even after treatment phase.	physical functioning remains deteriorated 1 year after inclusion for HDC patients comparatively to conventional chemotherapy patients (85.99 vs. 76.65, P = 0.021)
__label__noRel	HDC has a negative impact on QOL even after treatment phase.	and the pain score was still higher in the HDC group at that time (28.32 vs. 15.97, P = 0.004).
__label__noRel	HDC has a negative impact on QOL even after treatment phase.	Toxicity of HDC has a strong negative impact on patients' QOL during the treatment phase.
__label__noRel	Toxicity of HDC has a strong negative impact on patients' QOL during the treatment phase.	This negative impact tended to last longer in the HDC group, as for most of the QLQ-C30 scales, the QOL scores of HDC patients tend to improve at a slower rate than that of patients receiving standard chemotherapy.
__label__noRel	Toxicity of HDC has a strong negative impact on patients' QOL during the treatment phase.	physical functioning remains deteriorated 1 year after inclusion for HDC patients comparatively to conventional chemotherapy patients (85.99 vs. 76.65, P = 0.021)
__label__noRel	Toxicity of HDC has a strong negative impact on patients' QOL during the treatment phase.	and the pain score was still higher in the HDC group at that time (28.32 vs. 15.97, P = 0.004).
__label__Support	Toxicity of HDC has a strong negative impact on patients' QOL during the treatment phase.	HDC has a negative impact on QOL even after treatment phase.
__label__noRel	Patients allocated to oxaliplatin plus LV5FU2 had significantly longer progression-free survival (median, 9.0 v 6.2 months; P =.0003) and better response rate (50.7% v 22.3%; P =.0001) when compared with the control arm.	The improvement in overall survival did not reach significance (median, 16.2 v 14.7 months; P =. 12).
__label__noRel	Patients allocated to oxaliplatin plus LV5FU2 had significantly longer progression-free survival (median, 9.0 v 6.2 months; P =.0003) and better response rate (50.7% v 22.3%; P =.0001) when compared with the control arm.	LV5FU2 plus oxaliplatin gave higher frequencies of National Cancer Institute common toxicity criteria grade 3/4 neutropenia (41. 7% v 5.3% of patients), grade 3/4 diarrhea (11.9% v 5.3%), and grade 3 neurosensory toxicity (18.2% v 0%), but this did not result in impairment of quality of life (QoL).
__label__noRel	Patients allocated to oxaliplatin plus LV5FU2 had significantly longer progression-free survival (median, 9.0 v 6.2 months; P =.0003) and better response rate (50.7% v 22.3%; P =.0001) when compared with the control arm.	Survival without disease progression or deterioration in global health status was longer in patients allocated to oxaliplatin treatment (P =.004).
__label__Support	Patients allocated to oxaliplatin plus LV5FU2 had significantly longer progression-free survival (median, 9.0 v 6.2 months; P =.0003) and better response rate (50.7% v 22.3%; P =.0001) when compared with the control arm.	The LV5FU2-oxaliplatin combination seems beneficial as first-line therapy in advanced colorectal cancer, demonstrating a prolonged progression-free survival with acceptable tolerability and maintenance of QoL.
__label__noRel	The improvement in overall survival did not reach significance (median, 16.2 v 14.7 months; P =. 12).	Patients allocated to oxaliplatin plus LV5FU2 had significantly longer progression-free survival (median, 9.0 v 6.2 months; P =.0003) and better response rate (50.7% v 22.3%; P =.0001) when compared with the control arm.
__label__noRel	The improvement in overall survival did not reach significance (median, 16.2 v 14.7 months; P =. 12).	LV5FU2 plus oxaliplatin gave higher frequencies of National Cancer Institute common toxicity criteria grade 3/4 neutropenia (41. 7% v 5.3% of patients), grade 3/4 diarrhea (11.9% v 5.3%), and grade 3 neurosensory toxicity (18.2% v 0%), but this did not result in impairment of quality of life (QoL).
__label__noRel	The improvement in overall survival did not reach significance (median, 16.2 v 14.7 months; P =. 12).	Survival without disease progression or deterioration in global health status was longer in patients allocated to oxaliplatin treatment (P =.004).
__label__noRel	The improvement in overall survival did not reach significance (median, 16.2 v 14.7 months; P =. 12).	The LV5FU2-oxaliplatin combination seems beneficial as first-line therapy in advanced colorectal cancer, demonstrating a prolonged progression-free survival with acceptable tolerability and maintenance of QoL.
__label__noRel	LV5FU2 plus oxaliplatin gave higher frequencies of National Cancer Institute common toxicity criteria grade 3/4 neutropenia (41. 7% v 5.3% of patients), grade 3/4 diarrhea (11.9% v 5.3%), and grade 3 neurosensory toxicity (18.2% v 0%), but this did not result in impairment of quality of life (QoL).	Patients allocated to oxaliplatin plus LV5FU2 had significantly longer progression-free survival (median, 9.0 v 6.2 months; P =.0003) and better response rate (50.7% v 22.3%; P =.0001) when compared with the control arm.
__label__noRel	LV5FU2 plus oxaliplatin gave higher frequencies of National Cancer Institute common toxicity criteria grade 3/4 neutropenia (41. 7% v 5.3% of patients), grade 3/4 diarrhea (11.9% v 5.3%), and grade 3 neurosensory toxicity (18.2% v 0%), but this did not result in impairment of quality of life (QoL).	The improvement in overall survival did not reach significance (median, 16.2 v 14.7 months; P =. 12).
__label__noRel	LV5FU2 plus oxaliplatin gave higher frequencies of National Cancer Institute common toxicity criteria grade 3/4 neutropenia (41. 7% v 5.3% of patients), grade 3/4 diarrhea (11.9% v 5.3%), and grade 3 neurosensory toxicity (18.2% v 0%), but this did not result in impairment of quality of life (QoL).	Survival without disease progression or deterioration in global health status was longer in patients allocated to oxaliplatin treatment (P =.004).
__label__Support	LV5FU2 plus oxaliplatin gave higher frequencies of National Cancer Institute common toxicity criteria grade 3/4 neutropenia (41. 7% v 5.3% of patients), grade 3/4 diarrhea (11.9% v 5.3%), and grade 3 neurosensory toxicity (18.2% v 0%), but this did not result in impairment of quality of life (QoL).	The LV5FU2-oxaliplatin combination seems beneficial as first-line therapy in advanced colorectal cancer, demonstrating a prolonged progression-free survival with acceptable tolerability and maintenance of QoL.
__label__noRel	Survival without disease progression or deterioration in global health status was longer in patients allocated to oxaliplatin treatment (P =.004).	Patients allocated to oxaliplatin plus LV5FU2 had significantly longer progression-free survival (median, 9.0 v 6.2 months; P =.0003) and better response rate (50.7% v 22.3%; P =.0001) when compared with the control arm.
__label__noRel	Survival without disease progression or deterioration in global health status was longer in patients allocated to oxaliplatin treatment (P =.004).	The improvement in overall survival did not reach significance (median, 16.2 v 14.7 months; P =. 12).
__label__noRel	Survival without disease progression or deterioration in global health status was longer in patients allocated to oxaliplatin treatment (P =.004).	LV5FU2 plus oxaliplatin gave higher frequencies of National Cancer Institute common toxicity criteria grade 3/4 neutropenia (41. 7% v 5.3% of patients), grade 3/4 diarrhea (11.9% v 5.3%), and grade 3 neurosensory toxicity (18.2% v 0%), but this did not result in impairment of quality of life (QoL).
__label__Support	Survival without disease progression or deterioration in global health status was longer in patients allocated to oxaliplatin treatment (P =.004).	The LV5FU2-oxaliplatin combination seems beneficial as first-line therapy in advanced colorectal cancer, demonstrating a prolonged progression-free survival with acceptable tolerability and maintenance of QoL.
__label__noRel	The LV5FU2-oxaliplatin combination seems beneficial as first-line therapy in advanced colorectal cancer, demonstrating a prolonged progression-free survival with acceptable tolerability and maintenance of QoL.	Patients allocated to oxaliplatin plus LV5FU2 had significantly longer progression-free survival (median, 9.0 v 6.2 months; P =.0003) and better response rate (50.7% v 22.3%; P =.0001) when compared with the control arm.
__label__noRel	The LV5FU2-oxaliplatin combination seems beneficial as first-line therapy in advanced colorectal cancer, demonstrating a prolonged progression-free survival with acceptable tolerability and maintenance of QoL.	The improvement in overall survival did not reach significance (median, 16.2 v 14.7 months; P =. 12).
__label__noRel	The LV5FU2-oxaliplatin combination seems beneficial as first-line therapy in advanced colorectal cancer, demonstrating a prolonged progression-free survival with acceptable tolerability and maintenance of QoL.	LV5FU2 plus oxaliplatin gave higher frequencies of National Cancer Institute common toxicity criteria grade 3/4 neutropenia (41. 7% v 5.3% of patients), grade 3/4 diarrhea (11.9% v 5.3%), and grade 3 neurosensory toxicity (18.2% v 0%), but this did not result in impairment of quality of life (QoL).
__label__noRel	The LV5FU2-oxaliplatin combination seems beneficial as first-line therapy in advanced colorectal cancer, demonstrating a prolonged progression-free survival with acceptable tolerability and maintenance of QoL.	Survival without disease progression or deterioration in global health status was longer in patients allocated to oxaliplatin treatment (P =.004).
__label__noRel	In all study groups, serum TSH levels showed very good stimulation (mean, 82.24 +/- 18.21 mU/L), without significant between-group differences (p = 0.5213).	The successful ablation rate was 91.0% in T4-WD Group, 91.7% in T3-WD Group, and 91.3% in rhTSH Group, without significant between-preparation differences (p = 0.2061).
__label__noRel	In all study groups, serum TSH levels showed very good stimulation (mean, 82.24 +/- 18.21 mU/L), without significant between-group differences (p = 0.5213).	QoL was better preserved in rhTSH Group than in T4-WD and T3-WD Groups (p < 0.0001).
__label__noRel	In all study groups, serum TSH levels showed very good stimulation (mean, 82.24 +/- 18.21 mU/L), without significant between-group differences (p = 0.5213).	However, there was no QoL difference at the time of ablation between T4-WD and T3-WD Groups.
__label__Support	In all study groups, serum TSH levels showed very good stimulation (mean, 82.24 +/- 18.21 mU/L), without significant between-group differences (p = 0.5213).	Our study indicates that use of rhTSH preserves QoL in patients undergoing RI ablation and affords an ablation success rate comparable to that seen after thyroid hormone withdrawal.
__label__noRel	The successful ablation rate was 91.0% in T4-WD Group, 91.7% in T3-WD Group, and 91.3% in rhTSH Group, without significant between-preparation differences (p = 0.2061).	In all study groups, serum TSH levels showed very good stimulation (mean, 82.24 +/- 18.21 mU/L), without significant between-group differences (p = 0.5213).
__label__noRel	The successful ablation rate was 91.0% in T4-WD Group, 91.7% in T3-WD Group, and 91.3% in rhTSH Group, without significant between-preparation differences (p = 0.2061).	QoL was better preserved in rhTSH Group than in T4-WD and T3-WD Groups (p < 0.0001).
__label__noRel	The successful ablation rate was 91.0% in T4-WD Group, 91.7% in T3-WD Group, and 91.3% in rhTSH Group, without significant between-preparation differences (p = 0.2061).	However, there was no QoL difference at the time of ablation between T4-WD and T3-WD Groups.
__label__Support	The successful ablation rate was 91.0% in T4-WD Group, 91.7% in T3-WD Group, and 91.3% in rhTSH Group, without significant between-preparation differences (p = 0.2061).	Our study indicates that use of rhTSH preserves QoL in patients undergoing RI ablation and affords an ablation success rate comparable to that seen after thyroid hormone withdrawal.
__label__noRel	QoL was better preserved in rhTSH Group than in T4-WD and T3-WD Groups (p < 0.0001).	In all study groups, serum TSH levels showed very good stimulation (mean, 82.24 +/- 18.21 mU/L), without significant between-group differences (p = 0.5213).
__label__noRel	QoL was better preserved in rhTSH Group than in T4-WD and T3-WD Groups (p < 0.0001).	The successful ablation rate was 91.0% in T4-WD Group, 91.7% in T3-WD Group, and 91.3% in rhTSH Group, without significant between-preparation differences (p = 0.2061).
__label__noRel	QoL was better preserved in rhTSH Group than in T4-WD and T3-WD Groups (p < 0.0001).	However, there was no QoL difference at the time of ablation between T4-WD and T3-WD Groups.
__label__Support	QoL was better preserved in rhTSH Group than in T4-WD and T3-WD Groups (p < 0.0001).	Our study indicates that use of rhTSH preserves QoL in patients undergoing RI ablation and affords an ablation success rate comparable to that seen after thyroid hormone withdrawal.
__label__noRel	However, there was no QoL difference at the time of ablation between T4-WD and T3-WD Groups.	In all study groups, serum TSH levels showed very good stimulation (mean, 82.24 +/- 18.21 mU/L), without significant between-group differences (p = 0.5213).
__label__noRel	However, there was no QoL difference at the time of ablation between T4-WD and T3-WD Groups.	The successful ablation rate was 91.0% in T4-WD Group, 91.7% in T3-WD Group, and 91.3% in rhTSH Group, without significant between-preparation differences (p = 0.2061).
__label__Attack	However, there was no QoL difference at the time of ablation between T4-WD and T3-WD Groups.	QoL was better preserved in rhTSH Group than in T4-WD and T3-WD Groups (p < 0.0001).
__label__noRel	However, there was no QoL difference at the time of ablation between T4-WD and T3-WD Groups.	Our study indicates that use of rhTSH preserves QoL in patients undergoing RI ablation and affords an ablation success rate comparable to that seen after thyroid hormone withdrawal.
__label__noRel	Our study indicates that use of rhTSH preserves QoL in patients undergoing RI ablation and affords an ablation success rate comparable to that seen after thyroid hormone withdrawal.	In all study groups, serum TSH levels showed very good stimulation (mean, 82.24 +/- 18.21 mU/L), without significant between-group differences (p = 0.5213).
__label__noRel	Our study indicates that use of rhTSH preserves QoL in patients undergoing RI ablation and affords an ablation success rate comparable to that seen after thyroid hormone withdrawal.	The successful ablation rate was 91.0% in T4-WD Group, 91.7% in T3-WD Group, and 91.3% in rhTSH Group, without significant between-preparation differences (p = 0.2061).
__label__noRel	Our study indicates that use of rhTSH preserves QoL in patients undergoing RI ablation and affords an ablation success rate comparable to that seen after thyroid hormone withdrawal.	QoL was better preserved in rhTSH Group than in T4-WD and T3-WD Groups (p < 0.0001).
__label__noRel	Our study indicates that use of rhTSH preserves QoL in patients undergoing RI ablation and affords an ablation success rate comparable to that seen after thyroid hormone withdrawal.	However, there was no QoL difference at the time of ablation between T4-WD and T3-WD Groups.
__label__noRel	Overall, patients receiving goserelin alone showed a marked improvement or less deterioration in QOL measures over the first 6 months than those patients treated with CMF.	There were no differences at 3 years after random assignment according to treatment except for hot flashes.
__label__noRel	Overall, patients receiving goserelin alone showed a marked improvement or less deterioration in QOL measures over the first 6 months than those patients treated with CMF.	As reflected in the hot flashes scores, patients in all three treatment groups experienced induced amenorrhea,
__label__noRel	Overall, patients receiving goserelin alone showed a marked improvement or less deterioration in QOL measures over the first 6 months than those patients treated with CMF.	but the onset of ovarian function suppression was slightly delayed for patients receiving chemotherapy.
__label__noRel	Overall, patients receiving goserelin alone showed a marked improvement or less deterioration in QOL measures over the first 6 months than those patients treated with CMF.	Younger patients (< 40 years) who received goserelin alone returned to their premenopausal status at 6 months after the cessation of therapy, while those who received CMF showed marginal changes from their baseline hot flashes scores.
__label__Support	Overall, patients receiving goserelin alone showed a marked improvement or less deterioration in QOL measures over the first 6 months than those patients treated with CMF.	Age-adjusted risk profiles that consider patient-reported outcomes enable patients to adapt to their disease and treatment, such as considering the trade-offs between delayed endocrine symptoms, but higher risk of permanent menopause with chemotherapy, and immediate but reversible endocrine symptoms with goserelin, in younger premenopausal patients.
__label__noRel	There were no differences at 3 years after random assignment according to treatment except for hot flashes.	Overall, patients receiving goserelin alone showed a marked improvement or less deterioration in QOL measures over the first 6 months than those patients treated with CMF.
__label__noRel	There were no differences at 3 years after random assignment according to treatment except for hot flashes.	As reflected in the hot flashes scores, patients in all three treatment groups experienced induced amenorrhea,
__label__noRel	There were no differences at 3 years after random assignment according to treatment except for hot flashes.	but the onset of ovarian function suppression was slightly delayed for patients receiving chemotherapy.
__label__noRel	There were no differences at 3 years after random assignment according to treatment except for hot flashes.	Younger patients (< 40 years) who received goserelin alone returned to their premenopausal status at 6 months after the cessation of therapy, while those who received CMF showed marginal changes from their baseline hot flashes scores.
__label__Support	There were no differences at 3 years after random assignment according to treatment except for hot flashes.	Age-adjusted risk profiles that consider patient-reported outcomes enable patients to adapt to their disease and treatment, such as considering the trade-offs between delayed endocrine symptoms, but higher risk of permanent menopause with chemotherapy, and immediate but reversible endocrine symptoms with goserelin, in younger premenopausal patients.
__label__noRel	As reflected in the hot flashes scores, patients in all three treatment groups experienced induced amenorrhea,	Overall, patients receiving goserelin alone showed a marked improvement or less deterioration in QOL measures over the first 6 months than those patients treated with CMF.
__label__noRel	As reflected in the hot flashes scores, patients in all three treatment groups experienced induced amenorrhea,	There were no differences at 3 years after random assignment according to treatment except for hot flashes.
__label__noRel	As reflected in the hot flashes scores, patients in all three treatment groups experienced induced amenorrhea,	but the onset of ovarian function suppression was slightly delayed for patients receiving chemotherapy.
__label__noRel	As reflected in the hot flashes scores, patients in all three treatment groups experienced induced amenorrhea,	Younger patients (< 40 years) who received goserelin alone returned to their premenopausal status at 6 months after the cessation of therapy, while those who received CMF showed marginal changes from their baseline hot flashes scores.
__label__Support	As reflected in the hot flashes scores, patients in all three treatment groups experienced induced amenorrhea,	Age-adjusted risk profiles that consider patient-reported outcomes enable patients to adapt to their disease and treatment, such as considering the trade-offs between delayed endocrine symptoms, but higher risk of permanent menopause with chemotherapy, and immediate but reversible endocrine symptoms with goserelin, in younger premenopausal patients.
__label__noRel	but the onset of ovarian function suppression was slightly delayed for patients receiving chemotherapy.	Overall, patients receiving goserelin alone showed a marked improvement or less deterioration in QOL measures over the first 6 months than those patients treated with CMF.
__label__noRel	but the onset of ovarian function suppression was slightly delayed for patients receiving chemotherapy.	There were no differences at 3 years after random assignment according to treatment except for hot flashes.
__label__Attack	but the onset of ovarian function suppression was slightly delayed for patients receiving chemotherapy.	As reflected in the hot flashes scores, patients in all three treatment groups experienced induced amenorrhea,
__label__noRel	but the onset of ovarian function suppression was slightly delayed for patients receiving chemotherapy.	Younger patients (< 40 years) who received goserelin alone returned to their premenopausal status at 6 months after the cessation of therapy, while those who received CMF showed marginal changes from their baseline hot flashes scores.
__label__noRel	but the onset of ovarian function suppression was slightly delayed for patients receiving chemotherapy.	Age-adjusted risk profiles that consider patient-reported outcomes enable patients to adapt to their disease and treatment, such as considering the trade-offs between delayed endocrine symptoms, but higher risk of permanent menopause with chemotherapy, and immediate but reversible endocrine symptoms with goserelin, in younger premenopausal patients.
__label__noRel	Younger patients (< 40 years) who received goserelin alone returned to their premenopausal status at 6 months after the cessation of therapy, while those who received CMF showed marginal changes from their baseline hot flashes scores.	Overall, patients receiving goserelin alone showed a marked improvement or less deterioration in QOL measures over the first 6 months than those patients treated with CMF.
__label__noRel	Younger patients (< 40 years) who received goserelin alone returned to their premenopausal status at 6 months after the cessation of therapy, while those who received CMF showed marginal changes from their baseline hot flashes scores.	There were no differences at 3 years after random assignment according to treatment except for hot flashes.
__label__noRel	Younger patients (< 40 years) who received goserelin alone returned to their premenopausal status at 6 months after the cessation of therapy, while those who received CMF showed marginal changes from their baseline hot flashes scores.	As reflected in the hot flashes scores, patients in all three treatment groups experienced induced amenorrhea,
__label__noRel	Younger patients (< 40 years) who received goserelin alone returned to their premenopausal status at 6 months after the cessation of therapy, while those who received CMF showed marginal changes from their baseline hot flashes scores.	but the onset of ovarian function suppression was slightly delayed for patients receiving chemotherapy.
__label__Support	Younger patients (< 40 years) who received goserelin alone returned to their premenopausal status at 6 months after the cessation of therapy, while those who received CMF showed marginal changes from their baseline hot flashes scores.	Age-adjusted risk profiles that consider patient-reported outcomes enable patients to adapt to their disease and treatment, such as considering the trade-offs between delayed endocrine symptoms, but higher risk of permanent menopause with chemotherapy, and immediate but reversible endocrine symptoms with goserelin, in younger premenopausal patients.
__label__noRel	Age-adjusted risk profiles that consider patient-reported outcomes enable patients to adapt to their disease and treatment, such as considering the trade-offs between delayed endocrine symptoms, but higher risk of permanent menopause with chemotherapy, and immediate but reversible endocrine symptoms with goserelin, in younger premenopausal patients.	Overall, patients receiving goserelin alone showed a marked improvement or less deterioration in QOL measures over the first 6 months than those patients treated with CMF.
__label__noRel	Age-adjusted risk profiles that consider patient-reported outcomes enable patients to adapt to their disease and treatment, such as considering the trade-offs between delayed endocrine symptoms, but higher risk of permanent menopause with chemotherapy, and immediate but reversible endocrine symptoms with goserelin, in younger premenopausal patients.	There were no differences at 3 years after random assignment according to treatment except for hot flashes.
__label__noRel	Age-adjusted risk profiles that consider patient-reported outcomes enable patients to adapt to their disease and treatment, such as considering the trade-offs between delayed endocrine symptoms, but higher risk of permanent menopause with chemotherapy, and immediate but reversible endocrine symptoms with goserelin, in younger premenopausal patients.	As reflected in the hot flashes scores, patients in all three treatment groups experienced induced amenorrhea,
__label__noRel	Age-adjusted risk profiles that consider patient-reported outcomes enable patients to adapt to their disease and treatment, such as considering the trade-offs between delayed endocrine symptoms, but higher risk of permanent menopause with chemotherapy, and immediate but reversible endocrine symptoms with goserelin, in younger premenopausal patients.	but the onset of ovarian function suppression was slightly delayed for patients receiving chemotherapy.
__label__noRel	Age-adjusted risk profiles that consider patient-reported outcomes enable patients to adapt to their disease and treatment, such as considering the trade-offs between delayed endocrine symptoms, but higher risk of permanent menopause with chemotherapy, and immediate but reversible endocrine symptoms with goserelin, in younger premenopausal patients.	Younger patients (< 40 years) who received goserelin alone returned to their premenopausal status at 6 months after the cessation of therapy, while those who received CMF showed marginal changes from their baseline hot flashes scores.
__label__noRel	Rigorous standard operating procedures for data collection are required.	A blinded RCT investigating the role of epidural and WIC administration for postoperative analgesia following LCR is feasible.
__label__noRel	Rigorous standard operating procedures for data collection are required.	Qualitative interviews suggested that patients found participation in the trial acceptable and that they would consider participating in a future trial.
__label__noRel	Rigorous standard operating procedures for data collection are required.	Mean(s.d.) pain scores on the day of discharge were 19(31) in the epidural group and 07(07) in the WIC group.
__label__noRel	Rigorous standard operating procedures for data collection are required.	Median length of stay was 4 (range 2-35, interquartile range 3-5) days.
__label__noRel	Rigorous standard operating procedures for data collection are required.	Mean use of additional analgesia (intravenous morphine equivalents) was 12 mg in the WIC arm and 9 mg in the epidural arm.
__label__noRel	A blinded RCT investigating the role of epidural and WIC administration for postoperative analgesia following LCR is feasible.	Rigorous standard operating procedures for data collection are required.
__label__noRel	A blinded RCT investigating the role of epidural and WIC administration for postoperative analgesia following LCR is feasible.	Qualitative interviews suggested that patients found participation in the trial acceptable and that they would consider participating in a future trial.
__label__noRel	A blinded RCT investigating the role of epidural and WIC administration for postoperative analgesia following LCR is feasible.	Mean(s.d.) pain scores on the day of discharge were 19(31) in the epidural group and 07(07) in the WIC group.
__label__noRel	A blinded RCT investigating the role of epidural and WIC administration for postoperative analgesia following LCR is feasible.	Median length of stay was 4 (range 2-35, interquartile range 3-5) days.
__label__noRel	A blinded RCT investigating the role of epidural and WIC administration for postoperative analgesia following LCR is feasible.	Mean use of additional analgesia (intravenous morphine equivalents) was 12 mg in the WIC arm and 9 mg in the epidural arm.
__label__noRel	Qualitative interviews suggested that patients found participation in the trial acceptable and that they would consider participating in a future trial.	Rigorous standard operating procedures for data collection are required.
__label__Support	Qualitative interviews suggested that patients found participation in the trial acceptable and that they would consider participating in a future trial.	A blinded RCT investigating the role of epidural and WIC administration for postoperative analgesia following LCR is feasible.
__label__noRel	Qualitative interviews suggested that patients found participation in the trial acceptable and that they would consider participating in a future trial.	Mean(s.d.) pain scores on the day of discharge were 19(31) in the epidural group and 07(07) in the WIC group.
__label__noRel	Qualitative interviews suggested that patients found participation in the trial acceptable and that they would consider participating in a future trial.	Median length of stay was 4 (range 2-35, interquartile range 3-5) days.
__label__noRel	Qualitative interviews suggested that patients found participation in the trial acceptable and that they would consider participating in a future trial.	Mean use of additional analgesia (intravenous morphine equivalents) was 12 mg in the WIC arm and 9 mg in the epidural arm.
__label__noRel	Mean(s.d.) pain scores on the day of discharge were 19(31) in the epidural group and 07(07) in the WIC group.	Rigorous standard operating procedures for data collection are required.
__label__noRel	Mean(s.d.) pain scores on the day of discharge were 19(31) in the epidural group and 07(07) in the WIC group.	A blinded RCT investigating the role of epidural and WIC administration for postoperative analgesia following LCR is feasible.
__label__noRel	Mean(s.d.) pain scores on the day of discharge were 19(31) in the epidural group and 07(07) in the WIC group.	Qualitative interviews suggested that patients found participation in the trial acceptable and that they would consider participating in a future trial.
__label__noRel	Mean(s.d.) pain scores on the day of discharge were 19(31) in the epidural group and 07(07) in the WIC group.	Median length of stay was 4 (range 2-35, interquartile range 3-5) days.
__label__noRel	Mean(s.d.) pain scores on the day of discharge were 19(31) in the epidural group and 07(07) in the WIC group.	Mean use of additional analgesia (intravenous morphine equivalents) was 12 mg in the WIC arm and 9 mg in the epidural arm.
__label__noRel	Median length of stay was 4 (range 2-35, interquartile range 3-5) days.	Rigorous standard operating procedures for data collection are required.
__label__noRel	Median length of stay was 4 (range 2-35, interquartile range 3-5) days.	A blinded RCT investigating the role of epidural and WIC administration for postoperative analgesia following LCR is feasible.
__label__noRel	Median length of stay was 4 (range 2-35, interquartile range 3-5) days.	Qualitative interviews suggested that patients found participation in the trial acceptable and that they would consider participating in a future trial.
__label__noRel	Median length of stay was 4 (range 2-35, interquartile range 3-5) days.	Mean(s.d.) pain scores on the day of discharge were 19(31) in the epidural group and 07(07) in the WIC group.
__label__noRel	Median length of stay was 4 (range 2-35, interquartile range 3-5) days.	Mean use of additional analgesia (intravenous morphine equivalents) was 12 mg in the WIC arm and 9 mg in the epidural arm.
__label__noRel	Mean use of additional analgesia (intravenous morphine equivalents) was 12 mg in the WIC arm and 9 mg in the epidural arm.	Rigorous standard operating procedures for data collection are required.
__label__noRel	Mean use of additional analgesia (intravenous morphine equivalents) was 12 mg in the WIC arm and 9 mg in the epidural arm.	A blinded RCT investigating the role of epidural and WIC administration for postoperative analgesia following LCR is feasible.
__label__noRel	Mean use of additional analgesia (intravenous morphine equivalents) was 12 mg in the WIC arm and 9 mg in the epidural arm.	Qualitative interviews suggested that patients found participation in the trial acceptable and that they would consider participating in a future trial.
__label__noRel	Mean use of additional analgesia (intravenous morphine equivalents) was 12 mg in the WIC arm and 9 mg in the epidural arm.	Mean(s.d.) pain scores on the day of discharge were 19(31) in the epidural group and 07(07) in the WIC group.
__label__noRel	Mean use of additional analgesia (intravenous morphine equivalents) was 12 mg in the WIC arm and 9 mg in the epidural arm.	Median length of stay was 4 (range 2-35, interquartile range 3-5) days.
__label__noRel	Anemia was the most common hematological toxicity (88 % of patients).	Most frequent non-hematological toxicities were nausea (76 %), constipation (68 %), and fatigue (64 %).
__label__noRel	Anemia was the most common hematological toxicity (88 % of patients).	Treatment was generally well tolerated despite the fact that most patients suffered from multiple comorbidities and were heavily pretreated.
__label__Support	Anemia was the most common hematological toxicity (88 % of patients).	There were no unexpected hematological or non-hematological toxicities.
__label__noRel	Most frequent non-hematological toxicities were nausea (76 %), constipation (68 %), and fatigue (64 %).	Anemia was the most common hematological toxicity (88 % of patients).
__label__noRel	Most frequent non-hematological toxicities were nausea (76 %), constipation (68 %), and fatigue (64 %).	Treatment was generally well tolerated despite the fact that most patients suffered from multiple comorbidities and were heavily pretreated.
__label__Support	Most frequent non-hematological toxicities were nausea (76 %), constipation (68 %), and fatigue (64 %).	There were no unexpected hematological or non-hematological toxicities.
__label__noRel	Treatment was generally well tolerated despite the fact that most patients suffered from multiple comorbidities and were heavily pretreated.	Anemia was the most common hematological toxicity (88 % of patients).
__label__noRel	Treatment was generally well tolerated despite the fact that most patients suffered from multiple comorbidities and were heavily pretreated.	Most frequent non-hematological toxicities were nausea (76 %), constipation (68 %), and fatigue (64 %).
__label__noRel	Treatment was generally well tolerated despite the fact that most patients suffered from multiple comorbidities and were heavily pretreated.	There were no unexpected hematological or non-hematological toxicities.
__label__noRel	There were no unexpected hematological or non-hematological toxicities.	Anemia was the most common hematological toxicity (88 % of patients).
__label__noRel	There were no unexpected hematological or non-hematological toxicities.	Most frequent non-hematological toxicities were nausea (76 %), constipation (68 %), and fatigue (64 %).
__label__Support	There were no unexpected hematological or non-hematological toxicities.	Treatment was generally well tolerated despite the fact that most patients suffered from multiple comorbidities and were heavily pretreated.
__label__noRel	Survival was significantly longer (hazard ratio, 0.70; P < .0001) in the erlotinib arm.	Compliance with QOL was 87% at baseline and more than 70% during treatment.
__label__noRel	Survival was significantly longer (hazard ratio, 0.70; P < .0001) in the erlotinib arm.	Patients receiving erlotinib had significantly longer median time to deterioration for all three symptoms (4.9 v 3.7 months for cough [P = .04]; 4.7 v 2.9 months for dyspnea [P = .04], and 2.8 v 1.9 months for pain [P = .03]).
__label__noRel	Survival was significantly longer (hazard ratio, 0.70; P < .0001) in the erlotinib arm.	QOL response analyses showed that 44%, 34%, and 42% of patients receiving erlotinib had improvement in these three symptoms, respectively.
__label__noRel	Survival was significantly longer (hazard ratio, 0.70; P < .0001) in the erlotinib arm.	This was accompanied by a significant improvement in the physical function (31% erlotinib v 19% placebo, P = .01), and global QOL (35% v 26%, P < .0001).
__label__noRel	Survival was significantly longer (hazard ratio, 0.70; P < .0001) in the erlotinib arm.	Patients with complete or partial response were more likely to have improvement in the QOL response than patients with stable or progressive disease (P < .01).
__label__Support	Survival was significantly longer (hazard ratio, 0.70; P < .0001) in the erlotinib arm.	Erlotinib not only improves survival in previously treated patients with NSCLC, but also improves tumor-related symptoms and important aspects of QOL.
__label__noRel	Compliance with QOL was 87% at baseline and more than 70% during treatment.	Survival was significantly longer (hazard ratio, 0.70; P < .0001) in the erlotinib arm.
__label__noRel	Compliance with QOL was 87% at baseline and more than 70% during treatment.	Patients receiving erlotinib had significantly longer median time to deterioration for all three symptoms (4.9 v 3.7 months for cough [P = .04]; 4.7 v 2.9 months for dyspnea [P = .04], and 2.8 v 1.9 months for pain [P = .03]).
__label__noRel	Compliance with QOL was 87% at baseline and more than 70% during treatment.	QOL response analyses showed that 44%, 34%, and 42% of patients receiving erlotinib had improvement in these three symptoms, respectively.
__label__noRel	Compliance with QOL was 87% at baseline and more than 70% during treatment.	This was accompanied by a significant improvement in the physical function (31% erlotinib v 19% placebo, P = .01), and global QOL (35% v 26%, P < .0001).
__label__noRel	Compliance with QOL was 87% at baseline and more than 70% during treatment.	Patients with complete or partial response were more likely to have improvement in the QOL response than patients with stable or progressive disease (P < .01).
__label__Support	Compliance with QOL was 87% at baseline and more than 70% during treatment.	Erlotinib not only improves survival in previously treated patients with NSCLC, but also improves tumor-related symptoms and important aspects of QOL.
__label__noRel	Patients receiving erlotinib had significantly longer median time to deterioration for all three symptoms (4.9 v 3.7 months for cough [P = .04]; 4.7 v 2.9 months for dyspnea [P = .04], and 2.8 v 1.9 months for pain [P = .03]).	Survival was significantly longer (hazard ratio, 0.70; P < .0001) in the erlotinib arm.
__label__noRel	Patients receiving erlotinib had significantly longer median time to deterioration for all three symptoms (4.9 v 3.7 months for cough [P = .04]; 4.7 v 2.9 months for dyspnea [P = .04], and 2.8 v 1.9 months for pain [P = .03]).	Compliance with QOL was 87% at baseline and more than 70% during treatment.
__label__noRel	Patients receiving erlotinib had significantly longer median time to deterioration for all three symptoms (4.9 v 3.7 months for cough [P = .04]; 4.7 v 2.9 months for dyspnea [P = .04], and 2.8 v 1.9 months for pain [P = .03]).	QOL response analyses showed that 44%, 34%, and 42% of patients receiving erlotinib had improvement in these three symptoms, respectively.
__label__noRel	Patients receiving erlotinib had significantly longer median time to deterioration for all three symptoms (4.9 v 3.7 months for cough [P = .04]; 4.7 v 2.9 months for dyspnea [P = .04], and 2.8 v 1.9 months for pain [P = .03]).	This was accompanied by a significant improvement in the physical function (31% erlotinib v 19% placebo, P = .01), and global QOL (35% v 26%, P < .0001).
__label__noRel	Patients receiving erlotinib had significantly longer median time to deterioration for all three symptoms (4.9 v 3.7 months for cough [P = .04]; 4.7 v 2.9 months for dyspnea [P = .04], and 2.8 v 1.9 months for pain [P = .03]).	Patients with complete or partial response were more likely to have improvement in the QOL response than patients with stable or progressive disease (P < .01).
__label__Support	Patients receiving erlotinib had significantly longer median time to deterioration for all three symptoms (4.9 v 3.7 months for cough [P = .04]; 4.7 v 2.9 months for dyspnea [P = .04], and 2.8 v 1.9 months for pain [P = .03]).	Erlotinib not only improves survival in previously treated patients with NSCLC, but also improves tumor-related symptoms and important aspects of QOL.
__label__noRel	QOL response analyses showed that 44%, 34%, and 42% of patients receiving erlotinib had improvement in these three symptoms, respectively.	Survival was significantly longer (hazard ratio, 0.70; P < .0001) in the erlotinib arm.
__label__noRel	QOL response analyses showed that 44%, 34%, and 42% of patients receiving erlotinib had improvement in these three symptoms, respectively.	Compliance with QOL was 87% at baseline and more than 70% during treatment.
__label__noRel	QOL response analyses showed that 44%, 34%, and 42% of patients receiving erlotinib had improvement in these three symptoms, respectively.	Patients receiving erlotinib had significantly longer median time to deterioration for all three symptoms (4.9 v 3.7 months for cough [P = .04]; 4.7 v 2.9 months for dyspnea [P = .04], and 2.8 v 1.9 months for pain [P = .03]).
__label__noRel	QOL response analyses showed that 44%, 34%, and 42% of patients receiving erlotinib had improvement in these three symptoms, respectively.	This was accompanied by a significant improvement in the physical function (31% erlotinib v 19% placebo, P = .01), and global QOL (35% v 26%, P < .0001).
__label__noRel	QOL response analyses showed that 44%, 34%, and 42% of patients receiving erlotinib had improvement in these three symptoms, respectively.	Patients with complete or partial response were more likely to have improvement in the QOL response than patients with stable or progressive disease (P < .01).
__label__Support	QOL response analyses showed that 44%, 34%, and 42% of patients receiving erlotinib had improvement in these three symptoms, respectively.	Erlotinib not only improves survival in previously treated patients with NSCLC, but also improves tumor-related symptoms and important aspects of QOL.
__label__noRel	This was accompanied by a significant improvement in the physical function (31% erlotinib v 19% placebo, P = .01), and global QOL (35% v 26%, P < .0001).	Survival was significantly longer (hazard ratio, 0.70; P < .0001) in the erlotinib arm.
__label__noRel	This was accompanied by a significant improvement in the physical function (31% erlotinib v 19% placebo, P = .01), and global QOL (35% v 26%, P < .0001).	Compliance with QOL was 87% at baseline and more than 70% during treatment.
__label__noRel	This was accompanied by a significant improvement in the physical function (31% erlotinib v 19% placebo, P = .01), and global QOL (35% v 26%, P < .0001).	Patients receiving erlotinib had significantly longer median time to deterioration for all three symptoms (4.9 v 3.7 months for cough [P = .04]; 4.7 v 2.9 months for dyspnea [P = .04], and 2.8 v 1.9 months for pain [P = .03]).
__label__noRel	This was accompanied by a significant improvement in the physical function (31% erlotinib v 19% placebo, P = .01), and global QOL (35% v 26%, P < .0001).	QOL response analyses showed that 44%, 34%, and 42% of patients receiving erlotinib had improvement in these three symptoms, respectively.
__label__noRel	This was accompanied by a significant improvement in the physical function (31% erlotinib v 19% placebo, P = .01), and global QOL (35% v 26%, P < .0001).	Patients with complete or partial response were more likely to have improvement in the QOL response than patients with stable or progressive disease (P < .01).
__label__Support	This was accompanied by a significant improvement in the physical function (31% erlotinib v 19% placebo, P = .01), and global QOL (35% v 26%, P < .0001).	Erlotinib not only improves survival in previously treated patients with NSCLC, but also improves tumor-related symptoms and important aspects of QOL.
__label__noRel	Patients with complete or partial response were more likely to have improvement in the QOL response than patients with stable or progressive disease (P < .01).	Survival was significantly longer (hazard ratio, 0.70; P < .0001) in the erlotinib arm.
__label__noRel	Patients with complete or partial response were more likely to have improvement in the QOL response than patients with stable or progressive disease (P < .01).	Compliance with QOL was 87% at baseline and more than 70% during treatment.
__label__noRel	Patients with complete or partial response were more likely to have improvement in the QOL response than patients with stable or progressive disease (P < .01).	Patients receiving erlotinib had significantly longer median time to deterioration for all three symptoms (4.9 v 3.7 months for cough [P = .04]; 4.7 v 2.9 months for dyspnea [P = .04], and 2.8 v 1.9 months for pain [P = .03]).
__label__noRel	Patients with complete or partial response were more likely to have improvement in the QOL response than patients with stable or progressive disease (P < .01).	QOL response analyses showed that 44%, 34%, and 42% of patients receiving erlotinib had improvement in these three symptoms, respectively.
__label__noRel	Patients with complete or partial response were more likely to have improvement in the QOL response than patients with stable or progressive disease (P < .01).	This was accompanied by a significant improvement in the physical function (31% erlotinib v 19% placebo, P = .01), and global QOL (35% v 26%, P < .0001).
__label__noRel	Patients with complete or partial response were more likely to have improvement in the QOL response than patients with stable or progressive disease (P < .01).	Erlotinib not only improves survival in previously treated patients with NSCLC, but also improves tumor-related symptoms and important aspects of QOL.
__label__noRel	Erlotinib not only improves survival in previously treated patients with NSCLC, but also improves tumor-related symptoms and important aspects of QOL.	Survival was significantly longer (hazard ratio, 0.70; P < .0001) in the erlotinib arm.
__label__noRel	Erlotinib not only improves survival in previously treated patients with NSCLC, but also improves tumor-related symptoms and important aspects of QOL.	Compliance with QOL was 87% at baseline and more than 70% during treatment.
__label__noRel	Erlotinib not only improves survival in previously treated patients with NSCLC, but also improves tumor-related symptoms and important aspects of QOL.	Patients receiving erlotinib had significantly longer median time to deterioration for all three symptoms (4.9 v 3.7 months for cough [P = .04]; 4.7 v 2.9 months for dyspnea [P = .04], and 2.8 v 1.9 months for pain [P = .03]).
__label__noRel	Erlotinib not only improves survival in previously treated patients with NSCLC, but also improves tumor-related symptoms and important aspects of QOL.	QOL response analyses showed that 44%, 34%, and 42% of patients receiving erlotinib had improvement in these three symptoms, respectively.
__label__noRel	Erlotinib not only improves survival in previously treated patients with NSCLC, but also improves tumor-related symptoms and important aspects of QOL.	This was accompanied by a significant improvement in the physical function (31% erlotinib v 19% placebo, P = .01), and global QOL (35% v 26%, P < .0001).
__label__noRel	Erlotinib not only improves survival in previously treated patients with NSCLC, but also improves tumor-related symptoms and important aspects of QOL.	Patients with complete or partial response were more likely to have improvement in the QOL response than patients with stable or progressive disease (P < .01).
__label__noRel	There were significant differences between treatment groups favouring the SNB group throughout the 18 months assessment.	Patients in the standard treatment group showed a greater decline in Trial Outcome Index (TOI) scores (physical well-being, functional well-being and breast cancer concerns subscales in FACT-B+4) and recovered more slowly than patients in the SNB group (p < 0.01).
__label__noRel	There were significant differences between treatment groups favouring the SNB group throughout the 18 months assessment.	The change in total FACT-B+4 scores (measuring global QOL) closely resembled the TOI results.
__label__noRel	There were significant differences between treatment groups favouring the SNB group throughout the 18 months assessment.	18 months post-surgery approximately twice as many patients in the standard group compared with the SNB group reported substantial arm swelling (14% versus 7%) (p = 0.002) or numbness (19% versus 8.7%) (p < 0.001).
__label__noRel	There were significant differences between treatment groups favouring the SNB group throughout the 18 months assessment.	there was no evidence of increased anxiety amongst patients randomised to SNB (p > 0.05).
__label__noRel	There were significant differences between treatment groups favouring the SNB group throughout the 18 months assessment.	For 6 months post-surgery younger patients reported less favourable QOL scores (p < 0.001) and greater levels of anxiety (p < 0.01).
__label__noRel	There were significant differences between treatment groups favouring the SNB group throughout the 18 months assessment.	In view of the benefits regarding arm functioning and quality of life, the data from this randomised study support the use of SNB in patients with clinically node negative breast cancer.
__label__Support	Patients in the standard treatment group showed a greater decline in Trial Outcome Index (TOI) scores (physical well-being, functional well-being and breast cancer concerns subscales in FACT-B+4) and recovered more slowly than patients in the SNB group (p < 0.01).	There were significant differences between treatment groups favouring the SNB group throughout the 18 months assessment.
__label__noRel	Patients in the standard treatment group showed a greater decline in Trial Outcome Index (TOI) scores (physical well-being, functional well-being and breast cancer concerns subscales in FACT-B+4) and recovered more slowly than patients in the SNB group (p < 0.01).	The change in total FACT-B+4 scores (measuring global QOL) closely resembled the TOI results.
__label__noRel	Patients in the standard treatment group showed a greater decline in Trial Outcome Index (TOI) scores (physical well-being, functional well-being and breast cancer concerns subscales in FACT-B+4) and recovered more slowly than patients in the SNB group (p < 0.01).	18 months post-surgery approximately twice as many patients in the standard group compared with the SNB group reported substantial arm swelling (14% versus 7%) (p = 0.002) or numbness (19% versus 8.7%) (p < 0.001).
__label__noRel	Patients in the standard treatment group showed a greater decline in Trial Outcome Index (TOI) scores (physical well-being, functional well-being and breast cancer concerns subscales in FACT-B+4) and recovered more slowly than patients in the SNB group (p < 0.01).	there was no evidence of increased anxiety amongst patients randomised to SNB (p > 0.05).
__label__noRel	Patients in the standard treatment group showed a greater decline in Trial Outcome Index (TOI) scores (physical well-being, functional well-being and breast cancer concerns subscales in FACT-B+4) and recovered more slowly than patients in the SNB group (p < 0.01).	For 6 months post-surgery younger patients reported less favourable QOL scores (p < 0.001) and greater levels of anxiety (p < 0.01).
__label__noRel	Patients in the standard treatment group showed a greater decline in Trial Outcome Index (TOI) scores (physical well-being, functional well-being and breast cancer concerns subscales in FACT-B+4) and recovered more slowly than patients in the SNB group (p < 0.01).	In view of the benefits regarding arm functioning and quality of life, the data from this randomised study support the use of SNB in patients with clinically node negative breast cancer.
__label__Support	The change in total FACT-B+4 scores (measuring global QOL) closely resembled the TOI results.	There were significant differences between treatment groups favouring the SNB group throughout the 18 months assessment.
__label__noRel	The change in total FACT-B+4 scores (measuring global QOL) closely resembled the TOI results.	Patients in the standard treatment group showed a greater decline in Trial Outcome Index (TOI) scores (physical well-being, functional well-being and breast cancer concerns subscales in FACT-B+4) and recovered more slowly than patients in the SNB group (p < 0.01).
__label__noRel	The change in total FACT-B+4 scores (measuring global QOL) closely resembled the TOI results.	18 months post-surgery approximately twice as many patients in the standard group compared with the SNB group reported substantial arm swelling (14% versus 7%) (p = 0.002) or numbness (19% versus 8.7%) (p < 0.001).
__label__noRel	The change in total FACT-B+4 scores (measuring global QOL) closely resembled the TOI results.	there was no evidence of increased anxiety amongst patients randomised to SNB (p > 0.05).
__label__noRel	The change in total FACT-B+4 scores (measuring global QOL) closely resembled the TOI results.	For 6 months post-surgery younger patients reported less favourable QOL scores (p < 0.001) and greater levels of anxiety (p < 0.01).
__label__noRel	The change in total FACT-B+4 scores (measuring global QOL) closely resembled the TOI results.	In view of the benefits regarding arm functioning and quality of life, the data from this randomised study support the use of SNB in patients with clinically node negative breast cancer.
__label__noRel	18 months post-surgery approximately twice as many patients in the standard group compared with the SNB group reported substantial arm swelling (14% versus 7%) (p = 0.002) or numbness (19% versus 8.7%) (p < 0.001).	There were significant differences between treatment groups favouring the SNB group throughout the 18 months assessment.
__label__noRel	18 months post-surgery approximately twice as many patients in the standard group compared with the SNB group reported substantial arm swelling (14% versus 7%) (p = 0.002) or numbness (19% versus 8.7%) (p < 0.001).	Patients in the standard treatment group showed a greater decline in Trial Outcome Index (TOI) scores (physical well-being, functional well-being and breast cancer concerns subscales in FACT-B+4) and recovered more slowly than patients in the SNB group (p < 0.01).
__label__noRel	18 months post-surgery approximately twice as many patients in the standard group compared with the SNB group reported substantial arm swelling (14% versus 7%) (p = 0.002) or numbness (19% versus 8.7%) (p < 0.001).	The change in total FACT-B+4 scores (measuring global QOL) closely resembled the TOI results.
__label__noRel	18 months post-surgery approximately twice as many patients in the standard group compared with the SNB group reported substantial arm swelling (14% versus 7%) (p = 0.002) or numbness (19% versus 8.7%) (p < 0.001).	there was no evidence of increased anxiety amongst patients randomised to SNB (p > 0.05).
__label__noRel	18 months post-surgery approximately twice as many patients in the standard group compared with the SNB group reported substantial arm swelling (14% versus 7%) (p = 0.002) or numbness (19% versus 8.7%) (p < 0.001).	For 6 months post-surgery younger patients reported less favourable QOL scores (p < 0.001) and greater levels of anxiety (p < 0.01).
__label__Support	18 months post-surgery approximately twice as many patients in the standard group compared with the SNB group reported substantial arm swelling (14% versus 7%) (p = 0.002) or numbness (19% versus 8.7%) (p < 0.001).	In view of the benefits regarding arm functioning and quality of life, the data from this randomised study support the use of SNB in patients with clinically node negative breast cancer.
__label__noRel	there was no evidence of increased anxiety amongst patients randomised to SNB (p > 0.05).	There were significant differences between treatment groups favouring the SNB group throughout the 18 months assessment.
__label__noRel	there was no evidence of increased anxiety amongst patients randomised to SNB (p > 0.05).	Patients in the standard treatment group showed a greater decline in Trial Outcome Index (TOI) scores (physical well-being, functional well-being and breast cancer concerns subscales in FACT-B+4) and recovered more slowly than patients in the SNB group (p < 0.01).
__label__noRel	there was no evidence of increased anxiety amongst patients randomised to SNB (p > 0.05).	The change in total FACT-B+4 scores (measuring global QOL) closely resembled the TOI results.
__label__noRel	there was no evidence of increased anxiety amongst patients randomised to SNB (p > 0.05).	18 months post-surgery approximately twice as many patients in the standard group compared with the SNB group reported substantial arm swelling (14% versus 7%) (p = 0.002) or numbness (19% versus 8.7%) (p < 0.001).
__label__noRel	there was no evidence of increased anxiety amongst patients randomised to SNB (p > 0.05).	For 6 months post-surgery younger patients reported less favourable QOL scores (p < 0.001) and greater levels of anxiety (p < 0.01).
__label__Support	there was no evidence of increased anxiety amongst patients randomised to SNB (p > 0.05).	In view of the benefits regarding arm functioning and quality of life, the data from this randomised study support the use of SNB in patients with clinically node negative breast cancer.
__label__noRel	For 6 months post-surgery younger patients reported less favourable QOL scores (p < 0.001) and greater levels of anxiety (p < 0.01).	There were significant differences between treatment groups favouring the SNB group throughout the 18 months assessment.
__label__noRel	For 6 months post-surgery younger patients reported less favourable QOL scores (p < 0.001) and greater levels of anxiety (p < 0.01).	Patients in the standard treatment group showed a greater decline in Trial Outcome Index (TOI) scores (physical well-being, functional well-being and breast cancer concerns subscales in FACT-B+4) and recovered more slowly than patients in the SNB group (p < 0.01).
__label__noRel	For 6 months post-surgery younger patients reported less favourable QOL scores (p < 0.001) and greater levels of anxiety (p < 0.01).	The change in total FACT-B+4 scores (measuring global QOL) closely resembled the TOI results.
__label__noRel	For 6 months post-surgery younger patients reported less favourable QOL scores (p < 0.001) and greater levels of anxiety (p < 0.01).	18 months post-surgery approximately twice as many patients in the standard group compared with the SNB group reported substantial arm swelling (14% versus 7%) (p = 0.002) or numbness (19% versus 8.7%) (p < 0.001).
__label__noRel	For 6 months post-surgery younger patients reported less favourable QOL scores (p < 0.001) and greater levels of anxiety (p < 0.01).	there was no evidence of increased anxiety amongst patients randomised to SNB (p > 0.05).
__label__Support	For 6 months post-surgery younger patients reported less favourable QOL scores (p < 0.001) and greater levels of anxiety (p < 0.01).	In view of the benefits regarding arm functioning and quality of life, the data from this randomised study support the use of SNB in patients with clinically node negative breast cancer.
__label__noRel	In view of the benefits regarding arm functioning and quality of life, the data from this randomised study support the use of SNB in patients with clinically node negative breast cancer.	There were significant differences between treatment groups favouring the SNB group throughout the 18 months assessment.
__label__noRel	In view of the benefits regarding arm functioning and quality of life, the data from this randomised study support the use of SNB in patients with clinically node negative breast cancer.	Patients in the standard treatment group showed a greater decline in Trial Outcome Index (TOI) scores (physical well-being, functional well-being and breast cancer concerns subscales in FACT-B+4) and recovered more slowly than patients in the SNB group (p < 0.01).
__label__noRel	In view of the benefits regarding arm functioning and quality of life, the data from this randomised study support the use of SNB in patients with clinically node negative breast cancer.	The change in total FACT-B+4 scores (measuring global QOL) closely resembled the TOI results.
__label__noRel	In view of the benefits regarding arm functioning and quality of life, the data from this randomised study support the use of SNB in patients with clinically node negative breast cancer.	18 months post-surgery approximately twice as many patients in the standard group compared with the SNB group reported substantial arm swelling (14% versus 7%) (p = 0.002) or numbness (19% versus 8.7%) (p < 0.001).
__label__noRel	In view of the benefits regarding arm functioning and quality of life, the data from this randomised study support the use of SNB in patients with clinically node negative breast cancer.	there was no evidence of increased anxiety amongst patients randomised to SNB (p > 0.05).
__label__noRel	In view of the benefits regarding arm functioning and quality of life, the data from this randomised study support the use of SNB in patients with clinically node negative breast cancer.	For 6 months post-surgery younger patients reported less favourable QOL scores (p < 0.001) and greater levels of anxiety (p < 0.01).
__label__noRel	Menopausal symptoms (e.g., hot flashes, vaginal dryness, and stress urinary incontinence) are very common in breast cancer survivors and cannot be managed with standard estrogen replacement therapy (ERT) in these patients.	Patients receiving the intervention demonstrated statistically significant improvement (P =.0004) in menopausal symptoms but no significant change in vitality (P =.77).
__label__noRel	Menopausal symptoms (e.g., hot flashes, vaginal dryness, and stress urinary incontinence) are very common in breast cancer survivors and cannot be managed with standard estrogen replacement therapy (ERT) in these patients.	Sexual functioning was statistically significantly improved (P =.04) in the treatment group compared with the usual-care group.
__label__noRel	Menopausal symptoms (e.g., hot flashes, vaginal dryness, and stress urinary incontinence) are very common in breast cancer survivors and cannot be managed with standard estrogen replacement therapy (ERT) in these patients.	A clinical assessment and intervention program for menopausal symptom management in breast cancer survivors is feasible and acceptable to patients, leading to reduction in symptoms and improvement in sexual functioning.
__label__noRel	Menopausal symptoms (e.g., hot flashes, vaginal dryness, and stress urinary incontinence) are very common in breast cancer survivors and cannot be managed with standard estrogen replacement therapy (ERT) in these patients.	Measurable improvement in a general QOL measure was not demonstrated.
__label__noRel	Patients receiving the intervention demonstrated statistically significant improvement (P =.0004) in menopausal symptoms but no significant change in vitality (P =.77).	Menopausal symptoms (e.g., hot flashes, vaginal dryness, and stress urinary incontinence) are very common in breast cancer survivors and cannot be managed with standard estrogen replacement therapy (ERT) in these patients.
__label__noRel	Patients receiving the intervention demonstrated statistically significant improvement (P =.0004) in menopausal symptoms but no significant change in vitality (P =.77).	Sexual functioning was statistically significantly improved (P =.04) in the treatment group compared with the usual-care group.
__label__Support	Patients receiving the intervention demonstrated statistically significant improvement (P =.0004) in menopausal symptoms but no significant change in vitality (P =.77).	A clinical assessment and intervention program for menopausal symptom management in breast cancer survivors is feasible and acceptable to patients, leading to reduction in symptoms and improvement in sexual functioning.
__label__noRel	Patients receiving the intervention demonstrated statistically significant improvement (P =.0004) in menopausal symptoms but no significant change in vitality (P =.77).	Measurable improvement in a general QOL measure was not demonstrated.
__label__noRel	Sexual functioning was statistically significantly improved (P =.04) in the treatment group compared with the usual-care group.	Menopausal symptoms (e.g., hot flashes, vaginal dryness, and stress urinary incontinence) are very common in breast cancer survivors and cannot be managed with standard estrogen replacement therapy (ERT) in these patients.
__label__noRel	Sexual functioning was statistically significantly improved (P =.04) in the treatment group compared with the usual-care group.	Patients receiving the intervention demonstrated statistically significant improvement (P =.0004) in menopausal symptoms but no significant change in vitality (P =.77).
__label__Support	Sexual functioning was statistically significantly improved (P =.04) in the treatment group compared with the usual-care group.	A clinical assessment and intervention program for menopausal symptom management in breast cancer survivors is feasible and acceptable to patients, leading to reduction in symptoms and improvement in sexual functioning.
__label__noRel	Sexual functioning was statistically significantly improved (P =.04) in the treatment group compared with the usual-care group.	Measurable improvement in a general QOL measure was not demonstrated.
__label__noRel	A clinical assessment and intervention program for menopausal symptom management in breast cancer survivors is feasible and acceptable to patients, leading to reduction in symptoms and improvement in sexual functioning.	Menopausal symptoms (e.g., hot flashes, vaginal dryness, and stress urinary incontinence) are very common in breast cancer survivors and cannot be managed with standard estrogen replacement therapy (ERT) in these patients.
__label__noRel	A clinical assessment and intervention program for menopausal symptom management in breast cancer survivors is feasible and acceptable to patients, leading to reduction in symptoms and improvement in sexual functioning.	Patients receiving the intervention demonstrated statistically significant improvement (P =.0004) in menopausal symptoms but no significant change in vitality (P =.77).
__label__noRel	A clinical assessment and intervention program for menopausal symptom management in breast cancer survivors is feasible and acceptable to patients, leading to reduction in symptoms and improvement in sexual functioning.	Sexual functioning was statistically significantly improved (P =.04) in the treatment group compared with the usual-care group.
__label__noRel	A clinical assessment and intervention program for menopausal symptom management in breast cancer survivors is feasible and acceptable to patients, leading to reduction in symptoms and improvement in sexual functioning.	Measurable improvement in a general QOL measure was not demonstrated.
__label__noRel	Measurable improvement in a general QOL measure was not demonstrated.	Menopausal symptoms (e.g., hot flashes, vaginal dryness, and stress urinary incontinence) are very common in breast cancer survivors and cannot be managed with standard estrogen replacement therapy (ERT) in these patients.
__label__noRel	Measurable improvement in a general QOL measure was not demonstrated.	Patients receiving the intervention demonstrated statistically significant improvement (P =.0004) in menopausal symptoms but no significant change in vitality (P =.77).
__label__noRel	Measurable improvement in a general QOL measure was not demonstrated.	Sexual functioning was statistically significantly improved (P =.04) in the treatment group compared with the usual-care group.
__label__Attack	Measurable improvement in a general QOL measure was not demonstrated.	A clinical assessment and intervention program for menopausal symptom management in breast cancer survivors is feasible and acceptable to patients, leading to reduction in symptoms and improvement in sexual functioning.
__label__noRel	It is not known whether imatinib may be stopped in patients in whom disease is controlled.	As of October 15, 2005, eight of 26 patients in the CONT group and 26 of 32 patients in the INT group had documented disease progression (P < .0001).
__label__noRel	It is not known whether imatinib may be stopped in patients in whom disease is controlled.	Twenty-four of 26 patients with documented progression in the INT arm responded to imatinib reintroduction.
__label__noRel	It is not known whether imatinib may be stopped in patients in whom disease is controlled.	No differences in overall survival or imatinib resistance were observed between the two arms.
__label__noRel	It is not known whether imatinib may be stopped in patients in whom disease is controlled.	Quality of life evaluated 6 months after random assignment using the 30-item Quality of Life Questionnaire was not significantly different between the two groups of randomly assigned patients.
__label__noRel	It is not known whether imatinib may be stopped in patients in whom disease is controlled.	Imatinib interruption results in rapid progression in most patients with advanced GIST, and cannot be recommended in routine practice unless patient experience significant toxicity.
__label__noRel	As of October 15, 2005, eight of 26 patients in the CONT group and 26 of 32 patients in the INT group had documented disease progression (P < .0001).	It is not known whether imatinib may be stopped in patients in whom disease is controlled.
__label__noRel	As of October 15, 2005, eight of 26 patients in the CONT group and 26 of 32 patients in the INT group had documented disease progression (P < .0001).	Twenty-four of 26 patients with documented progression in the INT arm responded to imatinib reintroduction.
__label__noRel	As of October 15, 2005, eight of 26 patients in the CONT group and 26 of 32 patients in the INT group had documented disease progression (P < .0001).	No differences in overall survival or imatinib resistance were observed between the two arms.
__label__noRel	As of October 15, 2005, eight of 26 patients in the CONT group and 26 of 32 patients in the INT group had documented disease progression (P < .0001).	Quality of life evaluated 6 months after random assignment using the 30-item Quality of Life Questionnaire was not significantly different between the two groups of randomly assigned patients.
__label__Support	As of October 15, 2005, eight of 26 patients in the CONT group and 26 of 32 patients in the INT group had documented disease progression (P < .0001).	Imatinib interruption results in rapid progression in most patients with advanced GIST, and cannot be recommended in routine practice unless patient experience significant toxicity.
__label__noRel	Twenty-four of 26 patients with documented progression in the INT arm responded to imatinib reintroduction.	It is not known whether imatinib may be stopped in patients in whom disease is controlled.
__label__noRel	Twenty-four of 26 patients with documented progression in the INT arm responded to imatinib reintroduction.	As of October 15, 2005, eight of 26 patients in the CONT group and 26 of 32 patients in the INT group had documented disease progression (P < .0001).
__label__noRel	Twenty-four of 26 patients with documented progression in the INT arm responded to imatinib reintroduction.	No differences in overall survival or imatinib resistance were observed between the two arms.
__label__noRel	Twenty-four of 26 patients with documented progression in the INT arm responded to imatinib reintroduction.	Quality of life evaluated 6 months after random assignment using the 30-item Quality of Life Questionnaire was not significantly different between the two groups of randomly assigned patients.
__label__Support	Twenty-four of 26 patients with documented progression in the INT arm responded to imatinib reintroduction.	Imatinib interruption results in rapid progression in most patients with advanced GIST, and cannot be recommended in routine practice unless patient experience significant toxicity.
__label__noRel	No differences in overall survival or imatinib resistance were observed between the two arms.	It is not known whether imatinib may be stopped in patients in whom disease is controlled.
__label__noRel	No differences in overall survival or imatinib resistance were observed between the two arms.	As of October 15, 2005, eight of 26 patients in the CONT group and 26 of 32 patients in the INT group had documented disease progression (P < .0001).
__label__noRel	No differences in overall survival or imatinib resistance were observed between the two arms.	Twenty-four of 26 patients with documented progression in the INT arm responded to imatinib reintroduction.
__label__noRel	No differences in overall survival or imatinib resistance were observed between the two arms.	Quality of life evaluated 6 months after random assignment using the 30-item Quality of Life Questionnaire was not significantly different between the two groups of randomly assigned patients.
__label__noRel	No differences in overall survival or imatinib resistance were observed between the two arms.	Imatinib interruption results in rapid progression in most patients with advanced GIST, and cannot be recommended in routine practice unless patient experience significant toxicity.
__label__noRel	Quality of life evaluated 6 months after random assignment using the 30-item Quality of Life Questionnaire was not significantly different between the two groups of randomly assigned patients.	It is not known whether imatinib may be stopped in patients in whom disease is controlled.
__label__noRel	Quality of life evaluated 6 months after random assignment using the 30-item Quality of Life Questionnaire was not significantly different between the two groups of randomly assigned patients.	As of October 15, 2005, eight of 26 patients in the CONT group and 26 of 32 patients in the INT group had documented disease progression (P < .0001).
__label__noRel	Quality of life evaluated 6 months after random assignment using the 30-item Quality of Life Questionnaire was not significantly different between the two groups of randomly assigned patients.	Twenty-four of 26 patients with documented progression in the INT arm responded to imatinib reintroduction.
__label__noRel	Quality of life evaluated 6 months after random assignment using the 30-item Quality of Life Questionnaire was not significantly different between the two groups of randomly assigned patients.	No differences in overall survival or imatinib resistance were observed between the two arms.
__label__noRel	Quality of life evaluated 6 months after random assignment using the 30-item Quality of Life Questionnaire was not significantly different between the two groups of randomly assigned patients.	Imatinib interruption results in rapid progression in most patients with advanced GIST, and cannot be recommended in routine practice unless patient experience significant toxicity.
__label__noRel	Imatinib interruption results in rapid progression in most patients with advanced GIST, and cannot be recommended in routine practice unless patient experience significant toxicity.	It is not known whether imatinib may be stopped in patients in whom disease is controlled.
__label__noRel	Imatinib interruption results in rapid progression in most patients with advanced GIST, and cannot be recommended in routine practice unless patient experience significant toxicity.	As of October 15, 2005, eight of 26 patients in the CONT group and 26 of 32 patients in the INT group had documented disease progression (P < .0001).
__label__noRel	Imatinib interruption results in rapid progression in most patients with advanced GIST, and cannot be recommended in routine practice unless patient experience significant toxicity.	Twenty-four of 26 patients with documented progression in the INT arm responded to imatinib reintroduction.
__label__noRel	Imatinib interruption results in rapid progression in most patients with advanced GIST, and cannot be recommended in routine practice unless patient experience significant toxicity.	No differences in overall survival or imatinib resistance were observed between the two arms.
__label__noRel	Imatinib interruption results in rapid progression in most patients with advanced GIST, and cannot be recommended in routine practice unless patient experience significant toxicity.	Quality of life evaluated 6 months after random assignment using the 30-item Quality of Life Questionnaire was not significantly different between the two groups of randomly assigned patients.
__label__noRel	When combined hormone therapy (n=2196) was compared with placebo (n=2189), there was a significant increase in the number of major cardiovascular events (7 v 0, P=0.016) and venous thromboembolisms (22 v 3, hazard ratio 7.36 (95% CI 2.20 to 24.60)).	There were no statistically significant differences in numbers of breast or other cancers (22 v 25, hazard ratio 0.88 (0.49 to 1.56)), cerebrovascular events (14 v 19, 0.73 (0.37 to 1.46)), fractures (40 v 58, 0.69 (0.46 to 1.03)), and overall deaths (8 v 5, 1.60 (0.52 to 4.89)).
__label__noRel	When combined hormone therapy (n=2196) was compared with placebo (n=2189), there was a significant increase in the number of major cardiovascular events (7 v 0, P=0.016) and venous thromboembolisms (22 v 3, hazard ratio 7.36 (95% CI 2.20 to 24.60)).	Comparison of combined hormone therapy (n=815) versus oestrogen therapy (n=826) outcomes revealed no significant differences.
__label__Support	When combined hormone therapy (n=2196) was compared with placebo (n=2189), there was a significant increase in the number of major cardiovascular events (7 v 0, P=0.016) and venous thromboembolisms (22 v 3, hazard ratio 7.36 (95% CI 2.20 to 24.60)).	Hormone replacement therapy increases cardiovascular and thromboembolic risk when started many years after the menopause.
__label__noRel	When combined hormone therapy (n=2196) was compared with placebo (n=2189), there was a significant increase in the number of major cardiovascular events (7 v 0, P=0.016) and venous thromboembolisms (22 v 3, hazard ratio 7.36 (95% CI 2.20 to 24.60)).	The results are consistent with the findings of the women's health initiative study and secondary prevention studies.
__label__noRel	When combined hormone therapy (n=2196) was compared with placebo (n=2189), there was a significant increase in the number of major cardiovascular events (7 v 0, P=0.016) and venous thromboembolisms (22 v 3, hazard ratio 7.36 (95% CI 2.20 to 24.60)).	Research is needed to assess the long term risks and benefits of starting hormone replacement therapy near the menopause, when the effect may be different.
__label__noRel	There were no statistically significant differences in numbers of breast or other cancers (22 v 25, hazard ratio 0.88 (0.49 to 1.56)), cerebrovascular events (14 v 19, 0.73 (0.37 to 1.46)), fractures (40 v 58, 0.69 (0.46 to 1.03)), and overall deaths (8 v 5, 1.60 (0.52 to 4.89)).	When combined hormone therapy (n=2196) was compared with placebo (n=2189), there was a significant increase in the number of major cardiovascular events (7 v 0, P=0.016) and venous thromboembolisms (22 v 3, hazard ratio 7.36 (95% CI 2.20 to 24.60)).
__label__noRel	There were no statistically significant differences in numbers of breast or other cancers (22 v 25, hazard ratio 0.88 (0.49 to 1.56)), cerebrovascular events (14 v 19, 0.73 (0.37 to 1.46)), fractures (40 v 58, 0.69 (0.46 to 1.03)), and overall deaths (8 v 5, 1.60 (0.52 to 4.89)).	Comparison of combined hormone therapy (n=815) versus oestrogen therapy (n=826) outcomes revealed no significant differences.
__label__noRel	There were no statistically significant differences in numbers of breast or other cancers (22 v 25, hazard ratio 0.88 (0.49 to 1.56)), cerebrovascular events (14 v 19, 0.73 (0.37 to 1.46)), fractures (40 v 58, 0.69 (0.46 to 1.03)), and overall deaths (8 v 5, 1.60 (0.52 to 4.89)).	Hormone replacement therapy increases cardiovascular and thromboembolic risk when started many years after the menopause.
__label__noRel	There were no statistically significant differences in numbers of breast or other cancers (22 v 25, hazard ratio 0.88 (0.49 to 1.56)), cerebrovascular events (14 v 19, 0.73 (0.37 to 1.46)), fractures (40 v 58, 0.69 (0.46 to 1.03)), and overall deaths (8 v 5, 1.60 (0.52 to 4.89)).	The results are consistent with the findings of the women's health initiative study and secondary prevention studies.
__label__noRel	There were no statistically significant differences in numbers of breast or other cancers (22 v 25, hazard ratio 0.88 (0.49 to 1.56)), cerebrovascular events (14 v 19, 0.73 (0.37 to 1.46)), fractures (40 v 58, 0.69 (0.46 to 1.03)), and overall deaths (8 v 5, 1.60 (0.52 to 4.89)).	Research is needed to assess the long term risks and benefits of starting hormone replacement therapy near the menopause, when the effect may be different.
__label__noRel	Comparison of combined hormone therapy (n=815) versus oestrogen therapy (n=826) outcomes revealed no significant differences.	When combined hormone therapy (n=2196) was compared with placebo (n=2189), there was a significant increase in the number of major cardiovascular events (7 v 0, P=0.016) and venous thromboembolisms (22 v 3, hazard ratio 7.36 (95% CI 2.20 to 24.60)).
__label__noRel	Comparison of combined hormone therapy (n=815) versus oestrogen therapy (n=826) outcomes revealed no significant differences.	There were no statistically significant differences in numbers of breast or other cancers (22 v 25, hazard ratio 0.88 (0.49 to 1.56)), cerebrovascular events (14 v 19, 0.73 (0.37 to 1.46)), fractures (40 v 58, 0.69 (0.46 to 1.03)), and overall deaths (8 v 5, 1.60 (0.52 to 4.89)).
__label__noRel	Comparison of combined hormone therapy (n=815) versus oestrogen therapy (n=826) outcomes revealed no significant differences.	Hormone replacement therapy increases cardiovascular and thromboembolic risk when started many years after the menopause.
__label__noRel	Comparison of combined hormone therapy (n=815) versus oestrogen therapy (n=826) outcomes revealed no significant differences.	The results are consistent with the findings of the women's health initiative study and secondary prevention studies.
__label__noRel	Comparison of combined hormone therapy (n=815) versus oestrogen therapy (n=826) outcomes revealed no significant differences.	Research is needed to assess the long term risks and benefits of starting hormone replacement therapy near the menopause, when the effect may be different.
__label__noRel	Hormone replacement therapy increases cardiovascular and thromboembolic risk when started many years after the menopause.	When combined hormone therapy (n=2196) was compared with placebo (n=2189), there was a significant increase in the number of major cardiovascular events (7 v 0, P=0.016) and venous thromboembolisms (22 v 3, hazard ratio 7.36 (95% CI 2.20 to 24.60)).
__label__noRel	Hormone replacement therapy increases cardiovascular and thromboembolic risk when started many years after the menopause.	There were no statistically significant differences in numbers of breast or other cancers (22 v 25, hazard ratio 0.88 (0.49 to 1.56)), cerebrovascular events (14 v 19, 0.73 (0.37 to 1.46)), fractures (40 v 58, 0.69 (0.46 to 1.03)), and overall deaths (8 v 5, 1.60 (0.52 to 4.89)).
__label__noRel	Hormone replacement therapy increases cardiovascular and thromboembolic risk when started many years after the menopause.	Comparison of combined hormone therapy (n=815) versus oestrogen therapy (n=826) outcomes revealed no significant differences.
__label__noRel	Hormone replacement therapy increases cardiovascular and thromboembolic risk when started many years after the menopause.	The results are consistent with the findings of the women's health initiative study and secondary prevention studies.
__label__noRel	Hormone replacement therapy increases cardiovascular and thromboembolic risk when started many years after the menopause.	Research is needed to assess the long term risks and benefits of starting hormone replacement therapy near the menopause, when the effect may be different.
__label__noRel	The results are consistent with the findings of the women's health initiative study and secondary prevention studies.	When combined hormone therapy (n=2196) was compared with placebo (n=2189), there was a significant increase in the number of major cardiovascular events (7 v 0, P=0.016) and venous thromboembolisms (22 v 3, hazard ratio 7.36 (95% CI 2.20 to 24.60)).
__label__noRel	The results are consistent with the findings of the women's health initiative study and secondary prevention studies.	There were no statistically significant differences in numbers of breast or other cancers (22 v 25, hazard ratio 0.88 (0.49 to 1.56)), cerebrovascular events (14 v 19, 0.73 (0.37 to 1.46)), fractures (40 v 58, 0.69 (0.46 to 1.03)), and overall deaths (8 v 5, 1.60 (0.52 to 4.89)).
__label__noRel	The results are consistent with the findings of the women's health initiative study and secondary prevention studies.	Comparison of combined hormone therapy (n=815) versus oestrogen therapy (n=826) outcomes revealed no significant differences.
__label__noRel	The results are consistent with the findings of the women's health initiative study and secondary prevention studies.	Hormone replacement therapy increases cardiovascular and thromboembolic risk when started many years after the menopause.
__label__noRel	The results are consistent with the findings of the women's health initiative study and secondary prevention studies.	Research is needed to assess the long term risks and benefits of starting hormone replacement therapy near the menopause, when the effect may be different.
__label__noRel	Research is needed to assess the long term risks and benefits of starting hormone replacement therapy near the menopause, when the effect may be different.	When combined hormone therapy (n=2196) was compared with placebo (n=2189), there was a significant increase in the number of major cardiovascular events (7 v 0, P=0.016) and venous thromboembolisms (22 v 3, hazard ratio 7.36 (95% CI 2.20 to 24.60)).
__label__noRel	Research is needed to assess the long term risks and benefits of starting hormone replacement therapy near the menopause, when the effect may be different.	There were no statistically significant differences in numbers of breast or other cancers (22 v 25, hazard ratio 0.88 (0.49 to 1.56)), cerebrovascular events (14 v 19, 0.73 (0.37 to 1.46)), fractures (40 v 58, 0.69 (0.46 to 1.03)), and overall deaths (8 v 5, 1.60 (0.52 to 4.89)).
__label__noRel	Research is needed to assess the long term risks and benefits of starting hormone replacement therapy near the menopause, when the effect may be different.	Comparison of combined hormone therapy (n=815) versus oestrogen therapy (n=826) outcomes revealed no significant differences.
__label__Attack	Research is needed to assess the long term risks and benefits of starting hormone replacement therapy near the menopause, when the effect may be different.	Hormone replacement therapy increases cardiovascular and thromboembolic risk when started many years after the menopause.
__label__noRel	Research is needed to assess the long term risks and benefits of starting hormone replacement therapy near the menopause, when the effect may be different.	The results are consistent with the findings of the women's health initiative study and secondary prevention studies.
__label__noRel	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).
__label__noRel	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.
__label__noRel	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).
__label__noRel	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).
__label__noRel	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.
__label__noRel	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).	Quality of life (QOL) declined significantly over the 6 months.
__label__noRel	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).	QOL scores were not significantly different among the regimens.
__label__noRel	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.
__label__noRel	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).
__label__noRel	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.
__label__noRel	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).
__label__noRel	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).
__label__noRel	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.
__label__noRel	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).	Quality of life (QOL) declined significantly over the 6 months.
__label__noRel	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).	QOL scores were not significantly different among the regimens.
__label__Support	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.
__label__noRel	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).
__label__noRel	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).
__label__noRel	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).
__label__noRel	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).
__label__noRel	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.
__label__noRel	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.	Quality of life (QOL) declined significantly over the 6 months.
__label__noRel	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.	QOL scores were not significantly different among the regimens.
__label__noRel	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.
__label__noRel	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).
__label__noRel	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).
__label__noRel	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.
__label__noRel	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).
__label__noRel	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.
__label__noRel	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).	Quality of life (QOL) declined significantly over the 6 months.
__label__noRel	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).	QOL scores were not significantly different among the regimens.
__label__Support	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.
__label__noRel	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).
__label__noRel	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).
__label__noRel	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.
__label__noRel	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).
__label__noRel	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.
__label__noRel	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).	Quality of life (QOL) declined significantly over the 6 months.
__label__noRel	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).	QOL scores were not significantly different among the regimens.
__label__Support	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.
__label__noRel	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).
__label__noRel	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).
__label__noRel	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.
__label__noRel	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).
__label__noRel	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).
__label__noRel	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.	Quality of life (QOL) declined significantly over the 6 months.
__label__noRel	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.	QOL scores were not significantly different among the regimens.
__label__Support	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.
__label__noRel	Quality of life (QOL) declined significantly over the 6 months.	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).
__label__noRel	Quality of life (QOL) declined significantly over the 6 months.	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).
__label__noRel	Quality of life (QOL) declined significantly over the 6 months.	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.
__label__noRel	Quality of life (QOL) declined significantly over the 6 months.	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).
__label__noRel	Quality of life (QOL) declined significantly over the 6 months.	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).
__label__noRel	Quality of life (QOL) declined significantly over the 6 months.	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.
__label__noRel	Quality of life (QOL) declined significantly over the 6 months.	QOL scores were not significantly different among the regimens.
__label__noRel	Quality of life (QOL) declined significantly over the 6 months.	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.
__label__noRel	QOL scores were not significantly different among the regimens.	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).
__label__noRel	QOL scores were not significantly different among the regimens.	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).
__label__noRel	QOL scores were not significantly different among the regimens.	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.
__label__noRel	QOL scores were not significantly different among the regimens.	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).
__label__noRel	QOL scores were not significantly different among the regimens.	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).
__label__noRel	QOL scores were not significantly different among the regimens.	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.
__label__noRel	QOL scores were not significantly different among the regimens.	Quality of life (QOL) declined significantly over the 6 months.
__label__Support	QOL scores were not significantly different among the regimens.	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.
__label__noRel	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).
__label__noRel	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).
__label__noRel	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.
__label__noRel	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).
__label__noRel	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).
__label__noRel	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.
__label__noRel	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.	Quality of life (QOL) declined significantly over the 6 months.
__label__noRel	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.	QOL scores were not significantly different among the regimens.
__label__noRel	Patients in the IG had significantly improved scores on the FACIT-Fatigue Scale at study completion, improved fatigue and pain scores, as well as overall physical functioning and mental health composite scores.	At study completion, participants in the IG were walking twice as far and were significantly more likely to have continued walking or another form of exercise as compared with the UCG.
__label__noRel	Patients in the IG had significantly improved scores on the FACIT-Fatigue Scale at study completion, improved fatigue and pain scores, as well as overall physical functioning and mental health composite scores.	Kaplan-Meier survival analysis did not indicate an overall survival benefit for the IG.
__label__Support	Patients in the IG had significantly improved scores on the FACIT-Fatigue Scale at study completion, improved fatigue and pain scores, as well as overall physical functioning and mental health composite scores.	This is the first prospective, randomized controlled trial to report that participation in a home walking program confers a significant benefit in resected PPC patients with regard to fatigue levels, physical functioning, and health-related quality of life.
__label__noRel	At study completion, participants in the IG were walking twice as far and were significantly more likely to have continued walking or another form of exercise as compared with the UCG.	Patients in the IG had significantly improved scores on the FACIT-Fatigue Scale at study completion, improved fatigue and pain scores, as well as overall physical functioning and mental health composite scores.
__label__noRel	At study completion, participants in the IG were walking twice as far and were significantly more likely to have continued walking or another form of exercise as compared with the UCG.	Kaplan-Meier survival analysis did not indicate an overall survival benefit for the IG.
__label__Support	At study completion, participants in the IG were walking twice as far and were significantly more likely to have continued walking or another form of exercise as compared with the UCG.	This is the first prospective, randomized controlled trial to report that participation in a home walking program confers a significant benefit in resected PPC patients with regard to fatigue levels, physical functioning, and health-related quality of life.
__label__noRel	Kaplan-Meier survival analysis did not indicate an overall survival benefit for the IG.	Patients in the IG had significantly improved scores on the FACIT-Fatigue Scale at study completion, improved fatigue and pain scores, as well as overall physical functioning and mental health composite scores.
__label__noRel	Kaplan-Meier survival analysis did not indicate an overall survival benefit for the IG.	At study completion, participants in the IG were walking twice as far and were significantly more likely to have continued walking or another form of exercise as compared with the UCG.
__label__noRel	Kaplan-Meier survival analysis did not indicate an overall survival benefit for the IG.	This is the first prospective, randomized controlled trial to report that participation in a home walking program confers a significant benefit in resected PPC patients with regard to fatigue levels, physical functioning, and health-related quality of life.
__label__noRel	This is the first prospective, randomized controlled trial to report that participation in a home walking program confers a significant benefit in resected PPC patients with regard to fatigue levels, physical functioning, and health-related quality of life.	Patients in the IG had significantly improved scores on the FACIT-Fatigue Scale at study completion, improved fatigue and pain scores, as well as overall physical functioning and mental health composite scores.
__label__noRel	This is the first prospective, randomized controlled trial to report that participation in a home walking program confers a significant benefit in resected PPC patients with regard to fatigue levels, physical functioning, and health-related quality of life.	At study completion, participants in the IG were walking twice as far and were significantly more likely to have continued walking or another form of exercise as compared with the UCG.
__label__noRel	This is the first prospective, randomized controlled trial to report that participation in a home walking program confers a significant benefit in resected PPC patients with regard to fatigue levels, physical functioning, and health-related quality of life.	Kaplan-Meier survival analysis did not indicate an overall survival benefit for the IG.
__label__noRel	This procedure has been performed with the patient in the hypothyroid state to promote endogenous TSH stimulation and is often associated with hypothyroid symptoms and impaired quality of life.	Quality of life was well preserved in the euthyroid group, compared with the hypothyroid group, as demonstrated by their lower pretreatment scores on the Billewicz scale for hypothyroid signs and symptoms, 27 +/- 7 vs. 18 +/- 4 (P < 0.0001) and their significantly higher Short Form-36 Health Assessment Scale scores in five of eight categories.
__label__noRel	This procedure has been performed with the patient in the hypothyroid state to promote endogenous TSH stimulation and is often associated with hypothyroid symptoms and impaired quality of life.	Euthyroid patients had a statistically significant one third lower radiation dose to the blood, compared with patients in the hypothyroid group.
__label__noRel	This procedure has been performed with the patient in the hypothyroid state to promote endogenous TSH stimulation and is often associated with hypothyroid symptoms and impaired quality of life.	This study demonstrates comparable remnant ablation rates in patients prepared for 131I remnant ablation with 3.7 GBq by either administering rhTSH or withholding thyroid hormone.
__label__noRel	This procedure has been performed with the patient in the hypothyroid state to promote endogenous TSH stimulation and is often associated with hypothyroid symptoms and impaired quality of life.	rhTSH-prepared patients maintained a higher quality of life and received less radiation exposure to the blood.
__label__noRel	Quality of life was well preserved in the euthyroid group, compared with the hypothyroid group, as demonstrated by their lower pretreatment scores on the Billewicz scale for hypothyroid signs and symptoms, 27 +/- 7 vs. 18 +/- 4 (P < 0.0001) and their significantly higher Short Form-36 Health Assessment Scale scores in five of eight categories.	This procedure has been performed with the patient in the hypothyroid state to promote endogenous TSH stimulation and is often associated with hypothyroid symptoms and impaired quality of life.
__label__noRel	Quality of life was well preserved in the euthyroid group, compared with the hypothyroid group, as demonstrated by their lower pretreatment scores on the Billewicz scale for hypothyroid signs and symptoms, 27 +/- 7 vs. 18 +/- 4 (P < 0.0001) and their significantly higher Short Form-36 Health Assessment Scale scores in five of eight categories.	Euthyroid patients had a statistically significant one third lower radiation dose to the blood, compared with patients in the hypothyroid group.
__label__noRel	Quality of life was well preserved in the euthyroid group, compared with the hypothyroid group, as demonstrated by their lower pretreatment scores on the Billewicz scale for hypothyroid signs and symptoms, 27 +/- 7 vs. 18 +/- 4 (P < 0.0001) and their significantly higher Short Form-36 Health Assessment Scale scores in five of eight categories.	This study demonstrates comparable remnant ablation rates in patients prepared for 131I remnant ablation with 3.7 GBq by either administering rhTSH or withholding thyroid hormone.
__label__Support	Quality of life was well preserved in the euthyroid group, compared with the hypothyroid group, as demonstrated by their lower pretreatment scores on the Billewicz scale for hypothyroid signs and symptoms, 27 +/- 7 vs. 18 +/- 4 (P < 0.0001) and their significantly higher Short Form-36 Health Assessment Scale scores in five of eight categories.	rhTSH-prepared patients maintained a higher quality of life and received less radiation exposure to the blood.
__label__noRel	Euthyroid patients had a statistically significant one third lower radiation dose to the blood, compared with patients in the hypothyroid group.	This procedure has been performed with the patient in the hypothyroid state to promote endogenous TSH stimulation and is often associated with hypothyroid symptoms and impaired quality of life.
__label__noRel	Euthyroid patients had a statistically significant one third lower radiation dose to the blood, compared with patients in the hypothyroid group.	Quality of life was well preserved in the euthyroid group, compared with the hypothyroid group, as demonstrated by their lower pretreatment scores on the Billewicz scale for hypothyroid signs and symptoms, 27 +/- 7 vs. 18 +/- 4 (P < 0.0001) and their significantly higher Short Form-36 Health Assessment Scale scores in five of eight categories.
__label__Support	Euthyroid patients had a statistically significant one third lower radiation dose to the blood, compared with patients in the hypothyroid group.	This study demonstrates comparable remnant ablation rates in patients prepared for 131I remnant ablation with 3.7 GBq by either administering rhTSH or withholding thyroid hormone.
__label__noRel	Euthyroid patients had a statistically significant one third lower radiation dose to the blood, compared with patients in the hypothyroid group.	rhTSH-prepared patients maintained a higher quality of life and received less radiation exposure to the blood.
__label__noRel	This study demonstrates comparable remnant ablation rates in patients prepared for 131I remnant ablation with 3.7 GBq by either administering rhTSH or withholding thyroid hormone.	This procedure has been performed with the patient in the hypothyroid state to promote endogenous TSH stimulation and is often associated with hypothyroid symptoms and impaired quality of life.
__label__noRel	This study demonstrates comparable remnant ablation rates in patients prepared for 131I remnant ablation with 3.7 GBq by either administering rhTSH or withholding thyroid hormone.	Quality of life was well preserved in the euthyroid group, compared with the hypothyroid group, as demonstrated by their lower pretreatment scores on the Billewicz scale for hypothyroid signs and symptoms, 27 +/- 7 vs. 18 +/- 4 (P < 0.0001) and their significantly higher Short Form-36 Health Assessment Scale scores in five of eight categories.
__label__noRel	This study demonstrates comparable remnant ablation rates in patients prepared for 131I remnant ablation with 3.7 GBq by either administering rhTSH or withholding thyroid hormone.	Euthyroid patients had a statistically significant one third lower radiation dose to the blood, compared with patients in the hypothyroid group.
__label__noRel	This study demonstrates comparable remnant ablation rates in patients prepared for 131I remnant ablation with 3.7 GBq by either administering rhTSH or withholding thyroid hormone.	rhTSH-prepared patients maintained a higher quality of life and received less radiation exposure to the blood.
__label__noRel	rhTSH-prepared patients maintained a higher quality of life and received less radiation exposure to the blood.	This procedure has been performed with the patient in the hypothyroid state to promote endogenous TSH stimulation and is often associated with hypothyroid symptoms and impaired quality of life.
__label__noRel	rhTSH-prepared patients maintained a higher quality of life and received less radiation exposure to the blood.	Quality of life was well preserved in the euthyroid group, compared with the hypothyroid group, as demonstrated by their lower pretreatment scores on the Billewicz scale for hypothyroid signs and symptoms, 27 +/- 7 vs. 18 +/- 4 (P < 0.0001) and their significantly higher Short Form-36 Health Assessment Scale scores in five of eight categories.
__label__noRel	rhTSH-prepared patients maintained a higher quality of life and received less radiation exposure to the blood.	Euthyroid patients had a statistically significant one third lower radiation dose to the blood, compared with patients in the hypothyroid group.
__label__noRel	rhTSH-prepared patients maintained a higher quality of life and received less radiation exposure to the blood.	This study demonstrates comparable remnant ablation rates in patients prepared for 131I remnant ablation with 3.7 GBq by either administering rhTSH or withholding thyroid hormone.
__label__noRel	Chemotherapy is moderately efficient as a treatment for pancreatic adenocarcinoma,	but patient survival and quality of life has improved with this modality in some trials.
__label__noRel	Chemotherapy is moderately efficient as a treatment for pancreatic adenocarcinoma,	Toxicity (WHO grade 3-4) was lower with FU than with FUP (20% versus 48%, P <0.001), as was neutropenia (6% versus 23%), vomiting (4% versus 17%) and toxicity-related deaths (one versus four early in the trial).
__label__noRel	Chemotherapy is moderately efficient as a treatment for pancreatic adenocarcinoma,	The response rate was low in both arms, but superior in the FUP arm: 12% versus 0% (intention-to-treat analysis, P <0.01).
__label__noRel	Chemotherapy is moderately efficient as a treatment for pancreatic adenocarcinoma,	The survival rates at 6 months were 28% and 38% for the FU and FUP arms, respectively, and 1-year survival rates were 9% and 17% (log-rank test, P = 0.10).
__label__noRel	Chemotherapy is moderately efficient as a treatment for pancreatic adenocarcinoma,	One-year progression-free survival was 0% with FU versus 10% with FUP (log-rank test, P = 0.0001).
__label__noRel	Chemotherapy is moderately efficient as a treatment for pancreatic adenocarcinoma,	In advanced pancreatic carcinomas with a poor prognosis, FUP was superior to FU in terms of response and progression-free survival, but not in terms of overall survival.
__label__noRel	Chemotherapy is moderately efficient as a treatment for pancreatic adenocarcinoma,	A more effective, better tolerated version of this FUP combination is needed.
__label__Support	but patient survival and quality of life has improved with this modality in some trials.	Chemotherapy is moderately efficient as a treatment for pancreatic adenocarcinoma,
__label__noRel	but patient survival and quality of life has improved with this modality in some trials.	Toxicity (WHO grade 3-4) was lower with FU than with FUP (20% versus 48%, P <0.001), as was neutropenia (6% versus 23%), vomiting (4% versus 17%) and toxicity-related deaths (one versus four early in the trial).
__label__noRel	but patient survival and quality of life has improved with this modality in some trials.	The response rate was low in both arms, but superior in the FUP arm: 12% versus 0% (intention-to-treat analysis, P <0.01).
__label__noRel	but patient survival and quality of life has improved with this modality in some trials.	The survival rates at 6 months were 28% and 38% for the FU and FUP arms, respectively, and 1-year survival rates were 9% and 17% (log-rank test, P = 0.10).
__label__noRel	but patient survival and quality of life has improved with this modality in some trials.	One-year progression-free survival was 0% with FU versus 10% with FUP (log-rank test, P = 0.0001).
__label__noRel	but patient survival and quality of life has improved with this modality in some trials.	In advanced pancreatic carcinomas with a poor prognosis, FUP was superior to FU in terms of response and progression-free survival, but not in terms of overall survival.
__label__noRel	but patient survival and quality of life has improved with this modality in some trials.	A more effective, better tolerated version of this FUP combination is needed.
__label__noRel	Toxicity (WHO grade 3-4) was lower with FU than with FUP (20% versus 48%, P <0.001), as was neutropenia (6% versus 23%), vomiting (4% versus 17%) and toxicity-related deaths (one versus four early in the trial).	Chemotherapy is moderately efficient as a treatment for pancreatic adenocarcinoma,
__label__noRel	Toxicity (WHO grade 3-4) was lower with FU than with FUP (20% versus 48%, P <0.001), as was neutropenia (6% versus 23%), vomiting (4% versus 17%) and toxicity-related deaths (one versus four early in the trial).	but patient survival and quality of life has improved with this modality in some trials.
__label__noRel	Toxicity (WHO grade 3-4) was lower with FU than with FUP (20% versus 48%, P <0.001), as was neutropenia (6% versus 23%), vomiting (4% versus 17%) and toxicity-related deaths (one versus four early in the trial).	The response rate was low in both arms, but superior in the FUP arm: 12% versus 0% (intention-to-treat analysis, P <0.01).
__label__noRel	Toxicity (WHO grade 3-4) was lower with FU than with FUP (20% versus 48%, P <0.001), as was neutropenia (6% versus 23%), vomiting (4% versus 17%) and toxicity-related deaths (one versus four early in the trial).	The survival rates at 6 months were 28% and 38% for the FU and FUP arms, respectively, and 1-year survival rates were 9% and 17% (log-rank test, P = 0.10).
__label__noRel	Toxicity (WHO grade 3-4) was lower with FU than with FUP (20% versus 48%, P <0.001), as was neutropenia (6% versus 23%), vomiting (4% versus 17%) and toxicity-related deaths (one versus four early in the trial).	One-year progression-free survival was 0% with FU versus 10% with FUP (log-rank test, P = 0.0001).
__label__noRel	Toxicity (WHO grade 3-4) was lower with FU than with FUP (20% versus 48%, P <0.001), as was neutropenia (6% versus 23%), vomiting (4% versus 17%) and toxicity-related deaths (one versus four early in the trial).	In advanced pancreatic carcinomas with a poor prognosis, FUP was superior to FU in terms of response and progression-free survival, but not in terms of overall survival.
__label__noRel	Toxicity (WHO grade 3-4) was lower with FU than with FUP (20% versus 48%, P <0.001), as was neutropenia (6% versus 23%), vomiting (4% versus 17%) and toxicity-related deaths (one versus four early in the trial).	A more effective, better tolerated version of this FUP combination is needed.
__label__noRel	The response rate was low in both arms, but superior in the FUP arm: 12% versus 0% (intention-to-treat analysis, P <0.01).	Chemotherapy is moderately efficient as a treatment for pancreatic adenocarcinoma,
__label__noRel	The response rate was low in both arms, but superior in the FUP arm: 12% versus 0% (intention-to-treat analysis, P <0.01).	but patient survival and quality of life has improved with this modality in some trials.
__label__noRel	The response rate was low in both arms, but superior in the FUP arm: 12% versus 0% (intention-to-treat analysis, P <0.01).	Toxicity (WHO grade 3-4) was lower with FU than with FUP (20% versus 48%, P <0.001), as was neutropenia (6% versus 23%), vomiting (4% versus 17%) and toxicity-related deaths (one versus four early in the trial).
__label__noRel	The response rate was low in both arms, but superior in the FUP arm: 12% versus 0% (intention-to-treat analysis, P <0.01).	The survival rates at 6 months were 28% and 38% for the FU and FUP arms, respectively, and 1-year survival rates were 9% and 17% (log-rank test, P = 0.10).
__label__noRel	The response rate was low in both arms, but superior in the FUP arm: 12% versus 0% (intention-to-treat analysis, P <0.01).	One-year progression-free survival was 0% with FU versus 10% with FUP (log-rank test, P = 0.0001).
__label__Support	The response rate was low in both arms, but superior in the FUP arm: 12% versus 0% (intention-to-treat analysis, P <0.01).	In advanced pancreatic carcinomas with a poor prognosis, FUP was superior to FU in terms of response and progression-free survival, but not in terms of overall survival.
__label__noRel	The response rate was low in both arms, but superior in the FUP arm: 12% versus 0% (intention-to-treat analysis, P <0.01).	A more effective, better tolerated version of this FUP combination is needed.
__label__noRel	The survival rates at 6 months were 28% and 38% for the FU and FUP arms, respectively, and 1-year survival rates were 9% and 17% (log-rank test, P = 0.10).	Chemotherapy is moderately efficient as a treatment for pancreatic adenocarcinoma,
__label__noRel	The survival rates at 6 months were 28% and 38% for the FU and FUP arms, respectively, and 1-year survival rates were 9% and 17% (log-rank test, P = 0.10).	but patient survival and quality of life has improved with this modality in some trials.
__label__noRel	The survival rates at 6 months were 28% and 38% for the FU and FUP arms, respectively, and 1-year survival rates were 9% and 17% (log-rank test, P = 0.10).	Toxicity (WHO grade 3-4) was lower with FU than with FUP (20% versus 48%, P <0.001), as was neutropenia (6% versus 23%), vomiting (4% versus 17%) and toxicity-related deaths (one versus four early in the trial).
__label__noRel	The survival rates at 6 months were 28% and 38% for the FU and FUP arms, respectively, and 1-year survival rates were 9% and 17% (log-rank test, P = 0.10).	The response rate was low in both arms, but superior in the FUP arm: 12% versus 0% (intention-to-treat analysis, P <0.01).
__label__noRel	The survival rates at 6 months were 28% and 38% for the FU and FUP arms, respectively, and 1-year survival rates were 9% and 17% (log-rank test, P = 0.10).	One-year progression-free survival was 0% with FU versus 10% with FUP (log-rank test, P = 0.0001).
__label__Support	The survival rates at 6 months were 28% and 38% for the FU and FUP arms, respectively, and 1-year survival rates were 9% and 17% (log-rank test, P = 0.10).	In advanced pancreatic carcinomas with a poor prognosis, FUP was superior to FU in terms of response and progression-free survival, but not in terms of overall survival.
__label__noRel	The survival rates at 6 months were 28% and 38% for the FU and FUP arms, respectively, and 1-year survival rates were 9% and 17% (log-rank test, P = 0.10).	A more effective, better tolerated version of this FUP combination is needed.
__label__noRel	One-year progression-free survival was 0% with FU versus 10% with FUP (log-rank test, P = 0.0001).	Chemotherapy is moderately efficient as a treatment for pancreatic adenocarcinoma,
__label__noRel	One-year progression-free survival was 0% with FU versus 10% with FUP (log-rank test, P = 0.0001).	but patient survival and quality of life has improved with this modality in some trials.
__label__noRel	One-year progression-free survival was 0% with FU versus 10% with FUP (log-rank test, P = 0.0001).	Toxicity (WHO grade 3-4) was lower with FU than with FUP (20% versus 48%, P <0.001), as was neutropenia (6% versus 23%), vomiting (4% versus 17%) and toxicity-related deaths (one versus four early in the trial).
__label__noRel	One-year progression-free survival was 0% with FU versus 10% with FUP (log-rank test, P = 0.0001).	The response rate was low in both arms, but superior in the FUP arm: 12% versus 0% (intention-to-treat analysis, P <0.01).
__label__noRel	One-year progression-free survival was 0% with FU versus 10% with FUP (log-rank test, P = 0.0001).	The survival rates at 6 months were 28% and 38% for the FU and FUP arms, respectively, and 1-year survival rates were 9% and 17% (log-rank test, P = 0.10).
__label__Support	One-year progression-free survival was 0% with FU versus 10% with FUP (log-rank test, P = 0.0001).	In advanced pancreatic carcinomas with a poor prognosis, FUP was superior to FU in terms of response and progression-free survival, but not in terms of overall survival.
__label__noRel	One-year progression-free survival was 0% with FU versus 10% with FUP (log-rank test, P = 0.0001).	A more effective, better tolerated version of this FUP combination is needed.
__label__noRel	In advanced pancreatic carcinomas with a poor prognosis, FUP was superior to FU in terms of response and progression-free survival, but not in terms of overall survival.	Chemotherapy is moderately efficient as a treatment for pancreatic adenocarcinoma,
__label__noRel	In advanced pancreatic carcinomas with a poor prognosis, FUP was superior to FU in terms of response and progression-free survival, but not in terms of overall survival.	but patient survival and quality of life has improved with this modality in some trials.
__label__noRel	In advanced pancreatic carcinomas with a poor prognosis, FUP was superior to FU in terms of response and progression-free survival, but not in terms of overall survival.	Toxicity (WHO grade 3-4) was lower with FU than with FUP (20% versus 48%, P <0.001), as was neutropenia (6% versus 23%), vomiting (4% versus 17%) and toxicity-related deaths (one versus four early in the trial).
__label__noRel	In advanced pancreatic carcinomas with a poor prognosis, FUP was superior to FU in terms of response and progression-free survival, but not in terms of overall survival.	The response rate was low in both arms, but superior in the FUP arm: 12% versus 0% (intention-to-treat analysis, P <0.01).
__label__noRel	In advanced pancreatic carcinomas with a poor prognosis, FUP was superior to FU in terms of response and progression-free survival, but not in terms of overall survival.	The survival rates at 6 months were 28% and 38% for the FU and FUP arms, respectively, and 1-year survival rates were 9% and 17% (log-rank test, P = 0.10).
__label__noRel	In advanced pancreatic carcinomas with a poor prognosis, FUP was superior to FU in terms of response and progression-free survival, but not in terms of overall survival.	One-year progression-free survival was 0% with FU versus 10% with FUP (log-rank test, P = 0.0001).
__label__noRel	In advanced pancreatic carcinomas with a poor prognosis, FUP was superior to FU in terms of response and progression-free survival, but not in terms of overall survival.	A more effective, better tolerated version of this FUP combination is needed.
__label__noRel	A more effective, better tolerated version of this FUP combination is needed.	Chemotherapy is moderately efficient as a treatment for pancreatic adenocarcinoma,
__label__noRel	A more effective, better tolerated version of this FUP combination is needed.	but patient survival and quality of life has improved with this modality in some trials.
__label__noRel	A more effective, better tolerated version of this FUP combination is needed.	Toxicity (WHO grade 3-4) was lower with FU than with FUP (20% versus 48%, P <0.001), as was neutropenia (6% versus 23%), vomiting (4% versus 17%) and toxicity-related deaths (one versus four early in the trial).
__label__noRel	A more effective, better tolerated version of this FUP combination is needed.	The response rate was low in both arms, but superior in the FUP arm: 12% versus 0% (intention-to-treat analysis, P <0.01).
__label__noRel	A more effective, better tolerated version of this FUP combination is needed.	The survival rates at 6 months were 28% and 38% for the FU and FUP arms, respectively, and 1-year survival rates were 9% and 17% (log-rank test, P = 0.10).
__label__noRel	A more effective, better tolerated version of this FUP combination is needed.	One-year progression-free survival was 0% with FU versus 10% with FUP (log-rank test, P = 0.0001).
__label__noRel	A more effective, better tolerated version of this FUP combination is needed.	In advanced pancreatic carcinomas with a poor prognosis, FUP was superior to FU in terms of response and progression-free survival, but not in terms of overall survival.
__label__noRel	Axillary clearance in early breast cancer aims to improve locoregional control and provide staging information	In both the patients' subjective assessment of their QL and the physicians' perception of the patients' QL, the largest adverse QL effects of Ax were observed from baseline to the first postoperative assessment,
__label__noRel	Axillary clearance in early breast cancer aims to improve locoregional control and provide staging information	but the differences tended to disappear in 6 to 12 months.
__label__noRel	Axillary clearance in early breast cancer aims to improve locoregional control and provide staging information	At a median follow-up of 6.6 years, results for Sx + Ax and Sx yielded similar DFS (6-year DFS, 67% v 66%; hazard ratio [HR] Sx + Ax/Sx, 1.06; 95% CI, 0.79 to 1.42; P = .69) and OS (6-year OS, 75% v 73%; HR Sx + Ax/Sx, 1.05; 95% CI, 0.76 to 1.46; P = .77).
__label__noRel	Axillary clearance in early breast cancer aims to improve locoregional control and provide staging information	Avoiding axillary clearance for women > or = 60 years old who have clinically node-negative disease and receive Tam for endocrine-responsive disease yields similar efficacy with better early QL.
__label__noRel	In both the patients' subjective assessment of their QL and the physicians' perception of the patients' QL, the largest adverse QL effects of Ax were observed from baseline to the first postoperative assessment,	Axillary clearance in early breast cancer aims to improve locoregional control and provide staging information
__label__noRel	In both the patients' subjective assessment of their QL and the physicians' perception of the patients' QL, the largest adverse QL effects of Ax were observed from baseline to the first postoperative assessment,	but the differences tended to disappear in 6 to 12 months.
__label__noRel	In both the patients' subjective assessment of their QL and the physicians' perception of the patients' QL, the largest adverse QL effects of Ax were observed from baseline to the first postoperative assessment,	At a median follow-up of 6.6 years, results for Sx + Ax and Sx yielded similar DFS (6-year DFS, 67% v 66%; hazard ratio [HR] Sx + Ax/Sx, 1.06; 95% CI, 0.79 to 1.42; P = .69) and OS (6-year OS, 75% v 73%; HR Sx + Ax/Sx, 1.05; 95% CI, 0.76 to 1.46; P = .77).
__label__Support	In both the patients' subjective assessment of their QL and the physicians' perception of the patients' QL, the largest adverse QL effects of Ax were observed from baseline to the first postoperative assessment,	Avoiding axillary clearance for women > or = 60 years old who have clinically node-negative disease and receive Tam for endocrine-responsive disease yields similar efficacy with better early QL.
__label__noRel	but the differences tended to disappear in 6 to 12 months.	Axillary clearance in early breast cancer aims to improve locoregional control and provide staging information
__label__Attack	but the differences tended to disappear in 6 to 12 months.	In both the patients' subjective assessment of their QL and the physicians' perception of the patients' QL, the largest adverse QL effects of Ax were observed from baseline to the first postoperative assessment,
__label__noRel	but the differences tended to disappear in 6 to 12 months.	At a median follow-up of 6.6 years, results for Sx + Ax and Sx yielded similar DFS (6-year DFS, 67% v 66%; hazard ratio [HR] Sx + Ax/Sx, 1.06; 95% CI, 0.79 to 1.42; P = .69) and OS (6-year OS, 75% v 73%; HR Sx + Ax/Sx, 1.05; 95% CI, 0.76 to 1.46; P = .77).
__label__noRel	but the differences tended to disappear in 6 to 12 months.	Avoiding axillary clearance for women > or = 60 years old who have clinically node-negative disease and receive Tam for endocrine-responsive disease yields similar efficacy with better early QL.
__label__noRel	At a median follow-up of 6.6 years, results for Sx + Ax and Sx yielded similar DFS (6-year DFS, 67% v 66%; hazard ratio [HR] Sx + Ax/Sx, 1.06; 95% CI, 0.79 to 1.42; P = .69) and OS (6-year OS, 75% v 73%; HR Sx + Ax/Sx, 1.05; 95% CI, 0.76 to 1.46; P = .77).	Axillary clearance in early breast cancer aims to improve locoregional control and provide staging information
__label__noRel	At a median follow-up of 6.6 years, results for Sx + Ax and Sx yielded similar DFS (6-year DFS, 67% v 66%; hazard ratio [HR] Sx + Ax/Sx, 1.06; 95% CI, 0.79 to 1.42; P = .69) and OS (6-year OS, 75% v 73%; HR Sx + Ax/Sx, 1.05; 95% CI, 0.76 to 1.46; P = .77).	In both the patients' subjective assessment of their QL and the physicians' perception of the patients' QL, the largest adverse QL effects of Ax were observed from baseline to the first postoperative assessment,
__label__noRel	At a median follow-up of 6.6 years, results for Sx + Ax and Sx yielded similar DFS (6-year DFS, 67% v 66%; hazard ratio [HR] Sx + Ax/Sx, 1.06; 95% CI, 0.79 to 1.42; P = .69) and OS (6-year OS, 75% v 73%; HR Sx + Ax/Sx, 1.05; 95% CI, 0.76 to 1.46; P = .77).	but the differences tended to disappear in 6 to 12 months.
__label__Support	At a median follow-up of 6.6 years, results for Sx + Ax and Sx yielded similar DFS (6-year DFS, 67% v 66%; hazard ratio [HR] Sx + Ax/Sx, 1.06; 95% CI, 0.79 to 1.42; P = .69) and OS (6-year OS, 75% v 73%; HR Sx + Ax/Sx, 1.05; 95% CI, 0.76 to 1.46; P = .77).	Avoiding axillary clearance for women > or = 60 years old who have clinically node-negative disease and receive Tam for endocrine-responsive disease yields similar efficacy with better early QL.
__label__noRel	Avoiding axillary clearance for women > or = 60 years old who have clinically node-negative disease and receive Tam for endocrine-responsive disease yields similar efficacy with better early QL.	Axillary clearance in early breast cancer aims to improve locoregional control and provide staging information
__label__noRel	Avoiding axillary clearance for women > or = 60 years old who have clinically node-negative disease and receive Tam for endocrine-responsive disease yields similar efficacy with better early QL.	In both the patients' subjective assessment of their QL and the physicians' perception of the patients' QL, the largest adverse QL effects of Ax were observed from baseline to the first postoperative assessment,
__label__noRel	Avoiding axillary clearance for women > or = 60 years old who have clinically node-negative disease and receive Tam for endocrine-responsive disease yields similar efficacy with better early QL.	but the differences tended to disappear in 6 to 12 months.
__label__noRel	Avoiding axillary clearance for women > or = 60 years old who have clinically node-negative disease and receive Tam for endocrine-responsive disease yields similar efficacy with better early QL.	At a median follow-up of 6.6 years, results for Sx + Ax and Sx yielded similar DFS (6-year DFS, 67% v 66%; hazard ratio [HR] Sx + Ax/Sx, 1.06; 95% CI, 0.79 to 1.42; P = .69) and OS (6-year OS, 75% v 73%; HR Sx + Ax/Sx, 1.05; 95% CI, 0.76 to 1.46; P = .77).
__label__noRel	The estimated median overall survival times for RS+WBRT and S+WBRT patients were 6.2 and 2.8 months, respectively (hazard ratio 0.53,95%confidence interval 0.20-1.43, P=0.20).	Corresponding median failure-free survival times were 3.1 and 1.7 months (P=0.20).
__label__noRel	The estimated median overall survival times for RS+WBRT and S+WBRT patients were 6.2 and 2.8 months, respectively (hazard ratio 0.53,95%confidence interval 0.20-1.43, P=0.20).	For 19 'per protocol' patients, 2/10 in the RS+WBRT arm had distant intracranial failure (one also had local failure) and 3/9 S+WBRT patients had distant intracranial failure (no local failures).
__label__noRel	The estimated median overall survival times for RS+WBRT and S+WBRT patients were 6.2 and 2.8 months, respectively (hazard ratio 0.53,95%confidence interval 0.20-1.43, P=0.20).	There were no grade 3-4 late radiation toxicities.
__label__noRel	The estimated median overall survival times for RS+WBRT and S+WBRT patients were 6.2 and 2.8 months, respectively (hazard ratio 0.53,95%confidence interval 0.20-1.43, P=0.20).	Two months after starting treatment there were no significant differences in quality of life between the arms.
__label__noRel	The estimated median overall survival times for RS+WBRT and S+WBRT patients were 6.2 and 2.8 months, respectively (hazard ratio 0.53,95%confidence interval 0.20-1.43, P=0.20).	This randomised trial encountered the accrual difficulties and consequent low statistical power commonly associated with interdisciplinary studies drawing from a small eligible population,
__label__noRel	Corresponding median failure-free survival times were 3.1 and 1.7 months (P=0.20).	The estimated median overall survival times for RS+WBRT and S+WBRT patients were 6.2 and 2.8 months, respectively (hazard ratio 0.53,95%confidence interval 0.20-1.43, P=0.20).
__label__noRel	Corresponding median failure-free survival times were 3.1 and 1.7 months (P=0.20).	For 19 'per protocol' patients, 2/10 in the RS+WBRT arm had distant intracranial failure (one also had local failure) and 3/9 S+WBRT patients had distant intracranial failure (no local failures).
__label__noRel	Corresponding median failure-free survival times were 3.1 and 1.7 months (P=0.20).	There were no grade 3-4 late radiation toxicities.
__label__noRel	Corresponding median failure-free survival times were 3.1 and 1.7 months (P=0.20).	Two months after starting treatment there were no significant differences in quality of life between the arms.
__label__noRel	Corresponding median failure-free survival times were 3.1 and 1.7 months (P=0.20).	This randomised trial encountered the accrual difficulties and consequent low statistical power commonly associated with interdisciplinary studies drawing from a small eligible population,
__label__noRel	For 19 'per protocol' patients, 2/10 in the RS+WBRT arm had distant intracranial failure (one also had local failure) and 3/9 S+WBRT patients had distant intracranial failure (no local failures).	The estimated median overall survival times for RS+WBRT and S+WBRT patients were 6.2 and 2.8 months, respectively (hazard ratio 0.53,95%confidence interval 0.20-1.43, P=0.20).
__label__noRel	For 19 'per protocol' patients, 2/10 in the RS+WBRT arm had distant intracranial failure (one also had local failure) and 3/9 S+WBRT patients had distant intracranial failure (no local failures).	Corresponding median failure-free survival times were 3.1 and 1.7 months (P=0.20).
__label__noRel	For 19 'per protocol' patients, 2/10 in the RS+WBRT arm had distant intracranial failure (one also had local failure) and 3/9 S+WBRT patients had distant intracranial failure (no local failures).	There were no grade 3-4 late radiation toxicities.
__label__noRel	For 19 'per protocol' patients, 2/10 in the RS+WBRT arm had distant intracranial failure (one also had local failure) and 3/9 S+WBRT patients had distant intracranial failure (no local failures).	Two months after starting treatment there were no significant differences in quality of life between the arms.
__label__noRel	For 19 'per protocol' patients, 2/10 in the RS+WBRT arm had distant intracranial failure (one also had local failure) and 3/9 S+WBRT patients had distant intracranial failure (no local failures).	This randomised trial encountered the accrual difficulties and consequent low statistical power commonly associated with interdisciplinary studies drawing from a small eligible population,
__label__noRel	There were no grade 3-4 late radiation toxicities.	The estimated median overall survival times for RS+WBRT and S+WBRT patients were 6.2 and 2.8 months, respectively (hazard ratio 0.53,95%confidence interval 0.20-1.43, P=0.20).
__label__noRel	There were no grade 3-4 late radiation toxicities.	Corresponding median failure-free survival times were 3.1 and 1.7 months (P=0.20).
__label__noRel	There were no grade 3-4 late radiation toxicities.	For 19 'per protocol' patients, 2/10 in the RS+WBRT arm had distant intracranial failure (one also had local failure) and 3/9 S+WBRT patients had distant intracranial failure (no local failures).
__label__Support	There were no grade 3-4 late radiation toxicities.	Two months after starting treatment there were no significant differences in quality of life between the arms.
__label__noRel	There were no grade 3-4 late radiation toxicities.	This randomised trial encountered the accrual difficulties and consequent low statistical power commonly associated with interdisciplinary studies drawing from a small eligible population,
__label__noRel	Two months after starting treatment there were no significant differences in quality of life between the arms.	The estimated median overall survival times for RS+WBRT and S+WBRT patients were 6.2 and 2.8 months, respectively (hazard ratio 0.53,95%confidence interval 0.20-1.43, P=0.20).
__label__noRel	Two months after starting treatment there were no significant differences in quality of life between the arms.	Corresponding median failure-free survival times were 3.1 and 1.7 months (P=0.20).
__label__noRel	Two months after starting treatment there were no significant differences in quality of life between the arms.	For 19 'per protocol' patients, 2/10 in the RS+WBRT arm had distant intracranial failure (one also had local failure) and 3/9 S+WBRT patients had distant intracranial failure (no local failures).
__label__noRel	Two months after starting treatment there were no significant differences in quality of life between the arms.	There were no grade 3-4 late radiation toxicities.
__label__noRel	Two months after starting treatment there were no significant differences in quality of life between the arms.	This randomised trial encountered the accrual difficulties and consequent low statistical power commonly associated with interdisciplinary studies drawing from a small eligible population,
__label__noRel	This randomised trial encountered the accrual difficulties and consequent low statistical power commonly associated with interdisciplinary studies drawing from a small eligible population,	The estimated median overall survival times for RS+WBRT and S+WBRT patients were 6.2 and 2.8 months, respectively (hazard ratio 0.53,95%confidence interval 0.20-1.43, P=0.20).
__label__noRel	This randomised trial encountered the accrual difficulties and consequent low statistical power commonly associated with interdisciplinary studies drawing from a small eligible population,	Corresponding median failure-free survival times were 3.1 and 1.7 months (P=0.20).
__label__noRel	This randomised trial encountered the accrual difficulties and consequent low statistical power commonly associated with interdisciplinary studies drawing from a small eligible population,	For 19 'per protocol' patients, 2/10 in the RS+WBRT arm had distant intracranial failure (one also had local failure) and 3/9 S+WBRT patients had distant intracranial failure (no local failures).
__label__noRel	This randomised trial encountered the accrual difficulties and consequent low statistical power commonly associated with interdisciplinary studies drawing from a small eligible population,	There were no grade 3-4 late radiation toxicities.
__label__Attack	This randomised trial encountered the accrual difficulties and consequent low statistical power commonly associated with interdisciplinary studies drawing from a small eligible population,	Two months after starting treatment there were no significant differences in quality of life between the arms.
__label__noRel	The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer.	As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years.
__label__noRel	The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer.	There were no statistically significant differences between treatment groups in ES total scores.
__label__noRel	The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer.	there were differences between treatment groups in patient-reported side effects:
__label__noRel	The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer.	diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen.
__label__noRel	The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer.	Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen.
__label__noRel	The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer.	In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.
__label__noRel	As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years.	The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer.
__label__noRel	As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years.	There were no statistically significant differences between treatment groups in ES total scores.
__label__noRel	As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years.	there were differences between treatment groups in patient-reported side effects:
__label__noRel	As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years.	diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen.
__label__noRel	As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years.	Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen.
__label__Support	As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years.	In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.
__label__noRel	There were no statistically significant differences between treatment groups in ES total scores.	The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer.
__label__noRel	There were no statistically significant differences between treatment groups in ES total scores.	As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years.
__label__noRel	There were no statistically significant differences between treatment groups in ES total scores.	there were differences between treatment groups in patient-reported side effects:
__label__noRel	There were no statistically significant differences between treatment groups in ES total scores.	diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen.
__label__noRel	There were no statistically significant differences between treatment groups in ES total scores.	Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen.
__label__Support	There were no statistically significant differences between treatment groups in ES total scores.	In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.
__label__noRel	there were differences between treatment groups in patient-reported side effects:	The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer.
__label__noRel	there were differences between treatment groups in patient-reported side effects:	As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years.
__label__noRel	there were differences between treatment groups in patient-reported side effects:	There were no statistically significant differences between treatment groups in ES total scores.
__label__noRel	there were differences between treatment groups in patient-reported side effects:	diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen.
__label__noRel	there were differences between treatment groups in patient-reported side effects:	Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen.
__label__noRel	there were differences between treatment groups in patient-reported side effects:	In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.
__label__noRel	diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen.	The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer.
__label__noRel	diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen.	As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years.
__label__noRel	diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen.	There were no statistically significant differences between treatment groups in ES total scores.
__label__Support	diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen.	there were differences between treatment groups in patient-reported side effects:
__label__noRel	diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen.	Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen.
__label__noRel	diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen.	In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.
__label__noRel	Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen.	The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer.
__label__noRel	Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen.	As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years.
__label__noRel	Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen.	There were no statistically significant differences between treatment groups in ES total scores.
__label__Support	Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen.	there were differences between treatment groups in patient-reported side effects:
__label__noRel	Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen.	diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen.
__label__noRel	Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen.	In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.
__label__noRel	In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.	The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer.
__label__noRel	In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.	As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years.
__label__noRel	In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.	There were no statistically significant differences between treatment groups in ES total scores.
__label__noRel	In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.	there were differences between treatment groups in patient-reported side effects:
__label__noRel	In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.	diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen.
__label__noRel	In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.	Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen.
__label__noRel	A combination regimen of MA and thalidomide is more effective than MA alone in the treatment of CACS.	Toxicity was found to be relatively negligible in both groups.
__label__noRel	A combination regimen of MA and thalidomide is more effective than MA alone in the treatment of CACS.	Analysis of the trial group demonstrated a significant increase from baseline in body weight (<0.01), quality of life (p = 0.02), appetite (p = 0.01), and grip strength (p = 0.01), and a significant decrease in fatigue, Glasgow Prognostic Score (p = 0.05), Eastern Cooperative Oncology Group performance status (p = 0.03), IL-6 (p < 0.01), and tumor necrosis factor- (p = 0.02).
__label__noRel	A combination regimen of MA and thalidomide is more effective than MA alone in the treatment of CACS.	In contrast, in the control group, endpoints with a significant improvement from baseline included body weight (p < 0.02) and appetite (p = 0.02).
__label__noRel	A combination regimen of MA and thalidomide is more effective than MA alone in the treatment of CACS.	The mean changes in the endpoints from baseline in the trial group were significantly greater compared with the control group: in the primary endpoints, body weight (p = 0.05), fatigue (p < 0.01) and quality of life (p = 0.01), and in the secondary endpoints, grip strength (p = 0.05), Glasgow Prognostic Score (p = 0.02), Eastern Cooperative Oncology Group performance status (p = 0.02), IL-6 (p < 0.01) and tumor necrosis factor- (p = 0.01).
__label__Support	Toxicity was found to be relatively negligible in both groups.	A combination regimen of MA and thalidomide is more effective than MA alone in the treatment of CACS.
__label__noRel	Toxicity was found to be relatively negligible in both groups.	Analysis of the trial group demonstrated a significant increase from baseline in body weight (<0.01), quality of life (p = 0.02), appetite (p = 0.01), and grip strength (p = 0.01), and a significant decrease in fatigue, Glasgow Prognostic Score (p = 0.05), Eastern Cooperative Oncology Group performance status (p = 0.03), IL-6 (p < 0.01), and tumor necrosis factor- (p = 0.02).
__label__noRel	Toxicity was found to be relatively negligible in both groups.	In contrast, in the control group, endpoints with a significant improvement from baseline included body weight (p < 0.02) and appetite (p = 0.02).
__label__noRel	Toxicity was found to be relatively negligible in both groups.	The mean changes in the endpoints from baseline in the trial group were significantly greater compared with the control group: in the primary endpoints, body weight (p = 0.05), fatigue (p < 0.01) and quality of life (p = 0.01), and in the secondary endpoints, grip strength (p = 0.05), Glasgow Prognostic Score (p = 0.02), Eastern Cooperative Oncology Group performance status (p = 0.02), IL-6 (p < 0.01) and tumor necrosis factor- (p = 0.01).
__label__Support	Analysis of the trial group demonstrated a significant increase from baseline in body weight (<0.01), quality of life (p = 0.02), appetite (p = 0.01), and grip strength (p = 0.01), and a significant decrease in fatigue, Glasgow Prognostic Score (p = 0.05), Eastern Cooperative Oncology Group performance status (p = 0.03), IL-6 (p < 0.01), and tumor necrosis factor- (p = 0.02).	A combination regimen of MA and thalidomide is more effective than MA alone in the treatment of CACS.
__label__noRel	Analysis of the trial group demonstrated a significant increase from baseline in body weight (<0.01), quality of life (p = 0.02), appetite (p = 0.01), and grip strength (p = 0.01), and a significant decrease in fatigue, Glasgow Prognostic Score (p = 0.05), Eastern Cooperative Oncology Group performance status (p = 0.03), IL-6 (p < 0.01), and tumor necrosis factor- (p = 0.02).	Toxicity was found to be relatively negligible in both groups.
__label__noRel	Analysis of the trial group demonstrated a significant increase from baseline in body weight (<0.01), quality of life (p = 0.02), appetite (p = 0.01), and grip strength (p = 0.01), and a significant decrease in fatigue, Glasgow Prognostic Score (p = 0.05), Eastern Cooperative Oncology Group performance status (p = 0.03), IL-6 (p < 0.01), and tumor necrosis factor- (p = 0.02).	In contrast, in the control group, endpoints with a significant improvement from baseline included body weight (p < 0.02) and appetite (p = 0.02).
__label__noRel	Analysis of the trial group demonstrated a significant increase from baseline in body weight (<0.01), quality of life (p = 0.02), appetite (p = 0.01), and grip strength (p = 0.01), and a significant decrease in fatigue, Glasgow Prognostic Score (p = 0.05), Eastern Cooperative Oncology Group performance status (p = 0.03), IL-6 (p < 0.01), and tumor necrosis factor- (p = 0.02).	The mean changes in the endpoints from baseline in the trial group were significantly greater compared with the control group: in the primary endpoints, body weight (p = 0.05), fatigue (p < 0.01) and quality of life (p = 0.01), and in the secondary endpoints, grip strength (p = 0.05), Glasgow Prognostic Score (p = 0.02), Eastern Cooperative Oncology Group performance status (p = 0.02), IL-6 (p < 0.01) and tumor necrosis factor- (p = 0.01).
__label__Support	In contrast, in the control group, endpoints with a significant improvement from baseline included body weight (p < 0.02) and appetite (p = 0.02).	A combination regimen of MA and thalidomide is more effective than MA alone in the treatment of CACS.
__label__noRel	In contrast, in the control group, endpoints with a significant improvement from baseline included body weight (p < 0.02) and appetite (p = 0.02).	Toxicity was found to be relatively negligible in both groups.
__label__noRel	In contrast, in the control group, endpoints with a significant improvement from baseline included body weight (p < 0.02) and appetite (p = 0.02).	Analysis of the trial group demonstrated a significant increase from baseline in body weight (<0.01), quality of life (p = 0.02), appetite (p = 0.01), and grip strength (p = 0.01), and a significant decrease in fatigue, Glasgow Prognostic Score (p = 0.05), Eastern Cooperative Oncology Group performance status (p = 0.03), IL-6 (p < 0.01), and tumor necrosis factor- (p = 0.02).
__label__noRel	In contrast, in the control group, endpoints with a significant improvement from baseline included body weight (p < 0.02) and appetite (p = 0.02).	The mean changes in the endpoints from baseline in the trial group were significantly greater compared with the control group: in the primary endpoints, body weight (p = 0.05), fatigue (p < 0.01) and quality of life (p = 0.01), and in the secondary endpoints, grip strength (p = 0.05), Glasgow Prognostic Score (p = 0.02), Eastern Cooperative Oncology Group performance status (p = 0.02), IL-6 (p < 0.01) and tumor necrosis factor- (p = 0.01).
__label__Support	The mean changes in the endpoints from baseline in the trial group were significantly greater compared with the control group: in the primary endpoints, body weight (p = 0.05), fatigue (p < 0.01) and quality of life (p = 0.01), and in the secondary endpoints, grip strength (p = 0.05), Glasgow Prognostic Score (p = 0.02), Eastern Cooperative Oncology Group performance status (p = 0.02), IL-6 (p < 0.01) and tumor necrosis factor- (p = 0.01).	A combination regimen of MA and thalidomide is more effective than MA alone in the treatment of CACS.
__label__noRel	The mean changes in the endpoints from baseline in the trial group were significantly greater compared with the control group: in the primary endpoints, body weight (p = 0.05), fatigue (p < 0.01) and quality of life (p = 0.01), and in the secondary endpoints, grip strength (p = 0.05), Glasgow Prognostic Score (p = 0.02), Eastern Cooperative Oncology Group performance status (p = 0.02), IL-6 (p < 0.01) and tumor necrosis factor- (p = 0.01).	Toxicity was found to be relatively negligible in both groups.
__label__noRel	The mean changes in the endpoints from baseline in the trial group were significantly greater compared with the control group: in the primary endpoints, body weight (p = 0.05), fatigue (p < 0.01) and quality of life (p = 0.01), and in the secondary endpoints, grip strength (p = 0.05), Glasgow Prognostic Score (p = 0.02), Eastern Cooperative Oncology Group performance status (p = 0.02), IL-6 (p < 0.01) and tumor necrosis factor- (p = 0.01).	Analysis of the trial group demonstrated a significant increase from baseline in body weight (<0.01), quality of life (p = 0.02), appetite (p = 0.01), and grip strength (p = 0.01), and a significant decrease in fatigue, Glasgow Prognostic Score (p = 0.05), Eastern Cooperative Oncology Group performance status (p = 0.03), IL-6 (p < 0.01), and tumor necrosis factor- (p = 0.02).
__label__noRel	The mean changes in the endpoints from baseline in the trial group were significantly greater compared with the control group: in the primary endpoints, body weight (p = 0.05), fatigue (p < 0.01) and quality of life (p = 0.01), and in the secondary endpoints, grip strength (p = 0.05), Glasgow Prognostic Score (p = 0.02), Eastern Cooperative Oncology Group performance status (p = 0.02), IL-6 (p < 0.01) and tumor necrosis factor- (p = 0.01).	In contrast, in the control group, endpoints with a significant improvement from baseline included body weight (p < 0.02) and appetite (p = 0.02).
__label__noRel	Vinorelbine, a semisynthetic vinca alkaloid, represents a well-tolerated treatment for elderly patients with advanced non-small-cell lung cancer (NSCLC).	Vinorelbine-treated patients scored better than control patients on QoL functioning scales, and they reported fewer lung cancer-related symptoms but reported worse toxicity-related symptoms.
__label__noRel	Vinorelbine, a semisynthetic vinca alkaloid, represents a well-tolerated treatment for elderly patients with advanced non-small-cell lung cancer (NSCLC).	There was a statistically significant (two-sided P = .03) survival advantage for patients receiving vinorelbine;
__label__noRel	Vinorelbine, a semisynthetic vinca alkaloid, represents a well-tolerated treatment for elderly patients with advanced non-small-cell lung cancer (NSCLC).	median survival increased from 21 to 28 weeks in the vinorelbine-treated group.
__label__noRel	Vinorelbine, a semisynthetic vinca alkaloid, represents a well-tolerated treatment for elderly patients with advanced non-small-cell lung cancer (NSCLC).	The relative hazard of death for vinorelbine-treated patients was 0.65 (95% CI = 0.45-0.93).
__label__noRel	Vinorelbine, a semisynthetic vinca alkaloid, represents a well-tolerated treatment for elderly patients with advanced non-small-cell lung cancer (NSCLC).	Vinorelbine improves survival of elderly patients with advanced NSCLC and possibly improves overall QoL.
__label__noRel	Vinorelbine-treated patients scored better than control patients on QoL functioning scales, and they reported fewer lung cancer-related symptoms but reported worse toxicity-related symptoms.	Vinorelbine, a semisynthetic vinca alkaloid, represents a well-tolerated treatment for elderly patients with advanced non-small-cell lung cancer (NSCLC).
__label__noRel	Vinorelbine-treated patients scored better than control patients on QoL functioning scales, and they reported fewer lung cancer-related symptoms but reported worse toxicity-related symptoms.	There was a statistically significant (two-sided P = .03) survival advantage for patients receiving vinorelbine;
__label__noRel	Vinorelbine-treated patients scored better than control patients on QoL functioning scales, and they reported fewer lung cancer-related symptoms but reported worse toxicity-related symptoms.	median survival increased from 21 to 28 weeks in the vinorelbine-treated group.
__label__noRel	Vinorelbine-treated patients scored better than control patients on QoL functioning scales, and they reported fewer lung cancer-related symptoms but reported worse toxicity-related symptoms.	The relative hazard of death for vinorelbine-treated patients was 0.65 (95% CI = 0.45-0.93).
__label__Support	Vinorelbine-treated patients scored better than control patients on QoL functioning scales, and they reported fewer lung cancer-related symptoms but reported worse toxicity-related symptoms.	Vinorelbine improves survival of elderly patients with advanced NSCLC and possibly improves overall QoL.
__label__noRel	There was a statistically significant (two-sided P = .03) survival advantage for patients receiving vinorelbine;	Vinorelbine, a semisynthetic vinca alkaloid, represents a well-tolerated treatment for elderly patients with advanced non-small-cell lung cancer (NSCLC).
__label__noRel	There was a statistically significant (two-sided P = .03) survival advantage for patients receiving vinorelbine;	Vinorelbine-treated patients scored better than control patients on QoL functioning scales, and they reported fewer lung cancer-related symptoms but reported worse toxicity-related symptoms.
__label__noRel	There was a statistically significant (two-sided P = .03) survival advantage for patients receiving vinorelbine;	median survival increased from 21 to 28 weeks in the vinorelbine-treated group.
__label__noRel	There was a statistically significant (two-sided P = .03) survival advantage for patients receiving vinorelbine;	The relative hazard of death for vinorelbine-treated patients was 0.65 (95% CI = 0.45-0.93).
__label__Support	There was a statistically significant (two-sided P = .03) survival advantage for patients receiving vinorelbine;	Vinorelbine improves survival of elderly patients with advanced NSCLC and possibly improves overall QoL.
__label__noRel	median survival increased from 21 to 28 weeks in the vinorelbine-treated group.	Vinorelbine, a semisynthetic vinca alkaloid, represents a well-tolerated treatment for elderly patients with advanced non-small-cell lung cancer (NSCLC).
__label__noRel	median survival increased from 21 to 28 weeks in the vinorelbine-treated group.	Vinorelbine-treated patients scored better than control patients on QoL functioning scales, and they reported fewer lung cancer-related symptoms but reported worse toxicity-related symptoms.
__label__noRel	median survival increased from 21 to 28 weeks in the vinorelbine-treated group.	There was a statistically significant (two-sided P = .03) survival advantage for patients receiving vinorelbine;
__label__noRel	median survival increased from 21 to 28 weeks in the vinorelbine-treated group.	The relative hazard of death for vinorelbine-treated patients was 0.65 (95% CI = 0.45-0.93).
__label__Support	median survival increased from 21 to 28 weeks in the vinorelbine-treated group.	Vinorelbine improves survival of elderly patients with advanced NSCLC and possibly improves overall QoL.
__label__noRel	The relative hazard of death for vinorelbine-treated patients was 0.65 (95% CI = 0.45-0.93).	Vinorelbine, a semisynthetic vinca alkaloid, represents a well-tolerated treatment for elderly patients with advanced non-small-cell lung cancer (NSCLC).
__label__noRel	The relative hazard of death for vinorelbine-treated patients was 0.65 (95% CI = 0.45-0.93).	Vinorelbine-treated patients scored better than control patients on QoL functioning scales, and they reported fewer lung cancer-related symptoms but reported worse toxicity-related symptoms.
__label__noRel	The relative hazard of death for vinorelbine-treated patients was 0.65 (95% CI = 0.45-0.93).	There was a statistically significant (two-sided P = .03) survival advantage for patients receiving vinorelbine;
__label__noRel	The relative hazard of death for vinorelbine-treated patients was 0.65 (95% CI = 0.45-0.93).	median survival increased from 21 to 28 weeks in the vinorelbine-treated group.
__label__Support	The relative hazard of death for vinorelbine-treated patients was 0.65 (95% CI = 0.45-0.93).	Vinorelbine improves survival of elderly patients with advanced NSCLC and possibly improves overall QoL.
__label__Support	Vinorelbine improves survival of elderly patients with advanced NSCLC and possibly improves overall QoL.	Vinorelbine, a semisynthetic vinca alkaloid, represents a well-tolerated treatment for elderly patients with advanced non-small-cell lung cancer (NSCLC).
__label__noRel	Vinorelbine improves survival of elderly patients with advanced NSCLC and possibly improves overall QoL.	Vinorelbine-treated patients scored better than control patients on QoL functioning scales, and they reported fewer lung cancer-related symptoms but reported worse toxicity-related symptoms.
__label__noRel	Vinorelbine improves survival of elderly patients with advanced NSCLC and possibly improves overall QoL.	There was a statistically significant (two-sided P = .03) survival advantage for patients receiving vinorelbine;
__label__noRel	Vinorelbine improves survival of elderly patients with advanced NSCLC and possibly improves overall QoL.	median survival increased from 21 to 28 weeks in the vinorelbine-treated group.
__label__noRel	Vinorelbine improves survival of elderly patients with advanced NSCLC and possibly improves overall QoL.	The relative hazard of death for vinorelbine-treated patients was 0.65 (95% CI = 0.45-0.93).
__label__noRel	The median overall survival was 10.5 months (placebo) and 10.1 months (thalidomide) (HR for death = 1.09, 95% confidence interval [CI] = 0.93 to 1.27; P = .28).	Among patients with limited-stage disease, there was no evidence of a survival difference (HR for death = 0.91, 95% CI = 0.73 to 1.15),
__label__noRel	The median overall survival was 10.5 months (placebo) and 10.1 months (thalidomide) (HR for death = 1.09, 95% confidence interval [CI] = 0.93 to 1.27; P = .28).	but among patients with extensive disease, survival was worse in the thalidomide group (HR for death = 1.36, 95% CI = 1.10 to 1.68).
__label__noRel	The median overall survival was 10.5 months (placebo) and 10.1 months (thalidomide) (HR for death = 1.09, 95% confidence interval [CI] = 0.93 to 1.27; P = .28).	Progression-free survival rates were also similar in the two groups (HR = 1.07, 95% CI = 0.92 to 1.24).
__label__noRel	The median overall survival was 10.5 months (placebo) and 10.1 months (thalidomide) (HR for death = 1.09, 95% confidence interval [CI] = 0.93 to 1.27; P = .28).	Thalidomide was associated with an increased risk of having a thrombotic event, mainly pulmonary embolus and deep vein thrombosis (19% thalidomide vs 10% placebo; HR = 2.13, 95% CI = 1.41 to 3.20; P < .001).
__label__noRel	The median overall survival was 10.5 months (placebo) and 10.1 months (thalidomide) (HR for death = 1.09, 95% confidence interval [CI] = 0.93 to 1.27; P = .28).	There were no statistically significant differences between treatments in hematological and nonhematological toxic effects,
__label__noRel	The median overall survival was 10.5 months (placebo) and 10.1 months (thalidomide) (HR for death = 1.09, 95% confidence interval [CI] = 0.93 to 1.27; P = .28).	except more patients in the thalidomide group had rash, constipation, or neuropathy.
__label__noRel	The median overall survival was 10.5 months (placebo) and 10.1 months (thalidomide) (HR for death = 1.09, 95% confidence interval [CI] = 0.93 to 1.27; P = .28).	QoL scores were similar in the two treatment groups,
__label__noRel	The median overall survival was 10.5 months (placebo) and 10.1 months (thalidomide) (HR for death = 1.09, 95% confidence interval [CI] = 0.93 to 1.27; P = .28).	but thalidomide was associated with less insomnia and diarrhea and more constipation and peripheral neuropathy.
__label__Support	The median overall survival was 10.5 months (placebo) and 10.1 months (thalidomide) (HR for death = 1.09, 95% confidence interval [CI] = 0.93 to 1.27; P = .28).	thalidomide in combination with chemotherapy did not improve survival of patients with SCLC but was associated with an increased risk of thrombotic events.
__label__noRel	Among patients with limited-stage disease, there was no evidence of a survival difference (HR for death = 0.91, 95% CI = 0.73 to 1.15),	The median overall survival was 10.5 months (placebo) and 10.1 months (thalidomide) (HR for death = 1.09, 95% confidence interval [CI] = 0.93 to 1.27; P = .28).
__label__noRel	Among patients with limited-stage disease, there was no evidence of a survival difference (HR for death = 0.91, 95% CI = 0.73 to 1.15),	but among patients with extensive disease, survival was worse in the thalidomide group (HR for death = 1.36, 95% CI = 1.10 to 1.68).
__label__noRel	Among patients with limited-stage disease, there was no evidence of a survival difference (HR for death = 0.91, 95% CI = 0.73 to 1.15),	Progression-free survival rates were also similar in the two groups (HR = 1.07, 95% CI = 0.92 to 1.24).
__label__noRel	Among patients with limited-stage disease, there was no evidence of a survival difference (HR for death = 0.91, 95% CI = 0.73 to 1.15),	Thalidomide was associated with an increased risk of having a thrombotic event, mainly pulmonary embolus and deep vein thrombosis (19% thalidomide vs 10% placebo; HR = 2.13, 95% CI = 1.41 to 3.20; P < .001).
__label__noRel	Among patients with limited-stage disease, there was no evidence of a survival difference (HR for death = 0.91, 95% CI = 0.73 to 1.15),	There were no statistically significant differences between treatments in hematological and nonhematological toxic effects,
__label__noRel	Among patients with limited-stage disease, there was no evidence of a survival difference (HR for death = 0.91, 95% CI = 0.73 to 1.15),	except more patients in the thalidomide group had rash, constipation, or neuropathy.
__label__noRel	Among patients with limited-stage disease, there was no evidence of a survival difference (HR for death = 0.91, 95% CI = 0.73 to 1.15),	QoL scores were similar in the two treatment groups,
__label__noRel	Among patients with limited-stage disease, there was no evidence of a survival difference (HR for death = 0.91, 95% CI = 0.73 to 1.15),	but thalidomide was associated with less insomnia and diarrhea and more constipation and peripheral neuropathy.
__label__Support	Among patients with limited-stage disease, there was no evidence of a survival difference (HR for death = 0.91, 95% CI = 0.73 to 1.15),	thalidomide in combination with chemotherapy did not improve survival of patients with SCLC but was associated with an increased risk of thrombotic events.
__label__noRel	but among patients with extensive disease, survival was worse in the thalidomide group (HR for death = 1.36, 95% CI = 1.10 to 1.68).	The median overall survival was 10.5 months (placebo) and 10.1 months (thalidomide) (HR for death = 1.09, 95% confidence interval [CI] = 0.93 to 1.27; P = .28).
__label__Attack	but among patients with extensive disease, survival was worse in the thalidomide group (HR for death = 1.36, 95% CI = 1.10 to 1.68).	Among patients with limited-stage disease, there was no evidence of a survival difference (HR for death = 0.91, 95% CI = 0.73 to 1.15),
__label__noRel	but among patients with extensive disease, survival was worse in the thalidomide group (HR for death = 1.36, 95% CI = 1.10 to 1.68).	Progression-free survival rates were also similar in the two groups (HR = 1.07, 95% CI = 0.92 to 1.24).
__label__noRel	but among patients with extensive disease, survival was worse in the thalidomide group (HR for death = 1.36, 95% CI = 1.10 to 1.68).	Thalidomide was associated with an increased risk of having a thrombotic event, mainly pulmonary embolus and deep vein thrombosis (19% thalidomide vs 10% placebo; HR = 2.13, 95% CI = 1.41 to 3.20; P < .001).
__label__noRel	but among patients with extensive disease, survival was worse in the thalidomide group (HR for death = 1.36, 95% CI = 1.10 to 1.68).	There were no statistically significant differences between treatments in hematological and nonhematological toxic effects,
__label__noRel	but among patients with extensive disease, survival was worse in the thalidomide group (HR for death = 1.36, 95% CI = 1.10 to 1.68).	except more patients in the thalidomide group had rash, constipation, or neuropathy.
__label__noRel	but among patients with extensive disease, survival was worse in the thalidomide group (HR for death = 1.36, 95% CI = 1.10 to 1.68).	QoL scores were similar in the two treatment groups,
__label__noRel	but among patients with extensive disease, survival was worse in the thalidomide group (HR for death = 1.36, 95% CI = 1.10 to 1.68).	but thalidomide was associated with less insomnia and diarrhea and more constipation and peripheral neuropathy.
__label__noRel	but among patients with extensive disease, survival was worse in the thalidomide group (HR for death = 1.36, 95% CI = 1.10 to 1.68).	thalidomide in combination with chemotherapy did not improve survival of patients with SCLC but was associated with an increased risk of thrombotic events.
__label__noRel	Progression-free survival rates were also similar in the two groups (HR = 1.07, 95% CI = 0.92 to 1.24).	The median overall survival was 10.5 months (placebo) and 10.1 months (thalidomide) (HR for death = 1.09, 95% confidence interval [CI] = 0.93 to 1.27; P = .28).
__label__noRel	Progression-free survival rates were also similar in the two groups (HR = 1.07, 95% CI = 0.92 to 1.24).	Among patients with limited-stage disease, there was no evidence of a survival difference (HR for death = 0.91, 95% CI = 0.73 to 1.15),
__label__noRel	Progression-free survival rates were also similar in the two groups (HR = 1.07, 95% CI = 0.92 to 1.24).	but among patients with extensive disease, survival was worse in the thalidomide group (HR for death = 1.36, 95% CI = 1.10 to 1.68).
__label__noRel	Progression-free survival rates were also similar in the two groups (HR = 1.07, 95% CI = 0.92 to 1.24).	Thalidomide was associated with an increased risk of having a thrombotic event, mainly pulmonary embolus and deep vein thrombosis (19% thalidomide vs 10% placebo; HR = 2.13, 95% CI = 1.41 to 3.20; P < .001).
__label__noRel	Progression-free survival rates were also similar in the two groups (HR = 1.07, 95% CI = 0.92 to 1.24).	There were no statistically significant differences between treatments in hematological and nonhematological toxic effects,
__label__noRel	Progression-free survival rates were also similar in the two groups (HR = 1.07, 95% CI = 0.92 to 1.24).	except more patients in the thalidomide group had rash, constipation, or neuropathy.
__label__noRel	Progression-free survival rates were also similar in the two groups (HR = 1.07, 95% CI = 0.92 to 1.24).	QoL scores were similar in the two treatment groups,
__label__noRel	Progression-free survival rates were also similar in the two groups (HR = 1.07, 95% CI = 0.92 to 1.24).	but thalidomide was associated with less insomnia and diarrhea and more constipation and peripheral neuropathy.
__label__Support	Progression-free survival rates were also similar in the two groups (HR = 1.07, 95% CI = 0.92 to 1.24).	thalidomide in combination with chemotherapy did not improve survival of patients with SCLC but was associated with an increased risk of thrombotic events.
__label__noRel	Thalidomide was associated with an increased risk of having a thrombotic event, mainly pulmonary embolus and deep vein thrombosis (19% thalidomide vs 10% placebo; HR = 2.13, 95% CI = 1.41 to 3.20; P < .001).	The median overall survival was 10.5 months (placebo) and 10.1 months (thalidomide) (HR for death = 1.09, 95% confidence interval [CI] = 0.93 to 1.27; P = .28).
__label__noRel	Thalidomide was associated with an increased risk of having a thrombotic event, mainly pulmonary embolus and deep vein thrombosis (19% thalidomide vs 10% placebo; HR = 2.13, 95% CI = 1.41 to 3.20; P < .001).	Among patients with limited-stage disease, there was no evidence of a survival difference (HR for death = 0.91, 95% CI = 0.73 to 1.15),
__label__noRel	Thalidomide was associated with an increased risk of having a thrombotic event, mainly pulmonary embolus and deep vein thrombosis (19% thalidomide vs 10% placebo; HR = 2.13, 95% CI = 1.41 to 3.20; P < .001).	but among patients with extensive disease, survival was worse in the thalidomide group (HR for death = 1.36, 95% CI = 1.10 to 1.68).
__label__noRel	Thalidomide was associated with an increased risk of having a thrombotic event, mainly pulmonary embolus and deep vein thrombosis (19% thalidomide vs 10% placebo; HR = 2.13, 95% CI = 1.41 to 3.20; P < .001).	Progression-free survival rates were also similar in the two groups (HR = 1.07, 95% CI = 0.92 to 1.24).
__label__noRel	Thalidomide was associated with an increased risk of having a thrombotic event, mainly pulmonary embolus and deep vein thrombosis (19% thalidomide vs 10% placebo; HR = 2.13, 95% CI = 1.41 to 3.20; P < .001).	There were no statistically significant differences between treatments in hematological and nonhematological toxic effects,
__label__noRel	Thalidomide was associated with an increased risk of having a thrombotic event, mainly pulmonary embolus and deep vein thrombosis (19% thalidomide vs 10% placebo; HR = 2.13, 95% CI = 1.41 to 3.20; P < .001).	except more patients in the thalidomide group had rash, constipation, or neuropathy.
__label__noRel	Thalidomide was associated with an increased risk of having a thrombotic event, mainly pulmonary embolus and deep vein thrombosis (19% thalidomide vs 10% placebo; HR = 2.13, 95% CI = 1.41 to 3.20; P < .001).	QoL scores were similar in the two treatment groups,
__label__noRel	Thalidomide was associated with an increased risk of having a thrombotic event, mainly pulmonary embolus and deep vein thrombosis (19% thalidomide vs 10% placebo; HR = 2.13, 95% CI = 1.41 to 3.20; P < .001).	but thalidomide was associated with less insomnia and diarrhea and more constipation and peripheral neuropathy.
__label__Support	Thalidomide was associated with an increased risk of having a thrombotic event, mainly pulmonary embolus and deep vein thrombosis (19% thalidomide vs 10% placebo; HR = 2.13, 95% CI = 1.41 to 3.20; P < .001).	thalidomide in combination with chemotherapy did not improve survival of patients with SCLC but was associated with an increased risk of thrombotic events.
__label__noRel	There were no statistically significant differences between treatments in hematological and nonhematological toxic effects,	The median overall survival was 10.5 months (placebo) and 10.1 months (thalidomide) (HR for death = 1.09, 95% confidence interval [CI] = 0.93 to 1.27; P = .28).
__label__noRel	There were no statistically significant differences between treatments in hematological and nonhematological toxic effects,	Among patients with limited-stage disease, there was no evidence of a survival difference (HR for death = 0.91, 95% CI = 0.73 to 1.15),
__label__noRel	There were no statistically significant differences between treatments in hematological and nonhematological toxic effects,	but among patients with extensive disease, survival was worse in the thalidomide group (HR for death = 1.36, 95% CI = 1.10 to 1.68).
__label__noRel	There were no statistically significant differences between treatments in hematological and nonhematological toxic effects,	Progression-free survival rates were also similar in the two groups (HR = 1.07, 95% CI = 0.92 to 1.24).
__label__noRel	There were no statistically significant differences between treatments in hematological and nonhematological toxic effects,	Thalidomide was associated with an increased risk of having a thrombotic event, mainly pulmonary embolus and deep vein thrombosis (19% thalidomide vs 10% placebo; HR = 2.13, 95% CI = 1.41 to 3.20; P < .001).
__label__noRel	There were no statistically significant differences between treatments in hematological and nonhematological toxic effects,	except more patients in the thalidomide group had rash, constipation, or neuropathy.
__label__Support	There were no statistically significant differences between treatments in hematological and nonhematological toxic effects,	QoL scores were similar in the two treatment groups,
__label__noRel	There were no statistically significant differences between treatments in hematological and nonhematological toxic effects,	but thalidomide was associated with less insomnia and diarrhea and more constipation and peripheral neuropathy.
__label__noRel	There were no statistically significant differences between treatments in hematological and nonhematological toxic effects,	thalidomide in combination with chemotherapy did not improve survival of patients with SCLC but was associated with an increased risk of thrombotic events.
__label__noRel	except more patients in the thalidomide group had rash, constipation, or neuropathy.	The median overall survival was 10.5 months (placebo) and 10.1 months (thalidomide) (HR for death = 1.09, 95% confidence interval [CI] = 0.93 to 1.27; P = .28).
__label__noRel	except more patients in the thalidomide group had rash, constipation, or neuropathy.	Among patients with limited-stage disease, there was no evidence of a survival difference (HR for death = 0.91, 95% CI = 0.73 to 1.15),
__label__noRel	except more patients in the thalidomide group had rash, constipation, or neuropathy.	but among patients with extensive disease, survival was worse in the thalidomide group (HR for death = 1.36, 95% CI = 1.10 to 1.68).
__label__noRel	except more patients in the thalidomide group had rash, constipation, or neuropathy.	Progression-free survival rates were also similar in the two groups (HR = 1.07, 95% CI = 0.92 to 1.24).
__label__noRel	except more patients in the thalidomide group had rash, constipation, or neuropathy.	Thalidomide was associated with an increased risk of having a thrombotic event, mainly pulmonary embolus and deep vein thrombosis (19% thalidomide vs 10% placebo; HR = 2.13, 95% CI = 1.41 to 3.20; P < .001).
__label__Attack	except more patients in the thalidomide group had rash, constipation, or neuropathy.	There were no statistically significant differences between treatments in hematological and nonhematological toxic effects,
__label__noRel	except more patients in the thalidomide group had rash, constipation, or neuropathy.	QoL scores were similar in the two treatment groups,
__label__noRel	except more patients in the thalidomide group had rash, constipation, or neuropathy.	but thalidomide was associated with less insomnia and diarrhea and more constipation and peripheral neuropathy.
__label__noRel	except more patients in the thalidomide group had rash, constipation, or neuropathy.	thalidomide in combination with chemotherapy did not improve survival of patients with SCLC but was associated with an increased risk of thrombotic events.
__label__noRel	QoL scores were similar in the two treatment groups,	The median overall survival was 10.5 months (placebo) and 10.1 months (thalidomide) (HR for death = 1.09, 95% confidence interval [CI] = 0.93 to 1.27; P = .28).
__label__noRel	QoL scores were similar in the two treatment groups,	Among patients with limited-stage disease, there was no evidence of a survival difference (HR for death = 0.91, 95% CI = 0.73 to 1.15),
__label__noRel	QoL scores were similar in the two treatment groups,	but among patients with extensive disease, survival was worse in the thalidomide group (HR for death = 1.36, 95% CI = 1.10 to 1.68).
__label__noRel	QoL scores were similar in the two treatment groups,	Progression-free survival rates were also similar in the two groups (HR = 1.07, 95% CI = 0.92 to 1.24).
__label__noRel	QoL scores were similar in the two treatment groups,	Thalidomide was associated with an increased risk of having a thrombotic event, mainly pulmonary embolus and deep vein thrombosis (19% thalidomide vs 10% placebo; HR = 2.13, 95% CI = 1.41 to 3.20; P < .001).
__label__noRel	QoL scores were similar in the two treatment groups,	There were no statistically significant differences between treatments in hematological and nonhematological toxic effects,
__label__noRel	QoL scores were similar in the two treatment groups,	except more patients in the thalidomide group had rash, constipation, or neuropathy.
__label__noRel	QoL scores were similar in the two treatment groups,	but thalidomide was associated with less insomnia and diarrhea and more constipation and peripheral neuropathy.
__label__noRel	QoL scores were similar in the two treatment groups,	thalidomide in combination with chemotherapy did not improve survival of patients with SCLC but was associated with an increased risk of thrombotic events.
__label__noRel	but thalidomide was associated with less insomnia and diarrhea and more constipation and peripheral neuropathy.	The median overall survival was 10.5 months (placebo) and 10.1 months (thalidomide) (HR for death = 1.09, 95% confidence interval [CI] = 0.93 to 1.27; P = .28).
__label__noRel	but thalidomide was associated with less insomnia and diarrhea and more constipation and peripheral neuropathy.	Among patients with limited-stage disease, there was no evidence of a survival difference (HR for death = 0.91, 95% CI = 0.73 to 1.15),
__label__noRel	but thalidomide was associated with less insomnia and diarrhea and more constipation and peripheral neuropathy.	but among patients with extensive disease, survival was worse in the thalidomide group (HR for death = 1.36, 95% CI = 1.10 to 1.68).
__label__noRel	but thalidomide was associated with less insomnia and diarrhea and more constipation and peripheral neuropathy.	Progression-free survival rates were also similar in the two groups (HR = 1.07, 95% CI = 0.92 to 1.24).
__label__noRel	but thalidomide was associated with less insomnia and diarrhea and more constipation and peripheral neuropathy.	Thalidomide was associated with an increased risk of having a thrombotic event, mainly pulmonary embolus and deep vein thrombosis (19% thalidomide vs 10% placebo; HR = 2.13, 95% CI = 1.41 to 3.20; P < .001).
__label__noRel	but thalidomide was associated with less insomnia and diarrhea and more constipation and peripheral neuropathy.	There were no statistically significant differences between treatments in hematological and nonhematological toxic effects,
__label__noRel	but thalidomide was associated with less insomnia and diarrhea and more constipation and peripheral neuropathy.	except more patients in the thalidomide group had rash, constipation, or neuropathy.
__label__Attack	but thalidomide was associated with less insomnia and diarrhea and more constipation and peripheral neuropathy.	QoL scores were similar in the two treatment groups,
__label__noRel	but thalidomide was associated with less insomnia and diarrhea and more constipation and peripheral neuropathy.	thalidomide in combination with chemotherapy did not improve survival of patients with SCLC but was associated with an increased risk of thrombotic events.
__label__noRel	thalidomide in combination with chemotherapy did not improve survival of patients with SCLC but was associated with an increased risk of thrombotic events.	The median overall survival was 10.5 months (placebo) and 10.1 months (thalidomide) (HR for death = 1.09, 95% confidence interval [CI] = 0.93 to 1.27; P = .28).
__label__noRel	thalidomide in combination with chemotherapy did not improve survival of patients with SCLC but was associated with an increased risk of thrombotic events.	Among patients with limited-stage disease, there was no evidence of a survival difference (HR for death = 0.91, 95% CI = 0.73 to 1.15),
__label__noRel	thalidomide in combination with chemotherapy did not improve survival of patients with SCLC but was associated with an increased risk of thrombotic events.	but among patients with extensive disease, survival was worse in the thalidomide group (HR for death = 1.36, 95% CI = 1.10 to 1.68).
__label__noRel	thalidomide in combination with chemotherapy did not improve survival of patients with SCLC but was associated with an increased risk of thrombotic events.	Progression-free survival rates were also similar in the two groups (HR = 1.07, 95% CI = 0.92 to 1.24).
__label__noRel	thalidomide in combination with chemotherapy did not improve survival of patients with SCLC but was associated with an increased risk of thrombotic events.	Thalidomide was associated with an increased risk of having a thrombotic event, mainly pulmonary embolus and deep vein thrombosis (19% thalidomide vs 10% placebo; HR = 2.13, 95% CI = 1.41 to 3.20; P < .001).
__label__noRel	thalidomide in combination with chemotherapy did not improve survival of patients with SCLC but was associated with an increased risk of thrombotic events.	There were no statistically significant differences between treatments in hematological and nonhematological toxic effects,
__label__noRel	thalidomide in combination with chemotherapy did not improve survival of patients with SCLC but was associated with an increased risk of thrombotic events.	except more patients in the thalidomide group had rash, constipation, or neuropathy.
__label__noRel	thalidomide in combination with chemotherapy did not improve survival of patients with SCLC but was associated with an increased risk of thrombotic events.	QoL scores were similar in the two treatment groups,
__label__noRel	thalidomide in combination with chemotherapy did not improve survival of patients with SCLC but was associated with an increased risk of thrombotic events.	but thalidomide was associated with less insomnia and diarrhea and more constipation and peripheral neuropathy.
__label__noRel	TSS improved in 49 patients (77%) on regimen 1, and in 57 (92%) patients on regimen 2, a difference of 15% (95% confidence interval [CI] 3-28) in the proportion improving between the two regimens.	A complete resolution of all symptoms was achieved in three (5%) on regimen 1, and in 14 (23%) patients on regimen 2 (P < 0.001), a difference in the proportion between the two regimens of 21% (95% CI 10-33).
__label__noRel	TSS improved in 49 patients (77%) on regimen 1, and in 57 (92%) patients on regimen 2, a difference of 15% (95% confidence interval [CI] 3-28) in the proportion improving between the two regimens.	A significantly higher proportion of patients experienced palliation and complete resolution of chest pain and dyspnoea with regimen 2.
__label__noRel	TSS improved in 49 patients (77%) on regimen 1, and in 57 (92%) patients on regimen 2, a difference of 15% (95% confidence interval [CI] 3-28) in the proportion improving between the two regimens.	No differences were observed in toxicity.
__label__noRel	TSS improved in 49 patients (77%) on regimen 1, and in 57 (92%) patients on regimen 2, a difference of 15% (95% confidence interval [CI] 3-28) in the proportion improving between the two regimens.	The median survival was 22.7 weeks for regimen 1 and 28.3 weeks for regimen 2 (P = 0.197).
__label__noRel	TSS improved in 49 patients (77%) on regimen 1, and in 57 (92%) patients on regimen 2, a difference of 15% (95% confidence interval [CI] 3-28) in the proportion improving between the two regimens.	Although this trial met the pre-determined criteria for equivalence between the two palliative regimens,
__label__Support	TSS improved in 49 patients (77%) on regimen 1, and in 57 (92%) patients on regimen 2, a difference of 15% (95% confidence interval [CI] 3-28) in the proportion improving between the two regimens.	significantly more patients achieved complete resolution of symptoms and palliation of chest pain and dyspnoea with the fractionated regimen.
__label__noRel	A complete resolution of all symptoms was achieved in three (5%) on regimen 1, and in 14 (23%) patients on regimen 2 (P < 0.001), a difference in the proportion between the two regimens of 21% (95% CI 10-33).	TSS improved in 49 patients (77%) on regimen 1, and in 57 (92%) patients on regimen 2, a difference of 15% (95% confidence interval [CI] 3-28) in the proportion improving between the two regimens.
__label__noRel	A complete resolution of all symptoms was achieved in three (5%) on regimen 1, and in 14 (23%) patients on regimen 2 (P < 0.001), a difference in the proportion between the two regimens of 21% (95% CI 10-33).	A significantly higher proportion of patients experienced palliation and complete resolution of chest pain and dyspnoea with regimen 2.
__label__noRel	A complete resolution of all symptoms was achieved in three (5%) on regimen 1, and in 14 (23%) patients on regimen 2 (P < 0.001), a difference in the proportion between the two regimens of 21% (95% CI 10-33).	No differences were observed in toxicity.
__label__noRel	A complete resolution of all symptoms was achieved in three (5%) on regimen 1, and in 14 (23%) patients on regimen 2 (P < 0.001), a difference in the proportion between the two regimens of 21% (95% CI 10-33).	The median survival was 22.7 weeks for regimen 1 and 28.3 weeks for regimen 2 (P = 0.197).
__label__noRel	A complete resolution of all symptoms was achieved in three (5%) on regimen 1, and in 14 (23%) patients on regimen 2 (P < 0.001), a difference in the proportion between the two regimens of 21% (95% CI 10-33).	Although this trial met the pre-determined criteria for equivalence between the two palliative regimens,
__label__Support	A complete resolution of all symptoms was achieved in three (5%) on regimen 1, and in 14 (23%) patients on regimen 2 (P < 0.001), a difference in the proportion between the two regimens of 21% (95% CI 10-33).	significantly more patients achieved complete resolution of symptoms and palliation of chest pain and dyspnoea with the fractionated regimen.
__label__noRel	A significantly higher proportion of patients experienced palliation and complete resolution of chest pain and dyspnoea with regimen 2.	TSS improved in 49 patients (77%) on regimen 1, and in 57 (92%) patients on regimen 2, a difference of 15% (95% confidence interval [CI] 3-28) in the proportion improving between the two regimens.
__label__noRel	A significantly higher proportion of patients experienced palliation and complete resolution of chest pain and dyspnoea with regimen 2.	A complete resolution of all symptoms was achieved in three (5%) on regimen 1, and in 14 (23%) patients on regimen 2 (P < 0.001), a difference in the proportion between the two regimens of 21% (95% CI 10-33).
__label__noRel	A significantly higher proportion of patients experienced palliation and complete resolution of chest pain and dyspnoea with regimen 2.	No differences were observed in toxicity.
__label__noRel	A significantly higher proportion of patients experienced palliation and complete resolution of chest pain and dyspnoea with regimen 2.	The median survival was 22.7 weeks for regimen 1 and 28.3 weeks for regimen 2 (P = 0.197).
__label__noRel	A significantly higher proportion of patients experienced palliation and complete resolution of chest pain and dyspnoea with regimen 2.	Although this trial met the pre-determined criteria for equivalence between the two palliative regimens,
__label__Support	A significantly higher proportion of patients experienced palliation and complete resolution of chest pain and dyspnoea with regimen 2.	significantly more patients achieved complete resolution of symptoms and palliation of chest pain and dyspnoea with the fractionated regimen.
__label__noRel	No differences were observed in toxicity.	TSS improved in 49 patients (77%) on regimen 1, and in 57 (92%) patients on regimen 2, a difference of 15% (95% confidence interval [CI] 3-28) in the proportion improving between the two regimens.
__label__noRel	No differences were observed in toxicity.	A complete resolution of all symptoms was achieved in three (5%) on regimen 1, and in 14 (23%) patients on regimen 2 (P < 0.001), a difference in the proportion between the two regimens of 21% (95% CI 10-33).
__label__noRel	No differences were observed in toxicity.	A significantly higher proportion of patients experienced palliation and complete resolution of chest pain and dyspnoea with regimen 2.
__label__noRel	No differences were observed in toxicity.	The median survival was 22.7 weeks for regimen 1 and 28.3 weeks for regimen 2 (P = 0.197).
__label__noRel	No differences were observed in toxicity.	Although this trial met the pre-determined criteria for equivalence between the two palliative regimens,
__label__noRel	No differences were observed in toxicity.	significantly more patients achieved complete resolution of symptoms and palliation of chest pain and dyspnoea with the fractionated regimen.
__label__noRel	The median survival was 22.7 weeks for regimen 1 and 28.3 weeks for regimen 2 (P = 0.197).	TSS improved in 49 patients (77%) on regimen 1, and in 57 (92%) patients on regimen 2, a difference of 15% (95% confidence interval [CI] 3-28) in the proportion improving between the two regimens.
__label__noRel	The median survival was 22.7 weeks for regimen 1 and 28.3 weeks for regimen 2 (P = 0.197).	A complete resolution of all symptoms was achieved in three (5%) on regimen 1, and in 14 (23%) patients on regimen 2 (P < 0.001), a difference in the proportion between the two regimens of 21% (95% CI 10-33).
__label__noRel	The median survival was 22.7 weeks for regimen 1 and 28.3 weeks for regimen 2 (P = 0.197).	A significantly higher proportion of patients experienced palliation and complete resolution of chest pain and dyspnoea with regimen 2.
__label__noRel	The median survival was 22.7 weeks for regimen 1 and 28.3 weeks for regimen 2 (P = 0.197).	No differences were observed in toxicity.
__label__noRel	The median survival was 22.7 weeks for regimen 1 and 28.3 weeks for regimen 2 (P = 0.197).	Although this trial met the pre-determined criteria for equivalence between the two palliative regimens,
__label__noRel	The median survival was 22.7 weeks for regimen 1 and 28.3 weeks for regimen 2 (P = 0.197).	significantly more patients achieved complete resolution of symptoms and palliation of chest pain and dyspnoea with the fractionated regimen.
__label__noRel	Although this trial met the pre-determined criteria for equivalence between the two palliative regimens,	TSS improved in 49 patients (77%) on regimen 1, and in 57 (92%) patients on regimen 2, a difference of 15% (95% confidence interval [CI] 3-28) in the proportion improving between the two regimens.
__label__noRel	Although this trial met the pre-determined criteria for equivalence between the two palliative regimens,	A complete resolution of all symptoms was achieved in three (5%) on regimen 1, and in 14 (23%) patients on regimen 2 (P < 0.001), a difference in the proportion between the two regimens of 21% (95% CI 10-33).
__label__noRel	Although this trial met the pre-determined criteria for equivalence between the two palliative regimens,	A significantly higher proportion of patients experienced palliation and complete resolution of chest pain and dyspnoea with regimen 2.
__label__noRel	Although this trial met the pre-determined criteria for equivalence between the two palliative regimens,	No differences were observed in toxicity.
__label__noRel	Although this trial met the pre-determined criteria for equivalence between the two palliative regimens,	The median survival was 22.7 weeks for regimen 1 and 28.3 weeks for regimen 2 (P = 0.197).
__label__Support	Although this trial met the pre-determined criteria for equivalence between the two palliative regimens,	significantly more patients achieved complete resolution of symptoms and palliation of chest pain and dyspnoea with the fractionated regimen.
__label__noRel	significantly more patients achieved complete resolution of symptoms and palliation of chest pain and dyspnoea with the fractionated regimen.	TSS improved in 49 patients (77%) on regimen 1, and in 57 (92%) patients on regimen 2, a difference of 15% (95% confidence interval [CI] 3-28) in the proportion improving between the two regimens.
__label__noRel	significantly more patients achieved complete resolution of symptoms and palliation of chest pain and dyspnoea with the fractionated regimen.	A complete resolution of all symptoms was achieved in three (5%) on regimen 1, and in 14 (23%) patients on regimen 2 (P < 0.001), a difference in the proportion between the two regimens of 21% (95% CI 10-33).
__label__noRel	significantly more patients achieved complete resolution of symptoms and palliation of chest pain and dyspnoea with the fractionated regimen.	A significantly higher proportion of patients experienced palliation and complete resolution of chest pain and dyspnoea with regimen 2.
__label__noRel	significantly more patients achieved complete resolution of symptoms and palliation of chest pain and dyspnoea with the fractionated regimen.	No differences were observed in toxicity.
__label__noRel	significantly more patients achieved complete resolution of symptoms and palliation of chest pain and dyspnoea with the fractionated regimen.	The median survival was 22.7 weeks for regimen 1 and 28.3 weeks for regimen 2 (P = 0.197).
__label__noRel	significantly more patients achieved complete resolution of symptoms and palliation of chest pain and dyspnoea with the fractionated regimen.	Although this trial met the pre-determined criteria for equivalence between the two palliative regimens,
__label__noRel	Improvements in self-esteem observed with RET during breast cancer chemotherapy were maintained at 6-month follow-up	reductions in anxiety not observed with AET during breast cancer chemotherapy emerged at 6-month follow-up.
__label__noRel	Improvements in self-esteem observed with RET during breast cancer chemotherapy were maintained at 6-month follow-up	adopting a combined aerobic and resistance exercise program after breast cancer chemotherapy was associated with further improvements in patient-rated outcomes.
__label__Support	Improvements in self-esteem observed with RET during breast cancer chemotherapy were maintained at 6-month follow-up	Exercise training during breast cancer chemotherapy may result in some longer-term and late effects for selected patient-rated outcomes.
__label__noRel	Improvements in self-esteem observed with RET during breast cancer chemotherapy were maintained at 6-month follow-up	Adjusted linear mixed-model analyses showed that, at 6-month follow-up, the RET group reported higher self-esteem [adjusted mean difference, 1.6; 95% confidence interval (95% CI), 0.1-3.2; P = 0.032] and the AET group reported lower anxiety (adjusted mean difference, -4.7; 95% CI, -0.0 to -9.3; P = 0.049) compared with the usual care group.
__label__noRel	Improvements in self-esteem observed with RET during breast cancer chemotherapy were maintained at 6-month follow-up	compared with participants reporting no regular exercise during the follow-up period, those reporting regular aerobic and resistance exercise also reported better patient-rated outcomes, including quality of life (adjusted mean difference, 9.5; 95% CI, 1.2-17.8; P = 0.025).
__label__noRel	reductions in anxiety not observed with AET during breast cancer chemotherapy emerged at 6-month follow-up.	Improvements in self-esteem observed with RET during breast cancer chemotherapy were maintained at 6-month follow-up
__label__noRel	reductions in anxiety not observed with AET during breast cancer chemotherapy emerged at 6-month follow-up.	adopting a combined aerobic and resistance exercise program after breast cancer chemotherapy was associated with further improvements in patient-rated outcomes.
__label__Support	reductions in anxiety not observed with AET during breast cancer chemotherapy emerged at 6-month follow-up.	Exercise training during breast cancer chemotherapy may result in some longer-term and late effects for selected patient-rated outcomes.
__label__noRel	reductions in anxiety not observed with AET during breast cancer chemotherapy emerged at 6-month follow-up.	Adjusted linear mixed-model analyses showed that, at 6-month follow-up, the RET group reported higher self-esteem [adjusted mean difference, 1.6; 95% confidence interval (95% CI), 0.1-3.2; P = 0.032] and the AET group reported lower anxiety (adjusted mean difference, -4.7; 95% CI, -0.0 to -9.3; P = 0.049) compared with the usual care group.
__label__noRel	reductions in anxiety not observed with AET during breast cancer chemotherapy emerged at 6-month follow-up.	compared with participants reporting no regular exercise during the follow-up period, those reporting regular aerobic and resistance exercise also reported better patient-rated outcomes, including quality of life (adjusted mean difference, 9.5; 95% CI, 1.2-17.8; P = 0.025).
__label__noRel	adopting a combined aerobic and resistance exercise program after breast cancer chemotherapy was associated with further improvements in patient-rated outcomes.	Improvements in self-esteem observed with RET during breast cancer chemotherapy were maintained at 6-month follow-up
__label__noRel	adopting a combined aerobic and resistance exercise program after breast cancer chemotherapy was associated with further improvements in patient-rated outcomes.	reductions in anxiety not observed with AET during breast cancer chemotherapy emerged at 6-month follow-up.
__label__Support	adopting a combined aerobic and resistance exercise program after breast cancer chemotherapy was associated with further improvements in patient-rated outcomes.	Exercise training during breast cancer chemotherapy may result in some longer-term and late effects for selected patient-rated outcomes.
__label__noRel	adopting a combined aerobic and resistance exercise program after breast cancer chemotherapy was associated with further improvements in patient-rated outcomes.	Adjusted linear mixed-model analyses showed that, at 6-month follow-up, the RET group reported higher self-esteem [adjusted mean difference, 1.6; 95% confidence interval (95% CI), 0.1-3.2; P = 0.032] and the AET group reported lower anxiety (adjusted mean difference, -4.7; 95% CI, -0.0 to -9.3; P = 0.049) compared with the usual care group.
__label__noRel	adopting a combined aerobic and resistance exercise program after breast cancer chemotherapy was associated with further improvements in patient-rated outcomes.	compared with participants reporting no regular exercise during the follow-up period, those reporting regular aerobic and resistance exercise also reported better patient-rated outcomes, including quality of life (adjusted mean difference, 9.5; 95% CI, 1.2-17.8; P = 0.025).
__label__noRel	Exercise training during breast cancer chemotherapy may result in some longer-term and late effects for selected patient-rated outcomes.	Improvements in self-esteem observed with RET during breast cancer chemotherapy were maintained at 6-month follow-up
__label__noRel	Exercise training during breast cancer chemotherapy may result in some longer-term and late effects for selected patient-rated outcomes.	reductions in anxiety not observed with AET during breast cancer chemotherapy emerged at 6-month follow-up.
__label__noRel	Exercise training during breast cancer chemotherapy may result in some longer-term and late effects for selected patient-rated outcomes.	adopting a combined aerobic and resistance exercise program after breast cancer chemotherapy was associated with further improvements in patient-rated outcomes.
__label__noRel	Exercise training during breast cancer chemotherapy may result in some longer-term and late effects for selected patient-rated outcomes.	Adjusted linear mixed-model analyses showed that, at 6-month follow-up, the RET group reported higher self-esteem [adjusted mean difference, 1.6; 95% confidence interval (95% CI), 0.1-3.2; P = 0.032] and the AET group reported lower anxiety (adjusted mean difference, -4.7; 95% CI, -0.0 to -9.3; P = 0.049) compared with the usual care group.
__label__noRel	Exercise training during breast cancer chemotherapy may result in some longer-term and late effects for selected patient-rated outcomes.	compared with participants reporting no regular exercise during the follow-up period, those reporting regular aerobic and resistance exercise also reported better patient-rated outcomes, including quality of life (adjusted mean difference, 9.5; 95% CI, 1.2-17.8; P = 0.025).
__label__noRel	Adjusted linear mixed-model analyses showed that, at 6-month follow-up, the RET group reported higher self-esteem [adjusted mean difference, 1.6; 95% confidence interval (95% CI), 0.1-3.2; P = 0.032] and the AET group reported lower anxiety (adjusted mean difference, -4.7; 95% CI, -0.0 to -9.3; P = 0.049) compared with the usual care group.	Improvements in self-esteem observed with RET during breast cancer chemotherapy were maintained at 6-month follow-up
__label__noRel	Adjusted linear mixed-model analyses showed that, at 6-month follow-up, the RET group reported higher self-esteem [adjusted mean difference, 1.6; 95% confidence interval (95% CI), 0.1-3.2; P = 0.032] and the AET group reported lower anxiety (adjusted mean difference, -4.7; 95% CI, -0.0 to -9.3; P = 0.049) compared with the usual care group.	reductions in anxiety not observed with AET during breast cancer chemotherapy emerged at 6-month follow-up.
__label__Support	Adjusted linear mixed-model analyses showed that, at 6-month follow-up, the RET group reported higher self-esteem [adjusted mean difference, 1.6; 95% confidence interval (95% CI), 0.1-3.2; P = 0.032] and the AET group reported lower anxiety (adjusted mean difference, -4.7; 95% CI, -0.0 to -9.3; P = 0.049) compared with the usual care group.	adopting a combined aerobic and resistance exercise program after breast cancer chemotherapy was associated with further improvements in patient-rated outcomes.
__label__noRel	Adjusted linear mixed-model analyses showed that, at 6-month follow-up, the RET group reported higher self-esteem [adjusted mean difference, 1.6; 95% confidence interval (95% CI), 0.1-3.2; P = 0.032] and the AET group reported lower anxiety (adjusted mean difference, -4.7; 95% CI, -0.0 to -9.3; P = 0.049) compared with the usual care group.	Exercise training during breast cancer chemotherapy may result in some longer-term and late effects for selected patient-rated outcomes.
__label__noRel	Adjusted linear mixed-model analyses showed that, at 6-month follow-up, the RET group reported higher self-esteem [adjusted mean difference, 1.6; 95% confidence interval (95% CI), 0.1-3.2; P = 0.032] and the AET group reported lower anxiety (adjusted mean difference, -4.7; 95% CI, -0.0 to -9.3; P = 0.049) compared with the usual care group.	compared with participants reporting no regular exercise during the follow-up period, those reporting regular aerobic and resistance exercise also reported better patient-rated outcomes, including quality of life (adjusted mean difference, 9.5; 95% CI, 1.2-17.8; P = 0.025).
__label__noRel	compared with participants reporting no regular exercise during the follow-up period, those reporting regular aerobic and resistance exercise also reported better patient-rated outcomes, including quality of life (adjusted mean difference, 9.5; 95% CI, 1.2-17.8; P = 0.025).	Improvements in self-esteem observed with RET during breast cancer chemotherapy were maintained at 6-month follow-up
__label__noRel	compared with participants reporting no regular exercise during the follow-up period, those reporting regular aerobic and resistance exercise also reported better patient-rated outcomes, including quality of life (adjusted mean difference, 9.5; 95% CI, 1.2-17.8; P = 0.025).	reductions in anxiety not observed with AET during breast cancer chemotherapy emerged at 6-month follow-up.
__label__Support	compared with participants reporting no regular exercise during the follow-up period, those reporting regular aerobic and resistance exercise also reported better patient-rated outcomes, including quality of life (adjusted mean difference, 9.5; 95% CI, 1.2-17.8; P = 0.025).	adopting a combined aerobic and resistance exercise program after breast cancer chemotherapy was associated with further improvements in patient-rated outcomes.
__label__noRel	compared with participants reporting no regular exercise during the follow-up period, those reporting regular aerobic and resistance exercise also reported better patient-rated outcomes, including quality of life (adjusted mean difference, 9.5; 95% CI, 1.2-17.8; P = 0.025).	Exercise training during breast cancer chemotherapy may result in some longer-term and late effects for selected patient-rated outcomes.
__label__noRel	compared with participants reporting no regular exercise during the follow-up period, those reporting regular aerobic and resistance exercise also reported better patient-rated outcomes, including quality of life (adjusted mean difference, 9.5; 95% CI, 1.2-17.8; P = 0.025).	Adjusted linear mixed-model analyses showed that, at 6-month follow-up, the RET group reported higher self-esteem [adjusted mean difference, 1.6; 95% confidence interval (95% CI), 0.1-3.2; P = 0.032] and the AET group reported lower anxiety (adjusted mean difference, -4.7; 95% CI, -0.0 to -9.3; P = 0.049) compared with the usual care group.
__label__noRel	No evidence of a difference was observed between the two treatment groups in terms of activity level, anxiety, depression, and psychological distress, as recorded by the patients.	Adverse events were more common in the immediate treatment group.
__label__noRel	No evidence of a difference was observed between the two treatment groups in terms of activity level, anxiety, depression, and psychological distress, as recorded by the patients.	Neither group had a survival advantage (hazard ratio 0.95, 0.73 to 1.24; P=0.71).
__label__noRel	No evidence of a difference was observed between the two treatment groups in terms of activity level, anxiety, depression, and psychological distress, as recorded by the patients.	Median survival was 8.3 months and 7.9 months,
__label__noRel	No evidence of a difference was observed between the two treatment groups in terms of activity level, anxiety, depression, and psychological distress, as recorded by the patients.	the survival rates were 31% and 29% at 12 months, for the immediate and delayed treatment groups, respectively.
__label__Support	No evidence of a difference was observed between the two treatment groups in terms of activity level, anxiety, depression, and psychological distress, as recorded by the patients.	In minimally symptomatic patients with locally advanced non-small cell lung cancer, no persuasive evidence was found to indicate that giving immediate palliative thoracic radiotherapy improves symptom control, quality of life, or survival when compared with delaying until symptoms require treatment.
__label__noRel	No evidence of a difference was observed between the two treatment groups in terms of activity level, anxiety, depression, and psychological distress, as recorded by the patients.	The primary outcome measure was achieved in 28% of the immediate treatment group and 26% of patients from the delayed treatment group (27/97 and 27/103, respectively; absolute difference 1.6%, 95% confidence interval -10.7% to 13.9%).
__label__noRel	Adverse events were more common in the immediate treatment group.	No evidence of a difference was observed between the two treatment groups in terms of activity level, anxiety, depression, and psychological distress, as recorded by the patients.
__label__noRel	Adverse events were more common in the immediate treatment group.	Neither group had a survival advantage (hazard ratio 0.95, 0.73 to 1.24; P=0.71).
__label__noRel	Adverse events were more common in the immediate treatment group.	Median survival was 8.3 months and 7.9 months,
__label__noRel	Adverse events were more common in the immediate treatment group.	the survival rates were 31% and 29% at 12 months, for the immediate and delayed treatment groups, respectively.
__label__noRel	Adverse events were more common in the immediate treatment group.	In minimally symptomatic patients with locally advanced non-small cell lung cancer, no persuasive evidence was found to indicate that giving immediate palliative thoracic radiotherapy improves symptom control, quality of life, or survival when compared with delaying until symptoms require treatment.
__label__noRel	Adverse events were more common in the immediate treatment group.	The primary outcome measure was achieved in 28% of the immediate treatment group and 26% of patients from the delayed treatment group (27/97 and 27/103, respectively; absolute difference 1.6%, 95% confidence interval -10.7% to 13.9%).
__label__noRel	Neither group had a survival advantage (hazard ratio 0.95, 0.73 to 1.24; P=0.71).	No evidence of a difference was observed between the two treatment groups in terms of activity level, anxiety, depression, and psychological distress, as recorded by the patients.
__label__noRel	Neither group had a survival advantage (hazard ratio 0.95, 0.73 to 1.24; P=0.71).	Adverse events were more common in the immediate treatment group.
__label__noRel	Neither group had a survival advantage (hazard ratio 0.95, 0.73 to 1.24; P=0.71).	Median survival was 8.3 months and 7.9 months,
__label__noRel	Neither group had a survival advantage (hazard ratio 0.95, 0.73 to 1.24; P=0.71).	the survival rates were 31% and 29% at 12 months, for the immediate and delayed treatment groups, respectively.
__label__Support	Neither group had a survival advantage (hazard ratio 0.95, 0.73 to 1.24; P=0.71).	In minimally symptomatic patients with locally advanced non-small cell lung cancer, no persuasive evidence was found to indicate that giving immediate palliative thoracic radiotherapy improves symptom control, quality of life, or survival when compared with delaying until symptoms require treatment.
__label__noRel	Neither group had a survival advantage (hazard ratio 0.95, 0.73 to 1.24; P=0.71).	The primary outcome measure was achieved in 28% of the immediate treatment group and 26% of patients from the delayed treatment group (27/97 and 27/103, respectively; absolute difference 1.6%, 95% confidence interval -10.7% to 13.9%).
__label__noRel	Median survival was 8.3 months and 7.9 months,	No evidence of a difference was observed between the two treatment groups in terms of activity level, anxiety, depression, and psychological distress, as recorded by the patients.
__label__noRel	Median survival was 8.3 months and 7.9 months,	Adverse events were more common in the immediate treatment group.
__label__noRel	Median survival was 8.3 months and 7.9 months,	Neither group had a survival advantage (hazard ratio 0.95, 0.73 to 1.24; P=0.71).
__label__noRel	Median survival was 8.3 months and 7.9 months,	the survival rates were 31% and 29% at 12 months, for the immediate and delayed treatment groups, respectively.
__label__Support	Median survival was 8.3 months and 7.9 months,	In minimally symptomatic patients with locally advanced non-small cell lung cancer, no persuasive evidence was found to indicate that giving immediate palliative thoracic radiotherapy improves symptom control, quality of life, or survival when compared with delaying until symptoms require treatment.
__label__noRel	Median survival was 8.3 months and 7.9 months,	The primary outcome measure was achieved in 28% of the immediate treatment group and 26% of patients from the delayed treatment group (27/97 and 27/103, respectively; absolute difference 1.6%, 95% confidence interval -10.7% to 13.9%).
__label__noRel	the survival rates were 31% and 29% at 12 months, for the immediate and delayed treatment groups, respectively.	No evidence of a difference was observed between the two treatment groups in terms of activity level, anxiety, depression, and psychological distress, as recorded by the patients.
__label__noRel	the survival rates were 31% and 29% at 12 months, for the immediate and delayed treatment groups, respectively.	Adverse events were more common in the immediate treatment group.
__label__noRel	the survival rates were 31% and 29% at 12 months, for the immediate and delayed treatment groups, respectively.	Neither group had a survival advantage (hazard ratio 0.95, 0.73 to 1.24; P=0.71).
__label__noRel	the survival rates were 31% and 29% at 12 months, for the immediate and delayed treatment groups, respectively.	Median survival was 8.3 months and 7.9 months,
__label__Support	the survival rates were 31% and 29% at 12 months, for the immediate and delayed treatment groups, respectively.	In minimally symptomatic patients with locally advanced non-small cell lung cancer, no persuasive evidence was found to indicate that giving immediate palliative thoracic radiotherapy improves symptom control, quality of life, or survival when compared with delaying until symptoms require treatment.
__label__noRel	the survival rates were 31% and 29% at 12 months, for the immediate and delayed treatment groups, respectively.	The primary outcome measure was achieved in 28% of the immediate treatment group and 26% of patients from the delayed treatment group (27/97 and 27/103, respectively; absolute difference 1.6%, 95% confidence interval -10.7% to 13.9%).
__label__noRel	In minimally symptomatic patients with locally advanced non-small cell lung cancer, no persuasive evidence was found to indicate that giving immediate palliative thoracic radiotherapy improves symptom control, quality of life, or survival when compared with delaying until symptoms require treatment.	No evidence of a difference was observed between the two treatment groups in terms of activity level, anxiety, depression, and psychological distress, as recorded by the patients.
__label__noRel	In minimally symptomatic patients with locally advanced non-small cell lung cancer, no persuasive evidence was found to indicate that giving immediate palliative thoracic radiotherapy improves symptom control, quality of life, or survival when compared with delaying until symptoms require treatment.	Adverse events were more common in the immediate treatment group.
__label__noRel	In minimally symptomatic patients with locally advanced non-small cell lung cancer, no persuasive evidence was found to indicate that giving immediate palliative thoracic radiotherapy improves symptom control, quality of life, or survival when compared with delaying until symptoms require treatment.	Neither group had a survival advantage (hazard ratio 0.95, 0.73 to 1.24; P=0.71).
__label__noRel	In minimally symptomatic patients with locally advanced non-small cell lung cancer, no persuasive evidence was found to indicate that giving immediate palliative thoracic radiotherapy improves symptom control, quality of life, or survival when compared with delaying until symptoms require treatment.	Median survival was 8.3 months and 7.9 months,
__label__noRel	In minimally symptomatic patients with locally advanced non-small cell lung cancer, no persuasive evidence was found to indicate that giving immediate palliative thoracic radiotherapy improves symptom control, quality of life, or survival when compared with delaying until symptoms require treatment.	the survival rates were 31% and 29% at 12 months, for the immediate and delayed treatment groups, respectively.
__label__noRel	In minimally symptomatic patients with locally advanced non-small cell lung cancer, no persuasive evidence was found to indicate that giving immediate palliative thoracic radiotherapy improves symptom control, quality of life, or survival when compared with delaying until symptoms require treatment.	The primary outcome measure was achieved in 28% of the immediate treatment group and 26% of patients from the delayed treatment group (27/97 and 27/103, respectively; absolute difference 1.6%, 95% confidence interval -10.7% to 13.9%).
__label__noRel	The primary outcome measure was achieved in 28% of the immediate treatment group and 26% of patients from the delayed treatment group (27/97 and 27/103, respectively; absolute difference 1.6%, 95% confidence interval -10.7% to 13.9%).	No evidence of a difference was observed between the two treatment groups in terms of activity level, anxiety, depression, and psychological distress, as recorded by the patients.
__label__noRel	The primary outcome measure was achieved in 28% of the immediate treatment group and 26% of patients from the delayed treatment group (27/97 and 27/103, respectively; absolute difference 1.6%, 95% confidence interval -10.7% to 13.9%).	Adverse events were more common in the immediate treatment group.
__label__noRel	The primary outcome measure was achieved in 28% of the immediate treatment group and 26% of patients from the delayed treatment group (27/97 and 27/103, respectively; absolute difference 1.6%, 95% confidence interval -10.7% to 13.9%).	Neither group had a survival advantage (hazard ratio 0.95, 0.73 to 1.24; P=0.71).
__label__noRel	The primary outcome measure was achieved in 28% of the immediate treatment group and 26% of patients from the delayed treatment group (27/97 and 27/103, respectively; absolute difference 1.6%, 95% confidence interval -10.7% to 13.9%).	Median survival was 8.3 months and 7.9 months,
__label__noRel	The primary outcome measure was achieved in 28% of the immediate treatment group and 26% of patients from the delayed treatment group (27/97 and 27/103, respectively; absolute difference 1.6%, 95% confidence interval -10.7% to 13.9%).	the survival rates were 31% and 29% at 12 months, for the immediate and delayed treatment groups, respectively.
__label__noRel	The primary outcome measure was achieved in 28% of the immediate treatment group and 26% of patients from the delayed treatment group (27/97 and 27/103, respectively; absolute difference 1.6%, 95% confidence interval -10.7% to 13.9%).	In minimally symptomatic patients with locally advanced non-small cell lung cancer, no persuasive evidence was found to indicate that giving immediate palliative thoracic radiotherapy improves symptom control, quality of life, or survival when compared with delaying until symptoms require treatment.
__label__noRel	Intention-to-treat analyses indicated that AET resulted in a nonsignificant (P = 0.16) improvement in global sleep quality compared with usual care [mean group difference = -0.64; 95% confidence interval (CI), -1.56 to +0.27].	In planned subgroup analyses, statistically significant or borderline significant interactions were identified for type of lymphoma (P(interaction) = 0.006), current treatment status (P(interaction) = 0.036), time since diagnosis (P(interaction) = 0.010), body mass index (P(interaction) = 0.075), and baseline sleep quality (P(interaction) = 0.041).
__label__noRel	Intention-to-treat analyses indicated that AET resulted in a nonsignificant (P = 0.16) improvement in global sleep quality compared with usual care [mean group difference = -0.64; 95% confidence interval (CI), -1.56 to +0.27].	AET improved global sleep quality in patients with lymphoma who had indolent non-Hodgkin lymphoma (P = 0.001), were receiving chemotherapy (P = 0.013), were <2 years post-diagnosis (P = 0.005), were obese (P = 0.025), and were poor sleepers at baseline (P = 0.007).
__label__Support	Intention-to-treat analyses indicated that AET resulted in a nonsignificant (P = 0.16) improvement in global sleep quality compared with usual care [mean group difference = -0.64; 95% confidence interval (CI), -1.56 to +0.27].	AET did not significantly improve sleep quality in this heterogeneous sample of patients with lymphoma;
__label__noRel	Intention-to-treat analyses indicated that AET resulted in a nonsignificant (P = 0.16) improvement in global sleep quality compared with usual care [mean group difference = -0.64; 95% confidence interval (CI), -1.56 to +0.27].	however, clinically identifiable subgroups appeared to benefit.
__label__noRel	In planned subgroup analyses, statistically significant or borderline significant interactions were identified for type of lymphoma (P(interaction) = 0.006), current treatment status (P(interaction) = 0.036), time since diagnosis (P(interaction) = 0.010), body mass index (P(interaction) = 0.075), and baseline sleep quality (P(interaction) = 0.041).	Intention-to-treat analyses indicated that AET resulted in a nonsignificant (P = 0.16) improvement in global sleep quality compared with usual care [mean group difference = -0.64; 95% confidence interval (CI), -1.56 to +0.27].
__label__noRel	In planned subgroup analyses, statistically significant or borderline significant interactions were identified for type of lymphoma (P(interaction) = 0.006), current treatment status (P(interaction) = 0.036), time since diagnosis (P(interaction) = 0.010), body mass index (P(interaction) = 0.075), and baseline sleep quality (P(interaction) = 0.041).	AET improved global sleep quality in patients with lymphoma who had indolent non-Hodgkin lymphoma (P = 0.001), were receiving chemotherapy (P = 0.013), were <2 years post-diagnosis (P = 0.005), were obese (P = 0.025), and were poor sleepers at baseline (P = 0.007).
__label__noRel	In planned subgroup analyses, statistically significant or borderline significant interactions were identified for type of lymphoma (P(interaction) = 0.006), current treatment status (P(interaction) = 0.036), time since diagnosis (P(interaction) = 0.010), body mass index (P(interaction) = 0.075), and baseline sleep quality (P(interaction) = 0.041).	AET did not significantly improve sleep quality in this heterogeneous sample of patients with lymphoma;
__label__noRel	In planned subgroup analyses, statistically significant or borderline significant interactions were identified for type of lymphoma (P(interaction) = 0.006), current treatment status (P(interaction) = 0.036), time since diagnosis (P(interaction) = 0.010), body mass index (P(interaction) = 0.075), and baseline sleep quality (P(interaction) = 0.041).	however, clinically identifiable subgroups appeared to benefit.
__label__noRel	AET improved global sleep quality in patients with lymphoma who had indolent non-Hodgkin lymphoma (P = 0.001), were receiving chemotherapy (P = 0.013), were <2 years post-diagnosis (P = 0.005), were obese (P = 0.025), and were poor sleepers at baseline (P = 0.007).	Intention-to-treat analyses indicated that AET resulted in a nonsignificant (P = 0.16) improvement in global sleep quality compared with usual care [mean group difference = -0.64; 95% confidence interval (CI), -1.56 to +0.27].
__label__noRel	AET improved global sleep quality in patients with lymphoma who had indolent non-Hodgkin lymphoma (P = 0.001), were receiving chemotherapy (P = 0.013), were <2 years post-diagnosis (P = 0.005), were obese (P = 0.025), and were poor sleepers at baseline (P = 0.007).	In planned subgroup analyses, statistically significant or borderline significant interactions were identified for type of lymphoma (P(interaction) = 0.006), current treatment status (P(interaction) = 0.036), time since diagnosis (P(interaction) = 0.010), body mass index (P(interaction) = 0.075), and baseline sleep quality (P(interaction) = 0.041).
__label__noRel	AET improved global sleep quality in patients with lymphoma who had indolent non-Hodgkin lymphoma (P = 0.001), were receiving chemotherapy (P = 0.013), were <2 years post-diagnosis (P = 0.005), were obese (P = 0.025), and were poor sleepers at baseline (P = 0.007).	AET did not significantly improve sleep quality in this heterogeneous sample of patients with lymphoma;
__label__Support	AET improved global sleep quality in patients with lymphoma who had indolent non-Hodgkin lymphoma (P = 0.001), were receiving chemotherapy (P = 0.013), were <2 years post-diagnosis (P = 0.005), were obese (P = 0.025), and were poor sleepers at baseline (P = 0.007).	however, clinically identifiable subgroups appeared to benefit.
__label__noRel	AET did not significantly improve sleep quality in this heterogeneous sample of patients with lymphoma;	Intention-to-treat analyses indicated that AET resulted in a nonsignificant (P = 0.16) improvement in global sleep quality compared with usual care [mean group difference = -0.64; 95% confidence interval (CI), -1.56 to +0.27].
__label__noRel	AET did not significantly improve sleep quality in this heterogeneous sample of patients with lymphoma;	In planned subgroup analyses, statistically significant or borderline significant interactions were identified for type of lymphoma (P(interaction) = 0.006), current treatment status (P(interaction) = 0.036), time since diagnosis (P(interaction) = 0.010), body mass index (P(interaction) = 0.075), and baseline sleep quality (P(interaction) = 0.041).
__label__noRel	AET did not significantly improve sleep quality in this heterogeneous sample of patients with lymphoma;	AET improved global sleep quality in patients with lymphoma who had indolent non-Hodgkin lymphoma (P = 0.001), were receiving chemotherapy (P = 0.013), were <2 years post-diagnosis (P = 0.005), were obese (P = 0.025), and were poor sleepers at baseline (P = 0.007).
__label__noRel	AET did not significantly improve sleep quality in this heterogeneous sample of patients with lymphoma;	however, clinically identifiable subgroups appeared to benefit.
__label__noRel	however, clinically identifiable subgroups appeared to benefit.	Intention-to-treat analyses indicated that AET resulted in a nonsignificant (P = 0.16) improvement in global sleep quality compared with usual care [mean group difference = -0.64; 95% confidence interval (CI), -1.56 to +0.27].
__label__noRel	however, clinically identifiable subgroups appeared to benefit.	In planned subgroup analyses, statistically significant or borderline significant interactions were identified for type of lymphoma (P(interaction) = 0.006), current treatment status (P(interaction) = 0.036), time since diagnosis (P(interaction) = 0.010), body mass index (P(interaction) = 0.075), and baseline sleep quality (P(interaction) = 0.041).
__label__noRel	however, clinically identifiable subgroups appeared to benefit.	AET improved global sleep quality in patients with lymphoma who had indolent non-Hodgkin lymphoma (P = 0.001), were receiving chemotherapy (P = 0.013), were <2 years post-diagnosis (P = 0.005), were obese (P = 0.025), and were poor sleepers at baseline (P = 0.007).
__label__Attack	however, clinically identifiable subgroups appeared to benefit.	AET did not significantly improve sleep quality in this heterogeneous sample of patients with lymphoma;
__label__noRel	In vivo data have shown a more potent antiangiogenic effect and a higher antitumor activity of low-dose interferon (IFN) given twice daily.	There were no significant differences in either PFS or OS between IFN1 and IFN5 (median of 3.7 months and median of 3.4 months PFS, respectively; median of 25.5 months and median of 17.5 months OS, respectively).
__label__noRel	In vivo data have shown a more potent antiangiogenic effect and a higher antitumor activity of low-dose interferon (IFN) given twice daily.	The RRs were identical in the 2 arms (6.7%; 95% confidence interval [95% CI], 1.8-16.5%).
__label__noRel	In vivo data have shown a more potent antiangiogenic effect and a higher antitumor activity of low-dose interferon (IFN) given twice daily.	Two patients, 1 in each arm, remained in complete remission at the time of last follow-up, at 45+ and 38+ months from treatment.
__label__noRel	In vivo data have shown a more potent antiangiogenic effect and a higher antitumor activity of low-dose interferon (IFN) given twice daily.	Thirty-two patients receiving IFN5 and 19 patients receiving IFN1 experienced Grade 3 or higher adverse events (graded using the National Cancer Institute Common Toxicity Criteria [version 2.0]) (P = .025).
__label__noRel	In vivo data have shown a more potent antiangiogenic effect and a higher antitumor activity of low-dose interferon (IFN) given twice daily.	Eighteen patients receiving IFN5 and 4 patients receiving IFN1 had dose reductions (P = .002).
__label__noRel	In vivo data have shown a more potent antiangiogenic effect and a higher antitumor activity of low-dose interferon (IFN) given twice daily.	There was a significant deterioration in QOL and an increase in depression associated with IFN5 but no change was noted with IFN1.
__label__noRel	In vivo data have shown a more potent antiangiogenic effect and a higher antitumor activity of low-dose interferon (IFN) given twice daily.	Compared with IFN5, IFN1 is neither more nor less effective but is less toxic, with a better reported QOL.
__label__noRel	In vivo data have shown a more potent antiangiogenic effect and a higher antitumor activity of low-dose interferon (IFN) given twice daily.	These results may have implications for the design of combination regimens incorporating IFN with targeted agents.
__label__noRel	There were no significant differences in either PFS or OS between IFN1 and IFN5 (median of 3.7 months and median of 3.4 months PFS, respectively; median of 25.5 months and median of 17.5 months OS, respectively).	In vivo data have shown a more potent antiangiogenic effect and a higher antitumor activity of low-dose interferon (IFN) given twice daily.
__label__noRel	There were no significant differences in either PFS or OS between IFN1 and IFN5 (median of 3.7 months and median of 3.4 months PFS, respectively; median of 25.5 months and median of 17.5 months OS, respectively).	The RRs were identical in the 2 arms (6.7%; 95% confidence interval [95% CI], 1.8-16.5%).
__label__noRel	There were no significant differences in either PFS or OS between IFN1 and IFN5 (median of 3.7 months and median of 3.4 months PFS, respectively; median of 25.5 months and median of 17.5 months OS, respectively).	Two patients, 1 in each arm, remained in complete remission at the time of last follow-up, at 45+ and 38+ months from treatment.
__label__noRel	There were no significant differences in either PFS or OS between IFN1 and IFN5 (median of 3.7 months and median of 3.4 months PFS, respectively; median of 25.5 months and median of 17.5 months OS, respectively).	Thirty-two patients receiving IFN5 and 19 patients receiving IFN1 experienced Grade 3 or higher adverse events (graded using the National Cancer Institute Common Toxicity Criteria [version 2.0]) (P = .025).
__label__noRel	There were no significant differences in either PFS or OS between IFN1 and IFN5 (median of 3.7 months and median of 3.4 months PFS, respectively; median of 25.5 months and median of 17.5 months OS, respectively).	Eighteen patients receiving IFN5 and 4 patients receiving IFN1 had dose reductions (P = .002).
__label__noRel	There were no significant differences in either PFS or OS between IFN1 and IFN5 (median of 3.7 months and median of 3.4 months PFS, respectively; median of 25.5 months and median of 17.5 months OS, respectively).	There was a significant deterioration in QOL and an increase in depression associated with IFN5 but no change was noted with IFN1.
__label__Support	There were no significant differences in either PFS or OS between IFN1 and IFN5 (median of 3.7 months and median of 3.4 months PFS, respectively; median of 25.5 months and median of 17.5 months OS, respectively).	Compared with IFN5, IFN1 is neither more nor less effective but is less toxic, with a better reported QOL.
__label__noRel	There were no significant differences in either PFS or OS between IFN1 and IFN5 (median of 3.7 months and median of 3.4 months PFS, respectively; median of 25.5 months and median of 17.5 months OS, respectively).	These results may have implications for the design of combination regimens incorporating IFN with targeted agents.
__label__noRel	The RRs were identical in the 2 arms (6.7%; 95% confidence interval [95% CI], 1.8-16.5%).	In vivo data have shown a more potent antiangiogenic effect and a higher antitumor activity of low-dose interferon (IFN) given twice daily.
__label__noRel	The RRs were identical in the 2 arms (6.7%; 95% confidence interval [95% CI], 1.8-16.5%).	There were no significant differences in either PFS or OS between IFN1 and IFN5 (median of 3.7 months and median of 3.4 months PFS, respectively; median of 25.5 months and median of 17.5 months OS, respectively).
__label__noRel	The RRs were identical in the 2 arms (6.7%; 95% confidence interval [95% CI], 1.8-16.5%).	Two patients, 1 in each arm, remained in complete remission at the time of last follow-up, at 45+ and 38+ months from treatment.
__label__noRel	The RRs were identical in the 2 arms (6.7%; 95% confidence interval [95% CI], 1.8-16.5%).	Thirty-two patients receiving IFN5 and 19 patients receiving IFN1 experienced Grade 3 or higher adverse events (graded using the National Cancer Institute Common Toxicity Criteria [version 2.0]) (P = .025).
__label__noRel	The RRs were identical in the 2 arms (6.7%; 95% confidence interval [95% CI], 1.8-16.5%).	Eighteen patients receiving IFN5 and 4 patients receiving IFN1 had dose reductions (P = .002).
__label__noRel	The RRs were identical in the 2 arms (6.7%; 95% confidence interval [95% CI], 1.8-16.5%).	There was a significant deterioration in QOL and an increase in depression associated with IFN5 but no change was noted with IFN1.
__label__Support	The RRs were identical in the 2 arms (6.7%; 95% confidence interval [95% CI], 1.8-16.5%).	Compared with IFN5, IFN1 is neither more nor less effective but is less toxic, with a better reported QOL.
__label__noRel	The RRs were identical in the 2 arms (6.7%; 95% confidence interval [95% CI], 1.8-16.5%).	These results may have implications for the design of combination regimens incorporating IFN with targeted agents.
__label__noRel	Two patients, 1 in each arm, remained in complete remission at the time of last follow-up, at 45+ and 38+ months from treatment.	In vivo data have shown a more potent antiangiogenic effect and a higher antitumor activity of low-dose interferon (IFN) given twice daily.
__label__noRel	Two patients, 1 in each arm, remained in complete remission at the time of last follow-up, at 45+ and 38+ months from treatment.	There were no significant differences in either PFS or OS between IFN1 and IFN5 (median of 3.7 months and median of 3.4 months PFS, respectively; median of 25.5 months and median of 17.5 months OS, respectively).
__label__noRel	Two patients, 1 in each arm, remained in complete remission at the time of last follow-up, at 45+ and 38+ months from treatment.	The RRs were identical in the 2 arms (6.7%; 95% confidence interval [95% CI], 1.8-16.5%).
__label__noRel	Two patients, 1 in each arm, remained in complete remission at the time of last follow-up, at 45+ and 38+ months from treatment.	Thirty-two patients receiving IFN5 and 19 patients receiving IFN1 experienced Grade 3 or higher adverse events (graded using the National Cancer Institute Common Toxicity Criteria [version 2.0]) (P = .025).
__label__noRel	Two patients, 1 in each arm, remained in complete remission at the time of last follow-up, at 45+ and 38+ months from treatment.	Eighteen patients receiving IFN5 and 4 patients receiving IFN1 had dose reductions (P = .002).
__label__noRel	Two patients, 1 in each arm, remained in complete remission at the time of last follow-up, at 45+ and 38+ months from treatment.	There was a significant deterioration in QOL and an increase in depression associated with IFN5 but no change was noted with IFN1.
__label__Support	Two patients, 1 in each arm, remained in complete remission at the time of last follow-up, at 45+ and 38+ months from treatment.	Compared with IFN5, IFN1 is neither more nor less effective but is less toxic, with a better reported QOL.
__label__noRel	Two patients, 1 in each arm, remained in complete remission at the time of last follow-up, at 45+ and 38+ months from treatment.	These results may have implications for the design of combination regimens incorporating IFN with targeted agents.
__label__noRel	Thirty-two patients receiving IFN5 and 19 patients receiving IFN1 experienced Grade 3 or higher adverse events (graded using the National Cancer Institute Common Toxicity Criteria [version 2.0]) (P = .025).	In vivo data have shown a more potent antiangiogenic effect and a higher antitumor activity of low-dose interferon (IFN) given twice daily.
__label__noRel	Thirty-two patients receiving IFN5 and 19 patients receiving IFN1 experienced Grade 3 or higher adverse events (graded using the National Cancer Institute Common Toxicity Criteria [version 2.0]) (P = .025).	There were no significant differences in either PFS or OS between IFN1 and IFN5 (median of 3.7 months and median of 3.4 months PFS, respectively; median of 25.5 months and median of 17.5 months OS, respectively).
__label__noRel	Thirty-two patients receiving IFN5 and 19 patients receiving IFN1 experienced Grade 3 or higher adverse events (graded using the National Cancer Institute Common Toxicity Criteria [version 2.0]) (P = .025).	The RRs were identical in the 2 arms (6.7%; 95% confidence interval [95% CI], 1.8-16.5%).
__label__noRel	Thirty-two patients receiving IFN5 and 19 patients receiving IFN1 experienced Grade 3 or higher adverse events (graded using the National Cancer Institute Common Toxicity Criteria [version 2.0]) (P = .025).	Two patients, 1 in each arm, remained in complete remission at the time of last follow-up, at 45+ and 38+ months from treatment.
__label__noRel	Thirty-two patients receiving IFN5 and 19 patients receiving IFN1 experienced Grade 3 or higher adverse events (graded using the National Cancer Institute Common Toxicity Criteria [version 2.0]) (P = .025).	Eighteen patients receiving IFN5 and 4 patients receiving IFN1 had dose reductions (P = .002).
__label__noRel	Thirty-two patients receiving IFN5 and 19 patients receiving IFN1 experienced Grade 3 or higher adverse events (graded using the National Cancer Institute Common Toxicity Criteria [version 2.0]) (P = .025).	There was a significant deterioration in QOL and an increase in depression associated with IFN5 but no change was noted with IFN1.
__label__Support	Thirty-two patients receiving IFN5 and 19 patients receiving IFN1 experienced Grade 3 or higher adverse events (graded using the National Cancer Institute Common Toxicity Criteria [version 2.0]) (P = .025).	Compared with IFN5, IFN1 is neither more nor less effective but is less toxic, with a better reported QOL.
__label__noRel	Thirty-two patients receiving IFN5 and 19 patients receiving IFN1 experienced Grade 3 or higher adverse events (graded using the National Cancer Institute Common Toxicity Criteria [version 2.0]) (P = .025).	These results may have implications for the design of combination regimens incorporating IFN with targeted agents.
__label__noRel	Eighteen patients receiving IFN5 and 4 patients receiving IFN1 had dose reductions (P = .002).	In vivo data have shown a more potent antiangiogenic effect and a higher antitumor activity of low-dose interferon (IFN) given twice daily.
__label__noRel	Eighteen patients receiving IFN5 and 4 patients receiving IFN1 had dose reductions (P = .002).	There were no significant differences in either PFS or OS between IFN1 and IFN5 (median of 3.7 months and median of 3.4 months PFS, respectively; median of 25.5 months and median of 17.5 months OS, respectively).
__label__noRel	Eighteen patients receiving IFN5 and 4 patients receiving IFN1 had dose reductions (P = .002).	The RRs were identical in the 2 arms (6.7%; 95% confidence interval [95% CI], 1.8-16.5%).
__label__noRel	Eighteen patients receiving IFN5 and 4 patients receiving IFN1 had dose reductions (P = .002).	Two patients, 1 in each arm, remained in complete remission at the time of last follow-up, at 45+ and 38+ months from treatment.
__label__noRel	Eighteen patients receiving IFN5 and 4 patients receiving IFN1 had dose reductions (P = .002).	Thirty-two patients receiving IFN5 and 19 patients receiving IFN1 experienced Grade 3 or higher adverse events (graded using the National Cancer Institute Common Toxicity Criteria [version 2.0]) (P = .025).
__label__noRel	Eighteen patients receiving IFN5 and 4 patients receiving IFN1 had dose reductions (P = .002).	There was a significant deterioration in QOL and an increase in depression associated with IFN5 but no change was noted with IFN1.
__label__noRel	Eighteen patients receiving IFN5 and 4 patients receiving IFN1 had dose reductions (P = .002).	Compared with IFN5, IFN1 is neither more nor less effective but is less toxic, with a better reported QOL.
__label__noRel	Eighteen patients receiving IFN5 and 4 patients receiving IFN1 had dose reductions (P = .002).	These results may have implications for the design of combination regimens incorporating IFN with targeted agents.
__label__noRel	There was a significant deterioration in QOL and an increase in depression associated with IFN5 but no change was noted with IFN1.	In vivo data have shown a more potent antiangiogenic effect and a higher antitumor activity of low-dose interferon (IFN) given twice daily.
__label__noRel	There was a significant deterioration in QOL and an increase in depression associated with IFN5 but no change was noted with IFN1.	There were no significant differences in either PFS or OS between IFN1 and IFN5 (median of 3.7 months and median of 3.4 months PFS, respectively; median of 25.5 months and median of 17.5 months OS, respectively).
__label__noRel	There was a significant deterioration in QOL and an increase in depression associated with IFN5 but no change was noted with IFN1.	The RRs were identical in the 2 arms (6.7%; 95% confidence interval [95% CI], 1.8-16.5%).
__label__noRel	There was a significant deterioration in QOL and an increase in depression associated with IFN5 but no change was noted with IFN1.	Two patients, 1 in each arm, remained in complete remission at the time of last follow-up, at 45+ and 38+ months from treatment.
__label__noRel	There was a significant deterioration in QOL and an increase in depression associated with IFN5 but no change was noted with IFN1.	Thirty-two patients receiving IFN5 and 19 patients receiving IFN1 experienced Grade 3 or higher adverse events (graded using the National Cancer Institute Common Toxicity Criteria [version 2.0]) (P = .025).
__label__noRel	There was a significant deterioration in QOL and an increase in depression associated with IFN5 but no change was noted with IFN1.	Eighteen patients receiving IFN5 and 4 patients receiving IFN1 had dose reductions (P = .002).
__label__Support	There was a significant deterioration in QOL and an increase in depression associated with IFN5 but no change was noted with IFN1.	Compared with IFN5, IFN1 is neither more nor less effective but is less toxic, with a better reported QOL.
__label__noRel	There was a significant deterioration in QOL and an increase in depression associated with IFN5 but no change was noted with IFN1.	These results may have implications for the design of combination regimens incorporating IFN with targeted agents.
__label__noRel	Compared with IFN5, IFN1 is neither more nor less effective but is less toxic, with a better reported QOL.	In vivo data have shown a more potent antiangiogenic effect and a higher antitumor activity of low-dose interferon (IFN) given twice daily.
__label__noRel	Compared with IFN5, IFN1 is neither more nor less effective but is less toxic, with a better reported QOL.	There were no significant differences in either PFS or OS between IFN1 and IFN5 (median of 3.7 months and median of 3.4 months PFS, respectively; median of 25.5 months and median of 17.5 months OS, respectively).
__label__noRel	Compared with IFN5, IFN1 is neither more nor less effective but is less toxic, with a better reported QOL.	The RRs were identical in the 2 arms (6.7%; 95% confidence interval [95% CI], 1.8-16.5%).
__label__noRel	Compared with IFN5, IFN1 is neither more nor less effective but is less toxic, with a better reported QOL.	Two patients, 1 in each arm, remained in complete remission at the time of last follow-up, at 45+ and 38+ months from treatment.
__label__noRel	Compared with IFN5, IFN1 is neither more nor less effective but is less toxic, with a better reported QOL.	Thirty-two patients receiving IFN5 and 19 patients receiving IFN1 experienced Grade 3 or higher adverse events (graded using the National Cancer Institute Common Toxicity Criteria [version 2.0]) (P = .025).
__label__noRel	Compared with IFN5, IFN1 is neither more nor less effective but is less toxic, with a better reported QOL.	Eighteen patients receiving IFN5 and 4 patients receiving IFN1 had dose reductions (P = .002).
__label__noRel	Compared with IFN5, IFN1 is neither more nor less effective but is less toxic, with a better reported QOL.	There was a significant deterioration in QOL and an increase in depression associated with IFN5 but no change was noted with IFN1.
__label__Support	Compared with IFN5, IFN1 is neither more nor less effective but is less toxic, with a better reported QOL.	These results may have implications for the design of combination regimens incorporating IFN with targeted agents.
__label__noRel	These results may have implications for the design of combination regimens incorporating IFN with targeted agents.	In vivo data have shown a more potent antiangiogenic effect and a higher antitumor activity of low-dose interferon (IFN) given twice daily.
__label__noRel	These results may have implications for the design of combination regimens incorporating IFN with targeted agents.	There were no significant differences in either PFS or OS between IFN1 and IFN5 (median of 3.7 months and median of 3.4 months PFS, respectively; median of 25.5 months and median of 17.5 months OS, respectively).
__label__noRel	These results may have implications for the design of combination regimens incorporating IFN with targeted agents.	The RRs were identical in the 2 arms (6.7%; 95% confidence interval [95% CI], 1.8-16.5%).
__label__noRel	These results may have implications for the design of combination regimens incorporating IFN with targeted agents.	Two patients, 1 in each arm, remained in complete remission at the time of last follow-up, at 45+ and 38+ months from treatment.
__label__noRel	These results may have implications for the design of combination regimens incorporating IFN with targeted agents.	Thirty-two patients receiving IFN5 and 19 patients receiving IFN1 experienced Grade 3 or higher adverse events (graded using the National Cancer Institute Common Toxicity Criteria [version 2.0]) (P = .025).
__label__noRel	These results may have implications for the design of combination regimens incorporating IFN with targeted agents.	Eighteen patients receiving IFN5 and 4 patients receiving IFN1 had dose reductions (P = .002).
__label__noRel	These results may have implications for the design of combination regimens incorporating IFN with targeted agents.	There was a significant deterioration in QOL and an increase in depression associated with IFN5 but no change was noted with IFN1.
__label__noRel	These results may have implications for the design of combination regimens incorporating IFN with targeted agents.	Compared with IFN5, IFN1 is neither more nor less effective but is less toxic, with a better reported QOL.
__label__noRel	Complete and partial response rates to induction PE were 3% and 32%, respectively.	A 7% response rate was observed with topotecan (complete response, 2%; partial response, 5%).
__label__noRel	Complete and partial response rates to induction PE were 3% and 32%, respectively.	The median survival time for all 402 eligible patients was 9.6 months.
__label__noRel	Complete and partial response rates to induction PE were 3% and 32%, respectively.	Progression-free survival (PFS) from date of randomization on step 2 was significantly better with topotecan compared with observation (3.6 months v 2.3 months; P <.001).
__label__noRel	Complete and partial response rates to induction PE were 3% and 32%, respectively.	overall survival from date of randomization on step 2 was not significantly different between the observation and topotecan arms (8.9 months v 9.3 months; P =.43).
__label__noRel	Complete and partial response rates to induction PE were 3% and 32%, respectively.	Grade 4 neutropenia and thrombocytopenia occurred in 50% and 3%, respectively, of PE patients in step 1 and 60% and 13% of topotecan patients in step 2.
__label__noRel	Complete and partial response rates to induction PE were 3% and 32%, respectively.	Grade 4/5 infection was observed in 4.6% of PE patients and 1.8% of topotecan patients.
__label__noRel	Complete and partial response rates to induction PE were 3% and 32%, respectively.	Grade 3/4 anemia developed in 22% of patients who received topotecan.
__label__noRel	Complete and partial response rates to induction PE were 3% and 32%, respectively.	No difference in quality of life between topotecan and observation was observed at any assessment time or for any of the subscale scores.
__label__noRel	Complete and partial response rates to induction PE were 3% and 32%, respectively.	Four cycles of PE induction therapy followed by four cycles of topotecan improved PFS but failed to improve overall survival or quality of life in extensive-stage SCLC.
__label__Support	Complete and partial response rates to induction PE were 3% and 32%, respectively.	Four cycles of standard PE remains an appropriate first-line treatment for extensive-stage SCLC patients with good performance status.
__label__noRel	A 7% response rate was observed with topotecan (complete response, 2%; partial response, 5%).	Complete and partial response rates to induction PE were 3% and 32%, respectively.
__label__noRel	A 7% response rate was observed with topotecan (complete response, 2%; partial response, 5%).	The median survival time for all 402 eligible patients was 9.6 months.
__label__noRel	A 7% response rate was observed with topotecan (complete response, 2%; partial response, 5%).	Progression-free survival (PFS) from date of randomization on step 2 was significantly better with topotecan compared with observation (3.6 months v 2.3 months; P <.001).
__label__noRel	A 7% response rate was observed with topotecan (complete response, 2%; partial response, 5%).	overall survival from date of randomization on step 2 was not significantly different between the observation and topotecan arms (8.9 months v 9.3 months; P =.43).
__label__noRel	A 7% response rate was observed with topotecan (complete response, 2%; partial response, 5%).	Grade 4 neutropenia and thrombocytopenia occurred in 50% and 3%, respectively, of PE patients in step 1 and 60% and 13% of topotecan patients in step 2.
__label__noRel	A 7% response rate was observed with topotecan (complete response, 2%; partial response, 5%).	Grade 4/5 infection was observed in 4.6% of PE patients and 1.8% of topotecan patients.
__label__noRel	A 7% response rate was observed with topotecan (complete response, 2%; partial response, 5%).	Grade 3/4 anemia developed in 22% of patients who received topotecan.
__label__noRel	A 7% response rate was observed with topotecan (complete response, 2%; partial response, 5%).	No difference in quality of life between topotecan and observation was observed at any assessment time or for any of the subscale scores.
__label__noRel	A 7% response rate was observed with topotecan (complete response, 2%; partial response, 5%).	Four cycles of PE induction therapy followed by four cycles of topotecan improved PFS but failed to improve overall survival or quality of life in extensive-stage SCLC.
__label__noRel	A 7% response rate was observed with topotecan (complete response, 2%; partial response, 5%).	Four cycles of standard PE remains an appropriate first-line treatment for extensive-stage SCLC patients with good performance status.
__label__noRel	The median survival time for all 402 eligible patients was 9.6 months.	Complete and partial response rates to induction PE were 3% and 32%, respectively.
__label__noRel	The median survival time for all 402 eligible patients was 9.6 months.	A 7% response rate was observed with topotecan (complete response, 2%; partial response, 5%).
__label__noRel	The median survival time for all 402 eligible patients was 9.6 months.	Progression-free survival (PFS) from date of randomization on step 2 was significantly better with topotecan compared with observation (3.6 months v 2.3 months; P <.001).
__label__noRel	The median survival time for all 402 eligible patients was 9.6 months.	overall survival from date of randomization on step 2 was not significantly different between the observation and topotecan arms (8.9 months v 9.3 months; P =.43).
__label__noRel	The median survival time for all 402 eligible patients was 9.6 months.	Grade 4 neutropenia and thrombocytopenia occurred in 50% and 3%, respectively, of PE patients in step 1 and 60% and 13% of topotecan patients in step 2.
__label__noRel	The median survival time for all 402 eligible patients was 9.6 months.	Grade 4/5 infection was observed in 4.6% of PE patients and 1.8% of topotecan patients.
__label__noRel	The median survival time for all 402 eligible patients was 9.6 months.	Grade 3/4 anemia developed in 22% of patients who received topotecan.
__label__noRel	The median survival time for all 402 eligible patients was 9.6 months.	No difference in quality of life between topotecan and observation was observed at any assessment time or for any of the subscale scores.
__label__Support	The median survival time for all 402 eligible patients was 9.6 months.	Four cycles of PE induction therapy followed by four cycles of topotecan improved PFS but failed to improve overall survival or quality of life in extensive-stage SCLC.
__label__noRel	The median survival time for all 402 eligible patients was 9.6 months.	Four cycles of standard PE remains an appropriate first-line treatment for extensive-stage SCLC patients with good performance status.
__label__noRel	Progression-free survival (PFS) from date of randomization on step 2 was significantly better with topotecan compared with observation (3.6 months v 2.3 months; P <.001).	Complete and partial response rates to induction PE were 3% and 32%, respectively.
__label__noRel	Progression-free survival (PFS) from date of randomization on step 2 was significantly better with topotecan compared with observation (3.6 months v 2.3 months; P <.001).	A 7% response rate was observed with topotecan (complete response, 2%; partial response, 5%).
__label__noRel	Progression-free survival (PFS) from date of randomization on step 2 was significantly better with topotecan compared with observation (3.6 months v 2.3 months; P <.001).	The median survival time for all 402 eligible patients was 9.6 months.
__label__noRel	Progression-free survival (PFS) from date of randomization on step 2 was significantly better with topotecan compared with observation (3.6 months v 2.3 months; P <.001).	overall survival from date of randomization on step 2 was not significantly different between the observation and topotecan arms (8.9 months v 9.3 months; P =.43).
__label__noRel	Progression-free survival (PFS) from date of randomization on step 2 was significantly better with topotecan compared with observation (3.6 months v 2.3 months; P <.001).	Grade 4 neutropenia and thrombocytopenia occurred in 50% and 3%, respectively, of PE patients in step 1 and 60% and 13% of topotecan patients in step 2.
__label__noRel	Progression-free survival (PFS) from date of randomization on step 2 was significantly better with topotecan compared with observation (3.6 months v 2.3 months; P <.001).	Grade 4/5 infection was observed in 4.6% of PE patients and 1.8% of topotecan patients.
__label__noRel	Progression-free survival (PFS) from date of randomization on step 2 was significantly better with topotecan compared with observation (3.6 months v 2.3 months; P <.001).	Grade 3/4 anemia developed in 22% of patients who received topotecan.
__label__noRel	Progression-free survival (PFS) from date of randomization on step 2 was significantly better with topotecan compared with observation (3.6 months v 2.3 months; P <.001).	No difference in quality of life between topotecan and observation was observed at any assessment time or for any of the subscale scores.
__label__Support	Progression-free survival (PFS) from date of randomization on step 2 was significantly better with topotecan compared with observation (3.6 months v 2.3 months; P <.001).	Four cycles of PE induction therapy followed by four cycles of topotecan improved PFS but failed to improve overall survival or quality of life in extensive-stage SCLC.
__label__noRel	Progression-free survival (PFS) from date of randomization on step 2 was significantly better with topotecan compared with observation (3.6 months v 2.3 months; P <.001).	Four cycles of standard PE remains an appropriate first-line treatment for extensive-stage SCLC patients with good performance status.
__label__noRel	overall survival from date of randomization on step 2 was not significantly different between the observation and topotecan arms (8.9 months v 9.3 months; P =.43).	Complete and partial response rates to induction PE were 3% and 32%, respectively.
__label__noRel	overall survival from date of randomization on step 2 was not significantly different between the observation and topotecan arms (8.9 months v 9.3 months; P =.43).	A 7% response rate was observed with topotecan (complete response, 2%; partial response, 5%).
__label__noRel	overall survival from date of randomization on step 2 was not significantly different between the observation and topotecan arms (8.9 months v 9.3 months; P =.43).	The median survival time for all 402 eligible patients was 9.6 months.
__label__noRel	overall survival from date of randomization on step 2 was not significantly different between the observation and topotecan arms (8.9 months v 9.3 months; P =.43).	Progression-free survival (PFS) from date of randomization on step 2 was significantly better with topotecan compared with observation (3.6 months v 2.3 months; P <.001).
__label__noRel	overall survival from date of randomization on step 2 was not significantly different between the observation and topotecan arms (8.9 months v 9.3 months; P =.43).	Grade 4 neutropenia and thrombocytopenia occurred in 50% and 3%, respectively, of PE patients in step 1 and 60% and 13% of topotecan patients in step 2.
__label__noRel	overall survival from date of randomization on step 2 was not significantly different between the observation and topotecan arms (8.9 months v 9.3 months; P =.43).	Grade 4/5 infection was observed in 4.6% of PE patients and 1.8% of topotecan patients.
__label__noRel	overall survival from date of randomization on step 2 was not significantly different between the observation and topotecan arms (8.9 months v 9.3 months; P =.43).	Grade 3/4 anemia developed in 22% of patients who received topotecan.
__label__noRel	overall survival from date of randomization on step 2 was not significantly different between the observation and topotecan arms (8.9 months v 9.3 months; P =.43).	No difference in quality of life between topotecan and observation was observed at any assessment time or for any of the subscale scores.
__label__Support	overall survival from date of randomization on step 2 was not significantly different between the observation and topotecan arms (8.9 months v 9.3 months; P =.43).	Four cycles of PE induction therapy followed by four cycles of topotecan improved PFS but failed to improve overall survival or quality of life in extensive-stage SCLC.
__label__noRel	overall survival from date of randomization on step 2 was not significantly different between the observation and topotecan arms (8.9 months v 9.3 months; P =.43).	Four cycles of standard PE remains an appropriate first-line treatment for extensive-stage SCLC patients with good performance status.
__label__noRel	Grade 4 neutropenia and thrombocytopenia occurred in 50% and 3%, respectively, of PE patients in step 1 and 60% and 13% of topotecan patients in step 2.	Complete and partial response rates to induction PE were 3% and 32%, respectively.
__label__noRel	Grade 4 neutropenia and thrombocytopenia occurred in 50% and 3%, respectively, of PE patients in step 1 and 60% and 13% of topotecan patients in step 2.	A 7% response rate was observed with topotecan (complete response, 2%; partial response, 5%).
__label__noRel	Grade 4 neutropenia and thrombocytopenia occurred in 50% and 3%, respectively, of PE patients in step 1 and 60% and 13% of topotecan patients in step 2.	The median survival time for all 402 eligible patients was 9.6 months.
__label__noRel	Grade 4 neutropenia and thrombocytopenia occurred in 50% and 3%, respectively, of PE patients in step 1 and 60% and 13% of topotecan patients in step 2.	Progression-free survival (PFS) from date of randomization on step 2 was significantly better with topotecan compared with observation (3.6 months v 2.3 months; P <.001).
__label__noRel	Grade 4 neutropenia and thrombocytopenia occurred in 50% and 3%, respectively, of PE patients in step 1 and 60% and 13% of topotecan patients in step 2.	overall survival from date of randomization on step 2 was not significantly different between the observation and topotecan arms (8.9 months v 9.3 months; P =.43).
__label__noRel	Grade 4 neutropenia and thrombocytopenia occurred in 50% and 3%, respectively, of PE patients in step 1 and 60% and 13% of topotecan patients in step 2.	Grade 4/5 infection was observed in 4.6% of PE patients and 1.8% of topotecan patients.
__label__noRel	Grade 4 neutropenia and thrombocytopenia occurred in 50% and 3%, respectively, of PE patients in step 1 and 60% and 13% of topotecan patients in step 2.	Grade 3/4 anemia developed in 22% of patients who received topotecan.
__label__noRel	Grade 4 neutropenia and thrombocytopenia occurred in 50% and 3%, respectively, of PE patients in step 1 and 60% and 13% of topotecan patients in step 2.	No difference in quality of life between topotecan and observation was observed at any assessment time or for any of the subscale scores.
__label__noRel	Grade 4 neutropenia and thrombocytopenia occurred in 50% and 3%, respectively, of PE patients in step 1 and 60% and 13% of topotecan patients in step 2.	Four cycles of PE induction therapy followed by four cycles of topotecan improved PFS but failed to improve overall survival or quality of life in extensive-stage SCLC.
__label__noRel	Grade 4 neutropenia and thrombocytopenia occurred in 50% and 3%, respectively, of PE patients in step 1 and 60% and 13% of topotecan patients in step 2.	Four cycles of standard PE remains an appropriate first-line treatment for extensive-stage SCLC patients with good performance status.
__label__noRel	Grade 4/5 infection was observed in 4.6% of PE patients and 1.8% of topotecan patients.	Complete and partial response rates to induction PE were 3% and 32%, respectively.
__label__noRel	Grade 4/5 infection was observed in 4.6% of PE patients and 1.8% of topotecan patients.	A 7% response rate was observed with topotecan (complete response, 2%; partial response, 5%).
__label__noRel	Grade 4/5 infection was observed in 4.6% of PE patients and 1.8% of topotecan patients.	The median survival time for all 402 eligible patients was 9.6 months.
__label__noRel	Grade 4/5 infection was observed in 4.6% of PE patients and 1.8% of topotecan patients.	Progression-free survival (PFS) from date of randomization on step 2 was significantly better with topotecan compared with observation (3.6 months v 2.3 months; P <.001).
__label__noRel	Grade 4/5 infection was observed in 4.6% of PE patients and 1.8% of topotecan patients.	overall survival from date of randomization on step 2 was not significantly different between the observation and topotecan arms (8.9 months v 9.3 months; P =.43).
__label__noRel	Grade 4/5 infection was observed in 4.6% of PE patients and 1.8% of topotecan patients.	Grade 4 neutropenia and thrombocytopenia occurred in 50% and 3%, respectively, of PE patients in step 1 and 60% and 13% of topotecan patients in step 2.
__label__noRel	Grade 4/5 infection was observed in 4.6% of PE patients and 1.8% of topotecan patients.	Grade 3/4 anemia developed in 22% of patients who received topotecan.
__label__noRel	Grade 4/5 infection was observed in 4.6% of PE patients and 1.8% of topotecan patients.	No difference in quality of life between topotecan and observation was observed at any assessment time or for any of the subscale scores.
__label__noRel	Grade 4/5 infection was observed in 4.6% of PE patients and 1.8% of topotecan patients.	Four cycles of PE induction therapy followed by four cycles of topotecan improved PFS but failed to improve overall survival or quality of life in extensive-stage SCLC.
__label__noRel	Grade 4/5 infection was observed in 4.6% of PE patients and 1.8% of topotecan patients.	Four cycles of standard PE remains an appropriate first-line treatment for extensive-stage SCLC patients with good performance status.
__label__noRel	Grade 3/4 anemia developed in 22% of patients who received topotecan.	Complete and partial response rates to induction PE were 3% and 32%, respectively.
__label__noRel	Grade 3/4 anemia developed in 22% of patients who received topotecan.	A 7% response rate was observed with topotecan (complete response, 2%; partial response, 5%).
__label__noRel	Grade 3/4 anemia developed in 22% of patients who received topotecan.	The median survival time for all 402 eligible patients was 9.6 months.
__label__noRel	Grade 3/4 anemia developed in 22% of patients who received topotecan.	Progression-free survival (PFS) from date of randomization on step 2 was significantly better with topotecan compared with observation (3.6 months v 2.3 months; P <.001).
__label__noRel	Grade 3/4 anemia developed in 22% of patients who received topotecan.	overall survival from date of randomization on step 2 was not significantly different between the observation and topotecan arms (8.9 months v 9.3 months; P =.43).
__label__noRel	Grade 3/4 anemia developed in 22% of patients who received topotecan.	Grade 4 neutropenia and thrombocytopenia occurred in 50% and 3%, respectively, of PE patients in step 1 and 60% and 13% of topotecan patients in step 2.
__label__noRel	Grade 3/4 anemia developed in 22% of patients who received topotecan.	Grade 4/5 infection was observed in 4.6% of PE patients and 1.8% of topotecan patients.
__label__noRel	Grade 3/4 anemia developed in 22% of patients who received topotecan.	No difference in quality of life between topotecan and observation was observed at any assessment time or for any of the subscale scores.
__label__noRel	Grade 3/4 anemia developed in 22% of patients who received topotecan.	Four cycles of PE induction therapy followed by four cycles of topotecan improved PFS but failed to improve overall survival or quality of life in extensive-stage SCLC.
__label__noRel	Grade 3/4 anemia developed in 22% of patients who received topotecan.	Four cycles of standard PE remains an appropriate first-line treatment for extensive-stage SCLC patients with good performance status.
__label__noRel	No difference in quality of life between topotecan and observation was observed at any assessment time or for any of the subscale scores.	Complete and partial response rates to induction PE were 3% and 32%, respectively.
__label__noRel	No difference in quality of life between topotecan and observation was observed at any assessment time or for any of the subscale scores.	A 7% response rate was observed with topotecan (complete response, 2%; partial response, 5%).
__label__noRel	No difference in quality of life between topotecan and observation was observed at any assessment time or for any of the subscale scores.	The median survival time for all 402 eligible patients was 9.6 months.
__label__noRel	No difference in quality of life between topotecan and observation was observed at any assessment time or for any of the subscale scores.	Progression-free survival (PFS) from date of randomization on step 2 was significantly better with topotecan compared with observation (3.6 months v 2.3 months; P <.001).
__label__noRel	No difference in quality of life between topotecan and observation was observed at any assessment time or for any of the subscale scores.	overall survival from date of randomization on step 2 was not significantly different between the observation and topotecan arms (8.9 months v 9.3 months; P =.43).
__label__noRel	No difference in quality of life between topotecan and observation was observed at any assessment time or for any of the subscale scores.	Grade 4 neutropenia and thrombocytopenia occurred in 50% and 3%, respectively, of PE patients in step 1 and 60% and 13% of topotecan patients in step 2.
__label__noRel	No difference in quality of life between topotecan and observation was observed at any assessment time or for any of the subscale scores.	Grade 4/5 infection was observed in 4.6% of PE patients and 1.8% of topotecan patients.
__label__noRel	No difference in quality of life between topotecan and observation was observed at any assessment time or for any of the subscale scores.	Grade 3/4 anemia developed in 22% of patients who received topotecan.
__label__Support	No difference in quality of life between topotecan and observation was observed at any assessment time or for any of the subscale scores.	Four cycles of PE induction therapy followed by four cycles of topotecan improved PFS but failed to improve overall survival or quality of life in extensive-stage SCLC.
__label__noRel	No difference in quality of life between topotecan and observation was observed at any assessment time or for any of the subscale scores.	Four cycles of standard PE remains an appropriate first-line treatment for extensive-stage SCLC patients with good performance status.
__label__noRel	Four cycles of PE induction therapy followed by four cycles of topotecan improved PFS but failed to improve overall survival or quality of life in extensive-stage SCLC.	Complete and partial response rates to induction PE were 3% and 32%, respectively.
__label__noRel	Four cycles of PE induction therapy followed by four cycles of topotecan improved PFS but failed to improve overall survival or quality of life in extensive-stage SCLC.	A 7% response rate was observed with topotecan (complete response, 2%; partial response, 5%).
__label__noRel	Four cycles of PE induction therapy followed by four cycles of topotecan improved PFS but failed to improve overall survival or quality of life in extensive-stage SCLC.	The median survival time for all 402 eligible patients was 9.6 months.
__label__noRel	Four cycles of PE induction therapy followed by four cycles of topotecan improved PFS but failed to improve overall survival or quality of life in extensive-stage SCLC.	Progression-free survival (PFS) from date of randomization on step 2 was significantly better with topotecan compared with observation (3.6 months v 2.3 months; P <.001).
__label__noRel	Four cycles of PE induction therapy followed by four cycles of topotecan improved PFS but failed to improve overall survival or quality of life in extensive-stage SCLC.	overall survival from date of randomization on step 2 was not significantly different between the observation and topotecan arms (8.9 months v 9.3 months; P =.43).
__label__noRel	Four cycles of PE induction therapy followed by four cycles of topotecan improved PFS but failed to improve overall survival or quality of life in extensive-stage SCLC.	Grade 4 neutropenia and thrombocytopenia occurred in 50% and 3%, respectively, of PE patients in step 1 and 60% and 13% of topotecan patients in step 2.
__label__noRel	Four cycles of PE induction therapy followed by four cycles of topotecan improved PFS but failed to improve overall survival or quality of life in extensive-stage SCLC.	Grade 4/5 infection was observed in 4.6% of PE patients and 1.8% of topotecan patients.
__label__noRel	Four cycles of PE induction therapy followed by four cycles of topotecan improved PFS but failed to improve overall survival or quality of life in extensive-stage SCLC.	Grade 3/4 anemia developed in 22% of patients who received topotecan.
__label__noRel	Four cycles of PE induction therapy followed by four cycles of topotecan improved PFS but failed to improve overall survival or quality of life in extensive-stage SCLC.	No difference in quality of life between topotecan and observation was observed at any assessment time or for any of the subscale scores.
__label__Support	Four cycles of PE induction therapy followed by four cycles of topotecan improved PFS but failed to improve overall survival or quality of life in extensive-stage SCLC.	Four cycles of standard PE remains an appropriate first-line treatment for extensive-stage SCLC patients with good performance status.
__label__noRel	Four cycles of standard PE remains an appropriate first-line treatment for extensive-stage SCLC patients with good performance status.	Complete and partial response rates to induction PE were 3% and 32%, respectively.
__label__noRel	Four cycles of standard PE remains an appropriate first-line treatment for extensive-stage SCLC patients with good performance status.	A 7% response rate was observed with topotecan (complete response, 2%; partial response, 5%).
__label__noRel	Four cycles of standard PE remains an appropriate first-line treatment for extensive-stage SCLC patients with good performance status.	The median survival time for all 402 eligible patients was 9.6 months.
__label__noRel	Four cycles of standard PE remains an appropriate first-line treatment for extensive-stage SCLC patients with good performance status.	Progression-free survival (PFS) from date of randomization on step 2 was significantly better with topotecan compared with observation (3.6 months v 2.3 months; P <.001).
__label__noRel	Four cycles of standard PE remains an appropriate first-line treatment for extensive-stage SCLC patients with good performance status.	overall survival from date of randomization on step 2 was not significantly different between the observation and topotecan arms (8.9 months v 9.3 months; P =.43).
__label__noRel	Four cycles of standard PE remains an appropriate first-line treatment for extensive-stage SCLC patients with good performance status.	Grade 4 neutropenia and thrombocytopenia occurred in 50% and 3%, respectively, of PE patients in step 1 and 60% and 13% of topotecan patients in step 2.
__label__noRel	Four cycles of standard PE remains an appropriate first-line treatment for extensive-stage SCLC patients with good performance status.	Grade 4/5 infection was observed in 4.6% of PE patients and 1.8% of topotecan patients.
__label__noRel	Four cycles of standard PE remains an appropriate first-line treatment for extensive-stage SCLC patients with good performance status.	Grade 3/4 anemia developed in 22% of patients who received topotecan.
__label__noRel	Four cycles of standard PE remains an appropriate first-line treatment for extensive-stage SCLC patients with good performance status.	No difference in quality of life between topotecan and observation was observed at any assessment time or for any of the subscale scores.
__label__noRel	Four cycles of standard PE remains an appropriate first-line treatment for extensive-stage SCLC patients with good performance status.	Four cycles of PE induction therapy followed by four cycles of topotecan improved PFS but failed to improve overall survival or quality of life in extensive-stage SCLC.
__label__noRel	There were no differences in functional outcome, morbidity, or QOL between LRP and ORP.	The body image and cosmesis scores of female patients were significantly higher in the LRP group than in the ORP group (body image, 17.4 vs 14.9; cosmesis, 19.1 vs 13.0, respectively).
__label__noRel	There were no differences in functional outcome, morbidity, or QOL between LRP and ORP.	The female patients in the ORP group had significantly lower body image scores than the male patients (14.9 vs 18.3).
__label__noRel	There were no differences in functional outcome, morbidity, or QOL between LRP and ORP.	This study is the first to show that ORP has a negative impact on body image and cosmesis as compared with LRP.
__label__Support	There were no differences in functional outcome, morbidity, or QOL between LRP and ORP.	Functional outcome, QOL, and morbidity are similar for the two approaches.
__label__noRel	There were no differences in functional outcome, morbidity, or QOL between LRP and ORP.	The advantages of a long-lasting improved body image and cosmesis for this relatively young patient population may compensate for the longer operating times and higher costs, particularly for women.
__label__noRel	The body image and cosmesis scores of female patients were significantly higher in the LRP group than in the ORP group (body image, 17.4 vs 14.9; cosmesis, 19.1 vs 13.0, respectively).	There were no differences in functional outcome, morbidity, or QOL between LRP and ORP.
__label__noRel	The body image and cosmesis scores of female patients were significantly higher in the LRP group than in the ORP group (body image, 17.4 vs 14.9; cosmesis, 19.1 vs 13.0, respectively).	The female patients in the ORP group had significantly lower body image scores than the male patients (14.9 vs 18.3).
__label__Support	The body image and cosmesis scores of female patients were significantly higher in the LRP group than in the ORP group (body image, 17.4 vs 14.9; cosmesis, 19.1 vs 13.0, respectively).	This study is the first to show that ORP has a negative impact on body image and cosmesis as compared with LRP.
__label__noRel	The body image and cosmesis scores of female patients were significantly higher in the LRP group than in the ORP group (body image, 17.4 vs 14.9; cosmesis, 19.1 vs 13.0, respectively).	Functional outcome, QOL, and morbidity are similar for the two approaches.
__label__noRel	The body image and cosmesis scores of female patients were significantly higher in the LRP group than in the ORP group (body image, 17.4 vs 14.9; cosmesis, 19.1 vs 13.0, respectively).	The advantages of a long-lasting improved body image and cosmesis for this relatively young patient population may compensate for the longer operating times and higher costs, particularly for women.
__label__noRel	The female patients in the ORP group had significantly lower body image scores than the male patients (14.9 vs 18.3).	There were no differences in functional outcome, morbidity, or QOL between LRP and ORP.
__label__noRel	The female patients in the ORP group had significantly lower body image scores than the male patients (14.9 vs 18.3).	The body image and cosmesis scores of female patients were significantly higher in the LRP group than in the ORP group (body image, 17.4 vs 14.9; cosmesis, 19.1 vs 13.0, respectively).
__label__Support	The female patients in the ORP group had significantly lower body image scores than the male patients (14.9 vs 18.3).	This study is the first to show that ORP has a negative impact on body image and cosmesis as compared with LRP.
__label__noRel	The female patients in the ORP group had significantly lower body image scores than the male patients (14.9 vs 18.3).	Functional outcome, QOL, and morbidity are similar for the two approaches.
__label__noRel	The female patients in the ORP group had significantly lower body image scores than the male patients (14.9 vs 18.3).	The advantages of a long-lasting improved body image and cosmesis for this relatively young patient population may compensate for the longer operating times and higher costs, particularly for women.
__label__noRel	This study is the first to show that ORP has a negative impact on body image and cosmesis as compared with LRP.	There were no differences in functional outcome, morbidity, or QOL between LRP and ORP.
__label__noRel	This study is the first to show that ORP has a negative impact on body image and cosmesis as compared with LRP.	The body image and cosmesis scores of female patients were significantly higher in the LRP group than in the ORP group (body image, 17.4 vs 14.9; cosmesis, 19.1 vs 13.0, respectively).
__label__noRel	This study is the first to show that ORP has a negative impact on body image and cosmesis as compared with LRP.	The female patients in the ORP group had significantly lower body image scores than the male patients (14.9 vs 18.3).
__label__noRel	This study is the first to show that ORP has a negative impact on body image and cosmesis as compared with LRP.	Functional outcome, QOL, and morbidity are similar for the two approaches.
__label__noRel	This study is the first to show that ORP has a negative impact on body image and cosmesis as compared with LRP.	The advantages of a long-lasting improved body image and cosmesis for this relatively young patient population may compensate for the longer operating times and higher costs, particularly for women.
__label__noRel	Functional outcome, QOL, and morbidity are similar for the two approaches.	There were no differences in functional outcome, morbidity, or QOL between LRP and ORP.
__label__noRel	Functional outcome, QOL, and morbidity are similar for the two approaches.	The body image and cosmesis scores of female patients were significantly higher in the LRP group than in the ORP group (body image, 17.4 vs 14.9; cosmesis, 19.1 vs 13.0, respectively).
__label__noRel	Functional outcome, QOL, and morbidity are similar for the two approaches.	The female patients in the ORP group had significantly lower body image scores than the male patients (14.9 vs 18.3).
__label__noRel	Functional outcome, QOL, and morbidity are similar for the two approaches.	This study is the first to show that ORP has a negative impact on body image and cosmesis as compared with LRP.
__label__noRel	Functional outcome, QOL, and morbidity are similar for the two approaches.	The advantages of a long-lasting improved body image and cosmesis for this relatively young patient population may compensate for the longer operating times and higher costs, particularly for women.
__label__noRel	The advantages of a long-lasting improved body image and cosmesis for this relatively young patient population may compensate for the longer operating times and higher costs, particularly for women.	There were no differences in functional outcome, morbidity, or QOL between LRP and ORP.
__label__noRel	The advantages of a long-lasting improved body image and cosmesis for this relatively young patient population may compensate for the longer operating times and higher costs, particularly for women.	The body image and cosmesis scores of female patients were significantly higher in the LRP group than in the ORP group (body image, 17.4 vs 14.9; cosmesis, 19.1 vs 13.0, respectively).
__label__noRel	The advantages of a long-lasting improved body image and cosmesis for this relatively young patient population may compensate for the longer operating times and higher costs, particularly for women.	The female patients in the ORP group had significantly lower body image scores than the male patients (14.9 vs 18.3).
__label__noRel	The advantages of a long-lasting improved body image and cosmesis for this relatively young patient population may compensate for the longer operating times and higher costs, particularly for women.	This study is the first to show that ORP has a negative impact on body image and cosmesis as compared with LRP.
__label__noRel	The advantages of a long-lasting improved body image and cosmesis for this relatively young patient population may compensate for the longer operating times and higher costs, particularly for women.	Functional outcome, QOL, and morbidity are similar for the two approaches.
__label__noRel	The estimated treatment effects (intervention minus usual care) for all participants were a mean (SE) of 4.6 (2) for quality of life (P = .02), -27.8 (15) for symptom intensity (P = .06), and -1.8 (0.81) for depressed mood (P = .02).	The estimated treatment effects in participants who died during the study were a mean (SE) of 8.6 (3.6) for quality of life (P = .02), -24.2 (20.5) for symptom intensity (P = .24), and -2.7 (1.2) for depressed mood (P = .03).
__label__noRel	The estimated treatment effects (intervention minus usual care) for all participants were a mean (SE) of 4.6 (2) for quality of life (P = .02), -27.8 (15) for symptom intensity (P = .06), and -1.8 (0.81) for depressed mood (P = .02).	Compared with participants receiving usual oncology care, those receiving a nurse-led, palliative care-focused intervention addressing physical, psychosocial, and care coordination provided concurrently with oncology care had higher scores for quality of life and mood,
__label__Support	The estimated treatment effects (intervention minus usual care) for all participants were a mean (SE) of 4.6 (2) for quality of life (P = .02), -27.8 (15) for symptom intensity (P = .06), and -1.8 (0.81) for depressed mood (P = .02).	but did not have improvements in symptom intensity scores or reduced days in the hospital or ICU or emergency department visits.
__label__noRel	The estimated treatment effects in participants who died during the study were a mean (SE) of 8.6 (3.6) for quality of life (P = .02), -24.2 (20.5) for symptom intensity (P = .24), and -2.7 (1.2) for depressed mood (P = .03).	The estimated treatment effects (intervention minus usual care) for all participants were a mean (SE) of 4.6 (2) for quality of life (P = .02), -27.8 (15) for symptom intensity (P = .06), and -1.8 (0.81) for depressed mood (P = .02).
__label__noRel	The estimated treatment effects in participants who died during the study were a mean (SE) of 8.6 (3.6) for quality of life (P = .02), -24.2 (20.5) for symptom intensity (P = .24), and -2.7 (1.2) for depressed mood (P = .03).	Compared with participants receiving usual oncology care, those receiving a nurse-led, palliative care-focused intervention addressing physical, psychosocial, and care coordination provided concurrently with oncology care had higher scores for quality of life and mood,
__label__Support	The estimated treatment effects in participants who died during the study were a mean (SE) of 8.6 (3.6) for quality of life (P = .02), -24.2 (20.5) for symptom intensity (P = .24), and -2.7 (1.2) for depressed mood (P = .03).	but did not have improvements in symptom intensity scores or reduced days in the hospital or ICU or emergency department visits.
__label__noRel	Compared with participants receiving usual oncology care, those receiving a nurse-led, palliative care-focused intervention addressing physical, psychosocial, and care coordination provided concurrently with oncology care had higher scores for quality of life and mood,	The estimated treatment effects (intervention minus usual care) for all participants were a mean (SE) of 4.6 (2) for quality of life (P = .02), -27.8 (15) for symptom intensity (P = .06), and -1.8 (0.81) for depressed mood (P = .02).
__label__noRel	Compared with participants receiving usual oncology care, those receiving a nurse-led, palliative care-focused intervention addressing physical, psychosocial, and care coordination provided concurrently with oncology care had higher scores for quality of life and mood,	The estimated treatment effects in participants who died during the study were a mean (SE) of 8.6 (3.6) for quality of life (P = .02), -24.2 (20.5) for symptom intensity (P = .24), and -2.7 (1.2) for depressed mood (P = .03).
__label__noRel	Compared with participants receiving usual oncology care, those receiving a nurse-led, palliative care-focused intervention addressing physical, psychosocial, and care coordination provided concurrently with oncology care had higher scores for quality of life and mood,	but did not have improvements in symptom intensity scores or reduced days in the hospital or ICU or emergency department visits.
__label__noRel	but did not have improvements in symptom intensity scores or reduced days in the hospital or ICU or emergency department visits.	The estimated treatment effects (intervention minus usual care) for all participants were a mean (SE) of 4.6 (2) for quality of life (P = .02), -27.8 (15) for symptom intensity (P = .06), and -1.8 (0.81) for depressed mood (P = .02).
__label__noRel	but did not have improvements in symptom intensity scores or reduced days in the hospital or ICU or emergency department visits.	The estimated treatment effects in participants who died during the study were a mean (SE) of 8.6 (3.6) for quality of life (P = .02), -24.2 (20.5) for symptom intensity (P = .24), and -2.7 (1.2) for depressed mood (P = .03).
__label__Attack	but did not have improvements in symptom intensity scores or reduced days in the hospital or ICU or emergency department visits.	Compared with participants receiving usual oncology care, those receiving a nurse-led, palliative care-focused intervention addressing physical, psychosocial, and care coordination provided concurrently with oncology care had higher scores for quality of life and mood,
__label__Support	Breast IMRT significantly improved the dose distribution compared with standard radiation.	This translated into a lower proportion of patients experiencing moist desquamation during or up to 6 weeks after their radiation treatment; 31.2% with IMRT compared with 47.8% with standard treatment (P = .002).
__label__noRel	Breast IMRT significantly improved the dose distribution compared with standard radiation.	A multivariate analysis found the use of breast IMRT (P = .003) and smaller breast size (P < .001) were significantly associated with a decreased risk of moist desquamation.
__label__noRel	Breast IMRT significantly improved the dose distribution compared with standard radiation.	The use of IMRT did not correlate with pain and quality of life
__label__noRel	Breast IMRT significantly improved the dose distribution compared with standard radiation.	Breast IMRT significantly reduced the occurrence of moist desquamation compared with a standard wedged technique.
__label__noRel	Breast IMRT significantly improved the dose distribution compared with standard radiation.	Moist desquamation was correlated with increased pain and reduction in the quality of life.
__label__noRel	Breast IMRT significantly improved the dose distribution compared with standard radiation.	the presence of moist desquamation did significantly correlate with pain (P = .002) and a reduced quality of life (P = .003).
__label__noRel	Breast IMRT significantly improved the dose distribution compared with standard radiation.	It is more likely in full-breasted women and when the radiation is distributed nonhomogeneously in the breast.
__label__noRel	Breast IMRT significantly improved the dose distribution compared with standard radiation.	Dermatitis is a frequent adverse effect of adjuvant breast radiotherapy.
__label__noRel	This translated into a lower proportion of patients experiencing moist desquamation during or up to 6 weeks after their radiation treatment; 31.2% with IMRT compared with 47.8% with standard treatment (P = .002).	Breast IMRT significantly improved the dose distribution compared with standard radiation.
__label__noRel	This translated into a lower proportion of patients experiencing moist desquamation during or up to 6 weeks after their radiation treatment; 31.2% with IMRT compared with 47.8% with standard treatment (P = .002).	A multivariate analysis found the use of breast IMRT (P = .003) and smaller breast size (P < .001) were significantly associated with a decreased risk of moist desquamation.
__label__noRel	This translated into a lower proportion of patients experiencing moist desquamation during or up to 6 weeks after their radiation treatment; 31.2% with IMRT compared with 47.8% with standard treatment (P = .002).	The use of IMRT did not correlate with pain and quality of life
__label__noRel	This translated into a lower proportion of patients experiencing moist desquamation during or up to 6 weeks after their radiation treatment; 31.2% with IMRT compared with 47.8% with standard treatment (P = .002).	Breast IMRT significantly reduced the occurrence of moist desquamation compared with a standard wedged technique.
__label__noRel	This translated into a lower proportion of patients experiencing moist desquamation during or up to 6 weeks after their radiation treatment; 31.2% with IMRT compared with 47.8% with standard treatment (P = .002).	Moist desquamation was correlated with increased pain and reduction in the quality of life.
__label__noRel	This translated into a lower proportion of patients experiencing moist desquamation during or up to 6 weeks after their radiation treatment; 31.2% with IMRT compared with 47.8% with standard treatment (P = .002).	the presence of moist desquamation did significantly correlate with pain (P = .002) and a reduced quality of life (P = .003).
__label__noRel	This translated into a lower proportion of patients experiencing moist desquamation during or up to 6 weeks after their radiation treatment; 31.2% with IMRT compared with 47.8% with standard treatment (P = .002).	It is more likely in full-breasted women and when the radiation is distributed nonhomogeneously in the breast.
__label__noRel	This translated into a lower proportion of patients experiencing moist desquamation during or up to 6 weeks after their radiation treatment; 31.2% with IMRT compared with 47.8% with standard treatment (P = .002).	Dermatitis is a frequent adverse effect of adjuvant breast radiotherapy.
__label__noRel	A multivariate analysis found the use of breast IMRT (P = .003) and smaller breast size (P < .001) were significantly associated with a decreased risk of moist desquamation.	Breast IMRT significantly improved the dose distribution compared with standard radiation.
__label__noRel	A multivariate analysis found the use of breast IMRT (P = .003) and smaller breast size (P < .001) were significantly associated with a decreased risk of moist desquamation.	This translated into a lower proportion of patients experiencing moist desquamation during or up to 6 weeks after their radiation treatment; 31.2% with IMRT compared with 47.8% with standard treatment (P = .002).
__label__noRel	A multivariate analysis found the use of breast IMRT (P = .003) and smaller breast size (P < .001) were significantly associated with a decreased risk of moist desquamation.	The use of IMRT did not correlate with pain and quality of life
__label__Support	A multivariate analysis found the use of breast IMRT (P = .003) and smaller breast size (P < .001) were significantly associated with a decreased risk of moist desquamation.	Breast IMRT significantly reduced the occurrence of moist desquamation compared with a standard wedged technique.
__label__noRel	A multivariate analysis found the use of breast IMRT (P = .003) and smaller breast size (P < .001) were significantly associated with a decreased risk of moist desquamation.	Moist desquamation was correlated with increased pain and reduction in the quality of life.
__label__noRel	A multivariate analysis found the use of breast IMRT (P = .003) and smaller breast size (P < .001) were significantly associated with a decreased risk of moist desquamation.	the presence of moist desquamation did significantly correlate with pain (P = .002) and a reduced quality of life (P = .003).
__label__noRel	A multivariate analysis found the use of breast IMRT (P = .003) and smaller breast size (P < .001) were significantly associated with a decreased risk of moist desquamation.	It is more likely in full-breasted women and when the radiation is distributed nonhomogeneously in the breast.
__label__noRel	A multivariate analysis found the use of breast IMRT (P = .003) and smaller breast size (P < .001) were significantly associated with a decreased risk of moist desquamation.	Dermatitis is a frequent adverse effect of adjuvant breast radiotherapy.
__label__noRel	The use of IMRT did not correlate with pain and quality of life	Breast IMRT significantly improved the dose distribution compared with standard radiation.
__label__noRel	The use of IMRT did not correlate with pain and quality of life	This translated into a lower proportion of patients experiencing moist desquamation during or up to 6 weeks after their radiation treatment; 31.2% with IMRT compared with 47.8% with standard treatment (P = .002).
__label__noRel	The use of IMRT did not correlate with pain and quality of life	A multivariate analysis found the use of breast IMRT (P = .003) and smaller breast size (P < .001) were significantly associated with a decreased risk of moist desquamation.
__label__noRel	The use of IMRT did not correlate with pain and quality of life	Breast IMRT significantly reduced the occurrence of moist desquamation compared with a standard wedged technique.
__label__noRel	The use of IMRT did not correlate with pain and quality of life	Moist desquamation was correlated with increased pain and reduction in the quality of life.
__label__noRel	The use of IMRT did not correlate with pain and quality of life	the presence of moist desquamation did significantly correlate with pain (P = .002) and a reduced quality of life (P = .003).
__label__noRel	The use of IMRT did not correlate with pain and quality of life	It is more likely in full-breasted women and when the radiation is distributed nonhomogeneously in the breast.
__label__noRel	The use of IMRT did not correlate with pain and quality of life	Dermatitis is a frequent adverse effect of adjuvant breast radiotherapy.
__label__noRel	Breast IMRT significantly reduced the occurrence of moist desquamation compared with a standard wedged technique.	Breast IMRT significantly improved the dose distribution compared with standard radiation.
__label__noRel	Breast IMRT significantly reduced the occurrence of moist desquamation compared with a standard wedged technique.	This translated into a lower proportion of patients experiencing moist desquamation during or up to 6 weeks after their radiation treatment; 31.2% with IMRT compared with 47.8% with standard treatment (P = .002).
__label__noRel	Breast IMRT significantly reduced the occurrence of moist desquamation compared with a standard wedged technique.	A multivariate analysis found the use of breast IMRT (P = .003) and smaller breast size (P < .001) were significantly associated with a decreased risk of moist desquamation.
__label__noRel	Breast IMRT significantly reduced the occurrence of moist desquamation compared with a standard wedged technique.	The use of IMRT did not correlate with pain and quality of life
__label__noRel	Breast IMRT significantly reduced the occurrence of moist desquamation compared with a standard wedged technique.	Moist desquamation was correlated with increased pain and reduction in the quality of life.
__label__noRel	Breast IMRT significantly reduced the occurrence of moist desquamation compared with a standard wedged technique.	the presence of moist desquamation did significantly correlate with pain (P = .002) and a reduced quality of life (P = .003).
__label__noRel	Breast IMRT significantly reduced the occurrence of moist desquamation compared with a standard wedged technique.	It is more likely in full-breasted women and when the radiation is distributed nonhomogeneously in the breast.
__label__noRel	Breast IMRT significantly reduced the occurrence of moist desquamation compared with a standard wedged technique.	Dermatitis is a frequent adverse effect of adjuvant breast radiotherapy.
__label__noRel	Moist desquamation was correlated with increased pain and reduction in the quality of life.	Breast IMRT significantly improved the dose distribution compared with standard radiation.
__label__noRel	Moist desquamation was correlated with increased pain and reduction in the quality of life.	This translated into a lower proportion of patients experiencing moist desquamation during or up to 6 weeks after their radiation treatment; 31.2% with IMRT compared with 47.8% with standard treatment (P = .002).
__label__noRel	Moist desquamation was correlated with increased pain and reduction in the quality of life.	A multivariate analysis found the use of breast IMRT (P = .003) and smaller breast size (P < .001) were significantly associated with a decreased risk of moist desquamation.
__label__noRel	Moist desquamation was correlated with increased pain and reduction in the quality of life.	The use of IMRT did not correlate with pain and quality of life
__label__noRel	Moist desquamation was correlated with increased pain and reduction in the quality of life.	Breast IMRT significantly reduced the occurrence of moist desquamation compared with a standard wedged technique.
__label__noRel	Moist desquamation was correlated with increased pain and reduction in the quality of life.	the presence of moist desquamation did significantly correlate with pain (P = .002) and a reduced quality of life (P = .003).
__label__noRel	Moist desquamation was correlated with increased pain and reduction in the quality of life.	It is more likely in full-breasted women and when the radiation is distributed nonhomogeneously in the breast.
__label__noRel	Moist desquamation was correlated with increased pain and reduction in the quality of life.	Dermatitis is a frequent adverse effect of adjuvant breast radiotherapy.
__label__noRel	the presence of moist desquamation did significantly correlate with pain (P = .002) and a reduced quality of life (P = .003).	Breast IMRT significantly improved the dose distribution compared with standard radiation.
__label__noRel	the presence of moist desquamation did significantly correlate with pain (P = .002) and a reduced quality of life (P = .003).	This translated into a lower proportion of patients experiencing moist desquamation during or up to 6 weeks after their radiation treatment; 31.2% with IMRT compared with 47.8% with standard treatment (P = .002).
__label__noRel	the presence of moist desquamation did significantly correlate with pain (P = .002) and a reduced quality of life (P = .003).	A multivariate analysis found the use of breast IMRT (P = .003) and smaller breast size (P < .001) were significantly associated with a decreased risk of moist desquamation.
__label__noRel	the presence of moist desquamation did significantly correlate with pain (P = .002) and a reduced quality of life (P = .003).	The use of IMRT did not correlate with pain and quality of life
__label__noRel	the presence of moist desquamation did significantly correlate with pain (P = .002) and a reduced quality of life (P = .003).	Breast IMRT significantly reduced the occurrence of moist desquamation compared with a standard wedged technique.
__label__Support	the presence of moist desquamation did significantly correlate with pain (P = .002) and a reduced quality of life (P = .003).	Moist desquamation was correlated with increased pain and reduction in the quality of life.
__label__noRel	the presence of moist desquamation did significantly correlate with pain (P = .002) and a reduced quality of life (P = .003).	It is more likely in full-breasted women and when the radiation is distributed nonhomogeneously in the breast.
__label__noRel	the presence of moist desquamation did significantly correlate with pain (P = .002) and a reduced quality of life (P = .003).	Dermatitis is a frequent adverse effect of adjuvant breast radiotherapy.
__label__noRel	It is more likely in full-breasted women and when the radiation is distributed nonhomogeneously in the breast.	Breast IMRT significantly improved the dose distribution compared with standard radiation.
__label__noRel	It is more likely in full-breasted women and when the radiation is distributed nonhomogeneously in the breast.	This translated into a lower proportion of patients experiencing moist desquamation during or up to 6 weeks after their radiation treatment; 31.2% with IMRT compared with 47.8% with standard treatment (P = .002).
__label__noRel	It is more likely in full-breasted women and when the radiation is distributed nonhomogeneously in the breast.	A multivariate analysis found the use of breast IMRT (P = .003) and smaller breast size (P < .001) were significantly associated with a decreased risk of moist desquamation.
__label__noRel	It is more likely in full-breasted women and when the radiation is distributed nonhomogeneously in the breast.	The use of IMRT did not correlate with pain and quality of life
__label__noRel	It is more likely in full-breasted women and when the radiation is distributed nonhomogeneously in the breast.	Breast IMRT significantly reduced the occurrence of moist desquamation compared with a standard wedged technique.
__label__noRel	It is more likely in full-breasted women and when the radiation is distributed nonhomogeneously in the breast.	Moist desquamation was correlated with increased pain and reduction in the quality of life.
__label__noRel	It is more likely in full-breasted women and when the radiation is distributed nonhomogeneously in the breast.	the presence of moist desquamation did significantly correlate with pain (P = .002) and a reduced quality of life (P = .003).
__label__noRel	It is more likely in full-breasted women and when the radiation is distributed nonhomogeneously in the breast.	Dermatitis is a frequent adverse effect of adjuvant breast radiotherapy.
__label__noRel	Dermatitis is a frequent adverse effect of adjuvant breast radiotherapy.	Breast IMRT significantly improved the dose distribution compared with standard radiation.
__label__noRel	Dermatitis is a frequent adverse effect of adjuvant breast radiotherapy.	This translated into a lower proportion of patients experiencing moist desquamation during or up to 6 weeks after their radiation treatment; 31.2% with IMRT compared with 47.8% with standard treatment (P = .002).
__label__noRel	Dermatitis is a frequent adverse effect of adjuvant breast radiotherapy.	A multivariate analysis found the use of breast IMRT (P = .003) and smaller breast size (P < .001) were significantly associated with a decreased risk of moist desquamation.
__label__noRel	Dermatitis is a frequent adverse effect of adjuvant breast radiotherapy.	The use of IMRT did not correlate with pain and quality of life
__label__noRel	Dermatitis is a frequent adverse effect of adjuvant breast radiotherapy.	Breast IMRT significantly reduced the occurrence of moist desquamation compared with a standard wedged technique.
__label__noRel	Dermatitis is a frequent adverse effect of adjuvant breast radiotherapy.	Moist desquamation was correlated with increased pain and reduction in the quality of life.
__label__noRel	Dermatitis is a frequent adverse effect of adjuvant breast radiotherapy.	the presence of moist desquamation did significantly correlate with pain (P = .002) and a reduced quality of life (P = .003).
__label__noRel	Dermatitis is a frequent adverse effect of adjuvant breast radiotherapy.	It is more likely in full-breasted women and when the radiation is distributed nonhomogeneously in the breast.
__label__noRel	We found no difference in severe ARSR between the groups at any point of assessment.	The incidence of severe ARSR (RTOG/EORTC grade 2) at the follow-up visit was 23% (n = 45) in the Calendula group and 19% (n = 38) in the Essex group.
__label__noRel	We found no difference in severe ARSR between the groups at any point of assessment.	The patients reported low levels of skin related symptoms and no statistically significant differences between the groups were found.
__label__Support	We found no difference in severe ARSR between the groups at any point of assessment.	No differences in ARSR between patients randomised to Calendula or Essex cream was found.
__label__noRel	We found no difference in severe ARSR between the groups at any point of assessment.	ARSR seem to be a relatively limited problem, probably more influenced by treatment related factors than by choice of skin care products in this patient group.
__label__noRel	The incidence of severe ARSR (RTOG/EORTC grade 2) at the follow-up visit was 23% (n = 45) in the Calendula group and 19% (n = 38) in the Essex group.	We found no difference in severe ARSR between the groups at any point of assessment.
__label__noRel	The incidence of severe ARSR (RTOG/EORTC grade 2) at the follow-up visit was 23% (n = 45) in the Calendula group and 19% (n = 38) in the Essex group.	The patients reported low levels of skin related symptoms and no statistically significant differences between the groups were found.
__label__Support	The incidence of severe ARSR (RTOG/EORTC grade 2) at the follow-up visit was 23% (n = 45) in the Calendula group and 19% (n = 38) in the Essex group.	No differences in ARSR between patients randomised to Calendula or Essex cream was found.
__label__noRel	The incidence of severe ARSR (RTOG/EORTC grade 2) at the follow-up visit was 23% (n = 45) in the Calendula group and 19% (n = 38) in the Essex group.	ARSR seem to be a relatively limited problem, probably more influenced by treatment related factors than by choice of skin care products in this patient group.
__label__noRel	The patients reported low levels of skin related symptoms and no statistically significant differences between the groups were found.	We found no difference in severe ARSR between the groups at any point of assessment.
__label__noRel	The patients reported low levels of skin related symptoms and no statistically significant differences between the groups were found.	The incidence of severe ARSR (RTOG/EORTC grade 2) at the follow-up visit was 23% (n = 45) in the Calendula group and 19% (n = 38) in the Essex group.
__label__Support	The patients reported low levels of skin related symptoms and no statistically significant differences between the groups were found.	No differences in ARSR between patients randomised to Calendula or Essex cream was found.
__label__noRel	The patients reported low levels of skin related symptoms and no statistically significant differences between the groups were found.	ARSR seem to be a relatively limited problem, probably more influenced by treatment related factors than by choice of skin care products in this patient group.
__label__noRel	No differences in ARSR between patients randomised to Calendula or Essex cream was found.	We found no difference in severe ARSR between the groups at any point of assessment.
__label__noRel	No differences in ARSR between patients randomised to Calendula or Essex cream was found.	The incidence of severe ARSR (RTOG/EORTC grade 2) at the follow-up visit was 23% (n = 45) in the Calendula group and 19% (n = 38) in the Essex group.
__label__noRel	No differences in ARSR between patients randomised to Calendula or Essex cream was found.	The patients reported low levels of skin related symptoms and no statistically significant differences between the groups were found.
__label__noRel	No differences in ARSR between patients randomised to Calendula or Essex cream was found.	ARSR seem to be a relatively limited problem, probably more influenced by treatment related factors than by choice of skin care products in this patient group.
__label__noRel	ARSR seem to be a relatively limited problem, probably more influenced by treatment related factors than by choice of skin care products in this patient group.	We found no difference in severe ARSR between the groups at any point of assessment.
__label__noRel	ARSR seem to be a relatively limited problem, probably more influenced by treatment related factors than by choice of skin care products in this patient group.	The incidence of severe ARSR (RTOG/EORTC grade 2) at the follow-up visit was 23% (n = 45) in the Calendula group and 19% (n = 38) in the Essex group.
__label__noRel	ARSR seem to be a relatively limited problem, probably more influenced by treatment related factors than by choice of skin care products in this patient group.	The patients reported low levels of skin related symptoms and no statistically significant differences between the groups were found.
__label__noRel	ARSR seem to be a relatively limited problem, probably more influenced by treatment related factors than by choice of skin care products in this patient group.	No differences in ARSR between patients randomised to Calendula or Essex cream was found.
__label__noRel	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).	The event-free period (EFP), radiologic course of disease, and survival did not improve.
__label__noRel	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).	Subgroup analyses suggested a dose-dependent treatment effect.
__label__noRel	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).
__label__noRel	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).
__label__noRel	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,
__label__noRel	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).	but other cancer-associated factors seemed to contribute to this toxicity.
__label__Support	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.
__label__noRel	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).	The effect appeared to be dose-dependent.
__label__noRel	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).	Further research on dose and mode of treatment is mandatory.
__label__noRel	The event-free period (EFP), radiologic course of disease, and survival did not improve.	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).
__label__noRel	The event-free period (EFP), radiologic course of disease, and survival did not improve.	Subgroup analyses suggested a dose-dependent treatment effect.
__label__noRel	The event-free period (EFP), radiologic course of disease, and survival did not improve.	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).
__label__noRel	The event-free period (EFP), radiologic course of disease, and survival did not improve.	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).
__label__noRel	The event-free period (EFP), radiologic course of disease, and survival did not improve.	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,
__label__noRel	The event-free period (EFP), radiologic course of disease, and survival did not improve.	but other cancer-associated factors seemed to contribute to this toxicity.
__label__noRel	The event-free period (EFP), radiologic course of disease, and survival did not improve.	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.
__label__noRel	The event-free period (EFP), radiologic course of disease, and survival did not improve.	The effect appeared to be dose-dependent.
__label__noRel	The event-free period (EFP), radiologic course of disease, and survival did not improve.	Further research on dose and mode of treatment is mandatory.
__label__noRel	Subgroup analyses suggested a dose-dependent treatment effect.	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).
__label__noRel	Subgroup analyses suggested a dose-dependent treatment effect.	The event-free period (EFP), radiologic course of disease, and survival did not improve.
__label__noRel	Subgroup analyses suggested a dose-dependent treatment effect.	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).
__label__noRel	Subgroup analyses suggested a dose-dependent treatment effect.	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).
__label__noRel	Subgroup analyses suggested a dose-dependent treatment effect.	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,
__label__noRel	Subgroup analyses suggested a dose-dependent treatment effect.	but other cancer-associated factors seemed to contribute to this toxicity.
__label__noRel	Subgroup analyses suggested a dose-dependent treatment effect.	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.
__label__Support	Subgroup analyses suggested a dose-dependent treatment effect.	The effect appeared to be dose-dependent.
__label__noRel	Subgroup analyses suggested a dose-dependent treatment effect.	Further research on dose and mode of treatment is mandatory.
__label__noRel	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).
__label__noRel	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).	The event-free period (EFP), radiologic course of disease, and survival did not improve.
__label__noRel	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).	Subgroup analyses suggested a dose-dependent treatment effect.
__label__noRel	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).
__label__noRel	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,
__label__noRel	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).	but other cancer-associated factors seemed to contribute to this toxicity.
__label__Support	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.
__label__noRel	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).	The effect appeared to be dose-dependent.
__label__noRel	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).	Further research on dose and mode of treatment is mandatory.
__label__noRel	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).
__label__noRel	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).	The event-free period (EFP), radiologic course of disease, and survival did not improve.
__label__noRel	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).	Subgroup analyses suggested a dose-dependent treatment effect.
__label__noRel	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).
__label__noRel	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,
__label__noRel	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).	but other cancer-associated factors seemed to contribute to this toxicity.
__label__Support	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.
__label__noRel	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).	The effect appeared to be dose-dependent.
__label__noRel	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).	Further research on dose and mode of treatment is mandatory.
__label__noRel	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).
__label__noRel	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,	The event-free period (EFP), radiologic course of disease, and survival did not improve.
__label__noRel	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,	Subgroup analyses suggested a dose-dependent treatment effect.
__label__noRel	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).
__label__noRel	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).
__label__noRel	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,	but other cancer-associated factors seemed to contribute to this toxicity.
__label__noRel	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.
__label__noRel	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,	The effect appeared to be dose-dependent.
__label__noRel	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,	Further research on dose and mode of treatment is mandatory.
__label__noRel	but other cancer-associated factors seemed to contribute to this toxicity.	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).
__label__noRel	but other cancer-associated factors seemed to contribute to this toxicity.	The event-free period (EFP), radiologic course of disease, and survival did not improve.
__label__noRel	but other cancer-associated factors seemed to contribute to this toxicity.	Subgroup analyses suggested a dose-dependent treatment effect.
__label__noRel	but other cancer-associated factors seemed to contribute to this toxicity.	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).
__label__noRel	but other cancer-associated factors seemed to contribute to this toxicity.	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).
__label__Attack	but other cancer-associated factors seemed to contribute to this toxicity.	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,
__label__noRel	but other cancer-associated factors seemed to contribute to this toxicity.	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.
__label__noRel	but other cancer-associated factors seemed to contribute to this toxicity.	The effect appeared to be dose-dependent.
__label__noRel	but other cancer-associated factors seemed to contribute to this toxicity.	Further research on dose and mode of treatment is mandatory.
__label__noRel	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).
__label__noRel	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.	The event-free period (EFP), radiologic course of disease, and survival did not improve.
__label__noRel	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.	Subgroup analyses suggested a dose-dependent treatment effect.
__label__noRel	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).
__label__noRel	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).
__label__noRel	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,
__label__noRel	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.	but other cancer-associated factors seemed to contribute to this toxicity.
__label__noRel	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.	The effect appeared to be dose-dependent.
__label__noRel	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.	Further research on dose and mode of treatment is mandatory.
__label__noRel	The effect appeared to be dose-dependent.	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).
__label__noRel	The effect appeared to be dose-dependent.	The event-free period (EFP), radiologic course of disease, and survival did not improve.
__label__noRel	The effect appeared to be dose-dependent.	Subgroup analyses suggested a dose-dependent treatment effect.
__label__noRel	The effect appeared to be dose-dependent.	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).
__label__noRel	The effect appeared to be dose-dependent.	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).
__label__noRel	The effect appeared to be dose-dependent.	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,
__label__noRel	The effect appeared to be dose-dependent.	but other cancer-associated factors seemed to contribute to this toxicity.
__label__Attack	The effect appeared to be dose-dependent.	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.
__label__noRel	The effect appeared to be dose-dependent.	Further research on dose and mode of treatment is mandatory.
__label__noRel	Further research on dose and mode of treatment is mandatory.	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).
__label__noRel	Further research on dose and mode of treatment is mandatory.	The event-free period (EFP), radiologic course of disease, and survival did not improve.
__label__noRel	Further research on dose and mode of treatment is mandatory.	Subgroup analyses suggested a dose-dependent treatment effect.
__label__noRel	Further research on dose and mode of treatment is mandatory.	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).
__label__noRel	Further research on dose and mode of treatment is mandatory.	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).
__label__noRel	Further research on dose and mode of treatment is mandatory.	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,
__label__noRel	Further research on dose and mode of treatment is mandatory.	but other cancer-associated factors seemed to contribute to this toxicity.
__label__Attack	Further research on dose and mode of treatment is mandatory.	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.
__label__noRel	Further research on dose and mode of treatment is mandatory.	The effect appeared to be dose-dependent.
__label__noRel	The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93].	Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001).
__label__noRel	The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93].	The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001).
__label__noRel	The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93].	The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82).
__label__noRel	The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93].	In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value.
__label__noRel	The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93].	Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe.
__label__Support	The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93].	However, it provided no improvement in PFS or OS compared with flat dosing.
__label__noRel	Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001).	The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93].
__label__noRel	Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001).	The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001).
__label__noRel	Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001).	The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82).
__label__noRel	Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001).	In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value.
__label__Support	Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001).	Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe.
__label__noRel	Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001).	However, it provided no improvement in PFS or OS compared with flat dosing.
__label__noRel	The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001).	The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93].
__label__noRel	The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001).	Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001).
__label__noRel	The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001).	The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82).
__label__noRel	The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001).	In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value.
__label__Support	The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001).	Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe.
__label__noRel	The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001).	However, it provided no improvement in PFS or OS compared with flat dosing.
__label__noRel	The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82).	The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93].
__label__noRel	The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82).	Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001).
__label__noRel	The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82).	The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001).
__label__noRel	The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82).	In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value.
__label__noRel	The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82).	Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe.
__label__Support	The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82).	However, it provided no improvement in PFS or OS compared with flat dosing.
__label__noRel	In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value.	The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93].
__label__noRel	In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value.	Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001).
__label__noRel	In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value.	The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001).
__label__noRel	In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value.	The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82).
__label__noRel	In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value.	Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe.
__label__noRel	In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value.	However, it provided no improvement in PFS or OS compared with flat dosing.
__label__noRel	Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe.	The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93].
__label__noRel	Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe.	Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001).
__label__noRel	Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe.	The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001).
__label__noRel	Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe.	The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82).
__label__noRel	Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe.	In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value.
__label__noRel	Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe.	However, it provided no improvement in PFS or OS compared with flat dosing.
__label__noRel	However, it provided no improvement in PFS or OS compared with flat dosing.	The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93].
__label__noRel	However, it provided no improvement in PFS or OS compared with flat dosing.	Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001).
__label__noRel	However, it provided no improvement in PFS or OS compared with flat dosing.	The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001).
__label__noRel	However, it provided no improvement in PFS or OS compared with flat dosing.	The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82).
__label__noRel	However, it provided no improvement in PFS or OS compared with flat dosing.	In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value.
__label__Attack	However, it provided no improvement in PFS or OS compared with flat dosing.	Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe.
__label__noRel	At postintervention, AET was superior to UC for patient-rated physical functioning (mean group difference, +9.0; 95% CI, 2.0 to 16.0; P = .012), overall QoL (P = .021), fatigue (P = .013), happiness (P = .004), depression (P = .005), general health (P < .001), cardiovascular fitness (P < .001), and lean body mass (P = .008).	AET did not interfere with chemotherapy completion rate or treatment response.
__label__noRel	At postintervention, AET was superior to UC for patient-rated physical functioning (mean group difference, +9.0; 95% CI, 2.0 to 16.0; P = .012), overall QoL (P = .021), fatigue (P = .013), happiness (P = .004), depression (P = .005), general health (P < .001), cardiovascular fitness (P < .001), and lean body mass (P = .008).	At 6-month follow-up, AET was still borderline or significantly superior to UC for overall QoL (P = .054), happiness (P = .034), and depression (P = .009) without an increased risk of disease recurrence/progression.
__label__noRel	At postintervention, AET was superior to UC for patient-rated physical functioning (mean group difference, +9.0; 95% CI, 2.0 to 16.0; P = .012), overall QoL (P = .021), fatigue (P = .013), happiness (P = .004), depression (P = .005), general health (P < .001), cardiovascular fitness (P < .001), and lean body mass (P = .008).	Exercise training to improve cardiovascular fitness should be considered in the management of lymphoma patients.
__label__Support	At postintervention, AET was superior to UC for patient-rated physical functioning (mean group difference, +9.0; 95% CI, 2.0 to 16.0; P = .012), overall QoL (P = .021), fatigue (P = .013), happiness (P = .004), depression (P = .005), general health (P < .001), cardiovascular fitness (P < .001), and lean body mass (P = .008).	AET significantly improved important patient-rated outcomes and objective physical functioning in lymphoma patients without interfering with medical treatments or response.
__label__noRel	AET did not interfere with chemotherapy completion rate or treatment response.	At postintervention, AET was superior to UC for patient-rated physical functioning (mean group difference, +9.0; 95% CI, 2.0 to 16.0; P = .012), overall QoL (P = .021), fatigue (P = .013), happiness (P = .004), depression (P = .005), general health (P < .001), cardiovascular fitness (P < .001), and lean body mass (P = .008).
__label__noRel	AET did not interfere with chemotherapy completion rate or treatment response.	At 6-month follow-up, AET was still borderline or significantly superior to UC for overall QoL (P = .054), happiness (P = .034), and depression (P = .009) without an increased risk of disease recurrence/progression.
__label__noRel	AET did not interfere with chemotherapy completion rate or treatment response.	Exercise training to improve cardiovascular fitness should be considered in the management of lymphoma patients.
__label__Support	AET did not interfere with chemotherapy completion rate or treatment response.	AET significantly improved important patient-rated outcomes and objective physical functioning in lymphoma patients without interfering with medical treatments or response.
__label__noRel	At 6-month follow-up, AET was still borderline or significantly superior to UC for overall QoL (P = .054), happiness (P = .034), and depression (P = .009) without an increased risk of disease recurrence/progression.	At postintervention, AET was superior to UC for patient-rated physical functioning (mean group difference, +9.0; 95% CI, 2.0 to 16.0; P = .012), overall QoL (P = .021), fatigue (P = .013), happiness (P = .004), depression (P = .005), general health (P < .001), cardiovascular fitness (P < .001), and lean body mass (P = .008).
__label__noRel	At 6-month follow-up, AET was still borderline or significantly superior to UC for overall QoL (P = .054), happiness (P = .034), and depression (P = .009) without an increased risk of disease recurrence/progression.	AET did not interfere with chemotherapy completion rate or treatment response.
__label__noRel	At 6-month follow-up, AET was still borderline or significantly superior to UC for overall QoL (P = .054), happiness (P = .034), and depression (P = .009) without an increased risk of disease recurrence/progression.	Exercise training to improve cardiovascular fitness should be considered in the management of lymphoma patients.
__label__Support	At 6-month follow-up, AET was still borderline or significantly superior to UC for overall QoL (P = .054), happiness (P = .034), and depression (P = .009) without an increased risk of disease recurrence/progression.	AET significantly improved important patient-rated outcomes and objective physical functioning in lymphoma patients without interfering with medical treatments or response.
__label__noRel	Exercise training to improve cardiovascular fitness should be considered in the management of lymphoma patients.	At postintervention, AET was superior to UC for patient-rated physical functioning (mean group difference, +9.0; 95% CI, 2.0 to 16.0; P = .012), overall QoL (P = .021), fatigue (P = .013), happiness (P = .004), depression (P = .005), general health (P < .001), cardiovascular fitness (P < .001), and lean body mass (P = .008).
__label__noRel	Exercise training to improve cardiovascular fitness should be considered in the management of lymphoma patients.	AET did not interfere with chemotherapy completion rate or treatment response.
__label__noRel	Exercise training to improve cardiovascular fitness should be considered in the management of lymphoma patients.	At 6-month follow-up, AET was still borderline or significantly superior to UC for overall QoL (P = .054), happiness (P = .034), and depression (P = .009) without an increased risk of disease recurrence/progression.
__label__noRel	Exercise training to improve cardiovascular fitness should be considered in the management of lymphoma patients.	AET significantly improved important patient-rated outcomes and objective physical functioning in lymphoma patients without interfering with medical treatments or response.
__label__noRel	AET significantly improved important patient-rated outcomes and objective physical functioning in lymphoma patients without interfering with medical treatments or response.	At postintervention, AET was superior to UC for patient-rated physical functioning (mean group difference, +9.0; 95% CI, 2.0 to 16.0; P = .012), overall QoL (P = .021), fatigue (P = .013), happiness (P = .004), depression (P = .005), general health (P < .001), cardiovascular fitness (P < .001), and lean body mass (P = .008).
__label__noRel	AET significantly improved important patient-rated outcomes and objective physical functioning in lymphoma patients without interfering with medical treatments or response.	AET did not interfere with chemotherapy completion rate or treatment response.
__label__noRel	AET significantly improved important patient-rated outcomes and objective physical functioning in lymphoma patients without interfering with medical treatments or response.	At 6-month follow-up, AET was still borderline or significantly superior to UC for overall QoL (P = .054), happiness (P = .034), and depression (P = .009) without an increased risk of disease recurrence/progression.
__label__Support	AET significantly improved important patient-rated outcomes and objective physical functioning in lymphoma patients without interfering with medical treatments or response.	Exercise training to improve cardiovascular fitness should be considered in the management of lymphoma patients.
__label__noRel	16 (29%) patients in the open oesophagectomy group had pulmonary infection in the first 2 weeks compared with five (9%) in the minimally invasive group (relative risk [RR] 030, 95% CI 012-076; p=0005).	19 (34%) patients in the open oesophagectomy group had pulmonary infection in-hospital compared with seven (12%) in the minimally invasive group (035, 016-078; p=0005).
__label__noRel	16 (29%) patients in the open oesophagectomy group had pulmonary infection in the first 2 weeks compared with five (9%) in the minimally invasive group (relative risk [RR] 030, 95% CI 012-076; p=0005).	For in-hospital mortality, one patient in the open oesophagectomy group died from anastomotic leakage and two in the minimally invasive group from aspiration and mediastinitis after anastomotic leakage.
__label__Support	16 (29%) patients in the open oesophagectomy group had pulmonary infection in the first 2 weeks compared with five (9%) in the minimally invasive group (relative risk [RR] 030, 95% CI 012-076; p=0005).	These findings provide evidence for the short-term benefits of minimally invasive oesophagectomy for patients with resectable oesophageal cancer.
__label__noRel	19 (34%) patients in the open oesophagectomy group had pulmonary infection in-hospital compared with seven (12%) in the minimally invasive group (035, 016-078; p=0005).	16 (29%) patients in the open oesophagectomy group had pulmonary infection in the first 2 weeks compared with five (9%) in the minimally invasive group (relative risk [RR] 030, 95% CI 012-076; p=0005).
__label__noRel	19 (34%) patients in the open oesophagectomy group had pulmonary infection in-hospital compared with seven (12%) in the minimally invasive group (035, 016-078; p=0005).	For in-hospital mortality, one patient in the open oesophagectomy group died from anastomotic leakage and two in the minimally invasive group from aspiration and mediastinitis after anastomotic leakage.
__label__Support	19 (34%) patients in the open oesophagectomy group had pulmonary infection in-hospital compared with seven (12%) in the minimally invasive group (035, 016-078; p=0005).	These findings provide evidence for the short-term benefits of minimally invasive oesophagectomy for patients with resectable oesophageal cancer.
__label__noRel	For in-hospital mortality, one patient in the open oesophagectomy group died from anastomotic leakage and two in the minimally invasive group from aspiration and mediastinitis after anastomotic leakage.	16 (29%) patients in the open oesophagectomy group had pulmonary infection in the first 2 weeks compared with five (9%) in the minimally invasive group (relative risk [RR] 030, 95% CI 012-076; p=0005).
__label__noRel	For in-hospital mortality, one patient in the open oesophagectomy group died from anastomotic leakage and two in the minimally invasive group from aspiration and mediastinitis after anastomotic leakage.	19 (34%) patients in the open oesophagectomy group had pulmonary infection in-hospital compared with seven (12%) in the minimally invasive group (035, 016-078; p=0005).
__label__noRel	For in-hospital mortality, one patient in the open oesophagectomy group died from anastomotic leakage and two in the minimally invasive group from aspiration and mediastinitis after anastomotic leakage.	These findings provide evidence for the short-term benefits of minimally invasive oesophagectomy for patients with resectable oesophageal cancer.
__label__noRel	These findings provide evidence for the short-term benefits of minimally invasive oesophagectomy for patients with resectable oesophageal cancer.	16 (29%) patients in the open oesophagectomy group had pulmonary infection in the first 2 weeks compared with five (9%) in the minimally invasive group (relative risk [RR] 030, 95% CI 012-076; p=0005).
__label__noRel	These findings provide evidence for the short-term benefits of minimally invasive oesophagectomy for patients with resectable oesophageal cancer.	19 (34%) patients in the open oesophagectomy group had pulmonary infection in-hospital compared with seven (12%) in the minimally invasive group (035, 016-078; p=0005).
__label__noRel	These findings provide evidence for the short-term benefits of minimally invasive oesophagectomy for patients with resectable oesophageal cancer.	For in-hospital mortality, one patient in the open oesophagectomy group died from anastomotic leakage and two in the minimally invasive group from aspiration and mediastinitis after anastomotic leakage.
__label__noRel	At a median follow-up of 3.9 years, the estimated 4-year recurrence-free survival rate was 67.5% with the 16-week regimen versus 62.7% with CAF (P = .19, two-sided; P = .095, one-sided).	The estimated 4-year survival rate was 78.1% with the 16-week regimen versus 71.4% with CAF (P = .10, two-sided; P = .05, one-sided).
__label__noRel	At a median follow-up of 3.9 years, the estimated 4-year recurrence-free survival rate was 67.5% with the 16-week regimen versus 62.7% with CAF (P = .19, two-sided; P = .095, one-sided).	CAF produced significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as well as liver and cardiac toxicity,
__label__noRel	At a median follow-up of 3.9 years, the estimated 4-year recurrence-free survival rate was 67.5% with the 16-week regimen versus 62.7% with CAF (P = .19, two-sided; P = .095, one-sided).	the 16-week regimen produced significantly higher grades of anemia, nausea, stomatitis, and weight loss, as well as skin and neurotoxicity.
__label__noRel	At a median follow-up of 3.9 years, the estimated 4-year recurrence-free survival rate was 67.5% with the 16-week regimen versus 62.7% with CAF (P = .19, two-sided; P = .095, one-sided).	There were three treatment-related deaths with CAF
__label__noRel	At a median follow-up of 3.9 years, the estimated 4-year recurrence-free survival rate was 67.5% with the 16-week regimen versus 62.7% with CAF (P = .19, two-sided; P = .095, one-sided).	but none with the 16-week regimen.
__label__noRel	At a median follow-up of 3.9 years, the estimated 4-year recurrence-free survival rate was 67.5% with the 16-week regimen versus 62.7% with CAF (P = .19, two-sided; P = .095, one-sided).	During treatment, quality of life declined significantly more with the 16-week regimen than CAF,
__label__noRel	At a median follow-up of 3.9 years, the estimated 4-year recurrence-free survival rate was 67.5% with the 16-week regimen versus 62.7% with CAF (P = .19, two-sided; P = .095, one-sided).	but by 4 months posttreatment, there was no difference.
__label__noRel	At a median follow-up of 3.9 years, the estimated 4-year recurrence-free survival rate was 67.5% with the 16-week regimen versus 62.7% with CAF (P = .19, two-sided; P = .095, one-sided).	The 16-week regimen produced marginally better breast cancer outcomes than CAF with similar toxicity but a greater reduction in during-treatment quality of life.
__label__Support	At a median follow-up of 3.9 years, the estimated 4-year recurrence-free survival rate was 67.5% with the 16-week regimen versus 62.7% with CAF (P = .19, two-sided; P = .095, one-sided).	The 16-week regimen should not be used instead of a standard-dose regimen without careful consideration of the 16-week regimen's pros and cons, which include its complicated schedule.
__label__noRel	At a median follow-up of 3.9 years, the estimated 4-year recurrence-free survival rate was 67.5% with the 16-week regimen versus 62.7% with CAF (P = .19, two-sided; P = .095, one-sided).	It should probably not be tested further,
__label__noRel	At a median follow-up of 3.9 years, the estimated 4-year recurrence-free survival rate was 67.5% with the 16-week regimen versus 62.7% with CAF (P = .19, two-sided; P = .095, one-sided).	but its antimetabolite schedules and frequent drug administration (ie, dose density) should be considered in the development of new regimens.
__label__noRel	The estimated 4-year survival rate was 78.1% with the 16-week regimen versus 71.4% with CAF (P = .10, two-sided; P = .05, one-sided).	At a median follow-up of 3.9 years, the estimated 4-year recurrence-free survival rate was 67.5% with the 16-week regimen versus 62.7% with CAF (P = .19, two-sided; P = .095, one-sided).
__label__noRel	The estimated 4-year survival rate was 78.1% with the 16-week regimen versus 71.4% with CAF (P = .10, two-sided; P = .05, one-sided).	CAF produced significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as well as liver and cardiac toxicity,
__label__noRel	The estimated 4-year survival rate was 78.1% with the 16-week regimen versus 71.4% with CAF (P = .10, two-sided; P = .05, one-sided).	the 16-week regimen produced significantly higher grades of anemia, nausea, stomatitis, and weight loss, as well as skin and neurotoxicity.
__label__noRel	The estimated 4-year survival rate was 78.1% with the 16-week regimen versus 71.4% with CAF (P = .10, two-sided; P = .05, one-sided).	There were three treatment-related deaths with CAF
__label__noRel	The estimated 4-year survival rate was 78.1% with the 16-week regimen versus 71.4% with CAF (P = .10, two-sided; P = .05, one-sided).	but none with the 16-week regimen.
__label__noRel	The estimated 4-year survival rate was 78.1% with the 16-week regimen versus 71.4% with CAF (P = .10, two-sided; P = .05, one-sided).	During treatment, quality of life declined significantly more with the 16-week regimen than CAF,
__label__noRel	The estimated 4-year survival rate was 78.1% with the 16-week regimen versus 71.4% with CAF (P = .10, two-sided; P = .05, one-sided).	but by 4 months posttreatment, there was no difference.
__label__noRel	The estimated 4-year survival rate was 78.1% with the 16-week regimen versus 71.4% with CAF (P = .10, two-sided; P = .05, one-sided).	The 16-week regimen produced marginally better breast cancer outcomes than CAF with similar toxicity but a greater reduction in during-treatment quality of life.
__label__Support	The estimated 4-year survival rate was 78.1% with the 16-week regimen versus 71.4% with CAF (P = .10, two-sided; P = .05, one-sided).	The 16-week regimen should not be used instead of a standard-dose regimen without careful consideration of the 16-week regimen's pros and cons, which include its complicated schedule.
__label__noRel	The estimated 4-year survival rate was 78.1% with the 16-week regimen versus 71.4% with CAF (P = .10, two-sided; P = .05, one-sided).	It should probably not be tested further,
__label__noRel	The estimated 4-year survival rate was 78.1% with the 16-week regimen versus 71.4% with CAF (P = .10, two-sided; P = .05, one-sided).	but its antimetabolite schedules and frequent drug administration (ie, dose density) should be considered in the development of new regimens.
__label__noRel	CAF produced significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as well as liver and cardiac toxicity,	At a median follow-up of 3.9 years, the estimated 4-year recurrence-free survival rate was 67.5% with the 16-week regimen versus 62.7% with CAF (P = .19, two-sided; P = .095, one-sided).
__label__noRel	CAF produced significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as well as liver and cardiac toxicity,	The estimated 4-year survival rate was 78.1% with the 16-week regimen versus 71.4% with CAF (P = .10, two-sided; P = .05, one-sided).
__label__noRel	CAF produced significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as well as liver and cardiac toxicity,	the 16-week regimen produced significantly higher grades of anemia, nausea, stomatitis, and weight loss, as well as skin and neurotoxicity.
__label__noRel	CAF produced significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as well as liver and cardiac toxicity,	There were three treatment-related deaths with CAF
__label__noRel	CAF produced significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as well as liver and cardiac toxicity,	but none with the 16-week regimen.
__label__noRel	CAF produced significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as well as liver and cardiac toxicity,	During treatment, quality of life declined significantly more with the 16-week regimen than CAF,
__label__noRel	CAF produced significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as well as liver and cardiac toxicity,	but by 4 months posttreatment, there was no difference.
__label__noRel	CAF produced significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as well as liver and cardiac toxicity,	The 16-week regimen produced marginally better breast cancer outcomes than CAF with similar toxicity but a greater reduction in during-treatment quality of life.
__label__Support	CAF produced significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as well as liver and cardiac toxicity,	The 16-week regimen should not be used instead of a standard-dose regimen without careful consideration of the 16-week regimen's pros and cons, which include its complicated schedule.
__label__noRel	CAF produced significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as well as liver and cardiac toxicity,	It should probably not be tested further,
__label__noRel	CAF produced significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as well as liver and cardiac toxicity,	but its antimetabolite schedules and frequent drug administration (ie, dose density) should be considered in the development of new regimens.
__label__noRel	the 16-week regimen produced significantly higher grades of anemia, nausea, stomatitis, and weight loss, as well as skin and neurotoxicity.	At a median follow-up of 3.9 years, the estimated 4-year recurrence-free survival rate was 67.5% with the 16-week regimen versus 62.7% with CAF (P = .19, two-sided; P = .095, one-sided).
__label__noRel	the 16-week regimen produced significantly higher grades of anemia, nausea, stomatitis, and weight loss, as well as skin and neurotoxicity.	The estimated 4-year survival rate was 78.1% with the 16-week regimen versus 71.4% with CAF (P = .10, two-sided; P = .05, one-sided).
__label__noRel	the 16-week regimen produced significantly higher grades of anemia, nausea, stomatitis, and weight loss, as well as skin and neurotoxicity.	CAF produced significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as well as liver and cardiac toxicity,
__label__noRel	the 16-week regimen produced significantly higher grades of anemia, nausea, stomatitis, and weight loss, as well as skin and neurotoxicity.	There were three treatment-related deaths with CAF
__label__noRel	the 16-week regimen produced significantly higher grades of anemia, nausea, stomatitis, and weight loss, as well as skin and neurotoxicity.	but none with the 16-week regimen.
__label__noRel	the 16-week regimen produced significantly higher grades of anemia, nausea, stomatitis, and weight loss, as well as skin and neurotoxicity.	During treatment, quality of life declined significantly more with the 16-week regimen than CAF,
__label__noRel	the 16-week regimen produced significantly higher grades of anemia, nausea, stomatitis, and weight loss, as well as skin and neurotoxicity.	but by 4 months posttreatment, there was no difference.
__label__noRel	the 16-week regimen produced significantly higher grades of anemia, nausea, stomatitis, and weight loss, as well as skin and neurotoxicity.	The 16-week regimen produced marginally better breast cancer outcomes than CAF with similar toxicity but a greater reduction in during-treatment quality of life.
__label__Support	the 16-week regimen produced significantly higher grades of anemia, nausea, stomatitis, and weight loss, as well as skin and neurotoxicity.	The 16-week regimen should not be used instead of a standard-dose regimen without careful consideration of the 16-week regimen's pros and cons, which include its complicated schedule.
__label__noRel	the 16-week regimen produced significantly higher grades of anemia, nausea, stomatitis, and weight loss, as well as skin and neurotoxicity.	It should probably not be tested further,
__label__noRel	the 16-week regimen produced significantly higher grades of anemia, nausea, stomatitis, and weight loss, as well as skin and neurotoxicity.	but its antimetabolite schedules and frequent drug administration (ie, dose density) should be considered in the development of new regimens.
__label__noRel	There were three treatment-related deaths with CAF	At a median follow-up of 3.9 years, the estimated 4-year recurrence-free survival rate was 67.5% with the 16-week regimen versus 62.7% with CAF (P = .19, two-sided; P = .095, one-sided).
__label__noRel	There were three treatment-related deaths with CAF	The estimated 4-year survival rate was 78.1% with the 16-week regimen versus 71.4% with CAF (P = .10, two-sided; P = .05, one-sided).
__label__noRel	There were three treatment-related deaths with CAF	CAF produced significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as well as liver and cardiac toxicity,
__label__noRel	There were three treatment-related deaths with CAF	the 16-week regimen produced significantly higher grades of anemia, nausea, stomatitis, and weight loss, as well as skin and neurotoxicity.
__label__noRel	There were three treatment-related deaths with CAF	but none with the 16-week regimen.
__label__noRel	There were three treatment-related deaths with CAF	During treatment, quality of life declined significantly more with the 16-week regimen than CAF,
__label__noRel	There were three treatment-related deaths with CAF	but by 4 months posttreatment, there was no difference.
__label__noRel	There were three treatment-related deaths with CAF	The 16-week regimen produced marginally better breast cancer outcomes than CAF with similar toxicity but a greater reduction in during-treatment quality of life.
__label__Support	There were three treatment-related deaths with CAF	The 16-week regimen should not be used instead of a standard-dose regimen without careful consideration of the 16-week regimen's pros and cons, which include its complicated schedule.
__label__noRel	There were three treatment-related deaths with CAF	It should probably not be tested further,
__label__noRel	There were three treatment-related deaths with CAF	but its antimetabolite schedules and frequent drug administration (ie, dose density) should be considered in the development of new regimens.
__label__noRel	but none with the 16-week regimen.	At a median follow-up of 3.9 years, the estimated 4-year recurrence-free survival rate was 67.5% with the 16-week regimen versus 62.7% with CAF (P = .19, two-sided; P = .095, one-sided).
__label__noRel	but none with the 16-week regimen.	The estimated 4-year survival rate was 78.1% with the 16-week regimen versus 71.4% with CAF (P = .10, two-sided; P = .05, one-sided).
__label__noRel	but none with the 16-week regimen.	CAF produced significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as well as liver and cardiac toxicity,
__label__noRel	but none with the 16-week regimen.	the 16-week regimen produced significantly higher grades of anemia, nausea, stomatitis, and weight loss, as well as skin and neurotoxicity.
__label__Attack	but none with the 16-week regimen.	There were three treatment-related deaths with CAF
__label__noRel	but none with the 16-week regimen.	During treatment, quality of life declined significantly more with the 16-week regimen than CAF,
__label__noRel	but none with the 16-week regimen.	but by 4 months posttreatment, there was no difference.
__label__noRel	but none with the 16-week regimen.	The 16-week regimen produced marginally better breast cancer outcomes than CAF with similar toxicity but a greater reduction in during-treatment quality of life.
__label__noRel	but none with the 16-week regimen.	The 16-week regimen should not be used instead of a standard-dose regimen without careful consideration of the 16-week regimen's pros and cons, which include its complicated schedule.
__label__noRel	but none with the 16-week regimen.	It should probably not be tested further,
__label__noRel	but none with the 16-week regimen.	but its antimetabolite schedules and frequent drug administration (ie, dose density) should be considered in the development of new regimens.
__label__noRel	During treatment, quality of life declined significantly more with the 16-week regimen than CAF,	At a median follow-up of 3.9 years, the estimated 4-year recurrence-free survival rate was 67.5% with the 16-week regimen versus 62.7% with CAF (P = .19, two-sided; P = .095, one-sided).
__label__noRel	During treatment, quality of life declined significantly more with the 16-week regimen than CAF,	The estimated 4-year survival rate was 78.1% with the 16-week regimen versus 71.4% with CAF (P = .10, two-sided; P = .05, one-sided).
__label__noRel	During treatment, quality of life declined significantly more with the 16-week regimen than CAF,	CAF produced significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as well as liver and cardiac toxicity,
__label__noRel	During treatment, quality of life declined significantly more with the 16-week regimen than CAF,	the 16-week regimen produced significantly higher grades of anemia, nausea, stomatitis, and weight loss, as well as skin and neurotoxicity.
__label__noRel	During treatment, quality of life declined significantly more with the 16-week regimen than CAF,	There were three treatment-related deaths with CAF
__label__noRel	During treatment, quality of life declined significantly more with the 16-week regimen than CAF,	but none with the 16-week regimen.
__label__noRel	During treatment, quality of life declined significantly more with the 16-week regimen than CAF,	but by 4 months posttreatment, there was no difference.
__label__noRel	During treatment, quality of life declined significantly more with the 16-week regimen than CAF,	The 16-week regimen produced marginally better breast cancer outcomes than CAF with similar toxicity but a greater reduction in during-treatment quality of life.
__label__Support	During treatment, quality of life declined significantly more with the 16-week regimen than CAF,	The 16-week regimen should not be used instead of a standard-dose regimen without careful consideration of the 16-week regimen's pros and cons, which include its complicated schedule.
__label__noRel	During treatment, quality of life declined significantly more with the 16-week regimen than CAF,	It should probably not be tested further,
__label__noRel	During treatment, quality of life declined significantly more with the 16-week regimen than CAF,	but its antimetabolite schedules and frequent drug administration (ie, dose density) should be considered in the development of new regimens.
__label__noRel	but by 4 months posttreatment, there was no difference.	At a median follow-up of 3.9 years, the estimated 4-year recurrence-free survival rate was 67.5% with the 16-week regimen versus 62.7% with CAF (P = .19, two-sided; P = .095, one-sided).
__label__noRel	but by 4 months posttreatment, there was no difference.	The estimated 4-year survival rate was 78.1% with the 16-week regimen versus 71.4% with CAF (P = .10, two-sided; P = .05, one-sided).
__label__noRel	but by 4 months posttreatment, there was no difference.	CAF produced significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as well as liver and cardiac toxicity,
__label__noRel	but by 4 months posttreatment, there was no difference.	the 16-week regimen produced significantly higher grades of anemia, nausea, stomatitis, and weight loss, as well as skin and neurotoxicity.
__label__noRel	but by 4 months posttreatment, there was no difference.	There were three treatment-related deaths with CAF
__label__noRel	but by 4 months posttreatment, there was no difference.	but none with the 16-week regimen.
__label__Attack	but by 4 months posttreatment, there was no difference.	During treatment, quality of life declined significantly more with the 16-week regimen than CAF,
__label__noRel	but by 4 months posttreatment, there was no difference.	The 16-week regimen produced marginally better breast cancer outcomes than CAF with similar toxicity but a greater reduction in during-treatment quality of life.
__label__noRel	but by 4 months posttreatment, there was no difference.	The 16-week regimen should not be used instead of a standard-dose regimen without careful consideration of the 16-week regimen's pros and cons, which include its complicated schedule.
__label__noRel	but by 4 months posttreatment, there was no difference.	It should probably not be tested further,
__label__noRel	but by 4 months posttreatment, there was no difference.	but its antimetabolite schedules and frequent drug administration (ie, dose density) should be considered in the development of new regimens.
__label__noRel	The 16-week regimen produced marginally better breast cancer outcomes than CAF with similar toxicity but a greater reduction in during-treatment quality of life.	At a median follow-up of 3.9 years, the estimated 4-year recurrence-free survival rate was 67.5% with the 16-week regimen versus 62.7% with CAF (P = .19, two-sided; P = .095, one-sided).
__label__noRel	The 16-week regimen produced marginally better breast cancer outcomes than CAF with similar toxicity but a greater reduction in during-treatment quality of life.	The estimated 4-year survival rate was 78.1% with the 16-week regimen versus 71.4% with CAF (P = .10, two-sided; P = .05, one-sided).
__label__noRel	The 16-week regimen produced marginally better breast cancer outcomes than CAF with similar toxicity but a greater reduction in during-treatment quality of life.	CAF produced significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as well as liver and cardiac toxicity,
__label__noRel	The 16-week regimen produced marginally better breast cancer outcomes than CAF with similar toxicity but a greater reduction in during-treatment quality of life.	the 16-week regimen produced significantly higher grades of anemia, nausea, stomatitis, and weight loss, as well as skin and neurotoxicity.
__label__noRel	The 16-week regimen produced marginally better breast cancer outcomes than CAF with similar toxicity but a greater reduction in during-treatment quality of life.	There were three treatment-related deaths with CAF
__label__noRel	The 16-week regimen produced marginally better breast cancer outcomes than CAF with similar toxicity but a greater reduction in during-treatment quality of life.	but none with the 16-week regimen.
__label__noRel	The 16-week regimen produced marginally better breast cancer outcomes than CAF with similar toxicity but a greater reduction in during-treatment quality of life.	During treatment, quality of life declined significantly more with the 16-week regimen than CAF,
__label__noRel	The 16-week regimen produced marginally better breast cancer outcomes than CAF with similar toxicity but a greater reduction in during-treatment quality of life.	but by 4 months posttreatment, there was no difference.
__label__Support	The 16-week regimen produced marginally better breast cancer outcomes than CAF with similar toxicity but a greater reduction in during-treatment quality of life.	The 16-week regimen should not be used instead of a standard-dose regimen without careful consideration of the 16-week regimen's pros and cons, which include its complicated schedule.
__label__noRel	The 16-week regimen produced marginally better breast cancer outcomes than CAF with similar toxicity but a greater reduction in during-treatment quality of life.	It should probably not be tested further,
__label__noRel	The 16-week regimen produced marginally better breast cancer outcomes than CAF with similar toxicity but a greater reduction in during-treatment quality of life.	but its antimetabolite schedules and frequent drug administration (ie, dose density) should be considered in the development of new regimens.
__label__noRel	The 16-week regimen should not be used instead of a standard-dose regimen without careful consideration of the 16-week regimen's pros and cons, which include its complicated schedule.	At a median follow-up of 3.9 years, the estimated 4-year recurrence-free survival rate was 67.5% with the 16-week regimen versus 62.7% with CAF (P = .19, two-sided; P = .095, one-sided).
__label__noRel	The 16-week regimen should not be used instead of a standard-dose regimen without careful consideration of the 16-week regimen's pros and cons, which include its complicated schedule.	The estimated 4-year survival rate was 78.1% with the 16-week regimen versus 71.4% with CAF (P = .10, two-sided; P = .05, one-sided).
__label__noRel	The 16-week regimen should not be used instead of a standard-dose regimen without careful consideration of the 16-week regimen's pros and cons, which include its complicated schedule.	CAF produced significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as well as liver and cardiac toxicity,
__label__noRel	The 16-week regimen should not be used instead of a standard-dose regimen without careful consideration of the 16-week regimen's pros and cons, which include its complicated schedule.	the 16-week regimen produced significantly higher grades of anemia, nausea, stomatitis, and weight loss, as well as skin and neurotoxicity.
__label__noRel	The 16-week regimen should not be used instead of a standard-dose regimen without careful consideration of the 16-week regimen's pros and cons, which include its complicated schedule.	There were three treatment-related deaths with CAF
__label__noRel	The 16-week regimen should not be used instead of a standard-dose regimen without careful consideration of the 16-week regimen's pros and cons, which include its complicated schedule.	but none with the 16-week regimen.
__label__noRel	The 16-week regimen should not be used instead of a standard-dose regimen without careful consideration of the 16-week regimen's pros and cons, which include its complicated schedule.	During treatment, quality of life declined significantly more with the 16-week regimen than CAF,
__label__noRel	The 16-week regimen should not be used instead of a standard-dose regimen without careful consideration of the 16-week regimen's pros and cons, which include its complicated schedule.	but by 4 months posttreatment, there was no difference.
__label__noRel	The 16-week regimen should not be used instead of a standard-dose regimen without careful consideration of the 16-week regimen's pros and cons, which include its complicated schedule.	The 16-week regimen produced marginally better breast cancer outcomes than CAF with similar toxicity but a greater reduction in during-treatment quality of life.
__label__noRel	The 16-week regimen should not be used instead of a standard-dose regimen without careful consideration of the 16-week regimen's pros and cons, which include its complicated schedule.	It should probably not be tested further,
__label__noRel	The 16-week regimen should not be used instead of a standard-dose regimen without careful consideration of the 16-week regimen's pros and cons, which include its complicated schedule.	but its antimetabolite schedules and frequent drug administration (ie, dose density) should be considered in the development of new regimens.
__label__noRel	It should probably not be tested further,	At a median follow-up of 3.9 years, the estimated 4-year recurrence-free survival rate was 67.5% with the 16-week regimen versus 62.7% with CAF (P = .19, two-sided; P = .095, one-sided).
__label__noRel	It should probably not be tested further,	The estimated 4-year survival rate was 78.1% with the 16-week regimen versus 71.4% with CAF (P = .10, two-sided; P = .05, one-sided).
__label__noRel	It should probably not be tested further,	CAF produced significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as well as liver and cardiac toxicity,
__label__noRel	It should probably not be tested further,	the 16-week regimen produced significantly higher grades of anemia, nausea, stomatitis, and weight loss, as well as skin and neurotoxicity.
__label__noRel	It should probably not be tested further,	There were three treatment-related deaths with CAF
__label__noRel	It should probably not be tested further,	but none with the 16-week regimen.
__label__noRel	It should probably not be tested further,	During treatment, quality of life declined significantly more with the 16-week regimen than CAF,
__label__noRel	It should probably not be tested further,	but by 4 months posttreatment, there was no difference.
__label__noRel	It should probably not be tested further,	The 16-week regimen produced marginally better breast cancer outcomes than CAF with similar toxicity but a greater reduction in during-treatment quality of life.
__label__Attack	It should probably not be tested further,	The 16-week regimen should not be used instead of a standard-dose regimen without careful consideration of the 16-week regimen's pros and cons, which include its complicated schedule.
__label__noRel	It should probably not be tested further,	but its antimetabolite schedules and frequent drug administration (ie, dose density) should be considered in the development of new regimens.
__label__noRel	but its antimetabolite schedules and frequent drug administration (ie, dose density) should be considered in the development of new regimens.	At a median follow-up of 3.9 years, the estimated 4-year recurrence-free survival rate was 67.5% with the 16-week regimen versus 62.7% with CAF (P = .19, two-sided; P = .095, one-sided).
__label__noRel	but its antimetabolite schedules and frequent drug administration (ie, dose density) should be considered in the development of new regimens.	The estimated 4-year survival rate was 78.1% with the 16-week regimen versus 71.4% with CAF (P = .10, two-sided; P = .05, one-sided).
__label__noRel	but its antimetabolite schedules and frequent drug administration (ie, dose density) should be considered in the development of new regimens.	CAF produced significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as well as liver and cardiac toxicity,
__label__noRel	but its antimetabolite schedules and frequent drug administration (ie, dose density) should be considered in the development of new regimens.	the 16-week regimen produced significantly higher grades of anemia, nausea, stomatitis, and weight loss, as well as skin and neurotoxicity.
__label__noRel	but its antimetabolite schedules and frequent drug administration (ie, dose density) should be considered in the development of new regimens.	There were three treatment-related deaths with CAF
__label__noRel	but its antimetabolite schedules and frequent drug administration (ie, dose density) should be considered in the development of new regimens.	but none with the 16-week regimen.
__label__noRel	but its antimetabolite schedules and frequent drug administration (ie, dose density) should be considered in the development of new regimens.	During treatment, quality of life declined significantly more with the 16-week regimen than CAF,
__label__noRel	but its antimetabolite schedules and frequent drug administration (ie, dose density) should be considered in the development of new regimens.	but by 4 months posttreatment, there was no difference.
__label__noRel	but its antimetabolite schedules and frequent drug administration (ie, dose density) should be considered in the development of new regimens.	The 16-week regimen produced marginally better breast cancer outcomes than CAF with similar toxicity but a greater reduction in during-treatment quality of life.
__label__noRel	but its antimetabolite schedules and frequent drug administration (ie, dose density) should be considered in the development of new regimens.	The 16-week regimen should not be used instead of a standard-dose regimen without careful consideration of the 16-week regimen's pros and cons, which include its complicated schedule.
__label__Attack	but its antimetabolite schedules and frequent drug administration (ie, dose density) should be considered in the development of new regimens.	It should probably not be tested further,
__label__noRel	The difference in the mean General Fatigue score, between those who received the intervention and those who did not, was -3.11 (95% CI, -3.97 to -2.25; P < .001).	The intervention also improved all other fatigue aspects measured by MFI, including Physical Fatigue and Mental Fatigue (acupuncture effect, -2.36 and -1.94, respectively; both at P < .001), anxiety and depression (acupuncture effect, -1.83 and -2.13, respectively; both at P < .001), and quality of life (Physical Well-Being effect, 3.30; Functional Well-Being effect, 3.57; both at P < .001; Emotional Well-Being effect, 1.93; P = .001; and Social Functioning Well-Being effect, 1.05; P < .05).
__label__Support	The difference in the mean General Fatigue score, between those who received the intervention and those who did not, was -3.11 (95% CI, -3.97 to -2.25; P < .001).	Acupuncture is an effective intervention for managing the symptom of CRF and improving patients' quality of life.
__label__noRel	The intervention also improved all other fatigue aspects measured by MFI, including Physical Fatigue and Mental Fatigue (acupuncture effect, -2.36 and -1.94, respectively; both at P < .001), anxiety and depression (acupuncture effect, -1.83 and -2.13, respectively; both at P < .001), and quality of life (Physical Well-Being effect, 3.30; Functional Well-Being effect, 3.57; both at P < .001; Emotional Well-Being effect, 1.93; P = .001; and Social Functioning Well-Being effect, 1.05; P < .05).	The difference in the mean General Fatigue score, between those who received the intervention and those who did not, was -3.11 (95% CI, -3.97 to -2.25; P < .001).
__label__Support	The intervention also improved all other fatigue aspects measured by MFI, including Physical Fatigue and Mental Fatigue (acupuncture effect, -2.36 and -1.94, respectively; both at P < .001), anxiety and depression (acupuncture effect, -1.83 and -2.13, respectively; both at P < .001), and quality of life (Physical Well-Being effect, 3.30; Functional Well-Being effect, 3.57; both at P < .001; Emotional Well-Being effect, 1.93; P = .001; and Social Functioning Well-Being effect, 1.05; P < .05).	Acupuncture is an effective intervention for managing the symptom of CRF and improving patients' quality of life.
__label__noRel	Acupuncture is an effective intervention for managing the symptom of CRF and improving patients' quality of life.	The difference in the mean General Fatigue score, between those who received the intervention and those who did not, was -3.11 (95% CI, -3.97 to -2.25; P < .001).
__label__noRel	Acupuncture is an effective intervention for managing the symptom of CRF and improving patients' quality of life.	The intervention also improved all other fatigue aspects measured by MFI, including Physical Fatigue and Mental Fatigue (acupuncture effect, -2.36 and -1.94, respectively; both at P < .001), anxiety and depression (acupuncture effect, -1.83 and -2.13, respectively; both at P < .001), and quality of life (Physical Well-Being effect, 3.30; Functional Well-Being effect, 3.57; both at P < .001; Emotional Well-Being effect, 1.93; P = .001; and Social Functioning Well-Being effect, 1.05; P < .05).
__label__noRel	The survival benefit of D3P compared with MP has persisted with extended follow-up (P = .004).	More patients survived >/= 3 years in the D3P and D1P arms (18.6% and 16.6%, respectively) compared with the MP arm (13.5%).
__label__noRel	The survival benefit of D3P compared with MP has persisted with extended follow-up (P = .004).	Similar trends in survival between treatment arms were seen for men greater than and less than 65 years of age, for those with and without pain at baseline, and for those with baseline PSA greater than and less than the median value of 115 ng/mL.
__label__Support	The survival benefit of D3P compared with MP has persisted with extended follow-up (P = .004).	The present analysis confirms that survival of men with metastatic HRPC is significantly longer after treatment with D3P than with MP.
__label__noRel	More patients survived >/= 3 years in the D3P and D1P arms (18.6% and 16.6%, respectively) compared with the MP arm (13.5%).	The survival benefit of D3P compared with MP has persisted with extended follow-up (P = .004).
__label__noRel	More patients survived >/= 3 years in the D3P and D1P arms (18.6% and 16.6%, respectively) compared with the MP arm (13.5%).	Similar trends in survival between treatment arms were seen for men greater than and less than 65 years of age, for those with and without pain at baseline, and for those with baseline PSA greater than and less than the median value of 115 ng/mL.
__label__Support	More patients survived >/= 3 years in the D3P and D1P arms (18.6% and 16.6%, respectively) compared with the MP arm (13.5%).	The present analysis confirms that survival of men with metastatic HRPC is significantly longer after treatment with D3P than with MP.
__label__noRel	Similar trends in survival between treatment arms were seen for men greater than and less than 65 years of age, for those with and without pain at baseline, and for those with baseline PSA greater than and less than the median value of 115 ng/mL.	The survival benefit of D3P compared with MP has persisted with extended follow-up (P = .004).
__label__noRel	Similar trends in survival between treatment arms were seen for men greater than and less than 65 years of age, for those with and without pain at baseline, and for those with baseline PSA greater than and less than the median value of 115 ng/mL.	More patients survived >/= 3 years in the D3P and D1P arms (18.6% and 16.6%, respectively) compared with the MP arm (13.5%).
__label__Support	Similar trends in survival between treatment arms were seen for men greater than and less than 65 years of age, for those with and without pain at baseline, and for those with baseline PSA greater than and less than the median value of 115 ng/mL.	The present analysis confirms that survival of men with metastatic HRPC is significantly longer after treatment with D3P than with MP.
__label__noRel	The present analysis confirms that survival of men with metastatic HRPC is significantly longer after treatment with D3P than with MP.	The survival benefit of D3P compared with MP has persisted with extended follow-up (P = .004).
__label__noRel	The present analysis confirms that survival of men with metastatic HRPC is significantly longer after treatment with D3P than with MP.	More patients survived >/= 3 years in the D3P and D1P arms (18.6% and 16.6%, respectively) compared with the MP arm (13.5%).
__label__noRel	The present analysis confirms that survival of men with metastatic HRPC is significantly longer after treatment with D3P than with MP.	Similar trends in survival between treatment arms were seen for men greater than and less than 65 years of age, for those with and without pain at baseline, and for those with baseline PSA greater than and less than the median value of 115 ng/mL.
__label__noRel	Both groups exhibited significant decreases in hot flashes, depressive symptoms, and other quality-of-life symptoms, including significant improvements in mental health from pre- to post-treatment.	These changes were similar in both groups, indicating that acupuncture was as effective as venlafaxine.
__label__noRel	Both groups exhibited significant decreases in hot flashes, depressive symptoms, and other quality-of-life symptoms, including significant improvements in mental health from pre- to post-treatment.	By 2 weeks post-treatment, the venlafaxine group experienced significant increases in hot flashes, whereas hot flashes in the acupuncture group remained at low levels.
__label__noRel	Both groups exhibited significant decreases in hot flashes, depressive symptoms, and other quality-of-life symptoms, including significant improvements in mental health from pre- to post-treatment.	The venlafaxine group experienced 18 incidences of adverse effects (eg, nausea, dry mouth, dizziness, anxiety), whereas the acupuncture group experienced no negative adverse effects.
__label__noRel	Both groups exhibited significant decreases in hot flashes, depressive symptoms, and other quality-of-life symptoms, including significant improvements in mental health from pre- to post-treatment.	Acupuncture had the additional benefit of increased sex drive in some women, and most reported an improvement in their energy, clarity of thought, and sense of well-being.
__label__Support	Both groups exhibited significant decreases in hot flashes, depressive symptoms, and other quality-of-life symptoms, including significant improvements in mental health from pre- to post-treatment.	Acupuncture appears to be equivalent to drug therapy in these patients.
__label__noRel	Both groups exhibited significant decreases in hot flashes, depressive symptoms, and other quality-of-life symptoms, including significant improvements in mental health from pre- to post-treatment.	It is a safe, effective and durable treatment for vasomotor symptoms secondary to long-term antiestrogen hormone use in patients with breast cancer.
__label__noRel	These changes were similar in both groups, indicating that acupuncture was as effective as venlafaxine.	Both groups exhibited significant decreases in hot flashes, depressive symptoms, and other quality-of-life symptoms, including significant improvements in mental health from pre- to post-treatment.
__label__noRel	These changes were similar in both groups, indicating that acupuncture was as effective as venlafaxine.	By 2 weeks post-treatment, the venlafaxine group experienced significant increases in hot flashes, whereas hot flashes in the acupuncture group remained at low levels.
__label__noRel	These changes were similar in both groups, indicating that acupuncture was as effective as venlafaxine.	The venlafaxine group experienced 18 incidences of adverse effects (eg, nausea, dry mouth, dizziness, anxiety), whereas the acupuncture group experienced no negative adverse effects.
__label__noRel	These changes were similar in both groups, indicating that acupuncture was as effective as venlafaxine.	Acupuncture had the additional benefit of increased sex drive in some women, and most reported an improvement in their energy, clarity of thought, and sense of well-being.
__label__Support	These changes were similar in both groups, indicating that acupuncture was as effective as venlafaxine.	Acupuncture appears to be equivalent to drug therapy in these patients.
__label__noRel	These changes were similar in both groups, indicating that acupuncture was as effective as venlafaxine.	It is a safe, effective and durable treatment for vasomotor symptoms secondary to long-term antiestrogen hormone use in patients with breast cancer.
__label__noRel	By 2 weeks post-treatment, the venlafaxine group experienced significant increases in hot flashes, whereas hot flashes in the acupuncture group remained at low levels.	Both groups exhibited significant decreases in hot flashes, depressive symptoms, and other quality-of-life symptoms, including significant improvements in mental health from pre- to post-treatment.
__label__noRel	By 2 weeks post-treatment, the venlafaxine group experienced significant increases in hot flashes, whereas hot flashes in the acupuncture group remained at low levels.	These changes were similar in both groups, indicating that acupuncture was as effective as venlafaxine.
__label__noRel	By 2 weeks post-treatment, the venlafaxine group experienced significant increases in hot flashes, whereas hot flashes in the acupuncture group remained at low levels.	The venlafaxine group experienced 18 incidences of adverse effects (eg, nausea, dry mouth, dizziness, anxiety), whereas the acupuncture group experienced no negative adverse effects.
__label__noRel	By 2 weeks post-treatment, the venlafaxine group experienced significant increases in hot flashes, whereas hot flashes in the acupuncture group remained at low levels.	Acupuncture had the additional benefit of increased sex drive in some women, and most reported an improvement in their energy, clarity of thought, and sense of well-being.
__label__Support	By 2 weeks post-treatment, the venlafaxine group experienced significant increases in hot flashes, whereas hot flashes in the acupuncture group remained at low levels.	Acupuncture appears to be equivalent to drug therapy in these patients.
__label__noRel	By 2 weeks post-treatment, the venlafaxine group experienced significant increases in hot flashes, whereas hot flashes in the acupuncture group remained at low levels.	It is a safe, effective and durable treatment for vasomotor symptoms secondary to long-term antiestrogen hormone use in patients with breast cancer.
__label__noRel	The venlafaxine group experienced 18 incidences of adverse effects (eg, nausea, dry mouth, dizziness, anxiety), whereas the acupuncture group experienced no negative adverse effects.	Both groups exhibited significant decreases in hot flashes, depressive symptoms, and other quality-of-life symptoms, including significant improvements in mental health from pre- to post-treatment.
__label__noRel	The venlafaxine group experienced 18 incidences of adverse effects (eg, nausea, dry mouth, dizziness, anxiety), whereas the acupuncture group experienced no negative adverse effects.	These changes were similar in both groups, indicating that acupuncture was as effective as venlafaxine.
__label__noRel	The venlafaxine group experienced 18 incidences of adverse effects (eg, nausea, dry mouth, dizziness, anxiety), whereas the acupuncture group experienced no negative adverse effects.	By 2 weeks post-treatment, the venlafaxine group experienced significant increases in hot flashes, whereas hot flashes in the acupuncture group remained at low levels.
__label__noRel	The venlafaxine group experienced 18 incidences of adverse effects (eg, nausea, dry mouth, dizziness, anxiety), whereas the acupuncture group experienced no negative adverse effects.	Acupuncture had the additional benefit of increased sex drive in some women, and most reported an improvement in their energy, clarity of thought, and sense of well-being.
__label__noRel	The venlafaxine group experienced 18 incidences of adverse effects (eg, nausea, dry mouth, dizziness, anxiety), whereas the acupuncture group experienced no negative adverse effects.	Acupuncture appears to be equivalent to drug therapy in these patients.
__label__Support	The venlafaxine group experienced 18 incidences of adverse effects (eg, nausea, dry mouth, dizziness, anxiety), whereas the acupuncture group experienced no negative adverse effects.	It is a safe, effective and durable treatment for vasomotor symptoms secondary to long-term antiestrogen hormone use in patients with breast cancer.
__label__noRel	Acupuncture had the additional benefit of increased sex drive in some women, and most reported an improvement in their energy, clarity of thought, and sense of well-being.	Both groups exhibited significant decreases in hot flashes, depressive symptoms, and other quality-of-life symptoms, including significant improvements in mental health from pre- to post-treatment.
__label__noRel	Acupuncture had the additional benefit of increased sex drive in some women, and most reported an improvement in their energy, clarity of thought, and sense of well-being.	These changes were similar in both groups, indicating that acupuncture was as effective as venlafaxine.
__label__noRel	Acupuncture had the additional benefit of increased sex drive in some women, and most reported an improvement in their energy, clarity of thought, and sense of well-being.	By 2 weeks post-treatment, the venlafaxine group experienced significant increases in hot flashes, whereas hot flashes in the acupuncture group remained at low levels.
__label__noRel	Acupuncture had the additional benefit of increased sex drive in some women, and most reported an improvement in their energy, clarity of thought, and sense of well-being.	The venlafaxine group experienced 18 incidences of adverse effects (eg, nausea, dry mouth, dizziness, anxiety), whereas the acupuncture group experienced no negative adverse effects.
__label__noRel	Acupuncture had the additional benefit of increased sex drive in some women, and most reported an improvement in their energy, clarity of thought, and sense of well-being.	Acupuncture appears to be equivalent to drug therapy in these patients.
__label__noRel	Acupuncture had the additional benefit of increased sex drive in some women, and most reported an improvement in their energy, clarity of thought, and sense of well-being.	It is a safe, effective and durable treatment for vasomotor symptoms secondary to long-term antiestrogen hormone use in patients with breast cancer.
__label__noRel	Acupuncture appears to be equivalent to drug therapy in these patients.	Both groups exhibited significant decreases in hot flashes, depressive symptoms, and other quality-of-life symptoms, including significant improvements in mental health from pre- to post-treatment.
__label__noRel	Acupuncture appears to be equivalent to drug therapy in these patients.	These changes were similar in both groups, indicating that acupuncture was as effective as venlafaxine.
__label__noRel	Acupuncture appears to be equivalent to drug therapy in these patients.	By 2 weeks post-treatment, the venlafaxine group experienced significant increases in hot flashes, whereas hot flashes in the acupuncture group remained at low levels.
__label__noRel	Acupuncture appears to be equivalent to drug therapy in these patients.	The venlafaxine group experienced 18 incidences of adverse effects (eg, nausea, dry mouth, dizziness, anxiety), whereas the acupuncture group experienced no negative adverse effects.
__label__noRel	Acupuncture appears to be equivalent to drug therapy in these patients.	Acupuncture had the additional benefit of increased sex drive in some women, and most reported an improvement in their energy, clarity of thought, and sense of well-being.
__label__Support	Acupuncture appears to be equivalent to drug therapy in these patients.	It is a safe, effective and durable treatment for vasomotor symptoms secondary to long-term antiestrogen hormone use in patients with breast cancer.
__label__noRel	It is a safe, effective and durable treatment for vasomotor symptoms secondary to long-term antiestrogen hormone use in patients with breast cancer.	Both groups exhibited significant decreases in hot flashes, depressive symptoms, and other quality-of-life symptoms, including significant improvements in mental health from pre- to post-treatment.
__label__noRel	It is a safe, effective and durable treatment for vasomotor symptoms secondary to long-term antiestrogen hormone use in patients with breast cancer.	These changes were similar in both groups, indicating that acupuncture was as effective as venlafaxine.
__label__noRel	It is a safe, effective and durable treatment for vasomotor symptoms secondary to long-term antiestrogen hormone use in patients with breast cancer.	By 2 weeks post-treatment, the venlafaxine group experienced significant increases in hot flashes, whereas hot flashes in the acupuncture group remained at low levels.
__label__noRel	It is a safe, effective and durable treatment for vasomotor symptoms secondary to long-term antiestrogen hormone use in patients with breast cancer.	The venlafaxine group experienced 18 incidences of adverse effects (eg, nausea, dry mouth, dizziness, anxiety), whereas the acupuncture group experienced no negative adverse effects.
__label__noRel	It is a safe, effective and durable treatment for vasomotor symptoms secondary to long-term antiestrogen hormone use in patients with breast cancer.	Acupuncture had the additional benefit of increased sex drive in some women, and most reported an improvement in their energy, clarity of thought, and sense of well-being.
__label__noRel	It is a safe, effective and durable treatment for vasomotor symptoms secondary to long-term antiestrogen hormone use in patients with breast cancer.	Acupuncture appears to be equivalent to drug therapy in these patients.
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)	Despite slow initial symptom improvement,
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.
__label__Support	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)	Because stent placement was associated with better short-term outcomes,
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)	this treatment is preferable for patients expected to live less than 2 months.
__label__noRel	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)
__label__noRel	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.
__label__noRel	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).
__label__noRel	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.
__label__noRel	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).
__label__noRel	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).	Despite slow initial symptom improvement,
__label__Support	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.
__label__noRel	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).	Because stent placement was associated with better short-term outcomes,
__label__noRel	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).	this treatment is preferable for patients expected to live less than 2 months.
__label__noRel	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)
__label__noRel	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).
__label__noRel	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).
__label__noRel	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.
__label__noRel	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).
__label__noRel	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.	Despite slow initial symptom improvement,
__label__Support	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.
__label__noRel	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.	Because stent placement was associated with better short-term outcomes,
__label__noRel	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.	this treatment is preferable for patients expected to live less than 2 months.
__label__noRel	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)
__label__noRel	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).
__label__noRel	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.
__label__noRel	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.
__label__noRel	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).
__label__noRel	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).	Despite slow initial symptom improvement,
__label__Support	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.
__label__noRel	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).	Because stent placement was associated with better short-term outcomes,
__label__noRel	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).	this treatment is preferable for patients expected to live less than 2 months.
__label__noRel	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)
__label__noRel	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).
__label__noRel	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.
__label__noRel	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).
__label__noRel	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).
__label__noRel	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.	Despite slow initial symptom improvement,
__label__Support	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.
__label__noRel	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.	Because stent placement was associated with better short-term outcomes,
__label__noRel	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.	this treatment is preferable for patients expected to live less than 2 months.
__label__noRel	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)
__label__noRel	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).
__label__noRel	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.
__label__noRel	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).
__label__noRel	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.
__label__noRel	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).	Despite slow initial symptom improvement,
__label__Support	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.
__label__noRel	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).	Because stent placement was associated with better short-term outcomes,
__label__noRel	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).	this treatment is preferable for patients expected to live less than 2 months.
__label__noRel	Despite slow initial symptom improvement,	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)
__label__noRel	Despite slow initial symptom improvement,	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).
__label__noRel	Despite slow initial symptom improvement,	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.
__label__noRel	Despite slow initial symptom improvement,	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).
__label__noRel	Despite slow initial symptom improvement,	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.
__label__noRel	Despite slow initial symptom improvement,	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).
__label__Attack	Despite slow initial symptom improvement,	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.
__label__noRel	Despite slow initial symptom improvement,	Because stent placement was associated with better short-term outcomes,
__label__noRel	Despite slow initial symptom improvement,	this treatment is preferable for patients expected to live less than 2 months.
__label__noRel	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)
__label__noRel	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).
__label__noRel	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.
__label__noRel	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).
__label__noRel	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.
__label__noRel	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).
__label__noRel	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.	Despite slow initial symptom improvement,
__label__noRel	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.	Because stent placement was associated with better short-term outcomes,
__label__noRel	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.	this treatment is preferable for patients expected to live less than 2 months.
__label__noRel	Because stent placement was associated with better short-term outcomes,	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)
__label__noRel	Because stent placement was associated with better short-term outcomes,	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).
__label__noRel	Because stent placement was associated with better short-term outcomes,	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.
__label__noRel	Because stent placement was associated with better short-term outcomes,	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).
__label__noRel	Because stent placement was associated with better short-term outcomes,	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.
__label__noRel	Because stent placement was associated with better short-term outcomes,	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).
__label__noRel	Because stent placement was associated with better short-term outcomes,	Despite slow initial symptom improvement,
__label__noRel	Because stent placement was associated with better short-term outcomes,	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.
__label__Support	Because stent placement was associated with better short-term outcomes,	this treatment is preferable for patients expected to live less than 2 months.
__label__noRel	this treatment is preferable for patients expected to live less than 2 months.	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)
__label__noRel	this treatment is preferable for patients expected to live less than 2 months.	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).
__label__noRel	this treatment is preferable for patients expected to live less than 2 months.	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.
__label__noRel	this treatment is preferable for patients expected to live less than 2 months.	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).
__label__noRel	this treatment is preferable for patients expected to live less than 2 months.	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.
__label__noRel	this treatment is preferable for patients expected to live less than 2 months.	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).
__label__noRel	this treatment is preferable for patients expected to live less than 2 months.	Despite slow initial symptom improvement,
__label__noRel	this treatment is preferable for patients expected to live less than 2 months.	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.
__label__noRel	this treatment is preferable for patients expected to live less than 2 months.	Because stent placement was associated with better short-term outcomes,
__label__noRel	Hot flashes are a significant problem for many breast cancer survivors.	Hot flashes can cause discomfort, disrupted sleep, anxiety, and decreased quality of life.
__label__noRel	Hot flashes are a significant problem for many breast cancer survivors.	By the end of the treatment period, hot flash scores (frequency x average severity) decreased 68% from baseline to end point in the hypnosis arm (P < .001).
__label__noRel	Hot flashes are a significant problem for many breast cancer survivors.	Significant improvements in self-reported anxiety, depression, interference of hot flashes on daily activities, and sleep were observed for patients who received the hypnosis intervention (P < .005) in comparison to the no treatment control group.
__label__noRel	Hot flashes are a significant problem for many breast cancer survivors.	Hypnosis appears to reduce perceived hot flashes in breast cancer survivors and may have additional benefits such as reduced anxiety and depression, and improved sleep.
__label__noRel	Hot flashes can cause discomfort, disrupted sleep, anxiety, and decreased quality of life.	Hot flashes are a significant problem for many breast cancer survivors.
__label__noRel	Hot flashes can cause discomfort, disrupted sleep, anxiety, and decreased quality of life.	By the end of the treatment period, hot flash scores (frequency x average severity) decreased 68% from baseline to end point in the hypnosis arm (P < .001).
__label__noRel	Hot flashes can cause discomfort, disrupted sleep, anxiety, and decreased quality of life.	Significant improvements in self-reported anxiety, depression, interference of hot flashes on daily activities, and sleep were observed for patients who received the hypnosis intervention (P < .005) in comparison to the no treatment control group.
__label__noRel	Hot flashes can cause discomfort, disrupted sleep, anxiety, and decreased quality of life.	Hypnosis appears to reduce perceived hot flashes in breast cancer survivors and may have additional benefits such as reduced anxiety and depression, and improved sleep.
__label__noRel	By the end of the treatment period, hot flash scores (frequency x average severity) decreased 68% from baseline to end point in the hypnosis arm (P < .001).	Hot flashes are a significant problem for many breast cancer survivors.
__label__noRel	By the end of the treatment period, hot flash scores (frequency x average severity) decreased 68% from baseline to end point in the hypnosis arm (P < .001).	Hot flashes can cause discomfort, disrupted sleep, anxiety, and decreased quality of life.
__label__noRel	By the end of the treatment period, hot flash scores (frequency x average severity) decreased 68% from baseline to end point in the hypnosis arm (P < .001).	Significant improvements in self-reported anxiety, depression, interference of hot flashes on daily activities, and sleep were observed for patients who received the hypnosis intervention (P < .005) in comparison to the no treatment control group.
__label__Support	By the end of the treatment period, hot flash scores (frequency x average severity) decreased 68% from baseline to end point in the hypnosis arm (P < .001).	Hypnosis appears to reduce perceived hot flashes in breast cancer survivors and may have additional benefits such as reduced anxiety and depression, and improved sleep.
__label__noRel	Significant improvements in self-reported anxiety, depression, interference of hot flashes on daily activities, and sleep were observed for patients who received the hypnosis intervention (P < .005) in comparison to the no treatment control group.	Hot flashes are a significant problem for many breast cancer survivors.
__label__noRel	Significant improvements in self-reported anxiety, depression, interference of hot flashes on daily activities, and sleep were observed for patients who received the hypnosis intervention (P < .005) in comparison to the no treatment control group.	Hot flashes can cause discomfort, disrupted sleep, anxiety, and decreased quality of life.
__label__noRel	Significant improvements in self-reported anxiety, depression, interference of hot flashes on daily activities, and sleep were observed for patients who received the hypnosis intervention (P < .005) in comparison to the no treatment control group.	By the end of the treatment period, hot flash scores (frequency x average severity) decreased 68% from baseline to end point in the hypnosis arm (P < .001).
__label__Support	Significant improvements in self-reported anxiety, depression, interference of hot flashes on daily activities, and sleep were observed for patients who received the hypnosis intervention (P < .005) in comparison to the no treatment control group.	Hypnosis appears to reduce perceived hot flashes in breast cancer survivors and may have additional benefits such as reduced anxiety and depression, and improved sleep.
__label__noRel	Hypnosis appears to reduce perceived hot flashes in breast cancer survivors and may have additional benefits such as reduced anxiety and depression, and improved sleep.	Hot flashes are a significant problem for many breast cancer survivors.
__label__noRel	Hypnosis appears to reduce perceived hot flashes in breast cancer survivors and may have additional benefits such as reduced anxiety and depression, and improved sleep.	Hot flashes can cause discomfort, disrupted sleep, anxiety, and decreased quality of life.
__label__noRel	Hypnosis appears to reduce perceived hot flashes in breast cancer survivors and may have additional benefits such as reduced anxiety and depression, and improved sleep.	By the end of the treatment period, hot flash scores (frequency x average severity) decreased 68% from baseline to end point in the hypnosis arm (P < .001).
__label__noRel	Hypnosis appears to reduce perceived hot flashes in breast cancer survivors and may have additional benefits such as reduced anxiety and depression, and improved sleep.	Significant improvements in self-reported anxiety, depression, interference of hot flashes on daily activities, and sleep were observed for patients who received the hypnosis intervention (P < .005) in comparison to the no treatment control group.
__label__noRel	The operation time was significantly longer, and the leakage rate was higher in the transthoracic group (Student's t-test and Fischer's exact test, respectively).	intraoperative blood loss and postoperative hospital stay were not significantly different (Student t-test).
__label__noRel	The operation time was significantly longer, and the leakage rate was higher in the transthoracic group (Student's t-test and Fischer's exact test, respectively).	the Kaplan-Meier survival curves of these two groups were not significantly different by log-rank test (p=0.286).
__label__noRel	The operation time was significantly longer, and the leakage rate was higher in the transthoracic group (Student's t-test and Fischer's exact test, respectively).	The score on the quality of life of transhiatal patients was significantly higher than that of transthoracic patients in the third, sixth and twelfth month.
__label__noRel	The operation time was significantly longer, and the leakage rate was higher in the transthoracic group (Student's t-test and Fischer's exact test, respectively).	Transhiatal esophagectomy is a safe and fast procedure.
__label__noRel	The operation time was significantly longer, and the leakage rate was higher in the transthoracic group (Student's t-test and Fischer's exact test, respectively).	The survival was similar to that of transthoracic approach.
__label__Support	The operation time was significantly longer, and the leakage rate was higher in the transthoracic group (Student's t-test and Fischer's exact test, respectively).	Its leakage rate was lower and quality of life was better.
__label__noRel	intraoperative blood loss and postoperative hospital stay were not significantly different (Student t-test).	The operation time was significantly longer, and the leakage rate was higher in the transthoracic group (Student's t-test and Fischer's exact test, respectively).
__label__noRel	intraoperative blood loss and postoperative hospital stay were not significantly different (Student t-test).	the Kaplan-Meier survival curves of these two groups were not significantly different by log-rank test (p=0.286).
__label__noRel	intraoperative blood loss and postoperative hospital stay were not significantly different (Student t-test).	The score on the quality of life of transhiatal patients was significantly higher than that of transthoracic patients in the third, sixth and twelfth month.
__label__noRel	intraoperative blood loss and postoperative hospital stay were not significantly different (Student t-test).	Transhiatal esophagectomy is a safe and fast procedure.
__label__noRel	intraoperative blood loss and postoperative hospital stay were not significantly different (Student t-test).	The survival was similar to that of transthoracic approach.
__label__noRel	intraoperative blood loss and postoperative hospital stay were not significantly different (Student t-test).	Its leakage rate was lower and quality of life was better.
__label__noRel	the Kaplan-Meier survival curves of these two groups were not significantly different by log-rank test (p=0.286).	The operation time was significantly longer, and the leakage rate was higher in the transthoracic group (Student's t-test and Fischer's exact test, respectively).
__label__noRel	the Kaplan-Meier survival curves of these two groups were not significantly different by log-rank test (p=0.286).	intraoperative blood loss and postoperative hospital stay were not significantly different (Student t-test).
__label__noRel	the Kaplan-Meier survival curves of these two groups were not significantly different by log-rank test (p=0.286).	The score on the quality of life of transhiatal patients was significantly higher than that of transthoracic patients in the third, sixth and twelfth month.
__label__noRel	the Kaplan-Meier survival curves of these two groups were not significantly different by log-rank test (p=0.286).	Transhiatal esophagectomy is a safe and fast procedure.
__label__Support	the Kaplan-Meier survival curves of these two groups were not significantly different by log-rank test (p=0.286).	The survival was similar to that of transthoracic approach.
__label__noRel	the Kaplan-Meier survival curves of these two groups were not significantly different by log-rank test (p=0.286).	Its leakage rate was lower and quality of life was better.
__label__noRel	The score on the quality of life of transhiatal patients was significantly higher than that of transthoracic patients in the third, sixth and twelfth month.	The operation time was significantly longer, and the leakage rate was higher in the transthoracic group (Student's t-test and Fischer's exact test, respectively).
__label__noRel	The score on the quality of life of transhiatal patients was significantly higher than that of transthoracic patients in the third, sixth and twelfth month.	intraoperative blood loss and postoperative hospital stay were not significantly different (Student t-test).
__label__noRel	The score on the quality of life of transhiatal patients was significantly higher than that of transthoracic patients in the third, sixth and twelfth month.	the Kaplan-Meier survival curves of these two groups were not significantly different by log-rank test (p=0.286).
__label__noRel	The score on the quality of life of transhiatal patients was significantly higher than that of transthoracic patients in the third, sixth and twelfth month.	Transhiatal esophagectomy is a safe and fast procedure.
__label__noRel	The score on the quality of life of transhiatal patients was significantly higher than that of transthoracic patients in the third, sixth and twelfth month.	The survival was similar to that of transthoracic approach.
__label__Support	The score on the quality of life of transhiatal patients was significantly higher than that of transthoracic patients in the third, sixth and twelfth month.	Its leakage rate was lower and quality of life was better.
__label__noRel	Transhiatal esophagectomy is a safe and fast procedure.	The operation time was significantly longer, and the leakage rate was higher in the transthoracic group (Student's t-test and Fischer's exact test, respectively).
__label__noRel	Transhiatal esophagectomy is a safe and fast procedure.	intraoperative blood loss and postoperative hospital stay were not significantly different (Student t-test).
__label__noRel	Transhiatal esophagectomy is a safe and fast procedure.	the Kaplan-Meier survival curves of these two groups were not significantly different by log-rank test (p=0.286).
__label__noRel	Transhiatal esophagectomy is a safe and fast procedure.	The score on the quality of life of transhiatal patients was significantly higher than that of transthoracic patients in the third, sixth and twelfth month.
__label__noRel	Transhiatal esophagectomy is a safe and fast procedure.	The survival was similar to that of transthoracic approach.
__label__noRel	Transhiatal esophagectomy is a safe and fast procedure.	Its leakage rate was lower and quality of life was better.
__label__noRel	The survival was similar to that of transthoracic approach.	The operation time was significantly longer, and the leakage rate was higher in the transthoracic group (Student's t-test and Fischer's exact test, respectively).
__label__noRel	The survival was similar to that of transthoracic approach.	intraoperative blood loss and postoperative hospital stay were not significantly different (Student t-test).
__label__noRel	The survival was similar to that of transthoracic approach.	the Kaplan-Meier survival curves of these two groups were not significantly different by log-rank test (p=0.286).
__label__noRel	The survival was similar to that of transthoracic approach.	The score on the quality of life of transhiatal patients was significantly higher than that of transthoracic patients in the third, sixth and twelfth month.
__label__Support	The survival was similar to that of transthoracic approach.	Transhiatal esophagectomy is a safe and fast procedure.
__label__noRel	The survival was similar to that of transthoracic approach.	Its leakage rate was lower and quality of life was better.
__label__noRel	Its leakage rate was lower and quality of life was better.	The operation time was significantly longer, and the leakage rate was higher in the transthoracic group (Student's t-test and Fischer's exact test, respectively).
__label__noRel	Its leakage rate was lower and quality of life was better.	intraoperative blood loss and postoperative hospital stay were not significantly different (Student t-test).
__label__noRel	Its leakage rate was lower and quality of life was better.	the Kaplan-Meier survival curves of these two groups were not significantly different by log-rank test (p=0.286).
__label__noRel	Its leakage rate was lower and quality of life was better.	The score on the quality of life of transhiatal patients was significantly higher than that of transthoracic patients in the third, sixth and twelfth month.
__label__Support	Its leakage rate was lower and quality of life was better.	Transhiatal esophagectomy is a safe and fast procedure.
__label__noRel	Its leakage rate was lower and quality of life was better.	The survival was similar to that of transthoracic approach.
__label__noRel	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).
__label__noRel	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).
__label__noRel	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).
__label__noRel	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.
__label__noRel	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).	Lower scores were associated with the combination therapy.
__label__Support	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.
__label__noRel	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.
__label__noRel	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).	Treatment, particularly the combination therapy, was associated with a decrease in QOL.
__label__noRel	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).
__label__noRel	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).
__label__noRel	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).
__label__noRel	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.
__label__noRel	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).	Lower scores were associated with the combination therapy.
__label__noRel	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.
__label__Support	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.
__label__noRel	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).	Treatment, particularly the combination therapy, was associated with a decrease in QOL.
__label__noRel	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).
__label__noRel	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).
__label__noRel	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).
__label__noRel	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.
__label__noRel	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).	Lower scores were associated with the combination therapy.
__label__noRel	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.
__label__noRel	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.
__label__noRel	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).	Treatment, particularly the combination therapy, was associated with a decrease in QOL.
__label__noRel	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).
__label__noRel	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).
__label__noRel	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).
__label__noRel	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.
__label__noRel	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).	Lower scores were associated with the combination therapy.
__label__Support	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.
__label__noRel	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.
__label__noRel	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).	Treatment, particularly the combination therapy, was associated with a decrease in QOL.
__label__noRel	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).
__label__noRel	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).
__label__noRel	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).
__label__noRel	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).
__label__noRel	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.	Lower scores were associated with the combination therapy.
__label__noRel	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.
__label__noRel	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.
__label__Support	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.	Treatment, particularly the combination therapy, was associated with a decrease in QOL.
__label__noRel	Lower scores were associated with the combination therapy.	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).
__label__noRel	Lower scores were associated with the combination therapy.	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).
__label__noRel	Lower scores were associated with the combination therapy.	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).
__label__noRel	Lower scores were associated with the combination therapy.	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).
__label__noRel	Lower scores were associated with the combination therapy.	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.
__label__noRel	Lower scores were associated with the combination therapy.	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.
__label__noRel	Lower scores were associated with the combination therapy.	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.
__label__noRel	Lower scores were associated with the combination therapy.	Treatment, particularly the combination therapy, was associated with a decrease in QOL.
__label__noRel	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).
__label__noRel	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).
__label__noRel	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).
__label__noRel	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).
__label__noRel	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.
__label__noRel	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.	Lower scores were associated with the combination therapy.
__label__noRel	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.
__label__noRel	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.	Treatment, particularly the combination therapy, was associated with a decrease in QOL.
__label__noRel	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).
__label__noRel	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).
__label__noRel	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).
__label__noRel	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).
__label__noRel	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.
__label__noRel	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.	Lower scores were associated with the combination therapy.
__label__noRel	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.
__label__noRel	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.	Treatment, particularly the combination therapy, was associated with a decrease in QOL.
__label__noRel	Treatment, particularly the combination therapy, was associated with a decrease in QOL.	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).
__label__noRel	Treatment, particularly the combination therapy, was associated with a decrease in QOL.	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).
__label__noRel	Treatment, particularly the combination therapy, was associated with a decrease in QOL.	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).
__label__noRel	Treatment, particularly the combination therapy, was associated with a decrease in QOL.	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).
__label__noRel	Treatment, particularly the combination therapy, was associated with a decrease in QOL.	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.
__label__noRel	Treatment, particularly the combination therapy, was associated with a decrease in QOL.	Lower scores were associated with the combination therapy.
__label__noRel	Treatment, particularly the combination therapy, was associated with a decrease in QOL.	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.
__label__noRel	Treatment, particularly the combination therapy, was associated with a decrease in QOL.	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.
__label__noRel	The average increase in arm volume was 2.8% in the SNBM group and 4.2% in the RAC group (P = 0.002).	Patients in the SNBM group gave lower ratings for arm swelling (P < 0.001), symptoms (P < 0.001), and dysfunctions (P = 0.02), but not disabilities (P = 0.5).
__label__noRel	The average increase in arm volume was 2.8% in the SNBM group and 4.2% in the RAC group (P = 0.002).	Sentinel nodes were found in 95% of the SNBM group (29% positive) and 93% of the RAC group (25% positive).
__label__Support	The average increase in arm volume was 2.8% in the SNBM group and 4.2% in the RAC group (P = 0.002).	SNBM was successfully undertaken in a wide range of surgical centers and caused significantly less morbidity than RAC.
__label__noRel	Patients in the SNBM group gave lower ratings for arm swelling (P < 0.001), symptoms (P < 0.001), and dysfunctions (P = 0.02), but not disabilities (P = 0.5).	The average increase in arm volume was 2.8% in the SNBM group and 4.2% in the RAC group (P = 0.002).
__label__noRel	Patients in the SNBM group gave lower ratings for arm swelling (P < 0.001), symptoms (P < 0.001), and dysfunctions (P = 0.02), but not disabilities (P = 0.5).	Sentinel nodes were found in 95% of the SNBM group (29% positive) and 93% of the RAC group (25% positive).
__label__Support	Patients in the SNBM group gave lower ratings for arm swelling (P < 0.001), symptoms (P < 0.001), and dysfunctions (P = 0.02), but not disabilities (P = 0.5).	SNBM was successfully undertaken in a wide range of surgical centers and caused significantly less morbidity than RAC.
__label__noRel	Sentinel nodes were found in 95% of the SNBM group (29% positive) and 93% of the RAC group (25% positive).	The average increase in arm volume was 2.8% in the SNBM group and 4.2% in the RAC group (P = 0.002).
__label__noRel	Sentinel nodes were found in 95% of the SNBM group (29% positive) and 93% of the RAC group (25% positive).	Patients in the SNBM group gave lower ratings for arm swelling (P < 0.001), symptoms (P < 0.001), and dysfunctions (P = 0.02), but not disabilities (P = 0.5).
__label__Support	Sentinel nodes were found in 95% of the SNBM group (29% positive) and 93% of the RAC group (25% positive).	SNBM was successfully undertaken in a wide range of surgical centers and caused significantly less morbidity than RAC.
__label__noRel	SNBM was successfully undertaken in a wide range of surgical centers and caused significantly less morbidity than RAC.	The average increase in arm volume was 2.8% in the SNBM group and 4.2% in the RAC group (P = 0.002).
__label__noRel	SNBM was successfully undertaken in a wide range of surgical centers and caused significantly less morbidity than RAC.	Patients in the SNBM group gave lower ratings for arm swelling (P < 0.001), symptoms (P < 0.001), and dysfunctions (P = 0.02), but not disabilities (P = 0.5).
__label__noRel	SNBM was successfully undertaken in a wide range of surgical centers and caused significantly less morbidity than RAC.	Sentinel nodes were found in 95% of the SNBM group (29% positive) and 93% of the RAC group (25% positive).
__label__noRel	Overall objective response (OR) rates were higher in patients treated with EXE than in those treated with MA (15.0% v 12.4%);	a similar trend was noted in patients with visceral metastases (13.5% v 10.5%).
__label__noRel	Overall objective response (OR) rates were higher in patients treated with EXE than in those treated with MA (15.0% v 12.4%);	Median survival time was significantly longer with EXE (median not reached) than with MA (123.4 weeks; P =.039), as were the median duration of overall success (OR or stable disease > or = 24 weeks; 60.1 v 49.1 weeks; P =.025), time to tumor progression (20.3 v 16.6 weeks; P =.037), and time to treatment failure (16.3 v 15.7 weeks; P =.042).
__label__noRel	Overall objective response (OR) rates were higher in patients treated with EXE than in those treated with MA (15.0% v 12.4%);	Compared with MA, there were similar or greater improvements in pain, TRSS, and QOL with EXE.
__label__noRel	Overall objective response (OR) rates were higher in patients treated with EXE than in those treated with MA (15.0% v 12.4%);	Both drugs were well tolerated.
__label__noRel	Overall objective response (OR) rates were higher in patients treated with EXE than in those treated with MA (15.0% v 12.4%);	Grade 3 or 4 weight changes were more common with MA (17.1% v 7.6%; P =.001).
__label__Support	Overall objective response (OR) rates were higher in patients treated with EXE than in those treated with MA (15.0% v 12.4%);	EXE prolongs survival time, time to tumor progression, and time to treatment failure compared with MA and offers a well-tolerated treatment option for postmenopausal women with progressive advanced breast cancer who experienced failure of tamoxifen.
__label__noRel	a similar trend was noted in patients with visceral metastases (13.5% v 10.5%).	Overall objective response (OR) rates were higher in patients treated with EXE than in those treated with MA (15.0% v 12.4%);
__label__noRel	a similar trend was noted in patients with visceral metastases (13.5% v 10.5%).	Median survival time was significantly longer with EXE (median not reached) than with MA (123.4 weeks; P =.039), as were the median duration of overall success (OR or stable disease > or = 24 weeks; 60.1 v 49.1 weeks; P =.025), time to tumor progression (20.3 v 16.6 weeks; P =.037), and time to treatment failure (16.3 v 15.7 weeks; P =.042).
__label__noRel	a similar trend was noted in patients with visceral metastases (13.5% v 10.5%).	Compared with MA, there were similar or greater improvements in pain, TRSS, and QOL with EXE.
__label__noRel	a similar trend was noted in patients with visceral metastases (13.5% v 10.5%).	Both drugs were well tolerated.
__label__noRel	a similar trend was noted in patients with visceral metastases (13.5% v 10.5%).	Grade 3 or 4 weight changes were more common with MA (17.1% v 7.6%; P =.001).
__label__noRel	a similar trend was noted in patients with visceral metastases (13.5% v 10.5%).	EXE prolongs survival time, time to tumor progression, and time to treatment failure compared with MA and offers a well-tolerated treatment option for postmenopausal women with progressive advanced breast cancer who experienced failure of tamoxifen.
__label__noRel	Median survival time was significantly longer with EXE (median not reached) than with MA (123.4 weeks; P =.039), as were the median duration of overall success (OR or stable disease > or = 24 weeks; 60.1 v 49.1 weeks; P =.025), time to tumor progression (20.3 v 16.6 weeks; P =.037), and time to treatment failure (16.3 v 15.7 weeks; P =.042).	Overall objective response (OR) rates were higher in patients treated with EXE than in those treated with MA (15.0% v 12.4%);
__label__noRel	Median survival time was significantly longer with EXE (median not reached) than with MA (123.4 weeks; P =.039), as were the median duration of overall success (OR or stable disease > or = 24 weeks; 60.1 v 49.1 weeks; P =.025), time to tumor progression (20.3 v 16.6 weeks; P =.037), and time to treatment failure (16.3 v 15.7 weeks; P =.042).	a similar trend was noted in patients with visceral metastases (13.5% v 10.5%).
__label__noRel	Median survival time was significantly longer with EXE (median not reached) than with MA (123.4 weeks; P =.039), as were the median duration of overall success (OR or stable disease > or = 24 weeks; 60.1 v 49.1 weeks; P =.025), time to tumor progression (20.3 v 16.6 weeks; P =.037), and time to treatment failure (16.3 v 15.7 weeks; P =.042).	Compared with MA, there were similar or greater improvements in pain, TRSS, and QOL with EXE.
__label__noRel	Median survival time was significantly longer with EXE (median not reached) than with MA (123.4 weeks; P =.039), as were the median duration of overall success (OR or stable disease > or = 24 weeks; 60.1 v 49.1 weeks; P =.025), time to tumor progression (20.3 v 16.6 weeks; P =.037), and time to treatment failure (16.3 v 15.7 weeks; P =.042).	Both drugs were well tolerated.
__label__noRel	Median survival time was significantly longer with EXE (median not reached) than with MA (123.4 weeks; P =.039), as were the median duration of overall success (OR or stable disease > or = 24 weeks; 60.1 v 49.1 weeks; P =.025), time to tumor progression (20.3 v 16.6 weeks; P =.037), and time to treatment failure (16.3 v 15.7 weeks; P =.042).	Grade 3 or 4 weight changes were more common with MA (17.1% v 7.6%; P =.001).
__label__Support	Median survival time was significantly longer with EXE (median not reached) than with MA (123.4 weeks; P =.039), as were the median duration of overall success (OR or stable disease > or = 24 weeks; 60.1 v 49.1 weeks; P =.025), time to tumor progression (20.3 v 16.6 weeks; P =.037), and time to treatment failure (16.3 v 15.7 weeks; P =.042).	EXE prolongs survival time, time to tumor progression, and time to treatment failure compared with MA and offers a well-tolerated treatment option for postmenopausal women with progressive advanced breast cancer who experienced failure of tamoxifen.
__label__noRel	Compared with MA, there were similar or greater improvements in pain, TRSS, and QOL with EXE.	Overall objective response (OR) rates were higher in patients treated with EXE than in those treated with MA (15.0% v 12.4%);
__label__noRel	Compared with MA, there were similar or greater improvements in pain, TRSS, and QOL with EXE.	a similar trend was noted in patients with visceral metastases (13.5% v 10.5%).
__label__noRel	Compared with MA, there were similar or greater improvements in pain, TRSS, and QOL with EXE.	Median survival time was significantly longer with EXE (median not reached) than with MA (123.4 weeks; P =.039), as were the median duration of overall success (OR or stable disease > or = 24 weeks; 60.1 v 49.1 weeks; P =.025), time to tumor progression (20.3 v 16.6 weeks; P =.037), and time to treatment failure (16.3 v 15.7 weeks; P =.042).
__label__noRel	Compared with MA, there were similar or greater improvements in pain, TRSS, and QOL with EXE.	Both drugs were well tolerated.
__label__noRel	Compared with MA, there were similar or greater improvements in pain, TRSS, and QOL with EXE.	Grade 3 or 4 weight changes were more common with MA (17.1% v 7.6%; P =.001).
__label__Support	Compared with MA, there were similar or greater improvements in pain, TRSS, and QOL with EXE.	EXE prolongs survival time, time to tumor progression, and time to treatment failure compared with MA and offers a well-tolerated treatment option for postmenopausal women with progressive advanced breast cancer who experienced failure of tamoxifen.
__label__noRel	Both drugs were well tolerated.	Overall objective response (OR) rates were higher in patients treated with EXE than in those treated with MA (15.0% v 12.4%);
__label__noRel	Both drugs were well tolerated.	a similar trend was noted in patients with visceral metastases (13.5% v 10.5%).
__label__noRel	Both drugs were well tolerated.	Median survival time was significantly longer with EXE (median not reached) than with MA (123.4 weeks; P =.039), as were the median duration of overall success (OR or stable disease > or = 24 weeks; 60.1 v 49.1 weeks; P =.025), time to tumor progression (20.3 v 16.6 weeks; P =.037), and time to treatment failure (16.3 v 15.7 weeks; P =.042).
__label__noRel	Both drugs were well tolerated.	Compared with MA, there were similar or greater improvements in pain, TRSS, and QOL with EXE.
__label__noRel	Both drugs were well tolerated.	Grade 3 or 4 weight changes were more common with MA (17.1% v 7.6%; P =.001).
__label__Support	Both drugs were well tolerated.	EXE prolongs survival time, time to tumor progression, and time to treatment failure compared with MA and offers a well-tolerated treatment option for postmenopausal women with progressive advanced breast cancer who experienced failure of tamoxifen.
__label__noRel	Grade 3 or 4 weight changes were more common with MA (17.1% v 7.6%; P =.001).	Overall objective response (OR) rates were higher in patients treated with EXE than in those treated with MA (15.0% v 12.4%);
__label__noRel	Grade 3 or 4 weight changes were more common with MA (17.1% v 7.6%; P =.001).	a similar trend was noted in patients with visceral metastases (13.5% v 10.5%).
__label__noRel	Grade 3 or 4 weight changes were more common with MA (17.1% v 7.6%; P =.001).	Median survival time was significantly longer with EXE (median not reached) than with MA (123.4 weeks; P =.039), as were the median duration of overall success (OR or stable disease > or = 24 weeks; 60.1 v 49.1 weeks; P =.025), time to tumor progression (20.3 v 16.6 weeks; P =.037), and time to treatment failure (16.3 v 15.7 weeks; P =.042).
__label__noRel	Grade 3 or 4 weight changes were more common with MA (17.1% v 7.6%; P =.001).	Compared with MA, there were similar or greater improvements in pain, TRSS, and QOL with EXE.
__label__noRel	Grade 3 or 4 weight changes were more common with MA (17.1% v 7.6%; P =.001).	Both drugs were well tolerated.
__label__noRel	Grade 3 or 4 weight changes were more common with MA (17.1% v 7.6%; P =.001).	EXE prolongs survival time, time to tumor progression, and time to treatment failure compared with MA and offers a well-tolerated treatment option for postmenopausal women with progressive advanced breast cancer who experienced failure of tamoxifen.
__label__noRel	EXE prolongs survival time, time to tumor progression, and time to treatment failure compared with MA and offers a well-tolerated treatment option for postmenopausal women with progressive advanced breast cancer who experienced failure of tamoxifen.	Overall objective response (OR) rates were higher in patients treated with EXE than in those treated with MA (15.0% v 12.4%);
__label__noRel	EXE prolongs survival time, time to tumor progression, and time to treatment failure compared with MA and offers a well-tolerated treatment option for postmenopausal women with progressive advanced breast cancer who experienced failure of tamoxifen.	a similar trend was noted in patients with visceral metastases (13.5% v 10.5%).
__label__noRel	EXE prolongs survival time, time to tumor progression, and time to treatment failure compared with MA and offers a well-tolerated treatment option for postmenopausal women with progressive advanced breast cancer who experienced failure of tamoxifen.	Median survival time was significantly longer with EXE (median not reached) than with MA (123.4 weeks; P =.039), as were the median duration of overall success (OR or stable disease > or = 24 weeks; 60.1 v 49.1 weeks; P =.025), time to tumor progression (20.3 v 16.6 weeks; P =.037), and time to treatment failure (16.3 v 15.7 weeks; P =.042).
__label__noRel	EXE prolongs survival time, time to tumor progression, and time to treatment failure compared with MA and offers a well-tolerated treatment option for postmenopausal women with progressive advanced breast cancer who experienced failure of tamoxifen.	Compared with MA, there were similar or greater improvements in pain, TRSS, and QOL with EXE.
__label__noRel	EXE prolongs survival time, time to tumor progression, and time to treatment failure compared with MA and offers a well-tolerated treatment option for postmenopausal women with progressive advanced breast cancer who experienced failure of tamoxifen.	Both drugs were well tolerated.
__label__noRel	EXE prolongs survival time, time to tumor progression, and time to treatment failure compared with MA and offers a well-tolerated treatment option for postmenopausal women with progressive advanced breast cancer who experienced failure of tamoxifen.	Grade 3 or 4 weight changes were more common with MA (17.1% v 7.6%; P =.001).
__label__noRel	No differences in pain and symptom intensity were observed.	At the doses used, methadone was significantly less expensive (p<0.0001), while the use and costs of supportive drugs and other analgesics were similar in the three groups.
__label__noRel	No differences in pain and symptom intensity were observed.	No relevant differences in adverse effects were observed among the groups during either the titration phase and chronic treatment.
__label__Support	No differences in pain and symptom intensity were observed.	All the three opioids used as first-line therapy were effective, well tolerated, and required similar amounts of symptomatic drugs or co-analgesics.
__label__noRel	No differences in pain and symptom intensity were observed.	Opioid escalation index was significantly lower in patients receiving methadone (p<0.0001), although requiring up and down changes in doses.
__label__noRel	No differences in pain and symptom intensity were observed.	Methadone was significantly less expensive, but required more changes, up and down, of the doses, suggesting that dose titration of this drug requires major clinical expertise.
__label__noRel	At the doses used, methadone was significantly less expensive (p<0.0001), while the use and costs of supportive drugs and other analgesics were similar in the three groups.	No differences in pain and symptom intensity were observed.
__label__noRel	At the doses used, methadone was significantly less expensive (p<0.0001), while the use and costs of supportive drugs and other analgesics were similar in the three groups.	No relevant differences in adverse effects were observed among the groups during either the titration phase and chronic treatment.
__label__noRel	At the doses used, methadone was significantly less expensive (p<0.0001), while the use and costs of supportive drugs and other analgesics were similar in the three groups.	All the three opioids used as first-line therapy were effective, well tolerated, and required similar amounts of symptomatic drugs or co-analgesics.
__label__noRel	At the doses used, methadone was significantly less expensive (p<0.0001), while the use and costs of supportive drugs and other analgesics were similar in the three groups.	Opioid escalation index was significantly lower in patients receiving methadone (p<0.0001), although requiring up and down changes in doses.
__label__Support	At the doses used, methadone was significantly less expensive (p<0.0001), while the use and costs of supportive drugs and other analgesics were similar in the three groups.	Methadone was significantly less expensive, but required more changes, up and down, of the doses, suggesting that dose titration of this drug requires major clinical expertise.
__label__noRel	No relevant differences in adverse effects were observed among the groups during either the titration phase and chronic treatment.	No differences in pain and symptom intensity were observed.
__label__noRel	No relevant differences in adverse effects were observed among the groups during either the titration phase and chronic treatment.	At the doses used, methadone was significantly less expensive (p<0.0001), while the use and costs of supportive drugs and other analgesics were similar in the three groups.
__label__Support	No relevant differences in adverse effects were observed among the groups during either the titration phase and chronic treatment.	All the three opioids used as first-line therapy were effective, well tolerated, and required similar amounts of symptomatic drugs or co-analgesics.
__label__noRel	No relevant differences in adverse effects were observed among the groups during either the titration phase and chronic treatment.	Opioid escalation index was significantly lower in patients receiving methadone (p<0.0001), although requiring up and down changes in doses.
__label__noRel	No relevant differences in adverse effects were observed among the groups during either the titration phase and chronic treatment.	Methadone was significantly less expensive, but required more changes, up and down, of the doses, suggesting that dose titration of this drug requires major clinical expertise.
__label__noRel	All the three opioids used as first-line therapy were effective, well tolerated, and required similar amounts of symptomatic drugs or co-analgesics.	No differences in pain and symptom intensity were observed.
__label__noRel	All the three opioids used as first-line therapy were effective, well tolerated, and required similar amounts of symptomatic drugs or co-analgesics.	At the doses used, methadone was significantly less expensive (p<0.0001), while the use and costs of supportive drugs and other analgesics were similar in the three groups.
__label__noRel	All the three opioids used as first-line therapy were effective, well tolerated, and required similar amounts of symptomatic drugs or co-analgesics.	No relevant differences in adverse effects were observed among the groups during either the titration phase and chronic treatment.
__label__noRel	All the three opioids used as first-line therapy were effective, well tolerated, and required similar amounts of symptomatic drugs or co-analgesics.	Opioid escalation index was significantly lower in patients receiving methadone (p<0.0001), although requiring up and down changes in doses.
__label__noRel	All the three opioids used as first-line therapy were effective, well tolerated, and required similar amounts of symptomatic drugs or co-analgesics.	Methadone was significantly less expensive, but required more changes, up and down, of the doses, suggesting that dose titration of this drug requires major clinical expertise.
__label__noRel	Opioid escalation index was significantly lower in patients receiving methadone (p<0.0001), although requiring up and down changes in doses.	No differences in pain and symptom intensity were observed.
__label__noRel	Opioid escalation index was significantly lower in patients receiving methadone (p<0.0001), although requiring up and down changes in doses.	At the doses used, methadone was significantly less expensive (p<0.0001), while the use and costs of supportive drugs and other analgesics were similar in the three groups.
__label__noRel	Opioid escalation index was significantly lower in patients receiving methadone (p<0.0001), although requiring up and down changes in doses.	No relevant differences in adverse effects were observed among the groups during either the titration phase and chronic treatment.
__label__Support	Opioid escalation index was significantly lower in patients receiving methadone (p<0.0001), although requiring up and down changes in doses.	All the three opioids used as first-line therapy were effective, well tolerated, and required similar amounts of symptomatic drugs or co-analgesics.
__label__noRel	Opioid escalation index was significantly lower in patients receiving methadone (p<0.0001), although requiring up and down changes in doses.	Methadone was significantly less expensive, but required more changes, up and down, of the doses, suggesting that dose titration of this drug requires major clinical expertise.
__label__noRel	Methadone was significantly less expensive, but required more changes, up and down, of the doses, suggesting that dose titration of this drug requires major clinical expertise.	No differences in pain and symptom intensity were observed.
__label__noRel	Methadone was significantly less expensive, but required more changes, up and down, of the doses, suggesting that dose titration of this drug requires major clinical expertise.	At the doses used, methadone was significantly less expensive (p<0.0001), while the use and costs of supportive drugs and other analgesics were similar in the three groups.
__label__noRel	Methadone was significantly less expensive, but required more changes, up and down, of the doses, suggesting that dose titration of this drug requires major clinical expertise.	No relevant differences in adverse effects were observed among the groups during either the titration phase and chronic treatment.
__label__noRel	Methadone was significantly less expensive, but required more changes, up and down, of the doses, suggesting that dose titration of this drug requires major clinical expertise.	All the three opioids used as first-line therapy were effective, well tolerated, and required similar amounts of symptomatic drugs or co-analgesics.
__label__noRel	Methadone was significantly less expensive, but required more changes, up and down, of the doses, suggesting that dose titration of this drug requires major clinical expertise.	Opioid escalation index was significantly lower in patients receiving methadone (p<0.0001), although requiring up and down changes in doses.
__label__noRel	High self-assessed quality of life was reported by 62 (35%) of 179 men allocated radical prostatectomy, 55 (34%) of 160 men assigned to watchful waiting, and 93 (45%) of 208 men in the control group.	Anxiety was higher in the SPCG-4 groups (77 [43%] of 178 and 69 [43%] of 161 men) than in the control group (68 [33%] of 208 men; relative risk 142, 95% CI 107-188).
__label__noRel	High self-assessed quality of life was reported by 62 (35%) of 179 men allocated radical prostatectomy, 55 (34%) of 160 men assigned to watchful waiting, and 93 (45%) of 208 men in the control group.	Prevalence of erectile dysfunction was 84% (146 of 173 men) in the radical prostatectomy group, 80% (122 of 153) in the watchful-waiting group, and 46% (95 of 208) in the control group and prevalence of urinary leakage was 41% (71 of 173), 11% (18 of 164), and 3% (six of 209), respectively.
__label__noRel	High self-assessed quality of life was reported by 62 (35%) of 179 men allocated radical prostatectomy, 55 (34%) of 160 men assigned to watchful waiting, and 93 (45%) of 208 men in the control group.	Distress caused by these symptoms was reported significantly more often by men allocated radical prostatectomy than by men assigned to watchful waiting.
__label__noRel	High self-assessed quality of life was reported by 62 (35%) of 179 men allocated radical prostatectomy, 55 (34%) of 160 men assigned to watchful waiting, and 93 (45%) of 208 men in the control group.	In a longitudinal analysis of men in SPCG-4 who provided information at two follow-up points 9 years apart, 38 (45%) of 85 men allocated radical prostatectomy and 48 (60%) of 80 men allocated watchful waiting reported an increase in number of physical symptoms; 50 (61%) of 82 and 47 (64%) of 74 men, respectively, reported a reduction in quality of life.
__label__noRel	High self-assessed quality of life was reported by 62 (35%) of 179 men allocated radical prostatectomy, 55 (34%) of 160 men assigned to watchful waiting, and 93 (45%) of 208 men in the control group.	For men in SPCG-4, negative side-effects were common and added more stress than was reported in the control population.
__label__noRel	High self-assessed quality of life was reported by 62 (35%) of 179 men allocated radical prostatectomy, 55 (34%) of 160 men assigned to watchful waiting, and 93 (45%) of 208 men in the control group.	In the radical prostatectomy group, erectile dysfunction and urinary leakage were often consequences of surgery.
__label__noRel	High self-assessed quality of life was reported by 62 (35%) of 179 men allocated radical prostatectomy, 55 (34%) of 160 men assigned to watchful waiting, and 93 (45%) of 208 men in the control group.	In the watchful-waiting group, side-effects can be caused by tumour progression.
__label__noRel	High self-assessed quality of life was reported by 62 (35%) of 179 men allocated radical prostatectomy, 55 (34%) of 160 men assigned to watchful waiting, and 93 (45%) of 208 men in the control group.	The number and severity of side-effects changes over time at a higher rate than is caused by normal ageing and a loss of sexual ability is a persistent psychological problem for both interventions.
__label__noRel	High self-assessed quality of life was reported by 62 (35%) of 179 men allocated radical prostatectomy, 55 (34%) of 160 men assigned to watchful waiting, and 93 (45%) of 208 men in the control group.	For men with localised prostate cancer, surgery provides a survival benefit compared with watchful waiting.
__label__noRel	Anxiety was higher in the SPCG-4 groups (77 [43%] of 178 and 69 [43%] of 161 men) than in the control group (68 [33%] of 208 men; relative risk 142, 95% CI 107-188).	High self-assessed quality of life was reported by 62 (35%) of 179 men allocated radical prostatectomy, 55 (34%) of 160 men assigned to watchful waiting, and 93 (45%) of 208 men in the control group.
__label__noRel	Anxiety was higher in the SPCG-4 groups (77 [43%] of 178 and 69 [43%] of 161 men) than in the control group (68 [33%] of 208 men; relative risk 142, 95% CI 107-188).	Prevalence of erectile dysfunction was 84% (146 of 173 men) in the radical prostatectomy group, 80% (122 of 153) in the watchful-waiting group, and 46% (95 of 208) in the control group and prevalence of urinary leakage was 41% (71 of 173), 11% (18 of 164), and 3% (six of 209), respectively.
__label__noRel	Anxiety was higher in the SPCG-4 groups (77 [43%] of 178 and 69 [43%] of 161 men) than in the control group (68 [33%] of 208 men; relative risk 142, 95% CI 107-188).	Distress caused by these symptoms was reported significantly more often by men allocated radical prostatectomy than by men assigned to watchful waiting.
__label__noRel	Anxiety was higher in the SPCG-4 groups (77 [43%] of 178 and 69 [43%] of 161 men) than in the control group (68 [33%] of 208 men; relative risk 142, 95% CI 107-188).	In a longitudinal analysis of men in SPCG-4 who provided information at two follow-up points 9 years apart, 38 (45%) of 85 men allocated radical prostatectomy and 48 (60%) of 80 men allocated watchful waiting reported an increase in number of physical symptoms; 50 (61%) of 82 and 47 (64%) of 74 men, respectively, reported a reduction in quality of life.
__label__noRel	Anxiety was higher in the SPCG-4 groups (77 [43%] of 178 and 69 [43%] of 161 men) than in the control group (68 [33%] of 208 men; relative risk 142, 95% CI 107-188).	For men in SPCG-4, negative side-effects were common and added more stress than was reported in the control population.
__label__noRel	Anxiety was higher in the SPCG-4 groups (77 [43%] of 178 and 69 [43%] of 161 men) than in the control group (68 [33%] of 208 men; relative risk 142, 95% CI 107-188).	In the radical prostatectomy group, erectile dysfunction and urinary leakage were often consequences of surgery.
__label__noRel	Anxiety was higher in the SPCG-4 groups (77 [43%] of 178 and 69 [43%] of 161 men) than in the control group (68 [33%] of 208 men; relative risk 142, 95% CI 107-188).	In the watchful-waiting group, side-effects can be caused by tumour progression.
__label__noRel	Anxiety was higher in the SPCG-4 groups (77 [43%] of 178 and 69 [43%] of 161 men) than in the control group (68 [33%] of 208 men; relative risk 142, 95% CI 107-188).	The number and severity of side-effects changes over time at a higher rate than is caused by normal ageing and a loss of sexual ability is a persistent psychological problem for both interventions.
__label__noRel	Anxiety was higher in the SPCG-4 groups (77 [43%] of 178 and 69 [43%] of 161 men) than in the control group (68 [33%] of 208 men; relative risk 142, 95% CI 107-188).	For men with localised prostate cancer, surgery provides a survival benefit compared with watchful waiting.
__label__noRel	Prevalence of erectile dysfunction was 84% (146 of 173 men) in the radical prostatectomy group, 80% (122 of 153) in the watchful-waiting group, and 46% (95 of 208) in the control group and prevalence of urinary leakage was 41% (71 of 173), 11% (18 of 164), and 3% (six of 209), respectively.	High self-assessed quality of life was reported by 62 (35%) of 179 men allocated radical prostatectomy, 55 (34%) of 160 men assigned to watchful waiting, and 93 (45%) of 208 men in the control group.
__label__noRel	Prevalence of erectile dysfunction was 84% (146 of 173 men) in the radical prostatectomy group, 80% (122 of 153) in the watchful-waiting group, and 46% (95 of 208) in the control group and prevalence of urinary leakage was 41% (71 of 173), 11% (18 of 164), and 3% (six of 209), respectively.	Anxiety was higher in the SPCG-4 groups (77 [43%] of 178 and 69 [43%] of 161 men) than in the control group (68 [33%] of 208 men; relative risk 142, 95% CI 107-188).
__label__noRel	Prevalence of erectile dysfunction was 84% (146 of 173 men) in the radical prostatectomy group, 80% (122 of 153) in the watchful-waiting group, and 46% (95 of 208) in the control group and prevalence of urinary leakage was 41% (71 of 173), 11% (18 of 164), and 3% (six of 209), respectively.	Distress caused by these symptoms was reported significantly more often by men allocated radical prostatectomy than by men assigned to watchful waiting.
__label__noRel	Prevalence of erectile dysfunction was 84% (146 of 173 men) in the radical prostatectomy group, 80% (122 of 153) in the watchful-waiting group, and 46% (95 of 208) in the control group and prevalence of urinary leakage was 41% (71 of 173), 11% (18 of 164), and 3% (six of 209), respectively.	In a longitudinal analysis of men in SPCG-4 who provided information at two follow-up points 9 years apart, 38 (45%) of 85 men allocated radical prostatectomy and 48 (60%) of 80 men allocated watchful waiting reported an increase in number of physical symptoms; 50 (61%) of 82 and 47 (64%) of 74 men, respectively, reported a reduction in quality of life.
__label__noRel	Prevalence of erectile dysfunction was 84% (146 of 173 men) in the radical prostatectomy group, 80% (122 of 153) in the watchful-waiting group, and 46% (95 of 208) in the control group and prevalence of urinary leakage was 41% (71 of 173), 11% (18 of 164), and 3% (six of 209), respectively.	For men in SPCG-4, negative side-effects were common and added more stress than was reported in the control population.
__label__noRel	Prevalence of erectile dysfunction was 84% (146 of 173 men) in the radical prostatectomy group, 80% (122 of 153) in the watchful-waiting group, and 46% (95 of 208) in the control group and prevalence of urinary leakage was 41% (71 of 173), 11% (18 of 164), and 3% (six of 209), respectively.	In the radical prostatectomy group, erectile dysfunction and urinary leakage were often consequences of surgery.
__label__noRel	Prevalence of erectile dysfunction was 84% (146 of 173 men) in the radical prostatectomy group, 80% (122 of 153) in the watchful-waiting group, and 46% (95 of 208) in the control group and prevalence of urinary leakage was 41% (71 of 173), 11% (18 of 164), and 3% (six of 209), respectively.	In the watchful-waiting group, side-effects can be caused by tumour progression.
__label__noRel	Prevalence of erectile dysfunction was 84% (146 of 173 men) in the radical prostatectomy group, 80% (122 of 153) in the watchful-waiting group, and 46% (95 of 208) in the control group and prevalence of urinary leakage was 41% (71 of 173), 11% (18 of 164), and 3% (six of 209), respectively.	The number and severity of side-effects changes over time at a higher rate than is caused by normal ageing and a loss of sexual ability is a persistent psychological problem for both interventions.
__label__noRel	Prevalence of erectile dysfunction was 84% (146 of 173 men) in the radical prostatectomy group, 80% (122 of 153) in the watchful-waiting group, and 46% (95 of 208) in the control group and prevalence of urinary leakage was 41% (71 of 173), 11% (18 of 164), and 3% (six of 209), respectively.	For men with localised prostate cancer, surgery provides a survival benefit compared with watchful waiting.
__label__noRel	Distress caused by these symptoms was reported significantly more often by men allocated radical prostatectomy than by men assigned to watchful waiting.	High self-assessed quality of life was reported by 62 (35%) of 179 men allocated radical prostatectomy, 55 (34%) of 160 men assigned to watchful waiting, and 93 (45%) of 208 men in the control group.
__label__noRel	Distress caused by these symptoms was reported significantly more often by men allocated radical prostatectomy than by men assigned to watchful waiting.	Anxiety was higher in the SPCG-4 groups (77 [43%] of 178 and 69 [43%] of 161 men) than in the control group (68 [33%] of 208 men; relative risk 142, 95% CI 107-188).
__label__noRel	Distress caused by these symptoms was reported significantly more often by men allocated radical prostatectomy than by men assigned to watchful waiting.	Prevalence of erectile dysfunction was 84% (146 of 173 men) in the radical prostatectomy group, 80% (122 of 153) in the watchful-waiting group, and 46% (95 of 208) in the control group and prevalence of urinary leakage was 41% (71 of 173), 11% (18 of 164), and 3% (six of 209), respectively.
__label__noRel	Distress caused by these symptoms was reported significantly more often by men allocated radical prostatectomy than by men assigned to watchful waiting.	In a longitudinal analysis of men in SPCG-4 who provided information at two follow-up points 9 years apart, 38 (45%) of 85 men allocated radical prostatectomy and 48 (60%) of 80 men allocated watchful waiting reported an increase in number of physical symptoms; 50 (61%) of 82 and 47 (64%) of 74 men, respectively, reported a reduction in quality of life.
__label__noRel	Distress caused by these symptoms was reported significantly more often by men allocated radical prostatectomy than by men assigned to watchful waiting.	For men in SPCG-4, negative side-effects were common and added more stress than was reported in the control population.
__label__noRel	Distress caused by these symptoms was reported significantly more often by men allocated radical prostatectomy than by men assigned to watchful waiting.	In the radical prostatectomy group, erectile dysfunction and urinary leakage were often consequences of surgery.
__label__noRel	Distress caused by these symptoms was reported significantly more often by men allocated radical prostatectomy than by men assigned to watchful waiting.	In the watchful-waiting group, side-effects can be caused by tumour progression.
__label__noRel	Distress caused by these symptoms was reported significantly more often by men allocated radical prostatectomy than by men assigned to watchful waiting.	The number and severity of side-effects changes over time at a higher rate than is caused by normal ageing and a loss of sexual ability is a persistent psychological problem for both interventions.
__label__noRel	Distress caused by these symptoms was reported significantly more often by men allocated radical prostatectomy than by men assigned to watchful waiting.	For men with localised prostate cancer, surgery provides a survival benefit compared with watchful waiting.
__label__noRel	In a longitudinal analysis of men in SPCG-4 who provided information at two follow-up points 9 years apart, 38 (45%) of 85 men allocated radical prostatectomy and 48 (60%) of 80 men allocated watchful waiting reported an increase in number of physical symptoms; 50 (61%) of 82 and 47 (64%) of 74 men, respectively, reported a reduction in quality of life.	High self-assessed quality of life was reported by 62 (35%) of 179 men allocated radical prostatectomy, 55 (34%) of 160 men assigned to watchful waiting, and 93 (45%) of 208 men in the control group.
__label__noRel	In a longitudinal analysis of men in SPCG-4 who provided information at two follow-up points 9 years apart, 38 (45%) of 85 men allocated radical prostatectomy and 48 (60%) of 80 men allocated watchful waiting reported an increase in number of physical symptoms; 50 (61%) of 82 and 47 (64%) of 74 men, respectively, reported a reduction in quality of life.	Anxiety was higher in the SPCG-4 groups (77 [43%] of 178 and 69 [43%] of 161 men) than in the control group (68 [33%] of 208 men; relative risk 142, 95% CI 107-188).
__label__noRel	In a longitudinal analysis of men in SPCG-4 who provided information at two follow-up points 9 years apart, 38 (45%) of 85 men allocated radical prostatectomy and 48 (60%) of 80 men allocated watchful waiting reported an increase in number of physical symptoms; 50 (61%) of 82 and 47 (64%) of 74 men, respectively, reported a reduction in quality of life.	Prevalence of erectile dysfunction was 84% (146 of 173 men) in the radical prostatectomy group, 80% (122 of 153) in the watchful-waiting group, and 46% (95 of 208) in the control group and prevalence of urinary leakage was 41% (71 of 173), 11% (18 of 164), and 3% (six of 209), respectively.
__label__noRel	In a longitudinal analysis of men in SPCG-4 who provided information at two follow-up points 9 years apart, 38 (45%) of 85 men allocated radical prostatectomy and 48 (60%) of 80 men allocated watchful waiting reported an increase in number of physical symptoms; 50 (61%) of 82 and 47 (64%) of 74 men, respectively, reported a reduction in quality of life.	Distress caused by these symptoms was reported significantly more often by men allocated radical prostatectomy than by men assigned to watchful waiting.
__label__noRel	In a longitudinal analysis of men in SPCG-4 who provided information at two follow-up points 9 years apart, 38 (45%) of 85 men allocated radical prostatectomy and 48 (60%) of 80 men allocated watchful waiting reported an increase in number of physical symptoms; 50 (61%) of 82 and 47 (64%) of 74 men, respectively, reported a reduction in quality of life.	For men in SPCG-4, negative side-effects were common and added more stress than was reported in the control population.
__label__noRel	In a longitudinal analysis of men in SPCG-4 who provided information at two follow-up points 9 years apart, 38 (45%) of 85 men allocated radical prostatectomy and 48 (60%) of 80 men allocated watchful waiting reported an increase in number of physical symptoms; 50 (61%) of 82 and 47 (64%) of 74 men, respectively, reported a reduction in quality of life.	In the radical prostatectomy group, erectile dysfunction and urinary leakage were often consequences of surgery.
__label__noRel	In a longitudinal analysis of men in SPCG-4 who provided information at two follow-up points 9 years apart, 38 (45%) of 85 men allocated radical prostatectomy and 48 (60%) of 80 men allocated watchful waiting reported an increase in number of physical symptoms; 50 (61%) of 82 and 47 (64%) of 74 men, respectively, reported a reduction in quality of life.	In the watchful-waiting group, side-effects can be caused by tumour progression.
__label__Support	In a longitudinal analysis of men in SPCG-4 who provided information at two follow-up points 9 years apart, 38 (45%) of 85 men allocated radical prostatectomy and 48 (60%) of 80 men allocated watchful waiting reported an increase in number of physical symptoms; 50 (61%) of 82 and 47 (64%) of 74 men, respectively, reported a reduction in quality of life.	The number and severity of side-effects changes over time at a higher rate than is caused by normal ageing and a loss of sexual ability is a persistent psychological problem for both interventions.
__label__noRel	In a longitudinal analysis of men in SPCG-4 who provided information at two follow-up points 9 years apart, 38 (45%) of 85 men allocated radical prostatectomy and 48 (60%) of 80 men allocated watchful waiting reported an increase in number of physical symptoms; 50 (61%) of 82 and 47 (64%) of 74 men, respectively, reported a reduction in quality of life.	For men with localised prostate cancer, surgery provides a survival benefit compared with watchful waiting.
__label__noRel	For men in SPCG-4, negative side-effects were common and added more stress than was reported in the control population.	High self-assessed quality of life was reported by 62 (35%) of 179 men allocated radical prostatectomy, 55 (34%) of 160 men assigned to watchful waiting, and 93 (45%) of 208 men in the control group.
__label__noRel	For men in SPCG-4, negative side-effects were common and added more stress than was reported in the control population.	Anxiety was higher in the SPCG-4 groups (77 [43%] of 178 and 69 [43%] of 161 men) than in the control group (68 [33%] of 208 men; relative risk 142, 95% CI 107-188).
__label__noRel	For men in SPCG-4, negative side-effects were common and added more stress than was reported in the control population.	Prevalence of erectile dysfunction was 84% (146 of 173 men) in the radical prostatectomy group, 80% (122 of 153) in the watchful-waiting group, and 46% (95 of 208) in the control group and prevalence of urinary leakage was 41% (71 of 173), 11% (18 of 164), and 3% (six of 209), respectively.
__label__noRel	For men in SPCG-4, negative side-effects were common and added more stress than was reported in the control population.	Distress caused by these symptoms was reported significantly more often by men allocated radical prostatectomy than by men assigned to watchful waiting.
__label__noRel	For men in SPCG-4, negative side-effects were common and added more stress than was reported in the control population.	In a longitudinal analysis of men in SPCG-4 who provided information at two follow-up points 9 years apart, 38 (45%) of 85 men allocated radical prostatectomy and 48 (60%) of 80 men allocated watchful waiting reported an increase in number of physical symptoms; 50 (61%) of 82 and 47 (64%) of 74 men, respectively, reported a reduction in quality of life.
__label__noRel	For men in SPCG-4, negative side-effects were common and added more stress than was reported in the control population.	In the radical prostatectomy group, erectile dysfunction and urinary leakage were often consequences of surgery.
__label__noRel	For men in SPCG-4, negative side-effects were common and added more stress than was reported in the control population.	In the watchful-waiting group, side-effects can be caused by tumour progression.
__label__Support	For men in SPCG-4, negative side-effects were common and added more stress than was reported in the control population.	The number and severity of side-effects changes over time at a higher rate than is caused by normal ageing and a loss of sexual ability is a persistent psychological problem for both interventions.
__label__noRel	For men in SPCG-4, negative side-effects were common and added more stress than was reported in the control population.	For men with localised prostate cancer, surgery provides a survival benefit compared with watchful waiting.
__label__noRel	In the radical prostatectomy group, erectile dysfunction and urinary leakage were often consequences of surgery.	High self-assessed quality of life was reported by 62 (35%) of 179 men allocated radical prostatectomy, 55 (34%) of 160 men assigned to watchful waiting, and 93 (45%) of 208 men in the control group.
__label__noRel	In the radical prostatectomy group, erectile dysfunction and urinary leakage were often consequences of surgery.	Anxiety was higher in the SPCG-4 groups (77 [43%] of 178 and 69 [43%] of 161 men) than in the control group (68 [33%] of 208 men; relative risk 142, 95% CI 107-188).
__label__noRel	In the radical prostatectomy group, erectile dysfunction and urinary leakage were often consequences of surgery.	Prevalence of erectile dysfunction was 84% (146 of 173 men) in the radical prostatectomy group, 80% (122 of 153) in the watchful-waiting group, and 46% (95 of 208) in the control group and prevalence of urinary leakage was 41% (71 of 173), 11% (18 of 164), and 3% (six of 209), respectively.
__label__noRel	In the radical prostatectomy group, erectile dysfunction and urinary leakage were often consequences of surgery.	Distress caused by these symptoms was reported significantly more often by men allocated radical prostatectomy than by men assigned to watchful waiting.
__label__noRel	In the radical prostatectomy group, erectile dysfunction and urinary leakage were often consequences of surgery.	In a longitudinal analysis of men in SPCG-4 who provided information at two follow-up points 9 years apart, 38 (45%) of 85 men allocated radical prostatectomy and 48 (60%) of 80 men allocated watchful waiting reported an increase in number of physical symptoms; 50 (61%) of 82 and 47 (64%) of 74 men, respectively, reported a reduction in quality of life.
__label__noRel	In the radical prostatectomy group, erectile dysfunction and urinary leakage were often consequences of surgery.	For men in SPCG-4, negative side-effects were common and added more stress than was reported in the control population.
__label__noRel	In the radical prostatectomy group, erectile dysfunction and urinary leakage were often consequences of surgery.	In the watchful-waiting group, side-effects can be caused by tumour progression.
__label__noRel	In the radical prostatectomy group, erectile dysfunction and urinary leakage were often consequences of surgery.	The number and severity of side-effects changes over time at a higher rate than is caused by normal ageing and a loss of sexual ability is a persistent psychological problem for both interventions.
__label__noRel	In the radical prostatectomy group, erectile dysfunction and urinary leakage were often consequences of surgery.	For men with localised prostate cancer, surgery provides a survival benefit compared with watchful waiting.
__label__noRel	In the watchful-waiting group, side-effects can be caused by tumour progression.	High self-assessed quality of life was reported by 62 (35%) of 179 men allocated radical prostatectomy, 55 (34%) of 160 men assigned to watchful waiting, and 93 (45%) of 208 men in the control group.
__label__noRel	In the watchful-waiting group, side-effects can be caused by tumour progression.	Anxiety was higher in the SPCG-4 groups (77 [43%] of 178 and 69 [43%] of 161 men) than in the control group (68 [33%] of 208 men; relative risk 142, 95% CI 107-188).
__label__noRel	In the watchful-waiting group, side-effects can be caused by tumour progression.	Prevalence of erectile dysfunction was 84% (146 of 173 men) in the radical prostatectomy group, 80% (122 of 153) in the watchful-waiting group, and 46% (95 of 208) in the control group and prevalence of urinary leakage was 41% (71 of 173), 11% (18 of 164), and 3% (six of 209), respectively.
__label__noRel	In the watchful-waiting group, side-effects can be caused by tumour progression.	Distress caused by these symptoms was reported significantly more often by men allocated radical prostatectomy than by men assigned to watchful waiting.
__label__noRel	In the watchful-waiting group, side-effects can be caused by tumour progression.	In a longitudinal analysis of men in SPCG-4 who provided information at two follow-up points 9 years apart, 38 (45%) of 85 men allocated radical prostatectomy and 48 (60%) of 80 men allocated watchful waiting reported an increase in number of physical symptoms; 50 (61%) of 82 and 47 (64%) of 74 men, respectively, reported a reduction in quality of life.
__label__noRel	In the watchful-waiting group, side-effects can be caused by tumour progression.	For men in SPCG-4, negative side-effects were common and added more stress than was reported in the control population.
__label__noRel	In the watchful-waiting group, side-effects can be caused by tumour progression.	In the radical prostatectomy group, erectile dysfunction and urinary leakage were often consequences of surgery.
__label__noRel	In the watchful-waiting group, side-effects can be caused by tumour progression.	The number and severity of side-effects changes over time at a higher rate than is caused by normal ageing and a loss of sexual ability is a persistent psychological problem for both interventions.
__label__noRel	In the watchful-waiting group, side-effects can be caused by tumour progression.	For men with localised prostate cancer, surgery provides a survival benefit compared with watchful waiting.
__label__noRel	The number and severity of side-effects changes over time at a higher rate than is caused by normal ageing and a loss of sexual ability is a persistent psychological problem for both interventions.	High self-assessed quality of life was reported by 62 (35%) of 179 men allocated radical prostatectomy, 55 (34%) of 160 men assigned to watchful waiting, and 93 (45%) of 208 men in the control group.
__label__noRel	The number and severity of side-effects changes over time at a higher rate than is caused by normal ageing and a loss of sexual ability is a persistent psychological problem for both interventions.	Anxiety was higher in the SPCG-4 groups (77 [43%] of 178 and 69 [43%] of 161 men) than in the control group (68 [33%] of 208 men; relative risk 142, 95% CI 107-188).
__label__noRel	The number and severity of side-effects changes over time at a higher rate than is caused by normal ageing and a loss of sexual ability is a persistent psychological problem for both interventions.	Prevalence of erectile dysfunction was 84% (146 of 173 men) in the radical prostatectomy group, 80% (122 of 153) in the watchful-waiting group, and 46% (95 of 208) in the control group and prevalence of urinary leakage was 41% (71 of 173), 11% (18 of 164), and 3% (six of 209), respectively.
__label__noRel	The number and severity of side-effects changes over time at a higher rate than is caused by normal ageing and a loss of sexual ability is a persistent psychological problem for both interventions.	Distress caused by these symptoms was reported significantly more often by men allocated radical prostatectomy than by men assigned to watchful waiting.
__label__noRel	The number and severity of side-effects changes over time at a higher rate than is caused by normal ageing and a loss of sexual ability is a persistent psychological problem for both interventions.	In a longitudinal analysis of men in SPCG-4 who provided information at two follow-up points 9 years apart, 38 (45%) of 85 men allocated radical prostatectomy and 48 (60%) of 80 men allocated watchful waiting reported an increase in number of physical symptoms; 50 (61%) of 82 and 47 (64%) of 74 men, respectively, reported a reduction in quality of life.
__label__noRel	The number and severity of side-effects changes over time at a higher rate than is caused by normal ageing and a loss of sexual ability is a persistent psychological problem for both interventions.	For men in SPCG-4, negative side-effects were common and added more stress than was reported in the control population.
__label__noRel	The number and severity of side-effects changes over time at a higher rate than is caused by normal ageing and a loss of sexual ability is a persistent psychological problem for both interventions.	In the radical prostatectomy group, erectile dysfunction and urinary leakage were often consequences of surgery.
__label__noRel	The number and severity of side-effects changes over time at a higher rate than is caused by normal ageing and a loss of sexual ability is a persistent psychological problem for both interventions.	In the watchful-waiting group, side-effects can be caused by tumour progression.
__label__noRel	The number and severity of side-effects changes over time at a higher rate than is caused by normal ageing and a loss of sexual ability is a persistent psychological problem for both interventions.	For men with localised prostate cancer, surgery provides a survival benefit compared with watchful waiting.
__label__noRel	For men with localised prostate cancer, surgery provides a survival benefit compared with watchful waiting.	High self-assessed quality of life was reported by 62 (35%) of 179 men allocated radical prostatectomy, 55 (34%) of 160 men assigned to watchful waiting, and 93 (45%) of 208 men in the control group.
__label__noRel	For men with localised prostate cancer, surgery provides a survival benefit compared with watchful waiting.	Anxiety was higher in the SPCG-4 groups (77 [43%] of 178 and 69 [43%] of 161 men) than in the control group (68 [33%] of 208 men; relative risk 142, 95% CI 107-188).
__label__noRel	For men with localised prostate cancer, surgery provides a survival benefit compared with watchful waiting.	Prevalence of erectile dysfunction was 84% (146 of 173 men) in the radical prostatectomy group, 80% (122 of 153) in the watchful-waiting group, and 46% (95 of 208) in the control group and prevalence of urinary leakage was 41% (71 of 173), 11% (18 of 164), and 3% (six of 209), respectively.
__label__noRel	For men with localised prostate cancer, surgery provides a survival benefit compared with watchful waiting.	Distress caused by these symptoms was reported significantly more often by men allocated radical prostatectomy than by men assigned to watchful waiting.
__label__noRel	For men with localised prostate cancer, surgery provides a survival benefit compared with watchful waiting.	In a longitudinal analysis of men in SPCG-4 who provided information at two follow-up points 9 years apart, 38 (45%) of 85 men allocated radical prostatectomy and 48 (60%) of 80 men allocated watchful waiting reported an increase in number of physical symptoms; 50 (61%) of 82 and 47 (64%) of 74 men, respectively, reported a reduction in quality of life.
__label__noRel	For men with localised prostate cancer, surgery provides a survival benefit compared with watchful waiting.	For men in SPCG-4, negative side-effects were common and added more stress than was reported in the control population.
__label__noRel	For men with localised prostate cancer, surgery provides a survival benefit compared with watchful waiting.	In the radical prostatectomy group, erectile dysfunction and urinary leakage were often consequences of surgery.
__label__noRel	For men with localised prostate cancer, surgery provides a survival benefit compared with watchful waiting.	In the watchful-waiting group, side-effects can be caused by tumour progression.
__label__noRel	For men with localised prostate cancer, surgery provides a survival benefit compared with watchful waiting.	The number and severity of side-effects changes over time at a higher rate than is caused by normal ageing and a loss of sexual ability is a persistent psychological problem for both interventions.
__label__noRel	Mucositis occurs in almost all patients treated with radiotherapy for head and neck cancer.	Toxicity profiles were similar between the two arms of the study.
__label__noRel	Mucositis occurs in almost all patients treated with radiotherapy for head and neck cancer.	The median time to development of severe mucositis from the start of radiotherapy was 3.61 weeks on BCoG and 3.96 weeks on placebo (P =.61).
__label__noRel	Mucositis occurs in almost all patients treated with radiotherapy for head and neck cancer.	There were no statistically significant differences between the arms in the extent of severe mucositis as measured by physician, in oral toxicities as recorded by patients, or in radiotherapy delays.
__label__noRel	Mucositis occurs in almost all patients treated with radiotherapy for head and neck cancer.	in this group of patients treated with conventional radiotherapy, the lozenge did not impact significantly on the severity of mucositis.
__label__noRel	Mucositis occurs in almost all patients treated with radiotherapy for head and neck cancer.	Whether such a lozenge would be beneficial in treatment situations where rate of severe mucositis is higher (ie, in patients treated with unconventional fractionation or with concomitant chemotherapy) is unknown.
__label__noRel	Toxicity profiles were similar between the two arms of the study.	Mucositis occurs in almost all patients treated with radiotherapy for head and neck cancer.
__label__noRel	Toxicity profiles were similar between the two arms of the study.	The median time to development of severe mucositis from the start of radiotherapy was 3.61 weeks on BCoG and 3.96 weeks on placebo (P =.61).
__label__noRel	Toxicity profiles were similar between the two arms of the study.	There were no statistically significant differences between the arms in the extent of severe mucositis as measured by physician, in oral toxicities as recorded by patients, or in radiotherapy delays.
__label__noRel	Toxicity profiles were similar between the two arms of the study.	in this group of patients treated with conventional radiotherapy, the lozenge did not impact significantly on the severity of mucositis.
__label__noRel	Toxicity profiles were similar between the two arms of the study.	Whether such a lozenge would be beneficial in treatment situations where rate of severe mucositis is higher (ie, in patients treated with unconventional fractionation or with concomitant chemotherapy) is unknown.
__label__noRel	The median time to development of severe mucositis from the start of radiotherapy was 3.61 weeks on BCoG and 3.96 weeks on placebo (P =.61).	Mucositis occurs in almost all patients treated with radiotherapy for head and neck cancer.
__label__noRel	The median time to development of severe mucositis from the start of radiotherapy was 3.61 weeks on BCoG and 3.96 weeks on placebo (P =.61).	Toxicity profiles were similar between the two arms of the study.
__label__noRel	The median time to development of severe mucositis from the start of radiotherapy was 3.61 weeks on BCoG and 3.96 weeks on placebo (P =.61).	There were no statistically significant differences between the arms in the extent of severe mucositis as measured by physician, in oral toxicities as recorded by patients, or in radiotherapy delays.
__label__Support	The median time to development of severe mucositis from the start of radiotherapy was 3.61 weeks on BCoG and 3.96 weeks on placebo (P =.61).	in this group of patients treated with conventional radiotherapy, the lozenge did not impact significantly on the severity of mucositis.
__label__noRel	The median time to development of severe mucositis from the start of radiotherapy was 3.61 weeks on BCoG and 3.96 weeks on placebo (P =.61).	Whether such a lozenge would be beneficial in treatment situations where rate of severe mucositis is higher (ie, in patients treated with unconventional fractionation or with concomitant chemotherapy) is unknown.
__label__noRel	There were no statistically significant differences between the arms in the extent of severe mucositis as measured by physician, in oral toxicities as recorded by patients, or in radiotherapy delays.	Mucositis occurs in almost all patients treated with radiotherapy for head and neck cancer.
__label__noRel	There were no statistically significant differences between the arms in the extent of severe mucositis as measured by physician, in oral toxicities as recorded by patients, or in radiotherapy delays.	Toxicity profiles were similar between the two arms of the study.
__label__noRel	There were no statistically significant differences between the arms in the extent of severe mucositis as measured by physician, in oral toxicities as recorded by patients, or in radiotherapy delays.	The median time to development of severe mucositis from the start of radiotherapy was 3.61 weeks on BCoG and 3.96 weeks on placebo (P =.61).
__label__Support	There were no statistically significant differences between the arms in the extent of severe mucositis as measured by physician, in oral toxicities as recorded by patients, or in radiotherapy delays.	in this group of patients treated with conventional radiotherapy, the lozenge did not impact significantly on the severity of mucositis.
__label__noRel	There were no statistically significant differences between the arms in the extent of severe mucositis as measured by physician, in oral toxicities as recorded by patients, or in radiotherapy delays.	Whether such a lozenge would be beneficial in treatment situations where rate of severe mucositis is higher (ie, in patients treated with unconventional fractionation or with concomitant chemotherapy) is unknown.
__label__noRel	in this group of patients treated with conventional radiotherapy, the lozenge did not impact significantly on the severity of mucositis.	Mucositis occurs in almost all patients treated with radiotherapy for head and neck cancer.
__label__noRel	in this group of patients treated with conventional radiotherapy, the lozenge did not impact significantly on the severity of mucositis.	Toxicity profiles were similar between the two arms of the study.
__label__noRel	in this group of patients treated with conventional radiotherapy, the lozenge did not impact significantly on the severity of mucositis.	The median time to development of severe mucositis from the start of radiotherapy was 3.61 weeks on BCoG and 3.96 weeks on placebo (P =.61).
__label__noRel	in this group of patients treated with conventional radiotherapy, the lozenge did not impact significantly on the severity of mucositis.	There were no statistically significant differences between the arms in the extent of severe mucositis as measured by physician, in oral toxicities as recorded by patients, or in radiotherapy delays.
__label__Support	in this group of patients treated with conventional radiotherapy, the lozenge did not impact significantly on the severity of mucositis.	Whether such a lozenge would be beneficial in treatment situations where rate of severe mucositis is higher (ie, in patients treated with unconventional fractionation or with concomitant chemotherapy) is unknown.
__label__noRel	Whether such a lozenge would be beneficial in treatment situations where rate of severe mucositis is higher (ie, in patients treated with unconventional fractionation or with concomitant chemotherapy) is unknown.	Mucositis occurs in almost all patients treated with radiotherapy for head and neck cancer.
__label__noRel	Whether such a lozenge would be beneficial in treatment situations where rate of severe mucositis is higher (ie, in patients treated with unconventional fractionation or with concomitant chemotherapy) is unknown.	Toxicity profiles were similar between the two arms of the study.
__label__noRel	Whether such a lozenge would be beneficial in treatment situations where rate of severe mucositis is higher (ie, in patients treated with unconventional fractionation or with concomitant chemotherapy) is unknown.	The median time to development of severe mucositis from the start of radiotherapy was 3.61 weeks on BCoG and 3.96 weeks on placebo (P =.61).
__label__noRel	Whether such a lozenge would be beneficial in treatment situations where rate of severe mucositis is higher (ie, in patients treated with unconventional fractionation or with concomitant chemotherapy) is unknown.	There were no statistically significant differences between the arms in the extent of severe mucositis as measured by physician, in oral toxicities as recorded by patients, or in radiotherapy delays.
__label__noRel	Whether such a lozenge would be beneficial in treatment situations where rate of severe mucositis is higher (ie, in patients treated with unconventional fractionation or with concomitant chemotherapy) is unknown.	in this group of patients treated with conventional radiotherapy, the lozenge did not impact significantly on the severity of mucositis.
__label__noRel	The median TDD in HRQOL was 8.3 months with EVE + EXE versus 5.8 months with PBO + EXE (hazard ratio, 0.74; P = .0084).	At the 10-point minimal important difference, the median TDD with EVE + EXE was 11.7 months versus 8.4 months with PBO + EXE (hazard ratio, 0.80; P = .1017).
__label__Support	The median TDD in HRQOL was 8.3 months with EVE + EXE versus 5.8 months with PBO + EXE (hazard ratio, 0.74; P = .0084).	In patients with advanced breast cancer who develop disease progression after treatment with nonsteroidal aromatase inhibitors, EVE + EXE was associated with a longer TDD in global HRQOL versus PBO + EXE.
__label__noRel	At the 10-point minimal important difference, the median TDD with EVE + EXE was 11.7 months versus 8.4 months with PBO + EXE (hazard ratio, 0.80; P = .1017).	The median TDD in HRQOL was 8.3 months with EVE + EXE versus 5.8 months with PBO + EXE (hazard ratio, 0.74; P = .0084).
__label__Support	At the 10-point minimal important difference, the median TDD with EVE + EXE was 11.7 months versus 8.4 months with PBO + EXE (hazard ratio, 0.80; P = .1017).	In patients with advanced breast cancer who develop disease progression after treatment with nonsteroidal aromatase inhibitors, EVE + EXE was associated with a longer TDD in global HRQOL versus PBO + EXE.
__label__noRel	In patients with advanced breast cancer who develop disease progression after treatment with nonsteroidal aromatase inhibitors, EVE + EXE was associated with a longer TDD in global HRQOL versus PBO + EXE.	The median TDD in HRQOL was 8.3 months with EVE + EXE versus 5.8 months with PBO + EXE (hazard ratio, 0.74; P = .0084).
__label__noRel	In patients with advanced breast cancer who develop disease progression after treatment with nonsteroidal aromatase inhibitors, EVE + EXE was associated with a longer TDD in global HRQOL versus PBO + EXE.	At the 10-point minimal important difference, the median TDD with EVE + EXE was 11.7 months versus 8.4 months with PBO + EXE (hazard ratio, 0.80; P = .1017).
__label__noRel	Preliminary results suggested a positive impact on survival.	There was a high rate of grade 3/4 neutropenia (97%) but not neutropenic fever (12%) during neoadjuvant chemotherapy.
__label__noRel	Preliminary results suggested a positive impact on survival.	No significant differences in rates of acute toxicities were observed between the two arms during CRT.
__label__noRel	Preliminary results suggested a positive impact on survival.	Dose intensities of concurrent cisplatin, late RT toxicities and quality of life scores were comparable in both arms.
__label__noRel	Preliminary results suggested a positive impact on survival.	The 3-year progression-free survival for neoadjuvant versus control arm was 88.2% and 59.5% (hazard ratio = 0.49; 95% CI, 0.20 to 1.19; P = .12).
__label__noRel	Preliminary results suggested a positive impact on survival.	The 3-year overall survival for neoadjuvant versus control arm was 94.1% and 67.7% (hazard ratio = 0.24; 95% CI, 0.078 to 0.73; P = .012).
__label__noRel	Preliminary results suggested a positive impact on survival.	Neoadjuvant docetaxel-cisplatin followed by CRT was well tolerated with a manageable toxicity profile that allowed subsequent delivery of full-dose CRT.
__label__noRel	There was a high rate of grade 3/4 neutropenia (97%) but not neutropenic fever (12%) during neoadjuvant chemotherapy.	Preliminary results suggested a positive impact on survival.
__label__noRel	There was a high rate of grade 3/4 neutropenia (97%) but not neutropenic fever (12%) during neoadjuvant chemotherapy.	No significant differences in rates of acute toxicities were observed between the two arms during CRT.
__label__noRel	There was a high rate of grade 3/4 neutropenia (97%) but not neutropenic fever (12%) during neoadjuvant chemotherapy.	Dose intensities of concurrent cisplatin, late RT toxicities and quality of life scores were comparable in both arms.
__label__noRel	There was a high rate of grade 3/4 neutropenia (97%) but not neutropenic fever (12%) during neoadjuvant chemotherapy.	The 3-year progression-free survival for neoadjuvant versus control arm was 88.2% and 59.5% (hazard ratio = 0.49; 95% CI, 0.20 to 1.19; P = .12).
__label__noRel	There was a high rate of grade 3/4 neutropenia (97%) but not neutropenic fever (12%) during neoadjuvant chemotherapy.	The 3-year overall survival for neoadjuvant versus control arm was 94.1% and 67.7% (hazard ratio = 0.24; 95% CI, 0.078 to 0.73; P = .012).
__label__Attack	There was a high rate of grade 3/4 neutropenia (97%) but not neutropenic fever (12%) during neoadjuvant chemotherapy.	Neoadjuvant docetaxel-cisplatin followed by CRT was well tolerated with a manageable toxicity profile that allowed subsequent delivery of full-dose CRT.
__label__noRel	No significant differences in rates of acute toxicities were observed between the two arms during CRT.	Preliminary results suggested a positive impact on survival.
__label__noRel	No significant differences in rates of acute toxicities were observed between the two arms during CRT.	There was a high rate of grade 3/4 neutropenia (97%) but not neutropenic fever (12%) during neoadjuvant chemotherapy.
__label__noRel	No significant differences in rates of acute toxicities were observed between the two arms during CRT.	Dose intensities of concurrent cisplatin, late RT toxicities and quality of life scores were comparable in both arms.
__label__noRel	No significant differences in rates of acute toxicities were observed between the two arms during CRT.	The 3-year progression-free survival for neoadjuvant versus control arm was 88.2% and 59.5% (hazard ratio = 0.49; 95% CI, 0.20 to 1.19; P = .12).
__label__noRel	No significant differences in rates of acute toxicities were observed between the two arms during CRT.	The 3-year overall survival for neoadjuvant versus control arm was 94.1% and 67.7% (hazard ratio = 0.24; 95% CI, 0.078 to 0.73; P = .012).
__label__Support	No significant differences in rates of acute toxicities were observed between the two arms during CRT.	Neoadjuvant docetaxel-cisplatin followed by CRT was well tolerated with a manageable toxicity profile that allowed subsequent delivery of full-dose CRT.
__label__noRel	Dose intensities of concurrent cisplatin, late RT toxicities and quality of life scores were comparable in both arms.	Preliminary results suggested a positive impact on survival.
__label__noRel	Dose intensities of concurrent cisplatin, late RT toxicities and quality of life scores were comparable in both arms.	There was a high rate of grade 3/4 neutropenia (97%) but not neutropenic fever (12%) during neoadjuvant chemotherapy.
__label__noRel	Dose intensities of concurrent cisplatin, late RT toxicities and quality of life scores were comparable in both arms.	No significant differences in rates of acute toxicities were observed between the two arms during CRT.
__label__noRel	Dose intensities of concurrent cisplatin, late RT toxicities and quality of life scores were comparable in both arms.	The 3-year progression-free survival for neoadjuvant versus control arm was 88.2% and 59.5% (hazard ratio = 0.49; 95% CI, 0.20 to 1.19; P = .12).
__label__noRel	Dose intensities of concurrent cisplatin, late RT toxicities and quality of life scores were comparable in both arms.	The 3-year overall survival for neoadjuvant versus control arm was 94.1% and 67.7% (hazard ratio = 0.24; 95% CI, 0.078 to 0.73; P = .012).
__label__Support	Dose intensities of concurrent cisplatin, late RT toxicities and quality of life scores were comparable in both arms.	Neoadjuvant docetaxel-cisplatin followed by CRT was well tolerated with a manageable toxicity profile that allowed subsequent delivery of full-dose CRT.
__label__Support	The 3-year progression-free survival for neoadjuvant versus control arm was 88.2% and 59.5% (hazard ratio = 0.49; 95% CI, 0.20 to 1.19; P = .12).	Preliminary results suggested a positive impact on survival.
__label__noRel	The 3-year progression-free survival for neoadjuvant versus control arm was 88.2% and 59.5% (hazard ratio = 0.49; 95% CI, 0.20 to 1.19; P = .12).	There was a high rate of grade 3/4 neutropenia (97%) but not neutropenic fever (12%) during neoadjuvant chemotherapy.
__label__noRel	The 3-year progression-free survival for neoadjuvant versus control arm was 88.2% and 59.5% (hazard ratio = 0.49; 95% CI, 0.20 to 1.19; P = .12).	No significant differences in rates of acute toxicities were observed between the two arms during CRT.
__label__noRel	The 3-year progression-free survival for neoadjuvant versus control arm was 88.2% and 59.5% (hazard ratio = 0.49; 95% CI, 0.20 to 1.19; P = .12).	Dose intensities of concurrent cisplatin, late RT toxicities and quality of life scores were comparable in both arms.
__label__noRel	The 3-year progression-free survival for neoadjuvant versus control arm was 88.2% and 59.5% (hazard ratio = 0.49; 95% CI, 0.20 to 1.19; P = .12).	The 3-year overall survival for neoadjuvant versus control arm was 94.1% and 67.7% (hazard ratio = 0.24; 95% CI, 0.078 to 0.73; P = .012).
__label__noRel	The 3-year progression-free survival for neoadjuvant versus control arm was 88.2% and 59.5% (hazard ratio = 0.49; 95% CI, 0.20 to 1.19; P = .12).	Neoadjuvant docetaxel-cisplatin followed by CRT was well tolerated with a manageable toxicity profile that allowed subsequent delivery of full-dose CRT.
__label__Support	The 3-year overall survival for neoadjuvant versus control arm was 94.1% and 67.7% (hazard ratio = 0.24; 95% CI, 0.078 to 0.73; P = .012).	Preliminary results suggested a positive impact on survival.
__label__noRel	The 3-year overall survival for neoadjuvant versus control arm was 94.1% and 67.7% (hazard ratio = 0.24; 95% CI, 0.078 to 0.73; P = .012).	There was a high rate of grade 3/4 neutropenia (97%) but not neutropenic fever (12%) during neoadjuvant chemotherapy.
__label__noRel	The 3-year overall survival for neoadjuvant versus control arm was 94.1% and 67.7% (hazard ratio = 0.24; 95% CI, 0.078 to 0.73; P = .012).	No significant differences in rates of acute toxicities were observed between the two arms during CRT.
__label__noRel	The 3-year overall survival for neoadjuvant versus control arm was 94.1% and 67.7% (hazard ratio = 0.24; 95% CI, 0.078 to 0.73; P = .012).	Dose intensities of concurrent cisplatin, late RT toxicities and quality of life scores were comparable in both arms.
__label__noRel	The 3-year overall survival for neoadjuvant versus control arm was 94.1% and 67.7% (hazard ratio = 0.24; 95% CI, 0.078 to 0.73; P = .012).	The 3-year progression-free survival for neoadjuvant versus control arm was 88.2% and 59.5% (hazard ratio = 0.49; 95% CI, 0.20 to 1.19; P = .12).
__label__noRel	The 3-year overall survival for neoadjuvant versus control arm was 94.1% and 67.7% (hazard ratio = 0.24; 95% CI, 0.078 to 0.73; P = .012).	Neoadjuvant docetaxel-cisplatin followed by CRT was well tolerated with a manageable toxicity profile that allowed subsequent delivery of full-dose CRT.
__label__noRel	Neoadjuvant docetaxel-cisplatin followed by CRT was well tolerated with a manageable toxicity profile that allowed subsequent delivery of full-dose CRT.	Preliminary results suggested a positive impact on survival.
__label__noRel	Neoadjuvant docetaxel-cisplatin followed by CRT was well tolerated with a manageable toxicity profile that allowed subsequent delivery of full-dose CRT.	There was a high rate of grade 3/4 neutropenia (97%) but not neutropenic fever (12%) during neoadjuvant chemotherapy.
__label__noRel	Neoadjuvant docetaxel-cisplatin followed by CRT was well tolerated with a manageable toxicity profile that allowed subsequent delivery of full-dose CRT.	No significant differences in rates of acute toxicities were observed between the two arms during CRT.
__label__noRel	Neoadjuvant docetaxel-cisplatin followed by CRT was well tolerated with a manageable toxicity profile that allowed subsequent delivery of full-dose CRT.	Dose intensities of concurrent cisplatin, late RT toxicities and quality of life scores were comparable in both arms.
__label__noRel	Neoadjuvant docetaxel-cisplatin followed by CRT was well tolerated with a manageable toxicity profile that allowed subsequent delivery of full-dose CRT.	The 3-year progression-free survival for neoadjuvant versus control arm was 88.2% and 59.5% (hazard ratio = 0.49; 95% CI, 0.20 to 1.19; P = .12).
__label__noRel	Neoadjuvant docetaxel-cisplatin followed by CRT was well tolerated with a manageable toxicity profile that allowed subsequent delivery of full-dose CRT.	The 3-year overall survival for neoadjuvant versus control arm was 94.1% and 67.7% (hazard ratio = 0.24; 95% CI, 0.078 to 0.73; P = .012).
__label__noRel	Aerobic exercise and psychosocial interventions have been shown to reduce the severity of this symptom in cancer patients.	Physical performance of the training group improved significantly during the programme (9.4+/-20 watts, p=0.01) but remained unchanged in the relaxation group (1.5+/-14.8 watts, p=0.37).
__label__noRel	Aerobic exercise and psychosocial interventions have been shown to reduce the severity of this symptom in cancer patients.	Fatigue and global health scores improved in both groups during the intervention (fatigue: training group 21%, relaxation group 19%; global health of both groups 19%, p for all < or =0.01);
__label__noRel	Aerobic exercise and psychosocial interventions have been shown to reduce the severity of this symptom in cancer patients.	however, there was no significant difference between changes in the scores of both groups (p=0.67).
__label__noRel	Aerobic exercise and psychosocial interventions have been shown to reduce the severity of this symptom in cancer patients.	We conclude that a structured aerobic training programme improves the physical performance of patients recovering from surgery for solid tumours.
__label__noRel	Aerobic exercise and psychosocial interventions have been shown to reduce the severity of this symptom in cancer patients.	However, exercise is not better than progressive relaxation training for the treatment of fatigue in this setting.
__label__noRel	Physical performance of the training group improved significantly during the programme (9.4+/-20 watts, p=0.01) but remained unchanged in the relaxation group (1.5+/-14.8 watts, p=0.37).	Aerobic exercise and psychosocial interventions have been shown to reduce the severity of this symptom in cancer patients.
__label__noRel	Physical performance of the training group improved significantly during the programme (9.4+/-20 watts, p=0.01) but remained unchanged in the relaxation group (1.5+/-14.8 watts, p=0.37).	Fatigue and global health scores improved in both groups during the intervention (fatigue: training group 21%, relaxation group 19%; global health of both groups 19%, p for all < or =0.01);
__label__noRel	Physical performance of the training group improved significantly during the programme (9.4+/-20 watts, p=0.01) but remained unchanged in the relaxation group (1.5+/-14.8 watts, p=0.37).	however, there was no significant difference between changes in the scores of both groups (p=0.67).
__label__Support	Physical performance of the training group improved significantly during the programme (9.4+/-20 watts, p=0.01) but remained unchanged in the relaxation group (1.5+/-14.8 watts, p=0.37).	We conclude that a structured aerobic training programme improves the physical performance of patients recovering from surgery for solid tumours.
__label__noRel	Physical performance of the training group improved significantly during the programme (9.4+/-20 watts, p=0.01) but remained unchanged in the relaxation group (1.5+/-14.8 watts, p=0.37).	However, exercise is not better than progressive relaxation training for the treatment of fatigue in this setting.
__label__noRel	Fatigue and global health scores improved in both groups during the intervention (fatigue: training group 21%, relaxation group 19%; global health of both groups 19%, p for all < or =0.01);	Aerobic exercise and psychosocial interventions have been shown to reduce the severity of this symptom in cancer patients.
__label__noRel	Fatigue and global health scores improved in both groups during the intervention (fatigue: training group 21%, relaxation group 19%; global health of both groups 19%, p for all < or =0.01);	Physical performance of the training group improved significantly during the programme (9.4+/-20 watts, p=0.01) but remained unchanged in the relaxation group (1.5+/-14.8 watts, p=0.37).
__label__noRel	Fatigue and global health scores improved in both groups during the intervention (fatigue: training group 21%, relaxation group 19%; global health of both groups 19%, p for all < or =0.01);	however, there was no significant difference between changes in the scores of both groups (p=0.67).
__label__noRel	Fatigue and global health scores improved in both groups during the intervention (fatigue: training group 21%, relaxation group 19%; global health of both groups 19%, p for all < or =0.01);	We conclude that a structured aerobic training programme improves the physical performance of patients recovering from surgery for solid tumours.
__label__Support	Fatigue and global health scores improved in both groups during the intervention (fatigue: training group 21%, relaxation group 19%; global health of both groups 19%, p for all < or =0.01);	However, exercise is not better than progressive relaxation training for the treatment of fatigue in this setting.
__label__noRel	however, there was no significant difference between changes in the scores of both groups (p=0.67).	Aerobic exercise and psychosocial interventions have been shown to reduce the severity of this symptom in cancer patients.
__label__noRel	however, there was no significant difference between changes in the scores of both groups (p=0.67).	Physical performance of the training group improved significantly during the programme (9.4+/-20 watts, p=0.01) but remained unchanged in the relaxation group (1.5+/-14.8 watts, p=0.37).
__label__Attack	however, there was no significant difference between changes in the scores of both groups (p=0.67).	Fatigue and global health scores improved in both groups during the intervention (fatigue: training group 21%, relaxation group 19%; global health of both groups 19%, p for all < or =0.01);
__label__noRel	however, there was no significant difference between changes in the scores of both groups (p=0.67).	We conclude that a structured aerobic training programme improves the physical performance of patients recovering from surgery for solid tumours.
__label__noRel	however, there was no significant difference between changes in the scores of both groups (p=0.67).	However, exercise is not better than progressive relaxation training for the treatment of fatigue in this setting.
__label__noRel	We conclude that a structured aerobic training programme improves the physical performance of patients recovering from surgery for solid tumours.	Aerobic exercise and psychosocial interventions have been shown to reduce the severity of this symptom in cancer patients.
__label__noRel	We conclude that a structured aerobic training programme improves the physical performance of patients recovering from surgery for solid tumours.	Physical performance of the training group improved significantly during the programme (9.4+/-20 watts, p=0.01) but remained unchanged in the relaxation group (1.5+/-14.8 watts, p=0.37).
__label__noRel	We conclude that a structured aerobic training programme improves the physical performance of patients recovering from surgery for solid tumours.	Fatigue and global health scores improved in both groups during the intervention (fatigue: training group 21%, relaxation group 19%; global health of both groups 19%, p for all < or =0.01);
__label__noRel	We conclude that a structured aerobic training programme improves the physical performance of patients recovering from surgery for solid tumours.	however, there was no significant difference between changes in the scores of both groups (p=0.67).
__label__noRel	We conclude that a structured aerobic training programme improves the physical performance of patients recovering from surgery for solid tumours.	However, exercise is not better than progressive relaxation training for the treatment of fatigue in this setting.
__label__noRel	However, exercise is not better than progressive relaxation training for the treatment of fatigue in this setting.	Aerobic exercise and psychosocial interventions have been shown to reduce the severity of this symptom in cancer patients.
__label__noRel	However, exercise is not better than progressive relaxation training for the treatment of fatigue in this setting.	Physical performance of the training group improved significantly during the programme (9.4+/-20 watts, p=0.01) but remained unchanged in the relaxation group (1.5+/-14.8 watts, p=0.37).
__label__noRel	However, exercise is not better than progressive relaxation training for the treatment of fatigue in this setting.	Fatigue and global health scores improved in both groups during the intervention (fatigue: training group 21%, relaxation group 19%; global health of both groups 19%, p for all < or =0.01);
__label__noRel	However, exercise is not better than progressive relaxation training for the treatment of fatigue in this setting.	however, there was no significant difference between changes in the scores of both groups (p=0.67).
__label__Attack	However, exercise is not better than progressive relaxation training for the treatment of fatigue in this setting.	We conclude that a structured aerobic training programme improves the physical performance of patients recovering from surgery for solid tumours.
__label__noRel	there was no significant difference regarding time to definitive deterioration of global health status/quality of life from baseline (primary endpoint).	Patients receiving FLOT exhibited higher response rates and had improved disease-free and progression-free survival (PFS).
__label__noRel	there was no significant difference regarding time to definitive deterioration of global health status/quality of life from baseline (primary endpoint).	patients receiving FLO or FLOT as palliative treatment (n = 98) achieved comparable QOL results.
__label__noRel	there was no significant difference regarding time to definitive deterioration of global health status/quality of life from baseline (primary endpoint).	Although toxicity was higher in patients receiving FLOT,
__label__noRel	there was no significant difference regarding time to definitive deterioration of global health status/quality of life from baseline (primary endpoint).	no negative impact of the addition of docetaxel on QOL parameters could be demonstrated.
__label__Support	there was no significant difference regarding time to definitive deterioration of global health status/quality of life from baseline (primary endpoint).	elderly patients in need of intensified chemotherapy may receive FLOT without compromising patient-reported outcome parameters.
__label__noRel	Patients receiving FLOT exhibited higher response rates and had improved disease-free and progression-free survival (PFS).	there was no significant difference regarding time to definitive deterioration of global health status/quality of life from baseline (primary endpoint).
__label__noRel	Patients receiving FLOT exhibited higher response rates and had improved disease-free and progression-free survival (PFS).	patients receiving FLO or FLOT as palliative treatment (n = 98) achieved comparable QOL results.
__label__noRel	Patients receiving FLOT exhibited higher response rates and had improved disease-free and progression-free survival (PFS).	Although toxicity was higher in patients receiving FLOT,
__label__noRel	Patients receiving FLOT exhibited higher response rates and had improved disease-free and progression-free survival (PFS).	no negative impact of the addition of docetaxel on QOL parameters could be demonstrated.
__label__Support	Patients receiving FLOT exhibited higher response rates and had improved disease-free and progression-free survival (PFS).	elderly patients in need of intensified chemotherapy may receive FLOT without compromising patient-reported outcome parameters.
__label__noRel	patients receiving FLO or FLOT as palliative treatment (n = 98) achieved comparable QOL results.	there was no significant difference regarding time to definitive deterioration of global health status/quality of life from baseline (primary endpoint).
__label__noRel	patients receiving FLO or FLOT as palliative treatment (n = 98) achieved comparable QOL results.	Patients receiving FLOT exhibited higher response rates and had improved disease-free and progression-free survival (PFS).
__label__noRel	patients receiving FLO or FLOT as palliative treatment (n = 98) achieved comparable QOL results.	Although toxicity was higher in patients receiving FLOT,
__label__noRel	patients receiving FLO or FLOT as palliative treatment (n = 98) achieved comparable QOL results.	no negative impact of the addition of docetaxel on QOL parameters could be demonstrated.
__label__Support	patients receiving FLO or FLOT as palliative treatment (n = 98) achieved comparable QOL results.	elderly patients in need of intensified chemotherapy may receive FLOT without compromising patient-reported outcome parameters.
__label__noRel	Although toxicity was higher in patients receiving FLOT,	there was no significant difference regarding time to definitive deterioration of global health status/quality of life from baseline (primary endpoint).
__label__noRel	Although toxicity was higher in patients receiving FLOT,	Patients receiving FLOT exhibited higher response rates and had improved disease-free and progression-free survival (PFS).
__label__noRel	Although toxicity was higher in patients receiving FLOT,	patients receiving FLO or FLOT as palliative treatment (n = 98) achieved comparable QOL results.
__label__noRel	Although toxicity was higher in patients receiving FLOT,	no negative impact of the addition of docetaxel on QOL parameters could be demonstrated.
__label__Attack	Although toxicity was higher in patients receiving FLOT,	elderly patients in need of intensified chemotherapy may receive FLOT without compromising patient-reported outcome parameters.
__label__noRel	no negative impact of the addition of docetaxel on QOL parameters could be demonstrated.	there was no significant difference regarding time to definitive deterioration of global health status/quality of life from baseline (primary endpoint).
__label__noRel	no negative impact of the addition of docetaxel on QOL parameters could be demonstrated.	Patients receiving FLOT exhibited higher response rates and had improved disease-free and progression-free survival (PFS).
__label__noRel	no negative impact of the addition of docetaxel on QOL parameters could be demonstrated.	patients receiving FLO or FLOT as palliative treatment (n = 98) achieved comparable QOL results.
__label__Attack	no negative impact of the addition of docetaxel on QOL parameters could be demonstrated.	Although toxicity was higher in patients receiving FLOT,
__label__noRel	no negative impact of the addition of docetaxel on QOL parameters could be demonstrated.	elderly patients in need of intensified chemotherapy may receive FLOT without compromising patient-reported outcome parameters.
__label__noRel	elderly patients in need of intensified chemotherapy may receive FLOT without compromising patient-reported outcome parameters.	there was no significant difference regarding time to definitive deterioration of global health status/quality of life from baseline (primary endpoint).
__label__noRel	elderly patients in need of intensified chemotherapy may receive FLOT without compromising patient-reported outcome parameters.	Patients receiving FLOT exhibited higher response rates and had improved disease-free and progression-free survival (PFS).
__label__noRel	elderly patients in need of intensified chemotherapy may receive FLOT without compromising patient-reported outcome parameters.	patients receiving FLO or FLOT as palliative treatment (n = 98) achieved comparable QOL results.
__label__noRel	elderly patients in need of intensified chemotherapy may receive FLOT without compromising patient-reported outcome parameters.	Although toxicity was higher in patients receiving FLOT,
__label__noRel	elderly patients in need of intensified chemotherapy may receive FLOT without compromising patient-reported outcome parameters.	no negative impact of the addition of docetaxel on QOL parameters could be demonstrated.
__label__noRel	Nocturnal administration of BCAA granules in patients with cirrhosis reduced the occurrence of muscle cramps in the leg but did not improve the patients' QOL.	There was no significant difference in any of the subjects revealed by the questionnaire regarding subjective or objective symptoms, or by the SF-8 between the daytime group and the nocturnal group after 3 months of treatment.
__label__noRel	Nocturnal administration of BCAA granules in patients with cirrhosis reduced the occurrence of muscle cramps in the leg but did not improve the patients' QOL.	The daytime group showed a significant effect on general health, vitality, social functioning, mental health, and role emotional as revealed on the SF-8.
__label__noRel	Nocturnal administration of BCAA granules in patients with cirrhosis reduced the occurrence of muscle cramps in the leg but did not improve the patients' QOL.	Conversely, the nocturnal group exhibited a significant decrease in the occurrence of muscle cramps in the legs (P = 0.014) and significantly improved Fisher's ratio after 3 months (P = 0.04).
__label__noRel	There was no significant difference in any of the subjects revealed by the questionnaire regarding subjective or objective symptoms, or by the SF-8 between the daytime group and the nocturnal group after 3 months of treatment.	Nocturnal administration of BCAA granules in patients with cirrhosis reduced the occurrence of muscle cramps in the leg but did not improve the patients' QOL.
__label__noRel	There was no significant difference in any of the subjects revealed by the questionnaire regarding subjective or objective symptoms, or by the SF-8 between the daytime group and the nocturnal group after 3 months of treatment.	The daytime group showed a significant effect on general health, vitality, social functioning, mental health, and role emotional as revealed on the SF-8.
__label__noRel	There was no significant difference in any of the subjects revealed by the questionnaire regarding subjective or objective symptoms, or by the SF-8 between the daytime group and the nocturnal group after 3 months of treatment.	Conversely, the nocturnal group exhibited a significant decrease in the occurrence of muscle cramps in the legs (P = 0.014) and significantly improved Fisher's ratio after 3 months (P = 0.04).
__label__noRel	The daytime group showed a significant effect on general health, vitality, social functioning, mental health, and role emotional as revealed on the SF-8.	Nocturnal administration of BCAA granules in patients with cirrhosis reduced the occurrence of muscle cramps in the leg but did not improve the patients' QOL.
__label__noRel	The daytime group showed a significant effect on general health, vitality, social functioning, mental health, and role emotional as revealed on the SF-8.	There was no significant difference in any of the subjects revealed by the questionnaire regarding subjective or objective symptoms, or by the SF-8 between the daytime group and the nocturnal group after 3 months of treatment.
__label__noRel	The daytime group showed a significant effect on general health, vitality, social functioning, mental health, and role emotional as revealed on the SF-8.	Conversely, the nocturnal group exhibited a significant decrease in the occurrence of muscle cramps in the legs (P = 0.014) and significantly improved Fisher's ratio after 3 months (P = 0.04).
__label__Support	Conversely, the nocturnal group exhibited a significant decrease in the occurrence of muscle cramps in the legs (P = 0.014) and significantly improved Fisher's ratio after 3 months (P = 0.04).	Nocturnal administration of BCAA granules in patients with cirrhosis reduced the occurrence of muscle cramps in the leg but did not improve the patients' QOL.
__label__noRel	Conversely, the nocturnal group exhibited a significant decrease in the occurrence of muscle cramps in the legs (P = 0.014) and significantly improved Fisher's ratio after 3 months (P = 0.04).	There was no significant difference in any of the subjects revealed by the questionnaire regarding subjective or objective symptoms, or by the SF-8 between the daytime group and the nocturnal group after 3 months of treatment.
__label__noRel	Conversely, the nocturnal group exhibited a significant decrease in the occurrence of muscle cramps in the legs (P = 0.014) and significantly improved Fisher's ratio after 3 months (P = 0.04).	The daytime group showed a significant effect on general health, vitality, social functioning, mental health, and role emotional as revealed on the SF-8.
__label__Support	Postoperative side effects were significantly less in the SLN group and there was no negative impact of the SLN procedure on psychologic well being.	SLN biopsy is an effective and well-tolerated procedure.
__label__noRel	Postoperative side effects were significantly less in the SLN group and there was no negative impact of the SLN procedure on psychologic well being.	However, its safety should be confirmed by the results of larger randomized trials and meta-analyses.
__label__noRel	Postoperative side effects were significantly less in the SLN group and there was no negative impact of the SLN procedure on psychologic well being.	However, the number of enrolled patients was not sufficient to draw definitive conclusions.
__label__noRel	SLN biopsy is an effective and well-tolerated procedure.	Postoperative side effects were significantly less in the SLN group and there was no negative impact of the SLN procedure on psychologic well being.
__label__noRel	SLN biopsy is an effective and well-tolerated procedure.	However, its safety should be confirmed by the results of larger randomized trials and meta-analyses.
__label__noRel	SLN biopsy is an effective and well-tolerated procedure.	However, the number of enrolled patients was not sufficient to draw definitive conclusions.
__label__noRel	However, its safety should be confirmed by the results of larger randomized trials and meta-analyses.	Postoperative side effects were significantly less in the SLN group and there was no negative impact of the SLN procedure on psychologic well being.
__label__Attack	However, its safety should be confirmed by the results of larger randomized trials and meta-analyses.	SLN biopsy is an effective and well-tolerated procedure.
__label__noRel	However, its safety should be confirmed by the results of larger randomized trials and meta-analyses.	However, the number of enrolled patients was not sufficient to draw definitive conclusions.
__label__noRel	However, the number of enrolled patients was not sufficient to draw definitive conclusions.	Postoperative side effects were significantly less in the SLN group and there was no negative impact of the SLN procedure on psychologic well being.
__label__noRel	However, the number of enrolled patients was not sufficient to draw definitive conclusions.	SLN biopsy is an effective and well-tolerated procedure.
__label__Support	However, the number of enrolled patients was not sufficient to draw definitive conclusions.	However, its safety should be confirmed by the results of larger randomized trials and meta-analyses.
__label__noRel	The mean reduction in AK count was 59.2% for ALA-PDT and 41.4% for imiquimod 5% cream (p=.002).	The 75% AK clearance rate was 34.6% for ALA-PDT and 25% for imiquimod 5% cream (p=.30).
__label__noRel	The mean reduction in AK count was 59.2% for ALA-PDT and 41.4% for imiquimod 5% cream (p=.002).	Dermatology Life Quality Index (DLQI) scores were assessed for each treatment modality at week 4 and were 1.95 and 1.38, respectively (p=.20).
__label__noRel	The mean reduction in AK count was 59.2% for ALA-PDT and 41.4% for imiquimod 5% cream (p=.002).	The sample size was small, and patients applied a small amount of imiquimod 5% cream (half a sachet) to a large surface area.
__label__noRel	The mean reduction in AK count was 59.2% for ALA-PDT and 41.4% for imiquimod 5% cream (p=.002).	There was no statistically significant difference in treatment response when the 100% or 75% clearance rate cutoff was used,
__label__Support	The mean reduction in AK count was 59.2% for ALA-PDT and 41.4% for imiquimod 5% cream (p=.002).	but our secondary outcome suggests that two sessions of ALA-PDT is superior to imiquimod 5% cream for the treatment of AKs.
__label__noRel	The mean reduction in AK count was 59.2% for ALA-PDT and 41.4% for imiquimod 5% cream (p=.002).	There was no statistically significant difference in effect on quality of life as assessed using the DLQI.
__label__noRel	The 75% AK clearance rate was 34.6% for ALA-PDT and 25% for imiquimod 5% cream (p=.30).	The mean reduction in AK count was 59.2% for ALA-PDT and 41.4% for imiquimod 5% cream (p=.002).
__label__noRel	The 75% AK clearance rate was 34.6% for ALA-PDT and 25% for imiquimod 5% cream (p=.30).	Dermatology Life Quality Index (DLQI) scores were assessed for each treatment modality at week 4 and were 1.95 and 1.38, respectively (p=.20).
__label__noRel	The 75% AK clearance rate was 34.6% for ALA-PDT and 25% for imiquimod 5% cream (p=.30).	The sample size was small, and patients applied a small amount of imiquimod 5% cream (half a sachet) to a large surface area.
__label__noRel	The 75% AK clearance rate was 34.6% for ALA-PDT and 25% for imiquimod 5% cream (p=.30).	There was no statistically significant difference in treatment response when the 100% or 75% clearance rate cutoff was used,
__label__Support	The 75% AK clearance rate was 34.6% for ALA-PDT and 25% for imiquimod 5% cream (p=.30).	but our secondary outcome suggests that two sessions of ALA-PDT is superior to imiquimod 5% cream for the treatment of AKs.
__label__noRel	The 75% AK clearance rate was 34.6% for ALA-PDT and 25% for imiquimod 5% cream (p=.30).	There was no statistically significant difference in effect on quality of life as assessed using the DLQI.
__label__noRel	Dermatology Life Quality Index (DLQI) scores were assessed for each treatment modality at week 4 and were 1.95 and 1.38, respectively (p=.20).	The mean reduction in AK count was 59.2% for ALA-PDT and 41.4% for imiquimod 5% cream (p=.002).
__label__noRel	Dermatology Life Quality Index (DLQI) scores were assessed for each treatment modality at week 4 and were 1.95 and 1.38, respectively (p=.20).	The 75% AK clearance rate was 34.6% for ALA-PDT and 25% for imiquimod 5% cream (p=.30).
__label__noRel	Dermatology Life Quality Index (DLQI) scores were assessed for each treatment modality at week 4 and were 1.95 and 1.38, respectively (p=.20).	The sample size was small, and patients applied a small amount of imiquimod 5% cream (half a sachet) to a large surface area.
__label__noRel	Dermatology Life Quality Index (DLQI) scores were assessed for each treatment modality at week 4 and were 1.95 and 1.38, respectively (p=.20).	There was no statistically significant difference in treatment response when the 100% or 75% clearance rate cutoff was used,
__label__noRel	Dermatology Life Quality Index (DLQI) scores were assessed for each treatment modality at week 4 and were 1.95 and 1.38, respectively (p=.20).	but our secondary outcome suggests that two sessions of ALA-PDT is superior to imiquimod 5% cream for the treatment of AKs.
__label__Support	Dermatology Life Quality Index (DLQI) scores were assessed for each treatment modality at week 4 and were 1.95 and 1.38, respectively (p=.20).	There was no statistically significant difference in effect on quality of life as assessed using the DLQI.
__label__noRel	The sample size was small, and patients applied a small amount of imiquimod 5% cream (half a sachet) to a large surface area.	The mean reduction in AK count was 59.2% for ALA-PDT and 41.4% for imiquimod 5% cream (p=.002).
__label__noRel	The sample size was small, and patients applied a small amount of imiquimod 5% cream (half a sachet) to a large surface area.	The 75% AK clearance rate was 34.6% for ALA-PDT and 25% for imiquimod 5% cream (p=.30).
__label__noRel	The sample size was small, and patients applied a small amount of imiquimod 5% cream (half a sachet) to a large surface area.	Dermatology Life Quality Index (DLQI) scores were assessed for each treatment modality at week 4 and were 1.95 and 1.38, respectively (p=.20).
__label__noRel	The sample size was small, and patients applied a small amount of imiquimod 5% cream (half a sachet) to a large surface area.	There was no statistically significant difference in treatment response when the 100% or 75% clearance rate cutoff was used,
__label__noRel	The sample size was small, and patients applied a small amount of imiquimod 5% cream (half a sachet) to a large surface area.	but our secondary outcome suggests that two sessions of ALA-PDT is superior to imiquimod 5% cream for the treatment of AKs.
__label__Attack	The sample size was small, and patients applied a small amount of imiquimod 5% cream (half a sachet) to a large surface area.	There was no statistically significant difference in effect on quality of life as assessed using the DLQI.
__label__noRel	There was no statistically significant difference in treatment response when the 100% or 75% clearance rate cutoff was used,	The mean reduction in AK count was 59.2% for ALA-PDT and 41.4% for imiquimod 5% cream (p=.002).
__label__noRel	There was no statistically significant difference in treatment response when the 100% or 75% clearance rate cutoff was used,	The 75% AK clearance rate was 34.6% for ALA-PDT and 25% for imiquimod 5% cream (p=.30).
__label__noRel	There was no statistically significant difference in treatment response when the 100% or 75% clearance rate cutoff was used,	Dermatology Life Quality Index (DLQI) scores were assessed for each treatment modality at week 4 and were 1.95 and 1.38, respectively (p=.20).
__label__noRel	There was no statistically significant difference in treatment response when the 100% or 75% clearance rate cutoff was used,	The sample size was small, and patients applied a small amount of imiquimod 5% cream (half a sachet) to a large surface area.
__label__noRel	There was no statistically significant difference in treatment response when the 100% or 75% clearance rate cutoff was used,	but our secondary outcome suggests that two sessions of ALA-PDT is superior to imiquimod 5% cream for the treatment of AKs.
__label__noRel	There was no statistically significant difference in treatment response when the 100% or 75% clearance rate cutoff was used,	There was no statistically significant difference in effect on quality of life as assessed using the DLQI.
__label__noRel	but our secondary outcome suggests that two sessions of ALA-PDT is superior to imiquimod 5% cream for the treatment of AKs.	The mean reduction in AK count was 59.2% for ALA-PDT and 41.4% for imiquimod 5% cream (p=.002).
__label__noRel	but our secondary outcome suggests that two sessions of ALA-PDT is superior to imiquimod 5% cream for the treatment of AKs.	The 75% AK clearance rate was 34.6% for ALA-PDT and 25% for imiquimod 5% cream (p=.30).
__label__noRel	but our secondary outcome suggests that two sessions of ALA-PDT is superior to imiquimod 5% cream for the treatment of AKs.	Dermatology Life Quality Index (DLQI) scores were assessed for each treatment modality at week 4 and were 1.95 and 1.38, respectively (p=.20).
__label__noRel	but our secondary outcome suggests that two sessions of ALA-PDT is superior to imiquimod 5% cream for the treatment of AKs.	The sample size was small, and patients applied a small amount of imiquimod 5% cream (half a sachet) to a large surface area.
__label__Attack	but our secondary outcome suggests that two sessions of ALA-PDT is superior to imiquimod 5% cream for the treatment of AKs.	There was no statistically significant difference in treatment response when the 100% or 75% clearance rate cutoff was used,
__label__noRel	but our secondary outcome suggests that two sessions of ALA-PDT is superior to imiquimod 5% cream for the treatment of AKs.	There was no statistically significant difference in effect on quality of life as assessed using the DLQI.
__label__noRel	There was no statistically significant difference in effect on quality of life as assessed using the DLQI.	The mean reduction in AK count was 59.2% for ALA-PDT and 41.4% for imiquimod 5% cream (p=.002).
__label__noRel	There was no statistically significant difference in effect on quality of life as assessed using the DLQI.	The 75% AK clearance rate was 34.6% for ALA-PDT and 25% for imiquimod 5% cream (p=.30).
__label__noRel	There was no statistically significant difference in effect on quality of life as assessed using the DLQI.	Dermatology Life Quality Index (DLQI) scores were assessed for each treatment modality at week 4 and were 1.95 and 1.38, respectively (p=.20).
__label__noRel	There was no statistically significant difference in effect on quality of life as assessed using the DLQI.	The sample size was small, and patients applied a small amount of imiquimod 5% cream (half a sachet) to a large surface area.
__label__noRel	There was no statistically significant difference in effect on quality of life as assessed using the DLQI.	There was no statistically significant difference in treatment response when the 100% or 75% clearance rate cutoff was used,
__label__noRel	There was no statistically significant difference in effect on quality of life as assessed using the DLQI.	but our secondary outcome suggests that two sessions of ALA-PDT is superior to imiquimod 5% cream for the treatment of AKs.
__label__noRel	The overall response rate was 16% in the PLD arm compared with 29% in the GEM arm (P = .056).	No statistically significant difference in time to progression (TTP) curves according to treatment allocation was documented (P = .411).
__label__noRel	The overall response rate was 16% in the PLD arm compared with 29% in the GEM arm (P = .056).	However, a trend for more favorable overall survival was documented in the PLD arm compared with the GEM arm,
__label__noRel	The overall response rate was 16% in the PLD arm compared with 29% in the GEM arm (P = .056).	although the P value was of borderline statistical significance (P = .048).
__label__noRel	The overall response rate was 16% in the PLD arm compared with 29% in the GEM arm (P = .056).	Statistically significantly higher global QOL scores were found in PLD-treated patients at the first and second postbaseline QOL assessments.
__label__noRel	The overall response rate was 16% in the PLD arm compared with 29% in the GEM arm (P = .056).	GEM does not provide an advantage compared with PLD in terms of TTP in ovarian cancer patients who experience recurrence within 12 months after primary treatment but should be considered in the spectrum of drugs to be possibly used in the salvage setting.
__label__noRel	No statistically significant difference in time to progression (TTP) curves according to treatment allocation was documented (P = .411).	The overall response rate was 16% in the PLD arm compared with 29% in the GEM arm (P = .056).
__label__noRel	No statistically significant difference in time to progression (TTP) curves according to treatment allocation was documented (P = .411).	However, a trend for more favorable overall survival was documented in the PLD arm compared with the GEM arm,
__label__noRel	No statistically significant difference in time to progression (TTP) curves according to treatment allocation was documented (P = .411).	although the P value was of borderline statistical significance (P = .048).
__label__noRel	No statistically significant difference in time to progression (TTP) curves according to treatment allocation was documented (P = .411).	Statistically significantly higher global QOL scores were found in PLD-treated patients at the first and second postbaseline QOL assessments.
__label__Support	No statistically significant difference in time to progression (TTP) curves according to treatment allocation was documented (P = .411).	GEM does not provide an advantage compared with PLD in terms of TTP in ovarian cancer patients who experience recurrence within 12 months after primary treatment but should be considered in the spectrum of drugs to be possibly used in the salvage setting.
__label__noRel	However, a trend for more favorable overall survival was documented in the PLD arm compared with the GEM arm,	The overall response rate was 16% in the PLD arm compared with 29% in the GEM arm (P = .056).
__label__Attack	However, a trend for more favorable overall survival was documented in the PLD arm compared with the GEM arm,	No statistically significant difference in time to progression (TTP) curves according to treatment allocation was documented (P = .411).
__label__noRel	However, a trend for more favorable overall survival was documented in the PLD arm compared with the GEM arm,	although the P value was of borderline statistical significance (P = .048).
__label__noRel	However, a trend for more favorable overall survival was documented in the PLD arm compared with the GEM arm,	Statistically significantly higher global QOL scores were found in PLD-treated patients at the first and second postbaseline QOL assessments.
__label__noRel	However, a trend for more favorable overall survival was documented in the PLD arm compared with the GEM arm,	GEM does not provide an advantage compared with PLD in terms of TTP in ovarian cancer patients who experience recurrence within 12 months after primary treatment but should be considered in the spectrum of drugs to be possibly used in the salvage setting.
__label__noRel	although the P value was of borderline statistical significance (P = .048).	The overall response rate was 16% in the PLD arm compared with 29% in the GEM arm (P = .056).
__label__noRel	although the P value was of borderline statistical significance (P = .048).	No statistically significant difference in time to progression (TTP) curves according to treatment allocation was documented (P = .411).
__label__Attack	although the P value was of borderline statistical significance (P = .048).	However, a trend for more favorable overall survival was documented in the PLD arm compared with the GEM arm,
__label__noRel	although the P value was of borderline statistical significance (P = .048).	Statistically significantly higher global QOL scores were found in PLD-treated patients at the first and second postbaseline QOL assessments.
__label__noRel	although the P value was of borderline statistical significance (P = .048).	GEM does not provide an advantage compared with PLD in terms of TTP in ovarian cancer patients who experience recurrence within 12 months after primary treatment but should be considered in the spectrum of drugs to be possibly used in the salvage setting.
__label__noRel	Statistically significantly higher global QOL scores were found in PLD-treated patients at the first and second postbaseline QOL assessments.	The overall response rate was 16% in the PLD arm compared with 29% in the GEM arm (P = .056).
__label__noRel	Statistically significantly higher global QOL scores were found in PLD-treated patients at the first and second postbaseline QOL assessments.	No statistically significant difference in time to progression (TTP) curves according to treatment allocation was documented (P = .411).
__label__noRel	Statistically significantly higher global QOL scores were found in PLD-treated patients at the first and second postbaseline QOL assessments.	However, a trend for more favorable overall survival was documented in the PLD arm compared with the GEM arm,
__label__noRel	Statistically significantly higher global QOL scores were found in PLD-treated patients at the first and second postbaseline QOL assessments.	although the P value was of borderline statistical significance (P = .048).
__label__noRel	Statistically significantly higher global QOL scores were found in PLD-treated patients at the first and second postbaseline QOL assessments.	GEM does not provide an advantage compared with PLD in terms of TTP in ovarian cancer patients who experience recurrence within 12 months after primary treatment but should be considered in the spectrum of drugs to be possibly used in the salvage setting.
__label__noRel	GEM does not provide an advantage compared with PLD in terms of TTP in ovarian cancer patients who experience recurrence within 12 months after primary treatment but should be considered in the spectrum of drugs to be possibly used in the salvage setting.	The overall response rate was 16% in the PLD arm compared with 29% in the GEM arm (P = .056).
__label__noRel	GEM does not provide an advantage compared with PLD in terms of TTP in ovarian cancer patients who experience recurrence within 12 months after primary treatment but should be considered in the spectrum of drugs to be possibly used in the salvage setting.	No statistically significant difference in time to progression (TTP) curves according to treatment allocation was documented (P = .411).
__label__noRel	GEM does not provide an advantage compared with PLD in terms of TTP in ovarian cancer patients who experience recurrence within 12 months after primary treatment but should be considered in the spectrum of drugs to be possibly used in the salvage setting.	However, a trend for more favorable overall survival was documented in the PLD arm compared with the GEM arm,
__label__noRel	GEM does not provide an advantage compared with PLD in terms of TTP in ovarian cancer patients who experience recurrence within 12 months after primary treatment but should be considered in the spectrum of drugs to be possibly used in the salvage setting.	although the P value was of borderline statistical significance (P = .048).
__label__noRel	GEM does not provide an advantage compared with PLD in terms of TTP in ovarian cancer patients who experience recurrence within 12 months after primary treatment but should be considered in the spectrum of drugs to be possibly used in the salvage setting.	Statistically significantly higher global QOL scores were found in PLD-treated patients at the first and second postbaseline QOL assessments.
__label__noRel	Utility scores were significantly lower in the DTX group than in the ACP and ACD groups.	Mean utility scores in the DTX group were lowest at 7 months and tended to remain low for a long time.
__label__noRel	Utility scores were significantly lower in the DTX group than in the ACP and ACD groups.	The combined anthracycline followed by taxane group had significantly higher utility scores that the taxane-alone group, with no significant difference depending on the type of taxane.
__label__noRel	Utility scores were significantly lower in the DTX group than in the ACP and ACD groups.	Only the FACT-G social/family well-being subscale had no relationship with EQ-5D responses and utility scores.
__label__Support	Utility scores were significantly lower in the DTX group than in the ACP and ACD groups.	Although the regimens in this study were similar in that they included taxane, the mean utility scores and longitudinal patterns of utility scores were different among regimens.
__label__noRel	Mean utility scores in the DTX group were lowest at 7 months and tended to remain low for a long time.	Utility scores were significantly lower in the DTX group than in the ACP and ACD groups.
__label__noRel	Mean utility scores in the DTX group were lowest at 7 months and tended to remain low for a long time.	The combined anthracycline followed by taxane group had significantly higher utility scores that the taxane-alone group, with no significant difference depending on the type of taxane.
__label__noRel	Mean utility scores in the DTX group were lowest at 7 months and tended to remain low for a long time.	Only the FACT-G social/family well-being subscale had no relationship with EQ-5D responses and utility scores.
__label__noRel	Mean utility scores in the DTX group were lowest at 7 months and tended to remain low for a long time.	Although the regimens in this study were similar in that they included taxane, the mean utility scores and longitudinal patterns of utility scores were different among regimens.
__label__noRel	The combined anthracycline followed by taxane group had significantly higher utility scores that the taxane-alone group, with no significant difference depending on the type of taxane.	Utility scores were significantly lower in the DTX group than in the ACP and ACD groups.
__label__noRel	The combined anthracycline followed by taxane group had significantly higher utility scores that the taxane-alone group, with no significant difference depending on the type of taxane.	Mean utility scores in the DTX group were lowest at 7 months and tended to remain low for a long time.
__label__noRel	The combined anthracycline followed by taxane group had significantly higher utility scores that the taxane-alone group, with no significant difference depending on the type of taxane.	Only the FACT-G social/family well-being subscale had no relationship with EQ-5D responses and utility scores.
__label__Support	The combined anthracycline followed by taxane group had significantly higher utility scores that the taxane-alone group, with no significant difference depending on the type of taxane.	Although the regimens in this study were similar in that they included taxane, the mean utility scores and longitudinal patterns of utility scores were different among regimens.
__label__noRel	Only the FACT-G social/family well-being subscale had no relationship with EQ-5D responses and utility scores.	Utility scores were significantly lower in the DTX group than in the ACP and ACD groups.
__label__noRel	Only the FACT-G social/family well-being subscale had no relationship with EQ-5D responses and utility scores.	Mean utility scores in the DTX group were lowest at 7 months and tended to remain low for a long time.
__label__noRel	Only the FACT-G social/family well-being subscale had no relationship with EQ-5D responses and utility scores.	The combined anthracycline followed by taxane group had significantly higher utility scores that the taxane-alone group, with no significant difference depending on the type of taxane.
__label__noRel	Only the FACT-G social/family well-being subscale had no relationship with EQ-5D responses and utility scores.	Although the regimens in this study were similar in that they included taxane, the mean utility scores and longitudinal patterns of utility scores were different among regimens.
__label__noRel	Although the regimens in this study were similar in that they included taxane, the mean utility scores and longitudinal patterns of utility scores were different among regimens.	Utility scores were significantly lower in the DTX group than in the ACP and ACD groups.
__label__noRel	Although the regimens in this study were similar in that they included taxane, the mean utility scores and longitudinal patterns of utility scores were different among regimens.	Mean utility scores in the DTX group were lowest at 7 months and tended to remain low for a long time.
__label__noRel	Although the regimens in this study were similar in that they included taxane, the mean utility scores and longitudinal patterns of utility scores were different among regimens.	The combined anthracycline followed by taxane group had significantly higher utility scores that the taxane-alone group, with no significant difference depending on the type of taxane.
__label__noRel	Although the regimens in this study were similar in that they included taxane, the mean utility scores and longitudinal patterns of utility scores were different among regimens.	Only the FACT-G social/family well-being subscale had no relationship with EQ-5D responses and utility scores.
__label__noRel	Median progression-free survival was 18.2 months in the TC-Top arm versus 18.5 months in the TC arm (stratum-adjusted HR = 0.97 [95% CI = 0.85 to 1.10]; P = .688).	Median overall survival was 43.1 months for the TC-Top arm versus 44.5 months for the TC arm (stratum-adjusted HR = 1.01 [95% CI = 0.86 to 1.18]; P = .885).
__label__noRel	Median progression-free survival was 18.2 months in the TC-Top arm versus 18.5 months in the TC arm (stratum-adjusted HR = 0.97 [95% CI = 0.85 to 1.10]; P = .688).	At 3 years, overall survival in both arms was 57% (58.5% in the TC arm and 55.7% in the TC-Top arm).
__label__noRel	Median progression-free survival was 18.2 months in the TC-Top arm versus 18.5 months in the TC arm (stratum-adjusted HR = 0.97 [95% CI = 0.85 to 1.10]; P = .688).	Compared with patients in the TC arm, patients in the TC-Top arm had more grade 3-4 hematologic toxic effects (requiring more supportive care) and more grade 3-4 infections (5.1% versus 2.7%; P = .034) but did not have a statistically significant increase in febrile neutropenia (3.3% versus 3.1%; P = .80).
__label__noRel	Median progression-free survival was 18.2 months in the TC-Top arm versus 18.5 months in the TC arm (stratum-adjusted HR = 0.97 [95% CI = 0.85 to 1.10]; P = .688).	Among patients who had measurable disease (TC, n = 147; TC-Top, n = 145), overall (i.e., complete or partial) response was 69.0% (95% CI = 61.4% to 76.5%) in the TC-Top arm and 76.2% (95% CI = 69.3% to 83.1%) in the TC arm (P = .166).
__label__Support	Median progression-free survival was 18.2 months in the TC-Top arm versus 18.5 months in the TC arm (stratum-adjusted HR = 0.97 [95% CI = 0.85 to 1.10]; P = .688).	The sequential addition of topotecan to carboplatin-paclitaxel did not result in superior overall response or progression-free or overall survival.
__label__noRel	Median progression-free survival was 18.2 months in the TC-Top arm versus 18.5 months in the TC arm (stratum-adjusted HR = 0.97 [95% CI = 0.85 to 1.10]; P = .688).	Therefore, this regimen is not recommended as standard of care treatment for ovarian cancer.
__label__noRel	Median overall survival was 43.1 months for the TC-Top arm versus 44.5 months for the TC arm (stratum-adjusted HR = 1.01 [95% CI = 0.86 to 1.18]; P = .885).	Median progression-free survival was 18.2 months in the TC-Top arm versus 18.5 months in the TC arm (stratum-adjusted HR = 0.97 [95% CI = 0.85 to 1.10]; P = .688).
__label__noRel	Median overall survival was 43.1 months for the TC-Top arm versus 44.5 months for the TC arm (stratum-adjusted HR = 1.01 [95% CI = 0.86 to 1.18]; P = .885).	At 3 years, overall survival in both arms was 57% (58.5% in the TC arm and 55.7% in the TC-Top arm).
__label__noRel	Median overall survival was 43.1 months for the TC-Top arm versus 44.5 months for the TC arm (stratum-adjusted HR = 1.01 [95% CI = 0.86 to 1.18]; P = .885).	Compared with patients in the TC arm, patients in the TC-Top arm had more grade 3-4 hematologic toxic effects (requiring more supportive care) and more grade 3-4 infections (5.1% versus 2.7%; P = .034) but did not have a statistically significant increase in febrile neutropenia (3.3% versus 3.1%; P = .80).
__label__noRel	Median overall survival was 43.1 months for the TC-Top arm versus 44.5 months for the TC arm (stratum-adjusted HR = 1.01 [95% CI = 0.86 to 1.18]; P = .885).	Among patients who had measurable disease (TC, n = 147; TC-Top, n = 145), overall (i.e., complete or partial) response was 69.0% (95% CI = 61.4% to 76.5%) in the TC-Top arm and 76.2% (95% CI = 69.3% to 83.1%) in the TC arm (P = .166).
__label__Support	Median overall survival was 43.1 months for the TC-Top arm versus 44.5 months for the TC arm (stratum-adjusted HR = 1.01 [95% CI = 0.86 to 1.18]; P = .885).	The sequential addition of topotecan to carboplatin-paclitaxel did not result in superior overall response or progression-free or overall survival.
__label__noRel	Median overall survival was 43.1 months for the TC-Top arm versus 44.5 months for the TC arm (stratum-adjusted HR = 1.01 [95% CI = 0.86 to 1.18]; P = .885).	Therefore, this regimen is not recommended as standard of care treatment for ovarian cancer.
__label__noRel	At 3 years, overall survival in both arms was 57% (58.5% in the TC arm and 55.7% in the TC-Top arm).	Median progression-free survival was 18.2 months in the TC-Top arm versus 18.5 months in the TC arm (stratum-adjusted HR = 0.97 [95% CI = 0.85 to 1.10]; P = .688).
__label__noRel	At 3 years, overall survival in both arms was 57% (58.5% in the TC arm and 55.7% in the TC-Top arm).	Median overall survival was 43.1 months for the TC-Top arm versus 44.5 months for the TC arm (stratum-adjusted HR = 1.01 [95% CI = 0.86 to 1.18]; P = .885).
__label__noRel	At 3 years, overall survival in both arms was 57% (58.5% in the TC arm and 55.7% in the TC-Top arm).	Compared with patients in the TC arm, patients in the TC-Top arm had more grade 3-4 hematologic toxic effects (requiring more supportive care) and more grade 3-4 infections (5.1% versus 2.7%; P = .034) but did not have a statistically significant increase in febrile neutropenia (3.3% versus 3.1%; P = .80).
__label__noRel	At 3 years, overall survival in both arms was 57% (58.5% in the TC arm and 55.7% in the TC-Top arm).	Among patients who had measurable disease (TC, n = 147; TC-Top, n = 145), overall (i.e., complete or partial) response was 69.0% (95% CI = 61.4% to 76.5%) in the TC-Top arm and 76.2% (95% CI = 69.3% to 83.1%) in the TC arm (P = .166).
__label__Support	At 3 years, overall survival in both arms was 57% (58.5% in the TC arm and 55.7% in the TC-Top arm).	The sequential addition of topotecan to carboplatin-paclitaxel did not result in superior overall response or progression-free or overall survival.
__label__noRel	At 3 years, overall survival in both arms was 57% (58.5% in the TC arm and 55.7% in the TC-Top arm).	Therefore, this regimen is not recommended as standard of care treatment for ovarian cancer.
__label__noRel	Compared with patients in the TC arm, patients in the TC-Top arm had more grade 3-4 hematologic toxic effects (requiring more supportive care) and more grade 3-4 infections (5.1% versus 2.7%; P = .034) but did not have a statistically significant increase in febrile neutropenia (3.3% versus 3.1%; P = .80).	Median progression-free survival was 18.2 months in the TC-Top arm versus 18.5 months in the TC arm (stratum-adjusted HR = 0.97 [95% CI = 0.85 to 1.10]; P = .688).
__label__noRel	Compared with patients in the TC arm, patients in the TC-Top arm had more grade 3-4 hematologic toxic effects (requiring more supportive care) and more grade 3-4 infections (5.1% versus 2.7%; P = .034) but did not have a statistically significant increase in febrile neutropenia (3.3% versus 3.1%; P = .80).	Median overall survival was 43.1 months for the TC-Top arm versus 44.5 months for the TC arm (stratum-adjusted HR = 1.01 [95% CI = 0.86 to 1.18]; P = .885).
__label__noRel	Compared with patients in the TC arm, patients in the TC-Top arm had more grade 3-4 hematologic toxic effects (requiring more supportive care) and more grade 3-4 infections (5.1% versus 2.7%; P = .034) but did not have a statistically significant increase in febrile neutropenia (3.3% versus 3.1%; P = .80).	At 3 years, overall survival in both arms was 57% (58.5% in the TC arm and 55.7% in the TC-Top arm).
__label__noRel	Compared with patients in the TC arm, patients in the TC-Top arm had more grade 3-4 hematologic toxic effects (requiring more supportive care) and more grade 3-4 infections (5.1% versus 2.7%; P = .034) but did not have a statistically significant increase in febrile neutropenia (3.3% versus 3.1%; P = .80).	Among patients who had measurable disease (TC, n = 147; TC-Top, n = 145), overall (i.e., complete or partial) response was 69.0% (95% CI = 61.4% to 76.5%) in the TC-Top arm and 76.2% (95% CI = 69.3% to 83.1%) in the TC arm (P = .166).
__label__noRel	Compared with patients in the TC arm, patients in the TC-Top arm had more grade 3-4 hematologic toxic effects (requiring more supportive care) and more grade 3-4 infections (5.1% versus 2.7%; P = .034) but did not have a statistically significant increase in febrile neutropenia (3.3% versus 3.1%; P = .80).	The sequential addition of topotecan to carboplatin-paclitaxel did not result in superior overall response or progression-free or overall survival.
__label__Support	Compared with patients in the TC arm, patients in the TC-Top arm had more grade 3-4 hematologic toxic effects (requiring more supportive care) and more grade 3-4 infections (5.1% versus 2.7%; P = .034) but did not have a statistically significant increase in febrile neutropenia (3.3% versus 3.1%; P = .80).	Therefore, this regimen is not recommended as standard of care treatment for ovarian cancer.
__label__noRel	Among patients who had measurable disease (TC, n = 147; TC-Top, n = 145), overall (i.e., complete or partial) response was 69.0% (95% CI = 61.4% to 76.5%) in the TC-Top arm and 76.2% (95% CI = 69.3% to 83.1%) in the TC arm (P = .166).	Median progression-free survival was 18.2 months in the TC-Top arm versus 18.5 months in the TC arm (stratum-adjusted HR = 0.97 [95% CI = 0.85 to 1.10]; P = .688).
__label__noRel	Among patients who had measurable disease (TC, n = 147; TC-Top, n = 145), overall (i.e., complete or partial) response was 69.0% (95% CI = 61.4% to 76.5%) in the TC-Top arm and 76.2% (95% CI = 69.3% to 83.1%) in the TC arm (P = .166).	Median overall survival was 43.1 months for the TC-Top arm versus 44.5 months for the TC arm (stratum-adjusted HR = 1.01 [95% CI = 0.86 to 1.18]; P = .885).
__label__noRel	Among patients who had measurable disease (TC, n = 147; TC-Top, n = 145), overall (i.e., complete or partial) response was 69.0% (95% CI = 61.4% to 76.5%) in the TC-Top arm and 76.2% (95% CI = 69.3% to 83.1%) in the TC arm (P = .166).	At 3 years, overall survival in both arms was 57% (58.5% in the TC arm and 55.7% in the TC-Top arm).
__label__noRel	Among patients who had measurable disease (TC, n = 147; TC-Top, n = 145), overall (i.e., complete or partial) response was 69.0% (95% CI = 61.4% to 76.5%) in the TC-Top arm and 76.2% (95% CI = 69.3% to 83.1%) in the TC arm (P = .166).	Compared with patients in the TC arm, patients in the TC-Top arm had more grade 3-4 hematologic toxic effects (requiring more supportive care) and more grade 3-4 infections (5.1% versus 2.7%; P = .034) but did not have a statistically significant increase in febrile neutropenia (3.3% versus 3.1%; P = .80).
__label__Support	Among patients who had measurable disease (TC, n = 147; TC-Top, n = 145), overall (i.e., complete or partial) response was 69.0% (95% CI = 61.4% to 76.5%) in the TC-Top arm and 76.2% (95% CI = 69.3% to 83.1%) in the TC arm (P = .166).	The sequential addition of topotecan to carboplatin-paclitaxel did not result in superior overall response or progression-free or overall survival.
__label__noRel	Among patients who had measurable disease (TC, n = 147; TC-Top, n = 145), overall (i.e., complete or partial) response was 69.0% (95% CI = 61.4% to 76.5%) in the TC-Top arm and 76.2% (95% CI = 69.3% to 83.1%) in the TC arm (P = .166).	Therefore, this regimen is not recommended as standard of care treatment for ovarian cancer.
__label__noRel	The sequential addition of topotecan to carboplatin-paclitaxel did not result in superior overall response or progression-free or overall survival.	Median progression-free survival was 18.2 months in the TC-Top arm versus 18.5 months in the TC arm (stratum-adjusted HR = 0.97 [95% CI = 0.85 to 1.10]; P = .688).
__label__noRel	The sequential addition of topotecan to carboplatin-paclitaxel did not result in superior overall response or progression-free or overall survival.	Median overall survival was 43.1 months for the TC-Top arm versus 44.5 months for the TC arm (stratum-adjusted HR = 1.01 [95% CI = 0.86 to 1.18]; P = .885).
__label__noRel	The sequential addition of topotecan to carboplatin-paclitaxel did not result in superior overall response or progression-free or overall survival.	At 3 years, overall survival in both arms was 57% (58.5% in the TC arm and 55.7% in the TC-Top arm).
__label__noRel	The sequential addition of topotecan to carboplatin-paclitaxel did not result in superior overall response or progression-free or overall survival.	Compared with patients in the TC arm, patients in the TC-Top arm had more grade 3-4 hematologic toxic effects (requiring more supportive care) and more grade 3-4 infections (5.1% versus 2.7%; P = .034) but did not have a statistically significant increase in febrile neutropenia (3.3% versus 3.1%; P = .80).
__label__noRel	The sequential addition of topotecan to carboplatin-paclitaxel did not result in superior overall response or progression-free or overall survival.	Among patients who had measurable disease (TC, n = 147; TC-Top, n = 145), overall (i.e., complete or partial) response was 69.0% (95% CI = 61.4% to 76.5%) in the TC-Top arm and 76.2% (95% CI = 69.3% to 83.1%) in the TC arm (P = .166).
__label__Support	The sequential addition of topotecan to carboplatin-paclitaxel did not result in superior overall response or progression-free or overall survival.	Therefore, this regimen is not recommended as standard of care treatment for ovarian cancer.
__label__noRel	Therefore, this regimen is not recommended as standard of care treatment for ovarian cancer.	Median progression-free survival was 18.2 months in the TC-Top arm versus 18.5 months in the TC arm (stratum-adjusted HR = 0.97 [95% CI = 0.85 to 1.10]; P = .688).
__label__noRel	Therefore, this regimen is not recommended as standard of care treatment for ovarian cancer.	Median overall survival was 43.1 months for the TC-Top arm versus 44.5 months for the TC arm (stratum-adjusted HR = 1.01 [95% CI = 0.86 to 1.18]; P = .885).
__label__noRel	Therefore, this regimen is not recommended as standard of care treatment for ovarian cancer.	At 3 years, overall survival in both arms was 57% (58.5% in the TC arm and 55.7% in the TC-Top arm).
__label__noRel	Therefore, this regimen is not recommended as standard of care treatment for ovarian cancer.	Compared with patients in the TC arm, patients in the TC-Top arm had more grade 3-4 hematologic toxic effects (requiring more supportive care) and more grade 3-4 infections (5.1% versus 2.7%; P = .034) but did not have a statistically significant increase in febrile neutropenia (3.3% versus 3.1%; P = .80).
__label__noRel	Therefore, this regimen is not recommended as standard of care treatment for ovarian cancer.	Among patients who had measurable disease (TC, n = 147; TC-Top, n = 145), overall (i.e., complete or partial) response was 69.0% (95% CI = 61.4% to 76.5%) in the TC-Top arm and 76.2% (95% CI = 69.3% to 83.1%) in the TC arm (P = .166).
__label__noRel	Therefore, this regimen is not recommended as standard of care treatment for ovarian cancer.	The sequential addition of topotecan to carboplatin-paclitaxel did not result in superior overall response or progression-free or overall survival.
__label__noRel	In an intent-to-treat analysis, the 2-year OS rates were 65.7% for CIS and 66.2% for TPZ/CIS (TPZ/CIS--CIS: 95% CI, -5.9% to 6.9%).	There were no significant differences in failure-free survival, time to locoregional failure, or quality of life as measured by Functional Assessment of Cancer Therapy-Head and Neck.
__label__Support	In an intent-to-treat analysis, the 2-year OS rates were 65.7% for CIS and 66.2% for TPZ/CIS (TPZ/CIS--CIS: 95% CI, -5.9% to 6.9%).	We found no evidence that the addition of TPZ to chemoradiotherapy, in patients with advanced head and neck cancer not selected for the presence of hypoxia, improves OS.
__label__noRel	There were no significant differences in failure-free survival, time to locoregional failure, or quality of life as measured by Functional Assessment of Cancer Therapy-Head and Neck.	In an intent-to-treat analysis, the 2-year OS rates were 65.7% for CIS and 66.2% for TPZ/CIS (TPZ/CIS--CIS: 95% CI, -5.9% to 6.9%).
__label__Support	There were no significant differences in failure-free survival, time to locoregional failure, or quality of life as measured by Functional Assessment of Cancer Therapy-Head and Neck.	We found no evidence that the addition of TPZ to chemoradiotherapy, in patients with advanced head and neck cancer not selected for the presence of hypoxia, improves OS.
__label__noRel	We found no evidence that the addition of TPZ to chemoradiotherapy, in patients with advanced head and neck cancer not selected for the presence of hypoxia, improves OS.	In an intent-to-treat analysis, the 2-year OS rates were 65.7% for CIS and 66.2% for TPZ/CIS (TPZ/CIS--CIS: 95% CI, -5.9% to 6.9%).
__label__noRel	We found no evidence that the addition of TPZ to chemoradiotherapy, in patients with advanced head and neck cancer not selected for the presence of hypoxia, improves OS.	There were no significant differences in failure-free survival, time to locoregional failure, or quality of life as measured by Functional Assessment of Cancer Therapy-Head and Neck.
__label__noRel	fatigue, nausea, and vomiting worsened,	but there was a reduction in pain and no change in global QOL.
__label__noRel	fatigue, nausea, and vomiting worsened,	Patients in the observation arm showed considerable improvements in QOL by 3 months.
__label__noRel	fatigue, nausea, and vomiting worsened,	The two groups were comparable, with low global QOL scores and significant symptom burden, especially pain and fatigue, after thoracotomy.
__label__noRel	fatigue, nausea, and vomiting worsened,	QOL, except for symptoms of sensory neuropathy and hearing loss, in those treated with chemotherapy returned to baseline by 9 months.
__label__noRel	fatigue, nausea, and vomiting worsened,	The findings of this trial indicate that the negative effects of adjuvant chemotherapy on QOL appear to be temporary, and that improvements (with a return to baseline function) are likely in most patients.
__label__Attack	but there was a reduction in pain and no change in global QOL.	fatigue, nausea, and vomiting worsened,
__label__noRel	but there was a reduction in pain and no change in global QOL.	Patients in the observation arm showed considerable improvements in QOL by 3 months.
__label__noRel	but there was a reduction in pain and no change in global QOL.	The two groups were comparable, with low global QOL scores and significant symptom burden, especially pain and fatigue, after thoracotomy.
__label__noRel	but there was a reduction in pain and no change in global QOL.	QOL, except for symptoms of sensory neuropathy and hearing loss, in those treated with chemotherapy returned to baseline by 9 months.
__label__noRel	but there was a reduction in pain and no change in global QOL.	The findings of this trial indicate that the negative effects of adjuvant chemotherapy on QOL appear to be temporary, and that improvements (with a return to baseline function) are likely in most patients.
__label__noRel	Patients in the observation arm showed considerable improvements in QOL by 3 months.	fatigue, nausea, and vomiting worsened,
__label__noRel	Patients in the observation arm showed considerable improvements in QOL by 3 months.	but there was a reduction in pain and no change in global QOL.
__label__noRel	Patients in the observation arm showed considerable improvements in QOL by 3 months.	The two groups were comparable, with low global QOL scores and significant symptom burden, especially pain and fatigue, after thoracotomy.
__label__noRel	Patients in the observation arm showed considerable improvements in QOL by 3 months.	QOL, except for symptoms of sensory neuropathy and hearing loss, in those treated with chemotherapy returned to baseline by 9 months.
__label__noRel	Patients in the observation arm showed considerable improvements in QOL by 3 months.	The findings of this trial indicate that the negative effects of adjuvant chemotherapy on QOL appear to be temporary, and that improvements (with a return to baseline function) are likely in most patients.
__label__noRel	The two groups were comparable, with low global QOL scores and significant symptom burden, especially pain and fatigue, after thoracotomy.	fatigue, nausea, and vomiting worsened,
__label__noRel	The two groups were comparable, with low global QOL scores and significant symptom burden, especially pain and fatigue, after thoracotomy.	but there was a reduction in pain and no change in global QOL.
__label__noRel	The two groups were comparable, with low global QOL scores and significant symptom burden, especially pain and fatigue, after thoracotomy.	Patients in the observation arm showed considerable improvements in QOL by 3 months.
__label__noRel	The two groups were comparable, with low global QOL scores and significant symptom burden, especially pain and fatigue, after thoracotomy.	QOL, except for symptoms of sensory neuropathy and hearing loss, in those treated with chemotherapy returned to baseline by 9 months.
__label__noRel	The two groups were comparable, with low global QOL scores and significant symptom burden, especially pain and fatigue, after thoracotomy.	The findings of this trial indicate that the negative effects of adjuvant chemotherapy on QOL appear to be temporary, and that improvements (with a return to baseline function) are likely in most patients.
__label__noRel	QOL, except for symptoms of sensory neuropathy and hearing loss, in those treated with chemotherapy returned to baseline by 9 months.	fatigue, nausea, and vomiting worsened,
__label__noRel	QOL, except for symptoms of sensory neuropathy and hearing loss, in those treated with chemotherapy returned to baseline by 9 months.	but there was a reduction in pain and no change in global QOL.
__label__noRel	QOL, except for symptoms of sensory neuropathy and hearing loss, in those treated with chemotherapy returned to baseline by 9 months.	Patients in the observation arm showed considerable improvements in QOL by 3 months.
__label__noRel	QOL, except for symptoms of sensory neuropathy and hearing loss, in those treated with chemotherapy returned to baseline by 9 months.	The two groups were comparable, with low global QOL scores and significant symptom burden, especially pain and fatigue, after thoracotomy.
__label__Support	QOL, except for symptoms of sensory neuropathy and hearing loss, in those treated with chemotherapy returned to baseline by 9 months.	The findings of this trial indicate that the negative effects of adjuvant chemotherapy on QOL appear to be temporary, and that improvements (with a return to baseline function) are likely in most patients.
__label__noRel	The findings of this trial indicate that the negative effects of adjuvant chemotherapy on QOL appear to be temporary, and that improvements (with a return to baseline function) are likely in most patients.	fatigue, nausea, and vomiting worsened,
__label__noRel	The findings of this trial indicate that the negative effects of adjuvant chemotherapy on QOL appear to be temporary, and that improvements (with a return to baseline function) are likely in most patients.	but there was a reduction in pain and no change in global QOL.
__label__noRel	The findings of this trial indicate that the negative effects of adjuvant chemotherapy on QOL appear to be temporary, and that improvements (with a return to baseline function) are likely in most patients.	Patients in the observation arm showed considerable improvements in QOL by 3 months.
__label__noRel	The findings of this trial indicate that the negative effects of adjuvant chemotherapy on QOL appear to be temporary, and that improvements (with a return to baseline function) are likely in most patients.	The two groups were comparable, with low global QOL scores and significant symptom burden, especially pain and fatigue, after thoracotomy.
__label__noRel	The findings of this trial indicate that the negative effects of adjuvant chemotherapy on QOL appear to be temporary, and that improvements (with a return to baseline function) are likely in most patients.	QOL, except for symptoms of sensory neuropathy and hearing loss, in those treated with chemotherapy returned to baseline by 9 months.
__label__noRel	After a median follow-up time of 62 (range 18-108) weeks, the median time to progression was 38, 25, and 27 weeks for arm A, B, and C, respectively.	With 94 patients still alive, the one-year probability of survival was 61%, 54%, and 59%, respectively.
__label__noRel	After a median follow-up time of 62 (range 18-108) weeks, the median time to progression was 38, 25, and 27 weeks for arm A, B, and C, respectively.	WHO grade 3 or 4 neutropenia and diarrhoea affected 46% and 16%, respectively, of patients treated with CPT-11 + LFA 5-FU.
__label__noRel	After a median follow-up time of 62 (range 18-108) weeks, the median time to progression was 38, 25, and 27 weeks for arm A, B, and C, respectively.	Median relative dose intensity over eight cycles (DI8) was 78% for CPT-11 and 82% for 5-FU.
__label__noRel	After a median follow-up time of 62 (range 18-108) weeks, the median time to progression was 38, 25, and 27 weeks for arm A, B, and C, respectively.	Severe toxicities of TOM + LFA-5-FU were neutropenia (16%) and diarrhoea (16%), but median relative DI8 was 93% for TOM, and 82% for 5-FU.
__label__noRel	After a median follow-up time of 62 (range 18-108) weeks, the median time to progression was 38, 25, and 27 weeks for arm A, B, and C, respectively.	CPT-11 + LFA-5-FU compares favorably in term of activity and toxicity with other combination regimens including CPT-11 and continuous infusional 5-FU.
__label__noRel	After a median follow-up time of 62 (range 18-108) weeks, the median time to progression was 38, 25, and 27 weeks for arm A, B, and C, respectively.	The hypothesis of a RR 15% higher than the MTX + LFA-5-FU treatment can not be ruled out after this interim analysis.
__label__Support	After a median follow-up time of 62 (range 18-108) weeks, the median time to progression was 38, 25, and 27 weeks for arm A, B, and C, respectively.	The TOM + LFA 5-FU regimen showed a RR and a toxicity profile very close to the MTX + LFA 5-FU combination, and does not deserve further evaluation in advanced colorectal cancer patients.
__label__noRel	With 94 patients still alive, the one-year probability of survival was 61%, 54%, and 59%, respectively.	After a median follow-up time of 62 (range 18-108) weeks, the median time to progression was 38, 25, and 27 weeks for arm A, B, and C, respectively.
__label__noRel	With 94 patients still alive, the one-year probability of survival was 61%, 54%, and 59%, respectively.	WHO grade 3 or 4 neutropenia and diarrhoea affected 46% and 16%, respectively, of patients treated with CPT-11 + LFA 5-FU.
__label__noRel	With 94 patients still alive, the one-year probability of survival was 61%, 54%, and 59%, respectively.	Median relative dose intensity over eight cycles (DI8) was 78% for CPT-11 and 82% for 5-FU.
__label__noRel	With 94 patients still alive, the one-year probability of survival was 61%, 54%, and 59%, respectively.	Severe toxicities of TOM + LFA-5-FU were neutropenia (16%) and diarrhoea (16%), but median relative DI8 was 93% for TOM, and 82% for 5-FU.
__label__noRel	With 94 patients still alive, the one-year probability of survival was 61%, 54%, and 59%, respectively.	CPT-11 + LFA-5-FU compares favorably in term of activity and toxicity with other combination regimens including CPT-11 and continuous infusional 5-FU.
__label__noRel	With 94 patients still alive, the one-year probability of survival was 61%, 54%, and 59%, respectively.	The hypothesis of a RR 15% higher than the MTX + LFA-5-FU treatment can not be ruled out after this interim analysis.
__label__Support	With 94 patients still alive, the one-year probability of survival was 61%, 54%, and 59%, respectively.	The TOM + LFA 5-FU regimen showed a RR and a toxicity profile very close to the MTX + LFA 5-FU combination, and does not deserve further evaluation in advanced colorectal cancer patients.
__label__noRel	WHO grade 3 or 4 neutropenia and diarrhoea affected 46% and 16%, respectively, of patients treated with CPT-11 + LFA 5-FU.	After a median follow-up time of 62 (range 18-108) weeks, the median time to progression was 38, 25, and 27 weeks for arm A, B, and C, respectively.
__label__noRel	WHO grade 3 or 4 neutropenia and diarrhoea affected 46% and 16%, respectively, of patients treated with CPT-11 + LFA 5-FU.	With 94 patients still alive, the one-year probability of survival was 61%, 54%, and 59%, respectively.
__label__noRel	WHO grade 3 or 4 neutropenia and diarrhoea affected 46% and 16%, respectively, of patients treated with CPT-11 + LFA 5-FU.	Median relative dose intensity over eight cycles (DI8) was 78% for CPT-11 and 82% for 5-FU.
__label__noRel	WHO grade 3 or 4 neutropenia and diarrhoea affected 46% and 16%, respectively, of patients treated with CPT-11 + LFA 5-FU.	Severe toxicities of TOM + LFA-5-FU were neutropenia (16%) and diarrhoea (16%), but median relative DI8 was 93% for TOM, and 82% for 5-FU.
__label__noRel	WHO grade 3 or 4 neutropenia and diarrhoea affected 46% and 16%, respectively, of patients treated with CPT-11 + LFA 5-FU.	CPT-11 + LFA-5-FU compares favorably in term of activity and toxicity with other combination regimens including CPT-11 and continuous infusional 5-FU.
__label__noRel	WHO grade 3 or 4 neutropenia and diarrhoea affected 46% and 16%, respectively, of patients treated with CPT-11 + LFA 5-FU.	The hypothesis of a RR 15% higher than the MTX + LFA-5-FU treatment can not be ruled out after this interim analysis.
__label__Support	WHO grade 3 or 4 neutropenia and diarrhoea affected 46% and 16%, respectively, of patients treated with CPT-11 + LFA 5-FU.	The TOM + LFA 5-FU regimen showed a RR and a toxicity profile very close to the MTX + LFA 5-FU combination, and does not deserve further evaluation in advanced colorectal cancer patients.
__label__noRel	Median relative dose intensity over eight cycles (DI8) was 78% for CPT-11 and 82% for 5-FU.	After a median follow-up time of 62 (range 18-108) weeks, the median time to progression was 38, 25, and 27 weeks for arm A, B, and C, respectively.
__label__noRel	Median relative dose intensity over eight cycles (DI8) was 78% for CPT-11 and 82% for 5-FU.	With 94 patients still alive, the one-year probability of survival was 61%, 54%, and 59%, respectively.
__label__noRel	Median relative dose intensity over eight cycles (DI8) was 78% for CPT-11 and 82% for 5-FU.	WHO grade 3 or 4 neutropenia and diarrhoea affected 46% and 16%, respectively, of patients treated with CPT-11 + LFA 5-FU.
__label__noRel	Median relative dose intensity over eight cycles (DI8) was 78% for CPT-11 and 82% for 5-FU.	Severe toxicities of TOM + LFA-5-FU were neutropenia (16%) and diarrhoea (16%), but median relative DI8 was 93% for TOM, and 82% for 5-FU.
__label__noRel	Median relative dose intensity over eight cycles (DI8) was 78% for CPT-11 and 82% for 5-FU.	CPT-11 + LFA-5-FU compares favorably in term of activity and toxicity with other combination regimens including CPT-11 and continuous infusional 5-FU.
__label__noRel	Median relative dose intensity over eight cycles (DI8) was 78% for CPT-11 and 82% for 5-FU.	The hypothesis of a RR 15% higher than the MTX + LFA-5-FU treatment can not be ruled out after this interim analysis.
__label__noRel	Median relative dose intensity over eight cycles (DI8) was 78% for CPT-11 and 82% for 5-FU.	The TOM + LFA 5-FU regimen showed a RR and a toxicity profile very close to the MTX + LFA 5-FU combination, and does not deserve further evaluation in advanced colorectal cancer patients.
__label__noRel	Severe toxicities of TOM + LFA-5-FU were neutropenia (16%) and diarrhoea (16%), but median relative DI8 was 93% for TOM, and 82% for 5-FU.	After a median follow-up time of 62 (range 18-108) weeks, the median time to progression was 38, 25, and 27 weeks for arm A, B, and C, respectively.
__label__noRel	Severe toxicities of TOM + LFA-5-FU were neutropenia (16%) and diarrhoea (16%), but median relative DI8 was 93% for TOM, and 82% for 5-FU.	With 94 patients still alive, the one-year probability of survival was 61%, 54%, and 59%, respectively.
__label__noRel	Severe toxicities of TOM + LFA-5-FU were neutropenia (16%) and diarrhoea (16%), but median relative DI8 was 93% for TOM, and 82% for 5-FU.	WHO grade 3 or 4 neutropenia and diarrhoea affected 46% and 16%, respectively, of patients treated with CPT-11 + LFA 5-FU.
__label__noRel	Severe toxicities of TOM + LFA-5-FU were neutropenia (16%) and diarrhoea (16%), but median relative DI8 was 93% for TOM, and 82% for 5-FU.	Median relative dose intensity over eight cycles (DI8) was 78% for CPT-11 and 82% for 5-FU.
__label__noRel	Severe toxicities of TOM + LFA-5-FU were neutropenia (16%) and diarrhoea (16%), but median relative DI8 was 93% for TOM, and 82% for 5-FU.	CPT-11 + LFA-5-FU compares favorably in term of activity and toxicity with other combination regimens including CPT-11 and continuous infusional 5-FU.
__label__noRel	Severe toxicities of TOM + LFA-5-FU were neutropenia (16%) and diarrhoea (16%), but median relative DI8 was 93% for TOM, and 82% for 5-FU.	The hypothesis of a RR 15% higher than the MTX + LFA-5-FU treatment can not be ruled out after this interim analysis.
__label__Support	Severe toxicities of TOM + LFA-5-FU were neutropenia (16%) and diarrhoea (16%), but median relative DI8 was 93% for TOM, and 82% for 5-FU.	The TOM + LFA 5-FU regimen showed a RR and a toxicity profile very close to the MTX + LFA 5-FU combination, and does not deserve further evaluation in advanced colorectal cancer patients.
__label__noRel	CPT-11 + LFA-5-FU compares favorably in term of activity and toxicity with other combination regimens including CPT-11 and continuous infusional 5-FU.	After a median follow-up time of 62 (range 18-108) weeks, the median time to progression was 38, 25, and 27 weeks for arm A, B, and C, respectively.
__label__noRel	CPT-11 + LFA-5-FU compares favorably in term of activity and toxicity with other combination regimens including CPT-11 and continuous infusional 5-FU.	With 94 patients still alive, the one-year probability of survival was 61%, 54%, and 59%, respectively.
__label__noRel	CPT-11 + LFA-5-FU compares favorably in term of activity and toxicity with other combination regimens including CPT-11 and continuous infusional 5-FU.	WHO grade 3 or 4 neutropenia and diarrhoea affected 46% and 16%, respectively, of patients treated with CPT-11 + LFA 5-FU.
__label__noRel	CPT-11 + LFA-5-FU compares favorably in term of activity and toxicity with other combination regimens including CPT-11 and continuous infusional 5-FU.	Median relative dose intensity over eight cycles (DI8) was 78% for CPT-11 and 82% for 5-FU.
__label__noRel	CPT-11 + LFA-5-FU compares favorably in term of activity and toxicity with other combination regimens including CPT-11 and continuous infusional 5-FU.	Severe toxicities of TOM + LFA-5-FU were neutropenia (16%) and diarrhoea (16%), but median relative DI8 was 93% for TOM, and 82% for 5-FU.
__label__noRel	CPT-11 + LFA-5-FU compares favorably in term of activity and toxicity with other combination regimens including CPT-11 and continuous infusional 5-FU.	The hypothesis of a RR 15% higher than the MTX + LFA-5-FU treatment can not be ruled out after this interim analysis.
__label__noRel	CPT-11 + LFA-5-FU compares favorably in term of activity and toxicity with other combination regimens including CPT-11 and continuous infusional 5-FU.	The TOM + LFA 5-FU regimen showed a RR and a toxicity profile very close to the MTX + LFA 5-FU combination, and does not deserve further evaluation in advanced colorectal cancer patients.
__label__noRel	The hypothesis of a RR 15% higher than the MTX + LFA-5-FU treatment can not be ruled out after this interim analysis.	After a median follow-up time of 62 (range 18-108) weeks, the median time to progression was 38, 25, and 27 weeks for arm A, B, and C, respectively.
__label__noRel	The hypothesis of a RR 15% higher than the MTX + LFA-5-FU treatment can not be ruled out after this interim analysis.	With 94 patients still alive, the one-year probability of survival was 61%, 54%, and 59%, respectively.
__label__noRel	The hypothesis of a RR 15% higher than the MTX + LFA-5-FU treatment can not be ruled out after this interim analysis.	WHO grade 3 or 4 neutropenia and diarrhoea affected 46% and 16%, respectively, of patients treated with CPT-11 + LFA 5-FU.
__label__noRel	The hypothesis of a RR 15% higher than the MTX + LFA-5-FU treatment can not be ruled out after this interim analysis.	Median relative dose intensity over eight cycles (DI8) was 78% for CPT-11 and 82% for 5-FU.
__label__noRel	The hypothesis of a RR 15% higher than the MTX + LFA-5-FU treatment can not be ruled out after this interim analysis.	Severe toxicities of TOM + LFA-5-FU were neutropenia (16%) and diarrhoea (16%), but median relative DI8 was 93% for TOM, and 82% for 5-FU.
__label__noRel	The hypothesis of a RR 15% higher than the MTX + LFA-5-FU treatment can not be ruled out after this interim analysis.	CPT-11 + LFA-5-FU compares favorably in term of activity and toxicity with other combination regimens including CPT-11 and continuous infusional 5-FU.
__label__noRel	The hypothesis of a RR 15% higher than the MTX + LFA-5-FU treatment can not be ruled out after this interim analysis.	The TOM + LFA 5-FU regimen showed a RR and a toxicity profile very close to the MTX + LFA 5-FU combination, and does not deserve further evaluation in advanced colorectal cancer patients.
__label__noRel	The TOM + LFA 5-FU regimen showed a RR and a toxicity profile very close to the MTX + LFA 5-FU combination, and does not deserve further evaluation in advanced colorectal cancer patients.	After a median follow-up time of 62 (range 18-108) weeks, the median time to progression was 38, 25, and 27 weeks for arm A, B, and C, respectively.
__label__noRel	The TOM + LFA 5-FU regimen showed a RR and a toxicity profile very close to the MTX + LFA 5-FU combination, and does not deserve further evaluation in advanced colorectal cancer patients.	With 94 patients still alive, the one-year probability of survival was 61%, 54%, and 59%, respectively.
__label__noRel	The TOM + LFA 5-FU regimen showed a RR and a toxicity profile very close to the MTX + LFA 5-FU combination, and does not deserve further evaluation in advanced colorectal cancer patients.	WHO grade 3 or 4 neutropenia and diarrhoea affected 46% and 16%, respectively, of patients treated with CPT-11 + LFA 5-FU.
__label__noRel	The TOM + LFA 5-FU regimen showed a RR and a toxicity profile very close to the MTX + LFA 5-FU combination, and does not deserve further evaluation in advanced colorectal cancer patients.	Median relative dose intensity over eight cycles (DI8) was 78% for CPT-11 and 82% for 5-FU.
__label__noRel	The TOM + LFA 5-FU regimen showed a RR and a toxicity profile very close to the MTX + LFA 5-FU combination, and does not deserve further evaluation in advanced colorectal cancer patients.	Severe toxicities of TOM + LFA-5-FU were neutropenia (16%) and diarrhoea (16%), but median relative DI8 was 93% for TOM, and 82% for 5-FU.
__label__noRel	The TOM + LFA 5-FU regimen showed a RR and a toxicity profile very close to the MTX + LFA 5-FU combination, and does not deserve further evaluation in advanced colorectal cancer patients.	CPT-11 + LFA-5-FU compares favorably in term of activity and toxicity with other combination regimens including CPT-11 and continuous infusional 5-FU.
__label__noRel	The TOM + LFA 5-FU regimen showed a RR and a toxicity profile very close to the MTX + LFA 5-FU combination, and does not deserve further evaluation in advanced colorectal cancer patients.	The hypothesis of a RR 15% higher than the MTX + LFA-5-FU treatment can not be ruled out after this interim analysis.
__label__noRel	At 4 years, 64 (18%) of 353 patients on combined therapy and 39 (12%) of 337 on endocrine-alone therapy had moderate to severe urinary bother (p=0.005), and 16 (4%) of 355 on combined therapy and five (2%) of 338 on endocrine treatment alone had pain while urinating (p=0.024).	37 (11%) of 350 in the combined group and 23 (7%) of 35 in the endocrine-only group had overall bother from all bowel symptoms (p=0.022).
__label__noRel	At 4 years, 64 (18%) of 353 patients on combined therapy and 39 (12%) of 337 on endocrine-alone therapy had moderate to severe urinary bother (p=0.005), and 16 (4%) of 355 on combined therapy and five (2%) of 338 on endocrine treatment alone had pain while urinating (p=0.024).	281 (85%) of 332 in the combined-treatment group and 227 (72%) of 313 in the endocrine-only group had erectile dysfunction (p=0.0002).
__label__noRel	At 4 years, 64 (18%) of 353 patients on combined therapy and 39 (12%) of 337 on endocrine-alone therapy had moderate to severe urinary bother (p=0.005), and 16 (4%) of 355 on combined therapy and five (2%) of 338 on endocrine treatment alone had pain while urinating (p=0.024).	Quality of life at 4 years was similar, with the exception of decreased social function in patients receiving endocrine treatment plus radiotherapy.
__label__Support	At 4 years, 64 (18%) of 353 patients on combined therapy and 39 (12%) of 337 on endocrine-alone therapy had moderate to severe urinary bother (p=0.005), and 16 (4%) of 355 on combined therapy and five (2%) of 338 on endocrine treatment alone had pain while urinating (p=0.024).	Although addition of radiotherapy to endocrine treatment significantly increased some treatment-related symptoms, none were serious.
__label__noRel	At 4 years, 64 (18%) of 353 patients on combined therapy and 39 (12%) of 337 on endocrine-alone therapy had moderate to severe urinary bother (p=0.005), and 16 (4%) of 355 on combined therapy and five (2%) of 338 on endocrine treatment alone had pain while urinating (p=0.024).	the increase of symptoms seems acceptable and has little extra effect on quality of life after 4 years compared with endocrine treatment alone.
__label__noRel	37 (11%) of 350 in the combined group and 23 (7%) of 35 in the endocrine-only group had overall bother from all bowel symptoms (p=0.022).	At 4 years, 64 (18%) of 353 patients on combined therapy and 39 (12%) of 337 on endocrine-alone therapy had moderate to severe urinary bother (p=0.005), and 16 (4%) of 355 on combined therapy and five (2%) of 338 on endocrine treatment alone had pain while urinating (p=0.024).
__label__noRel	37 (11%) of 350 in the combined group and 23 (7%) of 35 in the endocrine-only group had overall bother from all bowel symptoms (p=0.022).	281 (85%) of 332 in the combined-treatment group and 227 (72%) of 313 in the endocrine-only group had erectile dysfunction (p=0.0002).
__label__noRel	37 (11%) of 350 in the combined group and 23 (7%) of 35 in the endocrine-only group had overall bother from all bowel symptoms (p=0.022).	Quality of life at 4 years was similar, with the exception of decreased social function in patients receiving endocrine treatment plus radiotherapy.
__label__Support	37 (11%) of 350 in the combined group and 23 (7%) of 35 in the endocrine-only group had overall bother from all bowel symptoms (p=0.022).	Although addition of radiotherapy to endocrine treatment significantly increased some treatment-related symptoms, none were serious.
__label__noRel	37 (11%) of 350 in the combined group and 23 (7%) of 35 in the endocrine-only group had overall bother from all bowel symptoms (p=0.022).	the increase of symptoms seems acceptable and has little extra effect on quality of life after 4 years compared with endocrine treatment alone.
__label__noRel	281 (85%) of 332 in the combined-treatment group and 227 (72%) of 313 in the endocrine-only group had erectile dysfunction (p=0.0002).	At 4 years, 64 (18%) of 353 patients on combined therapy and 39 (12%) of 337 on endocrine-alone therapy had moderate to severe urinary bother (p=0.005), and 16 (4%) of 355 on combined therapy and five (2%) of 338 on endocrine treatment alone had pain while urinating (p=0.024).
__label__noRel	281 (85%) of 332 in the combined-treatment group and 227 (72%) of 313 in the endocrine-only group had erectile dysfunction (p=0.0002).	37 (11%) of 350 in the combined group and 23 (7%) of 35 in the endocrine-only group had overall bother from all bowel symptoms (p=0.022).
__label__noRel	281 (85%) of 332 in the combined-treatment group and 227 (72%) of 313 in the endocrine-only group had erectile dysfunction (p=0.0002).	Quality of life at 4 years was similar, with the exception of decreased social function in patients receiving endocrine treatment plus radiotherapy.
__label__Support	281 (85%) of 332 in the combined-treatment group and 227 (72%) of 313 in the endocrine-only group had erectile dysfunction (p=0.0002).	Although addition of radiotherapy to endocrine treatment significantly increased some treatment-related symptoms, none were serious.
__label__noRel	281 (85%) of 332 in the combined-treatment group and 227 (72%) of 313 in the endocrine-only group had erectile dysfunction (p=0.0002).	the increase of symptoms seems acceptable and has little extra effect on quality of life after 4 years compared with endocrine treatment alone.
__label__noRel	Quality of life at 4 years was similar, with the exception of decreased social function in patients receiving endocrine treatment plus radiotherapy.	At 4 years, 64 (18%) of 353 patients on combined therapy and 39 (12%) of 337 on endocrine-alone therapy had moderate to severe urinary bother (p=0.005), and 16 (4%) of 355 on combined therapy and five (2%) of 338 on endocrine treatment alone had pain while urinating (p=0.024).
__label__noRel	Quality of life at 4 years was similar, with the exception of decreased social function in patients receiving endocrine treatment plus radiotherapy.	37 (11%) of 350 in the combined group and 23 (7%) of 35 in the endocrine-only group had overall bother from all bowel symptoms (p=0.022).
__label__noRel	Quality of life at 4 years was similar, with the exception of decreased social function in patients receiving endocrine treatment plus radiotherapy.	281 (85%) of 332 in the combined-treatment group and 227 (72%) of 313 in the endocrine-only group had erectile dysfunction (p=0.0002).
__label__Support	Quality of life at 4 years was similar, with the exception of decreased social function in patients receiving endocrine treatment plus radiotherapy.	Although addition of radiotherapy to endocrine treatment significantly increased some treatment-related symptoms, none were serious.
__label__noRel	Quality of life at 4 years was similar, with the exception of decreased social function in patients receiving endocrine treatment plus radiotherapy.	the increase of symptoms seems acceptable and has little extra effect on quality of life after 4 years compared with endocrine treatment alone.
__label__noRel	Although addition of radiotherapy to endocrine treatment significantly increased some treatment-related symptoms, none were serious.	At 4 years, 64 (18%) of 353 patients on combined therapy and 39 (12%) of 337 on endocrine-alone therapy had moderate to severe urinary bother (p=0.005), and 16 (4%) of 355 on combined therapy and five (2%) of 338 on endocrine treatment alone had pain while urinating (p=0.024).
__label__noRel	Although addition of radiotherapy to endocrine treatment significantly increased some treatment-related symptoms, none were serious.	37 (11%) of 350 in the combined group and 23 (7%) of 35 in the endocrine-only group had overall bother from all bowel symptoms (p=0.022).
__label__noRel	Although addition of radiotherapy to endocrine treatment significantly increased some treatment-related symptoms, none were serious.	281 (85%) of 332 in the combined-treatment group and 227 (72%) of 313 in the endocrine-only group had erectile dysfunction (p=0.0002).
__label__noRel	Although addition of radiotherapy to endocrine treatment significantly increased some treatment-related symptoms, none were serious.	Quality of life at 4 years was similar, with the exception of decreased social function in patients receiving endocrine treatment plus radiotherapy.
__label__Support	Although addition of radiotherapy to endocrine treatment significantly increased some treatment-related symptoms, none were serious.	the increase of symptoms seems acceptable and has little extra effect on quality of life after 4 years compared with endocrine treatment alone.
__label__noRel	the increase of symptoms seems acceptable and has little extra effect on quality of life after 4 years compared with endocrine treatment alone.	At 4 years, 64 (18%) of 353 patients on combined therapy and 39 (12%) of 337 on endocrine-alone therapy had moderate to severe urinary bother (p=0.005), and 16 (4%) of 355 on combined therapy and five (2%) of 338 on endocrine treatment alone had pain while urinating (p=0.024).
__label__noRel	the increase of symptoms seems acceptable and has little extra effect on quality of life after 4 years compared with endocrine treatment alone.	37 (11%) of 350 in the combined group and 23 (7%) of 35 in the endocrine-only group had overall bother from all bowel symptoms (p=0.022).
__label__noRel	the increase of symptoms seems acceptable and has little extra effect on quality of life after 4 years compared with endocrine treatment alone.	281 (85%) of 332 in the combined-treatment group and 227 (72%) of 313 in the endocrine-only group had erectile dysfunction (p=0.0002).
__label__noRel	the increase of symptoms seems acceptable and has little extra effect on quality of life after 4 years compared with endocrine treatment alone.	Quality of life at 4 years was similar, with the exception of decreased social function in patients receiving endocrine treatment plus radiotherapy.
__label__noRel	the increase of symptoms seems acceptable and has little extra effect on quality of life after 4 years compared with endocrine treatment alone.	Although addition of radiotherapy to endocrine treatment significantly increased some treatment-related symptoms, none were serious.
__label__noRel	CR after remission induction treatment was achieved in 55% of the patients in the control group and in 56% of the patients in the GM-CSF group (P = NS).	The duration of survival and disease-free survival at 2 years after randomization were estimated at 22% and 19% for the control group and 22% and 14% for the GM-CSF group (P = NS).
__label__noRel	CR after remission induction treatment was achieved in 55% of the patients in the control group and in 56% of the patients in the GM-CSF group (P = NS).	Considering the short-term quality of life, the administration of GM-CSF resulted in more problems with regard to depressed mood, diarrhoea and rash/eczema.
__label__noRel	CR after remission induction treatment was achieved in 55% of the patients in the control group and in 56% of the patients in the GM-CSF group (P = NS).	With regard to the long-term quality of life there were no significant differences between the two groups.
__label__noRel	CR after remission induction treatment was achieved in 55% of the patients in the control group and in 56% of the patients in the GM-CSF group (P = NS).	The average costs of the primary treatment were higher in GM-CSF-treated patients than in the control group, i.e. US$40782 and US$34465, respectively (P < 0.01).
__label__noRel	CR after remission induction treatment was achieved in 55% of the patients in the control group and in 56% of the patients in the GM-CSF group (P = NS).	The costs during the follow-up period did not differ between the two groups.
__label__noRel	CR after remission induction treatment was achieved in 55% of the patients in the control group and in 56% of the patients in the GM-CSF group (P = NS).	The results of this randomized clinical trial indicate that daunomycin-cytosine arabinoside plus GM-CSF is not a cost-effective treatment strategy when compared with daunomycin-cytosine arabinoside alone.
__label__noRel	The duration of survival and disease-free survival at 2 years after randomization were estimated at 22% and 19% for the control group and 22% and 14% for the GM-CSF group (P = NS).	CR after remission induction treatment was achieved in 55% of the patients in the control group and in 56% of the patients in the GM-CSF group (P = NS).
__label__noRel	The duration of survival and disease-free survival at 2 years after randomization were estimated at 22% and 19% for the control group and 22% and 14% for the GM-CSF group (P = NS).	Considering the short-term quality of life, the administration of GM-CSF resulted in more problems with regard to depressed mood, diarrhoea and rash/eczema.
__label__noRel	The duration of survival and disease-free survival at 2 years after randomization were estimated at 22% and 19% for the control group and 22% and 14% for the GM-CSF group (P = NS).	With regard to the long-term quality of life there were no significant differences between the two groups.
__label__noRel	The duration of survival and disease-free survival at 2 years after randomization were estimated at 22% and 19% for the control group and 22% and 14% for the GM-CSF group (P = NS).	The average costs of the primary treatment were higher in GM-CSF-treated patients than in the control group, i.e. US$40782 and US$34465, respectively (P < 0.01).
__label__noRel	The duration of survival and disease-free survival at 2 years after randomization were estimated at 22% and 19% for the control group and 22% and 14% for the GM-CSF group (P = NS).	The costs during the follow-up period did not differ between the two groups.
__label__noRel	The duration of survival and disease-free survival at 2 years after randomization were estimated at 22% and 19% for the control group and 22% and 14% for the GM-CSF group (P = NS).	The results of this randomized clinical trial indicate that daunomycin-cytosine arabinoside plus GM-CSF is not a cost-effective treatment strategy when compared with daunomycin-cytosine arabinoside alone.
__label__noRel	Considering the short-term quality of life, the administration of GM-CSF resulted in more problems with regard to depressed mood, diarrhoea and rash/eczema.	CR after remission induction treatment was achieved in 55% of the patients in the control group and in 56% of the patients in the GM-CSF group (P = NS).
__label__noRel	Considering the short-term quality of life, the administration of GM-CSF resulted in more problems with regard to depressed mood, diarrhoea and rash/eczema.	The duration of survival and disease-free survival at 2 years after randomization were estimated at 22% and 19% for the control group and 22% and 14% for the GM-CSF group (P = NS).
__label__noRel	Considering the short-term quality of life, the administration of GM-CSF resulted in more problems with regard to depressed mood, diarrhoea and rash/eczema.	With regard to the long-term quality of life there were no significant differences between the two groups.
__label__noRel	Considering the short-term quality of life, the administration of GM-CSF resulted in more problems with regard to depressed mood, diarrhoea and rash/eczema.	The average costs of the primary treatment were higher in GM-CSF-treated patients than in the control group, i.e. US$40782 and US$34465, respectively (P < 0.01).
__label__noRel	Considering the short-term quality of life, the administration of GM-CSF resulted in more problems with regard to depressed mood, diarrhoea and rash/eczema.	The costs during the follow-up period did not differ between the two groups.
__label__noRel	Considering the short-term quality of life, the administration of GM-CSF resulted in more problems with regard to depressed mood, diarrhoea and rash/eczema.	The results of this randomized clinical trial indicate that daunomycin-cytosine arabinoside plus GM-CSF is not a cost-effective treatment strategy when compared with daunomycin-cytosine arabinoside alone.
__label__noRel	With regard to the long-term quality of life there were no significant differences between the two groups.	CR after remission induction treatment was achieved in 55% of the patients in the control group and in 56% of the patients in the GM-CSF group (P = NS).
__label__noRel	With regard to the long-term quality of life there were no significant differences between the two groups.	The duration of survival and disease-free survival at 2 years after randomization were estimated at 22% and 19% for the control group and 22% and 14% for the GM-CSF group (P = NS).
__label__noRel	With regard to the long-term quality of life there were no significant differences between the two groups.	Considering the short-term quality of life, the administration of GM-CSF resulted in more problems with regard to depressed mood, diarrhoea and rash/eczema.
__label__noRel	With regard to the long-term quality of life there were no significant differences between the two groups.	The average costs of the primary treatment were higher in GM-CSF-treated patients than in the control group, i.e. US$40782 and US$34465, respectively (P < 0.01).
__label__noRel	With regard to the long-term quality of life there were no significant differences between the two groups.	The costs during the follow-up period did not differ between the two groups.
__label__noRel	With regard to the long-term quality of life there were no significant differences between the two groups.	The results of this randomized clinical trial indicate that daunomycin-cytosine arabinoside plus GM-CSF is not a cost-effective treatment strategy when compared with daunomycin-cytosine arabinoside alone.
__label__noRel	The average costs of the primary treatment were higher in GM-CSF-treated patients than in the control group, i.e. US$40782 and US$34465, respectively (P < 0.01).	CR after remission induction treatment was achieved in 55% of the patients in the control group and in 56% of the patients in the GM-CSF group (P = NS).
__label__noRel	The average costs of the primary treatment were higher in GM-CSF-treated patients than in the control group, i.e. US$40782 and US$34465, respectively (P < 0.01).	The duration of survival and disease-free survival at 2 years after randomization were estimated at 22% and 19% for the control group and 22% and 14% for the GM-CSF group (P = NS).
__label__noRel	The average costs of the primary treatment were higher in GM-CSF-treated patients than in the control group, i.e. US$40782 and US$34465, respectively (P < 0.01).	Considering the short-term quality of life, the administration of GM-CSF resulted in more problems with regard to depressed mood, diarrhoea and rash/eczema.
__label__noRel	The average costs of the primary treatment were higher in GM-CSF-treated patients than in the control group, i.e. US$40782 and US$34465, respectively (P < 0.01).	With regard to the long-term quality of life there were no significant differences between the two groups.
__label__noRel	The average costs of the primary treatment were higher in GM-CSF-treated patients than in the control group, i.e. US$40782 and US$34465, respectively (P < 0.01).	The costs during the follow-up period did not differ between the two groups.
__label__Support	The average costs of the primary treatment were higher in GM-CSF-treated patients than in the control group, i.e. US$40782 and US$34465, respectively (P < 0.01).	The results of this randomized clinical trial indicate that daunomycin-cytosine arabinoside plus GM-CSF is not a cost-effective treatment strategy when compared with daunomycin-cytosine arabinoside alone.
__label__noRel	The costs during the follow-up period did not differ between the two groups.	CR after remission induction treatment was achieved in 55% of the patients in the control group and in 56% of the patients in the GM-CSF group (P = NS).
__label__noRel	The costs during the follow-up period did not differ between the two groups.	The duration of survival and disease-free survival at 2 years after randomization were estimated at 22% and 19% for the control group and 22% and 14% for the GM-CSF group (P = NS).
__label__noRel	The costs during the follow-up period did not differ between the two groups.	Considering the short-term quality of life, the administration of GM-CSF resulted in more problems with regard to depressed mood, diarrhoea and rash/eczema.
__label__noRel	The costs during the follow-up period did not differ between the two groups.	With regard to the long-term quality of life there were no significant differences between the two groups.
__label__noRel	The costs during the follow-up period did not differ between the two groups.	The average costs of the primary treatment were higher in GM-CSF-treated patients than in the control group, i.e. US$40782 and US$34465, respectively (P < 0.01).
__label__Attack	The costs during the follow-up period did not differ between the two groups.	The results of this randomized clinical trial indicate that daunomycin-cytosine arabinoside plus GM-CSF is not a cost-effective treatment strategy when compared with daunomycin-cytosine arabinoside alone.
__label__noRel	The results of this randomized clinical trial indicate that daunomycin-cytosine arabinoside plus GM-CSF is not a cost-effective treatment strategy when compared with daunomycin-cytosine arabinoside alone.	CR after remission induction treatment was achieved in 55% of the patients in the control group and in 56% of the patients in the GM-CSF group (P = NS).
__label__noRel	The results of this randomized clinical trial indicate that daunomycin-cytosine arabinoside plus GM-CSF is not a cost-effective treatment strategy when compared with daunomycin-cytosine arabinoside alone.	The duration of survival and disease-free survival at 2 years after randomization were estimated at 22% and 19% for the control group and 22% and 14% for the GM-CSF group (P = NS).
__label__noRel	The results of this randomized clinical trial indicate that daunomycin-cytosine arabinoside plus GM-CSF is not a cost-effective treatment strategy when compared with daunomycin-cytosine arabinoside alone.	Considering the short-term quality of life, the administration of GM-CSF resulted in more problems with regard to depressed mood, diarrhoea and rash/eczema.
__label__noRel	The results of this randomized clinical trial indicate that daunomycin-cytosine arabinoside plus GM-CSF is not a cost-effective treatment strategy when compared with daunomycin-cytosine arabinoside alone.	With regard to the long-term quality of life there were no significant differences between the two groups.
__label__noRel	The results of this randomized clinical trial indicate that daunomycin-cytosine arabinoside plus GM-CSF is not a cost-effective treatment strategy when compared with daunomycin-cytosine arabinoside alone.	The average costs of the primary treatment were higher in GM-CSF-treated patients than in the control group, i.e. US$40782 and US$34465, respectively (P < 0.01).
__label__noRel	The results of this randomized clinical trial indicate that daunomycin-cytosine arabinoside plus GM-CSF is not a cost-effective treatment strategy when compared with daunomycin-cytosine arabinoside alone.	The costs during the follow-up period did not differ between the two groups.
__label__noRel	Vandetanib patients had more toxicity and required more dose modifications for gastrointestinal toxicity and rash.	Asymptomatic Corrected QT interval (QTC) prolongation was observed in eight vandetanib patients.
__label__noRel	Vandetanib patients had more toxicity and required more dose modifications for gastrointestinal toxicity and rash.	Median progression-free survival for vandetanib and placebo was 2.7 and 2.8 months, respectively (hazard ratio [HR], 1.01; 80% CI, 0.75 to 1.36; one-sided P = .51).
__label__noRel	Vandetanib patients had more toxicity and required more dose modifications for gastrointestinal toxicity and rash.	Overall survival for vandetanib was 10.6 versus 11.9 months for placebo (HR, 1.43; 80% CI, 1.00 to 2.05; one-sided P = 0.9).
__label__noRel	Vandetanib patients had more toxicity and required more dose modifications for gastrointestinal toxicity and rash.	In planned subgroup analyses, a significant interaction was noted (P = .01): limited-stage vandetanib patients had longer overall survival (HR, 0.45; one-sided P = .07) and extensive-stage vandetanib patients shorter survival compared with placebo (HR, 2.27; one-sided P = .996).
__label__Support	Vandetanib patients had more toxicity and required more dose modifications for gastrointestinal toxicity and rash.	Vandetanib failed to demonstrate efficacy as maintenance therapy for small-cell lung cancer.
__label__noRel	Asymptomatic Corrected QT interval (QTC) prolongation was observed in eight vandetanib patients.	Vandetanib patients had more toxicity and required more dose modifications for gastrointestinal toxicity and rash.
__label__noRel	Asymptomatic Corrected QT interval (QTC) prolongation was observed in eight vandetanib patients.	Median progression-free survival for vandetanib and placebo was 2.7 and 2.8 months, respectively (hazard ratio [HR], 1.01; 80% CI, 0.75 to 1.36; one-sided P = .51).
__label__noRel	Asymptomatic Corrected QT interval (QTC) prolongation was observed in eight vandetanib patients.	Overall survival for vandetanib was 10.6 versus 11.9 months for placebo (HR, 1.43; 80% CI, 1.00 to 2.05; one-sided P = 0.9).
__label__noRel	Asymptomatic Corrected QT interval (QTC) prolongation was observed in eight vandetanib patients.	In planned subgroup analyses, a significant interaction was noted (P = .01): limited-stage vandetanib patients had longer overall survival (HR, 0.45; one-sided P = .07) and extensive-stage vandetanib patients shorter survival compared with placebo (HR, 2.27; one-sided P = .996).
__label__Support	Asymptomatic Corrected QT interval (QTC) prolongation was observed in eight vandetanib patients.	Vandetanib failed to demonstrate efficacy as maintenance therapy for small-cell lung cancer.
__label__noRel	Median progression-free survival for vandetanib and placebo was 2.7 and 2.8 months, respectively (hazard ratio [HR], 1.01; 80% CI, 0.75 to 1.36; one-sided P = .51).	Vandetanib patients had more toxicity and required more dose modifications for gastrointestinal toxicity and rash.
__label__noRel	Median progression-free survival for vandetanib and placebo was 2.7 and 2.8 months, respectively (hazard ratio [HR], 1.01; 80% CI, 0.75 to 1.36; one-sided P = .51).	Asymptomatic Corrected QT interval (QTC) prolongation was observed in eight vandetanib patients.
__label__noRel	Median progression-free survival for vandetanib and placebo was 2.7 and 2.8 months, respectively (hazard ratio [HR], 1.01; 80% CI, 0.75 to 1.36; one-sided P = .51).	Overall survival for vandetanib was 10.6 versus 11.9 months for placebo (HR, 1.43; 80% CI, 1.00 to 2.05; one-sided P = 0.9).
__label__noRel	Median progression-free survival for vandetanib and placebo was 2.7 and 2.8 months, respectively (hazard ratio [HR], 1.01; 80% CI, 0.75 to 1.36; one-sided P = .51).	In planned subgroup analyses, a significant interaction was noted (P = .01): limited-stage vandetanib patients had longer overall survival (HR, 0.45; one-sided P = .07) and extensive-stage vandetanib patients shorter survival compared with placebo (HR, 2.27; one-sided P = .996).
__label__Support	Median progression-free survival for vandetanib and placebo was 2.7 and 2.8 months, respectively (hazard ratio [HR], 1.01; 80% CI, 0.75 to 1.36; one-sided P = .51).	Vandetanib failed to demonstrate efficacy as maintenance therapy for small-cell lung cancer.
__label__noRel	Overall survival for vandetanib was 10.6 versus 11.9 months for placebo (HR, 1.43; 80% CI, 1.00 to 2.05; one-sided P = 0.9).	Vandetanib patients had more toxicity and required more dose modifications for gastrointestinal toxicity and rash.
__label__noRel	Overall survival for vandetanib was 10.6 versus 11.9 months for placebo (HR, 1.43; 80% CI, 1.00 to 2.05; one-sided P = 0.9).	Asymptomatic Corrected QT interval (QTC) prolongation was observed in eight vandetanib patients.
__label__noRel	Overall survival for vandetanib was 10.6 versus 11.9 months for placebo (HR, 1.43; 80% CI, 1.00 to 2.05; one-sided P = 0.9).	Median progression-free survival for vandetanib and placebo was 2.7 and 2.8 months, respectively (hazard ratio [HR], 1.01; 80% CI, 0.75 to 1.36; one-sided P = .51).
__label__noRel	Overall survival for vandetanib was 10.6 versus 11.9 months for placebo (HR, 1.43; 80% CI, 1.00 to 2.05; one-sided P = 0.9).	In planned subgroup analyses, a significant interaction was noted (P = .01): limited-stage vandetanib patients had longer overall survival (HR, 0.45; one-sided P = .07) and extensive-stage vandetanib patients shorter survival compared with placebo (HR, 2.27; one-sided P = .996).
__label__Support	Overall survival for vandetanib was 10.6 versus 11.9 months for placebo (HR, 1.43; 80% CI, 1.00 to 2.05; one-sided P = 0.9).	Vandetanib failed to demonstrate efficacy as maintenance therapy for small-cell lung cancer.
__label__noRel	In planned subgroup analyses, a significant interaction was noted (P = .01): limited-stage vandetanib patients had longer overall survival (HR, 0.45; one-sided P = .07) and extensive-stage vandetanib patients shorter survival compared with placebo (HR, 2.27; one-sided P = .996).	Vandetanib patients had more toxicity and required more dose modifications for gastrointestinal toxicity and rash.
__label__noRel	In planned subgroup analyses, a significant interaction was noted (P = .01): limited-stage vandetanib patients had longer overall survival (HR, 0.45; one-sided P = .07) and extensive-stage vandetanib patients shorter survival compared with placebo (HR, 2.27; one-sided P = .996).	Asymptomatic Corrected QT interval (QTC) prolongation was observed in eight vandetanib patients.
__label__noRel	In planned subgroup analyses, a significant interaction was noted (P = .01): limited-stage vandetanib patients had longer overall survival (HR, 0.45; one-sided P = .07) and extensive-stage vandetanib patients shorter survival compared with placebo (HR, 2.27; one-sided P = .996).	Median progression-free survival for vandetanib and placebo was 2.7 and 2.8 months, respectively (hazard ratio [HR], 1.01; 80% CI, 0.75 to 1.36; one-sided P = .51).
__label__noRel	In planned subgroup analyses, a significant interaction was noted (P = .01): limited-stage vandetanib patients had longer overall survival (HR, 0.45; one-sided P = .07) and extensive-stage vandetanib patients shorter survival compared with placebo (HR, 2.27; one-sided P = .996).	Overall survival for vandetanib was 10.6 versus 11.9 months for placebo (HR, 1.43; 80% CI, 1.00 to 2.05; one-sided P = 0.9).
__label__Support	In planned subgroup analyses, a significant interaction was noted (P = .01): limited-stage vandetanib patients had longer overall survival (HR, 0.45; one-sided P = .07) and extensive-stage vandetanib patients shorter survival compared with placebo (HR, 2.27; one-sided P = .996).	Vandetanib failed to demonstrate efficacy as maintenance therapy for small-cell lung cancer.
__label__noRel	Vandetanib failed to demonstrate efficacy as maintenance therapy for small-cell lung cancer.	Vandetanib patients had more toxicity and required more dose modifications for gastrointestinal toxicity and rash.
__label__noRel	Vandetanib failed to demonstrate efficacy as maintenance therapy for small-cell lung cancer.	Asymptomatic Corrected QT interval (QTC) prolongation was observed in eight vandetanib patients.
__label__noRel	Vandetanib failed to demonstrate efficacy as maintenance therapy for small-cell lung cancer.	Median progression-free survival for vandetanib and placebo was 2.7 and 2.8 months, respectively (hazard ratio [HR], 1.01; 80% CI, 0.75 to 1.36; one-sided P = .51).
__label__noRel	Vandetanib failed to demonstrate efficacy as maintenance therapy for small-cell lung cancer.	Overall survival for vandetanib was 10.6 versus 11.9 months for placebo (HR, 1.43; 80% CI, 1.00 to 2.05; one-sided P = 0.9).
__label__noRel	Vandetanib failed to demonstrate efficacy as maintenance therapy for small-cell lung cancer.	In planned subgroup analyses, a significant interaction was noted (P = .01): limited-stage vandetanib patients had longer overall survival (HR, 0.45; one-sided P = .07) and extensive-stage vandetanib patients shorter survival compared with placebo (HR, 2.27; one-sided P = .996).
__label__noRel	Depression, anxiety, fatigue, and impaired wellbeing are common, important, and closely related in advanced cancer.	Sertraline had no significant effect (scale, benefit over placebo [95% CI]) on depression (CES-D 0.4 [-2.6 to 3.4]), anxiety (HADS-A 2.0 [-1.5 to 5.5]), fatigue (FACT-F 0.3 [-4.3 to 4.9]), overall quality of life (FACT-G 1.7 [-1.3 to 4.7]), or clinicians' ratings (SQLI 2.0 [-2.5 to 6.5]), and the 95% CI ruled out a clinically significant benefit for all main outcomes.
__label__noRel	Depression, anxiety, fatigue, and impaired wellbeing are common, important, and closely related in advanced cancer.	Sertraline was discontinued more often and earlier than was placebo (hazard ratio 1.46 [1.03-2.06], p=0.03).
__label__noRel	Depression, anxiety, fatigue, and impaired wellbeing are common, important, and closely related in advanced cancer.	the first planned interim analysis in February 2006 (n=150) showed that survival was longer in patients assigned placebo than in patients assigned sertraline (unadjusted hazard ratio 1.60 [95% CI 1.04-2.45], log-rank p=0.04; adjusted hazard ratio 1.62 [1.06-2.41], Cox model p=0.02).
__label__noRel	Depression, anxiety, fatigue, and impaired wellbeing are common, important, and closely related in advanced cancer.	However, at the final analysis in July 2006 of all patients (n=189) and with longer follow-up, survival did not differ significantly between the treatment groups (unadjusted hazard ratio 1.35 [0.95-1.91], log-rank p=0.09; adjusted hazard ratio 1.27 [0.87-1.84], Cox model p=0.20).
__label__noRel	Depression, anxiety, fatigue, and impaired wellbeing are common, important, and closely related in advanced cancer.	Sertraline did not improve symptoms, wellbeing, or survival in patients with advanced cancer who do not have major depression, and should be reserved for those with a proven indication.
__label__noRel	Sertraline had no significant effect (scale, benefit over placebo [95% CI]) on depression (CES-D 0.4 [-2.6 to 3.4]), anxiety (HADS-A 2.0 [-1.5 to 5.5]), fatigue (FACT-F 0.3 [-4.3 to 4.9]), overall quality of life (FACT-G 1.7 [-1.3 to 4.7]), or clinicians' ratings (SQLI 2.0 [-2.5 to 6.5]), and the 95% CI ruled out a clinically significant benefit for all main outcomes.	Depression, anxiety, fatigue, and impaired wellbeing are common, important, and closely related in advanced cancer.
__label__noRel	Sertraline had no significant effect (scale, benefit over placebo [95% CI]) on depression (CES-D 0.4 [-2.6 to 3.4]), anxiety (HADS-A 2.0 [-1.5 to 5.5]), fatigue (FACT-F 0.3 [-4.3 to 4.9]), overall quality of life (FACT-G 1.7 [-1.3 to 4.7]), or clinicians' ratings (SQLI 2.0 [-2.5 to 6.5]), and the 95% CI ruled out a clinically significant benefit for all main outcomes.	Sertraline was discontinued more often and earlier than was placebo (hazard ratio 1.46 [1.03-2.06], p=0.03).
__label__noRel	Sertraline had no significant effect (scale, benefit over placebo [95% CI]) on depression (CES-D 0.4 [-2.6 to 3.4]), anxiety (HADS-A 2.0 [-1.5 to 5.5]), fatigue (FACT-F 0.3 [-4.3 to 4.9]), overall quality of life (FACT-G 1.7 [-1.3 to 4.7]), or clinicians' ratings (SQLI 2.0 [-2.5 to 6.5]), and the 95% CI ruled out a clinically significant benefit for all main outcomes.	the first planned interim analysis in February 2006 (n=150) showed that survival was longer in patients assigned placebo than in patients assigned sertraline (unadjusted hazard ratio 1.60 [95% CI 1.04-2.45], log-rank p=0.04; adjusted hazard ratio 1.62 [1.06-2.41], Cox model p=0.02).
__label__noRel	Sertraline had no significant effect (scale, benefit over placebo [95% CI]) on depression (CES-D 0.4 [-2.6 to 3.4]), anxiety (HADS-A 2.0 [-1.5 to 5.5]), fatigue (FACT-F 0.3 [-4.3 to 4.9]), overall quality of life (FACT-G 1.7 [-1.3 to 4.7]), or clinicians' ratings (SQLI 2.0 [-2.5 to 6.5]), and the 95% CI ruled out a clinically significant benefit for all main outcomes.	However, at the final analysis in July 2006 of all patients (n=189) and with longer follow-up, survival did not differ significantly between the treatment groups (unadjusted hazard ratio 1.35 [0.95-1.91], log-rank p=0.09; adjusted hazard ratio 1.27 [0.87-1.84], Cox model p=0.20).
__label__Support	Sertraline had no significant effect (scale, benefit over placebo [95% CI]) on depression (CES-D 0.4 [-2.6 to 3.4]), anxiety (HADS-A 2.0 [-1.5 to 5.5]), fatigue (FACT-F 0.3 [-4.3 to 4.9]), overall quality of life (FACT-G 1.7 [-1.3 to 4.7]), or clinicians' ratings (SQLI 2.0 [-2.5 to 6.5]), and the 95% CI ruled out a clinically significant benefit for all main outcomes.	Sertraline did not improve symptoms, wellbeing, or survival in patients with advanced cancer who do not have major depression, and should be reserved for those with a proven indication.
__label__noRel	Sertraline was discontinued more often and earlier than was placebo (hazard ratio 1.46 [1.03-2.06], p=0.03).	Depression, anxiety, fatigue, and impaired wellbeing are common, important, and closely related in advanced cancer.
__label__noRel	Sertraline was discontinued more often and earlier than was placebo (hazard ratio 1.46 [1.03-2.06], p=0.03).	Sertraline had no significant effect (scale, benefit over placebo [95% CI]) on depression (CES-D 0.4 [-2.6 to 3.4]), anxiety (HADS-A 2.0 [-1.5 to 5.5]), fatigue (FACT-F 0.3 [-4.3 to 4.9]), overall quality of life (FACT-G 1.7 [-1.3 to 4.7]), or clinicians' ratings (SQLI 2.0 [-2.5 to 6.5]), and the 95% CI ruled out a clinically significant benefit for all main outcomes.
__label__noRel	Sertraline was discontinued more often and earlier than was placebo (hazard ratio 1.46 [1.03-2.06], p=0.03).	the first planned interim analysis in February 2006 (n=150) showed that survival was longer in patients assigned placebo than in patients assigned sertraline (unadjusted hazard ratio 1.60 [95% CI 1.04-2.45], log-rank p=0.04; adjusted hazard ratio 1.62 [1.06-2.41], Cox model p=0.02).
__label__noRel	Sertraline was discontinued more often and earlier than was placebo (hazard ratio 1.46 [1.03-2.06], p=0.03).	However, at the final analysis in July 2006 of all patients (n=189) and with longer follow-up, survival did not differ significantly between the treatment groups (unadjusted hazard ratio 1.35 [0.95-1.91], log-rank p=0.09; adjusted hazard ratio 1.27 [0.87-1.84], Cox model p=0.20).
__label__noRel	Sertraline was discontinued more often and earlier than was placebo (hazard ratio 1.46 [1.03-2.06], p=0.03).	Sertraline did not improve symptoms, wellbeing, or survival in patients with advanced cancer who do not have major depression, and should be reserved for those with a proven indication.
__label__noRel	the first planned interim analysis in February 2006 (n=150) showed that survival was longer in patients assigned placebo than in patients assigned sertraline (unadjusted hazard ratio 1.60 [95% CI 1.04-2.45], log-rank p=0.04; adjusted hazard ratio 1.62 [1.06-2.41], Cox model p=0.02).	Depression, anxiety, fatigue, and impaired wellbeing are common, important, and closely related in advanced cancer.
__label__noRel	the first planned interim analysis in February 2006 (n=150) showed that survival was longer in patients assigned placebo than in patients assigned sertraline (unadjusted hazard ratio 1.60 [95% CI 1.04-2.45], log-rank p=0.04; adjusted hazard ratio 1.62 [1.06-2.41], Cox model p=0.02).	Sertraline had no significant effect (scale, benefit over placebo [95% CI]) on depression (CES-D 0.4 [-2.6 to 3.4]), anxiety (HADS-A 2.0 [-1.5 to 5.5]), fatigue (FACT-F 0.3 [-4.3 to 4.9]), overall quality of life (FACT-G 1.7 [-1.3 to 4.7]), or clinicians' ratings (SQLI 2.0 [-2.5 to 6.5]), and the 95% CI ruled out a clinically significant benefit for all main outcomes.
__label__noRel	the first planned interim analysis in February 2006 (n=150) showed that survival was longer in patients assigned placebo than in patients assigned sertraline (unadjusted hazard ratio 1.60 [95% CI 1.04-2.45], log-rank p=0.04; adjusted hazard ratio 1.62 [1.06-2.41], Cox model p=0.02).	Sertraline was discontinued more often and earlier than was placebo (hazard ratio 1.46 [1.03-2.06], p=0.03).
__label__noRel	the first planned interim analysis in February 2006 (n=150) showed that survival was longer in patients assigned placebo than in patients assigned sertraline (unadjusted hazard ratio 1.60 [95% CI 1.04-2.45], log-rank p=0.04; adjusted hazard ratio 1.62 [1.06-2.41], Cox model p=0.02).	However, at the final analysis in July 2006 of all patients (n=189) and with longer follow-up, survival did not differ significantly between the treatment groups (unadjusted hazard ratio 1.35 [0.95-1.91], log-rank p=0.09; adjusted hazard ratio 1.27 [0.87-1.84], Cox model p=0.20).
__label__Attack	the first planned interim analysis in February 2006 (n=150) showed that survival was longer in patients assigned placebo than in patients assigned sertraline (unadjusted hazard ratio 1.60 [95% CI 1.04-2.45], log-rank p=0.04; adjusted hazard ratio 1.62 [1.06-2.41], Cox model p=0.02).	Sertraline did not improve symptoms, wellbeing, or survival in patients with advanced cancer who do not have major depression, and should be reserved for those with a proven indication.
__label__noRel	However, at the final analysis in July 2006 of all patients (n=189) and with longer follow-up, survival did not differ significantly between the treatment groups (unadjusted hazard ratio 1.35 [0.95-1.91], log-rank p=0.09; adjusted hazard ratio 1.27 [0.87-1.84], Cox model p=0.20).	Depression, anxiety, fatigue, and impaired wellbeing are common, important, and closely related in advanced cancer.
__label__noRel	However, at the final analysis in July 2006 of all patients (n=189) and with longer follow-up, survival did not differ significantly between the treatment groups (unadjusted hazard ratio 1.35 [0.95-1.91], log-rank p=0.09; adjusted hazard ratio 1.27 [0.87-1.84], Cox model p=0.20).	Sertraline had no significant effect (scale, benefit over placebo [95% CI]) on depression (CES-D 0.4 [-2.6 to 3.4]), anxiety (HADS-A 2.0 [-1.5 to 5.5]), fatigue (FACT-F 0.3 [-4.3 to 4.9]), overall quality of life (FACT-G 1.7 [-1.3 to 4.7]), or clinicians' ratings (SQLI 2.0 [-2.5 to 6.5]), and the 95% CI ruled out a clinically significant benefit for all main outcomes.
__label__noRel	However, at the final analysis in July 2006 of all patients (n=189) and with longer follow-up, survival did not differ significantly between the treatment groups (unadjusted hazard ratio 1.35 [0.95-1.91], log-rank p=0.09; adjusted hazard ratio 1.27 [0.87-1.84], Cox model p=0.20).	Sertraline was discontinued more often and earlier than was placebo (hazard ratio 1.46 [1.03-2.06], p=0.03).
__label__noRel	However, at the final analysis in July 2006 of all patients (n=189) and with longer follow-up, survival did not differ significantly between the treatment groups (unadjusted hazard ratio 1.35 [0.95-1.91], log-rank p=0.09; adjusted hazard ratio 1.27 [0.87-1.84], Cox model p=0.20).	the first planned interim analysis in February 2006 (n=150) showed that survival was longer in patients assigned placebo than in patients assigned sertraline (unadjusted hazard ratio 1.60 [95% CI 1.04-2.45], log-rank p=0.04; adjusted hazard ratio 1.62 [1.06-2.41], Cox model p=0.02).
__label__Support	However, at the final analysis in July 2006 of all patients (n=189) and with longer follow-up, survival did not differ significantly between the treatment groups (unadjusted hazard ratio 1.35 [0.95-1.91], log-rank p=0.09; adjusted hazard ratio 1.27 [0.87-1.84], Cox model p=0.20).	Sertraline did not improve symptoms, wellbeing, or survival in patients with advanced cancer who do not have major depression, and should be reserved for those with a proven indication.
__label__noRel	Sertraline did not improve symptoms, wellbeing, or survival in patients with advanced cancer who do not have major depression, and should be reserved for those with a proven indication.	Depression, anxiety, fatigue, and impaired wellbeing are common, important, and closely related in advanced cancer.
__label__noRel	Sertraline did not improve symptoms, wellbeing, or survival in patients with advanced cancer who do not have major depression, and should be reserved for those with a proven indication.	Sertraline had no significant effect (scale, benefit over placebo [95% CI]) on depression (CES-D 0.4 [-2.6 to 3.4]), anxiety (HADS-A 2.0 [-1.5 to 5.5]), fatigue (FACT-F 0.3 [-4.3 to 4.9]), overall quality of life (FACT-G 1.7 [-1.3 to 4.7]), or clinicians' ratings (SQLI 2.0 [-2.5 to 6.5]), and the 95% CI ruled out a clinically significant benefit for all main outcomes.
__label__noRel	Sertraline did not improve symptoms, wellbeing, or survival in patients with advanced cancer who do not have major depression, and should be reserved for those with a proven indication.	Sertraline was discontinued more often and earlier than was placebo (hazard ratio 1.46 [1.03-2.06], p=0.03).
__label__noRel	Sertraline did not improve symptoms, wellbeing, or survival in patients with advanced cancer who do not have major depression, and should be reserved for those with a proven indication.	the first planned interim analysis in February 2006 (n=150) showed that survival was longer in patients assigned placebo than in patients assigned sertraline (unadjusted hazard ratio 1.60 [95% CI 1.04-2.45], log-rank p=0.04; adjusted hazard ratio 1.62 [1.06-2.41], Cox model p=0.02).
__label__noRel	Sertraline did not improve symptoms, wellbeing, or survival in patients with advanced cancer who do not have major depression, and should be reserved for those with a proven indication.	However, at the final analysis in July 2006 of all patients (n=189) and with longer follow-up, survival did not differ significantly between the treatment groups (unadjusted hazard ratio 1.35 [0.95-1.91], log-rank p=0.09; adjusted hazard ratio 1.27 [0.87-1.84], Cox model p=0.20).
__label__noRel	Relative to women continuing tamoxifen, women switching to anastrozole experienced a decrease of 53% (95% CI, 41%-63%) in double endometrial thickness and a decrease of 51% (95% CI, 39%-60%) in uterine volume.	Vaginal dryness (b = 0.064; 95% CI, 0.016-0.112) and sexual problems (b = 0.054; 95% CI, 0.007-0.102) increased in women taking anastrozole compared with women taking tamoxifen.
__label__noRel	Relative to women continuing tamoxifen, women switching to anastrozole experienced a decrease of 53% (95% CI, 41%-63%) in double endometrial thickness and a decrease of 51% (95% CI, 39%-60%) in uterine volume.	Treatment arms did not differ regarding withdrawal rate and the experience of (serious) adverse events.
__label__Support	Relative to women continuing tamoxifen, women switching to anastrozole experienced a decrease of 53% (95% CI, 41%-63%) in double endometrial thickness and a decrease of 51% (95% CI, 39%-60%) in uterine volume.	Switching to anastrozole strongly decreased the endometrial thickness and uterine volume but increased sexual disturbances.
__label__noRel	Relative to women continuing tamoxifen, women switching to anastrozole experienced a decrease of 53% (95% CI, 41%-63%) in double endometrial thickness and a decrease of 51% (95% CI, 39%-60%) in uterine volume.	Safe and effective interventions are needed to alleviate sexual dysfunction.
__label__noRel	Vaginal dryness (b = 0.064; 95% CI, 0.016-0.112) and sexual problems (b = 0.054; 95% CI, 0.007-0.102) increased in women taking anastrozole compared with women taking tamoxifen.	Relative to women continuing tamoxifen, women switching to anastrozole experienced a decrease of 53% (95% CI, 41%-63%) in double endometrial thickness and a decrease of 51% (95% CI, 39%-60%) in uterine volume.
__label__noRel	Vaginal dryness (b = 0.064; 95% CI, 0.016-0.112) and sexual problems (b = 0.054; 95% CI, 0.007-0.102) increased in women taking anastrozole compared with women taking tamoxifen.	Treatment arms did not differ regarding withdrawal rate and the experience of (serious) adverse events.
__label__Support	Vaginal dryness (b = 0.064; 95% CI, 0.016-0.112) and sexual problems (b = 0.054; 95% CI, 0.007-0.102) increased in women taking anastrozole compared with women taking tamoxifen.	Switching to anastrozole strongly decreased the endometrial thickness and uterine volume but increased sexual disturbances.
__label__noRel	Vaginal dryness (b = 0.064; 95% CI, 0.016-0.112) and sexual problems (b = 0.054; 95% CI, 0.007-0.102) increased in women taking anastrozole compared with women taking tamoxifen.	Safe and effective interventions are needed to alleviate sexual dysfunction.
__label__noRel	Treatment arms did not differ regarding withdrawal rate and the experience of (serious) adverse events.	Relative to women continuing tamoxifen, women switching to anastrozole experienced a decrease of 53% (95% CI, 41%-63%) in double endometrial thickness and a decrease of 51% (95% CI, 39%-60%) in uterine volume.
__label__noRel	Treatment arms did not differ regarding withdrawal rate and the experience of (serious) adverse events.	Vaginal dryness (b = 0.064; 95% CI, 0.016-0.112) and sexual problems (b = 0.054; 95% CI, 0.007-0.102) increased in women taking anastrozole compared with women taking tamoxifen.
__label__noRel	Treatment arms did not differ regarding withdrawal rate and the experience of (serious) adverse events.	Switching to anastrozole strongly decreased the endometrial thickness and uterine volume but increased sexual disturbances.
__label__noRel	Treatment arms did not differ regarding withdrawal rate and the experience of (serious) adverse events.	Safe and effective interventions are needed to alleviate sexual dysfunction.
__label__noRel	Switching to anastrozole strongly decreased the endometrial thickness and uterine volume but increased sexual disturbances.	Relative to women continuing tamoxifen, women switching to anastrozole experienced a decrease of 53% (95% CI, 41%-63%) in double endometrial thickness and a decrease of 51% (95% CI, 39%-60%) in uterine volume.
__label__noRel	Switching to anastrozole strongly decreased the endometrial thickness and uterine volume but increased sexual disturbances.	Vaginal dryness (b = 0.064; 95% CI, 0.016-0.112) and sexual problems (b = 0.054; 95% CI, 0.007-0.102) increased in women taking anastrozole compared with women taking tamoxifen.
__label__noRel	Switching to anastrozole strongly decreased the endometrial thickness and uterine volume but increased sexual disturbances.	Treatment arms did not differ regarding withdrawal rate and the experience of (serious) adverse events.
__label__noRel	Switching to anastrozole strongly decreased the endometrial thickness and uterine volume but increased sexual disturbances.	Safe and effective interventions are needed to alleviate sexual dysfunction.
__label__noRel	Safe and effective interventions are needed to alleviate sexual dysfunction.	Relative to women continuing tamoxifen, women switching to anastrozole experienced a decrease of 53% (95% CI, 41%-63%) in double endometrial thickness and a decrease of 51% (95% CI, 39%-60%) in uterine volume.
__label__noRel	Safe and effective interventions are needed to alleviate sexual dysfunction.	Vaginal dryness (b = 0.064; 95% CI, 0.016-0.112) and sexual problems (b = 0.054; 95% CI, 0.007-0.102) increased in women taking anastrozole compared with women taking tamoxifen.
__label__noRel	Safe and effective interventions are needed to alleviate sexual dysfunction.	Treatment arms did not differ regarding withdrawal rate and the experience of (serious) adverse events.
__label__noRel	Safe and effective interventions are needed to alleviate sexual dysfunction.	Switching to anastrozole strongly decreased the endometrial thickness and uterine volume but increased sexual disturbances.
__label__noRel	Transient grade 4 neutropenia occurred in 18 and 2 patients, and grade 3 to 4 thrombosis in 7 patients and 1 patient in Arm A and Arm B respectively.	The PSA response rates were 50% and 23%, measurable disease response rates (CR+PR) 14% and 15%, and median overall survival 19.4 months and 13.9 months on Arm A and Arm B respectively.
__label__noRel	Transient grade 4 neutropenia occurred in 18 and 2 patients, and grade 3 to 4 thrombosis in 7 patients and 1 patient in Arm A and Arm B respectively.	Patients on Arm B reported a clinically significant decline in QOL between baseline and week 9/10 (.71 s.d.), and a significantly lower level of QOL than Arm A (p = 0.01).
__label__noRel	Transient grade 4 neutropenia occurred in 18 and 2 patients, and grade 3 to 4 thrombosis in 7 patients and 1 patient in Arm A and Arm B respectively.	As hypothesized, Bcl-2 levels decreased with CRA/IFN therapy only in Arm B (p = 0.03).
__label__Support	Transient grade 4 neutropenia occurred in 18 and 2 patients, and grade 3 to 4 thrombosis in 7 patients and 1 patient in Arm A and Arm B respectively.	Treatment with MEV was well tolerated and demonstrated clinical activity in patients with CRPC.
__label__noRel	Transient grade 4 neutropenia occurred in 18 and 2 patients, and grade 3 to 4 thrombosis in 7 patients and 1 patient in Arm A and Arm B respectively.	Given the adverse effect of CRA/IFN/TAX on QOL, the study of other novel agents that target Bcl-2 family proteins is warranted.
__label__noRel	The PSA response rates were 50% and 23%, measurable disease response rates (CR+PR) 14% and 15%, and median overall survival 19.4 months and 13.9 months on Arm A and Arm B respectively.	Transient grade 4 neutropenia occurred in 18 and 2 patients, and grade 3 to 4 thrombosis in 7 patients and 1 patient in Arm A and Arm B respectively.
__label__noRel	The PSA response rates were 50% and 23%, measurable disease response rates (CR+PR) 14% and 15%, and median overall survival 19.4 months and 13.9 months on Arm A and Arm B respectively.	Patients on Arm B reported a clinically significant decline in QOL between baseline and week 9/10 (.71 s.d.), and a significantly lower level of QOL than Arm A (p = 0.01).
__label__noRel	The PSA response rates were 50% and 23%, measurable disease response rates (CR+PR) 14% and 15%, and median overall survival 19.4 months and 13.9 months on Arm A and Arm B respectively.	As hypothesized, Bcl-2 levels decreased with CRA/IFN therapy only in Arm B (p = 0.03).
__label__Support	The PSA response rates were 50% and 23%, measurable disease response rates (CR+PR) 14% and 15%, and median overall survival 19.4 months and 13.9 months on Arm A and Arm B respectively.	Treatment with MEV was well tolerated and demonstrated clinical activity in patients with CRPC.
__label__noRel	The PSA response rates were 50% and 23%, measurable disease response rates (CR+PR) 14% and 15%, and median overall survival 19.4 months and 13.9 months on Arm A and Arm B respectively.	Given the adverse effect of CRA/IFN/TAX on QOL, the study of other novel agents that target Bcl-2 family proteins is warranted.
__label__noRel	Patients on Arm B reported a clinically significant decline in QOL between baseline and week 9/10 (.71 s.d.), and a significantly lower level of QOL than Arm A (p = 0.01).	Transient grade 4 neutropenia occurred in 18 and 2 patients, and grade 3 to 4 thrombosis in 7 patients and 1 patient in Arm A and Arm B respectively.
__label__noRel	Patients on Arm B reported a clinically significant decline in QOL between baseline and week 9/10 (.71 s.d.), and a significantly lower level of QOL than Arm A (p = 0.01).	The PSA response rates were 50% and 23%, measurable disease response rates (CR+PR) 14% and 15%, and median overall survival 19.4 months and 13.9 months on Arm A and Arm B respectively.
__label__noRel	Patients on Arm B reported a clinically significant decline in QOL between baseline and week 9/10 (.71 s.d.), and a significantly lower level of QOL than Arm A (p = 0.01).	As hypothesized, Bcl-2 levels decreased with CRA/IFN therapy only in Arm B (p = 0.03).
__label__Support	Patients on Arm B reported a clinically significant decline in QOL between baseline and week 9/10 (.71 s.d.), and a significantly lower level of QOL than Arm A (p = 0.01).	Treatment with MEV was well tolerated and demonstrated clinical activity in patients with CRPC.
__label__noRel	Patients on Arm B reported a clinically significant decline in QOL between baseline and week 9/10 (.71 s.d.), and a significantly lower level of QOL than Arm A (p = 0.01).	Given the adverse effect of CRA/IFN/TAX on QOL, the study of other novel agents that target Bcl-2 family proteins is warranted.
__label__noRel	As hypothesized, Bcl-2 levels decreased with CRA/IFN therapy only in Arm B (p = 0.03).	Transient grade 4 neutropenia occurred in 18 and 2 patients, and grade 3 to 4 thrombosis in 7 patients and 1 patient in Arm A and Arm B respectively.
__label__noRel	As hypothesized, Bcl-2 levels decreased with CRA/IFN therapy only in Arm B (p = 0.03).	The PSA response rates were 50% and 23%, measurable disease response rates (CR+PR) 14% and 15%, and median overall survival 19.4 months and 13.9 months on Arm A and Arm B respectively.
__label__noRel	As hypothesized, Bcl-2 levels decreased with CRA/IFN therapy only in Arm B (p = 0.03).	Patients on Arm B reported a clinically significant decline in QOL between baseline and week 9/10 (.71 s.d.), and a significantly lower level of QOL than Arm A (p = 0.01).
__label__Support	As hypothesized, Bcl-2 levels decreased with CRA/IFN therapy only in Arm B (p = 0.03).	Treatment with MEV was well tolerated and demonstrated clinical activity in patients with CRPC.
__label__noRel	As hypothesized, Bcl-2 levels decreased with CRA/IFN therapy only in Arm B (p = 0.03).	Given the adverse effect of CRA/IFN/TAX on QOL, the study of other novel agents that target Bcl-2 family proteins is warranted.
__label__noRel	Treatment with MEV was well tolerated and demonstrated clinical activity in patients with CRPC.	Transient grade 4 neutropenia occurred in 18 and 2 patients, and grade 3 to 4 thrombosis in 7 patients and 1 patient in Arm A and Arm B respectively.
__label__noRel	Treatment with MEV was well tolerated and demonstrated clinical activity in patients with CRPC.	The PSA response rates were 50% and 23%, measurable disease response rates (CR+PR) 14% and 15%, and median overall survival 19.4 months and 13.9 months on Arm A and Arm B respectively.
__label__noRel	Treatment with MEV was well tolerated and demonstrated clinical activity in patients with CRPC.	Patients on Arm B reported a clinically significant decline in QOL between baseline and week 9/10 (.71 s.d.), and a significantly lower level of QOL than Arm A (p = 0.01).
__label__noRel	Treatment with MEV was well tolerated and demonstrated clinical activity in patients with CRPC.	As hypothesized, Bcl-2 levels decreased with CRA/IFN therapy only in Arm B (p = 0.03).
__label__Support	Treatment with MEV was well tolerated and demonstrated clinical activity in patients with CRPC.	Given the adverse effect of CRA/IFN/TAX on QOL, the study of other novel agents that target Bcl-2 family proteins is warranted.
__label__noRel	Given the adverse effect of CRA/IFN/TAX on QOL, the study of other novel agents that target Bcl-2 family proteins is warranted.	Transient grade 4 neutropenia occurred in 18 and 2 patients, and grade 3 to 4 thrombosis in 7 patients and 1 patient in Arm A and Arm B respectively.
__label__noRel	Given the adverse effect of CRA/IFN/TAX on QOL, the study of other novel agents that target Bcl-2 family proteins is warranted.	The PSA response rates were 50% and 23%, measurable disease response rates (CR+PR) 14% and 15%, and median overall survival 19.4 months and 13.9 months on Arm A and Arm B respectively.
__label__noRel	Given the adverse effect of CRA/IFN/TAX on QOL, the study of other novel agents that target Bcl-2 family proteins is warranted.	Patients on Arm B reported a clinically significant decline in QOL between baseline and week 9/10 (.71 s.d.), and a significantly lower level of QOL than Arm A (p = 0.01).
__label__noRel	Given the adverse effect of CRA/IFN/TAX on QOL, the study of other novel agents that target Bcl-2 family proteins is warranted.	As hypothesized, Bcl-2 levels decreased with CRA/IFN therapy only in Arm B (p = 0.03).
__label__noRel	Given the adverse effect of CRA/IFN/TAX on QOL, the study of other novel agents that target Bcl-2 family proteins is warranted.	Treatment with MEV was well tolerated and demonstrated clinical activity in patients with CRPC.
__label__noRel	Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT) is a new anticancer agent with activity in a number of human tumors, including epithelial ovarian cancer.	Severe HSRs were rare (1.5% patients) and were not affected by either dose or schedule.
__label__noRel	Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT) is a new anticancer agent with activity in a number of human tumors, including epithelial ovarian cancer.	Response was slightly higher at the 175-mg/m2 dose (20%) than at 135 mg/m2 (15%),
__label__noRel	Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT) is a new anticancer agent with activity in a number of human tumors, including epithelial ovarian cancer.	but this was not statistically significant (P = .2).
__label__noRel	Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT) is a new anticancer agent with activity in a number of human tumors, including epithelial ovarian cancer.	However, progression-free survival was significantly longer in the high-dose group (19 v 14 weeks; P = .02).
__label__noRel	Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT) is a new anticancer agent with activity in a number of human tumors, including epithelial ovarian cancer.	Significantly more neutropenia was seen when Taxol was administered as a 24-hour infusion.
__label__noRel	Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT) is a new anticancer agent with activity in a number of human tumors, including epithelial ovarian cancer.	Response rates were similar in the 24- and 3-hour groups (19% and 16%, respectively; P = .6).
__label__noRel	Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT) is a new anticancer agent with activity in a number of human tumors, including epithelial ovarian cancer.	No survival differences were noted.
__label__noRel	Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT) is a new anticancer agent with activity in a number of human tumors, including epithelial ovarian cancer.	The 3-hour infusion of Taxol is safe when given with premedication and is associated with less neutropenia.
__label__noRel	Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT) is a new anticancer agent with activity in a number of human tumors, including epithelial ovarian cancer.	The observation that longer infusion produces more myelosuppression but does not yield higher response rates should lead to further studies to determine the optimal dose and schedule of this interesting new agent.
__label__noRel	Severe HSRs were rare (1.5% patients) and were not affected by either dose or schedule.	Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT) is a new anticancer agent with activity in a number of human tumors, including epithelial ovarian cancer.
__label__noRel	Severe HSRs were rare (1.5% patients) and were not affected by either dose or schedule.	Response was slightly higher at the 175-mg/m2 dose (20%) than at 135 mg/m2 (15%),
__label__noRel	Severe HSRs were rare (1.5% patients) and were not affected by either dose or schedule.	but this was not statistically significant (P = .2).
__label__noRel	Severe HSRs were rare (1.5% patients) and were not affected by either dose or schedule.	However, progression-free survival was significantly longer in the high-dose group (19 v 14 weeks; P = .02).
__label__noRel	Severe HSRs were rare (1.5% patients) and were not affected by either dose or schedule.	Significantly more neutropenia was seen when Taxol was administered as a 24-hour infusion.
__label__noRel	Severe HSRs were rare (1.5% patients) and were not affected by either dose or schedule.	Response rates were similar in the 24- and 3-hour groups (19% and 16%, respectively; P = .6).
__label__noRel	Severe HSRs were rare (1.5% patients) and were not affected by either dose or schedule.	No survival differences were noted.
__label__Support	Severe HSRs were rare (1.5% patients) and were not affected by either dose or schedule.	The 3-hour infusion of Taxol is safe when given with premedication and is associated with less neutropenia.
__label__noRel	Severe HSRs were rare (1.5% patients) and were not affected by either dose or schedule.	The observation that longer infusion produces more myelosuppression but does not yield higher response rates should lead to further studies to determine the optimal dose and schedule of this interesting new agent.
__label__noRel	Response was slightly higher at the 175-mg/m2 dose (20%) than at 135 mg/m2 (15%),	Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT) is a new anticancer agent with activity in a number of human tumors, including epithelial ovarian cancer.
__label__noRel	Response was slightly higher at the 175-mg/m2 dose (20%) than at 135 mg/m2 (15%),	Severe HSRs were rare (1.5% patients) and were not affected by either dose or schedule.
__label__noRel	Response was slightly higher at the 175-mg/m2 dose (20%) than at 135 mg/m2 (15%),	but this was not statistically significant (P = .2).
__label__noRel	Response was slightly higher at the 175-mg/m2 dose (20%) than at 135 mg/m2 (15%),	However, progression-free survival was significantly longer in the high-dose group (19 v 14 weeks; P = .02).
__label__noRel	Response was slightly higher at the 175-mg/m2 dose (20%) than at 135 mg/m2 (15%),	Significantly more neutropenia was seen when Taxol was administered as a 24-hour infusion.
__label__Attack	Response was slightly higher at the 175-mg/m2 dose (20%) than at 135 mg/m2 (15%),	Response rates were similar in the 24- and 3-hour groups (19% and 16%, respectively; P = .6).
__label__noRel	Response was slightly higher at the 175-mg/m2 dose (20%) than at 135 mg/m2 (15%),	No survival differences were noted.
__label__noRel	Response was slightly higher at the 175-mg/m2 dose (20%) than at 135 mg/m2 (15%),	The 3-hour infusion of Taxol is safe when given with premedication and is associated with less neutropenia.
__label__noRel	Response was slightly higher at the 175-mg/m2 dose (20%) than at 135 mg/m2 (15%),	The observation that longer infusion produces more myelosuppression but does not yield higher response rates should lead to further studies to determine the optimal dose and schedule of this interesting new agent.
__label__noRel	but this was not statistically significant (P = .2).	Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT) is a new anticancer agent with activity in a number of human tumors, including epithelial ovarian cancer.
__label__noRel	but this was not statistically significant (P = .2).	Severe HSRs were rare (1.5% patients) and were not affected by either dose or schedule.
__label__Attack	but this was not statistically significant (P = .2).	Response was slightly higher at the 175-mg/m2 dose (20%) than at 135 mg/m2 (15%),
__label__noRel	but this was not statistically significant (P = .2).	However, progression-free survival was significantly longer in the high-dose group (19 v 14 weeks; P = .02).
__label__noRel	but this was not statistically significant (P = .2).	Significantly more neutropenia was seen when Taxol was administered as a 24-hour infusion.
__label__noRel	but this was not statistically significant (P = .2).	Response rates were similar in the 24- and 3-hour groups (19% and 16%, respectively; P = .6).
__label__noRel	but this was not statistically significant (P = .2).	No survival differences were noted.
__label__noRel	but this was not statistically significant (P = .2).	The 3-hour infusion of Taxol is safe when given with premedication and is associated with less neutropenia.
__label__noRel	but this was not statistically significant (P = .2).	The observation that longer infusion produces more myelosuppression but does not yield higher response rates should lead to further studies to determine the optimal dose and schedule of this interesting new agent.
__label__noRel	However, progression-free survival was significantly longer in the high-dose group (19 v 14 weeks; P = .02).	Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT) is a new anticancer agent with activity in a number of human tumors, including epithelial ovarian cancer.
__label__noRel	However, progression-free survival was significantly longer in the high-dose group (19 v 14 weeks; P = .02).	Severe HSRs were rare (1.5% patients) and were not affected by either dose or schedule.
__label__noRel	However, progression-free survival was significantly longer in the high-dose group (19 v 14 weeks; P = .02).	Response was slightly higher at the 175-mg/m2 dose (20%) than at 135 mg/m2 (15%),
__label__noRel	However, progression-free survival was significantly longer in the high-dose group (19 v 14 weeks; P = .02).	but this was not statistically significant (P = .2).
__label__noRel	However, progression-free survival was significantly longer in the high-dose group (19 v 14 weeks; P = .02).	Significantly more neutropenia was seen when Taxol was administered as a 24-hour infusion.
__label__noRel	However, progression-free survival was significantly longer in the high-dose group (19 v 14 weeks; P = .02).	Response rates were similar in the 24- and 3-hour groups (19% and 16%, respectively; P = .6).
__label__noRel	However, progression-free survival was significantly longer in the high-dose group (19 v 14 weeks; P = .02).	No survival differences were noted.
__label__Support	However, progression-free survival was significantly longer in the high-dose group (19 v 14 weeks; P = .02).	The 3-hour infusion of Taxol is safe when given with premedication and is associated with less neutropenia.
__label__noRel	However, progression-free survival was significantly longer in the high-dose group (19 v 14 weeks; P = .02).	The observation that longer infusion produces more myelosuppression but does not yield higher response rates should lead to further studies to determine the optimal dose and schedule of this interesting new agent.
__label__noRel	Significantly more neutropenia was seen when Taxol was administered as a 24-hour infusion.	Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT) is a new anticancer agent with activity in a number of human tumors, including epithelial ovarian cancer.
__label__noRel	Significantly more neutropenia was seen when Taxol was administered as a 24-hour infusion.	Severe HSRs were rare (1.5% patients) and were not affected by either dose or schedule.
__label__noRel	Significantly more neutropenia was seen when Taxol was administered as a 24-hour infusion.	Response was slightly higher at the 175-mg/m2 dose (20%) than at 135 mg/m2 (15%),
__label__noRel	Significantly more neutropenia was seen when Taxol was administered as a 24-hour infusion.	but this was not statistically significant (P = .2).
__label__noRel	Significantly more neutropenia was seen when Taxol was administered as a 24-hour infusion.	However, progression-free survival was significantly longer in the high-dose group (19 v 14 weeks; P = .02).
__label__noRel	Significantly more neutropenia was seen when Taxol was administered as a 24-hour infusion.	Response rates were similar in the 24- and 3-hour groups (19% and 16%, respectively; P = .6).
__label__noRel	Significantly more neutropenia was seen when Taxol was administered as a 24-hour infusion.	No survival differences were noted.
__label__Support	Significantly more neutropenia was seen when Taxol was administered as a 24-hour infusion.	The 3-hour infusion of Taxol is safe when given with premedication and is associated with less neutropenia.
__label__noRel	Significantly more neutropenia was seen when Taxol was administered as a 24-hour infusion.	The observation that longer infusion produces more myelosuppression but does not yield higher response rates should lead to further studies to determine the optimal dose and schedule of this interesting new agent.
__label__noRel	Response rates were similar in the 24- and 3-hour groups (19% and 16%, respectively; P = .6).	Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT) is a new anticancer agent with activity in a number of human tumors, including epithelial ovarian cancer.
__label__noRel	Response rates were similar in the 24- and 3-hour groups (19% and 16%, respectively; P = .6).	Severe HSRs were rare (1.5% patients) and were not affected by either dose or schedule.
__label__noRel	Response rates were similar in the 24- and 3-hour groups (19% and 16%, respectively; P = .6).	Response was slightly higher at the 175-mg/m2 dose (20%) than at 135 mg/m2 (15%),
__label__noRel	Response rates were similar in the 24- and 3-hour groups (19% and 16%, respectively; P = .6).	but this was not statistically significant (P = .2).
__label__noRel	Response rates were similar in the 24- and 3-hour groups (19% and 16%, respectively; P = .6).	However, progression-free survival was significantly longer in the high-dose group (19 v 14 weeks; P = .02).
__label__noRel	Response rates were similar in the 24- and 3-hour groups (19% and 16%, respectively; P = .6).	Significantly more neutropenia was seen when Taxol was administered as a 24-hour infusion.
__label__noRel	Response rates were similar in the 24- and 3-hour groups (19% and 16%, respectively; P = .6).	No survival differences were noted.
__label__Support	Response rates were similar in the 24- and 3-hour groups (19% and 16%, respectively; P = .6).	The 3-hour infusion of Taxol is safe when given with premedication and is associated with less neutropenia.
__label__noRel	Response rates were similar in the 24- and 3-hour groups (19% and 16%, respectively; P = .6).	The observation that longer infusion produces more myelosuppression but does not yield higher response rates should lead to further studies to determine the optimal dose and schedule of this interesting new agent.
__label__noRel	No survival differences were noted.	Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT) is a new anticancer agent with activity in a number of human tumors, including epithelial ovarian cancer.
__label__noRel	No survival differences were noted.	Severe HSRs were rare (1.5% patients) and were not affected by either dose or schedule.
__label__noRel	No survival differences were noted.	Response was slightly higher at the 175-mg/m2 dose (20%) than at 135 mg/m2 (15%),
__label__noRel	No survival differences were noted.	but this was not statistically significant (P = .2).
__label__noRel	No survival differences were noted.	However, progression-free survival was significantly longer in the high-dose group (19 v 14 weeks; P = .02).
__label__noRel	No survival differences were noted.	Significantly more neutropenia was seen when Taxol was administered as a 24-hour infusion.
__label__noRel	No survival differences were noted.	Response rates were similar in the 24- and 3-hour groups (19% and 16%, respectively; P = .6).
__label__Support	No survival differences were noted.	The 3-hour infusion of Taxol is safe when given with premedication and is associated with less neutropenia.
__label__noRel	No survival differences were noted.	The observation that longer infusion produces more myelosuppression but does not yield higher response rates should lead to further studies to determine the optimal dose and schedule of this interesting new agent.
__label__noRel	The 3-hour infusion of Taxol is safe when given with premedication and is associated with less neutropenia.	Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT) is a new anticancer agent with activity in a number of human tumors, including epithelial ovarian cancer.
__label__noRel	The 3-hour infusion of Taxol is safe when given with premedication and is associated with less neutropenia.	Severe HSRs were rare (1.5% patients) and were not affected by either dose or schedule.
__label__noRel	The 3-hour infusion of Taxol is safe when given with premedication and is associated with less neutropenia.	Response was slightly higher at the 175-mg/m2 dose (20%) than at 135 mg/m2 (15%),
__label__noRel	The 3-hour infusion of Taxol is safe when given with premedication and is associated with less neutropenia.	but this was not statistically significant (P = .2).
__label__noRel	The 3-hour infusion of Taxol is safe when given with premedication and is associated with less neutropenia.	However, progression-free survival was significantly longer in the high-dose group (19 v 14 weeks; P = .02).
__label__noRel	The 3-hour infusion of Taxol is safe when given with premedication and is associated with less neutropenia.	Significantly more neutropenia was seen when Taxol was administered as a 24-hour infusion.
__label__noRel	The 3-hour infusion of Taxol is safe when given with premedication and is associated with less neutropenia.	Response rates were similar in the 24- and 3-hour groups (19% and 16%, respectively; P = .6).
__label__noRel	The 3-hour infusion of Taxol is safe when given with premedication and is associated with less neutropenia.	No survival differences were noted.
__label__noRel	The 3-hour infusion of Taxol is safe when given with premedication and is associated with less neutropenia.	The observation that longer infusion produces more myelosuppression but does not yield higher response rates should lead to further studies to determine the optimal dose and schedule of this interesting new agent.
__label__noRel	The observation that longer infusion produces more myelosuppression but does not yield higher response rates should lead to further studies to determine the optimal dose and schedule of this interesting new agent.	Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT) is a new anticancer agent with activity in a number of human tumors, including epithelial ovarian cancer.
__label__noRel	The observation that longer infusion produces more myelosuppression but does not yield higher response rates should lead to further studies to determine the optimal dose and schedule of this interesting new agent.	Severe HSRs were rare (1.5% patients) and were not affected by either dose or schedule.
__label__noRel	The observation that longer infusion produces more myelosuppression but does not yield higher response rates should lead to further studies to determine the optimal dose and schedule of this interesting new agent.	Response was slightly higher at the 175-mg/m2 dose (20%) than at 135 mg/m2 (15%),
__label__noRel	The observation that longer infusion produces more myelosuppression but does not yield higher response rates should lead to further studies to determine the optimal dose and schedule of this interesting new agent.	but this was not statistically significant (P = .2).
__label__noRel	The observation that longer infusion produces more myelosuppression but does not yield higher response rates should lead to further studies to determine the optimal dose and schedule of this interesting new agent.	However, progression-free survival was significantly longer in the high-dose group (19 v 14 weeks; P = .02).
__label__noRel	The observation that longer infusion produces more myelosuppression but does not yield higher response rates should lead to further studies to determine the optimal dose and schedule of this interesting new agent.	Significantly more neutropenia was seen when Taxol was administered as a 24-hour infusion.
__label__noRel	The observation that longer infusion produces more myelosuppression but does not yield higher response rates should lead to further studies to determine the optimal dose and schedule of this interesting new agent.	Response rates were similar in the 24- and 3-hour groups (19% and 16%, respectively; P = .6).
__label__noRel	The observation that longer infusion produces more myelosuppression but does not yield higher response rates should lead to further studies to determine the optimal dose and schedule of this interesting new agent.	No survival differences were noted.
__label__noRel	The observation that longer infusion produces more myelosuppression but does not yield higher response rates should lead to further studies to determine the optimal dose and schedule of this interesting new agent.	The 3-hour infusion of Taxol is safe when given with premedication and is associated with less neutropenia.
__label__noRel	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).
__label__noRel	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).
__label__noRel	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).
__label__noRel	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.	Treatments were well tolerated in the 3 groups.
__label__noRel	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.	No differences in QOL between groups 2 and 3 were found.
__label__noRel	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.	At a median followup of 26 months we observed 12 biochemical relapses.
__label__Support	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.
__label__noRel	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.	Tamoxifen has been shown to be more effective and safe than RT in this setting.
__label__noRel	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.	QOL and sexual function are not negatively influenced by these 2 treatment options
__label__noRel	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.
__label__noRel	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).
__label__noRel	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).
__label__noRel	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).	Treatments were well tolerated in the 3 groups.
__label__noRel	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).	No differences in QOL between groups 2 and 3 were found.
__label__noRel	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).	At a median followup of 26 months we observed 12 biochemical relapses.
__label__Support	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.
__label__noRel	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).	Tamoxifen has been shown to be more effective and safe than RT in this setting.
__label__noRel	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).	QOL and sexual function are not negatively influenced by these 2 treatment options
__label__noRel	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.
__label__Support	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).
__label__noRel	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).
__label__noRel	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).	Treatments were well tolerated in the 3 groups.
__label__noRel	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).	No differences in QOL between groups 2 and 3 were found.
__label__noRel	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).	At a median followup of 26 months we observed 12 biochemical relapses.
__label__noRel	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.
__label__noRel	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).	Tamoxifen has been shown to be more effective and safe than RT in this setting.
__label__noRel	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).	QOL and sexual function are not negatively influenced by these 2 treatment options
__label__noRel	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.
__label__noRel	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).
__label__noRel	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).
__label__noRel	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).	Treatments were well tolerated in the 3 groups.
__label__noRel	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).	No differences in QOL between groups 2 and 3 were found.
__label__noRel	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).	At a median followup of 26 months we observed 12 biochemical relapses.
__label__Support	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.
__label__noRel	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).	Tamoxifen has been shown to be more effective and safe than RT in this setting.
__label__noRel	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).	QOL and sexual function are not negatively influenced by these 2 treatment options
__label__noRel	Treatments were well tolerated in the 3 groups.	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.
__label__noRel	Treatments were well tolerated in the 3 groups.	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).
__label__noRel	Treatments were well tolerated in the 3 groups.	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).
__label__noRel	Treatments were well tolerated in the 3 groups.	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).
__label__noRel	Treatments were well tolerated in the 3 groups.	No differences in QOL between groups 2 and 3 were found.
__label__noRel	Treatments were well tolerated in the 3 groups.	At a median followup of 26 months we observed 12 biochemical relapses.
__label__noRel	Treatments were well tolerated in the 3 groups.	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.
__label__Support	Treatments were well tolerated in the 3 groups.	Tamoxifen has been shown to be more effective and safe than RT in this setting.
__label__noRel	Treatments were well tolerated in the 3 groups.	QOL and sexual function are not negatively influenced by these 2 treatment options
__label__noRel	No differences in QOL between groups 2 and 3 were found.	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.
__label__noRel	No differences in QOL between groups 2 and 3 were found.	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).
__label__noRel	No differences in QOL between groups 2 and 3 were found.	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).
__label__noRel	No differences in QOL between groups 2 and 3 were found.	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).
__label__noRel	No differences in QOL between groups 2 and 3 were found.	Treatments were well tolerated in the 3 groups.
__label__noRel	No differences in QOL between groups 2 and 3 were found.	At a median followup of 26 months we observed 12 biochemical relapses.
__label__noRel	No differences in QOL between groups 2 and 3 were found.	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.
__label__noRel	No differences in QOL between groups 2 and 3 were found.	Tamoxifen has been shown to be more effective and safe than RT in this setting.
__label__Support	No differences in QOL between groups 2 and 3 were found.	QOL and sexual function are not negatively influenced by these 2 treatment options
__label__noRel	At a median followup of 26 months we observed 12 biochemical relapses.	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.
__label__noRel	At a median followup of 26 months we observed 12 biochemical relapses.	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).
__label__noRel	At a median followup of 26 months we observed 12 biochemical relapses.	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).
__label__noRel	At a median followup of 26 months we observed 12 biochemical relapses.	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).
__label__noRel	At a median followup of 26 months we observed 12 biochemical relapses.	Treatments were well tolerated in the 3 groups.
__label__noRel	At a median followup of 26 months we observed 12 biochemical relapses.	No differences in QOL between groups 2 and 3 were found.
__label__noRel	At a median followup of 26 months we observed 12 biochemical relapses.	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.
__label__noRel	At a median followup of 26 months we observed 12 biochemical relapses.	Tamoxifen has been shown to be more effective and safe than RT in this setting.
__label__noRel	At a median followup of 26 months we observed 12 biochemical relapses.	QOL and sexual function are not negatively influenced by these 2 treatment options
__label__noRel	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.
__label__noRel	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).
__label__noRel	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).
__label__noRel	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).
__label__noRel	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.	Treatments were well tolerated in the 3 groups.
__label__noRel	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.	No differences in QOL between groups 2 and 3 were found.
__label__noRel	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.	At a median followup of 26 months we observed 12 biochemical relapses.
__label__noRel	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.	Tamoxifen has been shown to be more effective and safe than RT in this setting.
__label__noRel	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.	QOL and sexual function are not negatively influenced by these 2 treatment options
__label__noRel	Tamoxifen has been shown to be more effective and safe than RT in this setting.	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.
__label__noRel	Tamoxifen has been shown to be more effective and safe than RT in this setting.	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).
__label__noRel	Tamoxifen has been shown to be more effective and safe than RT in this setting.	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).
__label__noRel	Tamoxifen has been shown to be more effective and safe than RT in this setting.	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).
__label__noRel	Tamoxifen has been shown to be more effective and safe than RT in this setting.	Treatments were well tolerated in the 3 groups.
__label__noRel	Tamoxifen has been shown to be more effective and safe than RT in this setting.	No differences in QOL between groups 2 and 3 were found.
__label__noRel	Tamoxifen has been shown to be more effective and safe than RT in this setting.	At a median followup of 26 months we observed 12 biochemical relapses.
__label__noRel	Tamoxifen has been shown to be more effective and safe than RT in this setting.	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.
__label__noRel	Tamoxifen has been shown to be more effective and safe than RT in this setting.	QOL and sexual function are not negatively influenced by these 2 treatment options
__label__noRel	QOL and sexual function are not negatively influenced by these 2 treatment options	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.
__label__noRel	QOL and sexual function are not negatively influenced by these 2 treatment options	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).
__label__noRel	QOL and sexual function are not negatively influenced by these 2 treatment options	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).
__label__noRel	QOL and sexual function are not negatively influenced by these 2 treatment options	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).
__label__noRel	QOL and sexual function are not negatively influenced by these 2 treatment options	Treatments were well tolerated in the 3 groups.
__label__noRel	QOL and sexual function are not negatively influenced by these 2 treatment options	No differences in QOL between groups 2 and 3 were found.
__label__noRel	QOL and sexual function are not negatively influenced by these 2 treatment options	At a median followup of 26 months we observed 12 biochemical relapses.
__label__noRel	QOL and sexual function are not negatively influenced by these 2 treatment options	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.
__label__Support	QOL and sexual function are not negatively influenced by these 2 treatment options	Tamoxifen has been shown to be more effective and safe than RT in this setting.
__label__noRel	Mean (+/- SD) increase in Hb from baseline to week 12 was 1.75 +/- 2.15 g/dL in the 30,000 IU group (P = 0.008 vs. baseline) and 1.04 +/- 1.75 g/dL in the 20,000 IU group (non-significant).	Both epoetin beta regiments were well tolerated and there were no dose-dependent adverse events.
__label__Support	Mean (+/- SD) increase in Hb from baseline to week 12 was 1.75 +/- 2.15 g/dL in the 30,000 IU group (P = 0.008 vs. baseline) and 1.04 +/- 1.75 g/dL in the 20,000 IU group (non-significant).	Epoetin beta 30,000 IU once weekly is an effective and well-tolerated treatment of anaemia in patients with solid tumours.
__label__noRel	Mean (+/- SD) increase in Hb from baseline to week 12 was 1.75 +/- 2.15 g/dL in the 30,000 IU group (P = 0.008 vs. baseline) and 1.04 +/- 1.75 g/dL in the 20,000 IU group (non-significant).	Haemoglobin response (increase in Hb >or=2 g/dL from baseline) was observed in 78.3% of patients receiving epoetin beta 30,000 IU and 66.7% receiving epoetin beta 20,000 IU.
__label__noRel	Both epoetin beta regiments were well tolerated and there were no dose-dependent adverse events.	Mean (+/- SD) increase in Hb from baseline to week 12 was 1.75 +/- 2.15 g/dL in the 30,000 IU group (P = 0.008 vs. baseline) and 1.04 +/- 1.75 g/dL in the 20,000 IU group (non-significant).
__label__Support	Both epoetin beta regiments were well tolerated and there were no dose-dependent adverse events.	Epoetin beta 30,000 IU once weekly is an effective and well-tolerated treatment of anaemia in patients with solid tumours.
__label__noRel	Both epoetin beta regiments were well tolerated and there were no dose-dependent adverse events.	Haemoglobin response (increase in Hb >or=2 g/dL from baseline) was observed in 78.3% of patients receiving epoetin beta 30,000 IU and 66.7% receiving epoetin beta 20,000 IU.
__label__noRel	Epoetin beta 30,000 IU once weekly is an effective and well-tolerated treatment of anaemia in patients with solid tumours.	Mean (+/- SD) increase in Hb from baseline to week 12 was 1.75 +/- 2.15 g/dL in the 30,000 IU group (P = 0.008 vs. baseline) and 1.04 +/- 1.75 g/dL in the 20,000 IU group (non-significant).
__label__noRel	Epoetin beta 30,000 IU once weekly is an effective and well-tolerated treatment of anaemia in patients with solid tumours.	Both epoetin beta regiments were well tolerated and there were no dose-dependent adverse events.
__label__noRel	Epoetin beta 30,000 IU once weekly is an effective and well-tolerated treatment of anaemia in patients with solid tumours.	Haemoglobin response (increase in Hb >or=2 g/dL from baseline) was observed in 78.3% of patients receiving epoetin beta 30,000 IU and 66.7% receiving epoetin beta 20,000 IU.
__label__noRel	Haemoglobin response (increase in Hb >or=2 g/dL from baseline) was observed in 78.3% of patients receiving epoetin beta 30,000 IU and 66.7% receiving epoetin beta 20,000 IU.	Mean (+/- SD) increase in Hb from baseline to week 12 was 1.75 +/- 2.15 g/dL in the 30,000 IU group (P = 0.008 vs. baseline) and 1.04 +/- 1.75 g/dL in the 20,000 IU group (non-significant).
__label__noRel	Haemoglobin response (increase in Hb >or=2 g/dL from baseline) was observed in 78.3% of patients receiving epoetin beta 30,000 IU and 66.7% receiving epoetin beta 20,000 IU.	Both epoetin beta regiments were well tolerated and there were no dose-dependent adverse events.
__label__Support	Haemoglobin response (increase in Hb >or=2 g/dL from baseline) was observed in 78.3% of patients receiving epoetin beta 30,000 IU and 66.7% receiving epoetin beta 20,000 IU.	Epoetin beta 30,000 IU once weekly is an effective and well-tolerated treatment of anaemia in patients with solid tumours.
__label__noRel	Somatostatin has been shown to have antimitotic activity in endocrine as well as in a variety of nonendocrine tumors.	Expression of somatostatin receptors is found in HCCs,
__label__noRel	Somatostatin has been shown to have antimitotic activity in endocrine as well as in a variety of nonendocrine tumors.	the efficacy of the somatostatin analogue octreotide remains controversial.
__label__noRel	Somatostatin has been shown to have antimitotic activity in endocrine as well as in a variety of nonendocrine tumors.	There was no difference in the cumulative survival.
__label__noRel	Somatostatin has been shown to have antimitotic activity in endocrine as well as in a variety of nonendocrine tumors.	The median survival time was 4.7 months in the octreotide group compared with 5.3 months in the control group.
__label__noRel	Somatostatin has been shown to have antimitotic activity in endocrine as well as in a variety of nonendocrine tumors.	Six-month survival rates were 41% for octreotide patients and 42% for control patients, respectively.
__label__noRel	Somatostatin has been shown to have antimitotic activity in endocrine as well as in a variety of nonendocrine tumors.	The unadjusted relative risk for mortality in the octreotide group compared with patients in the control group was 1.11 (95% CI 0.76-1.63; P = 0.59).
__label__noRel	Somatostatin has been shown to have antimitotic activity in endocrine as well as in a variety of nonendocrine tumors.	When adjusted for Okuda, CTP, and Cancer of the Liver Italian Program (CLIP) scores, the relative risk for octreotide did not change markedly and was 1.05 (95% CI 0.71-1.55; P = 0.83).
__label__noRel	Somatostatin has been shown to have antimitotic activity in endocrine as well as in a variety of nonendocrine tumors.	The CLIP score seems to predict survival better than both Okuda and CTP score.
__label__noRel	Somatostatin has been shown to have antimitotic activity in endocrine as well as in a variety of nonendocrine tumors.	The randomized controlled double-blind HECTOR trial showed no survival benefit for HCC patients treated with long-acting octreotide compared with placebo.
__label__noRel	Expression of somatostatin receptors is found in HCCs,	Somatostatin has been shown to have antimitotic activity in endocrine as well as in a variety of nonendocrine tumors.
__label__noRel	Expression of somatostatin receptors is found in HCCs,	the efficacy of the somatostatin analogue octreotide remains controversial.
__label__noRel	Expression of somatostatin receptors is found in HCCs,	There was no difference in the cumulative survival.
__label__noRel	Expression of somatostatin receptors is found in HCCs,	The median survival time was 4.7 months in the octreotide group compared with 5.3 months in the control group.
__label__noRel	Expression of somatostatin receptors is found in HCCs,	Six-month survival rates were 41% for octreotide patients and 42% for control patients, respectively.
__label__noRel	Expression of somatostatin receptors is found in HCCs,	The unadjusted relative risk for mortality in the octreotide group compared with patients in the control group was 1.11 (95% CI 0.76-1.63; P = 0.59).
__label__noRel	Expression of somatostatin receptors is found in HCCs,	When adjusted for Okuda, CTP, and Cancer of the Liver Italian Program (CLIP) scores, the relative risk for octreotide did not change markedly and was 1.05 (95% CI 0.71-1.55; P = 0.83).
__label__noRel	Expression of somatostatin receptors is found in HCCs,	The CLIP score seems to predict survival better than both Okuda and CTP score.
__label__noRel	Expression of somatostatin receptors is found in HCCs,	The randomized controlled double-blind HECTOR trial showed no survival benefit for HCC patients treated with long-acting octreotide compared with placebo.
__label__noRel	the efficacy of the somatostatin analogue octreotide remains controversial.	Somatostatin has been shown to have antimitotic activity in endocrine as well as in a variety of nonendocrine tumors.
__label__noRel	the efficacy of the somatostatin analogue octreotide remains controversial.	Expression of somatostatin receptors is found in HCCs,
__label__noRel	the efficacy of the somatostatin analogue octreotide remains controversial.	There was no difference in the cumulative survival.
__label__noRel	the efficacy of the somatostatin analogue octreotide remains controversial.	The median survival time was 4.7 months in the octreotide group compared with 5.3 months in the control group.
__label__noRel	the efficacy of the somatostatin analogue octreotide remains controversial.	Six-month survival rates were 41% for octreotide patients and 42% for control patients, respectively.
__label__noRel	the efficacy of the somatostatin analogue octreotide remains controversial.	The unadjusted relative risk for mortality in the octreotide group compared with patients in the control group was 1.11 (95% CI 0.76-1.63; P = 0.59).
__label__noRel	the efficacy of the somatostatin analogue octreotide remains controversial.	When adjusted for Okuda, CTP, and Cancer of the Liver Italian Program (CLIP) scores, the relative risk for octreotide did not change markedly and was 1.05 (95% CI 0.71-1.55; P = 0.83).
__label__noRel	the efficacy of the somatostatin analogue octreotide remains controversial.	The CLIP score seems to predict survival better than both Okuda and CTP score.
__label__noRel	the efficacy of the somatostatin analogue octreotide remains controversial.	The randomized controlled double-blind HECTOR trial showed no survival benefit for HCC patients treated with long-acting octreotide compared with placebo.
__label__noRel	There was no difference in the cumulative survival.	Somatostatin has been shown to have antimitotic activity in endocrine as well as in a variety of nonendocrine tumors.
__label__noRel	There was no difference in the cumulative survival.	Expression of somatostatin receptors is found in HCCs,
__label__noRel	There was no difference in the cumulative survival.	the efficacy of the somatostatin analogue octreotide remains controversial.
__label__noRel	There was no difference in the cumulative survival.	The median survival time was 4.7 months in the octreotide group compared with 5.3 months in the control group.
__label__noRel	There was no difference in the cumulative survival.	Six-month survival rates were 41% for octreotide patients and 42% for control patients, respectively.
__label__noRel	There was no difference in the cumulative survival.	The unadjusted relative risk for mortality in the octreotide group compared with patients in the control group was 1.11 (95% CI 0.76-1.63; P = 0.59).
__label__noRel	There was no difference in the cumulative survival.	When adjusted for Okuda, CTP, and Cancer of the Liver Italian Program (CLIP) scores, the relative risk for octreotide did not change markedly and was 1.05 (95% CI 0.71-1.55; P = 0.83).
__label__noRel	There was no difference in the cumulative survival.	The CLIP score seems to predict survival better than both Okuda and CTP score.
__label__Support	There was no difference in the cumulative survival.	The randomized controlled double-blind HECTOR trial showed no survival benefit for HCC patients treated with long-acting octreotide compared with placebo.
__label__noRel	The median survival time was 4.7 months in the octreotide group compared with 5.3 months in the control group.	Somatostatin has been shown to have antimitotic activity in endocrine as well as in a variety of nonendocrine tumors.
__label__noRel	The median survival time was 4.7 months in the octreotide group compared with 5.3 months in the control group.	Expression of somatostatin receptors is found in HCCs,
__label__noRel	The median survival time was 4.7 months in the octreotide group compared with 5.3 months in the control group.	the efficacy of the somatostatin analogue octreotide remains controversial.
__label__noRel	The median survival time was 4.7 months in the octreotide group compared with 5.3 months in the control group.	There was no difference in the cumulative survival.
__label__noRel	The median survival time was 4.7 months in the octreotide group compared with 5.3 months in the control group.	Six-month survival rates were 41% for octreotide patients and 42% for control patients, respectively.
__label__noRel	The median survival time was 4.7 months in the octreotide group compared with 5.3 months in the control group.	The unadjusted relative risk for mortality in the octreotide group compared with patients in the control group was 1.11 (95% CI 0.76-1.63; P = 0.59).
__label__noRel	The median survival time was 4.7 months in the octreotide group compared with 5.3 months in the control group.	When adjusted for Okuda, CTP, and Cancer of the Liver Italian Program (CLIP) scores, the relative risk for octreotide did not change markedly and was 1.05 (95% CI 0.71-1.55; P = 0.83).
__label__noRel	The median survival time was 4.7 months in the octreotide group compared with 5.3 months in the control group.	The CLIP score seems to predict survival better than both Okuda and CTP score.
__label__Support	The median survival time was 4.7 months in the octreotide group compared with 5.3 months in the control group.	The randomized controlled double-blind HECTOR trial showed no survival benefit for HCC patients treated with long-acting octreotide compared with placebo.
__label__noRel	Six-month survival rates were 41% for octreotide patients and 42% for control patients, respectively.	Somatostatin has been shown to have antimitotic activity in endocrine as well as in a variety of nonendocrine tumors.
__label__noRel	Six-month survival rates were 41% for octreotide patients and 42% for control patients, respectively.	Expression of somatostatin receptors is found in HCCs,
__label__noRel	Six-month survival rates were 41% for octreotide patients and 42% for control patients, respectively.	the efficacy of the somatostatin analogue octreotide remains controversial.
__label__noRel	Six-month survival rates were 41% for octreotide patients and 42% for control patients, respectively.	There was no difference in the cumulative survival.
__label__noRel	Six-month survival rates were 41% for octreotide patients and 42% for control patients, respectively.	The median survival time was 4.7 months in the octreotide group compared with 5.3 months in the control group.
__label__noRel	Six-month survival rates were 41% for octreotide patients and 42% for control patients, respectively.	The unadjusted relative risk for mortality in the octreotide group compared with patients in the control group was 1.11 (95% CI 0.76-1.63; P = 0.59).
__label__noRel	Six-month survival rates were 41% for octreotide patients and 42% for control patients, respectively.	When adjusted for Okuda, CTP, and Cancer of the Liver Italian Program (CLIP) scores, the relative risk for octreotide did not change markedly and was 1.05 (95% CI 0.71-1.55; P = 0.83).
__label__noRel	Six-month survival rates were 41% for octreotide patients and 42% for control patients, respectively.	The CLIP score seems to predict survival better than both Okuda and CTP score.
__label__Support	Six-month survival rates were 41% for octreotide patients and 42% for control patients, respectively.	The randomized controlled double-blind HECTOR trial showed no survival benefit for HCC patients treated with long-acting octreotide compared with placebo.
__label__noRel	The unadjusted relative risk for mortality in the octreotide group compared with patients in the control group was 1.11 (95% CI 0.76-1.63; P = 0.59).	Somatostatin has been shown to have antimitotic activity in endocrine as well as in a variety of nonendocrine tumors.
__label__noRel	The unadjusted relative risk for mortality in the octreotide group compared with patients in the control group was 1.11 (95% CI 0.76-1.63; P = 0.59).	Expression of somatostatin receptors is found in HCCs,
__label__noRel	The unadjusted relative risk for mortality in the octreotide group compared with patients in the control group was 1.11 (95% CI 0.76-1.63; P = 0.59).	the efficacy of the somatostatin analogue octreotide remains controversial.
__label__noRel	The unadjusted relative risk for mortality in the octreotide group compared with patients in the control group was 1.11 (95% CI 0.76-1.63; P = 0.59).	There was no difference in the cumulative survival.
__label__noRel	The unadjusted relative risk for mortality in the octreotide group compared with patients in the control group was 1.11 (95% CI 0.76-1.63; P = 0.59).	The median survival time was 4.7 months in the octreotide group compared with 5.3 months in the control group.
__label__noRel	The unadjusted relative risk for mortality in the octreotide group compared with patients in the control group was 1.11 (95% CI 0.76-1.63; P = 0.59).	Six-month survival rates were 41% for octreotide patients and 42% for control patients, respectively.
__label__noRel	The unadjusted relative risk for mortality in the octreotide group compared with patients in the control group was 1.11 (95% CI 0.76-1.63; P = 0.59).	When adjusted for Okuda, CTP, and Cancer of the Liver Italian Program (CLIP) scores, the relative risk for octreotide did not change markedly and was 1.05 (95% CI 0.71-1.55; P = 0.83).
__label__noRel	The unadjusted relative risk for mortality in the octreotide group compared with patients in the control group was 1.11 (95% CI 0.76-1.63; P = 0.59).	The CLIP score seems to predict survival better than both Okuda and CTP score.
__label__Support	The unadjusted relative risk for mortality in the octreotide group compared with patients in the control group was 1.11 (95% CI 0.76-1.63; P = 0.59).	The randomized controlled double-blind HECTOR trial showed no survival benefit for HCC patients treated with long-acting octreotide compared with placebo.
__label__noRel	When adjusted for Okuda, CTP, and Cancer of the Liver Italian Program (CLIP) scores, the relative risk for octreotide did not change markedly and was 1.05 (95% CI 0.71-1.55; P = 0.83).	Somatostatin has been shown to have antimitotic activity in endocrine as well as in a variety of nonendocrine tumors.
__label__noRel	When adjusted for Okuda, CTP, and Cancer of the Liver Italian Program (CLIP) scores, the relative risk for octreotide did not change markedly and was 1.05 (95% CI 0.71-1.55; P = 0.83).	Expression of somatostatin receptors is found in HCCs,
__label__noRel	When adjusted for Okuda, CTP, and Cancer of the Liver Italian Program (CLIP) scores, the relative risk for octreotide did not change markedly and was 1.05 (95% CI 0.71-1.55; P = 0.83).	the efficacy of the somatostatin analogue octreotide remains controversial.
__label__noRel	When adjusted for Okuda, CTP, and Cancer of the Liver Italian Program (CLIP) scores, the relative risk for octreotide did not change markedly and was 1.05 (95% CI 0.71-1.55; P = 0.83).	There was no difference in the cumulative survival.
__label__noRel	When adjusted for Okuda, CTP, and Cancer of the Liver Italian Program (CLIP) scores, the relative risk for octreotide did not change markedly and was 1.05 (95% CI 0.71-1.55; P = 0.83).	The median survival time was 4.7 months in the octreotide group compared with 5.3 months in the control group.
__label__noRel	When adjusted for Okuda, CTP, and Cancer of the Liver Italian Program (CLIP) scores, the relative risk for octreotide did not change markedly and was 1.05 (95% CI 0.71-1.55; P = 0.83).	Six-month survival rates were 41% for octreotide patients and 42% for control patients, respectively.
__label__noRel	When adjusted for Okuda, CTP, and Cancer of the Liver Italian Program (CLIP) scores, the relative risk for octreotide did not change markedly and was 1.05 (95% CI 0.71-1.55; P = 0.83).	The unadjusted relative risk for mortality in the octreotide group compared with patients in the control group was 1.11 (95% CI 0.76-1.63; P = 0.59).
__label__noRel	When adjusted for Okuda, CTP, and Cancer of the Liver Italian Program (CLIP) scores, the relative risk for octreotide did not change markedly and was 1.05 (95% CI 0.71-1.55; P = 0.83).	The CLIP score seems to predict survival better than both Okuda and CTP score.
__label__Support	When adjusted for Okuda, CTP, and Cancer of the Liver Italian Program (CLIP) scores, the relative risk for octreotide did not change markedly and was 1.05 (95% CI 0.71-1.55; P = 0.83).	The randomized controlled double-blind HECTOR trial showed no survival benefit for HCC patients treated with long-acting octreotide compared with placebo.
__label__noRel	The CLIP score seems to predict survival better than both Okuda and CTP score.	Somatostatin has been shown to have antimitotic activity in endocrine as well as in a variety of nonendocrine tumors.
__label__noRel	The CLIP score seems to predict survival better than both Okuda and CTP score.	Expression of somatostatin receptors is found in HCCs,
__label__noRel	The CLIP score seems to predict survival better than both Okuda and CTP score.	the efficacy of the somatostatin analogue octreotide remains controversial.
__label__noRel	The CLIP score seems to predict survival better than both Okuda and CTP score.	There was no difference in the cumulative survival.
__label__noRel	The CLIP score seems to predict survival better than both Okuda and CTP score.	The median survival time was 4.7 months in the octreotide group compared with 5.3 months in the control group.
__label__noRel	The CLIP score seems to predict survival better than both Okuda and CTP score.	Six-month survival rates were 41% for octreotide patients and 42% for control patients, respectively.
__label__noRel	The CLIP score seems to predict survival better than both Okuda and CTP score.	The unadjusted relative risk for mortality in the octreotide group compared with patients in the control group was 1.11 (95% CI 0.76-1.63; P = 0.59).
__label__noRel	The CLIP score seems to predict survival better than both Okuda and CTP score.	When adjusted for Okuda, CTP, and Cancer of the Liver Italian Program (CLIP) scores, the relative risk for octreotide did not change markedly and was 1.05 (95% CI 0.71-1.55; P = 0.83).
__label__noRel	The CLIP score seems to predict survival better than both Okuda and CTP score.	The randomized controlled double-blind HECTOR trial showed no survival benefit for HCC patients treated with long-acting octreotide compared with placebo.
__label__noRel	The randomized controlled double-blind HECTOR trial showed no survival benefit for HCC patients treated with long-acting octreotide compared with placebo.	Somatostatin has been shown to have antimitotic activity in endocrine as well as in a variety of nonendocrine tumors.
__label__noRel	The randomized controlled double-blind HECTOR trial showed no survival benefit for HCC patients treated with long-acting octreotide compared with placebo.	Expression of somatostatin receptors is found in HCCs,
__label__noRel	The randomized controlled double-blind HECTOR trial showed no survival benefit for HCC patients treated with long-acting octreotide compared with placebo.	the efficacy of the somatostatin analogue octreotide remains controversial.
__label__noRel	The randomized controlled double-blind HECTOR trial showed no survival benefit for HCC patients treated with long-acting octreotide compared with placebo.	There was no difference in the cumulative survival.
__label__noRel	The randomized controlled double-blind HECTOR trial showed no survival benefit for HCC patients treated with long-acting octreotide compared with placebo.	The median survival time was 4.7 months in the octreotide group compared with 5.3 months in the control group.
__label__noRel	The randomized controlled double-blind HECTOR trial showed no survival benefit for HCC patients treated with long-acting octreotide compared with placebo.	Six-month survival rates were 41% for octreotide patients and 42% for control patients, respectively.
__label__noRel	The randomized controlled double-blind HECTOR trial showed no survival benefit for HCC patients treated with long-acting octreotide compared with placebo.	The unadjusted relative risk for mortality in the octreotide group compared with patients in the control group was 1.11 (95% CI 0.76-1.63; P = 0.59).
__label__noRel	The randomized controlled double-blind HECTOR trial showed no survival benefit for HCC patients treated with long-acting octreotide compared with placebo.	When adjusted for Okuda, CTP, and Cancer of the Liver Italian Program (CLIP) scores, the relative risk for octreotide did not change markedly and was 1.05 (95% CI 0.71-1.55; P = 0.83).
__label__noRel	The randomized controlled double-blind HECTOR trial showed no survival benefit for HCC patients treated with long-acting octreotide compared with placebo.	The CLIP score seems to predict survival better than both Okuda and CTP score.
__label__noRel	Analysing response to FUFA and FOLFIRI in the per protocol set (n=119) after un-blinding TS in the data base revealed a trend to better overall response to FOLFIRI (9/19, 47%) in TS high compared to FUFA (5/23, 22%, p=0.077).	In patients with biopsies taken from liver lesions (n=91) overall response to FOLFIRI and FUFA in TS high was 53% (9/17) and 18% (3/17), respectively (p=0.035).
__label__noRel	Analysing response to FUFA and FOLFIRI in the per protocol set (n=119) after un-blinding TS in the data base revealed a trend to better overall response to FOLFIRI (9/19, 47%) in TS high compared to FUFA (5/23, 22%, p=0.077).	In patients with low TS, no remarkable difference in overall response to FOLFIRI and FUFA was observed.
__label__noRel	Analysing response to FUFA and FOLFIRI in the per protocol set (n=119) after un-blinding TS in the data base revealed a trend to better overall response to FOLFIRI (9/19, 47%) in TS high compared to FUFA (5/23, 22%, p=0.077).	Taking a pre-treatment biopsy is a safe and feasible procedure in mCRC.
__label__Support	Analysing response to FUFA and FOLFIRI in the per protocol set (n=119) after un-blinding TS in the data base revealed a trend to better overall response to FOLFIRI (9/19, 47%) in TS high compared to FUFA (5/23, 22%, p=0.077).	After validation of our data in a larger group TS determination may have the potential to better help direct systemic treatment in patients with primarily non-resectable mCRC.
__label__noRel	In patients with biopsies taken from liver lesions (n=91) overall response to FOLFIRI and FUFA in TS high was 53% (9/17) and 18% (3/17), respectively (p=0.035).	Analysing response to FUFA and FOLFIRI in the per protocol set (n=119) after un-blinding TS in the data base revealed a trend to better overall response to FOLFIRI (9/19, 47%) in TS high compared to FUFA (5/23, 22%, p=0.077).
__label__noRel	In patients with biopsies taken from liver lesions (n=91) overall response to FOLFIRI and FUFA in TS high was 53% (9/17) and 18% (3/17), respectively (p=0.035).	In patients with low TS, no remarkable difference in overall response to FOLFIRI and FUFA was observed.
__label__Support	In patients with biopsies taken from liver lesions (n=91) overall response to FOLFIRI and FUFA in TS high was 53% (9/17) and 18% (3/17), respectively (p=0.035).	Taking a pre-treatment biopsy is a safe and feasible procedure in mCRC.
__label__noRel	In patients with biopsies taken from liver lesions (n=91) overall response to FOLFIRI and FUFA in TS high was 53% (9/17) and 18% (3/17), respectively (p=0.035).	After validation of our data in a larger group TS determination may have the potential to better help direct systemic treatment in patients with primarily non-resectable mCRC.
__label__noRel	In patients with low TS, no remarkable difference in overall response to FOLFIRI and FUFA was observed.	Analysing response to FUFA and FOLFIRI in the per protocol set (n=119) after un-blinding TS in the data base revealed a trend to better overall response to FOLFIRI (9/19, 47%) in TS high compared to FUFA (5/23, 22%, p=0.077).
__label__noRel	In patients with low TS, no remarkable difference in overall response to FOLFIRI and FUFA was observed.	In patients with biopsies taken from liver lesions (n=91) overall response to FOLFIRI and FUFA in TS high was 53% (9/17) and 18% (3/17), respectively (p=0.035).
__label__noRel	In patients with low TS, no remarkable difference in overall response to FOLFIRI and FUFA was observed.	Taking a pre-treatment biopsy is a safe and feasible procedure in mCRC.
__label__noRel	In patients with low TS, no remarkable difference in overall response to FOLFIRI and FUFA was observed.	After validation of our data in a larger group TS determination may have the potential to better help direct systemic treatment in patients with primarily non-resectable mCRC.
__label__noRel	Taking a pre-treatment biopsy is a safe and feasible procedure in mCRC.	Analysing response to FUFA and FOLFIRI in the per protocol set (n=119) after un-blinding TS in the data base revealed a trend to better overall response to FOLFIRI (9/19, 47%) in TS high compared to FUFA (5/23, 22%, p=0.077).
__label__noRel	Taking a pre-treatment biopsy is a safe and feasible procedure in mCRC.	In patients with biopsies taken from liver lesions (n=91) overall response to FOLFIRI and FUFA in TS high was 53% (9/17) and 18% (3/17), respectively (p=0.035).
__label__noRel	Taking a pre-treatment biopsy is a safe and feasible procedure in mCRC.	In patients with low TS, no remarkable difference in overall response to FOLFIRI and FUFA was observed.
__label__noRel	Taking a pre-treatment biopsy is a safe and feasible procedure in mCRC.	After validation of our data in a larger group TS determination may have the potential to better help direct systemic treatment in patients with primarily non-resectable mCRC.
__label__noRel	After validation of our data in a larger group TS determination may have the potential to better help direct systemic treatment in patients with primarily non-resectable mCRC.	Analysing response to FUFA and FOLFIRI in the per protocol set (n=119) after un-blinding TS in the data base revealed a trend to better overall response to FOLFIRI (9/19, 47%) in TS high compared to FUFA (5/23, 22%, p=0.077).
__label__noRel	After validation of our data in a larger group TS determination may have the potential to better help direct systemic treatment in patients with primarily non-resectable mCRC.	In patients with biopsies taken from liver lesions (n=91) overall response to FOLFIRI and FUFA in TS high was 53% (9/17) and 18% (3/17), respectively (p=0.035).
__label__noRel	After validation of our data in a larger group TS determination may have the potential to better help direct systemic treatment in patients with primarily non-resectable mCRC.	In patients with low TS, no remarkable difference in overall response to FOLFIRI and FUFA was observed.
__label__noRel	After validation of our data in a larger group TS determination may have the potential to better help direct systemic treatment in patients with primarily non-resectable mCRC.	Taking a pre-treatment biopsy is a safe and feasible procedure in mCRC.
__label__noRel	Ablation success rates were 85.0% in the group receiving low-dose radioiodine versus 88.9% in the group receiving the high dose and 87.1% in the thyrotropin alfa group versus 86.7% in the group undergoing thyroid hormone withdrawal.	All 95% confidence intervals for the differences were within 10 percentage points, indicating noninferiority.
__label__noRel	Ablation success rates were 85.0% in the group receiving low-dose radioiodine versus 88.9% in the group receiving the high dose and 87.1% in the thyrotropin alfa group versus 86.7% in the group undergoing thyroid hormone withdrawal.	Similar results were found for low-dose radioiodine plus thyrotropin alfa (84.3%) versus high-dose radioiodine plus thyroid hormone withdrawal (87.6%) or high-dose radioiodine plus thyrotropin alfa (90.2%).
__label__noRel	Ablation success rates were 85.0% in the group receiving low-dose radioiodine versus 88.9% in the group receiving the high dose and 87.1% in the thyrotropin alfa group versus 86.7% in the group undergoing thyroid hormone withdrawal.	More patients in the high-dose group than in the low-dose group were hospitalized for at least 3 days (36.3% vs. 13.0%, P<0.001).
__label__noRel	Ablation success rates were 85.0% in the group receiving low-dose radioiodine versus 88.9% in the group receiving the high dose and 87.1% in the thyrotropin alfa group versus 86.7% in the group undergoing thyroid hormone withdrawal.	The proportions of patients with adverse events were 21% in the low-dose group versus 33% in the high-dose group (P=0.007) and 23% in the thyrotropin alfa group versus 30% in the group undergoing thyroid hormone withdrawal (P=0.11).
__label__Support	Ablation success rates were 85.0% in the group receiving low-dose radioiodine versus 88.9% in the group receiving the high dose and 87.1% in the thyrotropin alfa group versus 86.7% in the group undergoing thyroid hormone withdrawal.	Low-dose radioiodine plus thyrotropin alfa was as effective as high-dose radioiodine, with a lower rate of adverse events.
__label__Support	All 95% confidence intervals for the differences were within 10 percentage points, indicating noninferiority.	Ablation success rates were 85.0% in the group receiving low-dose radioiodine versus 88.9% in the group receiving the high dose and 87.1% in the thyrotropin alfa group versus 86.7% in the group undergoing thyroid hormone withdrawal.
__label__noRel	All 95% confidence intervals for the differences were within 10 percentage points, indicating noninferiority.	Similar results were found for low-dose radioiodine plus thyrotropin alfa (84.3%) versus high-dose radioiodine plus thyroid hormone withdrawal (87.6%) or high-dose radioiodine plus thyrotropin alfa (90.2%).
__label__noRel	All 95% confidence intervals for the differences were within 10 percentage points, indicating noninferiority.	More patients in the high-dose group than in the low-dose group were hospitalized for at least 3 days (36.3% vs. 13.0%, P<0.001).
__label__noRel	All 95% confidence intervals for the differences were within 10 percentage points, indicating noninferiority.	The proportions of patients with adverse events were 21% in the low-dose group versus 33% in the high-dose group (P=0.007) and 23% in the thyrotropin alfa group versus 30% in the group undergoing thyroid hormone withdrawal (P=0.11).
__label__noRel	All 95% confidence intervals for the differences were within 10 percentage points, indicating noninferiority.	Low-dose radioiodine plus thyrotropin alfa was as effective as high-dose radioiodine, with a lower rate of adverse events.
__label__noRel	Similar results were found for low-dose radioiodine plus thyrotropin alfa (84.3%) versus high-dose radioiodine plus thyroid hormone withdrawal (87.6%) or high-dose radioiodine plus thyrotropin alfa (90.2%).	Ablation success rates were 85.0% in the group receiving low-dose radioiodine versus 88.9% in the group receiving the high dose and 87.1% in the thyrotropin alfa group versus 86.7% in the group undergoing thyroid hormone withdrawal.
__label__noRel	Similar results were found for low-dose radioiodine plus thyrotropin alfa (84.3%) versus high-dose radioiodine plus thyroid hormone withdrawal (87.6%) or high-dose radioiodine plus thyrotropin alfa (90.2%).	All 95% confidence intervals for the differences were within 10 percentage points, indicating noninferiority.
__label__noRel	Similar results were found for low-dose radioiodine plus thyrotropin alfa (84.3%) versus high-dose radioiodine plus thyroid hormone withdrawal (87.6%) or high-dose radioiodine plus thyrotropin alfa (90.2%).	More patients in the high-dose group than in the low-dose group were hospitalized for at least 3 days (36.3% vs. 13.0%, P<0.001).
__label__noRel	Similar results were found for low-dose radioiodine plus thyrotropin alfa (84.3%) versus high-dose radioiodine plus thyroid hormone withdrawal (87.6%) or high-dose radioiodine plus thyrotropin alfa (90.2%).	The proportions of patients with adverse events were 21% in the low-dose group versus 33% in the high-dose group (P=0.007) and 23% in the thyrotropin alfa group versus 30% in the group undergoing thyroid hormone withdrawal (P=0.11).
__label__Support	Similar results were found for low-dose radioiodine plus thyrotropin alfa (84.3%) versus high-dose radioiodine plus thyroid hormone withdrawal (87.6%) or high-dose radioiodine plus thyrotropin alfa (90.2%).	Low-dose radioiodine plus thyrotropin alfa was as effective as high-dose radioiodine, with a lower rate of adverse events.
__label__noRel	More patients in the high-dose group than in the low-dose group were hospitalized for at least 3 days (36.3% vs. 13.0%, P<0.001).	Ablation success rates were 85.0% in the group receiving low-dose radioiodine versus 88.9% in the group receiving the high dose and 87.1% in the thyrotropin alfa group versus 86.7% in the group undergoing thyroid hormone withdrawal.
__label__noRel	More patients in the high-dose group than in the low-dose group were hospitalized for at least 3 days (36.3% vs. 13.0%, P<0.001).	All 95% confidence intervals for the differences were within 10 percentage points, indicating noninferiority.
__label__noRel	More patients in the high-dose group than in the low-dose group were hospitalized for at least 3 days (36.3% vs. 13.0%, P<0.001).	Similar results were found for low-dose radioiodine plus thyrotropin alfa (84.3%) versus high-dose radioiodine plus thyroid hormone withdrawal (87.6%) or high-dose radioiodine plus thyrotropin alfa (90.2%).
__label__noRel	More patients in the high-dose group than in the low-dose group were hospitalized for at least 3 days (36.3% vs. 13.0%, P<0.001).	The proportions of patients with adverse events were 21% in the low-dose group versus 33% in the high-dose group (P=0.007) and 23% in the thyrotropin alfa group versus 30% in the group undergoing thyroid hormone withdrawal (P=0.11).
__label__Support	More patients in the high-dose group than in the low-dose group were hospitalized for at least 3 days (36.3% vs. 13.0%, P<0.001).	Low-dose radioiodine plus thyrotropin alfa was as effective as high-dose radioiodine, with a lower rate of adverse events.
__label__noRel	The proportions of patients with adverse events were 21% in the low-dose group versus 33% in the high-dose group (P=0.007) and 23% in the thyrotropin alfa group versus 30% in the group undergoing thyroid hormone withdrawal (P=0.11).	Ablation success rates were 85.0% in the group receiving low-dose radioiodine versus 88.9% in the group receiving the high dose and 87.1% in the thyrotropin alfa group versus 86.7% in the group undergoing thyroid hormone withdrawal.
__label__noRel	The proportions of patients with adverse events were 21% in the low-dose group versus 33% in the high-dose group (P=0.007) and 23% in the thyrotropin alfa group versus 30% in the group undergoing thyroid hormone withdrawal (P=0.11).	All 95% confidence intervals for the differences were within 10 percentage points, indicating noninferiority.
__label__noRel	The proportions of patients with adverse events were 21% in the low-dose group versus 33% in the high-dose group (P=0.007) and 23% in the thyrotropin alfa group versus 30% in the group undergoing thyroid hormone withdrawal (P=0.11).	Similar results were found for low-dose radioiodine plus thyrotropin alfa (84.3%) versus high-dose radioiodine plus thyroid hormone withdrawal (87.6%) or high-dose radioiodine plus thyrotropin alfa (90.2%).
__label__noRel	The proportions of patients with adverse events were 21% in the low-dose group versus 33% in the high-dose group (P=0.007) and 23% in the thyrotropin alfa group versus 30% in the group undergoing thyroid hormone withdrawal (P=0.11).	More patients in the high-dose group than in the low-dose group were hospitalized for at least 3 days (36.3% vs. 13.0%, P<0.001).
__label__Support	The proportions of patients with adverse events were 21% in the low-dose group versus 33% in the high-dose group (P=0.007) and 23% in the thyrotropin alfa group versus 30% in the group undergoing thyroid hormone withdrawal (P=0.11).	Low-dose radioiodine plus thyrotropin alfa was as effective as high-dose radioiodine, with a lower rate of adverse events.
__label__noRel	Low-dose radioiodine plus thyrotropin alfa was as effective as high-dose radioiodine, with a lower rate of adverse events.	Ablation success rates were 85.0% in the group receiving low-dose radioiodine versus 88.9% in the group receiving the high dose and 87.1% in the thyrotropin alfa group versus 86.7% in the group undergoing thyroid hormone withdrawal.
__label__noRel	Low-dose radioiodine plus thyrotropin alfa was as effective as high-dose radioiodine, with a lower rate of adverse events.	All 95% confidence intervals for the differences were within 10 percentage points, indicating noninferiority.
__label__noRel	Low-dose radioiodine plus thyrotropin alfa was as effective as high-dose radioiodine, with a lower rate of adverse events.	Similar results were found for low-dose radioiodine plus thyrotropin alfa (84.3%) versus high-dose radioiodine plus thyroid hormone withdrawal (87.6%) or high-dose radioiodine plus thyrotropin alfa (90.2%).
__label__noRel	Low-dose radioiodine plus thyrotropin alfa was as effective as high-dose radioiodine, with a lower rate of adverse events.	More patients in the high-dose group than in the low-dose group were hospitalized for at least 3 days (36.3% vs. 13.0%, P<0.001).
__label__noRel	Low-dose radioiodine plus thyrotropin alfa was as effective as high-dose radioiodine, with a lower rate of adverse events.	The proportions of patients with adverse events were 21% in the low-dose group versus 33% in the high-dose group (P=0.007) and 23% in the thyrotropin alfa group versus 30% in the group undergoing thyroid hormone withdrawal (P=0.11).
__label__noRel	Comparing the changes in low-frequency low-intensity electrotherapy with manual lymphatic drainage changes, there were no significant differences.	Low-frequency low-intensity electrotherapy did not reduce lymphoedema volume (mean of change = 19.77 mL, P = 0.36),
__label__noRel	Comparing the changes in low-frequency low-intensity electrotherapy with manual lymphatic drainage changes, there were no significant differences.	significant reductions were observed in pain, heaviness and tightness (mean of change = 13.1, 16.2 and 6.4 mm, respectively), and FACT-B+4 summaries improved significantly (Trial Outcome Index mean of change = 5.4, P = 0.015).
__label__noRel	Comparing the changes in low-frequency low-intensity electrotherapy with manual lymphatic drainage changes, there were no significant differences.	Manual lymphatic drainage showed no significant changes in any of the outcomes.
__label__noRel	Comparing the changes in low-frequency low-intensity electrotherapy with manual lymphatic drainage changes, there were no significant differences.	the observed trend towards a better health-related quality of life is remarkable in low-frequency low-intensity electrotherapy.
__label__Support	Comparing the changes in low-frequency low-intensity electrotherapy with manual lymphatic drainage changes, there were no significant differences.	Although there are no significant differences between treatment changes,
__label__noRel	Low-frequency low-intensity electrotherapy did not reduce lymphoedema volume (mean of change = 19.77 mL, P = 0.36),	Comparing the changes in low-frequency low-intensity electrotherapy with manual lymphatic drainage changes, there were no significant differences.
__label__noRel	Low-frequency low-intensity electrotherapy did not reduce lymphoedema volume (mean of change = 19.77 mL, P = 0.36),	significant reductions were observed in pain, heaviness and tightness (mean of change = 13.1, 16.2 and 6.4 mm, respectively), and FACT-B+4 summaries improved significantly (Trial Outcome Index mean of change = 5.4, P = 0.015).
__label__noRel	Low-frequency low-intensity electrotherapy did not reduce lymphoedema volume (mean of change = 19.77 mL, P = 0.36),	Manual lymphatic drainage showed no significant changes in any of the outcomes.
__label__Attack	Low-frequency low-intensity electrotherapy did not reduce lymphoedema volume (mean of change = 19.77 mL, P = 0.36),	the observed trend towards a better health-related quality of life is remarkable in low-frequency low-intensity electrotherapy.
__label__noRel	Low-frequency low-intensity electrotherapy did not reduce lymphoedema volume (mean of change = 19.77 mL, P = 0.36),	Although there are no significant differences between treatment changes,
__label__noRel	significant reductions were observed in pain, heaviness and tightness (mean of change = 13.1, 16.2 and 6.4 mm, respectively), and FACT-B+4 summaries improved significantly (Trial Outcome Index mean of change = 5.4, P = 0.015).	Comparing the changes in low-frequency low-intensity electrotherapy with manual lymphatic drainage changes, there were no significant differences.
__label__noRel	significant reductions were observed in pain, heaviness and tightness (mean of change = 13.1, 16.2 and 6.4 mm, respectively), and FACT-B+4 summaries improved significantly (Trial Outcome Index mean of change = 5.4, P = 0.015).	Low-frequency low-intensity electrotherapy did not reduce lymphoedema volume (mean of change = 19.77 mL, P = 0.36),
__label__noRel	significant reductions were observed in pain, heaviness and tightness (mean of change = 13.1, 16.2 and 6.4 mm, respectively), and FACT-B+4 summaries improved significantly (Trial Outcome Index mean of change = 5.4, P = 0.015).	Manual lymphatic drainage showed no significant changes in any of the outcomes.
__label__Support	significant reductions were observed in pain, heaviness and tightness (mean of change = 13.1, 16.2 and 6.4 mm, respectively), and FACT-B+4 summaries improved significantly (Trial Outcome Index mean of change = 5.4, P = 0.015).	the observed trend towards a better health-related quality of life is remarkable in low-frequency low-intensity electrotherapy.
__label__noRel	significant reductions were observed in pain, heaviness and tightness (mean of change = 13.1, 16.2 and 6.4 mm, respectively), and FACT-B+4 summaries improved significantly (Trial Outcome Index mean of change = 5.4, P = 0.015).	Although there are no significant differences between treatment changes,
__label__noRel	Manual lymphatic drainage showed no significant changes in any of the outcomes.	Comparing the changes in low-frequency low-intensity electrotherapy with manual lymphatic drainage changes, there were no significant differences.
__label__noRel	Manual lymphatic drainage showed no significant changes in any of the outcomes.	Low-frequency low-intensity electrotherapy did not reduce lymphoedema volume (mean of change = 19.77 mL, P = 0.36),
__label__noRel	Manual lymphatic drainage showed no significant changes in any of the outcomes.	significant reductions were observed in pain, heaviness and tightness (mean of change = 13.1, 16.2 and 6.4 mm, respectively), and FACT-B+4 summaries improved significantly (Trial Outcome Index mean of change = 5.4, P = 0.015).
__label__noRel	Manual lymphatic drainage showed no significant changes in any of the outcomes.	the observed trend towards a better health-related quality of life is remarkable in low-frequency low-intensity electrotherapy.
__label__Support	Manual lymphatic drainage showed no significant changes in any of the outcomes.	Although there are no significant differences between treatment changes,
__label__noRel	the observed trend towards a better health-related quality of life is remarkable in low-frequency low-intensity electrotherapy.	Comparing the changes in low-frequency low-intensity electrotherapy with manual lymphatic drainage changes, there were no significant differences.
__label__noRel	the observed trend towards a better health-related quality of life is remarkable in low-frequency low-intensity electrotherapy.	Low-frequency low-intensity electrotherapy did not reduce lymphoedema volume (mean of change = 19.77 mL, P = 0.36),
__label__noRel	the observed trend towards a better health-related quality of life is remarkable in low-frequency low-intensity electrotherapy.	significant reductions were observed in pain, heaviness and tightness (mean of change = 13.1, 16.2 and 6.4 mm, respectively), and FACT-B+4 summaries improved significantly (Trial Outcome Index mean of change = 5.4, P = 0.015).
__label__noRel	the observed trend towards a better health-related quality of life is remarkable in low-frequency low-intensity electrotherapy.	Manual lymphatic drainage showed no significant changes in any of the outcomes.
__label__noRel	the observed trend towards a better health-related quality of life is remarkable in low-frequency low-intensity electrotherapy.	Although there are no significant differences between treatment changes,
__label__noRel	Although there are no significant differences between treatment changes,	Comparing the changes in low-frequency low-intensity electrotherapy with manual lymphatic drainage changes, there were no significant differences.
__label__noRel	Although there are no significant differences between treatment changes,	Low-frequency low-intensity electrotherapy did not reduce lymphoedema volume (mean of change = 19.77 mL, P = 0.36),
__label__noRel	Although there are no significant differences between treatment changes,	significant reductions were observed in pain, heaviness and tightness (mean of change = 13.1, 16.2 and 6.4 mm, respectively), and FACT-B+4 summaries improved significantly (Trial Outcome Index mean of change = 5.4, P = 0.015).
__label__noRel	Although there are no significant differences between treatment changes,	Manual lymphatic drainage showed no significant changes in any of the outcomes.
__label__Attack	Although there are no significant differences between treatment changes,	the observed trend towards a better health-related quality of life is remarkable in low-frequency low-intensity electrotherapy.
__label__noRel	The 2-year risk of progression for PSA nadir  0.2 ng/ml, and > 0.2 to 4 ng/ml in CAD was 31% and 70% (P < 0.001), respectively.	In the IAD group, a similar trend was seen.
__label__noRel	The 2-year risk of progression for PSA nadir  0.2 ng/ml, and > 0.2 to 4 ng/ml in CAD was 31% and 70% (P < 0.001), respectively.	Patients with PSA nadir  0.2 ng/ml, though had significantly higher 2-year risk of progression compared to CAD (53% vs. 31% (P = 0.03), respectively.
__label__noRel	The 2-year risk of progression for PSA nadir  0.2 ng/ml, and > 0.2 to 4 ng/ml in CAD was 31% and 70% (P < 0.001), respectively.	Patients without pain had a significantly lower 2-year risk of progression in both groups.
__label__noRel	The 2-year risk of progression for PSA nadir  0.2 ng/ml, and > 0.2 to 4 ng/ml in CAD was 31% and 70% (P < 0.001), respectively.	No QOL difference was found, although more side effects occurred in CAD.
__label__noRel	The 2-year risk of progression for PSA nadir  0.2 ng/ml, and > 0.2 to 4 ng/ml in CAD was 31% and 70% (P < 0.001), respectively.	Metastatic prostate cancer patients with high baseline PSA, pain, and high PSA nadir have a poor prognosis with ADT.
__label__noRel	The 2-year risk of progression for PSA nadir  0.2 ng/ml, and > 0.2 to 4 ng/ml in CAD was 31% and 70% (P < 0.001), respectively.	Patients with low PSA nadir do significantly worse with IAD compared with CAD.
__label__noRel	The 2-year risk of progression for PSA nadir  0.2 ng/ml, and > 0.2 to 4 ng/ml in CAD was 31% and 70% (P < 0.001), respectively.	IAD is not a good treatment option for many metastatic prostate cancer patients.
__label__noRel	The 2-year risk of progression for PSA nadir  0.2 ng/ml, and > 0.2 to 4 ng/ml in CAD was 31% and 70% (P < 0.001), respectively.	Without ADT testosterone remained at castrate level for 4 months.
__label__noRel	In the IAD group, a similar trend was seen.	The 2-year risk of progression for PSA nadir  0.2 ng/ml, and > 0.2 to 4 ng/ml in CAD was 31% and 70% (P < 0.001), respectively.
__label__noRel	In the IAD group, a similar trend was seen.	Patients with PSA nadir  0.2 ng/ml, though had significantly higher 2-year risk of progression compared to CAD (53% vs. 31% (P = 0.03), respectively.
__label__noRel	In the IAD group, a similar trend was seen.	Patients without pain had a significantly lower 2-year risk of progression in both groups.
__label__noRel	In the IAD group, a similar trend was seen.	No QOL difference was found, although more side effects occurred in CAD.
__label__noRel	In the IAD group, a similar trend was seen.	Metastatic prostate cancer patients with high baseline PSA, pain, and high PSA nadir have a poor prognosis with ADT.
__label__noRel	In the IAD group, a similar trend was seen.	Patients with low PSA nadir do significantly worse with IAD compared with CAD.
__label__noRel	In the IAD group, a similar trend was seen.	IAD is not a good treatment option for many metastatic prostate cancer patients.
__label__noRel	In the IAD group, a similar trend was seen.	Without ADT testosterone remained at castrate level for 4 months.
__label__noRel	Patients with PSA nadir  0.2 ng/ml, though had significantly higher 2-year risk of progression compared to CAD (53% vs. 31% (P = 0.03), respectively.	The 2-year risk of progression for PSA nadir  0.2 ng/ml, and > 0.2 to 4 ng/ml in CAD was 31% and 70% (P < 0.001), respectively.
__label__noRel	Patients with PSA nadir  0.2 ng/ml, though had significantly higher 2-year risk of progression compared to CAD (53% vs. 31% (P = 0.03), respectively.	In the IAD group, a similar trend was seen.
__label__noRel	Patients with PSA nadir  0.2 ng/ml, though had significantly higher 2-year risk of progression compared to CAD (53% vs. 31% (P = 0.03), respectively.	Patients without pain had a significantly lower 2-year risk of progression in both groups.
__label__noRel	Patients with PSA nadir  0.2 ng/ml, though had significantly higher 2-year risk of progression compared to CAD (53% vs. 31% (P = 0.03), respectively.	No QOL difference was found, although more side effects occurred in CAD.
__label__noRel	Patients with PSA nadir  0.2 ng/ml, though had significantly higher 2-year risk of progression compared to CAD (53% vs. 31% (P = 0.03), respectively.	Metastatic prostate cancer patients with high baseline PSA, pain, and high PSA nadir have a poor prognosis with ADT.
__label__noRel	Patients with PSA nadir  0.2 ng/ml, though had significantly higher 2-year risk of progression compared to CAD (53% vs. 31% (P = 0.03), respectively.	Patients with low PSA nadir do significantly worse with IAD compared with CAD.
__label__noRel	Patients with PSA nadir  0.2 ng/ml, though had significantly higher 2-year risk of progression compared to CAD (53% vs. 31% (P = 0.03), respectively.	IAD is not a good treatment option for many metastatic prostate cancer patients.
__label__noRel	Patients with PSA nadir  0.2 ng/ml, though had significantly higher 2-year risk of progression compared to CAD (53% vs. 31% (P = 0.03), respectively.	Without ADT testosterone remained at castrate level for 4 months.
__label__noRel	Patients without pain had a significantly lower 2-year risk of progression in both groups.	The 2-year risk of progression for PSA nadir  0.2 ng/ml, and > 0.2 to 4 ng/ml in CAD was 31% and 70% (P < 0.001), respectively.
__label__noRel	Patients without pain had a significantly lower 2-year risk of progression in both groups.	In the IAD group, a similar trend was seen.
__label__noRel	Patients without pain had a significantly lower 2-year risk of progression in both groups.	Patients with PSA nadir  0.2 ng/ml, though had significantly higher 2-year risk of progression compared to CAD (53% vs. 31% (P = 0.03), respectively.
__label__noRel	Patients without pain had a significantly lower 2-year risk of progression in both groups.	No QOL difference was found, although more side effects occurred in CAD.
__label__Support	Patients without pain had a significantly lower 2-year risk of progression in both groups.	Metastatic prostate cancer patients with high baseline PSA, pain, and high PSA nadir have a poor prognosis with ADT.
__label__noRel	Patients without pain had a significantly lower 2-year risk of progression in both groups.	Patients with low PSA nadir do significantly worse with IAD compared with CAD.
__label__noRel	Patients without pain had a significantly lower 2-year risk of progression in both groups.	IAD is not a good treatment option for many metastatic prostate cancer patients.
__label__noRel	Patients without pain had a significantly lower 2-year risk of progression in both groups.	Without ADT testosterone remained at castrate level for 4 months.
__label__noRel	No QOL difference was found, although more side effects occurred in CAD.	The 2-year risk of progression for PSA nadir  0.2 ng/ml, and > 0.2 to 4 ng/ml in CAD was 31% and 70% (P < 0.001), respectively.
__label__noRel	No QOL difference was found, although more side effects occurred in CAD.	In the IAD group, a similar trend was seen.
__label__noRel	No QOL difference was found, although more side effects occurred in CAD.	Patients with PSA nadir  0.2 ng/ml, though had significantly higher 2-year risk of progression compared to CAD (53% vs. 31% (P = 0.03), respectively.
__label__noRel	No QOL difference was found, although more side effects occurred in CAD.	Patients without pain had a significantly lower 2-year risk of progression in both groups.
__label__noRel	No QOL difference was found, although more side effects occurred in CAD.	Metastatic prostate cancer patients with high baseline PSA, pain, and high PSA nadir have a poor prognosis with ADT.
__label__noRel	No QOL difference was found, although more side effects occurred in CAD.	Patients with low PSA nadir do significantly worse with IAD compared with CAD.
__label__noRel	No QOL difference was found, although more side effects occurred in CAD.	IAD is not a good treatment option for many metastatic prostate cancer patients.
__label__noRel	No QOL difference was found, although more side effects occurred in CAD.	Without ADT testosterone remained at castrate level for 4 months.
__label__noRel	Metastatic prostate cancer patients with high baseline PSA, pain, and high PSA nadir have a poor prognosis with ADT.	The 2-year risk of progression for PSA nadir  0.2 ng/ml, and > 0.2 to 4 ng/ml in CAD was 31% and 70% (P < 0.001), respectively.
__label__noRel	Metastatic prostate cancer patients with high baseline PSA, pain, and high PSA nadir have a poor prognosis with ADT.	In the IAD group, a similar trend was seen.
__label__noRel	Metastatic prostate cancer patients with high baseline PSA, pain, and high PSA nadir have a poor prognosis with ADT.	Patients with PSA nadir  0.2 ng/ml, though had significantly higher 2-year risk of progression compared to CAD (53% vs. 31% (P = 0.03), respectively.
__label__noRel	Metastatic prostate cancer patients with high baseline PSA, pain, and high PSA nadir have a poor prognosis with ADT.	Patients without pain had a significantly lower 2-year risk of progression in both groups.
__label__noRel	Metastatic prostate cancer patients with high baseline PSA, pain, and high PSA nadir have a poor prognosis with ADT.	No QOL difference was found, although more side effects occurred in CAD.
__label__noRel	Metastatic prostate cancer patients with high baseline PSA, pain, and high PSA nadir have a poor prognosis with ADT.	Patients with low PSA nadir do significantly worse with IAD compared with CAD.
__label__noRel	Metastatic prostate cancer patients with high baseline PSA, pain, and high PSA nadir have a poor prognosis with ADT.	IAD is not a good treatment option for many metastatic prostate cancer patients.
__label__noRel	Metastatic prostate cancer patients with high baseline PSA, pain, and high PSA nadir have a poor prognosis with ADT.	Without ADT testosterone remained at castrate level for 4 months.
__label__noRel	Patients with low PSA nadir do significantly worse with IAD compared with CAD.	The 2-year risk of progression for PSA nadir  0.2 ng/ml, and > 0.2 to 4 ng/ml in CAD was 31% and 70% (P < 0.001), respectively.
__label__noRel	Patients with low PSA nadir do significantly worse with IAD compared with CAD.	In the IAD group, a similar trend was seen.
__label__noRel	Patients with low PSA nadir do significantly worse with IAD compared with CAD.	Patients with PSA nadir  0.2 ng/ml, though had significantly higher 2-year risk of progression compared to CAD (53% vs. 31% (P = 0.03), respectively.
__label__noRel	Patients with low PSA nadir do significantly worse with IAD compared with CAD.	Patients without pain had a significantly lower 2-year risk of progression in both groups.
__label__noRel	Patients with low PSA nadir do significantly worse with IAD compared with CAD.	No QOL difference was found, although more side effects occurred in CAD.
__label__noRel	Patients with low PSA nadir do significantly worse with IAD compared with CAD.	Metastatic prostate cancer patients with high baseline PSA, pain, and high PSA nadir have a poor prognosis with ADT.
__label__Support	Patients with low PSA nadir do significantly worse with IAD compared with CAD.	IAD is not a good treatment option for many metastatic prostate cancer patients.
__label__noRel	Patients with low PSA nadir do significantly worse with IAD compared with CAD.	Without ADT testosterone remained at castrate level for 4 months.
__label__noRel	IAD is not a good treatment option for many metastatic prostate cancer patients.	The 2-year risk of progression for PSA nadir  0.2 ng/ml, and > 0.2 to 4 ng/ml in CAD was 31% and 70% (P < 0.001), respectively.
__label__noRel	IAD is not a good treatment option for many metastatic prostate cancer patients.	In the IAD group, a similar trend was seen.
__label__noRel	IAD is not a good treatment option for many metastatic prostate cancer patients.	Patients with PSA nadir  0.2 ng/ml, though had significantly higher 2-year risk of progression compared to CAD (53% vs. 31% (P = 0.03), respectively.
__label__noRel	IAD is not a good treatment option for many metastatic prostate cancer patients.	Patients without pain had a significantly lower 2-year risk of progression in both groups.
__label__noRel	IAD is not a good treatment option for many metastatic prostate cancer patients.	No QOL difference was found, although more side effects occurred in CAD.
__label__noRel	IAD is not a good treatment option for many metastatic prostate cancer patients.	Metastatic prostate cancer patients with high baseline PSA, pain, and high PSA nadir have a poor prognosis with ADT.
__label__noRel	IAD is not a good treatment option for many metastatic prostate cancer patients.	Patients with low PSA nadir do significantly worse with IAD compared with CAD.
__label__noRel	IAD is not a good treatment option for many metastatic prostate cancer patients.	Without ADT testosterone remained at castrate level for 4 months.
__label__noRel	Without ADT testosterone remained at castrate level for 4 months.	The 2-year risk of progression for PSA nadir  0.2 ng/ml, and > 0.2 to 4 ng/ml in CAD was 31% and 70% (P < 0.001), respectively.
__label__noRel	Without ADT testosterone remained at castrate level for 4 months.	In the IAD group, a similar trend was seen.
__label__noRel	Without ADT testosterone remained at castrate level for 4 months.	Patients with PSA nadir  0.2 ng/ml, though had significantly higher 2-year risk of progression compared to CAD (53% vs. 31% (P = 0.03), respectively.
__label__noRel	Without ADT testosterone remained at castrate level for 4 months.	Patients without pain had a significantly lower 2-year risk of progression in both groups.
__label__noRel	Without ADT testosterone remained at castrate level for 4 months.	No QOL difference was found, although more side effects occurred in CAD.
__label__noRel	Without ADT testosterone remained at castrate level for 4 months.	Metastatic prostate cancer patients with high baseline PSA, pain, and high PSA nadir have a poor prognosis with ADT.
__label__noRel	Without ADT testosterone remained at castrate level for 4 months.	Patients with low PSA nadir do significantly worse with IAD compared with CAD.
__label__noRel	Without ADT testosterone remained at castrate level for 4 months.	IAD is not a good treatment option for many metastatic prostate cancer patients.
__label__noRel	Both measures were responsive;	out of 24 changes over time, 19 were in the expected direction for the linear analogue self-assessment scale (p < or = 0.05 for 9 of 19) and 17 for the adjective checklist (p < or = 0.05 for 10 of 17).
__label__noRel	Both measures were responsive;	The linear analogue self-assessment scale was less but significantly efficient for detection of treatment effects, with relative efficiency estimates ranging from 0.16 to 2.45 and a median of 0.66 among the comparisons with relatively stable estimates (/t/ > or = 1.0) and more efficient for recurrence than the adjective checklist.
__label__noRel	Both measures were responsive;	The mood linear analogue self-assessment scale is a valid indicator of emotional well-being in patients with breast cancer in large multicenter, multicultural trials in which comprehensive scales are less feasible.
__label__noRel	Both measures were responsive;	This investigation supports the clinical relevance of linear analogue self-assessment scales as indicators of components of quality of life in cancer clinical trials.
__label__Support	out of 24 changes over time, 19 were in the expected direction for the linear analogue self-assessment scale (p < or = 0.05 for 9 of 19) and 17 for the adjective checklist (p < or = 0.05 for 10 of 17).	Both measures were responsive;
__label__noRel	out of 24 changes over time, 19 were in the expected direction for the linear analogue self-assessment scale (p < or = 0.05 for 9 of 19) and 17 for the adjective checklist (p < or = 0.05 for 10 of 17).	The linear analogue self-assessment scale was less but significantly efficient for detection of treatment effects, with relative efficiency estimates ranging from 0.16 to 2.45 and a median of 0.66 among the comparisons with relatively stable estimates (/t/ > or = 1.0) and more efficient for recurrence than the adjective checklist.
__label__noRel	out of 24 changes over time, 19 were in the expected direction for the linear analogue self-assessment scale (p < or = 0.05 for 9 of 19) and 17 for the adjective checklist (p < or = 0.05 for 10 of 17).	The mood linear analogue self-assessment scale is a valid indicator of emotional well-being in patients with breast cancer in large multicenter, multicultural trials in which comprehensive scales are less feasible.
__label__noRel	out of 24 changes over time, 19 were in the expected direction for the linear analogue self-assessment scale (p < or = 0.05 for 9 of 19) and 17 for the adjective checklist (p < or = 0.05 for 10 of 17).	This investigation supports the clinical relevance of linear analogue self-assessment scales as indicators of components of quality of life in cancer clinical trials.
__label__noRel	The linear analogue self-assessment scale was less but significantly efficient for detection of treatment effects, with relative efficiency estimates ranging from 0.16 to 2.45 and a median of 0.66 among the comparisons with relatively stable estimates (/t/ > or = 1.0) and more efficient for recurrence than the adjective checklist.	Both measures were responsive;
__label__noRel	The linear analogue self-assessment scale was less but significantly efficient for detection of treatment effects, with relative efficiency estimates ranging from 0.16 to 2.45 and a median of 0.66 among the comparisons with relatively stable estimates (/t/ > or = 1.0) and more efficient for recurrence than the adjective checklist.	out of 24 changes over time, 19 were in the expected direction for the linear analogue self-assessment scale (p < or = 0.05 for 9 of 19) and 17 for the adjective checklist (p < or = 0.05 for 10 of 17).
__label__Support	The linear analogue self-assessment scale was less but significantly efficient for detection of treatment effects, with relative efficiency estimates ranging from 0.16 to 2.45 and a median of 0.66 among the comparisons with relatively stable estimates (/t/ > or = 1.0) and more efficient for recurrence than the adjective checklist.	The mood linear analogue self-assessment scale is a valid indicator of emotional well-being in patients with breast cancer in large multicenter, multicultural trials in which comprehensive scales are less feasible.
__label__noRel	The linear analogue self-assessment scale was less but significantly efficient for detection of treatment effects, with relative efficiency estimates ranging from 0.16 to 2.45 and a median of 0.66 among the comparisons with relatively stable estimates (/t/ > or = 1.0) and more efficient for recurrence than the adjective checklist.	This investigation supports the clinical relevance of linear analogue self-assessment scales as indicators of components of quality of life in cancer clinical trials.
__label__noRel	The mood linear analogue self-assessment scale is a valid indicator of emotional well-being in patients with breast cancer in large multicenter, multicultural trials in which comprehensive scales are less feasible.	Both measures were responsive;
__label__noRel	The mood linear analogue self-assessment scale is a valid indicator of emotional well-being in patients with breast cancer in large multicenter, multicultural trials in which comprehensive scales are less feasible.	out of 24 changes over time, 19 were in the expected direction for the linear analogue self-assessment scale (p < or = 0.05 for 9 of 19) and 17 for the adjective checklist (p < or = 0.05 for 10 of 17).
__label__noRel	The mood linear analogue self-assessment scale is a valid indicator of emotional well-being in patients with breast cancer in large multicenter, multicultural trials in which comprehensive scales are less feasible.	The linear analogue self-assessment scale was less but significantly efficient for detection of treatment effects, with relative efficiency estimates ranging from 0.16 to 2.45 and a median of 0.66 among the comparisons with relatively stable estimates (/t/ > or = 1.0) and more efficient for recurrence than the adjective checklist.
__label__Support	The mood linear analogue self-assessment scale is a valid indicator of emotional well-being in patients with breast cancer in large multicenter, multicultural trials in which comprehensive scales are less feasible.	This investigation supports the clinical relevance of linear analogue self-assessment scales as indicators of components of quality of life in cancer clinical trials.
__label__noRel	This investigation supports the clinical relevance of linear analogue self-assessment scales as indicators of components of quality of life in cancer clinical trials.	Both measures were responsive;
__label__noRel	This investigation supports the clinical relevance of linear analogue self-assessment scales as indicators of components of quality of life in cancer clinical trials.	out of 24 changes over time, 19 were in the expected direction for the linear analogue self-assessment scale (p < or = 0.05 for 9 of 19) and 17 for the adjective checklist (p < or = 0.05 for 10 of 17).
__label__noRel	This investigation supports the clinical relevance of linear analogue self-assessment scales as indicators of components of quality of life in cancer clinical trials.	The linear analogue self-assessment scale was less but significantly efficient for detection of treatment effects, with relative efficiency estimates ranging from 0.16 to 2.45 and a median of 0.66 among the comparisons with relatively stable estimates (/t/ > or = 1.0) and more efficient for recurrence than the adjective checklist.
__label__noRel	This investigation supports the clinical relevance of linear analogue self-assessment scales as indicators of components of quality of life in cancer clinical trials.	The mood linear analogue self-assessment scale is a valid indicator of emotional well-being in patients with breast cancer in large multicenter, multicultural trials in which comprehensive scales are less feasible.
__label__noRel	Patients in the intervention arm discussed more symptoms over time compared with patients in the attention-control (P = .008) and control (P = .04) arms.	No study arm effect was observed for function discussions.
__label__noRel	Patients in the intervention arm discussed more symptoms over time compared with patients in the attention-control (P = .008) and control (P = .04) arms.	Clinic discussions were associated with severity of patient-reported symptoms but not with patient-reported functional concerns.
__label__noRel	Patients in the intervention arm discussed more symptoms over time compared with patients in the attention-control (P = .008) and control (P = .04) arms.	A positive longitudinal impact of the intervention on symptom discussion was observed,
__label__noRel	Patients in the intervention arm discussed more symptoms over time compared with patients in the attention-control (P = .008) and control (P = .04) arms.	but not for function discussion, suggesting that potentially serious problems may remain unaddressed.
__label__noRel	Patients in the intervention arm discussed more symptoms over time compared with patients in the attention-control (P = .008) and control (P = .04) arms.	Training oncologists in responding to patient-reported functional concerns may increase the impact of this intervention.
__label__noRel	No study arm effect was observed for function discussions.	Patients in the intervention arm discussed more symptoms over time compared with patients in the attention-control (P = .008) and control (P = .04) arms.
__label__noRel	No study arm effect was observed for function discussions.	Clinic discussions were associated with severity of patient-reported symptoms but not with patient-reported functional concerns.
__label__noRel	No study arm effect was observed for function discussions.	A positive longitudinal impact of the intervention on symptom discussion was observed,
__label__noRel	No study arm effect was observed for function discussions.	but not for function discussion, suggesting that potentially serious problems may remain unaddressed.
__label__Attack	No study arm effect was observed for function discussions.	Training oncologists in responding to patient-reported functional concerns may increase the impact of this intervention.
__label__noRel	Clinic discussions were associated with severity of patient-reported symptoms but not with patient-reported functional concerns.	Patients in the intervention arm discussed more symptoms over time compared with patients in the attention-control (P = .008) and control (P = .04) arms.
__label__noRel	Clinic discussions were associated with severity of patient-reported symptoms but not with patient-reported functional concerns.	No study arm effect was observed for function discussions.
__label__noRel	Clinic discussions were associated with severity of patient-reported symptoms but not with patient-reported functional concerns.	A positive longitudinal impact of the intervention on symptom discussion was observed,
__label__noRel	Clinic discussions were associated with severity of patient-reported symptoms but not with patient-reported functional concerns.	but not for function discussion, suggesting that potentially serious problems may remain unaddressed.
__label__Support	Clinic discussions were associated with severity of patient-reported symptoms but not with patient-reported functional concerns.	Training oncologists in responding to patient-reported functional concerns may increase the impact of this intervention.
__label__noRel	A positive longitudinal impact of the intervention on symptom discussion was observed,	Patients in the intervention arm discussed more symptoms over time compared with patients in the attention-control (P = .008) and control (P = .04) arms.
__label__noRel	A positive longitudinal impact of the intervention on symptom discussion was observed,	No study arm effect was observed for function discussions.
__label__noRel	A positive longitudinal impact of the intervention on symptom discussion was observed,	Clinic discussions were associated with severity of patient-reported symptoms but not with patient-reported functional concerns.
__label__noRel	A positive longitudinal impact of the intervention on symptom discussion was observed,	but not for function discussion, suggesting that potentially serious problems may remain unaddressed.
__label__Support	A positive longitudinal impact of the intervention on symptom discussion was observed,	Training oncologists in responding to patient-reported functional concerns may increase the impact of this intervention.
__label__noRel	but not for function discussion, suggesting that potentially serious problems may remain unaddressed.	Patients in the intervention arm discussed more symptoms over time compared with patients in the attention-control (P = .008) and control (P = .04) arms.
__label__noRel	but not for function discussion, suggesting that potentially serious problems may remain unaddressed.	No study arm effect was observed for function discussions.
__label__noRel	but not for function discussion, suggesting that potentially serious problems may remain unaddressed.	Clinic discussions were associated with severity of patient-reported symptoms but not with patient-reported functional concerns.
__label__Attack	but not for function discussion, suggesting that potentially serious problems may remain unaddressed.	A positive longitudinal impact of the intervention on symptom discussion was observed,
__label__noRel	but not for function discussion, suggesting that potentially serious problems may remain unaddressed.	Training oncologists in responding to patient-reported functional concerns may increase the impact of this intervention.
__label__noRel	Training oncologists in responding to patient-reported functional concerns may increase the impact of this intervention.	Patients in the intervention arm discussed more symptoms over time compared with patients in the attention-control (P = .008) and control (P = .04) arms.
__label__noRel	Training oncologists in responding to patient-reported functional concerns may increase the impact of this intervention.	No study arm effect was observed for function discussions.
__label__noRel	Training oncologists in responding to patient-reported functional concerns may increase the impact of this intervention.	Clinic discussions were associated with severity of patient-reported symptoms but not with patient-reported functional concerns.
__label__noRel	Training oncologists in responding to patient-reported functional concerns may increase the impact of this intervention.	A positive longitudinal impact of the intervention on symptom discussion was observed,
__label__noRel	Training oncologists in responding to patient-reported functional concerns may increase the impact of this intervention.	but not for function discussion, suggesting that potentially serious problems may remain unaddressed.
__label__noRel	No difference in QOL was observed.	A mean of 10.6 units of PRBCs over 5 months were administered to those who received epoetin alpha compared with 13 units for those who did not receive epoetin (P = .04).
__label__noRel	No difference in QOL was observed.	There was no significant difference in QOL as assessed by the FACT-Anemia or ESAS instruments.
__label__noRel	No difference in QOL was observed.	The CR rate and the 3-year CR duration were not affected adversely by use of epoetin alpha.
__label__noRel	No difference in QOL was observed.	Epoetin alpha decreased the number of PRBC transfusions and did not appear to have a negative impact on remission duration.
__label__noRel	No difference in QOL was observed.	The trial was stopped early because of poor accrual before the target of 123 evaluable patients was met.
__label__noRel	No difference in QOL was observed.	Anemia is an expected consequence of intensive chemotherapy regimens administered to patients with acute leukemia.
__label__noRel	A mean of 10.6 units of PRBCs over 5 months were administered to those who received epoetin alpha compared with 13 units for those who did not receive epoetin (P = .04).	No difference in QOL was observed.
__label__noRel	A mean of 10.6 units of PRBCs over 5 months were administered to those who received epoetin alpha compared with 13 units for those who did not receive epoetin (P = .04).	There was no significant difference in QOL as assessed by the FACT-Anemia or ESAS instruments.
__label__noRel	A mean of 10.6 units of PRBCs over 5 months were administered to those who received epoetin alpha compared with 13 units for those who did not receive epoetin (P = .04).	The CR rate and the 3-year CR duration were not affected adversely by use of epoetin alpha.
__label__Support	A mean of 10.6 units of PRBCs over 5 months were administered to those who received epoetin alpha compared with 13 units for those who did not receive epoetin (P = .04).	Epoetin alpha decreased the number of PRBC transfusions and did not appear to have a negative impact on remission duration.
__label__noRel	A mean of 10.6 units of PRBCs over 5 months were administered to those who received epoetin alpha compared with 13 units for those who did not receive epoetin (P = .04).	The trial was stopped early because of poor accrual before the target of 123 evaluable patients was met.
__label__noRel	A mean of 10.6 units of PRBCs over 5 months were administered to those who received epoetin alpha compared with 13 units for those who did not receive epoetin (P = .04).	Anemia is an expected consequence of intensive chemotherapy regimens administered to patients with acute leukemia.
__label__Support	There was no significant difference in QOL as assessed by the FACT-Anemia or ESAS instruments.	No difference in QOL was observed.
__label__noRel	There was no significant difference in QOL as assessed by the FACT-Anemia or ESAS instruments.	A mean of 10.6 units of PRBCs over 5 months were administered to those who received epoetin alpha compared with 13 units for those who did not receive epoetin (P = .04).
__label__noRel	There was no significant difference in QOL as assessed by the FACT-Anemia or ESAS instruments.	The CR rate and the 3-year CR duration were not affected adversely by use of epoetin alpha.
__label__noRel	There was no significant difference in QOL as assessed by the FACT-Anemia or ESAS instruments.	Epoetin alpha decreased the number of PRBC transfusions and did not appear to have a negative impact on remission duration.
__label__noRel	There was no significant difference in QOL as assessed by the FACT-Anemia or ESAS instruments.	The trial was stopped early because of poor accrual before the target of 123 evaluable patients was met.
__label__noRel	There was no significant difference in QOL as assessed by the FACT-Anemia or ESAS instruments.	Anemia is an expected consequence of intensive chemotherapy regimens administered to patients with acute leukemia.
__label__noRel	The CR rate and the 3-year CR duration were not affected adversely by use of epoetin alpha.	No difference in QOL was observed.
__label__noRel	The CR rate and the 3-year CR duration were not affected adversely by use of epoetin alpha.	A mean of 10.6 units of PRBCs over 5 months were administered to those who received epoetin alpha compared with 13 units for those who did not receive epoetin (P = .04).
__label__noRel	The CR rate and the 3-year CR duration were not affected adversely by use of epoetin alpha.	There was no significant difference in QOL as assessed by the FACT-Anemia or ESAS instruments.
__label__Support	The CR rate and the 3-year CR duration were not affected adversely by use of epoetin alpha.	Epoetin alpha decreased the number of PRBC transfusions and did not appear to have a negative impact on remission duration.
__label__noRel	The CR rate and the 3-year CR duration were not affected adversely by use of epoetin alpha.	The trial was stopped early because of poor accrual before the target of 123 evaluable patients was met.
__label__noRel	The CR rate and the 3-year CR duration were not affected adversely by use of epoetin alpha.	Anemia is an expected consequence of intensive chemotherapy regimens administered to patients with acute leukemia.
__label__noRel	Epoetin alpha decreased the number of PRBC transfusions and did not appear to have a negative impact on remission duration.	No difference in QOL was observed.
__label__noRel	Epoetin alpha decreased the number of PRBC transfusions and did not appear to have a negative impact on remission duration.	A mean of 10.6 units of PRBCs over 5 months were administered to those who received epoetin alpha compared with 13 units for those who did not receive epoetin (P = .04).
__label__noRel	Epoetin alpha decreased the number of PRBC transfusions and did not appear to have a negative impact on remission duration.	There was no significant difference in QOL as assessed by the FACT-Anemia or ESAS instruments.
__label__noRel	Epoetin alpha decreased the number of PRBC transfusions and did not appear to have a negative impact on remission duration.	The CR rate and the 3-year CR duration were not affected adversely by use of epoetin alpha.
__label__noRel	Epoetin alpha decreased the number of PRBC transfusions and did not appear to have a negative impact on remission duration.	The trial was stopped early because of poor accrual before the target of 123 evaluable patients was met.
__label__noRel	Epoetin alpha decreased the number of PRBC transfusions and did not appear to have a negative impact on remission duration.	Anemia is an expected consequence of intensive chemotherapy regimens administered to patients with acute leukemia.
__label__Attack	The trial was stopped early because of poor accrual before the target of 123 evaluable patients was met.	No difference in QOL was observed.
__label__noRel	The trial was stopped early because of poor accrual before the target of 123 evaluable patients was met.	A mean of 10.6 units of PRBCs over 5 months were administered to those who received epoetin alpha compared with 13 units for those who did not receive epoetin (P = .04).
__label__noRel	The trial was stopped early because of poor accrual before the target of 123 evaluable patients was met.	There was no significant difference in QOL as assessed by the FACT-Anemia or ESAS instruments.
__label__noRel	The trial was stopped early because of poor accrual before the target of 123 evaluable patients was met.	The CR rate and the 3-year CR duration were not affected adversely by use of epoetin alpha.
__label__noRel	The trial was stopped early because of poor accrual before the target of 123 evaluable patients was met.	Epoetin alpha decreased the number of PRBC transfusions and did not appear to have a negative impact on remission duration.
__label__noRel	The trial was stopped early because of poor accrual before the target of 123 evaluable patients was met.	Anemia is an expected consequence of intensive chemotherapy regimens administered to patients with acute leukemia.
__label__noRel	Anemia is an expected consequence of intensive chemotherapy regimens administered to patients with acute leukemia.	No difference in QOL was observed.
__label__noRel	Anemia is an expected consequence of intensive chemotherapy regimens administered to patients with acute leukemia.	A mean of 10.6 units of PRBCs over 5 months were administered to those who received epoetin alpha compared with 13 units for those who did not receive epoetin (P = .04).
__label__noRel	Anemia is an expected consequence of intensive chemotherapy regimens administered to patients with acute leukemia.	There was no significant difference in QOL as assessed by the FACT-Anemia or ESAS instruments.
__label__noRel	Anemia is an expected consequence of intensive chemotherapy regimens administered to patients with acute leukemia.	The CR rate and the 3-year CR duration were not affected adversely by use of epoetin alpha.
__label__noRel	Anemia is an expected consequence of intensive chemotherapy regimens administered to patients with acute leukemia.	Epoetin alpha decreased the number of PRBC transfusions and did not appear to have a negative impact on remission duration.
__label__noRel	Anemia is an expected consequence of intensive chemotherapy regimens administered to patients with acute leukemia.	The trial was stopped early because of poor accrual before the target of 123 evaluable patients was met.
__label__noRel	For patients with metastatic prostate cancer, treatment is primarily palliative, relying mainly on the suppression of systemic androgen hormone levels.	Cross-sectional analyses (corrected for multiple testing) identified statistically significant differences that favored orchiectomy plus placebo for two of the five primary QOL parameters as follows: patients receiving flutamide reported more diarrhea at 3 months (P = .001) and worse emotional functioning at 3 and 6 months (both P<.003).
__label__noRel	For patients with metastatic prostate cancer, treatment is primarily palliative, relying mainly on the suppression of systemic androgen hormone levels.	Longitudinal analyses replicated these findings.
__label__noRel	For patients with metastatic prostate cancer, treatment is primarily palliative, relying mainly on the suppression of systemic androgen hormone levels.	Other analyzed QOL parameters favored the group receiving placebo
__label__noRel	For patients with metastatic prostate cancer, treatment is primarily palliative, relying mainly on the suppression of systemic androgen hormone levels.	but were not statistically significant after adjustment for multiple testing.
__label__noRel	For patients with metastatic prostate cancer, treatment is primarily palliative, relying mainly on the suppression of systemic androgen hormone levels.	We found a consistent pattern of better QOL outcomes at each follow-up assessment during the first 6 months of treatment for orchiectomized patients with metastatic prostate cancer who received placebo versus flutamide.
__label__noRel	For patients with metastatic prostate cancer, treatment is primarily palliative, relying mainly on the suppression of systemic androgen hormone levels.	Improvement over time was evident in both treatment groups but more so for patients receiving placebo.
__label__noRel	Cross-sectional analyses (corrected for multiple testing) identified statistically significant differences that favored orchiectomy plus placebo for two of the five primary QOL parameters as follows: patients receiving flutamide reported more diarrhea at 3 months (P = .001) and worse emotional functioning at 3 and 6 months (both P<.003).	For patients with metastatic prostate cancer, treatment is primarily palliative, relying mainly on the suppression of systemic androgen hormone levels.
__label__noRel	Cross-sectional analyses (corrected for multiple testing) identified statistically significant differences that favored orchiectomy plus placebo for two of the five primary QOL parameters as follows: patients receiving flutamide reported more diarrhea at 3 months (P = .001) and worse emotional functioning at 3 and 6 months (both P<.003).	Longitudinal analyses replicated these findings.
__label__noRel	Cross-sectional analyses (corrected for multiple testing) identified statistically significant differences that favored orchiectomy plus placebo for two of the five primary QOL parameters as follows: patients receiving flutamide reported more diarrhea at 3 months (P = .001) and worse emotional functioning at 3 and 6 months (both P<.003).	Other analyzed QOL parameters favored the group receiving placebo
__label__noRel	Cross-sectional analyses (corrected for multiple testing) identified statistically significant differences that favored orchiectomy plus placebo for two of the five primary QOL parameters as follows: patients receiving flutamide reported more diarrhea at 3 months (P = .001) and worse emotional functioning at 3 and 6 months (both P<.003).	but were not statistically significant after adjustment for multiple testing.
__label__noRel	Cross-sectional analyses (corrected for multiple testing) identified statistically significant differences that favored orchiectomy plus placebo for two of the five primary QOL parameters as follows: patients receiving flutamide reported more diarrhea at 3 months (P = .001) and worse emotional functioning at 3 and 6 months (both P<.003).	We found a consistent pattern of better QOL outcomes at each follow-up assessment during the first 6 months of treatment for orchiectomized patients with metastatic prostate cancer who received placebo versus flutamide.
__label__Support	Cross-sectional analyses (corrected for multiple testing) identified statistically significant differences that favored orchiectomy plus placebo for two of the five primary QOL parameters as follows: patients receiving flutamide reported more diarrhea at 3 months (P = .001) and worse emotional functioning at 3 and 6 months (both P<.003).	Improvement over time was evident in both treatment groups but more so for patients receiving placebo.
__label__noRel	Longitudinal analyses replicated these findings.	For patients with metastatic prostate cancer, treatment is primarily palliative, relying mainly on the suppression of systemic androgen hormone levels.
__label__Support	Longitudinal analyses replicated these findings.	Cross-sectional analyses (corrected for multiple testing) identified statistically significant differences that favored orchiectomy plus placebo for two of the five primary QOL parameters as follows: patients receiving flutamide reported more diarrhea at 3 months (P = .001) and worse emotional functioning at 3 and 6 months (both P<.003).
__label__noRel	Longitudinal analyses replicated these findings.	Other analyzed QOL parameters favored the group receiving placebo
__label__noRel	Longitudinal analyses replicated these findings.	but were not statistically significant after adjustment for multiple testing.
__label__noRel	Longitudinal analyses replicated these findings.	We found a consistent pattern of better QOL outcomes at each follow-up assessment during the first 6 months of treatment for orchiectomized patients with metastatic prostate cancer who received placebo versus flutamide.
__label__noRel	Longitudinal analyses replicated these findings.	Improvement over time was evident in both treatment groups but more so for patients receiving placebo.
__label__noRel	Other analyzed QOL parameters favored the group receiving placebo	For patients with metastatic prostate cancer, treatment is primarily palliative, relying mainly on the suppression of systemic androgen hormone levels.
__label__noRel	Other analyzed QOL parameters favored the group receiving placebo	Cross-sectional analyses (corrected for multiple testing) identified statistically significant differences that favored orchiectomy plus placebo for two of the five primary QOL parameters as follows: patients receiving flutamide reported more diarrhea at 3 months (P = .001) and worse emotional functioning at 3 and 6 months (both P<.003).
__label__noRel	Other analyzed QOL parameters favored the group receiving placebo	Longitudinal analyses replicated these findings.
__label__noRel	Other analyzed QOL parameters favored the group receiving placebo	but were not statistically significant after adjustment for multiple testing.
__label__Support	Other analyzed QOL parameters favored the group receiving placebo	We found a consistent pattern of better QOL outcomes at each follow-up assessment during the first 6 months of treatment for orchiectomized patients with metastatic prostate cancer who received placebo versus flutamide.
__label__noRel	Other analyzed QOL parameters favored the group receiving placebo	Improvement over time was evident in both treatment groups but more so for patients receiving placebo.
__label__noRel	but were not statistically significant after adjustment for multiple testing.	For patients with metastatic prostate cancer, treatment is primarily palliative, relying mainly on the suppression of systemic androgen hormone levels.
__label__noRel	but were not statistically significant after adjustment for multiple testing.	Cross-sectional analyses (corrected for multiple testing) identified statistically significant differences that favored orchiectomy plus placebo for two of the five primary QOL parameters as follows: patients receiving flutamide reported more diarrhea at 3 months (P = .001) and worse emotional functioning at 3 and 6 months (both P<.003).
__label__noRel	but were not statistically significant after adjustment for multiple testing.	Longitudinal analyses replicated these findings.
__label__Attack	but were not statistically significant after adjustment for multiple testing.	Other analyzed QOL parameters favored the group receiving placebo
__label__noRel	but were not statistically significant after adjustment for multiple testing.	We found a consistent pattern of better QOL outcomes at each follow-up assessment during the first 6 months of treatment for orchiectomized patients with metastatic prostate cancer who received placebo versus flutamide.
__label__noRel	but were not statistically significant after adjustment for multiple testing.	Improvement over time was evident in both treatment groups but more so for patients receiving placebo.
__label__noRel	We found a consistent pattern of better QOL outcomes at each follow-up assessment during the first 6 months of treatment for orchiectomized patients with metastatic prostate cancer who received placebo versus flutamide.	For patients with metastatic prostate cancer, treatment is primarily palliative, relying mainly on the suppression of systemic androgen hormone levels.
__label__noRel	We found a consistent pattern of better QOL outcomes at each follow-up assessment during the first 6 months of treatment for orchiectomized patients with metastatic prostate cancer who received placebo versus flutamide.	Cross-sectional analyses (corrected for multiple testing) identified statistically significant differences that favored orchiectomy plus placebo for two of the five primary QOL parameters as follows: patients receiving flutamide reported more diarrhea at 3 months (P = .001) and worse emotional functioning at 3 and 6 months (both P<.003).
__label__noRel	We found a consistent pattern of better QOL outcomes at each follow-up assessment during the first 6 months of treatment for orchiectomized patients with metastatic prostate cancer who received placebo versus flutamide.	Longitudinal analyses replicated these findings.
__label__noRel	We found a consistent pattern of better QOL outcomes at each follow-up assessment during the first 6 months of treatment for orchiectomized patients with metastatic prostate cancer who received placebo versus flutamide.	Other analyzed QOL parameters favored the group receiving placebo
__label__noRel	We found a consistent pattern of better QOL outcomes at each follow-up assessment during the first 6 months of treatment for orchiectomized patients with metastatic prostate cancer who received placebo versus flutamide.	but were not statistically significant after adjustment for multiple testing.
__label__noRel	We found a consistent pattern of better QOL outcomes at each follow-up assessment during the first 6 months of treatment for orchiectomized patients with metastatic prostate cancer who received placebo versus flutamide.	Improvement over time was evident in both treatment groups but more so for patients receiving placebo.
__label__noRel	Improvement over time was evident in both treatment groups but more so for patients receiving placebo.	For patients with metastatic prostate cancer, treatment is primarily palliative, relying mainly on the suppression of systemic androgen hormone levels.
__label__noRel	Improvement over time was evident in both treatment groups but more so for patients receiving placebo.	Cross-sectional analyses (corrected for multiple testing) identified statistically significant differences that favored orchiectomy plus placebo for two of the five primary QOL parameters as follows: patients receiving flutamide reported more diarrhea at 3 months (P = .001) and worse emotional functioning at 3 and 6 months (both P<.003).
__label__noRel	Improvement over time was evident in both treatment groups but more so for patients receiving placebo.	Longitudinal analyses replicated these findings.
__label__noRel	Improvement over time was evident in both treatment groups but more so for patients receiving placebo.	Other analyzed QOL parameters favored the group receiving placebo
__label__noRel	Improvement over time was evident in both treatment groups but more so for patients receiving placebo.	but were not statistically significant after adjustment for multiple testing.
__label__noRel	Improvement over time was evident in both treatment groups but more so for patients receiving placebo.	We found a consistent pattern of better QOL outcomes at each follow-up assessment during the first 6 months of treatment for orchiectomized patients with metastatic prostate cancer who received placebo versus flutamide.
__label__noRel	There was a significant decrease in QoL from baseline (t0) to t1 (RRA period) in the hypothyroid group with significant differences in FACIT-F TOI (P < 10(-3)), FACT-G total score (P = 0.005) and FACIT-F total score (P = 0.003).	By contrast, QoL was preserved in the rhTSH group.
__label__noRel	There was a significant decrease in QoL from baseline (t0) to t1 (RRA period) in the hypothyroid group with significant differences in FACIT-F TOI (P < 10(-3)), FACT-G total score (P = 0.005) and FACIT-F total score (P = 0.003).	From 3 to 9 months, changes of QoL scales and subscales were no longer statistically different in both groups of patients.
__label__Support	There was a significant decrease in QoL from baseline (t0) to t1 (RRA period) in the hypothyroid group with significant differences in FACIT-F TOI (P < 10(-3)), FACT-G total score (P = 0.005) and FACIT-F total score (P = 0.003).	rhTSH preserves QoL of patients undergoing RRA with similar rates of ablation success compared to hypothyrodism.
__label__noRel	There was a significant decrease in QoL from baseline (t0) to t1 (RRA period) in the hypothyroid group with significant differences in FACIT-F TOI (P < 10(-3)), FACT-G total score (P = 0.005) and FACIT-F total score (P = 0.003).	A higher rate of persistent thyroid remnants was observed in the rhTSH arm,
__label__noRel	There was a significant decrease in QoL from baseline (t0) to t1 (RRA period) in the hypothyroid group with significant differences in FACIT-F TOI (P < 10(-3)), FACT-G total score (P = 0.005) and FACIT-F total score (P = 0.003).	although in most cases uptake was < 0.1% and of no clinical significance.
__label__noRel	There was a significant decrease in QoL from baseline (t0) to t1 (RRA period) in the hypothyroid group with significant differences in FACIT-F TOI (P < 10(-3)), FACT-G total score (P = 0.005) and FACIT-F total score (P = 0.003).	Based on serum rhTSH-stimulated Tg alone (Tg < 0.8 microg/l, BRAHMS Tg Kryptor), no difference in ablation success was observed between rhTSH and hypothyroidism groups, 91.7% and 97.1%, respectively.
__label__noRel	By contrast, QoL was preserved in the rhTSH group.	There was a significant decrease in QoL from baseline (t0) to t1 (RRA period) in the hypothyroid group with significant differences in FACIT-F TOI (P < 10(-3)), FACT-G total score (P = 0.005) and FACIT-F total score (P = 0.003).
__label__noRel	By contrast, QoL was preserved in the rhTSH group.	From 3 to 9 months, changes of QoL scales and subscales were no longer statistically different in both groups of patients.
__label__Support	By contrast, QoL was preserved in the rhTSH group.	rhTSH preserves QoL of patients undergoing RRA with similar rates of ablation success compared to hypothyrodism.
__label__noRel	By contrast, QoL was preserved in the rhTSH group.	A higher rate of persistent thyroid remnants was observed in the rhTSH arm,
__label__noRel	By contrast, QoL was preserved in the rhTSH group.	although in most cases uptake was < 0.1% and of no clinical significance.
__label__noRel	By contrast, QoL was preserved in the rhTSH group.	Based on serum rhTSH-stimulated Tg alone (Tg < 0.8 microg/l, BRAHMS Tg Kryptor), no difference in ablation success was observed between rhTSH and hypothyroidism groups, 91.7% and 97.1%, respectively.
__label__noRel	From 3 to 9 months, changes of QoL scales and subscales were no longer statistically different in both groups of patients.	There was a significant decrease in QoL from baseline (t0) to t1 (RRA period) in the hypothyroid group with significant differences in FACIT-F TOI (P < 10(-3)), FACT-G total score (P = 0.005) and FACIT-F total score (P = 0.003).
__label__noRel	From 3 to 9 months, changes of QoL scales and subscales were no longer statistically different in both groups of patients.	By contrast, QoL was preserved in the rhTSH group.
__label__Support	From 3 to 9 months, changes of QoL scales and subscales were no longer statistically different in both groups of patients.	rhTSH preserves QoL of patients undergoing RRA with similar rates of ablation success compared to hypothyrodism.
__label__noRel	From 3 to 9 months, changes of QoL scales and subscales were no longer statistically different in both groups of patients.	A higher rate of persistent thyroid remnants was observed in the rhTSH arm,
__label__noRel	From 3 to 9 months, changes of QoL scales and subscales were no longer statistically different in both groups of patients.	although in most cases uptake was < 0.1% and of no clinical significance.
__label__noRel	From 3 to 9 months, changes of QoL scales and subscales were no longer statistically different in both groups of patients.	Based on serum rhTSH-stimulated Tg alone (Tg < 0.8 microg/l, BRAHMS Tg Kryptor), no difference in ablation success was observed between rhTSH and hypothyroidism groups, 91.7% and 97.1%, respectively.
__label__noRel	rhTSH preserves QoL of patients undergoing RRA with similar rates of ablation success compared to hypothyrodism.	There was a significant decrease in QoL from baseline (t0) to t1 (RRA period) in the hypothyroid group with significant differences in FACIT-F TOI (P < 10(-3)), FACT-G total score (P = 0.005) and FACIT-F total score (P = 0.003).
__label__noRel	rhTSH preserves QoL of patients undergoing RRA with similar rates of ablation success compared to hypothyrodism.	By contrast, QoL was preserved in the rhTSH group.
__label__noRel	rhTSH preserves QoL of patients undergoing RRA with similar rates of ablation success compared to hypothyrodism.	From 3 to 9 months, changes of QoL scales and subscales were no longer statistically different in both groups of patients.
__label__noRel	rhTSH preserves QoL of patients undergoing RRA with similar rates of ablation success compared to hypothyrodism.	A higher rate of persistent thyroid remnants was observed in the rhTSH arm,
__label__noRel	rhTSH preserves QoL of patients undergoing RRA with similar rates of ablation success compared to hypothyrodism.	although in most cases uptake was < 0.1% and of no clinical significance.
__label__noRel	rhTSH preserves QoL of patients undergoing RRA with similar rates of ablation success compared to hypothyrodism.	Based on serum rhTSH-stimulated Tg alone (Tg < 0.8 microg/l, BRAHMS Tg Kryptor), no difference in ablation success was observed between rhTSH and hypothyroidism groups, 91.7% and 97.1%, respectively.
__label__noRel	A higher rate of persistent thyroid remnants was observed in the rhTSH arm,	There was a significant decrease in QoL from baseline (t0) to t1 (RRA period) in the hypothyroid group with significant differences in FACIT-F TOI (P < 10(-3)), FACT-G total score (P = 0.005) and FACIT-F total score (P = 0.003).
__label__noRel	A higher rate of persistent thyroid remnants was observed in the rhTSH arm,	By contrast, QoL was preserved in the rhTSH group.
__label__noRel	A higher rate of persistent thyroid remnants was observed in the rhTSH arm,	From 3 to 9 months, changes of QoL scales and subscales were no longer statistically different in both groups of patients.
__label__noRel	A higher rate of persistent thyroid remnants was observed in the rhTSH arm,	rhTSH preserves QoL of patients undergoing RRA with similar rates of ablation success compared to hypothyrodism.
__label__noRel	A higher rate of persistent thyroid remnants was observed in the rhTSH arm,	although in most cases uptake was < 0.1% and of no clinical significance.
__label__noRel	A higher rate of persistent thyroid remnants was observed in the rhTSH arm,	Based on serum rhTSH-stimulated Tg alone (Tg < 0.8 microg/l, BRAHMS Tg Kryptor), no difference in ablation success was observed between rhTSH and hypothyroidism groups, 91.7% and 97.1%, respectively.
__label__noRel	although in most cases uptake was < 0.1% and of no clinical significance.	There was a significant decrease in QoL from baseline (t0) to t1 (RRA period) in the hypothyroid group with significant differences in FACIT-F TOI (P < 10(-3)), FACT-G total score (P = 0.005) and FACIT-F total score (P = 0.003).
__label__noRel	although in most cases uptake was < 0.1% and of no clinical significance.	By contrast, QoL was preserved in the rhTSH group.
__label__noRel	although in most cases uptake was < 0.1% and of no clinical significance.	From 3 to 9 months, changes of QoL scales and subscales were no longer statistically different in both groups of patients.
__label__noRel	although in most cases uptake was < 0.1% and of no clinical significance.	rhTSH preserves QoL of patients undergoing RRA with similar rates of ablation success compared to hypothyrodism.
__label__Attack	although in most cases uptake was < 0.1% and of no clinical significance.	A higher rate of persistent thyroid remnants was observed in the rhTSH arm,
__label__noRel	although in most cases uptake was < 0.1% and of no clinical significance.	Based on serum rhTSH-stimulated Tg alone (Tg < 0.8 microg/l, BRAHMS Tg Kryptor), no difference in ablation success was observed between rhTSH and hypothyroidism groups, 91.7% and 97.1%, respectively.
__label__noRel	Based on serum rhTSH-stimulated Tg alone (Tg < 0.8 microg/l, BRAHMS Tg Kryptor), no difference in ablation success was observed between rhTSH and hypothyroidism groups, 91.7% and 97.1%, respectively.	There was a significant decrease in QoL from baseline (t0) to t1 (RRA period) in the hypothyroid group with significant differences in FACIT-F TOI (P < 10(-3)), FACT-G total score (P = 0.005) and FACIT-F total score (P = 0.003).
__label__noRel	Based on serum rhTSH-stimulated Tg alone (Tg < 0.8 microg/l, BRAHMS Tg Kryptor), no difference in ablation success was observed between rhTSH and hypothyroidism groups, 91.7% and 97.1%, respectively.	By contrast, QoL was preserved in the rhTSH group.
__label__noRel	Based on serum rhTSH-stimulated Tg alone (Tg < 0.8 microg/l, BRAHMS Tg Kryptor), no difference in ablation success was observed between rhTSH and hypothyroidism groups, 91.7% and 97.1%, respectively.	From 3 to 9 months, changes of QoL scales and subscales were no longer statistically different in both groups of patients.
__label__Support	Based on serum rhTSH-stimulated Tg alone (Tg < 0.8 microg/l, BRAHMS Tg Kryptor), no difference in ablation success was observed between rhTSH and hypothyroidism groups, 91.7% and 97.1%, respectively.	rhTSH preserves QoL of patients undergoing RRA with similar rates of ablation success compared to hypothyrodism.
__label__noRel	Based on serum rhTSH-stimulated Tg alone (Tg < 0.8 microg/l, BRAHMS Tg Kryptor), no difference in ablation success was observed between rhTSH and hypothyroidism groups, 91.7% and 97.1%, respectively.	A higher rate of persistent thyroid remnants was observed in the rhTSH arm,
__label__noRel	Based on serum rhTSH-stimulated Tg alone (Tg < 0.8 microg/l, BRAHMS Tg Kryptor), no difference in ablation success was observed between rhTSH and hypothyroidism groups, 91.7% and 97.1%, respectively.	although in most cases uptake was < 0.1% and of no clinical significance.
__label__Support	QOL improved in the study group.	ALT was found to be a safe method, with high adherence, in treating women who suffer from mild to moderate lymphedema.
__label__noRel	QOL improved in the study group.	A significant immediate and insignificant long-term effect on limb volume was noted.
__label__noRel	QOL improved in the study group.	ALT had a positive, statistically and clinically significant immediate effect on limb volume
__label__noRel	QOL improved in the study group.	but no long-term effect was noted.
__label__noRel	QOL improved in the study group.	There was no episode of arm infection or aggravation in limb volume during the study period.
__label__noRel	QOL improved in the study group.	The adherence rate to ALT was significantly higher than the adherence to self-management therapy.
__label__noRel	ALT was found to be a safe method, with high adherence, in treating women who suffer from mild to moderate lymphedema.	QOL improved in the study group.
__label__noRel	ALT was found to be a safe method, with high adherence, in treating women who suffer from mild to moderate lymphedema.	A significant immediate and insignificant long-term effect on limb volume was noted.
__label__noRel	ALT was found to be a safe method, with high adherence, in treating women who suffer from mild to moderate lymphedema.	ALT had a positive, statistically and clinically significant immediate effect on limb volume
__label__noRel	ALT was found to be a safe method, with high adherence, in treating women who suffer from mild to moderate lymphedema.	but no long-term effect was noted.
__label__noRel	ALT was found to be a safe method, with high adherence, in treating women who suffer from mild to moderate lymphedema.	There was no episode of arm infection or aggravation in limb volume during the study period.
__label__noRel	ALT was found to be a safe method, with high adherence, in treating women who suffer from mild to moderate lymphedema.	The adherence rate to ALT was significantly higher than the adherence to self-management therapy.
__label__noRel	A significant immediate and insignificant long-term effect on limb volume was noted.	QOL improved in the study group.
__label__noRel	A significant immediate and insignificant long-term effect on limb volume was noted.	ALT was found to be a safe method, with high adherence, in treating women who suffer from mild to moderate lymphedema.
__label__noRel	A significant immediate and insignificant long-term effect on limb volume was noted.	ALT had a positive, statistically and clinically significant immediate effect on limb volume
__label__noRel	A significant immediate and insignificant long-term effect on limb volume was noted.	but no long-term effect was noted.
__label__noRel	A significant immediate and insignificant long-term effect on limb volume was noted.	There was no episode of arm infection or aggravation in limb volume during the study period.
__label__noRel	A significant immediate and insignificant long-term effect on limb volume was noted.	The adherence rate to ALT was significantly higher than the adherence to self-management therapy.
__label__noRel	ALT had a positive, statistically and clinically significant immediate effect on limb volume	QOL improved in the study group.
__label__noRel	ALT had a positive, statistically and clinically significant immediate effect on limb volume	ALT was found to be a safe method, with high adherence, in treating women who suffer from mild to moderate lymphedema.
__label__Support	ALT had a positive, statistically and clinically significant immediate effect on limb volume	A significant immediate and insignificant long-term effect on limb volume was noted.
__label__noRel	ALT had a positive, statistically and clinically significant immediate effect on limb volume	but no long-term effect was noted.
__label__noRel	ALT had a positive, statistically and clinically significant immediate effect on limb volume	There was no episode of arm infection or aggravation in limb volume during the study period.
__label__noRel	ALT had a positive, statistically and clinically significant immediate effect on limb volume	The adherence rate to ALT was significantly higher than the adherence to self-management therapy.
__label__noRel	but no long-term effect was noted.	QOL improved in the study group.
__label__noRel	but no long-term effect was noted.	ALT was found to be a safe method, with high adherence, in treating women who suffer from mild to moderate lymphedema.
__label__noRel	but no long-term effect was noted.	A significant immediate and insignificant long-term effect on limb volume was noted.
__label__Attack	but no long-term effect was noted.	ALT had a positive, statistically and clinically significant immediate effect on limb volume
__label__noRel	but no long-term effect was noted.	There was no episode of arm infection or aggravation in limb volume during the study period.
__label__noRel	but no long-term effect was noted.	The adherence rate to ALT was significantly higher than the adherence to self-management therapy.
__label__noRel	There was no episode of arm infection or aggravation in limb volume during the study period.	QOL improved in the study group.
__label__noRel	There was no episode of arm infection or aggravation in limb volume during the study period.	ALT was found to be a safe method, with high adherence, in treating women who suffer from mild to moderate lymphedema.
__label__Support	There was no episode of arm infection or aggravation in limb volume during the study period.	A significant immediate and insignificant long-term effect on limb volume was noted.
__label__noRel	There was no episode of arm infection or aggravation in limb volume during the study period.	ALT had a positive, statistically and clinically significant immediate effect on limb volume
__label__noRel	There was no episode of arm infection or aggravation in limb volume during the study period.	but no long-term effect was noted.
__label__noRel	There was no episode of arm infection or aggravation in limb volume during the study period.	The adherence rate to ALT was significantly higher than the adherence to self-management therapy.
__label__noRel	The adherence rate to ALT was significantly higher than the adherence to self-management therapy.	QOL improved in the study group.
__label__Support	The adherence rate to ALT was significantly higher than the adherence to self-management therapy.	ALT was found to be a safe method, with high adherence, in treating women who suffer from mild to moderate lymphedema.
__label__noRel	The adherence rate to ALT was significantly higher than the adherence to self-management therapy.	A significant immediate and insignificant long-term effect on limb volume was noted.
__label__noRel	The adherence rate to ALT was significantly higher than the adherence to self-management therapy.	ALT had a positive, statistically and clinically significant immediate effect on limb volume
__label__noRel	The adherence rate to ALT was significantly higher than the adherence to self-management therapy.	but no long-term effect was noted.
__label__noRel	The adherence rate to ALT was significantly higher than the adherence to self-management therapy.	There was no episode of arm infection or aggravation in limb volume during the study period.
__label__noRel	Reported adverse events were similar between groups.	A slight increase in transfusions was reported in the QW group.
__label__Support	Reported adverse events were similar between groups.	Darbepoetin alfa, when administered synchronously with chemotherapy, on an EDS appears to be similarly efficacious to darbepoetin alfa weekly dosing with no unexpected adverse events.
__label__noRel	Reported adverse events were similar between groups.	Seventy-one percent of patients in the EDS group and 76% in the QW group achieved the target hemoglobin of 11.0 g/dL.
__label__noRel	A slight increase in transfusions was reported in the QW group.	Reported adverse events were similar between groups.
__label__noRel	A slight increase in transfusions was reported in the QW group.	Darbepoetin alfa, when administered synchronously with chemotherapy, on an EDS appears to be similarly efficacious to darbepoetin alfa weekly dosing with no unexpected adverse events.
__label__noRel	A slight increase in transfusions was reported in the QW group.	Seventy-one percent of patients in the EDS group and 76% in the QW group achieved the target hemoglobin of 11.0 g/dL.
__label__noRel	Darbepoetin alfa, when administered synchronously with chemotherapy, on an EDS appears to be similarly efficacious to darbepoetin alfa weekly dosing with no unexpected adverse events.	Reported adverse events were similar between groups.
__label__noRel	Darbepoetin alfa, when administered synchronously with chemotherapy, on an EDS appears to be similarly efficacious to darbepoetin alfa weekly dosing with no unexpected adverse events.	A slight increase in transfusions was reported in the QW group.
__label__noRel	Darbepoetin alfa, when administered synchronously with chemotherapy, on an EDS appears to be similarly efficacious to darbepoetin alfa weekly dosing with no unexpected adverse events.	Seventy-one percent of patients in the EDS group and 76% in the QW group achieved the target hemoglobin of 11.0 g/dL.
__label__noRel	Seventy-one percent of patients in the EDS group and 76% in the QW group achieved the target hemoglobin of 11.0 g/dL.	Reported adverse events were similar between groups.
__label__noRel	Seventy-one percent of patients in the EDS group and 76% in the QW group achieved the target hemoglobin of 11.0 g/dL.	A slight increase in transfusions was reported in the QW group.
__label__Support	Seventy-one percent of patients in the EDS group and 76% in the QW group achieved the target hemoglobin of 11.0 g/dL.	Darbepoetin alfa, when administered synchronously with chemotherapy, on an EDS appears to be similarly efficacious to darbepoetin alfa weekly dosing with no unexpected adverse events.
__label__noRel	At radiotherapy completion, energy intake increased in G1/G2 (P < or = .04), G1 more than G2 (P = .001), and decreased in G3 (P < .01).	Protein intake increased in G1/G2 (P < or = .007), G1 less than G2 (not significant), and decreased in G3 (P < .01).
__label__noRel	At radiotherapy completion, energy intake increased in G1/G2 (P < or = .04), G1 more than G2 (P = .001), and decreased in G3 (P < .01).	At 3 months, G1 maintained nutritional intake and G2/G3 returned to baseline.
__label__noRel	At radiotherapy completion, energy intake increased in G1/G2 (P < or = .04), G1 more than G2 (P = .001), and decreased in G3 (P < .01).	After radiotherapy and at 3 months, rates of anorexia, nausea, vomiting, and diarrhea were higher in G3 (P < .05).
__label__noRel	At radiotherapy completion, energy intake increased in G1/G2 (P < or = .04), G1 more than G2 (P = .001), and decreased in G3 (P < .01).	At radiotherapy completion, in G1 all QoL function scores improved proportionally to adequate intake or nutritional status (P < .05); whereas in G2 only three of six function scores improved proportionally to protein intake (P = .04), and in G3 all scores worsened (P < .05).
__label__noRel	At radiotherapy completion, energy intake increased in G1/G2 (P < or = .04), G1 more than G2 (P = .001), and decreased in G3 (P < .01).	At 3 months, G1 patients maintained/improved function, symptoms, and single-item scores (P < .02); in G2, only few function and symptom scales improved (P < .05); in G3, QoL remained as poor as after radiotherapy.
__label__noRel	At radiotherapy completion, energy intake increased in G1/G2 (P < or = .04), G1 more than G2 (P = .001), and decreased in G3 (P < .01).	In G1/G2, respectively, improvement/deterioration of QoL correlated with better or poorer intake or nutritional status (P < .003).
__label__Support	At radiotherapy completion, energy intake increased in G1/G2 (P < or = .04), G1 more than G2 (P = .001), and decreased in G3 (P < .01).	During radiotherapy, both interventions positively influenced outcomes;
__label__noRel	At radiotherapy completion, energy intake increased in G1/G2 (P < or = .04), G1 more than G2 (P = .001), and decreased in G3 (P < .01).	dietary counseling was of similar or higher benefit, whereas even 3 months after RT, it was the only method to sustain a significant impact on patient outcomes.
__label__noRel	Protein intake increased in G1/G2 (P < or = .007), G1 less than G2 (not significant), and decreased in G3 (P < .01).	At radiotherapy completion, energy intake increased in G1/G2 (P < or = .04), G1 more than G2 (P = .001), and decreased in G3 (P < .01).
__label__noRel	Protein intake increased in G1/G2 (P < or = .007), G1 less than G2 (not significant), and decreased in G3 (P < .01).	At 3 months, G1 maintained nutritional intake and G2/G3 returned to baseline.
__label__noRel	Protein intake increased in G1/G2 (P < or = .007), G1 less than G2 (not significant), and decreased in G3 (P < .01).	After radiotherapy and at 3 months, rates of anorexia, nausea, vomiting, and diarrhea were higher in G3 (P < .05).
__label__noRel	Protein intake increased in G1/G2 (P < or = .007), G1 less than G2 (not significant), and decreased in G3 (P < .01).	At radiotherapy completion, in G1 all QoL function scores improved proportionally to adequate intake or nutritional status (P < .05); whereas in G2 only three of six function scores improved proportionally to protein intake (P = .04), and in G3 all scores worsened (P < .05).
__label__noRel	Protein intake increased in G1/G2 (P < or = .007), G1 less than G2 (not significant), and decreased in G3 (P < .01).	At 3 months, G1 patients maintained/improved function, symptoms, and single-item scores (P < .02); in G2, only few function and symptom scales improved (P < .05); in G3, QoL remained as poor as after radiotherapy.
__label__noRel	Protein intake increased in G1/G2 (P < or = .007), G1 less than G2 (not significant), and decreased in G3 (P < .01).	In G1/G2, respectively, improvement/deterioration of QoL correlated with better or poorer intake or nutritional status (P < .003).
__label__Support	Protein intake increased in G1/G2 (P < or = .007), G1 less than G2 (not significant), and decreased in G3 (P < .01).	During radiotherapy, both interventions positively influenced outcomes;
__label__noRel	Protein intake increased in G1/G2 (P < or = .007), G1 less than G2 (not significant), and decreased in G3 (P < .01).	dietary counseling was of similar or higher benefit, whereas even 3 months after RT, it was the only method to sustain a significant impact on patient outcomes.
__label__noRel	At 3 months, G1 maintained nutritional intake and G2/G3 returned to baseline.	At radiotherapy completion, energy intake increased in G1/G2 (P < or = .04), G1 more than G2 (P = .001), and decreased in G3 (P < .01).
__label__noRel	At 3 months, G1 maintained nutritional intake and G2/G3 returned to baseline.	Protein intake increased in G1/G2 (P < or = .007), G1 less than G2 (not significant), and decreased in G3 (P < .01).
__label__noRel	At 3 months, G1 maintained nutritional intake and G2/G3 returned to baseline.	After radiotherapy and at 3 months, rates of anorexia, nausea, vomiting, and diarrhea were higher in G3 (P < .05).
__label__noRel	At 3 months, G1 maintained nutritional intake and G2/G3 returned to baseline.	At radiotherapy completion, in G1 all QoL function scores improved proportionally to adequate intake or nutritional status (P < .05); whereas in G2 only three of six function scores improved proportionally to protein intake (P = .04), and in G3 all scores worsened (P < .05).
__label__noRel	At 3 months, G1 maintained nutritional intake and G2/G3 returned to baseline.	At 3 months, G1 patients maintained/improved function, symptoms, and single-item scores (P < .02); in G2, only few function and symptom scales improved (P < .05); in G3, QoL remained as poor as after radiotherapy.
__label__noRel	At 3 months, G1 maintained nutritional intake and G2/G3 returned to baseline.	In G1/G2, respectively, improvement/deterioration of QoL correlated with better or poorer intake or nutritional status (P < .003).
__label__noRel	At 3 months, G1 maintained nutritional intake and G2/G3 returned to baseline.	During radiotherapy, both interventions positively influenced outcomes;
__label__Support	At 3 months, G1 maintained nutritional intake and G2/G3 returned to baseline.	dietary counseling was of similar or higher benefit, whereas even 3 months after RT, it was the only method to sustain a significant impact on patient outcomes.
__label__noRel	After radiotherapy and at 3 months, rates of anorexia, nausea, vomiting, and diarrhea were higher in G3 (P < .05).	At radiotherapy completion, energy intake increased in G1/G2 (P < or = .04), G1 more than G2 (P = .001), and decreased in G3 (P < .01).
__label__noRel	After radiotherapy and at 3 months, rates of anorexia, nausea, vomiting, and diarrhea were higher in G3 (P < .05).	Protein intake increased in G1/G2 (P < or = .007), G1 less than G2 (not significant), and decreased in G3 (P < .01).
__label__noRel	After radiotherapy and at 3 months, rates of anorexia, nausea, vomiting, and diarrhea were higher in G3 (P < .05).	At 3 months, G1 maintained nutritional intake and G2/G3 returned to baseline.
__label__noRel	After radiotherapy and at 3 months, rates of anorexia, nausea, vomiting, and diarrhea were higher in G3 (P < .05).	At radiotherapy completion, in G1 all QoL function scores improved proportionally to adequate intake or nutritional status (P < .05); whereas in G2 only three of six function scores improved proportionally to protein intake (P = .04), and in G3 all scores worsened (P < .05).
__label__noRel	After radiotherapy and at 3 months, rates of anorexia, nausea, vomiting, and diarrhea were higher in G3 (P < .05).	At 3 months, G1 patients maintained/improved function, symptoms, and single-item scores (P < .02); in G2, only few function and symptom scales improved (P < .05); in G3, QoL remained as poor as after radiotherapy.
__label__noRel	After radiotherapy and at 3 months, rates of anorexia, nausea, vomiting, and diarrhea were higher in G3 (P < .05).	In G1/G2, respectively, improvement/deterioration of QoL correlated with better or poorer intake or nutritional status (P < .003).
__label__noRel	After radiotherapy and at 3 months, rates of anorexia, nausea, vomiting, and diarrhea were higher in G3 (P < .05).	During radiotherapy, both interventions positively influenced outcomes;
__label__Support	After radiotherapy and at 3 months, rates of anorexia, nausea, vomiting, and diarrhea were higher in G3 (P < .05).	dietary counseling was of similar or higher benefit, whereas even 3 months after RT, it was the only method to sustain a significant impact on patient outcomes.
__label__noRel	At radiotherapy completion, in G1 all QoL function scores improved proportionally to adequate intake or nutritional status (P < .05); whereas in G2 only three of six function scores improved proportionally to protein intake (P = .04), and in G3 all scores worsened (P < .05).	At radiotherapy completion, energy intake increased in G1/G2 (P < or = .04), G1 more than G2 (P = .001), and decreased in G3 (P < .01).
__label__noRel	At radiotherapy completion, in G1 all QoL function scores improved proportionally to adequate intake or nutritional status (P < .05); whereas in G2 only three of six function scores improved proportionally to protein intake (P = .04), and in G3 all scores worsened (P < .05).	Protein intake increased in G1/G2 (P < or = .007), G1 less than G2 (not significant), and decreased in G3 (P < .01).
__label__noRel	At radiotherapy completion, in G1 all QoL function scores improved proportionally to adequate intake or nutritional status (P < .05); whereas in G2 only three of six function scores improved proportionally to protein intake (P = .04), and in G3 all scores worsened (P < .05).	At 3 months, G1 maintained nutritional intake and G2/G3 returned to baseline.
__label__noRel	At radiotherapy completion, in G1 all QoL function scores improved proportionally to adequate intake or nutritional status (P < .05); whereas in G2 only three of six function scores improved proportionally to protein intake (P = .04), and in G3 all scores worsened (P < .05).	After radiotherapy and at 3 months, rates of anorexia, nausea, vomiting, and diarrhea were higher in G3 (P < .05).
__label__noRel	At radiotherapy completion, in G1 all QoL function scores improved proportionally to adequate intake or nutritional status (P < .05); whereas in G2 only three of six function scores improved proportionally to protein intake (P = .04), and in G3 all scores worsened (P < .05).	At 3 months, G1 patients maintained/improved function, symptoms, and single-item scores (P < .02); in G2, only few function and symptom scales improved (P < .05); in G3, QoL remained as poor as after radiotherapy.
__label__noRel	At radiotherapy completion, in G1 all QoL function scores improved proportionally to adequate intake or nutritional status (P < .05); whereas in G2 only three of six function scores improved proportionally to protein intake (P = .04), and in G3 all scores worsened (P < .05).	In G1/G2, respectively, improvement/deterioration of QoL correlated with better or poorer intake or nutritional status (P < .003).
__label__Support	At radiotherapy completion, in G1 all QoL function scores improved proportionally to adequate intake or nutritional status (P < .05); whereas in G2 only three of six function scores improved proportionally to protein intake (P = .04), and in G3 all scores worsened (P < .05).	During radiotherapy, both interventions positively influenced outcomes;
__label__noRel	At radiotherapy completion, in G1 all QoL function scores improved proportionally to adequate intake or nutritional status (P < .05); whereas in G2 only three of six function scores improved proportionally to protein intake (P = .04), and in G3 all scores worsened (P < .05).	dietary counseling was of similar or higher benefit, whereas even 3 months after RT, it was the only method to sustain a significant impact on patient outcomes.
__label__noRel	At 3 months, G1 patients maintained/improved function, symptoms, and single-item scores (P < .02); in G2, only few function and symptom scales improved (P < .05); in G3, QoL remained as poor as after radiotherapy.	At radiotherapy completion, energy intake increased in G1/G2 (P < or = .04), G1 more than G2 (P = .001), and decreased in G3 (P < .01).
__label__noRel	At 3 months, G1 patients maintained/improved function, symptoms, and single-item scores (P < .02); in G2, only few function and symptom scales improved (P < .05); in G3, QoL remained as poor as after radiotherapy.	Protein intake increased in G1/G2 (P < or = .007), G1 less than G2 (not significant), and decreased in G3 (P < .01).
__label__noRel	At 3 months, G1 patients maintained/improved function, symptoms, and single-item scores (P < .02); in G2, only few function and symptom scales improved (P < .05); in G3, QoL remained as poor as after radiotherapy.	At 3 months, G1 maintained nutritional intake and G2/G3 returned to baseline.
__label__noRel	At 3 months, G1 patients maintained/improved function, symptoms, and single-item scores (P < .02); in G2, only few function and symptom scales improved (P < .05); in G3, QoL remained as poor as after radiotherapy.	After radiotherapy and at 3 months, rates of anorexia, nausea, vomiting, and diarrhea were higher in G3 (P < .05).
__label__noRel	At 3 months, G1 patients maintained/improved function, symptoms, and single-item scores (P < .02); in G2, only few function and symptom scales improved (P < .05); in G3, QoL remained as poor as after radiotherapy.	At radiotherapy completion, in G1 all QoL function scores improved proportionally to adequate intake or nutritional status (P < .05); whereas in G2 only three of six function scores improved proportionally to protein intake (P = .04), and in G3 all scores worsened (P < .05).
__label__noRel	At 3 months, G1 patients maintained/improved function, symptoms, and single-item scores (P < .02); in G2, only few function and symptom scales improved (P < .05); in G3, QoL remained as poor as after radiotherapy.	In G1/G2, respectively, improvement/deterioration of QoL correlated with better or poorer intake or nutritional status (P < .003).
__label__noRel	At 3 months, G1 patients maintained/improved function, symptoms, and single-item scores (P < .02); in G2, only few function and symptom scales improved (P < .05); in G3, QoL remained as poor as after radiotherapy.	During radiotherapy, both interventions positively influenced outcomes;
__label__Support	At 3 months, G1 patients maintained/improved function, symptoms, and single-item scores (P < .02); in G2, only few function and symptom scales improved (P < .05); in G3, QoL remained as poor as after radiotherapy.	dietary counseling was of similar or higher benefit, whereas even 3 months after RT, it was the only method to sustain a significant impact on patient outcomes.
__label__noRel	In G1/G2, respectively, improvement/deterioration of QoL correlated with better or poorer intake or nutritional status (P < .003).	At radiotherapy completion, energy intake increased in G1/G2 (P < or = .04), G1 more than G2 (P = .001), and decreased in G3 (P < .01).
__label__noRel	In G1/G2, respectively, improvement/deterioration of QoL correlated with better or poorer intake or nutritional status (P < .003).	Protein intake increased in G1/G2 (P < or = .007), G1 less than G2 (not significant), and decreased in G3 (P < .01).
__label__noRel	In G1/G2, respectively, improvement/deterioration of QoL correlated with better or poorer intake or nutritional status (P < .003).	At 3 months, G1 maintained nutritional intake and G2/G3 returned to baseline.
__label__noRel	In G1/G2, respectively, improvement/deterioration of QoL correlated with better or poorer intake or nutritional status (P < .003).	After radiotherapy and at 3 months, rates of anorexia, nausea, vomiting, and diarrhea were higher in G3 (P < .05).
__label__noRel	In G1/G2, respectively, improvement/deterioration of QoL correlated with better or poorer intake or nutritional status (P < .003).	At radiotherapy completion, in G1 all QoL function scores improved proportionally to adequate intake or nutritional status (P < .05); whereas in G2 only three of six function scores improved proportionally to protein intake (P = .04), and in G3 all scores worsened (P < .05).
__label__noRel	In G1/G2, respectively, improvement/deterioration of QoL correlated with better or poorer intake or nutritional status (P < .003).	At 3 months, G1 patients maintained/improved function, symptoms, and single-item scores (P < .02); in G2, only few function and symptom scales improved (P < .05); in G3, QoL remained as poor as after radiotherapy.
__label__noRel	In G1/G2, respectively, improvement/deterioration of QoL correlated with better or poorer intake or nutritional status (P < .003).	During radiotherapy, both interventions positively influenced outcomes;
__label__noRel	In G1/G2, respectively, improvement/deterioration of QoL correlated with better or poorer intake or nutritional status (P < .003).	dietary counseling was of similar or higher benefit, whereas even 3 months after RT, it was the only method to sustain a significant impact on patient outcomes.
__label__noRel	During radiotherapy, both interventions positively influenced outcomes;	At radiotherapy completion, energy intake increased in G1/G2 (P < or = .04), G1 more than G2 (P = .001), and decreased in G3 (P < .01).
__label__noRel	During radiotherapy, both interventions positively influenced outcomes;	Protein intake increased in G1/G2 (P < or = .007), G1 less than G2 (not significant), and decreased in G3 (P < .01).
__label__noRel	During radiotherapy, both interventions positively influenced outcomes;	At 3 months, G1 maintained nutritional intake and G2/G3 returned to baseline.
__label__noRel	During radiotherapy, both interventions positively influenced outcomes;	After radiotherapy and at 3 months, rates of anorexia, nausea, vomiting, and diarrhea were higher in G3 (P < .05).
__label__noRel	During radiotherapy, both interventions positively influenced outcomes;	At radiotherapy completion, in G1 all QoL function scores improved proportionally to adequate intake or nutritional status (P < .05); whereas in G2 only three of six function scores improved proportionally to protein intake (P = .04), and in G3 all scores worsened (P < .05).
__label__noRel	During radiotherapy, both interventions positively influenced outcomes;	At 3 months, G1 patients maintained/improved function, symptoms, and single-item scores (P < .02); in G2, only few function and symptom scales improved (P < .05); in G3, QoL remained as poor as after radiotherapy.
__label__noRel	During radiotherapy, both interventions positively influenced outcomes;	In G1/G2, respectively, improvement/deterioration of QoL correlated with better or poorer intake or nutritional status (P < .003).
__label__noRel	During radiotherapy, both interventions positively influenced outcomes;	dietary counseling was of similar or higher benefit, whereas even 3 months after RT, it was the only method to sustain a significant impact on patient outcomes.
__label__noRel	dietary counseling was of similar or higher benefit, whereas even 3 months after RT, it was the only method to sustain a significant impact on patient outcomes.	At radiotherapy completion, energy intake increased in G1/G2 (P < or = .04), G1 more than G2 (P = .001), and decreased in G3 (P < .01).
__label__noRel	dietary counseling was of similar or higher benefit, whereas even 3 months after RT, it was the only method to sustain a significant impact on patient outcomes.	Protein intake increased in G1/G2 (P < or = .007), G1 less than G2 (not significant), and decreased in G3 (P < .01).
__label__noRel	dietary counseling was of similar or higher benefit, whereas even 3 months after RT, it was the only method to sustain a significant impact on patient outcomes.	At 3 months, G1 maintained nutritional intake and G2/G3 returned to baseline.
__label__noRel	dietary counseling was of similar or higher benefit, whereas even 3 months after RT, it was the only method to sustain a significant impact on patient outcomes.	After radiotherapy and at 3 months, rates of anorexia, nausea, vomiting, and diarrhea were higher in G3 (P < .05).
__label__noRel	dietary counseling was of similar or higher benefit, whereas even 3 months after RT, it was the only method to sustain a significant impact on patient outcomes.	At radiotherapy completion, in G1 all QoL function scores improved proportionally to adequate intake or nutritional status (P < .05); whereas in G2 only three of six function scores improved proportionally to protein intake (P = .04), and in G3 all scores worsened (P < .05).
__label__noRel	dietary counseling was of similar or higher benefit, whereas even 3 months after RT, it was the only method to sustain a significant impact on patient outcomes.	At 3 months, G1 patients maintained/improved function, symptoms, and single-item scores (P < .02); in G2, only few function and symptom scales improved (P < .05); in G3, QoL remained as poor as after radiotherapy.
__label__noRel	dietary counseling was of similar or higher benefit, whereas even 3 months after RT, it was the only method to sustain a significant impact on patient outcomes.	In G1/G2, respectively, improvement/deterioration of QoL correlated with better or poorer intake or nutritional status (P < .003).
__label__noRel	dietary counseling was of similar or higher benefit, whereas even 3 months after RT, it was the only method to sustain a significant impact on patient outcomes.	During radiotherapy, both interventions positively influenced outcomes;
__label__noRel	Beyond tumor and nodal stage, Karnofsky performance status, primary site, cigarette use, use of concurrent chemotherapy, and altered fractionation schedules, the FACT-H&amp;N score was independently predictive of LRC (but not OS), with p = 0.0038.	The functional well-being component of the FACT-H&amp;N predicted most significantly for LRC (p = 0.0004).
__label__noRel	Beyond tumor and nodal stage, Karnofsky performance status, primary site, cigarette use, use of concurrent chemotherapy, and altered fractionation schedules, the FACT-H&amp;N score was independently predictive of LRC (but not OS), with p = 0.0038.	This study represents, to our knowledge, the largest analysis of HRQOL as a prognostic factor in locally advanced head and neck cancer patients.
__label__Support	Beyond tumor and nodal stage, Karnofsky performance status, primary site, cigarette use, use of concurrent chemotherapy, and altered fractionation schedules, the FACT-H&amp;N score was independently predictive of LRC (but not OS), with p = 0.0038.	The results of this study have demonstrated the importance of baseline HRQOL as a significant and independent predictor of LRC in patients with locally advanced head and neck cancer.
__label__noRel	The functional well-being component of the FACT-H&amp;N predicted most significantly for LRC (p = 0.0004).	Beyond tumor and nodal stage, Karnofsky performance status, primary site, cigarette use, use of concurrent chemotherapy, and altered fractionation schedules, the FACT-H&amp;N score was independently predictive of LRC (but not OS), with p = 0.0038.
__label__noRel	The functional well-being component of the FACT-H&amp;N predicted most significantly for LRC (p = 0.0004).	This study represents, to our knowledge, the largest analysis of HRQOL as a prognostic factor in locally advanced head and neck cancer patients.
__label__Support	The functional well-being component of the FACT-H&amp;N predicted most significantly for LRC (p = 0.0004).	The results of this study have demonstrated the importance of baseline HRQOL as a significant and independent predictor of LRC in patients with locally advanced head and neck cancer.
__label__noRel	This study represents, to our knowledge, the largest analysis of HRQOL as a prognostic factor in locally advanced head and neck cancer patients.	Beyond tumor and nodal stage, Karnofsky performance status, primary site, cigarette use, use of concurrent chemotherapy, and altered fractionation schedules, the FACT-H&amp;N score was independently predictive of LRC (but not OS), with p = 0.0038.
__label__noRel	This study represents, to our knowledge, the largest analysis of HRQOL as a prognostic factor in locally advanced head and neck cancer patients.	The functional well-being component of the FACT-H&amp;N predicted most significantly for LRC (p = 0.0004).
__label__noRel	This study represents, to our knowledge, the largest analysis of HRQOL as a prognostic factor in locally advanced head and neck cancer patients.	The results of this study have demonstrated the importance of baseline HRQOL as a significant and independent predictor of LRC in patients with locally advanced head and neck cancer.
__label__noRel	The results of this study have demonstrated the importance of baseline HRQOL as a significant and independent predictor of LRC in patients with locally advanced head and neck cancer.	Beyond tumor and nodal stage, Karnofsky performance status, primary site, cigarette use, use of concurrent chemotherapy, and altered fractionation schedules, the FACT-H&amp;N score was independently predictive of LRC (but not OS), with p = 0.0038.
__label__noRel	The results of this study have demonstrated the importance of baseline HRQOL as a significant and independent predictor of LRC in patients with locally advanced head and neck cancer.	The functional well-being component of the FACT-H&amp;N predicted most significantly for LRC (p = 0.0004).
__label__noRel	The results of this study have demonstrated the importance of baseline HRQOL as a significant and independent predictor of LRC in patients with locally advanced head and neck cancer.	This study represents, to our knowledge, the largest analysis of HRQOL as a prognostic factor in locally advanced head and neck cancer patients.
__label__noRel	The response rates, QOL, and median RD, TTP, and TTF were not significantly different between the arms.	Median OS was 13.8 months for arm 1 versus 14.4 months for arm 2 (P =.4).
__label__noRel	The response rates, QOL, and median RD, TTP, and TTF were not significantly different between the arms.	Grade 3 or 4 granulocytopenia was equivalent in both arms but more grade 3/4 neurotoxicity, mild venous toxicity, and FN were seen on arm 1.
__label__Support	The response rates, QOL, and median RD, TTP, and TTF were not significantly different between the arms.	The survival with DOX and VNB is not superior to DOX alone in MBC.
__label__noRel	Median OS was 13.8 months for arm 1 versus 14.4 months for arm 2 (P =.4).	The response rates, QOL, and median RD, TTP, and TTF were not significantly different between the arms.
__label__noRel	Median OS was 13.8 months for arm 1 versus 14.4 months for arm 2 (P =.4).	Grade 3 or 4 granulocytopenia was equivalent in both arms but more grade 3/4 neurotoxicity, mild venous toxicity, and FN were seen on arm 1.
__label__Support	Median OS was 13.8 months for arm 1 versus 14.4 months for arm 2 (P =.4).	The survival with DOX and VNB is not superior to DOX alone in MBC.
__label__noRel	Grade 3 or 4 granulocytopenia was equivalent in both arms but more grade 3/4 neurotoxicity, mild venous toxicity, and FN were seen on arm 1.	The response rates, QOL, and median RD, TTP, and TTF were not significantly different between the arms.
__label__noRel	Grade 3 or 4 granulocytopenia was equivalent in both arms but more grade 3/4 neurotoxicity, mild venous toxicity, and FN were seen on arm 1.	Median OS was 13.8 months for arm 1 versus 14.4 months for arm 2 (P =.4).
__label__noRel	Grade 3 or 4 granulocytopenia was equivalent in both arms but more grade 3/4 neurotoxicity, mild venous toxicity, and FN were seen on arm 1.	The survival with DOX and VNB is not superior to DOX alone in MBC.
__label__noRel	The survival with DOX and VNB is not superior to DOX alone in MBC.	The response rates, QOL, and median RD, TTP, and TTF were not significantly different between the arms.
__label__noRel	The survival with DOX and VNB is not superior to DOX alone in MBC.	Median OS was 13.8 months for arm 1 versus 14.4 months for arm 2 (P =.4).
__label__noRel	The survival with DOX and VNB is not superior to DOX alone in MBC.	Grade 3 or 4 granulocytopenia was equivalent in both arms but more grade 3/4 neurotoxicity, mild venous toxicity, and FN were seen on arm 1.
__label__noRel	There was no significant difference in HRQoL between nurse-led telephone and hospital follow-up at 12 months after treatment (p = 0.42; 95% confidence interval (CI) for difference: -1.93-4.64) and neither between follow-up with or without EGP (p = 0.86; 95% CI for difference: -3.59-3.00).	no differences between the intervention groups and their corresponding control groups were found in role and emotional functioning, and feelings of control and anxiety (all p-values > 0.05).
__label__Support	There was no significant difference in HRQoL between nurse-led telephone and hospital follow-up at 12 months after treatment (p = 0.42; 95% confidence interval (CI) for difference: -1.93-4.64) and neither between follow-up with or without EGP (p = 0.86; 95% CI for difference: -3.59-3.00).	Replacement of most hospital follow-up visits in the first year after breast cancer treatment by nurse-led telephone follow-up does not impede patient outcomes.
__label__noRel	There was no significant difference in HRQoL between nurse-led telephone and hospital follow-up at 12 months after treatment (p = 0.42; 95% confidence interval (CI) for difference: -1.93-4.64) and neither between follow-up with or without EGP (p = 0.86; 95% CI for difference: -3.59-3.00).	nurse-led telephone follow-up seems an appropriate way to reduce clinic visits and represents an accepted alternative strategy.
__label__noRel	no differences between the intervention groups and their corresponding control groups were found in role and emotional functioning, and feelings of control and anxiety (all p-values > 0.05).	There was no significant difference in HRQoL between nurse-led telephone and hospital follow-up at 12 months after treatment (p = 0.42; 95% confidence interval (CI) for difference: -1.93-4.64) and neither between follow-up with or without EGP (p = 0.86; 95% CI for difference: -3.59-3.00).
__label__Support	no differences between the intervention groups and their corresponding control groups were found in role and emotional functioning, and feelings of control and anxiety (all p-values > 0.05).	Replacement of most hospital follow-up visits in the first year after breast cancer treatment by nurse-led telephone follow-up does not impede patient outcomes.
__label__noRel	no differences between the intervention groups and their corresponding control groups were found in role and emotional functioning, and feelings of control and anxiety (all p-values > 0.05).	nurse-led telephone follow-up seems an appropriate way to reduce clinic visits and represents an accepted alternative strategy.
__label__noRel	Replacement of most hospital follow-up visits in the first year after breast cancer treatment by nurse-led telephone follow-up does not impede patient outcomes.	There was no significant difference in HRQoL between nurse-led telephone and hospital follow-up at 12 months after treatment (p = 0.42; 95% confidence interval (CI) for difference: -1.93-4.64) and neither between follow-up with or without EGP (p = 0.86; 95% CI for difference: -3.59-3.00).
__label__noRel	Replacement of most hospital follow-up visits in the first year after breast cancer treatment by nurse-led telephone follow-up does not impede patient outcomes.	no differences between the intervention groups and their corresponding control groups were found in role and emotional functioning, and feelings of control and anxiety (all p-values > 0.05).
__label__Support	Replacement of most hospital follow-up visits in the first year after breast cancer treatment by nurse-led telephone follow-up does not impede patient outcomes.	nurse-led telephone follow-up seems an appropriate way to reduce clinic visits and represents an accepted alternative strategy.
__label__noRel	nurse-led telephone follow-up seems an appropriate way to reduce clinic visits and represents an accepted alternative strategy.	There was no significant difference in HRQoL between nurse-led telephone and hospital follow-up at 12 months after treatment (p = 0.42; 95% confidence interval (CI) for difference: -1.93-4.64) and neither between follow-up with or without EGP (p = 0.86; 95% CI for difference: -3.59-3.00).
__label__noRel	nurse-led telephone follow-up seems an appropriate way to reduce clinic visits and represents an accepted alternative strategy.	no differences between the intervention groups and their corresponding control groups were found in role and emotional functioning, and feelings of control and anxiety (all p-values > 0.05).
__label__noRel	nurse-led telephone follow-up seems an appropriate way to reduce clinic visits and represents an accepted alternative strategy.	Replacement of most hospital follow-up visits in the first year after breast cancer treatment by nurse-led telephone follow-up does not impede patient outcomes.
__label__noRel	Amenorrhea 12 months after random assignment was significantly different between treatment groups: 69.8% for ACT, 57.7% for TAC, and 37.9% for AT (P < .001).	The AT group without tamoxifen had the lowest rate of amenorrhea.
__label__noRel	Amenorrhea 12 months after random assignment was significantly different between treatment groups: 69.8% for ACT, 57.7% for TAC, and 37.9% for AT (P < .001).	QOL was poorer for patients receiving ACT at 6 months but similar to others by 12 months.
__label__noRel	Amenorrhea 12 months after random assignment was significantly different between treatment groups: 69.8% for ACT, 57.7% for TAC, and 37.9% for AT (P < .001).	Post-treatment symptoms were increased above baseline for all treatments.
__label__noRel	Amenorrhea 12 months after random assignment was significantly different between treatment groups: 69.8% for ACT, 57.7% for TAC, and 37.9% for AT (P < .001).	Multivariable repeated measures modeling demonstrated that treatment arm, time point, age, and tamoxifen use were significantly associated with symptom severity (all P values < .002).
__label__Support	Amenorrhea 12 months after random assignment was significantly different between treatment groups: 69.8% for ACT, 57.7% for TAC, and 37.9% for AT (P < .001).	Amenorrhea rates differed significantly by treatment arm, with the AT arm having the lowest rate.
__label__noRel	Amenorrhea 12 months after random assignment was significantly different between treatment groups: 69.8% for ACT, 57.7% for TAC, and 37.9% for AT (P < .001).	Patients treated with longer duration therapy (ACT) had greater symptom severity and poorer QOL at 6 months, but did not differ from shorter duration treatments at 12 months.
__label__noRel	The AT group without tamoxifen had the lowest rate of amenorrhea.	Amenorrhea 12 months after random assignment was significantly different between treatment groups: 69.8% for ACT, 57.7% for TAC, and 37.9% for AT (P < .001).
__label__noRel	The AT group without tamoxifen had the lowest rate of amenorrhea.	QOL was poorer for patients receiving ACT at 6 months but similar to others by 12 months.
__label__noRel	The AT group without tamoxifen had the lowest rate of amenorrhea.	Post-treatment symptoms were increased above baseline for all treatments.
__label__noRel	The AT group without tamoxifen had the lowest rate of amenorrhea.	Multivariable repeated measures modeling demonstrated that treatment arm, time point, age, and tamoxifen use were significantly associated with symptom severity (all P values < .002).
__label__Support	The AT group without tamoxifen had the lowest rate of amenorrhea.	Amenorrhea rates differed significantly by treatment arm, with the AT arm having the lowest rate.
__label__noRel	The AT group without tamoxifen had the lowest rate of amenorrhea.	Patients treated with longer duration therapy (ACT) had greater symptom severity and poorer QOL at 6 months, but did not differ from shorter duration treatments at 12 months.
__label__noRel	QOL was poorer for patients receiving ACT at 6 months but similar to others by 12 months.	Amenorrhea 12 months after random assignment was significantly different between treatment groups: 69.8% for ACT, 57.7% for TAC, and 37.9% for AT (P < .001).
__label__noRel	QOL was poorer for patients receiving ACT at 6 months but similar to others by 12 months.	The AT group without tamoxifen had the lowest rate of amenorrhea.
__label__noRel	QOL was poorer for patients receiving ACT at 6 months but similar to others by 12 months.	Post-treatment symptoms were increased above baseline for all treatments.
__label__noRel	QOL was poorer for patients receiving ACT at 6 months but similar to others by 12 months.	Multivariable repeated measures modeling demonstrated that treatment arm, time point, age, and tamoxifen use were significantly associated with symptom severity (all P values < .002).
__label__noRel	QOL was poorer for patients receiving ACT at 6 months but similar to others by 12 months.	Amenorrhea rates differed significantly by treatment arm, with the AT arm having the lowest rate.
__label__Support	QOL was poorer for patients receiving ACT at 6 months but similar to others by 12 months.	Patients treated with longer duration therapy (ACT) had greater symptom severity and poorer QOL at 6 months, but did not differ from shorter duration treatments at 12 months.
__label__noRel	Post-treatment symptoms were increased above baseline for all treatments.	Amenorrhea 12 months after random assignment was significantly different between treatment groups: 69.8% for ACT, 57.7% for TAC, and 37.9% for AT (P < .001).
__label__noRel	Post-treatment symptoms were increased above baseline for all treatments.	The AT group without tamoxifen had the lowest rate of amenorrhea.
__label__noRel	Post-treatment symptoms were increased above baseline for all treatments.	QOL was poorer for patients receiving ACT at 6 months but similar to others by 12 months.
__label__noRel	Post-treatment symptoms were increased above baseline for all treatments.	Multivariable repeated measures modeling demonstrated that treatment arm, time point, age, and tamoxifen use were significantly associated with symptom severity (all P values < .002).
__label__noRel	Post-treatment symptoms were increased above baseline for all treatments.	Amenorrhea rates differed significantly by treatment arm, with the AT arm having the lowest rate.
__label__Support	Post-treatment symptoms were increased above baseline for all treatments.	Patients treated with longer duration therapy (ACT) had greater symptom severity and poorer QOL at 6 months, but did not differ from shorter duration treatments at 12 months.
__label__noRel	Multivariable repeated measures modeling demonstrated that treatment arm, time point, age, and tamoxifen use were significantly associated with symptom severity (all P values < .002).	Amenorrhea 12 months after random assignment was significantly different between treatment groups: 69.8% for ACT, 57.7% for TAC, and 37.9% for AT (P < .001).
__label__noRel	Multivariable repeated measures modeling demonstrated that treatment arm, time point, age, and tamoxifen use were significantly associated with symptom severity (all P values < .002).	The AT group without tamoxifen had the lowest rate of amenorrhea.
__label__noRel	Multivariable repeated measures modeling demonstrated that treatment arm, time point, age, and tamoxifen use were significantly associated with symptom severity (all P values < .002).	QOL was poorer for patients receiving ACT at 6 months but similar to others by 12 months.
__label__noRel	Multivariable repeated measures modeling demonstrated that treatment arm, time point, age, and tamoxifen use were significantly associated with symptom severity (all P values < .002).	Post-treatment symptoms were increased above baseline for all treatments.
__label__noRel	Multivariable repeated measures modeling demonstrated that treatment arm, time point, age, and tamoxifen use were significantly associated with symptom severity (all P values < .002).	Amenorrhea rates differed significantly by treatment arm, with the AT arm having the lowest rate.
__label__Support	Multivariable repeated measures modeling demonstrated that treatment arm, time point, age, and tamoxifen use were significantly associated with symptom severity (all P values < .002).	Patients treated with longer duration therapy (ACT) had greater symptom severity and poorer QOL at 6 months, but did not differ from shorter duration treatments at 12 months.
__label__noRel	Amenorrhea rates differed significantly by treatment arm, with the AT arm having the lowest rate.	Amenorrhea 12 months after random assignment was significantly different between treatment groups: 69.8% for ACT, 57.7% for TAC, and 37.9% for AT (P < .001).
__label__noRel	Amenorrhea rates differed significantly by treatment arm, with the AT arm having the lowest rate.	The AT group without tamoxifen had the lowest rate of amenorrhea.
__label__noRel	Amenorrhea rates differed significantly by treatment arm, with the AT arm having the lowest rate.	QOL was poorer for patients receiving ACT at 6 months but similar to others by 12 months.
__label__noRel	Amenorrhea rates differed significantly by treatment arm, with the AT arm having the lowest rate.	Post-treatment symptoms were increased above baseline for all treatments.
__label__noRel	Amenorrhea rates differed significantly by treatment arm, with the AT arm having the lowest rate.	Multivariable repeated measures modeling demonstrated that treatment arm, time point, age, and tamoxifen use were significantly associated with symptom severity (all P values < .002).
__label__noRel	Amenorrhea rates differed significantly by treatment arm, with the AT arm having the lowest rate.	Patients treated with longer duration therapy (ACT) had greater symptom severity and poorer QOL at 6 months, but did not differ from shorter duration treatments at 12 months.
__label__noRel	Patients treated with longer duration therapy (ACT) had greater symptom severity and poorer QOL at 6 months, but did not differ from shorter duration treatments at 12 months.	Amenorrhea 12 months after random assignment was significantly different between treatment groups: 69.8% for ACT, 57.7% for TAC, and 37.9% for AT (P < .001).
__label__noRel	Patients treated with longer duration therapy (ACT) had greater symptom severity and poorer QOL at 6 months, but did not differ from shorter duration treatments at 12 months.	The AT group without tamoxifen had the lowest rate of amenorrhea.
__label__noRel	Patients treated with longer duration therapy (ACT) had greater symptom severity and poorer QOL at 6 months, but did not differ from shorter duration treatments at 12 months.	QOL was poorer for patients receiving ACT at 6 months but similar to others by 12 months.
__label__noRel	Patients treated with longer duration therapy (ACT) had greater symptom severity and poorer QOL at 6 months, but did not differ from shorter duration treatments at 12 months.	Post-treatment symptoms were increased above baseline for all treatments.
__label__noRel	Patients treated with longer duration therapy (ACT) had greater symptom severity and poorer QOL at 6 months, but did not differ from shorter duration treatments at 12 months.	Multivariable repeated measures modeling demonstrated that treatment arm, time point, age, and tamoxifen use were significantly associated with symptom severity (all P values < .002).
__label__noRel	Patients treated with longer duration therapy (ACT) had greater symptom severity and poorer QOL at 6 months, but did not differ from shorter duration treatments at 12 months.	Amenorrhea rates differed significantly by treatment arm, with the AT arm having the lowest rate.
__label__noRel	Previous trials have suggested a quality-of-life (QOL) improvement for anemic cancer patients treated with erythropoietin, but few used QOL as the primary outcome.	This revealed a significant difference in the median survival in favor of the patients on the placebo arm of the trial (63 v 129 days; hazard ratio, 1.84; P = .04).
__label__noRel	Previous trials have suggested a quality-of-life (QOL) improvement for anemic cancer patients treated with erythropoietin, but few used QOL as the primary outcome.	Patient numbers compromised the interpretation of the QOL analysis,
__label__noRel	Previous trials have suggested a quality-of-life (QOL) improvement for anemic cancer patients treated with erythropoietin, but few used QOL as the primary outcome.	a positive Hgb response was noted with epoetin alfa treatment.
__label__noRel	Previous trials have suggested a quality-of-life (QOL) improvement for anemic cancer patients treated with erythropoietin, but few used QOL as the primary outcome.	An unplanned safety analysis suggested decreased overall survival in patients with advanced NSCLC treated with epoetin alfa.
__label__noRel	This revealed a significant difference in the median survival in favor of the patients on the placebo arm of the trial (63 v 129 days; hazard ratio, 1.84; P = .04).	Previous trials have suggested a quality-of-life (QOL) improvement for anemic cancer patients treated with erythropoietin, but few used QOL as the primary outcome.
__label__noRel	This revealed a significant difference in the median survival in favor of the patients on the placebo arm of the trial (63 v 129 days; hazard ratio, 1.84; P = .04).	Patient numbers compromised the interpretation of the QOL analysis,
__label__noRel	This revealed a significant difference in the median survival in favor of the patients on the placebo arm of the trial (63 v 129 days; hazard ratio, 1.84; P = .04).	a positive Hgb response was noted with epoetin alfa treatment.
__label__Support	This revealed a significant difference in the median survival in favor of the patients on the placebo arm of the trial (63 v 129 days; hazard ratio, 1.84; P = .04).	An unplanned safety analysis suggested decreased overall survival in patients with advanced NSCLC treated with epoetin alfa.
__label__noRel	Patient numbers compromised the interpretation of the QOL analysis,	Previous trials have suggested a quality-of-life (QOL) improvement for anemic cancer patients treated with erythropoietin, but few used QOL as the primary outcome.
__label__noRel	Patient numbers compromised the interpretation of the QOL analysis,	This revealed a significant difference in the median survival in favor of the patients on the placebo arm of the trial (63 v 129 days; hazard ratio, 1.84; P = .04).
__label__noRel	Patient numbers compromised the interpretation of the QOL analysis,	a positive Hgb response was noted with epoetin alfa treatment.
__label__Attack	Patient numbers compromised the interpretation of the QOL analysis,	An unplanned safety analysis suggested decreased overall survival in patients with advanced NSCLC treated with epoetin alfa.
__label__noRel	a positive Hgb response was noted with epoetin alfa treatment.	Previous trials have suggested a quality-of-life (QOL) improvement for anemic cancer patients treated with erythropoietin, but few used QOL as the primary outcome.
__label__noRel	a positive Hgb response was noted with epoetin alfa treatment.	This revealed a significant difference in the median survival in favor of the patients on the placebo arm of the trial (63 v 129 days; hazard ratio, 1.84; P = .04).
__label__noRel	a positive Hgb response was noted with epoetin alfa treatment.	Patient numbers compromised the interpretation of the QOL analysis,
__label__Support	a positive Hgb response was noted with epoetin alfa treatment.	An unplanned safety analysis suggested decreased overall survival in patients with advanced NSCLC treated with epoetin alfa.
__label__noRel	An unplanned safety analysis suggested decreased overall survival in patients with advanced NSCLC treated with epoetin alfa.	Previous trials have suggested a quality-of-life (QOL) improvement for anemic cancer patients treated with erythropoietin, but few used QOL as the primary outcome.
__label__noRel	An unplanned safety analysis suggested decreased overall survival in patients with advanced NSCLC treated with epoetin alfa.	This revealed a significant difference in the median survival in favor of the patients on the placebo arm of the trial (63 v 129 days; hazard ratio, 1.84; P = .04).
__label__noRel	An unplanned safety analysis suggested decreased overall survival in patients with advanced NSCLC treated with epoetin alfa.	Patient numbers compromised the interpretation of the QOL analysis,
__label__noRel	An unplanned safety analysis suggested decreased overall survival in patients with advanced NSCLC treated with epoetin alfa.	a positive Hgb response was noted with epoetin alfa treatment.
__label__noRel	An objective response (complete [CR] or partial [PR]) was obtained in 55%, 48%, 16%, and 7% of patients treated with CEF, E, M, and MV, respectively.	A response to CEF tended to last longer than a response to E (median, 12 v 10.5 months; P = .07).
__label__noRel	An objective response (complete [CR] or partial [PR]) was obtained in 55%, 48%, 16%, and 7% of patients treated with CEF, E, M, and MV, respectively.	Treatment-related toxicity was less in the single-agent arm and quality-of-life (QOL) analysis favored the single-agent arm.
__label__noRel	An objective response (complete [CR] or partial [PR]) was obtained in 55%, 48%, 16%, and 7% of patients treated with CEF, E, M, and MV, respectively.	No significant difference in time to progression or survival was found between the two arms.
__label__noRel	An objective response (complete [CR] or partial [PR]) was obtained in 55%, 48%, 16%, and 7% of patients treated with CEF, E, M, and MV, respectively.	Similarly, no difference in survival was found when the patients who received both the planned first-and second-line treatments were compared or when survival was calculated from the beginning of the second-line therapy.
__label__noRel	An objective response (complete [CR] or partial [PR]) was obtained in 55%, 48%, 16%, and 7% of patients treated with CEF, E, M, and MV, respectively.	Patients treated with single-agent E followed by single-agent M had similar survival, but less treatment-related toxicity and better QOL as compared with those treated with CEF followed by MV.
__label__noRel	A response to CEF tended to last longer than a response to E (median, 12 v 10.5 months; P = .07).	An objective response (complete [CR] or partial [PR]) was obtained in 55%, 48%, 16%, and 7% of patients treated with CEF, E, M, and MV, respectively.
__label__noRel	A response to CEF tended to last longer than a response to E (median, 12 v 10.5 months; P = .07).	Treatment-related toxicity was less in the single-agent arm and quality-of-life (QOL) analysis favored the single-agent arm.
__label__noRel	A response to CEF tended to last longer than a response to E (median, 12 v 10.5 months; P = .07).	No significant difference in time to progression or survival was found between the two arms.
__label__noRel	A response to CEF tended to last longer than a response to E (median, 12 v 10.5 months; P = .07).	Similarly, no difference in survival was found when the patients who received both the planned first-and second-line treatments were compared or when survival was calculated from the beginning of the second-line therapy.
__label__noRel	A response to CEF tended to last longer than a response to E (median, 12 v 10.5 months; P = .07).	Patients treated with single-agent E followed by single-agent M had similar survival, but less treatment-related toxicity and better QOL as compared with those treated with CEF followed by MV.
__label__noRel	Treatment-related toxicity was less in the single-agent arm and quality-of-life (QOL) analysis favored the single-agent arm.	An objective response (complete [CR] or partial [PR]) was obtained in 55%, 48%, 16%, and 7% of patients treated with CEF, E, M, and MV, respectively.
__label__noRel	Treatment-related toxicity was less in the single-agent arm and quality-of-life (QOL) analysis favored the single-agent arm.	A response to CEF tended to last longer than a response to E (median, 12 v 10.5 months; P = .07).
__label__noRel	Treatment-related toxicity was less in the single-agent arm and quality-of-life (QOL) analysis favored the single-agent arm.	No significant difference in time to progression or survival was found between the two arms.
__label__noRel	Treatment-related toxicity was less in the single-agent arm and quality-of-life (QOL) analysis favored the single-agent arm.	Similarly, no difference in survival was found when the patients who received both the planned first-and second-line treatments were compared or when survival was calculated from the beginning of the second-line therapy.
__label__Support	Treatment-related toxicity was less in the single-agent arm and quality-of-life (QOL) analysis favored the single-agent arm.	Patients treated with single-agent E followed by single-agent M had similar survival, but less treatment-related toxicity and better QOL as compared with those treated with CEF followed by MV.
__label__noRel	No significant difference in time to progression or survival was found between the two arms.	An objective response (complete [CR] or partial [PR]) was obtained in 55%, 48%, 16%, and 7% of patients treated with CEF, E, M, and MV, respectively.
__label__noRel	No significant difference in time to progression or survival was found between the two arms.	A response to CEF tended to last longer than a response to E (median, 12 v 10.5 months; P = .07).
__label__noRel	No significant difference in time to progression or survival was found between the two arms.	Treatment-related toxicity was less in the single-agent arm and quality-of-life (QOL) analysis favored the single-agent arm.
__label__noRel	No significant difference in time to progression or survival was found between the two arms.	Similarly, no difference in survival was found when the patients who received both the planned first-and second-line treatments were compared or when survival was calculated from the beginning of the second-line therapy.
__label__Support	No significant difference in time to progression or survival was found between the two arms.	Patients treated with single-agent E followed by single-agent M had similar survival, but less treatment-related toxicity and better QOL as compared with those treated with CEF followed by MV.
__label__noRel	Similarly, no difference in survival was found when the patients who received both the planned first-and second-line treatments were compared or when survival was calculated from the beginning of the second-line therapy.	An objective response (complete [CR] or partial [PR]) was obtained in 55%, 48%, 16%, and 7% of patients treated with CEF, E, M, and MV, respectively.
__label__noRel	Similarly, no difference in survival was found when the patients who received both the planned first-and second-line treatments were compared or when survival was calculated from the beginning of the second-line therapy.	A response to CEF tended to last longer than a response to E (median, 12 v 10.5 months; P = .07).
__label__noRel	Similarly, no difference in survival was found when the patients who received both the planned first-and second-line treatments were compared or when survival was calculated from the beginning of the second-line therapy.	Treatment-related toxicity was less in the single-agent arm and quality-of-life (QOL) analysis favored the single-agent arm.
__label__noRel	Similarly, no difference in survival was found when the patients who received both the planned first-and second-line treatments were compared or when survival was calculated from the beginning of the second-line therapy.	No significant difference in time to progression or survival was found between the two arms.
__label__Support	Similarly, no difference in survival was found when the patients who received both the planned first-and second-line treatments were compared or when survival was calculated from the beginning of the second-line therapy.	Patients treated with single-agent E followed by single-agent M had similar survival, but less treatment-related toxicity and better QOL as compared with those treated with CEF followed by MV.
__label__noRel	Patients treated with single-agent E followed by single-agent M had similar survival, but less treatment-related toxicity and better QOL as compared with those treated with CEF followed by MV.	An objective response (complete [CR] or partial [PR]) was obtained in 55%, 48%, 16%, and 7% of patients treated with CEF, E, M, and MV, respectively.
__label__noRel	Patients treated with single-agent E followed by single-agent M had similar survival, but less treatment-related toxicity and better QOL as compared with those treated with CEF followed by MV.	A response to CEF tended to last longer than a response to E (median, 12 v 10.5 months; P = .07).
__label__noRel	Patients treated with single-agent E followed by single-agent M had similar survival, but less treatment-related toxicity and better QOL as compared with those treated with CEF followed by MV.	Treatment-related toxicity was less in the single-agent arm and quality-of-life (QOL) analysis favored the single-agent arm.
__label__noRel	Patients treated with single-agent E followed by single-agent M had similar survival, but less treatment-related toxicity and better QOL as compared with those treated with CEF followed by MV.	No significant difference in time to progression or survival was found between the two arms.
__label__noRel	Patients treated with single-agent E followed by single-agent M had similar survival, but less treatment-related toxicity and better QOL as compared with those treated with CEF followed by MV.	Similarly, no difference in survival was found when the patients who received both the planned first-and second-line treatments were compared or when survival was calculated from the beginning of the second-line therapy.
__label__noRel	On average, there were significantly higher volumes of tris-acryl microspheres used (9.0 mL vs 3.0 mL; P =.0001),	microcatheter occlusion was more common with PVA (28% vs 4%, P =.001).
__label__noRel	On average, there were significantly higher volumes of tris-acryl microspheres used (9.0 mL vs 3.0 mL; P =.0001),	There were no differences in pain severity, other postprocedural symptoms, or medication use between the two treatment groups.
__label__noRel	On average, there were significantly higher volumes of tris-acryl microspheres used (9.0 mL vs 3.0 mL; P =.0001),	There were also no differences in the frequency of incompletely infarcted leiomyomas, degree of improvement in symptom score, patient satisfaction, or QOL.
__label__Support	On average, there were significantly higher volumes of tris-acryl microspheres used (9.0 mL vs 3.0 mL; P =.0001),	No substantive differences were detected between outcomes of embolization with PVA particles or tris-acryl gelatin microspheres.
__label__noRel	microcatheter occlusion was more common with PVA (28% vs 4%, P =.001).	On average, there were significantly higher volumes of tris-acryl microspheres used (9.0 mL vs 3.0 mL; P =.0001),
__label__noRel	microcatheter occlusion was more common with PVA (28% vs 4%, P =.001).	There were no differences in pain severity, other postprocedural symptoms, or medication use between the two treatment groups.
__label__noRel	microcatheter occlusion was more common with PVA (28% vs 4%, P =.001).	There were also no differences in the frequency of incompletely infarcted leiomyomas, degree of improvement in symptom score, patient satisfaction, or QOL.
__label__noRel	microcatheter occlusion was more common with PVA (28% vs 4%, P =.001).	No substantive differences were detected between outcomes of embolization with PVA particles or tris-acryl gelatin microspheres.
__label__noRel	There were no differences in pain severity, other postprocedural symptoms, or medication use between the two treatment groups.	On average, there were significantly higher volumes of tris-acryl microspheres used (9.0 mL vs 3.0 mL; P =.0001),
__label__noRel	There were no differences in pain severity, other postprocedural symptoms, or medication use between the two treatment groups.	microcatheter occlusion was more common with PVA (28% vs 4%, P =.001).
__label__noRel	There were no differences in pain severity, other postprocedural symptoms, or medication use between the two treatment groups.	There were also no differences in the frequency of incompletely infarcted leiomyomas, degree of improvement in symptom score, patient satisfaction, or QOL.
__label__Support	There were no differences in pain severity, other postprocedural symptoms, or medication use between the two treatment groups.	No substantive differences were detected between outcomes of embolization with PVA particles or tris-acryl gelatin microspheres.
__label__noRel	There were also no differences in the frequency of incompletely infarcted leiomyomas, degree of improvement in symptom score, patient satisfaction, or QOL.	On average, there were significantly higher volumes of tris-acryl microspheres used (9.0 mL vs 3.0 mL; P =.0001),
__label__noRel	There were also no differences in the frequency of incompletely infarcted leiomyomas, degree of improvement in symptom score, patient satisfaction, or QOL.	microcatheter occlusion was more common with PVA (28% vs 4%, P =.001).
__label__noRel	There were also no differences in the frequency of incompletely infarcted leiomyomas, degree of improvement in symptom score, patient satisfaction, or QOL.	There were no differences in pain severity, other postprocedural symptoms, or medication use between the two treatment groups.
__label__Support	There were also no differences in the frequency of incompletely infarcted leiomyomas, degree of improvement in symptom score, patient satisfaction, or QOL.	No substantive differences were detected between outcomes of embolization with PVA particles or tris-acryl gelatin microspheres.
__label__noRel	No substantive differences were detected between outcomes of embolization with PVA particles or tris-acryl gelatin microspheres.	On average, there were significantly higher volumes of tris-acryl microspheres used (9.0 mL vs 3.0 mL; P =.0001),
__label__noRel	No substantive differences were detected between outcomes of embolization with PVA particles or tris-acryl gelatin microspheres.	microcatheter occlusion was more common with PVA (28% vs 4%, P =.001).
__label__noRel	No substantive differences were detected between outcomes of embolization with PVA particles or tris-acryl gelatin microspheres.	There were no differences in pain severity, other postprocedural symptoms, or medication use between the two treatment groups.
__label__noRel	No substantive differences were detected between outcomes of embolization with PVA particles or tris-acryl gelatin microspheres.	There were also no differences in the frequency of incompletely infarcted leiomyomas, degree of improvement in symptom score, patient satisfaction, or QOL.
__label__noRel	The nutrition intervention group had a higher mean total energy (P=0.029) and protein intake (P<0.001) compared with the standard practice group.	Mean intake per kilogram of body weight for the nutrition intervention group ranged from 28 to 31 kcal/kg/day compared with 25 to 29 kcal/kg/day for the standard practice group (P=0.022).
__label__noRel	The nutrition intervention group had a higher mean total energy (P=0.029) and protein intake (P<0.001) compared with the standard practice group.	The nutrition intervention group had a higher mean protein intake (1.1 to 1.3 g/kg/day) compared with the standard practice group (1.0 to 1.1 g/kg/day) (P=0.001).
__label__noRel	The nutrition intervention group had a higher mean total energy (P=0.029) and protein intake (P<0.001) compared with the standard practice group.	Although the change in fiber intake between the groups was not significant,
__label__noRel	The nutrition intervention group had a higher mean total energy (P=0.029) and protein intake (P<0.001) compared with the standard practice group.	there was a trend in the anticipated direction (P=0.083).
__label__Support	The nutrition intervention group had a higher mean total energy (P=0.029) and protein intake (P<0.001) compared with the standard practice group.	Intensive nutrition intervention following the ADA MNT protocol results in improved dietary intake compared with standard practice and seems to beneficially impact nutrition-related outcomes previously observed in oncology outpatients receiving radiotherapy.
__label__noRel	The nutrition intervention group had a higher mean total energy (P=0.029) and protein intake (P<0.001) compared with the standard practice group.	The ADA MNT protocol for radiation oncology is a useful guide to the level of nutrition support required.
__label__noRel	Mean intake per kilogram of body weight for the nutrition intervention group ranged from 28 to 31 kcal/kg/day compared with 25 to 29 kcal/kg/day for the standard practice group (P=0.022).	The nutrition intervention group had a higher mean total energy (P=0.029) and protein intake (P<0.001) compared with the standard practice group.
__label__noRel	Mean intake per kilogram of body weight for the nutrition intervention group ranged from 28 to 31 kcal/kg/day compared with 25 to 29 kcal/kg/day for the standard practice group (P=0.022).	The nutrition intervention group had a higher mean protein intake (1.1 to 1.3 g/kg/day) compared with the standard practice group (1.0 to 1.1 g/kg/day) (P=0.001).
__label__noRel	Mean intake per kilogram of body weight for the nutrition intervention group ranged from 28 to 31 kcal/kg/day compared with 25 to 29 kcal/kg/day for the standard practice group (P=0.022).	Although the change in fiber intake between the groups was not significant,
__label__noRel	Mean intake per kilogram of body weight for the nutrition intervention group ranged from 28 to 31 kcal/kg/day compared with 25 to 29 kcal/kg/day for the standard practice group (P=0.022).	there was a trend in the anticipated direction (P=0.083).
__label__Support	Mean intake per kilogram of body weight for the nutrition intervention group ranged from 28 to 31 kcal/kg/day compared with 25 to 29 kcal/kg/day for the standard practice group (P=0.022).	Intensive nutrition intervention following the ADA MNT protocol results in improved dietary intake compared with standard practice and seems to beneficially impact nutrition-related outcomes previously observed in oncology outpatients receiving radiotherapy.
__label__noRel	Mean intake per kilogram of body weight for the nutrition intervention group ranged from 28 to 31 kcal/kg/day compared with 25 to 29 kcal/kg/day for the standard practice group (P=0.022).	The ADA MNT protocol for radiation oncology is a useful guide to the level of nutrition support required.
__label__noRel	The nutrition intervention group had a higher mean protein intake (1.1 to 1.3 g/kg/day) compared with the standard practice group (1.0 to 1.1 g/kg/day) (P=0.001).	The nutrition intervention group had a higher mean total energy (P=0.029) and protein intake (P<0.001) compared with the standard practice group.
__label__noRel	The nutrition intervention group had a higher mean protein intake (1.1 to 1.3 g/kg/day) compared with the standard practice group (1.0 to 1.1 g/kg/day) (P=0.001).	Mean intake per kilogram of body weight for the nutrition intervention group ranged from 28 to 31 kcal/kg/day compared with 25 to 29 kcal/kg/day for the standard practice group (P=0.022).
__label__noRel	The nutrition intervention group had a higher mean protein intake (1.1 to 1.3 g/kg/day) compared with the standard practice group (1.0 to 1.1 g/kg/day) (P=0.001).	Although the change in fiber intake between the groups was not significant,
__label__noRel	The nutrition intervention group had a higher mean protein intake (1.1 to 1.3 g/kg/day) compared with the standard practice group (1.0 to 1.1 g/kg/day) (P=0.001).	there was a trend in the anticipated direction (P=0.083).
__label__Support	The nutrition intervention group had a higher mean protein intake (1.1 to 1.3 g/kg/day) compared with the standard practice group (1.0 to 1.1 g/kg/day) (P=0.001).	Intensive nutrition intervention following the ADA MNT protocol results in improved dietary intake compared with standard practice and seems to beneficially impact nutrition-related outcomes previously observed in oncology outpatients receiving radiotherapy.
__label__noRel	The nutrition intervention group had a higher mean protein intake (1.1 to 1.3 g/kg/day) compared with the standard practice group (1.0 to 1.1 g/kg/day) (P=0.001).	The ADA MNT protocol for radiation oncology is a useful guide to the level of nutrition support required.
__label__noRel	Although the change in fiber intake between the groups was not significant,	The nutrition intervention group had a higher mean total energy (P=0.029) and protein intake (P<0.001) compared with the standard practice group.
__label__noRel	Although the change in fiber intake between the groups was not significant,	Mean intake per kilogram of body weight for the nutrition intervention group ranged from 28 to 31 kcal/kg/day compared with 25 to 29 kcal/kg/day for the standard practice group (P=0.022).
__label__noRel	Although the change in fiber intake between the groups was not significant,	The nutrition intervention group had a higher mean protein intake (1.1 to 1.3 g/kg/day) compared with the standard practice group (1.0 to 1.1 g/kg/day) (P=0.001).
__label__Attack	Although the change in fiber intake between the groups was not significant,	there was a trend in the anticipated direction (P=0.083).
__label__noRel	Although the change in fiber intake between the groups was not significant,	Intensive nutrition intervention following the ADA MNT protocol results in improved dietary intake compared with standard practice and seems to beneficially impact nutrition-related outcomes previously observed in oncology outpatients receiving radiotherapy.
__label__noRel	Although the change in fiber intake between the groups was not significant,	The ADA MNT protocol for radiation oncology is a useful guide to the level of nutrition support required.
__label__noRel	there was a trend in the anticipated direction (P=0.083).	The nutrition intervention group had a higher mean total energy (P=0.029) and protein intake (P<0.001) compared with the standard practice group.
__label__noRel	there was a trend in the anticipated direction (P=0.083).	Mean intake per kilogram of body weight for the nutrition intervention group ranged from 28 to 31 kcal/kg/day compared with 25 to 29 kcal/kg/day for the standard practice group (P=0.022).
__label__Attack	there was a trend in the anticipated direction (P=0.083).	The nutrition intervention group had a higher mean protein intake (1.1 to 1.3 g/kg/day) compared with the standard practice group (1.0 to 1.1 g/kg/day) (P=0.001).
__label__noRel	there was a trend in the anticipated direction (P=0.083).	Although the change in fiber intake between the groups was not significant,
__label__noRel	there was a trend in the anticipated direction (P=0.083).	Intensive nutrition intervention following the ADA MNT protocol results in improved dietary intake compared with standard practice and seems to beneficially impact nutrition-related outcomes previously observed in oncology outpatients receiving radiotherapy.
__label__noRel	there was a trend in the anticipated direction (P=0.083).	The ADA MNT protocol for radiation oncology is a useful guide to the level of nutrition support required.
__label__noRel	Intensive nutrition intervention following the ADA MNT protocol results in improved dietary intake compared with standard practice and seems to beneficially impact nutrition-related outcomes previously observed in oncology outpatients receiving radiotherapy.	The nutrition intervention group had a higher mean total energy (P=0.029) and protein intake (P<0.001) compared with the standard practice group.
__label__noRel	Intensive nutrition intervention following the ADA MNT protocol results in improved dietary intake compared with standard practice and seems to beneficially impact nutrition-related outcomes previously observed in oncology outpatients receiving radiotherapy.	Mean intake per kilogram of body weight for the nutrition intervention group ranged from 28 to 31 kcal/kg/day compared with 25 to 29 kcal/kg/day for the standard practice group (P=0.022).
__label__noRel	Intensive nutrition intervention following the ADA MNT protocol results in improved dietary intake compared with standard practice and seems to beneficially impact nutrition-related outcomes previously observed in oncology outpatients receiving radiotherapy.	The nutrition intervention group had a higher mean protein intake (1.1 to 1.3 g/kg/day) compared with the standard practice group (1.0 to 1.1 g/kg/day) (P=0.001).
__label__noRel	Intensive nutrition intervention following the ADA MNT protocol results in improved dietary intake compared with standard practice and seems to beneficially impact nutrition-related outcomes previously observed in oncology outpatients receiving radiotherapy.	Although the change in fiber intake between the groups was not significant,
__label__noRel	Intensive nutrition intervention following the ADA MNT protocol results in improved dietary intake compared with standard practice and seems to beneficially impact nutrition-related outcomes previously observed in oncology outpatients receiving radiotherapy.	there was a trend in the anticipated direction (P=0.083).
__label__Support	Intensive nutrition intervention following the ADA MNT protocol results in improved dietary intake compared with standard practice and seems to beneficially impact nutrition-related outcomes previously observed in oncology outpatients receiving radiotherapy.	The ADA MNT protocol for radiation oncology is a useful guide to the level of nutrition support required.
__label__noRel	The ADA MNT protocol for radiation oncology is a useful guide to the level of nutrition support required.	The nutrition intervention group had a higher mean total energy (P=0.029) and protein intake (P<0.001) compared with the standard practice group.
__label__noRel	The ADA MNT protocol for radiation oncology is a useful guide to the level of nutrition support required.	Mean intake per kilogram of body weight for the nutrition intervention group ranged from 28 to 31 kcal/kg/day compared with 25 to 29 kcal/kg/day for the standard practice group (P=0.022).
__label__noRel	The ADA MNT protocol for radiation oncology is a useful guide to the level of nutrition support required.	The nutrition intervention group had a higher mean protein intake (1.1 to 1.3 g/kg/day) compared with the standard practice group (1.0 to 1.1 g/kg/day) (P=0.001).
__label__noRel	The ADA MNT protocol for radiation oncology is a useful guide to the level of nutrition support required.	Although the change in fiber intake between the groups was not significant,
__label__noRel	The ADA MNT protocol for radiation oncology is a useful guide to the level of nutrition support required.	there was a trend in the anticipated direction (P=0.083).
__label__noRel	The ADA MNT protocol for radiation oncology is a useful guide to the level of nutrition support required.	Intensive nutrition intervention following the ADA MNT protocol results in improved dietary intake compared with standard practice and seems to beneficially impact nutrition-related outcomes previously observed in oncology outpatients receiving radiotherapy.
__label__noRel	PFS was significantly longer for fulvestrant 500 mg (n = 362) than 250 mg (n = 374) (hazard ratio [HR] = 0.80; 95% CI, 0.68 to 0.94; P = .006), corresponding to a 20% reduction in risk of progression.	Objective response rate was similar for fulvestrant 500 mg and 250 mg (9.1% v 10.2%, respectively).
__label__noRel	PFS was significantly longer for fulvestrant 500 mg (n = 362) than 250 mg (n = 374) (hazard ratio [HR] = 0.80; 95% CI, 0.68 to 0.94; P = .006), corresponding to a 20% reduction in risk of progression.	CBR was 45.6% for fulvestrant 500 mg and 39.6% for fulvestrant 250 mg.
__label__noRel	PFS was significantly longer for fulvestrant 500 mg (n = 362) than 250 mg (n = 374) (hazard ratio [HR] = 0.80; 95% CI, 0.68 to 0.94; P = .006), corresponding to a 20% reduction in risk of progression.	DoCB and OS were 16.6 and 25.1 months, respectively, for the 500-mg group, whereas DoCB and OS were 13.9 and 22.8 months, respectively, in the 250-mg group.
__label__noRel	PFS was significantly longer for fulvestrant 500 mg (n = 362) than 250 mg (n = 374) (hazard ratio [HR] = 0.80; 95% CI, 0.68 to 0.94; P = .006), corresponding to a 20% reduction in risk of progression.	Fulvestrant 500 mg was well tolerated with no dose-dependent adverse events.
__label__noRel	PFS was significantly longer for fulvestrant 500 mg (n = 362) than 250 mg (n = 374) (hazard ratio [HR] = 0.80; 95% CI, 0.68 to 0.94; P = .006), corresponding to a 20% reduction in risk of progression.	QOL was similar for both arms.
__label__Support	PFS was significantly longer for fulvestrant 500 mg (n = 362) than 250 mg (n = 374) (hazard ratio [HR] = 0.80; 95% CI, 0.68 to 0.94; P = .006), corresponding to a 20% reduction in risk of progression.	Fulvestrant 500 mg was associated with a statistically significant increase in PFS and not associated with increased toxicity,
__label__noRel	Objective response rate was similar for fulvestrant 500 mg and 250 mg (9.1% v 10.2%, respectively).	PFS was significantly longer for fulvestrant 500 mg (n = 362) than 250 mg (n = 374) (hazard ratio [HR] = 0.80; 95% CI, 0.68 to 0.94; P = .006), corresponding to a 20% reduction in risk of progression.
__label__noRel	Objective response rate was similar for fulvestrant 500 mg and 250 mg (9.1% v 10.2%, respectively).	CBR was 45.6% for fulvestrant 500 mg and 39.6% for fulvestrant 250 mg.
__label__noRel	Objective response rate was similar for fulvestrant 500 mg and 250 mg (9.1% v 10.2%, respectively).	DoCB and OS were 16.6 and 25.1 months, respectively, for the 500-mg group, whereas DoCB and OS were 13.9 and 22.8 months, respectively, in the 250-mg group.
__label__noRel	Objective response rate was similar for fulvestrant 500 mg and 250 mg (9.1% v 10.2%, respectively).	Fulvestrant 500 mg was well tolerated with no dose-dependent adverse events.
__label__noRel	Objective response rate was similar for fulvestrant 500 mg and 250 mg (9.1% v 10.2%, respectively).	QOL was similar for both arms.
__label__noRel	Objective response rate was similar for fulvestrant 500 mg and 250 mg (9.1% v 10.2%, respectively).	Fulvestrant 500 mg was associated with a statistically significant increase in PFS and not associated with increased toxicity,
__label__noRel	CBR was 45.6% for fulvestrant 500 mg and 39.6% for fulvestrant 250 mg.	PFS was significantly longer for fulvestrant 500 mg (n = 362) than 250 mg (n = 374) (hazard ratio [HR] = 0.80; 95% CI, 0.68 to 0.94; P = .006), corresponding to a 20% reduction in risk of progression.
__label__noRel	CBR was 45.6% for fulvestrant 500 mg and 39.6% for fulvestrant 250 mg.	Objective response rate was similar for fulvestrant 500 mg and 250 mg (9.1% v 10.2%, respectively).
__label__noRel	CBR was 45.6% for fulvestrant 500 mg and 39.6% for fulvestrant 250 mg.	DoCB and OS were 16.6 and 25.1 months, respectively, for the 500-mg group, whereas DoCB and OS were 13.9 and 22.8 months, respectively, in the 250-mg group.
__label__noRel	CBR was 45.6% for fulvestrant 500 mg and 39.6% for fulvestrant 250 mg.	Fulvestrant 500 mg was well tolerated with no dose-dependent adverse events.
__label__noRel	CBR was 45.6% for fulvestrant 500 mg and 39.6% for fulvestrant 250 mg.	QOL was similar for both arms.
__label__noRel	CBR was 45.6% for fulvestrant 500 mg and 39.6% for fulvestrant 250 mg.	Fulvestrant 500 mg was associated with a statistically significant increase in PFS and not associated with increased toxicity,
__label__noRel	DoCB and OS were 16.6 and 25.1 months, respectively, for the 500-mg group, whereas DoCB and OS were 13.9 and 22.8 months, respectively, in the 250-mg group.	PFS was significantly longer for fulvestrant 500 mg (n = 362) than 250 mg (n = 374) (hazard ratio [HR] = 0.80; 95% CI, 0.68 to 0.94; P = .006), corresponding to a 20% reduction in risk of progression.
__label__noRel	DoCB and OS were 16.6 and 25.1 months, respectively, for the 500-mg group, whereas DoCB and OS were 13.9 and 22.8 months, respectively, in the 250-mg group.	Objective response rate was similar for fulvestrant 500 mg and 250 mg (9.1% v 10.2%, respectively).
__label__noRel	DoCB and OS were 16.6 and 25.1 months, respectively, for the 500-mg group, whereas DoCB and OS were 13.9 and 22.8 months, respectively, in the 250-mg group.	CBR was 45.6% for fulvestrant 500 mg and 39.6% for fulvestrant 250 mg.
__label__noRel	DoCB and OS were 16.6 and 25.1 months, respectively, for the 500-mg group, whereas DoCB and OS were 13.9 and 22.8 months, respectively, in the 250-mg group.	Fulvestrant 500 mg was well tolerated with no dose-dependent adverse events.
__label__noRel	DoCB and OS were 16.6 and 25.1 months, respectively, for the 500-mg group, whereas DoCB and OS were 13.9 and 22.8 months, respectively, in the 250-mg group.	QOL was similar for both arms.
__label__noRel	DoCB and OS were 16.6 and 25.1 months, respectively, for the 500-mg group, whereas DoCB and OS were 13.9 and 22.8 months, respectively, in the 250-mg group.	Fulvestrant 500 mg was associated with a statistically significant increase in PFS and not associated with increased toxicity,
__label__noRel	Fulvestrant 500 mg was well tolerated with no dose-dependent adverse events.	PFS was significantly longer for fulvestrant 500 mg (n = 362) than 250 mg (n = 374) (hazard ratio [HR] = 0.80; 95% CI, 0.68 to 0.94; P = .006), corresponding to a 20% reduction in risk of progression.
__label__noRel	Fulvestrant 500 mg was well tolerated with no dose-dependent adverse events.	Objective response rate was similar for fulvestrant 500 mg and 250 mg (9.1% v 10.2%, respectively).
__label__noRel	Fulvestrant 500 mg was well tolerated with no dose-dependent adverse events.	CBR was 45.6% for fulvestrant 500 mg and 39.6% for fulvestrant 250 mg.
__label__noRel	Fulvestrant 500 mg was well tolerated with no dose-dependent adverse events.	DoCB and OS were 16.6 and 25.1 months, respectively, for the 500-mg group, whereas DoCB and OS were 13.9 and 22.8 months, respectively, in the 250-mg group.
__label__noRel	Fulvestrant 500 mg was well tolerated with no dose-dependent adverse events.	QOL was similar for both arms.
__label__noRel	Fulvestrant 500 mg was well tolerated with no dose-dependent adverse events.	Fulvestrant 500 mg was associated with a statistically significant increase in PFS and not associated with increased toxicity,
__label__noRel	QOL was similar for both arms.	PFS was significantly longer for fulvestrant 500 mg (n = 362) than 250 mg (n = 374) (hazard ratio [HR] = 0.80; 95% CI, 0.68 to 0.94; P = .006), corresponding to a 20% reduction in risk of progression.
__label__noRel	QOL was similar for both arms.	Objective response rate was similar for fulvestrant 500 mg and 250 mg (9.1% v 10.2%, respectively).
__label__noRel	QOL was similar for both arms.	CBR was 45.6% for fulvestrant 500 mg and 39.6% for fulvestrant 250 mg.
__label__noRel	QOL was similar for both arms.	DoCB and OS were 16.6 and 25.1 months, respectively, for the 500-mg group, whereas DoCB and OS were 13.9 and 22.8 months, respectively, in the 250-mg group.
__label__noRel	QOL was similar for both arms.	Fulvestrant 500 mg was well tolerated with no dose-dependent adverse events.
__label__noRel	QOL was similar for both arms.	Fulvestrant 500 mg was associated with a statistically significant increase in PFS and not associated with increased toxicity,
__label__noRel	Fulvestrant 500 mg was associated with a statistically significant increase in PFS and not associated with increased toxicity,	PFS was significantly longer for fulvestrant 500 mg (n = 362) than 250 mg (n = 374) (hazard ratio [HR] = 0.80; 95% CI, 0.68 to 0.94; P = .006), corresponding to a 20% reduction in risk of progression.
__label__noRel	Fulvestrant 500 mg was associated with a statistically significant increase in PFS and not associated with increased toxicity,	Objective response rate was similar for fulvestrant 500 mg and 250 mg (9.1% v 10.2%, respectively).
__label__noRel	Fulvestrant 500 mg was associated with a statistically significant increase in PFS and not associated with increased toxicity,	CBR was 45.6% for fulvestrant 500 mg and 39.6% for fulvestrant 250 mg.
__label__noRel	Fulvestrant 500 mg was associated with a statistically significant increase in PFS and not associated with increased toxicity,	DoCB and OS were 16.6 and 25.1 months, respectively, for the 500-mg group, whereas DoCB and OS were 13.9 and 22.8 months, respectively, in the 250-mg group.
__label__noRel	Fulvestrant 500 mg was associated with a statistically significant increase in PFS and not associated with increased toxicity,	Fulvestrant 500 mg was well tolerated with no dose-dependent adverse events.
__label__noRel	Fulvestrant 500 mg was associated with a statistically significant increase in PFS and not associated with increased toxicity,	QOL was similar for both arms.
__label__noRel	FACT-B scores increased after treatment began and remained significantly higher in the tamoxifen group than in the exemestane group or anastrozole group during the first year (P=0.045).	FACT-B scores were similar in the exemestane group and anastrozole group.
__label__noRel	FACT-B scores increased after treatment began and remained significantly higher in the tamoxifen group than in the exemestane group or anastrozole group during the first year (P=0.045).	ES scores and CES-D scores were similar in all treatment groups.
__label__noRel	FACT-B scores increased after treatment began and remained significantly higher in the tamoxifen group than in the exemestane group or anastrozole group during the first year (P=0.045).	Arthralgia and fatigue were less frequent, but vaginal discharge was more frequent in the tamoxifen group than in the exemestane group or anastrozole group.
__label__Support	FACT-B scores increased after treatment began and remained significantly higher in the tamoxifen group than in the exemestane group or anastrozole group during the first year (P=0.045).	HRQOL was better in Japanese postmenopausal women treated with tamoxifen than those treated with exemestane or anastrozole.
__label__noRel	FACT-B scores increased after treatment began and remained significantly higher in the tamoxifen group than in the exemestane group or anastrozole group during the first year (P=0.045).	HRQOL and AEs were similar with exemestane and anastrozole.
__label__noRel	FACT-B scores increased after treatment began and remained significantly higher in the tamoxifen group than in the exemestane group or anastrozole group during the first year (P=0.045).	Given the results of the TEAM trial, upfront use of tamoxifen followed by an aromatase inhibitor (AI) may be an important option for adjuvant endocrine therapy in Japanese postmenopausal women.
__label__noRel	FACT-B scores were similar in the exemestane group and anastrozole group.	FACT-B scores increased after treatment began and remained significantly higher in the tamoxifen group than in the exemestane group or anastrozole group during the first year (P=0.045).
__label__noRel	FACT-B scores were similar in the exemestane group and anastrozole group.	ES scores and CES-D scores were similar in all treatment groups.
__label__noRel	FACT-B scores were similar in the exemestane group and anastrozole group.	Arthralgia and fatigue were less frequent, but vaginal discharge was more frequent in the tamoxifen group than in the exemestane group or anastrozole group.
__label__noRel	FACT-B scores were similar in the exemestane group and anastrozole group.	HRQOL was better in Japanese postmenopausal women treated with tamoxifen than those treated with exemestane or anastrozole.
__label__Support	FACT-B scores were similar in the exemestane group and anastrozole group.	HRQOL and AEs were similar with exemestane and anastrozole.
__label__noRel	FACT-B scores were similar in the exemestane group and anastrozole group.	Given the results of the TEAM trial, upfront use of tamoxifen followed by an aromatase inhibitor (AI) may be an important option for adjuvant endocrine therapy in Japanese postmenopausal women.
__label__noRel	ES scores and CES-D scores were similar in all treatment groups.	FACT-B scores increased after treatment began and remained significantly higher in the tamoxifen group than in the exemestane group or anastrozole group during the first year (P=0.045).
__label__noRel	ES scores and CES-D scores were similar in all treatment groups.	FACT-B scores were similar in the exemestane group and anastrozole group.
__label__noRel	ES scores and CES-D scores were similar in all treatment groups.	Arthralgia and fatigue were less frequent, but vaginal discharge was more frequent in the tamoxifen group than in the exemestane group or anastrozole group.
__label__noRel	ES scores and CES-D scores were similar in all treatment groups.	HRQOL was better in Japanese postmenopausal women treated with tamoxifen than those treated with exemestane or anastrozole.
__label__Support	ES scores and CES-D scores were similar in all treatment groups.	HRQOL and AEs were similar with exemestane and anastrozole.
__label__noRel	ES scores and CES-D scores were similar in all treatment groups.	Given the results of the TEAM trial, upfront use of tamoxifen followed by an aromatase inhibitor (AI) may be an important option for adjuvant endocrine therapy in Japanese postmenopausal women.
__label__noRel	Arthralgia and fatigue were less frequent, but vaginal discharge was more frequent in the tamoxifen group than in the exemestane group or anastrozole group.	FACT-B scores increased after treatment began and remained significantly higher in the tamoxifen group than in the exemestane group or anastrozole group during the first year (P=0.045).
__label__noRel	Arthralgia and fatigue were less frequent, but vaginal discharge was more frequent in the tamoxifen group than in the exemestane group or anastrozole group.	FACT-B scores were similar in the exemestane group and anastrozole group.
__label__noRel	Arthralgia and fatigue were less frequent, but vaginal discharge was more frequent in the tamoxifen group than in the exemestane group or anastrozole group.	ES scores and CES-D scores were similar in all treatment groups.
__label__Support	Arthralgia and fatigue were less frequent, but vaginal discharge was more frequent in the tamoxifen group than in the exemestane group or anastrozole group.	HRQOL was better in Japanese postmenopausal women treated with tamoxifen than those treated with exemestane or anastrozole.
__label__noRel	Arthralgia and fatigue were less frequent, but vaginal discharge was more frequent in the tamoxifen group than in the exemestane group or anastrozole group.	HRQOL and AEs were similar with exemestane and anastrozole.
__label__noRel	Arthralgia and fatigue were less frequent, but vaginal discharge was more frequent in the tamoxifen group than in the exemestane group or anastrozole group.	Given the results of the TEAM trial, upfront use of tamoxifen followed by an aromatase inhibitor (AI) may be an important option for adjuvant endocrine therapy in Japanese postmenopausal women.
__label__noRel	HRQOL was better in Japanese postmenopausal women treated with tamoxifen than those treated with exemestane or anastrozole.	FACT-B scores increased after treatment began and remained significantly higher in the tamoxifen group than in the exemestane group or anastrozole group during the first year (P=0.045).
__label__noRel	HRQOL was better in Japanese postmenopausal women treated with tamoxifen than those treated with exemestane or anastrozole.	FACT-B scores were similar in the exemestane group and anastrozole group.
__label__noRel	HRQOL was better in Japanese postmenopausal women treated with tamoxifen than those treated with exemestane or anastrozole.	ES scores and CES-D scores were similar in all treatment groups.
__label__noRel	HRQOL was better in Japanese postmenopausal women treated with tamoxifen than those treated with exemestane or anastrozole.	Arthralgia and fatigue were less frequent, but vaginal discharge was more frequent in the tamoxifen group than in the exemestane group or anastrozole group.
__label__noRel	HRQOL was better in Japanese postmenopausal women treated with tamoxifen than those treated with exemestane or anastrozole.	HRQOL and AEs were similar with exemestane and anastrozole.
__label__Support	HRQOL was better in Japanese postmenopausal women treated with tamoxifen than those treated with exemestane or anastrozole.	Given the results of the TEAM trial, upfront use of tamoxifen followed by an aromatase inhibitor (AI) may be an important option for adjuvant endocrine therapy in Japanese postmenopausal women.
__label__noRel	HRQOL and AEs were similar with exemestane and anastrozole.	FACT-B scores increased after treatment began and remained significantly higher in the tamoxifen group than in the exemestane group or anastrozole group during the first year (P=0.045).
__label__noRel	HRQOL and AEs were similar with exemestane and anastrozole.	FACT-B scores were similar in the exemestane group and anastrozole group.
__label__noRel	HRQOL and AEs were similar with exemestane and anastrozole.	ES scores and CES-D scores were similar in all treatment groups.
__label__noRel	HRQOL and AEs were similar with exemestane and anastrozole.	Arthralgia and fatigue were less frequent, but vaginal discharge was more frequent in the tamoxifen group than in the exemestane group or anastrozole group.
__label__noRel	HRQOL and AEs were similar with exemestane and anastrozole.	HRQOL was better in Japanese postmenopausal women treated with tamoxifen than those treated with exemestane or anastrozole.
__label__Support	HRQOL and AEs were similar with exemestane and anastrozole.	Given the results of the TEAM trial, upfront use of tamoxifen followed by an aromatase inhibitor (AI) may be an important option for adjuvant endocrine therapy in Japanese postmenopausal women.
__label__noRel	Given the results of the TEAM trial, upfront use of tamoxifen followed by an aromatase inhibitor (AI) may be an important option for adjuvant endocrine therapy in Japanese postmenopausal women.	FACT-B scores increased after treatment began and remained significantly higher in the tamoxifen group than in the exemestane group or anastrozole group during the first year (P=0.045).
__label__noRel	Given the results of the TEAM trial, upfront use of tamoxifen followed by an aromatase inhibitor (AI) may be an important option for adjuvant endocrine therapy in Japanese postmenopausal women.	FACT-B scores were similar in the exemestane group and anastrozole group.
__label__noRel	Given the results of the TEAM trial, upfront use of tamoxifen followed by an aromatase inhibitor (AI) may be an important option for adjuvant endocrine therapy in Japanese postmenopausal women.	ES scores and CES-D scores were similar in all treatment groups.
__label__noRel	Given the results of the TEAM trial, upfront use of tamoxifen followed by an aromatase inhibitor (AI) may be an important option for adjuvant endocrine therapy in Japanese postmenopausal women.	Arthralgia and fatigue were less frequent, but vaginal discharge was more frequent in the tamoxifen group than in the exemestane group or anastrozole group.
__label__noRel	Given the results of the TEAM trial, upfront use of tamoxifen followed by an aromatase inhibitor (AI) may be an important option for adjuvant endocrine therapy in Japanese postmenopausal women.	HRQOL was better in Japanese postmenopausal women treated with tamoxifen than those treated with exemestane or anastrozole.
__label__noRel	Given the results of the TEAM trial, upfront use of tamoxifen followed by an aromatase inhibitor (AI) may be an important option for adjuvant endocrine therapy in Japanese postmenopausal women.	HRQOL and AEs were similar with exemestane and anastrozole.
__label__noRel	Numeric rating scale scores for pain intensity in group 1 and group 2 were significantly lower than those in group 3 at T(0-12) (P < .001); T(12-24) (P < .001); and T(24-48) (P < .001).	When group 1 with group 2 were compared, numeric rating scale scores were significantly lower in group 1 than in group 2 during the period of T(0-12) (P < .001)
__label__noRel	Numeric rating scale scores for pain intensity in group 1 and group 2 were significantly lower than those in group 3 at T(0-12) (P < .001); T(12-24) (P < .001); and T(24-48) (P < .001).	but were not significantly different at T(12-24) (P = .68) and T(24-48) (P = .10).
__label__noRel	Numeric rating scale scores for pain intensity in group 1 and group 2 were significantly lower than those in group 3 at T(0-12) (P < .001); T(12-24) (P < .001); and T(24-48) (P < .001).	Analgesic cost and hospital stay were significantly lower in treated groups than in the placebo group.
__label__noRel	Numeric rating scale scores for pain intensity in group 1 and group 2 were significantly lower than those in group 3 at T(0-12) (P < .001); T(12-24) (P < .001); and T(24-48) (P < .001).	No significant difference was observed in quality of life and adverse events between the treated groups and the placebo group.
__label__Support	Numeric rating scale scores for pain intensity in group 1 and group 2 were significantly lower than those in group 3 at T(0-12) (P < .001); T(12-24) (P < .001); and T(24-48) (P < .001).	CRO is effective, safe, and cost-effective in the control of postoperative pain after transarterial chemoembolization for patients with inoperable liver cancer.
__label__noRel	When group 1 with group 2 were compared, numeric rating scale scores were significantly lower in group 1 than in group 2 during the period of T(0-12) (P < .001)	Numeric rating scale scores for pain intensity in group 1 and group 2 were significantly lower than those in group 3 at T(0-12) (P < .001); T(12-24) (P < .001); and T(24-48) (P < .001).
__label__noRel	When group 1 with group 2 were compared, numeric rating scale scores were significantly lower in group 1 than in group 2 during the period of T(0-12) (P < .001)	but were not significantly different at T(12-24) (P = .68) and T(24-48) (P = .10).
__label__noRel	When group 1 with group 2 were compared, numeric rating scale scores were significantly lower in group 1 than in group 2 during the period of T(0-12) (P < .001)	Analgesic cost and hospital stay were significantly lower in treated groups than in the placebo group.
__label__noRel	When group 1 with group 2 were compared, numeric rating scale scores were significantly lower in group 1 than in group 2 during the period of T(0-12) (P < .001)	No significant difference was observed in quality of life and adverse events between the treated groups and the placebo group.
__label__Support	When group 1 with group 2 were compared, numeric rating scale scores were significantly lower in group 1 than in group 2 during the period of T(0-12) (P < .001)	CRO is effective, safe, and cost-effective in the control of postoperative pain after transarterial chemoembolization for patients with inoperable liver cancer.
__label__noRel	but were not significantly different at T(12-24) (P = .68) and T(24-48) (P = .10).	Numeric rating scale scores for pain intensity in group 1 and group 2 were significantly lower than those in group 3 at T(0-12) (P < .001); T(12-24) (P < .001); and T(24-48) (P < .001).
__label__Attack	but were not significantly different at T(12-24) (P = .68) and T(24-48) (P = .10).	When group 1 with group 2 were compared, numeric rating scale scores were significantly lower in group 1 than in group 2 during the period of T(0-12) (P < .001)
__label__noRel	but were not significantly different at T(12-24) (P = .68) and T(24-48) (P = .10).	Analgesic cost and hospital stay were significantly lower in treated groups than in the placebo group.
__label__noRel	but were not significantly different at T(12-24) (P = .68) and T(24-48) (P = .10).	No significant difference was observed in quality of life and adverse events between the treated groups and the placebo group.
__label__noRel	but were not significantly different at T(12-24) (P = .68) and T(24-48) (P = .10).	CRO is effective, safe, and cost-effective in the control of postoperative pain after transarterial chemoembolization for patients with inoperable liver cancer.
__label__noRel	Analgesic cost and hospital stay were significantly lower in treated groups than in the placebo group.	Numeric rating scale scores for pain intensity in group 1 and group 2 were significantly lower than those in group 3 at T(0-12) (P < .001); T(12-24) (P < .001); and T(24-48) (P < .001).
__label__noRel	Analgesic cost and hospital stay were significantly lower in treated groups than in the placebo group.	When group 1 with group 2 were compared, numeric rating scale scores were significantly lower in group 1 than in group 2 during the period of T(0-12) (P < .001)
__label__noRel	Analgesic cost and hospital stay were significantly lower in treated groups than in the placebo group.	but were not significantly different at T(12-24) (P = .68) and T(24-48) (P = .10).
__label__noRel	Analgesic cost and hospital stay were significantly lower in treated groups than in the placebo group.	No significant difference was observed in quality of life and adverse events between the treated groups and the placebo group.
__label__Support	Analgesic cost and hospital stay were significantly lower in treated groups than in the placebo group.	CRO is effective, safe, and cost-effective in the control of postoperative pain after transarterial chemoembolization for patients with inoperable liver cancer.
__label__noRel	No significant difference was observed in quality of life and adverse events between the treated groups and the placebo group.	Numeric rating scale scores for pain intensity in group 1 and group 2 were significantly lower than those in group 3 at T(0-12) (P < .001); T(12-24) (P < .001); and T(24-48) (P < .001).
__label__noRel	No significant difference was observed in quality of life and adverse events between the treated groups and the placebo group.	When group 1 with group 2 were compared, numeric rating scale scores were significantly lower in group 1 than in group 2 during the period of T(0-12) (P < .001)
__label__noRel	No significant difference was observed in quality of life and adverse events between the treated groups and the placebo group.	but were not significantly different at T(12-24) (P = .68) and T(24-48) (P = .10).
__label__noRel	No significant difference was observed in quality of life and adverse events between the treated groups and the placebo group.	Analgesic cost and hospital stay were significantly lower in treated groups than in the placebo group.
__label__Support	No significant difference was observed in quality of life and adverse events between the treated groups and the placebo group.	CRO is effective, safe, and cost-effective in the control of postoperative pain after transarterial chemoembolization for patients with inoperable liver cancer.
__label__noRel	CRO is effective, safe, and cost-effective in the control of postoperative pain after transarterial chemoembolization for patients with inoperable liver cancer.	Numeric rating scale scores for pain intensity in group 1 and group 2 were significantly lower than those in group 3 at T(0-12) (P < .001); T(12-24) (P < .001); and T(24-48) (P < .001).
__label__noRel	CRO is effective, safe, and cost-effective in the control of postoperative pain after transarterial chemoembolization for patients with inoperable liver cancer.	When group 1 with group 2 were compared, numeric rating scale scores were significantly lower in group 1 than in group 2 during the period of T(0-12) (P < .001)
__label__noRel	CRO is effective, safe, and cost-effective in the control of postoperative pain after transarterial chemoembolization for patients with inoperable liver cancer.	but were not significantly different at T(12-24) (P = .68) and T(24-48) (P = .10).
__label__noRel	CRO is effective, safe, and cost-effective in the control of postoperative pain after transarterial chemoembolization for patients with inoperable liver cancer.	Analgesic cost and hospital stay were significantly lower in treated groups than in the placebo group.
__label__noRel	CRO is effective, safe, and cost-effective in the control of postoperative pain after transarterial chemoembolization for patients with inoperable liver cancer.	No significant difference was observed in quality of life and adverse events between the treated groups and the placebo group.
__label__noRel	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).	The rate of grade 2 or above nausea was numerically higher in the GP arm,
__label__noRel	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).
__label__noRel	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).
__label__noRel	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).
__label__noRel	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).
__label__noRel	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.
__label__noRel	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.
__label__noRel	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).
__label__noRel	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).	This toxicity profile of GE is similar to GP,
__label__noRel	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).	but the apparent inferior efficacy may discourage further investigation
__label__noRel	The rate of grade 2 or above nausea was numerically higher in the GP arm,	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).
__label__noRel	The rate of grade 2 or above nausea was numerically higher in the GP arm,	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).
__label__noRel	The rate of grade 2 or above nausea was numerically higher in the GP arm,	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).
__label__noRel	The rate of grade 2 or above nausea was numerically higher in the GP arm,	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).
__label__noRel	The rate of grade 2 or above nausea was numerically higher in the GP arm,	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).
__label__noRel	The rate of grade 2 or above nausea was numerically higher in the GP arm,	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.
__label__noRel	The rate of grade 2 or above nausea was numerically higher in the GP arm,	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.
__label__noRel	The rate of grade 2 or above nausea was numerically higher in the GP arm,	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).
__label__noRel	The rate of grade 2 or above nausea was numerically higher in the GP arm,	This toxicity profile of GE is similar to GP,
__label__noRel	The rate of grade 2 or above nausea was numerically higher in the GP arm,	but the apparent inferior efficacy may discourage further investigation
__label__noRel	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).
__label__Attack	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).	The rate of grade 2 or above nausea was numerically higher in the GP arm,
__label__noRel	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).
__label__noRel	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).
__label__noRel	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).
__label__noRel	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.
__label__noRel	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.
__label__noRel	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).
__label__noRel	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).	This toxicity profile of GE is similar to GP,
__label__noRel	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).	but the apparent inferior efficacy may discourage further investigation
__label__noRel	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).
__label__noRel	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).	The rate of grade 2 or above nausea was numerically higher in the GP arm,
__label__noRel	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).
__label__noRel	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).
__label__noRel	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).
__label__noRel	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.
__label__noRel	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.
__label__noRel	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).
__label__noRel	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).	This toxicity profile of GE is similar to GP,
__label__noRel	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).	but the apparent inferior efficacy may discourage further investigation
__label__noRel	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).
__label__noRel	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).	The rate of grade 2 or above nausea was numerically higher in the GP arm,
__label__noRel	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).
__label__noRel	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).
__label__noRel	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).
__label__noRel	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.
__label__noRel	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.
__label__noRel	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).
__label__noRel	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).	This toxicity profile of GE is similar to GP,
__label__noRel	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).	but the apparent inferior efficacy may discourage further investigation
__label__noRel	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).
__label__noRel	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).	The rate of grade 2 or above nausea was numerically higher in the GP arm,
__label__noRel	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).
__label__noRel	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).
__label__noRel	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).
__label__noRel	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.
__label__noRel	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.
__label__noRel	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).
__label__noRel	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).	This toxicity profile of GE is similar to GP,
__label__noRel	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).	but the apparent inferior efficacy may discourage further investigation
__label__noRel	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).
__label__noRel	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.	The rate of grade 2 or above nausea was numerically higher in the GP arm,
__label__noRel	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).
__label__noRel	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).
__label__noRel	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).
__label__noRel	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).
__label__noRel	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.
__label__noRel	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).
__label__noRel	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.	This toxicity profile of GE is similar to GP,
__label__noRel	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.	but the apparent inferior efficacy may discourage further investigation
__label__noRel	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).
__label__noRel	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.	The rate of grade 2 or above nausea was numerically higher in the GP arm,
__label__noRel	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).
__label__noRel	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).
__label__noRel	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).
__label__noRel	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).
__label__noRel	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.
__label__noRel	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).
__label__noRel	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.	This toxicity profile of GE is similar to GP,
__label__Support	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.	but the apparent inferior efficacy may discourage further investigation
__label__noRel	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).
__label__noRel	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).	The rate of grade 2 or above nausea was numerically higher in the GP arm,
__label__noRel	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).
__label__noRel	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).
__label__noRel	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).
__label__noRel	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).
__label__noRel	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.
__label__noRel	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.
__label__noRel	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).	This toxicity profile of GE is similar to GP,
__label__Support	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).	but the apparent inferior efficacy may discourage further investigation
__label__noRel	This toxicity profile of GE is similar to GP,	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).
__label__noRel	This toxicity profile of GE is similar to GP,	The rate of grade 2 or above nausea was numerically higher in the GP arm,
__label__noRel	This toxicity profile of GE is similar to GP,	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).
__label__noRel	This toxicity profile of GE is similar to GP,	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).
__label__noRel	This toxicity profile of GE is similar to GP,	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).
__label__noRel	This toxicity profile of GE is similar to GP,	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).
__label__noRel	This toxicity profile of GE is similar to GP,	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.
__label__noRel	This toxicity profile of GE is similar to GP,	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.
__label__noRel	This toxicity profile of GE is similar to GP,	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).
__label__noRel	This toxicity profile of GE is similar to GP,	but the apparent inferior efficacy may discourage further investigation
__label__noRel	but the apparent inferior efficacy may discourage further investigation	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).
__label__noRel	but the apparent inferior efficacy may discourage further investigation	The rate of grade 2 or above nausea was numerically higher in the GP arm,
__label__noRel	but the apparent inferior efficacy may discourage further investigation	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).
__label__noRel	but the apparent inferior efficacy may discourage further investigation	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).
__label__noRel	but the apparent inferior efficacy may discourage further investigation	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).
__label__noRel	but the apparent inferior efficacy may discourage further investigation	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).
__label__noRel	but the apparent inferior efficacy may discourage further investigation	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.
__label__noRel	but the apparent inferior efficacy may discourage further investigation	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.
__label__noRel	but the apparent inferior efficacy may discourage further investigation	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).
__label__Attack	but the apparent inferior efficacy may discourage further investigation	This toxicity profile of GE is similar to GP,
__label__noRel	Tamoxifen (TMX) is believed to inhibit HCC positive for estrogen receptor (ER), but most HCCs are ER negative.	Results of previous phase 3 trials in inoperable HCC have been conflicting and inconclusive.
__label__noRel	Tamoxifen (TMX) is believed to inhibit HCC positive for estrogen receptor (ER), but most HCCs are ER negative.	At higher doses, however, TMX inhibits HCC through ER-independent mechanisms.
__label__noRel	Tamoxifen (TMX) is believed to inhibit HCC positive for estrogen receptor (ER), but most HCCs are ER negative.	Three-month survival rates for the P, TMX60, and TMX120 groups were 44%, 41%, and 35%, respectively, with a statistically significant trend difference in survival across the 3 treatment regimens (P =.011).
__label__noRel	Tamoxifen (TMX) is believed to inhibit HCC positive for estrogen receptor (ER), but most HCCs are ER negative.	There was a significantly higher risk of death in the TMX120 group compared with the P group (hazard ratio, 1.39; 95% confidence interval, 1.07-1.81).
__label__noRel	Tamoxifen (TMX) is believed to inhibit HCC positive for estrogen receptor (ER), but most HCCs are ER negative.	Adverse drug reactions were reported in 3% (9 patients),
__label__noRel	Tamoxifen (TMX) is believed to inhibit HCC positive for estrogen receptor (ER), but most HCCs are ER negative.	8 patients were lost to follow-up.
__label__noRel	Tamoxifen (TMX) is believed to inhibit HCC positive for estrogen receptor (ER), but most HCCs are ER negative.	TMX does not prolong survival in patients with inoperable HCC and has an increasingly negative impact with increasing dose.
__label__noRel	Tamoxifen (TMX) is believed to inhibit HCC positive for estrogen receptor (ER), but most HCCs are ER negative.	No appreciable advantage to QoL with TMX was observed.
__label__noRel	Results of previous phase 3 trials in inoperable HCC have been conflicting and inconclusive.	Tamoxifen (TMX) is believed to inhibit HCC positive for estrogen receptor (ER), but most HCCs are ER negative.
__label__noRel	Results of previous phase 3 trials in inoperable HCC have been conflicting and inconclusive.	At higher doses, however, TMX inhibits HCC through ER-independent mechanisms.
__label__noRel	Results of previous phase 3 trials in inoperable HCC have been conflicting and inconclusive.	Three-month survival rates for the P, TMX60, and TMX120 groups were 44%, 41%, and 35%, respectively, with a statistically significant trend difference in survival across the 3 treatment regimens (P =.011).
__label__noRel	Results of previous phase 3 trials in inoperable HCC have been conflicting and inconclusive.	There was a significantly higher risk of death in the TMX120 group compared with the P group (hazard ratio, 1.39; 95% confidence interval, 1.07-1.81).
__label__noRel	Results of previous phase 3 trials in inoperable HCC have been conflicting and inconclusive.	Adverse drug reactions were reported in 3% (9 patients),
__label__noRel	Results of previous phase 3 trials in inoperable HCC have been conflicting and inconclusive.	8 patients were lost to follow-up.
__label__noRel	Results of previous phase 3 trials in inoperable HCC have been conflicting and inconclusive.	TMX does not prolong survival in patients with inoperable HCC and has an increasingly negative impact with increasing dose.
__label__noRel	Results of previous phase 3 trials in inoperable HCC have been conflicting and inconclusive.	No appreciable advantage to QoL with TMX was observed.
__label__noRel	At higher doses, however, TMX inhibits HCC through ER-independent mechanisms.	Tamoxifen (TMX) is believed to inhibit HCC positive for estrogen receptor (ER), but most HCCs are ER negative.
__label__noRel	At higher doses, however, TMX inhibits HCC through ER-independent mechanisms.	Results of previous phase 3 trials in inoperable HCC have been conflicting and inconclusive.
__label__noRel	At higher doses, however, TMX inhibits HCC through ER-independent mechanisms.	Three-month survival rates for the P, TMX60, and TMX120 groups were 44%, 41%, and 35%, respectively, with a statistically significant trend difference in survival across the 3 treatment regimens (P =.011).
__label__noRel	At higher doses, however, TMX inhibits HCC through ER-independent mechanisms.	There was a significantly higher risk of death in the TMX120 group compared with the P group (hazard ratio, 1.39; 95% confidence interval, 1.07-1.81).
__label__noRel	At higher doses, however, TMX inhibits HCC through ER-independent mechanisms.	Adverse drug reactions were reported in 3% (9 patients),
__label__noRel	At higher doses, however, TMX inhibits HCC through ER-independent mechanisms.	8 patients were lost to follow-up.
__label__noRel	At higher doses, however, TMX inhibits HCC through ER-independent mechanisms.	TMX does not prolong survival in patients with inoperable HCC and has an increasingly negative impact with increasing dose.
__label__noRel	At higher doses, however, TMX inhibits HCC through ER-independent mechanisms.	No appreciable advantage to QoL with TMX was observed.
__label__noRel	Three-month survival rates for the P, TMX60, and TMX120 groups were 44%, 41%, and 35%, respectively, with a statistically significant trend difference in survival across the 3 treatment regimens (P =.011).	Tamoxifen (TMX) is believed to inhibit HCC positive for estrogen receptor (ER), but most HCCs are ER negative.
__label__noRel	Three-month survival rates for the P, TMX60, and TMX120 groups were 44%, 41%, and 35%, respectively, with a statistically significant trend difference in survival across the 3 treatment regimens (P =.011).	Results of previous phase 3 trials in inoperable HCC have been conflicting and inconclusive.
__label__noRel	Three-month survival rates for the P, TMX60, and TMX120 groups were 44%, 41%, and 35%, respectively, with a statistically significant trend difference in survival across the 3 treatment regimens (P =.011).	At higher doses, however, TMX inhibits HCC through ER-independent mechanisms.
__label__noRel	Three-month survival rates for the P, TMX60, and TMX120 groups were 44%, 41%, and 35%, respectively, with a statistically significant trend difference in survival across the 3 treatment regimens (P =.011).	There was a significantly higher risk of death in the TMX120 group compared with the P group (hazard ratio, 1.39; 95% confidence interval, 1.07-1.81).
__label__noRel	Three-month survival rates for the P, TMX60, and TMX120 groups were 44%, 41%, and 35%, respectively, with a statistically significant trend difference in survival across the 3 treatment regimens (P =.011).	Adverse drug reactions were reported in 3% (9 patients),
__label__noRel	Three-month survival rates for the P, TMX60, and TMX120 groups were 44%, 41%, and 35%, respectively, with a statistically significant trend difference in survival across the 3 treatment regimens (P =.011).	8 patients were lost to follow-up.
__label__Support	Three-month survival rates for the P, TMX60, and TMX120 groups were 44%, 41%, and 35%, respectively, with a statistically significant trend difference in survival across the 3 treatment regimens (P =.011).	TMX does not prolong survival in patients with inoperable HCC and has an increasingly negative impact with increasing dose.
__label__noRel	Three-month survival rates for the P, TMX60, and TMX120 groups were 44%, 41%, and 35%, respectively, with a statistically significant trend difference in survival across the 3 treatment regimens (P =.011).	No appreciable advantage to QoL with TMX was observed.
__label__noRel	There was a significantly higher risk of death in the TMX120 group compared with the P group (hazard ratio, 1.39; 95% confidence interval, 1.07-1.81).	Tamoxifen (TMX) is believed to inhibit HCC positive for estrogen receptor (ER), but most HCCs are ER negative.
__label__noRel	There was a significantly higher risk of death in the TMX120 group compared with the P group (hazard ratio, 1.39; 95% confidence interval, 1.07-1.81).	Results of previous phase 3 trials in inoperable HCC have been conflicting and inconclusive.
__label__noRel	There was a significantly higher risk of death in the TMX120 group compared with the P group (hazard ratio, 1.39; 95% confidence interval, 1.07-1.81).	At higher doses, however, TMX inhibits HCC through ER-independent mechanisms.
__label__noRel	There was a significantly higher risk of death in the TMX120 group compared with the P group (hazard ratio, 1.39; 95% confidence interval, 1.07-1.81).	Three-month survival rates for the P, TMX60, and TMX120 groups were 44%, 41%, and 35%, respectively, with a statistically significant trend difference in survival across the 3 treatment regimens (P =.011).
__label__noRel	There was a significantly higher risk of death in the TMX120 group compared with the P group (hazard ratio, 1.39; 95% confidence interval, 1.07-1.81).	Adverse drug reactions were reported in 3% (9 patients),
__label__noRel	There was a significantly higher risk of death in the TMX120 group compared with the P group (hazard ratio, 1.39; 95% confidence interval, 1.07-1.81).	8 patients were lost to follow-up.
__label__Support	There was a significantly higher risk of death in the TMX120 group compared with the P group (hazard ratio, 1.39; 95% confidence interval, 1.07-1.81).	TMX does not prolong survival in patients with inoperable HCC and has an increasingly negative impact with increasing dose.
__label__noRel	There was a significantly higher risk of death in the TMX120 group compared with the P group (hazard ratio, 1.39; 95% confidence interval, 1.07-1.81).	No appreciable advantage to QoL with TMX was observed.
__label__noRel	Adverse drug reactions were reported in 3% (9 patients),	Tamoxifen (TMX) is believed to inhibit HCC positive for estrogen receptor (ER), but most HCCs are ER negative.
__label__noRel	Adverse drug reactions were reported in 3% (9 patients),	Results of previous phase 3 trials in inoperable HCC have been conflicting and inconclusive.
__label__noRel	Adverse drug reactions were reported in 3% (9 patients),	At higher doses, however, TMX inhibits HCC through ER-independent mechanisms.
__label__noRel	Adverse drug reactions were reported in 3% (9 patients),	Three-month survival rates for the P, TMX60, and TMX120 groups were 44%, 41%, and 35%, respectively, with a statistically significant trend difference in survival across the 3 treatment regimens (P =.011).
__label__noRel	Adverse drug reactions were reported in 3% (9 patients),	There was a significantly higher risk of death in the TMX120 group compared with the P group (hazard ratio, 1.39; 95% confidence interval, 1.07-1.81).
__label__noRel	Adverse drug reactions were reported in 3% (9 patients),	8 patients were lost to follow-up.
__label__noRel	Adverse drug reactions were reported in 3% (9 patients),	TMX does not prolong survival in patients with inoperable HCC and has an increasingly negative impact with increasing dose.
__label__Support	Adverse drug reactions were reported in 3% (9 patients),	No appreciable advantage to QoL with TMX was observed.
__label__noRel	8 patients were lost to follow-up.	Tamoxifen (TMX) is believed to inhibit HCC positive for estrogen receptor (ER), but most HCCs are ER negative.
__label__noRel	8 patients were lost to follow-up.	Results of previous phase 3 trials in inoperable HCC have been conflicting and inconclusive.
__label__noRel	8 patients were lost to follow-up.	At higher doses, however, TMX inhibits HCC through ER-independent mechanisms.
__label__noRel	8 patients were lost to follow-up.	Three-month survival rates for the P, TMX60, and TMX120 groups were 44%, 41%, and 35%, respectively, with a statistically significant trend difference in survival across the 3 treatment regimens (P =.011).
__label__noRel	8 patients were lost to follow-up.	There was a significantly higher risk of death in the TMX120 group compared with the P group (hazard ratio, 1.39; 95% confidence interval, 1.07-1.81).
__label__noRel	8 patients were lost to follow-up.	Adverse drug reactions were reported in 3% (9 patients),
__label__Support	8 patients were lost to follow-up.	TMX does not prolong survival in patients with inoperable HCC and has an increasingly negative impact with increasing dose.
__label__noRel	8 patients were lost to follow-up.	No appreciable advantage to QoL with TMX was observed.
__label__noRel	TMX does not prolong survival in patients with inoperable HCC and has an increasingly negative impact with increasing dose.	Tamoxifen (TMX) is believed to inhibit HCC positive for estrogen receptor (ER), but most HCCs are ER negative.
__label__noRel	TMX does not prolong survival in patients with inoperable HCC and has an increasingly negative impact with increasing dose.	Results of previous phase 3 trials in inoperable HCC have been conflicting and inconclusive.
__label__noRel	TMX does not prolong survival in patients with inoperable HCC and has an increasingly negative impact with increasing dose.	At higher doses, however, TMX inhibits HCC through ER-independent mechanisms.
__label__noRel	TMX does not prolong survival in patients with inoperable HCC and has an increasingly negative impact with increasing dose.	Three-month survival rates for the P, TMX60, and TMX120 groups were 44%, 41%, and 35%, respectively, with a statistically significant trend difference in survival across the 3 treatment regimens (P =.011).
__label__noRel	TMX does not prolong survival in patients with inoperable HCC and has an increasingly negative impact with increasing dose.	There was a significantly higher risk of death in the TMX120 group compared with the P group (hazard ratio, 1.39; 95% confidence interval, 1.07-1.81).
__label__noRel	TMX does not prolong survival in patients with inoperable HCC and has an increasingly negative impact with increasing dose.	Adverse drug reactions were reported in 3% (9 patients),
__label__noRel	TMX does not prolong survival in patients with inoperable HCC and has an increasingly negative impact with increasing dose.	8 patients were lost to follow-up.
__label__noRel	TMX does not prolong survival in patients with inoperable HCC and has an increasingly negative impact with increasing dose.	No appreciable advantage to QoL with TMX was observed.
__label__noRel	No appreciable advantage to QoL with TMX was observed.	Tamoxifen (TMX) is believed to inhibit HCC positive for estrogen receptor (ER), but most HCCs are ER negative.
__label__noRel	No appreciable advantage to QoL with TMX was observed.	Results of previous phase 3 trials in inoperable HCC have been conflicting and inconclusive.
__label__noRel	No appreciable advantage to QoL with TMX was observed.	At higher doses, however, TMX inhibits HCC through ER-independent mechanisms.
__label__noRel	No appreciable advantage to QoL with TMX was observed.	Three-month survival rates for the P, TMX60, and TMX120 groups were 44%, 41%, and 35%, respectively, with a statistically significant trend difference in survival across the 3 treatment regimens (P =.011).
__label__noRel	No appreciable advantage to QoL with TMX was observed.	There was a significantly higher risk of death in the TMX120 group compared with the P group (hazard ratio, 1.39; 95% confidence interval, 1.07-1.81).
__label__noRel	No appreciable advantage to QoL with TMX was observed.	Adverse drug reactions were reported in 3% (9 patients),
__label__noRel	No appreciable advantage to QoL with TMX was observed.	8 patients were lost to follow-up.
__label__noRel	No appreciable advantage to QoL with TMX was observed.	TMX does not prolong survival in patients with inoperable HCC and has an increasingly negative impact with increasing dose.
__label__noRel	Impaired cognition, fatigue, and diminished quality of life (QOL) are commonly associated with breast cancer chemotherapy.	Mean change in EXIT25 scores from baseline to cycle 4 in the epoetin alfa group was 1.3 +/- 3.3;
__label__noRel	Impaired cognition, fatigue, and diminished quality of life (QOL) are commonly associated with breast cancer chemotherapy.	the mean change was 0.3 +/- 2.4 in the placebo group (a negative change indicates improved executive function).
__label__noRel	Impaired cognition, fatigue, and diminished quality of life (QOL) are commonly associated with breast cancer chemotherapy.	There was no difference between groups in mean change in EXIT25 score from baseline to 6-month follow-up assessment.
__label__noRel	Impaired cognition, fatigue, and diminished quality of life (QOL) are commonly associated with breast cancer chemotherapy.	Mean hemoglobin levels were higher in the epoetin alfa group compared with the placebo group after 4 cycles of chemotherapy.
__label__noRel	Impaired cognition, fatigue, and diminished quality of life (QOL) are commonly associated with breast cancer chemotherapy.	Epoetin alfa recipients had less of a decrease in FACT-An subscale scores from baseline to cycle 4 and improvement in FACT-An subscale scores at 6-month follow-up assessment compared with placebo.
__label__noRel	Impaired cognition, fatigue, and diminished quality of life (QOL) are commonly associated with breast cancer chemotherapy.	Epoetin alfa therapy was well tolerated.
__label__noRel	Impaired cognition, fatigue, and diminished quality of life (QOL) are commonly associated with breast cancer chemotherapy.	These data suggest that epoetin alfa may have attenuated the cognitive impairment and fatigue that occurred during adjuvant breast cancer chemotherapy.
__label__noRel	Mean change in EXIT25 scores from baseline to cycle 4 in the epoetin alfa group was 1.3 +/- 3.3;	Impaired cognition, fatigue, and diminished quality of life (QOL) are commonly associated with breast cancer chemotherapy.
__label__noRel	Mean change in EXIT25 scores from baseline to cycle 4 in the epoetin alfa group was 1.3 +/- 3.3;	the mean change was 0.3 +/- 2.4 in the placebo group (a negative change indicates improved executive function).
__label__noRel	Mean change in EXIT25 scores from baseline to cycle 4 in the epoetin alfa group was 1.3 +/- 3.3;	There was no difference between groups in mean change in EXIT25 score from baseline to 6-month follow-up assessment.
__label__noRel	Mean change in EXIT25 scores from baseline to cycle 4 in the epoetin alfa group was 1.3 +/- 3.3;	Mean hemoglobin levels were higher in the epoetin alfa group compared with the placebo group after 4 cycles of chemotherapy.
__label__noRel	Mean change in EXIT25 scores from baseline to cycle 4 in the epoetin alfa group was 1.3 +/- 3.3;	Epoetin alfa recipients had less of a decrease in FACT-An subscale scores from baseline to cycle 4 and improvement in FACT-An subscale scores at 6-month follow-up assessment compared with placebo.
__label__noRel	Mean change in EXIT25 scores from baseline to cycle 4 in the epoetin alfa group was 1.3 +/- 3.3;	Epoetin alfa therapy was well tolerated.
__label__Support	Mean change in EXIT25 scores from baseline to cycle 4 in the epoetin alfa group was 1.3 +/- 3.3;	These data suggest that epoetin alfa may have attenuated the cognitive impairment and fatigue that occurred during adjuvant breast cancer chemotherapy.
__label__noRel	the mean change was 0.3 +/- 2.4 in the placebo group (a negative change indicates improved executive function).	Impaired cognition, fatigue, and diminished quality of life (QOL) are commonly associated with breast cancer chemotherapy.
__label__noRel	the mean change was 0.3 +/- 2.4 in the placebo group (a negative change indicates improved executive function).	Mean change in EXIT25 scores from baseline to cycle 4 in the epoetin alfa group was 1.3 +/- 3.3;
__label__noRel	the mean change was 0.3 +/- 2.4 in the placebo group (a negative change indicates improved executive function).	There was no difference between groups in mean change in EXIT25 score from baseline to 6-month follow-up assessment.
__label__noRel	the mean change was 0.3 +/- 2.4 in the placebo group (a negative change indicates improved executive function).	Mean hemoglobin levels were higher in the epoetin alfa group compared with the placebo group after 4 cycles of chemotherapy.
__label__noRel	the mean change was 0.3 +/- 2.4 in the placebo group (a negative change indicates improved executive function).	Epoetin alfa recipients had less of a decrease in FACT-An subscale scores from baseline to cycle 4 and improvement in FACT-An subscale scores at 6-month follow-up assessment compared with placebo.
__label__noRel	the mean change was 0.3 +/- 2.4 in the placebo group (a negative change indicates improved executive function).	Epoetin alfa therapy was well tolerated.
__label__Support	the mean change was 0.3 +/- 2.4 in the placebo group (a negative change indicates improved executive function).	These data suggest that epoetin alfa may have attenuated the cognitive impairment and fatigue that occurred during adjuvant breast cancer chemotherapy.
__label__noRel	There was no difference between groups in mean change in EXIT25 score from baseline to 6-month follow-up assessment.	Impaired cognition, fatigue, and diminished quality of life (QOL) are commonly associated with breast cancer chemotherapy.
__label__noRel	There was no difference between groups in mean change in EXIT25 score from baseline to 6-month follow-up assessment.	Mean change in EXIT25 scores from baseline to cycle 4 in the epoetin alfa group was 1.3 +/- 3.3;
__label__noRel	There was no difference between groups in mean change in EXIT25 score from baseline to 6-month follow-up assessment.	the mean change was 0.3 +/- 2.4 in the placebo group (a negative change indicates improved executive function).
__label__noRel	There was no difference between groups in mean change in EXIT25 score from baseline to 6-month follow-up assessment.	Mean hemoglobin levels were higher in the epoetin alfa group compared with the placebo group after 4 cycles of chemotherapy.
__label__noRel	There was no difference between groups in mean change in EXIT25 score from baseline to 6-month follow-up assessment.	Epoetin alfa recipients had less of a decrease in FACT-An subscale scores from baseline to cycle 4 and improvement in FACT-An subscale scores at 6-month follow-up assessment compared with placebo.
__label__noRel	There was no difference between groups in mean change in EXIT25 score from baseline to 6-month follow-up assessment.	Epoetin alfa therapy was well tolerated.
__label__noRel	There was no difference between groups in mean change in EXIT25 score from baseline to 6-month follow-up assessment.	These data suggest that epoetin alfa may have attenuated the cognitive impairment and fatigue that occurred during adjuvant breast cancer chemotherapy.
__label__noRel	Mean hemoglobin levels were higher in the epoetin alfa group compared with the placebo group after 4 cycles of chemotherapy.	Impaired cognition, fatigue, and diminished quality of life (QOL) are commonly associated with breast cancer chemotherapy.
__label__noRel	Mean hemoglobin levels were higher in the epoetin alfa group compared with the placebo group after 4 cycles of chemotherapy.	Mean change in EXIT25 scores from baseline to cycle 4 in the epoetin alfa group was 1.3 +/- 3.3;
__label__noRel	Mean hemoglobin levels were higher in the epoetin alfa group compared with the placebo group after 4 cycles of chemotherapy.	the mean change was 0.3 +/- 2.4 in the placebo group (a negative change indicates improved executive function).
__label__noRel	Mean hemoglobin levels were higher in the epoetin alfa group compared with the placebo group after 4 cycles of chemotherapy.	There was no difference between groups in mean change in EXIT25 score from baseline to 6-month follow-up assessment.
__label__noRel	Mean hemoglobin levels were higher in the epoetin alfa group compared with the placebo group after 4 cycles of chemotherapy.	Epoetin alfa recipients had less of a decrease in FACT-An subscale scores from baseline to cycle 4 and improvement in FACT-An subscale scores at 6-month follow-up assessment compared with placebo.
__label__noRel	Mean hemoglobin levels were higher in the epoetin alfa group compared with the placebo group after 4 cycles of chemotherapy.	Epoetin alfa therapy was well tolerated.
__label__noRel	Mean hemoglobin levels were higher in the epoetin alfa group compared with the placebo group after 4 cycles of chemotherapy.	These data suggest that epoetin alfa may have attenuated the cognitive impairment and fatigue that occurred during adjuvant breast cancer chemotherapy.
__label__noRel	Epoetin alfa recipients had less of a decrease in FACT-An subscale scores from baseline to cycle 4 and improvement in FACT-An subscale scores at 6-month follow-up assessment compared with placebo.	Impaired cognition, fatigue, and diminished quality of life (QOL) are commonly associated with breast cancer chemotherapy.
__label__noRel	Epoetin alfa recipients had less of a decrease in FACT-An subscale scores from baseline to cycle 4 and improvement in FACT-An subscale scores at 6-month follow-up assessment compared with placebo.	Mean change in EXIT25 scores from baseline to cycle 4 in the epoetin alfa group was 1.3 +/- 3.3;
__label__noRel	Epoetin alfa recipients had less of a decrease in FACT-An subscale scores from baseline to cycle 4 and improvement in FACT-An subscale scores at 6-month follow-up assessment compared with placebo.	the mean change was 0.3 +/- 2.4 in the placebo group (a negative change indicates improved executive function).
__label__noRel	Epoetin alfa recipients had less of a decrease in FACT-An subscale scores from baseline to cycle 4 and improvement in FACT-An subscale scores at 6-month follow-up assessment compared with placebo.	There was no difference between groups in mean change in EXIT25 score from baseline to 6-month follow-up assessment.
__label__noRel	Epoetin alfa recipients had less of a decrease in FACT-An subscale scores from baseline to cycle 4 and improvement in FACT-An subscale scores at 6-month follow-up assessment compared with placebo.	Mean hemoglobin levels were higher in the epoetin alfa group compared with the placebo group after 4 cycles of chemotherapy.
__label__noRel	Epoetin alfa recipients had less of a decrease in FACT-An subscale scores from baseline to cycle 4 and improvement in FACT-An subscale scores at 6-month follow-up assessment compared with placebo.	Epoetin alfa therapy was well tolerated.
__label__Support	Epoetin alfa recipients had less of a decrease in FACT-An subscale scores from baseline to cycle 4 and improvement in FACT-An subscale scores at 6-month follow-up assessment compared with placebo.	These data suggest that epoetin alfa may have attenuated the cognitive impairment and fatigue that occurred during adjuvant breast cancer chemotherapy.
__label__noRel	Epoetin alfa therapy was well tolerated.	Impaired cognition, fatigue, and diminished quality of life (QOL) are commonly associated with breast cancer chemotherapy.
__label__noRel	Epoetin alfa therapy was well tolerated.	Mean change in EXIT25 scores from baseline to cycle 4 in the epoetin alfa group was 1.3 +/- 3.3;
__label__noRel	Epoetin alfa therapy was well tolerated.	the mean change was 0.3 +/- 2.4 in the placebo group (a negative change indicates improved executive function).
__label__noRel	Epoetin alfa therapy was well tolerated.	There was no difference between groups in mean change in EXIT25 score from baseline to 6-month follow-up assessment.
__label__noRel	Epoetin alfa therapy was well tolerated.	Mean hemoglobin levels were higher in the epoetin alfa group compared with the placebo group after 4 cycles of chemotherapy.
__label__noRel	Epoetin alfa therapy was well tolerated.	Epoetin alfa recipients had less of a decrease in FACT-An subscale scores from baseline to cycle 4 and improvement in FACT-An subscale scores at 6-month follow-up assessment compared with placebo.
__label__noRel	Epoetin alfa therapy was well tolerated.	These data suggest that epoetin alfa may have attenuated the cognitive impairment and fatigue that occurred during adjuvant breast cancer chemotherapy.
__label__noRel	These data suggest that epoetin alfa may have attenuated the cognitive impairment and fatigue that occurred during adjuvant breast cancer chemotherapy.	Impaired cognition, fatigue, and diminished quality of life (QOL) are commonly associated with breast cancer chemotherapy.
__label__noRel	These data suggest that epoetin alfa may have attenuated the cognitive impairment and fatigue that occurred during adjuvant breast cancer chemotherapy.	Mean change in EXIT25 scores from baseline to cycle 4 in the epoetin alfa group was 1.3 +/- 3.3;
__label__noRel	These data suggest that epoetin alfa may have attenuated the cognitive impairment and fatigue that occurred during adjuvant breast cancer chemotherapy.	the mean change was 0.3 +/- 2.4 in the placebo group (a negative change indicates improved executive function).
__label__noRel	These data suggest that epoetin alfa may have attenuated the cognitive impairment and fatigue that occurred during adjuvant breast cancer chemotherapy.	There was no difference between groups in mean change in EXIT25 score from baseline to 6-month follow-up assessment.
__label__noRel	These data suggest that epoetin alfa may have attenuated the cognitive impairment and fatigue that occurred during adjuvant breast cancer chemotherapy.	Mean hemoglobin levels were higher in the epoetin alfa group compared with the placebo group after 4 cycles of chemotherapy.
__label__noRel	These data suggest that epoetin alfa may have attenuated the cognitive impairment and fatigue that occurred during adjuvant breast cancer chemotherapy.	Epoetin alfa recipients had less of a decrease in FACT-An subscale scores from baseline to cycle 4 and improvement in FACT-An subscale scores at 6-month follow-up assessment compared with placebo.
__label__noRel	These data suggest that epoetin alfa may have attenuated the cognitive impairment and fatigue that occurred during adjuvant breast cancer chemotherapy.	Epoetin alfa therapy was well tolerated.
__label__noRel	Intraperitoneal administration limits cardiotoxicity of verapamil.	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.
__label__noRel	Intraperitoneal administration limits cardiotoxicity of verapamil.	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.
__label__noRel	Intraperitoneal administration limits cardiotoxicity of verapamil.	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.
__label__noRel	Intraperitoneal administration limits cardiotoxicity of verapamil.	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).
__label__noRel	Intraperitoneal administration limits cardiotoxicity of verapamil.	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).
__label__noRel	Intraperitoneal administration limits cardiotoxicity of verapamil.	cumulative survival rate was also significantly higher in the combined treatment group.
__label__noRel	Intraperitoneal administration limits cardiotoxicity of verapamil.	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.
__label__noRel	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.	Intraperitoneal administration limits cardiotoxicity of verapamil.
__label__noRel	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.
__label__noRel	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.
__label__noRel	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).
__label__noRel	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).
__label__noRel	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.	cumulative survival rate was also significantly higher in the combined treatment group.
__label__noRel	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.
__label__noRel	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.	Intraperitoneal administration limits cardiotoxicity of verapamil.
__label__noRel	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.
__label__noRel	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.
__label__noRel	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).
__label__noRel	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).
__label__noRel	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.	cumulative survival rate was also significantly higher in the combined treatment group.
__label__noRel	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.
__label__noRel	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.	Intraperitoneal administration limits cardiotoxicity of verapamil.
__label__noRel	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.
__label__noRel	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.
__label__noRel	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).
__label__noRel	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).
__label__noRel	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.	cumulative survival rate was also significantly higher in the combined treatment group.
__label__noRel	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.
__label__noRel	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).	Intraperitoneal administration limits cardiotoxicity of verapamil.
__label__Support	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.
__label__noRel	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.
__label__noRel	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.
__label__noRel	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).
__label__noRel	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).	cumulative survival rate was also significantly higher in the combined treatment group.
__label__noRel	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.
__label__noRel	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).	Intraperitoneal administration limits cardiotoxicity of verapamil.
__label__Support	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.
__label__noRel	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.
__label__noRel	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.
__label__noRel	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).
__label__noRel	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).	cumulative survival rate was also significantly higher in the combined treatment group.
__label__noRel	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.
__label__noRel	cumulative survival rate was also significantly higher in the combined treatment group.	Intraperitoneal administration limits cardiotoxicity of verapamil.
__label__Support	cumulative survival rate was also significantly higher in the combined treatment group.	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.
__label__noRel	cumulative survival rate was also significantly higher in the combined treatment group.	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.
__label__noRel	cumulative survival rate was also significantly higher in the combined treatment group.	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.
__label__noRel	cumulative survival rate was also significantly higher in the combined treatment group.	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).
__label__noRel	cumulative survival rate was also significantly higher in the combined treatment group.	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).
__label__noRel	cumulative survival rate was also significantly higher in the combined treatment group.	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.
__label__Support	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.	Intraperitoneal administration limits cardiotoxicity of verapamil.
__label__noRel	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.
__label__noRel	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.
__label__noRel	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.
__label__noRel	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).
__label__noRel	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).
__label__noRel	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.	cumulative survival rate was also significantly higher in the combined treatment group.
__label__noRel	Intent-to-treat analysis showed no significant differences between the three arms for appetite, QOL, or cannabinoid-related toxicity.	Increased appetite was reported by 73%, 58%, and 69% of patients receiving CE, THC, or PL, respectively.
__label__noRel	Intent-to-treat analysis showed no significant differences between the three arms for appetite, QOL, or cannabinoid-related toxicity.	CE at the oral dose administered was well tolerated by these patients with CACS.
__label__Support	Intent-to-treat analysis showed no significant differences between the three arms for appetite, QOL, or cannabinoid-related toxicity.	No differences in patients' appetite or QOL were found either between CE, THC, and PL or between CE and THC at the dosages investigated.
__label__noRel	Increased appetite was reported by 73%, 58%, and 69% of patients receiving CE, THC, or PL, respectively.	Intent-to-treat analysis showed no significant differences between the three arms for appetite, QOL, or cannabinoid-related toxicity.
__label__noRel	Increased appetite was reported by 73%, 58%, and 69% of patients receiving CE, THC, or PL, respectively.	CE at the oral dose administered was well tolerated by these patients with CACS.
__label__Support	Increased appetite was reported by 73%, 58%, and 69% of patients receiving CE, THC, or PL, respectively.	No differences in patients' appetite or QOL were found either between CE, THC, and PL or between CE and THC at the dosages investigated.
__label__noRel	CE at the oral dose administered was well tolerated by these patients with CACS.	Intent-to-treat analysis showed no significant differences between the three arms for appetite, QOL, or cannabinoid-related toxicity.
__label__noRel	CE at the oral dose administered was well tolerated by these patients with CACS.	Increased appetite was reported by 73%, 58%, and 69% of patients receiving CE, THC, or PL, respectively.
__label__noRel	CE at the oral dose administered was well tolerated by these patients with CACS.	No differences in patients' appetite or QOL were found either between CE, THC, and PL or between CE and THC at the dosages investigated.
__label__noRel	No differences in patients' appetite or QOL were found either between CE, THC, and PL or between CE and THC at the dosages investigated.	Intent-to-treat analysis showed no significant differences between the three arms for appetite, QOL, or cannabinoid-related toxicity.
__label__noRel	No differences in patients' appetite or QOL were found either between CE, THC, and PL or between CE and THC at the dosages investigated.	Increased appetite was reported by 73%, 58%, and 69% of patients receiving CE, THC, or PL, respectively.
__label__noRel	No differences in patients' appetite or QOL were found either between CE, THC, and PL or between CE and THC at the dosages investigated.	CE at the oral dose administered was well tolerated by these patients with CACS.
__label__noRel	Chemotherapy can profoundly affect patients' quality of life (QOL),	Overall (FACT-G) scores did not differ significantly between arms at the fourth assessment (C = 70.3 (19.6); CP = 72.8 (17.4)).
__label__noRel	Chemotherapy can profoundly affect patients' quality of life (QOL),	Scores were stable over time and considerably lower than the general population norms.
__label__noRel	Chemotherapy can profoundly affect patients' quality of life (QOL),	The BPI-SF revealed a decline in pain scores in both arms from the first to fourth assessments.
__label__noRel	Chemotherapy can profoundly affect patients' quality of life (QOL),	The CP arm produced a significantly higher response rate and progression-free survival (PFS)
__label__noRel	Chemotherapy can profoundly affect patients' quality of life (QOL),	but not overall survival (OS).
__label__noRel	Chemotherapy can profoundly affect patients' quality of life (QOL),	Greater myelosuppression was reported in the combination arm.
__label__noRel	Chemotherapy can profoundly affect patients' quality of life (QOL),	The rate of QOL drop-out for any reason was higher for C (53%) compared to CP (38%) (P < 0.05).
__label__noRel	Chemotherapy can profoundly affect patients' quality of life (QOL),	There was no significant difference in overall QOL scores between treatment arms or serially.
__label__noRel	Chemotherapy can profoundly affect patients' quality of life (QOL),	Combined with QOL results, the significant increase in response and PFS in the CP arm and the higher drop-out rate in the C arm suggest a better outcome for the combination regimen despite its increased myelosuppression.
__label__noRel	Overall (FACT-G) scores did not differ significantly between arms at the fourth assessment (C = 70.3 (19.6); CP = 72.8 (17.4)).	Chemotherapy can profoundly affect patients' quality of life (QOL),
__label__noRel	Overall (FACT-G) scores did not differ significantly between arms at the fourth assessment (C = 70.3 (19.6); CP = 72.8 (17.4)).	Scores were stable over time and considerably lower than the general population norms.
__label__noRel	Overall (FACT-G) scores did not differ significantly between arms at the fourth assessment (C = 70.3 (19.6); CP = 72.8 (17.4)).	The BPI-SF revealed a decline in pain scores in both arms from the first to fourth assessments.
__label__noRel	Overall (FACT-G) scores did not differ significantly between arms at the fourth assessment (C = 70.3 (19.6); CP = 72.8 (17.4)).	The CP arm produced a significantly higher response rate and progression-free survival (PFS)
__label__noRel	Overall (FACT-G) scores did not differ significantly between arms at the fourth assessment (C = 70.3 (19.6); CP = 72.8 (17.4)).	but not overall survival (OS).
__label__noRel	Overall (FACT-G) scores did not differ significantly between arms at the fourth assessment (C = 70.3 (19.6); CP = 72.8 (17.4)).	Greater myelosuppression was reported in the combination arm.
__label__noRel	Overall (FACT-G) scores did not differ significantly between arms at the fourth assessment (C = 70.3 (19.6); CP = 72.8 (17.4)).	The rate of QOL drop-out for any reason was higher for C (53%) compared to CP (38%) (P < 0.05).
__label__noRel	Overall (FACT-G) scores did not differ significantly between arms at the fourth assessment (C = 70.3 (19.6); CP = 72.8 (17.4)).	There was no significant difference in overall QOL scores between treatment arms or serially.
__label__noRel	Overall (FACT-G) scores did not differ significantly between arms at the fourth assessment (C = 70.3 (19.6); CP = 72.8 (17.4)).	Combined with QOL results, the significant increase in response and PFS in the CP arm and the higher drop-out rate in the C arm suggest a better outcome for the combination regimen despite its increased myelosuppression.
__label__noRel	Scores were stable over time and considerably lower than the general population norms.	Chemotherapy can profoundly affect patients' quality of life (QOL),
__label__noRel	Scores were stable over time and considerably lower than the general population norms.	Overall (FACT-G) scores did not differ significantly between arms at the fourth assessment (C = 70.3 (19.6); CP = 72.8 (17.4)).
__label__noRel	Scores were stable over time and considerably lower than the general population norms.	The BPI-SF revealed a decline in pain scores in both arms from the first to fourth assessments.
__label__noRel	Scores were stable over time and considerably lower than the general population norms.	The CP arm produced a significantly higher response rate and progression-free survival (PFS)
__label__noRel	Scores were stable over time and considerably lower than the general population norms.	but not overall survival (OS).
__label__noRel	Scores were stable over time and considerably lower than the general population norms.	Greater myelosuppression was reported in the combination arm.
__label__noRel	Scores were stable over time and considerably lower than the general population norms.	The rate of QOL drop-out for any reason was higher for C (53%) compared to CP (38%) (P < 0.05).
__label__noRel	Scores were stable over time and considerably lower than the general population norms.	There was no significant difference in overall QOL scores between treatment arms or serially.
__label__noRel	Scores were stable over time and considerably lower than the general population norms.	Combined with QOL results, the significant increase in response and PFS in the CP arm and the higher drop-out rate in the C arm suggest a better outcome for the combination regimen despite its increased myelosuppression.
__label__noRel	The BPI-SF revealed a decline in pain scores in both arms from the first to fourth assessments.	Chemotherapy can profoundly affect patients' quality of life (QOL),
__label__noRel	The BPI-SF revealed a decline in pain scores in both arms from the first to fourth assessments.	Overall (FACT-G) scores did not differ significantly between arms at the fourth assessment (C = 70.3 (19.6); CP = 72.8 (17.4)).
__label__noRel	The BPI-SF revealed a decline in pain scores in both arms from the first to fourth assessments.	Scores were stable over time and considerably lower than the general population norms.
__label__noRel	The BPI-SF revealed a decline in pain scores in both arms from the first to fourth assessments.	The CP arm produced a significantly higher response rate and progression-free survival (PFS)
__label__noRel	The BPI-SF revealed a decline in pain scores in both arms from the first to fourth assessments.	but not overall survival (OS).
__label__noRel	The BPI-SF revealed a decline in pain scores in both arms from the first to fourth assessments.	Greater myelosuppression was reported in the combination arm.
__label__noRel	The BPI-SF revealed a decline in pain scores in both arms from the first to fourth assessments.	The rate of QOL drop-out for any reason was higher for C (53%) compared to CP (38%) (P < 0.05).
__label__noRel	The BPI-SF revealed a decline in pain scores in both arms from the first to fourth assessments.	There was no significant difference in overall QOL scores between treatment arms or serially.
__label__Support	The BPI-SF revealed a decline in pain scores in both arms from the first to fourth assessments.	Combined with QOL results, the significant increase in response and PFS in the CP arm and the higher drop-out rate in the C arm suggest a better outcome for the combination regimen despite its increased myelosuppression.
__label__noRel	The CP arm produced a significantly higher response rate and progression-free survival (PFS)	Chemotherapy can profoundly affect patients' quality of life (QOL),
__label__noRel	The CP arm produced a significantly higher response rate and progression-free survival (PFS)	Overall (FACT-G) scores did not differ significantly between arms at the fourth assessment (C = 70.3 (19.6); CP = 72.8 (17.4)).
__label__noRel	The CP arm produced a significantly higher response rate and progression-free survival (PFS)	Scores were stable over time and considerably lower than the general population norms.
__label__noRel	The CP arm produced a significantly higher response rate and progression-free survival (PFS)	The BPI-SF revealed a decline in pain scores in both arms from the first to fourth assessments.
__label__noRel	The CP arm produced a significantly higher response rate and progression-free survival (PFS)	but not overall survival (OS).
__label__noRel	The CP arm produced a significantly higher response rate and progression-free survival (PFS)	Greater myelosuppression was reported in the combination arm.
__label__noRel	The CP arm produced a significantly higher response rate and progression-free survival (PFS)	The rate of QOL drop-out for any reason was higher for C (53%) compared to CP (38%) (P < 0.05).
__label__noRel	The CP arm produced a significantly higher response rate and progression-free survival (PFS)	There was no significant difference in overall QOL scores between treatment arms or serially.
__label__Support	The CP arm produced a significantly higher response rate and progression-free survival (PFS)	Combined with QOL results, the significant increase in response and PFS in the CP arm and the higher drop-out rate in the C arm suggest a better outcome for the combination regimen despite its increased myelosuppression.
__label__noRel	but not overall survival (OS).	Chemotherapy can profoundly affect patients' quality of life (QOL),
__label__noRel	but not overall survival (OS).	Overall (FACT-G) scores did not differ significantly between arms at the fourth assessment (C = 70.3 (19.6); CP = 72.8 (17.4)).
__label__noRel	but not overall survival (OS).	Scores were stable over time and considerably lower than the general population norms.
__label__noRel	but not overall survival (OS).	The BPI-SF revealed a decline in pain scores in both arms from the first to fourth assessments.
__label__Attack	but not overall survival (OS).	The CP arm produced a significantly higher response rate and progression-free survival (PFS)
__label__noRel	but not overall survival (OS).	Greater myelosuppression was reported in the combination arm.
__label__noRel	but not overall survival (OS).	The rate of QOL drop-out for any reason was higher for C (53%) compared to CP (38%) (P < 0.05).
__label__noRel	but not overall survival (OS).	There was no significant difference in overall QOL scores between treatment arms or serially.
__label__noRel	but not overall survival (OS).	Combined with QOL results, the significant increase in response and PFS in the CP arm and the higher drop-out rate in the C arm suggest a better outcome for the combination regimen despite its increased myelosuppression.
__label__noRel	Greater myelosuppression was reported in the combination arm.	Chemotherapy can profoundly affect patients' quality of life (QOL),
__label__noRel	Greater myelosuppression was reported in the combination arm.	Overall (FACT-G) scores did not differ significantly between arms at the fourth assessment (C = 70.3 (19.6); CP = 72.8 (17.4)).
__label__noRel	Greater myelosuppression was reported in the combination arm.	Scores were stable over time and considerably lower than the general population norms.
__label__noRel	Greater myelosuppression was reported in the combination arm.	The BPI-SF revealed a decline in pain scores in both arms from the first to fourth assessments.
__label__noRel	Greater myelosuppression was reported in the combination arm.	The CP arm produced a significantly higher response rate and progression-free survival (PFS)
__label__noRel	Greater myelosuppression was reported in the combination arm.	but not overall survival (OS).
__label__noRel	Greater myelosuppression was reported in the combination arm.	The rate of QOL drop-out for any reason was higher for C (53%) compared to CP (38%) (P < 0.05).
__label__noRel	Greater myelosuppression was reported in the combination arm.	There was no significant difference in overall QOL scores between treatment arms or serially.
__label__Support	Greater myelosuppression was reported in the combination arm.	Combined with QOL results, the significant increase in response and PFS in the CP arm and the higher drop-out rate in the C arm suggest a better outcome for the combination regimen despite its increased myelosuppression.
__label__noRel	The rate of QOL drop-out for any reason was higher for C (53%) compared to CP (38%) (P < 0.05).	Chemotherapy can profoundly affect patients' quality of life (QOL),
__label__noRel	The rate of QOL drop-out for any reason was higher for C (53%) compared to CP (38%) (P < 0.05).	Overall (FACT-G) scores did not differ significantly between arms at the fourth assessment (C = 70.3 (19.6); CP = 72.8 (17.4)).
__label__noRel	The rate of QOL drop-out for any reason was higher for C (53%) compared to CP (38%) (P < 0.05).	Scores were stable over time and considerably lower than the general population norms.
__label__noRel	The rate of QOL drop-out for any reason was higher for C (53%) compared to CP (38%) (P < 0.05).	The BPI-SF revealed a decline in pain scores in both arms from the first to fourth assessments.
__label__noRel	The rate of QOL drop-out for any reason was higher for C (53%) compared to CP (38%) (P < 0.05).	The CP arm produced a significantly higher response rate and progression-free survival (PFS)
__label__noRel	The rate of QOL drop-out for any reason was higher for C (53%) compared to CP (38%) (P < 0.05).	but not overall survival (OS).
__label__noRel	The rate of QOL drop-out for any reason was higher for C (53%) compared to CP (38%) (P < 0.05).	Greater myelosuppression was reported in the combination arm.
__label__noRel	The rate of QOL drop-out for any reason was higher for C (53%) compared to CP (38%) (P < 0.05).	There was no significant difference in overall QOL scores between treatment arms or serially.
__label__Support	The rate of QOL drop-out for any reason was higher for C (53%) compared to CP (38%) (P < 0.05).	Combined with QOL results, the significant increase in response and PFS in the CP arm and the higher drop-out rate in the C arm suggest a better outcome for the combination regimen despite its increased myelosuppression.
__label__noRel	There was no significant difference in overall QOL scores between treatment arms or serially.	Chemotherapy can profoundly affect patients' quality of life (QOL),
__label__noRel	There was no significant difference in overall QOL scores between treatment arms or serially.	Overall (FACT-G) scores did not differ significantly between arms at the fourth assessment (C = 70.3 (19.6); CP = 72.8 (17.4)).
__label__noRel	There was no significant difference in overall QOL scores between treatment arms or serially.	Scores were stable over time and considerably lower than the general population norms.
__label__noRel	There was no significant difference in overall QOL scores between treatment arms or serially.	The BPI-SF revealed a decline in pain scores in both arms from the first to fourth assessments.
__label__noRel	There was no significant difference in overall QOL scores between treatment arms or serially.	The CP arm produced a significantly higher response rate and progression-free survival (PFS)
__label__noRel	There was no significant difference in overall QOL scores between treatment arms or serially.	but not overall survival (OS).
__label__noRel	There was no significant difference in overall QOL scores between treatment arms or serially.	Greater myelosuppression was reported in the combination arm.
__label__noRel	There was no significant difference in overall QOL scores between treatment arms or serially.	The rate of QOL drop-out for any reason was higher for C (53%) compared to CP (38%) (P < 0.05).
__label__Support	There was no significant difference in overall QOL scores between treatment arms or serially.	Combined with QOL results, the significant increase in response and PFS in the CP arm and the higher drop-out rate in the C arm suggest a better outcome for the combination regimen despite its increased myelosuppression.
__label__noRel	Combined with QOL results, the significant increase in response and PFS in the CP arm and the higher drop-out rate in the C arm suggest a better outcome for the combination regimen despite its increased myelosuppression.	Chemotherapy can profoundly affect patients' quality of life (QOL),
__label__noRel	Combined with QOL results, the significant increase in response and PFS in the CP arm and the higher drop-out rate in the C arm suggest a better outcome for the combination regimen despite its increased myelosuppression.	Overall (FACT-G) scores did not differ significantly between arms at the fourth assessment (C = 70.3 (19.6); CP = 72.8 (17.4)).
__label__noRel	Combined with QOL results, the significant increase in response and PFS in the CP arm and the higher drop-out rate in the C arm suggest a better outcome for the combination regimen despite its increased myelosuppression.	Scores were stable over time and considerably lower than the general population norms.
__label__noRel	Combined with QOL results, the significant increase in response and PFS in the CP arm and the higher drop-out rate in the C arm suggest a better outcome for the combination regimen despite its increased myelosuppression.	The BPI-SF revealed a decline in pain scores in both arms from the first to fourth assessments.
__label__noRel	Combined with QOL results, the significant increase in response and PFS in the CP arm and the higher drop-out rate in the C arm suggest a better outcome for the combination regimen despite its increased myelosuppression.	The CP arm produced a significantly higher response rate and progression-free survival (PFS)
__label__noRel	Combined with QOL results, the significant increase in response and PFS in the CP arm and the higher drop-out rate in the C arm suggest a better outcome for the combination regimen despite its increased myelosuppression.	but not overall survival (OS).
__label__noRel	Combined with QOL results, the significant increase in response and PFS in the CP arm and the higher drop-out rate in the C arm suggest a better outcome for the combination regimen despite its increased myelosuppression.	Greater myelosuppression was reported in the combination arm.
__label__noRel	Combined with QOL results, the significant increase in response and PFS in the CP arm and the higher drop-out rate in the C arm suggest a better outcome for the combination regimen despite its increased myelosuppression.	The rate of QOL drop-out for any reason was higher for C (53%) compared to CP (38%) (P < 0.05).
__label__noRel	Combined with QOL results, the significant increase in response and PFS in the CP arm and the higher drop-out rate in the C arm suggest a better outcome for the combination regimen despite its increased myelosuppression.	There was no significant difference in overall QOL scores between treatment arms or serially.
__label__noRel	Results showed overall significant improvements in psychosocial stress and quality of life in both the MBAT and educational support groups immediately post-intervention;	however, participants with high stress levels at baseline had significantly improved overall outcomes only in the MBAT group, both immediately post-intervention and at 6 months.
__label__noRel	Results showed overall significant improvements in psychosocial stress and quality of life in both the MBAT and educational support groups immediately post-intervention;	at 6 months follow-up, participants attending five or more sessions trended toward retaining treatment effects better in the MBAT than in the control group.
__label__noRel	Results showed overall significant improvements in psychosocial stress and quality of life in both the MBAT and educational support groups immediately post-intervention;	black women and white women were similar in terms of how they benefited from the MBAT intervention, even though white participants tended to have higher educational level and marital status.
__label__Support	Results showed overall significant improvements in psychosocial stress and quality of life in both the MBAT and educational support groups immediately post-intervention;	In conclusion, MBAT is associated with significant, sustained benefits across a diverse range of breast cancer patients, particularly those with high stress levels.
__label__noRel	however, participants with high stress levels at baseline had significantly improved overall outcomes only in the MBAT group, both immediately post-intervention and at 6 months.	Results showed overall significant improvements in psychosocial stress and quality of life in both the MBAT and educational support groups immediately post-intervention;
__label__noRel	however, participants with high stress levels at baseline had significantly improved overall outcomes only in the MBAT group, both immediately post-intervention and at 6 months.	at 6 months follow-up, participants attending five or more sessions trended toward retaining treatment effects better in the MBAT than in the control group.
__label__noRel	however, participants with high stress levels at baseline had significantly improved overall outcomes only in the MBAT group, both immediately post-intervention and at 6 months.	black women and white women were similar in terms of how they benefited from the MBAT intervention, even though white participants tended to have higher educational level and marital status.
__label__Support	however, participants with high stress levels at baseline had significantly improved overall outcomes only in the MBAT group, both immediately post-intervention and at 6 months.	In conclusion, MBAT is associated with significant, sustained benefits across a diverse range of breast cancer patients, particularly those with high stress levels.
__label__noRel	at 6 months follow-up, participants attending five or more sessions trended toward retaining treatment effects better in the MBAT than in the control group.	Results showed overall significant improvements in psychosocial stress and quality of life in both the MBAT and educational support groups immediately post-intervention;
__label__noRel	at 6 months follow-up, participants attending five or more sessions trended toward retaining treatment effects better in the MBAT than in the control group.	however, participants with high stress levels at baseline had significantly improved overall outcomes only in the MBAT group, both immediately post-intervention and at 6 months.
__label__noRel	at 6 months follow-up, participants attending five or more sessions trended toward retaining treatment effects better in the MBAT than in the control group.	black women and white women were similar in terms of how they benefited from the MBAT intervention, even though white participants tended to have higher educational level and marital status.
__label__Support	at 6 months follow-up, participants attending five or more sessions trended toward retaining treatment effects better in the MBAT than in the control group.	In conclusion, MBAT is associated with significant, sustained benefits across a diverse range of breast cancer patients, particularly those with high stress levels.
__label__noRel	black women and white women were similar in terms of how they benefited from the MBAT intervention, even though white participants tended to have higher educational level and marital status.	Results showed overall significant improvements in psychosocial stress and quality of life in both the MBAT and educational support groups immediately post-intervention;
__label__noRel	black women and white women were similar in terms of how they benefited from the MBAT intervention, even though white participants tended to have higher educational level and marital status.	however, participants with high stress levels at baseline had significantly improved overall outcomes only in the MBAT group, both immediately post-intervention and at 6 months.
__label__noRel	black women and white women were similar in terms of how they benefited from the MBAT intervention, even though white participants tended to have higher educational level and marital status.	at 6 months follow-up, participants attending five or more sessions trended toward retaining treatment effects better in the MBAT than in the control group.
__label__Support	black women and white women were similar in terms of how they benefited from the MBAT intervention, even though white participants tended to have higher educational level and marital status.	In conclusion, MBAT is associated with significant, sustained benefits across a diverse range of breast cancer patients, particularly those with high stress levels.
__label__noRel	In conclusion, MBAT is associated with significant, sustained benefits across a diverse range of breast cancer patients, particularly those with high stress levels.	Results showed overall significant improvements in psychosocial stress and quality of life in both the MBAT and educational support groups immediately post-intervention;
__label__noRel	In conclusion, MBAT is associated with significant, sustained benefits across a diverse range of breast cancer patients, particularly those with high stress levels.	however, participants with high stress levels at baseline had significantly improved overall outcomes only in the MBAT group, both immediately post-intervention and at 6 months.
__label__noRel	In conclusion, MBAT is associated with significant, sustained benefits across a diverse range of breast cancer patients, particularly those with high stress levels.	at 6 months follow-up, participants attending five or more sessions trended toward retaining treatment effects better in the MBAT than in the control group.
__label__noRel	In conclusion, MBAT is associated with significant, sustained benefits across a diverse range of breast cancer patients, particularly those with high stress levels.	black women and white women were similar in terms of how they benefited from the MBAT intervention, even though white participants tended to have higher educational level and marital status.
__label__noRel	With a median follow-up of 13 months, the overall survival was significantly better in the irinotecan group (p=0.0001), with 36.2% 1-year survival in the irinotecan group versus 13.8% in the supportive-care group.	The survival benefit, adjusted for prognostic factors in a multivariate analysis, remained significant (p=0.001).
__label__noRel	With a median follow-up of 13 months, the overall survival was significantly better in the irinotecan group (p=0.0001), with 36.2% 1-year survival in the irinotecan group versus 13.8% in the supportive-care group.	Survival without performance-status deterioration (p=0.0001), without weight loss of more than 5% (p=0.018), and pain-free survival (p=0.003) were significantly better in the patients given irinotecan.
__label__noRel	With a median follow-up of 13 months, the overall survival was significantly better in the irinotecan group (p=0.0001), with 36.2% 1-year survival in the irinotecan group versus 13.8% in the supportive-care group.	In a quality-of-life analysis, all significant differences, except on diarrhoea score, were in favour of the irinotecan group.
__label__Support	With a median follow-up of 13 months, the overall survival was significantly better in the irinotecan group (p=0.0001), with 36.2% 1-year survival in the irinotecan group versus 13.8% in the supportive-care group.	Our study shows that despite the side-effects of treatment, patients who have metastatic colorectal cancer, and for whom fluorouracil has failed, have a longer survival, fewer tumour-related symptoms, and a better quality of life when treated with irinotecan than with supportive care alone.
__label__noRel	The survival benefit, adjusted for prognostic factors in a multivariate analysis, remained significant (p=0.001).	With a median follow-up of 13 months, the overall survival was significantly better in the irinotecan group (p=0.0001), with 36.2% 1-year survival in the irinotecan group versus 13.8% in the supportive-care group.
__label__noRel	The survival benefit, adjusted for prognostic factors in a multivariate analysis, remained significant (p=0.001).	Survival without performance-status deterioration (p=0.0001), without weight loss of more than 5% (p=0.018), and pain-free survival (p=0.003) were significantly better in the patients given irinotecan.
__label__noRel	The survival benefit, adjusted for prognostic factors in a multivariate analysis, remained significant (p=0.001).	In a quality-of-life analysis, all significant differences, except on diarrhoea score, were in favour of the irinotecan group.
__label__noRel	The survival benefit, adjusted for prognostic factors in a multivariate analysis, remained significant (p=0.001).	Our study shows that despite the side-effects of treatment, patients who have metastatic colorectal cancer, and for whom fluorouracil has failed, have a longer survival, fewer tumour-related symptoms, and a better quality of life when treated with irinotecan than with supportive care alone.
__label__noRel	Survival without performance-status deterioration (p=0.0001), without weight loss of more than 5% (p=0.018), and pain-free survival (p=0.003) were significantly better in the patients given irinotecan.	With a median follow-up of 13 months, the overall survival was significantly better in the irinotecan group (p=0.0001), with 36.2% 1-year survival in the irinotecan group versus 13.8% in the supportive-care group.
__label__noRel	Survival without performance-status deterioration (p=0.0001), without weight loss of more than 5% (p=0.018), and pain-free survival (p=0.003) were significantly better in the patients given irinotecan.	The survival benefit, adjusted for prognostic factors in a multivariate analysis, remained significant (p=0.001).
__label__noRel	Survival without performance-status deterioration (p=0.0001), without weight loss of more than 5% (p=0.018), and pain-free survival (p=0.003) were significantly better in the patients given irinotecan.	In a quality-of-life analysis, all significant differences, except on diarrhoea score, were in favour of the irinotecan group.
__label__Support	Survival without performance-status deterioration (p=0.0001), without weight loss of more than 5% (p=0.018), and pain-free survival (p=0.003) were significantly better in the patients given irinotecan.	Our study shows that despite the side-effects of treatment, patients who have metastatic colorectal cancer, and for whom fluorouracil has failed, have a longer survival, fewer tumour-related symptoms, and a better quality of life when treated with irinotecan than with supportive care alone.
__label__noRel	In a quality-of-life analysis, all significant differences, except on diarrhoea score, were in favour of the irinotecan group.	With a median follow-up of 13 months, the overall survival was significantly better in the irinotecan group (p=0.0001), with 36.2% 1-year survival in the irinotecan group versus 13.8% in the supportive-care group.
__label__noRel	In a quality-of-life analysis, all significant differences, except on diarrhoea score, were in favour of the irinotecan group.	The survival benefit, adjusted for prognostic factors in a multivariate analysis, remained significant (p=0.001).
__label__noRel	In a quality-of-life analysis, all significant differences, except on diarrhoea score, were in favour of the irinotecan group.	Survival without performance-status deterioration (p=0.0001), without weight loss of more than 5% (p=0.018), and pain-free survival (p=0.003) were significantly better in the patients given irinotecan.
__label__Support	In a quality-of-life analysis, all significant differences, except on diarrhoea score, were in favour of the irinotecan group.	Our study shows that despite the side-effects of treatment, patients who have metastatic colorectal cancer, and for whom fluorouracil has failed, have a longer survival, fewer tumour-related symptoms, and a better quality of life when treated with irinotecan than with supportive care alone.
__label__noRel	Our study shows that despite the side-effects of treatment, patients who have metastatic colorectal cancer, and for whom fluorouracil has failed, have a longer survival, fewer tumour-related symptoms, and a better quality of life when treated with irinotecan than with supportive care alone.	With a median follow-up of 13 months, the overall survival was significantly better in the irinotecan group (p=0.0001), with 36.2% 1-year survival in the irinotecan group versus 13.8% in the supportive-care group.
__label__noRel	Our study shows that despite the side-effects of treatment, patients who have metastatic colorectal cancer, and for whom fluorouracil has failed, have a longer survival, fewer tumour-related symptoms, and a better quality of life when treated with irinotecan than with supportive care alone.	The survival benefit, adjusted for prognostic factors in a multivariate analysis, remained significant (p=0.001).
__label__noRel	Our study shows that despite the side-effects of treatment, patients who have metastatic colorectal cancer, and for whom fluorouracil has failed, have a longer survival, fewer tumour-related symptoms, and a better quality of life when treated with irinotecan than with supportive care alone.	Survival without performance-status deterioration (p=0.0001), without weight loss of more than 5% (p=0.018), and pain-free survival (p=0.003) were significantly better in the patients given irinotecan.
__label__noRel	Our study shows that despite the side-effects of treatment, patients who have metastatic colorectal cancer, and for whom fluorouracil has failed, have a longer survival, fewer tumour-related symptoms, and a better quality of life when treated with irinotecan than with supportive care alone.	In a quality-of-life analysis, all significant differences, except on diarrhoea score, were in favour of the irinotecan group.
__label__noRel	The overall response rate was 34.6% for NP and 35.7% for NIP.	Median and 1-year survival rates were 10.0 months and 38.4% for NP, and 8.2 months and 33.7% for NIP, respectively.
__label__noRel	The overall response rate was 34.6% for NP and 35.7% for NIP.	The major World Health Organization grade 3-4 toxicities for NP and NIP, respectively, were: neutropenia (20.3% compared with 9% of cycles), anaemia (4.1% compared with 5% of cycles), nausea and vomiting (22.2% compared with 19.4% of patients) and alopecia (5.6% compared with 29.8% of patients).
__label__noRel	The overall response rate was 34.6% for NP and 35.7% for NIP.	Four toxic deaths occurred in the NP arm and eight in the NIP arm.
__label__noRel	The overall response rate was 34.6% for NP and 35.7% for NIP.	The different schedules of vinorelbine in the two arms led to a greater survival in the NP arm without impairing the tolerance profile,
__label__noRel	The overall response rate was 34.6% for NP and 35.7% for NIP.	although this is not statistically significant.
__label__noRel	The overall response rate was 34.6% for NP and 35.7% for NIP.	This confirms that the two-drug combination NP is a reference treatment for metastatic NSCLC.
__label__noRel	The overall response rate was 34.6% for NP and 35.7% for NIP.	The role of three-drug combinations remains questionable in this subset of patients.
__label__noRel	Median and 1-year survival rates were 10.0 months and 38.4% for NP, and 8.2 months and 33.7% for NIP, respectively.	The overall response rate was 34.6% for NP and 35.7% for NIP.
__label__noRel	Median and 1-year survival rates were 10.0 months and 38.4% for NP, and 8.2 months and 33.7% for NIP, respectively.	The major World Health Organization grade 3-4 toxicities for NP and NIP, respectively, were: neutropenia (20.3% compared with 9% of cycles), anaemia (4.1% compared with 5% of cycles), nausea and vomiting (22.2% compared with 19.4% of patients) and alopecia (5.6% compared with 29.8% of patients).
__label__noRel	Median and 1-year survival rates were 10.0 months and 38.4% for NP, and 8.2 months and 33.7% for NIP, respectively.	Four toxic deaths occurred in the NP arm and eight in the NIP arm.
__label__noRel	Median and 1-year survival rates were 10.0 months and 38.4% for NP, and 8.2 months and 33.7% for NIP, respectively.	The different schedules of vinorelbine in the two arms led to a greater survival in the NP arm without impairing the tolerance profile,
__label__noRel	Median and 1-year survival rates were 10.0 months and 38.4% for NP, and 8.2 months and 33.7% for NIP, respectively.	although this is not statistically significant.
__label__Support	Median and 1-year survival rates were 10.0 months and 38.4% for NP, and 8.2 months and 33.7% for NIP, respectively.	This confirms that the two-drug combination NP is a reference treatment for metastatic NSCLC.
__label__noRel	Median and 1-year survival rates were 10.0 months and 38.4% for NP, and 8.2 months and 33.7% for NIP, respectively.	The role of three-drug combinations remains questionable in this subset of patients.
__label__noRel	The major World Health Organization grade 3-4 toxicities for NP and NIP, respectively, were: neutropenia (20.3% compared with 9% of cycles), anaemia (4.1% compared with 5% of cycles), nausea and vomiting (22.2% compared with 19.4% of patients) and alopecia (5.6% compared with 29.8% of patients).	The overall response rate was 34.6% for NP and 35.7% for NIP.
__label__noRel	The major World Health Organization grade 3-4 toxicities for NP and NIP, respectively, were: neutropenia (20.3% compared with 9% of cycles), anaemia (4.1% compared with 5% of cycles), nausea and vomiting (22.2% compared with 19.4% of patients) and alopecia (5.6% compared with 29.8% of patients).	Median and 1-year survival rates were 10.0 months and 38.4% for NP, and 8.2 months and 33.7% for NIP, respectively.
__label__noRel	The major World Health Organization grade 3-4 toxicities for NP and NIP, respectively, were: neutropenia (20.3% compared with 9% of cycles), anaemia (4.1% compared with 5% of cycles), nausea and vomiting (22.2% compared with 19.4% of patients) and alopecia (5.6% compared with 29.8% of patients).	Four toxic deaths occurred in the NP arm and eight in the NIP arm.
__label__noRel	The major World Health Organization grade 3-4 toxicities for NP and NIP, respectively, were: neutropenia (20.3% compared with 9% of cycles), anaemia (4.1% compared with 5% of cycles), nausea and vomiting (22.2% compared with 19.4% of patients) and alopecia (5.6% compared with 29.8% of patients).	The different schedules of vinorelbine in the two arms led to a greater survival in the NP arm without impairing the tolerance profile,
__label__noRel	The major World Health Organization grade 3-4 toxicities for NP and NIP, respectively, were: neutropenia (20.3% compared with 9% of cycles), anaemia (4.1% compared with 5% of cycles), nausea and vomiting (22.2% compared with 19.4% of patients) and alopecia (5.6% compared with 29.8% of patients).	although this is not statistically significant.
__label__Support	The major World Health Organization grade 3-4 toxicities for NP and NIP, respectively, were: neutropenia (20.3% compared with 9% of cycles), anaemia (4.1% compared with 5% of cycles), nausea and vomiting (22.2% compared with 19.4% of patients) and alopecia (5.6% compared with 29.8% of patients).	This confirms that the two-drug combination NP is a reference treatment for metastatic NSCLC.
__label__noRel	The major World Health Organization grade 3-4 toxicities for NP and NIP, respectively, were: neutropenia (20.3% compared with 9% of cycles), anaemia (4.1% compared with 5% of cycles), nausea and vomiting (22.2% compared with 19.4% of patients) and alopecia (5.6% compared with 29.8% of patients).	The role of three-drug combinations remains questionable in this subset of patients.
__label__noRel	Four toxic deaths occurred in the NP arm and eight in the NIP arm.	The overall response rate was 34.6% for NP and 35.7% for NIP.
__label__noRel	Four toxic deaths occurred in the NP arm and eight in the NIP arm.	Median and 1-year survival rates were 10.0 months and 38.4% for NP, and 8.2 months and 33.7% for NIP, respectively.
__label__noRel	Four toxic deaths occurred in the NP arm and eight in the NIP arm.	The major World Health Organization grade 3-4 toxicities for NP and NIP, respectively, were: neutropenia (20.3% compared with 9% of cycles), anaemia (4.1% compared with 5% of cycles), nausea and vomiting (22.2% compared with 19.4% of patients) and alopecia (5.6% compared with 29.8% of patients).
__label__noRel	Four toxic deaths occurred in the NP arm and eight in the NIP arm.	The different schedules of vinorelbine in the two arms led to a greater survival in the NP arm without impairing the tolerance profile,
__label__noRel	Four toxic deaths occurred in the NP arm and eight in the NIP arm.	although this is not statistically significant.
__label__noRel	Four toxic deaths occurred in the NP arm and eight in the NIP arm.	This confirms that the two-drug combination NP is a reference treatment for metastatic NSCLC.
__label__Support	Four toxic deaths occurred in the NP arm and eight in the NIP arm.	The role of three-drug combinations remains questionable in this subset of patients.
__label__noRel	The different schedules of vinorelbine in the two arms led to a greater survival in the NP arm without impairing the tolerance profile,	The overall response rate was 34.6% for NP and 35.7% for NIP.
__label__noRel	The different schedules of vinorelbine in the two arms led to a greater survival in the NP arm without impairing the tolerance profile,	Median and 1-year survival rates were 10.0 months and 38.4% for NP, and 8.2 months and 33.7% for NIP, respectively.
__label__noRel	The different schedules of vinorelbine in the two arms led to a greater survival in the NP arm without impairing the tolerance profile,	The major World Health Organization grade 3-4 toxicities for NP and NIP, respectively, were: neutropenia (20.3% compared with 9% of cycles), anaemia (4.1% compared with 5% of cycles), nausea and vomiting (22.2% compared with 19.4% of patients) and alopecia (5.6% compared with 29.8% of patients).
__label__noRel	The different schedules of vinorelbine in the two arms led to a greater survival in the NP arm without impairing the tolerance profile,	Four toxic deaths occurred in the NP arm and eight in the NIP arm.
__label__noRel	The different schedules of vinorelbine in the two arms led to a greater survival in the NP arm without impairing the tolerance profile,	although this is not statistically significant.
__label__noRel	The different schedules of vinorelbine in the two arms led to a greater survival in the NP arm without impairing the tolerance profile,	This confirms that the two-drug combination NP is a reference treatment for metastatic NSCLC.
__label__noRel	The different schedules of vinorelbine in the two arms led to a greater survival in the NP arm without impairing the tolerance profile,	The role of three-drug combinations remains questionable in this subset of patients.
__label__noRel	although this is not statistically significant.	The overall response rate was 34.6% for NP and 35.7% for NIP.
__label__noRel	although this is not statistically significant.	Median and 1-year survival rates were 10.0 months and 38.4% for NP, and 8.2 months and 33.7% for NIP, respectively.
__label__noRel	although this is not statistically significant.	The major World Health Organization grade 3-4 toxicities for NP and NIP, respectively, were: neutropenia (20.3% compared with 9% of cycles), anaemia (4.1% compared with 5% of cycles), nausea and vomiting (22.2% compared with 19.4% of patients) and alopecia (5.6% compared with 29.8% of patients).
__label__noRel	although this is not statistically significant.	Four toxic deaths occurred in the NP arm and eight in the NIP arm.
__label__Attack	although this is not statistically significant.	The different schedules of vinorelbine in the two arms led to a greater survival in the NP arm without impairing the tolerance profile,
__label__noRel	although this is not statistically significant.	This confirms that the two-drug combination NP is a reference treatment for metastatic NSCLC.
__label__noRel	although this is not statistically significant.	The role of three-drug combinations remains questionable in this subset of patients.
__label__noRel	This confirms that the two-drug combination NP is a reference treatment for metastatic NSCLC.	The overall response rate was 34.6% for NP and 35.7% for NIP.
__label__noRel	This confirms that the two-drug combination NP is a reference treatment for metastatic NSCLC.	Median and 1-year survival rates were 10.0 months and 38.4% for NP, and 8.2 months and 33.7% for NIP, respectively.
__label__noRel	This confirms that the two-drug combination NP is a reference treatment for metastatic NSCLC.	The major World Health Organization grade 3-4 toxicities for NP and NIP, respectively, were: neutropenia (20.3% compared with 9% of cycles), anaemia (4.1% compared with 5% of cycles), nausea and vomiting (22.2% compared with 19.4% of patients) and alopecia (5.6% compared with 29.8% of patients).
__label__noRel	This confirms that the two-drug combination NP is a reference treatment for metastatic NSCLC.	Four toxic deaths occurred in the NP arm and eight in the NIP arm.
__label__noRel	This confirms that the two-drug combination NP is a reference treatment for metastatic NSCLC.	The different schedules of vinorelbine in the two arms led to a greater survival in the NP arm without impairing the tolerance profile,
__label__noRel	This confirms that the two-drug combination NP is a reference treatment for metastatic NSCLC.	although this is not statistically significant.
__label__noRel	This confirms that the two-drug combination NP is a reference treatment for metastatic NSCLC.	The role of three-drug combinations remains questionable in this subset of patients.
__label__noRel	The role of three-drug combinations remains questionable in this subset of patients.	The overall response rate was 34.6% for NP and 35.7% for NIP.
__label__noRel	The role of three-drug combinations remains questionable in this subset of patients.	Median and 1-year survival rates were 10.0 months and 38.4% for NP, and 8.2 months and 33.7% for NIP, respectively.
__label__noRel	The role of three-drug combinations remains questionable in this subset of patients.	The major World Health Organization grade 3-4 toxicities for NP and NIP, respectively, were: neutropenia (20.3% compared with 9% of cycles), anaemia (4.1% compared with 5% of cycles), nausea and vomiting (22.2% compared with 19.4% of patients) and alopecia (5.6% compared with 29.8% of patients).
__label__noRel	The role of three-drug combinations remains questionable in this subset of patients.	Four toxic deaths occurred in the NP arm and eight in the NIP arm.
__label__noRel	The role of three-drug combinations remains questionable in this subset of patients.	The different schedules of vinorelbine in the two arms led to a greater survival in the NP arm without impairing the tolerance profile,
__label__noRel	The role of three-drug combinations remains questionable in this subset of patients.	although this is not statistically significant.
__label__noRel	The role of three-drug combinations remains questionable in this subset of patients.	This confirms that the two-drug combination NP is a reference treatment for metastatic NSCLC.
__label__noRel	Therapy of patients with advanced gastric or gastroesophageal junction cancer should provide symptom relief and improve quality of life (QOL) because most patients are symptomatic at baseline.	Time to 5% deterioration of global health status (primary end point) significantly favored DCF over CF (log-rank test, P = .01).
__label__noRel	Therapy of patients with advanced gastric or gastroesophageal junction cancer should provide symptom relief and improve quality of life (QOL) because most patients are symptomatic at baseline.	QOL was preserved longer for patients on DCF than those on CF for all time to deterioration analyses, demonstrating the statistical superiority of DCF compared with CF.
__label__noRel	Therapy of patients with advanced gastric or gastroesophageal junction cancer should provide symptom relief and improve quality of life (QOL) because most patients are symptomatic at baseline.	In V325, advanced gastric or gastroesophageal junction cancer patients receiving DCF not only had statistically improved overall survival and time to tumor-progression, but they also had better preservation of QOL compared with patients receiving CF.
__label__noRel	Time to 5% deterioration of global health status (primary end point) significantly favored DCF over CF (log-rank test, P = .01).	Therapy of patients with advanced gastric or gastroesophageal junction cancer should provide symptom relief and improve quality of life (QOL) because most patients are symptomatic at baseline.
__label__noRel	Time to 5% deterioration of global health status (primary end point) significantly favored DCF over CF (log-rank test, P = .01).	QOL was preserved longer for patients on DCF than those on CF for all time to deterioration analyses, demonstrating the statistical superiority of DCF compared with CF.
__label__Support	Time to 5% deterioration of global health status (primary end point) significantly favored DCF over CF (log-rank test, P = .01).	In V325, advanced gastric or gastroesophageal junction cancer patients receiving DCF not only had statistically improved overall survival and time to tumor-progression, but they also had better preservation of QOL compared with patients receiving CF.
__label__noRel	QOL was preserved longer for patients on DCF than those on CF for all time to deterioration analyses, demonstrating the statistical superiority of DCF compared with CF.	Therapy of patients with advanced gastric or gastroesophageal junction cancer should provide symptom relief and improve quality of life (QOL) because most patients are symptomatic at baseline.
__label__noRel	QOL was preserved longer for patients on DCF than those on CF for all time to deterioration analyses, demonstrating the statistical superiority of DCF compared with CF.	Time to 5% deterioration of global health status (primary end point) significantly favored DCF over CF (log-rank test, P = .01).
__label__Support	QOL was preserved longer for patients on DCF than those on CF for all time to deterioration analyses, demonstrating the statistical superiority of DCF compared with CF.	In V325, advanced gastric or gastroesophageal junction cancer patients receiving DCF not only had statistically improved overall survival and time to tumor-progression, but they also had better preservation of QOL compared with patients receiving CF.
__label__noRel	In V325, advanced gastric or gastroesophageal junction cancer patients receiving DCF not only had statistically improved overall survival and time to tumor-progression, but they also had better preservation of QOL compared with patients receiving CF.	Therapy of patients with advanced gastric or gastroesophageal junction cancer should provide symptom relief and improve quality of life (QOL) because most patients are symptomatic at baseline.
__label__noRel	In V325, advanced gastric or gastroesophageal junction cancer patients receiving DCF not only had statistically improved overall survival and time to tumor-progression, but they also had better preservation of QOL compared with patients receiving CF.	Time to 5% deterioration of global health status (primary end point) significantly favored DCF over CF (log-rank test, P = .01).
__label__noRel	In V325, advanced gastric or gastroesophageal junction cancer patients receiving DCF not only had statistically improved overall survival and time to tumor-progression, but they also had better preservation of QOL compared with patients receiving CF.	QOL was preserved longer for patients on DCF than those on CF for all time to deterioration analyses, demonstrating the statistical superiority of DCF compared with CF.
__label__noRel	Quality of life is an important issue in pancreatic cancer patients.	The analysis of quality of live assessment showed a statistically significant decrease in quality of life after treatment in patients with resectable pancreatic cancer and treated with radiotherapy and gemcitabine.
__label__noRel	Quality of life is an important issue in pancreatic cancer patients.	Decreased quality of life later after treatment was also observed in patients diagnosed with unresectable pancreatic cancer and treated with the same regimen.
__label__noRel	Quality of life is an important issue in pancreatic cancer patients.	Treatment with radiotherapy and 5-fluorouracil changed only some aspects of quality of life and did not have a significant impact on quality of life.
__label__noRel	The analysis of quality of live assessment showed a statistically significant decrease in quality of life after treatment in patients with resectable pancreatic cancer and treated with radiotherapy and gemcitabine.	Quality of life is an important issue in pancreatic cancer patients.
__label__noRel	The analysis of quality of live assessment showed a statistically significant decrease in quality of life after treatment in patients with resectable pancreatic cancer and treated with radiotherapy and gemcitabine.	Decreased quality of life later after treatment was also observed in patients diagnosed with unresectable pancreatic cancer and treated with the same regimen.
__label__Support	The analysis of quality of live assessment showed a statistically significant decrease in quality of life after treatment in patients with resectable pancreatic cancer and treated with radiotherapy and gemcitabine.	Treatment with radiotherapy and 5-fluorouracil changed only some aspects of quality of life and did not have a significant impact on quality of life.
__label__noRel	Decreased quality of life later after treatment was also observed in patients diagnosed with unresectable pancreatic cancer and treated with the same regimen.	Quality of life is an important issue in pancreatic cancer patients.
__label__noRel	Decreased quality of life later after treatment was also observed in patients diagnosed with unresectable pancreatic cancer and treated with the same regimen.	The analysis of quality of live assessment showed a statistically significant decrease in quality of life after treatment in patients with resectable pancreatic cancer and treated with radiotherapy and gemcitabine.
__label__Support	Decreased quality of life later after treatment was also observed in patients diagnosed with unresectable pancreatic cancer and treated with the same regimen.	Treatment with radiotherapy and 5-fluorouracil changed only some aspects of quality of life and did not have a significant impact on quality of life.
__label__noRel	Treatment with radiotherapy and 5-fluorouracil changed only some aspects of quality of life and did not have a significant impact on quality of life.	Quality of life is an important issue in pancreatic cancer patients.
__label__noRel	Treatment with radiotherapy and 5-fluorouracil changed only some aspects of quality of life and did not have a significant impact on quality of life.	The analysis of quality of live assessment showed a statistically significant decrease in quality of life after treatment in patients with resectable pancreatic cancer and treated with radiotherapy and gemcitabine.
__label__noRel	Treatment with radiotherapy and 5-fluorouracil changed only some aspects of quality of life and did not have a significant impact on quality of life.	Decreased quality of life later after treatment was also observed in patients diagnosed with unresectable pancreatic cancer and treated with the same regimen.
__label__noRel	There was substantial deterioration in QOL scores immediate post-treatment (3-months) in both arms.	However, QOL scores gradually but definitely improved over time for most domains.
__label__noRel	There was substantial deterioration in QOL scores immediate post-treatment (3-months) in both arms.	Global QOL, emotional/role functioning, nausea/vomiting, pain, swallowing, speech, social contact/eating, insomnia showed rapid recovery (<6months) while physical/cognitive functioning, dry mouth, sticky saliva, fatigue, senses showed delayed recovery (>6months).
__label__noRel	There was substantial deterioration in QOL scores immediate post-treatment (3-months) in both arms.	There were no significant differences in loco-regional or survival between the two arms.
__label__Support	There was substantial deterioration in QOL scores immediate post-treatment (3-months) in both arms.	There is substantial deterioration in QOL after curative-intent head-neck irradiation that gradually improves over time.
__label__noRel	There was substantial deterioration in QOL scores immediate post-treatment (3-months) in both arms.	IMRT results in clinically meaningful and statistically better QOL scores for some domains compared to 3D-CRT at several time points with comparable disease outcomes that could support its widespread adoption in routine clinical practice.
__label__noRel	However, QOL scores gradually but definitely improved over time for most domains.	There was substantial deterioration in QOL scores immediate post-treatment (3-months) in both arms.
__label__noRel	However, QOL scores gradually but definitely improved over time for most domains.	Global QOL, emotional/role functioning, nausea/vomiting, pain, swallowing, speech, social contact/eating, insomnia showed rapid recovery (<6months) while physical/cognitive functioning, dry mouth, sticky saliva, fatigue, senses showed delayed recovery (>6months).
__label__noRel	However, QOL scores gradually but definitely improved over time for most domains.	There were no significant differences in loco-regional or survival between the two arms.
__label__noRel	However, QOL scores gradually but definitely improved over time for most domains.	There is substantial deterioration in QOL after curative-intent head-neck irradiation that gradually improves over time.
__label__Support	However, QOL scores gradually but definitely improved over time for most domains.	IMRT results in clinically meaningful and statistically better QOL scores for some domains compared to 3D-CRT at several time points with comparable disease outcomes that could support its widespread adoption in routine clinical practice.
__label__noRel	Global QOL, emotional/role functioning, nausea/vomiting, pain, swallowing, speech, social contact/eating, insomnia showed rapid recovery (<6months) while physical/cognitive functioning, dry mouth, sticky saliva, fatigue, senses showed delayed recovery (>6months).	There was substantial deterioration in QOL scores immediate post-treatment (3-months) in both arms.
__label__noRel	Global QOL, emotional/role functioning, nausea/vomiting, pain, swallowing, speech, social contact/eating, insomnia showed rapid recovery (<6months) while physical/cognitive functioning, dry mouth, sticky saliva, fatigue, senses showed delayed recovery (>6months).	However, QOL scores gradually but definitely improved over time for most domains.
__label__noRel	Global QOL, emotional/role functioning, nausea/vomiting, pain, swallowing, speech, social contact/eating, insomnia showed rapid recovery (<6months) while physical/cognitive functioning, dry mouth, sticky saliva, fatigue, senses showed delayed recovery (>6months).	There were no significant differences in loco-regional or survival between the two arms.
__label__noRel	Global QOL, emotional/role functioning, nausea/vomiting, pain, swallowing, speech, social contact/eating, insomnia showed rapid recovery (<6months) while physical/cognitive functioning, dry mouth, sticky saliva, fatigue, senses showed delayed recovery (>6months).	There is substantial deterioration in QOL after curative-intent head-neck irradiation that gradually improves over time.
__label__Support	Global QOL, emotional/role functioning, nausea/vomiting, pain, swallowing, speech, social contact/eating, insomnia showed rapid recovery (<6months) while physical/cognitive functioning, dry mouth, sticky saliva, fatigue, senses showed delayed recovery (>6months).	IMRT results in clinically meaningful and statistically better QOL scores for some domains compared to 3D-CRT at several time points with comparable disease outcomes that could support its widespread adoption in routine clinical practice.
__label__noRel	There were no significant differences in loco-regional or survival between the two arms.	There was substantial deterioration in QOL scores immediate post-treatment (3-months) in both arms.
__label__noRel	There were no significant differences in loco-regional or survival between the two arms.	However, QOL scores gradually but definitely improved over time for most domains.
__label__noRel	There were no significant differences in loco-regional or survival between the two arms.	Global QOL, emotional/role functioning, nausea/vomiting, pain, swallowing, speech, social contact/eating, insomnia showed rapid recovery (<6months) while physical/cognitive functioning, dry mouth, sticky saliva, fatigue, senses showed delayed recovery (>6months).
__label__noRel	There were no significant differences in loco-regional or survival between the two arms.	There is substantial deterioration in QOL after curative-intent head-neck irradiation that gradually improves over time.
__label__noRel	There were no significant differences in loco-regional or survival between the two arms.	IMRT results in clinically meaningful and statistically better QOL scores for some domains compared to 3D-CRT at several time points with comparable disease outcomes that could support its widespread adoption in routine clinical practice.
__label__noRel	There is substantial deterioration in QOL after curative-intent head-neck irradiation that gradually improves over time.	There was substantial deterioration in QOL scores immediate post-treatment (3-months) in both arms.
__label__noRel	There is substantial deterioration in QOL after curative-intent head-neck irradiation that gradually improves over time.	However, QOL scores gradually but definitely improved over time for most domains.
__label__noRel	There is substantial deterioration in QOL after curative-intent head-neck irradiation that gradually improves over time.	Global QOL, emotional/role functioning, nausea/vomiting, pain, swallowing, speech, social contact/eating, insomnia showed rapid recovery (<6months) while physical/cognitive functioning, dry mouth, sticky saliva, fatigue, senses showed delayed recovery (>6months).
__label__noRel	There is substantial deterioration in QOL after curative-intent head-neck irradiation that gradually improves over time.	There were no significant differences in loco-regional or survival between the two arms.
__label__noRel	There is substantial deterioration in QOL after curative-intent head-neck irradiation that gradually improves over time.	IMRT results in clinically meaningful and statistically better QOL scores for some domains compared to 3D-CRT at several time points with comparable disease outcomes that could support its widespread adoption in routine clinical practice.
__label__noRel	IMRT results in clinically meaningful and statistically better QOL scores for some domains compared to 3D-CRT at several time points with comparable disease outcomes that could support its widespread adoption in routine clinical practice.	There was substantial deterioration in QOL scores immediate post-treatment (3-months) in both arms.
__label__noRel	IMRT results in clinically meaningful and statistically better QOL scores for some domains compared to 3D-CRT at several time points with comparable disease outcomes that could support its widespread adoption in routine clinical practice.	However, QOL scores gradually but definitely improved over time for most domains.
__label__noRel	IMRT results in clinically meaningful and statistically better QOL scores for some domains compared to 3D-CRT at several time points with comparable disease outcomes that could support its widespread adoption in routine clinical practice.	Global QOL, emotional/role functioning, nausea/vomiting, pain, swallowing, speech, social contact/eating, insomnia showed rapid recovery (<6months) while physical/cognitive functioning, dry mouth, sticky saliva, fatigue, senses showed delayed recovery (>6months).
__label__noRel	IMRT results in clinically meaningful and statistically better QOL scores for some domains compared to 3D-CRT at several time points with comparable disease outcomes that could support its widespread adoption in routine clinical practice.	There were no significant differences in loco-regional or survival between the two arms.
__label__noRel	IMRT results in clinically meaningful and statistically better QOL scores for some domains compared to 3D-CRT at several time points with comparable disease outcomes that could support its widespread adoption in routine clinical practice.	There is substantial deterioration in QOL after curative-intent head-neck irradiation that gradually improves over time.
__label__noRel	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.
__label__noRel	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).
__label__noRel	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).	Toxicities were generally mild in both groups.
__label__noRel	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).
__label__noRel	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).
__label__Support	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.
__label__noRel	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.
__label__noRel	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).
__label__noRel	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).
__label__noRel	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.	Toxicities were generally mild in both groups.
__label__noRel	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).
__label__noRel	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).
__label__Support	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.
__label__noRel	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.
__label__noRel	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).
__label__noRel	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.
__label__noRel	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).	Toxicities were generally mild in both groups.
__label__noRel	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).
__label__noRel	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).
__label__Support	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.
__label__noRel	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.
__label__noRel	Toxicities were generally mild in both groups.	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).
__label__noRel	Toxicities were generally mild in both groups.	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.
__label__noRel	Toxicities were generally mild in both groups.	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).
__label__noRel	Toxicities were generally mild in both groups.	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).
__label__noRel	Toxicities were generally mild in both groups.	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).
__label__Support	Toxicities were generally mild in both groups.	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.
__label__noRel	Toxicities were generally mild in both groups.	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.
__label__noRel	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).
__label__noRel	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.
__label__noRel	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).
__label__noRel	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).	Toxicities were generally mild in both groups.
__label__noRel	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).
__label__noRel	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.
__label__Support	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.
__label__noRel	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).
__label__noRel	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.
__label__noRel	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).
__label__noRel	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).	Toxicities were generally mild in both groups.
__label__noRel	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).
__label__noRel	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.
__label__Support	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.
__label__noRel	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).
__label__noRel	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.
__label__noRel	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).
__label__noRel	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.	Toxicities were generally mild in both groups.
__label__noRel	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).
__label__noRel	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).
__label__noRel	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.
__label__noRel	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).
__label__noRel	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.
__label__noRel	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).
__label__noRel	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.	Toxicities were generally mild in both groups.
__label__noRel	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).
__label__noRel	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).
__label__noRel	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.
__label__Support	Participants randomized to the exercise group increased physical activity by more than 100 versus 22% in controls (54.5 vs. 14.6 min, P = 0.13), and experienced significant increases in fitness (increased 6-min walk test distance by 186.9 vs. 81.9 feet, P = 0.006) and physical functioning (7.1 vs. 2.6, P = 0.04) as compared to the control group.	Breast and colorectal cancer survivors enrolled in a multicenter, telephone-based physical activity intervention increased physical activity and experienced significant improvements in fitness and physical functioning.
__label__noRel	Participants randomized to the exercise group increased physical activity by more than 100 versus 22% in controls (54.5 vs. 14.6 min, P = 0.13), and experienced significant increases in fitness (increased 6-min walk test distance by 186.9 vs. 81.9 feet, P = 0.006) and physical functioning (7.1 vs. 2.6, P = 0.04) as compared to the control group.	Lifestyle intervention research is feasible in a cooperative group setting.
__label__noRel	Breast and colorectal cancer survivors enrolled in a multicenter, telephone-based physical activity intervention increased physical activity and experienced significant improvements in fitness and physical functioning.	Participants randomized to the exercise group increased physical activity by more than 100 versus 22% in controls (54.5 vs. 14.6 min, P = 0.13), and experienced significant increases in fitness (increased 6-min walk test distance by 186.9 vs. 81.9 feet, P = 0.006) and physical functioning (7.1 vs. 2.6, P = 0.04) as compared to the control group.
__label__Support	Breast and colorectal cancer survivors enrolled in a multicenter, telephone-based physical activity intervention increased physical activity and experienced significant improvements in fitness and physical functioning.	Lifestyle intervention research is feasible in a cooperative group setting.
__label__noRel	Lifestyle intervention research is feasible in a cooperative group setting.	Participants randomized to the exercise group increased physical activity by more than 100 versus 22% in controls (54.5 vs. 14.6 min, P = 0.13), and experienced significant increases in fitness (increased 6-min walk test distance by 186.9 vs. 81.9 feet, P = 0.006) and physical functioning (7.1 vs. 2.6, P = 0.04) as compared to the control group.
__label__noRel	Lifestyle intervention research is feasible in a cooperative group setting.	Breast and colorectal cancer survivors enrolled in a multicenter, telephone-based physical activity intervention increased physical activity and experienced significant improvements in fitness and physical functioning.
__label__noRel	ADAPt-C collaborative care is feasible and results in significant reduction in depressive symptoms, improvement in quality of life, and lower pain levels compared with EUC for patients with depressive disorders in a low-income, predominantly Hispanic population in public sector oncology clinics.	Intervention patients also experienced greater rates of depression treatment (72.3% v 10.4% of EUC patients; P < .0001) and significantly better quality-of-life outcomes, including social/family (adjusted mean difference between groups, 2.7; 95% CI, 1.22 to 4.17; P < .001), emotional (adjusted mean difference, 1.29; 95% CI, 0.26 to 2.22; P = .01), functional (adjusted mean difference, 1.34; 95% CI, 0.08 to 2.59; P = .04), and physical well-being (adjusted mean difference, 2.79; 95% CI, 0.49 to 5.1; P = .02).
__label__noRel	ADAPt-C collaborative care is feasible and results in significant reduction in depressive symptoms, improvement in quality of life, and lower pain levels compared with EUC for patients with depressive disorders in a low-income, predominantly Hispanic population in public sector oncology clinics.	Improvement was also found for 5-point decrease in PHQ-9 score among 72.2% of intervention patients compared with 59.7% of EUC patients (OR = 1.99; 95% CI, 1.14 to 3.50; P = .02).
__label__noRel	ADAPt-C collaborative care is feasible and results in significant reduction in depressive symptoms, improvement in quality of life, and lower pain levels compared with EUC for patients with depressive disorders in a low-income, predominantly Hispanic population in public sector oncology clinics.	At 12 months, 63% of intervention patients had a 50% or greater reduction in depressive symptoms from baseline as assessed by the Patient Health Questionnaire-9 (PHQ-9) depression scale compared with 50% of EUC patients (odds ratio [OR] = 1.98; 95% CI, 1.16 to 3.38; P = .01).
__label__Support	Intervention patients also experienced greater rates of depression treatment (72.3% v 10.4% of EUC patients; P < .0001) and significantly better quality-of-life outcomes, including social/family (adjusted mean difference between groups, 2.7; 95% CI, 1.22 to 4.17; P < .001), emotional (adjusted mean difference, 1.29; 95% CI, 0.26 to 2.22; P = .01), functional (adjusted mean difference, 1.34; 95% CI, 0.08 to 2.59; P = .04), and physical well-being (adjusted mean difference, 2.79; 95% CI, 0.49 to 5.1; P = .02).	ADAPt-C collaborative care is feasible and results in significant reduction in depressive symptoms, improvement in quality of life, and lower pain levels compared with EUC for patients with depressive disorders in a low-income, predominantly Hispanic population in public sector oncology clinics.
__label__noRel	Intervention patients also experienced greater rates of depression treatment (72.3% v 10.4% of EUC patients; P < .0001) and significantly better quality-of-life outcomes, including social/family (adjusted mean difference between groups, 2.7; 95% CI, 1.22 to 4.17; P < .001), emotional (adjusted mean difference, 1.29; 95% CI, 0.26 to 2.22; P = .01), functional (adjusted mean difference, 1.34; 95% CI, 0.08 to 2.59; P = .04), and physical well-being (adjusted mean difference, 2.79; 95% CI, 0.49 to 5.1; P = .02).	Improvement was also found for 5-point decrease in PHQ-9 score among 72.2% of intervention patients compared with 59.7% of EUC patients (OR = 1.99; 95% CI, 1.14 to 3.50; P = .02).
__label__noRel	Intervention patients also experienced greater rates of depression treatment (72.3% v 10.4% of EUC patients; P < .0001) and significantly better quality-of-life outcomes, including social/family (adjusted mean difference between groups, 2.7; 95% CI, 1.22 to 4.17; P < .001), emotional (adjusted mean difference, 1.29; 95% CI, 0.26 to 2.22; P = .01), functional (adjusted mean difference, 1.34; 95% CI, 0.08 to 2.59; P = .04), and physical well-being (adjusted mean difference, 2.79; 95% CI, 0.49 to 5.1; P = .02).	At 12 months, 63% of intervention patients had a 50% or greater reduction in depressive symptoms from baseline as assessed by the Patient Health Questionnaire-9 (PHQ-9) depression scale compared with 50% of EUC patients (odds ratio [OR] = 1.98; 95% CI, 1.16 to 3.38; P = .01).
__label__Support	Improvement was also found for 5-point decrease in PHQ-9 score among 72.2% of intervention patients compared with 59.7% of EUC patients (OR = 1.99; 95% CI, 1.14 to 3.50; P = .02).	ADAPt-C collaborative care is feasible and results in significant reduction in depressive symptoms, improvement in quality of life, and lower pain levels compared with EUC for patients with depressive disorders in a low-income, predominantly Hispanic population in public sector oncology clinics.
__label__noRel	Improvement was also found for 5-point decrease in PHQ-9 score among 72.2% of intervention patients compared with 59.7% of EUC patients (OR = 1.99; 95% CI, 1.14 to 3.50; P = .02).	Intervention patients also experienced greater rates of depression treatment (72.3% v 10.4% of EUC patients; P < .0001) and significantly better quality-of-life outcomes, including social/family (adjusted mean difference between groups, 2.7; 95% CI, 1.22 to 4.17; P < .001), emotional (adjusted mean difference, 1.29; 95% CI, 0.26 to 2.22; P = .01), functional (adjusted mean difference, 1.34; 95% CI, 0.08 to 2.59; P = .04), and physical well-being (adjusted mean difference, 2.79; 95% CI, 0.49 to 5.1; P = .02).
__label__noRel	Improvement was also found for 5-point decrease in PHQ-9 score among 72.2% of intervention patients compared with 59.7% of EUC patients (OR = 1.99; 95% CI, 1.14 to 3.50; P = .02).	At 12 months, 63% of intervention patients had a 50% or greater reduction in depressive symptoms from baseline as assessed by the Patient Health Questionnaire-9 (PHQ-9) depression scale compared with 50% of EUC patients (odds ratio [OR] = 1.98; 95% CI, 1.16 to 3.38; P = .01).
__label__Support	At 12 months, 63% of intervention patients had a 50% or greater reduction in depressive symptoms from baseline as assessed by the Patient Health Questionnaire-9 (PHQ-9) depression scale compared with 50% of EUC patients (odds ratio [OR] = 1.98; 95% CI, 1.16 to 3.38; P = .01).	ADAPt-C collaborative care is feasible and results in significant reduction in depressive symptoms, improvement in quality of life, and lower pain levels compared with EUC for patients with depressive disorders in a low-income, predominantly Hispanic population in public sector oncology clinics.
__label__noRel	At 12 months, 63% of intervention patients had a 50% or greater reduction in depressive symptoms from baseline as assessed by the Patient Health Questionnaire-9 (PHQ-9) depression scale compared with 50% of EUC patients (odds ratio [OR] = 1.98; 95% CI, 1.16 to 3.38; P = .01).	Intervention patients also experienced greater rates of depression treatment (72.3% v 10.4% of EUC patients; P < .0001) and significantly better quality-of-life outcomes, including social/family (adjusted mean difference between groups, 2.7; 95% CI, 1.22 to 4.17; P < .001), emotional (adjusted mean difference, 1.29; 95% CI, 0.26 to 2.22; P = .01), functional (adjusted mean difference, 1.34; 95% CI, 0.08 to 2.59; P = .04), and physical well-being (adjusted mean difference, 2.79; 95% CI, 0.49 to 5.1; P = .02).
__label__noRel	At 12 months, 63% of intervention patients had a 50% or greater reduction in depressive symptoms from baseline as assessed by the Patient Health Questionnaire-9 (PHQ-9) depression scale compared with 50% of EUC patients (odds ratio [OR] = 1.98; 95% CI, 1.16 to 3.38; P = .01).	Improvement was also found for 5-point decrease in PHQ-9 score among 72.2% of intervention patients compared with 59.7% of EUC patients (OR = 1.99; 95% CI, 1.14 to 3.50; P = .02).
__label__noRel	Docetaxel has shown activity in elderly patients with advanced non-small-cell lung cancer (NSCLC).	There was no statistical difference in median overall survival with docetaxel versus vinorelbine (14.3 months v 9.9 months; hazard ratio, 0.780; 95% CI, 0.561 to 1.085; P = .138).
__label__noRel	Docetaxel has shown activity in elderly patients with advanced non-small-cell lung cancer (NSCLC).	There was a significant difference in median progression-free survival (5.5 months v 3.1 months; P < .001).
__label__noRel	Docetaxel has shown activity in elderly patients with advanced non-small-cell lung cancer (NSCLC).	Response rates were also significantly improved with docetaxel versus vinorelbine (22.7% v 9.9%; P = .019).
__label__noRel	Docetaxel has shown activity in elderly patients with advanced non-small-cell lung cancer (NSCLC).	The most common grade 3 to 4 toxicities were neutropenia (82.9% for docetaxel; 69.2% for vinorelbine; P = .031) and leukopenia (58.0% for docetaxel; 51.7% for vinorelbine).
__label__noRel	Docetaxel has shown activity in elderly patients with advanced non-small-cell lung cancer (NSCLC).	Other toxicities were mild and generally well tolerated.
__label__noRel	Docetaxel has shown activity in elderly patients with advanced non-small-cell lung cancer (NSCLC).	Docetaxel improved overall disease-related symptoms over vinorelbine (odds ratio, 1.86; 95% CI, 1.09 to 3.20).
__label__noRel	Docetaxel has shown activity in elderly patients with advanced non-small-cell lung cancer (NSCLC).	Docetaxel improved progression-free survival, response rate, and disease-related symptoms versus vinorelbine.
__label__noRel	Docetaxel has shown activity in elderly patients with advanced non-small-cell lung cancer (NSCLC).	Overall survival was not statistically significantly improved at this time.
__label__noRel	Docetaxel has shown activity in elderly patients with advanced non-small-cell lung cancer (NSCLC).	Docetaxel monotherapy may be considered as an option in the standard treatment of elderly patients with advanced NSCLC.
__label__noRel	There was no statistical difference in median overall survival with docetaxel versus vinorelbine (14.3 months v 9.9 months; hazard ratio, 0.780; 95% CI, 0.561 to 1.085; P = .138).	Docetaxel has shown activity in elderly patients with advanced non-small-cell lung cancer (NSCLC).
__label__noRel	There was no statistical difference in median overall survival with docetaxel versus vinorelbine (14.3 months v 9.9 months; hazard ratio, 0.780; 95% CI, 0.561 to 1.085; P = .138).	There was a significant difference in median progression-free survival (5.5 months v 3.1 months; P < .001).
__label__noRel	There was no statistical difference in median overall survival with docetaxel versus vinorelbine (14.3 months v 9.9 months; hazard ratio, 0.780; 95% CI, 0.561 to 1.085; P = .138).	Response rates were also significantly improved with docetaxel versus vinorelbine (22.7% v 9.9%; P = .019).
__label__noRel	There was no statistical difference in median overall survival with docetaxel versus vinorelbine (14.3 months v 9.9 months; hazard ratio, 0.780; 95% CI, 0.561 to 1.085; P = .138).	The most common grade 3 to 4 toxicities were neutropenia (82.9% for docetaxel; 69.2% for vinorelbine; P = .031) and leukopenia (58.0% for docetaxel; 51.7% for vinorelbine).
__label__noRel	There was no statistical difference in median overall survival with docetaxel versus vinorelbine (14.3 months v 9.9 months; hazard ratio, 0.780; 95% CI, 0.561 to 1.085; P = .138).	Other toxicities were mild and generally well tolerated.
__label__noRel	There was no statistical difference in median overall survival with docetaxel versus vinorelbine (14.3 months v 9.9 months; hazard ratio, 0.780; 95% CI, 0.561 to 1.085; P = .138).	Docetaxel improved overall disease-related symptoms over vinorelbine (odds ratio, 1.86; 95% CI, 1.09 to 3.20).
__label__noRel	There was no statistical difference in median overall survival with docetaxel versus vinorelbine (14.3 months v 9.9 months; hazard ratio, 0.780; 95% CI, 0.561 to 1.085; P = .138).	Docetaxel improved progression-free survival, response rate, and disease-related symptoms versus vinorelbine.
__label__Support	There was no statistical difference in median overall survival with docetaxel versus vinorelbine (14.3 months v 9.9 months; hazard ratio, 0.780; 95% CI, 0.561 to 1.085; P = .138).	Overall survival was not statistically significantly improved at this time.
__label__noRel	There was no statistical difference in median overall survival with docetaxel versus vinorelbine (14.3 months v 9.9 months; hazard ratio, 0.780; 95% CI, 0.561 to 1.085; P = .138).	Docetaxel monotherapy may be considered as an option in the standard treatment of elderly patients with advanced NSCLC.
__label__noRel	There was a significant difference in median progression-free survival (5.5 months v 3.1 months; P < .001).	Docetaxel has shown activity in elderly patients with advanced non-small-cell lung cancer (NSCLC).
__label__noRel	There was a significant difference in median progression-free survival (5.5 months v 3.1 months; P < .001).	There was no statistical difference in median overall survival with docetaxel versus vinorelbine (14.3 months v 9.9 months; hazard ratio, 0.780; 95% CI, 0.561 to 1.085; P = .138).
__label__noRel	There was a significant difference in median progression-free survival (5.5 months v 3.1 months; P < .001).	Response rates were also significantly improved with docetaxel versus vinorelbine (22.7% v 9.9%; P = .019).
__label__noRel	There was a significant difference in median progression-free survival (5.5 months v 3.1 months; P < .001).	The most common grade 3 to 4 toxicities were neutropenia (82.9% for docetaxel; 69.2% for vinorelbine; P = .031) and leukopenia (58.0% for docetaxel; 51.7% for vinorelbine).
__label__noRel	There was a significant difference in median progression-free survival (5.5 months v 3.1 months; P < .001).	Other toxicities were mild and generally well tolerated.
__label__noRel	There was a significant difference in median progression-free survival (5.5 months v 3.1 months; P < .001).	Docetaxel improved overall disease-related symptoms over vinorelbine (odds ratio, 1.86; 95% CI, 1.09 to 3.20).
__label__noRel	There was a significant difference in median progression-free survival (5.5 months v 3.1 months; P < .001).	Docetaxel improved progression-free survival, response rate, and disease-related symptoms versus vinorelbine.
__label__noRel	There was a significant difference in median progression-free survival (5.5 months v 3.1 months; P < .001).	Overall survival was not statistically significantly improved at this time.
__label__Support	There was a significant difference in median progression-free survival (5.5 months v 3.1 months; P < .001).	Docetaxel monotherapy may be considered as an option in the standard treatment of elderly patients with advanced NSCLC.
__label__noRel	Response rates were also significantly improved with docetaxel versus vinorelbine (22.7% v 9.9%; P = .019).	Docetaxel has shown activity in elderly patients with advanced non-small-cell lung cancer (NSCLC).
__label__noRel	Response rates were also significantly improved with docetaxel versus vinorelbine (22.7% v 9.9%; P = .019).	There was no statistical difference in median overall survival with docetaxel versus vinorelbine (14.3 months v 9.9 months; hazard ratio, 0.780; 95% CI, 0.561 to 1.085; P = .138).
__label__noRel	Response rates were also significantly improved with docetaxel versus vinorelbine (22.7% v 9.9%; P = .019).	There was a significant difference in median progression-free survival (5.5 months v 3.1 months; P < .001).
__label__noRel	Response rates were also significantly improved with docetaxel versus vinorelbine (22.7% v 9.9%; P = .019).	The most common grade 3 to 4 toxicities were neutropenia (82.9% for docetaxel; 69.2% for vinorelbine; P = .031) and leukopenia (58.0% for docetaxel; 51.7% for vinorelbine).
__label__noRel	Response rates were also significantly improved with docetaxel versus vinorelbine (22.7% v 9.9%; P = .019).	Other toxicities were mild and generally well tolerated.
__label__noRel	Response rates were also significantly improved with docetaxel versus vinorelbine (22.7% v 9.9%; P = .019).	Docetaxel improved overall disease-related symptoms over vinorelbine (odds ratio, 1.86; 95% CI, 1.09 to 3.20).
__label__noRel	Response rates were also significantly improved with docetaxel versus vinorelbine (22.7% v 9.9%; P = .019).	Docetaxel improved progression-free survival, response rate, and disease-related symptoms versus vinorelbine.
__label__noRel	Response rates were also significantly improved with docetaxel versus vinorelbine (22.7% v 9.9%; P = .019).	Overall survival was not statistically significantly improved at this time.
__label__Support	Response rates were also significantly improved with docetaxel versus vinorelbine (22.7% v 9.9%; P = .019).	Docetaxel monotherapy may be considered as an option in the standard treatment of elderly patients with advanced NSCLC.
__label__noRel	The most common grade 3 to 4 toxicities were neutropenia (82.9% for docetaxel; 69.2% for vinorelbine; P = .031) and leukopenia (58.0% for docetaxel; 51.7% for vinorelbine).	Docetaxel has shown activity in elderly patients with advanced non-small-cell lung cancer (NSCLC).
__label__noRel	The most common grade 3 to 4 toxicities were neutropenia (82.9% for docetaxel; 69.2% for vinorelbine; P = .031) and leukopenia (58.0% for docetaxel; 51.7% for vinorelbine).	There was no statistical difference in median overall survival with docetaxel versus vinorelbine (14.3 months v 9.9 months; hazard ratio, 0.780; 95% CI, 0.561 to 1.085; P = .138).
__label__noRel	The most common grade 3 to 4 toxicities were neutropenia (82.9% for docetaxel; 69.2% for vinorelbine; P = .031) and leukopenia (58.0% for docetaxel; 51.7% for vinorelbine).	There was a significant difference in median progression-free survival (5.5 months v 3.1 months; P < .001).
__label__noRel	The most common grade 3 to 4 toxicities were neutropenia (82.9% for docetaxel; 69.2% for vinorelbine; P = .031) and leukopenia (58.0% for docetaxel; 51.7% for vinorelbine).	Response rates were also significantly improved with docetaxel versus vinorelbine (22.7% v 9.9%; P = .019).
__label__noRel	The most common grade 3 to 4 toxicities were neutropenia (82.9% for docetaxel; 69.2% for vinorelbine; P = .031) and leukopenia (58.0% for docetaxel; 51.7% for vinorelbine).	Other toxicities were mild and generally well tolerated.
__label__noRel	The most common grade 3 to 4 toxicities were neutropenia (82.9% for docetaxel; 69.2% for vinorelbine; P = .031) and leukopenia (58.0% for docetaxel; 51.7% for vinorelbine).	Docetaxel improved overall disease-related symptoms over vinorelbine (odds ratio, 1.86; 95% CI, 1.09 to 3.20).
__label__noRel	The most common grade 3 to 4 toxicities were neutropenia (82.9% for docetaxel; 69.2% for vinorelbine; P = .031) and leukopenia (58.0% for docetaxel; 51.7% for vinorelbine).	Docetaxel improved progression-free survival, response rate, and disease-related symptoms versus vinorelbine.
__label__noRel	The most common grade 3 to 4 toxicities were neutropenia (82.9% for docetaxel; 69.2% for vinorelbine; P = .031) and leukopenia (58.0% for docetaxel; 51.7% for vinorelbine).	Overall survival was not statistically significantly improved at this time.
__label__Support	The most common grade 3 to 4 toxicities were neutropenia (82.9% for docetaxel; 69.2% for vinorelbine; P = .031) and leukopenia (58.0% for docetaxel; 51.7% for vinorelbine).	Docetaxel monotherapy may be considered as an option in the standard treatment of elderly patients with advanced NSCLC.
__label__noRel	Other toxicities were mild and generally well tolerated.	Docetaxel has shown activity in elderly patients with advanced non-small-cell lung cancer (NSCLC).
__label__noRel	Other toxicities were mild and generally well tolerated.	There was no statistical difference in median overall survival with docetaxel versus vinorelbine (14.3 months v 9.9 months; hazard ratio, 0.780; 95% CI, 0.561 to 1.085; P = .138).
__label__noRel	Other toxicities were mild and generally well tolerated.	There was a significant difference in median progression-free survival (5.5 months v 3.1 months; P < .001).
__label__noRel	Other toxicities were mild and generally well tolerated.	Response rates were also significantly improved with docetaxel versus vinorelbine (22.7% v 9.9%; P = .019).
__label__noRel	Other toxicities were mild and generally well tolerated.	The most common grade 3 to 4 toxicities were neutropenia (82.9% for docetaxel; 69.2% for vinorelbine; P = .031) and leukopenia (58.0% for docetaxel; 51.7% for vinorelbine).
__label__noRel	Other toxicities were mild and generally well tolerated.	Docetaxel improved overall disease-related symptoms over vinorelbine (odds ratio, 1.86; 95% CI, 1.09 to 3.20).
__label__noRel	Other toxicities were mild and generally well tolerated.	Docetaxel improved progression-free survival, response rate, and disease-related symptoms versus vinorelbine.
__label__noRel	Other toxicities were mild and generally well tolerated.	Overall survival was not statistically significantly improved at this time.
__label__Support	Other toxicities were mild and generally well tolerated.	Docetaxel monotherapy may be considered as an option in the standard treatment of elderly patients with advanced NSCLC.
__label__noRel	Docetaxel improved overall disease-related symptoms over vinorelbine (odds ratio, 1.86; 95% CI, 1.09 to 3.20).	Docetaxel has shown activity in elderly patients with advanced non-small-cell lung cancer (NSCLC).
__label__noRel	Docetaxel improved overall disease-related symptoms over vinorelbine (odds ratio, 1.86; 95% CI, 1.09 to 3.20).	There was no statistical difference in median overall survival with docetaxel versus vinorelbine (14.3 months v 9.9 months; hazard ratio, 0.780; 95% CI, 0.561 to 1.085; P = .138).
__label__noRel	Docetaxel improved overall disease-related symptoms over vinorelbine (odds ratio, 1.86; 95% CI, 1.09 to 3.20).	There was a significant difference in median progression-free survival (5.5 months v 3.1 months; P < .001).
__label__noRel	Docetaxel improved overall disease-related symptoms over vinorelbine (odds ratio, 1.86; 95% CI, 1.09 to 3.20).	Response rates were also significantly improved with docetaxel versus vinorelbine (22.7% v 9.9%; P = .019).
__label__noRel	Docetaxel improved overall disease-related symptoms over vinorelbine (odds ratio, 1.86; 95% CI, 1.09 to 3.20).	The most common grade 3 to 4 toxicities were neutropenia (82.9% for docetaxel; 69.2% for vinorelbine; P = .031) and leukopenia (58.0% for docetaxel; 51.7% for vinorelbine).
__label__noRel	Docetaxel improved overall disease-related symptoms over vinorelbine (odds ratio, 1.86; 95% CI, 1.09 to 3.20).	Other toxicities were mild and generally well tolerated.
__label__noRel	Docetaxel improved overall disease-related symptoms over vinorelbine (odds ratio, 1.86; 95% CI, 1.09 to 3.20).	Docetaxel improved progression-free survival, response rate, and disease-related symptoms versus vinorelbine.
__label__noRel	Docetaxel improved overall disease-related symptoms over vinorelbine (odds ratio, 1.86; 95% CI, 1.09 to 3.20).	Overall survival was not statistically significantly improved at this time.
__label__Support	Docetaxel improved overall disease-related symptoms over vinorelbine (odds ratio, 1.86; 95% CI, 1.09 to 3.20).	Docetaxel monotherapy may be considered as an option in the standard treatment of elderly patients with advanced NSCLC.
__label__noRel	Docetaxel improved progression-free survival, response rate, and disease-related symptoms versus vinorelbine.	Docetaxel has shown activity in elderly patients with advanced non-small-cell lung cancer (NSCLC).
__label__noRel	Docetaxel improved progression-free survival, response rate, and disease-related symptoms versus vinorelbine.	There was no statistical difference in median overall survival with docetaxel versus vinorelbine (14.3 months v 9.9 months; hazard ratio, 0.780; 95% CI, 0.561 to 1.085; P = .138).
__label__noRel	Docetaxel improved progression-free survival, response rate, and disease-related symptoms versus vinorelbine.	There was a significant difference in median progression-free survival (5.5 months v 3.1 months; P < .001).
__label__noRel	Docetaxel improved progression-free survival, response rate, and disease-related symptoms versus vinorelbine.	Response rates were also significantly improved with docetaxel versus vinorelbine (22.7% v 9.9%; P = .019).
__label__noRel	Docetaxel improved progression-free survival, response rate, and disease-related symptoms versus vinorelbine.	The most common grade 3 to 4 toxicities were neutropenia (82.9% for docetaxel; 69.2% for vinorelbine; P = .031) and leukopenia (58.0% for docetaxel; 51.7% for vinorelbine).
__label__noRel	Docetaxel improved progression-free survival, response rate, and disease-related symptoms versus vinorelbine.	Other toxicities were mild and generally well tolerated.
__label__noRel	Docetaxel improved progression-free survival, response rate, and disease-related symptoms versus vinorelbine.	Docetaxel improved overall disease-related symptoms over vinorelbine (odds ratio, 1.86; 95% CI, 1.09 to 3.20).
__label__noRel	Docetaxel improved progression-free survival, response rate, and disease-related symptoms versus vinorelbine.	Overall survival was not statistically significantly improved at this time.
__label__Support	Docetaxel improved progression-free survival, response rate, and disease-related symptoms versus vinorelbine.	Docetaxel monotherapy may be considered as an option in the standard treatment of elderly patients with advanced NSCLC.
__label__noRel	Overall survival was not statistically significantly improved at this time.	Docetaxel has shown activity in elderly patients with advanced non-small-cell lung cancer (NSCLC).
__label__noRel	Overall survival was not statistically significantly improved at this time.	There was no statistical difference in median overall survival with docetaxel versus vinorelbine (14.3 months v 9.9 months; hazard ratio, 0.780; 95% CI, 0.561 to 1.085; P = .138).
__label__noRel	Overall survival was not statistically significantly improved at this time.	There was a significant difference in median progression-free survival (5.5 months v 3.1 months; P < .001).
__label__noRel	Overall survival was not statistically significantly improved at this time.	Response rates were also significantly improved with docetaxel versus vinorelbine (22.7% v 9.9%; P = .019).
__label__noRel	Overall survival was not statistically significantly improved at this time.	The most common grade 3 to 4 toxicities were neutropenia (82.9% for docetaxel; 69.2% for vinorelbine; P = .031) and leukopenia (58.0% for docetaxel; 51.7% for vinorelbine).
__label__noRel	Overall survival was not statistically significantly improved at this time.	Other toxicities were mild and generally well tolerated.
__label__noRel	Overall survival was not statistically significantly improved at this time.	Docetaxel improved overall disease-related symptoms over vinorelbine (odds ratio, 1.86; 95% CI, 1.09 to 3.20).
__label__noRel	Overall survival was not statistically significantly improved at this time.	Docetaxel improved progression-free survival, response rate, and disease-related symptoms versus vinorelbine.
__label__Attack	Overall survival was not statistically significantly improved at this time.	Docetaxel monotherapy may be considered as an option in the standard treatment of elderly patients with advanced NSCLC.
__label__noRel	Docetaxel monotherapy may be considered as an option in the standard treatment of elderly patients with advanced NSCLC.	Docetaxel has shown activity in elderly patients with advanced non-small-cell lung cancer (NSCLC).
__label__noRel	Docetaxel monotherapy may be considered as an option in the standard treatment of elderly patients with advanced NSCLC.	There was no statistical difference in median overall survival with docetaxel versus vinorelbine (14.3 months v 9.9 months; hazard ratio, 0.780; 95% CI, 0.561 to 1.085; P = .138).
__label__noRel	Docetaxel monotherapy may be considered as an option in the standard treatment of elderly patients with advanced NSCLC.	There was a significant difference in median progression-free survival (5.5 months v 3.1 months; P < .001).
__label__noRel	Docetaxel monotherapy may be considered as an option in the standard treatment of elderly patients with advanced NSCLC.	Response rates were also significantly improved with docetaxel versus vinorelbine (22.7% v 9.9%; P = .019).
__label__noRel	Docetaxel monotherapy may be considered as an option in the standard treatment of elderly patients with advanced NSCLC.	The most common grade 3 to 4 toxicities were neutropenia (82.9% for docetaxel; 69.2% for vinorelbine; P = .031) and leukopenia (58.0% for docetaxel; 51.7% for vinorelbine).
__label__noRel	Docetaxel monotherapy may be considered as an option in the standard treatment of elderly patients with advanced NSCLC.	Other toxicities were mild and generally well tolerated.
__label__noRel	Docetaxel monotherapy may be considered as an option in the standard treatment of elderly patients with advanced NSCLC.	Docetaxel improved overall disease-related symptoms over vinorelbine (odds ratio, 1.86; 95% CI, 1.09 to 3.20).
__label__noRel	Docetaxel monotherapy may be considered as an option in the standard treatment of elderly patients with advanced NSCLC.	Docetaxel improved progression-free survival, response rate, and disease-related symptoms versus vinorelbine.
__label__noRel	Docetaxel monotherapy may be considered as an option in the standard treatment of elderly patients with advanced NSCLC.	Overall survival was not statistically significantly improved at this time.
__label__noRel	There was no statistically significant QOL difference between treatment in the combined community locations relative to hospital (difference of -7.2, 95% confidence interval: -195 to +52, P=0.25).	There was a significant difference between the two community locations in favour of home (+152, 13 to 291, P=0.033).
__label__noRel	There was no statistically significant QOL difference between treatment in the combined community locations relative to hospital (difference of -7.2, 95% confidence interval: -195 to +52, P=0.25).	There was no evidence that community treatment compromised patient safety
__label__noRel	There was no statistically significant QOL difference between treatment in the combined community locations relative to hospital (difference of -7.2, 95% confidence interval: -195 to +52, P=0.25).	no significant difference between treatment arms in terms of overall costs or Quality Adjusted Life Year.
__label__noRel	There was no statistically significant QOL difference between treatment in the combined community locations relative to hospital (difference of -7.2, 95% confidence interval: -195 to +52, P=0.25).	Seventy-eight percent of patients expressed satisfaction with their treatment whatever their location, whereas 57% of patients preferred future treatment to continue at the hospital, 81% at GP surgeries and 90% at home.
__label__noRel	There was no statistically significant QOL difference between treatment in the combined community locations relative to hospital (difference of -7.2, 95% confidence interval: -195 to +52, P=0.25).	Patient QOL favours delivering cancer treatment in the home rather than GP surgeries.
__label__Support	There was no statistically significant QOL difference between treatment in the combined community locations relative to hospital (difference of -7.2, 95% confidence interval: -195 to +52, P=0.25).	Nevertheless, both community settings were acceptable to and preferred by patients compared with hospital, were safe, with no detrimental impact on overall health-care costs.
__label__noRel	There was a significant difference between the two community locations in favour of home (+152, 13 to 291, P=0.033).	There was no statistically significant QOL difference between treatment in the combined community locations relative to hospital (difference of -7.2, 95% confidence interval: -195 to +52, P=0.25).
__label__noRel	There was a significant difference between the two community locations in favour of home (+152, 13 to 291, P=0.033).	There was no evidence that community treatment compromised patient safety
__label__noRel	There was a significant difference between the two community locations in favour of home (+152, 13 to 291, P=0.033).	no significant difference between treatment arms in terms of overall costs or Quality Adjusted Life Year.
__label__noRel	There was a significant difference between the two community locations in favour of home (+152, 13 to 291, P=0.033).	Seventy-eight percent of patients expressed satisfaction with their treatment whatever their location, whereas 57% of patients preferred future treatment to continue at the hospital, 81% at GP surgeries and 90% at home.
__label__Support	There was a significant difference between the two community locations in favour of home (+152, 13 to 291, P=0.033).	Patient QOL favours delivering cancer treatment in the home rather than GP surgeries.
__label__noRel	There was a significant difference between the two community locations in favour of home (+152, 13 to 291, P=0.033).	Nevertheless, both community settings were acceptable to and preferred by patients compared with hospital, were safe, with no detrimental impact on overall health-care costs.
__label__noRel	There was no evidence that community treatment compromised patient safety	There was no statistically significant QOL difference between treatment in the combined community locations relative to hospital (difference of -7.2, 95% confidence interval: -195 to +52, P=0.25).
__label__noRel	There was no evidence that community treatment compromised patient safety	There was a significant difference between the two community locations in favour of home (+152, 13 to 291, P=0.033).
__label__noRel	There was no evidence that community treatment compromised patient safety	no significant difference between treatment arms in terms of overall costs or Quality Adjusted Life Year.
__label__noRel	There was no evidence that community treatment compromised patient safety	Seventy-eight percent of patients expressed satisfaction with their treatment whatever their location, whereas 57% of patients preferred future treatment to continue at the hospital, 81% at GP surgeries and 90% at home.
__label__noRel	There was no evidence that community treatment compromised patient safety	Patient QOL favours delivering cancer treatment in the home rather than GP surgeries.
__label__Support	There was no evidence that community treatment compromised patient safety	Nevertheless, both community settings were acceptable to and preferred by patients compared with hospital, were safe, with no detrimental impact on overall health-care costs.
__label__noRel	no significant difference between treatment arms in terms of overall costs or Quality Adjusted Life Year.	There was no statistically significant QOL difference between treatment in the combined community locations relative to hospital (difference of -7.2, 95% confidence interval: -195 to +52, P=0.25).
__label__noRel	no significant difference between treatment arms in terms of overall costs or Quality Adjusted Life Year.	There was a significant difference between the two community locations in favour of home (+152, 13 to 291, P=0.033).
__label__noRel	no significant difference between treatment arms in terms of overall costs or Quality Adjusted Life Year.	There was no evidence that community treatment compromised patient safety
__label__noRel	no significant difference between treatment arms in terms of overall costs or Quality Adjusted Life Year.	Seventy-eight percent of patients expressed satisfaction with their treatment whatever their location, whereas 57% of patients preferred future treatment to continue at the hospital, 81% at GP surgeries and 90% at home.
__label__noRel	no significant difference between treatment arms in terms of overall costs or Quality Adjusted Life Year.	Patient QOL favours delivering cancer treatment in the home rather than GP surgeries.
__label__Support	no significant difference between treatment arms in terms of overall costs or Quality Adjusted Life Year.	Nevertheless, both community settings were acceptable to and preferred by patients compared with hospital, were safe, with no detrimental impact on overall health-care costs.
__label__noRel	Seventy-eight percent of patients expressed satisfaction with their treatment whatever their location, whereas 57% of patients preferred future treatment to continue at the hospital, 81% at GP surgeries and 90% at home.	There was no statistically significant QOL difference between treatment in the combined community locations relative to hospital (difference of -7.2, 95% confidence interval: -195 to +52, P=0.25).
__label__noRel	Seventy-eight percent of patients expressed satisfaction with their treatment whatever their location, whereas 57% of patients preferred future treatment to continue at the hospital, 81% at GP surgeries and 90% at home.	There was a significant difference between the two community locations in favour of home (+152, 13 to 291, P=0.033).
__label__noRel	Seventy-eight percent of patients expressed satisfaction with their treatment whatever their location, whereas 57% of patients preferred future treatment to continue at the hospital, 81% at GP surgeries and 90% at home.	There was no evidence that community treatment compromised patient safety
__label__noRel	Seventy-eight percent of patients expressed satisfaction with their treatment whatever their location, whereas 57% of patients preferred future treatment to continue at the hospital, 81% at GP surgeries and 90% at home.	no significant difference between treatment arms in terms of overall costs or Quality Adjusted Life Year.
__label__noRel	Seventy-eight percent of patients expressed satisfaction with their treatment whatever their location, whereas 57% of patients preferred future treatment to continue at the hospital, 81% at GP surgeries and 90% at home.	Patient QOL favours delivering cancer treatment in the home rather than GP surgeries.
__label__Support	Seventy-eight percent of patients expressed satisfaction with their treatment whatever their location, whereas 57% of patients preferred future treatment to continue at the hospital, 81% at GP surgeries and 90% at home.	Nevertheless, both community settings were acceptable to and preferred by patients compared with hospital, were safe, with no detrimental impact on overall health-care costs.
__label__noRel	Patient QOL favours delivering cancer treatment in the home rather than GP surgeries.	There was no statistically significant QOL difference between treatment in the combined community locations relative to hospital (difference of -7.2, 95% confidence interval: -195 to +52, P=0.25).
__label__noRel	Patient QOL favours delivering cancer treatment in the home rather than GP surgeries.	There was a significant difference between the two community locations in favour of home (+152, 13 to 291, P=0.033).
__label__noRel	Patient QOL favours delivering cancer treatment in the home rather than GP surgeries.	There was no evidence that community treatment compromised patient safety
__label__noRel	Patient QOL favours delivering cancer treatment in the home rather than GP surgeries.	no significant difference between treatment arms in terms of overall costs or Quality Adjusted Life Year.
__label__noRel	Patient QOL favours delivering cancer treatment in the home rather than GP surgeries.	Seventy-eight percent of patients expressed satisfaction with their treatment whatever their location, whereas 57% of patients preferred future treatment to continue at the hospital, 81% at GP surgeries and 90% at home.
__label__noRel	Patient QOL favours delivering cancer treatment in the home rather than GP surgeries.	Nevertheless, both community settings were acceptable to and preferred by patients compared with hospital, were safe, with no detrimental impact on overall health-care costs.
__label__noRel	Nevertheless, both community settings were acceptable to and preferred by patients compared with hospital, were safe, with no detrimental impact on overall health-care costs.	There was no statistically significant QOL difference between treatment in the combined community locations relative to hospital (difference of -7.2, 95% confidence interval: -195 to +52, P=0.25).
__label__noRel	Nevertheless, both community settings were acceptable to and preferred by patients compared with hospital, were safe, with no detrimental impact on overall health-care costs.	There was a significant difference between the two community locations in favour of home (+152, 13 to 291, P=0.033).
__label__noRel	Nevertheless, both community settings were acceptable to and preferred by patients compared with hospital, were safe, with no detrimental impact on overall health-care costs.	There was no evidence that community treatment compromised patient safety
__label__noRel	Nevertheless, both community settings were acceptable to and preferred by patients compared with hospital, were safe, with no detrimental impact on overall health-care costs.	no significant difference between treatment arms in terms of overall costs or Quality Adjusted Life Year.
__label__noRel	Nevertheless, both community settings were acceptable to and preferred by patients compared with hospital, were safe, with no detrimental impact on overall health-care costs.	Seventy-eight percent of patients expressed satisfaction with their treatment whatever their location, whereas 57% of patients preferred future treatment to continue at the hospital, 81% at GP surgeries and 90% at home.
__label__noRel	Nevertheless, both community settings were acceptable to and preferred by patients compared with hospital, were safe, with no detrimental impact on overall health-care costs.	Patient QOL favours delivering cancer treatment in the home rather than GP surgeries.
__label__noRel	At 6 and 12 months, 55% and 39% of intervention patients had a 50% or greater reduction in depressive symptoms (SCL-20) from baseline compared to 34% and 20% of usual care participants (P = 0.003 and P = 0.029).	Intervention patients also experienced greater remission rates (P = 0.031), more depression-free days (P < 0.001), less functional impairment (P = 0.011), and greater quality of life (P = 0.039) at 12 months than usual care participants.
__label__Support	At 6 and 12 months, 55% and 39% of intervention patients had a 50% or greater reduction in depressive symptoms (SCL-20) from baseline compared to 34% and 20% of usual care participants (P = 0.003 and P = 0.029).	The IMPACT collaborative care program appears to be feasible and effective for depression among older cancer patients in diverse primary care settings.
__label__noRel	Intervention patients also experienced greater remission rates (P = 0.031), more depression-free days (P < 0.001), less functional impairment (P = 0.011), and greater quality of life (P = 0.039) at 12 months than usual care participants.	At 6 and 12 months, 55% and 39% of intervention patients had a 50% or greater reduction in depressive symptoms (SCL-20) from baseline compared to 34% and 20% of usual care participants (P = 0.003 and P = 0.029).
__label__Support	Intervention patients also experienced greater remission rates (P = 0.031), more depression-free days (P < 0.001), less functional impairment (P = 0.011), and greater quality of life (P = 0.039) at 12 months than usual care participants.	The IMPACT collaborative care program appears to be feasible and effective for depression among older cancer patients in diverse primary care settings.
__label__noRel	The IMPACT collaborative care program appears to be feasible and effective for depression among older cancer patients in diverse primary care settings.	At 6 and 12 months, 55% and 39% of intervention patients had a 50% or greater reduction in depressive symptoms (SCL-20) from baseline compared to 34% and 20% of usual care participants (P = 0.003 and P = 0.029).
__label__noRel	The IMPACT collaborative care program appears to be feasible and effective for depression among older cancer patients in diverse primary care settings.	Intervention patients also experienced greater remission rates (P = 0.031), more depression-free days (P < 0.001), less functional impairment (P = 0.011), and greater quality of life (P = 0.039) at 12 months than usual care participants.
__label__noRel	The most common grade 3 treatment-related AEs were asthenia/fatigue (16%), diarrhea (11%), hypertension (11%), hand-foot syndrome (9%), and anorexia (8%).	Efficacy, tolerability, and quality-of-life results were similar between patients dosed in the AM or PM.
__label__Support	The most common grade 3 treatment-related AEs were asthenia/fatigue (16%), diarrhea (11%), hypertension (11%), hand-foot syndrome (9%), and anorexia (8%).	Sunitinib 37.5 mg, administered on a continuous once-daily dosing regimen, has a manageable safety profile as second-line mRCC therapy, providing flexible dosing, which can be explored in combination studies.
__label__noRel	The most common grade 3 treatment-related AEs were asthenia/fatigue (16%), diarrhea (11%), hypertension (11%), hand-foot syndrome (9%), and anorexia (8%).	Median PFS and OS were 8.2 and 19.8 months, respectively, at median follow-up of 26.4 months.
__label__noRel	Efficacy, tolerability, and quality-of-life results were similar between patients dosed in the AM or PM.	The most common grade 3 treatment-related AEs were asthenia/fatigue (16%), diarrhea (11%), hypertension (11%), hand-foot syndrome (9%), and anorexia (8%).
__label__Support	Efficacy, tolerability, and quality-of-life results were similar between patients dosed in the AM or PM.	Sunitinib 37.5 mg, administered on a continuous once-daily dosing regimen, has a manageable safety profile as second-line mRCC therapy, providing flexible dosing, which can be explored in combination studies.
__label__noRel	Efficacy, tolerability, and quality-of-life results were similar between patients dosed in the AM or PM.	Median PFS and OS were 8.2 and 19.8 months, respectively, at median follow-up of 26.4 months.
__label__noRel	Sunitinib 37.5 mg, administered on a continuous once-daily dosing regimen, has a manageable safety profile as second-line mRCC therapy, providing flexible dosing, which can be explored in combination studies.	The most common grade 3 treatment-related AEs were asthenia/fatigue (16%), diarrhea (11%), hypertension (11%), hand-foot syndrome (9%), and anorexia (8%).
__label__noRel	Sunitinib 37.5 mg, administered on a continuous once-daily dosing regimen, has a manageable safety profile as second-line mRCC therapy, providing flexible dosing, which can be explored in combination studies.	Efficacy, tolerability, and quality-of-life results were similar between patients dosed in the AM or PM.
__label__noRel	Sunitinib 37.5 mg, administered on a continuous once-daily dosing regimen, has a manageable safety profile as second-line mRCC therapy, providing flexible dosing, which can be explored in combination studies.	Median PFS and OS were 8.2 and 19.8 months, respectively, at median follow-up of 26.4 months.
__label__noRel	Median PFS and OS were 8.2 and 19.8 months, respectively, at median follow-up of 26.4 months.	The most common grade 3 treatment-related AEs were asthenia/fatigue (16%), diarrhea (11%), hypertension (11%), hand-foot syndrome (9%), and anorexia (8%).
__label__noRel	Median PFS and OS were 8.2 and 19.8 months, respectively, at median follow-up of 26.4 months.	Efficacy, tolerability, and quality-of-life results were similar between patients dosed in the AM or PM.
__label__Support	Median PFS and OS were 8.2 and 19.8 months, respectively, at median follow-up of 26.4 months.	Sunitinib 37.5 mg, administered on a continuous once-daily dosing regimen, has a manageable safety profile as second-line mRCC therapy, providing flexible dosing, which can be explored in combination studies.
__label__noRel	After a median follow-up of 48 months, 79 deaths were observed in the HDCT arm and 77 deaths were observed in the ST arm;	seven patients (6%) in the HDCT arm died as a result of toxicity.
__label__noRel	After a median follow-up of 48 months, 79 deaths were observed in the HDCT arm and 77 deaths were observed in the ST arm;	The median OS was 24 months for the HDCT arm (95% CI, 21 to 35 months) and 28 months for ST (95% CI, 22 to 33 months; hazard ratio [HR], 0.9; 95% CI, 0.6 to 1.2; P = .43).
__label__noRel	After a median follow-up of 48 months, 79 deaths were observed in the HDCT arm and 77 deaths were observed in the ST arm;	PFS was 11 months for HDCT and 9 months for ST (HR, 0.6 in favor of HDCT; 95% CI, 0.5 to 0.9; P = .006).
__label__Support	After a median follow-up of 48 months, 79 deaths were observed in the HDCT arm and 77 deaths were observed in the ST arm;	HDCT did not improve OS in women with MBC when used as consolidation after response to induction chemotherapy.
__label__noRel	seven patients (6%) in the HDCT arm died as a result of toxicity.	After a median follow-up of 48 months, 79 deaths were observed in the HDCT arm and 77 deaths were observed in the ST arm;
__label__noRel	seven patients (6%) in the HDCT arm died as a result of toxicity.	The median OS was 24 months for the HDCT arm (95% CI, 21 to 35 months) and 28 months for ST (95% CI, 22 to 33 months; hazard ratio [HR], 0.9; 95% CI, 0.6 to 1.2; P = .43).
__label__noRel	seven patients (6%) in the HDCT arm died as a result of toxicity.	PFS was 11 months for HDCT and 9 months for ST (HR, 0.6 in favor of HDCT; 95% CI, 0.5 to 0.9; P = .006).
__label__Support	seven patients (6%) in the HDCT arm died as a result of toxicity.	HDCT did not improve OS in women with MBC when used as consolidation after response to induction chemotherapy.
__label__noRel	The median OS was 24 months for the HDCT arm (95% CI, 21 to 35 months) and 28 months for ST (95% CI, 22 to 33 months; hazard ratio [HR], 0.9; 95% CI, 0.6 to 1.2; P = .43).	After a median follow-up of 48 months, 79 deaths were observed in the HDCT arm and 77 deaths were observed in the ST arm;
__label__noRel	The median OS was 24 months for the HDCT arm (95% CI, 21 to 35 months) and 28 months for ST (95% CI, 22 to 33 months; hazard ratio [HR], 0.9; 95% CI, 0.6 to 1.2; P = .43).	seven patients (6%) in the HDCT arm died as a result of toxicity.
__label__noRel	The median OS was 24 months for the HDCT arm (95% CI, 21 to 35 months) and 28 months for ST (95% CI, 22 to 33 months; hazard ratio [HR], 0.9; 95% CI, 0.6 to 1.2; P = .43).	PFS was 11 months for HDCT and 9 months for ST (HR, 0.6 in favor of HDCT; 95% CI, 0.5 to 0.9; P = .006).
__label__Support	The median OS was 24 months for the HDCT arm (95% CI, 21 to 35 months) and 28 months for ST (95% CI, 22 to 33 months; hazard ratio [HR], 0.9; 95% CI, 0.6 to 1.2; P = .43).	HDCT did not improve OS in women with MBC when used as consolidation after response to induction chemotherapy.
__label__noRel	PFS was 11 months for HDCT and 9 months for ST (HR, 0.6 in favor of HDCT; 95% CI, 0.5 to 0.9; P = .006).	After a median follow-up of 48 months, 79 deaths were observed in the HDCT arm and 77 deaths were observed in the ST arm;
__label__noRel	PFS was 11 months for HDCT and 9 months for ST (HR, 0.6 in favor of HDCT; 95% CI, 0.5 to 0.9; P = .006).	seven patients (6%) in the HDCT arm died as a result of toxicity.
__label__noRel	PFS was 11 months for HDCT and 9 months for ST (HR, 0.6 in favor of HDCT; 95% CI, 0.5 to 0.9; P = .006).	The median OS was 24 months for the HDCT arm (95% CI, 21 to 35 months) and 28 months for ST (95% CI, 22 to 33 months; hazard ratio [HR], 0.9; 95% CI, 0.6 to 1.2; P = .43).
__label__Support	PFS was 11 months for HDCT and 9 months for ST (HR, 0.6 in favor of HDCT; 95% CI, 0.5 to 0.9; P = .006).	HDCT did not improve OS in women with MBC when used as consolidation after response to induction chemotherapy.
__label__noRel	HDCT did not improve OS in women with MBC when used as consolidation after response to induction chemotherapy.	After a median follow-up of 48 months, 79 deaths were observed in the HDCT arm and 77 deaths were observed in the ST arm;
__label__noRel	HDCT did not improve OS in women with MBC when used as consolidation after response to induction chemotherapy.	seven patients (6%) in the HDCT arm died as a result of toxicity.
__label__noRel	HDCT did not improve OS in women with MBC when used as consolidation after response to induction chemotherapy.	The median OS was 24 months for the HDCT arm (95% CI, 21 to 35 months) and 28 months for ST (95% CI, 22 to 33 months; hazard ratio [HR], 0.9; 95% CI, 0.6 to 1.2; P = .43).
__label__noRel	HDCT did not improve OS in women with MBC when used as consolidation after response to induction chemotherapy.	PFS was 11 months for HDCT and 9 months for ST (HR, 0.6 in favor of HDCT; 95% CI, 0.5 to 0.9; P = .006).
__label__noRel	At 6 months, there was a clinically relevant, but nonsignificant reduction in presentations to emergency departments (21% vs 33%; 1 = 1.41, P = .23) and readmission to the hospital (37% vs 47%; 1 = 0.82, P = .37) among intervention compared with control group participants.	Nonsignificant differences between groups were found for all unmet supportive care need and quality-of-life scores, change scores, and trends.
__label__noRel	At 6 months, there was a clinically relevant, but nonsignificant reduction in presentations to emergency departments (21% vs 33%; 1 = 1.41, P = .23) and readmission to the hospital (37% vs 47%; 1 = 0.82, P = .37) among intervention compared with control group participants.	However, at 6 months, total quality-of-life scores were higher for intervention group patients than controls (106.0 vs 98.6).
__label__noRel	At 6 months, there was a clinically relevant, but nonsignificant reduction in presentations to emergency departments (21% vs 33%; 1 = 1.41, P = .23) and readmission to the hospital (37% vs 47%; 1 = 0.82, P = .37) among intervention compared with control group participants.	Improvements in total quality-of-life change scores demonstrated that at 6 months, improvements were more than twice as large and clinically significant in the intervention compared with the control group.
__label__Support	At 6 months, there was a clinically relevant, but nonsignificant reduction in presentations to emergency departments (21% vs 33%; 1 = 1.41, P = .23) and readmission to the hospital (37% vs 47%; 1 = 0.82, P = .37) among intervention compared with control group participants.	CONNECT has shown promising indications on health system and patient outcomes that warrant a larger study to further investigate the potential of this intervention.
__label__noRel	Nonsignificant differences between groups were found for all unmet supportive care need and quality-of-life scores, change scores, and trends.	At 6 months, there was a clinically relevant, but nonsignificant reduction in presentations to emergency departments (21% vs 33%; 1 = 1.41, P = .23) and readmission to the hospital (37% vs 47%; 1 = 0.82, P = .37) among intervention compared with control group participants.
__label__noRel	Nonsignificant differences between groups were found for all unmet supportive care need and quality-of-life scores, change scores, and trends.	However, at 6 months, total quality-of-life scores were higher for intervention group patients than controls (106.0 vs 98.6).
__label__noRel	Nonsignificant differences between groups were found for all unmet supportive care need and quality-of-life scores, change scores, and trends.	Improvements in total quality-of-life change scores demonstrated that at 6 months, improvements were more than twice as large and clinically significant in the intervention compared with the control group.
__label__Support	Nonsignificant differences between groups were found for all unmet supportive care need and quality-of-life scores, change scores, and trends.	CONNECT has shown promising indications on health system and patient outcomes that warrant a larger study to further investigate the potential of this intervention.
__label__noRel	However, at 6 months, total quality-of-life scores were higher for intervention group patients than controls (106.0 vs 98.6).	At 6 months, there was a clinically relevant, but nonsignificant reduction in presentations to emergency departments (21% vs 33%; 1 = 1.41, P = .23) and readmission to the hospital (37% vs 47%; 1 = 0.82, P = .37) among intervention compared with control group participants.
__label__noRel	However, at 6 months, total quality-of-life scores were higher for intervention group patients than controls (106.0 vs 98.6).	Nonsignificant differences between groups were found for all unmet supportive care need and quality-of-life scores, change scores, and trends.
__label__Support	However, at 6 months, total quality-of-life scores were higher for intervention group patients than controls (106.0 vs 98.6).	Improvements in total quality-of-life change scores demonstrated that at 6 months, improvements were more than twice as large and clinically significant in the intervention compared with the control group.
__label__noRel	However, at 6 months, total quality-of-life scores were higher for intervention group patients than controls (106.0 vs 98.6).	CONNECT has shown promising indications on health system and patient outcomes that warrant a larger study to further investigate the potential of this intervention.
__label__noRel	Improvements in total quality-of-life change scores demonstrated that at 6 months, improvements were more than twice as large and clinically significant in the intervention compared with the control group.	At 6 months, there was a clinically relevant, but nonsignificant reduction in presentations to emergency departments (21% vs 33%; 1 = 1.41, P = .23) and readmission to the hospital (37% vs 47%; 1 = 0.82, P = .37) among intervention compared with control group participants.
__label__noRel	Improvements in total quality-of-life change scores demonstrated that at 6 months, improvements were more than twice as large and clinically significant in the intervention compared with the control group.	Nonsignificant differences between groups were found for all unmet supportive care need and quality-of-life scores, change scores, and trends.
__label__noRel	Improvements in total quality-of-life change scores demonstrated that at 6 months, improvements were more than twice as large and clinically significant in the intervention compared with the control group.	However, at 6 months, total quality-of-life scores were higher for intervention group patients than controls (106.0 vs 98.6).
__label__Support	Improvements in total quality-of-life change scores demonstrated that at 6 months, improvements were more than twice as large and clinically significant in the intervention compared with the control group.	CONNECT has shown promising indications on health system and patient outcomes that warrant a larger study to further investigate the potential of this intervention.
__label__noRel	CONNECT has shown promising indications on health system and patient outcomes that warrant a larger study to further investigate the potential of this intervention.	At 6 months, there was a clinically relevant, but nonsignificant reduction in presentations to emergency departments (21% vs 33%; 1 = 1.41, P = .23) and readmission to the hospital (37% vs 47%; 1 = 0.82, P = .37) among intervention compared with control group participants.
__label__noRel	CONNECT has shown promising indications on health system and patient outcomes that warrant a larger study to further investigate the potential of this intervention.	Nonsignificant differences between groups were found for all unmet supportive care need and quality-of-life scores, change scores, and trends.
__label__noRel	CONNECT has shown promising indications on health system and patient outcomes that warrant a larger study to further investigate the potential of this intervention.	However, at 6 months, total quality-of-life scores were higher for intervention group patients than controls (106.0 vs 98.6).
__label__noRel	CONNECT has shown promising indications on health system and patient outcomes that warrant a larger study to further investigate the potential of this intervention.	Improvements in total quality-of-life change scores demonstrated that at 6 months, improvements were more than twice as large and clinically significant in the intervention compared with the control group.
__label__noRel	Gastrointestinal and GU toxicity persisted 5 years after RT and did not differ between the two dose schedules other than in regard to urgency of defecation.	However, 1-month GI toxicity was not only worse in patients with the hypofractionated RT schedule but also adversely affected daily activities.
__label__noRel	Gastrointestinal and GU toxicity persisted 5 years after RT and did not differ between the two dose schedules other than in regard to urgency of defecation.	Nadir prostate-specific antigen values occurred at a median of 18.0 (3.0-54.0) months after RT.
__label__noRel	Gastrointestinal and GU toxicity persisted 5 years after RT and did not differ between the two dose schedules other than in regard to urgency of defecation.	A total of 76 biochemical relapses, with or without clinical relapses, have occurred since; of these, 37 were in the hypofractionated and 39 in the conventional schedule.
__label__noRel	Gastrointestinal and GU toxicity persisted 5 years after RT and did not differ between the two dose schedules other than in regard to urgency of defecation.	The 5-year biochemical +/- clinical relapse-free and overall survival was 55.9% and 85.3% respectively for all patients, and did not differ between the two schedules.
__label__Support	Gastrointestinal and GU toxicity persisted 5 years after RT and did not differ between the two dose schedules other than in regard to urgency of defecation.	The hypofractionated schedule is equivalent in efficacy to the conventional schedule.
__label__noRel	Gastrointestinal and GU toxicity persisted 5 years after RT and did not differ between the two dose schedules other than in regard to urgency of defecation.	Radiation therapy for prostate carcinoma causes persistent GI toxicity that is largely independent of the two dose schedules.
__label__noRel	However, 1-month GI toxicity was not only worse in patients with the hypofractionated RT schedule but also adversely affected daily activities.	Gastrointestinal and GU toxicity persisted 5 years after RT and did not differ between the two dose schedules other than in regard to urgency of defecation.
__label__noRel	However, 1-month GI toxicity was not only worse in patients with the hypofractionated RT schedule but also adversely affected daily activities.	Nadir prostate-specific antigen values occurred at a median of 18.0 (3.0-54.0) months after RT.
__label__noRel	However, 1-month GI toxicity was not only worse in patients with the hypofractionated RT schedule but also adversely affected daily activities.	A total of 76 biochemical relapses, with or without clinical relapses, have occurred since; of these, 37 were in the hypofractionated and 39 in the conventional schedule.
__label__noRel	However, 1-month GI toxicity was not only worse in patients with the hypofractionated RT schedule but also adversely affected daily activities.	The 5-year biochemical +/- clinical relapse-free and overall survival was 55.9% and 85.3% respectively for all patients, and did not differ between the two schedules.
__label__noRel	However, 1-month GI toxicity was not only worse in patients with the hypofractionated RT schedule but also adversely affected daily activities.	The hypofractionated schedule is equivalent in efficacy to the conventional schedule.
__label__Support	However, 1-month GI toxicity was not only worse in patients with the hypofractionated RT schedule but also adversely affected daily activities.	Radiation therapy for prostate carcinoma causes persistent GI toxicity that is largely independent of the two dose schedules.
__label__noRel	Nadir prostate-specific antigen values occurred at a median of 18.0 (3.0-54.0) months after RT.	Gastrointestinal and GU toxicity persisted 5 years after RT and did not differ between the two dose schedules other than in regard to urgency of defecation.
__label__noRel	Nadir prostate-specific antigen values occurred at a median of 18.0 (3.0-54.0) months after RT.	However, 1-month GI toxicity was not only worse in patients with the hypofractionated RT schedule but also adversely affected daily activities.
__label__noRel	Nadir prostate-specific antigen values occurred at a median of 18.0 (3.0-54.0) months after RT.	A total of 76 biochemical relapses, with or without clinical relapses, have occurred since; of these, 37 were in the hypofractionated and 39 in the conventional schedule.
__label__noRel	Nadir prostate-specific antigen values occurred at a median of 18.0 (3.0-54.0) months after RT.	The 5-year biochemical +/- clinical relapse-free and overall survival was 55.9% and 85.3% respectively for all patients, and did not differ between the two schedules.
__label__noRel	Nadir prostate-specific antigen values occurred at a median of 18.0 (3.0-54.0) months after RT.	The hypofractionated schedule is equivalent in efficacy to the conventional schedule.
__label__noRel	Nadir prostate-specific antigen values occurred at a median of 18.0 (3.0-54.0) months after RT.	Radiation therapy for prostate carcinoma causes persistent GI toxicity that is largely independent of the two dose schedules.
__label__noRel	A total of 76 biochemical relapses, with or without clinical relapses, have occurred since; of these, 37 were in the hypofractionated and 39 in the conventional schedule.	Gastrointestinal and GU toxicity persisted 5 years after RT and did not differ between the two dose schedules other than in regard to urgency of defecation.
__label__noRel	A total of 76 biochemical relapses, with or without clinical relapses, have occurred since; of these, 37 were in the hypofractionated and 39 in the conventional schedule.	However, 1-month GI toxicity was not only worse in patients with the hypofractionated RT schedule but also adversely affected daily activities.
__label__noRel	A total of 76 biochemical relapses, with or without clinical relapses, have occurred since; of these, 37 were in the hypofractionated and 39 in the conventional schedule.	Nadir prostate-specific antigen values occurred at a median of 18.0 (3.0-54.0) months after RT.
__label__noRel	A total of 76 biochemical relapses, with or without clinical relapses, have occurred since; of these, 37 were in the hypofractionated and 39 in the conventional schedule.	The 5-year biochemical +/- clinical relapse-free and overall survival was 55.9% and 85.3% respectively for all patients, and did not differ between the two schedules.
__label__Support	A total of 76 biochemical relapses, with or without clinical relapses, have occurred since; of these, 37 were in the hypofractionated and 39 in the conventional schedule.	The hypofractionated schedule is equivalent in efficacy to the conventional schedule.
__label__noRel	A total of 76 biochemical relapses, with or without clinical relapses, have occurred since; of these, 37 were in the hypofractionated and 39 in the conventional schedule.	Radiation therapy for prostate carcinoma causes persistent GI toxicity that is largely independent of the two dose schedules.
__label__noRel	The 5-year biochemical +/- clinical relapse-free and overall survival was 55.9% and 85.3% respectively for all patients, and did not differ between the two schedules.	Gastrointestinal and GU toxicity persisted 5 years after RT and did not differ between the two dose schedules other than in regard to urgency of defecation.
__label__noRel	The 5-year biochemical +/- clinical relapse-free and overall survival was 55.9% and 85.3% respectively for all patients, and did not differ between the two schedules.	However, 1-month GI toxicity was not only worse in patients with the hypofractionated RT schedule but also adversely affected daily activities.
__label__noRel	The 5-year biochemical +/- clinical relapse-free and overall survival was 55.9% and 85.3% respectively for all patients, and did not differ between the two schedules.	Nadir prostate-specific antigen values occurred at a median of 18.0 (3.0-54.0) months after RT.
__label__noRel	The 5-year biochemical +/- clinical relapse-free and overall survival was 55.9% and 85.3% respectively for all patients, and did not differ between the two schedules.	A total of 76 biochemical relapses, with or without clinical relapses, have occurred since; of these, 37 were in the hypofractionated and 39 in the conventional schedule.
__label__Support	The 5-year biochemical +/- clinical relapse-free and overall survival was 55.9% and 85.3% respectively for all patients, and did not differ between the two schedules.	The hypofractionated schedule is equivalent in efficacy to the conventional schedule.
__label__noRel	The 5-year biochemical +/- clinical relapse-free and overall survival was 55.9% and 85.3% respectively for all patients, and did not differ between the two schedules.	Radiation therapy for prostate carcinoma causes persistent GI toxicity that is largely independent of the two dose schedules.
__label__noRel	The hypofractionated schedule is equivalent in efficacy to the conventional schedule.	Gastrointestinal and GU toxicity persisted 5 years after RT and did not differ between the two dose schedules other than in regard to urgency of defecation.
__label__noRel	The hypofractionated schedule is equivalent in efficacy to the conventional schedule.	However, 1-month GI toxicity was not only worse in patients with the hypofractionated RT schedule but also adversely affected daily activities.
__label__noRel	The hypofractionated schedule is equivalent in efficacy to the conventional schedule.	Nadir prostate-specific antigen values occurred at a median of 18.0 (3.0-54.0) months after RT.
__label__noRel	The hypofractionated schedule is equivalent in efficacy to the conventional schedule.	A total of 76 biochemical relapses, with or without clinical relapses, have occurred since; of these, 37 were in the hypofractionated and 39 in the conventional schedule.
__label__noRel	The hypofractionated schedule is equivalent in efficacy to the conventional schedule.	The 5-year biochemical +/- clinical relapse-free and overall survival was 55.9% and 85.3% respectively for all patients, and did not differ between the two schedules.
__label__noRel	The hypofractionated schedule is equivalent in efficacy to the conventional schedule.	Radiation therapy for prostate carcinoma causes persistent GI toxicity that is largely independent of the two dose schedules.
__label__noRel	Radiation therapy for prostate carcinoma causes persistent GI toxicity that is largely independent of the two dose schedules.	Gastrointestinal and GU toxicity persisted 5 years after RT and did not differ between the two dose schedules other than in regard to urgency of defecation.
__label__noRel	Radiation therapy for prostate carcinoma causes persistent GI toxicity that is largely independent of the two dose schedules.	However, 1-month GI toxicity was not only worse in patients with the hypofractionated RT schedule but also adversely affected daily activities.
__label__noRel	Radiation therapy for prostate carcinoma causes persistent GI toxicity that is largely independent of the two dose schedules.	Nadir prostate-specific antigen values occurred at a median of 18.0 (3.0-54.0) months after RT.
__label__noRel	Radiation therapy for prostate carcinoma causes persistent GI toxicity that is largely independent of the two dose schedules.	A total of 76 biochemical relapses, with or without clinical relapses, have occurred since; of these, 37 were in the hypofractionated and 39 in the conventional schedule.
__label__noRel	Radiation therapy for prostate carcinoma causes persistent GI toxicity that is largely independent of the two dose schedules.	The 5-year biochemical +/- clinical relapse-free and overall survival was 55.9% and 85.3% respectively for all patients, and did not differ between the two schedules.
__label__noRel	Radiation therapy for prostate carcinoma causes persistent GI toxicity that is largely independent of the two dose schedules.	The hypofractionated schedule is equivalent in efficacy to the conventional schedule.
__label__noRel	With a median follow-up of more than 3 years, survival did not differ among the treatment groups (median FU + LV, 11.1 months [95% CI, 10.2 to 15.0 months]; FU24h, 13.0 months [95% CI, 10.4 to 15.4 months]; FU24h + LV, 13.7 months [95% CI, 12.0 to 16.4 months]; P =.724).	Progression-free survival (PFS) was significantly longer for FU24h + LV (median FU + LV, 4.0 months [95% CI, 3.4 to 4.9]; FU24h, 4.1 months [95% CI, 3.4 to 5.0]; FU24h + LV 5.6 months [95% CI, 4.4 to 6.7]; P =.029).
__label__noRel	With a median follow-up of more than 3 years, survival did not differ among the treatment groups (median FU + LV, 11.1 months [95% CI, 10.2 to 15.0 months]; FU24h, 13.0 months [95% CI, 10.4 to 15.4 months]; FU24h + LV, 13.7 months [95% CI, 12.0 to 16.4 months]; P =.724).	The response rates in the subgroup of patients with measurable disease were 12%, 10%, and 17% for FU + LV, FU24h, and FU24h + LV, respectively (not significant).
__label__noRel	With a median follow-up of more than 3 years, survival did not differ among the treatment groups (median FU + LV, 11.1 months [95% CI, 10.2 to 15.0 months]; FU24h, 13.0 months [95% CI, 10.4 to 15.4 months]; FU24h + LV, 13.7 months [95% CI, 12.0 to 16.4 months]; P =.724).	Occurrence of grade 3 and 4 diarrhea was higher in the FU24h + LV arm (22%) compared with the FU24h (6%) or FU + LV (9%) arms;
__label__noRel	With a median follow-up of more than 3 years, survival did not differ among the treatment groups (median FU + LV, 11.1 months [95% CI, 10.2 to 15.0 months]; FU24h, 13.0 months [95% CI, 10.4 to 15.4 months]; FU24h + LV, 13.7 months [95% CI, 12.0 to 16.4 months]; P =.724).	however, stomatitis (11% in FU + LV v 3% in FU24h v 5% in FU24h + LV arms) and hematologic toxicity were higher in the bolus FU + LV arm.
__label__noRel	With a median follow-up of more than 3 years, survival did not differ among the treatment groups (median FU + LV, 11.1 months [95% CI, 10.2 to 15.0 months]; FU24h, 13.0 months [95% CI, 10.4 to 15.4 months]; FU24h + LV, 13.7 months [95% CI, 12.0 to 16.4 months]; P =.724).	Global quality of life did not differ within the three arms.
__label__Support	With a median follow-up of more than 3 years, survival did not differ among the treatment groups (median FU + LV, 11.1 months [95% CI, 10.2 to 15.0 months]; FU24h, 13.0 months [95% CI, 10.4 to 15.4 months]; FU24h + LV, 13.7 months [95% CI, 12.0 to 16.4 months]; P =.724).	Neither FU24h + LV nor FU24h prolong survival, relative to bolus FU + LV.
__label__noRel	With a median follow-up of more than 3 years, survival did not differ among the treatment groups (median FU + LV, 11.1 months [95% CI, 10.2 to 15.0 months]; FU24h, 13.0 months [95% CI, 10.4 to 15.4 months]; FU24h + LV, 13.7 months [95% CI, 12.0 to 16.4 months]; P =.724).	Leucovorin increases PFS if added to FU24h, but increases toxicity.
__label__noRel	Progression-free survival (PFS) was significantly longer for FU24h + LV (median FU + LV, 4.0 months [95% CI, 3.4 to 4.9]; FU24h, 4.1 months [95% CI, 3.4 to 5.0]; FU24h + LV 5.6 months [95% CI, 4.4 to 6.7]; P =.029).	With a median follow-up of more than 3 years, survival did not differ among the treatment groups (median FU + LV, 11.1 months [95% CI, 10.2 to 15.0 months]; FU24h, 13.0 months [95% CI, 10.4 to 15.4 months]; FU24h + LV, 13.7 months [95% CI, 12.0 to 16.4 months]; P =.724).
__label__noRel	Progression-free survival (PFS) was significantly longer for FU24h + LV (median FU + LV, 4.0 months [95% CI, 3.4 to 4.9]; FU24h, 4.1 months [95% CI, 3.4 to 5.0]; FU24h + LV 5.6 months [95% CI, 4.4 to 6.7]; P =.029).	The response rates in the subgroup of patients with measurable disease were 12%, 10%, and 17% for FU + LV, FU24h, and FU24h + LV, respectively (not significant).
__label__noRel	Progression-free survival (PFS) was significantly longer for FU24h + LV (median FU + LV, 4.0 months [95% CI, 3.4 to 4.9]; FU24h, 4.1 months [95% CI, 3.4 to 5.0]; FU24h + LV 5.6 months [95% CI, 4.4 to 6.7]; P =.029).	Occurrence of grade 3 and 4 diarrhea was higher in the FU24h + LV arm (22%) compared with the FU24h (6%) or FU + LV (9%) arms;
__label__noRel	Progression-free survival (PFS) was significantly longer for FU24h + LV (median FU + LV, 4.0 months [95% CI, 3.4 to 4.9]; FU24h, 4.1 months [95% CI, 3.4 to 5.0]; FU24h + LV 5.6 months [95% CI, 4.4 to 6.7]; P =.029).	however, stomatitis (11% in FU + LV v 3% in FU24h v 5% in FU24h + LV arms) and hematologic toxicity were higher in the bolus FU + LV arm.
__label__noRel	Progression-free survival (PFS) was significantly longer for FU24h + LV (median FU + LV, 4.0 months [95% CI, 3.4 to 4.9]; FU24h, 4.1 months [95% CI, 3.4 to 5.0]; FU24h + LV 5.6 months [95% CI, 4.4 to 6.7]; P =.029).	Global quality of life did not differ within the three arms.
__label__noRel	Progression-free survival (PFS) was significantly longer for FU24h + LV (median FU + LV, 4.0 months [95% CI, 3.4 to 4.9]; FU24h, 4.1 months [95% CI, 3.4 to 5.0]; FU24h + LV 5.6 months [95% CI, 4.4 to 6.7]; P =.029).	Neither FU24h + LV nor FU24h prolong survival, relative to bolus FU + LV.
__label__Support	Progression-free survival (PFS) was significantly longer for FU24h + LV (median FU + LV, 4.0 months [95% CI, 3.4 to 4.9]; FU24h, 4.1 months [95% CI, 3.4 to 5.0]; FU24h + LV 5.6 months [95% CI, 4.4 to 6.7]; P =.029).	Leucovorin increases PFS if added to FU24h, but increases toxicity.
__label__noRel	The response rates in the subgroup of patients with measurable disease were 12%, 10%, and 17% for FU + LV, FU24h, and FU24h + LV, respectively (not significant).	With a median follow-up of more than 3 years, survival did not differ among the treatment groups (median FU + LV, 11.1 months [95% CI, 10.2 to 15.0 months]; FU24h, 13.0 months [95% CI, 10.4 to 15.4 months]; FU24h + LV, 13.7 months [95% CI, 12.0 to 16.4 months]; P =.724).
__label__noRel	The response rates in the subgroup of patients with measurable disease were 12%, 10%, and 17% for FU + LV, FU24h, and FU24h + LV, respectively (not significant).	Progression-free survival (PFS) was significantly longer for FU24h + LV (median FU + LV, 4.0 months [95% CI, 3.4 to 4.9]; FU24h, 4.1 months [95% CI, 3.4 to 5.0]; FU24h + LV 5.6 months [95% CI, 4.4 to 6.7]; P =.029).
__label__noRel	The response rates in the subgroup of patients with measurable disease were 12%, 10%, and 17% for FU + LV, FU24h, and FU24h + LV, respectively (not significant).	Occurrence of grade 3 and 4 diarrhea was higher in the FU24h + LV arm (22%) compared with the FU24h (6%) or FU + LV (9%) arms;
__label__noRel	The response rates in the subgroup of patients with measurable disease were 12%, 10%, and 17% for FU + LV, FU24h, and FU24h + LV, respectively (not significant).	however, stomatitis (11% in FU + LV v 3% in FU24h v 5% in FU24h + LV arms) and hematologic toxicity were higher in the bolus FU + LV arm.
__label__noRel	The response rates in the subgroup of patients with measurable disease were 12%, 10%, and 17% for FU + LV, FU24h, and FU24h + LV, respectively (not significant).	Global quality of life did not differ within the three arms.
__label__noRel	The response rates in the subgroup of patients with measurable disease were 12%, 10%, and 17% for FU + LV, FU24h, and FU24h + LV, respectively (not significant).	Neither FU24h + LV nor FU24h prolong survival, relative to bolus FU + LV.
__label__noRel	The response rates in the subgroup of patients with measurable disease were 12%, 10%, and 17% for FU + LV, FU24h, and FU24h + LV, respectively (not significant).	Leucovorin increases PFS if added to FU24h, but increases toxicity.
__label__noRel	Occurrence of grade 3 and 4 diarrhea was higher in the FU24h + LV arm (22%) compared with the FU24h (6%) or FU + LV (9%) arms;	With a median follow-up of more than 3 years, survival did not differ among the treatment groups (median FU + LV, 11.1 months [95% CI, 10.2 to 15.0 months]; FU24h, 13.0 months [95% CI, 10.4 to 15.4 months]; FU24h + LV, 13.7 months [95% CI, 12.0 to 16.4 months]; P =.724).
__label__noRel	Occurrence of grade 3 and 4 diarrhea was higher in the FU24h + LV arm (22%) compared with the FU24h (6%) or FU + LV (9%) arms;	Progression-free survival (PFS) was significantly longer for FU24h + LV (median FU + LV, 4.0 months [95% CI, 3.4 to 4.9]; FU24h, 4.1 months [95% CI, 3.4 to 5.0]; FU24h + LV 5.6 months [95% CI, 4.4 to 6.7]; P =.029).
__label__noRel	Occurrence of grade 3 and 4 diarrhea was higher in the FU24h + LV arm (22%) compared with the FU24h (6%) or FU + LV (9%) arms;	The response rates in the subgroup of patients with measurable disease were 12%, 10%, and 17% for FU + LV, FU24h, and FU24h + LV, respectively (not significant).
__label__noRel	Occurrence of grade 3 and 4 diarrhea was higher in the FU24h + LV arm (22%) compared with the FU24h (6%) or FU + LV (9%) arms;	however, stomatitis (11% in FU + LV v 3% in FU24h v 5% in FU24h + LV arms) and hematologic toxicity were higher in the bolus FU + LV arm.
__label__Support	Occurrence of grade 3 and 4 diarrhea was higher in the FU24h + LV arm (22%) compared with the FU24h (6%) or FU + LV (9%) arms;	Global quality of life did not differ within the three arms.
__label__noRel	Occurrence of grade 3 and 4 diarrhea was higher in the FU24h + LV arm (22%) compared with the FU24h (6%) or FU + LV (9%) arms;	Neither FU24h + LV nor FU24h prolong survival, relative to bolus FU + LV.
__label__noRel	Occurrence of grade 3 and 4 diarrhea was higher in the FU24h + LV arm (22%) compared with the FU24h (6%) or FU + LV (9%) arms;	Leucovorin increases PFS if added to FU24h, but increases toxicity.
__label__noRel	however, stomatitis (11% in FU + LV v 3% in FU24h v 5% in FU24h + LV arms) and hematologic toxicity were higher in the bolus FU + LV arm.	With a median follow-up of more than 3 years, survival did not differ among the treatment groups (median FU + LV, 11.1 months [95% CI, 10.2 to 15.0 months]; FU24h, 13.0 months [95% CI, 10.4 to 15.4 months]; FU24h + LV, 13.7 months [95% CI, 12.0 to 16.4 months]; P =.724).
__label__noRel	however, stomatitis (11% in FU + LV v 3% in FU24h v 5% in FU24h + LV arms) and hematologic toxicity were higher in the bolus FU + LV arm.	Progression-free survival (PFS) was significantly longer for FU24h + LV (median FU + LV, 4.0 months [95% CI, 3.4 to 4.9]; FU24h, 4.1 months [95% CI, 3.4 to 5.0]; FU24h + LV 5.6 months [95% CI, 4.4 to 6.7]; P =.029).
__label__noRel	however, stomatitis (11% in FU + LV v 3% in FU24h v 5% in FU24h + LV arms) and hematologic toxicity were higher in the bolus FU + LV arm.	The response rates in the subgroup of patients with measurable disease were 12%, 10%, and 17% for FU + LV, FU24h, and FU24h + LV, respectively (not significant).
__label__noRel	however, stomatitis (11% in FU + LV v 3% in FU24h v 5% in FU24h + LV arms) and hematologic toxicity were higher in the bolus FU + LV arm.	Occurrence of grade 3 and 4 diarrhea was higher in the FU24h + LV arm (22%) compared with the FU24h (6%) or FU + LV (9%) arms;
__label__Support	however, stomatitis (11% in FU + LV v 3% in FU24h v 5% in FU24h + LV arms) and hematologic toxicity were higher in the bolus FU + LV arm.	Global quality of life did not differ within the three arms.
__label__noRel	however, stomatitis (11% in FU + LV v 3% in FU24h v 5% in FU24h + LV arms) and hematologic toxicity were higher in the bolus FU + LV arm.	Neither FU24h + LV nor FU24h prolong survival, relative to bolus FU + LV.
__label__noRel	however, stomatitis (11% in FU + LV v 3% in FU24h v 5% in FU24h + LV arms) and hematologic toxicity were higher in the bolus FU + LV arm.	Leucovorin increases PFS if added to FU24h, but increases toxicity.
__label__noRel	Global quality of life did not differ within the three arms.	With a median follow-up of more than 3 years, survival did not differ among the treatment groups (median FU + LV, 11.1 months [95% CI, 10.2 to 15.0 months]; FU24h, 13.0 months [95% CI, 10.4 to 15.4 months]; FU24h + LV, 13.7 months [95% CI, 12.0 to 16.4 months]; P =.724).
__label__noRel	Global quality of life did not differ within the three arms.	Progression-free survival (PFS) was significantly longer for FU24h + LV (median FU + LV, 4.0 months [95% CI, 3.4 to 4.9]; FU24h, 4.1 months [95% CI, 3.4 to 5.0]; FU24h + LV 5.6 months [95% CI, 4.4 to 6.7]; P =.029).
__label__noRel	Global quality of life did not differ within the three arms.	The response rates in the subgroup of patients with measurable disease were 12%, 10%, and 17% for FU + LV, FU24h, and FU24h + LV, respectively (not significant).
__label__noRel	Global quality of life did not differ within the three arms.	Occurrence of grade 3 and 4 diarrhea was higher in the FU24h + LV arm (22%) compared with the FU24h (6%) or FU + LV (9%) arms;
__label__noRel	Global quality of life did not differ within the three arms.	however, stomatitis (11% in FU + LV v 3% in FU24h v 5% in FU24h + LV arms) and hematologic toxicity were higher in the bolus FU + LV arm.
__label__noRel	Global quality of life did not differ within the three arms.	Neither FU24h + LV nor FU24h prolong survival, relative to bolus FU + LV.
__label__noRel	Global quality of life did not differ within the three arms.	Leucovorin increases PFS if added to FU24h, but increases toxicity.
__label__noRel	Neither FU24h + LV nor FU24h prolong survival, relative to bolus FU + LV.	With a median follow-up of more than 3 years, survival did not differ among the treatment groups (median FU + LV, 11.1 months [95% CI, 10.2 to 15.0 months]; FU24h, 13.0 months [95% CI, 10.4 to 15.4 months]; FU24h + LV, 13.7 months [95% CI, 12.0 to 16.4 months]; P =.724).
__label__noRel	Neither FU24h + LV nor FU24h prolong survival, relative to bolus FU + LV.	Progression-free survival (PFS) was significantly longer for FU24h + LV (median FU + LV, 4.0 months [95% CI, 3.4 to 4.9]; FU24h, 4.1 months [95% CI, 3.4 to 5.0]; FU24h + LV 5.6 months [95% CI, 4.4 to 6.7]; P =.029).
__label__noRel	Neither FU24h + LV nor FU24h prolong survival, relative to bolus FU + LV.	The response rates in the subgroup of patients with measurable disease were 12%, 10%, and 17% for FU + LV, FU24h, and FU24h + LV, respectively (not significant).
__label__noRel	Neither FU24h + LV nor FU24h prolong survival, relative to bolus FU + LV.	Occurrence of grade 3 and 4 diarrhea was higher in the FU24h + LV arm (22%) compared with the FU24h (6%) or FU + LV (9%) arms;
__label__noRel	Neither FU24h + LV nor FU24h prolong survival, relative to bolus FU + LV.	however, stomatitis (11% in FU + LV v 3% in FU24h v 5% in FU24h + LV arms) and hematologic toxicity were higher in the bolus FU + LV arm.
__label__noRel	Neither FU24h + LV nor FU24h prolong survival, relative to bolus FU + LV.	Global quality of life did not differ within the three arms.
__label__noRel	Neither FU24h + LV nor FU24h prolong survival, relative to bolus FU + LV.	Leucovorin increases PFS if added to FU24h, but increases toxicity.
__label__noRel	Leucovorin increases PFS if added to FU24h, but increases toxicity.	With a median follow-up of more than 3 years, survival did not differ among the treatment groups (median FU + LV, 11.1 months [95% CI, 10.2 to 15.0 months]; FU24h, 13.0 months [95% CI, 10.4 to 15.4 months]; FU24h + LV, 13.7 months [95% CI, 12.0 to 16.4 months]; P =.724).
__label__noRel	Leucovorin increases PFS if added to FU24h, but increases toxicity.	Progression-free survival (PFS) was significantly longer for FU24h + LV (median FU + LV, 4.0 months [95% CI, 3.4 to 4.9]; FU24h, 4.1 months [95% CI, 3.4 to 5.0]; FU24h + LV 5.6 months [95% CI, 4.4 to 6.7]; P =.029).
__label__noRel	Leucovorin increases PFS if added to FU24h, but increases toxicity.	The response rates in the subgroup of patients with measurable disease were 12%, 10%, and 17% for FU + LV, FU24h, and FU24h + LV, respectively (not significant).
__label__noRel	Leucovorin increases PFS if added to FU24h, but increases toxicity.	Occurrence of grade 3 and 4 diarrhea was higher in the FU24h + LV arm (22%) compared with the FU24h (6%) or FU + LV (9%) arms;
__label__noRel	Leucovorin increases PFS if added to FU24h, but increases toxicity.	however, stomatitis (11% in FU + LV v 3% in FU24h v 5% in FU24h + LV arms) and hematologic toxicity were higher in the bolus FU + LV arm.
__label__noRel	Leucovorin increases PFS if added to FU24h, but increases toxicity.	Global quality of life did not differ within the three arms.
__label__noRel	Leucovorin increases PFS if added to FU24h, but increases toxicity.	Neither FU24h + LV nor FU24h prolong survival, relative to bolus FU + LV.
__label__noRel	For the chemotherapy group, the mean Quality Adjusted Life Months over 24 months (QALM-24) was 9.6 (95% CI: 8.7, 11.2) months compared with the mean QALM-24 of 8.6 (95% CI: 7.6, 10.5) months for the no chemotherapy group.	For the chemoradiation group, the mean QALM-24 was 7.1 (95% CI: 6.0, 9.0) months compared with the mean QALM-24 of 8.1 (95% CI: 7.0, 10.0) months for the no chemoradiation group.
__label__Support	For the chemotherapy group, the mean Quality Adjusted Life Months over 24 months (QALM-24) was 9.6 (95% CI: 8.7, 11.2) months compared with the mean QALM-24 of 8.6 (95% CI: 7.6, 10.5) months for the no chemotherapy group.	Chemotherapy provided on average an additional 1.0 quality-adjusted life months within a restricted 2-year time period from the time of resection.
__label__noRel	For the chemotherapy group, the mean Quality Adjusted Life Months over 24 months (QALM-24) was 9.6 (95% CI: 8.7, 11.2) months compared with the mean QALM-24 of 8.6 (95% CI: 7.6, 10.5) months for the no chemotherapy group.	The previously reported survival advantage supporting the use of adjuvant chemotherapy is maintained when adjusted using quality adjusted survival methodology.
__label__noRel	For the chemoradiation group, the mean QALM-24 was 7.1 (95% CI: 6.0, 9.0) months compared with the mean QALM-24 of 8.1 (95% CI: 7.0, 10.0) months for the no chemoradiation group.	For the chemotherapy group, the mean Quality Adjusted Life Months over 24 months (QALM-24) was 9.6 (95% CI: 8.7, 11.2) months compared with the mean QALM-24 of 8.6 (95% CI: 7.6, 10.5) months for the no chemotherapy group.
__label__Support	For the chemoradiation group, the mean QALM-24 was 7.1 (95% CI: 6.0, 9.0) months compared with the mean QALM-24 of 8.1 (95% CI: 7.0, 10.0) months for the no chemoradiation group.	Chemotherapy provided on average an additional 1.0 quality-adjusted life months within a restricted 2-year time period from the time of resection.
__label__noRel	For the chemoradiation group, the mean QALM-24 was 7.1 (95% CI: 6.0, 9.0) months compared with the mean QALM-24 of 8.1 (95% CI: 7.0, 10.0) months for the no chemoradiation group.	The previously reported survival advantage supporting the use of adjuvant chemotherapy is maintained when adjusted using quality adjusted survival methodology.
__label__noRel	Chemotherapy provided on average an additional 1.0 quality-adjusted life months within a restricted 2-year time period from the time of resection.	For the chemotherapy group, the mean Quality Adjusted Life Months over 24 months (QALM-24) was 9.6 (95% CI: 8.7, 11.2) months compared with the mean QALM-24 of 8.6 (95% CI: 7.6, 10.5) months for the no chemotherapy group.
__label__noRel	Chemotherapy provided on average an additional 1.0 quality-adjusted life months within a restricted 2-year time period from the time of resection.	For the chemoradiation group, the mean QALM-24 was 7.1 (95% CI: 6.0, 9.0) months compared with the mean QALM-24 of 8.1 (95% CI: 7.0, 10.0) months for the no chemoradiation group.
__label__noRel	Chemotherapy provided on average an additional 1.0 quality-adjusted life months within a restricted 2-year time period from the time of resection.	The previously reported survival advantage supporting the use of adjuvant chemotherapy is maintained when adjusted using quality adjusted survival methodology.
__label__noRel	The previously reported survival advantage supporting the use of adjuvant chemotherapy is maintained when adjusted using quality adjusted survival methodology.	For the chemotherapy group, the mean Quality Adjusted Life Months over 24 months (QALM-24) was 9.6 (95% CI: 8.7, 11.2) months compared with the mean QALM-24 of 8.6 (95% CI: 7.6, 10.5) months for the no chemotherapy group.
__label__noRel	The previously reported survival advantage supporting the use of adjuvant chemotherapy is maintained when adjusted using quality adjusted survival methodology.	For the chemoradiation group, the mean QALM-24 was 7.1 (95% CI: 6.0, 9.0) months compared with the mean QALM-24 of 8.1 (95% CI: 7.0, 10.0) months for the no chemoradiation group.
__label__noRel	The previously reported survival advantage supporting the use of adjuvant chemotherapy is maintained when adjusted using quality adjusted survival methodology.	Chemotherapy provided on average an additional 1.0 quality-adjusted life months within a restricted 2-year time period from the time of resection.
__label__noRel	MBSR is recommended to support survivors of breast cancer.	To our knowledge, this study provided novel evidence that MBSR can help alleviate long-term emotional and physical adverse effects of medical treatments, including endocrine treatments.
__label__noRel	MBSR is recommended to support survivors of breast cancer.	There were statistically significant improvements in outcome in the experimental group compared with control group at both 8 and 12 weeks (except as indicated) for POMS total mood disturbance (and its subscales of anxiety, depression [8 weeks only], anger [12 weeks only], vigor, fatigue, and confusion [8 weeks only]), FACT-B, FACT-ES, (and Functional Assessment of Cancer Therapy subscales of physical, social [8 weeks only], emotional, and functional well-being), and WHO-5.
__label__noRel	MBSR is recommended to support survivors of breast cancer.	MSBR improved mood, breast- and endocrine-related quality of life, and well-being more effectively than standard care in women with stage 0 to III breast cancer, and these results persisted at three months.
__label__Support	To our knowledge, this study provided novel evidence that MBSR can help alleviate long-term emotional and physical adverse effects of medical treatments, including endocrine treatments.	MBSR is recommended to support survivors of breast cancer.
__label__noRel	To our knowledge, this study provided novel evidence that MBSR can help alleviate long-term emotional and physical adverse effects of medical treatments, including endocrine treatments.	There were statistically significant improvements in outcome in the experimental group compared with control group at both 8 and 12 weeks (except as indicated) for POMS total mood disturbance (and its subscales of anxiety, depression [8 weeks only], anger [12 weeks only], vigor, fatigue, and confusion [8 weeks only]), FACT-B, FACT-ES, (and Functional Assessment of Cancer Therapy subscales of physical, social [8 weeks only], emotional, and functional well-being), and WHO-5.
__label__noRel	To our knowledge, this study provided novel evidence that MBSR can help alleviate long-term emotional and physical adverse effects of medical treatments, including endocrine treatments.	MSBR improved mood, breast- and endocrine-related quality of life, and well-being more effectively than standard care in women with stage 0 to III breast cancer, and these results persisted at three months.
__label__noRel	There were statistically significant improvements in outcome in the experimental group compared with control group at both 8 and 12 weeks (except as indicated) for POMS total mood disturbance (and its subscales of anxiety, depression [8 weeks only], anger [12 weeks only], vigor, fatigue, and confusion [8 weeks only]), FACT-B, FACT-ES, (and Functional Assessment of Cancer Therapy subscales of physical, social [8 weeks only], emotional, and functional well-being), and WHO-5.	MBSR is recommended to support survivors of breast cancer.
__label__Support	There were statistically significant improvements in outcome in the experimental group compared with control group at both 8 and 12 weeks (except as indicated) for POMS total mood disturbance (and its subscales of anxiety, depression [8 weeks only], anger [12 weeks only], vigor, fatigue, and confusion [8 weeks only]), FACT-B, FACT-ES, (and Functional Assessment of Cancer Therapy subscales of physical, social [8 weeks only], emotional, and functional well-being), and WHO-5.	To our knowledge, this study provided novel evidence that MBSR can help alleviate long-term emotional and physical adverse effects of medical treatments, including endocrine treatments.
__label__noRel	There were statistically significant improvements in outcome in the experimental group compared with control group at both 8 and 12 weeks (except as indicated) for POMS total mood disturbance (and its subscales of anxiety, depression [8 weeks only], anger [12 weeks only], vigor, fatigue, and confusion [8 weeks only]), FACT-B, FACT-ES, (and Functional Assessment of Cancer Therapy subscales of physical, social [8 weeks only], emotional, and functional well-being), and WHO-5.	MSBR improved mood, breast- and endocrine-related quality of life, and well-being more effectively than standard care in women with stage 0 to III breast cancer, and these results persisted at three months.
__label__noRel	MSBR improved mood, breast- and endocrine-related quality of life, and well-being more effectively than standard care in women with stage 0 to III breast cancer, and these results persisted at three months.	MBSR is recommended to support survivors of breast cancer.
__label__Support	MSBR improved mood, breast- and endocrine-related quality of life, and well-being more effectively than standard care in women with stage 0 to III breast cancer, and these results persisted at three months.	To our knowledge, this study provided novel evidence that MBSR can help alleviate long-term emotional and physical adverse effects of medical treatments, including endocrine treatments.
__label__noRel	MSBR improved mood, breast- and endocrine-related quality of life, and well-being more effectively than standard care in women with stage 0 to III breast cancer, and these results persisted at three months.	There were statistically significant improvements in outcome in the experimental group compared with control group at both 8 and 12 weeks (except as indicated) for POMS total mood disturbance (and its subscales of anxiety, depression [8 weeks only], anger [12 weeks only], vigor, fatigue, and confusion [8 weeks only]), FACT-B, FACT-ES, (and Functional Assessment of Cancer Therapy subscales of physical, social [8 weeks only], emotional, and functional well-being), and WHO-5.
__label__noRel	No between-treatment differences were observed for changes in quality of life or performance status,	patients started on strong opioids had significantly better pain relief than patients treated according to WHO guidelines (P=0.041).
__label__noRel	No between-treatment differences were observed for changes in quality of life or performance status,	Additionally, patients started on strong opioids required significantly fewer changes in therapy, had greater reduction in pain when a change was initiated, and reported greater satisfaction with treatment than the comparator group (P=0.041).
__label__noRel	No between-treatment differences were observed for changes in quality of life or performance status,	Strong opioids were safe and well-tolerated, with no development of tolerance or serious adverse events.
__label__Support	No between-treatment differences were observed for changes in quality of life or performance status,	These data suggest the utility of strong opioids for first-line treatment of pain in patients with terminal cancer.
__label__noRel	patients started on strong opioids had significantly better pain relief than patients treated according to WHO guidelines (P=0.041).	No between-treatment differences were observed for changes in quality of life or performance status,
__label__noRel	patients started on strong opioids had significantly better pain relief than patients treated according to WHO guidelines (P=0.041).	Additionally, patients started on strong opioids required significantly fewer changes in therapy, had greater reduction in pain when a change was initiated, and reported greater satisfaction with treatment than the comparator group (P=0.041).
__label__noRel	patients started on strong opioids had significantly better pain relief than patients treated according to WHO guidelines (P=0.041).	Strong opioids were safe and well-tolerated, with no development of tolerance or serious adverse events.
__label__Support	patients started on strong opioids had significantly better pain relief than patients treated according to WHO guidelines (P=0.041).	These data suggest the utility of strong opioids for first-line treatment of pain in patients with terminal cancer.
__label__noRel	Additionally, patients started on strong opioids required significantly fewer changes in therapy, had greater reduction in pain when a change was initiated, and reported greater satisfaction with treatment than the comparator group (P=0.041).	No between-treatment differences were observed for changes in quality of life or performance status,
__label__noRel	Additionally, patients started on strong opioids required significantly fewer changes in therapy, had greater reduction in pain when a change was initiated, and reported greater satisfaction with treatment than the comparator group (P=0.041).	patients started on strong opioids had significantly better pain relief than patients treated according to WHO guidelines (P=0.041).
__label__noRel	Additionally, patients started on strong opioids required significantly fewer changes in therapy, had greater reduction in pain when a change was initiated, and reported greater satisfaction with treatment than the comparator group (P=0.041).	Strong opioids were safe and well-tolerated, with no development of tolerance or serious adverse events.
__label__Support	Additionally, patients started on strong opioids required significantly fewer changes in therapy, had greater reduction in pain when a change was initiated, and reported greater satisfaction with treatment than the comparator group (P=0.041).	These data suggest the utility of strong opioids for first-line treatment of pain in patients with terminal cancer.
__label__noRel	Strong opioids were safe and well-tolerated, with no development of tolerance or serious adverse events.	No between-treatment differences were observed for changes in quality of life or performance status,
__label__noRel	Strong opioids were safe and well-tolerated, with no development of tolerance or serious adverse events.	patients started on strong opioids had significantly better pain relief than patients treated according to WHO guidelines (P=0.041).
__label__noRel	Strong opioids were safe and well-tolerated, with no development of tolerance or serious adverse events.	Additionally, patients started on strong opioids required significantly fewer changes in therapy, had greater reduction in pain when a change was initiated, and reported greater satisfaction with treatment than the comparator group (P=0.041).
__label__Support	Strong opioids were safe and well-tolerated, with no development of tolerance or serious adverse events.	These data suggest the utility of strong opioids for first-line treatment of pain in patients with terminal cancer.
__label__noRel	These data suggest the utility of strong opioids for first-line treatment of pain in patients with terminal cancer.	No between-treatment differences were observed for changes in quality of life or performance status,
__label__noRel	These data suggest the utility of strong opioids for first-line treatment of pain in patients with terminal cancer.	patients started on strong opioids had significantly better pain relief than patients treated according to WHO guidelines (P=0.041).
__label__noRel	These data suggest the utility of strong opioids for first-line treatment of pain in patients with terminal cancer.	Additionally, patients started on strong opioids required significantly fewer changes in therapy, had greater reduction in pain when a change was initiated, and reported greater satisfaction with treatment than the comparator group (P=0.041).
__label__noRel	These data suggest the utility of strong opioids for first-line treatment of pain in patients with terminal cancer.	Strong opioids were safe and well-tolerated, with no development of tolerance or serious adverse events.
__label__noRel	GEM-CAP significantly improved objective response rate (19.1% v 12.4%; P = .034) and progression-free survival (hazard ratio [HR], 0.78; 95% CI, 0.66 to 0.93; P = .004) and was associated with a trend toward improved OS (HR, 0.86; 95% CI, 0.72 to 1.02; P = .08) compared with GEM alone.	This trend for OS benefit for GEM-CAP was consistent across different prognostic subgroups according to baseline stratification factors (stage and performance status) and remained after adjusting for these stratification factors (P = .077).
__label__noRel	GEM-CAP significantly improved objective response rate (19.1% v 12.4%; P = .034) and progression-free survival (hazard ratio [HR], 0.78; 95% CI, 0.66 to 0.93; P = .004) and was associated with a trend toward improved OS (HR, 0.86; 95% CI, 0.72 to 1.02; P = .08) compared with GEM alone.	the meta-analysis of two additional studies involving 935 patients showed a significant survival benefit in favor of GEM-CAP (HR, 0.86; 95% CI, 0.75 to 0.98; P = .02) with no intertrial heterogeneity.
__label__Support	GEM-CAP significantly improved objective response rate (19.1% v 12.4%; P = .034) and progression-free survival (hazard ratio [HR], 0.78; 95% CI, 0.66 to 0.93; P = .004) and was associated with a trend toward improved OS (HR, 0.86; 95% CI, 0.72 to 1.02; P = .08) compared with GEM alone.	On the basis of our trial and the meta-analysis, GEM-CAP should be considered as one of the standard first-line options in locally advanced and metastatic pancreatic cancer.
__label__noRel	This trend for OS benefit for GEM-CAP was consistent across different prognostic subgroups according to baseline stratification factors (stage and performance status) and remained after adjusting for these stratification factors (P = .077).	GEM-CAP significantly improved objective response rate (19.1% v 12.4%; P = .034) and progression-free survival (hazard ratio [HR], 0.78; 95% CI, 0.66 to 0.93; P = .004) and was associated with a trend toward improved OS (HR, 0.86; 95% CI, 0.72 to 1.02; P = .08) compared with GEM alone.
__label__noRel	This trend for OS benefit for GEM-CAP was consistent across different prognostic subgroups according to baseline stratification factors (stage and performance status) and remained after adjusting for these stratification factors (P = .077).	the meta-analysis of two additional studies involving 935 patients showed a significant survival benefit in favor of GEM-CAP (HR, 0.86; 95% CI, 0.75 to 0.98; P = .02) with no intertrial heterogeneity.
__label__Support	This trend for OS benefit for GEM-CAP was consistent across different prognostic subgroups according to baseline stratification factors (stage and performance status) and remained after adjusting for these stratification factors (P = .077).	On the basis of our trial and the meta-analysis, GEM-CAP should be considered as one of the standard first-line options in locally advanced and metastatic pancreatic cancer.
__label__noRel	the meta-analysis of two additional studies involving 935 patients showed a significant survival benefit in favor of GEM-CAP (HR, 0.86; 95% CI, 0.75 to 0.98; P = .02) with no intertrial heterogeneity.	GEM-CAP significantly improved objective response rate (19.1% v 12.4%; P = .034) and progression-free survival (hazard ratio [HR], 0.78; 95% CI, 0.66 to 0.93; P = .004) and was associated with a trend toward improved OS (HR, 0.86; 95% CI, 0.72 to 1.02; P = .08) compared with GEM alone.
__label__noRel	the meta-analysis of two additional studies involving 935 patients showed a significant survival benefit in favor of GEM-CAP (HR, 0.86; 95% CI, 0.75 to 0.98; P = .02) with no intertrial heterogeneity.	This trend for OS benefit for GEM-CAP was consistent across different prognostic subgroups according to baseline stratification factors (stage and performance status) and remained after adjusting for these stratification factors (P = .077).
__label__Support	the meta-analysis of two additional studies involving 935 patients showed a significant survival benefit in favor of GEM-CAP (HR, 0.86; 95% CI, 0.75 to 0.98; P = .02) with no intertrial heterogeneity.	On the basis of our trial and the meta-analysis, GEM-CAP should be considered as one of the standard first-line options in locally advanced and metastatic pancreatic cancer.
__label__noRel	On the basis of our trial and the meta-analysis, GEM-CAP should be considered as one of the standard first-line options in locally advanced and metastatic pancreatic cancer.	GEM-CAP significantly improved objective response rate (19.1% v 12.4%; P = .034) and progression-free survival (hazard ratio [HR], 0.78; 95% CI, 0.66 to 0.93; P = .004) and was associated with a trend toward improved OS (HR, 0.86; 95% CI, 0.72 to 1.02; P = .08) compared with GEM alone.
__label__noRel	On the basis of our trial and the meta-analysis, GEM-CAP should be considered as one of the standard first-line options in locally advanced and metastatic pancreatic cancer.	This trend for OS benefit for GEM-CAP was consistent across different prognostic subgroups according to baseline stratification factors (stage and performance status) and remained after adjusting for these stratification factors (P = .077).
__label__noRel	On the basis of our trial and the meta-analysis, GEM-CAP should be considered as one of the standard first-line options in locally advanced and metastatic pancreatic cancer.	the meta-analysis of two additional studies involving 935 patients showed a significant survival benefit in favor of GEM-CAP (HR, 0.86; 95% CI, 0.75 to 0.98; P = .02) with no intertrial heterogeneity.
__label__noRel	This study demonstrates that a brief, predominantly group-based resilience training intervention is feasible in patients with previous breast cancer; also, it may be efficacious.	A statistically significant improvement in resilience, perceived stress, anxiety, and overall quality of life at 12 weeks, compared with baseline was observed in the study arm.
__label__noRel	This study demonstrates that a brief, predominantly group-based resilience training intervention is feasible in patients with previous breast cancer; also, it may be efficacious.	No significant difference in any of these measures was noted in the control group.
__label__Support	A statistically significant improvement in resilience, perceived stress, anxiety, and overall quality of life at 12 weeks, compared with baseline was observed in the study arm.	This study demonstrates that a brief, predominantly group-based resilience training intervention is feasible in patients with previous breast cancer; also, it may be efficacious.
__label__noRel	A statistically significant improvement in resilience, perceived stress, anxiety, and overall quality of life at 12 weeks, compared with baseline was observed in the study arm.	No significant difference in any of these measures was noted in the control group.
__label__Support	No significant difference in any of these measures was noted in the control group.	This study demonstrates that a brief, predominantly group-based resilience training intervention is feasible in patients with previous breast cancer; also, it may be efficacious.
__label__noRel	No significant difference in any of these measures was noted in the control group.	A statistically significant improvement in resilience, perceived stress, anxiety, and overall quality of life at 12 weeks, compared with baseline was observed in the study arm.
__label__noRel	There were no unexpected serious adverse events.	In the 684 patients with data that could be evaluated, ultrasonography of the neck was normal in 652 (95%), and the stimulated thyroglobulin level was 1.0 ng per milliliter or less in 621 of the 652 patients (95%) without detectable thyroglobulin antibodies.
__label__noRel	There were no unexpected serious adverse events.	Thyroid ablation was complete in 631 of the 684 patients (92%).
__label__noRel	There were no unexpected serious adverse events.	The ablation rate was equivalent between the (131)I doses and between the thyrotropin-stimulation methods.
__label__Support	There were no unexpected serious adverse events.	The use of recombinant human thyrotropin and low-dose (1.1 GBq) postoperative radioiodine ablation may be sufficient for the management of low-risk thyroid cancer.
__label__noRel	In the 684 patients with data that could be evaluated, ultrasonography of the neck was normal in 652 (95%), and the stimulated thyroglobulin level was 1.0 ng per milliliter or less in 621 of the 652 patients (95%) without detectable thyroglobulin antibodies.	There were no unexpected serious adverse events.
__label__noRel	In the 684 patients with data that could be evaluated, ultrasonography of the neck was normal in 652 (95%), and the stimulated thyroglobulin level was 1.0 ng per milliliter or less in 621 of the 652 patients (95%) without detectable thyroglobulin antibodies.	Thyroid ablation was complete in 631 of the 684 patients (92%).
__label__noRel	In the 684 patients with data that could be evaluated, ultrasonography of the neck was normal in 652 (95%), and the stimulated thyroglobulin level was 1.0 ng per milliliter or less in 621 of the 652 patients (95%) without detectable thyroglobulin antibodies.	The ablation rate was equivalent between the (131)I doses and between the thyrotropin-stimulation methods.
__label__Support	In the 684 patients with data that could be evaluated, ultrasonography of the neck was normal in 652 (95%), and the stimulated thyroglobulin level was 1.0 ng per milliliter or less in 621 of the 652 patients (95%) without detectable thyroglobulin antibodies.	The use of recombinant human thyrotropin and low-dose (1.1 GBq) postoperative radioiodine ablation may be sufficient for the management of low-risk thyroid cancer.
__label__noRel	Thyroid ablation was complete in 631 of the 684 patients (92%).	There were no unexpected serious adverse events.
__label__noRel	Thyroid ablation was complete in 631 of the 684 patients (92%).	In the 684 patients with data that could be evaluated, ultrasonography of the neck was normal in 652 (95%), and the stimulated thyroglobulin level was 1.0 ng per milliliter or less in 621 of the 652 patients (95%) without detectable thyroglobulin antibodies.
__label__noRel	Thyroid ablation was complete in 631 of the 684 patients (92%).	The ablation rate was equivalent between the (131)I doses and between the thyrotropin-stimulation methods.
__label__Support	Thyroid ablation was complete in 631 of the 684 patients (92%).	The use of recombinant human thyrotropin and low-dose (1.1 GBq) postoperative radioiodine ablation may be sufficient for the management of low-risk thyroid cancer.
__label__noRel	The ablation rate was equivalent between the (131)I doses and between the thyrotropin-stimulation methods.	There were no unexpected serious adverse events.
__label__noRel	The ablation rate was equivalent between the (131)I doses and between the thyrotropin-stimulation methods.	In the 684 patients with data that could be evaluated, ultrasonography of the neck was normal in 652 (95%), and the stimulated thyroglobulin level was 1.0 ng per milliliter or less in 621 of the 652 patients (95%) without detectable thyroglobulin antibodies.
__label__noRel	The ablation rate was equivalent between the (131)I doses and between the thyrotropin-stimulation methods.	Thyroid ablation was complete in 631 of the 684 patients (92%).
__label__Support	The ablation rate was equivalent between the (131)I doses and between the thyrotropin-stimulation methods.	The use of recombinant human thyrotropin and low-dose (1.1 GBq) postoperative radioiodine ablation may be sufficient for the management of low-risk thyroid cancer.
__label__noRel	The use of recombinant human thyrotropin and low-dose (1.1 GBq) postoperative radioiodine ablation may be sufficient for the management of low-risk thyroid cancer.	There were no unexpected serious adverse events.
__label__noRel	The use of recombinant human thyrotropin and low-dose (1.1 GBq) postoperative radioiodine ablation may be sufficient for the management of low-risk thyroid cancer.	In the 684 patients with data that could be evaluated, ultrasonography of the neck was normal in 652 (95%), and the stimulated thyroglobulin level was 1.0 ng per milliliter or less in 621 of the 652 patients (95%) without detectable thyroglobulin antibodies.
__label__noRel	The use of recombinant human thyrotropin and low-dose (1.1 GBq) postoperative radioiodine ablation may be sufficient for the management of low-risk thyroid cancer.	Thyroid ablation was complete in 631 of the 684 patients (92%).
__label__noRel	The use of recombinant human thyrotropin and low-dose (1.1 GBq) postoperative radioiodine ablation may be sufficient for the management of low-risk thyroid cancer.	The ablation rate was equivalent between the (131)I doses and between the thyrotropin-stimulation methods.
__label__noRel	There was no significant difference found in the primary outcome measure, the hot flash severity score,	although there was a positive trend in the single remedy group during the first 3 months of the study (p = 0.1).
__label__noRel	There was no significant difference found in the primary outcome measure, the hot flash severity score,	A statistically significant improvement in general health score in both homeopathy groups (p < 0.05) on the SF-36 after 1 year was found.
__label__noRel	There was no significant difference found in the primary outcome measure, the hot flash severity score,	Evidence of a homeopathic "drug proving" in the subjects receiving the homeopathic combination medicine who were not taking tamoxifen also was found.
__label__noRel	There was no significant difference found in the primary outcome measure, the hot flash severity score,	Small sample size precludes definitive answers,
__label__noRel	There was no significant difference found in the primary outcome measure, the hot flash severity score,	but results from this preliminary trial suggest that homeopathy may be of value in the treatment of menopausal symptoms and improving quality of life, especially in those women not on tamoxifen.
__label__noRel	There was no significant difference found in the primary outcome measure, the hot flash severity score,	Larger studies should be carried out that also include healthy women who want to avoid hormone replacement therapy.
__label__Attack	although there was a positive trend in the single remedy group during the first 3 months of the study (p = 0.1).	There was no significant difference found in the primary outcome measure, the hot flash severity score,
__label__noRel	although there was a positive trend in the single remedy group during the first 3 months of the study (p = 0.1).	A statistically significant improvement in general health score in both homeopathy groups (p < 0.05) on the SF-36 after 1 year was found.
__label__noRel	although there was a positive trend in the single remedy group during the first 3 months of the study (p = 0.1).	Evidence of a homeopathic "drug proving" in the subjects receiving the homeopathic combination medicine who were not taking tamoxifen also was found.
__label__noRel	although there was a positive trend in the single remedy group during the first 3 months of the study (p = 0.1).	Small sample size precludes definitive answers,
__label__noRel	although there was a positive trend in the single remedy group during the first 3 months of the study (p = 0.1).	but results from this preliminary trial suggest that homeopathy may be of value in the treatment of menopausal symptoms and improving quality of life, especially in those women not on tamoxifen.
__label__noRel	although there was a positive trend in the single remedy group during the first 3 months of the study (p = 0.1).	Larger studies should be carried out that also include healthy women who want to avoid hormone replacement therapy.
__label__noRel	A statistically significant improvement in general health score in both homeopathy groups (p < 0.05) on the SF-36 after 1 year was found.	There was no significant difference found in the primary outcome measure, the hot flash severity score,
__label__noRel	A statistically significant improvement in general health score in both homeopathy groups (p < 0.05) on the SF-36 after 1 year was found.	although there was a positive trend in the single remedy group during the first 3 months of the study (p = 0.1).
__label__noRel	A statistically significant improvement in general health score in both homeopathy groups (p < 0.05) on the SF-36 after 1 year was found.	Evidence of a homeopathic "drug proving" in the subjects receiving the homeopathic combination medicine who were not taking tamoxifen also was found.
__label__noRel	A statistically significant improvement in general health score in both homeopathy groups (p < 0.05) on the SF-36 after 1 year was found.	Small sample size precludes definitive answers,
__label__Support	A statistically significant improvement in general health score in both homeopathy groups (p < 0.05) on the SF-36 after 1 year was found.	but results from this preliminary trial suggest that homeopathy may be of value in the treatment of menopausal symptoms and improving quality of life, especially in those women not on tamoxifen.
__label__noRel	A statistically significant improvement in general health score in both homeopathy groups (p < 0.05) on the SF-36 after 1 year was found.	Larger studies should be carried out that also include healthy women who want to avoid hormone replacement therapy.
__label__noRel	Evidence of a homeopathic "drug proving" in the subjects receiving the homeopathic combination medicine who were not taking tamoxifen also was found.	There was no significant difference found in the primary outcome measure, the hot flash severity score,
__label__noRel	Evidence of a homeopathic "drug proving" in the subjects receiving the homeopathic combination medicine who were not taking tamoxifen also was found.	although there was a positive trend in the single remedy group during the first 3 months of the study (p = 0.1).
__label__noRel	Evidence of a homeopathic "drug proving" in the subjects receiving the homeopathic combination medicine who were not taking tamoxifen also was found.	A statistically significant improvement in general health score in both homeopathy groups (p < 0.05) on the SF-36 after 1 year was found.
__label__noRel	Evidence of a homeopathic "drug proving" in the subjects receiving the homeopathic combination medicine who were not taking tamoxifen also was found.	Small sample size precludes definitive answers,
__label__noRel	Evidence of a homeopathic "drug proving" in the subjects receiving the homeopathic combination medicine who were not taking tamoxifen also was found.	but results from this preliminary trial suggest that homeopathy may be of value in the treatment of menopausal symptoms and improving quality of life, especially in those women not on tamoxifen.
__label__noRel	Evidence of a homeopathic "drug proving" in the subjects receiving the homeopathic combination medicine who were not taking tamoxifen also was found.	Larger studies should be carried out that also include healthy women who want to avoid hormone replacement therapy.
__label__noRel	Small sample size precludes definitive answers,	There was no significant difference found in the primary outcome measure, the hot flash severity score,
__label__noRel	Small sample size precludes definitive answers,	although there was a positive trend in the single remedy group during the first 3 months of the study (p = 0.1).
__label__noRel	Small sample size precludes definitive answers,	A statistically significant improvement in general health score in both homeopathy groups (p < 0.05) on the SF-36 after 1 year was found.
__label__noRel	Small sample size precludes definitive answers,	Evidence of a homeopathic "drug proving" in the subjects receiving the homeopathic combination medicine who were not taking tamoxifen also was found.
__label__Attack	Small sample size precludes definitive answers,	but results from this preliminary trial suggest that homeopathy may be of value in the treatment of menopausal symptoms and improving quality of life, especially in those women not on tamoxifen.
__label__noRel	Small sample size precludes definitive answers,	Larger studies should be carried out that also include healthy women who want to avoid hormone replacement therapy.
__label__noRel	but results from this preliminary trial suggest that homeopathy may be of value in the treatment of menopausal symptoms and improving quality of life, especially in those women not on tamoxifen.	There was no significant difference found in the primary outcome measure, the hot flash severity score,
__label__noRel	but results from this preliminary trial suggest that homeopathy may be of value in the treatment of menopausal symptoms and improving quality of life, especially in those women not on tamoxifen.	although there was a positive trend in the single remedy group during the first 3 months of the study (p = 0.1).
__label__noRel	but results from this preliminary trial suggest that homeopathy may be of value in the treatment of menopausal symptoms and improving quality of life, especially in those women not on tamoxifen.	A statistically significant improvement in general health score in both homeopathy groups (p < 0.05) on the SF-36 after 1 year was found.
__label__noRel	but results from this preliminary trial suggest that homeopathy may be of value in the treatment of menopausal symptoms and improving quality of life, especially in those women not on tamoxifen.	Evidence of a homeopathic "drug proving" in the subjects receiving the homeopathic combination medicine who were not taking tamoxifen also was found.
__label__noRel	but results from this preliminary trial suggest that homeopathy may be of value in the treatment of menopausal symptoms and improving quality of life, especially in those women not on tamoxifen.	Small sample size precludes definitive answers,
__label__noRel	but results from this preliminary trial suggest that homeopathy may be of value in the treatment of menopausal symptoms and improving quality of life, especially in those women not on tamoxifen.	Larger studies should be carried out that also include healthy women who want to avoid hormone replacement therapy.
__label__noRel	Larger studies should be carried out that also include healthy women who want to avoid hormone replacement therapy.	There was no significant difference found in the primary outcome measure, the hot flash severity score,
__label__noRel	Larger studies should be carried out that also include healthy women who want to avoid hormone replacement therapy.	although there was a positive trend in the single remedy group during the first 3 months of the study (p = 0.1).
__label__noRel	Larger studies should be carried out that also include healthy women who want to avoid hormone replacement therapy.	A statistically significant improvement in general health score in both homeopathy groups (p < 0.05) on the SF-36 after 1 year was found.
__label__noRel	Larger studies should be carried out that also include healthy women who want to avoid hormone replacement therapy.	Evidence of a homeopathic "drug proving" in the subjects receiving the homeopathic combination medicine who were not taking tamoxifen also was found.
__label__noRel	Larger studies should be carried out that also include healthy women who want to avoid hormone replacement therapy.	Small sample size precludes definitive answers,
__label__Attack	Larger studies should be carried out that also include healthy women who want to avoid hormone replacement therapy.	but results from this preliminary trial suggest that homeopathy may be of value in the treatment of menopausal symptoms and improving quality of life, especially in those women not on tamoxifen.
__label__noRel	There were no significant differences between the narrow gastric tube group (NGT group, n=52) and the whole-stomach group (WS group, n=52) with regard to patient and cancer characteristics, operative procedure, postoperative intensive care unit (ICU) hospitalisation, and overall survival at 1 year.	Regarding the postoperative complication, there were more cases of postoperative reflux oesophagitis and impairment of pulmonary function in the WS group (P<0.05).
__label__noRel	There were no significant differences between the narrow gastric tube group (NGT group, n=52) and the whole-stomach group (WS group, n=52) with regard to patient and cancer characteristics, operative procedure, postoperative intensive care unit (ICU) hospitalisation, and overall survival at 1 year.	Regarding the QoL investigation, the scores of QoL dropped for all patients at 3 weeks after surgery.
__label__noRel	There were no significant differences between the narrow gastric tube group (NGT group, n=52) and the whole-stomach group (WS group, n=52) with regard to patient and cancer characteristics, operative procedure, postoperative intensive care unit (ICU) hospitalisation, and overall survival at 1 year.	recovery was found at both 6 months and 1 year in both groups.
__label__noRel	There were no significant differences between the narrow gastric tube group (NGT group, n=52) and the whole-stomach group (WS group, n=52) with regard to patient and cancer characteristics, operative procedure, postoperative intensive care unit (ICU) hospitalisation, and overall survival at 1 year.	Patients in the NGT group reported significantly (P<0.05) better scores of QoL at both 6 months and 1 year.
__label__Support	There were no significant differences between the narrow gastric tube group (NGT group, n=52) and the whole-stomach group (WS group, n=52) with regard to patient and cancer characteristics, operative procedure, postoperative intensive care unit (ICU) hospitalisation, and overall survival at 1 year.	Patients who underwent gastric tube reconstruction develop less postoperative digestive tract complications, and have a quicker recovery and a better QoL during the follow-up period.
__label__noRel	Regarding the postoperative complication, there were more cases of postoperative reflux oesophagitis and impairment of pulmonary function in the WS group (P<0.05).	There were no significant differences between the narrow gastric tube group (NGT group, n=52) and the whole-stomach group (WS group, n=52) with regard to patient and cancer characteristics, operative procedure, postoperative intensive care unit (ICU) hospitalisation, and overall survival at 1 year.
__label__noRel	Regarding the postoperative complication, there were more cases of postoperative reflux oesophagitis and impairment of pulmonary function in the WS group (P<0.05).	Regarding the QoL investigation, the scores of QoL dropped for all patients at 3 weeks after surgery.
__label__noRel	Regarding the postoperative complication, there were more cases of postoperative reflux oesophagitis and impairment of pulmonary function in the WS group (P<0.05).	recovery was found at both 6 months and 1 year in both groups.
__label__noRel	Regarding the postoperative complication, there were more cases of postoperative reflux oesophagitis and impairment of pulmonary function in the WS group (P<0.05).	Patients in the NGT group reported significantly (P<0.05) better scores of QoL at both 6 months and 1 year.
__label__Support	Regarding the postoperative complication, there were more cases of postoperative reflux oesophagitis and impairment of pulmonary function in the WS group (P<0.05).	Patients who underwent gastric tube reconstruction develop less postoperative digestive tract complications, and have a quicker recovery and a better QoL during the follow-up period.
__label__noRel	Regarding the QoL investigation, the scores of QoL dropped for all patients at 3 weeks after surgery.	There were no significant differences between the narrow gastric tube group (NGT group, n=52) and the whole-stomach group (WS group, n=52) with regard to patient and cancer characteristics, operative procedure, postoperative intensive care unit (ICU) hospitalisation, and overall survival at 1 year.
__label__noRel	Regarding the QoL investigation, the scores of QoL dropped for all patients at 3 weeks after surgery.	Regarding the postoperative complication, there were more cases of postoperative reflux oesophagitis and impairment of pulmonary function in the WS group (P<0.05).
__label__noRel	Regarding the QoL investigation, the scores of QoL dropped for all patients at 3 weeks after surgery.	recovery was found at both 6 months and 1 year in both groups.
__label__noRel	Regarding the QoL investigation, the scores of QoL dropped for all patients at 3 weeks after surgery.	Patients in the NGT group reported significantly (P<0.05) better scores of QoL at both 6 months and 1 year.
__label__Support	Regarding the QoL investigation, the scores of QoL dropped for all patients at 3 weeks after surgery.	Patients who underwent gastric tube reconstruction develop less postoperative digestive tract complications, and have a quicker recovery and a better QoL during the follow-up period.
__label__noRel	recovery was found at both 6 months and 1 year in both groups.	There were no significant differences between the narrow gastric tube group (NGT group, n=52) and the whole-stomach group (WS group, n=52) with regard to patient and cancer characteristics, operative procedure, postoperative intensive care unit (ICU) hospitalisation, and overall survival at 1 year.
__label__noRel	recovery was found at both 6 months and 1 year in both groups.	Regarding the postoperative complication, there were more cases of postoperative reflux oesophagitis and impairment of pulmonary function in the WS group (P<0.05).
__label__noRel	recovery was found at both 6 months and 1 year in both groups.	Regarding the QoL investigation, the scores of QoL dropped for all patients at 3 weeks after surgery.
__label__noRel	recovery was found at both 6 months and 1 year in both groups.	Patients in the NGT group reported significantly (P<0.05) better scores of QoL at both 6 months and 1 year.
__label__Support	recovery was found at both 6 months and 1 year in both groups.	Patients who underwent gastric tube reconstruction develop less postoperative digestive tract complications, and have a quicker recovery and a better QoL during the follow-up period.
__label__noRel	Patients in the NGT group reported significantly (P<0.05) better scores of QoL at both 6 months and 1 year.	There were no significant differences between the narrow gastric tube group (NGT group, n=52) and the whole-stomach group (WS group, n=52) with regard to patient and cancer characteristics, operative procedure, postoperative intensive care unit (ICU) hospitalisation, and overall survival at 1 year.
__label__noRel	Patients in the NGT group reported significantly (P<0.05) better scores of QoL at both 6 months and 1 year.	Regarding the postoperative complication, there were more cases of postoperative reflux oesophagitis and impairment of pulmonary function in the WS group (P<0.05).
__label__noRel	Patients in the NGT group reported significantly (P<0.05) better scores of QoL at both 6 months and 1 year.	Regarding the QoL investigation, the scores of QoL dropped for all patients at 3 weeks after surgery.
__label__noRel	Patients in the NGT group reported significantly (P<0.05) better scores of QoL at both 6 months and 1 year.	recovery was found at both 6 months and 1 year in both groups.
__label__Support	Patients in the NGT group reported significantly (P<0.05) better scores of QoL at both 6 months and 1 year.	Patients who underwent gastric tube reconstruction develop less postoperative digestive tract complications, and have a quicker recovery and a better QoL during the follow-up period.
__label__noRel	Patients who underwent gastric tube reconstruction develop less postoperative digestive tract complications, and have a quicker recovery and a better QoL during the follow-up period.	There were no significant differences between the narrow gastric tube group (NGT group, n=52) and the whole-stomach group (WS group, n=52) with regard to patient and cancer characteristics, operative procedure, postoperative intensive care unit (ICU) hospitalisation, and overall survival at 1 year.
__label__noRel	Patients who underwent gastric tube reconstruction develop less postoperative digestive tract complications, and have a quicker recovery and a better QoL during the follow-up period.	Regarding the postoperative complication, there were more cases of postoperative reflux oesophagitis and impairment of pulmonary function in the WS group (P<0.05).
__label__noRel	Patients who underwent gastric tube reconstruction develop less postoperative digestive tract complications, and have a quicker recovery and a better QoL during the follow-up period.	Regarding the QoL investigation, the scores of QoL dropped for all patients at 3 weeks after surgery.
__label__noRel	Patients who underwent gastric tube reconstruction develop less postoperative digestive tract complications, and have a quicker recovery and a better QoL during the follow-up period.	recovery was found at both 6 months and 1 year in both groups.
__label__noRel	Patients who underwent gastric tube reconstruction develop less postoperative digestive tract complications, and have a quicker recovery and a better QoL during the follow-up period.	Patients in the NGT group reported significantly (P<0.05) better scores of QoL at both 6 months and 1 year.
__label__noRel	Morbidity associated with wound complications may translate into disability and quality-of-life disadvantages for patients treated with radiotherapy (RT) for soft tissue sarcoma (STS) of the extremities.	Patients treated with postoperative RT had better function with higher MSTS (25.8 v 21.3, P <.01), TESS (69.8 v 60.6, P =.01), and SF-36 bodily pain (67.7 v 58.5, P =.03) scores at 6 weeks after surgery.
__label__noRel	Morbidity associated with wound complications may translate into disability and quality-of-life disadvantages for patients treated with radiotherapy (RT) for soft tissue sarcoma (STS) of the extremities.	Scores on the physical function, role-physical, and general health subscales of the SF-36 were significantly lower than Canadian normative data at all time points.
__label__noRel	Morbidity associated with wound complications may translate into disability and quality-of-life disadvantages for patients treated with radiotherapy (RT) for soft tissue sarcoma (STS) of the extremities.	When wound complication was included in the model, patients with complications had lower MSTS and TESS scores in the first 2 years after treatment.
__label__noRel	Morbidity associated with wound complications may translate into disability and quality-of-life disadvantages for patients treated with radiotherapy (RT) for soft tissue sarcoma (STS) of the extremities.	The timing of RT has minimal impact on the function of STS patients in the first year after surgery
__label__noRel	Morbidity associated with wound complications may translate into disability and quality-of-life disadvantages for patients treated with radiotherapy (RT) for soft tissue sarcoma (STS) of the extremities.	Tumor characteristics and wound complications have a detrimental effect on patient function.
__label__noRel	Patients treated with postoperative RT had better function with higher MSTS (25.8 v 21.3, P <.01), TESS (69.8 v 60.6, P =.01), and SF-36 bodily pain (67.7 v 58.5, P =.03) scores at 6 weeks after surgery.	Morbidity associated with wound complications may translate into disability and quality-of-life disadvantages for patients treated with radiotherapy (RT) for soft tissue sarcoma (STS) of the extremities.
__label__noRel	Patients treated with postoperative RT had better function with higher MSTS (25.8 v 21.3, P <.01), TESS (69.8 v 60.6, P =.01), and SF-36 bodily pain (67.7 v 58.5, P =.03) scores at 6 weeks after surgery.	Scores on the physical function, role-physical, and general health subscales of the SF-36 were significantly lower than Canadian normative data at all time points.
__label__noRel	Patients treated with postoperative RT had better function with higher MSTS (25.8 v 21.3, P <.01), TESS (69.8 v 60.6, P =.01), and SF-36 bodily pain (67.7 v 58.5, P =.03) scores at 6 weeks after surgery.	When wound complication was included in the model, patients with complications had lower MSTS and TESS scores in the first 2 years after treatment.
__label__noRel	Patients treated with postoperative RT had better function with higher MSTS (25.8 v 21.3, P <.01), TESS (69.8 v 60.6, P =.01), and SF-36 bodily pain (67.7 v 58.5, P =.03) scores at 6 weeks after surgery.	The timing of RT has minimal impact on the function of STS patients in the first year after surgery
__label__noRel	Patients treated with postoperative RT had better function with higher MSTS (25.8 v 21.3, P <.01), TESS (69.8 v 60.6, P =.01), and SF-36 bodily pain (67.7 v 58.5, P =.03) scores at 6 weeks after surgery.	Tumor characteristics and wound complications have a detrimental effect on patient function.
__label__noRel	Scores on the physical function, role-physical, and general health subscales of the SF-36 were significantly lower than Canadian normative data at all time points.	Morbidity associated with wound complications may translate into disability and quality-of-life disadvantages for patients treated with radiotherapy (RT) for soft tissue sarcoma (STS) of the extremities.
__label__noRel	Scores on the physical function, role-physical, and general health subscales of the SF-36 were significantly lower than Canadian normative data at all time points.	Patients treated with postoperative RT had better function with higher MSTS (25.8 v 21.3, P <.01), TESS (69.8 v 60.6, P =.01), and SF-36 bodily pain (67.7 v 58.5, P =.03) scores at 6 weeks after surgery.
__label__noRel	Scores on the physical function, role-physical, and general health subscales of the SF-36 were significantly lower than Canadian normative data at all time points.	When wound complication was included in the model, patients with complications had lower MSTS and TESS scores in the first 2 years after treatment.
__label__noRel	Scores on the physical function, role-physical, and general health subscales of the SF-36 were significantly lower than Canadian normative data at all time points.	The timing of RT has minimal impact on the function of STS patients in the first year after surgery
__label__noRel	Scores on the physical function, role-physical, and general health subscales of the SF-36 were significantly lower than Canadian normative data at all time points.	Tumor characteristics and wound complications have a detrimental effect on patient function.
__label__noRel	When wound complication was included in the model, patients with complications had lower MSTS and TESS scores in the first 2 years after treatment.	Morbidity associated with wound complications may translate into disability and quality-of-life disadvantages for patients treated with radiotherapy (RT) for soft tissue sarcoma (STS) of the extremities.
__label__noRel	When wound complication was included in the model, patients with complications had lower MSTS and TESS scores in the first 2 years after treatment.	Patients treated with postoperative RT had better function with higher MSTS (25.8 v 21.3, P <.01), TESS (69.8 v 60.6, P =.01), and SF-36 bodily pain (67.7 v 58.5, P =.03) scores at 6 weeks after surgery.
__label__noRel	When wound complication was included in the model, patients with complications had lower MSTS and TESS scores in the first 2 years after treatment.	Scores on the physical function, role-physical, and general health subscales of the SF-36 were significantly lower than Canadian normative data at all time points.
__label__noRel	When wound complication was included in the model, patients with complications had lower MSTS and TESS scores in the first 2 years after treatment.	The timing of RT has minimal impact on the function of STS patients in the first year after surgery
__label__Support	When wound complication was included in the model, patients with complications had lower MSTS and TESS scores in the first 2 years after treatment.	Tumor characteristics and wound complications have a detrimental effect on patient function.
__label__noRel	The timing of RT has minimal impact on the function of STS patients in the first year after surgery	Morbidity associated with wound complications may translate into disability and quality-of-life disadvantages for patients treated with radiotherapy (RT) for soft tissue sarcoma (STS) of the extremities.
__label__noRel	The timing of RT has minimal impact on the function of STS patients in the first year after surgery	Patients treated with postoperative RT had better function with higher MSTS (25.8 v 21.3, P <.01), TESS (69.8 v 60.6, P =.01), and SF-36 bodily pain (67.7 v 58.5, P =.03) scores at 6 weeks after surgery.
__label__noRel	The timing of RT has minimal impact on the function of STS patients in the first year after surgery	Scores on the physical function, role-physical, and general health subscales of the SF-36 were significantly lower than Canadian normative data at all time points.
__label__noRel	The timing of RT has minimal impact on the function of STS patients in the first year after surgery	When wound complication was included in the model, patients with complications had lower MSTS and TESS scores in the first 2 years after treatment.
__label__noRel	The timing of RT has minimal impact on the function of STS patients in the first year after surgery	Tumor characteristics and wound complications have a detrimental effect on patient function.
__label__noRel	Tumor characteristics and wound complications have a detrimental effect on patient function.	Morbidity associated with wound complications may translate into disability and quality-of-life disadvantages for patients treated with radiotherapy (RT) for soft tissue sarcoma (STS) of the extremities.
__label__noRel	Tumor characteristics and wound complications have a detrimental effect on patient function.	Patients treated with postoperative RT had better function with higher MSTS (25.8 v 21.3, P <.01), TESS (69.8 v 60.6, P =.01), and SF-36 bodily pain (67.7 v 58.5, P =.03) scores at 6 weeks after surgery.
__label__noRel	Tumor characteristics and wound complications have a detrimental effect on patient function.	Scores on the physical function, role-physical, and general health subscales of the SF-36 were significantly lower than Canadian normative data at all time points.
__label__noRel	Tumor characteristics and wound complications have a detrimental effect on patient function.	When wound complication was included in the model, patients with complications had lower MSTS and TESS scores in the first 2 years after treatment.
__label__noRel	Tumor characteristics and wound complications have a detrimental effect on patient function.	The timing of RT has minimal impact on the function of STS patients in the first year after surgery
__label__noRel	Increased expression of metalloproteinases is associated with poor prognosis in small-cell lung cancer (SCLC).	Best response to induction therapy was complete remission for 176 patients (33%), partial remission for 341 (64%), and 15 patients (3%) had undergone surgical resection.
__label__noRel	Increased expression of metalloproteinases is associated with poor prognosis in small-cell lung cancer (SCLC).	Median survivals for marimastat and placebo patients were 9.3 months and 9.7 months, respectively (P =.90).
__label__noRel	Increased expression of metalloproteinases is associated with poor prognosis in small-cell lung cancer (SCLC).	The median time to progression for marimastat patients was 4.3 months compared with 4.4 months for placebo patients (P =.81).
__label__noRel	Increased expression of metalloproteinases is associated with poor prognosis in small-cell lung cancer (SCLC).	Toxicity was generally limited to musculoskeletal symptoms (18% grade 3/4 for marimastat).
__label__noRel	Increased expression of metalloproteinases is associated with poor prognosis in small-cell lung cancer (SCLC).	Dose modifications for musculoskeletal toxicity were required in 90 patients (33%) on the marimastat arm, and 87 (32%) permanently stopped marimastat because of toxicity.
__label__noRel	Increased expression of metalloproteinases is associated with poor prognosis in small-cell lung cancer (SCLC).	Patients on marimastat had significantly poorer quality of life at 3 and 6 months.
__label__noRel	Increased expression of metalloproteinases is associated with poor prognosis in small-cell lung cancer (SCLC).	Treatment with marimastat after induction therapy for SCLC did not result in improved survival and had a negative impact on quality of life.
__label__noRel	Best response to induction therapy was complete remission for 176 patients (33%), partial remission for 341 (64%), and 15 patients (3%) had undergone surgical resection.	Increased expression of metalloproteinases is associated with poor prognosis in small-cell lung cancer (SCLC).
__label__noRel	Best response to induction therapy was complete remission for 176 patients (33%), partial remission for 341 (64%), and 15 patients (3%) had undergone surgical resection.	Median survivals for marimastat and placebo patients were 9.3 months and 9.7 months, respectively (P =.90).
__label__noRel	Best response to induction therapy was complete remission for 176 patients (33%), partial remission for 341 (64%), and 15 patients (3%) had undergone surgical resection.	The median time to progression for marimastat patients was 4.3 months compared with 4.4 months for placebo patients (P =.81).
__label__noRel	Best response to induction therapy was complete remission for 176 patients (33%), partial remission for 341 (64%), and 15 patients (3%) had undergone surgical resection.	Toxicity was generally limited to musculoskeletal symptoms (18% grade 3/4 for marimastat).
__label__noRel	Best response to induction therapy was complete remission for 176 patients (33%), partial remission for 341 (64%), and 15 patients (3%) had undergone surgical resection.	Dose modifications for musculoskeletal toxicity were required in 90 patients (33%) on the marimastat arm, and 87 (32%) permanently stopped marimastat because of toxicity.
__label__noRel	Best response to induction therapy was complete remission for 176 patients (33%), partial remission for 341 (64%), and 15 patients (3%) had undergone surgical resection.	Patients on marimastat had significantly poorer quality of life at 3 and 6 months.
__label__noRel	Best response to induction therapy was complete remission for 176 patients (33%), partial remission for 341 (64%), and 15 patients (3%) had undergone surgical resection.	Treatment with marimastat after induction therapy for SCLC did not result in improved survival and had a negative impact on quality of life.
__label__noRel	Median survivals for marimastat and placebo patients were 9.3 months and 9.7 months, respectively (P =.90).	Increased expression of metalloproteinases is associated with poor prognosis in small-cell lung cancer (SCLC).
__label__noRel	Median survivals for marimastat and placebo patients were 9.3 months and 9.7 months, respectively (P =.90).	Best response to induction therapy was complete remission for 176 patients (33%), partial remission for 341 (64%), and 15 patients (3%) had undergone surgical resection.
__label__noRel	Median survivals for marimastat and placebo patients were 9.3 months and 9.7 months, respectively (P =.90).	The median time to progression for marimastat patients was 4.3 months compared with 4.4 months for placebo patients (P =.81).
__label__noRel	Median survivals for marimastat and placebo patients were 9.3 months and 9.7 months, respectively (P =.90).	Toxicity was generally limited to musculoskeletal symptoms (18% grade 3/4 for marimastat).
__label__noRel	Median survivals for marimastat and placebo patients were 9.3 months and 9.7 months, respectively (P =.90).	Dose modifications for musculoskeletal toxicity were required in 90 patients (33%) on the marimastat arm, and 87 (32%) permanently stopped marimastat because of toxicity.
__label__noRel	Median survivals for marimastat and placebo patients were 9.3 months and 9.7 months, respectively (P =.90).	Patients on marimastat had significantly poorer quality of life at 3 and 6 months.
__label__Support	Median survivals for marimastat and placebo patients were 9.3 months and 9.7 months, respectively (P =.90).	Treatment with marimastat after induction therapy for SCLC did not result in improved survival and had a negative impact on quality of life.
__label__noRel	The median time to progression for marimastat patients was 4.3 months compared with 4.4 months for placebo patients (P =.81).	Increased expression of metalloproteinases is associated with poor prognosis in small-cell lung cancer (SCLC).
__label__noRel	The median time to progression for marimastat patients was 4.3 months compared with 4.4 months for placebo patients (P =.81).	Best response to induction therapy was complete remission for 176 patients (33%), partial remission for 341 (64%), and 15 patients (3%) had undergone surgical resection.
__label__noRel	The median time to progression for marimastat patients was 4.3 months compared with 4.4 months for placebo patients (P =.81).	Median survivals for marimastat and placebo patients were 9.3 months and 9.7 months, respectively (P =.90).
__label__noRel	The median time to progression for marimastat patients was 4.3 months compared with 4.4 months for placebo patients (P =.81).	Toxicity was generally limited to musculoskeletal symptoms (18% grade 3/4 for marimastat).
__label__noRel	The median time to progression for marimastat patients was 4.3 months compared with 4.4 months for placebo patients (P =.81).	Dose modifications for musculoskeletal toxicity were required in 90 patients (33%) on the marimastat arm, and 87 (32%) permanently stopped marimastat because of toxicity.
__label__noRel	The median time to progression for marimastat patients was 4.3 months compared with 4.4 months for placebo patients (P =.81).	Patients on marimastat had significantly poorer quality of life at 3 and 6 months.
__label__noRel	The median time to progression for marimastat patients was 4.3 months compared with 4.4 months for placebo patients (P =.81).	Treatment with marimastat after induction therapy for SCLC did not result in improved survival and had a negative impact on quality of life.
__label__noRel	Toxicity was generally limited to musculoskeletal symptoms (18% grade 3/4 for marimastat).	Increased expression of metalloproteinases is associated with poor prognosis in small-cell lung cancer (SCLC).
__label__noRel	Toxicity was generally limited to musculoskeletal symptoms (18% grade 3/4 for marimastat).	Best response to induction therapy was complete remission for 176 patients (33%), partial remission for 341 (64%), and 15 patients (3%) had undergone surgical resection.
__label__noRel	Toxicity was generally limited to musculoskeletal symptoms (18% grade 3/4 for marimastat).	Median survivals for marimastat and placebo patients were 9.3 months and 9.7 months, respectively (P =.90).
__label__noRel	Toxicity was generally limited to musculoskeletal symptoms (18% grade 3/4 for marimastat).	The median time to progression for marimastat patients was 4.3 months compared with 4.4 months for placebo patients (P =.81).
__label__noRel	Toxicity was generally limited to musculoskeletal symptoms (18% grade 3/4 for marimastat).	Dose modifications for musculoskeletal toxicity were required in 90 patients (33%) on the marimastat arm, and 87 (32%) permanently stopped marimastat because of toxicity.
__label__noRel	Toxicity was generally limited to musculoskeletal symptoms (18% grade 3/4 for marimastat).	Patients on marimastat had significantly poorer quality of life at 3 and 6 months.
__label__Support	Toxicity was generally limited to musculoskeletal symptoms (18% grade 3/4 for marimastat).	Treatment with marimastat after induction therapy for SCLC did not result in improved survival and had a negative impact on quality of life.
__label__noRel	Dose modifications for musculoskeletal toxicity were required in 90 patients (33%) on the marimastat arm, and 87 (32%) permanently stopped marimastat because of toxicity.	Increased expression of metalloproteinases is associated with poor prognosis in small-cell lung cancer (SCLC).
__label__noRel	Dose modifications for musculoskeletal toxicity were required in 90 patients (33%) on the marimastat arm, and 87 (32%) permanently stopped marimastat because of toxicity.	Best response to induction therapy was complete remission for 176 patients (33%), partial remission for 341 (64%), and 15 patients (3%) had undergone surgical resection.
__label__noRel	Dose modifications for musculoskeletal toxicity were required in 90 patients (33%) on the marimastat arm, and 87 (32%) permanently stopped marimastat because of toxicity.	Median survivals for marimastat and placebo patients were 9.3 months and 9.7 months, respectively (P =.90).
__label__noRel	Dose modifications for musculoskeletal toxicity were required in 90 patients (33%) on the marimastat arm, and 87 (32%) permanently stopped marimastat because of toxicity.	The median time to progression for marimastat patients was 4.3 months compared with 4.4 months for placebo patients (P =.81).
__label__noRel	Dose modifications for musculoskeletal toxicity were required in 90 patients (33%) on the marimastat arm, and 87 (32%) permanently stopped marimastat because of toxicity.	Toxicity was generally limited to musculoskeletal symptoms (18% grade 3/4 for marimastat).
__label__noRel	Dose modifications for musculoskeletal toxicity were required in 90 patients (33%) on the marimastat arm, and 87 (32%) permanently stopped marimastat because of toxicity.	Patients on marimastat had significantly poorer quality of life at 3 and 6 months.
__label__noRel	Dose modifications for musculoskeletal toxicity were required in 90 patients (33%) on the marimastat arm, and 87 (32%) permanently stopped marimastat because of toxicity.	Treatment with marimastat after induction therapy for SCLC did not result in improved survival and had a negative impact on quality of life.
__label__noRel	Patients on marimastat had significantly poorer quality of life at 3 and 6 months.	Increased expression of metalloproteinases is associated with poor prognosis in small-cell lung cancer (SCLC).
__label__noRel	Patients on marimastat had significantly poorer quality of life at 3 and 6 months.	Best response to induction therapy was complete remission for 176 patients (33%), partial remission for 341 (64%), and 15 patients (3%) had undergone surgical resection.
__label__noRel	Patients on marimastat had significantly poorer quality of life at 3 and 6 months.	Median survivals for marimastat and placebo patients were 9.3 months and 9.7 months, respectively (P =.90).
__label__noRel	Patients on marimastat had significantly poorer quality of life at 3 and 6 months.	The median time to progression for marimastat patients was 4.3 months compared with 4.4 months for placebo patients (P =.81).
__label__noRel	Patients on marimastat had significantly poorer quality of life at 3 and 6 months.	Toxicity was generally limited to musculoskeletal symptoms (18% grade 3/4 for marimastat).
__label__noRel	Patients on marimastat had significantly poorer quality of life at 3 and 6 months.	Dose modifications for musculoskeletal toxicity were required in 90 patients (33%) on the marimastat arm, and 87 (32%) permanently stopped marimastat because of toxicity.
__label__Support	Patients on marimastat had significantly poorer quality of life at 3 and 6 months.	Treatment with marimastat after induction therapy for SCLC did not result in improved survival and had a negative impact on quality of life.
__label__noRel	Treatment with marimastat after induction therapy for SCLC did not result in improved survival and had a negative impact on quality of life.	Increased expression of metalloproteinases is associated with poor prognosis in small-cell lung cancer (SCLC).
__label__noRel	Treatment with marimastat after induction therapy for SCLC did not result in improved survival and had a negative impact on quality of life.	Best response to induction therapy was complete remission for 176 patients (33%), partial remission for 341 (64%), and 15 patients (3%) had undergone surgical resection.
__label__noRel	Treatment with marimastat after induction therapy for SCLC did not result in improved survival and had a negative impact on quality of life.	Median survivals for marimastat and placebo patients were 9.3 months and 9.7 months, respectively (P =.90).
__label__noRel	Treatment with marimastat after induction therapy for SCLC did not result in improved survival and had a negative impact on quality of life.	The median time to progression for marimastat patients was 4.3 months compared with 4.4 months for placebo patients (P =.81).
__label__noRel	Treatment with marimastat after induction therapy for SCLC did not result in improved survival and had a negative impact on quality of life.	Toxicity was generally limited to musculoskeletal symptoms (18% grade 3/4 for marimastat).
__label__noRel	Treatment with marimastat after induction therapy for SCLC did not result in improved survival and had a negative impact on quality of life.	Dose modifications for musculoskeletal toxicity were required in 90 patients (33%) on the marimastat arm, and 87 (32%) permanently stopped marimastat because of toxicity.
__label__noRel	Treatment with marimastat after induction therapy for SCLC did not result in improved survival and had a negative impact on quality of life.	Patients on marimastat had significantly poorer quality of life at 3 and 6 months.
__label__noRel	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).
__label__noRel	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).
__label__noRel	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).
__label__noRel	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,
__label__noRel	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.
__label__noRel	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,
__label__noRel	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.	the 8-mg dose was associated with renal function deterioration.
__label__noRel	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.
__label__noRel	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.
__label__noRel	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).
__label__noRel	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).
__label__noRel	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,
__label__noRel	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.
__label__noRel	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,
__label__noRel	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).	the 8-mg dose was associated with renal function deterioration.
__label__Support	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.
__label__noRel	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.
__label__noRel	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).
__label__noRel	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).
__label__noRel	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,
__label__noRel	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.
__label__noRel	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,
__label__noRel	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).	the 8-mg dose was associated with renal function deterioration.
__label__Support	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.
__label__noRel	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.
__label__noRel	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).
__label__noRel	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).
__label__noRel	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,
__label__noRel	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.
__label__noRel	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,
__label__noRel	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).	the 8-mg dose was associated with renal function deterioration.
__label__noRel	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.
__label__noRel	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.
__label__noRel	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).
__label__noRel	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).
__label__noRel	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).
__label__noRel	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.
__label__noRel	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,
__label__noRel	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,	the 8-mg dose was associated with renal function deterioration.
__label__noRel	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.
__label__noRel	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.
__label__noRel	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).
__label__noRel	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).
__label__noRel	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).
__label__noRel	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,
__label__noRel	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,
__label__noRel	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.	the 8-mg dose was associated with renal function deterioration.
__label__noRel	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.
__label__noRel	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.
__label__noRel	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).
__label__noRel	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).
__label__noRel	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).
__label__noRel	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,
__label__noRel	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.
__label__noRel	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,	the 8-mg dose was associated with renal function deterioration.
__label__noRel	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.
__label__noRel	the 8-mg dose was associated with renal function deterioration.	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.
__label__noRel	the 8-mg dose was associated with renal function deterioration.	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).
__label__noRel	the 8-mg dose was associated with renal function deterioration.	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).
__label__noRel	the 8-mg dose was associated with renal function deterioration.	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).
__label__noRel	the 8-mg dose was associated with renal function deterioration.	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,
__label__noRel	the 8-mg dose was associated with renal function deterioration.	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.
__label__noRel	the 8-mg dose was associated with renal function deterioration.	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,
__label__noRel	the 8-mg dose was associated with renal function deterioration.	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.
__label__noRel	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.
__label__noRel	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).
__label__noRel	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).
__label__noRel	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).
__label__noRel	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,
__label__noRel	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.
__label__noRel	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,
__label__noRel	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.	the 8-mg dose was associated with renal function deterioration.
__label__noRel	Mean physical function at 12 months was 66 points (95% CI 629-700) in the 90 mg group and 68 points (646-714) in the 30 mg group (95% CI of difference -66 to 33; p=052).	Median time to first skeletal-related event in patients who had such an event was 92 months (81-107) in the 90 mg group and 102 months (73-140) in the 30 mg group (p=063).
__label__noRel	Mean physical function at 12 months was 66 points (95% CI 629-700) in the 90 mg group and 68 points (646-714) in the 30 mg group (95% CI of difference -66 to 33; p=052).	eight patients in the pamidronate 90 mg group developed osteonecrosis of the jaw compared with two patients in the 30 mg group.
__label__Support	Mean physical function at 12 months was 66 points (95% CI 629-700) in the 90 mg group and 68 points (646-714) in the 30 mg group (95% CI of difference -66 to 33; p=052).	Monthly infusion of pamidronate 30 mg should be the recommended dose for prevention of bone disease in patients with multiple myeloma.
__label__noRel	Median time to first skeletal-related event in patients who had such an event was 92 months (81-107) in the 90 mg group and 102 months (73-140) in the 30 mg group (p=063).	Mean physical function at 12 months was 66 points (95% CI 629-700) in the 90 mg group and 68 points (646-714) in the 30 mg group (95% CI of difference -66 to 33; p=052).
__label__noRel	Median time to first skeletal-related event in patients who had such an event was 92 months (81-107) in the 90 mg group and 102 months (73-140) in the 30 mg group (p=063).	eight patients in the pamidronate 90 mg group developed osteonecrosis of the jaw compared with two patients in the 30 mg group.
__label__Support	Median time to first skeletal-related event in patients who had such an event was 92 months (81-107) in the 90 mg group and 102 months (73-140) in the 30 mg group (p=063).	Monthly infusion of pamidronate 30 mg should be the recommended dose for prevention of bone disease in patients with multiple myeloma.
__label__noRel	eight patients in the pamidronate 90 mg group developed osteonecrosis of the jaw compared with two patients in the 30 mg group.	Mean physical function at 12 months was 66 points (95% CI 629-700) in the 90 mg group and 68 points (646-714) in the 30 mg group (95% CI of difference -66 to 33; p=052).
__label__noRel	eight patients in the pamidronate 90 mg group developed osteonecrosis of the jaw compared with two patients in the 30 mg group.	Median time to first skeletal-related event in patients who had such an event was 92 months (81-107) in the 90 mg group and 102 months (73-140) in the 30 mg group (p=063).
__label__Support	eight patients in the pamidronate 90 mg group developed osteonecrosis of the jaw compared with two patients in the 30 mg group.	Monthly infusion of pamidronate 30 mg should be the recommended dose for prevention of bone disease in patients with multiple myeloma.
__label__noRel	Monthly infusion of pamidronate 30 mg should be the recommended dose for prevention of bone disease in patients with multiple myeloma.	Mean physical function at 12 months was 66 points (95% CI 629-700) in the 90 mg group and 68 points (646-714) in the 30 mg group (95% CI of difference -66 to 33; p=052).
__label__noRel	Monthly infusion of pamidronate 30 mg should be the recommended dose for prevention of bone disease in patients with multiple myeloma.	Median time to first skeletal-related event in patients who had such an event was 92 months (81-107) in the 90 mg group and 102 months (73-140) in the 30 mg group (p=063).
__label__noRel	Monthly infusion of pamidronate 30 mg should be the recommended dose for prevention of bone disease in patients with multiple myeloma.	eight patients in the pamidronate 90 mg group developed osteonecrosis of the jaw compared with two patients in the 30 mg group.
__label__noRel	Depression scores yielded a linear interaction comparing UCO and SMEX (p = 0.019), with decreases in SMEX but not UCO.	Anxiety scores yielded a quadratic interaction comparing UCO and SMEX (p = 0.049), with trends for changes in SMEX but not UCO.
__label__noRel	Depression scores yielded a linear interaction comparing UCO and SMEX (p = 0.019), with decreases in SMEX but not UCO.	Interaction effects for mental and physical well-being scores were not significant.
__label__noRel	Depression scores yielded a linear interaction comparing UCO and SMEX (p = 0.019), with decreases in SMEX but not UCO.	Additional analyses yielded quadratic interactions for exercise activity comparing UCO and SMEX (p = 0.022), with positive changes in SMEX but not UCO, and for stress management activity comparing UCO and SM (p < 0.001) and UCO and SMEX (p = 0.013), with positive changes in SM and SMEX but not UCO.
__label__Support	Depression scores yielded a linear interaction comparing UCO and SMEX (p = 0.019), with decreases in SMEX but not UCO.	Only the combined intervention yielded effects on quality of life outcomes, and these were limited to anxiety and depression.
__label__noRel	Depression scores yielded a linear interaction comparing UCO and SMEX (p = 0.019), with decreases in SMEX but not UCO.	These findings are consistent with evidence that only the combined intervention yielded increases in both exercise and stress management activity.
__label__noRel	Anxiety scores yielded a quadratic interaction comparing UCO and SMEX (p = 0.049), with trends for changes in SMEX but not UCO.	Depression scores yielded a linear interaction comparing UCO and SMEX (p = 0.019), with decreases in SMEX but not UCO.
__label__noRel	Anxiety scores yielded a quadratic interaction comparing UCO and SMEX (p = 0.049), with trends for changes in SMEX but not UCO.	Interaction effects for mental and physical well-being scores were not significant.
__label__noRel	Anxiety scores yielded a quadratic interaction comparing UCO and SMEX (p = 0.049), with trends for changes in SMEX but not UCO.	Additional analyses yielded quadratic interactions for exercise activity comparing UCO and SMEX (p = 0.022), with positive changes in SMEX but not UCO, and for stress management activity comparing UCO and SM (p < 0.001) and UCO and SMEX (p = 0.013), with positive changes in SM and SMEX but not UCO.
__label__Support	Anxiety scores yielded a quadratic interaction comparing UCO and SMEX (p = 0.049), with trends for changes in SMEX but not UCO.	Only the combined intervention yielded effects on quality of life outcomes, and these were limited to anxiety and depression.
__label__noRel	Anxiety scores yielded a quadratic interaction comparing UCO and SMEX (p = 0.049), with trends for changes in SMEX but not UCO.	These findings are consistent with evidence that only the combined intervention yielded increases in both exercise and stress management activity.
__label__noRel	Interaction effects for mental and physical well-being scores were not significant.	Depression scores yielded a linear interaction comparing UCO and SMEX (p = 0.019), with decreases in SMEX but not UCO.
__label__noRel	Interaction effects for mental and physical well-being scores were not significant.	Anxiety scores yielded a quadratic interaction comparing UCO and SMEX (p = 0.049), with trends for changes in SMEX but not UCO.
__label__noRel	Interaction effects for mental and physical well-being scores were not significant.	Additional analyses yielded quadratic interactions for exercise activity comparing UCO and SMEX (p = 0.022), with positive changes in SMEX but not UCO, and for stress management activity comparing UCO and SM (p < 0.001) and UCO and SMEX (p = 0.013), with positive changes in SM and SMEX but not UCO.
__label__Support	Interaction effects for mental and physical well-being scores were not significant.	Only the combined intervention yielded effects on quality of life outcomes, and these were limited to anxiety and depression.
__label__noRel	Interaction effects for mental and physical well-being scores were not significant.	These findings are consistent with evidence that only the combined intervention yielded increases in both exercise and stress management activity.
__label__noRel	Additional analyses yielded quadratic interactions for exercise activity comparing UCO and SMEX (p = 0.022), with positive changes in SMEX but not UCO, and for stress management activity comparing UCO and SM (p < 0.001) and UCO and SMEX (p = 0.013), with positive changes in SM and SMEX but not UCO.	Depression scores yielded a linear interaction comparing UCO and SMEX (p = 0.019), with decreases in SMEX but not UCO.
__label__noRel	Additional analyses yielded quadratic interactions for exercise activity comparing UCO and SMEX (p = 0.022), with positive changes in SMEX but not UCO, and for stress management activity comparing UCO and SM (p < 0.001) and UCO and SMEX (p = 0.013), with positive changes in SM and SMEX but not UCO.	Anxiety scores yielded a quadratic interaction comparing UCO and SMEX (p = 0.049), with trends for changes in SMEX but not UCO.
__label__noRel	Additional analyses yielded quadratic interactions for exercise activity comparing UCO and SMEX (p = 0.022), with positive changes in SMEX but not UCO, and for stress management activity comparing UCO and SM (p < 0.001) and UCO and SMEX (p = 0.013), with positive changes in SM and SMEX but not UCO.	Interaction effects for mental and physical well-being scores were not significant.
__label__Support	Additional analyses yielded quadratic interactions for exercise activity comparing UCO and SMEX (p = 0.022), with positive changes in SMEX but not UCO, and for stress management activity comparing UCO and SM (p < 0.001) and UCO and SMEX (p = 0.013), with positive changes in SM and SMEX but not UCO.	Only the combined intervention yielded effects on quality of life outcomes, and these were limited to anxiety and depression.
__label__noRel	Additional analyses yielded quadratic interactions for exercise activity comparing UCO and SMEX (p = 0.022), with positive changes in SMEX but not UCO, and for stress management activity comparing UCO and SM (p < 0.001) and UCO and SMEX (p = 0.013), with positive changes in SM and SMEX but not UCO.	These findings are consistent with evidence that only the combined intervention yielded increases in both exercise and stress management activity.
__label__noRel	Only the combined intervention yielded effects on quality of life outcomes, and these were limited to anxiety and depression.	Depression scores yielded a linear interaction comparing UCO and SMEX (p = 0.019), with decreases in SMEX but not UCO.
__label__noRel	Only the combined intervention yielded effects on quality of life outcomes, and these were limited to anxiety and depression.	Anxiety scores yielded a quadratic interaction comparing UCO and SMEX (p = 0.049), with trends for changes in SMEX but not UCO.
__label__noRel	Only the combined intervention yielded effects on quality of life outcomes, and these were limited to anxiety and depression.	Interaction effects for mental and physical well-being scores were not significant.
__label__noRel	Only the combined intervention yielded effects on quality of life outcomes, and these were limited to anxiety and depression.	Additional analyses yielded quadratic interactions for exercise activity comparing UCO and SMEX (p = 0.022), with positive changes in SMEX but not UCO, and for stress management activity comparing UCO and SM (p < 0.001) and UCO and SMEX (p = 0.013), with positive changes in SM and SMEX but not UCO.
__label__noRel	Only the combined intervention yielded effects on quality of life outcomes, and these were limited to anxiety and depression.	These findings are consistent with evidence that only the combined intervention yielded increases in both exercise and stress management activity.
__label__noRel	These findings are consistent with evidence that only the combined intervention yielded increases in both exercise and stress management activity.	Depression scores yielded a linear interaction comparing UCO and SMEX (p = 0.019), with decreases in SMEX but not UCO.
__label__noRel	These findings are consistent with evidence that only the combined intervention yielded increases in both exercise and stress management activity.	Anxiety scores yielded a quadratic interaction comparing UCO and SMEX (p = 0.049), with trends for changes in SMEX but not UCO.
__label__noRel	These findings are consistent with evidence that only the combined intervention yielded increases in both exercise and stress management activity.	Interaction effects for mental and physical well-being scores were not significant.
__label__noRel	These findings are consistent with evidence that only the combined intervention yielded increases in both exercise and stress management activity.	Additional analyses yielded quadratic interactions for exercise activity comparing UCO and SMEX (p = 0.022), with positive changes in SMEX but not UCO, and for stress management activity comparing UCO and SM (p < 0.001) and UCO and SMEX (p = 0.013), with positive changes in SM and SMEX but not UCO.
__label__Support	These findings are consistent with evidence that only the combined intervention yielded increases in both exercise and stress management activity.	Only the combined intervention yielded effects on quality of life outcomes, and these were limited to anxiety and depression.
__label__noRel	The 15-year actuarial locoregional recurrence rates were 5.8% for EBRT versus 15.5% for NAT (P < .001), and 15-year overall survival was 52% versus 60% (P = .14).	Patients treated with EBRT reported significant (P < .01) and clinically relevant higher rates of urinary incontinence, diarrhea, and fecal leakage leading to more limitations in daily activities.
__label__noRel	The 15-year actuarial locoregional recurrence rates were 5.8% for EBRT versus 15.5% for NAT (P < .001), and 15-year overall survival was 52% versus 60% (P = .14).	Increased symptoms were reflected by the frequent use of incontinence materials after EBRT (day and night use, 42.9% v 15.2% for NAT; P < .001).
__label__noRel	The 15-year actuarial locoregional recurrence rates were 5.8% for EBRT versus 15.5% for NAT (P < .001), and 15-year overall survival was 52% versus 60% (P = .14).	Patients treated with EBRT reported lower scores on the SF-36 scales "physical functioning" (P = .004) and "role-physical" (P = .003).
__label__Support	The 15-year actuarial locoregional recurrence rates were 5.8% for EBRT versus 15.5% for NAT (P < .001), and 15-year overall survival was 52% versus 60% (P = .14).	EBRT for endometrial cancer is associated with long-term urinary and bowel symptoms and lower physical and role-physical functioning, even 15 years after treatment.
__label__noRel	The 15-year actuarial locoregional recurrence rates were 5.8% for EBRT versus 15.5% for NAT (P < .001), and 15-year overall survival was 52% versus 60% (P = .14).	Despite its efficacy in reducing locoregional recurrence, EBRT should be avoided in patients with low- and intermediate-risk EC.
__label__noRel	Patients treated with EBRT reported significant (P < .01) and clinically relevant higher rates of urinary incontinence, diarrhea, and fecal leakage leading to more limitations in daily activities.	The 15-year actuarial locoregional recurrence rates were 5.8% for EBRT versus 15.5% for NAT (P < .001), and 15-year overall survival was 52% versus 60% (P = .14).
__label__noRel	Patients treated with EBRT reported significant (P < .01) and clinically relevant higher rates of urinary incontinence, diarrhea, and fecal leakage leading to more limitations in daily activities.	Increased symptoms were reflected by the frequent use of incontinence materials after EBRT (day and night use, 42.9% v 15.2% for NAT; P < .001).
__label__noRel	Patients treated with EBRT reported significant (P < .01) and clinically relevant higher rates of urinary incontinence, diarrhea, and fecal leakage leading to more limitations in daily activities.	Patients treated with EBRT reported lower scores on the SF-36 scales "physical functioning" (P = .004) and "role-physical" (P = .003).
__label__Support	Patients treated with EBRT reported significant (P < .01) and clinically relevant higher rates of urinary incontinence, diarrhea, and fecal leakage leading to more limitations in daily activities.	EBRT for endometrial cancer is associated with long-term urinary and bowel symptoms and lower physical and role-physical functioning, even 15 years after treatment.
__label__noRel	Patients treated with EBRT reported significant (P < .01) and clinically relevant higher rates of urinary incontinence, diarrhea, and fecal leakage leading to more limitations in daily activities.	Despite its efficacy in reducing locoregional recurrence, EBRT should be avoided in patients with low- and intermediate-risk EC.
__label__noRel	Increased symptoms were reflected by the frequent use of incontinence materials after EBRT (day and night use, 42.9% v 15.2% for NAT; P < .001).	The 15-year actuarial locoregional recurrence rates were 5.8% for EBRT versus 15.5% for NAT (P < .001), and 15-year overall survival was 52% versus 60% (P = .14).
__label__noRel	Increased symptoms were reflected by the frequent use of incontinence materials after EBRT (day and night use, 42.9% v 15.2% for NAT; P < .001).	Patients treated with EBRT reported significant (P < .01) and clinically relevant higher rates of urinary incontinence, diarrhea, and fecal leakage leading to more limitations in daily activities.
__label__noRel	Increased symptoms were reflected by the frequent use of incontinence materials after EBRT (day and night use, 42.9% v 15.2% for NAT; P < .001).	Patients treated with EBRT reported lower scores on the SF-36 scales "physical functioning" (P = .004) and "role-physical" (P = .003).
__label__Support	Increased symptoms were reflected by the frequent use of incontinence materials after EBRT (day and night use, 42.9% v 15.2% for NAT; P < .001).	EBRT for endometrial cancer is associated with long-term urinary and bowel symptoms and lower physical and role-physical functioning, even 15 years after treatment.
__label__noRel	Increased symptoms were reflected by the frequent use of incontinence materials after EBRT (day and night use, 42.9% v 15.2% for NAT; P < .001).	Despite its efficacy in reducing locoregional recurrence, EBRT should be avoided in patients with low- and intermediate-risk EC.
__label__noRel	Patients treated with EBRT reported lower scores on the SF-36 scales "physical functioning" (P = .004) and "role-physical" (P = .003).	The 15-year actuarial locoregional recurrence rates were 5.8% for EBRT versus 15.5% for NAT (P < .001), and 15-year overall survival was 52% versus 60% (P = .14).
__label__noRel	Patients treated with EBRT reported lower scores on the SF-36 scales "physical functioning" (P = .004) and "role-physical" (P = .003).	Patients treated with EBRT reported significant (P < .01) and clinically relevant higher rates of urinary incontinence, diarrhea, and fecal leakage leading to more limitations in daily activities.
__label__noRel	Patients treated with EBRT reported lower scores on the SF-36 scales "physical functioning" (P = .004) and "role-physical" (P = .003).	Increased symptoms were reflected by the frequent use of incontinence materials after EBRT (day and night use, 42.9% v 15.2% for NAT; P < .001).
__label__Support	Patients treated with EBRT reported lower scores on the SF-36 scales "physical functioning" (P = .004) and "role-physical" (P = .003).	EBRT for endometrial cancer is associated with long-term urinary and bowel symptoms and lower physical and role-physical functioning, even 15 years after treatment.
__label__noRel	Patients treated with EBRT reported lower scores on the SF-36 scales "physical functioning" (P = .004) and "role-physical" (P = .003).	Despite its efficacy in reducing locoregional recurrence, EBRT should be avoided in patients with low- and intermediate-risk EC.
__label__noRel	EBRT for endometrial cancer is associated with long-term urinary and bowel symptoms and lower physical and role-physical functioning, even 15 years after treatment.	The 15-year actuarial locoregional recurrence rates were 5.8% for EBRT versus 15.5% for NAT (P < .001), and 15-year overall survival was 52% versus 60% (P = .14).
__label__noRel	EBRT for endometrial cancer is associated with long-term urinary and bowel symptoms and lower physical and role-physical functioning, even 15 years after treatment.	Patients treated with EBRT reported significant (P < .01) and clinically relevant higher rates of urinary incontinence, diarrhea, and fecal leakage leading to more limitations in daily activities.
__label__noRel	EBRT for endometrial cancer is associated with long-term urinary and bowel symptoms and lower physical and role-physical functioning, even 15 years after treatment.	Increased symptoms were reflected by the frequent use of incontinence materials after EBRT (day and night use, 42.9% v 15.2% for NAT; P < .001).
__label__noRel	EBRT for endometrial cancer is associated with long-term urinary and bowel symptoms and lower physical and role-physical functioning, even 15 years after treatment.	Patients treated with EBRT reported lower scores on the SF-36 scales "physical functioning" (P = .004) and "role-physical" (P = .003).
__label__Support	EBRT for endometrial cancer is associated with long-term urinary and bowel symptoms and lower physical and role-physical functioning, even 15 years after treatment.	Despite its efficacy in reducing locoregional recurrence, EBRT should be avoided in patients with low- and intermediate-risk EC.
__label__noRel	Despite its efficacy in reducing locoregional recurrence, EBRT should be avoided in patients with low- and intermediate-risk EC.	The 15-year actuarial locoregional recurrence rates were 5.8% for EBRT versus 15.5% for NAT (P < .001), and 15-year overall survival was 52% versus 60% (P = .14).
__label__noRel	Despite its efficacy in reducing locoregional recurrence, EBRT should be avoided in patients with low- and intermediate-risk EC.	Patients treated with EBRT reported significant (P < .01) and clinically relevant higher rates of urinary incontinence, diarrhea, and fecal leakage leading to more limitations in daily activities.
__label__noRel	Despite its efficacy in reducing locoregional recurrence, EBRT should be avoided in patients with low- and intermediate-risk EC.	Increased symptoms were reflected by the frequent use of incontinence materials after EBRT (day and night use, 42.9% v 15.2% for NAT; P < .001).
__label__noRel	Despite its efficacy in reducing locoregional recurrence, EBRT should be avoided in patients with low- and intermediate-risk EC.	Patients treated with EBRT reported lower scores on the SF-36 scales "physical functioning" (P = .004) and "role-physical" (P = .003).
__label__noRel	Despite its efficacy in reducing locoregional recurrence, EBRT should be avoided in patients with low- and intermediate-risk EC.	EBRT for endometrial cancer is associated with long-term urinary and bowel symptoms and lower physical and role-physical functioning, even 15 years after treatment.
__label__noRel	Kaplan-Meier survival curves demonstrated better survival for the experimental group than the control group.	The unadjusted significance level for group differences was P = .0006 for survival to 10 years.
__label__noRel	Kaplan-Meier survival curves demonstrated better survival for the experimental group than the control group.	Cox regression models that took TNM staging or the residual tumor classification and tumor site into account also found significant differences at 10 years.
__label__noRel	Kaplan-Meier survival curves demonstrated better survival for the experimental group than the control group.	Secondary analyses found that differences in favor of the experimental group occurred in patients with stomach, pancreatic, primary liver, or colorectal cancer.
__label__Support	Kaplan-Meier survival curves demonstrated better survival for the experimental group than the control group.	The results of this study indicate that patients with gastrointestinal cancer, who undergo surgery for stomach, pancreatic, primary liver, or colorectal cancer, benefit from a formal program of psychotherapeutic support during the inpatient hospital stay in terms of long-term survival.
__label__Support	The unadjusted significance level for group differences was P = .0006 for survival to 10 years.	Kaplan-Meier survival curves demonstrated better survival for the experimental group than the control group.
__label__noRel	The unadjusted significance level for group differences was P = .0006 for survival to 10 years.	Cox regression models that took TNM staging or the residual tumor classification and tumor site into account also found significant differences at 10 years.
__label__noRel	The unadjusted significance level for group differences was P = .0006 for survival to 10 years.	Secondary analyses found that differences in favor of the experimental group occurred in patients with stomach, pancreatic, primary liver, or colorectal cancer.
__label__noRel	The unadjusted significance level for group differences was P = .0006 for survival to 10 years.	The results of this study indicate that patients with gastrointestinal cancer, who undergo surgery for stomach, pancreatic, primary liver, or colorectal cancer, benefit from a formal program of psychotherapeutic support during the inpatient hospital stay in terms of long-term survival.
__label__noRel	Cox regression models that took TNM staging or the residual tumor classification and tumor site into account also found significant differences at 10 years.	Kaplan-Meier survival curves demonstrated better survival for the experimental group than the control group.
__label__noRel	Cox regression models that took TNM staging or the residual tumor classification and tumor site into account also found significant differences at 10 years.	The unadjusted significance level for group differences was P = .0006 for survival to 10 years.
__label__noRel	Cox regression models that took TNM staging or the residual tumor classification and tumor site into account also found significant differences at 10 years.	Secondary analyses found that differences in favor of the experimental group occurred in patients with stomach, pancreatic, primary liver, or colorectal cancer.
__label__Support	Cox regression models that took TNM staging or the residual tumor classification and tumor site into account also found significant differences at 10 years.	The results of this study indicate that patients with gastrointestinal cancer, who undergo surgery for stomach, pancreatic, primary liver, or colorectal cancer, benefit from a formal program of psychotherapeutic support during the inpatient hospital stay in terms of long-term survival.
__label__noRel	Secondary analyses found that differences in favor of the experimental group occurred in patients with stomach, pancreatic, primary liver, or colorectal cancer.	Kaplan-Meier survival curves demonstrated better survival for the experimental group than the control group.
__label__noRel	Secondary analyses found that differences in favor of the experimental group occurred in patients with stomach, pancreatic, primary liver, or colorectal cancer.	The unadjusted significance level for group differences was P = .0006 for survival to 10 years.
__label__noRel	Secondary analyses found that differences in favor of the experimental group occurred in patients with stomach, pancreatic, primary liver, or colorectal cancer.	Cox regression models that took TNM staging or the residual tumor classification and tumor site into account also found significant differences at 10 years.
__label__Support	Secondary analyses found that differences in favor of the experimental group occurred in patients with stomach, pancreatic, primary liver, or colorectal cancer.	The results of this study indicate that patients with gastrointestinal cancer, who undergo surgery for stomach, pancreatic, primary liver, or colorectal cancer, benefit from a formal program of psychotherapeutic support during the inpatient hospital stay in terms of long-term survival.
__label__noRel	The results of this study indicate that patients with gastrointestinal cancer, who undergo surgery for stomach, pancreatic, primary liver, or colorectal cancer, benefit from a formal program of psychotherapeutic support during the inpatient hospital stay in terms of long-term survival.	Kaplan-Meier survival curves demonstrated better survival for the experimental group than the control group.
__label__noRel	The results of this study indicate that patients with gastrointestinal cancer, who undergo surgery for stomach, pancreatic, primary liver, or colorectal cancer, benefit from a formal program of psychotherapeutic support during the inpatient hospital stay in terms of long-term survival.	The unadjusted significance level for group differences was P = .0006 for survival to 10 years.
__label__noRel	The results of this study indicate that patients with gastrointestinal cancer, who undergo surgery for stomach, pancreatic, primary liver, or colorectal cancer, benefit from a formal program of psychotherapeutic support during the inpatient hospital stay in terms of long-term survival.	Cox regression models that took TNM staging or the residual tumor classification and tumor site into account also found significant differences at 10 years.
__label__noRel	The results of this study indicate that patients with gastrointestinal cancer, who undergo surgery for stomach, pancreatic, primary liver, or colorectal cancer, benefit from a formal program of psychotherapeutic support during the inpatient hospital stay in terms of long-term survival.	Secondary analyses found that differences in favor of the experimental group occurred in patients with stomach, pancreatic, primary liver, or colorectal cancer.
__label__noRel	ORR was 25.0% (95% CI, 13% to 41%) for ECF, 18.5% (95% CI, 9% to 34%) for TC, and 36.6% (95% CI, 23% to 53%) for TCF (n = 119).	Median overall survival times were 8.3, 11.0, and 10.4 months for ECF, TC, and TCF, respectively.
__label__noRel	ORR was 25.0% (95% CI, 13% to 41%) for ECF, 18.5% (95% CI, 9% to 34%) for TC, and 36.6% (95% CI, 23% to 53%) for TCF (n = 119).	Toxicity was acceptable, with one toxic death (TC arm).
__label__noRel	ORR was 25.0% (95% CI, 13% to 41%) for ECF, 18.5% (95% CI, 9% to 34%) for TC, and 36.6% (95% CI, 23% to 53%) for TCF (n = 119).	Grade 3 or 4 neutropenia occurred in more treatment cycles with docetaxel (TC, 49%; TCF, 57%; ECF, 34%).
__label__Support	ORR was 25.0% (95% CI, 13% to 41%) for ECF, 18.5% (95% CI, 9% to 34%) for TC, and 36.6% (95% CI, 23% to 53%) for TCF (n = 119).	Global health status/QOL substantially improved with ECF and remained similar to baseline with both docetaxel regimens.
__label__noRel	ORR was 25.0% (95% CI, 13% to 41%) for ECF, 18.5% (95% CI, 9% to 34%) for TC, and 36.6% (95% CI, 23% to 53%) for TCF (n = 119).	A trend towards increased myelosuppression and infectious complications with TCF versus TC or ECF was observed.
__label__noRel	ORR was 25.0% (95% CI, 13% to 41%) for ECF, 18.5% (95% CI, 9% to 34%) for TC, and 36.6% (95% CI, 23% to 53%) for TCF (n = 119).	Time to response and ORR favor TCF over TC for further evaluation, particularly in the neoadjuvant setting.
__label__noRel	Median overall survival times were 8.3, 11.0, and 10.4 months for ECF, TC, and TCF, respectively.	ORR was 25.0% (95% CI, 13% to 41%) for ECF, 18.5% (95% CI, 9% to 34%) for TC, and 36.6% (95% CI, 23% to 53%) for TCF (n = 119).
__label__noRel	Median overall survival times were 8.3, 11.0, and 10.4 months for ECF, TC, and TCF, respectively.	Toxicity was acceptable, with one toxic death (TC arm).
__label__noRel	Median overall survival times were 8.3, 11.0, and 10.4 months for ECF, TC, and TCF, respectively.	Grade 3 or 4 neutropenia occurred in more treatment cycles with docetaxel (TC, 49%; TCF, 57%; ECF, 34%).
__label__Support	Median overall survival times were 8.3, 11.0, and 10.4 months for ECF, TC, and TCF, respectively.	Global health status/QOL substantially improved with ECF and remained similar to baseline with both docetaxel regimens.
__label__noRel	Median overall survival times were 8.3, 11.0, and 10.4 months for ECF, TC, and TCF, respectively.	A trend towards increased myelosuppression and infectious complications with TCF versus TC or ECF was observed.
__label__noRel	Median overall survival times were 8.3, 11.0, and 10.4 months for ECF, TC, and TCF, respectively.	Time to response and ORR favor TCF over TC for further evaluation, particularly in the neoadjuvant setting.
__label__noRel	Toxicity was acceptable, with one toxic death (TC arm).	ORR was 25.0% (95% CI, 13% to 41%) for ECF, 18.5% (95% CI, 9% to 34%) for TC, and 36.6% (95% CI, 23% to 53%) for TCF (n = 119).
__label__noRel	Toxicity was acceptable, with one toxic death (TC arm).	Median overall survival times were 8.3, 11.0, and 10.4 months for ECF, TC, and TCF, respectively.
__label__noRel	Toxicity was acceptable, with one toxic death (TC arm).	Grade 3 or 4 neutropenia occurred in more treatment cycles with docetaxel (TC, 49%; TCF, 57%; ECF, 34%).
__label__Support	Toxicity was acceptable, with one toxic death (TC arm).	Global health status/QOL substantially improved with ECF and remained similar to baseline with both docetaxel regimens.
__label__noRel	Toxicity was acceptable, with one toxic death (TC arm).	A trend towards increased myelosuppression and infectious complications with TCF versus TC or ECF was observed.
__label__noRel	Toxicity was acceptable, with one toxic death (TC arm).	Time to response and ORR favor TCF over TC for further evaluation, particularly in the neoadjuvant setting.
__label__noRel	Grade 3 or 4 neutropenia occurred in more treatment cycles with docetaxel (TC, 49%; TCF, 57%; ECF, 34%).	ORR was 25.0% (95% CI, 13% to 41%) for ECF, 18.5% (95% CI, 9% to 34%) for TC, and 36.6% (95% CI, 23% to 53%) for TCF (n = 119).
__label__noRel	Grade 3 or 4 neutropenia occurred in more treatment cycles with docetaxel (TC, 49%; TCF, 57%; ECF, 34%).	Median overall survival times were 8.3, 11.0, and 10.4 months for ECF, TC, and TCF, respectively.
__label__noRel	Grade 3 or 4 neutropenia occurred in more treatment cycles with docetaxel (TC, 49%; TCF, 57%; ECF, 34%).	Toxicity was acceptable, with one toxic death (TC arm).
__label__Support	Grade 3 or 4 neutropenia occurred in more treatment cycles with docetaxel (TC, 49%; TCF, 57%; ECF, 34%).	Global health status/QOL substantially improved with ECF and remained similar to baseline with both docetaxel regimens.
__label__noRel	Grade 3 or 4 neutropenia occurred in more treatment cycles with docetaxel (TC, 49%; TCF, 57%; ECF, 34%).	A trend towards increased myelosuppression and infectious complications with TCF versus TC or ECF was observed.
__label__noRel	Grade 3 or 4 neutropenia occurred in more treatment cycles with docetaxel (TC, 49%; TCF, 57%; ECF, 34%).	Time to response and ORR favor TCF over TC for further evaluation, particularly in the neoadjuvant setting.
__label__noRel	Global health status/QOL substantially improved with ECF and remained similar to baseline with both docetaxel regimens.	ORR was 25.0% (95% CI, 13% to 41%) for ECF, 18.5% (95% CI, 9% to 34%) for TC, and 36.6% (95% CI, 23% to 53%) for TCF (n = 119).
__label__noRel	Global health status/QOL substantially improved with ECF and remained similar to baseline with both docetaxel regimens.	Median overall survival times were 8.3, 11.0, and 10.4 months for ECF, TC, and TCF, respectively.
__label__noRel	Global health status/QOL substantially improved with ECF and remained similar to baseline with both docetaxel regimens.	Toxicity was acceptable, with one toxic death (TC arm).
__label__noRel	Global health status/QOL substantially improved with ECF and remained similar to baseline with both docetaxel regimens.	Grade 3 or 4 neutropenia occurred in more treatment cycles with docetaxel (TC, 49%; TCF, 57%; ECF, 34%).
__label__noRel	Global health status/QOL substantially improved with ECF and remained similar to baseline with both docetaxel regimens.	A trend towards increased myelosuppression and infectious complications with TCF versus TC or ECF was observed.
__label__noRel	Global health status/QOL substantially improved with ECF and remained similar to baseline with both docetaxel regimens.	Time to response and ORR favor TCF over TC for further evaluation, particularly in the neoadjuvant setting.
__label__noRel	A trend towards increased myelosuppression and infectious complications with TCF versus TC or ECF was observed.	ORR was 25.0% (95% CI, 13% to 41%) for ECF, 18.5% (95% CI, 9% to 34%) for TC, and 36.6% (95% CI, 23% to 53%) for TCF (n = 119).
__label__noRel	A trend towards increased myelosuppression and infectious complications with TCF versus TC or ECF was observed.	Median overall survival times were 8.3, 11.0, and 10.4 months for ECF, TC, and TCF, respectively.
__label__noRel	A trend towards increased myelosuppression and infectious complications with TCF versus TC or ECF was observed.	Toxicity was acceptable, with one toxic death (TC arm).
__label__noRel	A trend towards increased myelosuppression and infectious complications with TCF versus TC or ECF was observed.	Grade 3 or 4 neutropenia occurred in more treatment cycles with docetaxel (TC, 49%; TCF, 57%; ECF, 34%).
__label__noRel	A trend towards increased myelosuppression and infectious complications with TCF versus TC or ECF was observed.	Global health status/QOL substantially improved with ECF and remained similar to baseline with both docetaxel regimens.
__label__noRel	A trend towards increased myelosuppression and infectious complications with TCF versus TC or ECF was observed.	Time to response and ORR favor TCF over TC for further evaluation, particularly in the neoadjuvant setting.
__label__noRel	Time to response and ORR favor TCF over TC for further evaluation, particularly in the neoadjuvant setting.	ORR was 25.0% (95% CI, 13% to 41%) for ECF, 18.5% (95% CI, 9% to 34%) for TC, and 36.6% (95% CI, 23% to 53%) for TCF (n = 119).
__label__noRel	Time to response and ORR favor TCF over TC for further evaluation, particularly in the neoadjuvant setting.	Median overall survival times were 8.3, 11.0, and 10.4 months for ECF, TC, and TCF, respectively.
__label__noRel	Time to response and ORR favor TCF over TC for further evaluation, particularly in the neoadjuvant setting.	Toxicity was acceptable, with one toxic death (TC arm).
__label__noRel	Time to response and ORR favor TCF over TC for further evaluation, particularly in the neoadjuvant setting.	Grade 3 or 4 neutropenia occurred in more treatment cycles with docetaxel (TC, 49%; TCF, 57%; ECF, 34%).
__label__noRel	Time to response and ORR favor TCF over TC for further evaluation, particularly in the neoadjuvant setting.	Global health status/QOL substantially improved with ECF and remained similar to baseline with both docetaxel regimens.
__label__noRel	Time to response and ORR favor TCF over TC for further evaluation, particularly in the neoadjuvant setting.	A trend towards increased myelosuppression and infectious complications with TCF versus TC or ECF was observed.
__label__noRel	Intention-to-treat analysis based on participants with follow-up data indicated a significant difference in total exercise in favor of the recommendation-only group over the usual care group (mean difference, 3.4 MET hr per week; 95% confidence interval [CI], 0.7-6.1 MET hr per week; p = .011).	There was no significant difference between the recommendation-plus-referral group and the usual care group (mean difference, 1.5 MET hr per week; 95% CI, -1.0 to 4.0 MET hr per week; p = .244).
__label__noRel	Intention-to-treat analysis based on participants with follow-up data indicated a significant difference in total exercise in favor of the recommendation-only group over the usual care group (mean difference, 3.4 MET hr per week; 95% confidence interval [CI], 0.7-6.1 MET hr per week; p = .011).	Ancillary "on-treatment" analyzes showed that participants who recalled an exercise recommendation reported significantly more total exercise than participants who did not recall an exercise recommendation (mean difference, 4.1 MET hr per week: 95% CI, 1.9-6.4 MET hr per week; p < .001).
__label__Support	Intention-to-treat analysis based on participants with follow-up data indicated a significant difference in total exercise in favor of the recommendation-only group over the usual care group (mean difference, 3.4 MET hr per week; 95% confidence interval [CI], 0.7-6.1 MET hr per week; p = .011).	Our findings suggest that an oncologist recommendation may increase exercise behavior in newly diagnosed breast cancer survivors, particularly if it is recalled 1 week after the recommendation.
__label__noRel	There was no significant difference between the recommendation-plus-referral group and the usual care group (mean difference, 1.5 MET hr per week; 95% CI, -1.0 to 4.0 MET hr per week; p = .244).	Intention-to-treat analysis based on participants with follow-up data indicated a significant difference in total exercise in favor of the recommendation-only group over the usual care group (mean difference, 3.4 MET hr per week; 95% confidence interval [CI], 0.7-6.1 MET hr per week; p = .011).
__label__noRel	There was no significant difference between the recommendation-plus-referral group and the usual care group (mean difference, 1.5 MET hr per week; 95% CI, -1.0 to 4.0 MET hr per week; p = .244).	Ancillary "on-treatment" analyzes showed that participants who recalled an exercise recommendation reported significantly more total exercise than participants who did not recall an exercise recommendation (mean difference, 4.1 MET hr per week: 95% CI, 1.9-6.4 MET hr per week; p < .001).
__label__Attack	There was no significant difference between the recommendation-plus-referral group and the usual care group (mean difference, 1.5 MET hr per week; 95% CI, -1.0 to 4.0 MET hr per week; p = .244).	Our findings suggest that an oncologist recommendation may increase exercise behavior in newly diagnosed breast cancer survivors, particularly if it is recalled 1 week after the recommendation.
__label__noRel	Ancillary "on-treatment" analyzes showed that participants who recalled an exercise recommendation reported significantly more total exercise than participants who did not recall an exercise recommendation (mean difference, 4.1 MET hr per week: 95% CI, 1.9-6.4 MET hr per week; p < .001).	Intention-to-treat analysis based on participants with follow-up data indicated a significant difference in total exercise in favor of the recommendation-only group over the usual care group (mean difference, 3.4 MET hr per week; 95% confidence interval [CI], 0.7-6.1 MET hr per week; p = .011).
__label__noRel	Ancillary "on-treatment" analyzes showed that participants who recalled an exercise recommendation reported significantly more total exercise than participants who did not recall an exercise recommendation (mean difference, 4.1 MET hr per week: 95% CI, 1.9-6.4 MET hr per week; p < .001).	There was no significant difference between the recommendation-plus-referral group and the usual care group (mean difference, 1.5 MET hr per week; 95% CI, -1.0 to 4.0 MET hr per week; p = .244).
__label__Support	Ancillary "on-treatment" analyzes showed that participants who recalled an exercise recommendation reported significantly more total exercise than participants who did not recall an exercise recommendation (mean difference, 4.1 MET hr per week: 95% CI, 1.9-6.4 MET hr per week; p < .001).	Our findings suggest that an oncologist recommendation may increase exercise behavior in newly diagnosed breast cancer survivors, particularly if it is recalled 1 week after the recommendation.
__label__noRel	Our findings suggest that an oncologist recommendation may increase exercise behavior in newly diagnosed breast cancer survivors, particularly if it is recalled 1 week after the recommendation.	Intention-to-treat analysis based on participants with follow-up data indicated a significant difference in total exercise in favor of the recommendation-only group over the usual care group (mean difference, 3.4 MET hr per week; 95% confidence interval [CI], 0.7-6.1 MET hr per week; p = .011).
__label__noRel	Our findings suggest that an oncologist recommendation may increase exercise behavior in newly diagnosed breast cancer survivors, particularly if it is recalled 1 week after the recommendation.	There was no significant difference between the recommendation-plus-referral group and the usual care group (mean difference, 1.5 MET hr per week; 95% CI, -1.0 to 4.0 MET hr per week; p = .244).
__label__noRel	Our findings suggest that an oncologist recommendation may increase exercise behavior in newly diagnosed breast cancer survivors, particularly if it is recalled 1 week after the recommendation.	Ancillary "on-treatment" analyzes showed that participants who recalled an exercise recommendation reported significantly more total exercise than participants who did not recall an exercise recommendation (mean difference, 4.1 MET hr per week: 95% CI, 1.9-6.4 MET hr per week; p < .001).
__label__noRel	Amitriptyline is the most common analgesic adjuvant used in cancer patients with neuropathic pain,	no specific studies have demonstrated a benefit.
__label__noRel	Amitriptyline is the most common analgesic adjuvant used in cancer patients with neuropathic pain,	No significant benefits in analgesia were found in the global pain intensity of the previous week of treatment, the least pain intensity or the pain evaluated just after a week of treatment, at the moment of the visit, when amitriptyline was compared with placebo.
__label__noRel	Amitriptyline is the most common analgesic adjuvant used in cancer patients with neuropathic pain,	A significant difference was evidenced for the worst pain (P < 0.035).
__label__noRel	Amitriptyline is the most common analgesic adjuvant used in cancer patients with neuropathic pain,	No differences in opioid doses during the period of study were found.
__label__noRel	Amitriptyline is the most common analgesic adjuvant used in cancer patients with neuropathic pain,	Drowsiness, confusion and dry mouth were significantly more intense with amitriptyline than with placebo (P < 0.036, 0.003, and 0.034, respectively).
__label__noRel	Amitriptyline is the most common analgesic adjuvant used in cancer patients with neuropathic pain,	There were no substantial differences between the two treatments in Spitzer's quality of life score and for each item.
__label__noRel	Amitriptyline is the most common analgesic adjuvant used in cancer patients with neuropathic pain,	No differences in patients' preference for the two treatment periods were found.
__label__noRel	Amitriptyline is the most common analgesic adjuvant used in cancer patients with neuropathic pain,	The analgesic effects of amitriptyline were slight and associated with adverse effects.
__label__noRel	Amitriptyline is the most common analgesic adjuvant used in cancer patients with neuropathic pain,	the extensive use of the drug for cancer pain should be questioned.
__label__noRel	no specific studies have demonstrated a benefit.	Amitriptyline is the most common analgesic adjuvant used in cancer patients with neuropathic pain,
__label__noRel	no specific studies have demonstrated a benefit.	No significant benefits in analgesia were found in the global pain intensity of the previous week of treatment, the least pain intensity or the pain evaluated just after a week of treatment, at the moment of the visit, when amitriptyline was compared with placebo.
__label__noRel	no specific studies have demonstrated a benefit.	A significant difference was evidenced for the worst pain (P < 0.035).
__label__noRel	no specific studies have demonstrated a benefit.	No differences in opioid doses during the period of study were found.
__label__noRel	no specific studies have demonstrated a benefit.	Drowsiness, confusion and dry mouth were significantly more intense with amitriptyline than with placebo (P < 0.036, 0.003, and 0.034, respectively).
__label__noRel	no specific studies have demonstrated a benefit.	There were no substantial differences between the two treatments in Spitzer's quality of life score and for each item.
__label__noRel	no specific studies have demonstrated a benefit.	No differences in patients' preference for the two treatment periods were found.
__label__noRel	no specific studies have demonstrated a benefit.	The analgesic effects of amitriptyline were slight and associated with adverse effects.
__label__noRel	no specific studies have demonstrated a benefit.	the extensive use of the drug for cancer pain should be questioned.
__label__noRel	No significant benefits in analgesia were found in the global pain intensity of the previous week of treatment, the least pain intensity or the pain evaluated just after a week of treatment, at the moment of the visit, when amitriptyline was compared with placebo.	Amitriptyline is the most common analgesic adjuvant used in cancer patients with neuropathic pain,
__label__noRel	No significant benefits in analgesia were found in the global pain intensity of the previous week of treatment, the least pain intensity or the pain evaluated just after a week of treatment, at the moment of the visit, when amitriptyline was compared with placebo.	no specific studies have demonstrated a benefit.
__label__noRel	No significant benefits in analgesia were found in the global pain intensity of the previous week of treatment, the least pain intensity or the pain evaluated just after a week of treatment, at the moment of the visit, when amitriptyline was compared with placebo.	A significant difference was evidenced for the worst pain (P < 0.035).
__label__noRel	No significant benefits in analgesia were found in the global pain intensity of the previous week of treatment, the least pain intensity or the pain evaluated just after a week of treatment, at the moment of the visit, when amitriptyline was compared with placebo.	No differences in opioid doses during the period of study were found.
__label__noRel	No significant benefits in analgesia were found in the global pain intensity of the previous week of treatment, the least pain intensity or the pain evaluated just after a week of treatment, at the moment of the visit, when amitriptyline was compared with placebo.	Drowsiness, confusion and dry mouth were significantly more intense with amitriptyline than with placebo (P < 0.036, 0.003, and 0.034, respectively).
__label__noRel	No significant benefits in analgesia were found in the global pain intensity of the previous week of treatment, the least pain intensity or the pain evaluated just after a week of treatment, at the moment of the visit, when amitriptyline was compared with placebo.	There were no substantial differences between the two treatments in Spitzer's quality of life score and for each item.
__label__noRel	No significant benefits in analgesia were found in the global pain intensity of the previous week of treatment, the least pain intensity or the pain evaluated just after a week of treatment, at the moment of the visit, when amitriptyline was compared with placebo.	No differences in patients' preference for the two treatment periods were found.
__label__Support	No significant benefits in analgesia were found in the global pain intensity of the previous week of treatment, the least pain intensity or the pain evaluated just after a week of treatment, at the moment of the visit, when amitriptyline was compared with placebo.	The analgesic effects of amitriptyline were slight and associated with adverse effects.
__label__noRel	No significant benefits in analgesia were found in the global pain intensity of the previous week of treatment, the least pain intensity or the pain evaluated just after a week of treatment, at the moment of the visit, when amitriptyline was compared with placebo.	the extensive use of the drug for cancer pain should be questioned.
__label__noRel	A significant difference was evidenced for the worst pain (P < 0.035).	Amitriptyline is the most common analgesic adjuvant used in cancer patients with neuropathic pain,
__label__noRel	A significant difference was evidenced for the worst pain (P < 0.035).	no specific studies have demonstrated a benefit.
__label__noRel	A significant difference was evidenced for the worst pain (P < 0.035).	No significant benefits in analgesia were found in the global pain intensity of the previous week of treatment, the least pain intensity or the pain evaluated just after a week of treatment, at the moment of the visit, when amitriptyline was compared with placebo.
__label__noRel	A significant difference was evidenced for the worst pain (P < 0.035).	No differences in opioid doses during the period of study were found.
__label__noRel	A significant difference was evidenced for the worst pain (P < 0.035).	Drowsiness, confusion and dry mouth were significantly more intense with amitriptyline than with placebo (P < 0.036, 0.003, and 0.034, respectively).
__label__noRel	A significant difference was evidenced for the worst pain (P < 0.035).	There were no substantial differences between the two treatments in Spitzer's quality of life score and for each item.
__label__noRel	A significant difference was evidenced for the worst pain (P < 0.035).	No differences in patients' preference for the two treatment periods were found.
__label__Support	A significant difference was evidenced for the worst pain (P < 0.035).	The analgesic effects of amitriptyline were slight and associated with adverse effects.
__label__noRel	A significant difference was evidenced for the worst pain (P < 0.035).	the extensive use of the drug for cancer pain should be questioned.
__label__noRel	No differences in opioid doses during the period of study were found.	Amitriptyline is the most common analgesic adjuvant used in cancer patients with neuropathic pain,
__label__noRel	No differences in opioid doses during the period of study were found.	no specific studies have demonstrated a benefit.
__label__noRel	No differences in opioid doses during the period of study were found.	No significant benefits in analgesia were found in the global pain intensity of the previous week of treatment, the least pain intensity or the pain evaluated just after a week of treatment, at the moment of the visit, when amitriptyline was compared with placebo.
__label__noRel	No differences in opioid doses during the period of study were found.	A significant difference was evidenced for the worst pain (P < 0.035).
__label__noRel	No differences in opioid doses during the period of study were found.	Drowsiness, confusion and dry mouth were significantly more intense with amitriptyline than with placebo (P < 0.036, 0.003, and 0.034, respectively).
__label__noRel	No differences in opioid doses during the period of study were found.	There were no substantial differences between the two treatments in Spitzer's quality of life score and for each item.
__label__noRel	No differences in opioid doses during the period of study were found.	No differences in patients' preference for the two treatment periods were found.
__label__noRel	No differences in opioid doses during the period of study were found.	The analgesic effects of amitriptyline were slight and associated with adverse effects.
__label__Support	No differences in opioid doses during the period of study were found.	the extensive use of the drug for cancer pain should be questioned.
__label__noRel	Drowsiness, confusion and dry mouth were significantly more intense with amitriptyline than with placebo (P < 0.036, 0.003, and 0.034, respectively).	Amitriptyline is the most common analgesic adjuvant used in cancer patients with neuropathic pain,
__label__noRel	Drowsiness, confusion and dry mouth were significantly more intense with amitriptyline than with placebo (P < 0.036, 0.003, and 0.034, respectively).	no specific studies have demonstrated a benefit.
__label__noRel	Drowsiness, confusion and dry mouth were significantly more intense with amitriptyline than with placebo (P < 0.036, 0.003, and 0.034, respectively).	No significant benefits in analgesia were found in the global pain intensity of the previous week of treatment, the least pain intensity or the pain evaluated just after a week of treatment, at the moment of the visit, when amitriptyline was compared with placebo.
__label__noRel	Drowsiness, confusion and dry mouth were significantly more intense with amitriptyline than with placebo (P < 0.036, 0.003, and 0.034, respectively).	A significant difference was evidenced for the worst pain (P < 0.035).
__label__noRel	Drowsiness, confusion and dry mouth were significantly more intense with amitriptyline than with placebo (P < 0.036, 0.003, and 0.034, respectively).	No differences in opioid doses during the period of study were found.
__label__noRel	Drowsiness, confusion and dry mouth were significantly more intense with amitriptyline than with placebo (P < 0.036, 0.003, and 0.034, respectively).	There were no substantial differences between the two treatments in Spitzer's quality of life score and for each item.
__label__noRel	Drowsiness, confusion and dry mouth were significantly more intense with amitriptyline than with placebo (P < 0.036, 0.003, and 0.034, respectively).	No differences in patients' preference for the two treatment periods were found.
__label__Support	Drowsiness, confusion and dry mouth were significantly more intense with amitriptyline than with placebo (P < 0.036, 0.003, and 0.034, respectively).	The analgesic effects of amitriptyline were slight and associated with adverse effects.
__label__noRel	Drowsiness, confusion and dry mouth were significantly more intense with amitriptyline than with placebo (P < 0.036, 0.003, and 0.034, respectively).	the extensive use of the drug for cancer pain should be questioned.
__label__noRel	There were no substantial differences between the two treatments in Spitzer's quality of life score and for each item.	Amitriptyline is the most common analgesic adjuvant used in cancer patients with neuropathic pain,
__label__noRel	There were no substantial differences between the two treatments in Spitzer's quality of life score and for each item.	no specific studies have demonstrated a benefit.
__label__noRel	There were no substantial differences between the two treatments in Spitzer's quality of life score and for each item.	No significant benefits in analgesia were found in the global pain intensity of the previous week of treatment, the least pain intensity or the pain evaluated just after a week of treatment, at the moment of the visit, when amitriptyline was compared with placebo.
__label__noRel	There were no substantial differences between the two treatments in Spitzer's quality of life score and for each item.	A significant difference was evidenced for the worst pain (P < 0.035).
__label__noRel	There were no substantial differences between the two treatments in Spitzer's quality of life score and for each item.	No differences in opioid doses during the period of study were found.
__label__noRel	There were no substantial differences between the two treatments in Spitzer's quality of life score and for each item.	Drowsiness, confusion and dry mouth were significantly more intense with amitriptyline than with placebo (P < 0.036, 0.003, and 0.034, respectively).
__label__noRel	There were no substantial differences between the two treatments in Spitzer's quality of life score and for each item.	No differences in patients' preference for the two treatment periods were found.
__label__noRel	There were no substantial differences between the two treatments in Spitzer's quality of life score and for each item.	The analgesic effects of amitriptyline were slight and associated with adverse effects.
__label__Support	There were no substantial differences between the two treatments in Spitzer's quality of life score and for each item.	the extensive use of the drug for cancer pain should be questioned.
__label__noRel	No differences in patients' preference for the two treatment periods were found.	Amitriptyline is the most common analgesic adjuvant used in cancer patients with neuropathic pain,
__label__noRel	No differences in patients' preference for the two treatment periods were found.	no specific studies have demonstrated a benefit.
__label__noRel	No differences in patients' preference for the two treatment periods were found.	No significant benefits in analgesia were found in the global pain intensity of the previous week of treatment, the least pain intensity or the pain evaluated just after a week of treatment, at the moment of the visit, when amitriptyline was compared with placebo.
__label__noRel	No differences in patients' preference for the two treatment periods were found.	A significant difference was evidenced for the worst pain (P < 0.035).
__label__noRel	No differences in patients' preference for the two treatment periods were found.	No differences in opioid doses during the period of study were found.
__label__noRel	No differences in patients' preference for the two treatment periods were found.	Drowsiness, confusion and dry mouth were significantly more intense with amitriptyline than with placebo (P < 0.036, 0.003, and 0.034, respectively).
__label__noRel	No differences in patients' preference for the two treatment periods were found.	There were no substantial differences between the two treatments in Spitzer's quality of life score and for each item.
__label__noRel	No differences in patients' preference for the two treatment periods were found.	The analgesic effects of amitriptyline were slight and associated with adverse effects.
__label__noRel	No differences in patients' preference for the two treatment periods were found.	the extensive use of the drug for cancer pain should be questioned.
__label__noRel	The analgesic effects of amitriptyline were slight and associated with adverse effects.	Amitriptyline is the most common analgesic adjuvant used in cancer patients with neuropathic pain,
__label__noRel	The analgesic effects of amitriptyline were slight and associated with adverse effects.	no specific studies have demonstrated a benefit.
__label__noRel	The analgesic effects of amitriptyline were slight and associated with adverse effects.	No significant benefits in analgesia were found in the global pain intensity of the previous week of treatment, the least pain intensity or the pain evaluated just after a week of treatment, at the moment of the visit, when amitriptyline was compared with placebo.
__label__noRel	The analgesic effects of amitriptyline were slight and associated with adverse effects.	A significant difference was evidenced for the worst pain (P < 0.035).
__label__noRel	The analgesic effects of amitriptyline were slight and associated with adverse effects.	No differences in opioid doses during the period of study were found.
__label__noRel	The analgesic effects of amitriptyline were slight and associated with adverse effects.	Drowsiness, confusion and dry mouth were significantly more intense with amitriptyline than with placebo (P < 0.036, 0.003, and 0.034, respectively).
__label__noRel	The analgesic effects of amitriptyline were slight and associated with adverse effects.	There were no substantial differences between the two treatments in Spitzer's quality of life score and for each item.
__label__noRel	The analgesic effects of amitriptyline were slight and associated with adverse effects.	No differences in patients' preference for the two treatment periods were found.
__label__noRel	The analgesic effects of amitriptyline were slight and associated with adverse effects.	the extensive use of the drug for cancer pain should be questioned.
__label__noRel	the extensive use of the drug for cancer pain should be questioned.	Amitriptyline is the most common analgesic adjuvant used in cancer patients with neuropathic pain,
__label__noRel	the extensive use of the drug for cancer pain should be questioned.	no specific studies have demonstrated a benefit.
__label__noRel	the extensive use of the drug for cancer pain should be questioned.	No significant benefits in analgesia were found in the global pain intensity of the previous week of treatment, the least pain intensity or the pain evaluated just after a week of treatment, at the moment of the visit, when amitriptyline was compared with placebo.
__label__noRel	the extensive use of the drug for cancer pain should be questioned.	A significant difference was evidenced for the worst pain (P < 0.035).
__label__noRel	the extensive use of the drug for cancer pain should be questioned.	No differences in opioid doses during the period of study were found.
__label__noRel	the extensive use of the drug for cancer pain should be questioned.	Drowsiness, confusion and dry mouth were significantly more intense with amitriptyline than with placebo (P < 0.036, 0.003, and 0.034, respectively).
__label__noRel	the extensive use of the drug for cancer pain should be questioned.	There were no substantial differences between the two treatments in Spitzer's quality of life score and for each item.
__label__noRel	the extensive use of the drug for cancer pain should be questioned.	No differences in patients' preference for the two treatment periods were found.
__label__noRel	the extensive use of the drug for cancer pain should be questioned.	The analgesic effects of amitriptyline were slight and associated with adverse effects.
__label__noRel	Among the patients receiving treatment 3 times weekly, 16 of 49 patients (32.7%) achieved a clinical response at the end of the third treatment cycle (no CRs, 1 PR, and 15 SDs).	Concomitant or prior use of protease inhibitors did not appear to affect the patient's response to treatment (P = 0.183).
__label__noRel	Among the patients receiving treatment 3 times weekly, 16 of 49 patients (32.7%) achieved a clinical response at the end of the third treatment cycle (no CRs, 1 PR, and 15 SDs).	Liposomal tretinoin is a new therapeutic agent that has been reported to have some clinical activity in patients with AIDS-associated Kaposi sarcoma.
__label__Support	Among the patients receiving treatment 3 times weekly, 16 of 49 patients (32.7%) achieved a clinical response at the end of the third treatment cycle (no CRs, 1 PR, and 15 SDs).	A three-times-per-week dosing schedule was noted to be more effective compared with a once-a-week schedule without any significant difference in toxicity reported.
__label__noRel	Concomitant or prior use of protease inhibitors did not appear to affect the patient's response to treatment (P = 0.183).	Among the patients receiving treatment 3 times weekly, 16 of 49 patients (32.7%) achieved a clinical response at the end of the third treatment cycle (no CRs, 1 PR, and 15 SDs).
__label__noRel	Concomitant or prior use of protease inhibitors did not appear to affect the patient's response to treatment (P = 0.183).	Liposomal tretinoin is a new therapeutic agent that has been reported to have some clinical activity in patients with AIDS-associated Kaposi sarcoma.
__label__noRel	Concomitant or prior use of protease inhibitors did not appear to affect the patient's response to treatment (P = 0.183).	A three-times-per-week dosing schedule was noted to be more effective compared with a once-a-week schedule without any significant difference in toxicity reported.
__label__noRel	Liposomal tretinoin is a new therapeutic agent that has been reported to have some clinical activity in patients with AIDS-associated Kaposi sarcoma.	Among the patients receiving treatment 3 times weekly, 16 of 49 patients (32.7%) achieved a clinical response at the end of the third treatment cycle (no CRs, 1 PR, and 15 SDs).
__label__noRel	Liposomal tretinoin is a new therapeutic agent that has been reported to have some clinical activity in patients with AIDS-associated Kaposi sarcoma.	Concomitant or prior use of protease inhibitors did not appear to affect the patient's response to treatment (P = 0.183).
__label__noRel	Liposomal tretinoin is a new therapeutic agent that has been reported to have some clinical activity in patients with AIDS-associated Kaposi sarcoma.	A three-times-per-week dosing schedule was noted to be more effective compared with a once-a-week schedule without any significant difference in toxicity reported.
__label__noRel	A three-times-per-week dosing schedule was noted to be more effective compared with a once-a-week schedule without any significant difference in toxicity reported.	Among the patients receiving treatment 3 times weekly, 16 of 49 patients (32.7%) achieved a clinical response at the end of the third treatment cycle (no CRs, 1 PR, and 15 SDs).
__label__noRel	A three-times-per-week dosing schedule was noted to be more effective compared with a once-a-week schedule without any significant difference in toxicity reported.	Concomitant or prior use of protease inhibitors did not appear to affect the patient's response to treatment (P = 0.183).
__label__noRel	A three-times-per-week dosing schedule was noted to be more effective compared with a once-a-week schedule without any significant difference in toxicity reported.	Liposomal tretinoin is a new therapeutic agent that has been reported to have some clinical activity in patients with AIDS-associated Kaposi sarcoma.
__label__noRel	Anemia, highly common among cancer patients, is often an underlying cause of cancer-related fatigue and other quality-of-life (QOL) deficits.	Comparison of the population norm and clinical trial data showed that treatment with epoetin alfa resulted in clinically meaningful as well as statistically significant improvements in QOL (P <.01).
__label__noRel	Anemia, highly common among cancer patients, is often an underlying cause of cancer-related fatigue and other quality-of-life (QOL) deficits.	In the clinical trial, treatment with epoetin alfa overcame much of the QOL deficit seen in anemic cancer patients compared with the norm population sample.
__label__noRel	Comparison of the population norm and clinical trial data showed that treatment with epoetin alfa resulted in clinically meaningful as well as statistically significant improvements in QOL (P <.01).	Anemia, highly common among cancer patients, is often an underlying cause of cancer-related fatigue and other quality-of-life (QOL) deficits.
__label__Support	Comparison of the population norm and clinical trial data showed that treatment with epoetin alfa resulted in clinically meaningful as well as statistically significant improvements in QOL (P <.01).	In the clinical trial, treatment with epoetin alfa overcame much of the QOL deficit seen in anemic cancer patients compared with the norm population sample.
__label__noRel	In the clinical trial, treatment with epoetin alfa overcame much of the QOL deficit seen in anemic cancer patients compared with the norm population sample.	Anemia, highly common among cancer patients, is often an underlying cause of cancer-related fatigue and other quality-of-life (QOL) deficits.
__label__noRel	In the clinical trial, treatment with epoetin alfa overcame much of the QOL deficit seen in anemic cancer patients compared with the norm population sample.	Comparison of the population norm and clinical trial data showed that treatment with epoetin alfa resulted in clinically meaningful as well as statistically significant improvements in QOL (P <.01).
__label__noRel	Our findings suggest that, for most patients, this algorithm-based care can be given by a trained nurse.	Patients given targeted intervention following a detailed clinical algorithm had better improvements in radiotherapy-induced gastrointestinal symptoms than did patients given usual care.
__label__noRel	Our findings suggest that, for most patients, this algorithm-based care can be given by a trained nurse.	Outcomes in the nurse group were not inferior to outcomes in the gastroenterologist group (mean difference 136, one sided 95% CI -148).
__label__noRel	Our findings suggest that, for most patients, this algorithm-based care can be given by a trained nurse.	We recorded the following pair-wise mean difference in change in IBDQ-B score between groups: nurse versus booklet 412 (95% CI 004-819; p=004), gastroenterologist versus booklet 547 (114-981; p=001).
__label__noRel	Patients given targeted intervention following a detailed clinical algorithm had better improvements in radiotherapy-induced gastrointestinal symptoms than did patients given usual care.	Our findings suggest that, for most patients, this algorithm-based care can be given by a trained nurse.
__label__noRel	Patients given targeted intervention following a detailed clinical algorithm had better improvements in radiotherapy-induced gastrointestinal symptoms than did patients given usual care.	Outcomes in the nurse group were not inferior to outcomes in the gastroenterologist group (mean difference 136, one sided 95% CI -148).
__label__noRel	Patients given targeted intervention following a detailed clinical algorithm had better improvements in radiotherapy-induced gastrointestinal symptoms than did patients given usual care.	We recorded the following pair-wise mean difference in change in IBDQ-B score between groups: nurse versus booklet 412 (95% CI 004-819; p=004), gastroenterologist versus booklet 547 (114-981; p=001).
__label__Support	Outcomes in the nurse group were not inferior to outcomes in the gastroenterologist group (mean difference 136, one sided 95% CI -148).	Our findings suggest that, for most patients, this algorithm-based care can be given by a trained nurse.
__label__noRel	Outcomes in the nurse group were not inferior to outcomes in the gastroenterologist group (mean difference 136, one sided 95% CI -148).	Patients given targeted intervention following a detailed clinical algorithm had better improvements in radiotherapy-induced gastrointestinal symptoms than did patients given usual care.
__label__noRel	Outcomes in the nurse group were not inferior to outcomes in the gastroenterologist group (mean difference 136, one sided 95% CI -148).	We recorded the following pair-wise mean difference in change in IBDQ-B score between groups: nurse versus booklet 412 (95% CI 004-819; p=004), gastroenterologist versus booklet 547 (114-981; p=001).
__label__noRel	We recorded the following pair-wise mean difference in change in IBDQ-B score between groups: nurse versus booklet 412 (95% CI 004-819; p=004), gastroenterologist versus booklet 547 (114-981; p=001).	Our findings suggest that, for most patients, this algorithm-based care can be given by a trained nurse.
__label__Support	We recorded the following pair-wise mean difference in change in IBDQ-B score between groups: nurse versus booklet 412 (95% CI 004-819; p=004), gastroenterologist versus booklet 547 (114-981; p=001).	Patients given targeted intervention following a detailed clinical algorithm had better improvements in radiotherapy-induced gastrointestinal symptoms than did patients given usual care.
__label__noRel	We recorded the following pair-wise mean difference in change in IBDQ-B score between groups: nurse versus booklet 412 (95% CI 004-819; p=004), gastroenterologist versus booklet 547 (114-981; p=001).	Outcomes in the nurse group were not inferior to outcomes in the gastroenterologist group (mean difference 136, one sided 95% CI -148).
__label__noRel	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).
__label__noRel	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.	No acute Grade 4 radiation toxicity developed.
__label__noRel	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.	The incidences of long-term toxicity were equivalent across the arms.
__label__noRel	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).
__label__noRel	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.	Induction chemotherapy was completed in 78% of the patients.
__label__noRel	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.
__label__noRel	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.	Consolidation chemotherapy was completed in 75% of the patients.
__label__noRel	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.	No statistically significant difference was found among the treatment arms.
__label__noRel	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.
__label__noRel	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.	The median progression-free survival was 14 months.
__label__noRel	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.
__label__noRel	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.	The median survival in the patients receiving induction chemotherapy only was 8.9 months.
__label__noRel	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.	Mitomycin-C had no impact on survival (p = 0.75).
__label__noRel	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.
__label__noRel	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.	The patient accrual to this trial made its results inconclusive,
__label__noRel	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.
__label__noRel	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.	local control and survival were essentially equal between the surgical and RT arms.
__label__noRel	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.
__label__noRel	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.
__label__noRel	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).	No acute Grade 4 radiation toxicity developed.
__label__noRel	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).	The incidences of long-term toxicity were equivalent across the arms.
__label__noRel	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).
__label__noRel	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).	Induction chemotherapy was completed in 78% of the patients.
__label__noRel	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.
__label__noRel	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).	Consolidation chemotherapy was completed in 75% of the patients.
__label__noRel	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).	No statistically significant difference was found among the treatment arms.
__label__noRel	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.
__label__noRel	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).	The median progression-free survival was 14 months.
__label__noRel	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.
__label__noRel	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).	The median survival in the patients receiving induction chemotherapy only was 8.9 months.
__label__noRel	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).	Mitomycin-C had no impact on survival (p = 0.75).
__label__noRel	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.
__label__noRel	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).	The patient accrual to this trial made its results inconclusive,
__label__noRel	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.
__label__noRel	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).	local control and survival were essentially equal between the surgical and RT arms.
__label__noRel	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.
__label__noRel	No acute Grade 4 radiation toxicity developed.	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.
__label__noRel	No acute Grade 4 radiation toxicity developed.	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).
__label__noRel	No acute Grade 4 radiation toxicity developed.	The incidences of long-term toxicity were equivalent across the arms.
__label__noRel	No acute Grade 4 radiation toxicity developed.	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).
__label__noRel	No acute Grade 4 radiation toxicity developed.	Induction chemotherapy was completed in 78% of the patients.
__label__noRel	No acute Grade 4 radiation toxicity developed.	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.
__label__noRel	No acute Grade 4 radiation toxicity developed.	Consolidation chemotherapy was completed in 75% of the patients.
__label__noRel	No acute Grade 4 radiation toxicity developed.	No statistically significant difference was found among the treatment arms.
__label__noRel	No acute Grade 4 radiation toxicity developed.	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.
__label__noRel	No acute Grade 4 radiation toxicity developed.	The median progression-free survival was 14 months.
__label__noRel	No acute Grade 4 radiation toxicity developed.	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.
__label__noRel	No acute Grade 4 radiation toxicity developed.	The median survival in the patients receiving induction chemotherapy only was 8.9 months.
__label__noRel	No acute Grade 4 radiation toxicity developed.	Mitomycin-C had no impact on survival (p = 0.75).
__label__noRel	No acute Grade 4 radiation toxicity developed.	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.
__label__noRel	No acute Grade 4 radiation toxicity developed.	The patient accrual to this trial made its results inconclusive,
__label__noRel	No acute Grade 4 radiation toxicity developed.	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.
__label__noRel	No acute Grade 4 radiation toxicity developed.	local control and survival were essentially equal between the surgical and RT arms.
__label__noRel	No acute Grade 4 radiation toxicity developed.	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.
__label__noRel	The incidences of long-term toxicity were equivalent across the arms.	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.
__label__noRel	The incidences of long-term toxicity were equivalent across the arms.	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).
__label__noRel	The incidences of long-term toxicity were equivalent across the arms.	No acute Grade 4 radiation toxicity developed.
__label__noRel	The incidences of long-term toxicity were equivalent across the arms.	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).
__label__noRel	The incidences of long-term toxicity were equivalent across the arms.	Induction chemotherapy was completed in 78% of the patients.
__label__noRel	The incidences of long-term toxicity were equivalent across the arms.	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.
__label__noRel	The incidences of long-term toxicity were equivalent across the arms.	Consolidation chemotherapy was completed in 75% of the patients.
__label__noRel	The incidences of long-term toxicity were equivalent across the arms.	No statistically significant difference was found among the treatment arms.
__label__noRel	The incidences of long-term toxicity were equivalent across the arms.	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.
__label__noRel	The incidences of long-term toxicity were equivalent across the arms.	The median progression-free survival was 14 months.
__label__noRel	The incidences of long-term toxicity were equivalent across the arms.	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.
__label__noRel	The incidences of long-term toxicity were equivalent across the arms.	The median survival in the patients receiving induction chemotherapy only was 8.9 months.
__label__noRel	The incidences of long-term toxicity were equivalent across the arms.	Mitomycin-C had no impact on survival (p = 0.75).
__label__noRel	The incidences of long-term toxicity were equivalent across the arms.	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.
__label__noRel	The incidences of long-term toxicity were equivalent across the arms.	The patient accrual to this trial made its results inconclusive,
__label__noRel	The incidences of long-term toxicity were equivalent across the arms.	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.
__label__noRel	The incidences of long-term toxicity were equivalent across the arms.	local control and survival were essentially equal between the surgical and RT arms.
__label__noRel	The incidences of long-term toxicity were equivalent across the arms.	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.
__label__noRel	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.
__label__noRel	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).
__label__noRel	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).	No acute Grade 4 radiation toxicity developed.
__label__noRel	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).	The incidences of long-term toxicity were equivalent across the arms.
__label__noRel	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).	Induction chemotherapy was completed in 78% of the patients.
__label__noRel	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.
__label__noRel	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).	Consolidation chemotherapy was completed in 75% of the patients.
__label__noRel	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).	No statistically significant difference was found among the treatment arms.
__label__noRel	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.
__label__noRel	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).	The median progression-free survival was 14 months.
__label__noRel	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.
__label__noRel	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).	The median survival in the patients receiving induction chemotherapy only was 8.9 months.
__label__noRel	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).	Mitomycin-C had no impact on survival (p = 0.75).
__label__noRel	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.
__label__noRel	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).	The patient accrual to this trial made its results inconclusive,
__label__noRel	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.
__label__noRel	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).	local control and survival were essentially equal between the surgical and RT arms.
__label__noRel	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.
__label__noRel	Induction chemotherapy was completed in 78% of the patients.	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.
__label__noRel	Induction chemotherapy was completed in 78% of the patients.	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).
__label__noRel	Induction chemotherapy was completed in 78% of the patients.	No acute Grade 4 radiation toxicity developed.
__label__noRel	Induction chemotherapy was completed in 78% of the patients.	The incidences of long-term toxicity were equivalent across the arms.
__label__noRel	Induction chemotherapy was completed in 78% of the patients.	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).
__label__noRel	Induction chemotherapy was completed in 78% of the patients.	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.
__label__noRel	Induction chemotherapy was completed in 78% of the patients.	Consolidation chemotherapy was completed in 75% of the patients.
__label__noRel	Induction chemotherapy was completed in 78% of the patients.	No statistically significant difference was found among the treatment arms.
__label__noRel	Induction chemotherapy was completed in 78% of the patients.	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.
__label__noRel	Induction chemotherapy was completed in 78% of the patients.	The median progression-free survival was 14 months.
__label__noRel	Induction chemotherapy was completed in 78% of the patients.	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.
__label__noRel	Induction chemotherapy was completed in 78% of the patients.	The median survival in the patients receiving induction chemotherapy only was 8.9 months.
__label__noRel	Induction chemotherapy was completed in 78% of the patients.	Mitomycin-C had no impact on survival (p = 0.75).
__label__noRel	Induction chemotherapy was completed in 78% of the patients.	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.
__label__noRel	Induction chemotherapy was completed in 78% of the patients.	The patient accrual to this trial made its results inconclusive,
__label__noRel	Induction chemotherapy was completed in 78% of the patients.	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.
__label__noRel	Induction chemotherapy was completed in 78% of the patients.	local control and survival were essentially equal between the surgical and RT arms.
__label__noRel	Induction chemotherapy was completed in 78% of the patients.	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.
__label__noRel	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.
__label__noRel	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).
__label__noRel	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.	No acute Grade 4 radiation toxicity developed.
__label__noRel	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.	The incidences of long-term toxicity were equivalent across the arms.
__label__noRel	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).
__label__noRel	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.	Induction chemotherapy was completed in 78% of the patients.
__label__noRel	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.	Consolidation chemotherapy was completed in 75% of the patients.
__label__noRel	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.	No statistically significant difference was found among the treatment arms.
__label__noRel	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.
__label__noRel	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.	The median progression-free survival was 14 months.
__label__noRel	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.
__label__noRel	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.	The median survival in the patients receiving induction chemotherapy only was 8.9 months.
__label__noRel	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.	Mitomycin-C had no impact on survival (p = 0.75).
__label__noRel	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.
__label__noRel	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.	The patient accrual to this trial made its results inconclusive,
__label__noRel	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.
__label__noRel	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.	local control and survival were essentially equal between the surgical and RT arms.
__label__noRel	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.
__label__noRel	Consolidation chemotherapy was completed in 75% of the patients.	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.
__label__noRel	Consolidation chemotherapy was completed in 75% of the patients.	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).
__label__noRel	Consolidation chemotherapy was completed in 75% of the patients.	No acute Grade 4 radiation toxicity developed.
__label__noRel	Consolidation chemotherapy was completed in 75% of the patients.	The incidences of long-term toxicity were equivalent across the arms.
__label__noRel	Consolidation chemotherapy was completed in 75% of the patients.	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).
__label__noRel	Consolidation chemotherapy was completed in 75% of the patients.	Induction chemotherapy was completed in 78% of the patients.
__label__noRel	Consolidation chemotherapy was completed in 75% of the patients.	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.
__label__noRel	Consolidation chemotherapy was completed in 75% of the patients.	No statistically significant difference was found among the treatment arms.
__label__noRel	Consolidation chemotherapy was completed in 75% of the patients.	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.
__label__noRel	Consolidation chemotherapy was completed in 75% of the patients.	The median progression-free survival was 14 months.
__label__noRel	Consolidation chemotherapy was completed in 75% of the patients.	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.
__label__noRel	Consolidation chemotherapy was completed in 75% of the patients.	The median survival in the patients receiving induction chemotherapy only was 8.9 months.
__label__noRel	Consolidation chemotherapy was completed in 75% of the patients.	Mitomycin-C had no impact on survival (p = 0.75).
__label__noRel	Consolidation chemotherapy was completed in 75% of the patients.	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.
__label__noRel	Consolidation chemotherapy was completed in 75% of the patients.	The patient accrual to this trial made its results inconclusive,
__label__noRel	Consolidation chemotherapy was completed in 75% of the patients.	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.
__label__noRel	Consolidation chemotherapy was completed in 75% of the patients.	local control and survival were essentially equal between the surgical and RT arms.
__label__noRel	Consolidation chemotherapy was completed in 75% of the patients.	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.
__label__noRel	No statistically significant difference was found among the treatment arms.	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.
__label__noRel	No statistically significant difference was found among the treatment arms.	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).
__label__noRel	No statistically significant difference was found among the treatment arms.	No acute Grade 4 radiation toxicity developed.
__label__noRel	No statistically significant difference was found among the treatment arms.	The incidences of long-term toxicity were equivalent across the arms.
__label__noRel	No statistically significant difference was found among the treatment arms.	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).
__label__noRel	No statistically significant difference was found among the treatment arms.	Induction chemotherapy was completed in 78% of the patients.
__label__noRel	No statistically significant difference was found among the treatment arms.	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.
__label__noRel	No statistically significant difference was found among the treatment arms.	Consolidation chemotherapy was completed in 75% of the patients.
__label__noRel	No statistically significant difference was found among the treatment arms.	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.
__label__noRel	No statistically significant difference was found among the treatment arms.	The median progression-free survival was 14 months.
__label__noRel	No statistically significant difference was found among the treatment arms.	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.
__label__noRel	No statistically significant difference was found among the treatment arms.	The median survival in the patients receiving induction chemotherapy only was 8.9 months.
__label__noRel	No statistically significant difference was found among the treatment arms.	Mitomycin-C had no impact on survival (p = 0.75).
__label__noRel	No statistically significant difference was found among the treatment arms.	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.
__label__noRel	No statistically significant difference was found among the treatment arms.	The patient accrual to this trial made its results inconclusive,
__label__noRel	No statistically significant difference was found among the treatment arms.	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.
__label__Support	No statistically significant difference was found among the treatment arms.	local control and survival were essentially equal between the surgical and RT arms.
__label__noRel	No statistically significant difference was found among the treatment arms.	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.
__label__noRel	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.
__label__noRel	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).
__label__noRel	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.	No acute Grade 4 radiation toxicity developed.
__label__noRel	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.	The incidences of long-term toxicity were equivalent across the arms.
__label__noRel	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).
__label__noRel	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.	Induction chemotherapy was completed in 78% of the patients.
__label__noRel	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.
__label__noRel	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.	Consolidation chemotherapy was completed in 75% of the patients.
__label__noRel	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.	No statistically significant difference was found among the treatment arms.
__label__noRel	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.	The median progression-free survival was 14 months.
__label__noRel	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.
__label__noRel	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.	The median survival in the patients receiving induction chemotherapy only was 8.9 months.
__label__noRel	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.	Mitomycin-C had no impact on survival (p = 0.75).
__label__noRel	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.
__label__noRel	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.	The patient accrual to this trial made its results inconclusive,
__label__noRel	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.
__label__noRel	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.	local control and survival were essentially equal between the surgical and RT arms.
__label__noRel	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.
__label__noRel	The median progression-free survival was 14 months.	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.
__label__noRel	The median progression-free survival was 14 months.	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).
__label__noRel	The median progression-free survival was 14 months.	No acute Grade 4 radiation toxicity developed.
__label__noRel	The median progression-free survival was 14 months.	The incidences of long-term toxicity were equivalent across the arms.
__label__noRel	The median progression-free survival was 14 months.	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).
__label__noRel	The median progression-free survival was 14 months.	Induction chemotherapy was completed in 78% of the patients.
__label__noRel	The median progression-free survival was 14 months.	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.
__label__noRel	The median progression-free survival was 14 months.	Consolidation chemotherapy was completed in 75% of the patients.
__label__noRel	The median progression-free survival was 14 months.	No statistically significant difference was found among the treatment arms.
__label__noRel	The median progression-free survival was 14 months.	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.
__label__noRel	The median progression-free survival was 14 months.	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.
__label__noRel	The median progression-free survival was 14 months.	The median survival in the patients receiving induction chemotherapy only was 8.9 months.
__label__noRel	The median progression-free survival was 14 months.	Mitomycin-C had no impact on survival (p = 0.75).
__label__noRel	The median progression-free survival was 14 months.	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.
__label__noRel	The median progression-free survival was 14 months.	The patient accrual to this trial made its results inconclusive,
__label__noRel	The median progression-free survival was 14 months.	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.
__label__Support	The median progression-free survival was 14 months.	local control and survival were essentially equal between the surgical and RT arms.
__label__noRel	The median progression-free survival was 14 months.	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.
__label__noRel	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.
__label__noRel	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).
__label__noRel	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.	No acute Grade 4 radiation toxicity developed.
__label__noRel	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.	The incidences of long-term toxicity were equivalent across the arms.
__label__noRel	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).
__label__noRel	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.	Induction chemotherapy was completed in 78% of the patients.
__label__noRel	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.
__label__noRel	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.	Consolidation chemotherapy was completed in 75% of the patients.
__label__noRel	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.	No statistically significant difference was found among the treatment arms.
__label__noRel	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.
__label__noRel	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.	The median progression-free survival was 14 months.
__label__noRel	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.	The median survival in the patients receiving induction chemotherapy only was 8.9 months.
__label__noRel	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.	Mitomycin-C had no impact on survival (p = 0.75).
__label__noRel	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.
__label__noRel	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.	The patient accrual to this trial made its results inconclusive,
__label__noRel	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.
__label__Support	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.	local control and survival were essentially equal between the surgical and RT arms.
__label__noRel	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.
__label__noRel	The median survival in the patients receiving induction chemotherapy only was 8.9 months.	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.
__label__noRel	The median survival in the patients receiving induction chemotherapy only was 8.9 months.	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).
__label__noRel	The median survival in the patients receiving induction chemotherapy only was 8.9 months.	No acute Grade 4 radiation toxicity developed.
__label__noRel	The median survival in the patients receiving induction chemotherapy only was 8.9 months.	The incidences of long-term toxicity were equivalent across the arms.
__label__noRel	The median survival in the patients receiving induction chemotherapy only was 8.9 months.	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).
__label__noRel	The median survival in the patients receiving induction chemotherapy only was 8.9 months.	Induction chemotherapy was completed in 78% of the patients.
__label__noRel	The median survival in the patients receiving induction chemotherapy only was 8.9 months.	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.
__label__noRel	The median survival in the patients receiving induction chemotherapy only was 8.9 months.	Consolidation chemotherapy was completed in 75% of the patients.
__label__noRel	The median survival in the patients receiving induction chemotherapy only was 8.9 months.	No statistically significant difference was found among the treatment arms.
__label__noRel	The median survival in the patients receiving induction chemotherapy only was 8.9 months.	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.
__label__noRel	The median survival in the patients receiving induction chemotherapy only was 8.9 months.	The median progression-free survival was 14 months.
__label__noRel	The median survival in the patients receiving induction chemotherapy only was 8.9 months.	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.
__label__noRel	The median survival in the patients receiving induction chemotherapy only was 8.9 months.	Mitomycin-C had no impact on survival (p = 0.75).
__label__noRel	The median survival in the patients receiving induction chemotherapy only was 8.9 months.	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.
__label__noRel	The median survival in the patients receiving induction chemotherapy only was 8.9 months.	The patient accrual to this trial made its results inconclusive,
__label__noRel	The median survival in the patients receiving induction chemotherapy only was 8.9 months.	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.
__label__Support	The median survival in the patients receiving induction chemotherapy only was 8.9 months.	local control and survival were essentially equal between the surgical and RT arms.
__label__noRel	The median survival in the patients receiving induction chemotherapy only was 8.9 months.	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.
__label__noRel	Mitomycin-C had no impact on survival (p = 0.75).	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.
__label__noRel	Mitomycin-C had no impact on survival (p = 0.75).	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).
__label__noRel	Mitomycin-C had no impact on survival (p = 0.75).	No acute Grade 4 radiation toxicity developed.
__label__noRel	Mitomycin-C had no impact on survival (p = 0.75).	The incidences of long-term toxicity were equivalent across the arms.
__label__noRel	Mitomycin-C had no impact on survival (p = 0.75).	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).
__label__noRel	Mitomycin-C had no impact on survival (p = 0.75).	Induction chemotherapy was completed in 78% of the patients.
__label__noRel	Mitomycin-C had no impact on survival (p = 0.75).	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.
__label__noRel	Mitomycin-C had no impact on survival (p = 0.75).	Consolidation chemotherapy was completed in 75% of the patients.
__label__noRel	Mitomycin-C had no impact on survival (p = 0.75).	No statistically significant difference was found among the treatment arms.
__label__noRel	Mitomycin-C had no impact on survival (p = 0.75).	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.
__label__noRel	Mitomycin-C had no impact on survival (p = 0.75).	The median progression-free survival was 14 months.
__label__noRel	Mitomycin-C had no impact on survival (p = 0.75).	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.
__label__noRel	Mitomycin-C had no impact on survival (p = 0.75).	The median survival in the patients receiving induction chemotherapy only was 8.9 months.
__label__noRel	Mitomycin-C had no impact on survival (p = 0.75).	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.
__label__noRel	Mitomycin-C had no impact on survival (p = 0.75).	The patient accrual to this trial made its results inconclusive,
__label__noRel	Mitomycin-C had no impact on survival (p = 0.75).	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.
__label__noRel	Mitomycin-C had no impact on survival (p = 0.75).	local control and survival were essentially equal between the surgical and RT arms.
__label__noRel	Mitomycin-C had no impact on survival (p = 0.75).	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.
__label__noRel	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.
__label__noRel	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).
__label__noRel	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.	No acute Grade 4 radiation toxicity developed.
__label__noRel	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.	The incidences of long-term toxicity were equivalent across the arms.
__label__noRel	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).
__label__noRel	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.	Induction chemotherapy was completed in 78% of the patients.
__label__noRel	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.
__label__noRel	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.	Consolidation chemotherapy was completed in 75% of the patients.
__label__noRel	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.	No statistically significant difference was found among the treatment arms.
__label__noRel	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.
__label__noRel	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.	The median progression-free survival was 14 months.
__label__noRel	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.
__label__noRel	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.	The median survival in the patients receiving induction chemotherapy only was 8.9 months.
__label__noRel	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.	Mitomycin-C had no impact on survival (p = 0.75).
__label__noRel	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.	The patient accrual to this trial made its results inconclusive,
__label__noRel	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.
__label__noRel	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.	local control and survival were essentially equal between the surgical and RT arms.
__label__Support	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.
__label__noRel	The patient accrual to this trial made its results inconclusive,	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.
__label__noRel	The patient accrual to this trial made its results inconclusive,	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).
__label__noRel	The patient accrual to this trial made its results inconclusive,	No acute Grade 4 radiation toxicity developed.
__label__noRel	The patient accrual to this trial made its results inconclusive,	The incidences of long-term toxicity were equivalent across the arms.
__label__noRel	The patient accrual to this trial made its results inconclusive,	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).
__label__noRel	The patient accrual to this trial made its results inconclusive,	Induction chemotherapy was completed in 78% of the patients.
__label__noRel	The patient accrual to this trial made its results inconclusive,	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.
__label__noRel	The patient accrual to this trial made its results inconclusive,	Consolidation chemotherapy was completed in 75% of the patients.
__label__noRel	The patient accrual to this trial made its results inconclusive,	No statistically significant difference was found among the treatment arms.
__label__noRel	The patient accrual to this trial made its results inconclusive,	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.
__label__noRel	The patient accrual to this trial made its results inconclusive,	The median progression-free survival was 14 months.
__label__noRel	The patient accrual to this trial made its results inconclusive,	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.
__label__noRel	The patient accrual to this trial made its results inconclusive,	The median survival in the patients receiving induction chemotherapy only was 8.9 months.
__label__noRel	The patient accrual to this trial made its results inconclusive,	Mitomycin-C had no impact on survival (p = 0.75).
__label__noRel	The patient accrual to this trial made its results inconclusive,	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.
__label__noRel	The patient accrual to this trial made its results inconclusive,	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.
__label__Attack	The patient accrual to this trial made its results inconclusive,	local control and survival were essentially equal between the surgical and RT arms.
__label__noRel	The patient accrual to this trial made its results inconclusive,	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.
__label__noRel	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.
__label__noRel	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).
__label__noRel	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.	No acute Grade 4 radiation toxicity developed.
__label__noRel	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.	The incidences of long-term toxicity were equivalent across the arms.
__label__noRel	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).
__label__noRel	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.	Induction chemotherapy was completed in 78% of the patients.
__label__noRel	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.
__label__noRel	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.	Consolidation chemotherapy was completed in 75% of the patients.
__label__noRel	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.	No statistically significant difference was found among the treatment arms.
__label__noRel	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.
__label__noRel	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.	The median progression-free survival was 14 months.
__label__noRel	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.
__label__noRel	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.	The median survival in the patients receiving induction chemotherapy only was 8.9 months.
__label__noRel	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.	Mitomycin-C had no impact on survival (p = 0.75).
__label__noRel	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.
__label__noRel	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.	The patient accrual to this trial made its results inconclusive,
__label__noRel	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.	local control and survival were essentially equal between the surgical and RT arms.
__label__noRel	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.
__label__noRel	local control and survival were essentially equal between the surgical and RT arms.	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.
__label__noRel	local control and survival were essentially equal between the surgical and RT arms.	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).
__label__noRel	local control and survival were essentially equal between the surgical and RT arms.	No acute Grade 4 radiation toxicity developed.
__label__noRel	local control and survival were essentially equal between the surgical and RT arms.	The incidences of long-term toxicity were equivalent across the arms.
__label__noRel	local control and survival were essentially equal between the surgical and RT arms.	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).
__label__noRel	local control and survival were essentially equal between the surgical and RT arms.	Induction chemotherapy was completed in 78% of the patients.
__label__noRel	local control and survival were essentially equal between the surgical and RT arms.	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.
__label__noRel	local control and survival were essentially equal between the surgical and RT arms.	Consolidation chemotherapy was completed in 75% of the patients.
__label__noRel	local control and survival were essentially equal between the surgical and RT arms.	No statistically significant difference was found among the treatment arms.
__label__noRel	local control and survival were essentially equal between the surgical and RT arms.	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.
__label__noRel	local control and survival were essentially equal between the surgical and RT arms.	The median progression-free survival was 14 months.
__label__noRel	local control and survival were essentially equal between the surgical and RT arms.	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.
__label__noRel	local control and survival were essentially equal between the surgical and RT arms.	The median survival in the patients receiving induction chemotherapy only was 8.9 months.
__label__noRel	local control and survival were essentially equal between the surgical and RT arms.	Mitomycin-C had no impact on survival (p = 0.75).
__label__noRel	local control and survival were essentially equal between the surgical and RT arms.	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.
__label__noRel	local control and survival were essentially equal between the surgical and RT arms.	The patient accrual to this trial made its results inconclusive,
__label__noRel	local control and survival were essentially equal between the surgical and RT arms.	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.
__label__noRel	local control and survival were essentially equal between the surgical and RT arms.	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.
__label__noRel	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.	The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not.
__label__noRel	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.	Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting).
__label__noRel	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.	No acute Grade 4 radiation toxicity developed.
__label__noRel	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.	The incidences of long-term toxicity were equivalent across the arms.
__label__noRel	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.	Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis).
__label__noRel	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.	Induction chemotherapy was completed in 78% of the patients.
__label__noRel	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.	Complete resection was performed in 73% of 26 patients undergoing thoracotomy.
__label__noRel	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.	Consolidation chemotherapy was completed in 75% of the patients.
__label__noRel	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.	No statistically significant difference was found among the treatment arms.
__label__noRel	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.	The overall progression-free survival rate was 53% at 1 year and 17% at 3 years.
__label__noRel	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.	The median progression-free survival was 14 months.
__label__noRel	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.	No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms.
__label__noRel	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.	The median survival in the patients receiving induction chemotherapy only was 8.9 months.
__label__noRel	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.	Mitomycin-C had no impact on survival (p = 0.75).
__label__noRel	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.	No statistically significant difference was noted in the time to local failure between the surgical and RT arms.
__label__noRel	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.	The patient accrual to this trial made its results inconclusive,
__label__noRel	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.	histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging.
__label__noRel	The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease.	local control and survival were essentially equal between the surgical and RT arms.
__label__noRel	Two toxicity-related deaths were observed in the Tomudex arm.	The treatments gave rise to different rates of grade 3-4 neutropenia (3, 4, 11 and 14% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively, p = 0.028), leucopenia and vomiting.
__label__noRel	Two toxicity-related deaths were observed in the Tomudex arm.	At least one episode of grade 3-4 toxicity was observed in 27, 25, 38 and 47% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.016).
__label__noRel	Two toxicity-related deaths were observed in the Tomudex arm.	An objective response was observed in 28, 21, 22 and 10% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.04).
__label__noRel	Two toxicity-related deaths were observed in the Tomudex arm.	Progression-free survival (PFS) of the patients in the Tomudex arm was statistically lower compared to that of patients treated with LV5FU2 or ldLV5FU2 (combined group; p = 0.013, log rank test).
__label__Support	Two toxicity-related deaths were observed in the Tomudex arm.	In conclusion, Tomudex is more toxic and yields shorter PFS than infusional 5FU.
__label__noRel	Two toxicity-related deaths were observed in the Tomudex arm.	Despite the early closure of the study and the lack of power of the comparison, it seems that ldLV5FU2 could be considered as an active, easier and less expensive option for the treatment of metastatic colorectal cancer compared to classic LV5FU2 or weekly HD-FU.
__label__noRel	The treatments gave rise to different rates of grade 3-4 neutropenia (3, 4, 11 and 14% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively, p = 0.028), leucopenia and vomiting.	Two toxicity-related deaths were observed in the Tomudex arm.
__label__noRel	The treatments gave rise to different rates of grade 3-4 neutropenia (3, 4, 11 and 14% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively, p = 0.028), leucopenia and vomiting.	At least one episode of grade 3-4 toxicity was observed in 27, 25, 38 and 47% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.016).
__label__noRel	The treatments gave rise to different rates of grade 3-4 neutropenia (3, 4, 11 and 14% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively, p = 0.028), leucopenia and vomiting.	An objective response was observed in 28, 21, 22 and 10% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.04).
__label__noRel	The treatments gave rise to different rates of grade 3-4 neutropenia (3, 4, 11 and 14% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively, p = 0.028), leucopenia and vomiting.	Progression-free survival (PFS) of the patients in the Tomudex arm was statistically lower compared to that of patients treated with LV5FU2 or ldLV5FU2 (combined group; p = 0.013, log rank test).
__label__Support	The treatments gave rise to different rates of grade 3-4 neutropenia (3, 4, 11 and 14% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively, p = 0.028), leucopenia and vomiting.	In conclusion, Tomudex is more toxic and yields shorter PFS than infusional 5FU.
__label__noRel	The treatments gave rise to different rates of grade 3-4 neutropenia (3, 4, 11 and 14% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively, p = 0.028), leucopenia and vomiting.	Despite the early closure of the study and the lack of power of the comparison, it seems that ldLV5FU2 could be considered as an active, easier and less expensive option for the treatment of metastatic colorectal cancer compared to classic LV5FU2 or weekly HD-FU.
__label__noRel	At least one episode of grade 3-4 toxicity was observed in 27, 25, 38 and 47% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.016).	Two toxicity-related deaths were observed in the Tomudex arm.
__label__noRel	At least one episode of grade 3-4 toxicity was observed in 27, 25, 38 and 47% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.016).	The treatments gave rise to different rates of grade 3-4 neutropenia (3, 4, 11 and 14% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively, p = 0.028), leucopenia and vomiting.
__label__noRel	At least one episode of grade 3-4 toxicity was observed in 27, 25, 38 and 47% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.016).	An objective response was observed in 28, 21, 22 and 10% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.04).
__label__noRel	At least one episode of grade 3-4 toxicity was observed in 27, 25, 38 and 47% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.016).	Progression-free survival (PFS) of the patients in the Tomudex arm was statistically lower compared to that of patients treated with LV5FU2 or ldLV5FU2 (combined group; p = 0.013, log rank test).
__label__Support	At least one episode of grade 3-4 toxicity was observed in 27, 25, 38 and 47% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.016).	In conclusion, Tomudex is more toxic and yields shorter PFS than infusional 5FU.
__label__noRel	At least one episode of grade 3-4 toxicity was observed in 27, 25, 38 and 47% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.016).	Despite the early closure of the study and the lack of power of the comparison, it seems that ldLV5FU2 could be considered as an active, easier and less expensive option for the treatment of metastatic colorectal cancer compared to classic LV5FU2 or weekly HD-FU.
__label__noRel	An objective response was observed in 28, 21, 22 and 10% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.04).	Two toxicity-related deaths were observed in the Tomudex arm.
__label__noRel	An objective response was observed in 28, 21, 22 and 10% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.04).	The treatments gave rise to different rates of grade 3-4 neutropenia (3, 4, 11 and 14% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively, p = 0.028), leucopenia and vomiting.
__label__noRel	An objective response was observed in 28, 21, 22 and 10% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.04).	At least one episode of grade 3-4 toxicity was observed in 27, 25, 38 and 47% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.016).
__label__noRel	An objective response was observed in 28, 21, 22 and 10% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.04).	Progression-free survival (PFS) of the patients in the Tomudex arm was statistically lower compared to that of patients treated with LV5FU2 or ldLV5FU2 (combined group; p = 0.013, log rank test).
__label__noRel	An objective response was observed in 28, 21, 22 and 10% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.04).	In conclusion, Tomudex is more toxic and yields shorter PFS than infusional 5FU.
__label__Support	An objective response was observed in 28, 21, 22 and 10% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.04).	Despite the early closure of the study and the lack of power of the comparison, it seems that ldLV5FU2 could be considered as an active, easier and less expensive option for the treatment of metastatic colorectal cancer compared to classic LV5FU2 or weekly HD-FU.
__label__noRel	Progression-free survival (PFS) of the patients in the Tomudex arm was statistically lower compared to that of patients treated with LV5FU2 or ldLV5FU2 (combined group; p = 0.013, log rank test).	Two toxicity-related deaths were observed in the Tomudex arm.
__label__noRel	Progression-free survival (PFS) of the patients in the Tomudex arm was statistically lower compared to that of patients treated with LV5FU2 or ldLV5FU2 (combined group; p = 0.013, log rank test).	The treatments gave rise to different rates of grade 3-4 neutropenia (3, 4, 11 and 14% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively, p = 0.028), leucopenia and vomiting.
__label__noRel	Progression-free survival (PFS) of the patients in the Tomudex arm was statistically lower compared to that of patients treated with LV5FU2 or ldLV5FU2 (combined group; p = 0.013, log rank test).	At least one episode of grade 3-4 toxicity was observed in 27, 25, 38 and 47% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.016).
__label__noRel	Progression-free survival (PFS) of the patients in the Tomudex arm was statistically lower compared to that of patients treated with LV5FU2 or ldLV5FU2 (combined group; p = 0.013, log rank test).	An objective response was observed in 28, 21, 22 and 10% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.04).
__label__Support	Progression-free survival (PFS) of the patients in the Tomudex arm was statistically lower compared to that of patients treated with LV5FU2 or ldLV5FU2 (combined group; p = 0.013, log rank test).	In conclusion, Tomudex is more toxic and yields shorter PFS than infusional 5FU.
__label__noRel	Progression-free survival (PFS) of the patients in the Tomudex arm was statistically lower compared to that of patients treated with LV5FU2 or ldLV5FU2 (combined group; p = 0.013, log rank test).	Despite the early closure of the study and the lack of power of the comparison, it seems that ldLV5FU2 could be considered as an active, easier and less expensive option for the treatment of metastatic colorectal cancer compared to classic LV5FU2 or weekly HD-FU.
__label__noRel	In conclusion, Tomudex is more toxic and yields shorter PFS than infusional 5FU.	Two toxicity-related deaths were observed in the Tomudex arm.
__label__noRel	In conclusion, Tomudex is more toxic and yields shorter PFS than infusional 5FU.	The treatments gave rise to different rates of grade 3-4 neutropenia (3, 4, 11 and 14% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively, p = 0.028), leucopenia and vomiting.
__label__noRel	In conclusion, Tomudex is more toxic and yields shorter PFS than infusional 5FU.	At least one episode of grade 3-4 toxicity was observed in 27, 25, 38 and 47% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.016).
__label__noRel	In conclusion, Tomudex is more toxic and yields shorter PFS than infusional 5FU.	An objective response was observed in 28, 21, 22 and 10% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.04).
__label__noRel	In conclusion, Tomudex is more toxic and yields shorter PFS than infusional 5FU.	Progression-free survival (PFS) of the patients in the Tomudex arm was statistically lower compared to that of patients treated with LV5FU2 or ldLV5FU2 (combined group; p = 0.013, log rank test).
__label__noRel	In conclusion, Tomudex is more toxic and yields shorter PFS than infusional 5FU.	Despite the early closure of the study and the lack of power of the comparison, it seems that ldLV5FU2 could be considered as an active, easier and less expensive option for the treatment of metastatic colorectal cancer compared to classic LV5FU2 or weekly HD-FU.
__label__noRel	Despite the early closure of the study and the lack of power of the comparison, it seems that ldLV5FU2 could be considered as an active, easier and less expensive option for the treatment of metastatic colorectal cancer compared to classic LV5FU2 or weekly HD-FU.	Two toxicity-related deaths were observed in the Tomudex arm.
__label__noRel	Despite the early closure of the study and the lack of power of the comparison, it seems that ldLV5FU2 could be considered as an active, easier and less expensive option for the treatment of metastatic colorectal cancer compared to classic LV5FU2 or weekly HD-FU.	The treatments gave rise to different rates of grade 3-4 neutropenia (3, 4, 11 and 14% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively, p = 0.028), leucopenia and vomiting.
__label__noRel	Despite the early closure of the study and the lack of power of the comparison, it seems that ldLV5FU2 could be considered as an active, easier and less expensive option for the treatment of metastatic colorectal cancer compared to classic LV5FU2 or weekly HD-FU.	At least one episode of grade 3-4 toxicity was observed in 27, 25, 38 and 47% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.016).
__label__noRel	Despite the early closure of the study and the lack of power of the comparison, it seems that ldLV5FU2 could be considered as an active, easier and less expensive option for the treatment of metastatic colorectal cancer compared to classic LV5FU2 or weekly HD-FU.	An objective response was observed in 28, 21, 22 and 10% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.04).
__label__noRel	Despite the early closure of the study and the lack of power of the comparison, it seems that ldLV5FU2 could be considered as an active, easier and less expensive option for the treatment of metastatic colorectal cancer compared to classic LV5FU2 or weekly HD-FU.	Progression-free survival (PFS) of the patients in the Tomudex arm was statistically lower compared to that of patients treated with LV5FU2 or ldLV5FU2 (combined group; p = 0.013, log rank test).
__label__noRel	Despite the early closure of the study and the lack of power of the comparison, it seems that ldLV5FU2 could be considered as an active, easier and less expensive option for the treatment of metastatic colorectal cancer compared to classic LV5FU2 or weekly HD-FU.	In conclusion, Tomudex is more toxic and yields shorter PFS than infusional 5FU.
__label__noRel	The overall response rates, which were confirmed by an independent expert panel, were 13% (95% CI, 3.4% to 23.3%), 27% (95% CI, 14.1% to 40.4%), and 40% (95% CI, 25.7% to 54.3%) for arms A, B, and C, respectively.	Median progression-free survival and overall survival times were 3.2 months (95% CI, 1.8 to 4.6 months) and 6.8 months (95% CI, 2.6 to 11.1 months) with LV5FU2, respectively; 4.9 months (95% CI, 3.5 to 6.3 months) and 9.5 months (95% CI, 6.9 to 12.2 months) with LV5FU2-cisplatin, respectively; and 6.9 months (95% CI, 5.5 to 8.3 months) and 11.3 months (95% CI, 9.3 to 13.3 months) with LV5FU2-irinotecan, respectively.
__label__Support	The overall response rates, which were confirmed by an independent expert panel, were 13% (95% CI, 3.4% to 23.3%), 27% (95% CI, 14.1% to 40.4%), and 40% (95% CI, 25.7% to 54.3%) for arms A, B, and C, respectively.	Of the three regimens tested, the combination of LV5FU2-irinotecan is the most promising and will be assessed in a phase III trial.
__label__noRel	Median progression-free survival and overall survival times were 3.2 months (95% CI, 1.8 to 4.6 months) and 6.8 months (95% CI, 2.6 to 11.1 months) with LV5FU2, respectively; 4.9 months (95% CI, 3.5 to 6.3 months) and 9.5 months (95% CI, 6.9 to 12.2 months) with LV5FU2-cisplatin, respectively; and 6.9 months (95% CI, 5.5 to 8.3 months) and 11.3 months (95% CI, 9.3 to 13.3 months) with LV5FU2-irinotecan, respectively.	The overall response rates, which were confirmed by an independent expert panel, were 13% (95% CI, 3.4% to 23.3%), 27% (95% CI, 14.1% to 40.4%), and 40% (95% CI, 25.7% to 54.3%) for arms A, B, and C, respectively.
__label__Support	Median progression-free survival and overall survival times were 3.2 months (95% CI, 1.8 to 4.6 months) and 6.8 months (95% CI, 2.6 to 11.1 months) with LV5FU2, respectively; 4.9 months (95% CI, 3.5 to 6.3 months) and 9.5 months (95% CI, 6.9 to 12.2 months) with LV5FU2-cisplatin, respectively; and 6.9 months (95% CI, 5.5 to 8.3 months) and 11.3 months (95% CI, 9.3 to 13.3 months) with LV5FU2-irinotecan, respectively.	Of the three regimens tested, the combination of LV5FU2-irinotecan is the most promising and will be assessed in a phase III trial.
__label__noRel	Of the three regimens tested, the combination of LV5FU2-irinotecan is the most promising and will be assessed in a phase III trial.	The overall response rates, which were confirmed by an independent expert panel, were 13% (95% CI, 3.4% to 23.3%), 27% (95% CI, 14.1% to 40.4%), and 40% (95% CI, 25.7% to 54.3%) for arms A, B, and C, respectively.
__label__noRel	Of the three regimens tested, the combination of LV5FU2-irinotecan is the most promising and will be assessed in a phase III trial.	Median progression-free survival and overall survival times were 3.2 months (95% CI, 1.8 to 4.6 months) and 6.8 months (95% CI, 2.6 to 11.1 months) with LV5FU2, respectively; 4.9 months (95% CI, 3.5 to 6.3 months) and 9.5 months (95% CI, 6.9 to 12.2 months) with LV5FU2-cisplatin, respectively; and 6.9 months (95% CI, 5.5 to 8.3 months) and 11.3 months (95% CI, 9.3 to 13.3 months) with LV5FU2-irinotecan, respectively.
__label__noRel	Among the clinical outcome measures, QOL score improvement was greater for UAE with TAGMs compared with PVA (49.0 vs 27.9; P = .02),	but no other differences were noted.
__label__noRel	Among the clinical outcome measures, QOL score improvement was greater for UAE with TAGMs compared with PVA (49.0 vs 27.9; P = .02),	Of the 25 patients in whom 3-month MR imaging follow-up was completed, those treated with TAGM were significantly more likely to have complete infarction of all leiomyomas (six patients vs one patient; P = .02), were more likely to have at least 90% tumor infarction (eight patients vs four patients; P = .03), and had a lower mean percent of residual perfused fibroid tumor tissue (9.6% vs 44.3%; P = .004) compared with patients treated with PVA.
__label__noRel	Among the clinical outcome measures, QOL score improvement was greater for UAE with TAGMs compared with PVA (49.0 vs 27.9; P = .02),	The use of spherical PVA particles in the manner described herein results in an unacceptably high rate of failed tumor infarction in UAE.
__label__Attack	but no other differences were noted.	Among the clinical outcome measures, QOL score improvement was greater for UAE with TAGMs compared with PVA (49.0 vs 27.9; P = .02),
__label__noRel	but no other differences were noted.	Of the 25 patients in whom 3-month MR imaging follow-up was completed, those treated with TAGM were significantly more likely to have complete infarction of all leiomyomas (six patients vs one patient; P = .02), were more likely to have at least 90% tumor infarction (eight patients vs four patients; P = .03), and had a lower mean percent of residual perfused fibroid tumor tissue (9.6% vs 44.3%; P = .004) compared with patients treated with PVA.
__label__noRel	but no other differences were noted.	The use of spherical PVA particles in the manner described herein results in an unacceptably high rate of failed tumor infarction in UAE.
__label__noRel	Of the 25 patients in whom 3-month MR imaging follow-up was completed, those treated with TAGM were significantly more likely to have complete infarction of all leiomyomas (six patients vs one patient; P = .02), were more likely to have at least 90% tumor infarction (eight patients vs four patients; P = .03), and had a lower mean percent of residual perfused fibroid tumor tissue (9.6% vs 44.3%; P = .004) compared with patients treated with PVA.	Among the clinical outcome measures, QOL score improvement was greater for UAE with TAGMs compared with PVA (49.0 vs 27.9; P = .02),
__label__noRel	Of the 25 patients in whom 3-month MR imaging follow-up was completed, those treated with TAGM were significantly more likely to have complete infarction of all leiomyomas (six patients vs one patient; P = .02), were more likely to have at least 90% tumor infarction (eight patients vs four patients; P = .03), and had a lower mean percent of residual perfused fibroid tumor tissue (9.6% vs 44.3%; P = .004) compared with patients treated with PVA.	but no other differences were noted.
__label__Support	Of the 25 patients in whom 3-month MR imaging follow-up was completed, those treated with TAGM were significantly more likely to have complete infarction of all leiomyomas (six patients vs one patient; P = .02), were more likely to have at least 90% tumor infarction (eight patients vs four patients; P = .03), and had a lower mean percent of residual perfused fibroid tumor tissue (9.6% vs 44.3%; P = .004) compared with patients treated with PVA.	The use of spherical PVA particles in the manner described herein results in an unacceptably high rate of failed tumor infarction in UAE.
__label__noRel	The use of spherical PVA particles in the manner described herein results in an unacceptably high rate of failed tumor infarction in UAE.	Among the clinical outcome measures, QOL score improvement was greater for UAE with TAGMs compared with PVA (49.0 vs 27.9; P = .02),
__label__noRel	The use of spherical PVA particles in the manner described herein results in an unacceptably high rate of failed tumor infarction in UAE.	but no other differences were noted.
__label__noRel	The use of spherical PVA particles in the manner described herein results in an unacceptably high rate of failed tumor infarction in UAE.	Of the 25 patients in whom 3-month MR imaging follow-up was completed, those treated with TAGM were significantly more likely to have complete infarction of all leiomyomas (six patients vs one patient; P = .02), were more likely to have at least 90% tumor infarction (eight patients vs four patients; P = .03), and had a lower mean percent of residual perfused fibroid tumor tissue (9.6% vs 44.3%; P = .004) compared with patients treated with PVA.
__label__noRel	Sleep quality differed over 1 years time (F [4,162] = 7.7, P < .001; by group, F [1,173] = 4.8, P = .029; and over time by group, F [4,162] = 3.3, P = .013).	Pairwise comparisons revealed significant differences between groups at 90 days (P = .002)
__label__noRel	Sleep quality differed over 1 years time (F [4,162] = 7.7, P < .001; by group, F [1,173] = 4.8, P = .029; and over time by group, F [4,162] = 3.3, P = .013).	but not at 1 year (P = .052).
__label__noRel	Sleep quality differed over 1 years time (F [4,162] = 7.7, P < .001; by group, F [1,173] = 4.8, P = .029; and over time by group, F [4,162] = 3.3, P = .013).	The night awakenings (Actigraph) pattern was significantly different by group over time (P = .046), with no differences between groups at 90 days or at 1 year.
__label__noRel	Sleep quality differed over 1 years time (F [4,162] = 7.7, P < .001; by group, F [1,173] = 4.8, P = .029; and over time by group, F [4,162] = 3.3, P = .013).	Fatigue was lower at 1 year than before CTX;
__label__noRel	Sleep quality differed over 1 years time (F [4,162] = 7.7, P < .001; by group, F [1,173] = 4.8, P = .029; and over time by group, F [4,162] = 3.3, P = .013).	no group effects were found.
__label__Support	Sleep quality differed over 1 years time (F [4,162] = 7.7, P < .001; by group, F [1,173] = 4.8, P = .029; and over time by group, F [4,162] = 3.3, P = .013).	The BT group, on average, experienced significant improvement on global sleep quality compared with the HEC group,
__label__noRel	Sleep quality differed over 1 years time (F [4,162] = 7.7, P < .001; by group, F [1,173] = 4.8, P = .029; and over time by group, F [4,162] = 3.3, P = .013).	but not on objective sleep or fatigue outcomes.
__label__Support	Pairwise comparisons revealed significant differences between groups at 90 days (P = .002)	Sleep quality differed over 1 years time (F [4,162] = 7.7, P < .001; by group, F [1,173] = 4.8, P = .029; and over time by group, F [4,162] = 3.3, P = .013).
__label__noRel	Pairwise comparisons revealed significant differences between groups at 90 days (P = .002)	but not at 1 year (P = .052).
__label__noRel	Pairwise comparisons revealed significant differences between groups at 90 days (P = .002)	The night awakenings (Actigraph) pattern was significantly different by group over time (P = .046), with no differences between groups at 90 days or at 1 year.
__label__noRel	Pairwise comparisons revealed significant differences between groups at 90 days (P = .002)	Fatigue was lower at 1 year than before CTX;
__label__noRel	Pairwise comparisons revealed significant differences between groups at 90 days (P = .002)	no group effects were found.
__label__noRel	Pairwise comparisons revealed significant differences between groups at 90 days (P = .002)	The BT group, on average, experienced significant improvement on global sleep quality compared with the HEC group,
__label__noRel	Pairwise comparisons revealed significant differences between groups at 90 days (P = .002)	but not on objective sleep or fatigue outcomes.
__label__noRel	but not at 1 year (P = .052).	Sleep quality differed over 1 years time (F [4,162] = 7.7, P < .001; by group, F [1,173] = 4.8, P = .029; and over time by group, F [4,162] = 3.3, P = .013).
__label__Attack	but not at 1 year (P = .052).	Pairwise comparisons revealed significant differences between groups at 90 days (P = .002)
__label__noRel	but not at 1 year (P = .052).	The night awakenings (Actigraph) pattern was significantly different by group over time (P = .046), with no differences between groups at 90 days or at 1 year.
__label__noRel	but not at 1 year (P = .052).	Fatigue was lower at 1 year than before CTX;
__label__noRel	but not at 1 year (P = .052).	no group effects were found.
__label__noRel	but not at 1 year (P = .052).	The BT group, on average, experienced significant improvement on global sleep quality compared with the HEC group,
__label__noRel	but not at 1 year (P = .052).	but not on objective sleep or fatigue outcomes.
__label__noRel	The night awakenings (Actigraph) pattern was significantly different by group over time (P = .046), with no differences between groups at 90 days or at 1 year.	Sleep quality differed over 1 years time (F [4,162] = 7.7, P < .001; by group, F [1,173] = 4.8, P = .029; and over time by group, F [4,162] = 3.3, P = .013).
__label__noRel	The night awakenings (Actigraph) pattern was significantly different by group over time (P = .046), with no differences between groups at 90 days or at 1 year.	Pairwise comparisons revealed significant differences between groups at 90 days (P = .002)
__label__noRel	The night awakenings (Actigraph) pattern was significantly different by group over time (P = .046), with no differences between groups at 90 days or at 1 year.	but not at 1 year (P = .052).
__label__noRel	The night awakenings (Actigraph) pattern was significantly different by group over time (P = .046), with no differences between groups at 90 days or at 1 year.	Fatigue was lower at 1 year than before CTX;
__label__noRel	The night awakenings (Actigraph) pattern was significantly different by group over time (P = .046), with no differences between groups at 90 days or at 1 year.	no group effects were found.
__label__noRel	The night awakenings (Actigraph) pattern was significantly different by group over time (P = .046), with no differences between groups at 90 days or at 1 year.	The BT group, on average, experienced significant improvement on global sleep quality compared with the HEC group,
__label__noRel	The night awakenings (Actigraph) pattern was significantly different by group over time (P = .046), with no differences between groups at 90 days or at 1 year.	but not on objective sleep or fatigue outcomes.
__label__noRel	Fatigue was lower at 1 year than before CTX;	Sleep quality differed over 1 years time (F [4,162] = 7.7, P < .001; by group, F [1,173] = 4.8, P = .029; and over time by group, F [4,162] = 3.3, P = .013).
__label__noRel	Fatigue was lower at 1 year than before CTX;	Pairwise comparisons revealed significant differences between groups at 90 days (P = .002)
__label__noRel	Fatigue was lower at 1 year than before CTX;	but not at 1 year (P = .052).
__label__noRel	Fatigue was lower at 1 year than before CTX;	The night awakenings (Actigraph) pattern was significantly different by group over time (P = .046), with no differences between groups at 90 days or at 1 year.
__label__noRel	Fatigue was lower at 1 year than before CTX;	no group effects were found.
__label__noRel	Fatigue was lower at 1 year than before CTX;	The BT group, on average, experienced significant improvement on global sleep quality compared with the HEC group,
__label__Support	Fatigue was lower at 1 year than before CTX;	but not on objective sleep or fatigue outcomes.
__label__noRel	no group effects were found.	Sleep quality differed over 1 years time (F [4,162] = 7.7, P < .001; by group, F [1,173] = 4.8, P = .029; and over time by group, F [4,162] = 3.3, P = .013).
__label__noRel	no group effects were found.	Pairwise comparisons revealed significant differences between groups at 90 days (P = .002)
__label__noRel	no group effects were found.	but not at 1 year (P = .052).
__label__noRel	no group effects were found.	The night awakenings (Actigraph) pattern was significantly different by group over time (P = .046), with no differences between groups at 90 days or at 1 year.
__label__Attack	no group effects were found.	Fatigue was lower at 1 year than before CTX;
__label__noRel	no group effects were found.	The BT group, on average, experienced significant improvement on global sleep quality compared with the HEC group,
__label__noRel	no group effects were found.	but not on objective sleep or fatigue outcomes.
__label__noRel	The BT group, on average, experienced significant improvement on global sleep quality compared with the HEC group,	Sleep quality differed over 1 years time (F [4,162] = 7.7, P < .001; by group, F [1,173] = 4.8, P = .029; and over time by group, F [4,162] = 3.3, P = .013).
__label__noRel	The BT group, on average, experienced significant improvement on global sleep quality compared with the HEC group,	Pairwise comparisons revealed significant differences between groups at 90 days (P = .002)
__label__noRel	The BT group, on average, experienced significant improvement on global sleep quality compared with the HEC group,	but not at 1 year (P = .052).
__label__noRel	The BT group, on average, experienced significant improvement on global sleep quality compared with the HEC group,	The night awakenings (Actigraph) pattern was significantly different by group over time (P = .046), with no differences between groups at 90 days or at 1 year.
__label__noRel	The BT group, on average, experienced significant improvement on global sleep quality compared with the HEC group,	Fatigue was lower at 1 year than before CTX;
__label__noRel	The BT group, on average, experienced significant improvement on global sleep quality compared with the HEC group,	no group effects were found.
__label__noRel	The BT group, on average, experienced significant improvement on global sleep quality compared with the HEC group,	but not on objective sleep or fatigue outcomes.
__label__noRel	but not on objective sleep or fatigue outcomes.	Sleep quality differed over 1 years time (F [4,162] = 7.7, P < .001; by group, F [1,173] = 4.8, P = .029; and over time by group, F [4,162] = 3.3, P = .013).
__label__noRel	but not on objective sleep or fatigue outcomes.	Pairwise comparisons revealed significant differences between groups at 90 days (P = .002)
__label__noRel	but not on objective sleep or fatigue outcomes.	but not at 1 year (P = .052).
__label__noRel	but not on objective sleep or fatigue outcomes.	The night awakenings (Actigraph) pattern was significantly different by group over time (P = .046), with no differences between groups at 90 days or at 1 year.
__label__noRel	but not on objective sleep or fatigue outcomes.	Fatigue was lower at 1 year than before CTX;
__label__noRel	but not on objective sleep or fatigue outcomes.	no group effects were found.
__label__Attack	but not on objective sleep or fatigue outcomes.	The BT group, on average, experienced significant improvement on global sleep quality compared with the HEC group,
__label__noRel	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.	Chemotherapy seems to improve symptoms control,
__label__noRel	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).
__label__noRel	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.	The disease-related symptoms improved with time,
__label__noRel	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.	the benefits lasted for the entire treatment period.
__label__noRel	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).
__label__noRel	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.	The advantage lasted for all the duration of chemotherapy.
__label__noRel	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.
__label__noRel	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).
__label__noRel	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.
__label__noRel	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.
__label__noRel	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.
__label__noRel	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.
__label__noRel	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.
__label__noRel	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.
__label__noRel	Chemotherapy seems to improve symptoms control,	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.
__label__noRel	Chemotherapy seems to improve symptoms control,	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).
__label__noRel	Chemotherapy seems to improve symptoms control,	The disease-related symptoms improved with time,
__label__noRel	Chemotherapy seems to improve symptoms control,	the benefits lasted for the entire treatment period.
__label__noRel	Chemotherapy seems to improve symptoms control,	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).
__label__noRel	Chemotherapy seems to improve symptoms control,	The advantage lasted for all the duration of chemotherapy.
__label__noRel	Chemotherapy seems to improve symptoms control,	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.
__label__noRel	Chemotherapy seems to improve symptoms control,	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).
__label__noRel	Chemotherapy seems to improve symptoms control,	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.
__label__noRel	Chemotherapy seems to improve symptoms control,	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.
__label__noRel	Chemotherapy seems to improve symptoms control,	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.
__label__noRel	Chemotherapy seems to improve symptoms control,	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.
__label__noRel	Chemotherapy seems to improve symptoms control,	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.
__label__noRel	Chemotherapy seems to improve symptoms control,	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.
__label__noRel	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.
__label__noRel	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).	Chemotherapy seems to improve symptoms control,
__label__noRel	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).	The disease-related symptoms improved with time,
__label__noRel	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).	the benefits lasted for the entire treatment period.
__label__noRel	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).
__label__noRel	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).	The advantage lasted for all the duration of chemotherapy.
__label__noRel	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.
__label__noRel	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).
__label__noRel	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.
__label__noRel	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.
__label__Support	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.
__label__noRel	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.
__label__noRel	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.
__label__noRel	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.
__label__noRel	The disease-related symptoms improved with time,	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.
__label__noRel	The disease-related symptoms improved with time,	Chemotherapy seems to improve symptoms control,
__label__noRel	The disease-related symptoms improved with time,	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).
__label__noRel	The disease-related symptoms improved with time,	the benefits lasted for the entire treatment period.
__label__noRel	The disease-related symptoms improved with time,	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).
__label__noRel	The disease-related symptoms improved with time,	The advantage lasted for all the duration of chemotherapy.
__label__noRel	The disease-related symptoms improved with time,	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.
__label__noRel	The disease-related symptoms improved with time,	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).
__label__noRel	The disease-related symptoms improved with time,	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.
__label__noRel	The disease-related symptoms improved with time,	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.
__label__Support	The disease-related symptoms improved with time,	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.
__label__noRel	The disease-related symptoms improved with time,	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.
__label__noRel	The disease-related symptoms improved with time,	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.
__label__noRel	The disease-related symptoms improved with time,	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.
__label__noRel	the benefits lasted for the entire treatment period.	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.
__label__noRel	the benefits lasted for the entire treatment period.	Chemotherapy seems to improve symptoms control,
__label__noRel	the benefits lasted for the entire treatment period.	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).
__label__noRel	the benefits lasted for the entire treatment period.	The disease-related symptoms improved with time,
__label__noRel	the benefits lasted for the entire treatment period.	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).
__label__noRel	the benefits lasted for the entire treatment period.	The advantage lasted for all the duration of chemotherapy.
__label__noRel	the benefits lasted for the entire treatment period.	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.
__label__noRel	the benefits lasted for the entire treatment period.	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).
__label__noRel	the benefits lasted for the entire treatment period.	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.
__label__noRel	the benefits lasted for the entire treatment period.	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.
__label__Support	the benefits lasted for the entire treatment period.	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.
__label__noRel	the benefits lasted for the entire treatment period.	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.
__label__noRel	the benefits lasted for the entire treatment period.	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.
__label__noRel	the benefits lasted for the entire treatment period.	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.
__label__noRel	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.
__label__noRel	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).	Chemotherapy seems to improve symptoms control,
__label__noRel	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).
__label__noRel	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).	The disease-related symptoms improved with time,
__label__noRel	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).	the benefits lasted for the entire treatment period.
__label__noRel	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).	The advantage lasted for all the duration of chemotherapy.
__label__noRel	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.
__label__noRel	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).
__label__noRel	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.
__label__noRel	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.
__label__noRel	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.
__label__noRel	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.
__label__Support	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.
__label__noRel	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.
__label__noRel	The advantage lasted for all the duration of chemotherapy.	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.
__label__noRel	The advantage lasted for all the duration of chemotherapy.	Chemotherapy seems to improve symptoms control,
__label__noRel	The advantage lasted for all the duration of chemotherapy.	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).
__label__noRel	The advantage lasted for all the duration of chemotherapy.	The disease-related symptoms improved with time,
__label__noRel	The advantage lasted for all the duration of chemotherapy.	the benefits lasted for the entire treatment period.
__label__noRel	The advantage lasted for all the duration of chemotherapy.	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).
__label__noRel	The advantage lasted for all the duration of chemotherapy.	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.
__label__noRel	The advantage lasted for all the duration of chemotherapy.	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).
__label__noRel	The advantage lasted for all the duration of chemotherapy.	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.
__label__noRel	The advantage lasted for all the duration of chemotherapy.	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.
__label__noRel	The advantage lasted for all the duration of chemotherapy.	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.
__label__noRel	The advantage lasted for all the duration of chemotherapy.	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.
__label__noRel	The advantage lasted for all the duration of chemotherapy.	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.
__label__noRel	The advantage lasted for all the duration of chemotherapy.	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.
__label__noRel	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.
__label__noRel	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.	Chemotherapy seems to improve symptoms control,
__label__noRel	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).
__label__noRel	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.	The disease-related symptoms improved with time,
__label__noRel	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.	the benefits lasted for the entire treatment period.
__label__noRel	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).
__label__noRel	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.	The advantage lasted for all the duration of chemotherapy.
__label__noRel	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).
__label__noRel	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.
__label__noRel	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.
__label__noRel	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.
__label__noRel	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.
__label__Support	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.
__label__noRel	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.
__label__noRel	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.
__label__noRel	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).	Chemotherapy seems to improve symptoms control,
__label__noRel	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).
__label__noRel	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).	The disease-related symptoms improved with time,
__label__noRel	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).	the benefits lasted for the entire treatment period.
__label__noRel	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).
__label__noRel	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).	The advantage lasted for all the duration of chemotherapy.
__label__noRel	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.
__label__noRel	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.
__label__Support	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.
__label__noRel	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.
__label__noRel	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.
__label__noRel	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.
__label__noRel	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.
__label__noRel	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.
__label__noRel	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.	Chemotherapy seems to improve symptoms control,
__label__noRel	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).
__label__noRel	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.	The disease-related symptoms improved with time,
__label__noRel	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.	the benefits lasted for the entire treatment period.
__label__noRel	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).
__label__noRel	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.	The advantage lasted for all the duration of chemotherapy.
__label__noRel	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.
__label__noRel	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).
__label__noRel	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.
__label__noRel	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.
__label__noRel	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.
__label__noRel	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.
__label__noRel	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.
__label__noRel	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.
__label__noRel	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.	Chemotherapy seems to improve symptoms control,
__label__noRel	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).
__label__noRel	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.	The disease-related symptoms improved with time,
__label__noRel	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.	the benefits lasted for the entire treatment period.
__label__noRel	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).
__label__noRel	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.	The advantage lasted for all the duration of chemotherapy.
__label__noRel	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.
__label__noRel	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).
__label__noRel	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.
__label__noRel	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.
__label__noRel	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.
__label__noRel	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.
__label__Support	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.
__label__noRel	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.
__label__noRel	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.	Chemotherapy seems to improve symptoms control,
__label__noRel	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).
__label__noRel	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.	The disease-related symptoms improved with time,
__label__noRel	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.	the benefits lasted for the entire treatment period.
__label__noRel	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).
__label__noRel	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.	The advantage lasted for all the duration of chemotherapy.
__label__noRel	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.
__label__noRel	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).
__label__noRel	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.
__label__noRel	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.
__label__noRel	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.
__label__noRel	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.
__label__Support	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.
__label__noRel	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.
__label__noRel	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.	Chemotherapy seems to improve symptoms control,
__label__noRel	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).
__label__noRel	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.	The disease-related symptoms improved with time,
__label__noRel	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.	the benefits lasted for the entire treatment period.
__label__noRel	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).
__label__noRel	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.	The advantage lasted for all the duration of chemotherapy.
__label__noRel	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.
__label__noRel	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).
__label__noRel	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.
__label__noRel	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.
__label__noRel	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.
__label__noRel	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.
__label__noRel	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.
__label__noRel	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.
__label__noRel	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.	Chemotherapy seems to improve symptoms control,
__label__noRel	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).
__label__noRel	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.	The disease-related symptoms improved with time,
__label__noRel	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.	the benefits lasted for the entire treatment period.
__label__noRel	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).
__label__noRel	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.	The advantage lasted for all the duration of chemotherapy.
__label__noRel	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.
__label__noRel	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).
__label__noRel	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.
__label__noRel	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.
__label__noRel	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.
__label__Attack	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.
__label__noRel	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.
__label__noRel	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.	In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care.
__label__noRel	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.	Chemotherapy seems to improve symptoms control,
__label__noRel	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.	Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04).
__label__noRel	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.	The disease-related symptoms improved with time,
__label__noRel	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.	the benefits lasted for the entire treatment period.
__label__noRel	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.	When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05).
__label__noRel	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.	The advantage lasted for all the duration of chemotherapy.
__label__noRel	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.	No differences were observed in global quality of life subdomain (P=0.40) between the two regimen.
__label__noRel	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.	we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39).
__label__noRel	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.	The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians.
__label__noRel	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.	No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen.
__label__noRel	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.	The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire.
__label__noRel	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.	With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination.
__label__noRel	A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC.	This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires.
__label__noRel	There was no significant difference in RR, RD, or PFS between arms.	DPPE plus DOX was statistically superior to DOX in OS (hazard ratio, 0.66; 95% CI, 0.48 to 0.91; P =.021).
__label__noRel	There was no significant difference in RR, RD, or PFS between arms.	DPPE plus DOX was associated with more gastrointestinal and CNS toxicity.
__label__noRel	There was no significant difference in RR, RD, or PFS between arms.	No consistent influence on QOL was detected.
__label__Support	There was no significant difference in RR, RD, or PFS between arms.	This study demonstrated no advantage in RR, RD, or PFS but significantly superior OS for DPPE plus DOX.
__label__noRel	There was no significant difference in RR, RD, or PFS between arms.	Additional studies of DPPE are warranted.
__label__noRel	DPPE plus DOX was statistically superior to DOX in OS (hazard ratio, 0.66; 95% CI, 0.48 to 0.91; P =.021).	There was no significant difference in RR, RD, or PFS between arms.
__label__noRel	DPPE plus DOX was statistically superior to DOX in OS (hazard ratio, 0.66; 95% CI, 0.48 to 0.91; P =.021).	DPPE plus DOX was associated with more gastrointestinal and CNS toxicity.
__label__noRel	DPPE plus DOX was statistically superior to DOX in OS (hazard ratio, 0.66; 95% CI, 0.48 to 0.91; P =.021).	No consistent influence on QOL was detected.
__label__Support	DPPE plus DOX was statistically superior to DOX in OS (hazard ratio, 0.66; 95% CI, 0.48 to 0.91; P =.021).	This study demonstrated no advantage in RR, RD, or PFS but significantly superior OS for DPPE plus DOX.
__label__noRel	DPPE plus DOX was statistically superior to DOX in OS (hazard ratio, 0.66; 95% CI, 0.48 to 0.91; P =.021).	Additional studies of DPPE are warranted.
__label__noRel	DPPE plus DOX was associated with more gastrointestinal and CNS toxicity.	There was no significant difference in RR, RD, or PFS between arms.
__label__noRel	DPPE plus DOX was associated with more gastrointestinal and CNS toxicity.	DPPE plus DOX was statistically superior to DOX in OS (hazard ratio, 0.66; 95% CI, 0.48 to 0.91; P =.021).
__label__noRel	DPPE plus DOX was associated with more gastrointestinal and CNS toxicity.	No consistent influence on QOL was detected.
__label__noRel	DPPE plus DOX was associated with more gastrointestinal and CNS toxicity.	This study demonstrated no advantage in RR, RD, or PFS but significantly superior OS for DPPE plus DOX.
__label__noRel	DPPE plus DOX was associated with more gastrointestinal and CNS toxicity.	Additional studies of DPPE are warranted.
__label__noRel	No consistent influence on QOL was detected.	There was no significant difference in RR, RD, or PFS between arms.
__label__noRel	No consistent influence on QOL was detected.	DPPE plus DOX was statistically superior to DOX in OS (hazard ratio, 0.66; 95% CI, 0.48 to 0.91; P =.021).
__label__noRel	No consistent influence on QOL was detected.	DPPE plus DOX was associated with more gastrointestinal and CNS toxicity.
__label__noRel	No consistent influence on QOL was detected.	This study demonstrated no advantage in RR, RD, or PFS but significantly superior OS for DPPE plus DOX.
__label__Support	No consistent influence on QOL was detected.	Additional studies of DPPE are warranted.
__label__noRel	This study demonstrated no advantage in RR, RD, or PFS but significantly superior OS for DPPE plus DOX.	There was no significant difference in RR, RD, or PFS between arms.
__label__noRel	This study demonstrated no advantage in RR, RD, or PFS but significantly superior OS for DPPE plus DOX.	DPPE plus DOX was statistically superior to DOX in OS (hazard ratio, 0.66; 95% CI, 0.48 to 0.91; P =.021).
__label__noRel	This study demonstrated no advantage in RR, RD, or PFS but significantly superior OS for DPPE plus DOX.	DPPE plus DOX was associated with more gastrointestinal and CNS toxicity.
__label__noRel	This study demonstrated no advantage in RR, RD, or PFS but significantly superior OS for DPPE plus DOX.	No consistent influence on QOL was detected.
__label__Support	This study demonstrated no advantage in RR, RD, or PFS but significantly superior OS for DPPE plus DOX.	Additional studies of DPPE are warranted.
__label__noRel	Additional studies of DPPE are warranted.	There was no significant difference in RR, RD, or PFS between arms.
__label__noRel	Additional studies of DPPE are warranted.	DPPE plus DOX was statistically superior to DOX in OS (hazard ratio, 0.66; 95% CI, 0.48 to 0.91; P =.021).
__label__noRel	Additional studies of DPPE are warranted.	DPPE plus DOX was associated with more gastrointestinal and CNS toxicity.
__label__noRel	Additional studies of DPPE are warranted.	No consistent influence on QOL was detected.
__label__noRel	Additional studies of DPPE are warranted.	This study demonstrated no advantage in RR, RD, or PFS but significantly superior OS for DPPE plus DOX.
__label__noRel	Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma	Overall the treatment was well tolerated
__label__noRel	Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma	Mild or moderate nausea was the most common side effect of estramustine.
__label__noRel	Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma	For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group.
__label__noRel	Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma	In grade IV the corresponding median survival time was 12.3 (2.1-89.2) and 10.3 (0.3-91.7+) months, respectively.
__label__noRel	Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma	Median time to progress for radiotherapy only and radiotherapy and estramustin group in grade III tumours was 6.5 and 10.1 months, respectively.
__label__noRel	Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma	In grade IV tumours the corresponding figures were 5.1 and 3.3 months, respectively.
__label__noRel	Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma	Although there was a tendency for improved survival in grade III, no statistical significant differences were found between the treatment groups.
__label__noRel	Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma	No differences between the two treatment groups were evident with respect to quality of life according to the EORTC QLQ-protocol.
__label__noRel	Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma	In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy,
__label__noRel	Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma	however, a trend for a positive response for the estramustine group was found in patients with grade III glioma.
__label__noRel	Overall the treatment was well tolerated	Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma
__label__noRel	Overall the treatment was well tolerated	Mild or moderate nausea was the most common side effect of estramustine.
__label__noRel	Overall the treatment was well tolerated	For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group.
__label__noRel	Overall the treatment was well tolerated	In grade IV the corresponding median survival time was 12.3 (2.1-89.2) and 10.3 (0.3-91.7+) months, respectively.
__label__noRel	Overall the treatment was well tolerated	Median time to progress for radiotherapy only and radiotherapy and estramustin group in grade III tumours was 6.5 and 10.1 months, respectively.
__label__noRel	Overall the treatment was well tolerated	In grade IV tumours the corresponding figures were 5.1 and 3.3 months, respectively.
__label__noRel	Overall the treatment was well tolerated	Although there was a tendency for improved survival in grade III, no statistical significant differences were found between the treatment groups.
__label__noRel	Overall the treatment was well tolerated	No differences between the two treatment groups were evident with respect to quality of life according to the EORTC QLQ-protocol.
__label__noRel	Overall the treatment was well tolerated	In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy,
__label__noRel	Overall the treatment was well tolerated	however, a trend for a positive response for the estramustine group was found in patients with grade III glioma.
__label__noRel	Mild or moderate nausea was the most common side effect of estramustine.	Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma
__label__noRel	Mild or moderate nausea was the most common side effect of estramustine.	Overall the treatment was well tolerated
__label__noRel	Mild or moderate nausea was the most common side effect of estramustine.	For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group.
__label__noRel	Mild or moderate nausea was the most common side effect of estramustine.	In grade IV the corresponding median survival time was 12.3 (2.1-89.2) and 10.3 (0.3-91.7+) months, respectively.
__label__noRel	Mild or moderate nausea was the most common side effect of estramustine.	Median time to progress for radiotherapy only and radiotherapy and estramustin group in grade III tumours was 6.5 and 10.1 months, respectively.
__label__noRel	Mild or moderate nausea was the most common side effect of estramustine.	In grade IV tumours the corresponding figures were 5.1 and 3.3 months, respectively.
__label__noRel	Mild or moderate nausea was the most common side effect of estramustine.	Although there was a tendency for improved survival in grade III, no statistical significant differences were found between the treatment groups.
__label__noRel	Mild or moderate nausea was the most common side effect of estramustine.	No differences between the two treatment groups were evident with respect to quality of life according to the EORTC QLQ-protocol.
__label__noRel	Mild or moderate nausea was the most common side effect of estramustine.	In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy,
__label__noRel	Mild or moderate nausea was the most common side effect of estramustine.	however, a trend for a positive response for the estramustine group was found in patients with grade III glioma.
__label__noRel	For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group.	Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma
__label__noRel	For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group.	Overall the treatment was well tolerated
__label__noRel	For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group.	Mild or moderate nausea was the most common side effect of estramustine.
__label__noRel	For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group.	In grade IV the corresponding median survival time was 12.3 (2.1-89.2) and 10.3 (0.3-91.7+) months, respectively.
__label__noRel	For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group.	Median time to progress for radiotherapy only and radiotherapy and estramustin group in grade III tumours was 6.5 and 10.1 months, respectively.
__label__noRel	For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group.	In grade IV tumours the corresponding figures were 5.1 and 3.3 months, respectively.
__label__noRel	For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group.	Although there was a tendency for improved survival in grade III, no statistical significant differences were found between the treatment groups.
__label__noRel	For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group.	No differences between the two treatment groups were evident with respect to quality of life according to the EORTC QLQ-protocol.
__label__noRel	For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group.	In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy,
__label__Support	For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group.	however, a trend for a positive response for the estramustine group was found in patients with grade III glioma.
__label__noRel	In grade IV the corresponding median survival time was 12.3 (2.1-89.2) and 10.3 (0.3-91.7+) months, respectively.	Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma
__label__noRel	In grade IV the corresponding median survival time was 12.3 (2.1-89.2) and 10.3 (0.3-91.7+) months, respectively.	Overall the treatment was well tolerated
__label__noRel	In grade IV the corresponding median survival time was 12.3 (2.1-89.2) and 10.3 (0.3-91.7+) months, respectively.	Mild or moderate nausea was the most common side effect of estramustine.
__label__noRel	In grade IV the corresponding median survival time was 12.3 (2.1-89.2) and 10.3 (0.3-91.7+) months, respectively.	For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group.
__label__noRel	In grade IV the corresponding median survival time was 12.3 (2.1-89.2) and 10.3 (0.3-91.7+) months, respectively.	Median time to progress for radiotherapy only and radiotherapy and estramustin group in grade III tumours was 6.5 and 10.1 months, respectively.
__label__noRel	In grade IV the corresponding median survival time was 12.3 (2.1-89.2) and 10.3 (0.3-91.7+) months, respectively.	In grade IV tumours the corresponding figures were 5.1 and 3.3 months, respectively.
__label__noRel	In grade IV the corresponding median survival time was 12.3 (2.1-89.2) and 10.3 (0.3-91.7+) months, respectively.	Although there was a tendency for improved survival in grade III, no statistical significant differences were found between the treatment groups.
__label__noRel	In grade IV the corresponding median survival time was 12.3 (2.1-89.2) and 10.3 (0.3-91.7+) months, respectively.	No differences between the two treatment groups were evident with respect to quality of life according to the EORTC QLQ-protocol.
__label__Support	In grade IV the corresponding median survival time was 12.3 (2.1-89.2) and 10.3 (0.3-91.7+) months, respectively.	In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy,
__label__noRel	In grade IV the corresponding median survival time was 12.3 (2.1-89.2) and 10.3 (0.3-91.7+) months, respectively.	however, a trend for a positive response for the estramustine group was found in patients with grade III glioma.
__label__noRel	Median time to progress for radiotherapy only and radiotherapy and estramustin group in grade III tumours was 6.5 and 10.1 months, respectively.	Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma
__label__noRel	Median time to progress for radiotherapy only and radiotherapy and estramustin group in grade III tumours was 6.5 and 10.1 months, respectively.	Overall the treatment was well tolerated
__label__noRel	Median time to progress for radiotherapy only and radiotherapy and estramustin group in grade III tumours was 6.5 and 10.1 months, respectively.	Mild or moderate nausea was the most common side effect of estramustine.
__label__noRel	Median time to progress for radiotherapy only and radiotherapy and estramustin group in grade III tumours was 6.5 and 10.1 months, respectively.	For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group.
__label__noRel	Median time to progress for radiotherapy only and radiotherapy and estramustin group in grade III tumours was 6.5 and 10.1 months, respectively.	In grade IV the corresponding median survival time was 12.3 (2.1-89.2) and 10.3 (0.3-91.7+) months, respectively.
__label__noRel	Median time to progress for radiotherapy only and radiotherapy and estramustin group in grade III tumours was 6.5 and 10.1 months, respectively.	In grade IV tumours the corresponding figures were 5.1 and 3.3 months, respectively.
__label__noRel	Median time to progress for radiotherapy only and radiotherapy and estramustin group in grade III tumours was 6.5 and 10.1 months, respectively.	Although there was a tendency for improved survival in grade III, no statistical significant differences were found between the treatment groups.
__label__noRel	Median time to progress for radiotherapy only and radiotherapy and estramustin group in grade III tumours was 6.5 and 10.1 months, respectively.	No differences between the two treatment groups were evident with respect to quality of life according to the EORTC QLQ-protocol.
__label__noRel	Median time to progress for radiotherapy only and radiotherapy and estramustin group in grade III tumours was 6.5 and 10.1 months, respectively.	In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy,
__label__Support	Median time to progress for radiotherapy only and radiotherapy and estramustin group in grade III tumours was 6.5 and 10.1 months, respectively.	however, a trend for a positive response for the estramustine group was found in patients with grade III glioma.
__label__noRel	In grade IV tumours the corresponding figures were 5.1 and 3.3 months, respectively.	Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma
__label__noRel	In grade IV tumours the corresponding figures were 5.1 and 3.3 months, respectively.	Overall the treatment was well tolerated
__label__noRel	In grade IV tumours the corresponding figures were 5.1 and 3.3 months, respectively.	Mild or moderate nausea was the most common side effect of estramustine.
__label__noRel	In grade IV tumours the corresponding figures were 5.1 and 3.3 months, respectively.	For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group.
__label__noRel	In grade IV tumours the corresponding figures were 5.1 and 3.3 months, respectively.	In grade IV the corresponding median survival time was 12.3 (2.1-89.2) and 10.3 (0.3-91.7+) months, respectively.
__label__noRel	In grade IV tumours the corresponding figures were 5.1 and 3.3 months, respectively.	Median time to progress for radiotherapy only and radiotherapy and estramustin group in grade III tumours was 6.5 and 10.1 months, respectively.
__label__noRel	In grade IV tumours the corresponding figures were 5.1 and 3.3 months, respectively.	Although there was a tendency for improved survival in grade III, no statistical significant differences were found between the treatment groups.
__label__noRel	In grade IV tumours the corresponding figures were 5.1 and 3.3 months, respectively.	No differences between the two treatment groups were evident with respect to quality of life according to the EORTC QLQ-protocol.
__label__noRel	In grade IV tumours the corresponding figures were 5.1 and 3.3 months, respectively.	In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy,
__label__noRel	In grade IV tumours the corresponding figures were 5.1 and 3.3 months, respectively.	however, a trend for a positive response for the estramustine group was found in patients with grade III glioma.
__label__noRel	Although there was a tendency for improved survival in grade III, no statistical significant differences were found between the treatment groups.	Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma
__label__noRel	Although there was a tendency for improved survival in grade III, no statistical significant differences were found between the treatment groups.	Overall the treatment was well tolerated
__label__noRel	Although there was a tendency for improved survival in grade III, no statistical significant differences were found between the treatment groups.	Mild or moderate nausea was the most common side effect of estramustine.
__label__noRel	Although there was a tendency for improved survival in grade III, no statistical significant differences were found between the treatment groups.	For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group.
__label__noRel	Although there was a tendency for improved survival in grade III, no statistical significant differences were found between the treatment groups.	In grade IV the corresponding median survival time was 12.3 (2.1-89.2) and 10.3 (0.3-91.7+) months, respectively.
__label__noRel	Although there was a tendency for improved survival in grade III, no statistical significant differences were found between the treatment groups.	Median time to progress for radiotherapy only and radiotherapy and estramustin group in grade III tumours was 6.5 and 10.1 months, respectively.
__label__noRel	Although there was a tendency for improved survival in grade III, no statistical significant differences were found between the treatment groups.	In grade IV tumours the corresponding figures were 5.1 and 3.3 months, respectively.
__label__noRel	Although there was a tendency for improved survival in grade III, no statistical significant differences were found between the treatment groups.	No differences between the two treatment groups were evident with respect to quality of life according to the EORTC QLQ-protocol.
__label__noRel	Although there was a tendency for improved survival in grade III, no statistical significant differences were found between the treatment groups.	In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy,
__label__Support	Although there was a tendency for improved survival in grade III, no statistical significant differences were found between the treatment groups.	however, a trend for a positive response for the estramustine group was found in patients with grade III glioma.
__label__noRel	No differences between the two treatment groups were evident with respect to quality of life according to the EORTC QLQ-protocol.	Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma
__label__noRel	No differences between the two treatment groups were evident with respect to quality of life according to the EORTC QLQ-protocol.	Overall the treatment was well tolerated
__label__noRel	No differences between the two treatment groups were evident with respect to quality of life according to the EORTC QLQ-protocol.	Mild or moderate nausea was the most common side effect of estramustine.
__label__noRel	No differences between the two treatment groups were evident with respect to quality of life according to the EORTC QLQ-protocol.	For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group.
__label__noRel	No differences between the two treatment groups were evident with respect to quality of life according to the EORTC QLQ-protocol.	In grade IV the corresponding median survival time was 12.3 (2.1-89.2) and 10.3 (0.3-91.7+) months, respectively.
__label__noRel	No differences between the two treatment groups were evident with respect to quality of life according to the EORTC QLQ-protocol.	Median time to progress for radiotherapy only and radiotherapy and estramustin group in grade III tumours was 6.5 and 10.1 months, respectively.
__label__noRel	No differences between the two treatment groups were evident with respect to quality of life according to the EORTC QLQ-protocol.	In grade IV tumours the corresponding figures were 5.1 and 3.3 months, respectively.
__label__noRel	No differences between the two treatment groups were evident with respect to quality of life according to the EORTC QLQ-protocol.	Although there was a tendency for improved survival in grade III, no statistical significant differences were found between the treatment groups.
__label__Support	No differences between the two treatment groups were evident with respect to quality of life according to the EORTC QLQ-protocol.	In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy,
__label__noRel	No differences between the two treatment groups were evident with respect to quality of life according to the EORTC QLQ-protocol.	however, a trend for a positive response for the estramustine group was found in patients with grade III glioma.
__label__noRel	In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy,	Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma
__label__noRel	In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy,	Overall the treatment was well tolerated
__label__noRel	In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy,	Mild or moderate nausea was the most common side effect of estramustine.
__label__noRel	In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy,	For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group.
__label__noRel	In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy,	In grade IV the corresponding median survival time was 12.3 (2.1-89.2) and 10.3 (0.3-91.7+) months, respectively.
__label__noRel	In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy,	Median time to progress for radiotherapy only and radiotherapy and estramustin group in grade III tumours was 6.5 and 10.1 months, respectively.
__label__noRel	In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy,	In grade IV tumours the corresponding figures were 5.1 and 3.3 months, respectively.
__label__noRel	In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy,	Although there was a tendency for improved survival in grade III, no statistical significant differences were found between the treatment groups.
__label__noRel	In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy,	No differences between the two treatment groups were evident with respect to quality of life according to the EORTC QLQ-protocol.
__label__noRel	In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy,	however, a trend for a positive response for the estramustine group was found in patients with grade III glioma.
__label__noRel	however, a trend for a positive response for the estramustine group was found in patients with grade III glioma.	Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma
__label__noRel	however, a trend for a positive response for the estramustine group was found in patients with grade III glioma.	Overall the treatment was well tolerated
__label__noRel	however, a trend for a positive response for the estramustine group was found in patients with grade III glioma.	Mild or moderate nausea was the most common side effect of estramustine.
__label__noRel	however, a trend for a positive response for the estramustine group was found in patients with grade III glioma.	For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group.
__label__noRel	however, a trend for a positive response for the estramustine group was found in patients with grade III glioma.	In grade IV the corresponding median survival time was 12.3 (2.1-89.2) and 10.3 (0.3-91.7+) months, respectively.
__label__noRel	however, a trend for a positive response for the estramustine group was found in patients with grade III glioma.	Median time to progress for radiotherapy only and radiotherapy and estramustin group in grade III tumours was 6.5 and 10.1 months, respectively.
__label__noRel	however, a trend for a positive response for the estramustine group was found in patients with grade III glioma.	In grade IV tumours the corresponding figures were 5.1 and 3.3 months, respectively.
__label__noRel	however, a trend for a positive response for the estramustine group was found in patients with grade III glioma.	Although there was a tendency for improved survival in grade III, no statistical significant differences were found between the treatment groups.
__label__noRel	however, a trend for a positive response for the estramustine group was found in patients with grade III glioma.	No differences between the two treatment groups were evident with respect to quality of life according to the EORTC QLQ-protocol.
__label__Attack	however, a trend for a positive response for the estramustine group was found in patients with grade III glioma.	In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy,
__label__noRel	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.
__label__noRel	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).
__label__noRel	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.
__label__noRel	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.
__label__noRel	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.	There were no significant adverse effects associated with r-HuEPO.
__label__Support	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.
__label__noRel	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.
__label__noRel	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.
__label__noRel	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).
__label__noRel	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.
__label__noRel	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.
__label__noRel	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.	There were no significant adverse effects associated with r-HuEPO.
__label__noRel	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.
__label__Support	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.
__label__noRel	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.
__label__noRel	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.
__label__noRel	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.
__label__noRel	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.
__label__noRel	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).	There were no significant adverse effects associated with r-HuEPO.
__label__noRel	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.
__label__noRel	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.
__label__noRel	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.
__label__noRel	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.
__label__Attack	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).
__label__noRel	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.
__label__noRel	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.	There were no significant adverse effects associated with r-HuEPO.
__label__noRel	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.
__label__noRel	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.
__label__noRel	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.
__label__noRel	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.
__label__noRel	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).
__label__noRel	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.
__label__noRel	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.	There were no significant adverse effects associated with r-HuEPO.
__label__Support	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.
__label__noRel	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.
__label__noRel	There were no significant adverse effects associated with r-HuEPO.	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.
__label__noRel	There were no significant adverse effects associated with r-HuEPO.	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.
__label__noRel	There were no significant adverse effects associated with r-HuEPO.	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).
__label__noRel	There were no significant adverse effects associated with r-HuEPO.	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.
__label__noRel	There were no significant adverse effects associated with r-HuEPO.	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.
__label__Support	There were no significant adverse effects associated with r-HuEPO.	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.
__label__noRel	There were no significant adverse effects associated with r-HuEPO.	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.
__label__noRel	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.
__label__noRel	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.
__label__noRel	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).
__label__noRel	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.
__label__noRel	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.
__label__noRel	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.	There were no significant adverse effects associated with r-HuEPO.
__label__noRel	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.
__label__noRel	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.
__label__noRel	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.
__label__noRel	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).
__label__noRel	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.
__label__noRel	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.
__label__noRel	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.	There were no significant adverse effects associated with r-HuEPO.
__label__noRel	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.
__label__noRel	After intervention, EG participants showed improved QOL via decreased fear of recurrence and increased mindfulness attitude.	At 6 weeks, initial effects were retained.
__label__noRel	After intervention, EG participants showed improved QOL via decreased fear of recurrence and increased mindfulness attitude.	The MMP appears to benefit older BCSs by reducing fear of recurrence and improving mindfulness attitude.
__label__noRel	After intervention, EG participants showed improved QOL via decreased fear of recurrence and increased mindfulness attitude.	Although these findings are promising, a larger study is needed to determine more specifically what short- and long-term effects are possible.
__label__Support	After intervention, EG participants showed improved QOL via decreased fear of recurrence and increased mindfulness attitude.	The combination of self-directed movement and mindfulness, as tested here, may be a valuable tool for promoting health and well-being in older long-term survivors of breast cancer.
__label__noRel	At 6 weeks, initial effects were retained.	After intervention, EG participants showed improved QOL via decreased fear of recurrence and increased mindfulness attitude.
__label__noRel	At 6 weeks, initial effects were retained.	The MMP appears to benefit older BCSs by reducing fear of recurrence and improving mindfulness attitude.
__label__noRel	At 6 weeks, initial effects were retained.	Although these findings are promising, a larger study is needed to determine more specifically what short- and long-term effects are possible.
__label__Attack	At 6 weeks, initial effects were retained.	The combination of self-directed movement and mindfulness, as tested here, may be a valuable tool for promoting health and well-being in older long-term survivors of breast cancer.
__label__noRel	The MMP appears to benefit older BCSs by reducing fear of recurrence and improving mindfulness attitude.	After intervention, EG participants showed improved QOL via decreased fear of recurrence and increased mindfulness attitude.
__label__noRel	The MMP appears to benefit older BCSs by reducing fear of recurrence and improving mindfulness attitude.	At 6 weeks, initial effects were retained.
__label__noRel	The MMP appears to benefit older BCSs by reducing fear of recurrence and improving mindfulness attitude.	Although these findings are promising, a larger study is needed to determine more specifically what short- and long-term effects are possible.
__label__Support	The MMP appears to benefit older BCSs by reducing fear of recurrence and improving mindfulness attitude.	The combination of self-directed movement and mindfulness, as tested here, may be a valuable tool for promoting health and well-being in older long-term survivors of breast cancer.
__label__noRel	Although these findings are promising, a larger study is needed to determine more specifically what short- and long-term effects are possible.	After intervention, EG participants showed improved QOL via decreased fear of recurrence and increased mindfulness attitude.
__label__noRel	Although these findings are promising, a larger study is needed to determine more specifically what short- and long-term effects are possible.	At 6 weeks, initial effects were retained.
__label__noRel	Although these findings are promising, a larger study is needed to determine more specifically what short- and long-term effects are possible.	The MMP appears to benefit older BCSs by reducing fear of recurrence and improving mindfulness attitude.
__label__Attack	Although these findings are promising, a larger study is needed to determine more specifically what short- and long-term effects are possible.	The combination of self-directed movement and mindfulness, as tested here, may be a valuable tool for promoting health and well-being in older long-term survivors of breast cancer.
__label__noRel	The combination of self-directed movement and mindfulness, as tested here, may be a valuable tool for promoting health and well-being in older long-term survivors of breast cancer.	After intervention, EG participants showed improved QOL via decreased fear of recurrence and increased mindfulness attitude.
__label__noRel	The combination of self-directed movement and mindfulness, as tested here, may be a valuable tool for promoting health and well-being in older long-term survivors of breast cancer.	At 6 weeks, initial effects were retained.
__label__noRel	The combination of self-directed movement and mindfulness, as tested here, may be a valuable tool for promoting health and well-being in older long-term survivors of breast cancer.	The MMP appears to benefit older BCSs by reducing fear of recurrence and improving mindfulness attitude.
__label__noRel	The combination of self-directed movement and mindfulness, as tested here, may be a valuable tool for promoting health and well-being in older long-term survivors of breast cancer.	Although these findings are promising, a larger study is needed to determine more specifically what short- and long-term effects are possible.
__label__noRel	There was no evidence of a difference seen between groups for either activity (adjusted difference =-0.4, 95% confidence interval CI -1.0 to 0.2, p = 0.17) or profile scores (adjusted difference = -0.4, 95% CI -0.9 to 0.1, p = 0.13) using this trial design,	although post hoc power calculations suggests that 65-175 would be needed per group to detect differences of this magnitude with sufficient precision.
__label__noRel	There was no evidence of a difference seen between groups for either activity (adjusted difference =-0.4, 95% confidence interval CI -1.0 to 0.2, p = 0.17) or profile scores (adjusted difference = -0.4, 95% CI -0.9 to 0.1, p = 0.13) using this trial design,	Clinically relevant improvements in symptoms and mood disturbance were seen for both groups over the study period.
__label__noRel	There was no evidence of a difference seen between groups for either activity (adjusted difference =-0.4, 95% confidence interval CI -1.0 to 0.2, p = 0.17) or profile scores (adjusted difference = -0.4, 95% CI -0.9 to 0.1, p = 0.13) using this trial design,	Improvements were seen for symptom scores over the study period.
__label__Support	There was no evidence of a difference seen between groups for either activity (adjusted difference =-0.4, 95% confidence interval CI -1.0 to 0.2, p = 0.17) or profile scores (adjusted difference = -0.4, 95% CI -0.9 to 0.1, p = 0.13) using this trial design,	However, presuming these improvements were caused by the individualized homeopathic approach, the study failed to show clearly that the specific effect of the remedy added further to the nonspecific effects of the consultation.
__label__noRel	There was no evidence of a difference seen between groups for either activity (adjusted difference =-0.4, 95% confidence interval CI -1.0 to 0.2, p = 0.17) or profile scores (adjusted difference = -0.4, 95% CI -0.9 to 0.1, p = 0.13) using this trial design,	Future trial design must ensure adequate power to account for the nonspecific impact of such complex individualized interventions while pragmatic designs may more readily answer questions of clinical and cost effectiveness
__label__noRel	although post hoc power calculations suggests that 65-175 would be needed per group to detect differences of this magnitude with sufficient precision.	There was no evidence of a difference seen between groups for either activity (adjusted difference =-0.4, 95% confidence interval CI -1.0 to 0.2, p = 0.17) or profile scores (adjusted difference = -0.4, 95% CI -0.9 to 0.1, p = 0.13) using this trial design,
__label__noRel	although post hoc power calculations suggests that 65-175 would be needed per group to detect differences of this magnitude with sufficient precision.	Clinically relevant improvements in symptoms and mood disturbance were seen for both groups over the study period.
__label__noRel	although post hoc power calculations suggests that 65-175 would be needed per group to detect differences of this magnitude with sufficient precision.	Improvements were seen for symptom scores over the study period.
__label__noRel	although post hoc power calculations suggests that 65-175 would be needed per group to detect differences of this magnitude with sufficient precision.	However, presuming these improvements were caused by the individualized homeopathic approach, the study failed to show clearly that the specific effect of the remedy added further to the nonspecific effects of the consultation.
__label__Support	although post hoc power calculations suggests that 65-175 would be needed per group to detect differences of this magnitude with sufficient precision.	Future trial design must ensure adequate power to account for the nonspecific impact of such complex individualized interventions while pragmatic designs may more readily answer questions of clinical and cost effectiveness
__label__noRel	Clinically relevant improvements in symptoms and mood disturbance were seen for both groups over the study period.	There was no evidence of a difference seen between groups for either activity (adjusted difference =-0.4, 95% confidence interval CI -1.0 to 0.2, p = 0.17) or profile scores (adjusted difference = -0.4, 95% CI -0.9 to 0.1, p = 0.13) using this trial design,
__label__noRel	Clinically relevant improvements in symptoms and mood disturbance were seen for both groups over the study period.	although post hoc power calculations suggests that 65-175 would be needed per group to detect differences of this magnitude with sufficient precision.
__label__Support	Clinically relevant improvements in symptoms and mood disturbance were seen for both groups over the study period.	Improvements were seen for symptom scores over the study period.
__label__noRel	Clinically relevant improvements in symptoms and mood disturbance were seen for both groups over the study period.	However, presuming these improvements were caused by the individualized homeopathic approach, the study failed to show clearly that the specific effect of the remedy added further to the nonspecific effects of the consultation.
__label__noRel	Clinically relevant improvements in symptoms and mood disturbance were seen for both groups over the study period.	Future trial design must ensure adequate power to account for the nonspecific impact of such complex individualized interventions while pragmatic designs may more readily answer questions of clinical and cost effectiveness
__label__noRel	Improvements were seen for symptom scores over the study period.	There was no evidence of a difference seen between groups for either activity (adjusted difference =-0.4, 95% confidence interval CI -1.0 to 0.2, p = 0.17) or profile scores (adjusted difference = -0.4, 95% CI -0.9 to 0.1, p = 0.13) using this trial design,
__label__noRel	Improvements were seen for symptom scores over the study period.	although post hoc power calculations suggests that 65-175 would be needed per group to detect differences of this magnitude with sufficient precision.
__label__noRel	Improvements were seen for symptom scores over the study period.	Clinically relevant improvements in symptoms and mood disturbance were seen for both groups over the study period.
__label__noRel	Improvements were seen for symptom scores over the study period.	However, presuming these improvements were caused by the individualized homeopathic approach, the study failed to show clearly that the specific effect of the remedy added further to the nonspecific effects of the consultation.
__label__noRel	Improvements were seen for symptom scores over the study period.	Future trial design must ensure adequate power to account for the nonspecific impact of such complex individualized interventions while pragmatic designs may more readily answer questions of clinical and cost effectiveness
__label__noRel	However, presuming these improvements were caused by the individualized homeopathic approach, the study failed to show clearly that the specific effect of the remedy added further to the nonspecific effects of the consultation.	There was no evidence of a difference seen between groups for either activity (adjusted difference =-0.4, 95% confidence interval CI -1.0 to 0.2, p = 0.17) or profile scores (adjusted difference = -0.4, 95% CI -0.9 to 0.1, p = 0.13) using this trial design,
__label__noRel	However, presuming these improvements were caused by the individualized homeopathic approach, the study failed to show clearly that the specific effect of the remedy added further to the nonspecific effects of the consultation.	although post hoc power calculations suggests that 65-175 would be needed per group to detect differences of this magnitude with sufficient precision.
__label__noRel	However, presuming these improvements were caused by the individualized homeopathic approach, the study failed to show clearly that the specific effect of the remedy added further to the nonspecific effects of the consultation.	Clinically relevant improvements in symptoms and mood disturbance were seen for both groups over the study period.
__label__Attack	However, presuming these improvements were caused by the individualized homeopathic approach, the study failed to show clearly that the specific effect of the remedy added further to the nonspecific effects of the consultation.	Improvements were seen for symptom scores over the study period.
__label__noRel	However, presuming these improvements were caused by the individualized homeopathic approach, the study failed to show clearly that the specific effect of the remedy added further to the nonspecific effects of the consultation.	Future trial design must ensure adequate power to account for the nonspecific impact of such complex individualized interventions while pragmatic designs may more readily answer questions of clinical and cost effectiveness
__label__noRel	Future trial design must ensure adequate power to account for the nonspecific impact of such complex individualized interventions while pragmatic designs may more readily answer questions of clinical and cost effectiveness	There was no evidence of a difference seen between groups for either activity (adjusted difference =-0.4, 95% confidence interval CI -1.0 to 0.2, p = 0.17) or profile scores (adjusted difference = -0.4, 95% CI -0.9 to 0.1, p = 0.13) using this trial design,
__label__noRel	Future trial design must ensure adequate power to account for the nonspecific impact of such complex individualized interventions while pragmatic designs may more readily answer questions of clinical and cost effectiveness	although post hoc power calculations suggests that 65-175 would be needed per group to detect differences of this magnitude with sufficient precision.
__label__noRel	Future trial design must ensure adequate power to account for the nonspecific impact of such complex individualized interventions while pragmatic designs may more readily answer questions of clinical and cost effectiveness	Clinically relevant improvements in symptoms and mood disturbance were seen for both groups over the study period.
__label__Attack	Future trial design must ensure adequate power to account for the nonspecific impact of such complex individualized interventions while pragmatic designs may more readily answer questions of clinical and cost effectiveness	Improvements were seen for symptom scores over the study period.
__label__noRel	Future trial design must ensure adequate power to account for the nonspecific impact of such complex individualized interventions while pragmatic designs may more readily answer questions of clinical and cost effectiveness	However, presuming these improvements were caused by the individualized homeopathic approach, the study failed to show clearly that the specific effect of the remedy added further to the nonspecific effects of the consultation.
__label__noRel	Capecitabine treatment was associated with less nausea, vomiting, and constipation and with better appetite than standard treatment (P  .004), but worse hand-foot syndrome and diarrhea (P < .005).	Compared with patients who were treated with standard chemotherapy, patients who were treated with capecitabine had significantly better QoL, role function, and social function, fewer systemic adverse effects, less psychological distress, and less fatigue during and at the completion of treatment (P  .005).
__label__noRel	Capecitabine treatment was associated with less nausea, vomiting, and constipation and with better appetite than standard treatment (P  .004), but worse hand-foot syndrome and diarrhea (P < .005).	Standard chemotherapy was superior to capecitabine in improving relapse-free and overall survival for older women with early-stage breast cancer.
__label__Support	Capecitabine treatment was associated with less nausea, vomiting, and constipation and with better appetite than standard treatment (P  .004), but worse hand-foot syndrome and diarrhea (P < .005).	capecitabine was associated with better QoL during treatment
__label__noRel	Capecitabine treatment was associated with less nausea, vomiting, and constipation and with better appetite than standard treatment (P  .004), but worse hand-foot syndrome and diarrhea (P < .005).	QoL was similar for both groups at 1 year.
__label__noRel	Compared with patients who were treated with standard chemotherapy, patients who were treated with capecitabine had significantly better QoL, role function, and social function, fewer systemic adverse effects, less psychological distress, and less fatigue during and at the completion of treatment (P  .005).	Capecitabine treatment was associated with less nausea, vomiting, and constipation and with better appetite than standard treatment (P  .004), but worse hand-foot syndrome and diarrhea (P < .005).
__label__noRel	Compared with patients who were treated with standard chemotherapy, patients who were treated with capecitabine had significantly better QoL, role function, and social function, fewer systemic adverse effects, less psychological distress, and less fatigue during and at the completion of treatment (P  .005).	Standard chemotherapy was superior to capecitabine in improving relapse-free and overall survival for older women with early-stage breast cancer.
__label__Support	Compared with patients who were treated with standard chemotherapy, patients who were treated with capecitabine had significantly better QoL, role function, and social function, fewer systemic adverse effects, less psychological distress, and less fatigue during and at the completion of treatment (P  .005).	capecitabine was associated with better QoL during treatment
__label__noRel	Compared with patients who were treated with standard chemotherapy, patients who were treated with capecitabine had significantly better QoL, role function, and social function, fewer systemic adverse effects, less psychological distress, and less fatigue during and at the completion of treatment (P  .005).	QoL was similar for both groups at 1 year.
__label__noRel	Standard chemotherapy was superior to capecitabine in improving relapse-free and overall survival for older women with early-stage breast cancer.	Capecitabine treatment was associated with less nausea, vomiting, and constipation and with better appetite than standard treatment (P  .004), but worse hand-foot syndrome and diarrhea (P < .005).
__label__noRel	Standard chemotherapy was superior to capecitabine in improving relapse-free and overall survival for older women with early-stage breast cancer.	Compared with patients who were treated with standard chemotherapy, patients who were treated with capecitabine had significantly better QoL, role function, and social function, fewer systemic adverse effects, less psychological distress, and less fatigue during and at the completion of treatment (P  .005).
__label__noRel	Standard chemotherapy was superior to capecitabine in improving relapse-free and overall survival for older women with early-stage breast cancer.	capecitabine was associated with better QoL during treatment
__label__noRel	Standard chemotherapy was superior to capecitabine in improving relapse-free and overall survival for older women with early-stage breast cancer.	QoL was similar for both groups at 1 year.
__label__noRel	capecitabine was associated with better QoL during treatment	Capecitabine treatment was associated with less nausea, vomiting, and constipation and with better appetite than standard treatment (P  .004), but worse hand-foot syndrome and diarrhea (P < .005).
__label__noRel	capecitabine was associated with better QoL during treatment	Compared with patients who were treated with standard chemotherapy, patients who were treated with capecitabine had significantly better QoL, role function, and social function, fewer systemic adverse effects, less psychological distress, and less fatigue during and at the completion of treatment (P  .005).
__label__noRel	capecitabine was associated with better QoL during treatment	Standard chemotherapy was superior to capecitabine in improving relapse-free and overall survival for older women with early-stage breast cancer.
__label__noRel	capecitabine was associated with better QoL during treatment	QoL was similar for both groups at 1 year.
__label__noRel	QoL was similar for both groups at 1 year.	Capecitabine treatment was associated with less nausea, vomiting, and constipation and with better appetite than standard treatment (P  .004), but worse hand-foot syndrome and diarrhea (P < .005).
__label__noRel	QoL was similar for both groups at 1 year.	Compared with patients who were treated with standard chemotherapy, patients who were treated with capecitabine had significantly better QoL, role function, and social function, fewer systemic adverse effects, less psychological distress, and less fatigue during and at the completion of treatment (P  .005).
__label__noRel	QoL was similar for both groups at 1 year.	Standard chemotherapy was superior to capecitabine in improving relapse-free and overall survival for older women with early-stage breast cancer.
__label__Attack	QoL was similar for both groups at 1 year.	capecitabine was associated with better QoL during treatment
__label__noRel	There was a significant decrease in pad use in group A.	After 16 wk, 39 patients versus 27 were dry (p=0.007).
__label__noRel	There was a significant decrease in pad use in group A.	At 20 wk, 4 wk after planned interruption of duloxetine, we observed a U-turn, 23 patients were completely dry in group A versus 38 in group B (p=0.008).
__label__noRel	There was a significant decrease in pad use in group A.	Whereas, after 24 wk, 31 in group A versus 41 in group B were dry (p=0.08)
__label__noRel	There was a significant decrease in pad use in group A.	The decrease in IEF and improvements in I-QoL scores were significantly greater in group A for the first 16 wk.
__label__noRel	There was a significant decrease in pad use in group A.	The data suggest that combination therapy might provide another treatment option for SUI in men that might increase the percentage of early postsurgery continence.
__label__noRel	After 16 wk, 39 patients versus 27 were dry (p=0.007).	There was a significant decrease in pad use in group A.
__label__noRel	After 16 wk, 39 patients versus 27 were dry (p=0.007).	At 20 wk, 4 wk after planned interruption of duloxetine, we observed a U-turn, 23 patients were completely dry in group A versus 38 in group B (p=0.008).
__label__noRel	After 16 wk, 39 patients versus 27 were dry (p=0.007).	Whereas, after 24 wk, 31 in group A versus 41 in group B were dry (p=0.08)
__label__Support	After 16 wk, 39 patients versus 27 were dry (p=0.007).	The decrease in IEF and improvements in I-QoL scores were significantly greater in group A for the first 16 wk.
__label__noRel	After 16 wk, 39 patients versus 27 were dry (p=0.007).	The data suggest that combination therapy might provide another treatment option for SUI in men that might increase the percentage of early postsurgery continence.
__label__noRel	At 20 wk, 4 wk after planned interruption of duloxetine, we observed a U-turn, 23 patients were completely dry in group A versus 38 in group B (p=0.008).	There was a significant decrease in pad use in group A.
__label__noRel	At 20 wk, 4 wk after planned interruption of duloxetine, we observed a U-turn, 23 patients were completely dry in group A versus 38 in group B (p=0.008).	After 16 wk, 39 patients versus 27 were dry (p=0.007).
__label__noRel	At 20 wk, 4 wk after planned interruption of duloxetine, we observed a U-turn, 23 patients were completely dry in group A versus 38 in group B (p=0.008).	Whereas, after 24 wk, 31 in group A versus 41 in group B were dry (p=0.08)
__label__Support	At 20 wk, 4 wk after planned interruption of duloxetine, we observed a U-turn, 23 patients were completely dry in group A versus 38 in group B (p=0.008).	The decrease in IEF and improvements in I-QoL scores were significantly greater in group A for the first 16 wk.
__label__noRel	At 20 wk, 4 wk after planned interruption of duloxetine, we observed a U-turn, 23 patients were completely dry in group A versus 38 in group B (p=0.008).	The data suggest that combination therapy might provide another treatment option for SUI in men that might increase the percentage of early postsurgery continence.
__label__noRel	Whereas, after 24 wk, 31 in group A versus 41 in group B were dry (p=0.08)	There was a significant decrease in pad use in group A.
__label__noRel	Whereas, after 24 wk, 31 in group A versus 41 in group B were dry (p=0.08)	After 16 wk, 39 patients versus 27 were dry (p=0.007).
__label__noRel	Whereas, after 24 wk, 31 in group A versus 41 in group B were dry (p=0.08)	At 20 wk, 4 wk after planned interruption of duloxetine, we observed a U-turn, 23 patients were completely dry in group A versus 38 in group B (p=0.008).
__label__Support	Whereas, after 24 wk, 31 in group A versus 41 in group B were dry (p=0.08)	The decrease in IEF and improvements in I-QoL scores were significantly greater in group A for the first 16 wk.
__label__noRel	Whereas, after 24 wk, 31 in group A versus 41 in group B were dry (p=0.08)	The data suggest that combination therapy might provide another treatment option for SUI in men that might increase the percentage of early postsurgery continence.
__label__noRel	The decrease in IEF and improvements in I-QoL scores were significantly greater in group A for the first 16 wk.	There was a significant decrease in pad use in group A.
__label__noRel	The decrease in IEF and improvements in I-QoL scores were significantly greater in group A for the first 16 wk.	After 16 wk, 39 patients versus 27 were dry (p=0.007).
__label__noRel	The decrease in IEF and improvements in I-QoL scores were significantly greater in group A for the first 16 wk.	At 20 wk, 4 wk after planned interruption of duloxetine, we observed a U-turn, 23 patients were completely dry in group A versus 38 in group B (p=0.008).
__label__noRel	The decrease in IEF and improvements in I-QoL scores were significantly greater in group A for the first 16 wk.	Whereas, after 24 wk, 31 in group A versus 41 in group B were dry (p=0.08)
__label__Support	The decrease in IEF and improvements in I-QoL scores were significantly greater in group A for the first 16 wk.	The data suggest that combination therapy might provide another treatment option for SUI in men that might increase the percentage of early postsurgery continence.
__label__noRel	The data suggest that combination therapy might provide another treatment option for SUI in men that might increase the percentage of early postsurgery continence.	There was a significant decrease in pad use in group A.
__label__noRel	The data suggest that combination therapy might provide another treatment option for SUI in men that might increase the percentage of early postsurgery continence.	After 16 wk, 39 patients versus 27 were dry (p=0.007).
__label__noRel	The data suggest that combination therapy might provide another treatment option for SUI in men that might increase the percentage of early postsurgery continence.	At 20 wk, 4 wk after planned interruption of duloxetine, we observed a U-turn, 23 patients were completely dry in group A versus 38 in group B (p=0.008).
__label__noRel	The data suggest that combination therapy might provide another treatment option for SUI in men that might increase the percentage of early postsurgery continence.	Whereas, after 24 wk, 31 in group A versus 41 in group B were dry (p=0.08)
__label__noRel	The data suggest that combination therapy might provide another treatment option for SUI in men that might increase the percentage of early postsurgery continence.	The decrease in IEF and improvements in I-QoL scores were significantly greater in group A for the first 16 wk.
__label__noRel	The primary outcome was significantly lower in the intervention arm (adjusted difference -16.8, 95% CI -28.34 to -5.3; P=0.006).	The SCNS physical and patient care subscales (-14.2, 95% CI -26.2 to -2.2; P=0.02 and -7.4, 95% CI -13.7 to -1.1; P=0.02, respectively) and self-reported health state (12.8, 95% CI 3.2 to 22.4; P=0.01) also differed significantly.
__label__noRel	The primary outcome was significantly lower in the intervention arm (adjusted difference -16.8, 95% CI -28.34 to -5.3; P=0.006).	The incremental cost-effectiveness ratio was 19,390 per quality-adjusted life year.
__label__Support	The primary outcome was significantly lower in the intervention arm (adjusted difference -16.8, 95% CI -28.34 to -5.3; P=0.006).	This intervention significantly reduced the unmet needs of cancer survivors and it is likely that it is cost-effective.
__label__noRel	The primary outcome was significantly lower in the intervention arm (adjusted difference -16.8, 95% CI -28.34 to -5.3; P=0.006).	Despite small numbers, the main effect size was robust.
__label__noRel	The primary outcome was significantly lower in the intervention arm (adjusted difference -16.8, 95% CI -28.34 to -5.3; P=0.006).	We recommend implementation alongside evaluation inwider clinical settings and patient populations.
__label__noRel	The SCNS physical and patient care subscales (-14.2, 95% CI -26.2 to -2.2; P=0.02 and -7.4, 95% CI -13.7 to -1.1; P=0.02, respectively) and self-reported health state (12.8, 95% CI 3.2 to 22.4; P=0.01) also differed significantly.	The primary outcome was significantly lower in the intervention arm (adjusted difference -16.8, 95% CI -28.34 to -5.3; P=0.006).
__label__noRel	The SCNS physical and patient care subscales (-14.2, 95% CI -26.2 to -2.2; P=0.02 and -7.4, 95% CI -13.7 to -1.1; P=0.02, respectively) and self-reported health state (12.8, 95% CI 3.2 to 22.4; P=0.01) also differed significantly.	The incremental cost-effectiveness ratio was 19,390 per quality-adjusted life year.
__label__Support	The SCNS physical and patient care subscales (-14.2, 95% CI -26.2 to -2.2; P=0.02 and -7.4, 95% CI -13.7 to -1.1; P=0.02, respectively) and self-reported health state (12.8, 95% CI 3.2 to 22.4; P=0.01) also differed significantly.	This intervention significantly reduced the unmet needs of cancer survivors and it is likely that it is cost-effective.
__label__noRel	The SCNS physical and patient care subscales (-14.2, 95% CI -26.2 to -2.2; P=0.02 and -7.4, 95% CI -13.7 to -1.1; P=0.02, respectively) and self-reported health state (12.8, 95% CI 3.2 to 22.4; P=0.01) also differed significantly.	Despite small numbers, the main effect size was robust.
__label__noRel	The SCNS physical and patient care subscales (-14.2, 95% CI -26.2 to -2.2; P=0.02 and -7.4, 95% CI -13.7 to -1.1; P=0.02, respectively) and self-reported health state (12.8, 95% CI 3.2 to 22.4; P=0.01) also differed significantly.	We recommend implementation alongside evaluation inwider clinical settings and patient populations.
__label__noRel	The incremental cost-effectiveness ratio was 19,390 per quality-adjusted life year.	The primary outcome was significantly lower in the intervention arm (adjusted difference -16.8, 95% CI -28.34 to -5.3; P=0.006).
__label__noRel	The incremental cost-effectiveness ratio was 19,390 per quality-adjusted life year.	The SCNS physical and patient care subscales (-14.2, 95% CI -26.2 to -2.2; P=0.02 and -7.4, 95% CI -13.7 to -1.1; P=0.02, respectively) and self-reported health state (12.8, 95% CI 3.2 to 22.4; P=0.01) also differed significantly.
__label__Support	The incremental cost-effectiveness ratio was 19,390 per quality-adjusted life year.	This intervention significantly reduced the unmet needs of cancer survivors and it is likely that it is cost-effective.
__label__noRel	The incremental cost-effectiveness ratio was 19,390 per quality-adjusted life year.	Despite small numbers, the main effect size was robust.
__label__noRel	The incremental cost-effectiveness ratio was 19,390 per quality-adjusted life year.	We recommend implementation alongside evaluation inwider clinical settings and patient populations.
__label__noRel	This intervention significantly reduced the unmet needs of cancer survivors and it is likely that it is cost-effective.	The primary outcome was significantly lower in the intervention arm (adjusted difference -16.8, 95% CI -28.34 to -5.3; P=0.006).
__label__noRel	This intervention significantly reduced the unmet needs of cancer survivors and it is likely that it is cost-effective.	The SCNS physical and patient care subscales (-14.2, 95% CI -26.2 to -2.2; P=0.02 and -7.4, 95% CI -13.7 to -1.1; P=0.02, respectively) and self-reported health state (12.8, 95% CI 3.2 to 22.4; P=0.01) also differed significantly.
__label__noRel	This intervention significantly reduced the unmet needs of cancer survivors and it is likely that it is cost-effective.	The incremental cost-effectiveness ratio was 19,390 per quality-adjusted life year.
__label__noRel	This intervention significantly reduced the unmet needs of cancer survivors and it is likely that it is cost-effective.	Despite small numbers, the main effect size was robust.
__label__noRel	This intervention significantly reduced the unmet needs of cancer survivors and it is likely that it is cost-effective.	We recommend implementation alongside evaluation inwider clinical settings and patient populations.
__label__noRel	Despite small numbers, the main effect size was robust.	The primary outcome was significantly lower in the intervention arm (adjusted difference -16.8, 95% CI -28.34 to -5.3; P=0.006).
__label__noRel	Despite small numbers, the main effect size was robust.	The SCNS physical and patient care subscales (-14.2, 95% CI -26.2 to -2.2; P=0.02 and -7.4, 95% CI -13.7 to -1.1; P=0.02, respectively) and self-reported health state (12.8, 95% CI 3.2 to 22.4; P=0.01) also differed significantly.
__label__noRel	Despite small numbers, the main effect size was robust.	The incremental cost-effectiveness ratio was 19,390 per quality-adjusted life year.
__label__noRel	Despite small numbers, the main effect size was robust.	This intervention significantly reduced the unmet needs of cancer survivors and it is likely that it is cost-effective.
__label__Attack	Despite small numbers, the main effect size was robust.	We recommend implementation alongside evaluation inwider clinical settings and patient populations.
__label__noRel	We recommend implementation alongside evaluation inwider clinical settings and patient populations.	The primary outcome was significantly lower in the intervention arm (adjusted difference -16.8, 95% CI -28.34 to -5.3; P=0.006).
__label__noRel	We recommend implementation alongside evaluation inwider clinical settings and patient populations.	The SCNS physical and patient care subscales (-14.2, 95% CI -26.2 to -2.2; P=0.02 and -7.4, 95% CI -13.7 to -1.1; P=0.02, respectively) and self-reported health state (12.8, 95% CI 3.2 to 22.4; P=0.01) also differed significantly.
__label__noRel	We recommend implementation alongside evaluation inwider clinical settings and patient populations.	The incremental cost-effectiveness ratio was 19,390 per quality-adjusted life year.
__label__Attack	We recommend implementation alongside evaluation inwider clinical settings and patient populations.	This intervention significantly reduced the unmet needs of cancer survivors and it is likely that it is cost-effective.
__label__noRel	We recommend implementation alongside evaluation inwider clinical settings and patient populations.	Despite small numbers, the main effect size was robust.
__label__noRel	Nausea and vomiting frequency, duration, and distress were lower for experimental group members,	although a high attrition rate (50%) resulted in insufficient power to detect statistically significant differences over time.
__label__Support	Nausea and vomiting frequency, duration, and distress were lower for experimental group members,	Flavonoid-rich fruits and vegetables may provide additional protection against CINV.
__label__noRel	Nausea and vomiting frequency, duration, and distress were lower for experimental group members,	The effect of grape juice flavonoids on CINV should be investigated further with a larger sample to determine whether preliminary findings are supported.
__label__Attack	although a high attrition rate (50%) resulted in insufficient power to detect statistically significant differences over time.	Nausea and vomiting frequency, duration, and distress were lower for experimental group members,
__label__noRel	although a high attrition rate (50%) resulted in insufficient power to detect statistically significant differences over time.	Flavonoid-rich fruits and vegetables may provide additional protection against CINV.
__label__noRel	although a high attrition rate (50%) resulted in insufficient power to detect statistically significant differences over time.	The effect of grape juice flavonoids on CINV should be investigated further with a larger sample to determine whether preliminary findings are supported.
__label__noRel	Flavonoid-rich fruits and vegetables may provide additional protection against CINV.	Nausea and vomiting frequency, duration, and distress were lower for experimental group members,
__label__noRel	Flavonoid-rich fruits and vegetables may provide additional protection against CINV.	although a high attrition rate (50%) resulted in insufficient power to detect statistically significant differences over time.
__label__noRel	Flavonoid-rich fruits and vegetables may provide additional protection against CINV.	The effect of grape juice flavonoids on CINV should be investigated further with a larger sample to determine whether preliminary findings are supported.
__label__noRel	The effect of grape juice flavonoids on CINV should be investigated further with a larger sample to determine whether preliminary findings are supported.	Nausea and vomiting frequency, duration, and distress were lower for experimental group members,
__label__noRel	The effect of grape juice flavonoids on CINV should be investigated further with a larger sample to determine whether preliminary findings are supported.	although a high attrition rate (50%) resulted in insufficient power to detect statistically significant differences over time.
__label__Attack	The effect of grape juice flavonoids on CINV should be investigated further with a larger sample to determine whether preliminary findings are supported.	Flavonoid-rich fruits and vegetables may provide additional protection against CINV.
__label__noRel	The role of adjuvant chemotherapy in postmenopausal patients with lymph node-negative breast cancer is controversial.	The added benefit of CMF followed by tamoxifen over tamoxifen alone was statistically significantly dependent on ER status (tests for interaction: P =.01 for disease-free survival [DFS] and P =.07 for overall survival [OS]).
__label__noRel	The role of adjuvant chemotherapy in postmenopausal patients with lymph node-negative breast cancer is controversial.	For patients with ER-negative tumors, the addition of CMF statistically significantly improved DFS (5-year DFS = 84% for CMF-->tamoxifen versus 69% for tamoxifen alone; difference = 15%; 95% confidence interval [CI] = 6% to 24%; risk ratio [RR] = 0.52; 95% CI = 0.34 to 0.79; P =.003) and OS (5-year OS = 89% for CMF-->tamoxifen versus 81% for tamoxifen alone; difference = 8%; 95% CI = 0% to 16%; RR = 0.51; 95% CI = 0.30 to 0.87; P =.01).
__label__noRel	The role of adjuvant chemotherapy in postmenopausal patients with lymph node-negative breast cancer is controversial.	By contrast, for patients with ER-positive tumors, addition of CMF provided no benefit in terms of DFS (5-year DFS = 84% for CMF-->tamoxifen versus 85% for tamoxifen alone; difference = -1; 95% CI = -6% to 4%; RR = 0.99; 95% CI = 0.75 to 1.30; P =.92) or OS (5-year OS = 95% for CMF-->tamoxifen versus 93% for tamoxifen alone; difference = 2%; 95% CI = -1% to 5%; RR = 0.95; 95% CI = 0.64 to 1.40; P =.80).
__label__noRel	The role of adjuvant chemotherapy in postmenopausal patients with lymph node-negative breast cancer is controversial.	Postmenopausal patients with lymph node-negative breast cancer benefited substantially from adjuvant chemotherapy if their cancer was ER-negative (i.e., endocrine-nonresponsive).
__label__noRel	The role of adjuvant chemotherapy in postmenopausal patients with lymph node-negative breast cancer is controversial.	In contrast, if their cancer was ER-positive (i.e., endocrine-responsive), they obtained no benefit from the combination treatment compared with tamoxifen alone.
__label__noRel	The added benefit of CMF followed by tamoxifen over tamoxifen alone was statistically significantly dependent on ER status (tests for interaction: P =.01 for disease-free survival [DFS] and P =.07 for overall survival [OS]).	The role of adjuvant chemotherapy in postmenopausal patients with lymph node-negative breast cancer is controversial.
__label__noRel	The added benefit of CMF followed by tamoxifen over tamoxifen alone was statistically significantly dependent on ER status (tests for interaction: P =.01 for disease-free survival [DFS] and P =.07 for overall survival [OS]).	For patients with ER-negative tumors, the addition of CMF statistically significantly improved DFS (5-year DFS = 84% for CMF-->tamoxifen versus 69% for tamoxifen alone; difference = 15%; 95% confidence interval [CI] = 6% to 24%; risk ratio [RR] = 0.52; 95% CI = 0.34 to 0.79; P =.003) and OS (5-year OS = 89% for CMF-->tamoxifen versus 81% for tamoxifen alone; difference = 8%; 95% CI = 0% to 16%; RR = 0.51; 95% CI = 0.30 to 0.87; P =.01).
__label__noRel	The added benefit of CMF followed by tamoxifen over tamoxifen alone was statistically significantly dependent on ER status (tests for interaction: P =.01 for disease-free survival [DFS] and P =.07 for overall survival [OS]).	By contrast, for patients with ER-positive tumors, addition of CMF provided no benefit in terms of DFS (5-year DFS = 84% for CMF-->tamoxifen versus 85% for tamoxifen alone; difference = -1; 95% CI = -6% to 4%; RR = 0.99; 95% CI = 0.75 to 1.30; P =.92) or OS (5-year OS = 95% for CMF-->tamoxifen versus 93% for tamoxifen alone; difference = 2%; 95% CI = -1% to 5%; RR = 0.95; 95% CI = 0.64 to 1.40; P =.80).
__label__noRel	The added benefit of CMF followed by tamoxifen over tamoxifen alone was statistically significantly dependent on ER status (tests for interaction: P =.01 for disease-free survival [DFS] and P =.07 for overall survival [OS]).	Postmenopausal patients with lymph node-negative breast cancer benefited substantially from adjuvant chemotherapy if their cancer was ER-negative (i.e., endocrine-nonresponsive).
__label__noRel	The added benefit of CMF followed by tamoxifen over tamoxifen alone was statistically significantly dependent on ER status (tests for interaction: P =.01 for disease-free survival [DFS] and P =.07 for overall survival [OS]).	In contrast, if their cancer was ER-positive (i.e., endocrine-responsive), they obtained no benefit from the combination treatment compared with tamoxifen alone.
__label__noRel	For patients with ER-negative tumors, the addition of CMF statistically significantly improved DFS (5-year DFS = 84% for CMF-->tamoxifen versus 69% for tamoxifen alone; difference = 15%; 95% confidence interval [CI] = 6% to 24%; risk ratio [RR] = 0.52; 95% CI = 0.34 to 0.79; P =.003) and OS (5-year OS = 89% for CMF-->tamoxifen versus 81% for tamoxifen alone; difference = 8%; 95% CI = 0% to 16%; RR = 0.51; 95% CI = 0.30 to 0.87; P =.01).	The role of adjuvant chemotherapy in postmenopausal patients with lymph node-negative breast cancer is controversial.
__label__noRel	For patients with ER-negative tumors, the addition of CMF statistically significantly improved DFS (5-year DFS = 84% for CMF-->tamoxifen versus 69% for tamoxifen alone; difference = 15%; 95% confidence interval [CI] = 6% to 24%; risk ratio [RR] = 0.52; 95% CI = 0.34 to 0.79; P =.003) and OS (5-year OS = 89% for CMF-->tamoxifen versus 81% for tamoxifen alone; difference = 8%; 95% CI = 0% to 16%; RR = 0.51; 95% CI = 0.30 to 0.87; P =.01).	The added benefit of CMF followed by tamoxifen over tamoxifen alone was statistically significantly dependent on ER status (tests for interaction: P =.01 for disease-free survival [DFS] and P =.07 for overall survival [OS]).
__label__noRel	For patients with ER-negative tumors, the addition of CMF statistically significantly improved DFS (5-year DFS = 84% for CMF-->tamoxifen versus 69% for tamoxifen alone; difference = 15%; 95% confidence interval [CI] = 6% to 24%; risk ratio [RR] = 0.52; 95% CI = 0.34 to 0.79; P =.003) and OS (5-year OS = 89% for CMF-->tamoxifen versus 81% for tamoxifen alone; difference = 8%; 95% CI = 0% to 16%; RR = 0.51; 95% CI = 0.30 to 0.87; P =.01).	By contrast, for patients with ER-positive tumors, addition of CMF provided no benefit in terms of DFS (5-year DFS = 84% for CMF-->tamoxifen versus 85% for tamoxifen alone; difference = -1; 95% CI = -6% to 4%; RR = 0.99; 95% CI = 0.75 to 1.30; P =.92) or OS (5-year OS = 95% for CMF-->tamoxifen versus 93% for tamoxifen alone; difference = 2%; 95% CI = -1% to 5%; RR = 0.95; 95% CI = 0.64 to 1.40; P =.80).
__label__Support	For patients with ER-negative tumors, the addition of CMF statistically significantly improved DFS (5-year DFS = 84% for CMF-->tamoxifen versus 69% for tamoxifen alone; difference = 15%; 95% confidence interval [CI] = 6% to 24%; risk ratio [RR] = 0.52; 95% CI = 0.34 to 0.79; P =.003) and OS (5-year OS = 89% for CMF-->tamoxifen versus 81% for tamoxifen alone; difference = 8%; 95% CI = 0% to 16%; RR = 0.51; 95% CI = 0.30 to 0.87; P =.01).	Postmenopausal patients with lymph node-negative breast cancer benefited substantially from adjuvant chemotherapy if their cancer was ER-negative (i.e., endocrine-nonresponsive).
__label__noRel	For patients with ER-negative tumors, the addition of CMF statistically significantly improved DFS (5-year DFS = 84% for CMF-->tamoxifen versus 69% for tamoxifen alone; difference = 15%; 95% confidence interval [CI] = 6% to 24%; risk ratio [RR] = 0.52; 95% CI = 0.34 to 0.79; P =.003) and OS (5-year OS = 89% for CMF-->tamoxifen versus 81% for tamoxifen alone; difference = 8%; 95% CI = 0% to 16%; RR = 0.51; 95% CI = 0.30 to 0.87; P =.01).	In contrast, if their cancer was ER-positive (i.e., endocrine-responsive), they obtained no benefit from the combination treatment compared with tamoxifen alone.
__label__noRel	By contrast, for patients with ER-positive tumors, addition of CMF provided no benefit in terms of DFS (5-year DFS = 84% for CMF-->tamoxifen versus 85% for tamoxifen alone; difference = -1; 95% CI = -6% to 4%; RR = 0.99; 95% CI = 0.75 to 1.30; P =.92) or OS (5-year OS = 95% for CMF-->tamoxifen versus 93% for tamoxifen alone; difference = 2%; 95% CI = -1% to 5%; RR = 0.95; 95% CI = 0.64 to 1.40; P =.80).	The role of adjuvant chemotherapy in postmenopausal patients with lymph node-negative breast cancer is controversial.
__label__noRel	By contrast, for patients with ER-positive tumors, addition of CMF provided no benefit in terms of DFS (5-year DFS = 84% for CMF-->tamoxifen versus 85% for tamoxifen alone; difference = -1; 95% CI = -6% to 4%; RR = 0.99; 95% CI = 0.75 to 1.30; P =.92) or OS (5-year OS = 95% for CMF-->tamoxifen versus 93% for tamoxifen alone; difference = 2%; 95% CI = -1% to 5%; RR = 0.95; 95% CI = 0.64 to 1.40; P =.80).	The added benefit of CMF followed by tamoxifen over tamoxifen alone was statistically significantly dependent on ER status (tests for interaction: P =.01 for disease-free survival [DFS] and P =.07 for overall survival [OS]).
__label__noRel	By contrast, for patients with ER-positive tumors, addition of CMF provided no benefit in terms of DFS (5-year DFS = 84% for CMF-->tamoxifen versus 85% for tamoxifen alone; difference = -1; 95% CI = -6% to 4%; RR = 0.99; 95% CI = 0.75 to 1.30; P =.92) or OS (5-year OS = 95% for CMF-->tamoxifen versus 93% for tamoxifen alone; difference = 2%; 95% CI = -1% to 5%; RR = 0.95; 95% CI = 0.64 to 1.40; P =.80).	For patients with ER-negative tumors, the addition of CMF statistically significantly improved DFS (5-year DFS = 84% for CMF-->tamoxifen versus 69% for tamoxifen alone; difference = 15%; 95% confidence interval [CI] = 6% to 24%; risk ratio [RR] = 0.52; 95% CI = 0.34 to 0.79; P =.003) and OS (5-year OS = 89% for CMF-->tamoxifen versus 81% for tamoxifen alone; difference = 8%; 95% CI = 0% to 16%; RR = 0.51; 95% CI = 0.30 to 0.87; P =.01).
__label__noRel	By contrast, for patients with ER-positive tumors, addition of CMF provided no benefit in terms of DFS (5-year DFS = 84% for CMF-->tamoxifen versus 85% for tamoxifen alone; difference = -1; 95% CI = -6% to 4%; RR = 0.99; 95% CI = 0.75 to 1.30; P =.92) or OS (5-year OS = 95% for CMF-->tamoxifen versus 93% for tamoxifen alone; difference = 2%; 95% CI = -1% to 5%; RR = 0.95; 95% CI = 0.64 to 1.40; P =.80).	Postmenopausal patients with lymph node-negative breast cancer benefited substantially from adjuvant chemotherapy if their cancer was ER-negative (i.e., endocrine-nonresponsive).
__label__Support	By contrast, for patients with ER-positive tumors, addition of CMF provided no benefit in terms of DFS (5-year DFS = 84% for CMF-->tamoxifen versus 85% for tamoxifen alone; difference = -1; 95% CI = -6% to 4%; RR = 0.99; 95% CI = 0.75 to 1.30; P =.92) or OS (5-year OS = 95% for CMF-->tamoxifen versus 93% for tamoxifen alone; difference = 2%; 95% CI = -1% to 5%; RR = 0.95; 95% CI = 0.64 to 1.40; P =.80).	In contrast, if their cancer was ER-positive (i.e., endocrine-responsive), they obtained no benefit from the combination treatment compared with tamoxifen alone.
__label__noRel	Postmenopausal patients with lymph node-negative breast cancer benefited substantially from adjuvant chemotherapy if their cancer was ER-negative (i.e., endocrine-nonresponsive).	The role of adjuvant chemotherapy in postmenopausal patients with lymph node-negative breast cancer is controversial.
__label__noRel	Postmenopausal patients with lymph node-negative breast cancer benefited substantially from adjuvant chemotherapy if their cancer was ER-negative (i.e., endocrine-nonresponsive).	The added benefit of CMF followed by tamoxifen over tamoxifen alone was statistically significantly dependent on ER status (tests for interaction: P =.01 for disease-free survival [DFS] and P =.07 for overall survival [OS]).
__label__noRel	Postmenopausal patients with lymph node-negative breast cancer benefited substantially from adjuvant chemotherapy if their cancer was ER-negative (i.e., endocrine-nonresponsive).	For patients with ER-negative tumors, the addition of CMF statistically significantly improved DFS (5-year DFS = 84% for CMF-->tamoxifen versus 69% for tamoxifen alone; difference = 15%; 95% confidence interval [CI] = 6% to 24%; risk ratio [RR] = 0.52; 95% CI = 0.34 to 0.79; P =.003) and OS (5-year OS = 89% for CMF-->tamoxifen versus 81% for tamoxifen alone; difference = 8%; 95% CI = 0% to 16%; RR = 0.51; 95% CI = 0.30 to 0.87; P =.01).
__label__noRel	Postmenopausal patients with lymph node-negative breast cancer benefited substantially from adjuvant chemotherapy if their cancer was ER-negative (i.e., endocrine-nonresponsive).	By contrast, for patients with ER-positive tumors, addition of CMF provided no benefit in terms of DFS (5-year DFS = 84% for CMF-->tamoxifen versus 85% for tamoxifen alone; difference = -1; 95% CI = -6% to 4%; RR = 0.99; 95% CI = 0.75 to 1.30; P =.92) or OS (5-year OS = 95% for CMF-->tamoxifen versus 93% for tamoxifen alone; difference = 2%; 95% CI = -1% to 5%; RR = 0.95; 95% CI = 0.64 to 1.40; P =.80).
__label__noRel	Postmenopausal patients with lymph node-negative breast cancer benefited substantially from adjuvant chemotherapy if their cancer was ER-negative (i.e., endocrine-nonresponsive).	In contrast, if their cancer was ER-positive (i.e., endocrine-responsive), they obtained no benefit from the combination treatment compared with tamoxifen alone.
__label__noRel	In contrast, if their cancer was ER-positive (i.e., endocrine-responsive), they obtained no benefit from the combination treatment compared with tamoxifen alone.	The role of adjuvant chemotherapy in postmenopausal patients with lymph node-negative breast cancer is controversial.
__label__noRel	In contrast, if their cancer was ER-positive (i.e., endocrine-responsive), they obtained no benefit from the combination treatment compared with tamoxifen alone.	The added benefit of CMF followed by tamoxifen over tamoxifen alone was statistically significantly dependent on ER status (tests for interaction: P =.01 for disease-free survival [DFS] and P =.07 for overall survival [OS]).
__label__noRel	In contrast, if their cancer was ER-positive (i.e., endocrine-responsive), they obtained no benefit from the combination treatment compared with tamoxifen alone.	For patients with ER-negative tumors, the addition of CMF statistically significantly improved DFS (5-year DFS = 84% for CMF-->tamoxifen versus 69% for tamoxifen alone; difference = 15%; 95% confidence interval [CI] = 6% to 24%; risk ratio [RR] = 0.52; 95% CI = 0.34 to 0.79; P =.003) and OS (5-year OS = 89% for CMF-->tamoxifen versus 81% for tamoxifen alone; difference = 8%; 95% CI = 0% to 16%; RR = 0.51; 95% CI = 0.30 to 0.87; P =.01).
__label__noRel	In contrast, if their cancer was ER-positive (i.e., endocrine-responsive), they obtained no benefit from the combination treatment compared with tamoxifen alone.	By contrast, for patients with ER-positive tumors, addition of CMF provided no benefit in terms of DFS (5-year DFS = 84% for CMF-->tamoxifen versus 85% for tamoxifen alone; difference = -1; 95% CI = -6% to 4%; RR = 0.99; 95% CI = 0.75 to 1.30; P =.92) or OS (5-year OS = 95% for CMF-->tamoxifen versus 93% for tamoxifen alone; difference = 2%; 95% CI = -1% to 5%; RR = 0.95; 95% CI = 0.64 to 1.40; P =.80).
__label__noRel	In contrast, if their cancer was ER-positive (i.e., endocrine-responsive), they obtained no benefit from the combination treatment compared with tamoxifen alone.	Postmenopausal patients with lymph node-negative breast cancer benefited substantially from adjuvant chemotherapy if their cancer was ER-negative (i.e., endocrine-nonresponsive).
__label__noRel	The combination of interferon alfa (IFNalpha) and isotretinoin has shown a direct antiproliferative effect on human melanoma cell lines,	but it remained unclear whether this combination is more effective than IFNalpha alone in patients with metastatic melanoma.
__label__noRel	The combination of interferon alfa (IFNalpha) and isotretinoin has shown a direct antiproliferative effect on human melanoma cell lines,	A scheduled interim analysis revealed no significant differences in survival rates, with the isotretinoin group and the placebo group showing 5-year disease-free survival rates of 55% (95% CI, 46% to 65%) and 67% (95% CI, 59% to 75%), respectively, and overall 5-year survival rates of 76% (95% CI, 67% to 84%) and 81% (95% CI, 74% to 88%), respectively.
__label__noRel	The combination of interferon alfa (IFNalpha) and isotretinoin has shown a direct antiproliferative effect on human melanoma cell lines,	The addition of isotretinoin to an adjuvant treatment of low-dose IFNalpha in patients with stage IIA and IIB melanoma had no significant effect on disease-free or overall survival and is therefore not recommended.
__label__Attack	but it remained unclear whether this combination is more effective than IFNalpha alone in patients with metastatic melanoma.	The combination of interferon alfa (IFNalpha) and isotretinoin has shown a direct antiproliferative effect on human melanoma cell lines,
__label__noRel	but it remained unclear whether this combination is more effective than IFNalpha alone in patients with metastatic melanoma.	A scheduled interim analysis revealed no significant differences in survival rates, with the isotretinoin group and the placebo group showing 5-year disease-free survival rates of 55% (95% CI, 46% to 65%) and 67% (95% CI, 59% to 75%), respectively, and overall 5-year survival rates of 76% (95% CI, 67% to 84%) and 81% (95% CI, 74% to 88%), respectively.
__label__noRel	but it remained unclear whether this combination is more effective than IFNalpha alone in patients with metastatic melanoma.	The addition of isotretinoin to an adjuvant treatment of low-dose IFNalpha in patients with stage IIA and IIB melanoma had no significant effect on disease-free or overall survival and is therefore not recommended.
__label__noRel	A scheduled interim analysis revealed no significant differences in survival rates, with the isotretinoin group and the placebo group showing 5-year disease-free survival rates of 55% (95% CI, 46% to 65%) and 67% (95% CI, 59% to 75%), respectively, and overall 5-year survival rates of 76% (95% CI, 67% to 84%) and 81% (95% CI, 74% to 88%), respectively.	The combination of interferon alfa (IFNalpha) and isotretinoin has shown a direct antiproliferative effect on human melanoma cell lines,
__label__noRel	A scheduled interim analysis revealed no significant differences in survival rates, with the isotretinoin group and the placebo group showing 5-year disease-free survival rates of 55% (95% CI, 46% to 65%) and 67% (95% CI, 59% to 75%), respectively, and overall 5-year survival rates of 76% (95% CI, 67% to 84%) and 81% (95% CI, 74% to 88%), respectively.	but it remained unclear whether this combination is more effective than IFNalpha alone in patients with metastatic melanoma.
__label__Support	A scheduled interim analysis revealed no significant differences in survival rates, with the isotretinoin group and the placebo group showing 5-year disease-free survival rates of 55% (95% CI, 46% to 65%) and 67% (95% CI, 59% to 75%), respectively, and overall 5-year survival rates of 76% (95% CI, 67% to 84%) and 81% (95% CI, 74% to 88%), respectively.	The addition of isotretinoin to an adjuvant treatment of low-dose IFNalpha in patients with stage IIA and IIB melanoma had no significant effect on disease-free or overall survival and is therefore not recommended.
__label__noRel	The addition of isotretinoin to an adjuvant treatment of low-dose IFNalpha in patients with stage IIA and IIB melanoma had no significant effect on disease-free or overall survival and is therefore not recommended.	The combination of interferon alfa (IFNalpha) and isotretinoin has shown a direct antiproliferative effect on human melanoma cell lines,
__label__noRel	The addition of isotretinoin to an adjuvant treatment of low-dose IFNalpha in patients with stage IIA and IIB melanoma had no significant effect on disease-free or overall survival and is therefore not recommended.	but it remained unclear whether this combination is more effective than IFNalpha alone in patients with metastatic melanoma.
__label__noRel	The addition of isotretinoin to an adjuvant treatment of low-dose IFNalpha in patients with stage IIA and IIB melanoma had no significant effect on disease-free or overall survival and is therefore not recommended.	A scheduled interim analysis revealed no significant differences in survival rates, with the isotretinoin group and the placebo group showing 5-year disease-free survival rates of 55% (95% CI, 46% to 65%) and 67% (95% CI, 59% to 75%), respectively, and overall 5-year survival rates of 76% (95% CI, 67% to 84%) and 81% (95% CI, 74% to 88%), respectively.
__label__noRel	At first follow-up, groups differed only in social functioning, favouring the radiotherapy-only group (mean score 79.0 [SD 3.2] for patients assigned radiotherapy vs 67.4 [2.7] for those assigned radiotherapy and temozolomide; difference between groups 11.6 points [95% CI 3.5-19.7], p=0.0052).	Over subsequent assessments, HRQOL was much the same between treatment groups.
__label__Support	At first follow-up, groups differed only in social functioning, favouring the radiotherapy-only group (mean score 79.0 [SD 3.2] for patients assigned radiotherapy vs 67.4 [2.7] for those assigned radiotherapy and temozolomide; difference between groups 11.6 points [95% CI 3.5-19.7], p=0.0052).	Addition of temozolomide during and after radiotherapy for patients with newly diagnosed glioblastoma significantly improved survival without a negative effect on HRQOL.
__label__noRel	Over subsequent assessments, HRQOL was much the same between treatment groups.	At first follow-up, groups differed only in social functioning, favouring the radiotherapy-only group (mean score 79.0 [SD 3.2] for patients assigned radiotherapy vs 67.4 [2.7] for those assigned radiotherapy and temozolomide; difference between groups 11.6 points [95% CI 3.5-19.7], p=0.0052).
__label__Support	Over subsequent assessments, HRQOL was much the same between treatment groups.	Addition of temozolomide during and after radiotherapy for patients with newly diagnosed glioblastoma significantly improved survival without a negative effect on HRQOL.
__label__noRel	Addition of temozolomide during and after radiotherapy for patients with newly diagnosed glioblastoma significantly improved survival without a negative effect on HRQOL.	At first follow-up, groups differed only in social functioning, favouring the radiotherapy-only group (mean score 79.0 [SD 3.2] for patients assigned radiotherapy vs 67.4 [2.7] for those assigned radiotherapy and temozolomide; difference between groups 11.6 points [95% CI 3.5-19.7], p=0.0052).
__label__noRel	Addition of temozolomide during and after radiotherapy for patients with newly diagnosed glioblastoma significantly improved survival without a negative effect on HRQOL.	Over subsequent assessments, HRQOL was much the same between treatment groups.
__label__noRel	Cetuximab offers important HRQL and survival benefits for pretreated patients with advanced, wild-type KRAS CRC.	PF change scores were -3.9 for cetuximab and -8.6 for BSC (P = .046) at 8 weeks and were -5.9 and -12.5 for cetuximab and BSC, respectively, (P = .027) at 16 weeks.
__label__noRel	Cetuximab offers important HRQL and survival benefits for pretreated patients with advanced, wild-type KRAS CRC.	GHS change scores were -0.5 and -7.1 (P = .008) at 8 weeks and were -3.6 and -15.2 (P = .008) at 16 weeks for cetuximab and BSC, respectively.
__label__noRel	Cetuximab offers important HRQL and survival benefits for pretreated patients with advanced, wild-type KRAS CRC.	In patients who had tumors with wild-type KRAS status, cetuximab resulted in less PF deterioration at 8 weeks (-0.7 v -7.2; P = .11) and 16 weeks (-3.4 v -13.8; P = .008) compared with BSC.
__label__noRel	Cetuximab offers important HRQL and survival benefits for pretreated patients with advanced, wild-type KRAS CRC.	Patients with wild-type status who received cetuximab experienced improved GHS at 8 weeks, whereas patients who received BSC alone deteriorated (3.2 v -7.7; P = .002).
__label__noRel	Cetuximab offers important HRQL and survival benefits for pretreated patients with advanced, wild-type KRAS CRC.	No significant differences were noted between study arms for patients with mutated KRAS tumors.
__label__noRel	Cetuximab offers important HRQL and survival benefits for pretreated patients with advanced, wild-type KRAS CRC.	Cetuximab preserved GHS at 16 weeks (-0.2 v -18.1; P < .001).
__label__Support	PF change scores were -3.9 for cetuximab and -8.6 for BSC (P = .046) at 8 weeks and were -5.9 and -12.5 for cetuximab and BSC, respectively, (P = .027) at 16 weeks.	Cetuximab offers important HRQL and survival benefits for pretreated patients with advanced, wild-type KRAS CRC.
__label__noRel	PF change scores were -3.9 for cetuximab and -8.6 for BSC (P = .046) at 8 weeks and were -5.9 and -12.5 for cetuximab and BSC, respectively, (P = .027) at 16 weeks.	GHS change scores were -0.5 and -7.1 (P = .008) at 8 weeks and were -3.6 and -15.2 (P = .008) at 16 weeks for cetuximab and BSC, respectively.
__label__noRel	PF change scores were -3.9 for cetuximab and -8.6 for BSC (P = .046) at 8 weeks and were -5.9 and -12.5 for cetuximab and BSC, respectively, (P = .027) at 16 weeks.	In patients who had tumors with wild-type KRAS status, cetuximab resulted in less PF deterioration at 8 weeks (-0.7 v -7.2; P = .11) and 16 weeks (-3.4 v -13.8; P = .008) compared with BSC.
__label__noRel	PF change scores were -3.9 for cetuximab and -8.6 for BSC (P = .046) at 8 weeks and were -5.9 and -12.5 for cetuximab and BSC, respectively, (P = .027) at 16 weeks.	Patients with wild-type status who received cetuximab experienced improved GHS at 8 weeks, whereas patients who received BSC alone deteriorated (3.2 v -7.7; P = .002).
__label__noRel	PF change scores were -3.9 for cetuximab and -8.6 for BSC (P = .046) at 8 weeks and were -5.9 and -12.5 for cetuximab and BSC, respectively, (P = .027) at 16 weeks.	No significant differences were noted between study arms for patients with mutated KRAS tumors.
__label__noRel	PF change scores were -3.9 for cetuximab and -8.6 for BSC (P = .046) at 8 weeks and were -5.9 and -12.5 for cetuximab and BSC, respectively, (P = .027) at 16 weeks.	Cetuximab preserved GHS at 16 weeks (-0.2 v -18.1; P < .001).
__label__Support	GHS change scores were -0.5 and -7.1 (P = .008) at 8 weeks and were -3.6 and -15.2 (P = .008) at 16 weeks for cetuximab and BSC, respectively.	Cetuximab offers important HRQL and survival benefits for pretreated patients with advanced, wild-type KRAS CRC.
__label__noRel	GHS change scores were -0.5 and -7.1 (P = .008) at 8 weeks and were -3.6 and -15.2 (P = .008) at 16 weeks for cetuximab and BSC, respectively.	PF change scores were -3.9 for cetuximab and -8.6 for BSC (P = .046) at 8 weeks and were -5.9 and -12.5 for cetuximab and BSC, respectively, (P = .027) at 16 weeks.
__label__noRel	GHS change scores were -0.5 and -7.1 (P = .008) at 8 weeks and were -3.6 and -15.2 (P = .008) at 16 weeks for cetuximab and BSC, respectively.	In patients who had tumors with wild-type KRAS status, cetuximab resulted in less PF deterioration at 8 weeks (-0.7 v -7.2; P = .11) and 16 weeks (-3.4 v -13.8; P = .008) compared with BSC.
__label__noRel	GHS change scores were -0.5 and -7.1 (P = .008) at 8 weeks and were -3.6 and -15.2 (P = .008) at 16 weeks for cetuximab and BSC, respectively.	Patients with wild-type status who received cetuximab experienced improved GHS at 8 weeks, whereas patients who received BSC alone deteriorated (3.2 v -7.7; P = .002).
__label__noRel	GHS change scores were -0.5 and -7.1 (P = .008) at 8 weeks and were -3.6 and -15.2 (P = .008) at 16 weeks for cetuximab and BSC, respectively.	No significant differences were noted between study arms for patients with mutated KRAS tumors.
__label__noRel	GHS change scores were -0.5 and -7.1 (P = .008) at 8 weeks and were -3.6 and -15.2 (P = .008) at 16 weeks for cetuximab and BSC, respectively.	Cetuximab preserved GHS at 16 weeks (-0.2 v -18.1; P < .001).
__label__Support	In patients who had tumors with wild-type KRAS status, cetuximab resulted in less PF deterioration at 8 weeks (-0.7 v -7.2; P = .11) and 16 weeks (-3.4 v -13.8; P = .008) compared with BSC.	Cetuximab offers important HRQL and survival benefits for pretreated patients with advanced, wild-type KRAS CRC.
__label__noRel	In patients who had tumors with wild-type KRAS status, cetuximab resulted in less PF deterioration at 8 weeks (-0.7 v -7.2; P = .11) and 16 weeks (-3.4 v -13.8; P = .008) compared with BSC.	PF change scores were -3.9 for cetuximab and -8.6 for BSC (P = .046) at 8 weeks and were -5.9 and -12.5 for cetuximab and BSC, respectively, (P = .027) at 16 weeks.
__label__noRel	In patients who had tumors with wild-type KRAS status, cetuximab resulted in less PF deterioration at 8 weeks (-0.7 v -7.2; P = .11) and 16 weeks (-3.4 v -13.8; P = .008) compared with BSC.	GHS change scores were -0.5 and -7.1 (P = .008) at 8 weeks and were -3.6 and -15.2 (P = .008) at 16 weeks for cetuximab and BSC, respectively.
__label__noRel	In patients who had tumors with wild-type KRAS status, cetuximab resulted in less PF deterioration at 8 weeks (-0.7 v -7.2; P = .11) and 16 weeks (-3.4 v -13.8; P = .008) compared with BSC.	Patients with wild-type status who received cetuximab experienced improved GHS at 8 weeks, whereas patients who received BSC alone deteriorated (3.2 v -7.7; P = .002).
__label__noRel	In patients who had tumors with wild-type KRAS status, cetuximab resulted in less PF deterioration at 8 weeks (-0.7 v -7.2; P = .11) and 16 weeks (-3.4 v -13.8; P = .008) compared with BSC.	No significant differences were noted between study arms for patients with mutated KRAS tumors.
__label__noRel	In patients who had tumors with wild-type KRAS status, cetuximab resulted in less PF deterioration at 8 weeks (-0.7 v -7.2; P = .11) and 16 weeks (-3.4 v -13.8; P = .008) compared with BSC.	Cetuximab preserved GHS at 16 weeks (-0.2 v -18.1; P < .001).
__label__Support	Patients with wild-type status who received cetuximab experienced improved GHS at 8 weeks, whereas patients who received BSC alone deteriorated (3.2 v -7.7; P = .002).	Cetuximab offers important HRQL and survival benefits for pretreated patients with advanced, wild-type KRAS CRC.
__label__noRel	Patients with wild-type status who received cetuximab experienced improved GHS at 8 weeks, whereas patients who received BSC alone deteriorated (3.2 v -7.7; P = .002).	PF change scores were -3.9 for cetuximab and -8.6 for BSC (P = .046) at 8 weeks and were -5.9 and -12.5 for cetuximab and BSC, respectively, (P = .027) at 16 weeks.
__label__noRel	Patients with wild-type status who received cetuximab experienced improved GHS at 8 weeks, whereas patients who received BSC alone deteriorated (3.2 v -7.7; P = .002).	GHS change scores were -0.5 and -7.1 (P = .008) at 8 weeks and were -3.6 and -15.2 (P = .008) at 16 weeks for cetuximab and BSC, respectively.
__label__noRel	Patients with wild-type status who received cetuximab experienced improved GHS at 8 weeks, whereas patients who received BSC alone deteriorated (3.2 v -7.7; P = .002).	In patients who had tumors with wild-type KRAS status, cetuximab resulted in less PF deterioration at 8 weeks (-0.7 v -7.2; P = .11) and 16 weeks (-3.4 v -13.8; P = .008) compared with BSC.
__label__noRel	Patients with wild-type status who received cetuximab experienced improved GHS at 8 weeks, whereas patients who received BSC alone deteriorated (3.2 v -7.7; P = .002).	No significant differences were noted between study arms for patients with mutated KRAS tumors.
__label__noRel	Patients with wild-type status who received cetuximab experienced improved GHS at 8 weeks, whereas patients who received BSC alone deteriorated (3.2 v -7.7; P = .002).	Cetuximab preserved GHS at 16 weeks (-0.2 v -18.1; P < .001).
__label__Support	No significant differences were noted between study arms for patients with mutated KRAS tumors.	Cetuximab offers important HRQL and survival benefits for pretreated patients with advanced, wild-type KRAS CRC.
__label__noRel	No significant differences were noted between study arms for patients with mutated KRAS tumors.	PF change scores were -3.9 for cetuximab and -8.6 for BSC (P = .046) at 8 weeks and were -5.9 and -12.5 for cetuximab and BSC, respectively, (P = .027) at 16 weeks.
__label__noRel	No significant differences were noted between study arms for patients with mutated KRAS tumors.	GHS change scores were -0.5 and -7.1 (P = .008) at 8 weeks and were -3.6 and -15.2 (P = .008) at 16 weeks for cetuximab and BSC, respectively.
__label__noRel	No significant differences were noted between study arms for patients with mutated KRAS tumors.	In patients who had tumors with wild-type KRAS status, cetuximab resulted in less PF deterioration at 8 weeks (-0.7 v -7.2; P = .11) and 16 weeks (-3.4 v -13.8; P = .008) compared with BSC.
__label__noRel	No significant differences were noted between study arms for patients with mutated KRAS tumors.	Patients with wild-type status who received cetuximab experienced improved GHS at 8 weeks, whereas patients who received BSC alone deteriorated (3.2 v -7.7; P = .002).
__label__noRel	No significant differences were noted between study arms for patients with mutated KRAS tumors.	Cetuximab preserved GHS at 16 weeks (-0.2 v -18.1; P < .001).
__label__Support	Cetuximab preserved GHS at 16 weeks (-0.2 v -18.1; P < .001).	Cetuximab offers important HRQL and survival benefits for pretreated patients with advanced, wild-type KRAS CRC.
__label__noRel	Cetuximab preserved GHS at 16 weeks (-0.2 v -18.1; P < .001).	PF change scores were -3.9 for cetuximab and -8.6 for BSC (P = .046) at 8 weeks and were -5.9 and -12.5 for cetuximab and BSC, respectively, (P = .027) at 16 weeks.
__label__noRel	Cetuximab preserved GHS at 16 weeks (-0.2 v -18.1; P < .001).	GHS change scores were -0.5 and -7.1 (P = .008) at 8 weeks and were -3.6 and -15.2 (P = .008) at 16 weeks for cetuximab and BSC, respectively.
__label__noRel	Cetuximab preserved GHS at 16 weeks (-0.2 v -18.1; P < .001).	In patients who had tumors with wild-type KRAS status, cetuximab resulted in less PF deterioration at 8 weeks (-0.7 v -7.2; P = .11) and 16 weeks (-3.4 v -13.8; P = .008) compared with BSC.
__label__noRel	Cetuximab preserved GHS at 16 weeks (-0.2 v -18.1; P < .001).	Patients with wild-type status who received cetuximab experienced improved GHS at 8 weeks, whereas patients who received BSC alone deteriorated (3.2 v -7.7; P = .002).
__label__noRel	Cetuximab preserved GHS at 16 weeks (-0.2 v -18.1; P < .001).	No significant differences were noted between study arms for patients with mutated KRAS tumors.
__label__noRel	No differences were seen between groups in mean change scores from baseline for the SF-36 physical and mental component summary scores at 6, 12, 24, and 36 months.	Small (< 0.2 standard deviations) but statistically significant differences in mean change scores from baseline were seen for the SF-36 domains of physical functioning (12 months), bodily pain (6 months) and vitality (6 and 12 months), and the MENQOL vasomotor (6, 12, and 24 months) and sexual domains (12 and 24 months).
__label__noRel	No differences were seen between groups in mean change scores from baseline for the SF-36 physical and mental component summary scores at 6, 12, 24, and 36 months.	On the response analysis, a significant difference was seen between groups for the bodily pain domain (percentage of patients reporting a worsening of QOL, 47% placebo v 51% letrozole; P = .009) and the vasomotor domain (22% placebo v 29% letrozole; P = .001).
__label__noRel	No differences were seen between groups in mean change scores from baseline for the SF-36 physical and mental component summary scores at 6, 12, 24, and 36 months.	Letrozole did not have an adverse impact on overall QOL.
__label__noRel	No differences were seen between groups in mean change scores from baseline for the SF-36 physical and mental component summary scores at 6, 12, 24, and 36 months.	Small effects were seen in some domains consistent with a minority of patients experiencing changes in QOL compatible with a reduction in estrogen synthesis.
__label__noRel	Small (< 0.2 standard deviations) but statistically significant differences in mean change scores from baseline were seen for the SF-36 domains of physical functioning (12 months), bodily pain (6 months) and vitality (6 and 12 months), and the MENQOL vasomotor (6, 12, and 24 months) and sexual domains (12 and 24 months).	No differences were seen between groups in mean change scores from baseline for the SF-36 physical and mental component summary scores at 6, 12, 24, and 36 months.
__label__noRel	Small (< 0.2 standard deviations) but statistically significant differences in mean change scores from baseline were seen for the SF-36 domains of physical functioning (12 months), bodily pain (6 months) and vitality (6 and 12 months), and the MENQOL vasomotor (6, 12, and 24 months) and sexual domains (12 and 24 months).	On the response analysis, a significant difference was seen between groups for the bodily pain domain (percentage of patients reporting a worsening of QOL, 47% placebo v 51% letrozole; P = .009) and the vasomotor domain (22% placebo v 29% letrozole; P = .001).
__label__noRel	Small (< 0.2 standard deviations) but statistically significant differences in mean change scores from baseline were seen for the SF-36 domains of physical functioning (12 months), bodily pain (6 months) and vitality (6 and 12 months), and the MENQOL vasomotor (6, 12, and 24 months) and sexual domains (12 and 24 months).	Letrozole did not have an adverse impact on overall QOL.
__label__Support	Small (< 0.2 standard deviations) but statistically significant differences in mean change scores from baseline were seen for the SF-36 domains of physical functioning (12 months), bodily pain (6 months) and vitality (6 and 12 months), and the MENQOL vasomotor (6, 12, and 24 months) and sexual domains (12 and 24 months).	Small effects were seen in some domains consistent with a minority of patients experiencing changes in QOL compatible with a reduction in estrogen synthesis.
__label__noRel	On the response analysis, a significant difference was seen between groups for the bodily pain domain (percentage of patients reporting a worsening of QOL, 47% placebo v 51% letrozole; P = .009) and the vasomotor domain (22% placebo v 29% letrozole; P = .001).	No differences were seen between groups in mean change scores from baseline for the SF-36 physical and mental component summary scores at 6, 12, 24, and 36 months.
__label__noRel	On the response analysis, a significant difference was seen between groups for the bodily pain domain (percentage of patients reporting a worsening of QOL, 47% placebo v 51% letrozole; P = .009) and the vasomotor domain (22% placebo v 29% letrozole; P = .001).	Small (< 0.2 standard deviations) but statistically significant differences in mean change scores from baseline were seen for the SF-36 domains of physical functioning (12 months), bodily pain (6 months) and vitality (6 and 12 months), and the MENQOL vasomotor (6, 12, and 24 months) and sexual domains (12 and 24 months).
__label__Support	On the response analysis, a significant difference was seen between groups for the bodily pain domain (percentage of patients reporting a worsening of QOL, 47% placebo v 51% letrozole; P = .009) and the vasomotor domain (22% placebo v 29% letrozole; P = .001).	Letrozole did not have an adverse impact on overall QOL.
__label__noRel	On the response analysis, a significant difference was seen between groups for the bodily pain domain (percentage of patients reporting a worsening of QOL, 47% placebo v 51% letrozole; P = .009) and the vasomotor domain (22% placebo v 29% letrozole; P = .001).	Small effects were seen in some domains consistent with a minority of patients experiencing changes in QOL compatible with a reduction in estrogen synthesis.
__label__noRel	Letrozole did not have an adverse impact on overall QOL.	No differences were seen between groups in mean change scores from baseline for the SF-36 physical and mental component summary scores at 6, 12, 24, and 36 months.
__label__noRel	Letrozole did not have an adverse impact on overall QOL.	Small (< 0.2 standard deviations) but statistically significant differences in mean change scores from baseline were seen for the SF-36 domains of physical functioning (12 months), bodily pain (6 months) and vitality (6 and 12 months), and the MENQOL vasomotor (6, 12, and 24 months) and sexual domains (12 and 24 months).
__label__noRel	Letrozole did not have an adverse impact on overall QOL.	On the response analysis, a significant difference was seen between groups for the bodily pain domain (percentage of patients reporting a worsening of QOL, 47% placebo v 51% letrozole; P = .009) and the vasomotor domain (22% placebo v 29% letrozole; P = .001).
__label__noRel	Letrozole did not have an adverse impact on overall QOL.	Small effects were seen in some domains consistent with a minority of patients experiencing changes in QOL compatible with a reduction in estrogen synthesis.
__label__noRel	Small effects were seen in some domains consistent with a minority of patients experiencing changes in QOL compatible with a reduction in estrogen synthesis.	No differences were seen between groups in mean change scores from baseline for the SF-36 physical and mental component summary scores at 6, 12, 24, and 36 months.
__label__noRel	Small effects were seen in some domains consistent with a minority of patients experiencing changes in QOL compatible with a reduction in estrogen synthesis.	Small (< 0.2 standard deviations) but statistically significant differences in mean change scores from baseline were seen for the SF-36 domains of physical functioning (12 months), bodily pain (6 months) and vitality (6 and 12 months), and the MENQOL vasomotor (6, 12, and 24 months) and sexual domains (12 and 24 months).
__label__noRel	Small effects were seen in some domains consistent with a minority of patients experiencing changes in QOL compatible with a reduction in estrogen synthesis.	On the response analysis, a significant difference was seen between groups for the bodily pain domain (percentage of patients reporting a worsening of QOL, 47% placebo v 51% letrozole; P = .009) and the vasomotor domain (22% placebo v 29% letrozole; P = .001).
__label__noRel	Small effects were seen in some domains consistent with a minority of patients experiencing changes in QOL compatible with a reduction in estrogen synthesis.	Letrozole did not have an adverse impact on overall QOL.
__label__noRel	In phase II trials, paclitaxel has been shown to have antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC).	Survival was statistically significantly better in the paclitaxel plus supportive care arm than in the supportive care alone arm (two-sided P =.037) (median survival = 6.8 months versus 4.8 months).
__label__noRel	In phase II trials, paclitaxel has been shown to have antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC).	Cox multivariate analysis showed paclitaxel plus supportive care to be statistically significantly associated with improved survival (two-sided P =.048).
__label__noRel	In phase II trials, paclitaxel has been shown to have antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC).	QOL was similar for both treatment arms,
__label__noRel	In phase II trials, paclitaxel has been shown to have antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC).	except for the functional activity score of the Rotterdam Symptom Checklist, where QOL data statistically significantly favored the paclitaxel plus supportive care arm (two-sided P =.043).
__label__noRel	In phase II trials, paclitaxel has been shown to have antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC).	The addition of paclitaxel to best supportive care significantly improved survival and time to disease progression compared with best supportive care in patients with advanced NSCLC and may improve some aspects of QOL.
__label__noRel	Survival was statistically significantly better in the paclitaxel plus supportive care arm than in the supportive care alone arm (two-sided P =.037) (median survival = 6.8 months versus 4.8 months).	In phase II trials, paclitaxel has been shown to have antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC).
__label__noRel	Survival was statistically significantly better in the paclitaxel plus supportive care arm than in the supportive care alone arm (two-sided P =.037) (median survival = 6.8 months versus 4.8 months).	Cox multivariate analysis showed paclitaxel plus supportive care to be statistically significantly associated with improved survival (two-sided P =.048).
__label__noRel	Survival was statistically significantly better in the paclitaxel plus supportive care arm than in the supportive care alone arm (two-sided P =.037) (median survival = 6.8 months versus 4.8 months).	QOL was similar for both treatment arms,
__label__noRel	Survival was statistically significantly better in the paclitaxel plus supportive care arm than in the supportive care alone arm (two-sided P =.037) (median survival = 6.8 months versus 4.8 months).	except for the functional activity score of the Rotterdam Symptom Checklist, where QOL data statistically significantly favored the paclitaxel plus supportive care arm (two-sided P =.043).
__label__Support	Survival was statistically significantly better in the paclitaxel plus supportive care arm than in the supportive care alone arm (two-sided P =.037) (median survival = 6.8 months versus 4.8 months).	The addition of paclitaxel to best supportive care significantly improved survival and time to disease progression compared with best supportive care in patients with advanced NSCLC and may improve some aspects of QOL.
__label__noRel	Cox multivariate analysis showed paclitaxel plus supportive care to be statistically significantly associated with improved survival (two-sided P =.048).	In phase II trials, paclitaxel has been shown to have antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC).
__label__noRel	Cox multivariate analysis showed paclitaxel plus supportive care to be statistically significantly associated with improved survival (two-sided P =.048).	Survival was statistically significantly better in the paclitaxel plus supportive care arm than in the supportive care alone arm (two-sided P =.037) (median survival = 6.8 months versus 4.8 months).
__label__noRel	Cox multivariate analysis showed paclitaxel plus supportive care to be statistically significantly associated with improved survival (two-sided P =.048).	QOL was similar for both treatment arms,
__label__noRel	Cox multivariate analysis showed paclitaxel plus supportive care to be statistically significantly associated with improved survival (two-sided P =.048).	except for the functional activity score of the Rotterdam Symptom Checklist, where QOL data statistically significantly favored the paclitaxel plus supportive care arm (two-sided P =.043).
__label__Support	Cox multivariate analysis showed paclitaxel plus supportive care to be statistically significantly associated with improved survival (two-sided P =.048).	The addition of paclitaxel to best supportive care significantly improved survival and time to disease progression compared with best supportive care in patients with advanced NSCLC and may improve some aspects of QOL.
__label__noRel	QOL was similar for both treatment arms,	In phase II trials, paclitaxel has been shown to have antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC).
__label__noRel	QOL was similar for both treatment arms,	Survival was statistically significantly better in the paclitaxel plus supportive care arm than in the supportive care alone arm (two-sided P =.037) (median survival = 6.8 months versus 4.8 months).
__label__noRel	QOL was similar for both treatment arms,	Cox multivariate analysis showed paclitaxel plus supportive care to be statistically significantly associated with improved survival (two-sided P =.048).
__label__noRel	QOL was similar for both treatment arms,	except for the functional activity score of the Rotterdam Symptom Checklist, where QOL data statistically significantly favored the paclitaxel plus supportive care arm (two-sided P =.043).
__label__Support	QOL was similar for both treatment arms,	The addition of paclitaxel to best supportive care significantly improved survival and time to disease progression compared with best supportive care in patients with advanced NSCLC and may improve some aspects of QOL.
__label__noRel	except for the functional activity score of the Rotterdam Symptom Checklist, where QOL data statistically significantly favored the paclitaxel plus supportive care arm (two-sided P =.043).	In phase II trials, paclitaxel has been shown to have antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC).
__label__noRel	except for the functional activity score of the Rotterdam Symptom Checklist, where QOL data statistically significantly favored the paclitaxel plus supportive care arm (two-sided P =.043).	Survival was statistically significantly better in the paclitaxel plus supportive care arm than in the supportive care alone arm (two-sided P =.037) (median survival = 6.8 months versus 4.8 months).
__label__noRel	except for the functional activity score of the Rotterdam Symptom Checklist, where QOL data statistically significantly favored the paclitaxel plus supportive care arm (two-sided P =.043).	Cox multivariate analysis showed paclitaxel plus supportive care to be statistically significantly associated with improved survival (two-sided P =.048).
__label__Attack	except for the functional activity score of the Rotterdam Symptom Checklist, where QOL data statistically significantly favored the paclitaxel plus supportive care arm (two-sided P =.043).	QOL was similar for both treatment arms,
__label__noRel	except for the functional activity score of the Rotterdam Symptom Checklist, where QOL data statistically significantly favored the paclitaxel plus supportive care arm (two-sided P =.043).	The addition of paclitaxel to best supportive care significantly improved survival and time to disease progression compared with best supportive care in patients with advanced NSCLC and may improve some aspects of QOL.
__label__noRel	The addition of paclitaxel to best supportive care significantly improved survival and time to disease progression compared with best supportive care in patients with advanced NSCLC and may improve some aspects of QOL.	In phase II trials, paclitaxel has been shown to have antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC).
__label__noRel	The addition of paclitaxel to best supportive care significantly improved survival and time to disease progression compared with best supportive care in patients with advanced NSCLC and may improve some aspects of QOL.	Survival was statistically significantly better in the paclitaxel plus supportive care arm than in the supportive care alone arm (two-sided P =.037) (median survival = 6.8 months versus 4.8 months).
__label__noRel	The addition of paclitaxel to best supportive care significantly improved survival and time to disease progression compared with best supportive care in patients with advanced NSCLC and may improve some aspects of QOL.	Cox multivariate analysis showed paclitaxel plus supportive care to be statistically significantly associated with improved survival (two-sided P =.048).
__label__noRel	The addition of paclitaxel to best supportive care significantly improved survival and time to disease progression compared with best supportive care in patients with advanced NSCLC and may improve some aspects of QOL.	QOL was similar for both treatment arms,
__label__noRel	The addition of paclitaxel to best supportive care significantly improved survival and time to disease progression compared with best supportive care in patients with advanced NSCLC and may improve some aspects of QOL.	except for the functional activity score of the Rotterdam Symptom Checklist, where QOL data statistically significantly favored the paclitaxel plus supportive care arm (two-sided P =.043).
__label__noRel	Compared to EUC, TEC was associated with increased pain communication self-efficacy after the intervention (P<.001);	both groups showed significant (P<.0001), similar, reductions in pain misconceptions.
__label__noRel	Compared to EUC, TEC was associated with increased pain communication self-efficacy after the intervention (P<.001);	At 2 weeks, assignment to TEC was associated with improvement in pain-related impairment (-0.25 points on a 5-point scale, 95% confidence interval -0.43 to -0.06, P=.01)
__label__noRel	Compared to EUC, TEC was associated with increased pain communication self-efficacy after the intervention (P<.001);	but not in pain severity (-0.21 points on an 11-point scale, -0.60 to 0.17, P=.27).
__label__noRel	Compared to EUC, TEC was associated with increased pain communication self-efficacy after the intervention (P<.001);	The improvement in pain-related impairment was not sustained at 6 and 12 weeks.
__label__noRel	Compared to EUC, TEC was associated with increased pain communication self-efficacy after the intervention (P<.001);	There were no significant intervention by subgroup interactions (P>.10).
__label__Support	Compared to EUC, TEC was associated with increased pain communication self-efficacy after the intervention (P<.001);	We conclude that TEC, compared with EUC, resulted in improved pain communication self-efficacy and temporary improvement in pain-related impairment, but no improvement in pain severity.
__label__noRel	both groups showed significant (P<.0001), similar, reductions in pain misconceptions.	Compared to EUC, TEC was associated with increased pain communication self-efficacy after the intervention (P<.001);
__label__noRel	both groups showed significant (P<.0001), similar, reductions in pain misconceptions.	At 2 weeks, assignment to TEC was associated with improvement in pain-related impairment (-0.25 points on a 5-point scale, 95% confidence interval -0.43 to -0.06, P=.01)
__label__noRel	both groups showed significant (P<.0001), similar, reductions in pain misconceptions.	but not in pain severity (-0.21 points on an 11-point scale, -0.60 to 0.17, P=.27).
__label__noRel	both groups showed significant (P<.0001), similar, reductions in pain misconceptions.	The improvement in pain-related impairment was not sustained at 6 and 12 weeks.
__label__noRel	both groups showed significant (P<.0001), similar, reductions in pain misconceptions.	There were no significant intervention by subgroup interactions (P>.10).
__label__Support	both groups showed significant (P<.0001), similar, reductions in pain misconceptions.	We conclude that TEC, compared with EUC, resulted in improved pain communication self-efficacy and temporary improvement in pain-related impairment, but no improvement in pain severity.
__label__noRel	At 2 weeks, assignment to TEC was associated with improvement in pain-related impairment (-0.25 points on a 5-point scale, 95% confidence interval -0.43 to -0.06, P=.01)	Compared to EUC, TEC was associated with increased pain communication self-efficacy after the intervention (P<.001);
__label__noRel	At 2 weeks, assignment to TEC was associated with improvement in pain-related impairment (-0.25 points on a 5-point scale, 95% confidence interval -0.43 to -0.06, P=.01)	both groups showed significant (P<.0001), similar, reductions in pain misconceptions.
__label__noRel	At 2 weeks, assignment to TEC was associated with improvement in pain-related impairment (-0.25 points on a 5-point scale, 95% confidence interval -0.43 to -0.06, P=.01)	but not in pain severity (-0.21 points on an 11-point scale, -0.60 to 0.17, P=.27).
__label__noRel	At 2 weeks, assignment to TEC was associated with improvement in pain-related impairment (-0.25 points on a 5-point scale, 95% confidence interval -0.43 to -0.06, P=.01)	The improvement in pain-related impairment was not sustained at 6 and 12 weeks.
__label__noRel	At 2 weeks, assignment to TEC was associated with improvement in pain-related impairment (-0.25 points on a 5-point scale, 95% confidence interval -0.43 to -0.06, P=.01)	There were no significant intervention by subgroup interactions (P>.10).
__label__Support	At 2 weeks, assignment to TEC was associated with improvement in pain-related impairment (-0.25 points on a 5-point scale, 95% confidence interval -0.43 to -0.06, P=.01)	We conclude that TEC, compared with EUC, resulted in improved pain communication self-efficacy and temporary improvement in pain-related impairment, but no improvement in pain severity.
__label__noRel	but not in pain severity (-0.21 points on an 11-point scale, -0.60 to 0.17, P=.27).	Compared to EUC, TEC was associated with increased pain communication self-efficacy after the intervention (P<.001);
__label__noRel	but not in pain severity (-0.21 points on an 11-point scale, -0.60 to 0.17, P=.27).	both groups showed significant (P<.0001), similar, reductions in pain misconceptions.
__label__Attack	but not in pain severity (-0.21 points on an 11-point scale, -0.60 to 0.17, P=.27).	At 2 weeks, assignment to TEC was associated with improvement in pain-related impairment (-0.25 points on a 5-point scale, 95% confidence interval -0.43 to -0.06, P=.01)
__label__noRel	but not in pain severity (-0.21 points on an 11-point scale, -0.60 to 0.17, P=.27).	The improvement in pain-related impairment was not sustained at 6 and 12 weeks.
__label__noRel	but not in pain severity (-0.21 points on an 11-point scale, -0.60 to 0.17, P=.27).	There were no significant intervention by subgroup interactions (P>.10).
__label__noRel	but not in pain severity (-0.21 points on an 11-point scale, -0.60 to 0.17, P=.27).	We conclude that TEC, compared with EUC, resulted in improved pain communication self-efficacy and temporary improvement in pain-related impairment, but no improvement in pain severity.
__label__noRel	The improvement in pain-related impairment was not sustained at 6 and 12 weeks.	Compared to EUC, TEC was associated with increased pain communication self-efficacy after the intervention (P<.001);
__label__noRel	The improvement in pain-related impairment was not sustained at 6 and 12 weeks.	both groups showed significant (P<.0001), similar, reductions in pain misconceptions.
__label__Attack	The improvement in pain-related impairment was not sustained at 6 and 12 weeks.	At 2 weeks, assignment to TEC was associated with improvement in pain-related impairment (-0.25 points on a 5-point scale, 95% confidence interval -0.43 to -0.06, P=.01)
__label__noRel	The improvement in pain-related impairment was not sustained at 6 and 12 weeks.	but not in pain severity (-0.21 points on an 11-point scale, -0.60 to 0.17, P=.27).
__label__noRel	The improvement in pain-related impairment was not sustained at 6 and 12 weeks.	There were no significant intervention by subgroup interactions (P>.10).
__label__noRel	The improvement in pain-related impairment was not sustained at 6 and 12 weeks.	We conclude that TEC, compared with EUC, resulted in improved pain communication self-efficacy and temporary improvement in pain-related impairment, but no improvement in pain severity.
__label__noRel	There were no significant intervention by subgroup interactions (P>.10).	Compared to EUC, TEC was associated with increased pain communication self-efficacy after the intervention (P<.001);
__label__noRel	There were no significant intervention by subgroup interactions (P>.10).	both groups showed significant (P<.0001), similar, reductions in pain misconceptions.
__label__noRel	There were no significant intervention by subgroup interactions (P>.10).	At 2 weeks, assignment to TEC was associated with improvement in pain-related impairment (-0.25 points on a 5-point scale, 95% confidence interval -0.43 to -0.06, P=.01)
__label__noRel	There were no significant intervention by subgroup interactions (P>.10).	but not in pain severity (-0.21 points on an 11-point scale, -0.60 to 0.17, P=.27).
__label__noRel	There were no significant intervention by subgroup interactions (P>.10).	The improvement in pain-related impairment was not sustained at 6 and 12 weeks.
__label__noRel	There were no significant intervention by subgroup interactions (P>.10).	We conclude that TEC, compared with EUC, resulted in improved pain communication self-efficacy and temporary improvement in pain-related impairment, but no improvement in pain severity.
__label__noRel	We conclude that TEC, compared with EUC, resulted in improved pain communication self-efficacy and temporary improvement in pain-related impairment, but no improvement in pain severity.	Compared to EUC, TEC was associated with increased pain communication self-efficacy after the intervention (P<.001);
__label__noRel	We conclude that TEC, compared with EUC, resulted in improved pain communication self-efficacy and temporary improvement in pain-related impairment, but no improvement in pain severity.	both groups showed significant (P<.0001), similar, reductions in pain misconceptions.
__label__noRel	We conclude that TEC, compared with EUC, resulted in improved pain communication self-efficacy and temporary improvement in pain-related impairment, but no improvement in pain severity.	At 2 weeks, assignment to TEC was associated with improvement in pain-related impairment (-0.25 points on a 5-point scale, 95% confidence interval -0.43 to -0.06, P=.01)
__label__noRel	We conclude that TEC, compared with EUC, resulted in improved pain communication self-efficacy and temporary improvement in pain-related impairment, but no improvement in pain severity.	but not in pain severity (-0.21 points on an 11-point scale, -0.60 to 0.17, P=.27).
__label__noRel	We conclude that TEC, compared with EUC, resulted in improved pain communication self-efficacy and temporary improvement in pain-related impairment, but no improvement in pain severity.	The improvement in pain-related impairment was not sustained at 6 and 12 weeks.
__label__noRel	We conclude that TEC, compared with EUC, resulted in improved pain communication self-efficacy and temporary improvement in pain-related impairment, but no improvement in pain severity.	There were no significant intervention by subgroup interactions (P>.10).
__label__noRel	Hormonal breast cancer treatment increases menopausal symptoms in women.	There were no significant differences in vaginal bleeding, mood alteration, or low energy.
__label__noRel	Hormonal breast cancer treatment increases menopausal symptoms in women.	Patients receiving tamoxifen had significantly more vaginal discharge (P < .0001).
__label__noRel	Hormonal breast cancer treatment increases menopausal symptoms in women.	Exemestane patients reported more bone/muscle aches (P < .0001), vaginal dryness (P = .0004), and difficulty sleeping (P = .03).
__label__noRel	Hormonal breast cancer treatment increases menopausal symptoms in women.	In both groups, the hot flash score peaked at 3 months and decreased thereafter.
__label__noRel	Hormonal breast cancer treatment increases menopausal symptoms in women.	At 12 months, patients receiving tamoxifen had a significantly higher mean hot flash score (P = .03), with daily hot flashes increasing from baseline by 33% compared with a 7% increase from baseline with exemestane.
__label__noRel	Hormonal breast cancer treatment increases menopausal symptoms in women.	At 12 months, exemestane was associated with fewer hot flashes and less vaginal discharge than tamoxifen, but with more vaginal dryness, bone/muscle aches, and difficulty sleeping.
__label__noRel	Hormonal breast cancer treatment increases menopausal symptoms in women.	Symptoms were common in both groups.
__label__noRel	There were no significant differences in vaginal bleeding, mood alteration, or low energy.	Hormonal breast cancer treatment increases menopausal symptoms in women.
__label__noRel	There were no significant differences in vaginal bleeding, mood alteration, or low energy.	Patients receiving tamoxifen had significantly more vaginal discharge (P < .0001).
__label__noRel	There were no significant differences in vaginal bleeding, mood alteration, or low energy.	Exemestane patients reported more bone/muscle aches (P < .0001), vaginal dryness (P = .0004), and difficulty sleeping (P = .03).
__label__noRel	There were no significant differences in vaginal bleeding, mood alteration, or low energy.	In both groups, the hot flash score peaked at 3 months and decreased thereafter.
__label__noRel	There were no significant differences in vaginal bleeding, mood alteration, or low energy.	At 12 months, patients receiving tamoxifen had a significantly higher mean hot flash score (P = .03), with daily hot flashes increasing from baseline by 33% compared with a 7% increase from baseline with exemestane.
__label__noRel	There were no significant differences in vaginal bleeding, mood alteration, or low energy.	At 12 months, exemestane was associated with fewer hot flashes and less vaginal discharge than tamoxifen, but with more vaginal dryness, bone/muscle aches, and difficulty sleeping.
__label__noRel	There were no significant differences in vaginal bleeding, mood alteration, or low energy.	Symptoms were common in both groups.
__label__noRel	Patients receiving tamoxifen had significantly more vaginal discharge (P < .0001).	Hormonal breast cancer treatment increases menopausal symptoms in women.
__label__noRel	Patients receiving tamoxifen had significantly more vaginal discharge (P < .0001).	There were no significant differences in vaginal bleeding, mood alteration, or low energy.
__label__noRel	Patients receiving tamoxifen had significantly more vaginal discharge (P < .0001).	Exemestane patients reported more bone/muscle aches (P < .0001), vaginal dryness (P = .0004), and difficulty sleeping (P = .03).
__label__noRel	Patients receiving tamoxifen had significantly more vaginal discharge (P < .0001).	In both groups, the hot flash score peaked at 3 months and decreased thereafter.
__label__noRel	Patients receiving tamoxifen had significantly more vaginal discharge (P < .0001).	At 12 months, patients receiving tamoxifen had a significantly higher mean hot flash score (P = .03), with daily hot flashes increasing from baseline by 33% compared with a 7% increase from baseline with exemestane.
__label__noRel	Patients receiving tamoxifen had significantly more vaginal discharge (P < .0001).	At 12 months, exemestane was associated with fewer hot flashes and less vaginal discharge than tamoxifen, but with more vaginal dryness, bone/muscle aches, and difficulty sleeping.
__label__noRel	Patients receiving tamoxifen had significantly more vaginal discharge (P < .0001).	Symptoms were common in both groups.
__label__noRel	Exemestane patients reported more bone/muscle aches (P < .0001), vaginal dryness (P = .0004), and difficulty sleeping (P = .03).	Hormonal breast cancer treatment increases menopausal symptoms in women.
__label__noRel	Exemestane patients reported more bone/muscle aches (P < .0001), vaginal dryness (P = .0004), and difficulty sleeping (P = .03).	There were no significant differences in vaginal bleeding, mood alteration, or low energy.
__label__noRel	Exemestane patients reported more bone/muscle aches (P < .0001), vaginal dryness (P = .0004), and difficulty sleeping (P = .03).	Patients receiving tamoxifen had significantly more vaginal discharge (P < .0001).
__label__noRel	Exemestane patients reported more bone/muscle aches (P < .0001), vaginal dryness (P = .0004), and difficulty sleeping (P = .03).	In both groups, the hot flash score peaked at 3 months and decreased thereafter.
__label__noRel	Exemestane patients reported more bone/muscle aches (P < .0001), vaginal dryness (P = .0004), and difficulty sleeping (P = .03).	At 12 months, patients receiving tamoxifen had a significantly higher mean hot flash score (P = .03), with daily hot flashes increasing from baseline by 33% compared with a 7% increase from baseline with exemestane.
__label__noRel	Exemestane patients reported more bone/muscle aches (P < .0001), vaginal dryness (P = .0004), and difficulty sleeping (P = .03).	At 12 months, exemestane was associated with fewer hot flashes and less vaginal discharge than tamoxifen, but with more vaginal dryness, bone/muscle aches, and difficulty sleeping.
__label__noRel	Exemestane patients reported more bone/muscle aches (P < .0001), vaginal dryness (P = .0004), and difficulty sleeping (P = .03).	Symptoms were common in both groups.
__label__noRel	In both groups, the hot flash score peaked at 3 months and decreased thereafter.	Hormonal breast cancer treatment increases menopausal symptoms in women.
__label__noRel	In both groups, the hot flash score peaked at 3 months and decreased thereafter.	There were no significant differences in vaginal bleeding, mood alteration, or low energy.
__label__noRel	In both groups, the hot flash score peaked at 3 months and decreased thereafter.	Patients receiving tamoxifen had significantly more vaginal discharge (P < .0001).
__label__noRel	In both groups, the hot flash score peaked at 3 months and decreased thereafter.	Exemestane patients reported more bone/muscle aches (P < .0001), vaginal dryness (P = .0004), and difficulty sleeping (P = .03).
__label__noRel	In both groups, the hot flash score peaked at 3 months and decreased thereafter.	At 12 months, patients receiving tamoxifen had a significantly higher mean hot flash score (P = .03), with daily hot flashes increasing from baseline by 33% compared with a 7% increase from baseline with exemestane.
__label__noRel	In both groups, the hot flash score peaked at 3 months and decreased thereafter.	At 12 months, exemestane was associated with fewer hot flashes and less vaginal discharge than tamoxifen, but with more vaginal dryness, bone/muscle aches, and difficulty sleeping.
__label__Support	In both groups, the hot flash score peaked at 3 months and decreased thereafter.	Symptoms were common in both groups.
__label__noRel	At 12 months, patients receiving tamoxifen had a significantly higher mean hot flash score (P = .03), with daily hot flashes increasing from baseline by 33% compared with a 7% increase from baseline with exemestane.	Hormonal breast cancer treatment increases menopausal symptoms in women.
__label__noRel	At 12 months, patients receiving tamoxifen had a significantly higher mean hot flash score (P = .03), with daily hot flashes increasing from baseline by 33% compared with a 7% increase from baseline with exemestane.	There were no significant differences in vaginal bleeding, mood alteration, or low energy.
__label__noRel	At 12 months, patients receiving tamoxifen had a significantly higher mean hot flash score (P = .03), with daily hot flashes increasing from baseline by 33% compared with a 7% increase from baseline with exemestane.	Patients receiving tamoxifen had significantly more vaginal discharge (P < .0001).
__label__noRel	At 12 months, patients receiving tamoxifen had a significantly higher mean hot flash score (P = .03), with daily hot flashes increasing from baseline by 33% compared with a 7% increase from baseline with exemestane.	Exemestane patients reported more bone/muscle aches (P < .0001), vaginal dryness (P = .0004), and difficulty sleeping (P = .03).
__label__noRel	At 12 months, patients receiving tamoxifen had a significantly higher mean hot flash score (P = .03), with daily hot flashes increasing from baseline by 33% compared with a 7% increase from baseline with exemestane.	In both groups, the hot flash score peaked at 3 months and decreased thereafter.
__label__noRel	At 12 months, patients receiving tamoxifen had a significantly higher mean hot flash score (P = .03), with daily hot flashes increasing from baseline by 33% compared with a 7% increase from baseline with exemestane.	At 12 months, exemestane was associated with fewer hot flashes and less vaginal discharge than tamoxifen, but with more vaginal dryness, bone/muscle aches, and difficulty sleeping.
__label__Support	At 12 months, patients receiving tamoxifen had a significantly higher mean hot flash score (P = .03), with daily hot flashes increasing from baseline by 33% compared with a 7% increase from baseline with exemestane.	Symptoms were common in both groups.
__label__noRel	At 12 months, exemestane was associated with fewer hot flashes and less vaginal discharge than tamoxifen, but with more vaginal dryness, bone/muscle aches, and difficulty sleeping.	Hormonal breast cancer treatment increases menopausal symptoms in women.
__label__noRel	At 12 months, exemestane was associated with fewer hot flashes and less vaginal discharge than tamoxifen, but with more vaginal dryness, bone/muscle aches, and difficulty sleeping.	There were no significant differences in vaginal bleeding, mood alteration, or low energy.
__label__noRel	At 12 months, exemestane was associated with fewer hot flashes and less vaginal discharge than tamoxifen, but with more vaginal dryness, bone/muscle aches, and difficulty sleeping.	Patients receiving tamoxifen had significantly more vaginal discharge (P < .0001).
__label__noRel	At 12 months, exemestane was associated with fewer hot flashes and less vaginal discharge than tamoxifen, but with more vaginal dryness, bone/muscle aches, and difficulty sleeping.	Exemestane patients reported more bone/muscle aches (P < .0001), vaginal dryness (P = .0004), and difficulty sleeping (P = .03).
__label__noRel	At 12 months, exemestane was associated with fewer hot flashes and less vaginal discharge than tamoxifen, but with more vaginal dryness, bone/muscle aches, and difficulty sleeping.	In both groups, the hot flash score peaked at 3 months and decreased thereafter.
__label__noRel	At 12 months, exemestane was associated with fewer hot flashes and less vaginal discharge than tamoxifen, but with more vaginal dryness, bone/muscle aches, and difficulty sleeping.	At 12 months, patients receiving tamoxifen had a significantly higher mean hot flash score (P = .03), with daily hot flashes increasing from baseline by 33% compared with a 7% increase from baseline with exemestane.
__label__Support	At 12 months, exemestane was associated with fewer hot flashes and less vaginal discharge than tamoxifen, but with more vaginal dryness, bone/muscle aches, and difficulty sleeping.	Symptoms were common in both groups.
__label__noRel	Symptoms were common in both groups.	Hormonal breast cancer treatment increases menopausal symptoms in women.
__label__noRel	Symptoms were common in both groups.	There were no significant differences in vaginal bleeding, mood alteration, or low energy.
__label__noRel	Symptoms were common in both groups.	Patients receiving tamoxifen had significantly more vaginal discharge (P < .0001).
__label__noRel	Symptoms were common in both groups.	Exemestane patients reported more bone/muscle aches (P < .0001), vaginal dryness (P = .0004), and difficulty sleeping (P = .03).
__label__noRel	Symptoms were common in both groups.	In both groups, the hot flash score peaked at 3 months and decreased thereafter.
__label__noRel	Symptoms were common in both groups.	At 12 months, patients receiving tamoxifen had a significantly higher mean hot flash score (P = .03), with daily hot flashes increasing from baseline by 33% compared with a 7% increase from baseline with exemestane.
__label__noRel	Symptoms were common in both groups.	At 12 months, exemestane was associated with fewer hot flashes and less vaginal discharge than tamoxifen, but with more vaginal dryness, bone/muscle aches, and difficulty sleeping.
__label__noRel	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).	Two-year survival rate was 18% with DCF and 9% with CF.
__label__noRel	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).	Overall response rate was higher with DCF (chi2 P = .01).
__label__noRel	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.
__label__noRel	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).
__label__noRel	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).
__label__Support	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.
__label__noRel	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.
__label__noRel	Two-year survival rate was 18% with DCF and 9% with CF.	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).
__label__noRel	Two-year survival rate was 18% with DCF and 9% with CF.	Overall response rate was higher with DCF (chi2 P = .01).
__label__noRel	Two-year survival rate was 18% with DCF and 9% with CF.	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.
__label__noRel	Two-year survival rate was 18% with DCF and 9% with CF.	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).
__label__noRel	Two-year survival rate was 18% with DCF and 9% with CF.	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).
__label__Support	Two-year survival rate was 18% with DCF and 9% with CF.	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.
__label__noRel	Two-year survival rate was 18% with DCF and 9% with CF.	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.
__label__noRel	Overall response rate was higher with DCF (chi2 P = .01).	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).
__label__noRel	Overall response rate was higher with DCF (chi2 P = .01).	Two-year survival rate was 18% with DCF and 9% with CF.
__label__noRel	Overall response rate was higher with DCF (chi2 P = .01).	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.
__label__noRel	Overall response rate was higher with DCF (chi2 P = .01).	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).
__label__noRel	Overall response rate was higher with DCF (chi2 P = .01).	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).
__label__Support	Overall response rate was higher with DCF (chi2 P = .01).	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.
__label__noRel	Overall response rate was higher with DCF (chi2 P = .01).	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.
__label__noRel	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).
__label__noRel	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.	Two-year survival rate was 18% with DCF and 9% with CF.
__label__noRel	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.	Overall response rate was higher with DCF (chi2 P = .01).
__label__noRel	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).
__label__noRel	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).
__label__noRel	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.
__label__noRel	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.
__label__noRel	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).
__label__noRel	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).	Two-year survival rate was 18% with DCF and 9% with CF.
__label__noRel	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).	Overall response rate was higher with DCF (chi2 P = .01).
__label__noRel	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.
__label__noRel	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).
__label__Support	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.
__label__noRel	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.
__label__noRel	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).
__label__noRel	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).	Two-year survival rate was 18% with DCF and 9% with CF.
__label__noRel	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).	Overall response rate was higher with DCF (chi2 P = .01).
__label__noRel	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.
__label__noRel	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).
__label__Support	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.
__label__noRel	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.
__label__noRel	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).
__label__noRel	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.	Two-year survival rate was 18% with DCF and 9% with CF.
__label__noRel	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.	Overall response rate was higher with DCF (chi2 P = .01).
__label__noRel	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.
__label__noRel	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).
__label__noRel	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).
__label__Support	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.
__label__noRel	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).
__label__noRel	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.	Two-year survival rate was 18% with DCF and 9% with CF.
__label__noRel	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.	Overall response rate was higher with DCF (chi2 P = .01).
__label__noRel	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.
__label__noRel	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).
__label__noRel	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).
__label__noRel	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.
__label__noRel	Maintenance therapy with erlotinib did not impact on deterioration in HRQoL: TSP (hazard ratio [HR]=0.91 [95% confidence interval (CI) 0.74-1.12]; n=785), TTD in TOI (HR=1.06 [95% CI 0.87-1.31]; n=781) and TTD in HRQoL (HR=0.96 [95% CI 0.79-1.16]; n=776).	Time to pain and time to analgesic use were significantly delayed in patients receiving erlotinib compared with placebo (HR=0.61 [95% CI 0.42-0.88]; p=0.0080 and HR=0.66 [95% CI 0.46-0.94]; p=0.0199, respectively).
__label__noRel	Maintenance therapy with erlotinib did not impact on deterioration in HRQoL: TSP (hazard ratio [HR]=0.91 [95% confidence interval (CI) 0.74-1.12]; n=785), TTD in TOI (HR=1.06 [95% CI 0.87-1.31]; n=781) and TTD in HRQoL (HR=0.96 [95% CI 0.79-1.16]; n=776).	A non-significant trend towards delayed time to cough and time to dyspnoea (HR=0.77 [95% CI 0.49-1.21] and HR=0.75 [95% CI 0.48-1.17], respectively) was also observed.
__label__Support	Maintenance therapy with erlotinib did not impact on deterioration in HRQoL: TSP (hazard ratio [HR]=0.91 [95% confidence interval (CI) 0.74-1.12]; n=785), TTD in TOI (HR=1.06 [95% CI 0.87-1.31]; n=781) and TTD in HRQoL (HR=0.96 [95% CI 0.79-1.16]; n=776).	Erlotinib maintenance therapy significantly extends progression-free survival without compromising patient HRQoL in comparison with placebo, with some improvement in symptoms.
__label__noRel	Maintenance therapy with erlotinib did not impact on deterioration in HRQoL: TSP (hazard ratio [HR]=0.91 [95% confidence interval (CI) 0.74-1.12]; n=785), TTD in TOI (HR=1.06 [95% CI 0.87-1.31]; n=781) and TTD in HRQoL (HR=0.96 [95% CI 0.79-1.16]; n=776).	Compared with placebo, erlotinib maintenance therapy prolonged progression-free and overall survival by 41% and 23%, respectively.
__label__noRel	Time to pain and time to analgesic use were significantly delayed in patients receiving erlotinib compared with placebo (HR=0.61 [95% CI 0.42-0.88]; p=0.0080 and HR=0.66 [95% CI 0.46-0.94]; p=0.0199, respectively).	Maintenance therapy with erlotinib did not impact on deterioration in HRQoL: TSP (hazard ratio [HR]=0.91 [95% confidence interval (CI) 0.74-1.12]; n=785), TTD in TOI (HR=1.06 [95% CI 0.87-1.31]; n=781) and TTD in HRQoL (HR=0.96 [95% CI 0.79-1.16]; n=776).
__label__noRel	Time to pain and time to analgesic use were significantly delayed in patients receiving erlotinib compared with placebo (HR=0.61 [95% CI 0.42-0.88]; p=0.0080 and HR=0.66 [95% CI 0.46-0.94]; p=0.0199, respectively).	A non-significant trend towards delayed time to cough and time to dyspnoea (HR=0.77 [95% CI 0.49-1.21] and HR=0.75 [95% CI 0.48-1.17], respectively) was also observed.
__label__Support	Time to pain and time to analgesic use were significantly delayed in patients receiving erlotinib compared with placebo (HR=0.61 [95% CI 0.42-0.88]; p=0.0080 and HR=0.66 [95% CI 0.46-0.94]; p=0.0199, respectively).	Erlotinib maintenance therapy significantly extends progression-free survival without compromising patient HRQoL in comparison with placebo, with some improvement in symptoms.
__label__noRel	Time to pain and time to analgesic use were significantly delayed in patients receiving erlotinib compared with placebo (HR=0.61 [95% CI 0.42-0.88]; p=0.0080 and HR=0.66 [95% CI 0.46-0.94]; p=0.0199, respectively).	Compared with placebo, erlotinib maintenance therapy prolonged progression-free and overall survival by 41% and 23%, respectively.
__label__noRel	A non-significant trend towards delayed time to cough and time to dyspnoea (HR=0.77 [95% CI 0.49-1.21] and HR=0.75 [95% CI 0.48-1.17], respectively) was also observed.	Maintenance therapy with erlotinib did not impact on deterioration in HRQoL: TSP (hazard ratio [HR]=0.91 [95% confidence interval (CI) 0.74-1.12]; n=785), TTD in TOI (HR=1.06 [95% CI 0.87-1.31]; n=781) and TTD in HRQoL (HR=0.96 [95% CI 0.79-1.16]; n=776).
__label__noRel	A non-significant trend towards delayed time to cough and time to dyspnoea (HR=0.77 [95% CI 0.49-1.21] and HR=0.75 [95% CI 0.48-1.17], respectively) was also observed.	Time to pain and time to analgesic use were significantly delayed in patients receiving erlotinib compared with placebo (HR=0.61 [95% CI 0.42-0.88]; p=0.0080 and HR=0.66 [95% CI 0.46-0.94]; p=0.0199, respectively).
__label__Support	A non-significant trend towards delayed time to cough and time to dyspnoea (HR=0.77 [95% CI 0.49-1.21] and HR=0.75 [95% CI 0.48-1.17], respectively) was also observed.	Erlotinib maintenance therapy significantly extends progression-free survival without compromising patient HRQoL in comparison with placebo, with some improvement in symptoms.
__label__noRel	A non-significant trend towards delayed time to cough and time to dyspnoea (HR=0.77 [95% CI 0.49-1.21] and HR=0.75 [95% CI 0.48-1.17], respectively) was also observed.	Compared with placebo, erlotinib maintenance therapy prolonged progression-free and overall survival by 41% and 23%, respectively.
__label__noRel	Erlotinib maintenance therapy significantly extends progression-free survival without compromising patient HRQoL in comparison with placebo, with some improvement in symptoms.	Maintenance therapy with erlotinib did not impact on deterioration in HRQoL: TSP (hazard ratio [HR]=0.91 [95% confidence interval (CI) 0.74-1.12]; n=785), TTD in TOI (HR=1.06 [95% CI 0.87-1.31]; n=781) and TTD in HRQoL (HR=0.96 [95% CI 0.79-1.16]; n=776).
__label__noRel	Erlotinib maintenance therapy significantly extends progression-free survival without compromising patient HRQoL in comparison with placebo, with some improvement in symptoms.	Time to pain and time to analgesic use were significantly delayed in patients receiving erlotinib compared with placebo (HR=0.61 [95% CI 0.42-0.88]; p=0.0080 and HR=0.66 [95% CI 0.46-0.94]; p=0.0199, respectively).
__label__noRel	Erlotinib maintenance therapy significantly extends progression-free survival without compromising patient HRQoL in comparison with placebo, with some improvement in symptoms.	A non-significant trend towards delayed time to cough and time to dyspnoea (HR=0.77 [95% CI 0.49-1.21] and HR=0.75 [95% CI 0.48-1.17], respectively) was also observed.
__label__noRel	Erlotinib maintenance therapy significantly extends progression-free survival without compromising patient HRQoL in comparison with placebo, with some improvement in symptoms.	Compared with placebo, erlotinib maintenance therapy prolonged progression-free and overall survival by 41% and 23%, respectively.
__label__noRel	Compared with placebo, erlotinib maintenance therapy prolonged progression-free and overall survival by 41% and 23%, respectively.	Maintenance therapy with erlotinib did not impact on deterioration in HRQoL: TSP (hazard ratio [HR]=0.91 [95% confidence interval (CI) 0.74-1.12]; n=785), TTD in TOI (HR=1.06 [95% CI 0.87-1.31]; n=781) and TTD in HRQoL (HR=0.96 [95% CI 0.79-1.16]; n=776).
__label__noRel	Compared with placebo, erlotinib maintenance therapy prolonged progression-free and overall survival by 41% and 23%, respectively.	Time to pain and time to analgesic use were significantly delayed in patients receiving erlotinib compared with placebo (HR=0.61 [95% CI 0.42-0.88]; p=0.0080 and HR=0.66 [95% CI 0.46-0.94]; p=0.0199, respectively).
__label__noRel	Compared with placebo, erlotinib maintenance therapy prolonged progression-free and overall survival by 41% and 23%, respectively.	A non-significant trend towards delayed time to cough and time to dyspnoea (HR=0.77 [95% CI 0.49-1.21] and HR=0.75 [95% CI 0.48-1.17], respectively) was also observed.
__label__Support	Compared with placebo, erlotinib maintenance therapy prolonged progression-free and overall survival by 41% and 23%, respectively.	Erlotinib maintenance therapy significantly extends progression-free survival without compromising patient HRQoL in comparison with placebo, with some improvement in symptoms.
__label__noRel	Compared with RELP, patients receiving UM had significantly shorter duration of operation and hospital stay, shorter time periods to walk, return to daily activities, or sit without pain and to return to work or school, and fewer complications.	Time to final healing was significantly shorter and quality of life scores on the CWIS were higher in patients receiving RELP than in those receiving UM.
__label__noRel	Compared with RELP, patients receiving UM had significantly shorter duration of operation and hospital stay, shorter time periods to walk, return to daily activities, or sit without pain and to return to work or school, and fewer complications.	Patients with UM had lower levels of pain one week after surgery.
__label__Support	Compared with RELP, patients receiving UM had significantly shorter duration of operation and hospital stay, shorter time periods to walk, return to daily activities, or sit without pain and to return to work or school, and fewer complications.	The unroofing and marsupialization procedure provides more clinical benefits in the treatment of pilonidal disease than rhomboid excision and Limberg flap and should be considered the procedure of choice.
__label__noRel	Compared with RELP, patients receiving UM had significantly shorter duration of operation and hospital stay, shorter time periods to walk, return to daily activities, or sit without pain and to return to work or school, and fewer complications.	However, it may be associated with more inconvenience in wound care and longer healing time than rhomboid excision and Lindberg flap.
__label__noRel	Time to final healing was significantly shorter and quality of life scores on the CWIS were higher in patients receiving RELP than in those receiving UM.	Compared with RELP, patients receiving UM had significantly shorter duration of operation and hospital stay, shorter time periods to walk, return to daily activities, or sit without pain and to return to work or school, and fewer complications.
__label__noRel	Time to final healing was significantly shorter and quality of life scores on the CWIS were higher in patients receiving RELP than in those receiving UM.	Patients with UM had lower levels of pain one week after surgery.
__label__noRel	Time to final healing was significantly shorter and quality of life scores on the CWIS were higher in patients receiving RELP than in those receiving UM.	The unroofing and marsupialization procedure provides more clinical benefits in the treatment of pilonidal disease than rhomboid excision and Limberg flap and should be considered the procedure of choice.
__label__Support	Time to final healing was significantly shorter and quality of life scores on the CWIS were higher in patients receiving RELP than in those receiving UM.	However, it may be associated with more inconvenience in wound care and longer healing time than rhomboid excision and Lindberg flap.
__label__noRel	Patients with UM had lower levels of pain one week after surgery.	Compared with RELP, patients receiving UM had significantly shorter duration of operation and hospital stay, shorter time periods to walk, return to daily activities, or sit without pain and to return to work or school, and fewer complications.
__label__noRel	Patients with UM had lower levels of pain one week after surgery.	Time to final healing was significantly shorter and quality of life scores on the CWIS were higher in patients receiving RELP than in those receiving UM.
__label__Support	Patients with UM had lower levels of pain one week after surgery.	The unroofing and marsupialization procedure provides more clinical benefits in the treatment of pilonidal disease than rhomboid excision and Limberg flap and should be considered the procedure of choice.
__label__noRel	Patients with UM had lower levels of pain one week after surgery.	However, it may be associated with more inconvenience in wound care and longer healing time than rhomboid excision and Lindberg flap.
__label__noRel	The unroofing and marsupialization procedure provides more clinical benefits in the treatment of pilonidal disease than rhomboid excision and Limberg flap and should be considered the procedure of choice.	Compared with RELP, patients receiving UM had significantly shorter duration of operation and hospital stay, shorter time periods to walk, return to daily activities, or sit without pain and to return to work or school, and fewer complications.
__label__noRel	The unroofing and marsupialization procedure provides more clinical benefits in the treatment of pilonidal disease than rhomboid excision and Limberg flap and should be considered the procedure of choice.	Time to final healing was significantly shorter and quality of life scores on the CWIS were higher in patients receiving RELP than in those receiving UM.
__label__noRel	The unroofing and marsupialization procedure provides more clinical benefits in the treatment of pilonidal disease than rhomboid excision and Limberg flap and should be considered the procedure of choice.	Patients with UM had lower levels of pain one week after surgery.
__label__noRel	The unroofing and marsupialization procedure provides more clinical benefits in the treatment of pilonidal disease than rhomboid excision and Limberg flap and should be considered the procedure of choice.	However, it may be associated with more inconvenience in wound care and longer healing time than rhomboid excision and Lindberg flap.
__label__noRel	However, it may be associated with more inconvenience in wound care and longer healing time than rhomboid excision and Lindberg flap.	Compared with RELP, patients receiving UM had significantly shorter duration of operation and hospital stay, shorter time periods to walk, return to daily activities, or sit without pain and to return to work or school, and fewer complications.
__label__noRel	However, it may be associated with more inconvenience in wound care and longer healing time than rhomboid excision and Lindberg flap.	Time to final healing was significantly shorter and quality of life scores on the CWIS were higher in patients receiving RELP than in those receiving UM.
__label__noRel	However, it may be associated with more inconvenience in wound care and longer healing time than rhomboid excision and Lindberg flap.	Patients with UM had lower levels of pain one week after surgery.
__label__Attack	However, it may be associated with more inconvenience in wound care and longer healing time than rhomboid excision and Lindberg flap.	The unroofing and marsupialization procedure provides more clinical benefits in the treatment of pilonidal disease than rhomboid excision and Limberg flap and should be considered the procedure of choice.
__label__noRel	Median survival was: OSC+WBRT 49 days (95% confidence interval 39-61), OSC 51 days (95% confidence interval 27-57) - hazard ratio 1.11 (95% confidence interval 0.80-1.53) in favour of WBRT.	Quality of life assessed using EQ-5D showed no evidence of a difference.
__label__noRel	Median survival was: OSC+WBRT 49 days (95% confidence interval 39-61), OSC 51 days (95% confidence interval 27-57) - hazard ratio 1.11 (95% confidence interval 0.80-1.53) in favour of WBRT.	The estimated mean QALYs was: OSC+WBRT 31 days and OSC 30 days, difference -1 day (95% confidence interval -12.0 to +13.2 days).
__label__Support	Median survival was: OSC+WBRT 49 days (95% confidence interval 39-61), OSC 51 days (95% confidence interval 27-57) - hazard ratio 1.11 (95% confidence interval 0.80-1.53) in favour of WBRT.	These interim data indicate no early evidence of detriment to quality of life, overall survival or QALYs for patients allocated to OSC alone.
__label__noRel	Quality of life assessed using EQ-5D showed no evidence of a difference.	Median survival was: OSC+WBRT 49 days (95% confidence interval 39-61), OSC 51 days (95% confidence interval 27-57) - hazard ratio 1.11 (95% confidence interval 0.80-1.53) in favour of WBRT.
__label__noRel	Quality of life assessed using EQ-5D showed no evidence of a difference.	The estimated mean QALYs was: OSC+WBRT 31 days and OSC 30 days, difference -1 day (95% confidence interval -12.0 to +13.2 days).
__label__Support	Quality of life assessed using EQ-5D showed no evidence of a difference.	These interim data indicate no early evidence of detriment to quality of life, overall survival or QALYs for patients allocated to OSC alone.
__label__noRel	The estimated mean QALYs was: OSC+WBRT 31 days and OSC 30 days, difference -1 day (95% confidence interval -12.0 to +13.2 days).	Median survival was: OSC+WBRT 49 days (95% confidence interval 39-61), OSC 51 days (95% confidence interval 27-57) - hazard ratio 1.11 (95% confidence interval 0.80-1.53) in favour of WBRT.
__label__noRel	The estimated mean QALYs was: OSC+WBRT 31 days and OSC 30 days, difference -1 day (95% confidence interval -12.0 to +13.2 days).	Quality of life assessed using EQ-5D showed no evidence of a difference.
__label__Support	The estimated mean QALYs was: OSC+WBRT 31 days and OSC 30 days, difference -1 day (95% confidence interval -12.0 to +13.2 days).	These interim data indicate no early evidence of detriment to quality of life, overall survival or QALYs for patients allocated to OSC alone.
__label__noRel	These interim data indicate no early evidence of detriment to quality of life, overall survival or QALYs for patients allocated to OSC alone.	Median survival was: OSC+WBRT 49 days (95% confidence interval 39-61), OSC 51 days (95% confidence interval 27-57) - hazard ratio 1.11 (95% confidence interval 0.80-1.53) in favour of WBRT.
__label__noRel	These interim data indicate no early evidence of detriment to quality of life, overall survival or QALYs for patients allocated to OSC alone.	Quality of life assessed using EQ-5D showed no evidence of a difference.
__label__noRel	These interim data indicate no early evidence of detriment to quality of life, overall survival or QALYs for patients allocated to OSC alone.	The estimated mean QALYs was: OSC+WBRT 31 days and OSC 30 days, difference -1 day (95% confidence interval -12.0 to +13.2 days).
__label__noRel	Symptomatic response during the first four weeks was seen after pamidronate, but not with placebo (P < 0.05).	Quality of life was maintained with pamidronate and deteriorated after placebo (P < 0.05).
__label__noRel	Symptomatic response during the first four weeks was seen after pamidronate, but not with placebo (P < 0.05).	Resorption markers did not decrease after placebo,
__label__noRel	Symptomatic response during the first four weeks was seen after pamidronate, but not with placebo (P < 0.05).	but NTx and Crosslaps both decreased by 70% after pamidronate (P = 0.001).
__label__noRel	Symptomatic response during the first four weeks was seen after pamidronate, but not with placebo (P < 0.05).	A second infusion of pamidronate did not decrease resorption further,
__label__noRel	Symptomatic response during the first four weeks was seen after pamidronate, but not with placebo (P < 0.05).	but maintained the suppression of resorption at similar levels for a further four weeks.
__label__noRel	Symptomatic response during the first four weeks was seen after pamidronate, but not with placebo (P < 0.05).	Symptomatic response to pamidronate correlated closely with the rate of bone resorption;
__label__noRel	Symptomatic response during the first four weeks was seen after pamidronate, but not with placebo (P < 0.05).	it was more frequent in those patients with an initial NTx value of < 2 times the upper limit of normal (17 of 27, 62%) and in those where the level of Ntx returned to normal (19 of 32, 59%), than in the patients with either high baseline values of NTx (> 2 times the upper limit of normal) or Ntx levels which failed to normalise for whom the response frequencies were 2 of 16 (13%) and 0 of 11 (0%), respectively.
__label__Support	Symptomatic response during the first four weeks was seen after pamidronate, but not with placebo (P < 0.05).	Subjective benefit after intravenous pamidronate is confirmed in this placebo-controlled study.
__label__noRel	Symptomatic response during the first four weeks was seen after pamidronate, but not with placebo (P < 0.05).	The new bone resorption markers of collagen breakdown were able to predict clinical response to pamidronate.
__label__noRel	Quality of life was maintained with pamidronate and deteriorated after placebo (P < 0.05).	Symptomatic response during the first four weeks was seen after pamidronate, but not with placebo (P < 0.05).
__label__noRel	Quality of life was maintained with pamidronate and deteriorated after placebo (P < 0.05).	Resorption markers did not decrease after placebo,
__label__noRel	Quality of life was maintained with pamidronate and deteriorated after placebo (P < 0.05).	but NTx and Crosslaps both decreased by 70% after pamidronate (P = 0.001).
__label__noRel	Quality of life was maintained with pamidronate and deteriorated after placebo (P < 0.05).	A second infusion of pamidronate did not decrease resorption further,
__label__noRel	Quality of life was maintained with pamidronate and deteriorated after placebo (P < 0.05).	but maintained the suppression of resorption at similar levels for a further four weeks.
__label__noRel	Quality of life was maintained with pamidronate and deteriorated after placebo (P < 0.05).	Symptomatic response to pamidronate correlated closely with the rate of bone resorption;
__label__noRel	Quality of life was maintained with pamidronate and deteriorated after placebo (P < 0.05).	it was more frequent in those patients with an initial NTx value of < 2 times the upper limit of normal (17 of 27, 62%) and in those where the level of Ntx returned to normal (19 of 32, 59%), than in the patients with either high baseline values of NTx (> 2 times the upper limit of normal) or Ntx levels which failed to normalise for whom the response frequencies were 2 of 16 (13%) and 0 of 11 (0%), respectively.
__label__Support	Quality of life was maintained with pamidronate and deteriorated after placebo (P < 0.05).	Subjective benefit after intravenous pamidronate is confirmed in this placebo-controlled study.
__label__noRel	Quality of life was maintained with pamidronate and deteriorated after placebo (P < 0.05).	The new bone resorption markers of collagen breakdown were able to predict clinical response to pamidronate.
__label__noRel	Resorption markers did not decrease after placebo,	Symptomatic response during the first four weeks was seen after pamidronate, but not with placebo (P < 0.05).
__label__noRel	Resorption markers did not decrease after placebo,	Quality of life was maintained with pamidronate and deteriorated after placebo (P < 0.05).
__label__noRel	Resorption markers did not decrease after placebo,	but NTx and Crosslaps both decreased by 70% after pamidronate (P = 0.001).
__label__noRel	Resorption markers did not decrease after placebo,	A second infusion of pamidronate did not decrease resorption further,
__label__noRel	Resorption markers did not decrease after placebo,	but maintained the suppression of resorption at similar levels for a further four weeks.
__label__noRel	Resorption markers did not decrease after placebo,	Symptomatic response to pamidronate correlated closely with the rate of bone resorption;
__label__noRel	Resorption markers did not decrease after placebo,	it was more frequent in those patients with an initial NTx value of < 2 times the upper limit of normal (17 of 27, 62%) and in those where the level of Ntx returned to normal (19 of 32, 59%), than in the patients with either high baseline values of NTx (> 2 times the upper limit of normal) or Ntx levels which failed to normalise for whom the response frequencies were 2 of 16 (13%) and 0 of 11 (0%), respectively.
__label__noRel	Resorption markers did not decrease after placebo,	Subjective benefit after intravenous pamidronate is confirmed in this placebo-controlled study.
__label__Support	Resorption markers did not decrease after placebo,	The new bone resorption markers of collagen breakdown were able to predict clinical response to pamidronate.
__label__noRel	but NTx and Crosslaps both decreased by 70% after pamidronate (P = 0.001).	Symptomatic response during the first four weeks was seen after pamidronate, but not with placebo (P < 0.05).
__label__noRel	but NTx and Crosslaps both decreased by 70% after pamidronate (P = 0.001).	Quality of life was maintained with pamidronate and deteriorated after placebo (P < 0.05).
__label__Attack	but NTx and Crosslaps both decreased by 70% after pamidronate (P = 0.001).	Resorption markers did not decrease after placebo,
__label__noRel	but NTx and Crosslaps both decreased by 70% after pamidronate (P = 0.001).	A second infusion of pamidronate did not decrease resorption further,
__label__noRel	but NTx and Crosslaps both decreased by 70% after pamidronate (P = 0.001).	but maintained the suppression of resorption at similar levels for a further four weeks.
__label__noRel	but NTx and Crosslaps both decreased by 70% after pamidronate (P = 0.001).	Symptomatic response to pamidronate correlated closely with the rate of bone resorption;
__label__noRel	but NTx and Crosslaps both decreased by 70% after pamidronate (P = 0.001).	it was more frequent in those patients with an initial NTx value of < 2 times the upper limit of normal (17 of 27, 62%) and in those where the level of Ntx returned to normal (19 of 32, 59%), than in the patients with either high baseline values of NTx (> 2 times the upper limit of normal) or Ntx levels which failed to normalise for whom the response frequencies were 2 of 16 (13%) and 0 of 11 (0%), respectively.
__label__noRel	but NTx and Crosslaps both decreased by 70% after pamidronate (P = 0.001).	Subjective benefit after intravenous pamidronate is confirmed in this placebo-controlled study.
__label__noRel	but NTx and Crosslaps both decreased by 70% after pamidronate (P = 0.001).	The new bone resorption markers of collagen breakdown were able to predict clinical response to pamidronate.
__label__noRel	A second infusion of pamidronate did not decrease resorption further,	Symptomatic response during the first four weeks was seen after pamidronate, but not with placebo (P < 0.05).
__label__noRel	A second infusion of pamidronate did not decrease resorption further,	Quality of life was maintained with pamidronate and deteriorated after placebo (P < 0.05).
__label__noRel	A second infusion of pamidronate did not decrease resorption further,	Resorption markers did not decrease after placebo,
__label__noRel	A second infusion of pamidronate did not decrease resorption further,	but NTx and Crosslaps both decreased by 70% after pamidronate (P = 0.001).
__label__noRel	A second infusion of pamidronate did not decrease resorption further,	but maintained the suppression of resorption at similar levels for a further four weeks.
__label__noRel	A second infusion of pamidronate did not decrease resorption further,	Symptomatic response to pamidronate correlated closely with the rate of bone resorption;
__label__noRel	A second infusion of pamidronate did not decrease resorption further,	it was more frequent in those patients with an initial NTx value of < 2 times the upper limit of normal (17 of 27, 62%) and in those where the level of Ntx returned to normal (19 of 32, 59%), than in the patients with either high baseline values of NTx (> 2 times the upper limit of normal) or Ntx levels which failed to normalise for whom the response frequencies were 2 of 16 (13%) and 0 of 11 (0%), respectively.
__label__noRel	A second infusion of pamidronate did not decrease resorption further,	Subjective benefit after intravenous pamidronate is confirmed in this placebo-controlled study.
__label__noRel	A second infusion of pamidronate did not decrease resorption further,	The new bone resorption markers of collagen breakdown were able to predict clinical response to pamidronate.
__label__noRel	but maintained the suppression of resorption at similar levels for a further four weeks.	Symptomatic response during the first four weeks was seen after pamidronate, but not with placebo (P < 0.05).
__label__noRel	but maintained the suppression of resorption at similar levels for a further four weeks.	Quality of life was maintained with pamidronate and deteriorated after placebo (P < 0.05).
__label__noRel	but maintained the suppression of resorption at similar levels for a further four weeks.	Resorption markers did not decrease after placebo,
__label__noRel	but maintained the suppression of resorption at similar levels for a further four weeks.	but NTx and Crosslaps both decreased by 70% after pamidronate (P = 0.001).
__label__Attack	but maintained the suppression of resorption at similar levels for a further four weeks.	A second infusion of pamidronate did not decrease resorption further,
__label__noRel	but maintained the suppression of resorption at similar levels for a further four weeks.	Symptomatic response to pamidronate correlated closely with the rate of bone resorption;
__label__noRel	but maintained the suppression of resorption at similar levels for a further four weeks.	it was more frequent in those patients with an initial NTx value of < 2 times the upper limit of normal (17 of 27, 62%) and in those where the level of Ntx returned to normal (19 of 32, 59%), than in the patients with either high baseline values of NTx (> 2 times the upper limit of normal) or Ntx levels which failed to normalise for whom the response frequencies were 2 of 16 (13%) and 0 of 11 (0%), respectively.
__label__noRel	but maintained the suppression of resorption at similar levels for a further four weeks.	Subjective benefit after intravenous pamidronate is confirmed in this placebo-controlled study.
__label__noRel	but maintained the suppression of resorption at similar levels for a further four weeks.	The new bone resorption markers of collagen breakdown were able to predict clinical response to pamidronate.
__label__noRel	Symptomatic response to pamidronate correlated closely with the rate of bone resorption;	Symptomatic response during the first four weeks was seen after pamidronate, but not with placebo (P < 0.05).
__label__noRel	Symptomatic response to pamidronate correlated closely with the rate of bone resorption;	Quality of life was maintained with pamidronate and deteriorated after placebo (P < 0.05).
__label__noRel	Symptomatic response to pamidronate correlated closely with the rate of bone resorption;	Resorption markers did not decrease after placebo,
__label__noRel	Symptomatic response to pamidronate correlated closely with the rate of bone resorption;	but NTx and Crosslaps both decreased by 70% after pamidronate (P = 0.001).
__label__noRel	Symptomatic response to pamidronate correlated closely with the rate of bone resorption;	A second infusion of pamidronate did not decrease resorption further,
__label__noRel	Symptomatic response to pamidronate correlated closely with the rate of bone resorption;	but maintained the suppression of resorption at similar levels for a further four weeks.
__label__noRel	Symptomatic response to pamidronate correlated closely with the rate of bone resorption;	it was more frequent in those patients with an initial NTx value of < 2 times the upper limit of normal (17 of 27, 62%) and in those where the level of Ntx returned to normal (19 of 32, 59%), than in the patients with either high baseline values of NTx (> 2 times the upper limit of normal) or Ntx levels which failed to normalise for whom the response frequencies were 2 of 16 (13%) and 0 of 11 (0%), respectively.
__label__noRel	Symptomatic response to pamidronate correlated closely with the rate of bone resorption;	Subjective benefit after intravenous pamidronate is confirmed in this placebo-controlled study.
__label__Support	Symptomatic response to pamidronate correlated closely with the rate of bone resorption;	The new bone resorption markers of collagen breakdown were able to predict clinical response to pamidronate.
__label__noRel	it was more frequent in those patients with an initial NTx value of < 2 times the upper limit of normal (17 of 27, 62%) and in those where the level of Ntx returned to normal (19 of 32, 59%), than in the patients with either high baseline values of NTx (> 2 times the upper limit of normal) or Ntx levels which failed to normalise for whom the response frequencies were 2 of 16 (13%) and 0 of 11 (0%), respectively.	Symptomatic response during the first four weeks was seen after pamidronate, but not with placebo (P < 0.05).
__label__noRel	it was more frequent in those patients with an initial NTx value of < 2 times the upper limit of normal (17 of 27, 62%) and in those where the level of Ntx returned to normal (19 of 32, 59%), than in the patients with either high baseline values of NTx (> 2 times the upper limit of normal) or Ntx levels which failed to normalise for whom the response frequencies were 2 of 16 (13%) and 0 of 11 (0%), respectively.	Quality of life was maintained with pamidronate and deteriorated after placebo (P < 0.05).
__label__noRel	it was more frequent in those patients with an initial NTx value of < 2 times the upper limit of normal (17 of 27, 62%) and in those where the level of Ntx returned to normal (19 of 32, 59%), than in the patients with either high baseline values of NTx (> 2 times the upper limit of normal) or Ntx levels which failed to normalise for whom the response frequencies were 2 of 16 (13%) and 0 of 11 (0%), respectively.	Resorption markers did not decrease after placebo,
__label__noRel	it was more frequent in those patients with an initial NTx value of < 2 times the upper limit of normal (17 of 27, 62%) and in those where the level of Ntx returned to normal (19 of 32, 59%), than in the patients with either high baseline values of NTx (> 2 times the upper limit of normal) or Ntx levels which failed to normalise for whom the response frequencies were 2 of 16 (13%) and 0 of 11 (0%), respectively.	but NTx and Crosslaps both decreased by 70% after pamidronate (P = 0.001).
__label__noRel	it was more frequent in those patients with an initial NTx value of < 2 times the upper limit of normal (17 of 27, 62%) and in those where the level of Ntx returned to normal (19 of 32, 59%), than in the patients with either high baseline values of NTx (> 2 times the upper limit of normal) or Ntx levels which failed to normalise for whom the response frequencies were 2 of 16 (13%) and 0 of 11 (0%), respectively.	A second infusion of pamidronate did not decrease resorption further,
__label__noRel	it was more frequent in those patients with an initial NTx value of < 2 times the upper limit of normal (17 of 27, 62%) and in those where the level of Ntx returned to normal (19 of 32, 59%), than in the patients with either high baseline values of NTx (> 2 times the upper limit of normal) or Ntx levels which failed to normalise for whom the response frequencies were 2 of 16 (13%) and 0 of 11 (0%), respectively.	but maintained the suppression of resorption at similar levels for a further four weeks.
__label__noRel	it was more frequent in those patients with an initial NTx value of < 2 times the upper limit of normal (17 of 27, 62%) and in those where the level of Ntx returned to normal (19 of 32, 59%), than in the patients with either high baseline values of NTx (> 2 times the upper limit of normal) or Ntx levels which failed to normalise for whom the response frequencies were 2 of 16 (13%) and 0 of 11 (0%), respectively.	Symptomatic response to pamidronate correlated closely with the rate of bone resorption;
__label__noRel	it was more frequent in those patients with an initial NTx value of < 2 times the upper limit of normal (17 of 27, 62%) and in those where the level of Ntx returned to normal (19 of 32, 59%), than in the patients with either high baseline values of NTx (> 2 times the upper limit of normal) or Ntx levels which failed to normalise for whom the response frequencies were 2 of 16 (13%) and 0 of 11 (0%), respectively.	Subjective benefit after intravenous pamidronate is confirmed in this placebo-controlled study.
__label__noRel	it was more frequent in those patients with an initial NTx value of < 2 times the upper limit of normal (17 of 27, 62%) and in those where the level of Ntx returned to normal (19 of 32, 59%), than in the patients with either high baseline values of NTx (> 2 times the upper limit of normal) or Ntx levels which failed to normalise for whom the response frequencies were 2 of 16 (13%) and 0 of 11 (0%), respectively.	The new bone resorption markers of collagen breakdown were able to predict clinical response to pamidronate.
__label__noRel	Subjective benefit after intravenous pamidronate is confirmed in this placebo-controlled study.	Symptomatic response during the first four weeks was seen after pamidronate, but not with placebo (P < 0.05).
__label__noRel	Subjective benefit after intravenous pamidronate is confirmed in this placebo-controlled study.	Quality of life was maintained with pamidronate and deteriorated after placebo (P < 0.05).
__label__noRel	Subjective benefit after intravenous pamidronate is confirmed in this placebo-controlled study.	Resorption markers did not decrease after placebo,
__label__noRel	Subjective benefit after intravenous pamidronate is confirmed in this placebo-controlled study.	but NTx and Crosslaps both decreased by 70% after pamidronate (P = 0.001).
__label__noRel	Subjective benefit after intravenous pamidronate is confirmed in this placebo-controlled study.	A second infusion of pamidronate did not decrease resorption further,
__label__noRel	Subjective benefit after intravenous pamidronate is confirmed in this placebo-controlled study.	but maintained the suppression of resorption at similar levels for a further four weeks.
__label__noRel	Subjective benefit after intravenous pamidronate is confirmed in this placebo-controlled study.	Symptomatic response to pamidronate correlated closely with the rate of bone resorption;
__label__noRel	Subjective benefit after intravenous pamidronate is confirmed in this placebo-controlled study.	it was more frequent in those patients with an initial NTx value of < 2 times the upper limit of normal (17 of 27, 62%) and in those where the level of Ntx returned to normal (19 of 32, 59%), than in the patients with either high baseline values of NTx (> 2 times the upper limit of normal) or Ntx levels which failed to normalise for whom the response frequencies were 2 of 16 (13%) and 0 of 11 (0%), respectively.
__label__noRel	Subjective benefit after intravenous pamidronate is confirmed in this placebo-controlled study.	The new bone resorption markers of collagen breakdown were able to predict clinical response to pamidronate.
__label__noRel	The new bone resorption markers of collagen breakdown were able to predict clinical response to pamidronate.	Symptomatic response during the first four weeks was seen after pamidronate, but not with placebo (P < 0.05).
__label__noRel	The new bone resorption markers of collagen breakdown were able to predict clinical response to pamidronate.	Quality of life was maintained with pamidronate and deteriorated after placebo (P < 0.05).
__label__noRel	The new bone resorption markers of collagen breakdown were able to predict clinical response to pamidronate.	Resorption markers did not decrease after placebo,
__label__noRel	The new bone resorption markers of collagen breakdown were able to predict clinical response to pamidronate.	but NTx and Crosslaps both decreased by 70% after pamidronate (P = 0.001).
__label__noRel	The new bone resorption markers of collagen breakdown were able to predict clinical response to pamidronate.	A second infusion of pamidronate did not decrease resorption further,
__label__noRel	The new bone resorption markers of collagen breakdown were able to predict clinical response to pamidronate.	but maintained the suppression of resorption at similar levels for a further four weeks.
__label__noRel	The new bone resorption markers of collagen breakdown were able to predict clinical response to pamidronate.	Symptomatic response to pamidronate correlated closely with the rate of bone resorption;
__label__noRel	The new bone resorption markers of collagen breakdown were able to predict clinical response to pamidronate.	it was more frequent in those patients with an initial NTx value of < 2 times the upper limit of normal (17 of 27, 62%) and in those where the level of Ntx returned to normal (19 of 32, 59%), than in the patients with either high baseline values of NTx (> 2 times the upper limit of normal) or Ntx levels which failed to normalise for whom the response frequencies were 2 of 16 (13%) and 0 of 11 (0%), respectively.
__label__noRel	The new bone resorption markers of collagen breakdown were able to predict clinical response to pamidronate.	Subjective benefit after intravenous pamidronate is confirmed in this placebo-controlled study.
__label__noRel	The combination arm was more effective than arm 2 with respect to LBM, REE, fatigue, and global QoL.	As for the secondary efficacy endpoints, patient appetite increased, and ECOG PS decreased significantly in both arms.
__label__noRel	The combination arm was more effective than arm 2 with respect to LBM, REE, fatigue, and global QoL.	The inflammation and oxidative stress parameters IL-6, TNF-, CRP, and ROS decreased significantly in arm 1, while no significant change was observed in arm 2.
__label__Support	The combination arm was more effective than arm 2 with respect to LBM, REE, fatigue, and global QoL.	The combined treatment improved both immunometabolic alterations and patient QoL.
__label__noRel	The combination arm was more effective than arm 2 with respect to LBM, REE, fatigue, and global QoL.	Multimodality therapies for cachexia ideally should be introduced within a context of "best supportive care" that includes optimal symptom management and careful psychosocial counseling.
__label__noRel	As for the secondary efficacy endpoints, patient appetite increased, and ECOG PS decreased significantly in both arms.	The combination arm was more effective than arm 2 with respect to LBM, REE, fatigue, and global QoL.
__label__noRel	As for the secondary efficacy endpoints, patient appetite increased, and ECOG PS decreased significantly in both arms.	The inflammation and oxidative stress parameters IL-6, TNF-, CRP, and ROS decreased significantly in arm 1, while no significant change was observed in arm 2.
__label__Support	As for the secondary efficacy endpoints, patient appetite increased, and ECOG PS decreased significantly in both arms.	The combined treatment improved both immunometabolic alterations and patient QoL.
__label__noRel	As for the secondary efficacy endpoints, patient appetite increased, and ECOG PS decreased significantly in both arms.	Multimodality therapies for cachexia ideally should be introduced within a context of "best supportive care" that includes optimal symptom management and careful psychosocial counseling.
__label__noRel	The inflammation and oxidative stress parameters IL-6, TNF-, CRP, and ROS decreased significantly in arm 1, while no significant change was observed in arm 2.	The combination arm was more effective than arm 2 with respect to LBM, REE, fatigue, and global QoL.
__label__noRel	The inflammation and oxidative stress parameters IL-6, TNF-, CRP, and ROS decreased significantly in arm 1, while no significant change was observed in arm 2.	As for the secondary efficacy endpoints, patient appetite increased, and ECOG PS decreased significantly in both arms.
__label__Support	The inflammation and oxidative stress parameters IL-6, TNF-, CRP, and ROS decreased significantly in arm 1, while no significant change was observed in arm 2.	The combined treatment improved both immunometabolic alterations and patient QoL.
__label__noRel	The inflammation and oxidative stress parameters IL-6, TNF-, CRP, and ROS decreased significantly in arm 1, while no significant change was observed in arm 2.	Multimodality therapies for cachexia ideally should be introduced within a context of "best supportive care" that includes optimal symptom management and careful psychosocial counseling.
__label__noRel	The combined treatment improved both immunometabolic alterations and patient QoL.	The combination arm was more effective than arm 2 with respect to LBM, REE, fatigue, and global QoL.
__label__noRel	The combined treatment improved both immunometabolic alterations and patient QoL.	As for the secondary efficacy endpoints, patient appetite increased, and ECOG PS decreased significantly in both arms.
__label__noRel	The combined treatment improved both immunometabolic alterations and patient QoL.	The inflammation and oxidative stress parameters IL-6, TNF-, CRP, and ROS decreased significantly in arm 1, while no significant change was observed in arm 2.
__label__noRel	The combined treatment improved both immunometabolic alterations and patient QoL.	Multimodality therapies for cachexia ideally should be introduced within a context of "best supportive care" that includes optimal symptom management and careful psychosocial counseling.
__label__noRel	Multimodality therapies for cachexia ideally should be introduced within a context of "best supportive care" that includes optimal symptom management and careful psychosocial counseling.	The combination arm was more effective than arm 2 with respect to LBM, REE, fatigue, and global QoL.
__label__noRel	Multimodality therapies for cachexia ideally should be introduced within a context of "best supportive care" that includes optimal symptom management and careful psychosocial counseling.	As for the secondary efficacy endpoints, patient appetite increased, and ECOG PS decreased significantly in both arms.
__label__noRel	Multimodality therapies for cachexia ideally should be introduced within a context of "best supportive care" that includes optimal symptom management and careful psychosocial counseling.	The inflammation and oxidative stress parameters IL-6, TNF-, CRP, and ROS decreased significantly in arm 1, while no significant change was observed in arm 2.
__label__noRel	Multimodality therapies for cachexia ideally should be introduced within a context of "best supportive care" that includes optimal symptom management and careful psychosocial counseling.	The combined treatment improved both immunometabolic alterations and patient QoL.
__label__noRel	In cachectic patients with advanced cancer, oral melatonin 20 mg at night did not improve appetite, weight, or quality of life compared with placebo.	There were no significant differences between groups for appetite (P = .78) or other symptoms, weight (P = .17), FAACT score (P = .95), toxicity, or survival from baseline to day 28.
__label__Support	There were no significant differences between groups for appetite (P = .78) or other symptoms, weight (P = .17), FAACT score (P = .95), toxicity, or survival from baseline to day 28.	In cachectic patients with advanced cancer, oral melatonin 20 mg at night did not improve appetite, weight, or quality of life compared with placebo.
__label__noRel	Results of this randomized study incorporating prospective QOL measurements suggested that in patients with locally advanced NSCLC, analyzing QOL data by either gender or performance status alone may not accurately reflect how these factors depend upon each another.	There was a significant interaction between gender and KPS using FLIC (P = 0.009), which also showed a trend toward significance with FACT (P = 0.09).
__label__noRel	Results of this randomized study incorporating prospective QOL measurements suggested that in patients with locally advanced NSCLC, analyzing QOL data by either gender or performance status alone may not accurately reflect how these factors depend upon each another.	Significant KPS-by-gender interactions were noted for FACT-L in the physical well-being and additional concerns-lung subscales (P = 0.012 and P = 0.0003, respectively).
__label__noRel	Results of this randomized study incorporating prospective QOL measurements suggested that in patients with locally advanced NSCLC, analyzing QOL data by either gender or performance status alone may not accurately reflect how these factors depend upon each another.	The results of both the FLIC and FACT-L demonstrated significantly lower scores corresponding to lower KPS values (P = 0.009 and P = 0.016, respectively).
__label__Support	There was a significant interaction between gender and KPS using FLIC (P = 0.009), which also showed a trend toward significance with FACT (P = 0.09).	Results of this randomized study incorporating prospective QOL measurements suggested that in patients with locally advanced NSCLC, analyzing QOL data by either gender or performance status alone may not accurately reflect how these factors depend upon each another.
__label__noRel	There was a significant interaction between gender and KPS using FLIC (P = 0.009), which also showed a trend toward significance with FACT (P = 0.09).	Significant KPS-by-gender interactions were noted for FACT-L in the physical well-being and additional concerns-lung subscales (P = 0.012 and P = 0.0003, respectively).
__label__noRel	There was a significant interaction between gender and KPS using FLIC (P = 0.009), which also showed a trend toward significance with FACT (P = 0.09).	The results of both the FLIC and FACT-L demonstrated significantly lower scores corresponding to lower KPS values (P = 0.009 and P = 0.016, respectively).
__label__Support	Significant KPS-by-gender interactions were noted for FACT-L in the physical well-being and additional concerns-lung subscales (P = 0.012 and P = 0.0003, respectively).	Results of this randomized study incorporating prospective QOL measurements suggested that in patients with locally advanced NSCLC, analyzing QOL data by either gender or performance status alone may not accurately reflect how these factors depend upon each another.
__label__noRel	Significant KPS-by-gender interactions were noted for FACT-L in the physical well-being and additional concerns-lung subscales (P = 0.012 and P = 0.0003, respectively).	There was a significant interaction between gender and KPS using FLIC (P = 0.009), which also showed a trend toward significance with FACT (P = 0.09).
__label__noRel	Significant KPS-by-gender interactions were noted for FACT-L in the physical well-being and additional concerns-lung subscales (P = 0.012 and P = 0.0003, respectively).	The results of both the FLIC and FACT-L demonstrated significantly lower scores corresponding to lower KPS values (P = 0.009 and P = 0.016, respectively).
__label__Support	The results of both the FLIC and FACT-L demonstrated significantly lower scores corresponding to lower KPS values (P = 0.009 and P = 0.016, respectively).	Results of this randomized study incorporating prospective QOL measurements suggested that in patients with locally advanced NSCLC, analyzing QOL data by either gender or performance status alone may not accurately reflect how these factors depend upon each another.
__label__noRel	The results of both the FLIC and FACT-L demonstrated significantly lower scores corresponding to lower KPS values (P = 0.009 and P = 0.016, respectively).	There was a significant interaction between gender and KPS using FLIC (P = 0.009), which also showed a trend toward significance with FACT (P = 0.09).
__label__noRel	The results of both the FLIC and FACT-L demonstrated significantly lower scores corresponding to lower KPS values (P = 0.009 and P = 0.016, respectively).	Significant KPS-by-gender interactions were noted for FACT-L in the physical well-being and additional concerns-lung subscales (P = 0.012 and P = 0.0003, respectively).
__label__noRel	An average weight gain in group B contrasted with an average weight loss in group A after four (P < 0.01) and eight weeks (P < 0.05).	Fat-free mass showed an intergroup difference in favor of group B after eight weeks (P < 0.05).
__label__noRel	An average weight gain in group B contrasted with an average weight loss in group A after four (P < 0.01) and eight weeks (P < 0.05).	Body cell mass was maintained throughout the study in group B, but declined significantly up to weeks 4 and 8 in group A (intergroup difference: P < 0.05 and 0.01, respectively).
__label__noRel	An average weight gain in group B contrasted with an average weight loss in group A after four (P < 0.01) and eight weeks (P < 0.05).	A decrease in the total lymphocyte count by 559 cells/mul occurred with the fat-enriched diet (P < 0.05).
__label__noRel	An average weight gain in group B contrasted with an average weight loss in group A after four (P < 0.01) and eight weeks (P < 0.05).	Several aspects of the quality of life were rated to be better in group B than in group A,
__label__noRel	An average weight gain in group B contrasted with an average weight loss in group A after four (P < 0.01) and eight weeks (P < 0.05).	although not all differences reached statistical significance.
__label__Support	An average weight gain in group B contrasted with an average weight loss in group A after four (P < 0.01) and eight weeks (P < 0.05).	In patients with cancer, a high-fat diet may possibly support the maintenance of both body weight and body cell mass.
__label__noRel	An average weight gain in group B contrasted with an average weight loss in group A after four (P < 0.01) and eight weeks (P < 0.05).	However, monitoring the lymphocyte count is advisable.
__label__noRel	Fat-free mass showed an intergroup difference in favor of group B after eight weeks (P < 0.05).	An average weight gain in group B contrasted with an average weight loss in group A after four (P < 0.01) and eight weeks (P < 0.05).
__label__noRel	Fat-free mass showed an intergroup difference in favor of group B after eight weeks (P < 0.05).	Body cell mass was maintained throughout the study in group B, but declined significantly up to weeks 4 and 8 in group A (intergroup difference: P < 0.05 and 0.01, respectively).
__label__noRel	Fat-free mass showed an intergroup difference in favor of group B after eight weeks (P < 0.05).	A decrease in the total lymphocyte count by 559 cells/mul occurred with the fat-enriched diet (P < 0.05).
__label__noRel	Fat-free mass showed an intergroup difference in favor of group B after eight weeks (P < 0.05).	Several aspects of the quality of life were rated to be better in group B than in group A,
__label__noRel	Fat-free mass showed an intergroup difference in favor of group B after eight weeks (P < 0.05).	although not all differences reached statistical significance.
__label__Support	Fat-free mass showed an intergroup difference in favor of group B after eight weeks (P < 0.05).	In patients with cancer, a high-fat diet may possibly support the maintenance of both body weight and body cell mass.
__label__noRel	Fat-free mass showed an intergroup difference in favor of group B after eight weeks (P < 0.05).	However, monitoring the lymphocyte count is advisable.
__label__noRel	Body cell mass was maintained throughout the study in group B, but declined significantly up to weeks 4 and 8 in group A (intergroup difference: P < 0.05 and 0.01, respectively).	An average weight gain in group B contrasted with an average weight loss in group A after four (P < 0.01) and eight weeks (P < 0.05).
__label__noRel	Body cell mass was maintained throughout the study in group B, but declined significantly up to weeks 4 and 8 in group A (intergroup difference: P < 0.05 and 0.01, respectively).	Fat-free mass showed an intergroup difference in favor of group B after eight weeks (P < 0.05).
__label__noRel	Body cell mass was maintained throughout the study in group B, but declined significantly up to weeks 4 and 8 in group A (intergroup difference: P < 0.05 and 0.01, respectively).	A decrease in the total lymphocyte count by 559 cells/mul occurred with the fat-enriched diet (P < 0.05).
__label__noRel	Body cell mass was maintained throughout the study in group B, but declined significantly up to weeks 4 and 8 in group A (intergroup difference: P < 0.05 and 0.01, respectively).	Several aspects of the quality of life were rated to be better in group B than in group A,
__label__noRel	Body cell mass was maintained throughout the study in group B, but declined significantly up to weeks 4 and 8 in group A (intergroup difference: P < 0.05 and 0.01, respectively).	although not all differences reached statistical significance.
__label__Support	Body cell mass was maintained throughout the study in group B, but declined significantly up to weeks 4 and 8 in group A (intergroup difference: P < 0.05 and 0.01, respectively).	In patients with cancer, a high-fat diet may possibly support the maintenance of both body weight and body cell mass.
__label__noRel	Body cell mass was maintained throughout the study in group B, but declined significantly up to weeks 4 and 8 in group A (intergroup difference: P < 0.05 and 0.01, respectively).	However, monitoring the lymphocyte count is advisable.
__label__noRel	A decrease in the total lymphocyte count by 559 cells/mul occurred with the fat-enriched diet (P < 0.05).	An average weight gain in group B contrasted with an average weight loss in group A after four (P < 0.01) and eight weeks (P < 0.05).
__label__noRel	A decrease in the total lymphocyte count by 559 cells/mul occurred with the fat-enriched diet (P < 0.05).	Fat-free mass showed an intergroup difference in favor of group B after eight weeks (P < 0.05).
__label__noRel	A decrease in the total lymphocyte count by 559 cells/mul occurred with the fat-enriched diet (P < 0.05).	Body cell mass was maintained throughout the study in group B, but declined significantly up to weeks 4 and 8 in group A (intergroup difference: P < 0.05 and 0.01, respectively).
__label__noRel	A decrease in the total lymphocyte count by 559 cells/mul occurred with the fat-enriched diet (P < 0.05).	Several aspects of the quality of life were rated to be better in group B than in group A,
__label__noRel	A decrease in the total lymphocyte count by 559 cells/mul occurred with the fat-enriched diet (P < 0.05).	although not all differences reached statistical significance.
__label__noRel	A decrease in the total lymphocyte count by 559 cells/mul occurred with the fat-enriched diet (P < 0.05).	In patients with cancer, a high-fat diet may possibly support the maintenance of both body weight and body cell mass.
__label__Support	A decrease in the total lymphocyte count by 559 cells/mul occurred with the fat-enriched diet (P < 0.05).	However, monitoring the lymphocyte count is advisable.
__label__noRel	Several aspects of the quality of life were rated to be better in group B than in group A,	An average weight gain in group B contrasted with an average weight loss in group A after four (P < 0.01) and eight weeks (P < 0.05).
__label__noRel	Several aspects of the quality of life were rated to be better in group B than in group A,	Fat-free mass showed an intergroup difference in favor of group B after eight weeks (P < 0.05).
__label__noRel	Several aspects of the quality of life were rated to be better in group B than in group A,	Body cell mass was maintained throughout the study in group B, but declined significantly up to weeks 4 and 8 in group A (intergroup difference: P < 0.05 and 0.01, respectively).
__label__noRel	Several aspects of the quality of life were rated to be better in group B than in group A,	A decrease in the total lymphocyte count by 559 cells/mul occurred with the fat-enriched diet (P < 0.05).
__label__noRel	Several aspects of the quality of life were rated to be better in group B than in group A,	although not all differences reached statistical significance.
__label__Support	Several aspects of the quality of life were rated to be better in group B than in group A,	In patients with cancer, a high-fat diet may possibly support the maintenance of both body weight and body cell mass.
__label__noRel	Several aspects of the quality of life were rated to be better in group B than in group A,	However, monitoring the lymphocyte count is advisable.
__label__noRel	although not all differences reached statistical significance.	An average weight gain in group B contrasted with an average weight loss in group A after four (P < 0.01) and eight weeks (P < 0.05).
__label__noRel	although not all differences reached statistical significance.	Fat-free mass showed an intergroup difference in favor of group B after eight weeks (P < 0.05).
__label__noRel	although not all differences reached statistical significance.	Body cell mass was maintained throughout the study in group B, but declined significantly up to weeks 4 and 8 in group A (intergroup difference: P < 0.05 and 0.01, respectively).
__label__noRel	although not all differences reached statistical significance.	A decrease in the total lymphocyte count by 559 cells/mul occurred with the fat-enriched diet (P < 0.05).
__label__Attack	although not all differences reached statistical significance.	Several aspects of the quality of life were rated to be better in group B than in group A,
__label__noRel	although not all differences reached statistical significance.	In patients with cancer, a high-fat diet may possibly support the maintenance of both body weight and body cell mass.
__label__noRel	although not all differences reached statistical significance.	However, monitoring the lymphocyte count is advisable.
__label__noRel	In patients with cancer, a high-fat diet may possibly support the maintenance of both body weight and body cell mass.	An average weight gain in group B contrasted with an average weight loss in group A after four (P < 0.01) and eight weeks (P < 0.05).
__label__noRel	In patients with cancer, a high-fat diet may possibly support the maintenance of both body weight and body cell mass.	Fat-free mass showed an intergroup difference in favor of group B after eight weeks (P < 0.05).
__label__noRel	In patients with cancer, a high-fat diet may possibly support the maintenance of both body weight and body cell mass.	Body cell mass was maintained throughout the study in group B, but declined significantly up to weeks 4 and 8 in group A (intergroup difference: P < 0.05 and 0.01, respectively).
__label__noRel	In patients with cancer, a high-fat diet may possibly support the maintenance of both body weight and body cell mass.	A decrease in the total lymphocyte count by 559 cells/mul occurred with the fat-enriched diet (P < 0.05).
__label__noRel	In patients with cancer, a high-fat diet may possibly support the maintenance of both body weight and body cell mass.	Several aspects of the quality of life were rated to be better in group B than in group A,
__label__noRel	In patients with cancer, a high-fat diet may possibly support the maintenance of both body weight and body cell mass.	although not all differences reached statistical significance.
__label__noRel	In patients with cancer, a high-fat diet may possibly support the maintenance of both body weight and body cell mass.	However, monitoring the lymphocyte count is advisable.
__label__noRel	However, monitoring the lymphocyte count is advisable.	An average weight gain in group B contrasted with an average weight loss in group A after four (P < 0.01) and eight weeks (P < 0.05).
__label__noRel	However, monitoring the lymphocyte count is advisable.	Fat-free mass showed an intergroup difference in favor of group B after eight weeks (P < 0.05).
__label__noRel	However, monitoring the lymphocyte count is advisable.	Body cell mass was maintained throughout the study in group B, but declined significantly up to weeks 4 and 8 in group A (intergroup difference: P < 0.05 and 0.01, respectively).
__label__noRel	However, monitoring the lymphocyte count is advisable.	A decrease in the total lymphocyte count by 559 cells/mul occurred with the fat-enriched diet (P < 0.05).
__label__noRel	However, monitoring the lymphocyte count is advisable.	Several aspects of the quality of life were rated to be better in group B than in group A,
__label__noRel	However, monitoring the lymphocyte count is advisable.	although not all differences reached statistical significance.
__label__noRel	However, monitoring the lymphocyte count is advisable.	In patients with cancer, a high-fat diet may possibly support the maintenance of both body weight and body cell mass.
__label__noRel	The 1-, 2-, and 3-year survival rates were 88.9%, 44.4%, and 16.7% for the vaccine group, respectively, and 75.0%, 18.8%, and 0%, respectively, for the control group, (P = 0.299, 0.0035, 0.0014, respectively).	The median OS for the vaccine group was 31.9 months and for the control group was 15.0 months (P < 0.002).
__label__noRel	The 1-, 2-, and 3-year survival rates were 88.9%, 44.4%, and 16.7% for the vaccine group, respectively, and 75.0%, 18.8%, and 0%, respectively, for the control group, (P = 0.299, 0.0035, 0.0014, respectively).	The median progression-free survival (PFS) for the vaccine group was 8.5 months, and 8.0 months for the control group (P = 0.075).
__label__noRel	The 1-, 2-, and 3-year survival rates were 88.9%, 44.4%, and 16.7% for the vaccine group, respectively, and 75.0%, 18.8%, and 0%, respectively, for the control group, (P = 0.299, 0.0035, 0.0014, respectively).	The surviving fraction was significantly higher in the vaccine group based on Kaplan-Meier analysis.
__label__Support	The 1-, 2-, and 3-year survival rates were 88.9%, 44.4%, and 16.7% for the vaccine group, respectively, and 75.0%, 18.8%, and 0%, respectively, for the control group, (P = 0.299, 0.0035, 0.0014, respectively).	Adjuvant immunotherapy with whole-cell lysate dendritic cell vaccine may improve short-term survival.
__label__noRel	The 1-, 2-, and 3-year survival rates were 88.9%, 44.4%, and 16.7% for the vaccine group, respectively, and 75.0%, 18.8%, and 0%, respectively, for the control group, (P = 0.299, 0.0035, 0.0014, respectively).	It seems to be safe, and its long-term effectiveness is worthy of further investigation.
__label__noRel	The median OS for the vaccine group was 31.9 months and for the control group was 15.0 months (P < 0.002).	The 1-, 2-, and 3-year survival rates were 88.9%, 44.4%, and 16.7% for the vaccine group, respectively, and 75.0%, 18.8%, and 0%, respectively, for the control group, (P = 0.299, 0.0035, 0.0014, respectively).
__label__noRel	The median OS for the vaccine group was 31.9 months and for the control group was 15.0 months (P < 0.002).	The median progression-free survival (PFS) for the vaccine group was 8.5 months, and 8.0 months for the control group (P = 0.075).
__label__noRel	The median OS for the vaccine group was 31.9 months and for the control group was 15.0 months (P < 0.002).	The surviving fraction was significantly higher in the vaccine group based on Kaplan-Meier analysis.
__label__Support	The median OS for the vaccine group was 31.9 months and for the control group was 15.0 months (P < 0.002).	Adjuvant immunotherapy with whole-cell lysate dendritic cell vaccine may improve short-term survival.
__label__noRel	The median OS for the vaccine group was 31.9 months and for the control group was 15.0 months (P < 0.002).	It seems to be safe, and its long-term effectiveness is worthy of further investigation.
__label__noRel	The median progression-free survival (PFS) for the vaccine group was 8.5 months, and 8.0 months for the control group (P = 0.075).	The 1-, 2-, and 3-year survival rates were 88.9%, 44.4%, and 16.7% for the vaccine group, respectively, and 75.0%, 18.8%, and 0%, respectively, for the control group, (P = 0.299, 0.0035, 0.0014, respectively).
__label__noRel	The median progression-free survival (PFS) for the vaccine group was 8.5 months, and 8.0 months for the control group (P = 0.075).	The median OS for the vaccine group was 31.9 months and for the control group was 15.0 months (P < 0.002).
__label__noRel	The median progression-free survival (PFS) for the vaccine group was 8.5 months, and 8.0 months for the control group (P = 0.075).	The surviving fraction was significantly higher in the vaccine group based on Kaplan-Meier analysis.
__label__Support	The median progression-free survival (PFS) for the vaccine group was 8.5 months, and 8.0 months for the control group (P = 0.075).	Adjuvant immunotherapy with whole-cell lysate dendritic cell vaccine may improve short-term survival.
__label__noRel	The median progression-free survival (PFS) for the vaccine group was 8.5 months, and 8.0 months for the control group (P = 0.075).	It seems to be safe, and its long-term effectiveness is worthy of further investigation.
__label__noRel	The surviving fraction was significantly higher in the vaccine group based on Kaplan-Meier analysis.	The 1-, 2-, and 3-year survival rates were 88.9%, 44.4%, and 16.7% for the vaccine group, respectively, and 75.0%, 18.8%, and 0%, respectively, for the control group, (P = 0.299, 0.0035, 0.0014, respectively).
__label__noRel	The surviving fraction was significantly higher in the vaccine group based on Kaplan-Meier analysis.	The median OS for the vaccine group was 31.9 months and for the control group was 15.0 months (P < 0.002).
__label__noRel	The surviving fraction was significantly higher in the vaccine group based on Kaplan-Meier analysis.	The median progression-free survival (PFS) for the vaccine group was 8.5 months, and 8.0 months for the control group (P = 0.075).
__label__Support	The surviving fraction was significantly higher in the vaccine group based on Kaplan-Meier analysis.	Adjuvant immunotherapy with whole-cell lysate dendritic cell vaccine may improve short-term survival.
__label__noRel	The surviving fraction was significantly higher in the vaccine group based on Kaplan-Meier analysis.	It seems to be safe, and its long-term effectiveness is worthy of further investigation.
__label__noRel	Adjuvant immunotherapy with whole-cell lysate dendritic cell vaccine may improve short-term survival.	The 1-, 2-, and 3-year survival rates were 88.9%, 44.4%, and 16.7% for the vaccine group, respectively, and 75.0%, 18.8%, and 0%, respectively, for the control group, (P = 0.299, 0.0035, 0.0014, respectively).
__label__noRel	Adjuvant immunotherapy with whole-cell lysate dendritic cell vaccine may improve short-term survival.	The median OS for the vaccine group was 31.9 months and for the control group was 15.0 months (P < 0.002).
__label__noRel	Adjuvant immunotherapy with whole-cell lysate dendritic cell vaccine may improve short-term survival.	The median progression-free survival (PFS) for the vaccine group was 8.5 months, and 8.0 months for the control group (P = 0.075).
__label__noRel	Adjuvant immunotherapy with whole-cell lysate dendritic cell vaccine may improve short-term survival.	The surviving fraction was significantly higher in the vaccine group based on Kaplan-Meier analysis.
__label__noRel	Adjuvant immunotherapy with whole-cell lysate dendritic cell vaccine may improve short-term survival.	It seems to be safe, and its long-term effectiveness is worthy of further investigation.
__label__noRel	It seems to be safe, and its long-term effectiveness is worthy of further investigation.	The 1-, 2-, and 3-year survival rates were 88.9%, 44.4%, and 16.7% for the vaccine group, respectively, and 75.0%, 18.8%, and 0%, respectively, for the control group, (P = 0.299, 0.0035, 0.0014, respectively).
__label__noRel	It seems to be safe, and its long-term effectiveness is worthy of further investigation.	The median OS for the vaccine group was 31.9 months and for the control group was 15.0 months (P < 0.002).
__label__noRel	It seems to be safe, and its long-term effectiveness is worthy of further investigation.	The median progression-free survival (PFS) for the vaccine group was 8.5 months, and 8.0 months for the control group (P = 0.075).
__label__noRel	It seems to be safe, and its long-term effectiveness is worthy of further investigation.	The surviving fraction was significantly higher in the vaccine group based on Kaplan-Meier analysis.
__label__noRel	It seems to be safe, and its long-term effectiveness is worthy of further investigation.	Adjuvant immunotherapy with whole-cell lysate dendritic cell vaccine may improve short-term survival.
__label__noRel	There were no statistically significant differences in FOIS scores between intervention and control patients immediately after CRT (immediately after CRT: intervention group median score, 3 [range, 1-7], vs median control score, 4 [range, 1-6] (P=.88).	intervention patients had significantly better scores at months 3 and 6 (median 3-month intervention score, 7 [range, 5-7], vs median control score, 5 [range, 3-7] [P=.03]; median 6-month intervention score, 7 [range, 6-7], vs median control score, 6 [range, 3-7] [P=.009]).
__label__noRel	There were no statistically significant differences in FOIS scores between intervention and control patients immediately after CRT (immediately after CRT: intervention group median score, 3 [range, 1-7], vs median control score, 4 [range, 1-6] (P=.88).	There was no significant difference in scores at months 9 and 12 (P=.24 and P=.93, respectively).
__label__noRel	There were no statistically significant differences in FOIS scores between intervention and control patients immediately after CRT (immediately after CRT: intervention group median score, 3 [range, 1-7], vs median control score, 4 [range, 1-6] (P=.88).	The same pattern between intervention and control patients was observed for scores on the PSS-H&N.
__label__Support	There were no statistically significant differences in FOIS scores between intervention and control patients immediately after CRT (immediately after CRT: intervention group median score, 3 [range, 1-7], vs median control score, 4 [range, 1-6] (P=.88).	Patients who performed prophylactic swallowing exercises had improved swallowing function at 3 and 6 months after CRT but not immediately after CRT or at 9 and 12 months after CRT.
__label__noRel	There were no statistically significant differences in FOIS scores between intervention and control patients immediately after CRT (immediately after CRT: intervention group median score, 3 [range, 1-7], vs median control score, 4 [range, 1-6] (P=.88).	The small sample size may have limited our ability to detect significant differences beyond 6 months of observation as well as additional significant differences in our study.
__label__noRel	intervention patients had significantly better scores at months 3 and 6 (median 3-month intervention score, 7 [range, 5-7], vs median control score, 5 [range, 3-7] [P=.03]; median 6-month intervention score, 7 [range, 6-7], vs median control score, 6 [range, 3-7] [P=.009]).	There were no statistically significant differences in FOIS scores between intervention and control patients immediately after CRT (immediately after CRT: intervention group median score, 3 [range, 1-7], vs median control score, 4 [range, 1-6] (P=.88).
__label__noRel	intervention patients had significantly better scores at months 3 and 6 (median 3-month intervention score, 7 [range, 5-7], vs median control score, 5 [range, 3-7] [P=.03]; median 6-month intervention score, 7 [range, 6-7], vs median control score, 6 [range, 3-7] [P=.009]).	There was no significant difference in scores at months 9 and 12 (P=.24 and P=.93, respectively).
__label__noRel	intervention patients had significantly better scores at months 3 and 6 (median 3-month intervention score, 7 [range, 5-7], vs median control score, 5 [range, 3-7] [P=.03]; median 6-month intervention score, 7 [range, 6-7], vs median control score, 6 [range, 3-7] [P=.009]).	The same pattern between intervention and control patients was observed for scores on the PSS-H&N.
__label__Support	intervention patients had significantly better scores at months 3 and 6 (median 3-month intervention score, 7 [range, 5-7], vs median control score, 5 [range, 3-7] [P=.03]; median 6-month intervention score, 7 [range, 6-7], vs median control score, 6 [range, 3-7] [P=.009]).	Patients who performed prophylactic swallowing exercises had improved swallowing function at 3 and 6 months after CRT but not immediately after CRT or at 9 and 12 months after CRT.
__label__noRel	intervention patients had significantly better scores at months 3 and 6 (median 3-month intervention score, 7 [range, 5-7], vs median control score, 5 [range, 3-7] [P=.03]; median 6-month intervention score, 7 [range, 6-7], vs median control score, 6 [range, 3-7] [P=.009]).	The small sample size may have limited our ability to detect significant differences beyond 6 months of observation as well as additional significant differences in our study.
__label__noRel	There was no significant difference in scores at months 9 and 12 (P=.24 and P=.93, respectively).	There were no statistically significant differences in FOIS scores between intervention and control patients immediately after CRT (immediately after CRT: intervention group median score, 3 [range, 1-7], vs median control score, 4 [range, 1-6] (P=.88).
__label__noRel	There was no significant difference in scores at months 9 and 12 (P=.24 and P=.93, respectively).	intervention patients had significantly better scores at months 3 and 6 (median 3-month intervention score, 7 [range, 5-7], vs median control score, 5 [range, 3-7] [P=.03]; median 6-month intervention score, 7 [range, 6-7], vs median control score, 6 [range, 3-7] [P=.009]).
__label__noRel	There was no significant difference in scores at months 9 and 12 (P=.24 and P=.93, respectively).	The same pattern between intervention and control patients was observed for scores on the PSS-H&N.
__label__Support	There was no significant difference in scores at months 9 and 12 (P=.24 and P=.93, respectively).	Patients who performed prophylactic swallowing exercises had improved swallowing function at 3 and 6 months after CRT but not immediately after CRT or at 9 and 12 months after CRT.
__label__noRel	There was no significant difference in scores at months 9 and 12 (P=.24 and P=.93, respectively).	The small sample size may have limited our ability to detect significant differences beyond 6 months of observation as well as additional significant differences in our study.
__label__noRel	The same pattern between intervention and control patients was observed for scores on the PSS-H&N.	There were no statistically significant differences in FOIS scores between intervention and control patients immediately after CRT (immediately after CRT: intervention group median score, 3 [range, 1-7], vs median control score, 4 [range, 1-6] (P=.88).
__label__noRel	The same pattern between intervention and control patients was observed for scores on the PSS-H&N.	intervention patients had significantly better scores at months 3 and 6 (median 3-month intervention score, 7 [range, 5-7], vs median control score, 5 [range, 3-7] [P=.03]; median 6-month intervention score, 7 [range, 6-7], vs median control score, 6 [range, 3-7] [P=.009]).
__label__noRel	The same pattern between intervention and control patients was observed for scores on the PSS-H&N.	There was no significant difference in scores at months 9 and 12 (P=.24 and P=.93, respectively).
__label__noRel	The same pattern between intervention and control patients was observed for scores on the PSS-H&N.	Patients who performed prophylactic swallowing exercises had improved swallowing function at 3 and 6 months after CRT but not immediately after CRT or at 9 and 12 months after CRT.
__label__noRel	The same pattern between intervention and control patients was observed for scores on the PSS-H&N.	The small sample size may have limited our ability to detect significant differences beyond 6 months of observation as well as additional significant differences in our study.
__label__noRel	Patients who performed prophylactic swallowing exercises had improved swallowing function at 3 and 6 months after CRT but not immediately after CRT or at 9 and 12 months after CRT.	There were no statistically significant differences in FOIS scores between intervention and control patients immediately after CRT (immediately after CRT: intervention group median score, 3 [range, 1-7], vs median control score, 4 [range, 1-6] (P=.88).
__label__noRel	Patients who performed prophylactic swallowing exercises had improved swallowing function at 3 and 6 months after CRT but not immediately after CRT or at 9 and 12 months after CRT.	intervention patients had significantly better scores at months 3 and 6 (median 3-month intervention score, 7 [range, 5-7], vs median control score, 5 [range, 3-7] [P=.03]; median 6-month intervention score, 7 [range, 6-7], vs median control score, 6 [range, 3-7] [P=.009]).
__label__noRel	Patients who performed prophylactic swallowing exercises had improved swallowing function at 3 and 6 months after CRT but not immediately after CRT or at 9 and 12 months after CRT.	There was no significant difference in scores at months 9 and 12 (P=.24 and P=.93, respectively).
__label__noRel	Patients who performed prophylactic swallowing exercises had improved swallowing function at 3 and 6 months after CRT but not immediately after CRT or at 9 and 12 months after CRT.	The same pattern between intervention and control patients was observed for scores on the PSS-H&N.
__label__noRel	Patients who performed prophylactic swallowing exercises had improved swallowing function at 3 and 6 months after CRT but not immediately after CRT or at 9 and 12 months after CRT.	The small sample size may have limited our ability to detect significant differences beyond 6 months of observation as well as additional significant differences in our study.
__label__noRel	The small sample size may have limited our ability to detect significant differences beyond 6 months of observation as well as additional significant differences in our study.	There were no statistically significant differences in FOIS scores between intervention and control patients immediately after CRT (immediately after CRT: intervention group median score, 3 [range, 1-7], vs median control score, 4 [range, 1-6] (P=.88).
__label__noRel	The small sample size may have limited our ability to detect significant differences beyond 6 months of observation as well as additional significant differences in our study.	intervention patients had significantly better scores at months 3 and 6 (median 3-month intervention score, 7 [range, 5-7], vs median control score, 5 [range, 3-7] [P=.03]; median 6-month intervention score, 7 [range, 6-7], vs median control score, 6 [range, 3-7] [P=.009]).
__label__noRel	The small sample size may have limited our ability to detect significant differences beyond 6 months of observation as well as additional significant differences in our study.	There was no significant difference in scores at months 9 and 12 (P=.24 and P=.93, respectively).
__label__noRel	The small sample size may have limited our ability to detect significant differences beyond 6 months of observation as well as additional significant differences in our study.	The same pattern between intervention and control patients was observed for scores on the PSS-H&N.
__label__Attack	The small sample size may have limited our ability to detect significant differences beyond 6 months of observation as well as additional significant differences in our study.	Patients who performed prophylactic swallowing exercises had improved swallowing function at 3 and 6 months after CRT but not immediately after CRT or at 9 and 12 months after CRT.
__label__noRel	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.	Group differences were smaller within the psychosocial domain,
__label__noRel	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.	although trends were seen in favour of the chemotherapy group.
__label__noRel	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.	No significant differences were seen in favour of the supportive care group,
__label__noRel	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.	except for hair loss.
__label__noRel	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.
__label__noRel	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.
__label__noRel	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.	No treatment-related deaths occurred.
__label__Support	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.
__label__noRel	Group differences were smaller within the psychosocial domain,	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.
__label__noRel	Group differences were smaller within the psychosocial domain,	although trends were seen in favour of the chemotherapy group.
__label__noRel	Group differences were smaller within the psychosocial domain,	No significant differences were seen in favour of the supportive care group,
__label__noRel	Group differences were smaller within the psychosocial domain,	except for hair loss.
__label__noRel	Group differences were smaller within the psychosocial domain,	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.
__label__noRel	Group differences were smaller within the psychosocial domain,	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.
__label__noRel	Group differences were smaller within the psychosocial domain,	No treatment-related deaths occurred.
__label__noRel	Group differences were smaller within the psychosocial domain,	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.
__label__noRel	although trends were seen in favour of the chemotherapy group.	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.
__label__Attack	although trends were seen in favour of the chemotherapy group.	Group differences were smaller within the psychosocial domain,
__label__noRel	although trends were seen in favour of the chemotherapy group.	No significant differences were seen in favour of the supportive care group,
__label__noRel	although trends were seen in favour of the chemotherapy group.	except for hair loss.
__label__noRel	although trends were seen in favour of the chemotherapy group.	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.
__label__noRel	although trends were seen in favour of the chemotherapy group.	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.
__label__noRel	although trends were seen in favour of the chemotherapy group.	No treatment-related deaths occurred.
__label__noRel	although trends were seen in favour of the chemotherapy group.	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.
__label__noRel	No significant differences were seen in favour of the supportive care group,	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.
__label__noRel	No significant differences were seen in favour of the supportive care group,	Group differences were smaller within the psychosocial domain,
__label__noRel	No significant differences were seen in favour of the supportive care group,	although trends were seen in favour of the chemotherapy group.
__label__noRel	No significant differences were seen in favour of the supportive care group,	except for hair loss.
__label__noRel	No significant differences were seen in favour of the supportive care group,	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.
__label__noRel	No significant differences were seen in favour of the supportive care group,	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.
__label__noRel	No significant differences were seen in favour of the supportive care group,	No treatment-related deaths occurred.
__label__noRel	No significant differences were seen in favour of the supportive care group,	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.
__label__noRel	except for hair loss.	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.
__label__noRel	except for hair loss.	Group differences were smaller within the psychosocial domain,
__label__noRel	except for hair loss.	although trends were seen in favour of the chemotherapy group.
__label__Attack	except for hair loss.	No significant differences were seen in favour of the supportive care group,
__label__noRel	except for hair loss.	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.
__label__noRel	except for hair loss.	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.
__label__noRel	except for hair loss.	No treatment-related deaths occurred.
__label__noRel	except for hair loss.	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.
__label__noRel	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.
__label__noRel	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.	Group differences were smaller within the psychosocial domain,
__label__noRel	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.	although trends were seen in favour of the chemotherapy group.
__label__noRel	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.	No significant differences were seen in favour of the supportive care group,
__label__noRel	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.	except for hair loss.
__label__noRel	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.
__label__noRel	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.	No treatment-related deaths occurred.
__label__Support	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.
__label__noRel	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.
__label__noRel	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.	Group differences were smaller within the psychosocial domain,
__label__noRel	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.	although trends were seen in favour of the chemotherapy group.
__label__noRel	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.	No significant differences were seen in favour of the supportive care group,
__label__noRel	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.	except for hair loss.
__label__noRel	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.
__label__noRel	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.	No treatment-related deaths occurred.
__label__Support	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.
__label__noRel	No treatment-related deaths occurred.	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.
__label__noRel	No treatment-related deaths occurred.	Group differences were smaller within the psychosocial domain,
__label__noRel	No treatment-related deaths occurred.	although trends were seen in favour of the chemotherapy group.
__label__noRel	No treatment-related deaths occurred.	No significant differences were seen in favour of the supportive care group,
__label__noRel	No treatment-related deaths occurred.	except for hair loss.
__label__noRel	No treatment-related deaths occurred.	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.
__label__noRel	No treatment-related deaths occurred.	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.
__label__noRel	No treatment-related deaths occurred.	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.
__label__noRel	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.
__label__noRel	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.	Group differences were smaller within the psychosocial domain,
__label__noRel	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.	although trends were seen in favour of the chemotherapy group.
__label__noRel	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.	No significant differences were seen in favour of the supportive care group,
__label__noRel	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.	except for hair loss.
__label__noRel	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.
__label__noRel	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.
__label__noRel	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.	No treatment-related deaths occurred.
__label__noRel	Incidence of adverse events was consistent with previously reported rates.	In this updated final analysis of all patients randomly assigned with strata (n = 291), lapatinib plus trastuzumab continued to show superiority to lapatinib monotherapy in PFS (hazard ratio [HR], 0.74; 95% CI, 0.58 to 0.94; P = .011) and offered significant OS benefit (HR, 0.74; 95% CI, 0.57 to 0.97; P = .026).
__label__noRel	Incidence of adverse events was consistent with previously reported rates.	Improvements in absolute OS rates were 10% at 6 months and 15% at 12 months in the combination arm compared with the monotherapy arm.
__label__noRel	Incidence of adverse events was consistent with previously reported rates.	Multiple baseline factors, including Eastern Cooperative Oncology Group performance status of 0, nonvisceral disease, < three metastatic sites, and less time from initial diagnosis until random assignment, were associated with improved OS.
__label__noRel	Incidence of adverse events was consistent with previously reported rates.	These data demonstrated a significant 4.5-month median OS advantage with the lapatinib and trastuzumab combination and support dual HER2 blockade in patients with heavily pretreated HER2-positive MBC.
__label__noRel	In this updated final analysis of all patients randomly assigned with strata (n = 291), lapatinib plus trastuzumab continued to show superiority to lapatinib monotherapy in PFS (hazard ratio [HR], 0.74; 95% CI, 0.58 to 0.94; P = .011) and offered significant OS benefit (HR, 0.74; 95% CI, 0.57 to 0.97; P = .026).	Incidence of adverse events was consistent with previously reported rates.
__label__noRel	In this updated final analysis of all patients randomly assigned with strata (n = 291), lapatinib plus trastuzumab continued to show superiority to lapatinib monotherapy in PFS (hazard ratio [HR], 0.74; 95% CI, 0.58 to 0.94; P = .011) and offered significant OS benefit (HR, 0.74; 95% CI, 0.57 to 0.97; P = .026).	Improvements in absolute OS rates were 10% at 6 months and 15% at 12 months in the combination arm compared with the monotherapy arm.
__label__noRel	In this updated final analysis of all patients randomly assigned with strata (n = 291), lapatinib plus trastuzumab continued to show superiority to lapatinib monotherapy in PFS (hazard ratio [HR], 0.74; 95% CI, 0.58 to 0.94; P = .011) and offered significant OS benefit (HR, 0.74; 95% CI, 0.57 to 0.97; P = .026).	Multiple baseline factors, including Eastern Cooperative Oncology Group performance status of 0, nonvisceral disease, < three metastatic sites, and less time from initial diagnosis until random assignment, were associated with improved OS.
__label__Support	In this updated final analysis of all patients randomly assigned with strata (n = 291), lapatinib plus trastuzumab continued to show superiority to lapatinib monotherapy in PFS (hazard ratio [HR], 0.74; 95% CI, 0.58 to 0.94; P = .011) and offered significant OS benefit (HR, 0.74; 95% CI, 0.57 to 0.97; P = .026).	These data demonstrated a significant 4.5-month median OS advantage with the lapatinib and trastuzumab combination and support dual HER2 blockade in patients with heavily pretreated HER2-positive MBC.
__label__noRel	Improvements in absolute OS rates were 10% at 6 months and 15% at 12 months in the combination arm compared with the monotherapy arm.	Incidence of adverse events was consistent with previously reported rates.
__label__noRel	Improvements in absolute OS rates were 10% at 6 months and 15% at 12 months in the combination arm compared with the monotherapy arm.	In this updated final analysis of all patients randomly assigned with strata (n = 291), lapatinib plus trastuzumab continued to show superiority to lapatinib monotherapy in PFS (hazard ratio [HR], 0.74; 95% CI, 0.58 to 0.94; P = .011) and offered significant OS benefit (HR, 0.74; 95% CI, 0.57 to 0.97; P = .026).
__label__noRel	Improvements in absolute OS rates were 10% at 6 months and 15% at 12 months in the combination arm compared with the monotherapy arm.	Multiple baseline factors, including Eastern Cooperative Oncology Group performance status of 0, nonvisceral disease, < three metastatic sites, and less time from initial diagnosis until random assignment, were associated with improved OS.
__label__Support	Improvements in absolute OS rates were 10% at 6 months and 15% at 12 months in the combination arm compared with the monotherapy arm.	These data demonstrated a significant 4.5-month median OS advantage with the lapatinib and trastuzumab combination and support dual HER2 blockade in patients with heavily pretreated HER2-positive MBC.
__label__noRel	Multiple baseline factors, including Eastern Cooperative Oncology Group performance status of 0, nonvisceral disease, < three metastatic sites, and less time from initial diagnosis until random assignment, were associated with improved OS.	Incidence of adverse events was consistent with previously reported rates.
__label__noRel	Multiple baseline factors, including Eastern Cooperative Oncology Group performance status of 0, nonvisceral disease, < three metastatic sites, and less time from initial diagnosis until random assignment, were associated with improved OS.	In this updated final analysis of all patients randomly assigned with strata (n = 291), lapatinib plus trastuzumab continued to show superiority to lapatinib monotherapy in PFS (hazard ratio [HR], 0.74; 95% CI, 0.58 to 0.94; P = .011) and offered significant OS benefit (HR, 0.74; 95% CI, 0.57 to 0.97; P = .026).
__label__noRel	Multiple baseline factors, including Eastern Cooperative Oncology Group performance status of 0, nonvisceral disease, < three metastatic sites, and less time from initial diagnosis until random assignment, were associated with improved OS.	Improvements in absolute OS rates were 10% at 6 months and 15% at 12 months in the combination arm compared with the monotherapy arm.
__label__noRel	Multiple baseline factors, including Eastern Cooperative Oncology Group performance status of 0, nonvisceral disease, < three metastatic sites, and less time from initial diagnosis until random assignment, were associated with improved OS.	These data demonstrated a significant 4.5-month median OS advantage with the lapatinib and trastuzumab combination and support dual HER2 blockade in patients with heavily pretreated HER2-positive MBC.
__label__noRel	These data demonstrated a significant 4.5-month median OS advantage with the lapatinib and trastuzumab combination and support dual HER2 blockade in patients with heavily pretreated HER2-positive MBC.	Incidence of adverse events was consistent with previously reported rates.
__label__noRel	These data demonstrated a significant 4.5-month median OS advantage with the lapatinib and trastuzumab combination and support dual HER2 blockade in patients with heavily pretreated HER2-positive MBC.	In this updated final analysis of all patients randomly assigned with strata (n = 291), lapatinib plus trastuzumab continued to show superiority to lapatinib monotherapy in PFS (hazard ratio [HR], 0.74; 95% CI, 0.58 to 0.94; P = .011) and offered significant OS benefit (HR, 0.74; 95% CI, 0.57 to 0.97; P = .026).
__label__noRel	These data demonstrated a significant 4.5-month median OS advantage with the lapatinib and trastuzumab combination and support dual HER2 blockade in patients with heavily pretreated HER2-positive MBC.	Improvements in absolute OS rates were 10% at 6 months and 15% at 12 months in the combination arm compared with the monotherapy arm.
__label__noRel	These data demonstrated a significant 4.5-month median OS advantage with the lapatinib and trastuzumab combination and support dual HER2 blockade in patients with heavily pretreated HER2-positive MBC.	Multiple baseline factors, including Eastern Cooperative Oncology Group performance status of 0, nonvisceral disease, < three metastatic sites, and less time from initial diagnosis until random assignment, were associated with improved OS.
__label__noRel	there was no difference in OS seen between ASA404 (n = 649) and placebo (n = 650) arms: median OS was 13.4 and 12.7 months respectively (hazard ratio [HR], 1.01; 95% CI, 0.85 to 1.19; P = .535).	no OS difference was seen in the histologic (squamous or nonsquamous) and sex (male or female) strata.
__label__noRel	there was no difference in OS seen between ASA404 (n = 649) and placebo (n = 650) arms: median OS was 13.4 and 12.7 months respectively (hazard ratio [HR], 1.01; 95% CI, 0.85 to 1.19; P = .535).	Median PFS was 5.5 months in both arms (HR, 1.04; P = .727), while ORR was 25% in both arms (P = 1.0).
__label__noRel	there was no difference in OS seen between ASA404 (n = 649) and placebo (n = 650) arms: median OS was 13.4 and 12.7 months respectively (hazard ratio [HR], 1.01; 95% CI, 0.85 to 1.19; P = .535).	Overall rate of adverse events (AEs) was comparable between the ASA404 and placebo arms.
__label__noRel	there was no difference in OS seen between ASA404 (n = 649) and placebo (n = 650) arms: median OS was 13.4 and 12.7 months respectively (hazard ratio [HR], 1.01; 95% CI, 0.85 to 1.19; P = .535).	Grade 4 neutropenia (27% v 19%) and infusion site pain (10% v 0.5%) were reported more frequently in the ASA404 arm.
__label__Support	there was no difference in OS seen between ASA404 (n = 649) and placebo (n = 650) arms: median OS was 13.4 and 12.7 months respectively (hazard ratio [HR], 1.01; 95% CI, 0.85 to 1.19; P = .535).	The addition of ASA404 to carboplatin and paclitaxel, although generally well tolerated, failed to improve frontline efficacy in advanced NSCLC.
__label__noRel	no OS difference was seen in the histologic (squamous or nonsquamous) and sex (male or female) strata.	there was no difference in OS seen between ASA404 (n = 649) and placebo (n = 650) arms: median OS was 13.4 and 12.7 months respectively (hazard ratio [HR], 1.01; 95% CI, 0.85 to 1.19; P = .535).
__label__noRel	no OS difference was seen in the histologic (squamous or nonsquamous) and sex (male or female) strata.	Median PFS was 5.5 months in both arms (HR, 1.04; P = .727), while ORR was 25% in both arms (P = 1.0).
__label__noRel	no OS difference was seen in the histologic (squamous or nonsquamous) and sex (male or female) strata.	Overall rate of adverse events (AEs) was comparable between the ASA404 and placebo arms.
__label__noRel	no OS difference was seen in the histologic (squamous or nonsquamous) and sex (male or female) strata.	Grade 4 neutropenia (27% v 19%) and infusion site pain (10% v 0.5%) were reported more frequently in the ASA404 arm.
__label__Support	no OS difference was seen in the histologic (squamous or nonsquamous) and sex (male or female) strata.	The addition of ASA404 to carboplatin and paclitaxel, although generally well tolerated, failed to improve frontline efficacy in advanced NSCLC.
__label__noRel	Median PFS was 5.5 months in both arms (HR, 1.04; P = .727), while ORR was 25% in both arms (P = 1.0).	there was no difference in OS seen between ASA404 (n = 649) and placebo (n = 650) arms: median OS was 13.4 and 12.7 months respectively (hazard ratio [HR], 1.01; 95% CI, 0.85 to 1.19; P = .535).
__label__noRel	Median PFS was 5.5 months in both arms (HR, 1.04; P = .727), while ORR was 25% in both arms (P = 1.0).	no OS difference was seen in the histologic (squamous or nonsquamous) and sex (male or female) strata.
__label__noRel	Median PFS was 5.5 months in both arms (HR, 1.04; P = .727), while ORR was 25% in both arms (P = 1.0).	Overall rate of adverse events (AEs) was comparable between the ASA404 and placebo arms.
__label__noRel	Median PFS was 5.5 months in both arms (HR, 1.04; P = .727), while ORR was 25% in both arms (P = 1.0).	Grade 4 neutropenia (27% v 19%) and infusion site pain (10% v 0.5%) were reported more frequently in the ASA404 arm.
__label__Support	Median PFS was 5.5 months in both arms (HR, 1.04; P = .727), while ORR was 25% in both arms (P = 1.0).	The addition of ASA404 to carboplatin and paclitaxel, although generally well tolerated, failed to improve frontline efficacy in advanced NSCLC.
__label__noRel	Overall rate of adverse events (AEs) was comparable between the ASA404 and placebo arms.	there was no difference in OS seen between ASA404 (n = 649) and placebo (n = 650) arms: median OS was 13.4 and 12.7 months respectively (hazard ratio [HR], 1.01; 95% CI, 0.85 to 1.19; P = .535).
__label__noRel	Overall rate of adverse events (AEs) was comparable between the ASA404 and placebo arms.	no OS difference was seen in the histologic (squamous or nonsquamous) and sex (male or female) strata.
__label__noRel	Overall rate of adverse events (AEs) was comparable between the ASA404 and placebo arms.	Median PFS was 5.5 months in both arms (HR, 1.04; P = .727), while ORR was 25% in both arms (P = 1.0).
__label__noRel	Overall rate of adverse events (AEs) was comparable between the ASA404 and placebo arms.	Grade 4 neutropenia (27% v 19%) and infusion site pain (10% v 0.5%) were reported more frequently in the ASA404 arm.
__label__Support	Overall rate of adverse events (AEs) was comparable between the ASA404 and placebo arms.	The addition of ASA404 to carboplatin and paclitaxel, although generally well tolerated, failed to improve frontline efficacy in advanced NSCLC.
__label__noRel	Grade 4 neutropenia (27% v 19%) and infusion site pain (10% v 0.5%) were reported more frequently in the ASA404 arm.	there was no difference in OS seen between ASA404 (n = 649) and placebo (n = 650) arms: median OS was 13.4 and 12.7 months respectively (hazard ratio [HR], 1.01; 95% CI, 0.85 to 1.19; P = .535).
__label__noRel	Grade 4 neutropenia (27% v 19%) and infusion site pain (10% v 0.5%) were reported more frequently in the ASA404 arm.	no OS difference was seen in the histologic (squamous or nonsquamous) and sex (male or female) strata.
__label__noRel	Grade 4 neutropenia (27% v 19%) and infusion site pain (10% v 0.5%) were reported more frequently in the ASA404 arm.	Median PFS was 5.5 months in both arms (HR, 1.04; P = .727), while ORR was 25% in both arms (P = 1.0).
__label__noRel	Grade 4 neutropenia (27% v 19%) and infusion site pain (10% v 0.5%) were reported more frequently in the ASA404 arm.	Overall rate of adverse events (AEs) was comparable between the ASA404 and placebo arms.
__label__Attack	Grade 4 neutropenia (27% v 19%) and infusion site pain (10% v 0.5%) were reported more frequently in the ASA404 arm.	The addition of ASA404 to carboplatin and paclitaxel, although generally well tolerated, failed to improve frontline efficacy in advanced NSCLC.
__label__noRel	The addition of ASA404 to carboplatin and paclitaxel, although generally well tolerated, failed to improve frontline efficacy in advanced NSCLC.	there was no difference in OS seen between ASA404 (n = 649) and placebo (n = 650) arms: median OS was 13.4 and 12.7 months respectively (hazard ratio [HR], 1.01; 95% CI, 0.85 to 1.19; P = .535).
__label__noRel	The addition of ASA404 to carboplatin and paclitaxel, although generally well tolerated, failed to improve frontline efficacy in advanced NSCLC.	no OS difference was seen in the histologic (squamous or nonsquamous) and sex (male or female) strata.
__label__noRel	The addition of ASA404 to carboplatin and paclitaxel, although generally well tolerated, failed to improve frontline efficacy in advanced NSCLC.	Median PFS was 5.5 months in both arms (HR, 1.04; P = .727), while ORR was 25% in both arms (P = 1.0).
__label__noRel	The addition of ASA404 to carboplatin and paclitaxel, although generally well tolerated, failed to improve frontline efficacy in advanced NSCLC.	Overall rate of adverse events (AEs) was comparable between the ASA404 and placebo arms.
__label__noRel	The addition of ASA404 to carboplatin and paclitaxel, although generally well tolerated, failed to improve frontline efficacy in advanced NSCLC.	Grade 4 neutropenia (27% v 19%) and infusion site pain (10% v 0.5%) were reported more frequently in the ASA404 arm.
__label__noRel	Standard chemotherapy regimens are generally considered too toxic for elderly patients.	Among these 32 patients, 8 had a partial response (intent-to-treat response rate, 20%), and 10 (25%) had stable disease.
__label__noRel	Standard chemotherapy regimens are generally considered too toxic for elderly patients.	The median survival was 7.8 months (range, 4-11.6 months).
__label__noRel	Standard chemotherapy regimens are generally considered too toxic for elderly patients.	The 1- and 2-year survival rates were 25% and 7%, respectively;
__label__noRel	Standard chemotherapy regimens are generally considered too toxic for elderly patients.	median time to progression was 4.3 months (range, 0.2-13.8 months).
__label__noRel	Standard chemotherapy regimens are generally considered too toxic for elderly patients.	Grade 3/4 neutropenia was seen in 27 patients (68%), and grade 3/4 anemia was seen in 5 patients (13%).
__label__noRel	Standard chemotherapy regimens are generally considered too toxic for elderly patients.	One patient died of febrile neutropenia during treatment.
__label__noRel	Standard chemotherapy regimens are generally considered too toxic for elderly patients.	The main nonhematologic adverse effect was fatigue (grade 3/4 in 18% of patients).
__label__noRel	Standard chemotherapy regimens are generally considered too toxic for elderly patients.	Carboplatin/vinorelbine is well tolerated by elderly patients with extensive-stage NSCLC.
__label__noRel	Standard chemotherapy regimens are generally considered too toxic for elderly patients.	Efficacy is low but similar to that of other treatments used in this setting.
__label__noRel	Among these 32 patients, 8 had a partial response (intent-to-treat response rate, 20%), and 10 (25%) had stable disease.	Standard chemotherapy regimens are generally considered too toxic for elderly patients.
__label__noRel	Among these 32 patients, 8 had a partial response (intent-to-treat response rate, 20%), and 10 (25%) had stable disease.	The median survival was 7.8 months (range, 4-11.6 months).
__label__noRel	Among these 32 patients, 8 had a partial response (intent-to-treat response rate, 20%), and 10 (25%) had stable disease.	The 1- and 2-year survival rates were 25% and 7%, respectively;
__label__noRel	Among these 32 patients, 8 had a partial response (intent-to-treat response rate, 20%), and 10 (25%) had stable disease.	median time to progression was 4.3 months (range, 0.2-13.8 months).
__label__noRel	Among these 32 patients, 8 had a partial response (intent-to-treat response rate, 20%), and 10 (25%) had stable disease.	Grade 3/4 neutropenia was seen in 27 patients (68%), and grade 3/4 anemia was seen in 5 patients (13%).
__label__noRel	Among these 32 patients, 8 had a partial response (intent-to-treat response rate, 20%), and 10 (25%) had stable disease.	One patient died of febrile neutropenia during treatment.
__label__noRel	Among these 32 patients, 8 had a partial response (intent-to-treat response rate, 20%), and 10 (25%) had stable disease.	The main nonhematologic adverse effect was fatigue (grade 3/4 in 18% of patients).
__label__noRel	Among these 32 patients, 8 had a partial response (intent-to-treat response rate, 20%), and 10 (25%) had stable disease.	Carboplatin/vinorelbine is well tolerated by elderly patients with extensive-stage NSCLC.
__label__Support	Among these 32 patients, 8 had a partial response (intent-to-treat response rate, 20%), and 10 (25%) had stable disease.	Efficacy is low but similar to that of other treatments used in this setting.
__label__noRel	The median survival was 7.8 months (range, 4-11.6 months).	Standard chemotherapy regimens are generally considered too toxic for elderly patients.
__label__noRel	The median survival was 7.8 months (range, 4-11.6 months).	Among these 32 patients, 8 had a partial response (intent-to-treat response rate, 20%), and 10 (25%) had stable disease.
__label__noRel	The median survival was 7.8 months (range, 4-11.6 months).	The 1- and 2-year survival rates were 25% and 7%, respectively;
__label__noRel	The median survival was 7.8 months (range, 4-11.6 months).	median time to progression was 4.3 months (range, 0.2-13.8 months).
__label__noRel	The median survival was 7.8 months (range, 4-11.6 months).	Grade 3/4 neutropenia was seen in 27 patients (68%), and grade 3/4 anemia was seen in 5 patients (13%).
__label__noRel	The median survival was 7.8 months (range, 4-11.6 months).	One patient died of febrile neutropenia during treatment.
__label__noRel	The median survival was 7.8 months (range, 4-11.6 months).	The main nonhematologic adverse effect was fatigue (grade 3/4 in 18% of patients).
__label__noRel	The median survival was 7.8 months (range, 4-11.6 months).	Carboplatin/vinorelbine is well tolerated by elderly patients with extensive-stage NSCLC.
__label__Support	The median survival was 7.8 months (range, 4-11.6 months).	Efficacy is low but similar to that of other treatments used in this setting.
__label__noRel	The 1- and 2-year survival rates were 25% and 7%, respectively;	Standard chemotherapy regimens are generally considered too toxic for elderly patients.
__label__noRel	The 1- and 2-year survival rates were 25% and 7%, respectively;	Among these 32 patients, 8 had a partial response (intent-to-treat response rate, 20%), and 10 (25%) had stable disease.
__label__noRel	The 1- and 2-year survival rates were 25% and 7%, respectively;	The median survival was 7.8 months (range, 4-11.6 months).
__label__noRel	The 1- and 2-year survival rates were 25% and 7%, respectively;	median time to progression was 4.3 months (range, 0.2-13.8 months).
__label__noRel	The 1- and 2-year survival rates were 25% and 7%, respectively;	Grade 3/4 neutropenia was seen in 27 patients (68%), and grade 3/4 anemia was seen in 5 patients (13%).
__label__noRel	The 1- and 2-year survival rates were 25% and 7%, respectively;	One patient died of febrile neutropenia during treatment.
__label__noRel	The 1- and 2-year survival rates were 25% and 7%, respectively;	The main nonhematologic adverse effect was fatigue (grade 3/4 in 18% of patients).
__label__noRel	The 1- and 2-year survival rates were 25% and 7%, respectively;	Carboplatin/vinorelbine is well tolerated by elderly patients with extensive-stage NSCLC.
__label__Support	The 1- and 2-year survival rates were 25% and 7%, respectively;	Efficacy is low but similar to that of other treatments used in this setting.
__label__noRel	median time to progression was 4.3 months (range, 0.2-13.8 months).	Standard chemotherapy regimens are generally considered too toxic for elderly patients.
__label__noRel	median time to progression was 4.3 months (range, 0.2-13.8 months).	Among these 32 patients, 8 had a partial response (intent-to-treat response rate, 20%), and 10 (25%) had stable disease.
__label__noRel	median time to progression was 4.3 months (range, 0.2-13.8 months).	The median survival was 7.8 months (range, 4-11.6 months).
__label__noRel	median time to progression was 4.3 months (range, 0.2-13.8 months).	The 1- and 2-year survival rates were 25% and 7%, respectively;
__label__noRel	median time to progression was 4.3 months (range, 0.2-13.8 months).	Grade 3/4 neutropenia was seen in 27 patients (68%), and grade 3/4 anemia was seen in 5 patients (13%).
__label__noRel	median time to progression was 4.3 months (range, 0.2-13.8 months).	One patient died of febrile neutropenia during treatment.
__label__noRel	median time to progression was 4.3 months (range, 0.2-13.8 months).	The main nonhematologic adverse effect was fatigue (grade 3/4 in 18% of patients).
__label__noRel	median time to progression was 4.3 months (range, 0.2-13.8 months).	Carboplatin/vinorelbine is well tolerated by elderly patients with extensive-stage NSCLC.
__label__Support	median time to progression was 4.3 months (range, 0.2-13.8 months).	Efficacy is low but similar to that of other treatments used in this setting.
__label__noRel	Grade 3/4 neutropenia was seen in 27 patients (68%), and grade 3/4 anemia was seen in 5 patients (13%).	Standard chemotherapy regimens are generally considered too toxic for elderly patients.
__label__noRel	Grade 3/4 neutropenia was seen in 27 patients (68%), and grade 3/4 anemia was seen in 5 patients (13%).	Among these 32 patients, 8 had a partial response (intent-to-treat response rate, 20%), and 10 (25%) had stable disease.
__label__noRel	Grade 3/4 neutropenia was seen in 27 patients (68%), and grade 3/4 anemia was seen in 5 patients (13%).	The median survival was 7.8 months (range, 4-11.6 months).
__label__noRel	Grade 3/4 neutropenia was seen in 27 patients (68%), and grade 3/4 anemia was seen in 5 patients (13%).	The 1- and 2-year survival rates were 25% and 7%, respectively;
__label__noRel	Grade 3/4 neutropenia was seen in 27 patients (68%), and grade 3/4 anemia was seen in 5 patients (13%).	median time to progression was 4.3 months (range, 0.2-13.8 months).
__label__noRel	Grade 3/4 neutropenia was seen in 27 patients (68%), and grade 3/4 anemia was seen in 5 patients (13%).	One patient died of febrile neutropenia during treatment.
__label__noRel	Grade 3/4 neutropenia was seen in 27 patients (68%), and grade 3/4 anemia was seen in 5 patients (13%).	The main nonhematologic adverse effect was fatigue (grade 3/4 in 18% of patients).
__label__Support	Grade 3/4 neutropenia was seen in 27 patients (68%), and grade 3/4 anemia was seen in 5 patients (13%).	Carboplatin/vinorelbine is well tolerated by elderly patients with extensive-stage NSCLC.
__label__noRel	Grade 3/4 neutropenia was seen in 27 patients (68%), and grade 3/4 anemia was seen in 5 patients (13%).	Efficacy is low but similar to that of other treatments used in this setting.
__label__noRel	One patient died of febrile neutropenia during treatment.	Standard chemotherapy regimens are generally considered too toxic for elderly patients.
__label__noRel	One patient died of febrile neutropenia during treatment.	Among these 32 patients, 8 had a partial response (intent-to-treat response rate, 20%), and 10 (25%) had stable disease.
__label__noRel	One patient died of febrile neutropenia during treatment.	The median survival was 7.8 months (range, 4-11.6 months).
__label__noRel	One patient died of febrile neutropenia during treatment.	The 1- and 2-year survival rates were 25% and 7%, respectively;
__label__noRel	One patient died of febrile neutropenia during treatment.	median time to progression was 4.3 months (range, 0.2-13.8 months).
__label__noRel	One patient died of febrile neutropenia during treatment.	Grade 3/4 neutropenia was seen in 27 patients (68%), and grade 3/4 anemia was seen in 5 patients (13%).
__label__noRel	One patient died of febrile neutropenia during treatment.	The main nonhematologic adverse effect was fatigue (grade 3/4 in 18% of patients).
__label__Support	One patient died of febrile neutropenia during treatment.	Carboplatin/vinorelbine is well tolerated by elderly patients with extensive-stage NSCLC.
__label__noRel	One patient died of febrile neutropenia during treatment.	Efficacy is low but similar to that of other treatments used in this setting.
__label__noRel	The main nonhematologic adverse effect was fatigue (grade 3/4 in 18% of patients).	Standard chemotherapy regimens are generally considered too toxic for elderly patients.
__label__noRel	The main nonhematologic adverse effect was fatigue (grade 3/4 in 18% of patients).	Among these 32 patients, 8 had a partial response (intent-to-treat response rate, 20%), and 10 (25%) had stable disease.
__label__noRel	The main nonhematologic adverse effect was fatigue (grade 3/4 in 18% of patients).	The median survival was 7.8 months (range, 4-11.6 months).
__label__noRel	The main nonhematologic adverse effect was fatigue (grade 3/4 in 18% of patients).	The 1- and 2-year survival rates were 25% and 7%, respectively;
__label__noRel	The main nonhematologic adverse effect was fatigue (grade 3/4 in 18% of patients).	median time to progression was 4.3 months (range, 0.2-13.8 months).
__label__noRel	The main nonhematologic adverse effect was fatigue (grade 3/4 in 18% of patients).	Grade 3/4 neutropenia was seen in 27 patients (68%), and grade 3/4 anemia was seen in 5 patients (13%).
__label__noRel	The main nonhematologic adverse effect was fatigue (grade 3/4 in 18% of patients).	One patient died of febrile neutropenia during treatment.
__label__Support	The main nonhematologic adverse effect was fatigue (grade 3/4 in 18% of patients).	Carboplatin/vinorelbine is well tolerated by elderly patients with extensive-stage NSCLC.
__label__noRel	The main nonhematologic adverse effect was fatigue (grade 3/4 in 18% of patients).	Efficacy is low but similar to that of other treatments used in this setting.
__label__noRel	Carboplatin/vinorelbine is well tolerated by elderly patients with extensive-stage NSCLC.	Standard chemotherapy regimens are generally considered too toxic for elderly patients.
__label__noRel	Carboplatin/vinorelbine is well tolerated by elderly patients with extensive-stage NSCLC.	Among these 32 patients, 8 had a partial response (intent-to-treat response rate, 20%), and 10 (25%) had stable disease.
__label__noRel	Carboplatin/vinorelbine is well tolerated by elderly patients with extensive-stage NSCLC.	The median survival was 7.8 months (range, 4-11.6 months).
__label__noRel	Carboplatin/vinorelbine is well tolerated by elderly patients with extensive-stage NSCLC.	The 1- and 2-year survival rates were 25% and 7%, respectively;
__label__noRel	Carboplatin/vinorelbine is well tolerated by elderly patients with extensive-stage NSCLC.	median time to progression was 4.3 months (range, 0.2-13.8 months).
__label__noRel	Carboplatin/vinorelbine is well tolerated by elderly patients with extensive-stage NSCLC.	Grade 3/4 neutropenia was seen in 27 patients (68%), and grade 3/4 anemia was seen in 5 patients (13%).
__label__noRel	Carboplatin/vinorelbine is well tolerated by elderly patients with extensive-stage NSCLC.	One patient died of febrile neutropenia during treatment.
__label__noRel	Carboplatin/vinorelbine is well tolerated by elderly patients with extensive-stage NSCLC.	The main nonhematologic adverse effect was fatigue (grade 3/4 in 18% of patients).
__label__noRel	Carboplatin/vinorelbine is well tolerated by elderly patients with extensive-stage NSCLC.	Efficacy is low but similar to that of other treatments used in this setting.
__label__noRel	Efficacy is low but similar to that of other treatments used in this setting.	Standard chemotherapy regimens are generally considered too toxic for elderly patients.
__label__noRel	Efficacy is low but similar to that of other treatments used in this setting.	Among these 32 patients, 8 had a partial response (intent-to-treat response rate, 20%), and 10 (25%) had stable disease.
__label__noRel	Efficacy is low but similar to that of other treatments used in this setting.	The median survival was 7.8 months (range, 4-11.6 months).
__label__noRel	Efficacy is low but similar to that of other treatments used in this setting.	The 1- and 2-year survival rates were 25% and 7%, respectively;
__label__noRel	Efficacy is low but similar to that of other treatments used in this setting.	median time to progression was 4.3 months (range, 0.2-13.8 months).
__label__noRel	Efficacy is low but similar to that of other treatments used in this setting.	Grade 3/4 neutropenia was seen in 27 patients (68%), and grade 3/4 anemia was seen in 5 patients (13%).
__label__noRel	Efficacy is low but similar to that of other treatments used in this setting.	One patient died of febrile neutropenia during treatment.
__label__noRel	Efficacy is low but similar to that of other treatments used in this setting.	The main nonhematologic adverse effect was fatigue (grade 3/4 in 18% of patients).
__label__noRel	Efficacy is low but similar to that of other treatments used in this setting.	Carboplatin/vinorelbine is well tolerated by elderly patients with extensive-stage NSCLC.
__label__noRel	In response to training, QOL, VO2peak (mean 3.9 ml/kg/min; 95 % CI, 0.93, 6.90) performance in leg press (17.9 kg; 95 % CI, 12.8, 22.4) and sit-stand test (- 0.67 s; 95 % CI, - 0.52, - 1.2) improved (p < or = 0.05).	We observed no significant changes in the control group.
__label__Support	In response to training, QOL, VO2peak (mean 3.9 ml/kg/min; 95 % CI, 0.93, 6.90) performance in leg press (17.9 kg; 95 % CI, 12.8, 22.4) and sit-stand test (- 0.67 s; 95 % CI, - 0.52, - 1.2) improved (p < or = 0.05).	Combined cardiorespiratory and resistance training, even of very brief duration, improves the QOL and the overall physical fitness of women breast cancer survivors.
__label__noRel	We observed no significant changes in the control group.	In response to training, QOL, VO2peak (mean 3.9 ml/kg/min; 95 % CI, 0.93, 6.90) performance in leg press (17.9 kg; 95 % CI, 12.8, 22.4) and sit-stand test (- 0.67 s; 95 % CI, - 0.52, - 1.2) improved (p < or = 0.05).
__label__Support	We observed no significant changes in the control group.	Combined cardiorespiratory and resistance training, even of very brief duration, improves the QOL and the overall physical fitness of women breast cancer survivors.
__label__noRel	Combined cardiorespiratory and resistance training, even of very brief duration, improves the QOL and the overall physical fitness of women breast cancer survivors.	In response to training, QOL, VO2peak (mean 3.9 ml/kg/min; 95 % CI, 0.93, 6.90) performance in leg press (17.9 kg; 95 % CI, 12.8, 22.4) and sit-stand test (- 0.67 s; 95 % CI, - 0.52, - 1.2) improved (p < or = 0.05).
__label__noRel	Combined cardiorespiratory and resistance training, even of very brief duration, improves the QOL and the overall physical fitness of women breast cancer survivors.	We observed no significant changes in the control group.
__label__noRel	QOL scores were increased and complication scores were improved in the postoperative periods (P < .01).	Postoperative BMI significantly deteriorated compared with preoperative BMI in each group.
__label__noRel	QOL scores were increased and complication scores were improved in the postoperative periods (P < .01).	The postoperative QOL and complication scores at 60 months after surgery were significantly better than those at 3 months after surgery in each group (P < .01).
__label__noRel	QOL scores were increased and complication scores were improved in the postoperative periods (P < .01).	there was no significant difference of QOL scores and postoperative complication scores between the 2 reconstruction groups.
__label__noRel	QOL scores were increased and complication scores were improved in the postoperative periods (P < .01).	The nutritional condition in the INT group was nearly the same as that in the RY group.
__label__noRel	QOL scores were increased and complication scores were improved in the postoperative periods (P < .01).	Although our patient sample was small and patients who did not complete the follow-up survey were present,
__label__noRel	QOL scores were increased and complication scores were improved in the postoperative periods (P < .01).	we could not identify any clinical difference between INT and RY after total gastrectomy 60 months after surgery.
__label__noRel	QOL scores were increased and complication scores were improved in the postoperative periods (P < .01).	The safer and simpler RY method may be a more suitable reconstruction method than INT after total gastrectomy.
__label__noRel	QOL scores were increased and complication scores were improved in the postoperative periods (P < .01).	The postoperative clinical superiority of the interposition of jejunum reconstruction (INT) to Roux-en-Y reconstruction (RY) after total gastrectomy has not been clarified.
__label__noRel	Postoperative BMI significantly deteriorated compared with preoperative BMI in each group.	QOL scores were increased and complication scores were improved in the postoperative periods (P < .01).
__label__noRel	Postoperative BMI significantly deteriorated compared with preoperative BMI in each group.	The postoperative QOL and complication scores at 60 months after surgery were significantly better than those at 3 months after surgery in each group (P < .01).
__label__noRel	Postoperative BMI significantly deteriorated compared with preoperative BMI in each group.	there was no significant difference of QOL scores and postoperative complication scores between the 2 reconstruction groups.
__label__noRel	Postoperative BMI significantly deteriorated compared with preoperative BMI in each group.	The nutritional condition in the INT group was nearly the same as that in the RY group.
__label__noRel	Postoperative BMI significantly deteriorated compared with preoperative BMI in each group.	Although our patient sample was small and patients who did not complete the follow-up survey were present,
__label__noRel	Postoperative BMI significantly deteriorated compared with preoperative BMI in each group.	we could not identify any clinical difference between INT and RY after total gastrectomy 60 months after surgery.
__label__noRel	Postoperative BMI significantly deteriorated compared with preoperative BMI in each group.	The safer and simpler RY method may be a more suitable reconstruction method than INT after total gastrectomy.
__label__noRel	Postoperative BMI significantly deteriorated compared with preoperative BMI in each group.	The postoperative clinical superiority of the interposition of jejunum reconstruction (INT) to Roux-en-Y reconstruction (RY) after total gastrectomy has not been clarified.
__label__noRel	The postoperative QOL and complication scores at 60 months after surgery were significantly better than those at 3 months after surgery in each group (P < .01).	QOL scores were increased and complication scores were improved in the postoperative periods (P < .01).
__label__noRel	The postoperative QOL and complication scores at 60 months after surgery were significantly better than those at 3 months after surgery in each group (P < .01).	Postoperative BMI significantly deteriorated compared with preoperative BMI in each group.
__label__noRel	The postoperative QOL and complication scores at 60 months after surgery were significantly better than those at 3 months after surgery in each group (P < .01).	there was no significant difference of QOL scores and postoperative complication scores between the 2 reconstruction groups.
__label__noRel	The postoperative QOL and complication scores at 60 months after surgery were significantly better than those at 3 months after surgery in each group (P < .01).	The nutritional condition in the INT group was nearly the same as that in the RY group.
__label__noRel	The postoperative QOL and complication scores at 60 months after surgery were significantly better than those at 3 months after surgery in each group (P < .01).	Although our patient sample was small and patients who did not complete the follow-up survey were present,
__label__noRel	The postoperative QOL and complication scores at 60 months after surgery were significantly better than those at 3 months after surgery in each group (P < .01).	we could not identify any clinical difference between INT and RY after total gastrectomy 60 months after surgery.
__label__noRel	The postoperative QOL and complication scores at 60 months after surgery were significantly better than those at 3 months after surgery in each group (P < .01).	The safer and simpler RY method may be a more suitable reconstruction method than INT after total gastrectomy.
__label__noRel	The postoperative QOL and complication scores at 60 months after surgery were significantly better than those at 3 months after surgery in each group (P < .01).	The postoperative clinical superiority of the interposition of jejunum reconstruction (INT) to Roux-en-Y reconstruction (RY) after total gastrectomy has not been clarified.
__label__noRel	there was no significant difference of QOL scores and postoperative complication scores between the 2 reconstruction groups.	QOL scores were increased and complication scores were improved in the postoperative periods (P < .01).
__label__noRel	there was no significant difference of QOL scores and postoperative complication scores between the 2 reconstruction groups.	Postoperative BMI significantly deteriorated compared with preoperative BMI in each group.
__label__noRel	there was no significant difference of QOL scores and postoperative complication scores between the 2 reconstruction groups.	The postoperative QOL and complication scores at 60 months after surgery were significantly better than those at 3 months after surgery in each group (P < .01).
__label__noRel	there was no significant difference of QOL scores and postoperative complication scores between the 2 reconstruction groups.	The nutritional condition in the INT group was nearly the same as that in the RY group.
__label__noRel	there was no significant difference of QOL scores and postoperative complication scores between the 2 reconstruction groups.	Although our patient sample was small and patients who did not complete the follow-up survey were present,
__label__Support	there was no significant difference of QOL scores and postoperative complication scores between the 2 reconstruction groups.	we could not identify any clinical difference between INT and RY after total gastrectomy 60 months after surgery.
__label__noRel	there was no significant difference of QOL scores and postoperative complication scores between the 2 reconstruction groups.	The safer and simpler RY method may be a more suitable reconstruction method than INT after total gastrectomy.
__label__noRel	there was no significant difference of QOL scores and postoperative complication scores between the 2 reconstruction groups.	The postoperative clinical superiority of the interposition of jejunum reconstruction (INT) to Roux-en-Y reconstruction (RY) after total gastrectomy has not been clarified.
__label__noRel	The nutritional condition in the INT group was nearly the same as that in the RY group.	QOL scores were increased and complication scores were improved in the postoperative periods (P < .01).
__label__noRel	The nutritional condition in the INT group was nearly the same as that in the RY group.	Postoperative BMI significantly deteriorated compared with preoperative BMI in each group.
__label__noRel	The nutritional condition in the INT group was nearly the same as that in the RY group.	The postoperative QOL and complication scores at 60 months after surgery were significantly better than those at 3 months after surgery in each group (P < .01).
__label__noRel	The nutritional condition in the INT group was nearly the same as that in the RY group.	there was no significant difference of QOL scores and postoperative complication scores between the 2 reconstruction groups.
__label__noRel	The nutritional condition in the INT group was nearly the same as that in the RY group.	Although our patient sample was small and patients who did not complete the follow-up survey were present,
__label__Support	The nutritional condition in the INT group was nearly the same as that in the RY group.	we could not identify any clinical difference between INT and RY after total gastrectomy 60 months after surgery.
__label__noRel	The nutritional condition in the INT group was nearly the same as that in the RY group.	The safer and simpler RY method may be a more suitable reconstruction method than INT after total gastrectomy.
__label__noRel	The nutritional condition in the INT group was nearly the same as that in the RY group.	The postoperative clinical superiority of the interposition of jejunum reconstruction (INT) to Roux-en-Y reconstruction (RY) after total gastrectomy has not been clarified.
__label__noRel	Although our patient sample was small and patients who did not complete the follow-up survey were present,	QOL scores were increased and complication scores were improved in the postoperative periods (P < .01).
__label__noRel	Although our patient sample was small and patients who did not complete the follow-up survey were present,	Postoperative BMI significantly deteriorated compared with preoperative BMI in each group.
__label__noRel	Although our patient sample was small and patients who did not complete the follow-up survey were present,	The postoperative QOL and complication scores at 60 months after surgery were significantly better than those at 3 months after surgery in each group (P < .01).
__label__noRel	Although our patient sample was small and patients who did not complete the follow-up survey were present,	there was no significant difference of QOL scores and postoperative complication scores between the 2 reconstruction groups.
__label__noRel	Although our patient sample was small and patients who did not complete the follow-up survey were present,	The nutritional condition in the INT group was nearly the same as that in the RY group.
__label__Attack	Although our patient sample was small and patients who did not complete the follow-up survey were present,	we could not identify any clinical difference between INT and RY after total gastrectomy 60 months after surgery.
__label__noRel	Although our patient sample was small and patients who did not complete the follow-up survey were present,	The safer and simpler RY method may be a more suitable reconstruction method than INT after total gastrectomy.
__label__noRel	Although our patient sample was small and patients who did not complete the follow-up survey were present,	The postoperative clinical superiority of the interposition of jejunum reconstruction (INT) to Roux-en-Y reconstruction (RY) after total gastrectomy has not been clarified.
__label__noRel	we could not identify any clinical difference between INT and RY after total gastrectomy 60 months after surgery.	QOL scores were increased and complication scores were improved in the postoperative periods (P < .01).
__label__noRel	we could not identify any clinical difference between INT and RY after total gastrectomy 60 months after surgery.	Postoperative BMI significantly deteriorated compared with preoperative BMI in each group.
__label__noRel	we could not identify any clinical difference between INT and RY after total gastrectomy 60 months after surgery.	The postoperative QOL and complication scores at 60 months after surgery were significantly better than those at 3 months after surgery in each group (P < .01).
__label__noRel	we could not identify any clinical difference between INT and RY after total gastrectomy 60 months after surgery.	there was no significant difference of QOL scores and postoperative complication scores between the 2 reconstruction groups.
__label__noRel	we could not identify any clinical difference between INT and RY after total gastrectomy 60 months after surgery.	The nutritional condition in the INT group was nearly the same as that in the RY group.
__label__noRel	we could not identify any clinical difference between INT and RY after total gastrectomy 60 months after surgery.	Although our patient sample was small and patients who did not complete the follow-up survey were present,
__label__noRel	we could not identify any clinical difference between INT and RY after total gastrectomy 60 months after surgery.	The safer and simpler RY method may be a more suitable reconstruction method than INT after total gastrectomy.
__label__Support	we could not identify any clinical difference between INT and RY after total gastrectomy 60 months after surgery.	The postoperative clinical superiority of the interposition of jejunum reconstruction (INT) to Roux-en-Y reconstruction (RY) after total gastrectomy has not been clarified.
__label__noRel	The safer and simpler RY method may be a more suitable reconstruction method than INT after total gastrectomy.	QOL scores were increased and complication scores were improved in the postoperative periods (P < .01).
__label__noRel	The safer and simpler RY method may be a more suitable reconstruction method than INT after total gastrectomy.	Postoperative BMI significantly deteriorated compared with preoperative BMI in each group.
__label__noRel	The safer and simpler RY method may be a more suitable reconstruction method than INT after total gastrectomy.	The postoperative QOL and complication scores at 60 months after surgery were significantly better than those at 3 months after surgery in each group (P < .01).
__label__noRel	The safer and simpler RY method may be a more suitable reconstruction method than INT after total gastrectomy.	there was no significant difference of QOL scores and postoperative complication scores between the 2 reconstruction groups.
__label__noRel	The safer and simpler RY method may be a more suitable reconstruction method than INT after total gastrectomy.	The nutritional condition in the INT group was nearly the same as that in the RY group.
__label__noRel	The safer and simpler RY method may be a more suitable reconstruction method than INT after total gastrectomy.	Although our patient sample was small and patients who did not complete the follow-up survey were present,
__label__noRel	The safer and simpler RY method may be a more suitable reconstruction method than INT after total gastrectomy.	we could not identify any clinical difference between INT and RY after total gastrectomy 60 months after surgery.
__label__noRel	The safer and simpler RY method may be a more suitable reconstruction method than INT after total gastrectomy.	The postoperative clinical superiority of the interposition of jejunum reconstruction (INT) to Roux-en-Y reconstruction (RY) after total gastrectomy has not been clarified.
__label__noRel	The postoperative clinical superiority of the interposition of jejunum reconstruction (INT) to Roux-en-Y reconstruction (RY) after total gastrectomy has not been clarified.	QOL scores were increased and complication scores were improved in the postoperative periods (P < .01).
__label__noRel	The postoperative clinical superiority of the interposition of jejunum reconstruction (INT) to Roux-en-Y reconstruction (RY) after total gastrectomy has not been clarified.	Postoperative BMI significantly deteriorated compared with preoperative BMI in each group.
__label__noRel	The postoperative clinical superiority of the interposition of jejunum reconstruction (INT) to Roux-en-Y reconstruction (RY) after total gastrectomy has not been clarified.	The postoperative QOL and complication scores at 60 months after surgery were significantly better than those at 3 months after surgery in each group (P < .01).
__label__noRel	The postoperative clinical superiority of the interposition of jejunum reconstruction (INT) to Roux-en-Y reconstruction (RY) after total gastrectomy has not been clarified.	there was no significant difference of QOL scores and postoperative complication scores between the 2 reconstruction groups.
__label__noRel	The postoperative clinical superiority of the interposition of jejunum reconstruction (INT) to Roux-en-Y reconstruction (RY) after total gastrectomy has not been clarified.	The nutritional condition in the INT group was nearly the same as that in the RY group.
__label__noRel	The postoperative clinical superiority of the interposition of jejunum reconstruction (INT) to Roux-en-Y reconstruction (RY) after total gastrectomy has not been clarified.	Although our patient sample was small and patients who did not complete the follow-up survey were present,
__label__noRel	The postoperative clinical superiority of the interposition of jejunum reconstruction (INT) to Roux-en-Y reconstruction (RY) after total gastrectomy has not been clarified.	we could not identify any clinical difference between INT and RY after total gastrectomy 60 months after surgery.
__label__noRel	The postoperative clinical superiority of the interposition of jejunum reconstruction (INT) to Roux-en-Y reconstruction (RY) after total gastrectomy has not been clarified.	The safer and simpler RY method may be a more suitable reconstruction method than INT after total gastrectomy.
__label__noRel	Upon the completion of PMP, pain scores were significantly reduced in both groups,	yet patients in the experimental group showed a significant increase in the use of PRN analgesics and nonpharmacological strategies to relieve pain (P < .05) and significantly reduce barriers to managing their cancer pain (P < .05) compared with the control group.
__label__noRel	Upon the completion of PMP, pain scores were significantly reduced in both groups,	Cancer patients should be empowered with pain management education to gain knowledge and correct misconceptions in managing their cancer pain.
__label__noRel	Upon the completion of PMP, pain scores were significantly reduced in both groups,	Integration of the PMP into routine clinical work may help to improve the standard of care for cancer patients.
__label__Attack	yet patients in the experimental group showed a significant increase in the use of PRN analgesics and nonpharmacological strategies to relieve pain (P < .05) and significantly reduce barriers to managing their cancer pain (P < .05) compared with the control group.	Upon the completion of PMP, pain scores were significantly reduced in both groups,
__label__noRel	yet patients in the experimental group showed a significant increase in the use of PRN analgesics and nonpharmacological strategies to relieve pain (P < .05) and significantly reduce barriers to managing their cancer pain (P < .05) compared with the control group.	Cancer patients should be empowered with pain management education to gain knowledge and correct misconceptions in managing their cancer pain.
__label__noRel	yet patients in the experimental group showed a significant increase in the use of PRN analgesics and nonpharmacological strategies to relieve pain (P < .05) and significantly reduce barriers to managing their cancer pain (P < .05) compared with the control group.	Integration of the PMP into routine clinical work may help to improve the standard of care for cancer patients.
__label__noRel	Cancer patients should be empowered with pain management education to gain knowledge and correct misconceptions in managing their cancer pain.	Upon the completion of PMP, pain scores were significantly reduced in both groups,
__label__noRel	Cancer patients should be empowered with pain management education to gain knowledge and correct misconceptions in managing their cancer pain.	yet patients in the experimental group showed a significant increase in the use of PRN analgesics and nonpharmacological strategies to relieve pain (P < .05) and significantly reduce barriers to managing their cancer pain (P < .05) compared with the control group.
__label__noRel	Cancer patients should be empowered with pain management education to gain knowledge and correct misconceptions in managing their cancer pain.	Integration of the PMP into routine clinical work may help to improve the standard of care for cancer patients.
__label__noRel	Integration of the PMP into routine clinical work may help to improve the standard of care for cancer patients.	Upon the completion of PMP, pain scores were significantly reduced in both groups,
__label__noRel	Integration of the PMP into routine clinical work may help to improve the standard of care for cancer patients.	yet patients in the experimental group showed a significant increase in the use of PRN analgesics and nonpharmacological strategies to relieve pain (P < .05) and significantly reduce barriers to managing their cancer pain (P < .05) compared with the control group.
__label__noRel	Integration of the PMP into routine clinical work may help to improve the standard of care for cancer patients.	Cancer patients should be empowered with pain management education to gain knowledge and correct misconceptions in managing their cancer pain.
__label__noRel	The efficacy and safety of uterine-artery embolization, as compared with standard surgical methods, for the treatment of symptomatic uterine fibroids remain uncertain.	There were no significant differences between groups in any of the eight components of the SF-36 scores at 1 year.
__label__noRel	The efficacy and safety of uterine-artery embolization, as compared with standard surgical methods, for the treatment of symptomatic uterine fibroids remain uncertain.	The embolization group had a shorter median duration of hospitalization than the surgical group (1 day vs. 5 days, P<0.001) and a shorter time before returning to work (P<0.001).
__label__noRel	The efficacy and safety of uterine-artery embolization, as compared with standard surgical methods, for the treatment of symptomatic uterine fibroids remain uncertain.	At 1 year, symptom scores were better in the surgical group (P=0.03).
__label__noRel	The efficacy and safety of uterine-artery embolization, as compared with standard surgical methods, for the treatment of symptomatic uterine fibroids remain uncertain.	During the first year of follow-up, there were 13 major adverse events in the embolization group (12%) and 10 in the surgical group (20%) (P=0.22), mostly related to the intervention.
__label__noRel	The efficacy and safety of uterine-artery embolization, as compared with standard surgical methods, for the treatment of symptomatic uterine fibroids remain uncertain.	Ten patients in the embolization group (9%) required repeated embolization or hysterectomy for inadequate symptom control.
__label__noRel	The efficacy and safety of uterine-artery embolization, as compared with standard surgical methods, for the treatment of symptomatic uterine fibroids remain uncertain.	After the first year of follow-up, 14 women in the embolization group (13%) required hospitalization, 3 of them for major adverse events and 11 for reintervention for treatment failure.
__label__noRel	The efficacy and safety of uterine-artery embolization, as compared with standard surgical methods, for the treatment of symptomatic uterine fibroids remain uncertain.	In women with symptomatic fibroids, the faster recovery after embolization must be weighed against the need for further treatment in a minority of patients.
__label__noRel	There were no significant differences between groups in any of the eight components of the SF-36 scores at 1 year.	The efficacy and safety of uterine-artery embolization, as compared with standard surgical methods, for the treatment of symptomatic uterine fibroids remain uncertain.
__label__noRel	There were no significant differences between groups in any of the eight components of the SF-36 scores at 1 year.	The embolization group had a shorter median duration of hospitalization than the surgical group (1 day vs. 5 days, P<0.001) and a shorter time before returning to work (P<0.001).
__label__noRel	There were no significant differences between groups in any of the eight components of the SF-36 scores at 1 year.	At 1 year, symptom scores were better in the surgical group (P=0.03).
__label__noRel	There were no significant differences between groups in any of the eight components of the SF-36 scores at 1 year.	During the first year of follow-up, there were 13 major adverse events in the embolization group (12%) and 10 in the surgical group (20%) (P=0.22), mostly related to the intervention.
__label__noRel	There were no significant differences between groups in any of the eight components of the SF-36 scores at 1 year.	Ten patients in the embolization group (9%) required repeated embolization or hysterectomy for inadequate symptom control.
__label__noRel	There were no significant differences between groups in any of the eight components of the SF-36 scores at 1 year.	After the first year of follow-up, 14 women in the embolization group (13%) required hospitalization, 3 of them for major adverse events and 11 for reintervention for treatment failure.
__label__Support	There were no significant differences between groups in any of the eight components of the SF-36 scores at 1 year.	In women with symptomatic fibroids, the faster recovery after embolization must be weighed against the need for further treatment in a minority of patients.
__label__noRel	The embolization group had a shorter median duration of hospitalization than the surgical group (1 day vs. 5 days, P<0.001) and a shorter time before returning to work (P<0.001).	The efficacy and safety of uterine-artery embolization, as compared with standard surgical methods, for the treatment of symptomatic uterine fibroids remain uncertain.
__label__noRel	The embolization group had a shorter median duration of hospitalization than the surgical group (1 day vs. 5 days, P<0.001) and a shorter time before returning to work (P<0.001).	There were no significant differences between groups in any of the eight components of the SF-36 scores at 1 year.
__label__noRel	The embolization group had a shorter median duration of hospitalization than the surgical group (1 day vs. 5 days, P<0.001) and a shorter time before returning to work (P<0.001).	At 1 year, symptom scores were better in the surgical group (P=0.03).
__label__noRel	The embolization group had a shorter median duration of hospitalization than the surgical group (1 day vs. 5 days, P<0.001) and a shorter time before returning to work (P<0.001).	During the first year of follow-up, there were 13 major adverse events in the embolization group (12%) and 10 in the surgical group (20%) (P=0.22), mostly related to the intervention.
__label__noRel	The embolization group had a shorter median duration of hospitalization than the surgical group (1 day vs. 5 days, P<0.001) and a shorter time before returning to work (P<0.001).	Ten patients in the embolization group (9%) required repeated embolization or hysterectomy for inadequate symptom control.
__label__noRel	The embolization group had a shorter median duration of hospitalization than the surgical group (1 day vs. 5 days, P<0.001) and a shorter time before returning to work (P<0.001).	After the first year of follow-up, 14 women in the embolization group (13%) required hospitalization, 3 of them for major adverse events and 11 for reintervention for treatment failure.
__label__Support	The embolization group had a shorter median duration of hospitalization than the surgical group (1 day vs. 5 days, P<0.001) and a shorter time before returning to work (P<0.001).	In women with symptomatic fibroids, the faster recovery after embolization must be weighed against the need for further treatment in a minority of patients.
__label__noRel	At 1 year, symptom scores were better in the surgical group (P=0.03).	The efficacy and safety of uterine-artery embolization, as compared with standard surgical methods, for the treatment of symptomatic uterine fibroids remain uncertain.
__label__noRel	At 1 year, symptom scores were better in the surgical group (P=0.03).	There were no significant differences between groups in any of the eight components of the SF-36 scores at 1 year.
__label__noRel	At 1 year, symptom scores were better in the surgical group (P=0.03).	The embolization group had a shorter median duration of hospitalization than the surgical group (1 day vs. 5 days, P<0.001) and a shorter time before returning to work (P<0.001).
__label__noRel	At 1 year, symptom scores were better in the surgical group (P=0.03).	During the first year of follow-up, there were 13 major adverse events in the embolization group (12%) and 10 in the surgical group (20%) (P=0.22), mostly related to the intervention.
__label__noRel	At 1 year, symptom scores were better in the surgical group (P=0.03).	Ten patients in the embolization group (9%) required repeated embolization or hysterectomy for inadequate symptom control.
__label__noRel	At 1 year, symptom scores were better in the surgical group (P=0.03).	After the first year of follow-up, 14 women in the embolization group (13%) required hospitalization, 3 of them for major adverse events and 11 for reintervention for treatment failure.
__label__Support	At 1 year, symptom scores were better in the surgical group (P=0.03).	In women with symptomatic fibroids, the faster recovery after embolization must be weighed against the need for further treatment in a minority of patients.
__label__noRel	During the first year of follow-up, there were 13 major adverse events in the embolization group (12%) and 10 in the surgical group (20%) (P=0.22), mostly related to the intervention.	The efficacy and safety of uterine-artery embolization, as compared with standard surgical methods, for the treatment of symptomatic uterine fibroids remain uncertain.
__label__noRel	During the first year of follow-up, there were 13 major adverse events in the embolization group (12%) and 10 in the surgical group (20%) (P=0.22), mostly related to the intervention.	There were no significant differences between groups in any of the eight components of the SF-36 scores at 1 year.
__label__noRel	During the first year of follow-up, there were 13 major adverse events in the embolization group (12%) and 10 in the surgical group (20%) (P=0.22), mostly related to the intervention.	The embolization group had a shorter median duration of hospitalization than the surgical group (1 day vs. 5 days, P<0.001) and a shorter time before returning to work (P<0.001).
__label__noRel	During the first year of follow-up, there were 13 major adverse events in the embolization group (12%) and 10 in the surgical group (20%) (P=0.22), mostly related to the intervention.	At 1 year, symptom scores were better in the surgical group (P=0.03).
__label__noRel	During the first year of follow-up, there were 13 major adverse events in the embolization group (12%) and 10 in the surgical group (20%) (P=0.22), mostly related to the intervention.	Ten patients in the embolization group (9%) required repeated embolization or hysterectomy for inadequate symptom control.
__label__noRel	During the first year of follow-up, there were 13 major adverse events in the embolization group (12%) and 10 in the surgical group (20%) (P=0.22), mostly related to the intervention.	After the first year of follow-up, 14 women in the embolization group (13%) required hospitalization, 3 of them for major adverse events and 11 for reintervention for treatment failure.
__label__Support	During the first year of follow-up, there were 13 major adverse events in the embolization group (12%) and 10 in the surgical group (20%) (P=0.22), mostly related to the intervention.	In women with symptomatic fibroids, the faster recovery after embolization must be weighed against the need for further treatment in a minority of patients.
__label__noRel	Ten patients in the embolization group (9%) required repeated embolization or hysterectomy for inadequate symptom control.	The efficacy and safety of uterine-artery embolization, as compared with standard surgical methods, for the treatment of symptomatic uterine fibroids remain uncertain.
__label__noRel	Ten patients in the embolization group (9%) required repeated embolization or hysterectomy for inadequate symptom control.	There were no significant differences between groups in any of the eight components of the SF-36 scores at 1 year.
__label__noRel	Ten patients in the embolization group (9%) required repeated embolization or hysterectomy for inadequate symptom control.	The embolization group had a shorter median duration of hospitalization than the surgical group (1 day vs. 5 days, P<0.001) and a shorter time before returning to work (P<0.001).
__label__noRel	Ten patients in the embolization group (9%) required repeated embolization or hysterectomy for inadequate symptom control.	At 1 year, symptom scores were better in the surgical group (P=0.03).
__label__noRel	Ten patients in the embolization group (9%) required repeated embolization or hysterectomy for inadequate symptom control.	During the first year of follow-up, there were 13 major adverse events in the embolization group (12%) and 10 in the surgical group (20%) (P=0.22), mostly related to the intervention.
__label__noRel	Ten patients in the embolization group (9%) required repeated embolization or hysterectomy for inadequate symptom control.	After the first year of follow-up, 14 women in the embolization group (13%) required hospitalization, 3 of them for major adverse events and 11 for reintervention for treatment failure.
__label__Support	Ten patients in the embolization group (9%) required repeated embolization or hysterectomy for inadequate symptom control.	In women with symptomatic fibroids, the faster recovery after embolization must be weighed against the need for further treatment in a minority of patients.
__label__noRel	After the first year of follow-up, 14 women in the embolization group (13%) required hospitalization, 3 of them for major adverse events and 11 for reintervention for treatment failure.	The efficacy and safety of uterine-artery embolization, as compared with standard surgical methods, for the treatment of symptomatic uterine fibroids remain uncertain.
__label__noRel	After the first year of follow-up, 14 women in the embolization group (13%) required hospitalization, 3 of them for major adverse events and 11 for reintervention for treatment failure.	There were no significant differences between groups in any of the eight components of the SF-36 scores at 1 year.
__label__noRel	After the first year of follow-up, 14 women in the embolization group (13%) required hospitalization, 3 of them for major adverse events and 11 for reintervention for treatment failure.	The embolization group had a shorter median duration of hospitalization than the surgical group (1 day vs. 5 days, P<0.001) and a shorter time before returning to work (P<0.001).
__label__noRel	After the first year of follow-up, 14 women in the embolization group (13%) required hospitalization, 3 of them for major adverse events and 11 for reintervention for treatment failure.	At 1 year, symptom scores were better in the surgical group (P=0.03).
__label__noRel	After the first year of follow-up, 14 women in the embolization group (13%) required hospitalization, 3 of them for major adverse events and 11 for reintervention for treatment failure.	During the first year of follow-up, there were 13 major adverse events in the embolization group (12%) and 10 in the surgical group (20%) (P=0.22), mostly related to the intervention.
__label__noRel	After the first year of follow-up, 14 women in the embolization group (13%) required hospitalization, 3 of them for major adverse events and 11 for reintervention for treatment failure.	Ten patients in the embolization group (9%) required repeated embolization or hysterectomy for inadequate symptom control.
__label__Support	After the first year of follow-up, 14 women in the embolization group (13%) required hospitalization, 3 of them for major adverse events and 11 for reintervention for treatment failure.	In women with symptomatic fibroids, the faster recovery after embolization must be weighed against the need for further treatment in a minority of patients.
__label__noRel	In women with symptomatic fibroids, the faster recovery after embolization must be weighed against the need for further treatment in a minority of patients.	The efficacy and safety of uterine-artery embolization, as compared with standard surgical methods, for the treatment of symptomatic uterine fibroids remain uncertain.
__label__noRel	In women with symptomatic fibroids, the faster recovery after embolization must be weighed against the need for further treatment in a minority of patients.	There were no significant differences between groups in any of the eight components of the SF-36 scores at 1 year.
__label__noRel	In women with symptomatic fibroids, the faster recovery after embolization must be weighed against the need for further treatment in a minority of patients.	The embolization group had a shorter median duration of hospitalization than the surgical group (1 day vs. 5 days, P<0.001) and a shorter time before returning to work (P<0.001).
__label__noRel	In women with symptomatic fibroids, the faster recovery after embolization must be weighed against the need for further treatment in a minority of patients.	At 1 year, symptom scores were better in the surgical group (P=0.03).
__label__noRel	In women with symptomatic fibroids, the faster recovery after embolization must be weighed against the need for further treatment in a minority of patients.	During the first year of follow-up, there were 13 major adverse events in the embolization group (12%) and 10 in the surgical group (20%) (P=0.22), mostly related to the intervention.
__label__noRel	In women with symptomatic fibroids, the faster recovery after embolization must be weighed against the need for further treatment in a minority of patients.	Ten patients in the embolization group (9%) required repeated embolization or hysterectomy for inadequate symptom control.
__label__noRel	In women with symptomatic fibroids, the faster recovery after embolization must be weighed against the need for further treatment in a minority of patients.	After the first year of follow-up, 14 women in the embolization group (13%) required hospitalization, 3 of them for major adverse events and 11 for reintervention for treatment failure.
__label__noRel	Psychological interventions are efficacious in reducing emotional distress for cancer patients.	However, it is not clear whether psychological improvements are, in turn, related to improved health.
__label__noRel	Psychological interventions are efficacious in reducing emotional distress for cancer patients.	A path model revealed that intervention participation directly improved health (p<.05) at 12 months.
__label__noRel	Psychological interventions are efficacious in reducing emotional distress for cancer patients.	These effects remained when statistically controlling for baseline levels of distress, immunity, and health as well as sociodemographic, disease, and cancer treatment variables.
__label__noRel	Psychological interventions are efficacious in reducing emotional distress for cancer patients.	Regarding the mechanisms for achieving better health, support was found for an indirect effect of distress reduction.
__label__noRel	Psychological interventions are efficacious in reducing emotional distress for cancer patients.	That is, by specifically lowering intervention patients' distress at 4 months, their health was improved at 12 months (p<.05).
__label__noRel	Psychological interventions are efficacious in reducing emotional distress for cancer patients.	Although the intervention simultaneously improved patients' T-cell blastogenesis in response to phytohemagglutinin (PHA),
__label__noRel	Psychological interventions are efficacious in reducing emotional distress for cancer patients.	the latter increases were unrelated to improved health.
__label__noRel	Psychological interventions are efficacious in reducing emotional distress for cancer patients.	A convergence of biobehavioral effects and health improvements were observed.
__label__noRel	Psychological interventions are efficacious in reducing emotional distress for cancer patients.	Behavioral change, rather than immunity change, was influential in achieving lower levels of symptomatology and higher functional status.
__label__noRel	Psychological interventions are efficacious in reducing emotional distress for cancer patients.	Distress reduction is highlighted as an important mechanism by which health can be improved.
__label__noRel	However, it is not clear whether psychological improvements are, in turn, related to improved health.	Psychological interventions are efficacious in reducing emotional distress for cancer patients.
__label__noRel	However, it is not clear whether psychological improvements are, in turn, related to improved health.	A path model revealed that intervention participation directly improved health (p<.05) at 12 months.
__label__noRel	However, it is not clear whether psychological improvements are, in turn, related to improved health.	These effects remained when statistically controlling for baseline levels of distress, immunity, and health as well as sociodemographic, disease, and cancer treatment variables.
__label__noRel	However, it is not clear whether psychological improvements are, in turn, related to improved health.	Regarding the mechanisms for achieving better health, support was found for an indirect effect of distress reduction.
__label__noRel	However, it is not clear whether psychological improvements are, in turn, related to improved health.	That is, by specifically lowering intervention patients' distress at 4 months, their health was improved at 12 months (p<.05).
__label__noRel	However, it is not clear whether psychological improvements are, in turn, related to improved health.	Although the intervention simultaneously improved patients' T-cell blastogenesis in response to phytohemagglutinin (PHA),
__label__noRel	However, it is not clear whether psychological improvements are, in turn, related to improved health.	the latter increases were unrelated to improved health.
__label__noRel	However, it is not clear whether psychological improvements are, in turn, related to improved health.	A convergence of biobehavioral effects and health improvements were observed.
__label__noRel	However, it is not clear whether psychological improvements are, in turn, related to improved health.	Behavioral change, rather than immunity change, was influential in achieving lower levels of symptomatology and higher functional status.
__label__noRel	However, it is not clear whether psychological improvements are, in turn, related to improved health.	Distress reduction is highlighted as an important mechanism by which health can be improved.
__label__noRel	A path model revealed that intervention participation directly improved health (p<.05) at 12 months.	Psychological interventions are efficacious in reducing emotional distress for cancer patients.
__label__noRel	A path model revealed that intervention participation directly improved health (p<.05) at 12 months.	However, it is not clear whether psychological improvements are, in turn, related to improved health.
__label__noRel	A path model revealed that intervention participation directly improved health (p<.05) at 12 months.	These effects remained when statistically controlling for baseline levels of distress, immunity, and health as well as sociodemographic, disease, and cancer treatment variables.
__label__noRel	A path model revealed that intervention participation directly improved health (p<.05) at 12 months.	Regarding the mechanisms for achieving better health, support was found for an indirect effect of distress reduction.
__label__noRel	A path model revealed that intervention participation directly improved health (p<.05) at 12 months.	That is, by specifically lowering intervention patients' distress at 4 months, their health was improved at 12 months (p<.05).
__label__noRel	A path model revealed that intervention participation directly improved health (p<.05) at 12 months.	Although the intervention simultaneously improved patients' T-cell blastogenesis in response to phytohemagglutinin (PHA),
__label__noRel	A path model revealed that intervention participation directly improved health (p<.05) at 12 months.	the latter increases were unrelated to improved health.
__label__noRel	A path model revealed that intervention participation directly improved health (p<.05) at 12 months.	A convergence of biobehavioral effects and health improvements were observed.
__label__noRel	A path model revealed that intervention participation directly improved health (p<.05) at 12 months.	Behavioral change, rather than immunity change, was influential in achieving lower levels of symptomatology and higher functional status.
__label__Support	A path model revealed that intervention participation directly improved health (p<.05) at 12 months.	Distress reduction is highlighted as an important mechanism by which health can be improved.
__label__noRel	These effects remained when statistically controlling for baseline levels of distress, immunity, and health as well as sociodemographic, disease, and cancer treatment variables.	Psychological interventions are efficacious in reducing emotional distress for cancer patients.
__label__noRel	These effects remained when statistically controlling for baseline levels of distress, immunity, and health as well as sociodemographic, disease, and cancer treatment variables.	However, it is not clear whether psychological improvements are, in turn, related to improved health.
__label__Support	These effects remained when statistically controlling for baseline levels of distress, immunity, and health as well as sociodemographic, disease, and cancer treatment variables.	A path model revealed that intervention participation directly improved health (p<.05) at 12 months.
__label__noRel	These effects remained when statistically controlling for baseline levels of distress, immunity, and health as well as sociodemographic, disease, and cancer treatment variables.	Regarding the mechanisms for achieving better health, support was found for an indirect effect of distress reduction.
__label__noRel	These effects remained when statistically controlling for baseline levels of distress, immunity, and health as well as sociodemographic, disease, and cancer treatment variables.	That is, by specifically lowering intervention patients' distress at 4 months, their health was improved at 12 months (p<.05).
__label__noRel	These effects remained when statistically controlling for baseline levels of distress, immunity, and health as well as sociodemographic, disease, and cancer treatment variables.	Although the intervention simultaneously improved patients' T-cell blastogenesis in response to phytohemagglutinin (PHA),
__label__noRel	These effects remained when statistically controlling for baseline levels of distress, immunity, and health as well as sociodemographic, disease, and cancer treatment variables.	the latter increases were unrelated to improved health.
__label__noRel	These effects remained when statistically controlling for baseline levels of distress, immunity, and health as well as sociodemographic, disease, and cancer treatment variables.	A convergence of biobehavioral effects and health improvements were observed.
__label__noRel	These effects remained when statistically controlling for baseline levels of distress, immunity, and health as well as sociodemographic, disease, and cancer treatment variables.	Behavioral change, rather than immunity change, was influential in achieving lower levels of symptomatology and higher functional status.
__label__noRel	These effects remained when statistically controlling for baseline levels of distress, immunity, and health as well as sociodemographic, disease, and cancer treatment variables.	Distress reduction is highlighted as an important mechanism by which health can be improved.
__label__noRel	Regarding the mechanisms for achieving better health, support was found for an indirect effect of distress reduction.	Psychological interventions are efficacious in reducing emotional distress for cancer patients.
__label__noRel	Regarding the mechanisms for achieving better health, support was found for an indirect effect of distress reduction.	However, it is not clear whether psychological improvements are, in turn, related to improved health.
__label__noRel	Regarding the mechanisms for achieving better health, support was found for an indirect effect of distress reduction.	A path model revealed that intervention participation directly improved health (p<.05) at 12 months.
__label__noRel	Regarding the mechanisms for achieving better health, support was found for an indirect effect of distress reduction.	These effects remained when statistically controlling for baseline levels of distress, immunity, and health as well as sociodemographic, disease, and cancer treatment variables.
__label__noRel	Regarding the mechanisms for achieving better health, support was found for an indirect effect of distress reduction.	That is, by specifically lowering intervention patients' distress at 4 months, their health was improved at 12 months (p<.05).
__label__noRel	Regarding the mechanisms for achieving better health, support was found for an indirect effect of distress reduction.	Although the intervention simultaneously improved patients' T-cell blastogenesis in response to phytohemagglutinin (PHA),
__label__noRel	Regarding the mechanisms for achieving better health, support was found for an indirect effect of distress reduction.	the latter increases were unrelated to improved health.
__label__noRel	Regarding the mechanisms for achieving better health, support was found for an indirect effect of distress reduction.	A convergence of biobehavioral effects and health improvements were observed.
__label__noRel	Regarding the mechanisms for achieving better health, support was found for an indirect effect of distress reduction.	Behavioral change, rather than immunity change, was influential in achieving lower levels of symptomatology and higher functional status.
__label__Support	Regarding the mechanisms for achieving better health, support was found for an indirect effect of distress reduction.	Distress reduction is highlighted as an important mechanism by which health can be improved.
__label__noRel	That is, by specifically lowering intervention patients' distress at 4 months, their health was improved at 12 months (p<.05).	Psychological interventions are efficacious in reducing emotional distress for cancer patients.
__label__noRel	That is, by specifically lowering intervention patients' distress at 4 months, their health was improved at 12 months (p<.05).	However, it is not clear whether psychological improvements are, in turn, related to improved health.
__label__noRel	That is, by specifically lowering intervention patients' distress at 4 months, their health was improved at 12 months (p<.05).	A path model revealed that intervention participation directly improved health (p<.05) at 12 months.
__label__noRel	That is, by specifically lowering intervention patients' distress at 4 months, their health was improved at 12 months (p<.05).	These effects remained when statistically controlling for baseline levels of distress, immunity, and health as well as sociodemographic, disease, and cancer treatment variables.
__label__noRel	That is, by specifically lowering intervention patients' distress at 4 months, their health was improved at 12 months (p<.05).	Regarding the mechanisms for achieving better health, support was found for an indirect effect of distress reduction.
__label__noRel	That is, by specifically lowering intervention patients' distress at 4 months, their health was improved at 12 months (p<.05).	Although the intervention simultaneously improved patients' T-cell blastogenesis in response to phytohemagglutinin (PHA),
__label__noRel	That is, by specifically lowering intervention patients' distress at 4 months, their health was improved at 12 months (p<.05).	the latter increases were unrelated to improved health.
__label__noRel	That is, by specifically lowering intervention patients' distress at 4 months, their health was improved at 12 months (p<.05).	A convergence of biobehavioral effects and health improvements were observed.
__label__noRel	That is, by specifically lowering intervention patients' distress at 4 months, their health was improved at 12 months (p<.05).	Behavioral change, rather than immunity change, was influential in achieving lower levels of symptomatology and higher functional status.
__label__Support	That is, by specifically lowering intervention patients' distress at 4 months, their health was improved at 12 months (p<.05).	Distress reduction is highlighted as an important mechanism by which health can be improved.
__label__noRel	Although the intervention simultaneously improved patients' T-cell blastogenesis in response to phytohemagglutinin (PHA),	Psychological interventions are efficacious in reducing emotional distress for cancer patients.
__label__noRel	Although the intervention simultaneously improved patients' T-cell blastogenesis in response to phytohemagglutinin (PHA),	However, it is not clear whether psychological improvements are, in turn, related to improved health.
__label__noRel	Although the intervention simultaneously improved patients' T-cell blastogenesis in response to phytohemagglutinin (PHA),	A path model revealed that intervention participation directly improved health (p<.05) at 12 months.
__label__noRel	Although the intervention simultaneously improved patients' T-cell blastogenesis in response to phytohemagglutinin (PHA),	These effects remained when statistically controlling for baseline levels of distress, immunity, and health as well as sociodemographic, disease, and cancer treatment variables.
__label__noRel	Although the intervention simultaneously improved patients' T-cell blastogenesis in response to phytohemagglutinin (PHA),	Regarding the mechanisms for achieving better health, support was found for an indirect effect of distress reduction.
__label__noRel	Although the intervention simultaneously improved patients' T-cell blastogenesis in response to phytohemagglutinin (PHA),	That is, by specifically lowering intervention patients' distress at 4 months, their health was improved at 12 months (p<.05).
__label__noRel	Although the intervention simultaneously improved patients' T-cell blastogenesis in response to phytohemagglutinin (PHA),	the latter increases were unrelated to improved health.
__label__noRel	Although the intervention simultaneously improved patients' T-cell blastogenesis in response to phytohemagglutinin (PHA),	A convergence of biobehavioral effects and health improvements were observed.
__label__noRel	Although the intervention simultaneously improved patients' T-cell blastogenesis in response to phytohemagglutinin (PHA),	Behavioral change, rather than immunity change, was influential in achieving lower levels of symptomatology and higher functional status.
__label__noRel	Although the intervention simultaneously improved patients' T-cell blastogenesis in response to phytohemagglutinin (PHA),	Distress reduction is highlighted as an important mechanism by which health can be improved.
__label__noRel	the latter increases were unrelated to improved health.	Psychological interventions are efficacious in reducing emotional distress for cancer patients.
__label__noRel	the latter increases were unrelated to improved health.	However, it is not clear whether psychological improvements are, in turn, related to improved health.
__label__noRel	the latter increases were unrelated to improved health.	A path model revealed that intervention participation directly improved health (p<.05) at 12 months.
__label__noRel	the latter increases were unrelated to improved health.	These effects remained when statistically controlling for baseline levels of distress, immunity, and health as well as sociodemographic, disease, and cancer treatment variables.
__label__noRel	the latter increases were unrelated to improved health.	Regarding the mechanisms for achieving better health, support was found for an indirect effect of distress reduction.
__label__noRel	the latter increases were unrelated to improved health.	That is, by specifically lowering intervention patients' distress at 4 months, their health was improved at 12 months (p<.05).
__label__Attack	the latter increases were unrelated to improved health.	Although the intervention simultaneously improved patients' T-cell blastogenesis in response to phytohemagglutinin (PHA),
__label__noRel	the latter increases were unrelated to improved health.	A convergence of biobehavioral effects and health improvements were observed.
__label__noRel	the latter increases were unrelated to improved health.	Behavioral change, rather than immunity change, was influential in achieving lower levels of symptomatology and higher functional status.
__label__noRel	the latter increases were unrelated to improved health.	Distress reduction is highlighted as an important mechanism by which health can be improved.
__label__noRel	A convergence of biobehavioral effects and health improvements were observed.	Psychological interventions are efficacious in reducing emotional distress for cancer patients.
__label__noRel	A convergence of biobehavioral effects and health improvements were observed.	However, it is not clear whether psychological improvements are, in turn, related to improved health.
__label__noRel	A convergence of biobehavioral effects and health improvements were observed.	A path model revealed that intervention participation directly improved health (p<.05) at 12 months.
__label__noRel	A convergence of biobehavioral effects and health improvements were observed.	These effects remained when statistically controlling for baseline levels of distress, immunity, and health as well as sociodemographic, disease, and cancer treatment variables.
__label__noRel	A convergence of biobehavioral effects and health improvements were observed.	Regarding the mechanisms for achieving better health, support was found for an indirect effect of distress reduction.
__label__noRel	A convergence of biobehavioral effects and health improvements were observed.	That is, by specifically lowering intervention patients' distress at 4 months, their health was improved at 12 months (p<.05).
__label__noRel	A convergence of biobehavioral effects and health improvements were observed.	Although the intervention simultaneously improved patients' T-cell blastogenesis in response to phytohemagglutinin (PHA),
__label__noRel	A convergence of biobehavioral effects and health improvements were observed.	the latter increases were unrelated to improved health.
__label__noRel	A convergence of biobehavioral effects and health improvements were observed.	Behavioral change, rather than immunity change, was influential in achieving lower levels of symptomatology and higher functional status.
__label__Support	A convergence of biobehavioral effects and health improvements were observed.	Distress reduction is highlighted as an important mechanism by which health can be improved.
__label__noRel	Behavioral change, rather than immunity change, was influential in achieving lower levels of symptomatology and higher functional status.	Psychological interventions are efficacious in reducing emotional distress for cancer patients.
__label__noRel	Behavioral change, rather than immunity change, was influential in achieving lower levels of symptomatology and higher functional status.	However, it is not clear whether psychological improvements are, in turn, related to improved health.
__label__noRel	Behavioral change, rather than immunity change, was influential in achieving lower levels of symptomatology and higher functional status.	A path model revealed that intervention participation directly improved health (p<.05) at 12 months.
__label__noRel	Behavioral change, rather than immunity change, was influential in achieving lower levels of symptomatology and higher functional status.	These effects remained when statistically controlling for baseline levels of distress, immunity, and health as well as sociodemographic, disease, and cancer treatment variables.
__label__noRel	Behavioral change, rather than immunity change, was influential in achieving lower levels of symptomatology and higher functional status.	Regarding the mechanisms for achieving better health, support was found for an indirect effect of distress reduction.
__label__noRel	Behavioral change, rather than immunity change, was influential in achieving lower levels of symptomatology and higher functional status.	That is, by specifically lowering intervention patients' distress at 4 months, their health was improved at 12 months (p<.05).
__label__noRel	Behavioral change, rather than immunity change, was influential in achieving lower levels of symptomatology and higher functional status.	Although the intervention simultaneously improved patients' T-cell blastogenesis in response to phytohemagglutinin (PHA),
__label__noRel	Behavioral change, rather than immunity change, was influential in achieving lower levels of symptomatology and higher functional status.	the latter increases were unrelated to improved health.
__label__noRel	Behavioral change, rather than immunity change, was influential in achieving lower levels of symptomatology and higher functional status.	A convergence of biobehavioral effects and health improvements were observed.
__label__noRel	Behavioral change, rather than immunity change, was influential in achieving lower levels of symptomatology and higher functional status.	Distress reduction is highlighted as an important mechanism by which health can be improved.
__label__noRel	Distress reduction is highlighted as an important mechanism by which health can be improved.	Psychological interventions are efficacious in reducing emotional distress for cancer patients.
__label__Attack	Distress reduction is highlighted as an important mechanism by which health can be improved.	However, it is not clear whether psychological improvements are, in turn, related to improved health.
__label__noRel	Distress reduction is highlighted as an important mechanism by which health can be improved.	A path model revealed that intervention participation directly improved health (p<.05) at 12 months.
__label__noRel	Distress reduction is highlighted as an important mechanism by which health can be improved.	These effects remained when statistically controlling for baseline levels of distress, immunity, and health as well as sociodemographic, disease, and cancer treatment variables.
__label__noRel	Distress reduction is highlighted as an important mechanism by which health can be improved.	Regarding the mechanisms for achieving better health, support was found for an indirect effect of distress reduction.
__label__noRel	Distress reduction is highlighted as an important mechanism by which health can be improved.	That is, by specifically lowering intervention patients' distress at 4 months, their health was improved at 12 months (p<.05).
__label__noRel	Distress reduction is highlighted as an important mechanism by which health can be improved.	Although the intervention simultaneously improved patients' T-cell blastogenesis in response to phytohemagglutinin (PHA),
__label__noRel	Distress reduction is highlighted as an important mechanism by which health can be improved.	the latter increases were unrelated to improved health.
__label__noRel	Distress reduction is highlighted as an important mechanism by which health can be improved.	A convergence of biobehavioral effects and health improvements were observed.
__label__noRel	Distress reduction is highlighted as an important mechanism by which health can be improved.	Behavioral change, rather than immunity change, was influential in achieving lower levels of symptomatology and higher functional status.
__label__noRel	There was a significant difference in mean dysphagia grade between treatment arms 6 weeks following treatment (P=0.046), with worse swallowing reported by rigid stent-treated patients (mean dysphagia score difference=-0.49; 95% confidence interval (CI) -0.10 to -0.89, P=0.014).	Global QL scores were lower at both 1 and 6 weeks following treatment for patients treated by SEMSs (mean difference QL index week 1=-0.66; 95% CI: -0.02 to -1.30, P=0.04; mean difference QL index week 6=-1.01; 95% CI -0.30 to -1.72, P=0.006).
__label__noRel	There was a significant difference in mean dysphagia grade between treatment arms 6 weeks following treatment (P=0.046), with worse swallowing reported by rigid stent-treated patients (mean dysphagia score difference=-0.49; 95% confidence interval (CI) -0.10 to -0.89, P=0.014).	These findings were associated with higher post-procedure pain scores in the SEMS patient group (mean difference of the European Organisation for Research and Treatment of Cancer QLQ C-30 pain symptom score at week 1=11.13; 95% CI: 2.89-19.4; P=0.01).
__label__noRel	There was a significant difference in mean dysphagia grade between treatment arms 6 weeks following treatment (P=0.046), with worse swallowing reported by rigid stent-treated patients (mean dysphagia score difference=-0.49; 95% confidence interval (CI) -0.10 to -0.89, P=0.014).	Although mean EQ-5D QL values differed between the treatments (P<0.001), this difference dissipated following generation of quality-adjusted life year values.
__label__noRel	There was a significant difference in mean dysphagia grade between treatment arms 6 weeks following treatment (P=0.046), with worse swallowing reported by rigid stent-treated patients (mean dysphagia score difference=-0.49; 95% confidence interval (CI) -0.10 to -0.89, P=0.014).	There were no differences in the in-hospital mortality or early complication rates,
__label__noRel	There was a significant difference in mean dysphagia grade between treatment arms 6 weeks following treatment (P=0.046), with worse swallowing reported by rigid stent-treated patients (mean dysphagia score difference=-0.49; 95% confidence interval (CI) -0.10 to -0.89, P=0.014).	but late complications were more frequent after rigid stenting (risk ratio=2.47; 95% CI 1.88-3.04).
__label__noRel	There was a significant difference in mean dysphagia grade between treatment arms 6 weeks following treatment (P=0.046), with worse swallowing reported by rigid stent-treated patients (mean dysphagia score difference=-0.49; 95% confidence interval (CI) -0.10 to -0.89, P=0.014).	There was a survival advantage for non-stent-treated patients (log-rank statistic=4.21, P=0.04).
__label__noRel	There was a significant difference in mean dysphagia grade between treatment arms 6 weeks following treatment (P=0.046), with worse swallowing reported by rigid stent-treated patients (mean dysphagia score difference=-0.49; 95% confidence interval (CI) -0.10 to -0.89, P=0.014).	The treatment choice for patients with inoperable esophageal cancer should be between a SEMS or a non-stent treatment after consideration has been given to both patient and tumor characteristics and clinician and patient preferences.
__label__noRel	Global QL scores were lower at both 1 and 6 weeks following treatment for patients treated by SEMSs (mean difference QL index week 1=-0.66; 95% CI: -0.02 to -1.30, P=0.04; mean difference QL index week 6=-1.01; 95% CI -0.30 to -1.72, P=0.006).	There was a significant difference in mean dysphagia grade between treatment arms 6 weeks following treatment (P=0.046), with worse swallowing reported by rigid stent-treated patients (mean dysphagia score difference=-0.49; 95% confidence interval (CI) -0.10 to -0.89, P=0.014).
__label__noRel	Global QL scores were lower at both 1 and 6 weeks following treatment for patients treated by SEMSs (mean difference QL index week 1=-0.66; 95% CI: -0.02 to -1.30, P=0.04; mean difference QL index week 6=-1.01; 95% CI -0.30 to -1.72, P=0.006).	These findings were associated with higher post-procedure pain scores in the SEMS patient group (mean difference of the European Organisation for Research and Treatment of Cancer QLQ C-30 pain symptom score at week 1=11.13; 95% CI: 2.89-19.4; P=0.01).
__label__noRel	Global QL scores were lower at both 1 and 6 weeks following treatment for patients treated by SEMSs (mean difference QL index week 1=-0.66; 95% CI: -0.02 to -1.30, P=0.04; mean difference QL index week 6=-1.01; 95% CI -0.30 to -1.72, P=0.006).	Although mean EQ-5D QL values differed between the treatments (P<0.001), this difference dissipated following generation of quality-adjusted life year values.
__label__noRel	Global QL scores were lower at both 1 and 6 weeks following treatment for patients treated by SEMSs (mean difference QL index week 1=-0.66; 95% CI: -0.02 to -1.30, P=0.04; mean difference QL index week 6=-1.01; 95% CI -0.30 to -1.72, P=0.006).	There were no differences in the in-hospital mortality or early complication rates,
__label__noRel	Global QL scores were lower at both 1 and 6 weeks following treatment for patients treated by SEMSs (mean difference QL index week 1=-0.66; 95% CI: -0.02 to -1.30, P=0.04; mean difference QL index week 6=-1.01; 95% CI -0.30 to -1.72, P=0.006).	but late complications were more frequent after rigid stenting (risk ratio=2.47; 95% CI 1.88-3.04).
__label__noRel	Global QL scores were lower at both 1 and 6 weeks following treatment for patients treated by SEMSs (mean difference QL index week 1=-0.66; 95% CI: -0.02 to -1.30, P=0.04; mean difference QL index week 6=-1.01; 95% CI -0.30 to -1.72, P=0.006).	There was a survival advantage for non-stent-treated patients (log-rank statistic=4.21, P=0.04).
__label__noRel	Global QL scores were lower at both 1 and 6 weeks following treatment for patients treated by SEMSs (mean difference QL index week 1=-0.66; 95% CI: -0.02 to -1.30, P=0.04; mean difference QL index week 6=-1.01; 95% CI -0.30 to -1.72, P=0.006).	The treatment choice for patients with inoperable esophageal cancer should be between a SEMS or a non-stent treatment after consideration has been given to both patient and tumor characteristics and clinician and patient preferences.
__label__noRel	These findings were associated with higher post-procedure pain scores in the SEMS patient group (mean difference of the European Organisation for Research and Treatment of Cancer QLQ C-30 pain symptom score at week 1=11.13; 95% CI: 2.89-19.4; P=0.01).	There was a significant difference in mean dysphagia grade between treatment arms 6 weeks following treatment (P=0.046), with worse swallowing reported by rigid stent-treated patients (mean dysphagia score difference=-0.49; 95% confidence interval (CI) -0.10 to -0.89, P=0.014).
__label__noRel	These findings were associated with higher post-procedure pain scores in the SEMS patient group (mean difference of the European Organisation for Research and Treatment of Cancer QLQ C-30 pain symptom score at week 1=11.13; 95% CI: 2.89-19.4; P=0.01).	Global QL scores were lower at both 1 and 6 weeks following treatment for patients treated by SEMSs (mean difference QL index week 1=-0.66; 95% CI: -0.02 to -1.30, P=0.04; mean difference QL index week 6=-1.01; 95% CI -0.30 to -1.72, P=0.006).
__label__noRel	These findings were associated with higher post-procedure pain scores in the SEMS patient group (mean difference of the European Organisation for Research and Treatment of Cancer QLQ C-30 pain symptom score at week 1=11.13; 95% CI: 2.89-19.4; P=0.01).	Although mean EQ-5D QL values differed between the treatments (P<0.001), this difference dissipated following generation of quality-adjusted life year values.
__label__noRel	These findings were associated with higher post-procedure pain scores in the SEMS patient group (mean difference of the European Organisation for Research and Treatment of Cancer QLQ C-30 pain symptom score at week 1=11.13; 95% CI: 2.89-19.4; P=0.01).	There were no differences in the in-hospital mortality or early complication rates,
__label__noRel	These findings were associated with higher post-procedure pain scores in the SEMS patient group (mean difference of the European Organisation for Research and Treatment of Cancer QLQ C-30 pain symptom score at week 1=11.13; 95% CI: 2.89-19.4; P=0.01).	but late complications were more frequent after rigid stenting (risk ratio=2.47; 95% CI 1.88-3.04).
__label__noRel	These findings were associated with higher post-procedure pain scores in the SEMS patient group (mean difference of the European Organisation for Research and Treatment of Cancer QLQ C-30 pain symptom score at week 1=11.13; 95% CI: 2.89-19.4; P=0.01).	There was a survival advantage for non-stent-treated patients (log-rank statistic=4.21, P=0.04).
__label__noRel	These findings were associated with higher post-procedure pain scores in the SEMS patient group (mean difference of the European Organisation for Research and Treatment of Cancer QLQ C-30 pain symptom score at week 1=11.13; 95% CI: 2.89-19.4; P=0.01).	The treatment choice for patients with inoperable esophageal cancer should be between a SEMS or a non-stent treatment after consideration has been given to both patient and tumor characteristics and clinician and patient preferences.
__label__noRel	Although mean EQ-5D QL values differed between the treatments (P<0.001), this difference dissipated following generation of quality-adjusted life year values.	There was a significant difference in mean dysphagia grade between treatment arms 6 weeks following treatment (P=0.046), with worse swallowing reported by rigid stent-treated patients (mean dysphagia score difference=-0.49; 95% confidence interval (CI) -0.10 to -0.89, P=0.014).
__label__noRel	Although mean EQ-5D QL values differed between the treatments (P<0.001), this difference dissipated following generation of quality-adjusted life year values.	Global QL scores were lower at both 1 and 6 weeks following treatment for patients treated by SEMSs (mean difference QL index week 1=-0.66; 95% CI: -0.02 to -1.30, P=0.04; mean difference QL index week 6=-1.01; 95% CI -0.30 to -1.72, P=0.006).
__label__noRel	Although mean EQ-5D QL values differed between the treatments (P<0.001), this difference dissipated following generation of quality-adjusted life year values.	These findings were associated with higher post-procedure pain scores in the SEMS patient group (mean difference of the European Organisation for Research and Treatment of Cancer QLQ C-30 pain symptom score at week 1=11.13; 95% CI: 2.89-19.4; P=0.01).
__label__noRel	Although mean EQ-5D QL values differed between the treatments (P<0.001), this difference dissipated following generation of quality-adjusted life year values.	There were no differences in the in-hospital mortality or early complication rates,
__label__noRel	Although mean EQ-5D QL values differed between the treatments (P<0.001), this difference dissipated following generation of quality-adjusted life year values.	but late complications were more frequent after rigid stenting (risk ratio=2.47; 95% CI 1.88-3.04).
__label__noRel	Although mean EQ-5D QL values differed between the treatments (P<0.001), this difference dissipated following generation of quality-adjusted life year values.	There was a survival advantage for non-stent-treated patients (log-rank statistic=4.21, P=0.04).
__label__noRel	Although mean EQ-5D QL values differed between the treatments (P<0.001), this difference dissipated following generation of quality-adjusted life year values.	The treatment choice for patients with inoperable esophageal cancer should be between a SEMS or a non-stent treatment after consideration has been given to both patient and tumor characteristics and clinician and patient preferences.
__label__noRel	There were no differences in the in-hospital mortality or early complication rates,	There was a significant difference in mean dysphagia grade between treatment arms 6 weeks following treatment (P=0.046), with worse swallowing reported by rigid stent-treated patients (mean dysphagia score difference=-0.49; 95% confidence interval (CI) -0.10 to -0.89, P=0.014).
__label__noRel	There were no differences in the in-hospital mortality or early complication rates,	Global QL scores were lower at both 1 and 6 weeks following treatment for patients treated by SEMSs (mean difference QL index week 1=-0.66; 95% CI: -0.02 to -1.30, P=0.04; mean difference QL index week 6=-1.01; 95% CI -0.30 to -1.72, P=0.006).
__label__noRel	There were no differences in the in-hospital mortality or early complication rates,	These findings were associated with higher post-procedure pain scores in the SEMS patient group (mean difference of the European Organisation for Research and Treatment of Cancer QLQ C-30 pain symptom score at week 1=11.13; 95% CI: 2.89-19.4; P=0.01).
__label__noRel	There were no differences in the in-hospital mortality or early complication rates,	Although mean EQ-5D QL values differed between the treatments (P<0.001), this difference dissipated following generation of quality-adjusted life year values.
__label__noRel	There were no differences in the in-hospital mortality or early complication rates,	but late complications were more frequent after rigid stenting (risk ratio=2.47; 95% CI 1.88-3.04).
__label__noRel	There were no differences in the in-hospital mortality or early complication rates,	There was a survival advantage for non-stent-treated patients (log-rank statistic=4.21, P=0.04).
__label__noRel	There were no differences in the in-hospital mortality or early complication rates,	The treatment choice for patients with inoperable esophageal cancer should be between a SEMS or a non-stent treatment after consideration has been given to both patient and tumor characteristics and clinician and patient preferences.
__label__noRel	but late complications were more frequent after rigid stenting (risk ratio=2.47; 95% CI 1.88-3.04).	There was a significant difference in mean dysphagia grade between treatment arms 6 weeks following treatment (P=0.046), with worse swallowing reported by rigid stent-treated patients (mean dysphagia score difference=-0.49; 95% confidence interval (CI) -0.10 to -0.89, P=0.014).
__label__noRel	but late complications were more frequent after rigid stenting (risk ratio=2.47; 95% CI 1.88-3.04).	Global QL scores were lower at both 1 and 6 weeks following treatment for patients treated by SEMSs (mean difference QL index week 1=-0.66; 95% CI: -0.02 to -1.30, P=0.04; mean difference QL index week 6=-1.01; 95% CI -0.30 to -1.72, P=0.006).
__label__noRel	but late complications were more frequent after rigid stenting (risk ratio=2.47; 95% CI 1.88-3.04).	These findings were associated with higher post-procedure pain scores in the SEMS patient group (mean difference of the European Organisation for Research and Treatment of Cancer QLQ C-30 pain symptom score at week 1=11.13; 95% CI: 2.89-19.4; P=0.01).
__label__noRel	but late complications were more frequent after rigid stenting (risk ratio=2.47; 95% CI 1.88-3.04).	Although mean EQ-5D QL values differed between the treatments (P<0.001), this difference dissipated following generation of quality-adjusted life year values.
__label__Attack	but late complications were more frequent after rigid stenting (risk ratio=2.47; 95% CI 1.88-3.04).	There were no differences in the in-hospital mortality or early complication rates,
__label__noRel	but late complications were more frequent after rigid stenting (risk ratio=2.47; 95% CI 1.88-3.04).	There was a survival advantage for non-stent-treated patients (log-rank statistic=4.21, P=0.04).
__label__noRel	but late complications were more frequent after rigid stenting (risk ratio=2.47; 95% CI 1.88-3.04).	The treatment choice for patients with inoperable esophageal cancer should be between a SEMS or a non-stent treatment after consideration has been given to both patient and tumor characteristics and clinician and patient preferences.
__label__noRel	There was a survival advantage for non-stent-treated patients (log-rank statistic=4.21, P=0.04).	There was a significant difference in mean dysphagia grade between treatment arms 6 weeks following treatment (P=0.046), with worse swallowing reported by rigid stent-treated patients (mean dysphagia score difference=-0.49; 95% confidence interval (CI) -0.10 to -0.89, P=0.014).
__label__noRel	There was a survival advantage for non-stent-treated patients (log-rank statistic=4.21, P=0.04).	Global QL scores were lower at both 1 and 6 weeks following treatment for patients treated by SEMSs (mean difference QL index week 1=-0.66; 95% CI: -0.02 to -1.30, P=0.04; mean difference QL index week 6=-1.01; 95% CI -0.30 to -1.72, P=0.006).
__label__noRel	There was a survival advantage for non-stent-treated patients (log-rank statistic=4.21, P=0.04).	These findings were associated with higher post-procedure pain scores in the SEMS patient group (mean difference of the European Organisation for Research and Treatment of Cancer QLQ C-30 pain symptom score at week 1=11.13; 95% CI: 2.89-19.4; P=0.01).
__label__noRel	There was a survival advantage for non-stent-treated patients (log-rank statistic=4.21, P=0.04).	Although mean EQ-5D QL values differed between the treatments (P<0.001), this difference dissipated following generation of quality-adjusted life year values.
__label__noRel	There was a survival advantage for non-stent-treated patients (log-rank statistic=4.21, P=0.04).	There were no differences in the in-hospital mortality or early complication rates,
__label__noRel	There was a survival advantage for non-stent-treated patients (log-rank statistic=4.21, P=0.04).	but late complications were more frequent after rigid stenting (risk ratio=2.47; 95% CI 1.88-3.04).
__label__noRel	There was a survival advantage for non-stent-treated patients (log-rank statistic=4.21, P=0.04).	The treatment choice for patients with inoperable esophageal cancer should be between a SEMS or a non-stent treatment after consideration has been given to both patient and tumor characteristics and clinician and patient preferences.
__label__noRel	The treatment choice for patients with inoperable esophageal cancer should be between a SEMS or a non-stent treatment after consideration has been given to both patient and tumor characteristics and clinician and patient preferences.	There was a significant difference in mean dysphagia grade between treatment arms 6 weeks following treatment (P=0.046), with worse swallowing reported by rigid stent-treated patients (mean dysphagia score difference=-0.49; 95% confidence interval (CI) -0.10 to -0.89, P=0.014).
__label__noRel	The treatment choice for patients with inoperable esophageal cancer should be between a SEMS or a non-stent treatment after consideration has been given to both patient and tumor characteristics and clinician and patient preferences.	Global QL scores were lower at both 1 and 6 weeks following treatment for patients treated by SEMSs (mean difference QL index week 1=-0.66; 95% CI: -0.02 to -1.30, P=0.04; mean difference QL index week 6=-1.01; 95% CI -0.30 to -1.72, P=0.006).
__label__noRel	The treatment choice for patients with inoperable esophageal cancer should be between a SEMS or a non-stent treatment after consideration has been given to both patient and tumor characteristics and clinician and patient preferences.	These findings were associated with higher post-procedure pain scores in the SEMS patient group (mean difference of the European Organisation for Research and Treatment of Cancer QLQ C-30 pain symptom score at week 1=11.13; 95% CI: 2.89-19.4; P=0.01).
__label__noRel	The treatment choice for patients with inoperable esophageal cancer should be between a SEMS or a non-stent treatment after consideration has been given to both patient and tumor characteristics and clinician and patient preferences.	Although mean EQ-5D QL values differed between the treatments (P<0.001), this difference dissipated following generation of quality-adjusted life year values.
__label__noRel	The treatment choice for patients with inoperable esophageal cancer should be between a SEMS or a non-stent treatment after consideration has been given to both patient and tumor characteristics and clinician and patient preferences.	There were no differences in the in-hospital mortality or early complication rates,
__label__noRel	The treatment choice for patients with inoperable esophageal cancer should be between a SEMS or a non-stent treatment after consideration has been given to both patient and tumor characteristics and clinician and patient preferences.	but late complications were more frequent after rigid stenting (risk ratio=2.47; 95% CI 1.88-3.04).
__label__noRel	The treatment choice for patients with inoperable esophageal cancer should be between a SEMS or a non-stent treatment after consideration has been given to both patient and tumor characteristics and clinician and patient preferences.	There was a survival advantage for non-stent-treated patients (log-rank statistic=4.21, P=0.04).
__label__noRel	Forty-six patients (88%) were in disease remission 12 months after radiotherapy.	At 12 months postradiotherapy, 12 (50.0%) and 20 patients (83.3%) in the IMRT group had recovered at least 25% of preradiotherapy SWS and SPS flow respectively, compared with 1 (4.8%) and 2 patients (9.5%), respectively, in the CRT group.
__label__noRel	Forty-six patients (88%) were in disease remission 12 months after radiotherapy.	Global health scores showed continuous improvement in QoL after both treatments (p < 0.001).
__label__noRel	Forty-six patients (88%) were in disease remission 12 months after radiotherapy.	However, after 12 months subscale scores for role-physical, bodily pain, and physical function were significantly higher in the IMRT group, indicating a better condition (p < 0.05).
__label__noRel	Forty-six patients (88%) were in disease remission 12 months after radiotherapy.	Dry mouth and sticky saliva were problems in both groups 2 months after treatment.
__label__noRel	Forty-six patients (88%) were in disease remission 12 months after radiotherapy.	In the IMRT group, there was consistent improvement over time with xerostomia-related symptoms significantly less common than in the CRT group at 12 months postradiotherapy.
__label__noRel	Forty-six patients (88%) were in disease remission 12 months after radiotherapy.	IMRT was significantly better than CRT in terms of parotid sparing and improved QoL for early-stage disease.
__label__noRel	Forty-six patients (88%) were in disease remission 12 months after radiotherapy.	The findings support the case for assessment of health-related QoL in relation to head-and-neck cancer using a site-specific approach
__label__noRel	At 12 months postradiotherapy, 12 (50.0%) and 20 patients (83.3%) in the IMRT group had recovered at least 25% of preradiotherapy SWS and SPS flow respectively, compared with 1 (4.8%) and 2 patients (9.5%), respectively, in the CRT group.	Forty-six patients (88%) were in disease remission 12 months after radiotherapy.
__label__noRel	At 12 months postradiotherapy, 12 (50.0%) and 20 patients (83.3%) in the IMRT group had recovered at least 25% of preradiotherapy SWS and SPS flow respectively, compared with 1 (4.8%) and 2 patients (9.5%), respectively, in the CRT group.	Global health scores showed continuous improvement in QoL after both treatments (p < 0.001).
__label__noRel	At 12 months postradiotherapy, 12 (50.0%) and 20 patients (83.3%) in the IMRT group had recovered at least 25% of preradiotherapy SWS and SPS flow respectively, compared with 1 (4.8%) and 2 patients (9.5%), respectively, in the CRT group.	However, after 12 months subscale scores for role-physical, bodily pain, and physical function were significantly higher in the IMRT group, indicating a better condition (p < 0.05).
__label__noRel	At 12 months postradiotherapy, 12 (50.0%) and 20 patients (83.3%) in the IMRT group had recovered at least 25% of preradiotherapy SWS and SPS flow respectively, compared with 1 (4.8%) and 2 patients (9.5%), respectively, in the CRT group.	Dry mouth and sticky saliva were problems in both groups 2 months after treatment.
__label__noRel	At 12 months postradiotherapy, 12 (50.0%) and 20 patients (83.3%) in the IMRT group had recovered at least 25% of preradiotherapy SWS and SPS flow respectively, compared with 1 (4.8%) and 2 patients (9.5%), respectively, in the CRT group.	In the IMRT group, there was consistent improvement over time with xerostomia-related symptoms significantly less common than in the CRT group at 12 months postradiotherapy.
__label__Support	At 12 months postradiotherapy, 12 (50.0%) and 20 patients (83.3%) in the IMRT group had recovered at least 25% of preradiotherapy SWS and SPS flow respectively, compared with 1 (4.8%) and 2 patients (9.5%), respectively, in the CRT group.	IMRT was significantly better than CRT in terms of parotid sparing and improved QoL for early-stage disease.
__label__noRel	At 12 months postradiotherapy, 12 (50.0%) and 20 patients (83.3%) in the IMRT group had recovered at least 25% of preradiotherapy SWS and SPS flow respectively, compared with 1 (4.8%) and 2 patients (9.5%), respectively, in the CRT group.	The findings support the case for assessment of health-related QoL in relation to head-and-neck cancer using a site-specific approach
__label__noRel	Global health scores showed continuous improvement in QoL after both treatments (p < 0.001).	Forty-six patients (88%) were in disease remission 12 months after radiotherapy.
__label__noRel	Global health scores showed continuous improvement in QoL after both treatments (p < 0.001).	At 12 months postradiotherapy, 12 (50.0%) and 20 patients (83.3%) in the IMRT group had recovered at least 25% of preradiotherapy SWS and SPS flow respectively, compared with 1 (4.8%) and 2 patients (9.5%), respectively, in the CRT group.
__label__noRel	Global health scores showed continuous improvement in QoL after both treatments (p < 0.001).	However, after 12 months subscale scores for role-physical, bodily pain, and physical function were significantly higher in the IMRT group, indicating a better condition (p < 0.05).
__label__noRel	Global health scores showed continuous improvement in QoL after both treatments (p < 0.001).	Dry mouth and sticky saliva were problems in both groups 2 months after treatment.
__label__noRel	Global health scores showed continuous improvement in QoL after both treatments (p < 0.001).	In the IMRT group, there was consistent improvement over time with xerostomia-related symptoms significantly less common than in the CRT group at 12 months postradiotherapy.
__label__Support	Global health scores showed continuous improvement in QoL after both treatments (p < 0.001).	IMRT was significantly better than CRT in terms of parotid sparing and improved QoL for early-stage disease.
__label__noRel	Global health scores showed continuous improvement in QoL after both treatments (p < 0.001).	The findings support the case for assessment of health-related QoL in relation to head-and-neck cancer using a site-specific approach
__label__noRel	However, after 12 months subscale scores for role-physical, bodily pain, and physical function were significantly higher in the IMRT group, indicating a better condition (p < 0.05).	Forty-six patients (88%) were in disease remission 12 months after radiotherapy.
__label__noRel	However, after 12 months subscale scores for role-physical, bodily pain, and physical function were significantly higher in the IMRT group, indicating a better condition (p < 0.05).	At 12 months postradiotherapy, 12 (50.0%) and 20 patients (83.3%) in the IMRT group had recovered at least 25% of preradiotherapy SWS and SPS flow respectively, compared with 1 (4.8%) and 2 patients (9.5%), respectively, in the CRT group.
__label__noRel	However, after 12 months subscale scores for role-physical, bodily pain, and physical function were significantly higher in the IMRT group, indicating a better condition (p < 0.05).	Global health scores showed continuous improvement in QoL after both treatments (p < 0.001).
__label__noRel	However, after 12 months subscale scores for role-physical, bodily pain, and physical function were significantly higher in the IMRT group, indicating a better condition (p < 0.05).	Dry mouth and sticky saliva were problems in both groups 2 months after treatment.
__label__noRel	However, after 12 months subscale scores for role-physical, bodily pain, and physical function were significantly higher in the IMRT group, indicating a better condition (p < 0.05).	In the IMRT group, there was consistent improvement over time with xerostomia-related symptoms significantly less common than in the CRT group at 12 months postradiotherapy.
__label__Support	However, after 12 months subscale scores for role-physical, bodily pain, and physical function were significantly higher in the IMRT group, indicating a better condition (p < 0.05).	IMRT was significantly better than CRT in terms of parotid sparing and improved QoL for early-stage disease.
__label__noRel	However, after 12 months subscale scores for role-physical, bodily pain, and physical function were significantly higher in the IMRT group, indicating a better condition (p < 0.05).	The findings support the case for assessment of health-related QoL in relation to head-and-neck cancer using a site-specific approach
__label__noRel	Dry mouth and sticky saliva were problems in both groups 2 months after treatment.	Forty-six patients (88%) were in disease remission 12 months after radiotherapy.
__label__noRel	Dry mouth and sticky saliva were problems in both groups 2 months after treatment.	At 12 months postradiotherapy, 12 (50.0%) and 20 patients (83.3%) in the IMRT group had recovered at least 25% of preradiotherapy SWS and SPS flow respectively, compared with 1 (4.8%) and 2 patients (9.5%), respectively, in the CRT group.
__label__noRel	Dry mouth and sticky saliva were problems in both groups 2 months after treatment.	Global health scores showed continuous improvement in QoL after both treatments (p < 0.001).
__label__noRel	Dry mouth and sticky saliva were problems in both groups 2 months after treatment.	However, after 12 months subscale scores for role-physical, bodily pain, and physical function were significantly higher in the IMRT group, indicating a better condition (p < 0.05).
__label__noRel	Dry mouth and sticky saliva were problems in both groups 2 months after treatment.	In the IMRT group, there was consistent improvement over time with xerostomia-related symptoms significantly less common than in the CRT group at 12 months postradiotherapy.
__label__Support	Dry mouth and sticky saliva were problems in both groups 2 months after treatment.	IMRT was significantly better than CRT in terms of parotid sparing and improved QoL for early-stage disease.
__label__noRel	Dry mouth and sticky saliva were problems in both groups 2 months after treatment.	The findings support the case for assessment of health-related QoL in relation to head-and-neck cancer using a site-specific approach
__label__noRel	In the IMRT group, there was consistent improvement over time with xerostomia-related symptoms significantly less common than in the CRT group at 12 months postradiotherapy.	Forty-six patients (88%) were in disease remission 12 months after radiotherapy.
__label__noRel	In the IMRT group, there was consistent improvement over time with xerostomia-related symptoms significantly less common than in the CRT group at 12 months postradiotherapy.	At 12 months postradiotherapy, 12 (50.0%) and 20 patients (83.3%) in the IMRT group had recovered at least 25% of preradiotherapy SWS and SPS flow respectively, compared with 1 (4.8%) and 2 patients (9.5%), respectively, in the CRT group.
__label__noRel	In the IMRT group, there was consistent improvement over time with xerostomia-related symptoms significantly less common than in the CRT group at 12 months postradiotherapy.	Global health scores showed continuous improvement in QoL after both treatments (p < 0.001).
__label__noRel	In the IMRT group, there was consistent improvement over time with xerostomia-related symptoms significantly less common than in the CRT group at 12 months postradiotherapy.	However, after 12 months subscale scores for role-physical, bodily pain, and physical function were significantly higher in the IMRT group, indicating a better condition (p < 0.05).
__label__noRel	In the IMRT group, there was consistent improvement over time with xerostomia-related symptoms significantly less common than in the CRT group at 12 months postradiotherapy.	Dry mouth and sticky saliva were problems in both groups 2 months after treatment.
__label__Support	In the IMRT group, there was consistent improvement over time with xerostomia-related symptoms significantly less common than in the CRT group at 12 months postradiotherapy.	IMRT was significantly better than CRT in terms of parotid sparing and improved QoL for early-stage disease.
__label__noRel	In the IMRT group, there was consistent improvement over time with xerostomia-related symptoms significantly less common than in the CRT group at 12 months postradiotherapy.	The findings support the case for assessment of health-related QoL in relation to head-and-neck cancer using a site-specific approach
__label__noRel	IMRT was significantly better than CRT in terms of parotid sparing and improved QoL for early-stage disease.	Forty-six patients (88%) were in disease remission 12 months after radiotherapy.
__label__noRel	IMRT was significantly better than CRT in terms of parotid sparing and improved QoL for early-stage disease.	At 12 months postradiotherapy, 12 (50.0%) and 20 patients (83.3%) in the IMRT group had recovered at least 25% of preradiotherapy SWS and SPS flow respectively, compared with 1 (4.8%) and 2 patients (9.5%), respectively, in the CRT group.
__label__noRel	IMRT was significantly better than CRT in terms of parotid sparing and improved QoL for early-stage disease.	Global health scores showed continuous improvement in QoL after both treatments (p < 0.001).
__label__noRel	IMRT was significantly better than CRT in terms of parotid sparing and improved QoL for early-stage disease.	However, after 12 months subscale scores for role-physical, bodily pain, and physical function were significantly higher in the IMRT group, indicating a better condition (p < 0.05).
__label__noRel	IMRT was significantly better than CRT in terms of parotid sparing and improved QoL for early-stage disease.	Dry mouth and sticky saliva were problems in both groups 2 months after treatment.
__label__noRel	IMRT was significantly better than CRT in terms of parotid sparing and improved QoL for early-stage disease.	In the IMRT group, there was consistent improvement over time with xerostomia-related symptoms significantly less common than in the CRT group at 12 months postradiotherapy.
__label__Support	IMRT was significantly better than CRT in terms of parotid sparing and improved QoL for early-stage disease.	The findings support the case for assessment of health-related QoL in relation to head-and-neck cancer using a site-specific approach
__label__noRel	The findings support the case for assessment of health-related QoL in relation to head-and-neck cancer using a site-specific approach	Forty-six patients (88%) were in disease remission 12 months after radiotherapy.
__label__noRel	The findings support the case for assessment of health-related QoL in relation to head-and-neck cancer using a site-specific approach	At 12 months postradiotherapy, 12 (50.0%) and 20 patients (83.3%) in the IMRT group had recovered at least 25% of preradiotherapy SWS and SPS flow respectively, compared with 1 (4.8%) and 2 patients (9.5%), respectively, in the CRT group.
__label__noRel	The findings support the case for assessment of health-related QoL in relation to head-and-neck cancer using a site-specific approach	Global health scores showed continuous improvement in QoL after both treatments (p < 0.001).
__label__noRel	The findings support the case for assessment of health-related QoL in relation to head-and-neck cancer using a site-specific approach	However, after 12 months subscale scores for role-physical, bodily pain, and physical function were significantly higher in the IMRT group, indicating a better condition (p < 0.05).
__label__noRel	The findings support the case for assessment of health-related QoL in relation to head-and-neck cancer using a site-specific approach	Dry mouth and sticky saliva were problems in both groups 2 months after treatment.
__label__noRel	The findings support the case for assessment of health-related QoL in relation to head-and-neck cancer using a site-specific approach	In the IMRT group, there was consistent improvement over time with xerostomia-related symptoms significantly less common than in the CRT group at 12 months postradiotherapy.
__label__noRel	The findings support the case for assessment of health-related QoL in relation to head-and-neck cancer using a site-specific approach	IMRT was significantly better than CRT in terms of parotid sparing and improved QoL for early-stage disease.
__label__noRel	During follow-up, 71% of the patients showed unaltered or improved lung expansion and 9 patients (15%) needed new pleural procedures (VATS group, 5 recurrences; TS group, 4 recurrences; p = 0.999).	No differences were found between groups regarding quality of life, complications, drainage time, hospital stay, and survival.
__label__noRel	During follow-up, 71% of the patients showed unaltered or improved lung expansion and 9 patients (15%) needed new pleural procedures (VATS group, 5 recurrences; TS group, 4 recurrences; p = 0.999).	Immediate lung expansion did not correlate with radiologic recurrence, clinical recurrence, or complications (p = 0.60, 0.15, and 0.20, respectively).
__label__noRel	During follow-up, 71% of the patients showed unaltered or improved lung expansion and 9 patients (15%) needed new pleural procedures (VATS group, 5 recurrences; TS group, 4 recurrences; p = 0.999).	Immediate partial lung expansion was a frequent finding and was more frequent after TS.
__label__noRel	During follow-up, 71% of the patients showed unaltered or improved lung expansion and 9 patients (15%) needed new pleural procedures (VATS group, 5 recurrences; TS group, 4 recurrences; p = 0.999).	no correlation between immediate lung expansion and clinical outcome was found in this study.
__label__noRel	No differences were found between groups regarding quality of life, complications, drainage time, hospital stay, and survival.	During follow-up, 71% of the patients showed unaltered or improved lung expansion and 9 patients (15%) needed new pleural procedures (VATS group, 5 recurrences; TS group, 4 recurrences; p = 0.999).
__label__noRel	No differences were found between groups regarding quality of life, complications, drainage time, hospital stay, and survival.	Immediate lung expansion did not correlate with radiologic recurrence, clinical recurrence, or complications (p = 0.60, 0.15, and 0.20, respectively).
__label__noRel	No differences were found between groups regarding quality of life, complications, drainage time, hospital stay, and survival.	Immediate partial lung expansion was a frequent finding and was more frequent after TS.
__label__noRel	No differences were found between groups regarding quality of life, complications, drainage time, hospital stay, and survival.	no correlation between immediate lung expansion and clinical outcome was found in this study.
__label__noRel	Immediate lung expansion did not correlate with radiologic recurrence, clinical recurrence, or complications (p = 0.60, 0.15, and 0.20, respectively).	During follow-up, 71% of the patients showed unaltered or improved lung expansion and 9 patients (15%) needed new pleural procedures (VATS group, 5 recurrences; TS group, 4 recurrences; p = 0.999).
__label__noRel	Immediate lung expansion did not correlate with radiologic recurrence, clinical recurrence, or complications (p = 0.60, 0.15, and 0.20, respectively).	No differences were found between groups regarding quality of life, complications, drainage time, hospital stay, and survival.
__label__noRel	Immediate lung expansion did not correlate with radiologic recurrence, clinical recurrence, or complications (p = 0.60, 0.15, and 0.20, respectively).	Immediate partial lung expansion was a frequent finding and was more frequent after TS.
__label__Support	Immediate lung expansion did not correlate with radiologic recurrence, clinical recurrence, or complications (p = 0.60, 0.15, and 0.20, respectively).	no correlation between immediate lung expansion and clinical outcome was found in this study.
__label__noRel	Immediate partial lung expansion was a frequent finding and was more frequent after TS.	During follow-up, 71% of the patients showed unaltered or improved lung expansion and 9 patients (15%) needed new pleural procedures (VATS group, 5 recurrences; TS group, 4 recurrences; p = 0.999).
__label__noRel	Immediate partial lung expansion was a frequent finding and was more frequent after TS.	No differences were found between groups regarding quality of life, complications, drainage time, hospital stay, and survival.
__label__noRel	Immediate partial lung expansion was a frequent finding and was more frequent after TS.	Immediate lung expansion did not correlate with radiologic recurrence, clinical recurrence, or complications (p = 0.60, 0.15, and 0.20, respectively).
__label__noRel	Immediate partial lung expansion was a frequent finding and was more frequent after TS.	no correlation between immediate lung expansion and clinical outcome was found in this study.
__label__noRel	no correlation between immediate lung expansion and clinical outcome was found in this study.	During follow-up, 71% of the patients showed unaltered or improved lung expansion and 9 patients (15%) needed new pleural procedures (VATS group, 5 recurrences; TS group, 4 recurrences; p = 0.999).
__label__noRel	no correlation between immediate lung expansion and clinical outcome was found in this study.	No differences were found between groups regarding quality of life, complications, drainage time, hospital stay, and survival.
__label__noRel	no correlation between immediate lung expansion and clinical outcome was found in this study.	Immediate lung expansion did not correlate with radiologic recurrence, clinical recurrence, or complications (p = 0.60, 0.15, and 0.20, respectively).
__label__noRel	no correlation between immediate lung expansion and clinical outcome was found in this study.	Immediate partial lung expansion was a frequent finding and was more frequent after TS.
__label__noRel	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.
__label__noRel	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).	Body weight and whole body fat declined similarly over time in all groups (P < .005),
__label__noRel	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).	lean body mass was unchanged during follow-up compared to preoperative values.
__label__noRel	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.
__label__noRel	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).	There was no difference in recovery of food intake among the groups.
__label__noRel	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).	Parenteral feeding was associated with the highest rate of nutrition-related complications,
__label__noRel	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).	enteral feeding reduced quality of life most extensively.
__label__Support	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.
__label__noRel	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).
__label__noRel	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.	Body weight and whole body fat declined similarly over time in all groups (P < .005),
__label__noRel	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.	lean body mass was unchanged during follow-up compared to preoperative values.
__label__noRel	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.
__label__noRel	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.	There was no difference in recovery of food intake among the groups.
__label__noRel	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.	Parenteral feeding was associated with the highest rate of nutrition-related complications,
__label__noRel	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.	enteral feeding reduced quality of life most extensively.
__label__Support	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.
__label__noRel	Body weight and whole body fat declined similarly over time in all groups (P < .005),	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).
__label__noRel	Body weight and whole body fat declined similarly over time in all groups (P < .005),	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.
__label__noRel	Body weight and whole body fat declined similarly over time in all groups (P < .005),	lean body mass was unchanged during follow-up compared to preoperative values.
__label__noRel	Body weight and whole body fat declined similarly over time in all groups (P < .005),	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.
__label__noRel	Body weight and whole body fat declined similarly over time in all groups (P < .005),	There was no difference in recovery of food intake among the groups.
__label__noRel	Body weight and whole body fat declined similarly over time in all groups (P < .005),	Parenteral feeding was associated with the highest rate of nutrition-related complications,
__label__noRel	Body weight and whole body fat declined similarly over time in all groups (P < .005),	enteral feeding reduced quality of life most extensively.
__label__Support	Body weight and whole body fat declined similarly over time in all groups (P < .005),	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.
__label__noRel	lean body mass was unchanged during follow-up compared to preoperative values.	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).
__label__noRel	lean body mass was unchanged during follow-up compared to preoperative values.	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.
__label__noRel	lean body mass was unchanged during follow-up compared to preoperative values.	Body weight and whole body fat declined similarly over time in all groups (P < .005),
__label__noRel	lean body mass was unchanged during follow-up compared to preoperative values.	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.
__label__noRel	lean body mass was unchanged during follow-up compared to preoperative values.	There was no difference in recovery of food intake among the groups.
__label__noRel	lean body mass was unchanged during follow-up compared to preoperative values.	Parenteral feeding was associated with the highest rate of nutrition-related complications,
__label__noRel	lean body mass was unchanged during follow-up compared to preoperative values.	enteral feeding reduced quality of life most extensively.
__label__Support	lean body mass was unchanged during follow-up compared to preoperative values.	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.
__label__noRel	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).
__label__noRel	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.
__label__noRel	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.	Body weight and whole body fat declined similarly over time in all groups (P < .005),
__label__noRel	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.	lean body mass was unchanged during follow-up compared to preoperative values.
__label__noRel	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.	There was no difference in recovery of food intake among the groups.
__label__noRel	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.	Parenteral feeding was associated with the highest rate of nutrition-related complications,
__label__noRel	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.	enteral feeding reduced quality of life most extensively.
__label__noRel	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.
__label__noRel	There was no difference in recovery of food intake among the groups.	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).
__label__noRel	There was no difference in recovery of food intake among the groups.	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.
__label__noRel	There was no difference in recovery of food intake among the groups.	Body weight and whole body fat declined similarly over time in all groups (P < .005),
__label__noRel	There was no difference in recovery of food intake among the groups.	lean body mass was unchanged during follow-up compared to preoperative values.
__label__noRel	There was no difference in recovery of food intake among the groups.	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.
__label__noRel	There was no difference in recovery of food intake among the groups.	Parenteral feeding was associated with the highest rate of nutrition-related complications,
__label__noRel	There was no difference in recovery of food intake among the groups.	enteral feeding reduced quality of life most extensively.
__label__Support	There was no difference in recovery of food intake among the groups.	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.
__label__noRel	Parenteral feeding was associated with the highest rate of nutrition-related complications,	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).
__label__noRel	Parenteral feeding was associated with the highest rate of nutrition-related complications,	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.
__label__noRel	Parenteral feeding was associated with the highest rate of nutrition-related complications,	Body weight and whole body fat declined similarly over time in all groups (P < .005),
__label__noRel	Parenteral feeding was associated with the highest rate of nutrition-related complications,	lean body mass was unchanged during follow-up compared to preoperative values.
__label__noRel	Parenteral feeding was associated with the highest rate of nutrition-related complications,	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.
__label__noRel	Parenteral feeding was associated with the highest rate of nutrition-related complications,	There was no difference in recovery of food intake among the groups.
__label__noRel	Parenteral feeding was associated with the highest rate of nutrition-related complications,	enteral feeding reduced quality of life most extensively.
__label__Support	Parenteral feeding was associated with the highest rate of nutrition-related complications,	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.
__label__noRel	enteral feeding reduced quality of life most extensively.	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).
__label__noRel	enteral feeding reduced quality of life most extensively.	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.
__label__noRel	enteral feeding reduced quality of life most extensively.	Body weight and whole body fat declined similarly over time in all groups (P < .005),
__label__noRel	enteral feeding reduced quality of life most extensively.	lean body mass was unchanged during follow-up compared to preoperative values.
__label__noRel	enteral feeding reduced quality of life most extensively.	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.
__label__noRel	enteral feeding reduced quality of life most extensively.	There was no difference in recovery of food intake among the groups.
__label__noRel	enteral feeding reduced quality of life most extensively.	Parenteral feeding was associated with the highest rate of nutrition-related complications,
__label__Support	enteral feeding reduced quality of life most extensively.	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.
__label__noRel	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).
__label__noRel	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.
__label__noRel	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.	Body weight and whole body fat declined similarly over time in all groups (P < .005),
__label__noRel	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.	lean body mass was unchanged during follow-up compared to preoperative values.
__label__noRel	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.
__label__noRel	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.	There was no difference in recovery of food intake among the groups.
__label__noRel	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.	Parenteral feeding was associated with the highest rate of nutrition-related complications,
__label__noRel	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.	enteral feeding reduced quality of life most extensively.
__label__noRel	Findings suggest that self-efficacy may influence long-term maintenance of healthy lifestyle practices among cancer survivors.	Results suggest that change in self-efficacy for fat restriction partially explained the intervention's effect on fat intake (mean indirect effect=-0.28), and change in self-efficacy for F&V consumption partially explained the intervention's effect on daily F&V intake (mean indirect effect=.11).
__label__noRel	Findings suggest that self-efficacy may influence long-term maintenance of healthy lifestyle practices among cancer survivors.	Change in self-efficacy for fat restriction partially accounted for the intervention's impact on overall diet quality among men only (mean indirect effect=0.60).
__label__noRel	Results suggest that change in self-efficacy for fat restriction partially explained the intervention's effect on fat intake (mean indirect effect=-0.28), and change in self-efficacy for F&V consumption partially explained the intervention's effect on daily F&V intake (mean indirect effect=.11).	Findings suggest that self-efficacy may influence long-term maintenance of healthy lifestyle practices among cancer survivors.
__label__noRel	Results suggest that change in self-efficacy for fat restriction partially explained the intervention's effect on fat intake (mean indirect effect=-0.28), and change in self-efficacy for F&V consumption partially explained the intervention's effect on daily F&V intake (mean indirect effect=.11).	Change in self-efficacy for fat restriction partially accounted for the intervention's impact on overall diet quality among men only (mean indirect effect=0.60).
__label__Support	Change in self-efficacy for fat restriction partially accounted for the intervention's impact on overall diet quality among men only (mean indirect effect=0.60).	Findings suggest that self-efficacy may influence long-term maintenance of healthy lifestyle practices among cancer survivors.
__label__noRel	Change in self-efficacy for fat restriction partially accounted for the intervention's impact on overall diet quality among men only (mean indirect effect=0.60).	Results suggest that change in self-efficacy for fat restriction partially explained the intervention's effect on fat intake (mean indirect effect=-0.28), and change in self-efficacy for F&V consumption partially explained the intervention's effect on daily F&V intake (mean indirect effect=.11).
__label__noRel	Long-term benefits for older patients were seen in the anger-hostility scale at week 27 (92.2 vs. 84.2, p = 0.027) and week 52 (96.3 vs. 85.9, p = 0.005).	Older adult patients reported better overall QOL (LASA 74.4 vs. 62.9, p = 0.040), higher social well-being (FACT-G 91.1 vs. 83.3, p = 0.045), and fewer problems with anger (POMS anger-hostility 95.0 vs. 86.4, p = 0.028).
__label__Support	Long-term benefits for older patients were seen in the anger-hostility scale at week 27 (92.2 vs. 84.2, p = 0.027) and week 52 (96.3 vs. 85.9, p = 0.005).	Older adult patients who received a multidisciplinary intervention to improve QOL while undergoing advanced cancer treatments benefited differently in some QOL domains, compared to younger adult patients.
__label__noRel	Older adult patients reported better overall QOL (LASA 74.4 vs. 62.9, p = 0.040), higher social well-being (FACT-G 91.1 vs. 83.3, p = 0.045), and fewer problems with anger (POMS anger-hostility 95.0 vs. 86.4, p = 0.028).	Long-term benefits for older patients were seen in the anger-hostility scale at week 27 (92.2 vs. 84.2, p = 0.027) and week 52 (96.3 vs. 85.9, p = 0.005).
__label__Support	Older adult patients reported better overall QOL (LASA 74.4 vs. 62.9, p = 0.040), higher social well-being (FACT-G 91.1 vs. 83.3, p = 0.045), and fewer problems with anger (POMS anger-hostility 95.0 vs. 86.4, p = 0.028).	Older adult patients who received a multidisciplinary intervention to improve QOL while undergoing advanced cancer treatments benefited differently in some QOL domains, compared to younger adult patients.
__label__noRel	Older adult patients who received a multidisciplinary intervention to improve QOL while undergoing advanced cancer treatments benefited differently in some QOL domains, compared to younger adult patients.	Long-term benefits for older patients were seen in the anger-hostility scale at week 27 (92.2 vs. 84.2, p = 0.027) and week 52 (96.3 vs. 85.9, p = 0.005).
__label__noRel	Older adult patients who received a multidisciplinary intervention to improve QOL while undergoing advanced cancer treatments benefited differently in some QOL domains, compared to younger adult patients.	Older adult patients reported better overall QOL (LASA 74.4 vs. 62.9, p = 0.040), higher social well-being (FACT-G 91.1 vs. 83.3, p = 0.045), and fewer problems with anger (POMS anger-hostility 95.0 vs. 86.4, p = 0.028).
__label__noRel	Operative time was 53 minutes longer in the laparoscopic group (P < 0.0001).	Postoperative morbidity rate was 28.9 percent in the laparoscopic vs. 40 percent in the open group (P = 0.18).
__label__noRel	Operative time was 53 minutes longer in the laparoscopic group (P < 0.0001).	The mean length of hospital stay was 10 (4.9) days in the laparoscopic group and 13.6 (10) days in the open group (P = 0.004).
__label__noRel	Operative time was 53 minutes longer in the laparoscopic group (P < 0.0001).	Local recurrence rate and five-year survival were similar in both groups;
__label__noRel	Operative time was 53 minutes longer in the laparoscopic group (P < 0.0001).	however, the limited number of patients does not allow firm conclusions.
__label__noRel	Operative time was 53 minutes longer in the laparoscopic group (P < 0.0001).	Quality of life was better in the laparoscopic group only in the first year after surgery (P < 0.0001).
__label__noRel	Operative time was 53 minutes longer in the laparoscopic group (P < 0.0001).	The additional charge in the laparoscopic group was $1,748 per patient randomized ($1,194 the result of surgical instruments and $554 the result of longer operative time).
__label__noRel	Operative time was 53 minutes longer in the laparoscopic group (P < 0.0001).	The saving in the laparoscopic group was $1,396 per patient randomized ($647 the result of shorter length of hospital stay and $749 the result of the lower cost of postoperative complications).
__label__noRel	Operative time was 53 minutes longer in the laparoscopic group (P < 0.0001).	The net balance resulted in $351 extra cost per patient randomly allocated to the laparoscopic group.
__label__noRel	Operative time was 53 minutes longer in the laparoscopic group (P < 0.0001).	Short-term postoperative morbidity was similar in the two groups.
__label__noRel	Operative time was 53 minutes longer in the laparoscopic group (P < 0.0001).	Laparoscopic resection reduced length of hospital stay, improved first-year quality of life, and slightly increased hospital costs.
__label__noRel	Postoperative morbidity rate was 28.9 percent in the laparoscopic vs. 40 percent in the open group (P = 0.18).	Operative time was 53 minutes longer in the laparoscopic group (P < 0.0001).
__label__noRel	Postoperative morbidity rate was 28.9 percent in the laparoscopic vs. 40 percent in the open group (P = 0.18).	The mean length of hospital stay was 10 (4.9) days in the laparoscopic group and 13.6 (10) days in the open group (P = 0.004).
__label__noRel	Postoperative morbidity rate was 28.9 percent in the laparoscopic vs. 40 percent in the open group (P = 0.18).	Local recurrence rate and five-year survival were similar in both groups;
__label__noRel	Postoperative morbidity rate was 28.9 percent in the laparoscopic vs. 40 percent in the open group (P = 0.18).	however, the limited number of patients does not allow firm conclusions.
__label__noRel	Postoperative morbidity rate was 28.9 percent in the laparoscopic vs. 40 percent in the open group (P = 0.18).	Quality of life was better in the laparoscopic group only in the first year after surgery (P < 0.0001).
__label__noRel	Postoperative morbidity rate was 28.9 percent in the laparoscopic vs. 40 percent in the open group (P = 0.18).	The additional charge in the laparoscopic group was $1,748 per patient randomized ($1,194 the result of surgical instruments and $554 the result of longer operative time).
__label__noRel	Postoperative morbidity rate was 28.9 percent in the laparoscopic vs. 40 percent in the open group (P = 0.18).	The saving in the laparoscopic group was $1,396 per patient randomized ($647 the result of shorter length of hospital stay and $749 the result of the lower cost of postoperative complications).
__label__noRel	Postoperative morbidity rate was 28.9 percent in the laparoscopic vs. 40 percent in the open group (P = 0.18).	The net balance resulted in $351 extra cost per patient randomly allocated to the laparoscopic group.
__label__Support	Postoperative morbidity rate was 28.9 percent in the laparoscopic vs. 40 percent in the open group (P = 0.18).	Short-term postoperative morbidity was similar in the two groups.
__label__noRel	Postoperative morbidity rate was 28.9 percent in the laparoscopic vs. 40 percent in the open group (P = 0.18).	Laparoscopic resection reduced length of hospital stay, improved first-year quality of life, and slightly increased hospital costs.
__label__noRel	The mean length of hospital stay was 10 (4.9) days in the laparoscopic group and 13.6 (10) days in the open group (P = 0.004).	Operative time was 53 minutes longer in the laparoscopic group (P < 0.0001).
__label__noRel	The mean length of hospital stay was 10 (4.9) days in the laparoscopic group and 13.6 (10) days in the open group (P = 0.004).	Postoperative morbidity rate was 28.9 percent in the laparoscopic vs. 40 percent in the open group (P = 0.18).
__label__noRel	The mean length of hospital stay was 10 (4.9) days in the laparoscopic group and 13.6 (10) days in the open group (P = 0.004).	Local recurrence rate and five-year survival were similar in both groups;
__label__noRel	The mean length of hospital stay was 10 (4.9) days in the laparoscopic group and 13.6 (10) days in the open group (P = 0.004).	however, the limited number of patients does not allow firm conclusions.
__label__noRel	The mean length of hospital stay was 10 (4.9) days in the laparoscopic group and 13.6 (10) days in the open group (P = 0.004).	Quality of life was better in the laparoscopic group only in the first year after surgery (P < 0.0001).
__label__noRel	The mean length of hospital stay was 10 (4.9) days in the laparoscopic group and 13.6 (10) days in the open group (P = 0.004).	The additional charge in the laparoscopic group was $1,748 per patient randomized ($1,194 the result of surgical instruments and $554 the result of longer operative time).
__label__noRel	The mean length of hospital stay was 10 (4.9) days in the laparoscopic group and 13.6 (10) days in the open group (P = 0.004).	The saving in the laparoscopic group was $1,396 per patient randomized ($647 the result of shorter length of hospital stay and $749 the result of the lower cost of postoperative complications).
__label__noRel	The mean length of hospital stay was 10 (4.9) days in the laparoscopic group and 13.6 (10) days in the open group (P = 0.004).	The net balance resulted in $351 extra cost per patient randomly allocated to the laparoscopic group.
__label__noRel	The mean length of hospital stay was 10 (4.9) days in the laparoscopic group and 13.6 (10) days in the open group (P = 0.004).	Short-term postoperative morbidity was similar in the two groups.
__label__Support	The mean length of hospital stay was 10 (4.9) days in the laparoscopic group and 13.6 (10) days in the open group (P = 0.004).	Laparoscopic resection reduced length of hospital stay, improved first-year quality of life, and slightly increased hospital costs.
__label__noRel	Local recurrence rate and five-year survival were similar in both groups;	Operative time was 53 minutes longer in the laparoscopic group (P < 0.0001).
__label__noRel	Local recurrence rate and five-year survival were similar in both groups;	Postoperative morbidity rate was 28.9 percent in the laparoscopic vs. 40 percent in the open group (P = 0.18).
__label__noRel	Local recurrence rate and five-year survival were similar in both groups;	The mean length of hospital stay was 10 (4.9) days in the laparoscopic group and 13.6 (10) days in the open group (P = 0.004).
__label__noRel	Local recurrence rate and five-year survival were similar in both groups;	however, the limited number of patients does not allow firm conclusions.
__label__noRel	Local recurrence rate and five-year survival were similar in both groups;	Quality of life was better in the laparoscopic group only in the first year after surgery (P < 0.0001).
__label__noRel	Local recurrence rate and five-year survival were similar in both groups;	The additional charge in the laparoscopic group was $1,748 per patient randomized ($1,194 the result of surgical instruments and $554 the result of longer operative time).
__label__noRel	Local recurrence rate and five-year survival were similar in both groups;	The saving in the laparoscopic group was $1,396 per patient randomized ($647 the result of shorter length of hospital stay and $749 the result of the lower cost of postoperative complications).
__label__noRel	Local recurrence rate and five-year survival were similar in both groups;	The net balance resulted in $351 extra cost per patient randomly allocated to the laparoscopic group.
__label__noRel	Local recurrence rate and five-year survival were similar in both groups;	Short-term postoperative morbidity was similar in the two groups.
__label__noRel	Local recurrence rate and five-year survival were similar in both groups;	Laparoscopic resection reduced length of hospital stay, improved first-year quality of life, and slightly increased hospital costs.
__label__noRel	however, the limited number of patients does not allow firm conclusions.	Operative time was 53 minutes longer in the laparoscopic group (P < 0.0001).
__label__noRel	however, the limited number of patients does not allow firm conclusions.	Postoperative morbidity rate was 28.9 percent in the laparoscopic vs. 40 percent in the open group (P = 0.18).
__label__noRel	however, the limited number of patients does not allow firm conclusions.	The mean length of hospital stay was 10 (4.9) days in the laparoscopic group and 13.6 (10) days in the open group (P = 0.004).
__label__Attack	however, the limited number of patients does not allow firm conclusions.	Local recurrence rate and five-year survival were similar in both groups;
__label__noRel	however, the limited number of patients does not allow firm conclusions.	Quality of life was better in the laparoscopic group only in the first year after surgery (P < 0.0001).
__label__noRel	however, the limited number of patients does not allow firm conclusions.	The additional charge in the laparoscopic group was $1,748 per patient randomized ($1,194 the result of surgical instruments and $554 the result of longer operative time).
__label__noRel	however, the limited number of patients does not allow firm conclusions.	The saving in the laparoscopic group was $1,396 per patient randomized ($647 the result of shorter length of hospital stay and $749 the result of the lower cost of postoperative complications).
__label__noRel	however, the limited number of patients does not allow firm conclusions.	The net balance resulted in $351 extra cost per patient randomly allocated to the laparoscopic group.
__label__noRel	however, the limited number of patients does not allow firm conclusions.	Short-term postoperative morbidity was similar in the two groups.
__label__noRel	however, the limited number of patients does not allow firm conclusions.	Laparoscopic resection reduced length of hospital stay, improved first-year quality of life, and slightly increased hospital costs.
__label__noRel	Quality of life was better in the laparoscopic group only in the first year after surgery (P < 0.0001).	Operative time was 53 minutes longer in the laparoscopic group (P < 0.0001).
__label__noRel	Quality of life was better in the laparoscopic group only in the first year after surgery (P < 0.0001).	Postoperative morbidity rate was 28.9 percent in the laparoscopic vs. 40 percent in the open group (P = 0.18).
__label__noRel	Quality of life was better in the laparoscopic group only in the first year after surgery (P < 0.0001).	The mean length of hospital stay was 10 (4.9) days in the laparoscopic group and 13.6 (10) days in the open group (P = 0.004).
__label__noRel	Quality of life was better in the laparoscopic group only in the first year after surgery (P < 0.0001).	Local recurrence rate and five-year survival were similar in both groups;
__label__noRel	Quality of life was better in the laparoscopic group only in the first year after surgery (P < 0.0001).	however, the limited number of patients does not allow firm conclusions.
__label__noRel	Quality of life was better in the laparoscopic group only in the first year after surgery (P < 0.0001).	The additional charge in the laparoscopic group was $1,748 per patient randomized ($1,194 the result of surgical instruments and $554 the result of longer operative time).
__label__noRel	Quality of life was better in the laparoscopic group only in the first year after surgery (P < 0.0001).	The saving in the laparoscopic group was $1,396 per patient randomized ($647 the result of shorter length of hospital stay and $749 the result of the lower cost of postoperative complications).
__label__noRel	Quality of life was better in the laparoscopic group only in the first year after surgery (P < 0.0001).	The net balance resulted in $351 extra cost per patient randomly allocated to the laparoscopic group.
__label__noRel	Quality of life was better in the laparoscopic group only in the first year after surgery (P < 0.0001).	Short-term postoperative morbidity was similar in the two groups.
__label__Support	Quality of life was better in the laparoscopic group only in the first year after surgery (P < 0.0001).	Laparoscopic resection reduced length of hospital stay, improved first-year quality of life, and slightly increased hospital costs.
__label__noRel	The additional charge in the laparoscopic group was $1,748 per patient randomized ($1,194 the result of surgical instruments and $554 the result of longer operative time).	Operative time was 53 minutes longer in the laparoscopic group (P < 0.0001).
__label__noRel	The additional charge in the laparoscopic group was $1,748 per patient randomized ($1,194 the result of surgical instruments and $554 the result of longer operative time).	Postoperative morbidity rate was 28.9 percent in the laparoscopic vs. 40 percent in the open group (P = 0.18).
__label__noRel	The additional charge in the laparoscopic group was $1,748 per patient randomized ($1,194 the result of surgical instruments and $554 the result of longer operative time).	The mean length of hospital stay was 10 (4.9) days in the laparoscopic group and 13.6 (10) days in the open group (P = 0.004).
__label__noRel	The additional charge in the laparoscopic group was $1,748 per patient randomized ($1,194 the result of surgical instruments and $554 the result of longer operative time).	Local recurrence rate and five-year survival were similar in both groups;
__label__noRel	The additional charge in the laparoscopic group was $1,748 per patient randomized ($1,194 the result of surgical instruments and $554 the result of longer operative time).	however, the limited number of patients does not allow firm conclusions.
__label__noRel	The additional charge in the laparoscopic group was $1,748 per patient randomized ($1,194 the result of surgical instruments and $554 the result of longer operative time).	Quality of life was better in the laparoscopic group only in the first year after surgery (P < 0.0001).
__label__noRel	The additional charge in the laparoscopic group was $1,748 per patient randomized ($1,194 the result of surgical instruments and $554 the result of longer operative time).	The saving in the laparoscopic group was $1,396 per patient randomized ($647 the result of shorter length of hospital stay and $749 the result of the lower cost of postoperative complications).
__label__Support	The additional charge in the laparoscopic group was $1,748 per patient randomized ($1,194 the result of surgical instruments and $554 the result of longer operative time).	The net balance resulted in $351 extra cost per patient randomly allocated to the laparoscopic group.
__label__noRel	The additional charge in the laparoscopic group was $1,748 per patient randomized ($1,194 the result of surgical instruments and $554 the result of longer operative time).	Short-term postoperative morbidity was similar in the two groups.
__label__noRel	The additional charge in the laparoscopic group was $1,748 per patient randomized ($1,194 the result of surgical instruments and $554 the result of longer operative time).	Laparoscopic resection reduced length of hospital stay, improved first-year quality of life, and slightly increased hospital costs.
__label__noRel	The saving in the laparoscopic group was $1,396 per patient randomized ($647 the result of shorter length of hospital stay and $749 the result of the lower cost of postoperative complications).	Operative time was 53 minutes longer in the laparoscopic group (P < 0.0001).
__label__noRel	The saving in the laparoscopic group was $1,396 per patient randomized ($647 the result of shorter length of hospital stay and $749 the result of the lower cost of postoperative complications).	Postoperative morbidity rate was 28.9 percent in the laparoscopic vs. 40 percent in the open group (P = 0.18).
__label__noRel	The saving in the laparoscopic group was $1,396 per patient randomized ($647 the result of shorter length of hospital stay and $749 the result of the lower cost of postoperative complications).	The mean length of hospital stay was 10 (4.9) days in the laparoscopic group and 13.6 (10) days in the open group (P = 0.004).
__label__noRel	The saving in the laparoscopic group was $1,396 per patient randomized ($647 the result of shorter length of hospital stay and $749 the result of the lower cost of postoperative complications).	Local recurrence rate and five-year survival were similar in both groups;
__label__noRel	The saving in the laparoscopic group was $1,396 per patient randomized ($647 the result of shorter length of hospital stay and $749 the result of the lower cost of postoperative complications).	however, the limited number of patients does not allow firm conclusions.
__label__noRel	The saving in the laparoscopic group was $1,396 per patient randomized ($647 the result of shorter length of hospital stay and $749 the result of the lower cost of postoperative complications).	Quality of life was better in the laparoscopic group only in the first year after surgery (P < 0.0001).
__label__noRel	The saving in the laparoscopic group was $1,396 per patient randomized ($647 the result of shorter length of hospital stay and $749 the result of the lower cost of postoperative complications).	The additional charge in the laparoscopic group was $1,748 per patient randomized ($1,194 the result of surgical instruments and $554 the result of longer operative time).
__label__Support	The saving in the laparoscopic group was $1,396 per patient randomized ($647 the result of shorter length of hospital stay and $749 the result of the lower cost of postoperative complications).	The net balance resulted in $351 extra cost per patient randomly allocated to the laparoscopic group.
__label__noRel	The saving in the laparoscopic group was $1,396 per patient randomized ($647 the result of shorter length of hospital stay and $749 the result of the lower cost of postoperative complications).	Short-term postoperative morbidity was similar in the two groups.
__label__noRel	The saving in the laparoscopic group was $1,396 per patient randomized ($647 the result of shorter length of hospital stay and $749 the result of the lower cost of postoperative complications).	Laparoscopic resection reduced length of hospital stay, improved first-year quality of life, and slightly increased hospital costs.
__label__noRel	The net balance resulted in $351 extra cost per patient randomly allocated to the laparoscopic group.	Operative time was 53 minutes longer in the laparoscopic group (P < 0.0001).
__label__noRel	The net balance resulted in $351 extra cost per patient randomly allocated to the laparoscopic group.	Postoperative morbidity rate was 28.9 percent in the laparoscopic vs. 40 percent in the open group (P = 0.18).
__label__noRel	The net balance resulted in $351 extra cost per patient randomly allocated to the laparoscopic group.	The mean length of hospital stay was 10 (4.9) days in the laparoscopic group and 13.6 (10) days in the open group (P = 0.004).
__label__noRel	The net balance resulted in $351 extra cost per patient randomly allocated to the laparoscopic group.	Local recurrence rate and five-year survival were similar in both groups;
__label__noRel	The net balance resulted in $351 extra cost per patient randomly allocated to the laparoscopic group.	however, the limited number of patients does not allow firm conclusions.
__label__noRel	The net balance resulted in $351 extra cost per patient randomly allocated to the laparoscopic group.	Quality of life was better in the laparoscopic group only in the first year after surgery (P < 0.0001).
__label__noRel	The net balance resulted in $351 extra cost per patient randomly allocated to the laparoscopic group.	The additional charge in the laparoscopic group was $1,748 per patient randomized ($1,194 the result of surgical instruments and $554 the result of longer operative time).
__label__noRel	The net balance resulted in $351 extra cost per patient randomly allocated to the laparoscopic group.	The saving in the laparoscopic group was $1,396 per patient randomized ($647 the result of shorter length of hospital stay and $749 the result of the lower cost of postoperative complications).
__label__noRel	The net balance resulted in $351 extra cost per patient randomly allocated to the laparoscopic group.	Short-term postoperative morbidity was similar in the two groups.
__label__Support	The net balance resulted in $351 extra cost per patient randomly allocated to the laparoscopic group.	Laparoscopic resection reduced length of hospital stay, improved first-year quality of life, and slightly increased hospital costs.
__label__noRel	Short-term postoperative morbidity was similar in the two groups.	Operative time was 53 minutes longer in the laparoscopic group (P < 0.0001).
__label__noRel	Short-term postoperative morbidity was similar in the two groups.	Postoperative morbidity rate was 28.9 percent in the laparoscopic vs. 40 percent in the open group (P = 0.18).
__label__noRel	Short-term postoperative morbidity was similar in the two groups.	The mean length of hospital stay was 10 (4.9) days in the laparoscopic group and 13.6 (10) days in the open group (P = 0.004).
__label__noRel	Short-term postoperative morbidity was similar in the two groups.	Local recurrence rate and five-year survival were similar in both groups;
__label__noRel	Short-term postoperative morbidity was similar in the two groups.	however, the limited number of patients does not allow firm conclusions.
__label__noRel	Short-term postoperative morbidity was similar in the two groups.	Quality of life was better in the laparoscopic group only in the first year after surgery (P < 0.0001).
__label__noRel	Short-term postoperative morbidity was similar in the two groups.	The additional charge in the laparoscopic group was $1,748 per patient randomized ($1,194 the result of surgical instruments and $554 the result of longer operative time).
__label__noRel	Short-term postoperative morbidity was similar in the two groups.	The saving in the laparoscopic group was $1,396 per patient randomized ($647 the result of shorter length of hospital stay and $749 the result of the lower cost of postoperative complications).
__label__noRel	Short-term postoperative morbidity was similar in the two groups.	The net balance resulted in $351 extra cost per patient randomly allocated to the laparoscopic group.
__label__noRel	Short-term postoperative morbidity was similar in the two groups.	Laparoscopic resection reduced length of hospital stay, improved first-year quality of life, and slightly increased hospital costs.
__label__noRel	Laparoscopic resection reduced length of hospital stay, improved first-year quality of life, and slightly increased hospital costs.	Operative time was 53 minutes longer in the laparoscopic group (P < 0.0001).
__label__noRel	Laparoscopic resection reduced length of hospital stay, improved first-year quality of life, and slightly increased hospital costs.	Postoperative morbidity rate was 28.9 percent in the laparoscopic vs. 40 percent in the open group (P = 0.18).
__label__noRel	Laparoscopic resection reduced length of hospital stay, improved first-year quality of life, and slightly increased hospital costs.	The mean length of hospital stay was 10 (4.9) days in the laparoscopic group and 13.6 (10) days in the open group (P = 0.004).
__label__noRel	Laparoscopic resection reduced length of hospital stay, improved first-year quality of life, and slightly increased hospital costs.	Local recurrence rate and five-year survival were similar in both groups;
__label__noRel	Laparoscopic resection reduced length of hospital stay, improved first-year quality of life, and slightly increased hospital costs.	however, the limited number of patients does not allow firm conclusions.
__label__noRel	Laparoscopic resection reduced length of hospital stay, improved first-year quality of life, and slightly increased hospital costs.	Quality of life was better in the laparoscopic group only in the first year after surgery (P < 0.0001).
__label__noRel	Laparoscopic resection reduced length of hospital stay, improved first-year quality of life, and slightly increased hospital costs.	The additional charge in the laparoscopic group was $1,748 per patient randomized ($1,194 the result of surgical instruments and $554 the result of longer operative time).
__label__noRel	Laparoscopic resection reduced length of hospital stay, improved first-year quality of life, and slightly increased hospital costs.	The saving in the laparoscopic group was $1,396 per patient randomized ($647 the result of shorter length of hospital stay and $749 the result of the lower cost of postoperative complications).
__label__noRel	Laparoscopic resection reduced length of hospital stay, improved first-year quality of life, and slightly increased hospital costs.	The net balance resulted in $351 extra cost per patient randomly allocated to the laparoscopic group.
__label__noRel	Laparoscopic resection reduced length of hospital stay, improved first-year quality of life, and slightly increased hospital costs.	Short-term postoperative morbidity was similar in the two groups.
__label__noRel	Compared with standard TPN, a higher serum prealbumin level and better nitrogen balance were observed in glutamine-enriched TPN (P = 0.039 and 0.048 respectively).	A significantly lower serum interleukin-6 level was found in comparing glutamine-enriched with standard TPN (P = 0.01),
__label__noRel	Compared with standard TPN, a higher serum prealbumin level and better nitrogen balance were observed in glutamine-enriched TPN (P = 0.039 and 0.048 respectively).	but not in interleukin-10 (P = 0.374) and tumor necrosis factor- levels (P = 0.653).
__label__noRel	Compared with standard TPN, a higher serum prealbumin level and better nitrogen balance were observed in glutamine-enriched TPN (P = 0.039 and 0.048 respectively).	a significant lower serum C-reactive protein level was detected in glutamine-enriched TPN compared with standard TPN (P = 0.013).
__label__noRel	Compared with standard TPN, a higher serum prealbumin level and better nitrogen balance were observed in glutamine-enriched TPN (P = 0.039 and 0.048 respectively).	four cases of postoperative infectious complications were noted in the control group, but no postoperative infectious complications were observed in the interventional group (P = 0.037).
__label__Support	Compared with standard TPN, a higher serum prealbumin level and better nitrogen balance were observed in glutamine-enriched TPN (P = 0.039 and 0.048 respectively).	Our present study shows that glutamine-enriched TPN may be beneficial in improving the inflammatory status and decreasing the infectious morbidity in postoperative GI cancer patients.
__label__noRel	A significantly lower serum interleukin-6 level was found in comparing glutamine-enriched with standard TPN (P = 0.01),	Compared with standard TPN, a higher serum prealbumin level and better nitrogen balance were observed in glutamine-enriched TPN (P = 0.039 and 0.048 respectively).
__label__noRel	A significantly lower serum interleukin-6 level was found in comparing glutamine-enriched with standard TPN (P = 0.01),	but not in interleukin-10 (P = 0.374) and tumor necrosis factor- levels (P = 0.653).
__label__noRel	A significantly lower serum interleukin-6 level was found in comparing glutamine-enriched with standard TPN (P = 0.01),	a significant lower serum C-reactive protein level was detected in glutamine-enriched TPN compared with standard TPN (P = 0.013).
__label__noRel	A significantly lower serum interleukin-6 level was found in comparing glutamine-enriched with standard TPN (P = 0.01),	four cases of postoperative infectious complications were noted in the control group, but no postoperative infectious complications were observed in the interventional group (P = 0.037).
__label__Support	A significantly lower serum interleukin-6 level was found in comparing glutamine-enriched with standard TPN (P = 0.01),	Our present study shows that glutamine-enriched TPN may be beneficial in improving the inflammatory status and decreasing the infectious morbidity in postoperative GI cancer patients.
__label__noRel	but not in interleukin-10 (P = 0.374) and tumor necrosis factor- levels (P = 0.653).	Compared with standard TPN, a higher serum prealbumin level and better nitrogen balance were observed in glutamine-enriched TPN (P = 0.039 and 0.048 respectively).
__label__Attack	but not in interleukin-10 (P = 0.374) and tumor necrosis factor- levels (P = 0.653).	A significantly lower serum interleukin-6 level was found in comparing glutamine-enriched with standard TPN (P = 0.01),
__label__noRel	but not in interleukin-10 (P = 0.374) and tumor necrosis factor- levels (P = 0.653).	a significant lower serum C-reactive protein level was detected in glutamine-enriched TPN compared with standard TPN (P = 0.013).
__label__noRel	but not in interleukin-10 (P = 0.374) and tumor necrosis factor- levels (P = 0.653).	four cases of postoperative infectious complications were noted in the control group, but no postoperative infectious complications were observed in the interventional group (P = 0.037).
__label__noRel	but not in interleukin-10 (P = 0.374) and tumor necrosis factor- levels (P = 0.653).	Our present study shows that glutamine-enriched TPN may be beneficial in improving the inflammatory status and decreasing the infectious morbidity in postoperative GI cancer patients.
__label__noRel	a significant lower serum C-reactive protein level was detected in glutamine-enriched TPN compared with standard TPN (P = 0.013).	Compared with standard TPN, a higher serum prealbumin level and better nitrogen balance were observed in glutamine-enriched TPN (P = 0.039 and 0.048 respectively).
__label__noRel	a significant lower serum C-reactive protein level was detected in glutamine-enriched TPN compared with standard TPN (P = 0.013).	A significantly lower serum interleukin-6 level was found in comparing glutamine-enriched with standard TPN (P = 0.01),
__label__noRel	a significant lower serum C-reactive protein level was detected in glutamine-enriched TPN compared with standard TPN (P = 0.013).	but not in interleukin-10 (P = 0.374) and tumor necrosis factor- levels (P = 0.653).
__label__noRel	a significant lower serum C-reactive protein level was detected in glutamine-enriched TPN compared with standard TPN (P = 0.013).	four cases of postoperative infectious complications were noted in the control group, but no postoperative infectious complications were observed in the interventional group (P = 0.037).
__label__Support	a significant lower serum C-reactive protein level was detected in glutamine-enriched TPN compared with standard TPN (P = 0.013).	Our present study shows that glutamine-enriched TPN may be beneficial in improving the inflammatory status and decreasing the infectious morbidity in postoperative GI cancer patients.
__label__noRel	four cases of postoperative infectious complications were noted in the control group, but no postoperative infectious complications were observed in the interventional group (P = 0.037).	Compared with standard TPN, a higher serum prealbumin level and better nitrogen balance were observed in glutamine-enriched TPN (P = 0.039 and 0.048 respectively).
__label__noRel	four cases of postoperative infectious complications were noted in the control group, but no postoperative infectious complications were observed in the interventional group (P = 0.037).	A significantly lower serum interleukin-6 level was found in comparing glutamine-enriched with standard TPN (P = 0.01),
__label__noRel	four cases of postoperative infectious complications were noted in the control group, but no postoperative infectious complications were observed in the interventional group (P = 0.037).	but not in interleukin-10 (P = 0.374) and tumor necrosis factor- levels (P = 0.653).
__label__noRel	four cases of postoperative infectious complications were noted in the control group, but no postoperative infectious complications were observed in the interventional group (P = 0.037).	a significant lower serum C-reactive protein level was detected in glutamine-enriched TPN compared with standard TPN (P = 0.013).
__label__Support	four cases of postoperative infectious complications were noted in the control group, but no postoperative infectious complications were observed in the interventional group (P = 0.037).	Our present study shows that glutamine-enriched TPN may be beneficial in improving the inflammatory status and decreasing the infectious morbidity in postoperative GI cancer patients.
__label__noRel	Our present study shows that glutamine-enriched TPN may be beneficial in improving the inflammatory status and decreasing the infectious morbidity in postoperative GI cancer patients.	Compared with standard TPN, a higher serum prealbumin level and better nitrogen balance were observed in glutamine-enriched TPN (P = 0.039 and 0.048 respectively).
__label__noRel	Our present study shows that glutamine-enriched TPN may be beneficial in improving the inflammatory status and decreasing the infectious morbidity in postoperative GI cancer patients.	A significantly lower serum interleukin-6 level was found in comparing glutamine-enriched with standard TPN (P = 0.01),
__label__noRel	Our present study shows that glutamine-enriched TPN may be beneficial in improving the inflammatory status and decreasing the infectious morbidity in postoperative GI cancer patients.	but not in interleukin-10 (P = 0.374) and tumor necrosis factor- levels (P = 0.653).
__label__noRel	Our present study shows that glutamine-enriched TPN may be beneficial in improving the inflammatory status and decreasing the infectious morbidity in postoperative GI cancer patients.	a significant lower serum C-reactive protein level was detected in glutamine-enriched TPN compared with standard TPN (P = 0.013).
__label__noRel	Our present study shows that glutamine-enriched TPN may be beneficial in improving the inflammatory status and decreasing the infectious morbidity in postoperative GI cancer patients.	four cases of postoperative infectious complications were noted in the control group, but no postoperative infectious complications were observed in the interventional group (P = 0.037).
__label__noRel	Compared with the control group of the same period, the 6-month and 1-year WBC and Hb increased, the 1-year PLT increased in the treatment group, showing statistical difference (P<0.05, P<0.01).	Compared with 1-year treatment in the treatment group, the 2-and 3-year psychological functions and the general symptoms scores decreased (P<0.05, P<0.01).
__label__noRel	Compared with the control group of the same period, the 6-month and 1-year WBC and Hb increased, the 1-year PLT increased in the treatment group, showing statistical difference (P<0.05, P<0.01).	Compared with the control group of the same period, the 2-and 3-year somatic functions, psychological functions, and the general symptoms scores decreased in the treatment group;
__label__noRel	Compared with the control group of the same period, the 6-month and 1-year WBC and Hb increased, the 1-year PLT increased in the treatment group, showing statistical difference (P<0.05, P<0.01).	the 2-year somatic functions and psychological functions decreased in the treatment group;
__label__noRel	Compared with the control group of the same period, the 6-month and 1-year WBC and Hb increased, the 1-year PLT increased in the treatment group, showing statistical difference (P<0.05, P<0.01).	the 3-year psychological functions and the general symptoms scores decreased in the treatment group, all with statistical difference (all P<0.05).
__label__noRel	Compared with the control group of the same period, the 6-month and 1-year WBC and Hb increased, the 1-year PLT increased in the treatment group, showing statistical difference (P<0.05, P<0.01).	Compared with the control group, the death number decreased, the survival rate increased, the life span of dead children was prolonged in the treatment group, showing statistical difference (P<0.05).
__label__Support	Compared with the control group of the same period, the 6-month and 1-year WBC and Hb increased, the 1-year PLT increased in the treatment group, showing statistical difference (P<0.05, P<0.01).	FJD combined chemotherapy could effectively improve the QOL of solid tumor children patients, elevate their survival rate, and prolong their life spans.
__label__noRel	Compared with 1-year treatment in the treatment group, the 2-and 3-year psychological functions and the general symptoms scores decreased (P<0.05, P<0.01).	Compared with the control group of the same period, the 6-month and 1-year WBC and Hb increased, the 1-year PLT increased in the treatment group, showing statistical difference (P<0.05, P<0.01).
__label__noRel	Compared with 1-year treatment in the treatment group, the 2-and 3-year psychological functions and the general symptoms scores decreased (P<0.05, P<0.01).	Compared with the control group of the same period, the 2-and 3-year somatic functions, psychological functions, and the general symptoms scores decreased in the treatment group;
__label__noRel	Compared with 1-year treatment in the treatment group, the 2-and 3-year psychological functions and the general symptoms scores decreased (P<0.05, P<0.01).	the 2-year somatic functions and psychological functions decreased in the treatment group;
__label__noRel	Compared with 1-year treatment in the treatment group, the 2-and 3-year psychological functions and the general symptoms scores decreased (P<0.05, P<0.01).	the 3-year psychological functions and the general symptoms scores decreased in the treatment group, all with statistical difference (all P<0.05).
__label__noRel	Compared with 1-year treatment in the treatment group, the 2-and 3-year psychological functions and the general symptoms scores decreased (P<0.05, P<0.01).	Compared with the control group, the death number decreased, the survival rate increased, the life span of dead children was prolonged in the treatment group, showing statistical difference (P<0.05).
__label__Support	Compared with 1-year treatment in the treatment group, the 2-and 3-year psychological functions and the general symptoms scores decreased (P<0.05, P<0.01).	FJD combined chemotherapy could effectively improve the QOL of solid tumor children patients, elevate their survival rate, and prolong their life spans.
__label__noRel	Compared with the control group of the same period, the 2-and 3-year somatic functions, psychological functions, and the general symptoms scores decreased in the treatment group;	Compared with the control group of the same period, the 6-month and 1-year WBC and Hb increased, the 1-year PLT increased in the treatment group, showing statistical difference (P<0.05, P<0.01).
__label__noRel	Compared with the control group of the same period, the 2-and 3-year somatic functions, psychological functions, and the general symptoms scores decreased in the treatment group;	Compared with 1-year treatment in the treatment group, the 2-and 3-year psychological functions and the general symptoms scores decreased (P<0.05, P<0.01).
__label__noRel	Compared with the control group of the same period, the 2-and 3-year somatic functions, psychological functions, and the general symptoms scores decreased in the treatment group;	the 2-year somatic functions and psychological functions decreased in the treatment group;
__label__noRel	Compared with the control group of the same period, the 2-and 3-year somatic functions, psychological functions, and the general symptoms scores decreased in the treatment group;	the 3-year psychological functions and the general symptoms scores decreased in the treatment group, all with statistical difference (all P<0.05).
__label__noRel	Compared with the control group of the same period, the 2-and 3-year somatic functions, psychological functions, and the general symptoms scores decreased in the treatment group;	Compared with the control group, the death number decreased, the survival rate increased, the life span of dead children was prolonged in the treatment group, showing statistical difference (P<0.05).
__label__Support	Compared with the control group of the same period, the 2-and 3-year somatic functions, psychological functions, and the general symptoms scores decreased in the treatment group;	FJD combined chemotherapy could effectively improve the QOL of solid tumor children patients, elevate their survival rate, and prolong their life spans.
__label__noRel	the 2-year somatic functions and psychological functions decreased in the treatment group;	Compared with the control group of the same period, the 6-month and 1-year WBC and Hb increased, the 1-year PLT increased in the treatment group, showing statistical difference (P<0.05, P<0.01).
__label__noRel	the 2-year somatic functions and psychological functions decreased in the treatment group;	Compared with 1-year treatment in the treatment group, the 2-and 3-year psychological functions and the general symptoms scores decreased (P<0.05, P<0.01).
__label__noRel	the 2-year somatic functions and psychological functions decreased in the treatment group;	Compared with the control group of the same period, the 2-and 3-year somatic functions, psychological functions, and the general symptoms scores decreased in the treatment group;
__label__noRel	the 2-year somatic functions and psychological functions decreased in the treatment group;	the 3-year psychological functions and the general symptoms scores decreased in the treatment group, all with statistical difference (all P<0.05).
__label__noRel	the 2-year somatic functions and psychological functions decreased in the treatment group;	Compared with the control group, the death number decreased, the survival rate increased, the life span of dead children was prolonged in the treatment group, showing statistical difference (P<0.05).
__label__Support	the 2-year somatic functions and psychological functions decreased in the treatment group;	FJD combined chemotherapy could effectively improve the QOL of solid tumor children patients, elevate their survival rate, and prolong their life spans.
__label__noRel	the 3-year psychological functions and the general symptoms scores decreased in the treatment group, all with statistical difference (all P<0.05).	Compared with the control group of the same period, the 6-month and 1-year WBC and Hb increased, the 1-year PLT increased in the treatment group, showing statistical difference (P<0.05, P<0.01).
__label__noRel	the 3-year psychological functions and the general symptoms scores decreased in the treatment group, all with statistical difference (all P<0.05).	Compared with 1-year treatment in the treatment group, the 2-and 3-year psychological functions and the general symptoms scores decreased (P<0.05, P<0.01).
__label__noRel	the 3-year psychological functions and the general symptoms scores decreased in the treatment group, all with statistical difference (all P<0.05).	Compared with the control group of the same period, the 2-and 3-year somatic functions, psychological functions, and the general symptoms scores decreased in the treatment group;
__label__noRel	the 3-year psychological functions and the general symptoms scores decreased in the treatment group, all with statistical difference (all P<0.05).	the 2-year somatic functions and psychological functions decreased in the treatment group;
__label__noRel	the 3-year psychological functions and the general symptoms scores decreased in the treatment group, all with statistical difference (all P<0.05).	Compared with the control group, the death number decreased, the survival rate increased, the life span of dead children was prolonged in the treatment group, showing statistical difference (P<0.05).
__label__Support	the 3-year psychological functions and the general symptoms scores decreased in the treatment group, all with statistical difference (all P<0.05).	FJD combined chemotherapy could effectively improve the QOL of solid tumor children patients, elevate their survival rate, and prolong their life spans.
__label__noRel	Compared with the control group, the death number decreased, the survival rate increased, the life span of dead children was prolonged in the treatment group, showing statistical difference (P<0.05).	Compared with the control group of the same period, the 6-month and 1-year WBC and Hb increased, the 1-year PLT increased in the treatment group, showing statistical difference (P<0.05, P<0.01).
__label__noRel	Compared with the control group, the death number decreased, the survival rate increased, the life span of dead children was prolonged in the treatment group, showing statistical difference (P<0.05).	Compared with 1-year treatment in the treatment group, the 2-and 3-year psychological functions and the general symptoms scores decreased (P<0.05, P<0.01).
__label__noRel	Compared with the control group, the death number decreased, the survival rate increased, the life span of dead children was prolonged in the treatment group, showing statistical difference (P<0.05).	Compared with the control group of the same period, the 2-and 3-year somatic functions, psychological functions, and the general symptoms scores decreased in the treatment group;
__label__noRel	Compared with the control group, the death number decreased, the survival rate increased, the life span of dead children was prolonged in the treatment group, showing statistical difference (P<0.05).	the 2-year somatic functions and psychological functions decreased in the treatment group;
__label__noRel	Compared with the control group, the death number decreased, the survival rate increased, the life span of dead children was prolonged in the treatment group, showing statistical difference (P<0.05).	the 3-year psychological functions and the general symptoms scores decreased in the treatment group, all with statistical difference (all P<0.05).
__label__Support	Compared with the control group, the death number decreased, the survival rate increased, the life span of dead children was prolonged in the treatment group, showing statistical difference (P<0.05).	FJD combined chemotherapy could effectively improve the QOL of solid tumor children patients, elevate their survival rate, and prolong their life spans.
__label__noRel	FJD combined chemotherapy could effectively improve the QOL of solid tumor children patients, elevate their survival rate, and prolong their life spans.	Compared with the control group of the same period, the 6-month and 1-year WBC and Hb increased, the 1-year PLT increased in the treatment group, showing statistical difference (P<0.05, P<0.01).
__label__noRel	FJD combined chemotherapy could effectively improve the QOL of solid tumor children patients, elevate their survival rate, and prolong their life spans.	Compared with 1-year treatment in the treatment group, the 2-and 3-year psychological functions and the general symptoms scores decreased (P<0.05, P<0.01).
__label__noRel	FJD combined chemotherapy could effectively improve the QOL of solid tumor children patients, elevate their survival rate, and prolong their life spans.	Compared with the control group of the same period, the 2-and 3-year somatic functions, psychological functions, and the general symptoms scores decreased in the treatment group;
__label__noRel	FJD combined chemotherapy could effectively improve the QOL of solid tumor children patients, elevate their survival rate, and prolong their life spans.	the 2-year somatic functions and psychological functions decreased in the treatment group;
__label__noRel	FJD combined chemotherapy could effectively improve the QOL of solid tumor children patients, elevate their survival rate, and prolong their life spans.	the 3-year psychological functions and the general symptoms scores decreased in the treatment group, all with statistical difference (all P<0.05).
__label__noRel	FJD combined chemotherapy could effectively improve the QOL of solid tumor children patients, elevate their survival rate, and prolong their life spans.	Compared with the control group, the death number decreased, the survival rate increased, the life span of dead children was prolonged in the treatment group, showing statistical difference (P<0.05).
__label__noRel	No significant effect was seen for general quality of life (FACT-G), which was the primary outcome.	At the six month follow-up, most of these effects were maintained and an intervention effect for breast cancer specific quality of life emerged.
__label__noRel	No significant effect was seen for general quality of life (FACT-G), which was the primary outcome.	No adverse effects were noted.
__label__noRel	No significant effect was seen for general quality of life (FACT-G), which was the primary outcome.	Supervised group exercise provided functional and psychological benefit after a 12 week intervention and six months later.
__label__noRel	No significant effect was seen for general quality of life (FACT-G), which was the primary outcome.	Clinicians should encourage activity for their patients.
__label__noRel	No significant effect was seen for general quality of life (FACT-G), which was the primary outcome.	Policy makers should consider the inclusion of exercise opportunities in cancer rehabilitation services.
__label__noRel	No significant effect was seen for general quality of life (FACT-G), which was the primary outcome.	Mixed effects models with adjustment for baseline values, study site, treatment at baseline, and age gave intervention effect estimates (intervention minus control) at 12 weeks of 129 (95% confidence interval 83 to 176) for metres walked in 12 minutes, 182 (75 to 289) for minutes of moderate intensity activity reported in a week, 2.6 (1.6 to 3.7) for shoulder mobility, 2.5 (1.0 to 3.9) for breast cancer specific subscale of quality of life, and 4.0 (1.8 to 6.3) for positive mood.
__label__noRel	At the six month follow-up, most of these effects were maintained and an intervention effect for breast cancer specific quality of life emerged.	No significant effect was seen for general quality of life (FACT-G), which was the primary outcome.
__label__noRel	At the six month follow-up, most of these effects were maintained and an intervention effect for breast cancer specific quality of life emerged.	No adverse effects were noted.
__label__noRel	At the six month follow-up, most of these effects were maintained and an intervention effect for breast cancer specific quality of life emerged.	Supervised group exercise provided functional and psychological benefit after a 12 week intervention and six months later.
__label__noRel	At the six month follow-up, most of these effects were maintained and an intervention effect for breast cancer specific quality of life emerged.	Clinicians should encourage activity for their patients.
__label__noRel	At the six month follow-up, most of these effects were maintained and an intervention effect for breast cancer specific quality of life emerged.	Policy makers should consider the inclusion of exercise opportunities in cancer rehabilitation services.
__label__noRel	At the six month follow-up, most of these effects were maintained and an intervention effect for breast cancer specific quality of life emerged.	Mixed effects models with adjustment for baseline values, study site, treatment at baseline, and age gave intervention effect estimates (intervention minus control) at 12 weeks of 129 (95% confidence interval 83 to 176) for metres walked in 12 minutes, 182 (75 to 289) for minutes of moderate intensity activity reported in a week, 2.6 (1.6 to 3.7) for shoulder mobility, 2.5 (1.0 to 3.9) for breast cancer specific subscale of quality of life, and 4.0 (1.8 to 6.3) for positive mood.
__label__noRel	No adverse effects were noted.	No significant effect was seen for general quality of life (FACT-G), which was the primary outcome.
__label__noRel	No adverse effects were noted.	At the six month follow-up, most of these effects were maintained and an intervention effect for breast cancer specific quality of life emerged.
__label__noRel	No adverse effects were noted.	Supervised group exercise provided functional and psychological benefit after a 12 week intervention and six months later.
__label__Support	No adverse effects were noted.	Clinicians should encourage activity for their patients.
__label__noRel	No adverse effects were noted.	Policy makers should consider the inclusion of exercise opportunities in cancer rehabilitation services.
__label__noRel	No adverse effects were noted.	Mixed effects models with adjustment for baseline values, study site, treatment at baseline, and age gave intervention effect estimates (intervention minus control) at 12 weeks of 129 (95% confidence interval 83 to 176) for metres walked in 12 minutes, 182 (75 to 289) for minutes of moderate intensity activity reported in a week, 2.6 (1.6 to 3.7) for shoulder mobility, 2.5 (1.0 to 3.9) for breast cancer specific subscale of quality of life, and 4.0 (1.8 to 6.3) for positive mood.
__label__noRel	Supervised group exercise provided functional and psychological benefit after a 12 week intervention and six months later.	No significant effect was seen for general quality of life (FACT-G), which was the primary outcome.
__label__noRel	Supervised group exercise provided functional and psychological benefit after a 12 week intervention and six months later.	At the six month follow-up, most of these effects were maintained and an intervention effect for breast cancer specific quality of life emerged.
__label__noRel	Supervised group exercise provided functional and psychological benefit after a 12 week intervention and six months later.	No adverse effects were noted.
__label__Support	Supervised group exercise provided functional and psychological benefit after a 12 week intervention and six months later.	Clinicians should encourage activity for their patients.
__label__noRel	Supervised group exercise provided functional and psychological benefit after a 12 week intervention and six months later.	Policy makers should consider the inclusion of exercise opportunities in cancer rehabilitation services.
__label__noRel	Supervised group exercise provided functional and psychological benefit after a 12 week intervention and six months later.	Mixed effects models with adjustment for baseline values, study site, treatment at baseline, and age gave intervention effect estimates (intervention minus control) at 12 weeks of 129 (95% confidence interval 83 to 176) for metres walked in 12 minutes, 182 (75 to 289) for minutes of moderate intensity activity reported in a week, 2.6 (1.6 to 3.7) for shoulder mobility, 2.5 (1.0 to 3.9) for breast cancer specific subscale of quality of life, and 4.0 (1.8 to 6.3) for positive mood.
__label__noRel	Clinicians should encourage activity for their patients.	No significant effect was seen for general quality of life (FACT-G), which was the primary outcome.
__label__noRel	Clinicians should encourage activity for their patients.	At the six month follow-up, most of these effects were maintained and an intervention effect for breast cancer specific quality of life emerged.
__label__noRel	Clinicians should encourage activity for their patients.	No adverse effects were noted.
__label__noRel	Clinicians should encourage activity for their patients.	Supervised group exercise provided functional and psychological benefit after a 12 week intervention and six months later.
__label__noRel	Clinicians should encourage activity for their patients.	Policy makers should consider the inclusion of exercise opportunities in cancer rehabilitation services.
__label__noRel	Clinicians should encourage activity for their patients.	Mixed effects models with adjustment for baseline values, study site, treatment at baseline, and age gave intervention effect estimates (intervention minus control) at 12 weeks of 129 (95% confidence interval 83 to 176) for metres walked in 12 minutes, 182 (75 to 289) for minutes of moderate intensity activity reported in a week, 2.6 (1.6 to 3.7) for shoulder mobility, 2.5 (1.0 to 3.9) for breast cancer specific subscale of quality of life, and 4.0 (1.8 to 6.3) for positive mood.
__label__noRel	Policy makers should consider the inclusion of exercise opportunities in cancer rehabilitation services.	No significant effect was seen for general quality of life (FACT-G), which was the primary outcome.
__label__noRel	Policy makers should consider the inclusion of exercise opportunities in cancer rehabilitation services.	At the six month follow-up, most of these effects were maintained and an intervention effect for breast cancer specific quality of life emerged.
__label__noRel	Policy makers should consider the inclusion of exercise opportunities in cancer rehabilitation services.	No adverse effects were noted.
__label__noRel	Policy makers should consider the inclusion of exercise opportunities in cancer rehabilitation services.	Supervised group exercise provided functional and psychological benefit after a 12 week intervention and six months later.
__label__noRel	Policy makers should consider the inclusion of exercise opportunities in cancer rehabilitation services.	Clinicians should encourage activity for their patients.
__label__noRel	Policy makers should consider the inclusion of exercise opportunities in cancer rehabilitation services.	Mixed effects models with adjustment for baseline values, study site, treatment at baseline, and age gave intervention effect estimates (intervention minus control) at 12 weeks of 129 (95% confidence interval 83 to 176) for metres walked in 12 minutes, 182 (75 to 289) for minutes of moderate intensity activity reported in a week, 2.6 (1.6 to 3.7) for shoulder mobility, 2.5 (1.0 to 3.9) for breast cancer specific subscale of quality of life, and 4.0 (1.8 to 6.3) for positive mood.
__label__noRel	Mixed effects models with adjustment for baseline values, study site, treatment at baseline, and age gave intervention effect estimates (intervention minus control) at 12 weeks of 129 (95% confidence interval 83 to 176) for metres walked in 12 minutes, 182 (75 to 289) for minutes of moderate intensity activity reported in a week, 2.6 (1.6 to 3.7) for shoulder mobility, 2.5 (1.0 to 3.9) for breast cancer specific subscale of quality of life, and 4.0 (1.8 to 6.3) for positive mood.	No significant effect was seen for general quality of life (FACT-G), which was the primary outcome.
__label__noRel	Mixed effects models with adjustment for baseline values, study site, treatment at baseline, and age gave intervention effect estimates (intervention minus control) at 12 weeks of 129 (95% confidence interval 83 to 176) for metres walked in 12 minutes, 182 (75 to 289) for minutes of moderate intensity activity reported in a week, 2.6 (1.6 to 3.7) for shoulder mobility, 2.5 (1.0 to 3.9) for breast cancer specific subscale of quality of life, and 4.0 (1.8 to 6.3) for positive mood.	At the six month follow-up, most of these effects were maintained and an intervention effect for breast cancer specific quality of life emerged.
__label__noRel	Mixed effects models with adjustment for baseline values, study site, treatment at baseline, and age gave intervention effect estimates (intervention minus control) at 12 weeks of 129 (95% confidence interval 83 to 176) for metres walked in 12 minutes, 182 (75 to 289) for minutes of moderate intensity activity reported in a week, 2.6 (1.6 to 3.7) for shoulder mobility, 2.5 (1.0 to 3.9) for breast cancer specific subscale of quality of life, and 4.0 (1.8 to 6.3) for positive mood.	No adverse effects were noted.
__label__Support	Mixed effects models with adjustment for baseline values, study site, treatment at baseline, and age gave intervention effect estimates (intervention minus control) at 12 weeks of 129 (95% confidence interval 83 to 176) for metres walked in 12 minutes, 182 (75 to 289) for minutes of moderate intensity activity reported in a week, 2.6 (1.6 to 3.7) for shoulder mobility, 2.5 (1.0 to 3.9) for breast cancer specific subscale of quality of life, and 4.0 (1.8 to 6.3) for positive mood.	Supervised group exercise provided functional and psychological benefit after a 12 week intervention and six months later.
__label__noRel	Mixed effects models with adjustment for baseline values, study site, treatment at baseline, and age gave intervention effect estimates (intervention minus control) at 12 weeks of 129 (95% confidence interval 83 to 176) for metres walked in 12 minutes, 182 (75 to 289) for minutes of moderate intensity activity reported in a week, 2.6 (1.6 to 3.7) for shoulder mobility, 2.5 (1.0 to 3.9) for breast cancer specific subscale of quality of life, and 4.0 (1.8 to 6.3) for positive mood.	Clinicians should encourage activity for their patients.
__label__noRel	Mixed effects models with adjustment for baseline values, study site, treatment at baseline, and age gave intervention effect estimates (intervention minus control) at 12 weeks of 129 (95% confidence interval 83 to 176) for metres walked in 12 minutes, 182 (75 to 289) for minutes of moderate intensity activity reported in a week, 2.6 (1.6 to 3.7) for shoulder mobility, 2.5 (1.0 to 3.9) for breast cancer specific subscale of quality of life, and 4.0 (1.8 to 6.3) for positive mood.	Policy makers should consider the inclusion of exercise opportunities in cancer rehabilitation services.
__label__noRel	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).
__label__noRel	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.
__label__noRel	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.	There were no group differences with respect to survival.
__label__Support	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.
__label__noRel	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.
__label__noRel	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.
__label__noRel	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.
__label__noRel	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.
__label__noRel	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.
__label__noRel	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).	There were no group differences with respect to survival.
__label__noRel	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.
__label__Support	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.
__label__noRel	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.
__label__noRel	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.
__label__noRel	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.
__label__noRel	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).
__label__noRel	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.	There were no group differences with respect to survival.
__label__Support	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.
__label__noRel	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.
__label__noRel	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.
__label__noRel	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.
__label__noRel	There were no group differences with respect to survival.	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.
__label__noRel	There were no group differences with respect to survival.	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).
__label__noRel	There were no group differences with respect to survival.	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.
__label__noRel	There were no group differences with respect to survival.	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.
__label__noRel	There were no group differences with respect to survival.	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.
__label__noRel	There were no group differences with respect to survival.	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.
__label__noRel	There were no group differences with respect to survival.	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.
__label__noRel	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.
__label__noRel	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).
__label__noRel	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.
__label__noRel	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.	There were no group differences with respect to survival.
__label__noRel	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.
__label__Support	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.
__label__noRel	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.
__label__noRel	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.
__label__noRel	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).
__label__noRel	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.
__label__noRel	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.	There were no group differences with respect to survival.
__label__noRel	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.
__label__Support	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.
__label__noRel	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.
__label__noRel	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.
__label__noRel	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).
__label__noRel	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.
__label__noRel	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.	There were no group differences with respect to survival.
__label__noRel	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.
__label__noRel	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.
__label__noRel	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.
__label__noRel	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.
__label__noRel	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).
__label__noRel	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.
__label__noRel	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.	There were no group differences with respect to survival.
__label__noRel	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.
__label__noRel	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.
__label__noRel	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.
__label__noRel	The study results suggest that K-tape could replace the bandage in DLT, and it could be an alternative choice for the breast-cancer-related lymphedema patient with poor short-stretch bandage compliance after 1-month intervention.	The acceptance of K-tape was better than the bandage, and benefits included longer wearing time, less difficulty in usage, and increased comfort and convenience (P < 0.05).
__label__noRel	The study results suggest that K-tape could replace the bandage in DLT, and it could be an alternative choice for the breast-cancer-related lymphedema patient with poor short-stretch bandage compliance after 1-month intervention.	There was no significant difference between groups in all outcome variables (P > 0.05) through the whole study period.
__label__noRel	The study results suggest that K-tape could replace the bandage in DLT, and it could be an alternative choice for the breast-cancer-related lymphedema patient with poor short-stretch bandage compliance after 1-month intervention.	Excess limb size (circumference and water displacement) and excess water composition were reduced significantly in the bandage group;
__label__noRel	The study results suggest that K-tape could replace the bandage in DLT, and it could be an alternative choice for the breast-cancer-related lymphedema patient with poor short-stretch bandage compliance after 1-month intervention.	excess circumference and excess water composition were reduced significantly in the tape group.
__label__noRel	The study results suggest that K-tape could replace the bandage in DLT, and it could be an alternative choice for the breast-cancer-related lymphedema patient with poor short-stretch bandage compliance after 1-month intervention.	More efficient treatment protocol is needed for clinical practice.
__label__noRel	The study results suggest that K-tape could replace the bandage in DLT, and it could be an alternative choice for the breast-cancer-related lymphedema patient with poor short-stretch bandage compliance after 1-month intervention.	these two treatment protocols are inefficient and cost time in application.
__label__Support	The acceptance of K-tape was better than the bandage, and benefits included longer wearing time, less difficulty in usage, and increased comfort and convenience (P < 0.05).	The study results suggest that K-tape could replace the bandage in DLT, and it could be an alternative choice for the breast-cancer-related lymphedema patient with poor short-stretch bandage compliance after 1-month intervention.
__label__noRel	The acceptance of K-tape was better than the bandage, and benefits included longer wearing time, less difficulty in usage, and increased comfort and convenience (P < 0.05).	There was no significant difference between groups in all outcome variables (P > 0.05) through the whole study period.
__label__noRel	The acceptance of K-tape was better than the bandage, and benefits included longer wearing time, less difficulty in usage, and increased comfort and convenience (P < 0.05).	Excess limb size (circumference and water displacement) and excess water composition were reduced significantly in the bandage group;
__label__noRel	The acceptance of K-tape was better than the bandage, and benefits included longer wearing time, less difficulty in usage, and increased comfort and convenience (P < 0.05).	excess circumference and excess water composition were reduced significantly in the tape group.
__label__noRel	The acceptance of K-tape was better than the bandage, and benefits included longer wearing time, less difficulty in usage, and increased comfort and convenience (P < 0.05).	More efficient treatment protocol is needed for clinical practice.
__label__noRel	The acceptance of K-tape was better than the bandage, and benefits included longer wearing time, less difficulty in usage, and increased comfort and convenience (P < 0.05).	these two treatment protocols are inefficient and cost time in application.
__label__Support	There was no significant difference between groups in all outcome variables (P > 0.05) through the whole study period.	The study results suggest that K-tape could replace the bandage in DLT, and it could be an alternative choice for the breast-cancer-related lymphedema patient with poor short-stretch bandage compliance after 1-month intervention.
__label__noRel	There was no significant difference between groups in all outcome variables (P > 0.05) through the whole study period.	The acceptance of K-tape was better than the bandage, and benefits included longer wearing time, less difficulty in usage, and increased comfort and convenience (P < 0.05).
__label__noRel	There was no significant difference between groups in all outcome variables (P > 0.05) through the whole study period.	Excess limb size (circumference and water displacement) and excess water composition were reduced significantly in the bandage group;
__label__noRel	There was no significant difference between groups in all outcome variables (P > 0.05) through the whole study period.	excess circumference and excess water composition were reduced significantly in the tape group.
__label__noRel	There was no significant difference between groups in all outcome variables (P > 0.05) through the whole study period.	More efficient treatment protocol is needed for clinical practice.
__label__noRel	There was no significant difference between groups in all outcome variables (P > 0.05) through the whole study period.	these two treatment protocols are inefficient and cost time in application.
__label__Support	Excess limb size (circumference and water displacement) and excess water composition were reduced significantly in the bandage group;	The study results suggest that K-tape could replace the bandage in DLT, and it could be an alternative choice for the breast-cancer-related lymphedema patient with poor short-stretch bandage compliance after 1-month intervention.
__label__noRel	Excess limb size (circumference and water displacement) and excess water composition were reduced significantly in the bandage group;	The acceptance of K-tape was better than the bandage, and benefits included longer wearing time, less difficulty in usage, and increased comfort and convenience (P < 0.05).
__label__noRel	Excess limb size (circumference and water displacement) and excess water composition were reduced significantly in the bandage group;	There was no significant difference between groups in all outcome variables (P > 0.05) through the whole study period.
__label__noRel	Excess limb size (circumference and water displacement) and excess water composition were reduced significantly in the bandage group;	excess circumference and excess water composition were reduced significantly in the tape group.
__label__noRel	Excess limb size (circumference and water displacement) and excess water composition were reduced significantly in the bandage group;	More efficient treatment protocol is needed for clinical practice.
__label__noRel	Excess limb size (circumference and water displacement) and excess water composition were reduced significantly in the bandage group;	these two treatment protocols are inefficient and cost time in application.
__label__Support	excess circumference and excess water composition were reduced significantly in the tape group.	The study results suggest that K-tape could replace the bandage in DLT, and it could be an alternative choice for the breast-cancer-related lymphedema patient with poor short-stretch bandage compliance after 1-month intervention.
__label__noRel	excess circumference and excess water composition were reduced significantly in the tape group.	The acceptance of K-tape was better than the bandage, and benefits included longer wearing time, less difficulty in usage, and increased comfort and convenience (P < 0.05).
__label__noRel	excess circumference and excess water composition were reduced significantly in the tape group.	There was no significant difference between groups in all outcome variables (P > 0.05) through the whole study period.
__label__noRel	excess circumference and excess water composition were reduced significantly in the tape group.	Excess limb size (circumference and water displacement) and excess water composition were reduced significantly in the bandage group;
__label__noRel	excess circumference and excess water composition were reduced significantly in the tape group.	More efficient treatment protocol is needed for clinical practice.
__label__noRel	excess circumference and excess water composition were reduced significantly in the tape group.	these two treatment protocols are inefficient and cost time in application.
__label__noRel	More efficient treatment protocol is needed for clinical practice.	The study results suggest that K-tape could replace the bandage in DLT, and it could be an alternative choice for the breast-cancer-related lymphedema patient with poor short-stretch bandage compliance after 1-month intervention.
__label__noRel	More efficient treatment protocol is needed for clinical practice.	The acceptance of K-tape was better than the bandage, and benefits included longer wearing time, less difficulty in usage, and increased comfort and convenience (P < 0.05).
__label__noRel	More efficient treatment protocol is needed for clinical practice.	There was no significant difference between groups in all outcome variables (P > 0.05) through the whole study period.
__label__noRel	More efficient treatment protocol is needed for clinical practice.	Excess limb size (circumference and water displacement) and excess water composition were reduced significantly in the bandage group;
__label__noRel	More efficient treatment protocol is needed for clinical practice.	excess circumference and excess water composition were reduced significantly in the tape group.
__label__noRel	More efficient treatment protocol is needed for clinical practice.	these two treatment protocols are inefficient and cost time in application.
__label__Attack	these two treatment protocols are inefficient and cost time in application.	The study results suggest that K-tape could replace the bandage in DLT, and it could be an alternative choice for the breast-cancer-related lymphedema patient with poor short-stretch bandage compliance after 1-month intervention.
__label__noRel	these two treatment protocols are inefficient and cost time in application.	The acceptance of K-tape was better than the bandage, and benefits included longer wearing time, less difficulty in usage, and increased comfort and convenience (P < 0.05).
__label__noRel	these two treatment protocols are inefficient and cost time in application.	There was no significant difference between groups in all outcome variables (P > 0.05) through the whole study period.
__label__noRel	these two treatment protocols are inefficient and cost time in application.	Excess limb size (circumference and water displacement) and excess water composition were reduced significantly in the bandage group;
__label__noRel	these two treatment protocols are inefficient and cost time in application.	excess circumference and excess water composition were reduced significantly in the tape group.
__label__noRel	these two treatment protocols are inefficient and cost time in application.	More efficient treatment protocol is needed for clinical practice.
__label__noRel	With a median follow-up of 569 months (IQR 374-818) from randomisation and 370 deaths (186 early, 184 delayed), there was no evidence of a difference in overall survival between early and delayed treatment (HR 098, 95% CI 080-120, p=085).	Median survival from randomisation was 257 months (95% CI 230-279) for patients on early treatment and 271 months (228-309) for those on delayed treatment.
__label__Support	With a median follow-up of 569 months (IQR 374-818) from randomisation and 370 deaths (186 early, 184 delayed), there was no evidence of a difference in overall survival between early and delayed treatment (HR 098, 95% CI 080-120, p=085).	Our findings showed no evidence of a survival benefit with early treatment of relapse on the basis of a raised CA125 concentration alone,
__label__noRel	With a median follow-up of 569 months (IQR 374-818) from randomisation and 370 deaths (186 early, 184 delayed), there was no evidence of a difference in overall survival between early and delayed treatment (HR 098, 95% CI 080-120, p=085).	and therefore the value of routine measurement of CA125 in the follow-up of patients with ovarian cancer who attain a complete response after first-line treatment is not proven.
__label__noRel	Median survival from randomisation was 257 months (95% CI 230-279) for patients on early treatment and 271 months (228-309) for those on delayed treatment.	With a median follow-up of 569 months (IQR 374-818) from randomisation and 370 deaths (186 early, 184 delayed), there was no evidence of a difference in overall survival between early and delayed treatment (HR 098, 95% CI 080-120, p=085).
__label__Support	Median survival from randomisation was 257 months (95% CI 230-279) for patients on early treatment and 271 months (228-309) for those on delayed treatment.	Our findings showed no evidence of a survival benefit with early treatment of relapse on the basis of a raised CA125 concentration alone,
__label__noRel	Median survival from randomisation was 257 months (95% CI 230-279) for patients on early treatment and 271 months (228-309) for those on delayed treatment.	and therefore the value of routine measurement of CA125 in the follow-up of patients with ovarian cancer who attain a complete response after first-line treatment is not proven.
__label__noRel	Our findings showed no evidence of a survival benefit with early treatment of relapse on the basis of a raised CA125 concentration alone,	With a median follow-up of 569 months (IQR 374-818) from randomisation and 370 deaths (186 early, 184 delayed), there was no evidence of a difference in overall survival between early and delayed treatment (HR 098, 95% CI 080-120, p=085).
__label__noRel	Our findings showed no evidence of a survival benefit with early treatment of relapse on the basis of a raised CA125 concentration alone,	Median survival from randomisation was 257 months (95% CI 230-279) for patients on early treatment and 271 months (228-309) for those on delayed treatment.
__label__Support	Our findings showed no evidence of a survival benefit with early treatment of relapse on the basis of a raised CA125 concentration alone,	and therefore the value of routine measurement of CA125 in the follow-up of patients with ovarian cancer who attain a complete response after first-line treatment is not proven.
__label__noRel	and therefore the value of routine measurement of CA125 in the follow-up of patients with ovarian cancer who attain a complete response after first-line treatment is not proven.	With a median follow-up of 569 months (IQR 374-818) from randomisation and 370 deaths (186 early, 184 delayed), there was no evidence of a difference in overall survival between early and delayed treatment (HR 098, 95% CI 080-120, p=085).
__label__noRel	and therefore the value of routine measurement of CA125 in the follow-up of patients with ovarian cancer who attain a complete response after first-line treatment is not proven.	Median survival from randomisation was 257 months (95% CI 230-279) for patients on early treatment and 271 months (228-309) for those on delayed treatment.
__label__noRel	and therefore the value of routine measurement of CA125 in the follow-up of patients with ovarian cancer who attain a complete response after first-line treatment is not proven.	Our findings showed no evidence of a survival benefit with early treatment of relapse on the basis of a raised CA125 concentration alone,
__label__noRel	Patients carrying a GCLC 77 genotype had a worse overall survival (hazard ratio (HR) = 1.5, p = 0.05).	Patients carrying the GPX1-CC genotype had a clinically significant decline in the UNISCALE (odds ratio (OR): 7.5; p = 0.04), total Functional Assessment of Cancer Therapy-Lung score (OR: 11.0; p = 0.04), physical (OR: 7.1; p = 0.03), functional (OR: 5.2; p = 0.04), and emotional well-being constructs (OR: 23.8; p = 0.01).
__label__noRel	Patients carrying a GCLC 77 genotype had a worse overall survival (hazard ratio (HR) = 1.5, p = 0.05).	Genotypes of glutathione-related enzymes, especially GCLC, may be used as host factors in predicting patients' survival after platinum-based chemotherapy.
__label__noRel	Patients carrying a GCLC 77 genotype had a worse overall survival (hazard ratio (HR) = 1.5, p = 0.05).	GPX1 may be an inherited factor in predicting patients' QOL.
__label__noRel	Patients carrying a GCLC 77 genotype had a worse overall survival (hazard ratio (HR) = 1.5, p = 0.05).	Further investigation to define and measure the effects of these genes in chemotherapeutic regimens, drug toxicities, disease progression, and QOL are critical.
__label__noRel	Patients carrying the GPX1-CC genotype had a clinically significant decline in the UNISCALE (odds ratio (OR): 7.5; p = 0.04), total Functional Assessment of Cancer Therapy-Lung score (OR: 11.0; p = 0.04), physical (OR: 7.1; p = 0.03), functional (OR: 5.2; p = 0.04), and emotional well-being constructs (OR: 23.8; p = 0.01).	Patients carrying a GCLC 77 genotype had a worse overall survival (hazard ratio (HR) = 1.5, p = 0.05).
__label__noRel	Patients carrying the GPX1-CC genotype had a clinically significant decline in the UNISCALE (odds ratio (OR): 7.5; p = 0.04), total Functional Assessment of Cancer Therapy-Lung score (OR: 11.0; p = 0.04), physical (OR: 7.1; p = 0.03), functional (OR: 5.2; p = 0.04), and emotional well-being constructs (OR: 23.8; p = 0.01).	Genotypes of glutathione-related enzymes, especially GCLC, may be used as host factors in predicting patients' survival after platinum-based chemotherapy.
__label__noRel	Patients carrying the GPX1-CC genotype had a clinically significant decline in the UNISCALE (odds ratio (OR): 7.5; p = 0.04), total Functional Assessment of Cancer Therapy-Lung score (OR: 11.0; p = 0.04), physical (OR: 7.1; p = 0.03), functional (OR: 5.2; p = 0.04), and emotional well-being constructs (OR: 23.8; p = 0.01).	GPX1 may be an inherited factor in predicting patients' QOL.
__label__noRel	Patients carrying the GPX1-CC genotype had a clinically significant decline in the UNISCALE (odds ratio (OR): 7.5; p = 0.04), total Functional Assessment of Cancer Therapy-Lung score (OR: 11.0; p = 0.04), physical (OR: 7.1; p = 0.03), functional (OR: 5.2; p = 0.04), and emotional well-being constructs (OR: 23.8; p = 0.01).	Further investigation to define and measure the effects of these genes in chemotherapeutic regimens, drug toxicities, disease progression, and QOL are critical.
__label__noRel	Genotypes of glutathione-related enzymes, especially GCLC, may be used as host factors in predicting patients' survival after platinum-based chemotherapy.	Patients carrying a GCLC 77 genotype had a worse overall survival (hazard ratio (HR) = 1.5, p = 0.05).
__label__noRel	Genotypes of glutathione-related enzymes, especially GCLC, may be used as host factors in predicting patients' survival after platinum-based chemotherapy.	Patients carrying the GPX1-CC genotype had a clinically significant decline in the UNISCALE (odds ratio (OR): 7.5; p = 0.04), total Functional Assessment of Cancer Therapy-Lung score (OR: 11.0; p = 0.04), physical (OR: 7.1; p = 0.03), functional (OR: 5.2; p = 0.04), and emotional well-being constructs (OR: 23.8; p = 0.01).
__label__noRel	Genotypes of glutathione-related enzymes, especially GCLC, may be used as host factors in predicting patients' survival after platinum-based chemotherapy.	GPX1 may be an inherited factor in predicting patients' QOL.
__label__noRel	Genotypes of glutathione-related enzymes, especially GCLC, may be used as host factors in predicting patients' survival after platinum-based chemotherapy.	Further investigation to define and measure the effects of these genes in chemotherapeutic regimens, drug toxicities, disease progression, and QOL are critical.
__label__noRel	GPX1 may be an inherited factor in predicting patients' QOL.	Patients carrying a GCLC 77 genotype had a worse overall survival (hazard ratio (HR) = 1.5, p = 0.05).
__label__noRel	GPX1 may be an inherited factor in predicting patients' QOL.	Patients carrying the GPX1-CC genotype had a clinically significant decline in the UNISCALE (odds ratio (OR): 7.5; p = 0.04), total Functional Assessment of Cancer Therapy-Lung score (OR: 11.0; p = 0.04), physical (OR: 7.1; p = 0.03), functional (OR: 5.2; p = 0.04), and emotional well-being constructs (OR: 23.8; p = 0.01).
__label__noRel	GPX1 may be an inherited factor in predicting patients' QOL.	Genotypes of glutathione-related enzymes, especially GCLC, may be used as host factors in predicting patients' survival after platinum-based chemotherapy.
__label__noRel	GPX1 may be an inherited factor in predicting patients' QOL.	Further investigation to define and measure the effects of these genes in chemotherapeutic regimens, drug toxicities, disease progression, and QOL are critical.
__label__noRel	Further investigation to define and measure the effects of these genes in chemotherapeutic regimens, drug toxicities, disease progression, and QOL are critical.	Patients carrying a GCLC 77 genotype had a worse overall survival (hazard ratio (HR) = 1.5, p = 0.05).
__label__noRel	Further investigation to define and measure the effects of these genes in chemotherapeutic regimens, drug toxicities, disease progression, and QOL are critical.	Patients carrying the GPX1-CC genotype had a clinically significant decline in the UNISCALE (odds ratio (OR): 7.5; p = 0.04), total Functional Assessment of Cancer Therapy-Lung score (OR: 11.0; p = 0.04), physical (OR: 7.1; p = 0.03), functional (OR: 5.2; p = 0.04), and emotional well-being constructs (OR: 23.8; p = 0.01).
__label__noRel	Further investigation to define and measure the effects of these genes in chemotherapeutic regimens, drug toxicities, disease progression, and QOL are critical.	Genotypes of glutathione-related enzymes, especially GCLC, may be used as host factors in predicting patients' survival after platinum-based chemotherapy.
__label__noRel	Further investigation to define and measure the effects of these genes in chemotherapeutic regimens, drug toxicities, disease progression, and QOL are critical.	GPX1 may be an inherited factor in predicting patients' QOL.
__label__noRel	The most common reason for dropout was patients feeling too ill.	Attrition rates did not vary significantly between study arms.
__label__noRel	The most common reason for dropout was patients feeling too ill.	There were no other significant associations between attrition and any demographic, medical, psychiatric, or study-related variables.
__label__noRel	The most common reason for dropout was patients feeling too ill.	These findings highlight the challenge of maintaining advanced cancer patients in longitudinal research and suggest the need to consider alternative approaches (e.g., telemedicine) for patients who might benefit from group interventions but are too ill to travel.
__label__noRel	The most common reason for dropout was patients feeling too ill.	The generalizability of palliative care intervention research is often limited by high rates of study attrition.
__label__noRel	The most common reason for dropout was patients feeling too ill.	The rates of attrition at these time points were 28.1%, 17.7%, and 11.1%, respectively; 43.1% of the participants (66 of 153) completed the entire study.
__label__noRel	Attrition rates did not vary significantly between study arms.	The most common reason for dropout was patients feeling too ill.
__label__noRel	Attrition rates did not vary significantly between study arms.	There were no other significant associations between attrition and any demographic, medical, psychiatric, or study-related variables.
__label__noRel	Attrition rates did not vary significantly between study arms.	These findings highlight the challenge of maintaining advanced cancer patients in longitudinal research and suggest the need to consider alternative approaches (e.g., telemedicine) for patients who might benefit from group interventions but are too ill to travel.
__label__noRel	Attrition rates did not vary significantly between study arms.	The generalizability of palliative care intervention research is often limited by high rates of study attrition.
__label__noRel	Attrition rates did not vary significantly between study arms.	The rates of attrition at these time points were 28.1%, 17.7%, and 11.1%, respectively; 43.1% of the participants (66 of 153) completed the entire study.
__label__noRel	There were no other significant associations between attrition and any demographic, medical, psychiatric, or study-related variables.	The most common reason for dropout was patients feeling too ill.
__label__noRel	There were no other significant associations between attrition and any demographic, medical, psychiatric, or study-related variables.	Attrition rates did not vary significantly between study arms.
__label__noRel	There were no other significant associations between attrition and any demographic, medical, psychiatric, or study-related variables.	These findings highlight the challenge of maintaining advanced cancer patients in longitudinal research and suggest the need to consider alternative approaches (e.g., telemedicine) for patients who might benefit from group interventions but are too ill to travel.
__label__noRel	There were no other significant associations between attrition and any demographic, medical, psychiatric, or study-related variables.	The generalizability of palliative care intervention research is often limited by high rates of study attrition.
__label__noRel	There were no other significant associations between attrition and any demographic, medical, psychiatric, or study-related variables.	The rates of attrition at these time points were 28.1%, 17.7%, and 11.1%, respectively; 43.1% of the participants (66 of 153) completed the entire study.
__label__noRel	These findings highlight the challenge of maintaining advanced cancer patients in longitudinal research and suggest the need to consider alternative approaches (e.g., telemedicine) for patients who might benefit from group interventions but are too ill to travel.	The most common reason for dropout was patients feeling too ill.
__label__noRel	These findings highlight the challenge of maintaining advanced cancer patients in longitudinal research and suggest the need to consider alternative approaches (e.g., telemedicine) for patients who might benefit from group interventions but are too ill to travel.	Attrition rates did not vary significantly between study arms.
__label__noRel	These findings highlight the challenge of maintaining advanced cancer patients in longitudinal research and suggest the need to consider alternative approaches (e.g., telemedicine) for patients who might benefit from group interventions but are too ill to travel.	There were no other significant associations between attrition and any demographic, medical, psychiatric, or study-related variables.
__label__noRel	These findings highlight the challenge of maintaining advanced cancer patients in longitudinal research and suggest the need to consider alternative approaches (e.g., telemedicine) for patients who might benefit from group interventions but are too ill to travel.	The generalizability of palliative care intervention research is often limited by high rates of study attrition.
__label__noRel	These findings highlight the challenge of maintaining advanced cancer patients in longitudinal research and suggest the need to consider alternative approaches (e.g., telemedicine) for patients who might benefit from group interventions but are too ill to travel.	The rates of attrition at these time points were 28.1%, 17.7%, and 11.1%, respectively; 43.1% of the participants (66 of 153) completed the entire study.
__label__noRel	The generalizability of palliative care intervention research is often limited by high rates of study attrition.	The most common reason for dropout was patients feeling too ill.
__label__noRel	The generalizability of palliative care intervention research is often limited by high rates of study attrition.	Attrition rates did not vary significantly between study arms.
__label__noRel	The generalizability of palliative care intervention research is often limited by high rates of study attrition.	There were no other significant associations between attrition and any demographic, medical, psychiatric, or study-related variables.
__label__noRel	The generalizability of palliative care intervention research is often limited by high rates of study attrition.	These findings highlight the challenge of maintaining advanced cancer patients in longitudinal research and suggest the need to consider alternative approaches (e.g., telemedicine) for patients who might benefit from group interventions but are too ill to travel.
__label__noRel	The generalizability of palliative care intervention research is often limited by high rates of study attrition.	The rates of attrition at these time points were 28.1%, 17.7%, and 11.1%, respectively; 43.1% of the participants (66 of 153) completed the entire study.
__label__noRel	The rates of attrition at these time points were 28.1%, 17.7%, and 11.1%, respectively; 43.1% of the participants (66 of 153) completed the entire study.	The most common reason for dropout was patients feeling too ill.
__label__noRel	The rates of attrition at these time points were 28.1%, 17.7%, and 11.1%, respectively; 43.1% of the participants (66 of 153) completed the entire study.	Attrition rates did not vary significantly between study arms.
__label__noRel	The rates of attrition at these time points were 28.1%, 17.7%, and 11.1%, respectively; 43.1% of the participants (66 of 153) completed the entire study.	There were no other significant associations between attrition and any demographic, medical, psychiatric, or study-related variables.
__label__noRel	The rates of attrition at these time points were 28.1%, 17.7%, and 11.1%, respectively; 43.1% of the participants (66 of 153) completed the entire study.	These findings highlight the challenge of maintaining advanced cancer patients in longitudinal research and suggest the need to consider alternative approaches (e.g., telemedicine) for patients who might benefit from group interventions but are too ill to travel.
__label__Support	The rates of attrition at these time points were 28.1%, 17.7%, and 11.1%, respectively; 43.1% of the participants (66 of 153) completed the entire study.	The generalizability of palliative care intervention research is often limited by high rates of study attrition.
__label__noRel	Patients in both treatment conditions showed improvements in pain, depression, QOL, and self-efficacy, and caregivers in both conditions showed improvements in anxiety and self-efficacy from baseline to four-month follow-up.	Results of exploratory analyses suggested that the CST intervention was more beneficial to patients/caregivers with Stage II and III cancers,
__label__noRel	Patients in both treatment conditions showed improvements in pain, depression, QOL, and self-efficacy, and caregivers in both conditions showed improvements in anxiety and self-efficacy from baseline to four-month follow-up.	the education/support intervention was more beneficial to patients/caregivers with Stage I cancer.
__label__Support	Patients in both treatment conditions showed improvements in pain, depression, QOL, and self-efficacy, and caregivers in both conditions showed improvements in anxiety and self-efficacy from baseline to four-month follow-up.	results from this study suggest that psychosocial interventions can lead to improvements in a range of outcomes for cancer patients.
__label__noRel	Patients in both treatment conditions showed improvements in pain, depression, QOL, and self-efficacy, and caregivers in both conditions showed improvements in anxiety and self-efficacy from baseline to four-month follow-up.	Taken together with the broader literature in this area,
__label__noRel	Results of exploratory analyses suggested that the CST intervention was more beneficial to patients/caregivers with Stage II and III cancers,	Patients in both treatment conditions showed improvements in pain, depression, QOL, and self-efficacy, and caregivers in both conditions showed improvements in anxiety and self-efficacy from baseline to four-month follow-up.
__label__noRel	Results of exploratory analyses suggested that the CST intervention was more beneficial to patients/caregivers with Stage II and III cancers,	the education/support intervention was more beneficial to patients/caregivers with Stage I cancer.
__label__Support	Results of exploratory analyses suggested that the CST intervention was more beneficial to patients/caregivers with Stage II and III cancers,	results from this study suggest that psychosocial interventions can lead to improvements in a range of outcomes for cancer patients.
__label__noRel	Results of exploratory analyses suggested that the CST intervention was more beneficial to patients/caregivers with Stage II and III cancers,	Taken together with the broader literature in this area,
__label__noRel	the education/support intervention was more beneficial to patients/caregivers with Stage I cancer.	Patients in both treatment conditions showed improvements in pain, depression, QOL, and self-efficacy, and caregivers in both conditions showed improvements in anxiety and self-efficacy from baseline to four-month follow-up.
__label__noRel	the education/support intervention was more beneficial to patients/caregivers with Stage I cancer.	Results of exploratory analyses suggested that the CST intervention was more beneficial to patients/caregivers with Stage II and III cancers,
__label__Attack	the education/support intervention was more beneficial to patients/caregivers with Stage I cancer.	results from this study suggest that psychosocial interventions can lead to improvements in a range of outcomes for cancer patients.
__label__noRel	the education/support intervention was more beneficial to patients/caregivers with Stage I cancer.	Taken together with the broader literature in this area,
__label__noRel	results from this study suggest that psychosocial interventions can lead to improvements in a range of outcomes for cancer patients.	Patients in both treatment conditions showed improvements in pain, depression, QOL, and self-efficacy, and caregivers in both conditions showed improvements in anxiety and self-efficacy from baseline to four-month follow-up.
__label__noRel	results from this study suggest that psychosocial interventions can lead to improvements in a range of outcomes for cancer patients.	Results of exploratory analyses suggested that the CST intervention was more beneficial to patients/caregivers with Stage II and III cancers,
__label__noRel	results from this study suggest that psychosocial interventions can lead to improvements in a range of outcomes for cancer patients.	the education/support intervention was more beneficial to patients/caregivers with Stage I cancer.
__label__noRel	results from this study suggest that psychosocial interventions can lead to improvements in a range of outcomes for cancer patients.	Taken together with the broader literature in this area,
__label__noRel	Taken together with the broader literature in this area,	Patients in both treatment conditions showed improvements in pain, depression, QOL, and self-efficacy, and caregivers in both conditions showed improvements in anxiety and self-efficacy from baseline to four-month follow-up.
__label__noRel	Taken together with the broader literature in this area,	Results of exploratory analyses suggested that the CST intervention was more beneficial to patients/caregivers with Stage II and III cancers,
__label__noRel	Taken together with the broader literature in this area,	the education/support intervention was more beneficial to patients/caregivers with Stage I cancer.
__label__Support	Taken together with the broader literature in this area,	results from this study suggest that psychosocial interventions can lead to improvements in a range of outcomes for cancer patients.
__label__noRel	Relapse after completing adjuvant tamoxifen therapy is a persistent threat for women with hormone-responsive breast cancer.	At a median follow-up of 30 months, letrozole significantly improved disease-free survival (DFS; P<0.001), the primary end point, compared with placebo (hazard ratio [HR] for recurrence or contralateral breast cancer 0.58; 95% confidence interval [CI] 0.45, 0.76] P<0.001).
__label__noRel	Relapse after completing adjuvant tamoxifen therapy is a persistent threat for women with hormone-responsive breast cancer.	Furthermore, letrozole significantly improved distant DFS (HR=0.60; 95% CI 0.43, 0.84; P=0.002) and, in women with node-positive tumors, overall survival (HR=0.61; 95% CI 0.38, 0.98; P=0.04).
__label__noRel	Relapse after completing adjuvant tamoxifen therapy is a persistent threat for women with hormone-responsive breast cancer.	Clinical benefits, including an overall survival advantage, were also seen in women who crossed over from placebo to letrozole after unblinding, indicating that tumors remain sensitive to hormone therapy despite a prolonged period since discontinuation of tamoxifen.
__label__noRel	Relapse after completing adjuvant tamoxifen therapy is a persistent threat for women with hormone-responsive breast cancer.	MA.17 showed that letrozole is extremely well-tolerated relative to placebo.
__label__noRel	Relapse after completing adjuvant tamoxifen therapy is a persistent threat for women with hormone-responsive breast cancer.	Letrozole should be considered for all women completing tamoxifen;
__label__noRel	Relapse after completing adjuvant tamoxifen therapy is a persistent threat for women with hormone-responsive breast cancer.	new results from the post-unblinding analysis suggest that letrozole treatment should also be considered for all disease-free women for periods up to 5 years following completion of adjuvant tamoxifen.
__label__noRel	At a median follow-up of 30 months, letrozole significantly improved disease-free survival (DFS; P<0.001), the primary end point, compared with placebo (hazard ratio [HR] for recurrence or contralateral breast cancer 0.58; 95% confidence interval [CI] 0.45, 0.76] P<0.001).	Relapse after completing adjuvant tamoxifen therapy is a persistent threat for women with hormone-responsive breast cancer.
__label__noRel	At a median follow-up of 30 months, letrozole significantly improved disease-free survival (DFS; P<0.001), the primary end point, compared with placebo (hazard ratio [HR] for recurrence or contralateral breast cancer 0.58; 95% confidence interval [CI] 0.45, 0.76] P<0.001).	Furthermore, letrozole significantly improved distant DFS (HR=0.60; 95% CI 0.43, 0.84; P=0.002) and, in women with node-positive tumors, overall survival (HR=0.61; 95% CI 0.38, 0.98; P=0.04).
__label__noRel	At a median follow-up of 30 months, letrozole significantly improved disease-free survival (DFS; P<0.001), the primary end point, compared with placebo (hazard ratio [HR] for recurrence or contralateral breast cancer 0.58; 95% confidence interval [CI] 0.45, 0.76] P<0.001).	Clinical benefits, including an overall survival advantage, were also seen in women who crossed over from placebo to letrozole after unblinding, indicating that tumors remain sensitive to hormone therapy despite a prolonged period since discontinuation of tamoxifen.
__label__Support	At a median follow-up of 30 months, letrozole significantly improved disease-free survival (DFS; P<0.001), the primary end point, compared with placebo (hazard ratio [HR] for recurrence or contralateral breast cancer 0.58; 95% confidence interval [CI] 0.45, 0.76] P<0.001).	MA.17 showed that letrozole is extremely well-tolerated relative to placebo.
__label__noRel	At a median follow-up of 30 months, letrozole significantly improved disease-free survival (DFS; P<0.001), the primary end point, compared with placebo (hazard ratio [HR] for recurrence or contralateral breast cancer 0.58; 95% confidence interval [CI] 0.45, 0.76] P<0.001).	Letrozole should be considered for all women completing tamoxifen;
__label__noRel	At a median follow-up of 30 months, letrozole significantly improved disease-free survival (DFS; P<0.001), the primary end point, compared with placebo (hazard ratio [HR] for recurrence or contralateral breast cancer 0.58; 95% confidence interval [CI] 0.45, 0.76] P<0.001).	new results from the post-unblinding analysis suggest that letrozole treatment should also be considered for all disease-free women for periods up to 5 years following completion of adjuvant tamoxifen.
__label__noRel	Furthermore, letrozole significantly improved distant DFS (HR=0.60; 95% CI 0.43, 0.84; P=0.002) and, in women with node-positive tumors, overall survival (HR=0.61; 95% CI 0.38, 0.98; P=0.04).	Relapse after completing adjuvant tamoxifen therapy is a persistent threat for women with hormone-responsive breast cancer.
__label__noRel	Furthermore, letrozole significantly improved distant DFS (HR=0.60; 95% CI 0.43, 0.84; P=0.002) and, in women with node-positive tumors, overall survival (HR=0.61; 95% CI 0.38, 0.98; P=0.04).	At a median follow-up of 30 months, letrozole significantly improved disease-free survival (DFS; P<0.001), the primary end point, compared with placebo (hazard ratio [HR] for recurrence or contralateral breast cancer 0.58; 95% confidence interval [CI] 0.45, 0.76] P<0.001).
__label__noRel	Furthermore, letrozole significantly improved distant DFS (HR=0.60; 95% CI 0.43, 0.84; P=0.002) and, in women with node-positive tumors, overall survival (HR=0.61; 95% CI 0.38, 0.98; P=0.04).	Clinical benefits, including an overall survival advantage, were also seen in women who crossed over from placebo to letrozole after unblinding, indicating that tumors remain sensitive to hormone therapy despite a prolonged period since discontinuation of tamoxifen.
__label__Support	Furthermore, letrozole significantly improved distant DFS (HR=0.60; 95% CI 0.43, 0.84; P=0.002) and, in women with node-positive tumors, overall survival (HR=0.61; 95% CI 0.38, 0.98; P=0.04).	MA.17 showed that letrozole is extremely well-tolerated relative to placebo.
__label__noRel	Furthermore, letrozole significantly improved distant DFS (HR=0.60; 95% CI 0.43, 0.84; P=0.002) and, in women with node-positive tumors, overall survival (HR=0.61; 95% CI 0.38, 0.98; P=0.04).	Letrozole should be considered for all women completing tamoxifen;
__label__noRel	Furthermore, letrozole significantly improved distant DFS (HR=0.60; 95% CI 0.43, 0.84; P=0.002) and, in women with node-positive tumors, overall survival (HR=0.61; 95% CI 0.38, 0.98; P=0.04).	new results from the post-unblinding analysis suggest that letrozole treatment should also be considered for all disease-free women for periods up to 5 years following completion of adjuvant tamoxifen.
__label__noRel	Clinical benefits, including an overall survival advantage, were also seen in women who crossed over from placebo to letrozole after unblinding, indicating that tumors remain sensitive to hormone therapy despite a prolonged period since discontinuation of tamoxifen.	Relapse after completing adjuvant tamoxifen therapy is a persistent threat for women with hormone-responsive breast cancer.
__label__noRel	Clinical benefits, including an overall survival advantage, were also seen in women who crossed over from placebo to letrozole after unblinding, indicating that tumors remain sensitive to hormone therapy despite a prolonged period since discontinuation of tamoxifen.	At a median follow-up of 30 months, letrozole significantly improved disease-free survival (DFS; P<0.001), the primary end point, compared with placebo (hazard ratio [HR] for recurrence or contralateral breast cancer 0.58; 95% confidence interval [CI] 0.45, 0.76] P<0.001).
__label__noRel	Clinical benefits, including an overall survival advantage, were also seen in women who crossed over from placebo to letrozole after unblinding, indicating that tumors remain sensitive to hormone therapy despite a prolonged period since discontinuation of tamoxifen.	Furthermore, letrozole significantly improved distant DFS (HR=0.60; 95% CI 0.43, 0.84; P=0.002) and, in women with node-positive tumors, overall survival (HR=0.61; 95% CI 0.38, 0.98; P=0.04).
__label__Support	Clinical benefits, including an overall survival advantage, were also seen in women who crossed over from placebo to letrozole after unblinding, indicating that tumors remain sensitive to hormone therapy despite a prolonged period since discontinuation of tamoxifen.	MA.17 showed that letrozole is extremely well-tolerated relative to placebo.
__label__noRel	Clinical benefits, including an overall survival advantage, were also seen in women who crossed over from placebo to letrozole after unblinding, indicating that tumors remain sensitive to hormone therapy despite a prolonged period since discontinuation of tamoxifen.	Letrozole should be considered for all women completing tamoxifen;
__label__noRel	Clinical benefits, including an overall survival advantage, were also seen in women who crossed over from placebo to letrozole after unblinding, indicating that tumors remain sensitive to hormone therapy despite a prolonged period since discontinuation of tamoxifen.	new results from the post-unblinding analysis suggest that letrozole treatment should also be considered for all disease-free women for periods up to 5 years following completion of adjuvant tamoxifen.
__label__noRel	MA.17 showed that letrozole is extremely well-tolerated relative to placebo.	Relapse after completing adjuvant tamoxifen therapy is a persistent threat for women with hormone-responsive breast cancer.
__label__noRel	MA.17 showed that letrozole is extremely well-tolerated relative to placebo.	At a median follow-up of 30 months, letrozole significantly improved disease-free survival (DFS; P<0.001), the primary end point, compared with placebo (hazard ratio [HR] for recurrence or contralateral breast cancer 0.58; 95% confidence interval [CI] 0.45, 0.76] P<0.001).
__label__noRel	MA.17 showed that letrozole is extremely well-tolerated relative to placebo.	Furthermore, letrozole significantly improved distant DFS (HR=0.60; 95% CI 0.43, 0.84; P=0.002) and, in women with node-positive tumors, overall survival (HR=0.61; 95% CI 0.38, 0.98; P=0.04).
__label__noRel	MA.17 showed that letrozole is extremely well-tolerated relative to placebo.	Clinical benefits, including an overall survival advantage, were also seen in women who crossed over from placebo to letrozole after unblinding, indicating that tumors remain sensitive to hormone therapy despite a prolonged period since discontinuation of tamoxifen.
__label__Support	MA.17 showed that letrozole is extremely well-tolerated relative to placebo.	Letrozole should be considered for all women completing tamoxifen;
__label__noRel	MA.17 showed that letrozole is extremely well-tolerated relative to placebo.	new results from the post-unblinding analysis suggest that letrozole treatment should also be considered for all disease-free women for periods up to 5 years following completion of adjuvant tamoxifen.
__label__noRel	Letrozole should be considered for all women completing tamoxifen;	Relapse after completing adjuvant tamoxifen therapy is a persistent threat for women with hormone-responsive breast cancer.
__label__noRel	Letrozole should be considered for all women completing tamoxifen;	At a median follow-up of 30 months, letrozole significantly improved disease-free survival (DFS; P<0.001), the primary end point, compared with placebo (hazard ratio [HR] for recurrence or contralateral breast cancer 0.58; 95% confidence interval [CI] 0.45, 0.76] P<0.001).
__label__noRel	Letrozole should be considered for all women completing tamoxifen;	Furthermore, letrozole significantly improved distant DFS (HR=0.60; 95% CI 0.43, 0.84; P=0.002) and, in women with node-positive tumors, overall survival (HR=0.61; 95% CI 0.38, 0.98; P=0.04).
__label__noRel	Letrozole should be considered for all women completing tamoxifen;	Clinical benefits, including an overall survival advantage, were also seen in women who crossed over from placebo to letrozole after unblinding, indicating that tumors remain sensitive to hormone therapy despite a prolonged period since discontinuation of tamoxifen.
__label__noRel	Letrozole should be considered for all women completing tamoxifen;	MA.17 showed that letrozole is extremely well-tolerated relative to placebo.
__label__Support	Letrozole should be considered for all women completing tamoxifen;	new results from the post-unblinding analysis suggest that letrozole treatment should also be considered for all disease-free women for periods up to 5 years following completion of adjuvant tamoxifen.
__label__noRel	new results from the post-unblinding analysis suggest that letrozole treatment should also be considered for all disease-free women for periods up to 5 years following completion of adjuvant tamoxifen.	Relapse after completing adjuvant tamoxifen therapy is a persistent threat for women with hormone-responsive breast cancer.
__label__noRel	new results from the post-unblinding analysis suggest that letrozole treatment should also be considered for all disease-free women for periods up to 5 years following completion of adjuvant tamoxifen.	At a median follow-up of 30 months, letrozole significantly improved disease-free survival (DFS; P<0.001), the primary end point, compared with placebo (hazard ratio [HR] for recurrence or contralateral breast cancer 0.58; 95% confidence interval [CI] 0.45, 0.76] P<0.001).
__label__noRel	new results from the post-unblinding analysis suggest that letrozole treatment should also be considered for all disease-free women for periods up to 5 years following completion of adjuvant tamoxifen.	Furthermore, letrozole significantly improved distant DFS (HR=0.60; 95% CI 0.43, 0.84; P=0.002) and, in women with node-positive tumors, overall survival (HR=0.61; 95% CI 0.38, 0.98; P=0.04).
__label__noRel	new results from the post-unblinding analysis suggest that letrozole treatment should also be considered for all disease-free women for periods up to 5 years following completion of adjuvant tamoxifen.	Clinical benefits, including an overall survival advantage, were also seen in women who crossed over from placebo to letrozole after unblinding, indicating that tumors remain sensitive to hormone therapy despite a prolonged period since discontinuation of tamoxifen.
__label__noRel	new results from the post-unblinding analysis suggest that letrozole treatment should also be considered for all disease-free women for periods up to 5 years following completion of adjuvant tamoxifen.	MA.17 showed that letrozole is extremely well-tolerated relative to placebo.
__label__noRel	new results from the post-unblinding analysis suggest that letrozole treatment should also be considered for all disease-free women for periods up to 5 years following completion of adjuvant tamoxifen.	Letrozole should be considered for all women completing tamoxifen;
__label__noRel	Patients with advanced non-small cell lung cancer (NSCLC) do not have curative treatment options;	Overall, patients treated with either docetaxel-containing regimen had better QoL than VC-treated patients (LCSS global item "QoL today": P=0.064 for DC and P=0.016 for DCb versus VC; EQ-5D global item "health state today": P=0.016 for DC and P<0.001 for DCb versus VC).
__label__noRel	Patients with advanced non-small cell lung cancer (NSCLC) do not have curative treatment options;	DC-treated patients experienced improved pain relief compared with VC (P=0.033),
__label__noRel	Patients with advanced non-small cell lung cancer (NSCLC) do not have curative treatment options;	pain relief with DCb and VC was similar.
__label__noRel	Patients with advanced non-small cell lung cancer (NSCLC) do not have curative treatment options;	Patients treated with either docetaxel regimen had more favorable changes in performance status (P=0.065 for DC and P<0.001 for DCb versus VC) and mean weight loss (0.06 kg, gain of 0.08 kg, and 2.27 kg for DC, DCb, and VC, respectively; P<0.001 for both DC versus VC and DCb versus VC).
__label__noRel	Patients with advanced non-small cell lung cancer (NSCLC) do not have curative treatment options;	The TAX 326 study shows that docetaxel-platinum regimens relieve symptoms and improve QoL in patients with advanced NSCLC.
__label__noRel	Patients with advanced non-small cell lung cancer (NSCLC) do not have curative treatment options;	DCb and DC were superior to VC in all QoL outcomes assessed except for the difference between DC and VC in LCSS "QoL today", which was not significant.
__label__noRel	Overall, patients treated with either docetaxel-containing regimen had better QoL than VC-treated patients (LCSS global item "QoL today": P=0.064 for DC and P=0.016 for DCb versus VC; EQ-5D global item "health state today": P=0.016 for DC and P<0.001 for DCb versus VC).	Patients with advanced non-small cell lung cancer (NSCLC) do not have curative treatment options;
__label__noRel	Overall, patients treated with either docetaxel-containing regimen had better QoL than VC-treated patients (LCSS global item "QoL today": P=0.064 for DC and P=0.016 for DCb versus VC; EQ-5D global item "health state today": P=0.016 for DC and P<0.001 for DCb versus VC).	DC-treated patients experienced improved pain relief compared with VC (P=0.033),
__label__noRel	Overall, patients treated with either docetaxel-containing regimen had better QoL than VC-treated patients (LCSS global item "QoL today": P=0.064 for DC and P=0.016 for DCb versus VC; EQ-5D global item "health state today": P=0.016 for DC and P<0.001 for DCb versus VC).	pain relief with DCb and VC was similar.
__label__noRel	Overall, patients treated with either docetaxel-containing regimen had better QoL than VC-treated patients (LCSS global item "QoL today": P=0.064 for DC and P=0.016 for DCb versus VC; EQ-5D global item "health state today": P=0.016 for DC and P<0.001 for DCb versus VC).	Patients treated with either docetaxel regimen had more favorable changes in performance status (P=0.065 for DC and P<0.001 for DCb versus VC) and mean weight loss (0.06 kg, gain of 0.08 kg, and 2.27 kg for DC, DCb, and VC, respectively; P<0.001 for both DC versus VC and DCb versus VC).
__label__noRel	Overall, patients treated with either docetaxel-containing regimen had better QoL than VC-treated patients (LCSS global item "QoL today": P=0.064 for DC and P=0.016 for DCb versus VC; EQ-5D global item "health state today": P=0.016 for DC and P<0.001 for DCb versus VC).	The TAX 326 study shows that docetaxel-platinum regimens relieve symptoms and improve QoL in patients with advanced NSCLC.
__label__Support	Overall, patients treated with either docetaxel-containing regimen had better QoL than VC-treated patients (LCSS global item "QoL today": P=0.064 for DC and P=0.016 for DCb versus VC; EQ-5D global item "health state today": P=0.016 for DC and P<0.001 for DCb versus VC).	DCb and DC were superior to VC in all QoL outcomes assessed except for the difference between DC and VC in LCSS "QoL today", which was not significant.
__label__noRel	DC-treated patients experienced improved pain relief compared with VC (P=0.033),	Patients with advanced non-small cell lung cancer (NSCLC) do not have curative treatment options;
__label__noRel	DC-treated patients experienced improved pain relief compared with VC (P=0.033),	Overall, patients treated with either docetaxel-containing regimen had better QoL than VC-treated patients (LCSS global item "QoL today": P=0.064 for DC and P=0.016 for DCb versus VC; EQ-5D global item "health state today": P=0.016 for DC and P<0.001 for DCb versus VC).
__label__noRel	DC-treated patients experienced improved pain relief compared with VC (P=0.033),	pain relief with DCb and VC was similar.
__label__noRel	DC-treated patients experienced improved pain relief compared with VC (P=0.033),	Patients treated with either docetaxel regimen had more favorable changes in performance status (P=0.065 for DC and P<0.001 for DCb versus VC) and mean weight loss (0.06 kg, gain of 0.08 kg, and 2.27 kg for DC, DCb, and VC, respectively; P<0.001 for both DC versus VC and DCb versus VC).
__label__noRel	DC-treated patients experienced improved pain relief compared with VC (P=0.033),	The TAX 326 study shows that docetaxel-platinum regimens relieve symptoms and improve QoL in patients with advanced NSCLC.
__label__Support	DC-treated patients experienced improved pain relief compared with VC (P=0.033),	DCb and DC were superior to VC in all QoL outcomes assessed except for the difference between DC and VC in LCSS "QoL today", which was not significant.
__label__noRel	pain relief with DCb and VC was similar.	Patients with advanced non-small cell lung cancer (NSCLC) do not have curative treatment options;
__label__noRel	pain relief with DCb and VC was similar.	Overall, patients treated with either docetaxel-containing regimen had better QoL than VC-treated patients (LCSS global item "QoL today": P=0.064 for DC and P=0.016 for DCb versus VC; EQ-5D global item "health state today": P=0.016 for DC and P<0.001 for DCb versus VC).
__label__noRel	pain relief with DCb and VC was similar.	DC-treated patients experienced improved pain relief compared with VC (P=0.033),
__label__noRel	pain relief with DCb and VC was similar.	Patients treated with either docetaxel regimen had more favorable changes in performance status (P=0.065 for DC and P<0.001 for DCb versus VC) and mean weight loss (0.06 kg, gain of 0.08 kg, and 2.27 kg for DC, DCb, and VC, respectively; P<0.001 for both DC versus VC and DCb versus VC).
__label__Support	pain relief with DCb and VC was similar.	The TAX 326 study shows that docetaxel-platinum regimens relieve symptoms and improve QoL in patients with advanced NSCLC.
__label__noRel	pain relief with DCb and VC was similar.	DCb and DC were superior to VC in all QoL outcomes assessed except for the difference between DC and VC in LCSS "QoL today", which was not significant.
__label__noRel	Patients treated with either docetaxel regimen had more favorable changes in performance status (P=0.065 for DC and P<0.001 for DCb versus VC) and mean weight loss (0.06 kg, gain of 0.08 kg, and 2.27 kg for DC, DCb, and VC, respectively; P<0.001 for both DC versus VC and DCb versus VC).	Patients with advanced non-small cell lung cancer (NSCLC) do not have curative treatment options;
__label__noRel	Patients treated with either docetaxel regimen had more favorable changes in performance status (P=0.065 for DC and P<0.001 for DCb versus VC) and mean weight loss (0.06 kg, gain of 0.08 kg, and 2.27 kg for DC, DCb, and VC, respectively; P<0.001 for both DC versus VC and DCb versus VC).	Overall, patients treated with either docetaxel-containing regimen had better QoL than VC-treated patients (LCSS global item "QoL today": P=0.064 for DC and P=0.016 for DCb versus VC; EQ-5D global item "health state today": P=0.016 for DC and P<0.001 for DCb versus VC).
__label__noRel	Patients treated with either docetaxel regimen had more favorable changes in performance status (P=0.065 for DC and P<0.001 for DCb versus VC) and mean weight loss (0.06 kg, gain of 0.08 kg, and 2.27 kg for DC, DCb, and VC, respectively; P<0.001 for both DC versus VC and DCb versus VC).	DC-treated patients experienced improved pain relief compared with VC (P=0.033),
__label__noRel	Patients treated with either docetaxel regimen had more favorable changes in performance status (P=0.065 for DC and P<0.001 for DCb versus VC) and mean weight loss (0.06 kg, gain of 0.08 kg, and 2.27 kg for DC, DCb, and VC, respectively; P<0.001 for both DC versus VC and DCb versus VC).	pain relief with DCb and VC was similar.
__label__Support	Patients treated with either docetaxel regimen had more favorable changes in performance status (P=0.065 for DC and P<0.001 for DCb versus VC) and mean weight loss (0.06 kg, gain of 0.08 kg, and 2.27 kg for DC, DCb, and VC, respectively; P<0.001 for both DC versus VC and DCb versus VC).	The TAX 326 study shows that docetaxel-platinum regimens relieve symptoms and improve QoL in patients with advanced NSCLC.
__label__noRel	Patients treated with either docetaxel regimen had more favorable changes in performance status (P=0.065 for DC and P<0.001 for DCb versus VC) and mean weight loss (0.06 kg, gain of 0.08 kg, and 2.27 kg for DC, DCb, and VC, respectively; P<0.001 for both DC versus VC and DCb versus VC).	DCb and DC were superior to VC in all QoL outcomes assessed except for the difference between DC and VC in LCSS "QoL today", which was not significant.
__label__noRel	The TAX 326 study shows that docetaxel-platinum regimens relieve symptoms and improve QoL in patients with advanced NSCLC.	Patients with advanced non-small cell lung cancer (NSCLC) do not have curative treatment options;
__label__noRel	The TAX 326 study shows that docetaxel-platinum regimens relieve symptoms and improve QoL in patients with advanced NSCLC.	Overall, patients treated with either docetaxel-containing regimen had better QoL than VC-treated patients (LCSS global item "QoL today": P=0.064 for DC and P=0.016 for DCb versus VC; EQ-5D global item "health state today": P=0.016 for DC and P<0.001 for DCb versus VC).
__label__noRel	The TAX 326 study shows that docetaxel-platinum regimens relieve symptoms and improve QoL in patients with advanced NSCLC.	DC-treated patients experienced improved pain relief compared with VC (P=0.033),
__label__noRel	The TAX 326 study shows that docetaxel-platinum regimens relieve symptoms and improve QoL in patients with advanced NSCLC.	pain relief with DCb and VC was similar.
__label__noRel	The TAX 326 study shows that docetaxel-platinum regimens relieve symptoms and improve QoL in patients with advanced NSCLC.	Patients treated with either docetaxel regimen had more favorable changes in performance status (P=0.065 for DC and P<0.001 for DCb versus VC) and mean weight loss (0.06 kg, gain of 0.08 kg, and 2.27 kg for DC, DCb, and VC, respectively; P<0.001 for both DC versus VC and DCb versus VC).
__label__noRel	The TAX 326 study shows that docetaxel-platinum regimens relieve symptoms and improve QoL in patients with advanced NSCLC.	DCb and DC were superior to VC in all QoL outcomes assessed except for the difference between DC and VC in LCSS "QoL today", which was not significant.
__label__noRel	DCb and DC were superior to VC in all QoL outcomes assessed except for the difference between DC and VC in LCSS "QoL today", which was not significant.	Patients with advanced non-small cell lung cancer (NSCLC) do not have curative treatment options;
__label__noRel	DCb and DC were superior to VC in all QoL outcomes assessed except for the difference between DC and VC in LCSS "QoL today", which was not significant.	Overall, patients treated with either docetaxel-containing regimen had better QoL than VC-treated patients (LCSS global item "QoL today": P=0.064 for DC and P=0.016 for DCb versus VC; EQ-5D global item "health state today": P=0.016 for DC and P<0.001 for DCb versus VC).
__label__noRel	DCb and DC were superior to VC in all QoL outcomes assessed except for the difference between DC and VC in LCSS "QoL today", which was not significant.	DC-treated patients experienced improved pain relief compared with VC (P=0.033),
__label__noRel	DCb and DC were superior to VC in all QoL outcomes assessed except for the difference between DC and VC in LCSS "QoL today", which was not significant.	pain relief with DCb and VC was similar.
__label__noRel	DCb and DC were superior to VC in all QoL outcomes assessed except for the difference between DC and VC in LCSS "QoL today", which was not significant.	Patients treated with either docetaxel regimen had more favorable changes in performance status (P=0.065 for DC and P<0.001 for DCb versus VC) and mean weight loss (0.06 kg, gain of 0.08 kg, and 2.27 kg for DC, DCb, and VC, respectively; P<0.001 for both DC versus VC and DCb versus VC).
__label__noRel	DCb and DC were superior to VC in all QoL outcomes assessed except for the difference between DC and VC in LCSS "QoL today", which was not significant.	The TAX 326 study shows that docetaxel-platinum regimens relieve symptoms and improve QoL in patients with advanced NSCLC.
__label__noRel	For the Pemetrexed group, objective response rate (ORR) was 13.0% (3/23), disease control rate (DCR) was 30.4% (7/23), and median progression-free survival (mPFS) was 3.1 months.	In the Gefitinib group, ORR was 17.3% (4/23), DCR was 39.1% (9/23), and mPFS was 4.4 months.
__label__noRel	For the Pemetrexed group, objective response rate (ORR) was 13.0% (3/23), disease control rate (DCR) was 30.4% (7/23), and median progression-free survival (mPFS) was 3.1 months.	Compared with the Pemetrexed group, the ORR, DCR, and mPFS in the Gefitinib group exhibited no statistical significance (P>0.05).
__label__noRel	For the Pemetrexed group, objective response rate (ORR) was 13.0% (3/23), disease control rate (DCR) was 30.4% (7/23), and median progression-free survival (mPFS) was 3.1 months.	the most common toxicities in the Pemetrexed group were neutropenia (n=9, 39.13%) and fatigue (n=8, 34.78%), whereas those in the in Gefitinib group were skin rash (n=8, 34.78%) and diarrhea (n=4, 17.39%).
__label__noRel	For the Pemetrexed group, objective response rate (ORR) was 13.0% (3/23), disease control rate (DCR) was 30.4% (7/23), and median progression-free survival (mPFS) was 3.1 months.	Compared with baseline, the QoL improved in both groups but to different degrees.
__label__noRel	For the Pemetrexed group, objective response rate (ORR) was 13.0% (3/23), disease control rate (DCR) was 30.4% (7/23), and median progression-free survival (mPFS) was 3.1 months.	emotional, functional well-being, and QoL aspects specifically related to lung cancer were better improved in the Gefitinib group than in the Pemetrexed group (P<0.05).
__label__noRel	For the Pemetrexed group, objective response rate (ORR) was 13.0% (3/23), disease control rate (DCR) was 30.4% (7/23), and median progression-free survival (mPFS) was 3.1 months.	The effects of Pemetrexed and Gefitinib as second line therapy were similar,
__label__noRel	For the Pemetrexed group, objective response rate (ORR) was 13.0% (3/23), disease control rate (DCR) was 30.4% (7/23), and median progression-free survival (mPFS) was 3.1 months.	although with different AEs.
__label__noRel	For the Pemetrexed group, objective response rate (ORR) was 13.0% (3/23), disease control rate (DCR) was 30.4% (7/23), and median progression-free survival (mPFS) was 3.1 months.	Both drugs could improve the QoL,
__label__Support	For the Pemetrexed group, objective response rate (ORR) was 13.0% (3/23), disease control rate (DCR) was 30.4% (7/23), and median progression-free survival (mPFS) was 3.1 months.	Gefitinib showed better overall results than Pemetrexed.
__label__noRel	In the Gefitinib group, ORR was 17.3% (4/23), DCR was 39.1% (9/23), and mPFS was 4.4 months.	For the Pemetrexed group, objective response rate (ORR) was 13.0% (3/23), disease control rate (DCR) was 30.4% (7/23), and median progression-free survival (mPFS) was 3.1 months.
__label__noRel	In the Gefitinib group, ORR was 17.3% (4/23), DCR was 39.1% (9/23), and mPFS was 4.4 months.	Compared with the Pemetrexed group, the ORR, DCR, and mPFS in the Gefitinib group exhibited no statistical significance (P>0.05).
__label__noRel	In the Gefitinib group, ORR was 17.3% (4/23), DCR was 39.1% (9/23), and mPFS was 4.4 months.	the most common toxicities in the Pemetrexed group were neutropenia (n=9, 39.13%) and fatigue (n=8, 34.78%), whereas those in the in Gefitinib group were skin rash (n=8, 34.78%) and diarrhea (n=4, 17.39%).
__label__noRel	In the Gefitinib group, ORR was 17.3% (4/23), DCR was 39.1% (9/23), and mPFS was 4.4 months.	Compared with baseline, the QoL improved in both groups but to different degrees.
__label__noRel	In the Gefitinib group, ORR was 17.3% (4/23), DCR was 39.1% (9/23), and mPFS was 4.4 months.	emotional, functional well-being, and QoL aspects specifically related to lung cancer were better improved in the Gefitinib group than in the Pemetrexed group (P<0.05).
__label__noRel	In the Gefitinib group, ORR was 17.3% (4/23), DCR was 39.1% (9/23), and mPFS was 4.4 months.	The effects of Pemetrexed and Gefitinib as second line therapy were similar,
__label__noRel	In the Gefitinib group, ORR was 17.3% (4/23), DCR was 39.1% (9/23), and mPFS was 4.4 months.	although with different AEs.
__label__noRel	In the Gefitinib group, ORR was 17.3% (4/23), DCR was 39.1% (9/23), and mPFS was 4.4 months.	Both drugs could improve the QoL,
__label__Support	In the Gefitinib group, ORR was 17.3% (4/23), DCR was 39.1% (9/23), and mPFS was 4.4 months.	Gefitinib showed better overall results than Pemetrexed.
__label__noRel	Compared with the Pemetrexed group, the ORR, DCR, and mPFS in the Gefitinib group exhibited no statistical significance (P>0.05).	For the Pemetrexed group, objective response rate (ORR) was 13.0% (3/23), disease control rate (DCR) was 30.4% (7/23), and median progression-free survival (mPFS) was 3.1 months.
__label__noRel	Compared with the Pemetrexed group, the ORR, DCR, and mPFS in the Gefitinib group exhibited no statistical significance (P>0.05).	In the Gefitinib group, ORR was 17.3% (4/23), DCR was 39.1% (9/23), and mPFS was 4.4 months.
__label__noRel	Compared with the Pemetrexed group, the ORR, DCR, and mPFS in the Gefitinib group exhibited no statistical significance (P>0.05).	the most common toxicities in the Pemetrexed group were neutropenia (n=9, 39.13%) and fatigue (n=8, 34.78%), whereas those in the in Gefitinib group were skin rash (n=8, 34.78%) and diarrhea (n=4, 17.39%).
__label__noRel	Compared with the Pemetrexed group, the ORR, DCR, and mPFS in the Gefitinib group exhibited no statistical significance (P>0.05).	Compared with baseline, the QoL improved in both groups but to different degrees.
__label__noRel	Compared with the Pemetrexed group, the ORR, DCR, and mPFS in the Gefitinib group exhibited no statistical significance (P>0.05).	emotional, functional well-being, and QoL aspects specifically related to lung cancer were better improved in the Gefitinib group than in the Pemetrexed group (P<0.05).
__label__Support	Compared with the Pemetrexed group, the ORR, DCR, and mPFS in the Gefitinib group exhibited no statistical significance (P>0.05).	The effects of Pemetrexed and Gefitinib as second line therapy were similar,
__label__noRel	Compared with the Pemetrexed group, the ORR, DCR, and mPFS in the Gefitinib group exhibited no statistical significance (P>0.05).	although with different AEs.
__label__noRel	Compared with the Pemetrexed group, the ORR, DCR, and mPFS in the Gefitinib group exhibited no statistical significance (P>0.05).	Both drugs could improve the QoL,
__label__noRel	Compared with the Pemetrexed group, the ORR, DCR, and mPFS in the Gefitinib group exhibited no statistical significance (P>0.05).	Gefitinib showed better overall results than Pemetrexed.
__label__noRel	the most common toxicities in the Pemetrexed group were neutropenia (n=9, 39.13%) and fatigue (n=8, 34.78%), whereas those in the in Gefitinib group were skin rash (n=8, 34.78%) and diarrhea (n=4, 17.39%).	For the Pemetrexed group, objective response rate (ORR) was 13.0% (3/23), disease control rate (DCR) was 30.4% (7/23), and median progression-free survival (mPFS) was 3.1 months.
__label__noRel	the most common toxicities in the Pemetrexed group were neutropenia (n=9, 39.13%) and fatigue (n=8, 34.78%), whereas those in the in Gefitinib group were skin rash (n=8, 34.78%) and diarrhea (n=4, 17.39%).	In the Gefitinib group, ORR was 17.3% (4/23), DCR was 39.1% (9/23), and mPFS was 4.4 months.
__label__noRel	the most common toxicities in the Pemetrexed group were neutropenia (n=9, 39.13%) and fatigue (n=8, 34.78%), whereas those in the in Gefitinib group were skin rash (n=8, 34.78%) and diarrhea (n=4, 17.39%).	Compared with the Pemetrexed group, the ORR, DCR, and mPFS in the Gefitinib group exhibited no statistical significance (P>0.05).
__label__noRel	the most common toxicities in the Pemetrexed group were neutropenia (n=9, 39.13%) and fatigue (n=8, 34.78%), whereas those in the in Gefitinib group were skin rash (n=8, 34.78%) and diarrhea (n=4, 17.39%).	Compared with baseline, the QoL improved in both groups but to different degrees.
__label__noRel	the most common toxicities in the Pemetrexed group were neutropenia (n=9, 39.13%) and fatigue (n=8, 34.78%), whereas those in the in Gefitinib group were skin rash (n=8, 34.78%) and diarrhea (n=4, 17.39%).	emotional, functional well-being, and QoL aspects specifically related to lung cancer were better improved in the Gefitinib group than in the Pemetrexed group (P<0.05).
__label__Support	the most common toxicities in the Pemetrexed group were neutropenia (n=9, 39.13%) and fatigue (n=8, 34.78%), whereas those in the in Gefitinib group were skin rash (n=8, 34.78%) and diarrhea (n=4, 17.39%).	The effects of Pemetrexed and Gefitinib as second line therapy were similar,
__label__noRel	the most common toxicities in the Pemetrexed group were neutropenia (n=9, 39.13%) and fatigue (n=8, 34.78%), whereas those in the in Gefitinib group were skin rash (n=8, 34.78%) and diarrhea (n=4, 17.39%).	although with different AEs.
__label__noRel	the most common toxicities in the Pemetrexed group were neutropenia (n=9, 39.13%) and fatigue (n=8, 34.78%), whereas those in the in Gefitinib group were skin rash (n=8, 34.78%) and diarrhea (n=4, 17.39%).	Both drugs could improve the QoL,
__label__noRel	the most common toxicities in the Pemetrexed group were neutropenia (n=9, 39.13%) and fatigue (n=8, 34.78%), whereas those in the in Gefitinib group were skin rash (n=8, 34.78%) and diarrhea (n=4, 17.39%).	Gefitinib showed better overall results than Pemetrexed.
__label__noRel	Compared with baseline, the QoL improved in both groups but to different degrees.	For the Pemetrexed group, objective response rate (ORR) was 13.0% (3/23), disease control rate (DCR) was 30.4% (7/23), and median progression-free survival (mPFS) was 3.1 months.
__label__noRel	Compared with baseline, the QoL improved in both groups but to different degrees.	In the Gefitinib group, ORR was 17.3% (4/23), DCR was 39.1% (9/23), and mPFS was 4.4 months.
__label__noRel	Compared with baseline, the QoL improved in both groups but to different degrees.	Compared with the Pemetrexed group, the ORR, DCR, and mPFS in the Gefitinib group exhibited no statistical significance (P>0.05).
__label__noRel	Compared with baseline, the QoL improved in both groups but to different degrees.	the most common toxicities in the Pemetrexed group were neutropenia (n=9, 39.13%) and fatigue (n=8, 34.78%), whereas those in the in Gefitinib group were skin rash (n=8, 34.78%) and diarrhea (n=4, 17.39%).
__label__noRel	Compared with baseline, the QoL improved in both groups but to different degrees.	emotional, functional well-being, and QoL aspects specifically related to lung cancer were better improved in the Gefitinib group than in the Pemetrexed group (P<0.05).
__label__noRel	Compared with baseline, the QoL improved in both groups but to different degrees.	The effects of Pemetrexed and Gefitinib as second line therapy were similar,
__label__noRel	Compared with baseline, the QoL improved in both groups but to different degrees.	although with different AEs.
__label__Support	Compared with baseline, the QoL improved in both groups but to different degrees.	Both drugs could improve the QoL,
__label__noRel	Compared with baseline, the QoL improved in both groups but to different degrees.	Gefitinib showed better overall results than Pemetrexed.
__label__noRel	emotional, functional well-being, and QoL aspects specifically related to lung cancer were better improved in the Gefitinib group than in the Pemetrexed group (P<0.05).	For the Pemetrexed group, objective response rate (ORR) was 13.0% (3/23), disease control rate (DCR) was 30.4% (7/23), and median progression-free survival (mPFS) was 3.1 months.
__label__noRel	emotional, functional well-being, and QoL aspects specifically related to lung cancer were better improved in the Gefitinib group than in the Pemetrexed group (P<0.05).	In the Gefitinib group, ORR was 17.3% (4/23), DCR was 39.1% (9/23), and mPFS was 4.4 months.
__label__noRel	emotional, functional well-being, and QoL aspects specifically related to lung cancer were better improved in the Gefitinib group than in the Pemetrexed group (P<0.05).	Compared with the Pemetrexed group, the ORR, DCR, and mPFS in the Gefitinib group exhibited no statistical significance (P>0.05).
__label__noRel	emotional, functional well-being, and QoL aspects specifically related to lung cancer were better improved in the Gefitinib group than in the Pemetrexed group (P<0.05).	the most common toxicities in the Pemetrexed group were neutropenia (n=9, 39.13%) and fatigue (n=8, 34.78%), whereas those in the in Gefitinib group were skin rash (n=8, 34.78%) and diarrhea (n=4, 17.39%).
__label__noRel	emotional, functional well-being, and QoL aspects specifically related to lung cancer were better improved in the Gefitinib group than in the Pemetrexed group (P<0.05).	Compared with baseline, the QoL improved in both groups but to different degrees.
__label__noRel	emotional, functional well-being, and QoL aspects specifically related to lung cancer were better improved in the Gefitinib group than in the Pemetrexed group (P<0.05).	The effects of Pemetrexed and Gefitinib as second line therapy were similar,
__label__noRel	emotional, functional well-being, and QoL aspects specifically related to lung cancer were better improved in the Gefitinib group than in the Pemetrexed group (P<0.05).	although with different AEs.
__label__noRel	emotional, functional well-being, and QoL aspects specifically related to lung cancer were better improved in the Gefitinib group than in the Pemetrexed group (P<0.05).	Both drugs could improve the QoL,
__label__Support	emotional, functional well-being, and QoL aspects specifically related to lung cancer were better improved in the Gefitinib group than in the Pemetrexed group (P<0.05).	Gefitinib showed better overall results than Pemetrexed.
__label__noRel	The effects of Pemetrexed and Gefitinib as second line therapy were similar,	For the Pemetrexed group, objective response rate (ORR) was 13.0% (3/23), disease control rate (DCR) was 30.4% (7/23), and median progression-free survival (mPFS) was 3.1 months.
__label__noRel	The effects of Pemetrexed and Gefitinib as second line therapy were similar,	In the Gefitinib group, ORR was 17.3% (4/23), DCR was 39.1% (9/23), and mPFS was 4.4 months.
__label__noRel	The effects of Pemetrexed and Gefitinib as second line therapy were similar,	Compared with the Pemetrexed group, the ORR, DCR, and mPFS in the Gefitinib group exhibited no statistical significance (P>0.05).
__label__noRel	The effects of Pemetrexed and Gefitinib as second line therapy were similar,	the most common toxicities in the Pemetrexed group were neutropenia (n=9, 39.13%) and fatigue (n=8, 34.78%), whereas those in the in Gefitinib group were skin rash (n=8, 34.78%) and diarrhea (n=4, 17.39%).
__label__noRel	The effects of Pemetrexed and Gefitinib as second line therapy were similar,	Compared with baseline, the QoL improved in both groups but to different degrees.
__label__noRel	The effects of Pemetrexed and Gefitinib as second line therapy were similar,	emotional, functional well-being, and QoL aspects specifically related to lung cancer were better improved in the Gefitinib group than in the Pemetrexed group (P<0.05).
__label__noRel	The effects of Pemetrexed and Gefitinib as second line therapy were similar,	although with different AEs.
__label__noRel	The effects of Pemetrexed and Gefitinib as second line therapy were similar,	Both drugs could improve the QoL,
__label__noRel	The effects of Pemetrexed and Gefitinib as second line therapy were similar,	Gefitinib showed better overall results than Pemetrexed.
__label__noRel	although with different AEs.	For the Pemetrexed group, objective response rate (ORR) was 13.0% (3/23), disease control rate (DCR) was 30.4% (7/23), and median progression-free survival (mPFS) was 3.1 months.
__label__noRel	although with different AEs.	In the Gefitinib group, ORR was 17.3% (4/23), DCR was 39.1% (9/23), and mPFS was 4.4 months.
__label__noRel	although with different AEs.	Compared with the Pemetrexed group, the ORR, DCR, and mPFS in the Gefitinib group exhibited no statistical significance (P>0.05).
__label__noRel	although with different AEs.	the most common toxicities in the Pemetrexed group were neutropenia (n=9, 39.13%) and fatigue (n=8, 34.78%), whereas those in the in Gefitinib group were skin rash (n=8, 34.78%) and diarrhea (n=4, 17.39%).
__label__noRel	although with different AEs.	Compared with baseline, the QoL improved in both groups but to different degrees.
__label__noRel	although with different AEs.	emotional, functional well-being, and QoL aspects specifically related to lung cancer were better improved in the Gefitinib group than in the Pemetrexed group (P<0.05).
__label__Attack	although with different AEs.	The effects of Pemetrexed and Gefitinib as second line therapy were similar,
__label__noRel	although with different AEs.	Both drugs could improve the QoL,
__label__noRel	although with different AEs.	Gefitinib showed better overall results than Pemetrexed.
__label__noRel	Both drugs could improve the QoL,	For the Pemetrexed group, objective response rate (ORR) was 13.0% (3/23), disease control rate (DCR) was 30.4% (7/23), and median progression-free survival (mPFS) was 3.1 months.
__label__noRel	Both drugs could improve the QoL,	In the Gefitinib group, ORR was 17.3% (4/23), DCR was 39.1% (9/23), and mPFS was 4.4 months.
__label__noRel	Both drugs could improve the QoL,	Compared with the Pemetrexed group, the ORR, DCR, and mPFS in the Gefitinib group exhibited no statistical significance (P>0.05).
__label__noRel	Both drugs could improve the QoL,	the most common toxicities in the Pemetrexed group were neutropenia (n=9, 39.13%) and fatigue (n=8, 34.78%), whereas those in the in Gefitinib group were skin rash (n=8, 34.78%) and diarrhea (n=4, 17.39%).
__label__noRel	Both drugs could improve the QoL,	Compared with baseline, the QoL improved in both groups but to different degrees.
__label__noRel	Both drugs could improve the QoL,	emotional, functional well-being, and QoL aspects specifically related to lung cancer were better improved in the Gefitinib group than in the Pemetrexed group (P<0.05).
__label__Support	Both drugs could improve the QoL,	The effects of Pemetrexed and Gefitinib as second line therapy were similar,
__label__noRel	Both drugs could improve the QoL,	although with different AEs.
__label__noRel	Both drugs could improve the QoL,	Gefitinib showed better overall results than Pemetrexed.
__label__noRel	Gefitinib showed better overall results than Pemetrexed.	For the Pemetrexed group, objective response rate (ORR) was 13.0% (3/23), disease control rate (DCR) was 30.4% (7/23), and median progression-free survival (mPFS) was 3.1 months.
__label__noRel	Gefitinib showed better overall results than Pemetrexed.	In the Gefitinib group, ORR was 17.3% (4/23), DCR was 39.1% (9/23), and mPFS was 4.4 months.
__label__noRel	Gefitinib showed better overall results than Pemetrexed.	Compared with the Pemetrexed group, the ORR, DCR, and mPFS in the Gefitinib group exhibited no statistical significance (P>0.05).
__label__noRel	Gefitinib showed better overall results than Pemetrexed.	the most common toxicities in the Pemetrexed group were neutropenia (n=9, 39.13%) and fatigue (n=8, 34.78%), whereas those in the in Gefitinib group were skin rash (n=8, 34.78%) and diarrhea (n=4, 17.39%).
__label__noRel	Gefitinib showed better overall results than Pemetrexed.	Compared with baseline, the QoL improved in both groups but to different degrees.
__label__noRel	Gefitinib showed better overall results than Pemetrexed.	emotional, functional well-being, and QoL aspects specifically related to lung cancer were better improved in the Gefitinib group than in the Pemetrexed group (P<0.05).
__label__noRel	Gefitinib showed better overall results than Pemetrexed.	The effects of Pemetrexed and Gefitinib as second line therapy were similar,
__label__noRel	Gefitinib showed better overall results than Pemetrexed.	although with different AEs.
__label__noRel	Gefitinib showed better overall results than Pemetrexed.	Both drugs could improve the QoL,
__label__noRel	Randomized trials in fluorouracil (FU)-refractory colorectal cancer demonstrate significant survival advantages for patients receiving irinotecan.	With median follow-up of 15.8 months, there was no significant difference in 1-year survival (46% v 41%, respectively; P =.42), median survival (9.9 v 9.9 months, respectively; P =.43), or median time to progression (4.0 v 3.0 months, respectively; P =.54) between the two regimens.
__label__noRel	Randomized trials in fluorouracil (FU)-refractory colorectal cancer demonstrate significant survival advantages for patients receiving irinotecan.	Grade 3/4 diarrhea occurred in 36% of patients treated weekly and in 19% of those treated once every 3 weeks (P =.002).
__label__noRel	Randomized trials in fluorouracil (FU)-refractory colorectal cancer demonstrate significant survival advantages for patients receiving irinotecan.	Grade 3/4 neutropenia occurred in 29% of patients treated weekly and 34% of those treated once every 3 weeks (P =.35).
__label__noRel	Randomized trials in fluorouracil (FU)-refractory colorectal cancer demonstrate significant survival advantages for patients receiving irinotecan.	Treatment-related mortality occurred in five patients (5.3%) receiving irinotecan weekly and three patients (1.6%) given therapy once every 3 weeks (P =.12).
__label__noRel	Randomized trials in fluorouracil (FU)-refractory colorectal cancer demonstrate significant survival advantages for patients receiving irinotecan.	Global quality of life was not statistically different between treatment groups.
__label__noRel	Randomized trials in fluorouracil (FU)-refractory colorectal cancer demonstrate significant survival advantages for patients receiving irinotecan.	Irinotecan schedules of weekly and of once every 3 weeks demonstrated similar efficacy and quality of life in patients with FU-refractory, metastatic colorectal cancer.
__label__noRel	Randomized trials in fluorouracil (FU)-refractory colorectal cancer demonstrate significant survival advantages for patients receiving irinotecan.	The regimen of once every 3 weeks was associated with a significantly lower incidence of severe diarrhea.
__label__noRel	With median follow-up of 15.8 months, there was no significant difference in 1-year survival (46% v 41%, respectively; P =.42), median survival (9.9 v 9.9 months, respectively; P =.43), or median time to progression (4.0 v 3.0 months, respectively; P =.54) between the two regimens.	Randomized trials in fluorouracil (FU)-refractory colorectal cancer demonstrate significant survival advantages for patients receiving irinotecan.
__label__noRel	With median follow-up of 15.8 months, there was no significant difference in 1-year survival (46% v 41%, respectively; P =.42), median survival (9.9 v 9.9 months, respectively; P =.43), or median time to progression (4.0 v 3.0 months, respectively; P =.54) between the two regimens.	Grade 3/4 diarrhea occurred in 36% of patients treated weekly and in 19% of those treated once every 3 weeks (P =.002).
__label__noRel	With median follow-up of 15.8 months, there was no significant difference in 1-year survival (46% v 41%, respectively; P =.42), median survival (9.9 v 9.9 months, respectively; P =.43), or median time to progression (4.0 v 3.0 months, respectively; P =.54) between the two regimens.	Grade 3/4 neutropenia occurred in 29% of patients treated weekly and 34% of those treated once every 3 weeks (P =.35).
__label__noRel	With median follow-up of 15.8 months, there was no significant difference in 1-year survival (46% v 41%, respectively; P =.42), median survival (9.9 v 9.9 months, respectively; P =.43), or median time to progression (4.0 v 3.0 months, respectively; P =.54) between the two regimens.	Treatment-related mortality occurred in five patients (5.3%) receiving irinotecan weekly and three patients (1.6%) given therapy once every 3 weeks (P =.12).
__label__noRel	With median follow-up of 15.8 months, there was no significant difference in 1-year survival (46% v 41%, respectively; P =.42), median survival (9.9 v 9.9 months, respectively; P =.43), or median time to progression (4.0 v 3.0 months, respectively; P =.54) between the two regimens.	Global quality of life was not statistically different between treatment groups.
__label__Support	With median follow-up of 15.8 months, there was no significant difference in 1-year survival (46% v 41%, respectively; P =.42), median survival (9.9 v 9.9 months, respectively; P =.43), or median time to progression (4.0 v 3.0 months, respectively; P =.54) between the two regimens.	Irinotecan schedules of weekly and of once every 3 weeks demonstrated similar efficacy and quality of life in patients with FU-refractory, metastatic colorectal cancer.
__label__noRel	With median follow-up of 15.8 months, there was no significant difference in 1-year survival (46% v 41%, respectively; P =.42), median survival (9.9 v 9.9 months, respectively; P =.43), or median time to progression (4.0 v 3.0 months, respectively; P =.54) between the two regimens.	The regimen of once every 3 weeks was associated with a significantly lower incidence of severe diarrhea.
__label__noRel	Grade 3/4 diarrhea occurred in 36% of patients treated weekly and in 19% of those treated once every 3 weeks (P =.002).	Randomized trials in fluorouracil (FU)-refractory colorectal cancer demonstrate significant survival advantages for patients receiving irinotecan.
__label__noRel	Grade 3/4 diarrhea occurred in 36% of patients treated weekly and in 19% of those treated once every 3 weeks (P =.002).	With median follow-up of 15.8 months, there was no significant difference in 1-year survival (46% v 41%, respectively; P =.42), median survival (9.9 v 9.9 months, respectively; P =.43), or median time to progression (4.0 v 3.0 months, respectively; P =.54) between the two regimens.
__label__noRel	Grade 3/4 diarrhea occurred in 36% of patients treated weekly and in 19% of those treated once every 3 weeks (P =.002).	Grade 3/4 neutropenia occurred in 29% of patients treated weekly and 34% of those treated once every 3 weeks (P =.35).
__label__noRel	Grade 3/4 diarrhea occurred in 36% of patients treated weekly and in 19% of those treated once every 3 weeks (P =.002).	Treatment-related mortality occurred in five patients (5.3%) receiving irinotecan weekly and three patients (1.6%) given therapy once every 3 weeks (P =.12).
__label__noRel	Grade 3/4 diarrhea occurred in 36% of patients treated weekly and in 19% of those treated once every 3 weeks (P =.002).	Global quality of life was not statistically different between treatment groups.
__label__noRel	Grade 3/4 diarrhea occurred in 36% of patients treated weekly and in 19% of those treated once every 3 weeks (P =.002).	Irinotecan schedules of weekly and of once every 3 weeks demonstrated similar efficacy and quality of life in patients with FU-refractory, metastatic colorectal cancer.
__label__Support	Grade 3/4 diarrhea occurred in 36% of patients treated weekly and in 19% of those treated once every 3 weeks (P =.002).	The regimen of once every 3 weeks was associated with a significantly lower incidence of severe diarrhea.
__label__noRel	Grade 3/4 neutropenia occurred in 29% of patients treated weekly and 34% of those treated once every 3 weeks (P =.35).	Randomized trials in fluorouracil (FU)-refractory colorectal cancer demonstrate significant survival advantages for patients receiving irinotecan.
__label__noRel	Grade 3/4 neutropenia occurred in 29% of patients treated weekly and 34% of those treated once every 3 weeks (P =.35).	With median follow-up of 15.8 months, there was no significant difference in 1-year survival (46% v 41%, respectively; P =.42), median survival (9.9 v 9.9 months, respectively; P =.43), or median time to progression (4.0 v 3.0 months, respectively; P =.54) between the two regimens.
__label__noRel	Grade 3/4 neutropenia occurred in 29% of patients treated weekly and 34% of those treated once every 3 weeks (P =.35).	Grade 3/4 diarrhea occurred in 36% of patients treated weekly and in 19% of those treated once every 3 weeks (P =.002).
__label__noRel	Grade 3/4 neutropenia occurred in 29% of patients treated weekly and 34% of those treated once every 3 weeks (P =.35).	Treatment-related mortality occurred in five patients (5.3%) receiving irinotecan weekly and three patients (1.6%) given therapy once every 3 weeks (P =.12).
__label__noRel	Grade 3/4 neutropenia occurred in 29% of patients treated weekly and 34% of those treated once every 3 weeks (P =.35).	Global quality of life was not statistically different between treatment groups.
__label__Support	Grade 3/4 neutropenia occurred in 29% of patients treated weekly and 34% of those treated once every 3 weeks (P =.35).	Irinotecan schedules of weekly and of once every 3 weeks demonstrated similar efficacy and quality of life in patients with FU-refractory, metastatic colorectal cancer.
__label__noRel	Grade 3/4 neutropenia occurred in 29% of patients treated weekly and 34% of those treated once every 3 weeks (P =.35).	The regimen of once every 3 weeks was associated with a significantly lower incidence of severe diarrhea.
__label__noRel	Treatment-related mortality occurred in five patients (5.3%) receiving irinotecan weekly and three patients (1.6%) given therapy once every 3 weeks (P =.12).	Randomized trials in fluorouracil (FU)-refractory colorectal cancer demonstrate significant survival advantages for patients receiving irinotecan.
__label__noRel	Treatment-related mortality occurred in five patients (5.3%) receiving irinotecan weekly and three patients (1.6%) given therapy once every 3 weeks (P =.12).	With median follow-up of 15.8 months, there was no significant difference in 1-year survival (46% v 41%, respectively; P =.42), median survival (9.9 v 9.9 months, respectively; P =.43), or median time to progression (4.0 v 3.0 months, respectively; P =.54) between the two regimens.
__label__noRel	Treatment-related mortality occurred in five patients (5.3%) receiving irinotecan weekly and three patients (1.6%) given therapy once every 3 weeks (P =.12).	Grade 3/4 diarrhea occurred in 36% of patients treated weekly and in 19% of those treated once every 3 weeks (P =.002).
__label__noRel	Treatment-related mortality occurred in five patients (5.3%) receiving irinotecan weekly and three patients (1.6%) given therapy once every 3 weeks (P =.12).	Grade 3/4 neutropenia occurred in 29% of patients treated weekly and 34% of those treated once every 3 weeks (P =.35).
__label__noRel	Treatment-related mortality occurred in five patients (5.3%) receiving irinotecan weekly and three patients (1.6%) given therapy once every 3 weeks (P =.12).	Global quality of life was not statistically different between treatment groups.
__label__Support	Treatment-related mortality occurred in five patients (5.3%) receiving irinotecan weekly and three patients (1.6%) given therapy once every 3 weeks (P =.12).	Irinotecan schedules of weekly and of once every 3 weeks demonstrated similar efficacy and quality of life in patients with FU-refractory, metastatic colorectal cancer.
__label__noRel	Treatment-related mortality occurred in five patients (5.3%) receiving irinotecan weekly and three patients (1.6%) given therapy once every 3 weeks (P =.12).	The regimen of once every 3 weeks was associated with a significantly lower incidence of severe diarrhea.
__label__noRel	Global quality of life was not statistically different between treatment groups.	Randomized trials in fluorouracil (FU)-refractory colorectal cancer demonstrate significant survival advantages for patients receiving irinotecan.
__label__noRel	Global quality of life was not statistically different between treatment groups.	With median follow-up of 15.8 months, there was no significant difference in 1-year survival (46% v 41%, respectively; P =.42), median survival (9.9 v 9.9 months, respectively; P =.43), or median time to progression (4.0 v 3.0 months, respectively; P =.54) between the two regimens.
__label__noRel	Global quality of life was not statistically different between treatment groups.	Grade 3/4 diarrhea occurred in 36% of patients treated weekly and in 19% of those treated once every 3 weeks (P =.002).
__label__noRel	Global quality of life was not statistically different between treatment groups.	Grade 3/4 neutropenia occurred in 29% of patients treated weekly and 34% of those treated once every 3 weeks (P =.35).
__label__noRel	Global quality of life was not statistically different between treatment groups.	Treatment-related mortality occurred in five patients (5.3%) receiving irinotecan weekly and three patients (1.6%) given therapy once every 3 weeks (P =.12).
__label__noRel	Global quality of life was not statistically different between treatment groups.	Irinotecan schedules of weekly and of once every 3 weeks demonstrated similar efficacy and quality of life in patients with FU-refractory, metastatic colorectal cancer.
__label__noRel	Global quality of life was not statistically different between treatment groups.	The regimen of once every 3 weeks was associated with a significantly lower incidence of severe diarrhea.
__label__noRel	Irinotecan schedules of weekly and of once every 3 weeks demonstrated similar efficacy and quality of life in patients with FU-refractory, metastatic colorectal cancer.	Randomized trials in fluorouracil (FU)-refractory colorectal cancer demonstrate significant survival advantages for patients receiving irinotecan.
__label__noRel	Irinotecan schedules of weekly and of once every 3 weeks demonstrated similar efficacy and quality of life in patients with FU-refractory, metastatic colorectal cancer.	With median follow-up of 15.8 months, there was no significant difference in 1-year survival (46% v 41%, respectively; P =.42), median survival (9.9 v 9.9 months, respectively; P =.43), or median time to progression (4.0 v 3.0 months, respectively; P =.54) between the two regimens.
__label__noRel	Irinotecan schedules of weekly and of once every 3 weeks demonstrated similar efficacy and quality of life in patients with FU-refractory, metastatic colorectal cancer.	Grade 3/4 diarrhea occurred in 36% of patients treated weekly and in 19% of those treated once every 3 weeks (P =.002).
__label__noRel	Irinotecan schedules of weekly and of once every 3 weeks demonstrated similar efficacy and quality of life in patients with FU-refractory, metastatic colorectal cancer.	Grade 3/4 neutropenia occurred in 29% of patients treated weekly and 34% of those treated once every 3 weeks (P =.35).
__label__noRel	Irinotecan schedules of weekly and of once every 3 weeks demonstrated similar efficacy and quality of life in patients with FU-refractory, metastatic colorectal cancer.	Treatment-related mortality occurred in five patients (5.3%) receiving irinotecan weekly and three patients (1.6%) given therapy once every 3 weeks (P =.12).
__label__noRel	Irinotecan schedules of weekly and of once every 3 weeks demonstrated similar efficacy and quality of life in patients with FU-refractory, metastatic colorectal cancer.	Global quality of life was not statistically different between treatment groups.
__label__noRel	Irinotecan schedules of weekly and of once every 3 weeks demonstrated similar efficacy and quality of life in patients with FU-refractory, metastatic colorectal cancer.	The regimen of once every 3 weeks was associated with a significantly lower incidence of severe diarrhea.
__label__noRel	The regimen of once every 3 weeks was associated with a significantly lower incidence of severe diarrhea.	Randomized trials in fluorouracil (FU)-refractory colorectal cancer demonstrate significant survival advantages for patients receiving irinotecan.
__label__noRel	The regimen of once every 3 weeks was associated with a significantly lower incidence of severe diarrhea.	With median follow-up of 15.8 months, there was no significant difference in 1-year survival (46% v 41%, respectively; P =.42), median survival (9.9 v 9.9 months, respectively; P =.43), or median time to progression (4.0 v 3.0 months, respectively; P =.54) between the two regimens.
__label__noRel	The regimen of once every 3 weeks was associated with a significantly lower incidence of severe diarrhea.	Grade 3/4 diarrhea occurred in 36% of patients treated weekly and in 19% of those treated once every 3 weeks (P =.002).
__label__noRel	The regimen of once every 3 weeks was associated with a significantly lower incidence of severe diarrhea.	Grade 3/4 neutropenia occurred in 29% of patients treated weekly and 34% of those treated once every 3 weeks (P =.35).
__label__noRel	The regimen of once every 3 weeks was associated with a significantly lower incidence of severe diarrhea.	Treatment-related mortality occurred in five patients (5.3%) receiving irinotecan weekly and three patients (1.6%) given therapy once every 3 weeks (P =.12).
__label__noRel	The regimen of once every 3 weeks was associated with a significantly lower incidence of severe diarrhea.	Global quality of life was not statistically different between treatment groups.
__label__noRel	The regimen of once every 3 weeks was associated with a significantly lower incidence of severe diarrhea.	Irinotecan schedules of weekly and of once every 3 weeks demonstrated similar efficacy and quality of life in patients with FU-refractory, metastatic colorectal cancer.
__label__noRel	Compared with the control group, the intervention groups had a significant decrease in levels of endocrine symptoms (Functional Assessment of Cancer Therapy-Endocrine Symptoms; P<.001; effect size, 0.31-0.52) and urinary symptoms (Bristol Female Lower Urinary Tract Symptoms Questionnaire; P=.002; effect size, 0.29-0.33), and they showed an improvement in physical functioning (36-Item Short Form Health Survey physical functioning subscale; P=.002; effect size, 0.37-0.46).	The groups that included CBT also showed a significant decrease in the perceived burden of hot flashes and night sweats (problem rating scale of the Hot Flush Rating Scale; P<.001; effect size, 0.39-0.56) and an increase in sexual activity (Sexual Activity Questionnaire habit subscale; P=.027; effect size, 0.65).
__label__Support	Compared with the control group, the intervention groups had a significant decrease in levels of endocrine symptoms (Functional Assessment of Cancer Therapy-Endocrine Symptoms; P<.001; effect size, 0.31-0.52) and urinary symptoms (Bristol Female Lower Urinary Tract Symptoms Questionnaire; P=.002; effect size, 0.29-0.33), and they showed an improvement in physical functioning (36-Item Short Form Health Survey physical functioning subscale; P=.002; effect size, 0.37-0.46).	CBT and PE can have salutary effects on endocrine symptoms and, to a lesser degree, on sexuality and physical functioning of patients with breast cancer experiencing treatment-induced menopause.
__label__noRel	Compared with the control group, the intervention groups had a significant decrease in levels of endocrine symptoms (Functional Assessment of Cancer Therapy-Endocrine Symptoms; P<.001; effect size, 0.31-0.52) and urinary symptoms (Bristol Female Lower Urinary Tract Symptoms Questionnaire; P=.002; effect size, 0.29-0.33), and they showed an improvement in physical functioning (36-Item Short Form Health Survey physical functioning subscale; P=.002; effect size, 0.37-0.46).	Future work is needed to improve the design and the planning of these interventions to improve program adherence.
__label__noRel	The groups that included CBT also showed a significant decrease in the perceived burden of hot flashes and night sweats (problem rating scale of the Hot Flush Rating Scale; P<.001; effect size, 0.39-0.56) and an increase in sexual activity (Sexual Activity Questionnaire habit subscale; P=.027; effect size, 0.65).	Compared with the control group, the intervention groups had a significant decrease in levels of endocrine symptoms (Functional Assessment of Cancer Therapy-Endocrine Symptoms; P<.001; effect size, 0.31-0.52) and urinary symptoms (Bristol Female Lower Urinary Tract Symptoms Questionnaire; P=.002; effect size, 0.29-0.33), and they showed an improvement in physical functioning (36-Item Short Form Health Survey physical functioning subscale; P=.002; effect size, 0.37-0.46).
__label__Support	The groups that included CBT also showed a significant decrease in the perceived burden of hot flashes and night sweats (problem rating scale of the Hot Flush Rating Scale; P<.001; effect size, 0.39-0.56) and an increase in sexual activity (Sexual Activity Questionnaire habit subscale; P=.027; effect size, 0.65).	CBT and PE can have salutary effects on endocrine symptoms and, to a lesser degree, on sexuality and physical functioning of patients with breast cancer experiencing treatment-induced menopause.
__label__noRel	The groups that included CBT also showed a significant decrease in the perceived burden of hot flashes and night sweats (problem rating scale of the Hot Flush Rating Scale; P<.001; effect size, 0.39-0.56) and an increase in sexual activity (Sexual Activity Questionnaire habit subscale; P=.027; effect size, 0.65).	Future work is needed to improve the design and the planning of these interventions to improve program adherence.
__label__noRel	CBT and PE can have salutary effects on endocrine symptoms and, to a lesser degree, on sexuality and physical functioning of patients with breast cancer experiencing treatment-induced menopause.	Compared with the control group, the intervention groups had a significant decrease in levels of endocrine symptoms (Functional Assessment of Cancer Therapy-Endocrine Symptoms; P<.001; effect size, 0.31-0.52) and urinary symptoms (Bristol Female Lower Urinary Tract Symptoms Questionnaire; P=.002; effect size, 0.29-0.33), and they showed an improvement in physical functioning (36-Item Short Form Health Survey physical functioning subscale; P=.002; effect size, 0.37-0.46).
__label__noRel	CBT and PE can have salutary effects on endocrine symptoms and, to a lesser degree, on sexuality and physical functioning of patients with breast cancer experiencing treatment-induced menopause.	The groups that included CBT also showed a significant decrease in the perceived burden of hot flashes and night sweats (problem rating scale of the Hot Flush Rating Scale; P<.001; effect size, 0.39-0.56) and an increase in sexual activity (Sexual Activity Questionnaire habit subscale; P=.027; effect size, 0.65).
__label__noRel	CBT and PE can have salutary effects on endocrine symptoms and, to a lesser degree, on sexuality and physical functioning of patients with breast cancer experiencing treatment-induced menopause.	Future work is needed to improve the design and the planning of these interventions to improve program adherence.
__label__noRel	Future work is needed to improve the design and the planning of these interventions to improve program adherence.	Compared with the control group, the intervention groups had a significant decrease in levels of endocrine symptoms (Functional Assessment of Cancer Therapy-Endocrine Symptoms; P<.001; effect size, 0.31-0.52) and urinary symptoms (Bristol Female Lower Urinary Tract Symptoms Questionnaire; P=.002; effect size, 0.29-0.33), and they showed an improvement in physical functioning (36-Item Short Form Health Survey physical functioning subscale; P=.002; effect size, 0.37-0.46).
__label__noRel	Future work is needed to improve the design and the planning of these interventions to improve program adherence.	The groups that included CBT also showed a significant decrease in the perceived burden of hot flashes and night sweats (problem rating scale of the Hot Flush Rating Scale; P<.001; effect size, 0.39-0.56) and an increase in sexual activity (Sexual Activity Questionnaire habit subscale; P=.027; effect size, 0.65).
__label__Attack	Future work is needed to improve the design and the planning of these interventions to improve program adherence.	CBT and PE can have salutary effects on endocrine symptoms and, to a lesser degree, on sexuality and physical functioning of patients with breast cancer experiencing treatment-induced menopause.
__label__noRel	Thalidomide, which is an inhibitor of TNF-alpha synthesis, may represent a novel and rational approach to the treatment of cancer cachexia.	At four weeks, patients who received thalidomide had gained on average 0.37 kg in weight and 1.0 cm(3) in arm muscle mass (AMA) compared with a loss of 2.21 kg (absolute difference -2.59 kg (95% confidence interval (CI) -4.3 to -0.8); p = 0.005) and 4.46 cm(3) (absolute difference -5.6 cm(3) (95% CI -8.9 to -2.2); p = 0.002) in the placebo group.
__label__noRel	Thalidomide, which is an inhibitor of TNF-alpha synthesis, may represent a novel and rational approach to the treatment of cancer cachexia.	At eight weeks, patients in the thalidomide group had lost 0.06 kg in weight and 0.5 cm(3) in AMA compared with a loss of 3.62 kg (absolute difference -3.57 kg (95% CI -6.8 to -0.3); p = 0.034) and 8.4 cm(3) (absolute difference -7.9 cm(3) (95% CI -14.0 to -1.8); p = 0.014) in the placebo group.
__label__noRel	Thalidomide, which is an inhibitor of TNF-alpha synthesis, may represent a novel and rational approach to the treatment of cancer cachexia.	Improvement in physical functioning correlated positively with weight gain (r = 0.56, p = 0.001).
__label__noRel	Thalidomide, which is an inhibitor of TNF-alpha synthesis, may represent a novel and rational approach to the treatment of cancer cachexia.	Thalidomide was well tolerated and effective at attenuating loss of weight and lean body mass in patients with cachexia due to advanced pancreatic cancer.
__label__noRel	At four weeks, patients who received thalidomide had gained on average 0.37 kg in weight and 1.0 cm(3) in arm muscle mass (AMA) compared with a loss of 2.21 kg (absolute difference -2.59 kg (95% confidence interval (CI) -4.3 to -0.8); p = 0.005) and 4.46 cm(3) (absolute difference -5.6 cm(3) (95% CI -8.9 to -2.2); p = 0.002) in the placebo group.	Thalidomide, which is an inhibitor of TNF-alpha synthesis, may represent a novel and rational approach to the treatment of cancer cachexia.
__label__noRel	At four weeks, patients who received thalidomide had gained on average 0.37 kg in weight and 1.0 cm(3) in arm muscle mass (AMA) compared with a loss of 2.21 kg (absolute difference -2.59 kg (95% confidence interval (CI) -4.3 to -0.8); p = 0.005) and 4.46 cm(3) (absolute difference -5.6 cm(3) (95% CI -8.9 to -2.2); p = 0.002) in the placebo group.	At eight weeks, patients in the thalidomide group had lost 0.06 kg in weight and 0.5 cm(3) in AMA compared with a loss of 3.62 kg (absolute difference -3.57 kg (95% CI -6.8 to -0.3); p = 0.034) and 8.4 cm(3) (absolute difference -7.9 cm(3) (95% CI -14.0 to -1.8); p = 0.014) in the placebo group.
__label__noRel	At four weeks, patients who received thalidomide had gained on average 0.37 kg in weight and 1.0 cm(3) in arm muscle mass (AMA) compared with a loss of 2.21 kg (absolute difference -2.59 kg (95% confidence interval (CI) -4.3 to -0.8); p = 0.005) and 4.46 cm(3) (absolute difference -5.6 cm(3) (95% CI -8.9 to -2.2); p = 0.002) in the placebo group.	Improvement in physical functioning correlated positively with weight gain (r = 0.56, p = 0.001).
__label__Support	At four weeks, patients who received thalidomide had gained on average 0.37 kg in weight and 1.0 cm(3) in arm muscle mass (AMA) compared with a loss of 2.21 kg (absolute difference -2.59 kg (95% confidence interval (CI) -4.3 to -0.8); p = 0.005) and 4.46 cm(3) (absolute difference -5.6 cm(3) (95% CI -8.9 to -2.2); p = 0.002) in the placebo group.	Thalidomide was well tolerated and effective at attenuating loss of weight and lean body mass in patients with cachexia due to advanced pancreatic cancer.
__label__noRel	At eight weeks, patients in the thalidomide group had lost 0.06 kg in weight and 0.5 cm(3) in AMA compared with a loss of 3.62 kg (absolute difference -3.57 kg (95% CI -6.8 to -0.3); p = 0.034) and 8.4 cm(3) (absolute difference -7.9 cm(3) (95% CI -14.0 to -1.8); p = 0.014) in the placebo group.	Thalidomide, which is an inhibitor of TNF-alpha synthesis, may represent a novel and rational approach to the treatment of cancer cachexia.
__label__noRel	At eight weeks, patients in the thalidomide group had lost 0.06 kg in weight and 0.5 cm(3) in AMA compared with a loss of 3.62 kg (absolute difference -3.57 kg (95% CI -6.8 to -0.3); p = 0.034) and 8.4 cm(3) (absolute difference -7.9 cm(3) (95% CI -14.0 to -1.8); p = 0.014) in the placebo group.	At four weeks, patients who received thalidomide had gained on average 0.37 kg in weight and 1.0 cm(3) in arm muscle mass (AMA) compared with a loss of 2.21 kg (absolute difference -2.59 kg (95% confidence interval (CI) -4.3 to -0.8); p = 0.005) and 4.46 cm(3) (absolute difference -5.6 cm(3) (95% CI -8.9 to -2.2); p = 0.002) in the placebo group.
__label__noRel	At eight weeks, patients in the thalidomide group had lost 0.06 kg in weight and 0.5 cm(3) in AMA compared with a loss of 3.62 kg (absolute difference -3.57 kg (95% CI -6.8 to -0.3); p = 0.034) and 8.4 cm(3) (absolute difference -7.9 cm(3) (95% CI -14.0 to -1.8); p = 0.014) in the placebo group.	Improvement in physical functioning correlated positively with weight gain (r = 0.56, p = 0.001).
__label__Support	At eight weeks, patients in the thalidomide group had lost 0.06 kg in weight and 0.5 cm(3) in AMA compared with a loss of 3.62 kg (absolute difference -3.57 kg (95% CI -6.8 to -0.3); p = 0.034) and 8.4 cm(3) (absolute difference -7.9 cm(3) (95% CI -14.0 to -1.8); p = 0.014) in the placebo group.	Thalidomide was well tolerated and effective at attenuating loss of weight and lean body mass in patients with cachexia due to advanced pancreatic cancer.
__label__noRel	Improvement in physical functioning correlated positively with weight gain (r = 0.56, p = 0.001).	Thalidomide, which is an inhibitor of TNF-alpha synthesis, may represent a novel and rational approach to the treatment of cancer cachexia.
__label__noRel	Improvement in physical functioning correlated positively with weight gain (r = 0.56, p = 0.001).	At four weeks, patients who received thalidomide had gained on average 0.37 kg in weight and 1.0 cm(3) in arm muscle mass (AMA) compared with a loss of 2.21 kg (absolute difference -2.59 kg (95% confidence interval (CI) -4.3 to -0.8); p = 0.005) and 4.46 cm(3) (absolute difference -5.6 cm(3) (95% CI -8.9 to -2.2); p = 0.002) in the placebo group.
__label__noRel	Improvement in physical functioning correlated positively with weight gain (r = 0.56, p = 0.001).	At eight weeks, patients in the thalidomide group had lost 0.06 kg in weight and 0.5 cm(3) in AMA compared with a loss of 3.62 kg (absolute difference -3.57 kg (95% CI -6.8 to -0.3); p = 0.034) and 8.4 cm(3) (absolute difference -7.9 cm(3) (95% CI -14.0 to -1.8); p = 0.014) in the placebo group.
__label__Support	Improvement in physical functioning correlated positively with weight gain (r = 0.56, p = 0.001).	Thalidomide was well tolerated and effective at attenuating loss of weight and lean body mass in patients with cachexia due to advanced pancreatic cancer.
__label__noRel	Thalidomide was well tolerated and effective at attenuating loss of weight and lean body mass in patients with cachexia due to advanced pancreatic cancer.	Thalidomide, which is an inhibitor of TNF-alpha synthesis, may represent a novel and rational approach to the treatment of cancer cachexia.
__label__noRel	Thalidomide was well tolerated and effective at attenuating loss of weight and lean body mass in patients with cachexia due to advanced pancreatic cancer.	At four weeks, patients who received thalidomide had gained on average 0.37 kg in weight and 1.0 cm(3) in arm muscle mass (AMA) compared with a loss of 2.21 kg (absolute difference -2.59 kg (95% confidence interval (CI) -4.3 to -0.8); p = 0.005) and 4.46 cm(3) (absolute difference -5.6 cm(3) (95% CI -8.9 to -2.2); p = 0.002) in the placebo group.
__label__noRel	Thalidomide was well tolerated and effective at attenuating loss of weight and lean body mass in patients with cachexia due to advanced pancreatic cancer.	At eight weeks, patients in the thalidomide group had lost 0.06 kg in weight and 0.5 cm(3) in AMA compared with a loss of 3.62 kg (absolute difference -3.57 kg (95% CI -6.8 to -0.3); p = 0.034) and 8.4 cm(3) (absolute difference -7.9 cm(3) (95% CI -14.0 to -1.8); p = 0.014) in the placebo group.
__label__noRel	Thalidomide was well tolerated and effective at attenuating loss of weight and lean body mass in patients with cachexia due to advanced pancreatic cancer.	Improvement in physical functioning correlated positively with weight gain (r = 0.56, p = 0.001).
__label__noRel	The Pain Education Program proved to be feasible:	75.0% of the patients had read the entire pain brochure, 55.7% had listened to the audio cassette, and 85.6% of pain scores were completed in the pain diary.
__label__noRel	The Pain Education Program proved to be feasible:	Results showed a significant increase in pain knowledge in patients who received the Pain Education Program and a significant decrease in pain intensity.
__label__noRel	The Pain Education Program proved to be feasible:	However, pain relief was mainly found in the intervention group patients without district nursing.
__label__noRel	The Pain Education Program proved to be feasible:	It can be concluded that the tailored Pain Education Program is effective for cancer patients in chronic pain.
__label__Support	The Pain Education Program proved to be feasible:	The use of the Pain Education Program by nurses should be seriously considered on oncology units.
__label__Support	75.0% of the patients had read the entire pain brochure, 55.7% had listened to the audio cassette, and 85.6% of pain scores were completed in the pain diary.	The Pain Education Program proved to be feasible:
__label__noRel	75.0% of the patients had read the entire pain brochure, 55.7% had listened to the audio cassette, and 85.6% of pain scores were completed in the pain diary.	Results showed a significant increase in pain knowledge in patients who received the Pain Education Program and a significant decrease in pain intensity.
__label__noRel	75.0% of the patients had read the entire pain brochure, 55.7% had listened to the audio cassette, and 85.6% of pain scores were completed in the pain diary.	However, pain relief was mainly found in the intervention group patients without district nursing.
__label__noRel	75.0% of the patients had read the entire pain brochure, 55.7% had listened to the audio cassette, and 85.6% of pain scores were completed in the pain diary.	It can be concluded that the tailored Pain Education Program is effective for cancer patients in chronic pain.
__label__noRel	75.0% of the patients had read the entire pain brochure, 55.7% had listened to the audio cassette, and 85.6% of pain scores were completed in the pain diary.	The use of the Pain Education Program by nurses should be seriously considered on oncology units.
__label__noRel	Results showed a significant increase in pain knowledge in patients who received the Pain Education Program and a significant decrease in pain intensity.	The Pain Education Program proved to be feasible:
__label__noRel	Results showed a significant increase in pain knowledge in patients who received the Pain Education Program and a significant decrease in pain intensity.	75.0% of the patients had read the entire pain brochure, 55.7% had listened to the audio cassette, and 85.6% of pain scores were completed in the pain diary.
__label__noRel	Results showed a significant increase in pain knowledge in patients who received the Pain Education Program and a significant decrease in pain intensity.	However, pain relief was mainly found in the intervention group patients without district nursing.
__label__Support	Results showed a significant increase in pain knowledge in patients who received the Pain Education Program and a significant decrease in pain intensity.	It can be concluded that the tailored Pain Education Program is effective for cancer patients in chronic pain.
__label__noRel	Results showed a significant increase in pain knowledge in patients who received the Pain Education Program and a significant decrease in pain intensity.	The use of the Pain Education Program by nurses should be seriously considered on oncology units.
__label__noRel	However, pain relief was mainly found in the intervention group patients without district nursing.	The Pain Education Program proved to be feasible:
__label__noRel	However, pain relief was mainly found in the intervention group patients without district nursing.	75.0% of the patients had read the entire pain brochure, 55.7% had listened to the audio cassette, and 85.6% of pain scores were completed in the pain diary.
__label__Attack	However, pain relief was mainly found in the intervention group patients without district nursing.	Results showed a significant increase in pain knowledge in patients who received the Pain Education Program and a significant decrease in pain intensity.
__label__noRel	However, pain relief was mainly found in the intervention group patients without district nursing.	It can be concluded that the tailored Pain Education Program is effective for cancer patients in chronic pain.
__label__noRel	However, pain relief was mainly found in the intervention group patients without district nursing.	The use of the Pain Education Program by nurses should be seriously considered on oncology units.
__label__noRel	It can be concluded that the tailored Pain Education Program is effective for cancer patients in chronic pain.	The Pain Education Program proved to be feasible:
__label__noRel	It can be concluded that the tailored Pain Education Program is effective for cancer patients in chronic pain.	75.0% of the patients had read the entire pain brochure, 55.7% had listened to the audio cassette, and 85.6% of pain scores were completed in the pain diary.
__label__noRel	It can be concluded that the tailored Pain Education Program is effective for cancer patients in chronic pain.	Results showed a significant increase in pain knowledge in patients who received the Pain Education Program and a significant decrease in pain intensity.
__label__noRel	It can be concluded that the tailored Pain Education Program is effective for cancer patients in chronic pain.	However, pain relief was mainly found in the intervention group patients without district nursing.
__label__Support	It can be concluded that the tailored Pain Education Program is effective for cancer patients in chronic pain.	The use of the Pain Education Program by nurses should be seriously considered on oncology units.
__label__noRel	The use of the Pain Education Program by nurses should be seriously considered on oncology units.	The Pain Education Program proved to be feasible:
__label__noRel	The use of the Pain Education Program by nurses should be seriously considered on oncology units.	75.0% of the patients had read the entire pain brochure, 55.7% had listened to the audio cassette, and 85.6% of pain scores were completed in the pain diary.
__label__noRel	The use of the Pain Education Program by nurses should be seriously considered on oncology units.	Results showed a significant increase in pain knowledge in patients who received the Pain Education Program and a significant decrease in pain intensity.
__label__noRel	The use of the Pain Education Program by nurses should be seriously considered on oncology units.	However, pain relief was mainly found in the intervention group patients without district nursing.
__label__noRel	The use of the Pain Education Program by nurses should be seriously considered on oncology units.	It can be concluded that the tailored Pain Education Program is effective for cancer patients in chronic pain.
__label__noRel	The projected 2-year PFS is 90.4% on three cycles and 89.4% on four cycles.	The difference in PFS between three and four cycles is -1.0% (80% confidence limit [CL], -3.8%, +1.8%).
__label__noRel	The projected 2-year PFS is 90.4% on three cycles and 89.4% on four cycles.	Equivalence for three versus four cycles is claimed because both the upper and lower bounds of the 80% CL are less than 5%.
__label__noRel	The projected 2-year PFS is 90.4% on three cycles and 89.4% on four cycles.	In the 5- versus 3-day comparison, the projected 2-year PFS is 88.8% and 89.7%, respectively (difference, -0.9%, (80% CL, -4.1%, +2.2%).
__label__noRel	The projected 2-year PFS is 90.4% on three cycles and 89.4% on four cycles.	equivalence is claimed in this comparison also.
__label__noRel	The projected 2-year PFS is 90.4% on three cycles and 89.4% on four cycles.	Frequencies of hematologic and nonhematologic toxicities were essentially similar.
__label__noRel	The projected 2-year PFS is 90.4% on three cycles and 89.4% on four cycles.	Quality of life was maintained better in patients receiving three cycles;
__label__noRel	The projected 2-year PFS is 90.4% on three cycles and 89.4% on four cycles.	no differences were detected between 3 and 5 days of treatment.
__label__Support	The projected 2-year PFS is 90.4% on three cycles and 89.4% on four cycles.	three cycles of BEP, with etoposide at 500 mg/m(2), is sufficient therapy in good-prognosis germ cell cancer
__label__noRel	The projected 2-year PFS is 90.4% on three cycles and 89.4% on four cycles.	the administration of the chemotherapy in 3 days has no detrimental effect on the effectiveness of the BEP regimen.
__label__noRel	The difference in PFS between three and four cycles is -1.0% (80% confidence limit [CL], -3.8%, +1.8%).	The projected 2-year PFS is 90.4% on three cycles and 89.4% on four cycles.
__label__Support	The difference in PFS between three and four cycles is -1.0% (80% confidence limit [CL], -3.8%, +1.8%).	Equivalence for three versus four cycles is claimed because both the upper and lower bounds of the 80% CL are less than 5%.
__label__noRel	The difference in PFS between three and four cycles is -1.0% (80% confidence limit [CL], -3.8%, +1.8%).	In the 5- versus 3-day comparison, the projected 2-year PFS is 88.8% and 89.7%, respectively (difference, -0.9%, (80% CL, -4.1%, +2.2%).
__label__noRel	The difference in PFS between three and four cycles is -1.0% (80% confidence limit [CL], -3.8%, +1.8%).	equivalence is claimed in this comparison also.
__label__noRel	The difference in PFS between three and four cycles is -1.0% (80% confidence limit [CL], -3.8%, +1.8%).	Frequencies of hematologic and nonhematologic toxicities were essentially similar.
__label__noRel	The difference in PFS between three and four cycles is -1.0% (80% confidence limit [CL], -3.8%, +1.8%).	Quality of life was maintained better in patients receiving three cycles;
__label__noRel	The difference in PFS between three and four cycles is -1.0% (80% confidence limit [CL], -3.8%, +1.8%).	no differences were detected between 3 and 5 days of treatment.
__label__noRel	The difference in PFS between three and four cycles is -1.0% (80% confidence limit [CL], -3.8%, +1.8%).	three cycles of BEP, with etoposide at 500 mg/m(2), is sufficient therapy in good-prognosis germ cell cancer
__label__noRel	The difference in PFS between three and four cycles is -1.0% (80% confidence limit [CL], -3.8%, +1.8%).	the administration of the chemotherapy in 3 days has no detrimental effect on the effectiveness of the BEP regimen.
__label__noRel	Equivalence for three versus four cycles is claimed because both the upper and lower bounds of the 80% CL are less than 5%.	The projected 2-year PFS is 90.4% on three cycles and 89.4% on four cycles.
__label__noRel	Equivalence for three versus four cycles is claimed because both the upper and lower bounds of the 80% CL are less than 5%.	The difference in PFS between three and four cycles is -1.0% (80% confidence limit [CL], -3.8%, +1.8%).
__label__noRel	Equivalence for three versus four cycles is claimed because both the upper and lower bounds of the 80% CL are less than 5%.	In the 5- versus 3-day comparison, the projected 2-year PFS is 88.8% and 89.7%, respectively (difference, -0.9%, (80% CL, -4.1%, +2.2%).
__label__noRel	Equivalence for three versus four cycles is claimed because both the upper and lower bounds of the 80% CL are less than 5%.	equivalence is claimed in this comparison also.
__label__noRel	Equivalence for three versus four cycles is claimed because both the upper and lower bounds of the 80% CL are less than 5%.	Frequencies of hematologic and nonhematologic toxicities were essentially similar.
__label__noRel	Equivalence for three versus four cycles is claimed because both the upper and lower bounds of the 80% CL are less than 5%.	Quality of life was maintained better in patients receiving three cycles;
__label__noRel	Equivalence for three versus four cycles is claimed because both the upper and lower bounds of the 80% CL are less than 5%.	no differences were detected between 3 and 5 days of treatment.
__label__Support	Equivalence for three versus four cycles is claimed because both the upper and lower bounds of the 80% CL are less than 5%.	three cycles of BEP, with etoposide at 500 mg/m(2), is sufficient therapy in good-prognosis germ cell cancer
__label__noRel	Equivalence for three versus four cycles is claimed because both the upper and lower bounds of the 80% CL are less than 5%.	the administration of the chemotherapy in 3 days has no detrimental effect on the effectiveness of the BEP regimen.
__label__noRel	In the 5- versus 3-day comparison, the projected 2-year PFS is 88.8% and 89.7%, respectively (difference, -0.9%, (80% CL, -4.1%, +2.2%).	The projected 2-year PFS is 90.4% on three cycles and 89.4% on four cycles.
__label__noRel	In the 5- versus 3-day comparison, the projected 2-year PFS is 88.8% and 89.7%, respectively (difference, -0.9%, (80% CL, -4.1%, +2.2%).	The difference in PFS between three and four cycles is -1.0% (80% confidence limit [CL], -3.8%, +1.8%).
__label__noRel	In the 5- versus 3-day comparison, the projected 2-year PFS is 88.8% and 89.7%, respectively (difference, -0.9%, (80% CL, -4.1%, +2.2%).	Equivalence for three versus four cycles is claimed because both the upper and lower bounds of the 80% CL are less than 5%.
__label__Support	In the 5- versus 3-day comparison, the projected 2-year PFS is 88.8% and 89.7%, respectively (difference, -0.9%, (80% CL, -4.1%, +2.2%).	equivalence is claimed in this comparison also.
__label__noRel	In the 5- versus 3-day comparison, the projected 2-year PFS is 88.8% and 89.7%, respectively (difference, -0.9%, (80% CL, -4.1%, +2.2%).	Frequencies of hematologic and nonhematologic toxicities were essentially similar.
__label__noRel	In the 5- versus 3-day comparison, the projected 2-year PFS is 88.8% and 89.7%, respectively (difference, -0.9%, (80% CL, -4.1%, +2.2%).	Quality of life was maintained better in patients receiving three cycles;
__label__noRel	In the 5- versus 3-day comparison, the projected 2-year PFS is 88.8% and 89.7%, respectively (difference, -0.9%, (80% CL, -4.1%, +2.2%).	no differences were detected between 3 and 5 days of treatment.
__label__noRel	In the 5- versus 3-day comparison, the projected 2-year PFS is 88.8% and 89.7%, respectively (difference, -0.9%, (80% CL, -4.1%, +2.2%).	three cycles of BEP, with etoposide at 500 mg/m(2), is sufficient therapy in good-prognosis germ cell cancer
__label__noRel	In the 5- versus 3-day comparison, the projected 2-year PFS is 88.8% and 89.7%, respectively (difference, -0.9%, (80% CL, -4.1%, +2.2%).	the administration of the chemotherapy in 3 days has no detrimental effect on the effectiveness of the BEP regimen.
__label__noRel	equivalence is claimed in this comparison also.	The projected 2-year PFS is 90.4% on three cycles and 89.4% on four cycles.
__label__noRel	equivalence is claimed in this comparison also.	The difference in PFS between three and four cycles is -1.0% (80% confidence limit [CL], -3.8%, +1.8%).
__label__noRel	equivalence is claimed in this comparison also.	Equivalence for three versus four cycles is claimed because both the upper and lower bounds of the 80% CL are less than 5%.
__label__noRel	equivalence is claimed in this comparison also.	In the 5- versus 3-day comparison, the projected 2-year PFS is 88.8% and 89.7%, respectively (difference, -0.9%, (80% CL, -4.1%, +2.2%).
__label__noRel	equivalence is claimed in this comparison also.	Frequencies of hematologic and nonhematologic toxicities were essentially similar.
__label__noRel	equivalence is claimed in this comparison also.	Quality of life was maintained better in patients receiving three cycles;
__label__noRel	equivalence is claimed in this comparison also.	no differences were detected between 3 and 5 days of treatment.
__label__noRel	equivalence is claimed in this comparison also.	three cycles of BEP, with etoposide at 500 mg/m(2), is sufficient therapy in good-prognosis germ cell cancer
__label__Support	equivalence is claimed in this comparison also.	the administration of the chemotherapy in 3 days has no detrimental effect on the effectiveness of the BEP regimen.
__label__noRel	Frequencies of hematologic and nonhematologic toxicities were essentially similar.	The projected 2-year PFS is 90.4% on three cycles and 89.4% on four cycles.
__label__noRel	Frequencies of hematologic and nonhematologic toxicities were essentially similar.	The difference in PFS between three and four cycles is -1.0% (80% confidence limit [CL], -3.8%, +1.8%).
__label__noRel	Frequencies of hematologic and nonhematologic toxicities were essentially similar.	Equivalence for three versus four cycles is claimed because both the upper and lower bounds of the 80% CL are less than 5%.
__label__noRel	Frequencies of hematologic and nonhematologic toxicities were essentially similar.	In the 5- versus 3-day comparison, the projected 2-year PFS is 88.8% and 89.7%, respectively (difference, -0.9%, (80% CL, -4.1%, +2.2%).
__label__noRel	Frequencies of hematologic and nonhematologic toxicities were essentially similar.	equivalence is claimed in this comparison also.
__label__noRel	Frequencies of hematologic and nonhematologic toxicities were essentially similar.	Quality of life was maintained better in patients receiving three cycles;
__label__noRel	Frequencies of hematologic and nonhematologic toxicities were essentially similar.	no differences were detected between 3 and 5 days of treatment.
__label__noRel	Frequencies of hematologic and nonhematologic toxicities were essentially similar.	three cycles of BEP, with etoposide at 500 mg/m(2), is sufficient therapy in good-prognosis germ cell cancer
__label__noRel	Frequencies of hematologic and nonhematologic toxicities were essentially similar.	the administration of the chemotherapy in 3 days has no detrimental effect on the effectiveness of the BEP regimen.
__label__noRel	Quality of life was maintained better in patients receiving three cycles;	The projected 2-year PFS is 90.4% on three cycles and 89.4% on four cycles.
__label__noRel	Quality of life was maintained better in patients receiving three cycles;	The difference in PFS between three and four cycles is -1.0% (80% confidence limit [CL], -3.8%, +1.8%).
__label__noRel	Quality of life was maintained better in patients receiving three cycles;	Equivalence for three versus four cycles is claimed because both the upper and lower bounds of the 80% CL are less than 5%.
__label__noRel	Quality of life was maintained better in patients receiving three cycles;	In the 5- versus 3-day comparison, the projected 2-year PFS is 88.8% and 89.7%, respectively (difference, -0.9%, (80% CL, -4.1%, +2.2%).
__label__noRel	Quality of life was maintained better in patients receiving three cycles;	equivalence is claimed in this comparison also.
__label__noRel	Quality of life was maintained better in patients receiving three cycles;	Frequencies of hematologic and nonhematologic toxicities were essentially similar.
__label__noRel	Quality of life was maintained better in patients receiving three cycles;	no differences were detected between 3 and 5 days of treatment.
__label__Support	Quality of life was maintained better in patients receiving three cycles;	three cycles of BEP, with etoposide at 500 mg/m(2), is sufficient therapy in good-prognosis germ cell cancer
__label__noRel	Quality of life was maintained better in patients receiving three cycles;	the administration of the chemotherapy in 3 days has no detrimental effect on the effectiveness of the BEP regimen.
__label__noRel	no differences were detected between 3 and 5 days of treatment.	The projected 2-year PFS is 90.4% on three cycles and 89.4% on four cycles.
__label__noRel	no differences were detected between 3 and 5 days of treatment.	The difference in PFS between three and four cycles is -1.0% (80% confidence limit [CL], -3.8%, +1.8%).
__label__noRel	no differences were detected between 3 and 5 days of treatment.	Equivalence for three versus four cycles is claimed because both the upper and lower bounds of the 80% CL are less than 5%.
__label__noRel	no differences were detected between 3 and 5 days of treatment.	In the 5- versus 3-day comparison, the projected 2-year PFS is 88.8% and 89.7%, respectively (difference, -0.9%, (80% CL, -4.1%, +2.2%).
__label__noRel	no differences were detected between 3 and 5 days of treatment.	equivalence is claimed in this comparison also.
__label__noRel	no differences were detected between 3 and 5 days of treatment.	Frequencies of hematologic and nonhematologic toxicities were essentially similar.
__label__noRel	no differences were detected between 3 and 5 days of treatment.	Quality of life was maintained better in patients receiving three cycles;
__label__noRel	no differences were detected between 3 and 5 days of treatment.	three cycles of BEP, with etoposide at 500 mg/m(2), is sufficient therapy in good-prognosis germ cell cancer
__label__Support	no differences were detected between 3 and 5 days of treatment.	the administration of the chemotherapy in 3 days has no detrimental effect on the effectiveness of the BEP regimen.
__label__noRel	three cycles of BEP, with etoposide at 500 mg/m(2), is sufficient therapy in good-prognosis germ cell cancer	The projected 2-year PFS is 90.4% on three cycles and 89.4% on four cycles.
__label__noRel	three cycles of BEP, with etoposide at 500 mg/m(2), is sufficient therapy in good-prognosis germ cell cancer	The difference in PFS between three and four cycles is -1.0% (80% confidence limit [CL], -3.8%, +1.8%).
__label__noRel	three cycles of BEP, with etoposide at 500 mg/m(2), is sufficient therapy in good-prognosis germ cell cancer	Equivalence for three versus four cycles is claimed because both the upper and lower bounds of the 80% CL are less than 5%.
__label__noRel	three cycles of BEP, with etoposide at 500 mg/m(2), is sufficient therapy in good-prognosis germ cell cancer	In the 5- versus 3-day comparison, the projected 2-year PFS is 88.8% and 89.7%, respectively (difference, -0.9%, (80% CL, -4.1%, +2.2%).
__label__noRel	three cycles of BEP, with etoposide at 500 mg/m(2), is sufficient therapy in good-prognosis germ cell cancer	equivalence is claimed in this comparison also.
__label__noRel	three cycles of BEP, with etoposide at 500 mg/m(2), is sufficient therapy in good-prognosis germ cell cancer	Frequencies of hematologic and nonhematologic toxicities were essentially similar.
__label__noRel	three cycles of BEP, with etoposide at 500 mg/m(2), is sufficient therapy in good-prognosis germ cell cancer	Quality of life was maintained better in patients receiving three cycles;
__label__noRel	three cycles of BEP, with etoposide at 500 mg/m(2), is sufficient therapy in good-prognosis germ cell cancer	no differences were detected between 3 and 5 days of treatment.
__label__noRel	three cycles of BEP, with etoposide at 500 mg/m(2), is sufficient therapy in good-prognosis germ cell cancer	the administration of the chemotherapy in 3 days has no detrimental effect on the effectiveness of the BEP regimen.
__label__noRel	the administration of the chemotherapy in 3 days has no detrimental effect on the effectiveness of the BEP regimen.	The projected 2-year PFS is 90.4% on three cycles and 89.4% on four cycles.
__label__noRel	the administration of the chemotherapy in 3 days has no detrimental effect on the effectiveness of the BEP regimen.	The difference in PFS between three and four cycles is -1.0% (80% confidence limit [CL], -3.8%, +1.8%).
__label__noRel	the administration of the chemotherapy in 3 days has no detrimental effect on the effectiveness of the BEP regimen.	Equivalence for three versus four cycles is claimed because both the upper and lower bounds of the 80% CL are less than 5%.
__label__noRel	the administration of the chemotherapy in 3 days has no detrimental effect on the effectiveness of the BEP regimen.	In the 5- versus 3-day comparison, the projected 2-year PFS is 88.8% and 89.7%, respectively (difference, -0.9%, (80% CL, -4.1%, +2.2%).
__label__noRel	the administration of the chemotherapy in 3 days has no detrimental effect on the effectiveness of the BEP regimen.	equivalence is claimed in this comparison also.
__label__noRel	the administration of the chemotherapy in 3 days has no detrimental effect on the effectiveness of the BEP regimen.	Frequencies of hematologic and nonhematologic toxicities were essentially similar.
__label__noRel	the administration of the chemotherapy in 3 days has no detrimental effect on the effectiveness of the BEP regimen.	Quality of life was maintained better in patients receiving three cycles;
__label__noRel	the administration of the chemotherapy in 3 days has no detrimental effect on the effectiveness of the BEP regimen.	no differences were detected between 3 and 5 days of treatment.
__label__noRel	the administration of the chemotherapy in 3 days has no detrimental effect on the effectiveness of the BEP regimen.	three cycles of BEP, with etoposide at 500 mg/m(2), is sufficient therapy in good-prognosis germ cell cancer
__label__noRel	Treatment effects favored castration for both endpoints (P < or = 0.002), with hazard ratios (bicalutamide:castration) of 1.54 (95% confidence interval [CI], 1.18 to 2.00) for time to treatment failure and 1.6 (95% CI, 1.19 to 2.15) for time to disease progression.	From the 1-year survival analysis, the hazard ratio for probability of death was 1.29 (95% CI, 0.96 to 1.72).
__label__noRel	Treatment effects favored castration for both endpoints (P < or = 0.002), with hazard ratios (bicalutamide:castration) of 1.54 (95% confidence interval [CI], 1.18 to 2.00) for time to treatment failure and 1.6 (95% CI, 1.19 to 2.15) for time to disease progression.	Thus far, with a median follow-up of 86 weeks, median survival has not been reached in either group.
__label__noRel	Treatment effects favored castration for both endpoints (P < or = 0.002), with hazard ratios (bicalutamide:castration) of 1.54 (95% confidence interval [CI], 1.18 to 2.00) for time to treatment failure and 1.6 (95% CI, 1.19 to 2.15) for time to disease progression.	Changes from baseline in several quality of life variables were significantly different (P < or = 0.01) between treatment groups periodically from months 1 to 6, and all favored bicalutamide.
__label__noRel	Treatment effects favored castration for both endpoints (P < or = 0.002), with hazard ratios (bicalutamide:castration) of 1.54 (95% confidence interval [CI], 1.18 to 2.00) for time to treatment failure and 1.6 (95% CI, 1.19 to 2.15) for time to disease progression.	Overall, the antiandrogen was well tolerated compared with castration;
__label__noRel	Treatment effects favored castration for both endpoints (P < or = 0.002), with hazard ratios (bicalutamide:castration) of 1.54 (95% confidence interval [CI], 1.18 to 2.00) for time to treatment failure and 1.6 (95% CI, 1.19 to 2.15) for time to disease progression.	with bicalutamide, hot flushes occurred less often and breast tenderness and gynecomastia more often.
__label__noRel	Treatment effects favored castration for both endpoints (P < or = 0.002), with hazard ratios (bicalutamide:castration) of 1.54 (95% confidence interval [CI], 1.18 to 2.00) for time to treatment failure and 1.6 (95% CI, 1.19 to 2.15) for time to disease progression.	Although a dosage of 50 mg of bicalutamide once daily was not as effective as castration,
__label__Attack	Treatment effects favored castration for both endpoints (P < or = 0.002), with hazard ratios (bicalutamide:castration) of 1.54 (95% confidence interval [CI], 1.18 to 2.00) for time to treatment failure and 1.6 (95% CI, 1.19 to 2.15) for time to disease progression.	the favorable quality of life outcomes and the low incidence of nonhormonal adverse events provide reasons to evaluate bicalutamide, as a single therapeutic agent, at higher doses.
__label__noRel	From the 1-year survival analysis, the hazard ratio for probability of death was 1.29 (95% CI, 0.96 to 1.72).	Treatment effects favored castration for both endpoints (P < or = 0.002), with hazard ratios (bicalutamide:castration) of 1.54 (95% confidence interval [CI], 1.18 to 2.00) for time to treatment failure and 1.6 (95% CI, 1.19 to 2.15) for time to disease progression.
__label__noRel	From the 1-year survival analysis, the hazard ratio for probability of death was 1.29 (95% CI, 0.96 to 1.72).	Thus far, with a median follow-up of 86 weeks, median survival has not been reached in either group.
__label__noRel	From the 1-year survival analysis, the hazard ratio for probability of death was 1.29 (95% CI, 0.96 to 1.72).	Changes from baseline in several quality of life variables were significantly different (P < or = 0.01) between treatment groups periodically from months 1 to 6, and all favored bicalutamide.
__label__noRel	From the 1-year survival analysis, the hazard ratio for probability of death was 1.29 (95% CI, 0.96 to 1.72).	Overall, the antiandrogen was well tolerated compared with castration;
__label__noRel	From the 1-year survival analysis, the hazard ratio for probability of death was 1.29 (95% CI, 0.96 to 1.72).	with bicalutamide, hot flushes occurred less often and breast tenderness and gynecomastia more often.
__label__noRel	From the 1-year survival analysis, the hazard ratio for probability of death was 1.29 (95% CI, 0.96 to 1.72).	Although a dosage of 50 mg of bicalutamide once daily was not as effective as castration,
__label__Support	From the 1-year survival analysis, the hazard ratio for probability of death was 1.29 (95% CI, 0.96 to 1.72).	the favorable quality of life outcomes and the low incidence of nonhormonal adverse events provide reasons to evaluate bicalutamide, as a single therapeutic agent, at higher doses.
__label__noRel	Thus far, with a median follow-up of 86 weeks, median survival has not been reached in either group.	Treatment effects favored castration for both endpoints (P < or = 0.002), with hazard ratios (bicalutamide:castration) of 1.54 (95% confidence interval [CI], 1.18 to 2.00) for time to treatment failure and 1.6 (95% CI, 1.19 to 2.15) for time to disease progression.
__label__Attack	Thus far, with a median follow-up of 86 weeks, median survival has not been reached in either group.	From the 1-year survival analysis, the hazard ratio for probability of death was 1.29 (95% CI, 0.96 to 1.72).
__label__noRel	Thus far, with a median follow-up of 86 weeks, median survival has not been reached in either group.	Changes from baseline in several quality of life variables were significantly different (P < or = 0.01) between treatment groups periodically from months 1 to 6, and all favored bicalutamide.
__label__noRel	Thus far, with a median follow-up of 86 weeks, median survival has not been reached in either group.	Overall, the antiandrogen was well tolerated compared with castration;
__label__noRel	Thus far, with a median follow-up of 86 weeks, median survival has not been reached in either group.	with bicalutamide, hot flushes occurred less often and breast tenderness and gynecomastia more often.
__label__noRel	Thus far, with a median follow-up of 86 weeks, median survival has not been reached in either group.	Although a dosage of 50 mg of bicalutamide once daily was not as effective as castration,
__label__noRel	Thus far, with a median follow-up of 86 weeks, median survival has not been reached in either group.	the favorable quality of life outcomes and the low incidence of nonhormonal adverse events provide reasons to evaluate bicalutamide, as a single therapeutic agent, at higher doses.
__label__noRel	Changes from baseline in several quality of life variables were significantly different (P < or = 0.01) between treatment groups periodically from months 1 to 6, and all favored bicalutamide.	Treatment effects favored castration for both endpoints (P < or = 0.002), with hazard ratios (bicalutamide:castration) of 1.54 (95% confidence interval [CI], 1.18 to 2.00) for time to treatment failure and 1.6 (95% CI, 1.19 to 2.15) for time to disease progression.
__label__noRel	Changes from baseline in several quality of life variables were significantly different (P < or = 0.01) between treatment groups periodically from months 1 to 6, and all favored bicalutamide.	From the 1-year survival analysis, the hazard ratio for probability of death was 1.29 (95% CI, 0.96 to 1.72).
__label__noRel	Changes from baseline in several quality of life variables were significantly different (P < or = 0.01) between treatment groups periodically from months 1 to 6, and all favored bicalutamide.	Thus far, with a median follow-up of 86 weeks, median survival has not been reached in either group.
__label__noRel	Changes from baseline in several quality of life variables were significantly different (P < or = 0.01) between treatment groups periodically from months 1 to 6, and all favored bicalutamide.	Overall, the antiandrogen was well tolerated compared with castration;
__label__noRel	Changes from baseline in several quality of life variables were significantly different (P < or = 0.01) between treatment groups periodically from months 1 to 6, and all favored bicalutamide.	with bicalutamide, hot flushes occurred less often and breast tenderness and gynecomastia more often.
__label__noRel	Changes from baseline in several quality of life variables were significantly different (P < or = 0.01) between treatment groups periodically from months 1 to 6, and all favored bicalutamide.	Although a dosage of 50 mg of bicalutamide once daily was not as effective as castration,
__label__Support	Changes from baseline in several quality of life variables were significantly different (P < or = 0.01) between treatment groups periodically from months 1 to 6, and all favored bicalutamide.	the favorable quality of life outcomes and the low incidence of nonhormonal adverse events provide reasons to evaluate bicalutamide, as a single therapeutic agent, at higher doses.
__label__noRel	Overall, the antiandrogen was well tolerated compared with castration;	Treatment effects favored castration for both endpoints (P < or = 0.002), with hazard ratios (bicalutamide:castration) of 1.54 (95% confidence interval [CI], 1.18 to 2.00) for time to treatment failure and 1.6 (95% CI, 1.19 to 2.15) for time to disease progression.
__label__noRel	Overall, the antiandrogen was well tolerated compared with castration;	From the 1-year survival analysis, the hazard ratio for probability of death was 1.29 (95% CI, 0.96 to 1.72).
__label__noRel	Overall, the antiandrogen was well tolerated compared with castration;	Thus far, with a median follow-up of 86 weeks, median survival has not been reached in either group.
__label__noRel	Overall, the antiandrogen was well tolerated compared with castration;	Changes from baseline in several quality of life variables were significantly different (P < or = 0.01) between treatment groups periodically from months 1 to 6, and all favored bicalutamide.
__label__noRel	Overall, the antiandrogen was well tolerated compared with castration;	with bicalutamide, hot flushes occurred less often and breast tenderness and gynecomastia more often.
__label__noRel	Overall, the antiandrogen was well tolerated compared with castration;	Although a dosage of 50 mg of bicalutamide once daily was not as effective as castration,
__label__Support	Overall, the antiandrogen was well tolerated compared with castration;	the favorable quality of life outcomes and the low incidence of nonhormonal adverse events provide reasons to evaluate bicalutamide, as a single therapeutic agent, at higher doses.
__label__noRel	with bicalutamide, hot flushes occurred less often and breast tenderness and gynecomastia more often.	Treatment effects favored castration for both endpoints (P < or = 0.002), with hazard ratios (bicalutamide:castration) of 1.54 (95% confidence interval [CI], 1.18 to 2.00) for time to treatment failure and 1.6 (95% CI, 1.19 to 2.15) for time to disease progression.
__label__noRel	with bicalutamide, hot flushes occurred less often and breast tenderness and gynecomastia more often.	From the 1-year survival analysis, the hazard ratio for probability of death was 1.29 (95% CI, 0.96 to 1.72).
__label__noRel	with bicalutamide, hot flushes occurred less often and breast tenderness and gynecomastia more often.	Thus far, with a median follow-up of 86 weeks, median survival has not been reached in either group.
__label__noRel	with bicalutamide, hot flushes occurred less often and breast tenderness and gynecomastia more often.	Changes from baseline in several quality of life variables were significantly different (P < or = 0.01) between treatment groups periodically from months 1 to 6, and all favored bicalutamide.
__label__noRel	with bicalutamide, hot flushes occurred less often and breast tenderness and gynecomastia more often.	Overall, the antiandrogen was well tolerated compared with castration;
__label__noRel	with bicalutamide, hot flushes occurred less often and breast tenderness and gynecomastia more often.	Although a dosage of 50 mg of bicalutamide once daily was not as effective as castration,
__label__Support	with bicalutamide, hot flushes occurred less often and breast tenderness and gynecomastia more often.	the favorable quality of life outcomes and the low incidence of nonhormonal adverse events provide reasons to evaluate bicalutamide, as a single therapeutic agent, at higher doses.
__label__noRel	Although a dosage of 50 mg of bicalutamide once daily was not as effective as castration,	Treatment effects favored castration for both endpoints (P < or = 0.002), with hazard ratios (bicalutamide:castration) of 1.54 (95% confidence interval [CI], 1.18 to 2.00) for time to treatment failure and 1.6 (95% CI, 1.19 to 2.15) for time to disease progression.
__label__noRel	Although a dosage of 50 mg of bicalutamide once daily was not as effective as castration,	From the 1-year survival analysis, the hazard ratio for probability of death was 1.29 (95% CI, 0.96 to 1.72).
__label__noRel	Although a dosage of 50 mg of bicalutamide once daily was not as effective as castration,	Thus far, with a median follow-up of 86 weeks, median survival has not been reached in either group.
__label__noRel	Although a dosage of 50 mg of bicalutamide once daily was not as effective as castration,	Changes from baseline in several quality of life variables were significantly different (P < or = 0.01) between treatment groups periodically from months 1 to 6, and all favored bicalutamide.
__label__noRel	Although a dosage of 50 mg of bicalutamide once daily was not as effective as castration,	Overall, the antiandrogen was well tolerated compared with castration;
__label__noRel	Although a dosage of 50 mg of bicalutamide once daily was not as effective as castration,	with bicalutamide, hot flushes occurred less often and breast tenderness and gynecomastia more often.
__label__Attack	Although a dosage of 50 mg of bicalutamide once daily was not as effective as castration,	the favorable quality of life outcomes and the low incidence of nonhormonal adverse events provide reasons to evaluate bicalutamide, as a single therapeutic agent, at higher doses.
__label__noRel	the favorable quality of life outcomes and the low incidence of nonhormonal adverse events provide reasons to evaluate bicalutamide, as a single therapeutic agent, at higher doses.	Treatment effects favored castration for both endpoints (P < or = 0.002), with hazard ratios (bicalutamide:castration) of 1.54 (95% confidence interval [CI], 1.18 to 2.00) for time to treatment failure and 1.6 (95% CI, 1.19 to 2.15) for time to disease progression.
__label__noRel	the favorable quality of life outcomes and the low incidence of nonhormonal adverse events provide reasons to evaluate bicalutamide, as a single therapeutic agent, at higher doses.	From the 1-year survival analysis, the hazard ratio for probability of death was 1.29 (95% CI, 0.96 to 1.72).
__label__noRel	the favorable quality of life outcomes and the low incidence of nonhormonal adverse events provide reasons to evaluate bicalutamide, as a single therapeutic agent, at higher doses.	Thus far, with a median follow-up of 86 weeks, median survival has not been reached in either group.
__label__noRel	the favorable quality of life outcomes and the low incidence of nonhormonal adverse events provide reasons to evaluate bicalutamide, as a single therapeutic agent, at higher doses.	Changes from baseline in several quality of life variables were significantly different (P < or = 0.01) between treatment groups periodically from months 1 to 6, and all favored bicalutamide.
__label__noRel	the favorable quality of life outcomes and the low incidence of nonhormonal adverse events provide reasons to evaluate bicalutamide, as a single therapeutic agent, at higher doses.	Overall, the antiandrogen was well tolerated compared with castration;
__label__noRel	the favorable quality of life outcomes and the low incidence of nonhormonal adverse events provide reasons to evaluate bicalutamide, as a single therapeutic agent, at higher doses.	with bicalutamide, hot flushes occurred less often and breast tenderness and gynecomastia more often.
__label__noRel	the favorable quality of life outcomes and the low incidence of nonhormonal adverse events provide reasons to evaluate bicalutamide, as a single therapeutic agent, at higher doses.	Although a dosage of 50 mg of bicalutamide once daily was not as effective as castration,
__label__noRel	Sentinel lymph node biopsy in women with operable breast cancer is routinely used in some countries for staging the axilla despite limited data from randomized trials on morbidity and mortality outcomes.	The relative risks of any lymphedema and sensory loss for the sentinel lymph node biopsy group compared with the standard axillary treatment group at 12 months were 0.37 (95% confidence interval [CI] = 0.23 to 0.60; absolute rates: 5% versus 13%) and 0.37 (95% CI = 0.27 to 0.50; absolute rates: 11% versus 31%), respectively.
__label__noRel	Sentinel lymph node biopsy in women with operable breast cancer is routinely used in some countries for staging the axilla despite limited data from randomized trials on morbidity and mortality outcomes.	Drain usage, length of hospital stay, and time to resumption of normal day-to-day activities after surgery were statistically significantly lower in the sentinel lymph node biopsy group (all P < .001), and axillary operative time was reduced (P = .055).
__label__noRel	Sentinel lymph node biopsy in women with operable breast cancer is routinely used in some countries for staging the axilla despite limited data from randomized trials on morbidity and mortality outcomes.	Overall patient-recorded quality of life and arm functioning scores were statistically significantly better in the sentinel lymph node biopsy group throughout (all P < or = .003).
__label__noRel	Sentinel lymph node biopsy in women with operable breast cancer is routinely used in some countries for staging the axilla despite limited data from randomized trials on morbidity and mortality outcomes.	These benefits were seen with no increase in anxiety levels in the sentinel lymph node biopsy group (P > .05).
__label__noRel	Sentinel lymph node biopsy in women with operable breast cancer is routinely used in some countries for staging the axilla despite limited data from randomized trials on morbidity and mortality outcomes.	Sentinel lymph node biopsy is associated with reduced arm morbidity and better quality of life than standard axillary treatment and should be the treatment of choice for patients who have early-stage breast cancer with clinically negative nodes.
__label__noRel	The relative risks of any lymphedema and sensory loss for the sentinel lymph node biopsy group compared with the standard axillary treatment group at 12 months were 0.37 (95% confidence interval [CI] = 0.23 to 0.60; absolute rates: 5% versus 13%) and 0.37 (95% CI = 0.27 to 0.50; absolute rates: 11% versus 31%), respectively.	Sentinel lymph node biopsy in women with operable breast cancer is routinely used in some countries for staging the axilla despite limited data from randomized trials on morbidity and mortality outcomes.
__label__noRel	The relative risks of any lymphedema and sensory loss for the sentinel lymph node biopsy group compared with the standard axillary treatment group at 12 months were 0.37 (95% confidence interval [CI] = 0.23 to 0.60; absolute rates: 5% versus 13%) and 0.37 (95% CI = 0.27 to 0.50; absolute rates: 11% versus 31%), respectively.	Drain usage, length of hospital stay, and time to resumption of normal day-to-day activities after surgery were statistically significantly lower in the sentinel lymph node biopsy group (all P < .001), and axillary operative time was reduced (P = .055).
__label__noRel	The relative risks of any lymphedema and sensory loss for the sentinel lymph node biopsy group compared with the standard axillary treatment group at 12 months were 0.37 (95% confidence interval [CI] = 0.23 to 0.60; absolute rates: 5% versus 13%) and 0.37 (95% CI = 0.27 to 0.50; absolute rates: 11% versus 31%), respectively.	Overall patient-recorded quality of life and arm functioning scores were statistically significantly better in the sentinel lymph node biopsy group throughout (all P < or = .003).
__label__noRel	The relative risks of any lymphedema and sensory loss for the sentinel lymph node biopsy group compared with the standard axillary treatment group at 12 months were 0.37 (95% confidence interval [CI] = 0.23 to 0.60; absolute rates: 5% versus 13%) and 0.37 (95% CI = 0.27 to 0.50; absolute rates: 11% versus 31%), respectively.	These benefits were seen with no increase in anxiety levels in the sentinel lymph node biopsy group (P > .05).
__label__Support	The relative risks of any lymphedema and sensory loss for the sentinel lymph node biopsy group compared with the standard axillary treatment group at 12 months were 0.37 (95% confidence interval [CI] = 0.23 to 0.60; absolute rates: 5% versus 13%) and 0.37 (95% CI = 0.27 to 0.50; absolute rates: 11% versus 31%), respectively.	Sentinel lymph node biopsy is associated with reduced arm morbidity and better quality of life than standard axillary treatment and should be the treatment of choice for patients who have early-stage breast cancer with clinically negative nodes.
__label__noRel	Drain usage, length of hospital stay, and time to resumption of normal day-to-day activities after surgery were statistically significantly lower in the sentinel lymph node biopsy group (all P < .001), and axillary operative time was reduced (P = .055).	Sentinel lymph node biopsy in women with operable breast cancer is routinely used in some countries for staging the axilla despite limited data from randomized trials on morbidity and mortality outcomes.
__label__noRel	Drain usage, length of hospital stay, and time to resumption of normal day-to-day activities after surgery were statistically significantly lower in the sentinel lymph node biopsy group (all P < .001), and axillary operative time was reduced (P = .055).	The relative risks of any lymphedema and sensory loss for the sentinel lymph node biopsy group compared with the standard axillary treatment group at 12 months were 0.37 (95% confidence interval [CI] = 0.23 to 0.60; absolute rates: 5% versus 13%) and 0.37 (95% CI = 0.27 to 0.50; absolute rates: 11% versus 31%), respectively.
__label__noRel	Drain usage, length of hospital stay, and time to resumption of normal day-to-day activities after surgery were statistically significantly lower in the sentinel lymph node biopsy group (all P < .001), and axillary operative time was reduced (P = .055).	Overall patient-recorded quality of life and arm functioning scores were statistically significantly better in the sentinel lymph node biopsy group throughout (all P < or = .003).
__label__noRel	Drain usage, length of hospital stay, and time to resumption of normal day-to-day activities after surgery were statistically significantly lower in the sentinel lymph node biopsy group (all P < .001), and axillary operative time was reduced (P = .055).	These benefits were seen with no increase in anxiety levels in the sentinel lymph node biopsy group (P > .05).
__label__Support	Drain usage, length of hospital stay, and time to resumption of normal day-to-day activities after surgery were statistically significantly lower in the sentinel lymph node biopsy group (all P < .001), and axillary operative time was reduced (P = .055).	Sentinel lymph node biopsy is associated with reduced arm morbidity and better quality of life than standard axillary treatment and should be the treatment of choice for patients who have early-stage breast cancer with clinically negative nodes.
__label__noRel	Overall patient-recorded quality of life and arm functioning scores were statistically significantly better in the sentinel lymph node biopsy group throughout (all P < or = .003).	Sentinel lymph node biopsy in women with operable breast cancer is routinely used in some countries for staging the axilla despite limited data from randomized trials on morbidity and mortality outcomes.
__label__noRel	Overall patient-recorded quality of life and arm functioning scores were statistically significantly better in the sentinel lymph node biopsy group throughout (all P < or = .003).	The relative risks of any lymphedema and sensory loss for the sentinel lymph node biopsy group compared with the standard axillary treatment group at 12 months were 0.37 (95% confidence interval [CI] = 0.23 to 0.60; absolute rates: 5% versus 13%) and 0.37 (95% CI = 0.27 to 0.50; absolute rates: 11% versus 31%), respectively.
__label__noRel	Overall patient-recorded quality of life and arm functioning scores were statistically significantly better in the sentinel lymph node biopsy group throughout (all P < or = .003).	Drain usage, length of hospital stay, and time to resumption of normal day-to-day activities after surgery were statistically significantly lower in the sentinel lymph node biopsy group (all P < .001), and axillary operative time was reduced (P = .055).
__label__noRel	Overall patient-recorded quality of life and arm functioning scores were statistically significantly better in the sentinel lymph node biopsy group throughout (all P < or = .003).	These benefits were seen with no increase in anxiety levels in the sentinel lymph node biopsy group (P > .05).
__label__Support	Overall patient-recorded quality of life and arm functioning scores were statistically significantly better in the sentinel lymph node biopsy group throughout (all P < or = .003).	Sentinel lymph node biopsy is associated with reduced arm morbidity and better quality of life than standard axillary treatment and should be the treatment of choice for patients who have early-stage breast cancer with clinically negative nodes.
__label__noRel	These benefits were seen with no increase in anxiety levels in the sentinel lymph node biopsy group (P > .05).	Sentinel lymph node biopsy in women with operable breast cancer is routinely used in some countries for staging the axilla despite limited data from randomized trials on morbidity and mortality outcomes.
__label__noRel	These benefits were seen with no increase in anxiety levels in the sentinel lymph node biopsy group (P > .05).	The relative risks of any lymphedema and sensory loss for the sentinel lymph node biopsy group compared with the standard axillary treatment group at 12 months were 0.37 (95% confidence interval [CI] = 0.23 to 0.60; absolute rates: 5% versus 13%) and 0.37 (95% CI = 0.27 to 0.50; absolute rates: 11% versus 31%), respectively.
__label__noRel	These benefits were seen with no increase in anxiety levels in the sentinel lymph node biopsy group (P > .05).	Drain usage, length of hospital stay, and time to resumption of normal day-to-day activities after surgery were statistically significantly lower in the sentinel lymph node biopsy group (all P < .001), and axillary operative time was reduced (P = .055).
__label__noRel	These benefits were seen with no increase in anxiety levels in the sentinel lymph node biopsy group (P > .05).	Overall patient-recorded quality of life and arm functioning scores were statistically significantly better in the sentinel lymph node biopsy group throughout (all P < or = .003).
__label__Support	These benefits were seen with no increase in anxiety levels in the sentinel lymph node biopsy group (P > .05).	Sentinel lymph node biopsy is associated with reduced arm morbidity and better quality of life than standard axillary treatment and should be the treatment of choice for patients who have early-stage breast cancer with clinically negative nodes.
__label__noRel	Sentinel lymph node biopsy is associated with reduced arm morbidity and better quality of life than standard axillary treatment and should be the treatment of choice for patients who have early-stage breast cancer with clinically negative nodes.	Sentinel lymph node biopsy in women with operable breast cancer is routinely used in some countries for staging the axilla despite limited data from randomized trials on morbidity and mortality outcomes.
__label__noRel	Sentinel lymph node biopsy is associated with reduced arm morbidity and better quality of life than standard axillary treatment and should be the treatment of choice for patients who have early-stage breast cancer with clinically negative nodes.	The relative risks of any lymphedema and sensory loss for the sentinel lymph node biopsy group compared with the standard axillary treatment group at 12 months were 0.37 (95% confidence interval [CI] = 0.23 to 0.60; absolute rates: 5% versus 13%) and 0.37 (95% CI = 0.27 to 0.50; absolute rates: 11% versus 31%), respectively.
__label__noRel	Sentinel lymph node biopsy is associated with reduced arm morbidity and better quality of life than standard axillary treatment and should be the treatment of choice for patients who have early-stage breast cancer with clinically negative nodes.	Drain usage, length of hospital stay, and time to resumption of normal day-to-day activities after surgery were statistically significantly lower in the sentinel lymph node biopsy group (all P < .001), and axillary operative time was reduced (P = .055).
__label__noRel	Sentinel lymph node biopsy is associated with reduced arm morbidity and better quality of life than standard axillary treatment and should be the treatment of choice for patients who have early-stage breast cancer with clinically negative nodes.	Overall patient-recorded quality of life and arm functioning scores were statistically significantly better in the sentinel lymph node biopsy group throughout (all P < or = .003).
__label__noRel	Sentinel lymph node biopsy is associated with reduced arm morbidity and better quality of life than standard axillary treatment and should be the treatment of choice for patients who have early-stage breast cancer with clinically negative nodes.	These benefits were seen with no increase in anxiety levels in the sentinel lymph node biopsy group (P > .05).
__label__noRel	True acupuncture was associated with 0.8 fewer hot flashes per day than sham at 6 weeks	but the difference did not reach statistical significance (95% CI, -0.7 to 2.4; P = .3).
__label__noRel	True acupuncture was associated with 0.8 fewer hot flashes per day than sham at 6 weeks	When participants in the sham acupuncture group were crossed over to true acupuncture, a further reduction in the frequency of hot flashes was seen.
__label__Support	True acupuncture was associated with 0.8 fewer hot flashes per day than sham at 6 weeks	Hot flash frequency in breast cancer patients was reduced following acupuncture.
__label__noRel	True acupuncture was associated with 0.8 fewer hot flashes per day than sham at 6 weeks	We cannot exclude the possibility that a longer and more intense acupuncture intervention could produce a larger reduction of these symptoms.
__label__noRel	True acupuncture was associated with 0.8 fewer hot flashes per day than sham at 6 weeks	when compared with sham acupuncture, the reduction by the acupuncture regimen as provided in the current study did not reach statistical significance.
__label__Attack	but the difference did not reach statistical significance (95% CI, -0.7 to 2.4; P = .3).	True acupuncture was associated with 0.8 fewer hot flashes per day than sham at 6 weeks
__label__noRel	but the difference did not reach statistical significance (95% CI, -0.7 to 2.4; P = .3).	When participants in the sham acupuncture group were crossed over to true acupuncture, a further reduction in the frequency of hot flashes was seen.
__label__noRel	but the difference did not reach statistical significance (95% CI, -0.7 to 2.4; P = .3).	Hot flash frequency in breast cancer patients was reduced following acupuncture.
__label__noRel	but the difference did not reach statistical significance (95% CI, -0.7 to 2.4; P = .3).	We cannot exclude the possibility that a longer and more intense acupuncture intervention could produce a larger reduction of these symptoms.
__label__noRel	but the difference did not reach statistical significance (95% CI, -0.7 to 2.4; P = .3).	when compared with sham acupuncture, the reduction by the acupuncture regimen as provided in the current study did not reach statistical significance.
__label__noRel	When participants in the sham acupuncture group were crossed over to true acupuncture, a further reduction in the frequency of hot flashes was seen.	True acupuncture was associated with 0.8 fewer hot flashes per day than sham at 6 weeks
__label__noRel	When participants in the sham acupuncture group were crossed over to true acupuncture, a further reduction in the frequency of hot flashes was seen.	but the difference did not reach statistical significance (95% CI, -0.7 to 2.4; P = .3).
__label__Support	When participants in the sham acupuncture group were crossed over to true acupuncture, a further reduction in the frequency of hot flashes was seen.	Hot flash frequency in breast cancer patients was reduced following acupuncture.
__label__noRel	When participants in the sham acupuncture group were crossed over to true acupuncture, a further reduction in the frequency of hot flashes was seen.	We cannot exclude the possibility that a longer and more intense acupuncture intervention could produce a larger reduction of these symptoms.
__label__noRel	When participants in the sham acupuncture group were crossed over to true acupuncture, a further reduction in the frequency of hot flashes was seen.	when compared with sham acupuncture, the reduction by the acupuncture regimen as provided in the current study did not reach statistical significance.
__label__noRel	Hot flash frequency in breast cancer patients was reduced following acupuncture.	True acupuncture was associated with 0.8 fewer hot flashes per day than sham at 6 weeks
__label__noRel	Hot flash frequency in breast cancer patients was reduced following acupuncture.	but the difference did not reach statistical significance (95% CI, -0.7 to 2.4; P = .3).
__label__noRel	Hot flash frequency in breast cancer patients was reduced following acupuncture.	When participants in the sham acupuncture group were crossed over to true acupuncture, a further reduction in the frequency of hot flashes was seen.
__label__noRel	Hot flash frequency in breast cancer patients was reduced following acupuncture.	We cannot exclude the possibility that a longer and more intense acupuncture intervention could produce a larger reduction of these symptoms.
__label__noRel	Hot flash frequency in breast cancer patients was reduced following acupuncture.	when compared with sham acupuncture, the reduction by the acupuncture regimen as provided in the current study did not reach statistical significance.
__label__noRel	We cannot exclude the possibility that a longer and more intense acupuncture intervention could produce a larger reduction of these symptoms.	True acupuncture was associated with 0.8 fewer hot flashes per day than sham at 6 weeks
__label__noRel	We cannot exclude the possibility that a longer and more intense acupuncture intervention could produce a larger reduction of these symptoms.	but the difference did not reach statistical significance (95% CI, -0.7 to 2.4; P = .3).
__label__noRel	We cannot exclude the possibility that a longer and more intense acupuncture intervention could produce a larger reduction of these symptoms.	When participants in the sham acupuncture group were crossed over to true acupuncture, a further reduction in the frequency of hot flashes was seen.
__label__noRel	We cannot exclude the possibility that a longer and more intense acupuncture intervention could produce a larger reduction of these symptoms.	Hot flash frequency in breast cancer patients was reduced following acupuncture.
__label__noRel	We cannot exclude the possibility that a longer and more intense acupuncture intervention could produce a larger reduction of these symptoms.	when compared with sham acupuncture, the reduction by the acupuncture regimen as provided in the current study did not reach statistical significance.
__label__noRel	when compared with sham acupuncture, the reduction by the acupuncture regimen as provided in the current study did not reach statistical significance.	True acupuncture was associated with 0.8 fewer hot flashes per day than sham at 6 weeks
__label__noRel	when compared with sham acupuncture, the reduction by the acupuncture regimen as provided in the current study did not reach statistical significance.	but the difference did not reach statistical significance (95% CI, -0.7 to 2.4; P = .3).
__label__noRel	when compared with sham acupuncture, the reduction by the acupuncture regimen as provided in the current study did not reach statistical significance.	When participants in the sham acupuncture group were crossed over to true acupuncture, a further reduction in the frequency of hot flashes was seen.
__label__noRel	when compared with sham acupuncture, the reduction by the acupuncture regimen as provided in the current study did not reach statistical significance.	Hot flash frequency in breast cancer patients was reduced following acupuncture.
__label__Support	when compared with sham acupuncture, the reduction by the acupuncture regimen as provided in the current study did not reach statistical significance.	We cannot exclude the possibility that a longer and more intense acupuncture intervention could produce a larger reduction of these symptoms.
__label__noRel	Evidence suggests that the re-entry phase (ie, early period after medical treatment completion) presents distinct challenges for cancer patients.	In analyses controlling for study site and baseline depressive symptoms, VID produced significant improvement in energy/fatigue at 6 months relative to CTL, particularly among women who felt less prepared for re-entry at baseline.
__label__noRel	Evidence suggests that the re-entry phase (ie, early period after medical treatment completion) presents distinct challenges for cancer patients.	No significant main effect of the interventions emerged on cancer-specific distress,
__label__noRel	Evidence suggests that the re-entry phase (ie, early period after medical treatment completion) presents distinct challenges for cancer patients.	but EDU prompted greater reduction in this outcome relative to CTL at 6 months for patients who felt more prepared for re-entry.
__label__noRel	Evidence suggests that the re-entry phase (ie, early period after medical treatment completion) presents distinct challenges for cancer patients.	Between-group differences in the primary outcomes were not significant at 12 months,
__label__noRel	Evidence suggests that the re-entry phase (ie, early period after medical treatment completion) presents distinct challenges for cancer patients.	and no significant effects emerged on the secondary end points.
__label__noRel	Evidence suggests that the re-entry phase (ie, early period after medical treatment completion) presents distinct challenges for cancer patients.	A peer-modeling videotape can accelerate the recovery of energy during the re-entry phase in women treated for breast cancer, particularly among those who feel less prepared for re-entry.
__label__noRel	In analyses controlling for study site and baseline depressive symptoms, VID produced significant improvement in energy/fatigue at 6 months relative to CTL, particularly among women who felt less prepared for re-entry at baseline.	Evidence suggests that the re-entry phase (ie, early period after medical treatment completion) presents distinct challenges for cancer patients.
__label__noRel	In analyses controlling for study site and baseline depressive symptoms, VID produced significant improvement in energy/fatigue at 6 months relative to CTL, particularly among women who felt less prepared for re-entry at baseline.	No significant main effect of the interventions emerged on cancer-specific distress,
__label__noRel	In analyses controlling for study site and baseline depressive symptoms, VID produced significant improvement in energy/fatigue at 6 months relative to CTL, particularly among women who felt less prepared for re-entry at baseline.	but EDU prompted greater reduction in this outcome relative to CTL at 6 months for patients who felt more prepared for re-entry.
__label__noRel	In analyses controlling for study site and baseline depressive symptoms, VID produced significant improvement in energy/fatigue at 6 months relative to CTL, particularly among women who felt less prepared for re-entry at baseline.	Between-group differences in the primary outcomes were not significant at 12 months,
__label__noRel	In analyses controlling for study site and baseline depressive symptoms, VID produced significant improvement in energy/fatigue at 6 months relative to CTL, particularly among women who felt less prepared for re-entry at baseline.	and no significant effects emerged on the secondary end points.
__label__Support	In analyses controlling for study site and baseline depressive symptoms, VID produced significant improvement in energy/fatigue at 6 months relative to CTL, particularly among women who felt less prepared for re-entry at baseline.	A peer-modeling videotape can accelerate the recovery of energy during the re-entry phase in women treated for breast cancer, particularly among those who feel less prepared for re-entry.
__label__noRel	No significant main effect of the interventions emerged on cancer-specific distress,	Evidence suggests that the re-entry phase (ie, early period after medical treatment completion) presents distinct challenges for cancer patients.
__label__noRel	No significant main effect of the interventions emerged on cancer-specific distress,	In analyses controlling for study site and baseline depressive symptoms, VID produced significant improvement in energy/fatigue at 6 months relative to CTL, particularly among women who felt less prepared for re-entry at baseline.
__label__noRel	No significant main effect of the interventions emerged on cancer-specific distress,	but EDU prompted greater reduction in this outcome relative to CTL at 6 months for patients who felt more prepared for re-entry.
__label__noRel	No significant main effect of the interventions emerged on cancer-specific distress,	Between-group differences in the primary outcomes were not significant at 12 months,
__label__noRel	No significant main effect of the interventions emerged on cancer-specific distress,	and no significant effects emerged on the secondary end points.
__label__Attack	No significant main effect of the interventions emerged on cancer-specific distress,	A peer-modeling videotape can accelerate the recovery of energy during the re-entry phase in women treated for breast cancer, particularly among those who feel less prepared for re-entry.
__label__noRel	but EDU prompted greater reduction in this outcome relative to CTL at 6 months for patients who felt more prepared for re-entry.	Evidence suggests that the re-entry phase (ie, early period after medical treatment completion) presents distinct challenges for cancer patients.
__label__noRel	but EDU prompted greater reduction in this outcome relative to CTL at 6 months for patients who felt more prepared for re-entry.	In analyses controlling for study site and baseline depressive symptoms, VID produced significant improvement in energy/fatigue at 6 months relative to CTL, particularly among women who felt less prepared for re-entry at baseline.
__label__Attack	but EDU prompted greater reduction in this outcome relative to CTL at 6 months for patients who felt more prepared for re-entry.	No significant main effect of the interventions emerged on cancer-specific distress,
__label__noRel	but EDU prompted greater reduction in this outcome relative to CTL at 6 months for patients who felt more prepared for re-entry.	Between-group differences in the primary outcomes were not significant at 12 months,
__label__noRel	but EDU prompted greater reduction in this outcome relative to CTL at 6 months for patients who felt more prepared for re-entry.	and no significant effects emerged on the secondary end points.
__label__noRel	but EDU prompted greater reduction in this outcome relative to CTL at 6 months for patients who felt more prepared for re-entry.	A peer-modeling videotape can accelerate the recovery of energy during the re-entry phase in women treated for breast cancer, particularly among those who feel less prepared for re-entry.
__label__noRel	Between-group differences in the primary outcomes were not significant at 12 months,	Evidence suggests that the re-entry phase (ie, early period after medical treatment completion) presents distinct challenges for cancer patients.
__label__noRel	Between-group differences in the primary outcomes were not significant at 12 months,	In analyses controlling for study site and baseline depressive symptoms, VID produced significant improvement in energy/fatigue at 6 months relative to CTL, particularly among women who felt less prepared for re-entry at baseline.
__label__noRel	Between-group differences in the primary outcomes were not significant at 12 months,	No significant main effect of the interventions emerged on cancer-specific distress,
__label__noRel	Between-group differences in the primary outcomes were not significant at 12 months,	but EDU prompted greater reduction in this outcome relative to CTL at 6 months for patients who felt more prepared for re-entry.
__label__noRel	Between-group differences in the primary outcomes were not significant at 12 months,	and no significant effects emerged on the secondary end points.
__label__Support	Between-group differences in the primary outcomes were not significant at 12 months,	A peer-modeling videotape can accelerate the recovery of energy during the re-entry phase in women treated for breast cancer, particularly among those who feel less prepared for re-entry.
__label__noRel	and no significant effects emerged on the secondary end points.	Evidence suggests that the re-entry phase (ie, early period after medical treatment completion) presents distinct challenges for cancer patients.
__label__noRel	and no significant effects emerged on the secondary end points.	In analyses controlling for study site and baseline depressive symptoms, VID produced significant improvement in energy/fatigue at 6 months relative to CTL, particularly among women who felt less prepared for re-entry at baseline.
__label__noRel	and no significant effects emerged on the secondary end points.	No significant main effect of the interventions emerged on cancer-specific distress,
__label__noRel	and no significant effects emerged on the secondary end points.	but EDU prompted greater reduction in this outcome relative to CTL at 6 months for patients who felt more prepared for re-entry.
__label__Support	and no significant effects emerged on the secondary end points.	Between-group differences in the primary outcomes were not significant at 12 months,
__label__noRel	and no significant effects emerged on the secondary end points.	A peer-modeling videotape can accelerate the recovery of energy during the re-entry phase in women treated for breast cancer, particularly among those who feel less prepared for re-entry.
__label__noRel	A peer-modeling videotape can accelerate the recovery of energy during the re-entry phase in women treated for breast cancer, particularly among those who feel less prepared for re-entry.	Evidence suggests that the re-entry phase (ie, early period after medical treatment completion) presents distinct challenges for cancer patients.
__label__noRel	A peer-modeling videotape can accelerate the recovery of energy during the re-entry phase in women treated for breast cancer, particularly among those who feel less prepared for re-entry.	In analyses controlling for study site and baseline depressive symptoms, VID produced significant improvement in energy/fatigue at 6 months relative to CTL, particularly among women who felt less prepared for re-entry at baseline.
__label__noRel	A peer-modeling videotape can accelerate the recovery of energy during the re-entry phase in women treated for breast cancer, particularly among those who feel less prepared for re-entry.	No significant main effect of the interventions emerged on cancer-specific distress,
__label__noRel	A peer-modeling videotape can accelerate the recovery of energy during the re-entry phase in women treated for breast cancer, particularly among those who feel less prepared for re-entry.	but EDU prompted greater reduction in this outcome relative to CTL at 6 months for patients who felt more prepared for re-entry.
__label__noRel	A peer-modeling videotape can accelerate the recovery of energy during the re-entry phase in women treated for breast cancer, particularly among those who feel less prepared for re-entry.	Between-group differences in the primary outcomes were not significant at 12 months,
__label__noRel	A peer-modeling videotape can accelerate the recovery of energy during the re-entry phase in women treated for breast cancer, particularly among those who feel less prepared for re-entry.	and no significant effects emerged on the secondary end points.
__label__noRel	Time to progression (TTP; primary end point) and time to treatment failure (TTF) were significantly longer with AT than AC (median TTP, 37.3 v 31.9 weeks; log-rank P =.014; median TTF, 25.6 v 23.7 weeks; log-rank P =.048).	The overall response rate (ORR) was significantly greater for patients taking AT (59%, with 10% complete response [CR], 49% partial response [PR]) than for those taking AC (47%, with 7% CR, 39% PR) (P =.009).
__label__noRel	Time to progression (TTP; primary end point) and time to treatment failure (TTF) were significantly longer with AT than AC (median TTP, 37.3 v 31.9 weeks; log-rank P =.014; median TTF, 25.6 v 23.7 weeks; log-rank P =.048).	The ORR was also higher with AT in patients with visceral involvement (58% v 41%; liver, 62% v 42%; lung, 58% v 35%), three or more organs involved (59% v 40%), or prior adjuvant CT (53% v 41%).
__label__noRel	Time to progression (TTP; primary end point) and time to treatment failure (TTF) were significantly longer with AT than AC (median TTP, 37.3 v 31.9 weeks; log-rank P =.014; median TTF, 25.6 v 23.7 weeks; log-rank P =.048).	Overall survival (OS) was comparable in both arms.
__label__noRel	Time to progression (TTP; primary end point) and time to treatment failure (TTF) were significantly longer with AT than AC (median TTP, 37.3 v 31.9 weeks; log-rank P =.014; median TTF, 25.6 v 23.7 weeks; log-rank P =.048).	Grade 3/4 neutropenia was frequent in both groups,
__label__noRel	Time to progression (TTP; primary end point) and time to treatment failure (TTF) were significantly longer with AT than AC (median TTP, 37.3 v 31.9 weeks; log-rank P =.014; median TTF, 25.6 v 23.7 weeks; log-rank P =.048).	although febrile neutropenia and infections were more frequent for patients taking AT (respectively, 33% v 10%, P <.001; 8% v 2%, P =.01).
__label__noRel	Time to progression (TTP; primary end point) and time to treatment failure (TTF) were significantly longer with AT than AC (median TTP, 37.3 v 31.9 weeks; log-rank P =.014; median TTF, 25.6 v 23.7 weeks; log-rank P =.048).	Severe nonhematologic toxicity was infrequent in both groups, including grade 3/4 cardiac events (AT, 3%; AC, 4%).
__label__Support	Time to progression (TTP; primary end point) and time to treatment failure (TTF) were significantly longer with AT than AC (median TTP, 37.3 v 31.9 weeks; log-rank P =.014; median TTF, 25.6 v 23.7 weeks; log-rank P =.048).	AT significantly improves TTP and ORR compared with AC in patients with MBC,
__label__noRel	Time to progression (TTP; primary end point) and time to treatment failure (TTF) were significantly longer with AT than AC (median TTP, 37.3 v 31.9 weeks; log-rank P =.014; median TTF, 25.6 v 23.7 weeks; log-rank P =.048).	but there is no difference in OS.
__label__noRel	Time to progression (TTP; primary end point) and time to treatment failure (TTF) were significantly longer with AT than AC (median TTP, 37.3 v 31.9 weeks; log-rank P =.014; median TTF, 25.6 v 23.7 weeks; log-rank P =.048).	AT represents a valid option for the treatment of MBC.
__label__noRel	The overall response rate (ORR) was significantly greater for patients taking AT (59%, with 10% complete response [CR], 49% partial response [PR]) than for those taking AC (47%, with 7% CR, 39% PR) (P =.009).	Time to progression (TTP; primary end point) and time to treatment failure (TTF) were significantly longer with AT than AC (median TTP, 37.3 v 31.9 weeks; log-rank P =.014; median TTF, 25.6 v 23.7 weeks; log-rank P =.048).
__label__noRel	The overall response rate (ORR) was significantly greater for patients taking AT (59%, with 10% complete response [CR], 49% partial response [PR]) than for those taking AC (47%, with 7% CR, 39% PR) (P =.009).	The ORR was also higher with AT in patients with visceral involvement (58% v 41%; liver, 62% v 42%; lung, 58% v 35%), three or more organs involved (59% v 40%), or prior adjuvant CT (53% v 41%).
__label__noRel	The overall response rate (ORR) was significantly greater for patients taking AT (59%, with 10% complete response [CR], 49% partial response [PR]) than for those taking AC (47%, with 7% CR, 39% PR) (P =.009).	Overall survival (OS) was comparable in both arms.
__label__noRel	The overall response rate (ORR) was significantly greater for patients taking AT (59%, with 10% complete response [CR], 49% partial response [PR]) than for those taking AC (47%, with 7% CR, 39% PR) (P =.009).	Grade 3/4 neutropenia was frequent in both groups,
__label__noRel	The overall response rate (ORR) was significantly greater for patients taking AT (59%, with 10% complete response [CR], 49% partial response [PR]) than for those taking AC (47%, with 7% CR, 39% PR) (P =.009).	although febrile neutropenia and infections were more frequent for patients taking AT (respectively, 33% v 10%, P <.001; 8% v 2%, P =.01).
__label__noRel	The overall response rate (ORR) was significantly greater for patients taking AT (59%, with 10% complete response [CR], 49% partial response [PR]) than for those taking AC (47%, with 7% CR, 39% PR) (P =.009).	Severe nonhematologic toxicity was infrequent in both groups, including grade 3/4 cardiac events (AT, 3%; AC, 4%).
__label__Support	The overall response rate (ORR) was significantly greater for patients taking AT (59%, with 10% complete response [CR], 49% partial response [PR]) than for those taking AC (47%, with 7% CR, 39% PR) (P =.009).	AT significantly improves TTP and ORR compared with AC in patients with MBC,
__label__noRel	The overall response rate (ORR) was significantly greater for patients taking AT (59%, with 10% complete response [CR], 49% partial response [PR]) than for those taking AC (47%, with 7% CR, 39% PR) (P =.009).	but there is no difference in OS.
__label__noRel	The overall response rate (ORR) was significantly greater for patients taking AT (59%, with 10% complete response [CR], 49% partial response [PR]) than for those taking AC (47%, with 7% CR, 39% PR) (P =.009).	AT represents a valid option for the treatment of MBC.
__label__noRel	The ORR was also higher with AT in patients with visceral involvement (58% v 41%; liver, 62% v 42%; lung, 58% v 35%), three or more organs involved (59% v 40%), or prior adjuvant CT (53% v 41%).	Time to progression (TTP; primary end point) and time to treatment failure (TTF) were significantly longer with AT than AC (median TTP, 37.3 v 31.9 weeks; log-rank P =.014; median TTF, 25.6 v 23.7 weeks; log-rank P =.048).
__label__noRel	The ORR was also higher with AT in patients with visceral involvement (58% v 41%; liver, 62% v 42%; lung, 58% v 35%), three or more organs involved (59% v 40%), or prior adjuvant CT (53% v 41%).	The overall response rate (ORR) was significantly greater for patients taking AT (59%, with 10% complete response [CR], 49% partial response [PR]) than for those taking AC (47%, with 7% CR, 39% PR) (P =.009).
__label__noRel	The ORR was also higher with AT in patients with visceral involvement (58% v 41%; liver, 62% v 42%; lung, 58% v 35%), three or more organs involved (59% v 40%), or prior adjuvant CT (53% v 41%).	Overall survival (OS) was comparable in both arms.
__label__noRel	The ORR was also higher with AT in patients with visceral involvement (58% v 41%; liver, 62% v 42%; lung, 58% v 35%), three or more organs involved (59% v 40%), or prior adjuvant CT (53% v 41%).	Grade 3/4 neutropenia was frequent in both groups,
__label__noRel	The ORR was also higher with AT in patients with visceral involvement (58% v 41%; liver, 62% v 42%; lung, 58% v 35%), three or more organs involved (59% v 40%), or prior adjuvant CT (53% v 41%).	although febrile neutropenia and infections were more frequent for patients taking AT (respectively, 33% v 10%, P <.001; 8% v 2%, P =.01).
__label__noRel	The ORR was also higher with AT in patients with visceral involvement (58% v 41%; liver, 62% v 42%; lung, 58% v 35%), three or more organs involved (59% v 40%), or prior adjuvant CT (53% v 41%).	Severe nonhematologic toxicity was infrequent in both groups, including grade 3/4 cardiac events (AT, 3%; AC, 4%).
__label__Support	The ORR was also higher with AT in patients with visceral involvement (58% v 41%; liver, 62% v 42%; lung, 58% v 35%), three or more organs involved (59% v 40%), or prior adjuvant CT (53% v 41%).	AT significantly improves TTP and ORR compared with AC in patients with MBC,
__label__noRel	The ORR was also higher with AT in patients with visceral involvement (58% v 41%; liver, 62% v 42%; lung, 58% v 35%), three or more organs involved (59% v 40%), or prior adjuvant CT (53% v 41%).	but there is no difference in OS.
__label__noRel	The ORR was also higher with AT in patients with visceral involvement (58% v 41%; liver, 62% v 42%; lung, 58% v 35%), three or more organs involved (59% v 40%), or prior adjuvant CT (53% v 41%).	AT represents a valid option for the treatment of MBC.
__label__noRel	Overall survival (OS) was comparable in both arms.	Time to progression (TTP; primary end point) and time to treatment failure (TTF) were significantly longer with AT than AC (median TTP, 37.3 v 31.9 weeks; log-rank P =.014; median TTF, 25.6 v 23.7 weeks; log-rank P =.048).
__label__noRel	Overall survival (OS) was comparable in both arms.	The overall response rate (ORR) was significantly greater for patients taking AT (59%, with 10% complete response [CR], 49% partial response [PR]) than for those taking AC (47%, with 7% CR, 39% PR) (P =.009).
__label__noRel	Overall survival (OS) was comparable in both arms.	The ORR was also higher with AT in patients with visceral involvement (58% v 41%; liver, 62% v 42%; lung, 58% v 35%), three or more organs involved (59% v 40%), or prior adjuvant CT (53% v 41%).
__label__noRel	Overall survival (OS) was comparable in both arms.	Grade 3/4 neutropenia was frequent in both groups,
__label__noRel	Overall survival (OS) was comparable in both arms.	although febrile neutropenia and infections were more frequent for patients taking AT (respectively, 33% v 10%, P <.001; 8% v 2%, P =.01).
__label__noRel	Overall survival (OS) was comparable in both arms.	Severe nonhematologic toxicity was infrequent in both groups, including grade 3/4 cardiac events (AT, 3%; AC, 4%).
__label__noRel	Overall survival (OS) was comparable in both arms.	AT significantly improves TTP and ORR compared with AC in patients with MBC,
__label__Support	Overall survival (OS) was comparable in both arms.	but there is no difference in OS.
__label__noRel	Overall survival (OS) was comparable in both arms.	AT represents a valid option for the treatment of MBC.
__label__noRel	Grade 3/4 neutropenia was frequent in both groups,	Time to progression (TTP; primary end point) and time to treatment failure (TTF) were significantly longer with AT than AC (median TTP, 37.3 v 31.9 weeks; log-rank P =.014; median TTF, 25.6 v 23.7 weeks; log-rank P =.048).
__label__noRel	Grade 3/4 neutropenia was frequent in both groups,	The overall response rate (ORR) was significantly greater for patients taking AT (59%, with 10% complete response [CR], 49% partial response [PR]) than for those taking AC (47%, with 7% CR, 39% PR) (P =.009).
__label__noRel	Grade 3/4 neutropenia was frequent in both groups,	The ORR was also higher with AT in patients with visceral involvement (58% v 41%; liver, 62% v 42%; lung, 58% v 35%), three or more organs involved (59% v 40%), or prior adjuvant CT (53% v 41%).
__label__noRel	Grade 3/4 neutropenia was frequent in both groups,	Overall survival (OS) was comparable in both arms.
__label__noRel	Grade 3/4 neutropenia was frequent in both groups,	although febrile neutropenia and infections were more frequent for patients taking AT (respectively, 33% v 10%, P <.001; 8% v 2%, P =.01).
__label__noRel	Grade 3/4 neutropenia was frequent in both groups,	Severe nonhematologic toxicity was infrequent in both groups, including grade 3/4 cardiac events (AT, 3%; AC, 4%).
__label__noRel	Grade 3/4 neutropenia was frequent in both groups,	AT significantly improves TTP and ORR compared with AC in patients with MBC,
__label__noRel	Grade 3/4 neutropenia was frequent in both groups,	but there is no difference in OS.
__label__Support	Grade 3/4 neutropenia was frequent in both groups,	AT represents a valid option for the treatment of MBC.
__label__noRel	although febrile neutropenia and infections were more frequent for patients taking AT (respectively, 33% v 10%, P <.001; 8% v 2%, P =.01).	Time to progression (TTP; primary end point) and time to treatment failure (TTF) were significantly longer with AT than AC (median TTP, 37.3 v 31.9 weeks; log-rank P =.014; median TTF, 25.6 v 23.7 weeks; log-rank P =.048).
__label__noRel	although febrile neutropenia and infections were more frequent for patients taking AT (respectively, 33% v 10%, P <.001; 8% v 2%, P =.01).	The overall response rate (ORR) was significantly greater for patients taking AT (59%, with 10% complete response [CR], 49% partial response [PR]) than for those taking AC (47%, with 7% CR, 39% PR) (P =.009).
__label__noRel	although febrile neutropenia and infections were more frequent for patients taking AT (respectively, 33% v 10%, P <.001; 8% v 2%, P =.01).	The ORR was also higher with AT in patients with visceral involvement (58% v 41%; liver, 62% v 42%; lung, 58% v 35%), three or more organs involved (59% v 40%), or prior adjuvant CT (53% v 41%).
__label__noRel	although febrile neutropenia and infections were more frequent for patients taking AT (respectively, 33% v 10%, P <.001; 8% v 2%, P =.01).	Overall survival (OS) was comparable in both arms.
__label__Attack	although febrile neutropenia and infections were more frequent for patients taking AT (respectively, 33% v 10%, P <.001; 8% v 2%, P =.01).	Grade 3/4 neutropenia was frequent in both groups,
__label__noRel	although febrile neutropenia and infections were more frequent for patients taking AT (respectively, 33% v 10%, P <.001; 8% v 2%, P =.01).	Severe nonhematologic toxicity was infrequent in both groups, including grade 3/4 cardiac events (AT, 3%; AC, 4%).
__label__noRel	although febrile neutropenia and infections were more frequent for patients taking AT (respectively, 33% v 10%, P <.001; 8% v 2%, P =.01).	AT significantly improves TTP and ORR compared with AC in patients with MBC,
__label__noRel	although febrile neutropenia and infections were more frequent for patients taking AT (respectively, 33% v 10%, P <.001; 8% v 2%, P =.01).	but there is no difference in OS.
__label__noRel	although febrile neutropenia and infections were more frequent for patients taking AT (respectively, 33% v 10%, P <.001; 8% v 2%, P =.01).	AT represents a valid option for the treatment of MBC.
__label__noRel	Severe nonhematologic toxicity was infrequent in both groups, including grade 3/4 cardiac events (AT, 3%; AC, 4%).	Time to progression (TTP; primary end point) and time to treatment failure (TTF) were significantly longer with AT than AC (median TTP, 37.3 v 31.9 weeks; log-rank P =.014; median TTF, 25.6 v 23.7 weeks; log-rank P =.048).
__label__noRel	Severe nonhematologic toxicity was infrequent in both groups, including grade 3/4 cardiac events (AT, 3%; AC, 4%).	The overall response rate (ORR) was significantly greater for patients taking AT (59%, with 10% complete response [CR], 49% partial response [PR]) than for those taking AC (47%, with 7% CR, 39% PR) (P =.009).
__label__noRel	Severe nonhematologic toxicity was infrequent in both groups, including grade 3/4 cardiac events (AT, 3%; AC, 4%).	The ORR was also higher with AT in patients with visceral involvement (58% v 41%; liver, 62% v 42%; lung, 58% v 35%), three or more organs involved (59% v 40%), or prior adjuvant CT (53% v 41%).
__label__noRel	Severe nonhematologic toxicity was infrequent in both groups, including grade 3/4 cardiac events (AT, 3%; AC, 4%).	Overall survival (OS) was comparable in both arms.
__label__noRel	Severe nonhematologic toxicity was infrequent in both groups, including grade 3/4 cardiac events (AT, 3%; AC, 4%).	Grade 3/4 neutropenia was frequent in both groups,
__label__noRel	Severe nonhematologic toxicity was infrequent in both groups, including grade 3/4 cardiac events (AT, 3%; AC, 4%).	although febrile neutropenia and infections were more frequent for patients taking AT (respectively, 33% v 10%, P <.001; 8% v 2%, P =.01).
__label__noRel	Severe nonhematologic toxicity was infrequent in both groups, including grade 3/4 cardiac events (AT, 3%; AC, 4%).	AT significantly improves TTP and ORR compared with AC in patients with MBC,
__label__noRel	Severe nonhematologic toxicity was infrequent in both groups, including grade 3/4 cardiac events (AT, 3%; AC, 4%).	but there is no difference in OS.
__label__noRel	Severe nonhematologic toxicity was infrequent in both groups, including grade 3/4 cardiac events (AT, 3%; AC, 4%).	AT represents a valid option for the treatment of MBC.
__label__noRel	AT significantly improves TTP and ORR compared with AC in patients with MBC,	Time to progression (TTP; primary end point) and time to treatment failure (TTF) were significantly longer with AT than AC (median TTP, 37.3 v 31.9 weeks; log-rank P =.014; median TTF, 25.6 v 23.7 weeks; log-rank P =.048).
__label__noRel	AT significantly improves TTP and ORR compared with AC in patients with MBC,	The overall response rate (ORR) was significantly greater for patients taking AT (59%, with 10% complete response [CR], 49% partial response [PR]) than for those taking AC (47%, with 7% CR, 39% PR) (P =.009).
__label__noRel	AT significantly improves TTP and ORR compared with AC in patients with MBC,	The ORR was also higher with AT in patients with visceral involvement (58% v 41%; liver, 62% v 42%; lung, 58% v 35%), three or more organs involved (59% v 40%), or prior adjuvant CT (53% v 41%).
__label__noRel	AT significantly improves TTP and ORR compared with AC in patients with MBC,	Overall survival (OS) was comparable in both arms.
__label__noRel	AT significantly improves TTP and ORR compared with AC in patients with MBC,	Grade 3/4 neutropenia was frequent in both groups,
__label__noRel	AT significantly improves TTP and ORR compared with AC in patients with MBC,	although febrile neutropenia and infections were more frequent for patients taking AT (respectively, 33% v 10%, P <.001; 8% v 2%, P =.01).
__label__noRel	AT significantly improves TTP and ORR compared with AC in patients with MBC,	Severe nonhematologic toxicity was infrequent in both groups, including grade 3/4 cardiac events (AT, 3%; AC, 4%).
__label__noRel	AT significantly improves TTP and ORR compared with AC in patients with MBC,	but there is no difference in OS.
__label__Support	AT significantly improves TTP and ORR compared with AC in patients with MBC,	AT represents a valid option for the treatment of MBC.
__label__noRel	but there is no difference in OS.	Time to progression (TTP; primary end point) and time to treatment failure (TTF) were significantly longer with AT than AC (median TTP, 37.3 v 31.9 weeks; log-rank P =.014; median TTF, 25.6 v 23.7 weeks; log-rank P =.048).
__label__noRel	but there is no difference in OS.	The overall response rate (ORR) was significantly greater for patients taking AT (59%, with 10% complete response [CR], 49% partial response [PR]) than for those taking AC (47%, with 7% CR, 39% PR) (P =.009).
__label__noRel	but there is no difference in OS.	The ORR was also higher with AT in patients with visceral involvement (58% v 41%; liver, 62% v 42%; lung, 58% v 35%), three or more organs involved (59% v 40%), or prior adjuvant CT (53% v 41%).
__label__noRel	but there is no difference in OS.	Overall survival (OS) was comparable in both arms.
__label__noRel	but there is no difference in OS.	Grade 3/4 neutropenia was frequent in both groups,
__label__noRel	but there is no difference in OS.	although febrile neutropenia and infections were more frequent for patients taking AT (respectively, 33% v 10%, P <.001; 8% v 2%, P =.01).
__label__noRel	but there is no difference in OS.	Severe nonhematologic toxicity was infrequent in both groups, including grade 3/4 cardiac events (AT, 3%; AC, 4%).
__label__Attack	but there is no difference in OS.	AT significantly improves TTP and ORR compared with AC in patients with MBC,
__label__noRel	but there is no difference in OS.	AT represents a valid option for the treatment of MBC.
__label__noRel	AT represents a valid option for the treatment of MBC.	Time to progression (TTP; primary end point) and time to treatment failure (TTF) were significantly longer with AT than AC (median TTP, 37.3 v 31.9 weeks; log-rank P =.014; median TTF, 25.6 v 23.7 weeks; log-rank P =.048).
__label__noRel	AT represents a valid option for the treatment of MBC.	The overall response rate (ORR) was significantly greater for patients taking AT (59%, with 10% complete response [CR], 49% partial response [PR]) than for those taking AC (47%, with 7% CR, 39% PR) (P =.009).
__label__noRel	AT represents a valid option for the treatment of MBC.	The ORR was also higher with AT in patients with visceral involvement (58% v 41%; liver, 62% v 42%; lung, 58% v 35%), three or more organs involved (59% v 40%), or prior adjuvant CT (53% v 41%).
__label__noRel	AT represents a valid option for the treatment of MBC.	Overall survival (OS) was comparable in both arms.
__label__noRel	AT represents a valid option for the treatment of MBC.	Grade 3/4 neutropenia was frequent in both groups,
__label__noRel	AT represents a valid option for the treatment of MBC.	although febrile neutropenia and infections were more frequent for patients taking AT (respectively, 33% v 10%, P <.001; 8% v 2%, P =.01).
__label__noRel	AT represents a valid option for the treatment of MBC.	Severe nonhematologic toxicity was infrequent in both groups, including grade 3/4 cardiac events (AT, 3%; AC, 4%).
__label__noRel	AT represents a valid option for the treatment of MBC.	AT significantly improves TTP and ORR compared with AC in patients with MBC,
__label__noRel	AT represents a valid option for the treatment of MBC.	but there is no difference in OS.
__label__noRel	GHRQL was initially worse for the RP+RT arm but improved over time and was better at the end of the period than the GHRQL reported for RP alone (treatment arm x time interaction, P = .0004).	Symptom distress was significantly worse for the RP+RT arm compared with the RP alone arm
__label__noRel	GHRQL was initially worse for the RP+RT arm but improved over time and was better at the end of the period than the GHRQL reported for RP alone (treatment arm x time interaction, P = .0004).	but the treatment arms did not differ with respect to other general measures of HRQL.
__label__Support	GHRQL was initially worse for the RP+RT arm but improved over time and was better at the end of the period than the GHRQL reported for RP alone (treatment arm x time interaction, P = .0004).	The addition of RT did not negatively impact ED.
__label__noRel	GHRQL was initially worse for the RP+RT arm but improved over time and was better at the end of the period than the GHRQL reported for RP alone (treatment arm x time interaction, P = .0004).	The addition of RT to surgery resulted in more frequent urination, as well as early report of more bowel dysfunction
__label__noRel	GHRQL was initially worse for the RP+RT arm but improved over time and was better at the end of the period than the GHRQL reported for RP alone (treatment arm x time interaction, P = .0004).	although bowel function differences disappeared over the 5-year period.
__label__noRel	Symptom distress was significantly worse for the RP+RT arm compared with the RP alone arm	GHRQL was initially worse for the RP+RT arm but improved over time and was better at the end of the period than the GHRQL reported for RP alone (treatment arm x time interaction, P = .0004).
__label__noRel	Symptom distress was significantly worse for the RP+RT arm compared with the RP alone arm	but the treatment arms did not differ with respect to other general measures of HRQL.
__label__Attack	Symptom distress was significantly worse for the RP+RT arm compared with the RP alone arm	The addition of RT did not negatively impact ED.
__label__noRel	Symptom distress was significantly worse for the RP+RT arm compared with the RP alone arm	The addition of RT to surgery resulted in more frequent urination, as well as early report of more bowel dysfunction
__label__noRel	Symptom distress was significantly worse for the RP+RT arm compared with the RP alone arm	although bowel function differences disappeared over the 5-year period.
__label__noRel	but the treatment arms did not differ with respect to other general measures of HRQL.	GHRQL was initially worse for the RP+RT arm but improved over time and was better at the end of the period than the GHRQL reported for RP alone (treatment arm x time interaction, P = .0004).
__label__Attack	but the treatment arms did not differ with respect to other general measures of HRQL.	Symptom distress was significantly worse for the RP+RT arm compared with the RP alone arm
__label__noRel	but the treatment arms did not differ with respect to other general measures of HRQL.	The addition of RT did not negatively impact ED.
__label__noRel	but the treatment arms did not differ with respect to other general measures of HRQL.	The addition of RT to surgery resulted in more frequent urination, as well as early report of more bowel dysfunction
__label__noRel	but the treatment arms did not differ with respect to other general measures of HRQL.	although bowel function differences disappeared over the 5-year period.
__label__noRel	The addition of RT did not negatively impact ED.	GHRQL was initially worse for the RP+RT arm but improved over time and was better at the end of the period than the GHRQL reported for RP alone (treatment arm x time interaction, P = .0004).
__label__noRel	The addition of RT did not negatively impact ED.	Symptom distress was significantly worse for the RP+RT arm compared with the RP alone arm
__label__noRel	The addition of RT did not negatively impact ED.	but the treatment arms did not differ with respect to other general measures of HRQL.
__label__noRel	The addition of RT did not negatively impact ED.	The addition of RT to surgery resulted in more frequent urination, as well as early report of more bowel dysfunction
__label__noRel	The addition of RT did not negatively impact ED.	although bowel function differences disappeared over the 5-year period.
__label__noRel	The addition of RT to surgery resulted in more frequent urination, as well as early report of more bowel dysfunction	GHRQL was initially worse for the RP+RT arm but improved over time and was better at the end of the period than the GHRQL reported for RP alone (treatment arm x time interaction, P = .0004).
__label__noRel	The addition of RT to surgery resulted in more frequent urination, as well as early report of more bowel dysfunction	Symptom distress was significantly worse for the RP+RT arm compared with the RP alone arm
__label__noRel	The addition of RT to surgery resulted in more frequent urination, as well as early report of more bowel dysfunction	but the treatment arms did not differ with respect to other general measures of HRQL.
__label__Attack	The addition of RT to surgery resulted in more frequent urination, as well as early report of more bowel dysfunction	The addition of RT did not negatively impact ED.
__label__noRel	The addition of RT to surgery resulted in more frequent urination, as well as early report of more bowel dysfunction	although bowel function differences disappeared over the 5-year period.
__label__noRel	although bowel function differences disappeared over the 5-year period.	GHRQL was initially worse for the RP+RT arm but improved over time and was better at the end of the period than the GHRQL reported for RP alone (treatment arm x time interaction, P = .0004).
__label__noRel	although bowel function differences disappeared over the 5-year period.	Symptom distress was significantly worse for the RP+RT arm compared with the RP alone arm
__label__noRel	although bowel function differences disappeared over the 5-year period.	but the treatment arms did not differ with respect to other general measures of HRQL.
__label__noRel	although bowel function differences disappeared over the 5-year period.	The addition of RT did not negatively impact ED.
__label__Attack	although bowel function differences disappeared over the 5-year period.	The addition of RT to surgery resulted in more frequent urination, as well as early report of more bowel dysfunction
__label__noRel	Patients who preferred RET improved QoL when they were assigned to receive RET compared with UC (mean difference, 16.5; 95% confidence interval [95% CI], 4.3-28.7; P= .008) or AET (mean difference, 11; 95% CI, -1.1-23.4; P= .076).	Patients who had no preference had improved QoL when they were assigned to receive AET compared with RET (mean difference, 23; 95% CI, 4.9-41; P= .014).
__label__Support	Patients who preferred RET improved QoL when they were assigned to receive RET compared with UC (mean difference, 16.5; 95% confidence interval [95% CI], 4.3-28.7; P= .008) or AET (mean difference, 11; 95% CI, -1.1-23.4; P= .076).	Patient preference, demographic variables, and medical variables moderated the effects of exercise training in breast cancer patients who were receiving chemotherapy.
__label__noRel	Patients who preferred RET improved QoL when they were assigned to receive RET compared with UC (mean difference, 16.5; 95% confidence interval [95% CI], 4.3-28.7; P= .008) or AET (mean difference, 11; 95% CI, -1.1-23.4; P= .076).	Unmarried, younger patients who were receiving nontaxane-based therapies and had more advanced disease stage experienced better outcomes.
__label__noRel	Patients who preferred RET improved QoL when they were assigned to receive RET compared with UC (mean difference, 16.5; 95% confidence interval [95% CI], 4.3-28.7; P= .008) or AET (mean difference, 11; 95% CI, -1.1-23.4; P= .076).	Marital status also moderated QoL response (P= .026), age moderated aerobic fitness response (P= .029), chemotherapy regimen moderated strength gain (P= .009), and disease stage moderated both lean body mass gain (P< .001) and fat loss (P= .059).
__label__noRel	Patients who had no preference had improved QoL when they were assigned to receive AET compared with RET (mean difference, 23; 95% CI, 4.9-41; P= .014).	Patients who preferred RET improved QoL when they were assigned to receive RET compared with UC (mean difference, 16.5; 95% confidence interval [95% CI], 4.3-28.7; P= .008) or AET (mean difference, 11; 95% CI, -1.1-23.4; P= .076).
__label__Support	Patients who had no preference had improved QoL when they were assigned to receive AET compared with RET (mean difference, 23; 95% CI, 4.9-41; P= .014).	Patient preference, demographic variables, and medical variables moderated the effects of exercise training in breast cancer patients who were receiving chemotherapy.
__label__noRel	Patients who had no preference had improved QoL when they were assigned to receive AET compared with RET (mean difference, 23; 95% CI, 4.9-41; P= .014).	Unmarried, younger patients who were receiving nontaxane-based therapies and had more advanced disease stage experienced better outcomes.
__label__noRel	Patients who had no preference had improved QoL when they were assigned to receive AET compared with RET (mean difference, 23; 95% CI, 4.9-41; P= .014).	Marital status also moderated QoL response (P= .026), age moderated aerobic fitness response (P= .029), chemotherapy regimen moderated strength gain (P= .009), and disease stage moderated both lean body mass gain (P< .001) and fat loss (P= .059).
__label__noRel	Patient preference, demographic variables, and medical variables moderated the effects of exercise training in breast cancer patients who were receiving chemotherapy.	Patients who preferred RET improved QoL when they were assigned to receive RET compared with UC (mean difference, 16.5; 95% confidence interval [95% CI], 4.3-28.7; P= .008) or AET (mean difference, 11; 95% CI, -1.1-23.4; P= .076).
__label__noRel	Patient preference, demographic variables, and medical variables moderated the effects of exercise training in breast cancer patients who were receiving chemotherapy.	Patients who had no preference had improved QoL when they were assigned to receive AET compared with RET (mean difference, 23; 95% CI, 4.9-41; P= .014).
__label__noRel	Patient preference, demographic variables, and medical variables moderated the effects of exercise training in breast cancer patients who were receiving chemotherapy.	Unmarried, younger patients who were receiving nontaxane-based therapies and had more advanced disease stage experienced better outcomes.
__label__noRel	Patient preference, demographic variables, and medical variables moderated the effects of exercise training in breast cancer patients who were receiving chemotherapy.	Marital status also moderated QoL response (P= .026), age moderated aerobic fitness response (P= .029), chemotherapy regimen moderated strength gain (P= .009), and disease stage moderated both lean body mass gain (P< .001) and fat loss (P= .059).
__label__noRel	Unmarried, younger patients who were receiving nontaxane-based therapies and had more advanced disease stage experienced better outcomes.	Patients who preferred RET improved QoL when they were assigned to receive RET compared with UC (mean difference, 16.5; 95% confidence interval [95% CI], 4.3-28.7; P= .008) or AET (mean difference, 11; 95% CI, -1.1-23.4; P= .076).
__label__noRel	Unmarried, younger patients who were receiving nontaxane-based therapies and had more advanced disease stage experienced better outcomes.	Patients who had no preference had improved QoL when they were assigned to receive AET compared with RET (mean difference, 23; 95% CI, 4.9-41; P= .014).
__label__Support	Unmarried, younger patients who were receiving nontaxane-based therapies and had more advanced disease stage experienced better outcomes.	Patient preference, demographic variables, and medical variables moderated the effects of exercise training in breast cancer patients who were receiving chemotherapy.
__label__noRel	Unmarried, younger patients who were receiving nontaxane-based therapies and had more advanced disease stage experienced better outcomes.	Marital status also moderated QoL response (P= .026), age moderated aerobic fitness response (P= .029), chemotherapy regimen moderated strength gain (P= .009), and disease stage moderated both lean body mass gain (P< .001) and fat loss (P= .059).
__label__noRel	Marital status also moderated QoL response (P= .026), age moderated aerobic fitness response (P= .029), chemotherapy regimen moderated strength gain (P= .009), and disease stage moderated both lean body mass gain (P< .001) and fat loss (P= .059).	Patients who preferred RET improved QoL when they were assigned to receive RET compared with UC (mean difference, 16.5; 95% confidence interval [95% CI], 4.3-28.7; P= .008) or AET (mean difference, 11; 95% CI, -1.1-23.4; P= .076).
__label__noRel	Marital status also moderated QoL response (P= .026), age moderated aerobic fitness response (P= .029), chemotherapy regimen moderated strength gain (P= .009), and disease stage moderated both lean body mass gain (P< .001) and fat loss (P= .059).	Patients who had no preference had improved QoL when they were assigned to receive AET compared with RET (mean difference, 23; 95% CI, 4.9-41; P= .014).
__label__Support	Marital status also moderated QoL response (P= .026), age moderated aerobic fitness response (P= .029), chemotherapy regimen moderated strength gain (P= .009), and disease stage moderated both lean body mass gain (P< .001) and fat loss (P= .059).	Patient preference, demographic variables, and medical variables moderated the effects of exercise training in breast cancer patients who were receiving chemotherapy.
__label__noRel	Marital status also moderated QoL response (P= .026), age moderated aerobic fitness response (P= .029), chemotherapy regimen moderated strength gain (P= .009), and disease stage moderated both lean body mass gain (P< .001) and fat loss (P= .059).	Unmarried, younger patients who were receiving nontaxane-based therapies and had more advanced disease stage experienced better outcomes.
__label__noRel	At 4-month follow-up, intervention patients reported less uncertainty and better communication with spouses than control patients,	but they reported no other effects.
__label__noRel	At 4-month follow-up, intervention patients reported less uncertainty and better communication with spouses than control patients,	Intervention spouses reported higher quality of life, more self-efficacy, better communication, and less negative appraisal of caregiving, uncertainty, hopelessness, and symptom distress at 4 months compared with controls, and some effects were sustained to 8 months and 12 months.
__label__noRel	At 4-month follow-up, intervention patients reported less uncertainty and better communication with spouses than control patients,	Men with prostate cancer and their spouses reported positive outcomes from a family intervention that offered them information and support.
__label__Support	At 4-month follow-up, intervention patients reported less uncertainty and better communication with spouses than control patients,	Programs of care need to be extended to spouses who likely will experience multiple benefits from intervention.
__label__Attack	but they reported no other effects.	At 4-month follow-up, intervention patients reported less uncertainty and better communication with spouses than control patients,
__label__noRel	but they reported no other effects.	Intervention spouses reported higher quality of life, more self-efficacy, better communication, and less negative appraisal of caregiving, uncertainty, hopelessness, and symptom distress at 4 months compared with controls, and some effects were sustained to 8 months and 12 months.
__label__noRel	but they reported no other effects.	Men with prostate cancer and their spouses reported positive outcomes from a family intervention that offered them information and support.
__label__noRel	but they reported no other effects.	Programs of care need to be extended to spouses who likely will experience multiple benefits from intervention.
__label__noRel	Intervention spouses reported higher quality of life, more self-efficacy, better communication, and less negative appraisal of caregiving, uncertainty, hopelessness, and symptom distress at 4 months compared with controls, and some effects were sustained to 8 months and 12 months.	At 4-month follow-up, intervention patients reported less uncertainty and better communication with spouses than control patients,
__label__noRel	Intervention spouses reported higher quality of life, more self-efficacy, better communication, and less negative appraisal of caregiving, uncertainty, hopelessness, and symptom distress at 4 months compared with controls, and some effects were sustained to 8 months and 12 months.	but they reported no other effects.
__label__noRel	Intervention spouses reported higher quality of life, more self-efficacy, better communication, and less negative appraisal of caregiving, uncertainty, hopelessness, and symptom distress at 4 months compared with controls, and some effects were sustained to 8 months and 12 months.	Men with prostate cancer and their spouses reported positive outcomes from a family intervention that offered them information and support.
__label__Support	Intervention spouses reported higher quality of life, more self-efficacy, better communication, and less negative appraisal of caregiving, uncertainty, hopelessness, and symptom distress at 4 months compared with controls, and some effects were sustained to 8 months and 12 months.	Programs of care need to be extended to spouses who likely will experience multiple benefits from intervention.
__label__noRel	Men with prostate cancer and their spouses reported positive outcomes from a family intervention that offered them information and support.	At 4-month follow-up, intervention patients reported less uncertainty and better communication with spouses than control patients,
__label__noRel	Men with prostate cancer and their spouses reported positive outcomes from a family intervention that offered them information and support.	but they reported no other effects.
__label__noRel	Men with prostate cancer and their spouses reported positive outcomes from a family intervention that offered them information and support.	Intervention spouses reported higher quality of life, more self-efficacy, better communication, and less negative appraisal of caregiving, uncertainty, hopelessness, and symptom distress at 4 months compared with controls, and some effects were sustained to 8 months and 12 months.
__label__Support	Men with prostate cancer and their spouses reported positive outcomes from a family intervention that offered them information and support.	Programs of care need to be extended to spouses who likely will experience multiple benefits from intervention.
__label__noRel	Programs of care need to be extended to spouses who likely will experience multiple benefits from intervention.	At 4-month follow-up, intervention patients reported less uncertainty and better communication with spouses than control patients,
__label__noRel	Programs of care need to be extended to spouses who likely will experience multiple benefits from intervention.	but they reported no other effects.
__label__noRel	Programs of care need to be extended to spouses who likely will experience multiple benefits from intervention.	Intervention spouses reported higher quality of life, more self-efficacy, better communication, and less negative appraisal of caregiving, uncertainty, hopelessness, and symptom distress at 4 months compared with controls, and some effects were sustained to 8 months and 12 months.
__label__noRel	Programs of care need to be extended to spouses who likely will experience multiple benefits from intervention.	Men with prostate cancer and their spouses reported positive outcomes from a family intervention that offered them information and support.
__label__noRel	both treatment modalities resulted in significant decrease in the total arm volume (12.2% decrease in Group II and 14.9% decrease in Group I) (p<0.001),	no significant difference (p=0.582) was found between those two groups.
__label__noRel	both treatment modalities resulted in significant decrease in the total arm volume (12.2% decrease in Group II and 14.9% decrease in Group I) (p<0.001),	Similarly, ASES scores were significantly (p=0.001) improved in both Group I and II without any significant difference between the groups.
__label__noRel	both treatment modalities resulted in significant decrease in the total arm volume (12.2% decrease in Group II and 14.9% decrease in Group I) (p<0.001),	While emotional functioning, fatigue, and pain scores were significantly improved in both groups, global health status, functional and cognitive functioning scores appeared to be improved only in patients of group I.
__label__Support	both treatment modalities resulted in significant decrease in the total arm volume (12.2% decrease in Group II and 14.9% decrease in Group I) (p<0.001),	Different treatment modalities consisting of MLD and compression bandage(complex decongestive therapy) or IPC and SLD appear to be effective in the treatment of LE with similar therapeutic efficacy in patients with breast cancer.
__label__noRel	both treatment modalities resulted in significant decrease in the total arm volume (12.2% decrease in Group II and 14.9% decrease in Group I) (p<0.001),	However, combination modalities including IPC and SLD may be the preferred choices for their applicability at home.
__label__noRel	no significant difference (p=0.582) was found between those two groups.	both treatment modalities resulted in significant decrease in the total arm volume (12.2% decrease in Group II and 14.9% decrease in Group I) (p<0.001),
__label__noRel	no significant difference (p=0.582) was found between those two groups.	Similarly, ASES scores were significantly (p=0.001) improved in both Group I and II without any significant difference between the groups.
__label__noRel	no significant difference (p=0.582) was found between those two groups.	While emotional functioning, fatigue, and pain scores were significantly improved in both groups, global health status, functional and cognitive functioning scores appeared to be improved only in patients of group I.
__label__Support	no significant difference (p=0.582) was found between those two groups.	Different treatment modalities consisting of MLD and compression bandage(complex decongestive therapy) or IPC and SLD appear to be effective in the treatment of LE with similar therapeutic efficacy in patients with breast cancer.
__label__noRel	no significant difference (p=0.582) was found between those two groups.	However, combination modalities including IPC and SLD may be the preferred choices for their applicability at home.
__label__noRel	Similarly, ASES scores were significantly (p=0.001) improved in both Group I and II without any significant difference between the groups.	both treatment modalities resulted in significant decrease in the total arm volume (12.2% decrease in Group II and 14.9% decrease in Group I) (p<0.001),
__label__noRel	Similarly, ASES scores were significantly (p=0.001) improved in both Group I and II without any significant difference between the groups.	no significant difference (p=0.582) was found between those two groups.
__label__noRel	Similarly, ASES scores were significantly (p=0.001) improved in both Group I and II without any significant difference between the groups.	While emotional functioning, fatigue, and pain scores were significantly improved in both groups, global health status, functional and cognitive functioning scores appeared to be improved only in patients of group I.
__label__Support	Similarly, ASES scores were significantly (p=0.001) improved in both Group I and II without any significant difference between the groups.	Different treatment modalities consisting of MLD and compression bandage(complex decongestive therapy) or IPC and SLD appear to be effective in the treatment of LE with similar therapeutic efficacy in patients with breast cancer.
__label__noRel	Similarly, ASES scores were significantly (p=0.001) improved in both Group I and II without any significant difference between the groups.	However, combination modalities including IPC and SLD may be the preferred choices for their applicability at home.
__label__noRel	While emotional functioning, fatigue, and pain scores were significantly improved in both groups, global health status, functional and cognitive functioning scores appeared to be improved only in patients of group I.	both treatment modalities resulted in significant decrease in the total arm volume (12.2% decrease in Group II and 14.9% decrease in Group I) (p<0.001),
__label__noRel	While emotional functioning, fatigue, and pain scores were significantly improved in both groups, global health status, functional and cognitive functioning scores appeared to be improved only in patients of group I.	no significant difference (p=0.582) was found between those two groups.
__label__noRel	While emotional functioning, fatigue, and pain scores were significantly improved in both groups, global health status, functional and cognitive functioning scores appeared to be improved only in patients of group I.	Similarly, ASES scores were significantly (p=0.001) improved in both Group I and II without any significant difference between the groups.
__label__Support	While emotional functioning, fatigue, and pain scores were significantly improved in both groups, global health status, functional and cognitive functioning scores appeared to be improved only in patients of group I.	Different treatment modalities consisting of MLD and compression bandage(complex decongestive therapy) or IPC and SLD appear to be effective in the treatment of LE with similar therapeutic efficacy in patients with breast cancer.
__label__noRel	While emotional functioning, fatigue, and pain scores were significantly improved in both groups, global health status, functional and cognitive functioning scores appeared to be improved only in patients of group I.	However, combination modalities including IPC and SLD may be the preferred choices for their applicability at home.
__label__noRel	Different treatment modalities consisting of MLD and compression bandage(complex decongestive therapy) or IPC and SLD appear to be effective in the treatment of LE with similar therapeutic efficacy in patients with breast cancer.	both treatment modalities resulted in significant decrease in the total arm volume (12.2% decrease in Group II and 14.9% decrease in Group I) (p<0.001),
__label__noRel	Different treatment modalities consisting of MLD and compression bandage(complex decongestive therapy) or IPC and SLD appear to be effective in the treatment of LE with similar therapeutic efficacy in patients with breast cancer.	no significant difference (p=0.582) was found between those two groups.
__label__noRel	Different treatment modalities consisting of MLD and compression bandage(complex decongestive therapy) or IPC and SLD appear to be effective in the treatment of LE with similar therapeutic efficacy in patients with breast cancer.	Similarly, ASES scores were significantly (p=0.001) improved in both Group I and II without any significant difference between the groups.
__label__noRel	Different treatment modalities consisting of MLD and compression bandage(complex decongestive therapy) or IPC and SLD appear to be effective in the treatment of LE with similar therapeutic efficacy in patients with breast cancer.	While emotional functioning, fatigue, and pain scores were significantly improved in both groups, global health status, functional and cognitive functioning scores appeared to be improved only in patients of group I.
__label__noRel	Different treatment modalities consisting of MLD and compression bandage(complex decongestive therapy) or IPC and SLD appear to be effective in the treatment of LE with similar therapeutic efficacy in patients with breast cancer.	However, combination modalities including IPC and SLD may be the preferred choices for their applicability at home.
__label__noRel	However, combination modalities including IPC and SLD may be the preferred choices for their applicability at home.	both treatment modalities resulted in significant decrease in the total arm volume (12.2% decrease in Group II and 14.9% decrease in Group I) (p<0.001),
__label__noRel	However, combination modalities including IPC and SLD may be the preferred choices for their applicability at home.	no significant difference (p=0.582) was found between those two groups.
__label__noRel	However, combination modalities including IPC and SLD may be the preferred choices for their applicability at home.	Similarly, ASES scores were significantly (p=0.001) improved in both Group I and II without any significant difference between the groups.
__label__noRel	However, combination modalities including IPC and SLD may be the preferred choices for their applicability at home.	While emotional functioning, fatigue, and pain scores were significantly improved in both groups, global health status, functional and cognitive functioning scores appeared to be improved only in patients of group I.
__label__Attack	However, combination modalities including IPC and SLD may be the preferred choices for their applicability at home.	Different treatment modalities consisting of MLD and compression bandage(complex decongestive therapy) or IPC and SLD appear to be effective in the treatment of LE with similar therapeutic efficacy in patients with breast cancer.
__label__noRel	Participants completing the intervention demonstrated improvement in male overall distress (P < 0.01), male global sexual function (P < 0.0001), and female global sexual function (P < 0.05) at 3-month follow-up,	but regression toward baseline was noted at 6-month follow-up.
__label__noRel	Participants completing the intervention demonstrated improvement in male overall distress (P < 0.01), male global sexual function (P < 0.0001), and female global sexual function (P < 0.05) at 3-month follow-up,	However, utilization of ED treatments increased from 31% at the time of study entry to 49% at the 6-month follow-up (P = 0.003).
__label__Support	Participants completing the intervention demonstrated improvement in male overall distress (P < 0.01), male global sexual function (P < 0.0001), and female global sexual function (P < 0.05) at 3-month follow-up,	The results of this brief pilot counseling intervention demonstrated significant gains in sexual function and satisfaction and increased utilization of treatments for ED.
__label__noRel	Participants completing the intervention demonstrated improvement in male overall distress (P < 0.01), male global sexual function (P < 0.0001), and female global sexual function (P < 0.05) at 3-month follow-up,	However, modifications are needed in future randomized trials to reduce the rate of premature termination and to improve long-term maintenance of gains.
__label__Attack	but regression toward baseline was noted at 6-month follow-up.	Participants completing the intervention demonstrated improvement in male overall distress (P < 0.01), male global sexual function (P < 0.0001), and female global sexual function (P < 0.05) at 3-month follow-up,
__label__noRel	but regression toward baseline was noted at 6-month follow-up.	However, utilization of ED treatments increased from 31% at the time of study entry to 49% at the 6-month follow-up (P = 0.003).
__label__noRel	but regression toward baseline was noted at 6-month follow-up.	The results of this brief pilot counseling intervention demonstrated significant gains in sexual function and satisfaction and increased utilization of treatments for ED.
__label__noRel	but regression toward baseline was noted at 6-month follow-up.	However, modifications are needed in future randomized trials to reduce the rate of premature termination and to improve long-term maintenance of gains.
__label__noRel	However, utilization of ED treatments increased from 31% at the time of study entry to 49% at the 6-month follow-up (P = 0.003).	Participants completing the intervention demonstrated improvement in male overall distress (P < 0.01), male global sexual function (P < 0.0001), and female global sexual function (P < 0.05) at 3-month follow-up,
__label__noRel	However, utilization of ED treatments increased from 31% at the time of study entry to 49% at the 6-month follow-up (P = 0.003).	but regression toward baseline was noted at 6-month follow-up.
__label__Support	However, utilization of ED treatments increased from 31% at the time of study entry to 49% at the 6-month follow-up (P = 0.003).	The results of this brief pilot counseling intervention demonstrated significant gains in sexual function and satisfaction and increased utilization of treatments for ED.
__label__noRel	However, utilization of ED treatments increased from 31% at the time of study entry to 49% at the 6-month follow-up (P = 0.003).	However, modifications are needed in future randomized trials to reduce the rate of premature termination and to improve long-term maintenance of gains.
__label__noRel	The results of this brief pilot counseling intervention demonstrated significant gains in sexual function and satisfaction and increased utilization of treatments for ED.	Participants completing the intervention demonstrated improvement in male overall distress (P < 0.01), male global sexual function (P < 0.0001), and female global sexual function (P < 0.05) at 3-month follow-up,
__label__noRel	The results of this brief pilot counseling intervention demonstrated significant gains in sexual function and satisfaction and increased utilization of treatments for ED.	but regression toward baseline was noted at 6-month follow-up.
__label__noRel	The results of this brief pilot counseling intervention demonstrated significant gains in sexual function and satisfaction and increased utilization of treatments for ED.	However, utilization of ED treatments increased from 31% at the time of study entry to 49% at the 6-month follow-up (P = 0.003).
__label__noRel	The results of this brief pilot counseling intervention demonstrated significant gains in sexual function and satisfaction and increased utilization of treatments for ED.	However, modifications are needed in future randomized trials to reduce the rate of premature termination and to improve long-term maintenance of gains.
__label__noRel	However, modifications are needed in future randomized trials to reduce the rate of premature termination and to improve long-term maintenance of gains.	Participants completing the intervention demonstrated improvement in male overall distress (P < 0.01), male global sexual function (P < 0.0001), and female global sexual function (P < 0.05) at 3-month follow-up,
__label__noRel	However, modifications are needed in future randomized trials to reduce the rate of premature termination and to improve long-term maintenance of gains.	but regression toward baseline was noted at 6-month follow-up.
__label__noRel	However, modifications are needed in future randomized trials to reduce the rate of premature termination and to improve long-term maintenance of gains.	However, utilization of ED treatments increased from 31% at the time of study entry to 49% at the 6-month follow-up (P = 0.003).
__label__Attack	However, modifications are needed in future randomized trials to reduce the rate of premature termination and to improve long-term maintenance of gains.	The results of this brief pilot counseling intervention demonstrated significant gains in sexual function and satisfaction and increased utilization of treatments for ED.
__label__noRel	Individuals receiving duloxetine as their initial 5-week treatment reported a mean decrease in average pain of 1.06 (95% CI, 0.72-1.40) vs 0.34 (95% CI, 0.01-0.66) among those who received placebo (P = .003; effect size, 0.513).	The observed mean difference in the average pain score between duloxetine and placebo was 0.73 (95% CI, 0.26-1.20).
__label__noRel	Individuals receiving duloxetine as their initial 5-week treatment reported a mean decrease in average pain of 1.06 (95% CI, 0.72-1.40) vs 0.34 (95% CI, 0.01-0.66) among those who received placebo (P = .003; effect size, 0.513).	Fifty-nine percent of those initially receiving duloxetine vs 38% of those initially receiving placebo reported decreased pain of any amount.
__label__Support	Individuals receiving duloxetine as their initial 5-week treatment reported a mean decrease in average pain of 1.06 (95% CI, 0.72-1.40) vs 0.34 (95% CI, 0.01-0.66) among those who received placebo (P = .003; effect size, 0.513).	Among patients with painful chemotherapy-induced peripheral neuropathy, the use of duloxetine compared with placebo for 5 weeks resulted in a greater reduction in pain.
__label__noRel	The observed mean difference in the average pain score between duloxetine and placebo was 0.73 (95% CI, 0.26-1.20).	Individuals receiving duloxetine as their initial 5-week treatment reported a mean decrease in average pain of 1.06 (95% CI, 0.72-1.40) vs 0.34 (95% CI, 0.01-0.66) among those who received placebo (P = .003; effect size, 0.513).
__label__noRel	The observed mean difference in the average pain score between duloxetine and placebo was 0.73 (95% CI, 0.26-1.20).	Fifty-nine percent of those initially receiving duloxetine vs 38% of those initially receiving placebo reported decreased pain of any amount.
__label__Support	The observed mean difference in the average pain score between duloxetine and placebo was 0.73 (95% CI, 0.26-1.20).	Among patients with painful chemotherapy-induced peripheral neuropathy, the use of duloxetine compared with placebo for 5 weeks resulted in a greater reduction in pain.
__label__noRel	Fifty-nine percent of those initially receiving duloxetine vs 38% of those initially receiving placebo reported decreased pain of any amount.	Individuals receiving duloxetine as their initial 5-week treatment reported a mean decrease in average pain of 1.06 (95% CI, 0.72-1.40) vs 0.34 (95% CI, 0.01-0.66) among those who received placebo (P = .003; effect size, 0.513).
__label__noRel	Fifty-nine percent of those initially receiving duloxetine vs 38% of those initially receiving placebo reported decreased pain of any amount.	The observed mean difference in the average pain score between duloxetine and placebo was 0.73 (95% CI, 0.26-1.20).
__label__Support	Fifty-nine percent of those initially receiving duloxetine vs 38% of those initially receiving placebo reported decreased pain of any amount.	Among patients with painful chemotherapy-induced peripheral neuropathy, the use of duloxetine compared with placebo for 5 weeks resulted in a greater reduction in pain.
__label__noRel	Among patients with painful chemotherapy-induced peripheral neuropathy, the use of duloxetine compared with placebo for 5 weeks resulted in a greater reduction in pain.	Individuals receiving duloxetine as their initial 5-week treatment reported a mean decrease in average pain of 1.06 (95% CI, 0.72-1.40) vs 0.34 (95% CI, 0.01-0.66) among those who received placebo (P = .003; effect size, 0.513).
__label__noRel	Among patients with painful chemotherapy-induced peripheral neuropathy, the use of duloxetine compared with placebo for 5 weeks resulted in a greater reduction in pain.	The observed mean difference in the average pain score between duloxetine and placebo was 0.73 (95% CI, 0.26-1.20).
__label__noRel	Among patients with painful chemotherapy-induced peripheral neuropathy, the use of duloxetine compared with placebo for 5 weeks resulted in a greater reduction in pain.	Fifty-nine percent of those initially receiving duloxetine vs 38% of those initially receiving placebo reported decreased pain of any amount.
__label__Support	The SF-36 MCS and PCS, Health Utilities Index Mark 3, EuroQol 5D, and UDI scores were improved significantly in both groups at 6 months and afterward (P < .05).	Both UAE and hysterectomy improved HRQOL.
__label__noRel	The SF-36 MCS and PCS, Health Utilities Index Mark 3, EuroQol 5D, and UDI scores were improved significantly in both groups at 6 months and afterward (P < .05).	No differences were observed between groups regarding HRQOL at 24-month follow-up.
__label__noRel	The SF-36 MCS and PCS, Health Utilities Index Mark 3, EuroQol 5D, and UDI scores were improved significantly in both groups at 6 months and afterward (P < .05).	On the basis of HRQOL results, the authors determined that UAE is a good alternative to hysterectomy.
__label__noRel	The SF-36 MCS and PCS, Health Utilities Index Mark 3, EuroQol 5D, and UDI scores were improved significantly in both groups at 6 months and afterward (P < .05).	At 24-month follow-up, patients in the hysterectomy group were significantly more satisfied than those in the UAE group (P = .02).
__label__noRel	Both UAE and hysterectomy improved HRQOL.	The SF-36 MCS and PCS, Health Utilities Index Mark 3, EuroQol 5D, and UDI scores were improved significantly in both groups at 6 months and afterward (P < .05).
__label__noRel	Both UAE and hysterectomy improved HRQOL.	No differences were observed between groups regarding HRQOL at 24-month follow-up.
__label__Support	Both UAE and hysterectomy improved HRQOL.	On the basis of HRQOL results, the authors determined that UAE is a good alternative to hysterectomy.
__label__noRel	Both UAE and hysterectomy improved HRQOL.	At 24-month follow-up, patients in the hysterectomy group were significantly more satisfied than those in the UAE group (P = .02).
__label__noRel	No differences were observed between groups regarding HRQOL at 24-month follow-up.	The SF-36 MCS and PCS, Health Utilities Index Mark 3, EuroQol 5D, and UDI scores were improved significantly in both groups at 6 months and afterward (P < .05).
__label__noRel	No differences were observed between groups regarding HRQOL at 24-month follow-up.	Both UAE and hysterectomy improved HRQOL.
__label__Support	No differences were observed between groups regarding HRQOL at 24-month follow-up.	On the basis of HRQOL results, the authors determined that UAE is a good alternative to hysterectomy.
__label__noRel	No differences were observed between groups regarding HRQOL at 24-month follow-up.	At 24-month follow-up, patients in the hysterectomy group were significantly more satisfied than those in the UAE group (P = .02).
__label__noRel	On the basis of HRQOL results, the authors determined that UAE is a good alternative to hysterectomy.	The SF-36 MCS and PCS, Health Utilities Index Mark 3, EuroQol 5D, and UDI scores were improved significantly in both groups at 6 months and afterward (P < .05).
__label__noRel	On the basis of HRQOL results, the authors determined that UAE is a good alternative to hysterectomy.	Both UAE and hysterectomy improved HRQOL.
__label__noRel	On the basis of HRQOL results, the authors determined that UAE is a good alternative to hysterectomy.	No differences were observed between groups regarding HRQOL at 24-month follow-up.
__label__noRel	On the basis of HRQOL results, the authors determined that UAE is a good alternative to hysterectomy.	At 24-month follow-up, patients in the hysterectomy group were significantly more satisfied than those in the UAE group (P = .02).
__label__noRel	At 24-month follow-up, patients in the hysterectomy group were significantly more satisfied than those in the UAE group (P = .02).	The SF-36 MCS and PCS, Health Utilities Index Mark 3, EuroQol 5D, and UDI scores were improved significantly in both groups at 6 months and afterward (P < .05).
__label__noRel	At 24-month follow-up, patients in the hysterectomy group were significantly more satisfied than those in the UAE group (P = .02).	Both UAE and hysterectomy improved HRQOL.
__label__Attack	At 24-month follow-up, patients in the hysterectomy group were significantly more satisfied than those in the UAE group (P = .02).	No differences were observed between groups regarding HRQOL at 24-month follow-up.
__label__noRel	At 24-month follow-up, patients in the hysterectomy group were significantly more satisfied than those in the UAE group (P = .02).	On the basis of HRQOL results, the authors determined that UAE is a good alternative to hysterectomy.
__label__noRel	Decreasing depression symptoms over the first year were associated with longer subsequent survival for women with MBC in this sample.	There was a significant effect of change in CES-D over the first year on survival out to 14 years (P = .007)
__label__noRel	Decreasing depression symptoms over the first year were associated with longer subsequent survival for women with MBC in this sample.	but no significant interaction between treatment condition and CES-D change on survival.
__label__noRel	Decreasing depression symptoms over the first year were associated with longer subsequent survival for women with MBC in this sample.	Median survival time was 53.6 months for women with decreasing CES-D scores over 1 year and 25.1 months for women with increasing CES-D scores.
__label__noRel	Decreasing depression symptoms over the first year were associated with longer subsequent survival for women with MBC in this sample.	Further research is necessary to confirm this hypothesis in other samples, and causation cannot be assumed based on this analysis.
__label__Support	There was a significant effect of change in CES-D over the first year on survival out to 14 years (P = .007)	Decreasing depression symptoms over the first year were associated with longer subsequent survival for women with MBC in this sample.
__label__noRel	There was a significant effect of change in CES-D over the first year on survival out to 14 years (P = .007)	but no significant interaction between treatment condition and CES-D change on survival.
__label__noRel	There was a significant effect of change in CES-D over the first year on survival out to 14 years (P = .007)	Median survival time was 53.6 months for women with decreasing CES-D scores over 1 year and 25.1 months for women with increasing CES-D scores.
__label__noRel	There was a significant effect of change in CES-D over the first year on survival out to 14 years (P = .007)	Further research is necessary to confirm this hypothesis in other samples, and causation cannot be assumed based on this analysis.
__label__noRel	but no significant interaction between treatment condition and CES-D change on survival.	Decreasing depression symptoms over the first year were associated with longer subsequent survival for women with MBC in this sample.
__label__Attack	but no significant interaction between treatment condition and CES-D change on survival.	There was a significant effect of change in CES-D over the first year on survival out to 14 years (P = .007)
__label__noRel	but no significant interaction between treatment condition and CES-D change on survival.	Median survival time was 53.6 months for women with decreasing CES-D scores over 1 year and 25.1 months for women with increasing CES-D scores.
__label__noRel	but no significant interaction between treatment condition and CES-D change on survival.	Further research is necessary to confirm this hypothesis in other samples, and causation cannot be assumed based on this analysis.
__label__Support	Median survival time was 53.6 months for women with decreasing CES-D scores over 1 year and 25.1 months for women with increasing CES-D scores.	Decreasing depression symptoms over the first year were associated with longer subsequent survival for women with MBC in this sample.
__label__noRel	Median survival time was 53.6 months for women with decreasing CES-D scores over 1 year and 25.1 months for women with increasing CES-D scores.	There was a significant effect of change in CES-D over the first year on survival out to 14 years (P = .007)
__label__noRel	Median survival time was 53.6 months for women with decreasing CES-D scores over 1 year and 25.1 months for women with increasing CES-D scores.	but no significant interaction between treatment condition and CES-D change on survival.
__label__noRel	Median survival time was 53.6 months for women with decreasing CES-D scores over 1 year and 25.1 months for women with increasing CES-D scores.	Further research is necessary to confirm this hypothesis in other samples, and causation cannot be assumed based on this analysis.
__label__Attack	Further research is necessary to confirm this hypothesis in other samples, and causation cannot be assumed based on this analysis.	Decreasing depression symptoms over the first year were associated with longer subsequent survival for women with MBC in this sample.
__label__noRel	Further research is necessary to confirm this hypothesis in other samples, and causation cannot be assumed based on this analysis.	There was a significant effect of change in CES-D over the first year on survival out to 14 years (P = .007)
__label__noRel	Further research is necessary to confirm this hypothesis in other samples, and causation cannot be assumed based on this analysis.	but no significant interaction between treatment condition and CES-D change on survival.
__label__noRel	Further research is necessary to confirm this hypothesis in other samples, and causation cannot be assumed based on this analysis.	Median survival time was 53.6 months for women with decreasing CES-D scores over 1 year and 25.1 months for women with increasing CES-D scores.
__label__noRel	Complete remission was achieved in 91% (170/186) of all patients.	With a median follow-up of 8 years, the 5-year overall survival was 68% (+/- 3% standard error of the mean (SEM) and the 5-year event-free survival 53% (+/- 4% SEM).
__label__noRel	Complete remission was achieved in 91% (170/186) of all patients.	These results show an improvement over previous SIOP study (RMS75) in which survival was 52% and event-free survival was 47%.
__label__noRel	Complete remission was achieved in 91% (170/186) of all patients.	Among the 54 patients who exhibited isolated local relapse, 35% (19/54) survived in further remission longer than 2 years after retreatment, including local therapy (surgery +/- radiotherapy).
__label__noRel	Complete remission was achieved in 91% (170/186) of all patients.	Compared with the results obtained in the previous SIOP study, treatment in MMT84 was based on response to initial chemotherapy and, despite an overall reduction of the use of local therapy, significantly improved survival for patients with non-metastatic disease.
__label__Support	Complete remission was achieved in 91% (170/186) of all patients.	This trial, also for the first time, provides evidence that retreatment after local relapse can achieve long-term second remissions.
__label__noRel	With a median follow-up of 8 years, the 5-year overall survival was 68% (+/- 3% standard error of the mean (SEM) and the 5-year event-free survival 53% (+/- 4% SEM).	Complete remission was achieved in 91% (170/186) of all patients.
__label__noRel	With a median follow-up of 8 years, the 5-year overall survival was 68% (+/- 3% standard error of the mean (SEM) and the 5-year event-free survival 53% (+/- 4% SEM).	These results show an improvement over previous SIOP study (RMS75) in which survival was 52% and event-free survival was 47%.
__label__noRel	With a median follow-up of 8 years, the 5-year overall survival was 68% (+/- 3% standard error of the mean (SEM) and the 5-year event-free survival 53% (+/- 4% SEM).	Among the 54 patients who exhibited isolated local relapse, 35% (19/54) survived in further remission longer than 2 years after retreatment, including local therapy (surgery +/- radiotherapy).
__label__Support	With a median follow-up of 8 years, the 5-year overall survival was 68% (+/- 3% standard error of the mean (SEM) and the 5-year event-free survival 53% (+/- 4% SEM).	Compared with the results obtained in the previous SIOP study, treatment in MMT84 was based on response to initial chemotherapy and, despite an overall reduction of the use of local therapy, significantly improved survival for patients with non-metastatic disease.
__label__noRel	With a median follow-up of 8 years, the 5-year overall survival was 68% (+/- 3% standard error of the mean (SEM) and the 5-year event-free survival 53% (+/- 4% SEM).	This trial, also for the first time, provides evidence that retreatment after local relapse can achieve long-term second remissions.
__label__noRel	These results show an improvement over previous SIOP study (RMS75) in which survival was 52% and event-free survival was 47%.	Complete remission was achieved in 91% (170/186) of all patients.
__label__noRel	These results show an improvement over previous SIOP study (RMS75) in which survival was 52% and event-free survival was 47%.	With a median follow-up of 8 years, the 5-year overall survival was 68% (+/- 3% standard error of the mean (SEM) and the 5-year event-free survival 53% (+/- 4% SEM).
__label__noRel	These results show an improvement over previous SIOP study (RMS75) in which survival was 52% and event-free survival was 47%.	Among the 54 patients who exhibited isolated local relapse, 35% (19/54) survived in further remission longer than 2 years after retreatment, including local therapy (surgery +/- radiotherapy).
__label__Support	These results show an improvement over previous SIOP study (RMS75) in which survival was 52% and event-free survival was 47%.	Compared with the results obtained in the previous SIOP study, treatment in MMT84 was based on response to initial chemotherapy and, despite an overall reduction of the use of local therapy, significantly improved survival for patients with non-metastatic disease.
__label__noRel	These results show an improvement over previous SIOP study (RMS75) in which survival was 52% and event-free survival was 47%.	This trial, also for the first time, provides evidence that retreatment after local relapse can achieve long-term second remissions.
__label__noRel	Among the 54 patients who exhibited isolated local relapse, 35% (19/54) survived in further remission longer than 2 years after retreatment, including local therapy (surgery +/- radiotherapy).	Complete remission was achieved in 91% (170/186) of all patients.
__label__noRel	Among the 54 patients who exhibited isolated local relapse, 35% (19/54) survived in further remission longer than 2 years after retreatment, including local therapy (surgery +/- radiotherapy).	With a median follow-up of 8 years, the 5-year overall survival was 68% (+/- 3% standard error of the mean (SEM) and the 5-year event-free survival 53% (+/- 4% SEM).
__label__noRel	Among the 54 patients who exhibited isolated local relapse, 35% (19/54) survived in further remission longer than 2 years after retreatment, including local therapy (surgery +/- radiotherapy).	These results show an improvement over previous SIOP study (RMS75) in which survival was 52% and event-free survival was 47%.
__label__noRel	Among the 54 patients who exhibited isolated local relapse, 35% (19/54) survived in further remission longer than 2 years after retreatment, including local therapy (surgery +/- radiotherapy).	Compared with the results obtained in the previous SIOP study, treatment in MMT84 was based on response to initial chemotherapy and, despite an overall reduction of the use of local therapy, significantly improved survival for patients with non-metastatic disease.
__label__Support	Among the 54 patients who exhibited isolated local relapse, 35% (19/54) survived in further remission longer than 2 years after retreatment, including local therapy (surgery +/- radiotherapy).	This trial, also for the first time, provides evidence that retreatment after local relapse can achieve long-term second remissions.
__label__noRel	Compared with the results obtained in the previous SIOP study, treatment in MMT84 was based on response to initial chemotherapy and, despite an overall reduction of the use of local therapy, significantly improved survival for patients with non-metastatic disease.	Complete remission was achieved in 91% (170/186) of all patients.
__label__noRel	Compared with the results obtained in the previous SIOP study, treatment in MMT84 was based on response to initial chemotherapy and, despite an overall reduction of the use of local therapy, significantly improved survival for patients with non-metastatic disease.	With a median follow-up of 8 years, the 5-year overall survival was 68% (+/- 3% standard error of the mean (SEM) and the 5-year event-free survival 53% (+/- 4% SEM).
__label__noRel	Compared with the results obtained in the previous SIOP study, treatment in MMT84 was based on response to initial chemotherapy and, despite an overall reduction of the use of local therapy, significantly improved survival for patients with non-metastatic disease.	These results show an improvement over previous SIOP study (RMS75) in which survival was 52% and event-free survival was 47%.
__label__noRel	Compared with the results obtained in the previous SIOP study, treatment in MMT84 was based on response to initial chemotherapy and, despite an overall reduction of the use of local therapy, significantly improved survival for patients with non-metastatic disease.	Among the 54 patients who exhibited isolated local relapse, 35% (19/54) survived in further remission longer than 2 years after retreatment, including local therapy (surgery +/- radiotherapy).
__label__noRel	Compared with the results obtained in the previous SIOP study, treatment in MMT84 was based on response to initial chemotherapy and, despite an overall reduction of the use of local therapy, significantly improved survival for patients with non-metastatic disease.	This trial, also for the first time, provides evidence that retreatment after local relapse can achieve long-term second remissions.
__label__noRel	This trial, also for the first time, provides evidence that retreatment after local relapse can achieve long-term second remissions.	Complete remission was achieved in 91% (170/186) of all patients.
__label__noRel	This trial, also for the first time, provides evidence that retreatment after local relapse can achieve long-term second remissions.	With a median follow-up of 8 years, the 5-year overall survival was 68% (+/- 3% standard error of the mean (SEM) and the 5-year event-free survival 53% (+/- 4% SEM).
__label__noRel	This trial, also for the first time, provides evidence that retreatment after local relapse can achieve long-term second remissions.	These results show an improvement over previous SIOP study (RMS75) in which survival was 52% and event-free survival was 47%.
__label__noRel	This trial, also for the first time, provides evidence that retreatment after local relapse can achieve long-term second remissions.	Among the 54 patients who exhibited isolated local relapse, 35% (19/54) survived in further remission longer than 2 years after retreatment, including local therapy (surgery +/- radiotherapy).
__label__noRel	This trial, also for the first time, provides evidence that retreatment after local relapse can achieve long-term second remissions.	Compared with the results obtained in the previous SIOP study, treatment in MMT84 was based on response to initial chemotherapy and, despite an overall reduction of the use of local therapy, significantly improved survival for patients with non-metastatic disease.
__label__noRel	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).
__label__noRel	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).
__label__noRel	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.
__label__noRel	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.
__label__noRel	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.
__label__noRel	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.
__label__noRel	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.	Different analyses yielded slightly different conclusions
__label__Attack	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.
__label__noRel	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).
__label__noRel	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.
__label__noRel	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.
__label__noRel	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.
__label__noRel	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.
__label__noRel	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).	Different analyses yielded slightly different conclusions
__label__noRel	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.
__label__noRel	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).
__label__noRel	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.
__label__noRel	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.
__label__Support	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.
__label__noRel	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.
__label__noRel	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).	Different analyses yielded slightly different conclusions
__label__noRel	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.
__label__noRel	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).
__label__noRel	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).
__label__noRel	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.
__label__noRel	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.
__label__noRel	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.
__label__Support	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.	Different analyses yielded slightly different conclusions
__label__noRel	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.
__label__noRel	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).
__label__noRel	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).
__label__noRel	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.
__label__noRel	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.
__label__Support	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.
__label__noRel	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.	Different analyses yielded slightly different conclusions
__label__noRel	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.
__label__noRel	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).
__label__noRel	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).
__label__noRel	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.
__label__noRel	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.
__label__noRel	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.
__label__noRel	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.	Different analyses yielded slightly different conclusions
__label__noRel	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.
__label__noRel	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).
__label__noRel	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).
__label__noRel	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.
__label__noRel	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.
__label__noRel	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.
__label__noRel	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.	Different analyses yielded slightly different conclusions
__label__noRel	Different analyses yielded slightly different conclusions	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.
__label__noRel	Different analyses yielded slightly different conclusions	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).
__label__noRel	Different analyses yielded slightly different conclusions	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).
__label__noRel	Different analyses yielded slightly different conclusions	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.
__label__noRel	Different analyses yielded slightly different conclusions	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.
__label__Attack	Different analyses yielded slightly different conclusions	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.
__label__noRel	Different analyses yielded slightly different conclusions	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.
__label__noRel	Women with breast cancer may have an even higher risk of depression particularly in a postmenopausal or estrogen deficiency state.	The use of fluoxetine for 6 months resulted in an improvement in quality of life, a higher completion of adjuvant treatment (chemotherapy, hormonal therapy, chemotherapy plus hormonal therapy), and a reduction in depressive symptoms compared to patients who received placebo.
__label__noRel	Women with breast cancer may have an even higher risk of depression particularly in a postmenopausal or estrogen deficiency state.	An antidepressant should be considered for early stage breast cancer patients with depressive symptoms who are receiving adjuvant treatment.
__label__noRel	The use of fluoxetine for 6 months resulted in an improvement in quality of life, a higher completion of adjuvant treatment (chemotherapy, hormonal therapy, chemotherapy plus hormonal therapy), and a reduction in depressive symptoms compared to patients who received placebo.	Women with breast cancer may have an even higher risk of depression particularly in a postmenopausal or estrogen deficiency state.
__label__Support	The use of fluoxetine for 6 months resulted in an improvement in quality of life, a higher completion of adjuvant treatment (chemotherapy, hormonal therapy, chemotherapy plus hormonal therapy), and a reduction in depressive symptoms compared to patients who received placebo.	An antidepressant should be considered for early stage breast cancer patients with depressive symptoms who are receiving adjuvant treatment.
__label__noRel	An antidepressant should be considered for early stage breast cancer patients with depressive symptoms who are receiving adjuvant treatment.	Women with breast cancer may have an even higher risk of depression particularly in a postmenopausal or estrogen deficiency state.
__label__noRel	An antidepressant should be considered for early stage breast cancer patients with depressive symptoms who are receiving adjuvant treatment.	The use of fluoxetine for 6 months resulted in an improvement in quality of life, a higher completion of adjuvant treatment (chemotherapy, hormonal therapy, chemotherapy plus hormonal therapy), and a reduction in depressive symptoms compared to patients who received placebo.
__label__noRel	No changes were found in arm circumference or arm volume as a result of the exercise program.	Three of the quality-of-life domains showed trends toward increases in the exercise group: physical functioning (P =.050), general health (P =.048), and vitality (P =.023).
__label__noRel	No changes were found in arm circumference or arm volume as a result of the exercise program.	Mental health increased, although not significantly, for all subjects (P =.019).
__label__noRel	No changes were found in arm circumference or arm volume as a result of the exercise program.	Arm volume measured by water displacement was correlated with calculated arm volume (r =.973, P <.001),
__label__noRel	No changes were found in arm circumference or arm volume as a result of the exercise program.	although the exercise and control group means were significantly different (P <.001).
__label__noRel	No changes were found in arm circumference or arm volume as a result of the exercise program.	Additional studies should be done in this area to determine the optimum training program.
__label__Support	No changes were found in arm circumference or arm volume as a result of the exercise program.	Participation in an upper-body exercise program caused no changes in arm circumference or arm volume in women with lymphedema after breast cancer, and they may have experienced an increase in quality of life.
__label__noRel	Three of the quality-of-life domains showed trends toward increases in the exercise group: physical functioning (P =.050), general health (P =.048), and vitality (P =.023).	No changes were found in arm circumference or arm volume as a result of the exercise program.
__label__noRel	Three of the quality-of-life domains showed trends toward increases in the exercise group: physical functioning (P =.050), general health (P =.048), and vitality (P =.023).	Mental health increased, although not significantly, for all subjects (P =.019).
__label__noRel	Three of the quality-of-life domains showed trends toward increases in the exercise group: physical functioning (P =.050), general health (P =.048), and vitality (P =.023).	Arm volume measured by water displacement was correlated with calculated arm volume (r =.973, P <.001),
__label__noRel	Three of the quality-of-life domains showed trends toward increases in the exercise group: physical functioning (P =.050), general health (P =.048), and vitality (P =.023).	although the exercise and control group means were significantly different (P <.001).
__label__noRel	Three of the quality-of-life domains showed trends toward increases in the exercise group: physical functioning (P =.050), general health (P =.048), and vitality (P =.023).	Additional studies should be done in this area to determine the optimum training program.
__label__Support	Three of the quality-of-life domains showed trends toward increases in the exercise group: physical functioning (P =.050), general health (P =.048), and vitality (P =.023).	Participation in an upper-body exercise program caused no changes in arm circumference or arm volume in women with lymphedema after breast cancer, and they may have experienced an increase in quality of life.
__label__noRel	Mental health increased, although not significantly, for all subjects (P =.019).	No changes were found in arm circumference or arm volume as a result of the exercise program.
__label__noRel	Mental health increased, although not significantly, for all subjects (P =.019).	Three of the quality-of-life domains showed trends toward increases in the exercise group: physical functioning (P =.050), general health (P =.048), and vitality (P =.023).
__label__noRel	Mental health increased, although not significantly, for all subjects (P =.019).	Arm volume measured by water displacement was correlated with calculated arm volume (r =.973, P <.001),
__label__noRel	Mental health increased, although not significantly, for all subjects (P =.019).	although the exercise and control group means were significantly different (P <.001).
__label__noRel	Mental health increased, although not significantly, for all subjects (P =.019).	Additional studies should be done in this area to determine the optimum training program.
__label__noRel	Mental health increased, although not significantly, for all subjects (P =.019).	Participation in an upper-body exercise program caused no changes in arm circumference or arm volume in women with lymphedema after breast cancer, and they may have experienced an increase in quality of life.
__label__noRel	Arm volume measured by water displacement was correlated with calculated arm volume (r =.973, P <.001),	No changes were found in arm circumference or arm volume as a result of the exercise program.
__label__noRel	Arm volume measured by water displacement was correlated with calculated arm volume (r =.973, P <.001),	Three of the quality-of-life domains showed trends toward increases in the exercise group: physical functioning (P =.050), general health (P =.048), and vitality (P =.023).
__label__noRel	Arm volume measured by water displacement was correlated with calculated arm volume (r =.973, P <.001),	Mental health increased, although not significantly, for all subjects (P =.019).
__label__noRel	Arm volume measured by water displacement was correlated with calculated arm volume (r =.973, P <.001),	although the exercise and control group means were significantly different (P <.001).
__label__noRel	Arm volume measured by water displacement was correlated with calculated arm volume (r =.973, P <.001),	Additional studies should be done in this area to determine the optimum training program.
__label__noRel	Arm volume measured by water displacement was correlated with calculated arm volume (r =.973, P <.001),	Participation in an upper-body exercise program caused no changes in arm circumference or arm volume in women with lymphedema after breast cancer, and they may have experienced an increase in quality of life.
__label__noRel	although the exercise and control group means were significantly different (P <.001).	No changes were found in arm circumference or arm volume as a result of the exercise program.
__label__noRel	although the exercise and control group means were significantly different (P <.001).	Three of the quality-of-life domains showed trends toward increases in the exercise group: physical functioning (P =.050), general health (P =.048), and vitality (P =.023).
__label__noRel	although the exercise and control group means were significantly different (P <.001).	Mental health increased, although not significantly, for all subjects (P =.019).
__label__Attack	although the exercise and control group means were significantly different (P <.001).	Arm volume measured by water displacement was correlated with calculated arm volume (r =.973, P <.001),
__label__noRel	although the exercise and control group means were significantly different (P <.001).	Additional studies should be done in this area to determine the optimum training program.
__label__noRel	although the exercise and control group means were significantly different (P <.001).	Participation in an upper-body exercise program caused no changes in arm circumference or arm volume in women with lymphedema after breast cancer, and they may have experienced an increase in quality of life.
__label__noRel	Additional studies should be done in this area to determine the optimum training program.	No changes were found in arm circumference or arm volume as a result of the exercise program.
__label__noRel	Additional studies should be done in this area to determine the optimum training program.	Three of the quality-of-life domains showed trends toward increases in the exercise group: physical functioning (P =.050), general health (P =.048), and vitality (P =.023).
__label__noRel	Additional studies should be done in this area to determine the optimum training program.	Mental health increased, although not significantly, for all subjects (P =.019).
__label__noRel	Additional studies should be done in this area to determine the optimum training program.	Arm volume measured by water displacement was correlated with calculated arm volume (r =.973, P <.001),
__label__noRel	Additional studies should be done in this area to determine the optimum training program.	although the exercise and control group means were significantly different (P <.001).
__label__noRel	Additional studies should be done in this area to determine the optimum training program.	Participation in an upper-body exercise program caused no changes in arm circumference or arm volume in women with lymphedema after breast cancer, and they may have experienced an increase in quality of life.
__label__noRel	Participation in an upper-body exercise program caused no changes in arm circumference or arm volume in women with lymphedema after breast cancer, and they may have experienced an increase in quality of life.	No changes were found in arm circumference or arm volume as a result of the exercise program.
__label__noRel	Participation in an upper-body exercise program caused no changes in arm circumference or arm volume in women with lymphedema after breast cancer, and they may have experienced an increase in quality of life.	Three of the quality-of-life domains showed trends toward increases in the exercise group: physical functioning (P =.050), general health (P =.048), and vitality (P =.023).
__label__noRel	Participation in an upper-body exercise program caused no changes in arm circumference or arm volume in women with lymphedema after breast cancer, and they may have experienced an increase in quality of life.	Mental health increased, although not significantly, for all subjects (P =.019).
__label__noRel	Participation in an upper-body exercise program caused no changes in arm circumference or arm volume in women with lymphedema after breast cancer, and they may have experienced an increase in quality of life.	Arm volume measured by water displacement was correlated with calculated arm volume (r =.973, P <.001),
__label__noRel	Participation in an upper-body exercise program caused no changes in arm circumference or arm volume in women with lymphedema after breast cancer, and they may have experienced an increase in quality of life.	although the exercise and control group means were significantly different (P <.001).
__label__noRel	Participation in an upper-body exercise program caused no changes in arm circumference or arm volume in women with lymphedema after breast cancer, and they may have experienced an increase in quality of life.	Additional studies should be done in this area to determine the optimum training program.
__label__noRel	Linear mixed models (primary model) demonstrated no statistically significant overall difference between EVE+EXE and PBO+EXE for QL2 (LSM difference = -1.91; 95% CI = -4.61, 0.78), BRBS (LSM difference = -0.18; 95% CI = -1.98, 1.62), or BRAS (LSM difference = -0.42; 95% CI = -2.94, 2.10).	In the expanded pattern-mixture model, EVE+EXE-treated patients who did not drop out early had stable BRBS and BRAS relative to PBO+EXE.
__label__Support	Linear mixed models (primary model) demonstrated no statistically significant overall difference between EVE+EXE and PBO+EXE for QL2 (LSM difference = -1.91; 95% CI = -4.61, 0.78), BRBS (LSM difference = -0.18; 95% CI = -1.98, 1.62), or BRAS (LSM difference = -0.42; 95% CI = -2.94, 2.10).	These analyses confirm that EVE+EXE provides clinical benefit without adversely impacting HRQOL in patients with HR(+) ABC who recurred/progressed on prior NSAIs versus endocrine therapy alone.
__label__noRel	In the expanded pattern-mixture model, EVE+EXE-treated patients who did not drop out early had stable BRBS and BRAS relative to PBO+EXE.	Linear mixed models (primary model) demonstrated no statistically significant overall difference between EVE+EXE and PBO+EXE for QL2 (LSM difference = -1.91; 95% CI = -4.61, 0.78), BRBS (LSM difference = -0.18; 95% CI = -1.98, 1.62), or BRAS (LSM difference = -0.42; 95% CI = -2.94, 2.10).
__label__Support	In the expanded pattern-mixture model, EVE+EXE-treated patients who did not drop out early had stable BRBS and BRAS relative to PBO+EXE.	These analyses confirm that EVE+EXE provides clinical benefit without adversely impacting HRQOL in patients with HR(+) ABC who recurred/progressed on prior NSAIs versus endocrine therapy alone.
__label__noRel	These analyses confirm that EVE+EXE provides clinical benefit without adversely impacting HRQOL in patients with HR(+) ABC who recurred/progressed on prior NSAIs versus endocrine therapy alone.	Linear mixed models (primary model) demonstrated no statistically significant overall difference between EVE+EXE and PBO+EXE for QL2 (LSM difference = -1.91; 95% CI = -4.61, 0.78), BRBS (LSM difference = -0.18; 95% CI = -1.98, 1.62), or BRAS (LSM difference = -0.42; 95% CI = -2.94, 2.10).
__label__noRel	These analyses confirm that EVE+EXE provides clinical benefit without adversely impacting HRQOL in patients with HR(+) ABC who recurred/progressed on prior NSAIs versus endocrine therapy alone.	In the expanded pattern-mixture model, EVE+EXE-treated patients who did not drop out early had stable BRBS and BRAS relative to PBO+EXE.
__label__noRel	The final multivariate model predicted poor survival with multiple sites of visceral disease (P=0.003), DFI </=2 years (P=0.026) and pain (P=0.003).	For survival, multiple sites of visceral disease, pain, global QL and fatigue were significant prognostic factors in the univariate analysis.
__label__noRel	The final multivariate model predicted poor survival with multiple sites of visceral disease (P=0.003), DFI </=2 years (P=0.026) and pain (P=0.003).	For response, age, dyspnoea, fatigue and global QL were significant predictive factors in the univariate analysis.
__label__noRel	The final multivariate model predicted poor survival with multiple sites of visceral disease (P=0.003), DFI </=2 years (P=0.026) and pain (P=0.003).	The final multivariate model for response selected DFI (P=0.009), multiple sites of visceral disease (P=0.037) and dyspnoea (P=<0.001) using forward selection,
__label__noRel	The final multivariate model predicted poor survival with multiple sites of visceral disease (P=0.003), DFI </=2 years (P=0.026) and pain (P=0.003).	but model instability was indicated by the inclusion of fatigue and emotional function in the final model when backward selection was used.
__label__noRel	The final multivariate model predicted poor survival with multiple sites of visceral disease (P=0.003), DFI </=2 years (P=0.026) and pain (P=0.003).	patient-assessed QL variables appear to be prognostic for survival and response to chemotherapy in women with advanced breast cancer.
__label__noRel	The final multivariate model predicted poor survival with multiple sites of visceral disease (P=0.003), DFI </=2 years (P=0.026) and pain (P=0.003).	However, identification of prognostic factors from responses to questionnaires may be unstable, and their reliability and clinical utility should be tested prospectively.
__label__noRel	For survival, multiple sites of visceral disease, pain, global QL and fatigue were significant prognostic factors in the univariate analysis.	The final multivariate model predicted poor survival with multiple sites of visceral disease (P=0.003), DFI </=2 years (P=0.026) and pain (P=0.003).
__label__noRel	For survival, multiple sites of visceral disease, pain, global QL and fatigue were significant prognostic factors in the univariate analysis.	For response, age, dyspnoea, fatigue and global QL were significant predictive factors in the univariate analysis.
__label__noRel	For survival, multiple sites of visceral disease, pain, global QL and fatigue were significant prognostic factors in the univariate analysis.	The final multivariate model for response selected DFI (P=0.009), multiple sites of visceral disease (P=0.037) and dyspnoea (P=<0.001) using forward selection,
__label__noRel	For survival, multiple sites of visceral disease, pain, global QL and fatigue were significant prognostic factors in the univariate analysis.	but model instability was indicated by the inclusion of fatigue and emotional function in the final model when backward selection was used.
__label__Support	For survival, multiple sites of visceral disease, pain, global QL and fatigue were significant prognostic factors in the univariate analysis.	patient-assessed QL variables appear to be prognostic for survival and response to chemotherapy in women with advanced breast cancer.
__label__noRel	For survival, multiple sites of visceral disease, pain, global QL and fatigue were significant prognostic factors in the univariate analysis.	However, identification of prognostic factors from responses to questionnaires may be unstable, and their reliability and clinical utility should be tested prospectively.
__label__noRel	For response, age, dyspnoea, fatigue and global QL were significant predictive factors in the univariate analysis.	The final multivariate model predicted poor survival with multiple sites of visceral disease (P=0.003), DFI </=2 years (P=0.026) and pain (P=0.003).
__label__noRel	For response, age, dyspnoea, fatigue and global QL were significant predictive factors in the univariate analysis.	For survival, multiple sites of visceral disease, pain, global QL and fatigue were significant prognostic factors in the univariate analysis.
__label__noRel	For response, age, dyspnoea, fatigue and global QL were significant predictive factors in the univariate analysis.	The final multivariate model for response selected DFI (P=0.009), multiple sites of visceral disease (P=0.037) and dyspnoea (P=<0.001) using forward selection,
__label__noRel	For response, age, dyspnoea, fatigue and global QL were significant predictive factors in the univariate analysis.	but model instability was indicated by the inclusion of fatigue and emotional function in the final model when backward selection was used.
__label__Support	For response, age, dyspnoea, fatigue and global QL were significant predictive factors in the univariate analysis.	patient-assessed QL variables appear to be prognostic for survival and response to chemotherapy in women with advanced breast cancer.
__label__noRel	For response, age, dyspnoea, fatigue and global QL were significant predictive factors in the univariate analysis.	However, identification of prognostic factors from responses to questionnaires may be unstable, and their reliability and clinical utility should be tested prospectively.
__label__noRel	The final multivariate model for response selected DFI (P=0.009), multiple sites of visceral disease (P=0.037) and dyspnoea (P=<0.001) using forward selection,	The final multivariate model predicted poor survival with multiple sites of visceral disease (P=0.003), DFI </=2 years (P=0.026) and pain (P=0.003).
__label__noRel	The final multivariate model for response selected DFI (P=0.009), multiple sites of visceral disease (P=0.037) and dyspnoea (P=<0.001) using forward selection,	For survival, multiple sites of visceral disease, pain, global QL and fatigue were significant prognostic factors in the univariate analysis.
__label__noRel	The final multivariate model for response selected DFI (P=0.009), multiple sites of visceral disease (P=0.037) and dyspnoea (P=<0.001) using forward selection,	For response, age, dyspnoea, fatigue and global QL were significant predictive factors in the univariate analysis.
__label__noRel	The final multivariate model for response selected DFI (P=0.009), multiple sites of visceral disease (P=0.037) and dyspnoea (P=<0.001) using forward selection,	but model instability was indicated by the inclusion of fatigue and emotional function in the final model when backward selection was used.
__label__Support	The final multivariate model for response selected DFI (P=0.009), multiple sites of visceral disease (P=0.037) and dyspnoea (P=<0.001) using forward selection,	patient-assessed QL variables appear to be prognostic for survival and response to chemotherapy in women with advanced breast cancer.
__label__noRel	The final multivariate model for response selected DFI (P=0.009), multiple sites of visceral disease (P=0.037) and dyspnoea (P=<0.001) using forward selection,	However, identification of prognostic factors from responses to questionnaires may be unstable, and their reliability and clinical utility should be tested prospectively.
__label__noRel	but model instability was indicated by the inclusion of fatigue and emotional function in the final model when backward selection was used.	The final multivariate model predicted poor survival with multiple sites of visceral disease (P=0.003), DFI </=2 years (P=0.026) and pain (P=0.003).
__label__noRel	but model instability was indicated by the inclusion of fatigue and emotional function in the final model when backward selection was used.	For survival, multiple sites of visceral disease, pain, global QL and fatigue were significant prognostic factors in the univariate analysis.
__label__noRel	but model instability was indicated by the inclusion of fatigue and emotional function in the final model when backward selection was used.	For response, age, dyspnoea, fatigue and global QL were significant predictive factors in the univariate analysis.
__label__Attack	but model instability was indicated by the inclusion of fatigue and emotional function in the final model when backward selection was used.	The final multivariate model for response selected DFI (P=0.009), multiple sites of visceral disease (P=0.037) and dyspnoea (P=<0.001) using forward selection,
__label__noRel	but model instability was indicated by the inclusion of fatigue and emotional function in the final model when backward selection was used.	patient-assessed QL variables appear to be prognostic for survival and response to chemotherapy in women with advanced breast cancer.
__label__noRel	but model instability was indicated by the inclusion of fatigue and emotional function in the final model when backward selection was used.	However, identification of prognostic factors from responses to questionnaires may be unstable, and their reliability and clinical utility should be tested prospectively.
__label__noRel	patient-assessed QL variables appear to be prognostic for survival and response to chemotherapy in women with advanced breast cancer.	The final multivariate model predicted poor survival with multiple sites of visceral disease (P=0.003), DFI </=2 years (P=0.026) and pain (P=0.003).
__label__noRel	patient-assessed QL variables appear to be prognostic for survival and response to chemotherapy in women with advanced breast cancer.	For survival, multiple sites of visceral disease, pain, global QL and fatigue were significant prognostic factors in the univariate analysis.
__label__noRel	patient-assessed QL variables appear to be prognostic for survival and response to chemotherapy in women with advanced breast cancer.	For response, age, dyspnoea, fatigue and global QL were significant predictive factors in the univariate analysis.
__label__noRel	patient-assessed QL variables appear to be prognostic for survival and response to chemotherapy in women with advanced breast cancer.	The final multivariate model for response selected DFI (P=0.009), multiple sites of visceral disease (P=0.037) and dyspnoea (P=<0.001) using forward selection,
__label__noRel	patient-assessed QL variables appear to be prognostic for survival and response to chemotherapy in women with advanced breast cancer.	but model instability was indicated by the inclusion of fatigue and emotional function in the final model when backward selection was used.
__label__noRel	patient-assessed QL variables appear to be prognostic for survival and response to chemotherapy in women with advanced breast cancer.	However, identification of prognostic factors from responses to questionnaires may be unstable, and their reliability and clinical utility should be tested prospectively.
__label__noRel	However, identification of prognostic factors from responses to questionnaires may be unstable, and their reliability and clinical utility should be tested prospectively.	The final multivariate model predicted poor survival with multiple sites of visceral disease (P=0.003), DFI </=2 years (P=0.026) and pain (P=0.003).
__label__noRel	However, identification of prognostic factors from responses to questionnaires may be unstable, and their reliability and clinical utility should be tested prospectively.	For survival, multiple sites of visceral disease, pain, global QL and fatigue were significant prognostic factors in the univariate analysis.
__label__noRel	However, identification of prognostic factors from responses to questionnaires may be unstable, and their reliability and clinical utility should be tested prospectively.	For response, age, dyspnoea, fatigue and global QL were significant predictive factors in the univariate analysis.
__label__noRel	However, identification of prognostic factors from responses to questionnaires may be unstable, and their reliability and clinical utility should be tested prospectively.	The final multivariate model for response selected DFI (P=0.009), multiple sites of visceral disease (P=0.037) and dyspnoea (P=<0.001) using forward selection,
__label__noRel	However, identification of prognostic factors from responses to questionnaires may be unstable, and their reliability and clinical utility should be tested prospectively.	but model instability was indicated by the inclusion of fatigue and emotional function in the final model when backward selection was used.
__label__Attack	However, identification of prognostic factors from responses to questionnaires may be unstable, and their reliability and clinical utility should be tested prospectively.	patient-assessed QL variables appear to be prognostic for survival and response to chemotherapy in women with advanced breast cancer.
__label__noRel	The scapula-oriented exercise group showed improvements in pain, physical function, social function, and global quality of life compared with baseline, whereas the general exercise group showed improved fatigue and range of motion.	The change in global quality of life (P = 0.067; effect size, 0.33) and strength of external rotation (P = 0.001; effect size, 0.55) were significantly greater in the scapula-oriented exercise group than in the general exercise and control group.
__label__Support	The scapula-oriented exercise group showed improvements in pain, physical function, social function, and global quality of life compared with baseline, whereas the general exercise group showed improved fatigue and range of motion.	Scapula-oriented exercise had beneficial effects on pain, quality of life and aspects of strength.
__label__noRel	The change in global quality of life (P = 0.067; effect size, 0.33) and strength of external rotation (P = 0.001; effect size, 0.55) were significantly greater in the scapula-oriented exercise group than in the general exercise and control group.	The scapula-oriented exercise group showed improvements in pain, physical function, social function, and global quality of life compared with baseline, whereas the general exercise group showed improved fatigue and range of motion.
__label__Support	The change in global quality of life (P = 0.067; effect size, 0.33) and strength of external rotation (P = 0.001; effect size, 0.55) were significantly greater in the scapula-oriented exercise group than in the general exercise and control group.	Scapula-oriented exercise had beneficial effects on pain, quality of life and aspects of strength.
__label__noRel	Scapula-oriented exercise had beneficial effects on pain, quality of life and aspects of strength.	The scapula-oriented exercise group showed improvements in pain, physical function, social function, and global quality of life compared with baseline, whereas the general exercise group showed improved fatigue and range of motion.
__label__noRel	Scapula-oriented exercise had beneficial effects on pain, quality of life and aspects of strength.	The change in global quality of life (P = 0.067; effect size, 0.33) and strength of external rotation (P = 0.001; effect size, 0.55) were significantly greater in the scapula-oriented exercise group than in the general exercise and control group.
__label__noRel	The incidence and development of cancer are closely related to dysfunction of immune function.	DC/CIK treatment prolongs progression-free survival (3.20 months [95% CI, 2.94-3.50] vs 2.56 months [95% CI, 2.39-2.73]; P <0.05).
__label__noRel	The incidence and development of cancer are closely related to dysfunction of immune function.	In the treatment group, the proportion of NK cells, T-cell subgroups CD3+, CD4+ and CD8+ had a significant change before and after treatment.
__label__noRel	The incidence and development of cancer are closely related to dysfunction of immune function.	Liver and kidney function and blood tests of the treatment group were within the normal range before and after treatment.
__label__noRel	The incidence and development of cancer are closely related to dysfunction of immune function.	In the treatment group, 1 case suffered from chest distress, 3 cases suffered from acratia, and 4 cases suffered from pyrexia.
__label__noRel	The incidence and development of cancer are closely related to dysfunction of immune function.	DC/CIK treatment had potential benefit for patients with advanced non-small cell lung cancer compared with the control group and had no obvious side effects.
__label__noRel	The incidence and development of cancer are closely related to dysfunction of immune function.	DC/CIK treatment is a safe and effective method for maintenance therapy of advanced non-small cell lung cancer.
__label__noRel	DC/CIK treatment prolongs progression-free survival (3.20 months [95% CI, 2.94-3.50] vs 2.56 months [95% CI, 2.39-2.73]; P <0.05).	The incidence and development of cancer are closely related to dysfunction of immune function.
__label__noRel	DC/CIK treatment prolongs progression-free survival (3.20 months [95% CI, 2.94-3.50] vs 2.56 months [95% CI, 2.39-2.73]; P <0.05).	In the treatment group, the proportion of NK cells, T-cell subgroups CD3+, CD4+ and CD8+ had a significant change before and after treatment.
__label__noRel	DC/CIK treatment prolongs progression-free survival (3.20 months [95% CI, 2.94-3.50] vs 2.56 months [95% CI, 2.39-2.73]; P <0.05).	Liver and kidney function and blood tests of the treatment group were within the normal range before and after treatment.
__label__noRel	DC/CIK treatment prolongs progression-free survival (3.20 months [95% CI, 2.94-3.50] vs 2.56 months [95% CI, 2.39-2.73]; P <0.05).	In the treatment group, 1 case suffered from chest distress, 3 cases suffered from acratia, and 4 cases suffered from pyrexia.
__label__noRel	DC/CIK treatment prolongs progression-free survival (3.20 months [95% CI, 2.94-3.50] vs 2.56 months [95% CI, 2.39-2.73]; P <0.05).	DC/CIK treatment had potential benefit for patients with advanced non-small cell lung cancer compared with the control group and had no obvious side effects.
__label__Support	DC/CIK treatment prolongs progression-free survival (3.20 months [95% CI, 2.94-3.50] vs 2.56 months [95% CI, 2.39-2.73]; P <0.05).	DC/CIK treatment is a safe and effective method for maintenance therapy of advanced non-small cell lung cancer.
__label__noRel	In the treatment group, the proportion of NK cells, T-cell subgroups CD3+, CD4+ and CD8+ had a significant change before and after treatment.	The incidence and development of cancer are closely related to dysfunction of immune function.
__label__noRel	In the treatment group, the proportion of NK cells, T-cell subgroups CD3+, CD4+ and CD8+ had a significant change before and after treatment.	DC/CIK treatment prolongs progression-free survival (3.20 months [95% CI, 2.94-3.50] vs 2.56 months [95% CI, 2.39-2.73]; P <0.05).
__label__noRel	In the treatment group, the proportion of NK cells, T-cell subgroups CD3+, CD4+ and CD8+ had a significant change before and after treatment.	Liver and kidney function and blood tests of the treatment group were within the normal range before and after treatment.
__label__noRel	In the treatment group, the proportion of NK cells, T-cell subgroups CD3+, CD4+ and CD8+ had a significant change before and after treatment.	In the treatment group, 1 case suffered from chest distress, 3 cases suffered from acratia, and 4 cases suffered from pyrexia.
__label__Support	In the treatment group, the proportion of NK cells, T-cell subgroups CD3+, CD4+ and CD8+ had a significant change before and after treatment.	DC/CIK treatment had potential benefit for patients with advanced non-small cell lung cancer compared with the control group and had no obvious side effects.
__label__noRel	In the treatment group, the proportion of NK cells, T-cell subgroups CD3+, CD4+ and CD8+ had a significant change before and after treatment.	DC/CIK treatment is a safe and effective method for maintenance therapy of advanced non-small cell lung cancer.
__label__noRel	Liver and kidney function and blood tests of the treatment group were within the normal range before and after treatment.	The incidence and development of cancer are closely related to dysfunction of immune function.
__label__noRel	Liver and kidney function and blood tests of the treatment group were within the normal range before and after treatment.	DC/CIK treatment prolongs progression-free survival (3.20 months [95% CI, 2.94-3.50] vs 2.56 months [95% CI, 2.39-2.73]; P <0.05).
__label__noRel	Liver and kidney function and blood tests of the treatment group were within the normal range before and after treatment.	In the treatment group, the proportion of NK cells, T-cell subgroups CD3+, CD4+ and CD8+ had a significant change before and after treatment.
__label__noRel	Liver and kidney function and blood tests of the treatment group were within the normal range before and after treatment.	In the treatment group, 1 case suffered from chest distress, 3 cases suffered from acratia, and 4 cases suffered from pyrexia.
__label__noRel	Liver and kidney function and blood tests of the treatment group were within the normal range before and after treatment.	DC/CIK treatment had potential benefit for patients with advanced non-small cell lung cancer compared with the control group and had no obvious side effects.
__label__Support	Liver and kidney function and blood tests of the treatment group were within the normal range before and after treatment.	DC/CIK treatment is a safe and effective method for maintenance therapy of advanced non-small cell lung cancer.
__label__noRel	In the treatment group, 1 case suffered from chest distress, 3 cases suffered from acratia, and 4 cases suffered from pyrexia.	The incidence and development of cancer are closely related to dysfunction of immune function.
__label__noRel	In the treatment group, 1 case suffered from chest distress, 3 cases suffered from acratia, and 4 cases suffered from pyrexia.	DC/CIK treatment prolongs progression-free survival (3.20 months [95% CI, 2.94-3.50] vs 2.56 months [95% CI, 2.39-2.73]; P <0.05).
__label__noRel	In the treatment group, 1 case suffered from chest distress, 3 cases suffered from acratia, and 4 cases suffered from pyrexia.	In the treatment group, the proportion of NK cells, T-cell subgroups CD3+, CD4+ and CD8+ had a significant change before and after treatment.
__label__noRel	In the treatment group, 1 case suffered from chest distress, 3 cases suffered from acratia, and 4 cases suffered from pyrexia.	Liver and kidney function and blood tests of the treatment group were within the normal range before and after treatment.
__label__Support	In the treatment group, 1 case suffered from chest distress, 3 cases suffered from acratia, and 4 cases suffered from pyrexia.	DC/CIK treatment had potential benefit for patients with advanced non-small cell lung cancer compared with the control group and had no obvious side effects.
__label__noRel	In the treatment group, 1 case suffered from chest distress, 3 cases suffered from acratia, and 4 cases suffered from pyrexia.	DC/CIK treatment is a safe and effective method for maintenance therapy of advanced non-small cell lung cancer.
__label__noRel	DC/CIK treatment had potential benefit for patients with advanced non-small cell lung cancer compared with the control group and had no obvious side effects.	The incidence and development of cancer are closely related to dysfunction of immune function.
__label__noRel	DC/CIK treatment had potential benefit for patients with advanced non-small cell lung cancer compared with the control group and had no obvious side effects.	DC/CIK treatment prolongs progression-free survival (3.20 months [95% CI, 2.94-3.50] vs 2.56 months [95% CI, 2.39-2.73]; P <0.05).
__label__noRel	DC/CIK treatment had potential benefit for patients with advanced non-small cell lung cancer compared with the control group and had no obvious side effects.	In the treatment group, the proportion of NK cells, T-cell subgroups CD3+, CD4+ and CD8+ had a significant change before and after treatment.
__label__noRel	DC/CIK treatment had potential benefit for patients with advanced non-small cell lung cancer compared with the control group and had no obvious side effects.	Liver and kidney function and blood tests of the treatment group were within the normal range before and after treatment.
__label__noRel	DC/CIK treatment had potential benefit for patients with advanced non-small cell lung cancer compared with the control group and had no obvious side effects.	In the treatment group, 1 case suffered from chest distress, 3 cases suffered from acratia, and 4 cases suffered from pyrexia.
__label__noRel	DC/CIK treatment had potential benefit for patients with advanced non-small cell lung cancer compared with the control group and had no obvious side effects.	DC/CIK treatment is a safe and effective method for maintenance therapy of advanced non-small cell lung cancer.
__label__noRel	DC/CIK treatment is a safe and effective method for maintenance therapy of advanced non-small cell lung cancer.	The incidence and development of cancer are closely related to dysfunction of immune function.
__label__noRel	DC/CIK treatment is a safe and effective method for maintenance therapy of advanced non-small cell lung cancer.	DC/CIK treatment prolongs progression-free survival (3.20 months [95% CI, 2.94-3.50] vs 2.56 months [95% CI, 2.39-2.73]; P <0.05).
__label__noRel	DC/CIK treatment is a safe and effective method for maintenance therapy of advanced non-small cell lung cancer.	In the treatment group, the proportion of NK cells, T-cell subgroups CD3+, CD4+ and CD8+ had a significant change before and after treatment.
__label__noRel	DC/CIK treatment is a safe and effective method for maintenance therapy of advanced non-small cell lung cancer.	Liver and kidney function and blood tests of the treatment group were within the normal range before and after treatment.
__label__noRel	DC/CIK treatment is a safe and effective method for maintenance therapy of advanced non-small cell lung cancer.	In the treatment group, 1 case suffered from chest distress, 3 cases suffered from acratia, and 4 cases suffered from pyrexia.
__label__noRel	DC/CIK treatment is a safe and effective method for maintenance therapy of advanced non-small cell lung cancer.	DC/CIK treatment had potential benefit for patients with advanced non-small cell lung cancer compared with the control group and had no obvious side effects.
__label__noRel	We observed a significant reduction in anxiety (STAI, POMS) among group participants, a reduction in anger, depression and fatigue (POMS), a significant improvement in vigor and interpersonal relationships (POMS), in emotional and role functioning, in health status and fatigue level (EORTC QLQ-C30).	coping strategies (MAC) were not significantly different between groups.
__label__noRel	We observed a significant reduction in anxiety (STAI, POMS) among group participants, a reduction in anger, depression and fatigue (POMS), a significant improvement in vigor and interpersonal relationships (POMS), in emotional and role functioning, in health status and fatigue level (EORTC QLQ-C30).	No group-related negative effects were observed and the global satisfaction levels were very high.
__label__Support	We observed a significant reduction in anxiety (STAI, POMS) among group participants, a reduction in anger, depression and fatigue (POMS), a significant improvement in vigor and interpersonal relationships (POMS), in emotional and role functioning, in health status and fatigue level (EORTC QLQ-C30).	This study demonstrates the feasibility and effectiveness of a psycho-educational intervention, which can accelerate the reduction of those negative affects which are present at the end of treatment.
__label__noRel	We observed a significant reduction in anxiety (STAI, POMS) among group participants, a reduction in anger, depression and fatigue (POMS), a significant improvement in vigor and interpersonal relationships (POMS), in emotional and role functioning, in health status and fatigue level (EORTC QLQ-C30).	It represents an excellent complement or an alternative to individual psycho-oncologic therapeutic support,
__label__noRel	coping strategies (MAC) were not significantly different between groups.	We observed a significant reduction in anxiety (STAI, POMS) among group participants, a reduction in anger, depression and fatigue (POMS), a significant improvement in vigor and interpersonal relationships (POMS), in emotional and role functioning, in health status and fatigue level (EORTC QLQ-C30).
__label__noRel	coping strategies (MAC) were not significantly different between groups.	No group-related negative effects were observed and the global satisfaction levels were very high.
__label__Support	coping strategies (MAC) were not significantly different between groups.	This study demonstrates the feasibility and effectiveness of a psycho-educational intervention, which can accelerate the reduction of those negative affects which are present at the end of treatment.
__label__noRel	coping strategies (MAC) were not significantly different between groups.	It represents an excellent complement or an alternative to individual psycho-oncologic therapeutic support,
__label__noRel	No group-related negative effects were observed and the global satisfaction levels were very high.	We observed a significant reduction in anxiety (STAI, POMS) among group participants, a reduction in anger, depression and fatigue (POMS), a significant improvement in vigor and interpersonal relationships (POMS), in emotional and role functioning, in health status and fatigue level (EORTC QLQ-C30).
__label__noRel	No group-related negative effects were observed and the global satisfaction levels were very high.	coping strategies (MAC) were not significantly different between groups.
__label__Support	No group-related negative effects were observed and the global satisfaction levels were very high.	This study demonstrates the feasibility and effectiveness of a psycho-educational intervention, which can accelerate the reduction of those negative affects which are present at the end of treatment.
__label__noRel	No group-related negative effects were observed and the global satisfaction levels were very high.	It represents an excellent complement or an alternative to individual psycho-oncologic therapeutic support,
__label__noRel	This study demonstrates the feasibility and effectiveness of a psycho-educational intervention, which can accelerate the reduction of those negative affects which are present at the end of treatment.	We observed a significant reduction in anxiety (STAI, POMS) among group participants, a reduction in anger, depression and fatigue (POMS), a significant improvement in vigor and interpersonal relationships (POMS), in emotional and role functioning, in health status and fatigue level (EORTC QLQ-C30).
__label__noRel	This study demonstrates the feasibility and effectiveness of a psycho-educational intervention, which can accelerate the reduction of those negative affects which are present at the end of treatment.	coping strategies (MAC) were not significantly different between groups.
__label__noRel	This study demonstrates the feasibility and effectiveness of a psycho-educational intervention, which can accelerate the reduction of those negative affects which are present at the end of treatment.	No group-related negative effects were observed and the global satisfaction levels were very high.
__label__noRel	This study demonstrates the feasibility and effectiveness of a psycho-educational intervention, which can accelerate the reduction of those negative affects which are present at the end of treatment.	It represents an excellent complement or an alternative to individual psycho-oncologic therapeutic support,
__label__noRel	It represents an excellent complement or an alternative to individual psycho-oncologic therapeutic support,	We observed a significant reduction in anxiety (STAI, POMS) among group participants, a reduction in anger, depression and fatigue (POMS), a significant improvement in vigor and interpersonal relationships (POMS), in emotional and role functioning, in health status and fatigue level (EORTC QLQ-C30).
__label__noRel	It represents an excellent complement or an alternative to individual psycho-oncologic therapeutic support,	coping strategies (MAC) were not significantly different between groups.
__label__noRel	It represents an excellent complement or an alternative to individual psycho-oncologic therapeutic support,	No group-related negative effects were observed and the global satisfaction levels were very high.
__label__noRel	It represents an excellent complement or an alternative to individual psycho-oncologic therapeutic support,	This study demonstrates the feasibility and effectiveness of a psycho-educational intervention, which can accelerate the reduction of those negative affects which are present at the end of treatment.
__label__noRel	Urinary function declined when the IUS V285 was 0.4% (=-0.32, p=0.04);	bother worsened when the IUS V35 was 99% (=-0.31, p=0.05) or the EUS V240 was 63% (=-0.31, p=0.05);
__label__noRel	Urinary function declined when the IUS V285 was 0.4% (=-0.32, p=0.04);	irritation increased when the IUS V35 was 95% (=-0.37, p=0.02) and the EUS V265 was 24% (=-0.32, p=0.04);
__label__noRel	Urinary function declined when the IUS V285 was 0.4% (=-0.32, p=0.04);	urgency worsened when the IUS V35 was 99.5% (=-0.38, p=0.02).
__label__noRel	Urinary function declined when the IUS V285 was 0.4% (=-0.32, p=0.04);	Incontinence did not correlate with EUS or IUS dose.
__label__Support	Urinary function declined when the IUS V285 was 0.4% (=-0.32, p=0.04);	Doses to the IUS and EUS on MRI/CT predicted worse urinary function, with greater bother, irritative symptoms, and urgency.
__label__noRel	Urinary function declined when the IUS V285 was 0.4% (=-0.32, p=0.04);	Incorporating MRI-based dose-volume histogram analysis into the treatment planning process may reduce acute urinary morbidity after brachytherapy.
__label__noRel	bother worsened when the IUS V35 was 99% (=-0.31, p=0.05) or the EUS V240 was 63% (=-0.31, p=0.05);	Urinary function declined when the IUS V285 was 0.4% (=-0.32, p=0.04);
__label__noRel	bother worsened when the IUS V35 was 99% (=-0.31, p=0.05) or the EUS V240 was 63% (=-0.31, p=0.05);	irritation increased when the IUS V35 was 95% (=-0.37, p=0.02) and the EUS V265 was 24% (=-0.32, p=0.04);
__label__noRel	bother worsened when the IUS V35 was 99% (=-0.31, p=0.05) or the EUS V240 was 63% (=-0.31, p=0.05);	urgency worsened when the IUS V35 was 99.5% (=-0.38, p=0.02).
__label__noRel	bother worsened when the IUS V35 was 99% (=-0.31, p=0.05) or the EUS V240 was 63% (=-0.31, p=0.05);	Incontinence did not correlate with EUS or IUS dose.
__label__Support	bother worsened when the IUS V35 was 99% (=-0.31, p=0.05) or the EUS V240 was 63% (=-0.31, p=0.05);	Doses to the IUS and EUS on MRI/CT predicted worse urinary function, with greater bother, irritative symptoms, and urgency.
__label__noRel	bother worsened when the IUS V35 was 99% (=-0.31, p=0.05) or the EUS V240 was 63% (=-0.31, p=0.05);	Incorporating MRI-based dose-volume histogram analysis into the treatment planning process may reduce acute urinary morbidity after brachytherapy.
__label__noRel	irritation increased when the IUS V35 was 95% (=-0.37, p=0.02) and the EUS V265 was 24% (=-0.32, p=0.04);	Urinary function declined when the IUS V285 was 0.4% (=-0.32, p=0.04);
__label__noRel	irritation increased when the IUS V35 was 95% (=-0.37, p=0.02) and the EUS V265 was 24% (=-0.32, p=0.04);	bother worsened when the IUS V35 was 99% (=-0.31, p=0.05) or the EUS V240 was 63% (=-0.31, p=0.05);
__label__noRel	irritation increased when the IUS V35 was 95% (=-0.37, p=0.02) and the EUS V265 was 24% (=-0.32, p=0.04);	urgency worsened when the IUS V35 was 99.5% (=-0.38, p=0.02).
__label__noRel	irritation increased when the IUS V35 was 95% (=-0.37, p=0.02) and the EUS V265 was 24% (=-0.32, p=0.04);	Incontinence did not correlate with EUS or IUS dose.
__label__Support	irritation increased when the IUS V35 was 95% (=-0.37, p=0.02) and the EUS V265 was 24% (=-0.32, p=0.04);	Doses to the IUS and EUS on MRI/CT predicted worse urinary function, with greater bother, irritative symptoms, and urgency.
__label__noRel	irritation increased when the IUS V35 was 95% (=-0.37, p=0.02) and the EUS V265 was 24% (=-0.32, p=0.04);	Incorporating MRI-based dose-volume histogram analysis into the treatment planning process may reduce acute urinary morbidity after brachytherapy.
__label__noRel	urgency worsened when the IUS V35 was 99.5% (=-0.38, p=0.02).	Urinary function declined when the IUS V285 was 0.4% (=-0.32, p=0.04);
__label__noRel	urgency worsened when the IUS V35 was 99.5% (=-0.38, p=0.02).	bother worsened when the IUS V35 was 99% (=-0.31, p=0.05) or the EUS V240 was 63% (=-0.31, p=0.05);
__label__noRel	urgency worsened when the IUS V35 was 99.5% (=-0.38, p=0.02).	irritation increased when the IUS V35 was 95% (=-0.37, p=0.02) and the EUS V265 was 24% (=-0.32, p=0.04);
__label__noRel	urgency worsened when the IUS V35 was 99.5% (=-0.38, p=0.02).	Incontinence did not correlate with EUS or IUS dose.
__label__Support	urgency worsened when the IUS V35 was 99.5% (=-0.38, p=0.02).	Doses to the IUS and EUS on MRI/CT predicted worse urinary function, with greater bother, irritative symptoms, and urgency.
__label__noRel	urgency worsened when the IUS V35 was 99.5% (=-0.38, p=0.02).	Incorporating MRI-based dose-volume histogram analysis into the treatment planning process may reduce acute urinary morbidity after brachytherapy.
__label__noRel	Incontinence did not correlate with EUS or IUS dose.	Urinary function declined when the IUS V285 was 0.4% (=-0.32, p=0.04);
__label__noRel	Incontinence did not correlate with EUS or IUS dose.	bother worsened when the IUS V35 was 99% (=-0.31, p=0.05) or the EUS V240 was 63% (=-0.31, p=0.05);
__label__noRel	Incontinence did not correlate with EUS or IUS dose.	irritation increased when the IUS V35 was 95% (=-0.37, p=0.02) and the EUS V265 was 24% (=-0.32, p=0.04);
__label__noRel	Incontinence did not correlate with EUS or IUS dose.	urgency worsened when the IUS V35 was 99.5% (=-0.38, p=0.02).
__label__noRel	Incontinence did not correlate with EUS or IUS dose.	Doses to the IUS and EUS on MRI/CT predicted worse urinary function, with greater bother, irritative symptoms, and urgency.
__label__noRel	Incontinence did not correlate with EUS or IUS dose.	Incorporating MRI-based dose-volume histogram analysis into the treatment planning process may reduce acute urinary morbidity after brachytherapy.
__label__noRel	Doses to the IUS and EUS on MRI/CT predicted worse urinary function, with greater bother, irritative symptoms, and urgency.	Urinary function declined when the IUS V285 was 0.4% (=-0.32, p=0.04);
__label__noRel	Doses to the IUS and EUS on MRI/CT predicted worse urinary function, with greater bother, irritative symptoms, and urgency.	bother worsened when the IUS V35 was 99% (=-0.31, p=0.05) or the EUS V240 was 63% (=-0.31, p=0.05);
__label__noRel	Doses to the IUS and EUS on MRI/CT predicted worse urinary function, with greater bother, irritative symptoms, and urgency.	irritation increased when the IUS V35 was 95% (=-0.37, p=0.02) and the EUS V265 was 24% (=-0.32, p=0.04);
__label__noRel	Doses to the IUS and EUS on MRI/CT predicted worse urinary function, with greater bother, irritative symptoms, and urgency.	urgency worsened when the IUS V35 was 99.5% (=-0.38, p=0.02).
__label__noRel	Doses to the IUS and EUS on MRI/CT predicted worse urinary function, with greater bother, irritative symptoms, and urgency.	Incontinence did not correlate with EUS or IUS dose.
__label__Support	Doses to the IUS and EUS on MRI/CT predicted worse urinary function, with greater bother, irritative symptoms, and urgency.	Incorporating MRI-based dose-volume histogram analysis into the treatment planning process may reduce acute urinary morbidity after brachytherapy.
__label__noRel	Incorporating MRI-based dose-volume histogram analysis into the treatment planning process may reduce acute urinary morbidity after brachytherapy.	Urinary function declined when the IUS V285 was 0.4% (=-0.32, p=0.04);
__label__noRel	Incorporating MRI-based dose-volume histogram analysis into the treatment planning process may reduce acute urinary morbidity after brachytherapy.	bother worsened when the IUS V35 was 99% (=-0.31, p=0.05) or the EUS V240 was 63% (=-0.31, p=0.05);
__label__noRel	Incorporating MRI-based dose-volume histogram analysis into the treatment planning process may reduce acute urinary morbidity after brachytherapy.	irritation increased when the IUS V35 was 95% (=-0.37, p=0.02) and the EUS V265 was 24% (=-0.32, p=0.04);
__label__noRel	Incorporating MRI-based dose-volume histogram analysis into the treatment planning process may reduce acute urinary morbidity after brachytherapy.	urgency worsened when the IUS V35 was 99.5% (=-0.38, p=0.02).
__label__noRel	Incorporating MRI-based dose-volume histogram analysis into the treatment planning process may reduce acute urinary morbidity after brachytherapy.	Incontinence did not correlate with EUS or IUS dose.
__label__noRel	Incorporating MRI-based dose-volume histogram analysis into the treatment planning process may reduce acute urinary morbidity after brachytherapy.	Doses to the IUS and EUS on MRI/CT predicted worse urinary function, with greater bother, irritative symptoms, and urgency.
__label__noRel	Tamoxifen reduced the risk of invasive breast cancer by 49% (two-sided P<.00001), with cumulative incidence through 69 months of follow-up of 43.4 versus 22.0 per 1000 women in the placebo and tamoxifen groups, respectively.	risk was also reduced in women with a history of lobular carcinoma in situ (56%) or atypical hyperplasia (86%) and in those with any category of predicted 5-year risk.
__label__noRel	Tamoxifen reduced the risk of invasive breast cancer by 49% (two-sided P<.00001), with cumulative incidence through 69 months of follow-up of 43.4 versus 22.0 per 1000 women in the placebo and tamoxifen groups, respectively.	Tamoxifen reduced the risk of noninvasive breast cancer by 50% (two-sided P<.002).
__label__noRel	Tamoxifen reduced the risk of invasive breast cancer by 49% (two-sided P<.00001), with cumulative incidence through 69 months of follow-up of 43.4 versus 22.0 per 1000 women in the placebo and tamoxifen groups, respectively.	Tamoxifen reduced the occurrence of estrogen receptor-positive tumors by 69%, but no difference in the occurrence of estrogen receptor-negative tumors was seen.
__label__noRel	Tamoxifen reduced the risk of invasive breast cancer by 49% (two-sided P<.00001), with cumulative incidence through 69 months of follow-up of 43.4 versus 22.0 per 1000 women in the placebo and tamoxifen groups, respectively.	Tamoxifen administration did not alter the average annual rate of ischemic heart disease; however, a reduction in hip, radius (Colles'), and spine fractures was observed.
__label__noRel	Tamoxifen reduced the risk of invasive breast cancer by 49% (two-sided P<.00001), with cumulative incidence through 69 months of follow-up of 43.4 versus 22.0 per 1000 women in the placebo and tamoxifen groups, respectively.	The rate of endometrial cancer was increased in the tamoxifen group (risk ratio = 2.53; 95% confidence interval = 1.35-4.97); this increased risk occurred predominantly in women aged 50 years or older.
__label__noRel	Tamoxifen reduced the risk of invasive breast cancer by 49% (two-sided P<.00001), with cumulative incidence through 69 months of follow-up of 43.4 versus 22.0 per 1000 women in the placebo and tamoxifen groups, respectively.	no endometrial cancer deaths have occurred in this group.
__label__noRel	Tamoxifen reduced the risk of invasive breast cancer by 49% (two-sided P<.00001), with cumulative incidence through 69 months of follow-up of 43.4 versus 22.0 per 1000 women in the placebo and tamoxifen groups, respectively.	No liver cancers or increase in colon, rectal, ovarian, or other tumors was observed in the tamoxifen group.
__label__noRel	Tamoxifen reduced the risk of invasive breast cancer by 49% (two-sided P<.00001), with cumulative incidence through 69 months of follow-up of 43.4 versus 22.0 per 1000 women in the placebo and tamoxifen groups, respectively.	The rates of stroke, pulmonary embolism, and deep-vein thrombosis were elevated in the tamoxifen group; these events occurred more frequently in women aged 50 years or older.
__label__Support	Tamoxifen reduced the risk of invasive breast cancer by 49% (two-sided P<.00001), with cumulative incidence through 69 months of follow-up of 43.4 versus 22.0 per 1000 women in the placebo and tamoxifen groups, respectively.	Tamoxifen decreases the incidence of invasive and noninvasive breast cancer.
__label__noRel	Tamoxifen reduced the risk of invasive breast cancer by 49% (two-sided P<.00001), with cumulative incidence through 69 months of follow-up of 43.4 versus 22.0 per 1000 women in the placebo and tamoxifen groups, respectively.	Despite side effects resulting from administration of tamoxifen, its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.
__label__noRel	risk was also reduced in women with a history of lobular carcinoma in situ (56%) or atypical hyperplasia (86%) and in those with any category of predicted 5-year risk.	Tamoxifen reduced the risk of invasive breast cancer by 49% (two-sided P<.00001), with cumulative incidence through 69 months of follow-up of 43.4 versus 22.0 per 1000 women in the placebo and tamoxifen groups, respectively.
__label__noRel	risk was also reduced in women with a history of lobular carcinoma in situ (56%) or atypical hyperplasia (86%) and in those with any category of predicted 5-year risk.	Tamoxifen reduced the risk of noninvasive breast cancer by 50% (two-sided P<.002).
__label__noRel	risk was also reduced in women with a history of lobular carcinoma in situ (56%) or atypical hyperplasia (86%) and in those with any category of predicted 5-year risk.	Tamoxifen reduced the occurrence of estrogen receptor-positive tumors by 69%, but no difference in the occurrence of estrogen receptor-negative tumors was seen.
__label__noRel	risk was also reduced in women with a history of lobular carcinoma in situ (56%) or atypical hyperplasia (86%) and in those with any category of predicted 5-year risk.	Tamoxifen administration did not alter the average annual rate of ischemic heart disease; however, a reduction in hip, radius (Colles'), and spine fractures was observed.
__label__noRel	risk was also reduced in women with a history of lobular carcinoma in situ (56%) or atypical hyperplasia (86%) and in those with any category of predicted 5-year risk.	The rate of endometrial cancer was increased in the tamoxifen group (risk ratio = 2.53; 95% confidence interval = 1.35-4.97); this increased risk occurred predominantly in women aged 50 years or older.
__label__noRel	risk was also reduced in women with a history of lobular carcinoma in situ (56%) or atypical hyperplasia (86%) and in those with any category of predicted 5-year risk.	no endometrial cancer deaths have occurred in this group.
__label__noRel	risk was also reduced in women with a history of lobular carcinoma in situ (56%) or atypical hyperplasia (86%) and in those with any category of predicted 5-year risk.	No liver cancers or increase in colon, rectal, ovarian, or other tumors was observed in the tamoxifen group.
__label__noRel	risk was also reduced in women with a history of lobular carcinoma in situ (56%) or atypical hyperplasia (86%) and in those with any category of predicted 5-year risk.	The rates of stroke, pulmonary embolism, and deep-vein thrombosis were elevated in the tamoxifen group; these events occurred more frequently in women aged 50 years or older.
__label__noRel	risk was also reduced in women with a history of lobular carcinoma in situ (56%) or atypical hyperplasia (86%) and in those with any category of predicted 5-year risk.	Tamoxifen decreases the incidence of invasive and noninvasive breast cancer.
__label__Support	risk was also reduced in women with a history of lobular carcinoma in situ (56%) or atypical hyperplasia (86%) and in those with any category of predicted 5-year risk.	Despite side effects resulting from administration of tamoxifen, its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.
__label__noRel	Tamoxifen reduced the risk of noninvasive breast cancer by 50% (two-sided P<.002).	Tamoxifen reduced the risk of invasive breast cancer by 49% (two-sided P<.00001), with cumulative incidence through 69 months of follow-up of 43.4 versus 22.0 per 1000 women in the placebo and tamoxifen groups, respectively.
__label__noRel	Tamoxifen reduced the risk of noninvasive breast cancer by 50% (two-sided P<.002).	risk was also reduced in women with a history of lobular carcinoma in situ (56%) or atypical hyperplasia (86%) and in those with any category of predicted 5-year risk.
__label__noRel	Tamoxifen reduced the risk of noninvasive breast cancer by 50% (two-sided P<.002).	Tamoxifen reduced the occurrence of estrogen receptor-positive tumors by 69%, but no difference in the occurrence of estrogen receptor-negative tumors was seen.
__label__noRel	Tamoxifen reduced the risk of noninvasive breast cancer by 50% (two-sided P<.002).	Tamoxifen administration did not alter the average annual rate of ischemic heart disease; however, a reduction in hip, radius (Colles'), and spine fractures was observed.
__label__noRel	Tamoxifen reduced the risk of noninvasive breast cancer by 50% (two-sided P<.002).	The rate of endometrial cancer was increased in the tamoxifen group (risk ratio = 2.53; 95% confidence interval = 1.35-4.97); this increased risk occurred predominantly in women aged 50 years or older.
__label__noRel	Tamoxifen reduced the risk of noninvasive breast cancer by 50% (two-sided P<.002).	no endometrial cancer deaths have occurred in this group.
__label__noRel	Tamoxifen reduced the risk of noninvasive breast cancer by 50% (two-sided P<.002).	No liver cancers or increase in colon, rectal, ovarian, or other tumors was observed in the tamoxifen group.
__label__noRel	Tamoxifen reduced the risk of noninvasive breast cancer by 50% (two-sided P<.002).	The rates of stroke, pulmonary embolism, and deep-vein thrombosis were elevated in the tamoxifen group; these events occurred more frequently in women aged 50 years or older.
__label__Support	Tamoxifen reduced the risk of noninvasive breast cancer by 50% (two-sided P<.002).	Tamoxifen decreases the incidence of invasive and noninvasive breast cancer.
__label__noRel	Tamoxifen reduced the risk of noninvasive breast cancer by 50% (two-sided P<.002).	Despite side effects resulting from administration of tamoxifen, its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.
__label__noRel	Tamoxifen reduced the occurrence of estrogen receptor-positive tumors by 69%, but no difference in the occurrence of estrogen receptor-negative tumors was seen.	Tamoxifen reduced the risk of invasive breast cancer by 49% (two-sided P<.00001), with cumulative incidence through 69 months of follow-up of 43.4 versus 22.0 per 1000 women in the placebo and tamoxifen groups, respectively.
__label__noRel	Tamoxifen reduced the occurrence of estrogen receptor-positive tumors by 69%, but no difference in the occurrence of estrogen receptor-negative tumors was seen.	risk was also reduced in women with a history of lobular carcinoma in situ (56%) or atypical hyperplasia (86%) and in those with any category of predicted 5-year risk.
__label__noRel	Tamoxifen reduced the occurrence of estrogen receptor-positive tumors by 69%, but no difference in the occurrence of estrogen receptor-negative tumors was seen.	Tamoxifen reduced the risk of noninvasive breast cancer by 50% (two-sided P<.002).
__label__noRel	Tamoxifen reduced the occurrence of estrogen receptor-positive tumors by 69%, but no difference in the occurrence of estrogen receptor-negative tumors was seen.	Tamoxifen administration did not alter the average annual rate of ischemic heart disease; however, a reduction in hip, radius (Colles'), and spine fractures was observed.
__label__noRel	Tamoxifen reduced the occurrence of estrogen receptor-positive tumors by 69%, but no difference in the occurrence of estrogen receptor-negative tumors was seen.	The rate of endometrial cancer was increased in the tamoxifen group (risk ratio = 2.53; 95% confidence interval = 1.35-4.97); this increased risk occurred predominantly in women aged 50 years or older.
__label__noRel	Tamoxifen reduced the occurrence of estrogen receptor-positive tumors by 69%, but no difference in the occurrence of estrogen receptor-negative tumors was seen.	no endometrial cancer deaths have occurred in this group.
__label__noRel	Tamoxifen reduced the occurrence of estrogen receptor-positive tumors by 69%, but no difference in the occurrence of estrogen receptor-negative tumors was seen.	No liver cancers or increase in colon, rectal, ovarian, or other tumors was observed in the tamoxifen group.
__label__noRel	Tamoxifen reduced the occurrence of estrogen receptor-positive tumors by 69%, but no difference in the occurrence of estrogen receptor-negative tumors was seen.	The rates of stroke, pulmonary embolism, and deep-vein thrombosis were elevated in the tamoxifen group; these events occurred more frequently in women aged 50 years or older.
__label__noRel	Tamoxifen reduced the occurrence of estrogen receptor-positive tumors by 69%, but no difference in the occurrence of estrogen receptor-negative tumors was seen.	Tamoxifen decreases the incidence of invasive and noninvasive breast cancer.
__label__Support	Tamoxifen reduced the occurrence of estrogen receptor-positive tumors by 69%, but no difference in the occurrence of estrogen receptor-negative tumors was seen.	Despite side effects resulting from administration of tamoxifen, its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.
__label__noRel	Tamoxifen administration did not alter the average annual rate of ischemic heart disease; however, a reduction in hip, radius (Colles'), and spine fractures was observed.	Tamoxifen reduced the risk of invasive breast cancer by 49% (two-sided P<.00001), with cumulative incidence through 69 months of follow-up of 43.4 versus 22.0 per 1000 women in the placebo and tamoxifen groups, respectively.
__label__noRel	Tamoxifen administration did not alter the average annual rate of ischemic heart disease; however, a reduction in hip, radius (Colles'), and spine fractures was observed.	risk was also reduced in women with a history of lobular carcinoma in situ (56%) or atypical hyperplasia (86%) and in those with any category of predicted 5-year risk.
__label__noRel	Tamoxifen administration did not alter the average annual rate of ischemic heart disease; however, a reduction in hip, radius (Colles'), and spine fractures was observed.	Tamoxifen reduced the risk of noninvasive breast cancer by 50% (two-sided P<.002).
__label__noRel	Tamoxifen administration did not alter the average annual rate of ischemic heart disease; however, a reduction in hip, radius (Colles'), and spine fractures was observed.	Tamoxifen reduced the occurrence of estrogen receptor-positive tumors by 69%, but no difference in the occurrence of estrogen receptor-negative tumors was seen.
__label__noRel	Tamoxifen administration did not alter the average annual rate of ischemic heart disease; however, a reduction in hip, radius (Colles'), and spine fractures was observed.	The rate of endometrial cancer was increased in the tamoxifen group (risk ratio = 2.53; 95% confidence interval = 1.35-4.97); this increased risk occurred predominantly in women aged 50 years or older.
__label__noRel	Tamoxifen administration did not alter the average annual rate of ischemic heart disease; however, a reduction in hip, radius (Colles'), and spine fractures was observed.	no endometrial cancer deaths have occurred in this group.
__label__noRel	Tamoxifen administration did not alter the average annual rate of ischemic heart disease; however, a reduction in hip, radius (Colles'), and spine fractures was observed.	No liver cancers or increase in colon, rectal, ovarian, or other tumors was observed in the tamoxifen group.
__label__noRel	Tamoxifen administration did not alter the average annual rate of ischemic heart disease; however, a reduction in hip, radius (Colles'), and spine fractures was observed.	The rates of stroke, pulmonary embolism, and deep-vein thrombosis were elevated in the tamoxifen group; these events occurred more frequently in women aged 50 years or older.
__label__noRel	Tamoxifen administration did not alter the average annual rate of ischemic heart disease; however, a reduction in hip, radius (Colles'), and spine fractures was observed.	Tamoxifen decreases the incidence of invasive and noninvasive breast cancer.
__label__Support	Tamoxifen administration did not alter the average annual rate of ischemic heart disease; however, a reduction in hip, radius (Colles'), and spine fractures was observed.	Despite side effects resulting from administration of tamoxifen, its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.
__label__noRel	The rate of endometrial cancer was increased in the tamoxifen group (risk ratio = 2.53; 95% confidence interval = 1.35-4.97); this increased risk occurred predominantly in women aged 50 years or older.	Tamoxifen reduced the risk of invasive breast cancer by 49% (two-sided P<.00001), with cumulative incidence through 69 months of follow-up of 43.4 versus 22.0 per 1000 women in the placebo and tamoxifen groups, respectively.
__label__noRel	The rate of endometrial cancer was increased in the tamoxifen group (risk ratio = 2.53; 95% confidence interval = 1.35-4.97); this increased risk occurred predominantly in women aged 50 years or older.	risk was also reduced in women with a history of lobular carcinoma in situ (56%) or atypical hyperplasia (86%) and in those with any category of predicted 5-year risk.
__label__noRel	The rate of endometrial cancer was increased in the tamoxifen group (risk ratio = 2.53; 95% confidence interval = 1.35-4.97); this increased risk occurred predominantly in women aged 50 years or older.	Tamoxifen reduced the risk of noninvasive breast cancer by 50% (two-sided P<.002).
__label__noRel	The rate of endometrial cancer was increased in the tamoxifen group (risk ratio = 2.53; 95% confidence interval = 1.35-4.97); this increased risk occurred predominantly in women aged 50 years or older.	Tamoxifen reduced the occurrence of estrogen receptor-positive tumors by 69%, but no difference in the occurrence of estrogen receptor-negative tumors was seen.
__label__noRel	The rate of endometrial cancer was increased in the tamoxifen group (risk ratio = 2.53; 95% confidence interval = 1.35-4.97); this increased risk occurred predominantly in women aged 50 years or older.	Tamoxifen administration did not alter the average annual rate of ischemic heart disease; however, a reduction in hip, radius (Colles'), and spine fractures was observed.
__label__noRel	The rate of endometrial cancer was increased in the tamoxifen group (risk ratio = 2.53; 95% confidence interval = 1.35-4.97); this increased risk occurred predominantly in women aged 50 years or older.	no endometrial cancer deaths have occurred in this group.
__label__noRel	The rate of endometrial cancer was increased in the tamoxifen group (risk ratio = 2.53; 95% confidence interval = 1.35-4.97); this increased risk occurred predominantly in women aged 50 years or older.	No liver cancers or increase in colon, rectal, ovarian, or other tumors was observed in the tamoxifen group.
__label__noRel	The rate of endometrial cancer was increased in the tamoxifen group (risk ratio = 2.53; 95% confidence interval = 1.35-4.97); this increased risk occurred predominantly in women aged 50 years or older.	The rates of stroke, pulmonary embolism, and deep-vein thrombosis were elevated in the tamoxifen group; these events occurred more frequently in women aged 50 years or older.
__label__noRel	The rate of endometrial cancer was increased in the tamoxifen group (risk ratio = 2.53; 95% confidence interval = 1.35-4.97); this increased risk occurred predominantly in women aged 50 years or older.	Tamoxifen decreases the incidence of invasive and noninvasive breast cancer.
__label__Attack	The rate of endometrial cancer was increased in the tamoxifen group (risk ratio = 2.53; 95% confidence interval = 1.35-4.97); this increased risk occurred predominantly in women aged 50 years or older.	Despite side effects resulting from administration of tamoxifen, its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.
__label__noRel	no endometrial cancer deaths have occurred in this group.	Tamoxifen reduced the risk of invasive breast cancer by 49% (two-sided P<.00001), with cumulative incidence through 69 months of follow-up of 43.4 versus 22.0 per 1000 women in the placebo and tamoxifen groups, respectively.
__label__noRel	no endometrial cancer deaths have occurred in this group.	risk was also reduced in women with a history of lobular carcinoma in situ (56%) or atypical hyperplasia (86%) and in those with any category of predicted 5-year risk.
__label__noRel	no endometrial cancer deaths have occurred in this group.	Tamoxifen reduced the risk of noninvasive breast cancer by 50% (two-sided P<.002).
__label__noRel	no endometrial cancer deaths have occurred in this group.	Tamoxifen reduced the occurrence of estrogen receptor-positive tumors by 69%, but no difference in the occurrence of estrogen receptor-negative tumors was seen.
__label__noRel	no endometrial cancer deaths have occurred in this group.	Tamoxifen administration did not alter the average annual rate of ischemic heart disease; however, a reduction in hip, radius (Colles'), and spine fractures was observed.
__label__Attack	no endometrial cancer deaths have occurred in this group.	The rate of endometrial cancer was increased in the tamoxifen group (risk ratio = 2.53; 95% confidence interval = 1.35-4.97); this increased risk occurred predominantly in women aged 50 years or older.
__label__noRel	no endometrial cancer deaths have occurred in this group.	No liver cancers or increase in colon, rectal, ovarian, or other tumors was observed in the tamoxifen group.
__label__noRel	no endometrial cancer deaths have occurred in this group.	The rates of stroke, pulmonary embolism, and deep-vein thrombosis were elevated in the tamoxifen group; these events occurred more frequently in women aged 50 years or older.
__label__noRel	no endometrial cancer deaths have occurred in this group.	Tamoxifen decreases the incidence of invasive and noninvasive breast cancer.
__label__noRel	no endometrial cancer deaths have occurred in this group.	Despite side effects resulting from administration of tamoxifen, its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.
__label__noRel	No liver cancers or increase in colon, rectal, ovarian, or other tumors was observed in the tamoxifen group.	Tamoxifen reduced the risk of invasive breast cancer by 49% (two-sided P<.00001), with cumulative incidence through 69 months of follow-up of 43.4 versus 22.0 per 1000 women in the placebo and tamoxifen groups, respectively.
__label__noRel	No liver cancers or increase in colon, rectal, ovarian, or other tumors was observed in the tamoxifen group.	risk was also reduced in women with a history of lobular carcinoma in situ (56%) or atypical hyperplasia (86%) and in those with any category of predicted 5-year risk.
__label__noRel	No liver cancers or increase in colon, rectal, ovarian, or other tumors was observed in the tamoxifen group.	Tamoxifen reduced the risk of noninvasive breast cancer by 50% (two-sided P<.002).
__label__noRel	No liver cancers or increase in colon, rectal, ovarian, or other tumors was observed in the tamoxifen group.	Tamoxifen reduced the occurrence of estrogen receptor-positive tumors by 69%, but no difference in the occurrence of estrogen receptor-negative tumors was seen.
__label__noRel	No liver cancers or increase in colon, rectal, ovarian, or other tumors was observed in the tamoxifen group.	Tamoxifen administration did not alter the average annual rate of ischemic heart disease; however, a reduction in hip, radius (Colles'), and spine fractures was observed.
__label__noRel	No liver cancers or increase in colon, rectal, ovarian, or other tumors was observed in the tamoxifen group.	The rate of endometrial cancer was increased in the tamoxifen group (risk ratio = 2.53; 95% confidence interval = 1.35-4.97); this increased risk occurred predominantly in women aged 50 years or older.
__label__noRel	No liver cancers or increase in colon, rectal, ovarian, or other tumors was observed in the tamoxifen group.	no endometrial cancer deaths have occurred in this group.
__label__noRel	No liver cancers or increase in colon, rectal, ovarian, or other tumors was observed in the tamoxifen group.	The rates of stroke, pulmonary embolism, and deep-vein thrombosis were elevated in the tamoxifen group; these events occurred more frequently in women aged 50 years or older.
__label__noRel	No liver cancers or increase in colon, rectal, ovarian, or other tumors was observed in the tamoxifen group.	Tamoxifen decreases the incidence of invasive and noninvasive breast cancer.
__label__Support	No liver cancers or increase in colon, rectal, ovarian, or other tumors was observed in the tamoxifen group.	Despite side effects resulting from administration of tamoxifen, its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.
__label__noRel	The rates of stroke, pulmonary embolism, and deep-vein thrombosis were elevated in the tamoxifen group; these events occurred more frequently in women aged 50 years or older.	Tamoxifen reduced the risk of invasive breast cancer by 49% (two-sided P<.00001), with cumulative incidence through 69 months of follow-up of 43.4 versus 22.0 per 1000 women in the placebo and tamoxifen groups, respectively.
__label__noRel	The rates of stroke, pulmonary embolism, and deep-vein thrombosis were elevated in the tamoxifen group; these events occurred more frequently in women aged 50 years or older.	risk was also reduced in women with a history of lobular carcinoma in situ (56%) or atypical hyperplasia (86%) and in those with any category of predicted 5-year risk.
__label__noRel	The rates of stroke, pulmonary embolism, and deep-vein thrombosis were elevated in the tamoxifen group; these events occurred more frequently in women aged 50 years or older.	Tamoxifen reduced the risk of noninvasive breast cancer by 50% (two-sided P<.002).
__label__noRel	The rates of stroke, pulmonary embolism, and deep-vein thrombosis were elevated in the tamoxifen group; these events occurred more frequently in women aged 50 years or older.	Tamoxifen reduced the occurrence of estrogen receptor-positive tumors by 69%, but no difference in the occurrence of estrogen receptor-negative tumors was seen.
__label__noRel	The rates of stroke, pulmonary embolism, and deep-vein thrombosis were elevated in the tamoxifen group; these events occurred more frequently in women aged 50 years or older.	Tamoxifen administration did not alter the average annual rate of ischemic heart disease; however, a reduction in hip, radius (Colles'), and spine fractures was observed.
__label__noRel	The rates of stroke, pulmonary embolism, and deep-vein thrombosis were elevated in the tamoxifen group; these events occurred more frequently in women aged 50 years or older.	The rate of endometrial cancer was increased in the tamoxifen group (risk ratio = 2.53; 95% confidence interval = 1.35-4.97); this increased risk occurred predominantly in women aged 50 years or older.
__label__noRel	The rates of stroke, pulmonary embolism, and deep-vein thrombosis were elevated in the tamoxifen group; these events occurred more frequently in women aged 50 years or older.	no endometrial cancer deaths have occurred in this group.
__label__noRel	The rates of stroke, pulmonary embolism, and deep-vein thrombosis were elevated in the tamoxifen group; these events occurred more frequently in women aged 50 years or older.	No liver cancers or increase in colon, rectal, ovarian, or other tumors was observed in the tamoxifen group.
__label__noRel	The rates of stroke, pulmonary embolism, and deep-vein thrombosis were elevated in the tamoxifen group; these events occurred more frequently in women aged 50 years or older.	Tamoxifen decreases the incidence of invasive and noninvasive breast cancer.
__label__Support	The rates of stroke, pulmonary embolism, and deep-vein thrombosis were elevated in the tamoxifen group; these events occurred more frequently in women aged 50 years or older.	Despite side effects resulting from administration of tamoxifen, its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.
__label__noRel	Tamoxifen decreases the incidence of invasive and noninvasive breast cancer.	Tamoxifen reduced the risk of invasive breast cancer by 49% (two-sided P<.00001), with cumulative incidence through 69 months of follow-up of 43.4 versus 22.0 per 1000 women in the placebo and tamoxifen groups, respectively.
__label__noRel	Tamoxifen decreases the incidence of invasive and noninvasive breast cancer.	risk was also reduced in women with a history of lobular carcinoma in situ (56%) or atypical hyperplasia (86%) and in those with any category of predicted 5-year risk.
__label__noRel	Tamoxifen decreases the incidence of invasive and noninvasive breast cancer.	Tamoxifen reduced the risk of noninvasive breast cancer by 50% (two-sided P<.002).
__label__noRel	Tamoxifen decreases the incidence of invasive and noninvasive breast cancer.	Tamoxifen reduced the occurrence of estrogen receptor-positive tumors by 69%, but no difference in the occurrence of estrogen receptor-negative tumors was seen.
__label__noRel	Tamoxifen decreases the incidence of invasive and noninvasive breast cancer.	Tamoxifen administration did not alter the average annual rate of ischemic heart disease; however, a reduction in hip, radius (Colles'), and spine fractures was observed.
__label__noRel	Tamoxifen decreases the incidence of invasive and noninvasive breast cancer.	The rate of endometrial cancer was increased in the tamoxifen group (risk ratio = 2.53; 95% confidence interval = 1.35-4.97); this increased risk occurred predominantly in women aged 50 years or older.
__label__noRel	Tamoxifen decreases the incidence of invasive and noninvasive breast cancer.	no endometrial cancer deaths have occurred in this group.
__label__noRel	Tamoxifen decreases the incidence of invasive and noninvasive breast cancer.	No liver cancers or increase in colon, rectal, ovarian, or other tumors was observed in the tamoxifen group.
__label__noRel	Tamoxifen decreases the incidence of invasive and noninvasive breast cancer.	The rates of stroke, pulmonary embolism, and deep-vein thrombosis were elevated in the tamoxifen group; these events occurred more frequently in women aged 50 years or older.
__label__Support	Tamoxifen decreases the incidence of invasive and noninvasive breast cancer.	Despite side effects resulting from administration of tamoxifen, its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.
__label__noRel	Despite side effects resulting from administration of tamoxifen, its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.	Tamoxifen reduced the risk of invasive breast cancer by 49% (two-sided P<.00001), with cumulative incidence through 69 months of follow-up of 43.4 versus 22.0 per 1000 women in the placebo and tamoxifen groups, respectively.
__label__noRel	Despite side effects resulting from administration of tamoxifen, its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.	risk was also reduced in women with a history of lobular carcinoma in situ (56%) or atypical hyperplasia (86%) and in those with any category of predicted 5-year risk.
__label__noRel	Despite side effects resulting from administration of tamoxifen, its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.	Tamoxifen reduced the risk of noninvasive breast cancer by 50% (two-sided P<.002).
__label__noRel	Despite side effects resulting from administration of tamoxifen, its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.	Tamoxifen reduced the occurrence of estrogen receptor-positive tumors by 69%, but no difference in the occurrence of estrogen receptor-negative tumors was seen.
__label__noRel	Despite side effects resulting from administration of tamoxifen, its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.	Tamoxifen administration did not alter the average annual rate of ischemic heart disease; however, a reduction in hip, radius (Colles'), and spine fractures was observed.
__label__noRel	Despite side effects resulting from administration of tamoxifen, its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.	The rate of endometrial cancer was increased in the tamoxifen group (risk ratio = 2.53; 95% confidence interval = 1.35-4.97); this increased risk occurred predominantly in women aged 50 years or older.
__label__noRel	Despite side effects resulting from administration of tamoxifen, its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.	no endometrial cancer deaths have occurred in this group.
__label__noRel	Despite side effects resulting from administration of tamoxifen, its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.	No liver cancers or increase in colon, rectal, ovarian, or other tumors was observed in the tamoxifen group.
__label__noRel	Despite side effects resulting from administration of tamoxifen, its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.	The rates of stroke, pulmonary embolism, and deep-vein thrombosis were elevated in the tamoxifen group; these events occurred more frequently in women aged 50 years or older.
__label__noRel	Despite side effects resulting from administration of tamoxifen, its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.	Tamoxifen decreases the incidence of invasive and noninvasive breast cancer.
__label__noRel	No significant differences were noted in the distress levels before and after completion of the study in the three groups.	For the secondary outcomes, patients reported that dignity therapy was significantly more likely than the other two interventions to have been helpful ((2)=3550, df=2; p<00001), improve quality of life ((2)=1452; p=0001), increase sense of dignity ((2)=1266; p=0002), change how their family saw and appreciated them ((2)=3381; p<00001), and be helpful to their family ((2)=3386; p<00001).
__label__noRel	No significant differences were noted in the distress levels before and after completion of the study in the three groups.	Dignity therapy was significantly better than client-centred care in improving spiritual wellbeing ((2)=1035; p=0006), and was significantly better than standard palliative care in terms of lessening sadness or depression ((2)=938; p=0009);
__label__noRel	No significant differences were noted in the distress levels before and after completion of the study in the three groups.	significantly more patients who had received dignity therapy reported that the study group had been satisfactory, compared with those who received standard palliative care ((2)=2958; p<00001).
__label__Support	No significant differences were noted in the distress levels before and after completion of the study in the three groups.	Although the ability of dignity therapy to mitigate outright distress, such as depression, desire for death or suicidality, has yet to be proven,
__label__noRel	No significant differences were noted in the distress levels before and after completion of the study in the three groups.	its benefits in terms of self-reported end-of-life experiences support its clinical application for patients nearing death.
__label__noRel	For the secondary outcomes, patients reported that dignity therapy was significantly more likely than the other two interventions to have been helpful ((2)=3550, df=2; p<00001), improve quality of life ((2)=1452; p=0001), increase sense of dignity ((2)=1266; p=0002), change how their family saw and appreciated them ((2)=3381; p<00001), and be helpful to their family ((2)=3386; p<00001).	No significant differences were noted in the distress levels before and after completion of the study in the three groups.
__label__noRel	For the secondary outcomes, patients reported that dignity therapy was significantly more likely than the other two interventions to have been helpful ((2)=3550, df=2; p<00001), improve quality of life ((2)=1452; p=0001), increase sense of dignity ((2)=1266; p=0002), change how their family saw and appreciated them ((2)=3381; p<00001), and be helpful to their family ((2)=3386; p<00001).	Dignity therapy was significantly better than client-centred care in improving spiritual wellbeing ((2)=1035; p=0006), and was significantly better than standard palliative care in terms of lessening sadness or depression ((2)=938; p=0009);
__label__noRel	For the secondary outcomes, patients reported that dignity therapy was significantly more likely than the other two interventions to have been helpful ((2)=3550, df=2; p<00001), improve quality of life ((2)=1452; p=0001), increase sense of dignity ((2)=1266; p=0002), change how their family saw and appreciated them ((2)=3381; p<00001), and be helpful to their family ((2)=3386; p<00001).	significantly more patients who had received dignity therapy reported that the study group had been satisfactory, compared with those who received standard palliative care ((2)=2958; p<00001).
__label__Support	For the secondary outcomes, patients reported that dignity therapy was significantly more likely than the other two interventions to have been helpful ((2)=3550, df=2; p<00001), improve quality of life ((2)=1452; p=0001), increase sense of dignity ((2)=1266; p=0002), change how their family saw and appreciated them ((2)=3381; p<00001), and be helpful to their family ((2)=3386; p<00001).	Although the ability of dignity therapy to mitigate outright distress, such as depression, desire for death or suicidality, has yet to be proven,
__label__noRel	For the secondary outcomes, patients reported that dignity therapy was significantly more likely than the other two interventions to have been helpful ((2)=3550, df=2; p<00001), improve quality of life ((2)=1452; p=0001), increase sense of dignity ((2)=1266; p=0002), change how their family saw and appreciated them ((2)=3381; p<00001), and be helpful to their family ((2)=3386; p<00001).	its benefits in terms of self-reported end-of-life experiences support its clinical application for patients nearing death.
__label__noRel	Dignity therapy was significantly better than client-centred care in improving spiritual wellbeing ((2)=1035; p=0006), and was significantly better than standard palliative care in terms of lessening sadness or depression ((2)=938; p=0009);	No significant differences were noted in the distress levels before and after completion of the study in the three groups.
__label__noRel	Dignity therapy was significantly better than client-centred care in improving spiritual wellbeing ((2)=1035; p=0006), and was significantly better than standard palliative care in terms of lessening sadness or depression ((2)=938; p=0009);	For the secondary outcomes, patients reported that dignity therapy was significantly more likely than the other two interventions to have been helpful ((2)=3550, df=2; p<00001), improve quality of life ((2)=1452; p=0001), increase sense of dignity ((2)=1266; p=0002), change how their family saw and appreciated them ((2)=3381; p<00001), and be helpful to their family ((2)=3386; p<00001).
__label__noRel	Dignity therapy was significantly better than client-centred care in improving spiritual wellbeing ((2)=1035; p=0006), and was significantly better than standard palliative care in terms of lessening sadness or depression ((2)=938; p=0009);	significantly more patients who had received dignity therapy reported that the study group had been satisfactory, compared with those who received standard palliative care ((2)=2958; p<00001).
__label__noRel	Dignity therapy was significantly better than client-centred care in improving spiritual wellbeing ((2)=1035; p=0006), and was significantly better than standard palliative care in terms of lessening sadness or depression ((2)=938; p=0009);	Although the ability of dignity therapy to mitigate outright distress, such as depression, desire for death or suicidality, has yet to be proven,
__label__Support	Dignity therapy was significantly better than client-centred care in improving spiritual wellbeing ((2)=1035; p=0006), and was significantly better than standard palliative care in terms of lessening sadness or depression ((2)=938; p=0009);	its benefits in terms of self-reported end-of-life experiences support its clinical application for patients nearing death.
__label__noRel	significantly more patients who had received dignity therapy reported that the study group had been satisfactory, compared with those who received standard palliative care ((2)=2958; p<00001).	No significant differences were noted in the distress levels before and after completion of the study in the three groups.
__label__noRel	significantly more patients who had received dignity therapy reported that the study group had been satisfactory, compared with those who received standard palliative care ((2)=2958; p<00001).	For the secondary outcomes, patients reported that dignity therapy was significantly more likely than the other two interventions to have been helpful ((2)=3550, df=2; p<00001), improve quality of life ((2)=1452; p=0001), increase sense of dignity ((2)=1266; p=0002), change how their family saw and appreciated them ((2)=3381; p<00001), and be helpful to their family ((2)=3386; p<00001).
__label__noRel	significantly more patients who had received dignity therapy reported that the study group had been satisfactory, compared with those who received standard palliative care ((2)=2958; p<00001).	Dignity therapy was significantly better than client-centred care in improving spiritual wellbeing ((2)=1035; p=0006), and was significantly better than standard palliative care in terms of lessening sadness or depression ((2)=938; p=0009);
__label__noRel	significantly more patients who had received dignity therapy reported that the study group had been satisfactory, compared with those who received standard palliative care ((2)=2958; p<00001).	Although the ability of dignity therapy to mitigate outright distress, such as depression, desire for death or suicidality, has yet to be proven,
__label__Support	significantly more patients who had received dignity therapy reported that the study group had been satisfactory, compared with those who received standard palliative care ((2)=2958; p<00001).	its benefits in terms of self-reported end-of-life experiences support its clinical application for patients nearing death.
__label__noRel	Although the ability of dignity therapy to mitigate outright distress, such as depression, desire for death or suicidality, has yet to be proven,	No significant differences were noted in the distress levels before and after completion of the study in the three groups.
__label__noRel	Although the ability of dignity therapy to mitigate outright distress, such as depression, desire for death or suicidality, has yet to be proven,	For the secondary outcomes, patients reported that dignity therapy was significantly more likely than the other two interventions to have been helpful ((2)=3550, df=2; p<00001), improve quality of life ((2)=1452; p=0001), increase sense of dignity ((2)=1266; p=0002), change how their family saw and appreciated them ((2)=3381; p<00001), and be helpful to their family ((2)=3386; p<00001).
__label__noRel	Although the ability of dignity therapy to mitigate outright distress, such as depression, desire for death or suicidality, has yet to be proven,	Dignity therapy was significantly better than client-centred care in improving spiritual wellbeing ((2)=1035; p=0006), and was significantly better than standard palliative care in terms of lessening sadness or depression ((2)=938; p=0009);
__label__noRel	Although the ability of dignity therapy to mitigate outright distress, such as depression, desire for death or suicidality, has yet to be proven,	significantly more patients who had received dignity therapy reported that the study group had been satisfactory, compared with those who received standard palliative care ((2)=2958; p<00001).
__label__Attack	Although the ability of dignity therapy to mitigate outright distress, such as depression, desire for death or suicidality, has yet to be proven,	its benefits in terms of self-reported end-of-life experiences support its clinical application for patients nearing death.
__label__noRel	its benefits in terms of self-reported end-of-life experiences support its clinical application for patients nearing death.	No significant differences were noted in the distress levels before and after completion of the study in the three groups.
__label__noRel	its benefits in terms of self-reported end-of-life experiences support its clinical application for patients nearing death.	For the secondary outcomes, patients reported that dignity therapy was significantly more likely than the other two interventions to have been helpful ((2)=3550, df=2; p<00001), improve quality of life ((2)=1452; p=0001), increase sense of dignity ((2)=1266; p=0002), change how their family saw and appreciated them ((2)=3381; p<00001), and be helpful to their family ((2)=3386; p<00001).
__label__noRel	its benefits in terms of self-reported end-of-life experiences support its clinical application for patients nearing death.	Dignity therapy was significantly better than client-centred care in improving spiritual wellbeing ((2)=1035; p=0006), and was significantly better than standard palliative care in terms of lessening sadness or depression ((2)=938; p=0009);
__label__noRel	its benefits in terms of self-reported end-of-life experiences support its clinical application for patients nearing death.	significantly more patients who had received dignity therapy reported that the study group had been satisfactory, compared with those who received standard palliative care ((2)=2958; p<00001).
__label__noRel	its benefits in terms of self-reported end-of-life experiences support its clinical application for patients nearing death.	Although the ability of dignity therapy to mitigate outright distress, such as depression, desire for death or suicidality, has yet to be proven,
__label__noRel	The dose-intensified arm was slightly more emetogenic and generated more grade 3 to 4 anemia but less febrile neutropenia episodes.	The median PFS was 34 and 33.7 months for CEF and EC, respectively (P =.68), and the 5-year survival rate was 53% and 51% for CEF and EC, respectively (P =.94).
__label__Support	The dose-intensified arm was slightly more emetogenic and generated more grade 3 to 4 anemia but less febrile neutropenia episodes.	Dose-intensified EC does not provide a measurable therapeutic benefit over CEF as neoadjuvant chemotherapy for unselected locally advanced breast cancer patients.
__label__noRel	The median PFS was 34 and 33.7 months for CEF and EC, respectively (P =.68), and the 5-year survival rate was 53% and 51% for CEF and EC, respectively (P =.94).	The dose-intensified arm was slightly more emetogenic and generated more grade 3 to 4 anemia but less febrile neutropenia episodes.
__label__Support	The median PFS was 34 and 33.7 months for CEF and EC, respectively (P =.68), and the 5-year survival rate was 53% and 51% for CEF and EC, respectively (P =.94).	Dose-intensified EC does not provide a measurable therapeutic benefit over CEF as neoadjuvant chemotherapy for unselected locally advanced breast cancer patients.
__label__noRel	Dose-intensified EC does not provide a measurable therapeutic benefit over CEF as neoadjuvant chemotherapy for unselected locally advanced breast cancer patients.	The dose-intensified arm was slightly more emetogenic and generated more grade 3 to 4 anemia but less febrile neutropenia episodes.
__label__noRel	Dose-intensified EC does not provide a measurable therapeutic benefit over CEF as neoadjuvant chemotherapy for unselected locally advanced breast cancer patients.	The median PFS was 34 and 33.7 months for CEF and EC, respectively (P =.68), and the 5-year survival rate was 53% and 51% for CEF and EC, respectively (P =.94).
__label__noRel	Patients randomly assigned to the intervention arm showed significant improvements on symptoms of depression (p<0.05) and anxiety (p<0.05), health-related QOL (p<0.05) (i.e. better global health status, and physical and emotional functioning, and less insomnia) when compared with controls.	In the subset analysis, female patients, those that received high dose irradiation, and those that underwent adjuvant chemotherapy could benefit more from psychosocial intervention.
__label__noRel	Patients randomly assigned to the intervention arm showed significant improvements on symptoms of depression (p<0.05) and anxiety (p<0.05), health-related QOL (p<0.05) (i.e. better global health status, and physical and emotional functioning, and less insomnia) when compared with controls.	There was no difference between the two groups in disease-free survival (DFS) (2-year DFS 79.8% in the intervention arm and 76.4% in the control arm; p=0.527) and overall survival (OS) (2-year OS 83.1% in the intervention arm and 84.3% in the control arm; p=0.925).
__label__noRel	Patients randomly assigned to the intervention arm showed significant improvements on symptoms of depression (p<0.05) and anxiety (p<0.05), health-related QOL (p<0.05) (i.e. better global health status, and physical and emotional functioning, and less insomnia) when compared with controls.	However, the intervention was not found to reduce the risk of cancer recurrence and death.
__label__noRel	Patients randomly assigned to the intervention arm showed significant improvements on symptoms of depression (p<0.05) and anxiety (p<0.05), health-related QOL (p<0.05) (i.e. better global health status, and physical and emotional functioning, and less insomnia) when compared with controls.	Psychosocial intervention is a cost-effective approach that can improve a patient's mood and QOL both during and after RT.
__label__noRel	In the subset analysis, female patients, those that received high dose irradiation, and those that underwent adjuvant chemotherapy could benefit more from psychosocial intervention.	Patients randomly assigned to the intervention arm showed significant improvements on symptoms of depression (p<0.05) and anxiety (p<0.05), health-related QOL (p<0.05) (i.e. better global health status, and physical and emotional functioning, and less insomnia) when compared with controls.
__label__noRel	In the subset analysis, female patients, those that received high dose irradiation, and those that underwent adjuvant chemotherapy could benefit more from psychosocial intervention.	There was no difference between the two groups in disease-free survival (DFS) (2-year DFS 79.8% in the intervention arm and 76.4% in the control arm; p=0.527) and overall survival (OS) (2-year OS 83.1% in the intervention arm and 84.3% in the control arm; p=0.925).
__label__noRel	In the subset analysis, female patients, those that received high dose irradiation, and those that underwent adjuvant chemotherapy could benefit more from psychosocial intervention.	However, the intervention was not found to reduce the risk of cancer recurrence and death.
__label__noRel	In the subset analysis, female patients, those that received high dose irradiation, and those that underwent adjuvant chemotherapy could benefit more from psychosocial intervention.	Psychosocial intervention is a cost-effective approach that can improve a patient's mood and QOL both during and after RT.
__label__noRel	There was no difference between the two groups in disease-free survival (DFS) (2-year DFS 79.8% in the intervention arm and 76.4% in the control arm; p=0.527) and overall survival (OS) (2-year OS 83.1% in the intervention arm and 84.3% in the control arm; p=0.925).	Patients randomly assigned to the intervention arm showed significant improvements on symptoms of depression (p<0.05) and anxiety (p<0.05), health-related QOL (p<0.05) (i.e. better global health status, and physical and emotional functioning, and less insomnia) when compared with controls.
__label__noRel	There was no difference between the two groups in disease-free survival (DFS) (2-year DFS 79.8% in the intervention arm and 76.4% in the control arm; p=0.527) and overall survival (OS) (2-year OS 83.1% in the intervention arm and 84.3% in the control arm; p=0.925).	In the subset analysis, female patients, those that received high dose irradiation, and those that underwent adjuvant chemotherapy could benefit more from psychosocial intervention.
__label__noRel	There was no difference between the two groups in disease-free survival (DFS) (2-year DFS 79.8% in the intervention arm and 76.4% in the control arm; p=0.527) and overall survival (OS) (2-year OS 83.1% in the intervention arm and 84.3% in the control arm; p=0.925).	However, the intervention was not found to reduce the risk of cancer recurrence and death.
__label__noRel	There was no difference between the two groups in disease-free survival (DFS) (2-year DFS 79.8% in the intervention arm and 76.4% in the control arm; p=0.527) and overall survival (OS) (2-year OS 83.1% in the intervention arm and 84.3% in the control arm; p=0.925).	Psychosocial intervention is a cost-effective approach that can improve a patient's mood and QOL both during and after RT.
__label__noRel	However, the intervention was not found to reduce the risk of cancer recurrence and death.	Patients randomly assigned to the intervention arm showed significant improvements on symptoms of depression (p<0.05) and anxiety (p<0.05), health-related QOL (p<0.05) (i.e. better global health status, and physical and emotional functioning, and less insomnia) when compared with controls.
__label__noRel	However, the intervention was not found to reduce the risk of cancer recurrence and death.	In the subset analysis, female patients, those that received high dose irradiation, and those that underwent adjuvant chemotherapy could benefit more from psychosocial intervention.
__label__noRel	However, the intervention was not found to reduce the risk of cancer recurrence and death.	There was no difference between the two groups in disease-free survival (DFS) (2-year DFS 79.8% in the intervention arm and 76.4% in the control arm; p=0.527) and overall survival (OS) (2-year OS 83.1% in the intervention arm and 84.3% in the control arm; p=0.925).
__label__noRel	However, the intervention was not found to reduce the risk of cancer recurrence and death.	Psychosocial intervention is a cost-effective approach that can improve a patient's mood and QOL both during and after RT.
__label__noRel	Psychosocial intervention is a cost-effective approach that can improve a patient's mood and QOL both during and after RT.	Patients randomly assigned to the intervention arm showed significant improvements on symptoms of depression (p<0.05) and anxiety (p<0.05), health-related QOL (p<0.05) (i.e. better global health status, and physical and emotional functioning, and less insomnia) when compared with controls.
__label__noRel	Psychosocial intervention is a cost-effective approach that can improve a patient's mood and QOL both during and after RT.	In the subset analysis, female patients, those that received high dose irradiation, and those that underwent adjuvant chemotherapy could benefit more from psychosocial intervention.
__label__noRel	Psychosocial intervention is a cost-effective approach that can improve a patient's mood and QOL both during and after RT.	There was no difference between the two groups in disease-free survival (DFS) (2-year DFS 79.8% in the intervention arm and 76.4% in the control arm; p=0.527) and overall survival (OS) (2-year OS 83.1% in the intervention arm and 84.3% in the control arm; p=0.925).
__label__noRel	Psychosocial intervention is a cost-effective approach that can improve a patient's mood and QOL both during and after RT.	However, the intervention was not found to reduce the risk of cancer recurrence and death.
__label__noRel	We found significant improvements over time in favor of PPT for the primary outcome general fatigue (P = .01), with significant group differences at month 1 (effect size, 0.26; P = .007) and month 2 (effect size, 0.35; P = .005).	Improvements in favor of PPT were also found for the following secondary outcomes: fatigue dimensions "reduced activity" and "reduced motivation," fatigue NRS, symptom burden, interference of fatigue with daily life, and anxiety (all P  .03).
__label__Support	We found significant improvements over time in favor of PPT for the primary outcome general fatigue (P = .01), with significant group differences at month 1 (effect size, 0.26; P = .007) and month 2 (effect size, 0.35; P = .005).	In fatigued patients with advanced cancer, nurse-led monitoring and protocolized treatment of physical symptoms is effective in alleviating fatigue.
__label__noRel	Improvements in favor of PPT were also found for the following secondary outcomes: fatigue dimensions "reduced activity" and "reduced motivation," fatigue NRS, symptom burden, interference of fatigue with daily life, and anxiety (all P  .03).	We found significant improvements over time in favor of PPT for the primary outcome general fatigue (P = .01), with significant group differences at month 1 (effect size, 0.26; P = .007) and month 2 (effect size, 0.35; P = .005).
__label__Support	Improvements in favor of PPT were also found for the following secondary outcomes: fatigue dimensions "reduced activity" and "reduced motivation," fatigue NRS, symptom burden, interference of fatigue with daily life, and anxiety (all P  .03).	In fatigued patients with advanced cancer, nurse-led monitoring and protocolized treatment of physical symptoms is effective in alleviating fatigue.
__label__noRel	In fatigued patients with advanced cancer, nurse-led monitoring and protocolized treatment of physical symptoms is effective in alleviating fatigue.	We found significant improvements over time in favor of PPT for the primary outcome general fatigue (P = .01), with significant group differences at month 1 (effect size, 0.26; P = .007) and month 2 (effect size, 0.35; P = .005).
__label__noRel	In fatigued patients with advanced cancer, nurse-led monitoring and protocolized treatment of physical symptoms is effective in alleviating fatigue.	Improvements in favor of PPT were also found for the following secondary outcomes: fatigue dimensions "reduced activity" and "reduced motivation," fatigue NRS, symptom burden, interference of fatigue with daily life, and anxiety (all P  .03).
__label__noRel	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).
__label__noRel	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);
__label__noRel	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).	hazard ratio was 0.50; P = .0002
__label__noRel	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);
__label__noRel	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);
__label__noRel	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).	hazard ratio was 0.42; P = .088.
__label__noRel	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)
__label__noRel	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).	but was controlled with oral medication and did not cause study drug discontinuation.
__label__noRel	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.
__label__noRel	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).
__label__noRel	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);
__label__noRel	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).	hazard ratio was 0.50; P = .0002
__label__noRel	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);
__label__noRel	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);
__label__noRel	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).	hazard ratio was 0.42; P = .088.
__label__noRel	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)
__label__noRel	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).	but was controlled with oral medication and did not cause study drug discontinuation.
__label__Support	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.
__label__noRel	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).
__label__noRel	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).
__label__noRel	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);	hazard ratio was 0.50; P = .0002
__label__noRel	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);
__label__noRel	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);
__label__noRel	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);	hazard ratio was 0.42; P = .088.
__label__noRel	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)
__label__noRel	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);	but was controlled with oral medication and did not cause study drug discontinuation.
__label__Support	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.
__label__noRel	hazard ratio was 0.50; P = .0002	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).
__label__noRel	hazard ratio was 0.50; P = .0002	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).
__label__noRel	hazard ratio was 0.50; P = .0002	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);
__label__noRel	hazard ratio was 0.50; P = .0002	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);
__label__noRel	hazard ratio was 0.50; P = .0002	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);
__label__noRel	hazard ratio was 0.50; P = .0002	hazard ratio was 0.42; P = .088.
__label__noRel	hazard ratio was 0.50; P = .0002	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)
__label__noRel	hazard ratio was 0.50; P = .0002	but was controlled with oral medication and did not cause study drug discontinuation.
__label__Support	hazard ratio was 0.50; P = .0002	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.
__label__noRel	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).
__label__noRel	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).
__label__noRel	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);
__label__noRel	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);	hazard ratio was 0.50; P = .0002
__label__noRel	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);
__label__noRel	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);	hazard ratio was 0.42; P = .088.
__label__noRel	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)
__label__noRel	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);	but was controlled with oral medication and did not cause study drug discontinuation.
__label__Support	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.
__label__noRel	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).
__label__noRel	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).
__label__noRel	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);
__label__noRel	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);	hazard ratio was 0.50; P = .0002
__label__noRel	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);
__label__noRel	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);	hazard ratio was 0.42; P = .088.
__label__noRel	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)
__label__noRel	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);	but was controlled with oral medication and did not cause study drug discontinuation.
__label__Support	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.
__label__noRel	hazard ratio was 0.42; P = .088.	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).
__label__noRel	hazard ratio was 0.42; P = .088.	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).
__label__noRel	hazard ratio was 0.42; P = .088.	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);
__label__noRel	hazard ratio was 0.42; P = .088.	hazard ratio was 0.50; P = .0002
__label__noRel	hazard ratio was 0.42; P = .088.	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);
__label__noRel	hazard ratio was 0.42; P = .088.	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);
__label__noRel	hazard ratio was 0.42; P = .088.	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)
__label__noRel	hazard ratio was 0.42; P = .088.	but was controlled with oral medication and did not cause study drug discontinuation.
__label__Support	hazard ratio was 0.42; P = .088.	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.
__label__noRel	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).
__label__noRel	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).
__label__noRel	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);
__label__noRel	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)	hazard ratio was 0.50; P = .0002
__label__noRel	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);
__label__noRel	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);
__label__noRel	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)	hazard ratio was 0.42; P = .088.
__label__noRel	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)	but was controlled with oral medication and did not cause study drug discontinuation.
__label__noRel	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.
__label__noRel	but was controlled with oral medication and did not cause study drug discontinuation.	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).
__label__noRel	but was controlled with oral medication and did not cause study drug discontinuation.	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).
__label__noRel	but was controlled with oral medication and did not cause study drug discontinuation.	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);
__label__noRel	but was controlled with oral medication and did not cause study drug discontinuation.	hazard ratio was 0.50; P = .0002
__label__noRel	but was controlled with oral medication and did not cause study drug discontinuation.	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);
__label__noRel	but was controlled with oral medication and did not cause study drug discontinuation.	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);
__label__noRel	but was controlled with oral medication and did not cause study drug discontinuation.	hazard ratio was 0.42; P = .088.
__label__Attack	but was controlled with oral medication and did not cause study drug discontinuation.	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)
__label__noRel	but was controlled with oral medication and did not cause study drug discontinuation.	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.
__label__noRel	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).
__label__noRel	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).
__label__noRel	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);
__label__noRel	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.	hazard ratio was 0.50; P = .0002
__label__noRel	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);
__label__noRel	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);
__label__noRel	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.	hazard ratio was 0.42; P = .088.
__label__noRel	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)
__label__noRel	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.	but was controlled with oral medication and did not cause study drug discontinuation.
__label__noRel	55.6% patients treated over 4 days and 33.3% of patients treated over 11 days experienced acute grade  2 toxicity (p=0.085).	Dyspnea, fatigue and coughing domains were worse in the 11 day group at baseline.
__label__noRel	55.6% patients treated over 4 days and 33.3% of patients treated over 11 days experienced acute grade  2 toxicity (p=0.085).	At 1 and 4 months, more patients in the 4 day group experienced a clinically meaningful worsening in the dyspnea QOL domain compared to the 11 day group (44.5% vs 15.4%, p=0.02; 38.5% vs 12.0%, p=0.03, respectively).
__label__noRel	55.6% patients treated over 4 days and 33.3% of patients treated over 11 days experienced acute grade  2 toxicity (p=0.085).	However, raw QOL scores were not different at these time-points between treatment groups.
__label__Support	55.6% patients treated over 4 days and 33.3% of patients treated over 11 days experienced acute grade  2 toxicity (p=0.085).	Grade 2 or higher acute toxicity was more common in the 4 day group, approaching statistical significance.
__label__noRel	55.6% patients treated over 4 days and 33.3% of patients treated over 11 days experienced acute grade  2 toxicity (p=0.085).	More patients treated on 4 consecutive days reported a clinically meaningful increase in dyspnea,
__label__noRel	55.6% patients treated over 4 days and 33.3% of patients treated over 11 days experienced acute grade  2 toxicity (p=0.085).	although interpretation of these results is challenging due to baseline imbalance between treatment groups.
__label__noRel	55.6% patients treated over 4 days and 33.3% of patients treated over 11 days experienced acute grade  2 toxicity (p=0.085).	Larger studies are required to validate these results.
__label__noRel	Dyspnea, fatigue and coughing domains were worse in the 11 day group at baseline.	55.6% patients treated over 4 days and 33.3% of patients treated over 11 days experienced acute grade  2 toxicity (p=0.085).
__label__noRel	Dyspnea, fatigue and coughing domains were worse in the 11 day group at baseline.	At 1 and 4 months, more patients in the 4 day group experienced a clinically meaningful worsening in the dyspnea QOL domain compared to the 11 day group (44.5% vs 15.4%, p=0.02; 38.5% vs 12.0%, p=0.03, respectively).
__label__noRel	Dyspnea, fatigue and coughing domains were worse in the 11 day group at baseline.	However, raw QOL scores were not different at these time-points between treatment groups.
__label__noRel	Dyspnea, fatigue and coughing domains were worse in the 11 day group at baseline.	Grade 2 or higher acute toxicity was more common in the 4 day group, approaching statistical significance.
__label__Support	Dyspnea, fatigue and coughing domains were worse in the 11 day group at baseline.	More patients treated on 4 consecutive days reported a clinically meaningful increase in dyspnea,
__label__noRel	Dyspnea, fatigue and coughing domains were worse in the 11 day group at baseline.	although interpretation of these results is challenging due to baseline imbalance between treatment groups.
__label__noRel	Dyspnea, fatigue and coughing domains were worse in the 11 day group at baseline.	Larger studies are required to validate these results.
__label__noRel	At 1 and 4 months, more patients in the 4 day group experienced a clinically meaningful worsening in the dyspnea QOL domain compared to the 11 day group (44.5% vs 15.4%, p=0.02; 38.5% vs 12.0%, p=0.03, respectively).	55.6% patients treated over 4 days and 33.3% of patients treated over 11 days experienced acute grade  2 toxicity (p=0.085).
__label__noRel	At 1 and 4 months, more patients in the 4 day group experienced a clinically meaningful worsening in the dyspnea QOL domain compared to the 11 day group (44.5% vs 15.4%, p=0.02; 38.5% vs 12.0%, p=0.03, respectively).	Dyspnea, fatigue and coughing domains were worse in the 11 day group at baseline.
__label__noRel	At 1 and 4 months, more patients in the 4 day group experienced a clinically meaningful worsening in the dyspnea QOL domain compared to the 11 day group (44.5% vs 15.4%, p=0.02; 38.5% vs 12.0%, p=0.03, respectively).	However, raw QOL scores were not different at these time-points between treatment groups.
__label__noRel	At 1 and 4 months, more patients in the 4 day group experienced a clinically meaningful worsening in the dyspnea QOL domain compared to the 11 day group (44.5% vs 15.4%, p=0.02; 38.5% vs 12.0%, p=0.03, respectively).	Grade 2 or higher acute toxicity was more common in the 4 day group, approaching statistical significance.
__label__Support	At 1 and 4 months, more patients in the 4 day group experienced a clinically meaningful worsening in the dyspnea QOL domain compared to the 11 day group (44.5% vs 15.4%, p=0.02; 38.5% vs 12.0%, p=0.03, respectively).	More patients treated on 4 consecutive days reported a clinically meaningful increase in dyspnea,
__label__noRel	At 1 and 4 months, more patients in the 4 day group experienced a clinically meaningful worsening in the dyspnea QOL domain compared to the 11 day group (44.5% vs 15.4%, p=0.02; 38.5% vs 12.0%, p=0.03, respectively).	although interpretation of these results is challenging due to baseline imbalance between treatment groups.
__label__noRel	At 1 and 4 months, more patients in the 4 day group experienced a clinically meaningful worsening in the dyspnea QOL domain compared to the 11 day group (44.5% vs 15.4%, p=0.02; 38.5% vs 12.0%, p=0.03, respectively).	Larger studies are required to validate these results.
__label__noRel	However, raw QOL scores were not different at these time-points between treatment groups.	55.6% patients treated over 4 days and 33.3% of patients treated over 11 days experienced acute grade  2 toxicity (p=0.085).
__label__noRel	However, raw QOL scores were not different at these time-points between treatment groups.	Dyspnea, fatigue and coughing domains were worse in the 11 day group at baseline.
__label__noRel	However, raw QOL scores were not different at these time-points between treatment groups.	At 1 and 4 months, more patients in the 4 day group experienced a clinically meaningful worsening in the dyspnea QOL domain compared to the 11 day group (44.5% vs 15.4%, p=0.02; 38.5% vs 12.0%, p=0.03, respectively).
__label__noRel	However, raw QOL scores were not different at these time-points between treatment groups.	Grade 2 or higher acute toxicity was more common in the 4 day group, approaching statistical significance.
__label__noRel	However, raw QOL scores were not different at these time-points between treatment groups.	More patients treated on 4 consecutive days reported a clinically meaningful increase in dyspnea,
__label__noRel	However, raw QOL scores were not different at these time-points between treatment groups.	although interpretation of these results is challenging due to baseline imbalance between treatment groups.
__label__noRel	However, raw QOL scores were not different at these time-points between treatment groups.	Larger studies are required to validate these results.
__label__noRel	Grade 2 or higher acute toxicity was more common in the 4 day group, approaching statistical significance.	55.6% patients treated over 4 days and 33.3% of patients treated over 11 days experienced acute grade  2 toxicity (p=0.085).
__label__noRel	Grade 2 or higher acute toxicity was more common in the 4 day group, approaching statistical significance.	Dyspnea, fatigue and coughing domains were worse in the 11 day group at baseline.
__label__noRel	Grade 2 or higher acute toxicity was more common in the 4 day group, approaching statistical significance.	At 1 and 4 months, more patients in the 4 day group experienced a clinically meaningful worsening in the dyspnea QOL domain compared to the 11 day group (44.5% vs 15.4%, p=0.02; 38.5% vs 12.0%, p=0.03, respectively).
__label__noRel	Grade 2 or higher acute toxicity was more common in the 4 day group, approaching statistical significance.	However, raw QOL scores were not different at these time-points between treatment groups.
__label__noRel	Grade 2 or higher acute toxicity was more common in the 4 day group, approaching statistical significance.	More patients treated on 4 consecutive days reported a clinically meaningful increase in dyspnea,
__label__noRel	Grade 2 or higher acute toxicity was more common in the 4 day group, approaching statistical significance.	although interpretation of these results is challenging due to baseline imbalance between treatment groups.
__label__noRel	Grade 2 or higher acute toxicity was more common in the 4 day group, approaching statistical significance.	Larger studies are required to validate these results.
__label__noRel	More patients treated on 4 consecutive days reported a clinically meaningful increase in dyspnea,	55.6% patients treated over 4 days and 33.3% of patients treated over 11 days experienced acute grade  2 toxicity (p=0.085).
__label__noRel	More patients treated on 4 consecutive days reported a clinically meaningful increase in dyspnea,	Dyspnea, fatigue and coughing domains were worse in the 11 day group at baseline.
__label__noRel	More patients treated on 4 consecutive days reported a clinically meaningful increase in dyspnea,	At 1 and 4 months, more patients in the 4 day group experienced a clinically meaningful worsening in the dyspnea QOL domain compared to the 11 day group (44.5% vs 15.4%, p=0.02; 38.5% vs 12.0%, p=0.03, respectively).
__label__noRel	More patients treated on 4 consecutive days reported a clinically meaningful increase in dyspnea,	However, raw QOL scores were not different at these time-points between treatment groups.
__label__noRel	More patients treated on 4 consecutive days reported a clinically meaningful increase in dyspnea,	Grade 2 or higher acute toxicity was more common in the 4 day group, approaching statistical significance.
__label__noRel	More patients treated on 4 consecutive days reported a clinically meaningful increase in dyspnea,	although interpretation of these results is challenging due to baseline imbalance between treatment groups.
__label__noRel	More patients treated on 4 consecutive days reported a clinically meaningful increase in dyspnea,	Larger studies are required to validate these results.
__label__noRel	although interpretation of these results is challenging due to baseline imbalance between treatment groups.	55.6% patients treated over 4 days and 33.3% of patients treated over 11 days experienced acute grade  2 toxicity (p=0.085).
__label__noRel	although interpretation of these results is challenging due to baseline imbalance between treatment groups.	Dyspnea, fatigue and coughing domains were worse in the 11 day group at baseline.
__label__noRel	although interpretation of these results is challenging due to baseline imbalance between treatment groups.	At 1 and 4 months, more patients in the 4 day group experienced a clinically meaningful worsening in the dyspnea QOL domain compared to the 11 day group (44.5% vs 15.4%, p=0.02; 38.5% vs 12.0%, p=0.03, respectively).
__label__noRel	although interpretation of these results is challenging due to baseline imbalance between treatment groups.	However, raw QOL scores were not different at these time-points between treatment groups.
__label__noRel	although interpretation of these results is challenging due to baseline imbalance between treatment groups.	Grade 2 or higher acute toxicity was more common in the 4 day group, approaching statistical significance.
__label__Attack	although interpretation of these results is challenging due to baseline imbalance between treatment groups.	More patients treated on 4 consecutive days reported a clinically meaningful increase in dyspnea,
__label__noRel	although interpretation of these results is challenging due to baseline imbalance between treatment groups.	Larger studies are required to validate these results.
__label__noRel	Larger studies are required to validate these results.	55.6% patients treated over 4 days and 33.3% of patients treated over 11 days experienced acute grade  2 toxicity (p=0.085).
__label__noRel	Larger studies are required to validate these results.	Dyspnea, fatigue and coughing domains were worse in the 11 day group at baseline.
__label__noRel	Larger studies are required to validate these results.	At 1 and 4 months, more patients in the 4 day group experienced a clinically meaningful worsening in the dyspnea QOL domain compared to the 11 day group (44.5% vs 15.4%, p=0.02; 38.5% vs 12.0%, p=0.03, respectively).
__label__noRel	Larger studies are required to validate these results.	However, raw QOL scores were not different at these time-points between treatment groups.
__label__noRel	Larger studies are required to validate these results.	Grade 2 or higher acute toxicity was more common in the 4 day group, approaching statistical significance.
__label__Attack	Larger studies are required to validate these results.	More patients treated on 4 consecutive days reported a clinically meaningful increase in dyspnea,
__label__noRel	Larger studies are required to validate these results.	although interpretation of these results is challenging due to baseline imbalance between treatment groups.
__label__noRel	Intrusive thoughts were associated with higher levels of all symptoms at baseline and at the 12-month assessment.	Intrusive thoughts also influenced the trajectory of pain, depressive symptoms, negative affect, and physical functioning over time;
__label__noRel	Intrusive thoughts were associated with higher levels of all symptoms at baseline and at the 12-month assessment.	women with higher intrusions at baseline started worse and improved over time, whereas those with lower intrusions remained at a constant, lower level over time.
__label__noRel	Intrusive thoughts were associated with higher levels of all symptoms at baseline and at the 12-month assessment.	Intrusions were not associated with the trajectory of fatigue, sleep, breast cancer-specific symptoms, or mental functioning;
__label__noRel	Intrusive thoughts were associated with higher levels of all symptoms at baseline and at the 12-month assessment.	women with higher intrusions at baseline started worse and remained worse over time.
__label__Support	Intrusive thoughts were associated with higher levels of all symptoms at baseline and at the 12-month assessment.	Intrusive thoughts are associated with enduring elevations in behavioral symptoms and impaired quality of life in the year after breast cancer treatment and may be a risk factor for poor outcomes.
__label__noRel	Intrusive thoughts also influenced the trajectory of pain, depressive symptoms, negative affect, and physical functioning over time;	Intrusive thoughts were associated with higher levels of all symptoms at baseline and at the 12-month assessment.
__label__noRel	Intrusive thoughts also influenced the trajectory of pain, depressive symptoms, negative affect, and physical functioning over time;	women with higher intrusions at baseline started worse and improved over time, whereas those with lower intrusions remained at a constant, lower level over time.
__label__noRel	Intrusive thoughts also influenced the trajectory of pain, depressive symptoms, negative affect, and physical functioning over time;	Intrusions were not associated with the trajectory of fatigue, sleep, breast cancer-specific symptoms, or mental functioning;
__label__noRel	Intrusive thoughts also influenced the trajectory of pain, depressive symptoms, negative affect, and physical functioning over time;	women with higher intrusions at baseline started worse and remained worse over time.
__label__Support	Intrusive thoughts also influenced the trajectory of pain, depressive symptoms, negative affect, and physical functioning over time;	Intrusive thoughts are associated with enduring elevations in behavioral symptoms and impaired quality of life in the year after breast cancer treatment and may be a risk factor for poor outcomes.
__label__noRel	women with higher intrusions at baseline started worse and improved over time, whereas those with lower intrusions remained at a constant, lower level over time.	Intrusive thoughts were associated with higher levels of all symptoms at baseline and at the 12-month assessment.
__label__noRel	women with higher intrusions at baseline started worse and improved over time, whereas those with lower intrusions remained at a constant, lower level over time.	Intrusive thoughts also influenced the trajectory of pain, depressive symptoms, negative affect, and physical functioning over time;
__label__noRel	women with higher intrusions at baseline started worse and improved over time, whereas those with lower intrusions remained at a constant, lower level over time.	Intrusions were not associated with the trajectory of fatigue, sleep, breast cancer-specific symptoms, or mental functioning;
__label__noRel	women with higher intrusions at baseline started worse and improved over time, whereas those with lower intrusions remained at a constant, lower level over time.	women with higher intrusions at baseline started worse and remained worse over time.
__label__Support	women with higher intrusions at baseline started worse and improved over time, whereas those with lower intrusions remained at a constant, lower level over time.	Intrusive thoughts are associated with enduring elevations in behavioral symptoms and impaired quality of life in the year after breast cancer treatment and may be a risk factor for poor outcomes.
__label__noRel	Intrusions were not associated with the trajectory of fatigue, sleep, breast cancer-specific symptoms, or mental functioning;	Intrusive thoughts were associated with higher levels of all symptoms at baseline and at the 12-month assessment.
__label__noRel	Intrusions were not associated with the trajectory of fatigue, sleep, breast cancer-specific symptoms, or mental functioning;	Intrusive thoughts also influenced the trajectory of pain, depressive symptoms, negative affect, and physical functioning over time;
__label__noRel	Intrusions were not associated with the trajectory of fatigue, sleep, breast cancer-specific symptoms, or mental functioning;	women with higher intrusions at baseline started worse and improved over time, whereas those with lower intrusions remained at a constant, lower level over time.
__label__noRel	Intrusions were not associated with the trajectory of fatigue, sleep, breast cancer-specific symptoms, or mental functioning;	women with higher intrusions at baseline started worse and remained worse over time.
__label__Attack	Intrusions were not associated with the trajectory of fatigue, sleep, breast cancer-specific symptoms, or mental functioning;	Intrusive thoughts are associated with enduring elevations in behavioral symptoms and impaired quality of life in the year after breast cancer treatment and may be a risk factor for poor outcomes.
__label__noRel	women with higher intrusions at baseline started worse and remained worse over time.	Intrusive thoughts were associated with higher levels of all symptoms at baseline and at the 12-month assessment.
__label__noRel	women with higher intrusions at baseline started worse and remained worse over time.	Intrusive thoughts also influenced the trajectory of pain, depressive symptoms, negative affect, and physical functioning over time;
__label__noRel	women with higher intrusions at baseline started worse and remained worse over time.	women with higher intrusions at baseline started worse and improved over time, whereas those with lower intrusions remained at a constant, lower level over time.
__label__noRel	women with higher intrusions at baseline started worse and remained worse over time.	Intrusions were not associated with the trajectory of fatigue, sleep, breast cancer-specific symptoms, or mental functioning;
__label__Support	women with higher intrusions at baseline started worse and remained worse over time.	Intrusive thoughts are associated with enduring elevations in behavioral symptoms and impaired quality of life in the year after breast cancer treatment and may be a risk factor for poor outcomes.
__label__noRel	Intrusive thoughts are associated with enduring elevations in behavioral symptoms and impaired quality of life in the year after breast cancer treatment and may be a risk factor for poor outcomes.	Intrusive thoughts were associated with higher levels of all symptoms at baseline and at the 12-month assessment.
__label__noRel	Intrusive thoughts are associated with enduring elevations in behavioral symptoms and impaired quality of life in the year after breast cancer treatment and may be a risk factor for poor outcomes.	Intrusive thoughts also influenced the trajectory of pain, depressive symptoms, negative affect, and physical functioning over time;
__label__noRel	Intrusive thoughts are associated with enduring elevations in behavioral symptoms and impaired quality of life in the year after breast cancer treatment and may be a risk factor for poor outcomes.	women with higher intrusions at baseline started worse and improved over time, whereas those with lower intrusions remained at a constant, lower level over time.
__label__noRel	Intrusive thoughts are associated with enduring elevations in behavioral symptoms and impaired quality of life in the year after breast cancer treatment and may be a risk factor for poor outcomes.	Intrusions were not associated with the trajectory of fatigue, sleep, breast cancer-specific symptoms, or mental functioning;
__label__noRel	Intrusive thoughts are associated with enduring elevations in behavioral symptoms and impaired quality of life in the year after breast cancer treatment and may be a risk factor for poor outcomes.	women with higher intrusions at baseline started worse and remained worse over time.
__label__noRel	There was significant early attrition due to disease progression; only 61.5% of patients were alive at 2 months.	There was a significant improvement in KP from baseline to pre-cycle 3 in both arms, with a trend in favor of the 3w4 regimen for duration and faster onset of improvement.
__label__noRel	There was significant early attrition due to disease progression; only 61.5% of patients were alive at 2 months.	Eight of the 17 quality-of-life (QOL) variables assessed showed an improvement of more than 10% between baseline and the start of the third cycle of treatment.
__label__noRel	There was significant early attrition due to disease progression; only 61.5% of patients were alive at 2 months.	Response rate, survival, and duration were similar in both arms.
__label__Attack	There was significant early attrition due to disease progression; only 61.5% of patients were alive at 2 months.	There was no significant difference between the two schedules examined in terms of improvement in KP or QOL, but there seemed to be a trend in favor of the 3w4 schedule.
__label__noRel	There was a significant improvement in KP from baseline to pre-cycle 3 in both arms, with a trend in favor of the 3w4 regimen for duration and faster onset of improvement.	There was significant early attrition due to disease progression; only 61.5% of patients were alive at 2 months.
__label__noRel	There was a significant improvement in KP from baseline to pre-cycle 3 in both arms, with a trend in favor of the 3w4 regimen for duration and faster onset of improvement.	Eight of the 17 quality-of-life (QOL) variables assessed showed an improvement of more than 10% between baseline and the start of the third cycle of treatment.
__label__noRel	There was a significant improvement in KP from baseline to pre-cycle 3 in both arms, with a trend in favor of the 3w4 regimen for duration and faster onset of improvement.	Response rate, survival, and duration were similar in both arms.
__label__Support	There was a significant improvement in KP from baseline to pre-cycle 3 in both arms, with a trend in favor of the 3w4 regimen for duration and faster onset of improvement.	There was no significant difference between the two schedules examined in terms of improvement in KP or QOL, but there seemed to be a trend in favor of the 3w4 schedule.
__label__noRel	Eight of the 17 quality-of-life (QOL) variables assessed showed an improvement of more than 10% between baseline and the start of the third cycle of treatment.	There was significant early attrition due to disease progression; only 61.5% of patients were alive at 2 months.
__label__noRel	Eight of the 17 quality-of-life (QOL) variables assessed showed an improvement of more than 10% between baseline and the start of the third cycle of treatment.	There was a significant improvement in KP from baseline to pre-cycle 3 in both arms, with a trend in favor of the 3w4 regimen for duration and faster onset of improvement.
__label__noRel	Eight of the 17 quality-of-life (QOL) variables assessed showed an improvement of more than 10% between baseline and the start of the third cycle of treatment.	Response rate, survival, and duration were similar in both arms.
__label__Support	Eight of the 17 quality-of-life (QOL) variables assessed showed an improvement of more than 10% between baseline and the start of the third cycle of treatment.	There was no significant difference between the two schedules examined in terms of improvement in KP or QOL, but there seemed to be a trend in favor of the 3w4 schedule.
__label__noRel	Response rate, survival, and duration were similar in both arms.	There was significant early attrition due to disease progression; only 61.5% of patients were alive at 2 months.
__label__noRel	Response rate, survival, and duration were similar in both arms.	There was a significant improvement in KP from baseline to pre-cycle 3 in both arms, with a trend in favor of the 3w4 regimen for duration and faster onset of improvement.
__label__noRel	Response rate, survival, and duration were similar in both arms.	Eight of the 17 quality-of-life (QOL) variables assessed showed an improvement of more than 10% between baseline and the start of the third cycle of treatment.
__label__Support	Response rate, survival, and duration were similar in both arms.	There was no significant difference between the two schedules examined in terms of improvement in KP or QOL, but there seemed to be a trend in favor of the 3w4 schedule.
__label__noRel	There was no significant difference between the two schedules examined in terms of improvement in KP or QOL, but there seemed to be a trend in favor of the 3w4 schedule.	There was significant early attrition due to disease progression; only 61.5% of patients were alive at 2 months.
__label__noRel	There was no significant difference between the two schedules examined in terms of improvement in KP or QOL, but there seemed to be a trend in favor of the 3w4 schedule.	There was a significant improvement in KP from baseline to pre-cycle 3 in both arms, with a trend in favor of the 3w4 regimen for duration and faster onset of improvement.
__label__noRel	There was no significant difference between the two schedules examined in terms of improvement in KP or QOL, but there seemed to be a trend in favor of the 3w4 schedule.	Eight of the 17 quality-of-life (QOL) variables assessed showed an improvement of more than 10% between baseline and the start of the third cycle of treatment.
__label__noRel	There was no significant difference between the two schedules examined in terms of improvement in KP or QOL, but there seemed to be a trend in favor of the 3w4 schedule.	Response rate, survival, and duration were similar in both arms.
__label__noRel	Among the 17 participants with depressive symptoms at baseline, both the Onward and the III-only condition showed large reductions in the depression scale of HADS (d=1.27 and 0.89, respectively).	Improvement over time and time x treatment effects only reached trend significance levels (ps=0.07 &amp; 0.12) as this pilot was not powered to detect these differences.
__label__Support	Among the 17 participants with depressive symptoms at baseline, both the Onward and the III-only condition showed large reductions in the depression scale of HADS (d=1.27 and 0.89, respectively).	Both the III+ISG and III-only demonstrated pre-post reductions in depressive symptoms and high rates of utilization compared with other web-based treatments for depression.
__label__noRel	Among the 17 participants with depressive symptoms at baseline, both the Onward and the III-only condition showed large reductions in the depression scale of HADS (d=1.27 and 0.89, respectively).	Although it is premature to make any determination as to the efficacy of the interventions tested in this feasibility study,
__label__noRel	Among the 17 participants with depressive symptoms at baseline, both the Onward and the III-only condition showed large reductions in the depression scale of HADS (d=1.27 and 0.89, respectively).	these results indicate that pursuing the III+ISG model, as well as standard IIIs, may be fruitful areas of future research.
__label__noRel	Improvement over time and time x treatment effects only reached trend significance levels (ps=0.07 &amp; 0.12) as this pilot was not powered to detect these differences.	Among the 17 participants with depressive symptoms at baseline, both the Onward and the III-only condition showed large reductions in the depression scale of HADS (d=1.27 and 0.89, respectively).
__label__noRel	Improvement over time and time x treatment effects only reached trend significance levels (ps=0.07 &amp; 0.12) as this pilot was not powered to detect these differences.	Both the III+ISG and III-only demonstrated pre-post reductions in depressive symptoms and high rates of utilization compared with other web-based treatments for depression.
__label__Support	Improvement over time and time x treatment effects only reached trend significance levels (ps=0.07 &amp; 0.12) as this pilot was not powered to detect these differences.	Although it is premature to make any determination as to the efficacy of the interventions tested in this feasibility study,
__label__noRel	Improvement over time and time x treatment effects only reached trend significance levels (ps=0.07 &amp; 0.12) as this pilot was not powered to detect these differences.	these results indicate that pursuing the III+ISG model, as well as standard IIIs, may be fruitful areas of future research.
__label__noRel	Both the III+ISG and III-only demonstrated pre-post reductions in depressive symptoms and high rates of utilization compared with other web-based treatments for depression.	Among the 17 participants with depressive symptoms at baseline, both the Onward and the III-only condition showed large reductions in the depression scale of HADS (d=1.27 and 0.89, respectively).
__label__noRel	Both the III+ISG and III-only demonstrated pre-post reductions in depressive symptoms and high rates of utilization compared with other web-based treatments for depression.	Improvement over time and time x treatment effects only reached trend significance levels (ps=0.07 &amp; 0.12) as this pilot was not powered to detect these differences.
__label__noRel	Both the III+ISG and III-only demonstrated pre-post reductions in depressive symptoms and high rates of utilization compared with other web-based treatments for depression.	Although it is premature to make any determination as to the efficacy of the interventions tested in this feasibility study,
__label__Support	Both the III+ISG and III-only demonstrated pre-post reductions in depressive symptoms and high rates of utilization compared with other web-based treatments for depression.	these results indicate that pursuing the III+ISG model, as well as standard IIIs, may be fruitful areas of future research.
__label__noRel	Although it is premature to make any determination as to the efficacy of the interventions tested in this feasibility study,	Among the 17 participants with depressive symptoms at baseline, both the Onward and the III-only condition showed large reductions in the depression scale of HADS (d=1.27 and 0.89, respectively).
__label__noRel	Although it is premature to make any determination as to the efficacy of the interventions tested in this feasibility study,	Improvement over time and time x treatment effects only reached trend significance levels (ps=0.07 &amp; 0.12) as this pilot was not powered to detect these differences.
__label__Attack	Although it is premature to make any determination as to the efficacy of the interventions tested in this feasibility study,	Both the III+ISG and III-only demonstrated pre-post reductions in depressive symptoms and high rates of utilization compared with other web-based treatments for depression.
__label__noRel	Although it is premature to make any determination as to the efficacy of the interventions tested in this feasibility study,	these results indicate that pursuing the III+ISG model, as well as standard IIIs, may be fruitful areas of future research.
__label__noRel	these results indicate that pursuing the III+ISG model, as well as standard IIIs, may be fruitful areas of future research.	Among the 17 participants with depressive symptoms at baseline, both the Onward and the III-only condition showed large reductions in the depression scale of HADS (d=1.27 and 0.89, respectively).
__label__noRel	these results indicate that pursuing the III+ISG model, as well as standard IIIs, may be fruitful areas of future research.	Improvement over time and time x treatment effects only reached trend significance levels (ps=0.07 &amp; 0.12) as this pilot was not powered to detect these differences.
__label__noRel	these results indicate that pursuing the III+ISG model, as well as standard IIIs, may be fruitful areas of future research.	Both the III+ISG and III-only demonstrated pre-post reductions in depressive symptoms and high rates of utilization compared with other web-based treatments for depression.
__label__noRel	these results indicate that pursuing the III+ISG model, as well as standard IIIs, may be fruitful areas of future research.	Although it is premature to make any determination as to the efficacy of the interventions tested in this feasibility study,
__label__noRel	Adverse events during temozolomide treatment included thrombocytopenia, nausea, vomiting, anorexia, constipation, alopecia, headache, fatigue, and convulsions.	Median survival was 14.6 months (temozolomide + radiotherapy) versus 12.1 months (radiotherapy alone).
__label__noRel	Adverse events during temozolomide treatment included thrombocytopenia, nausea, vomiting, anorexia, constipation, alopecia, headache, fatigue, and convulsions.	The hazard ratio was 0.63 (95% confidence interval, 0.52-0.75; log-rank, P < 0.0001).
__label__noRel	Adverse events during temozolomide treatment included thrombocytopenia, nausea, vomiting, anorexia, constipation, alopecia, headache, fatigue, and convulsions.	Patients receiving concomitant and maintenance temozolomide + radiotherapy had significantly improved overall survival.
__label__noRel	Median survival was 14.6 months (temozolomide + radiotherapy) versus 12.1 months (radiotherapy alone).	Adverse events during temozolomide treatment included thrombocytopenia, nausea, vomiting, anorexia, constipation, alopecia, headache, fatigue, and convulsions.
__label__noRel	Median survival was 14.6 months (temozolomide + radiotherapy) versus 12.1 months (radiotherapy alone).	The hazard ratio was 0.63 (95% confidence interval, 0.52-0.75; log-rank, P < 0.0001).
__label__Support	Median survival was 14.6 months (temozolomide + radiotherapy) versus 12.1 months (radiotherapy alone).	Patients receiving concomitant and maintenance temozolomide + radiotherapy had significantly improved overall survival.
__label__noRel	The hazard ratio was 0.63 (95% confidence interval, 0.52-0.75; log-rank, P < 0.0001).	Adverse events during temozolomide treatment included thrombocytopenia, nausea, vomiting, anorexia, constipation, alopecia, headache, fatigue, and convulsions.
__label__noRel	The hazard ratio was 0.63 (95% confidence interval, 0.52-0.75; log-rank, P < 0.0001).	Median survival was 14.6 months (temozolomide + radiotherapy) versus 12.1 months (radiotherapy alone).
__label__noRel	The hazard ratio was 0.63 (95% confidence interval, 0.52-0.75; log-rank, P < 0.0001).	Patients receiving concomitant and maintenance temozolomide + radiotherapy had significantly improved overall survival.
__label__noRel	Patients receiving concomitant and maintenance temozolomide + radiotherapy had significantly improved overall survival.	Adverse events during temozolomide treatment included thrombocytopenia, nausea, vomiting, anorexia, constipation, alopecia, headache, fatigue, and convulsions.
__label__noRel	Patients receiving concomitant and maintenance temozolomide + radiotherapy had significantly improved overall survival.	Median survival was 14.6 months (temozolomide + radiotherapy) versus 12.1 months (radiotherapy alone).
__label__noRel	Patients receiving concomitant and maintenance temozolomide + radiotherapy had significantly improved overall survival.	The hazard ratio was 0.63 (95% confidence interval, 0.52-0.75; log-rank, P < 0.0001).
__label__noRel	There is no consensus on an accepted intervention that significantly reduces its severity.	We could not identify any significant difference in the incidence of severe mucositis based on whether patients were allocated to receive misoprostol or placebo.
__label__noRel	There is no consensus on an accepted intervention that significantly reduces its severity.	There was no significant difference in the mean area under the mucositis curve (13.2 vs 16.6; P = 0.1).
__label__noRel	There is no consensus on an accepted intervention that significantly reduces its severity.	Patients allocated to misoprostol did report slightly increased soreness (7.6 vs 6.9; P = 0.04) and a greater use of analgesics.
__label__noRel	There is no consensus on an accepted intervention that significantly reduces its severity.	However, this difference did not translate into a worse feeling of general well-being as measured by a simple visual analogue scale (5.8 vs 5.2; P = 0.3).
__label__noRel	There is no consensus on an accepted intervention that significantly reduces its severity.	In conclusion, we were unable to identify a reduction in radiation-induced mucositis in patients receiving misoprostol.
__label__noRel	There is no consensus on an accepted intervention that significantly reduces its severity.	There is a paucity of high-level evidence on potentially useful interventions and a continued need for new and innovative research, incorporating quality-of-life measurements, in patients experiencing radiation-induced mucositis.
__label__noRel	We could not identify any significant difference in the incidence of severe mucositis based on whether patients were allocated to receive misoprostol or placebo.	There is no consensus on an accepted intervention that significantly reduces its severity.
__label__noRel	We could not identify any significant difference in the incidence of severe mucositis based on whether patients were allocated to receive misoprostol or placebo.	There was no significant difference in the mean area under the mucositis curve (13.2 vs 16.6; P = 0.1).
__label__noRel	We could not identify any significant difference in the incidence of severe mucositis based on whether patients were allocated to receive misoprostol or placebo.	Patients allocated to misoprostol did report slightly increased soreness (7.6 vs 6.9; P = 0.04) and a greater use of analgesics.
__label__noRel	We could not identify any significant difference in the incidence of severe mucositis based on whether patients were allocated to receive misoprostol or placebo.	However, this difference did not translate into a worse feeling of general well-being as measured by a simple visual analogue scale (5.8 vs 5.2; P = 0.3).
__label__noRel	We could not identify any significant difference in the incidence of severe mucositis based on whether patients were allocated to receive misoprostol or placebo.	In conclusion, we were unable to identify a reduction in radiation-induced mucositis in patients receiving misoprostol.
__label__noRel	We could not identify any significant difference in the incidence of severe mucositis based on whether patients were allocated to receive misoprostol or placebo.	There is a paucity of high-level evidence on potentially useful interventions and a continued need for new and innovative research, incorporating quality-of-life measurements, in patients experiencing radiation-induced mucositis.
__label__noRel	There was no significant difference in the mean area under the mucositis curve (13.2 vs 16.6; P = 0.1).	There is no consensus on an accepted intervention that significantly reduces its severity.
__label__noRel	There was no significant difference in the mean area under the mucositis curve (13.2 vs 16.6; P = 0.1).	We could not identify any significant difference in the incidence of severe mucositis based on whether patients were allocated to receive misoprostol or placebo.
__label__noRel	There was no significant difference in the mean area under the mucositis curve (13.2 vs 16.6; P = 0.1).	Patients allocated to misoprostol did report slightly increased soreness (7.6 vs 6.9; P = 0.04) and a greater use of analgesics.
__label__noRel	There was no significant difference in the mean area under the mucositis curve (13.2 vs 16.6; P = 0.1).	However, this difference did not translate into a worse feeling of general well-being as measured by a simple visual analogue scale (5.8 vs 5.2; P = 0.3).
__label__Support	There was no significant difference in the mean area under the mucositis curve (13.2 vs 16.6; P = 0.1).	In conclusion, we were unable to identify a reduction in radiation-induced mucositis in patients receiving misoprostol.
__label__noRel	There was no significant difference in the mean area under the mucositis curve (13.2 vs 16.6; P = 0.1).	There is a paucity of high-level evidence on potentially useful interventions and a continued need for new and innovative research, incorporating quality-of-life measurements, in patients experiencing radiation-induced mucositis.
__label__noRel	Patients allocated to misoprostol did report slightly increased soreness (7.6 vs 6.9; P = 0.04) and a greater use of analgesics.	There is no consensus on an accepted intervention that significantly reduces its severity.
__label__noRel	Patients allocated to misoprostol did report slightly increased soreness (7.6 vs 6.9; P = 0.04) and a greater use of analgesics.	We could not identify any significant difference in the incidence of severe mucositis based on whether patients were allocated to receive misoprostol or placebo.
__label__noRel	Patients allocated to misoprostol did report slightly increased soreness (7.6 vs 6.9; P = 0.04) and a greater use of analgesics.	There was no significant difference in the mean area under the mucositis curve (13.2 vs 16.6; P = 0.1).
__label__noRel	Patients allocated to misoprostol did report slightly increased soreness (7.6 vs 6.9; P = 0.04) and a greater use of analgesics.	However, this difference did not translate into a worse feeling of general well-being as measured by a simple visual analogue scale (5.8 vs 5.2; P = 0.3).
__label__Attack	Patients allocated to misoprostol did report slightly increased soreness (7.6 vs 6.9; P = 0.04) and a greater use of analgesics.	In conclusion, we were unable to identify a reduction in radiation-induced mucositis in patients receiving misoprostol.
__label__noRel	Patients allocated to misoprostol did report slightly increased soreness (7.6 vs 6.9; P = 0.04) and a greater use of analgesics.	There is a paucity of high-level evidence on potentially useful interventions and a continued need for new and innovative research, incorporating quality-of-life measurements, in patients experiencing radiation-induced mucositis.
__label__noRel	However, this difference did not translate into a worse feeling of general well-being as measured by a simple visual analogue scale (5.8 vs 5.2; P = 0.3).	There is no consensus on an accepted intervention that significantly reduces its severity.
__label__noRel	However, this difference did not translate into a worse feeling of general well-being as measured by a simple visual analogue scale (5.8 vs 5.2; P = 0.3).	We could not identify any significant difference in the incidence of severe mucositis based on whether patients were allocated to receive misoprostol or placebo.
__label__noRel	However, this difference did not translate into a worse feeling of general well-being as measured by a simple visual analogue scale (5.8 vs 5.2; P = 0.3).	There was no significant difference in the mean area under the mucositis curve (13.2 vs 16.6; P = 0.1).
__label__Attack	However, this difference did not translate into a worse feeling of general well-being as measured by a simple visual analogue scale (5.8 vs 5.2; P = 0.3).	Patients allocated to misoprostol did report slightly increased soreness (7.6 vs 6.9; P = 0.04) and a greater use of analgesics.
__label__noRel	However, this difference did not translate into a worse feeling of general well-being as measured by a simple visual analogue scale (5.8 vs 5.2; P = 0.3).	In conclusion, we were unable to identify a reduction in radiation-induced mucositis in patients receiving misoprostol.
__label__noRel	However, this difference did not translate into a worse feeling of general well-being as measured by a simple visual analogue scale (5.8 vs 5.2; P = 0.3).	There is a paucity of high-level evidence on potentially useful interventions and a continued need for new and innovative research, incorporating quality-of-life measurements, in patients experiencing radiation-induced mucositis.
__label__noRel	In conclusion, we were unable to identify a reduction in radiation-induced mucositis in patients receiving misoprostol.	There is no consensus on an accepted intervention that significantly reduces its severity.
__label__noRel	In conclusion, we were unable to identify a reduction in radiation-induced mucositis in patients receiving misoprostol.	We could not identify any significant difference in the incidence of severe mucositis based on whether patients were allocated to receive misoprostol or placebo.
__label__noRel	In conclusion, we were unable to identify a reduction in radiation-induced mucositis in patients receiving misoprostol.	There was no significant difference in the mean area under the mucositis curve (13.2 vs 16.6; P = 0.1).
__label__noRel	In conclusion, we were unable to identify a reduction in radiation-induced mucositis in patients receiving misoprostol.	Patients allocated to misoprostol did report slightly increased soreness (7.6 vs 6.9; P = 0.04) and a greater use of analgesics.
__label__noRel	In conclusion, we were unable to identify a reduction in radiation-induced mucositis in patients receiving misoprostol.	However, this difference did not translate into a worse feeling of general well-being as measured by a simple visual analogue scale (5.8 vs 5.2; P = 0.3).
__label__noRel	In conclusion, we were unable to identify a reduction in radiation-induced mucositis in patients receiving misoprostol.	There is a paucity of high-level evidence on potentially useful interventions and a continued need for new and innovative research, incorporating quality-of-life measurements, in patients experiencing radiation-induced mucositis.
__label__noRel	There is a paucity of high-level evidence on potentially useful interventions and a continued need for new and innovative research, incorporating quality-of-life measurements, in patients experiencing radiation-induced mucositis.	There is no consensus on an accepted intervention that significantly reduces its severity.
__label__noRel	There is a paucity of high-level evidence on potentially useful interventions and a continued need for new and innovative research, incorporating quality-of-life measurements, in patients experiencing radiation-induced mucositis.	We could not identify any significant difference in the incidence of severe mucositis based on whether patients were allocated to receive misoprostol or placebo.
__label__noRel	There is a paucity of high-level evidence on potentially useful interventions and a continued need for new and innovative research, incorporating quality-of-life measurements, in patients experiencing radiation-induced mucositis.	There was no significant difference in the mean area under the mucositis curve (13.2 vs 16.6; P = 0.1).
__label__noRel	There is a paucity of high-level evidence on potentially useful interventions and a continued need for new and innovative research, incorporating quality-of-life measurements, in patients experiencing radiation-induced mucositis.	Patients allocated to misoprostol did report slightly increased soreness (7.6 vs 6.9; P = 0.04) and a greater use of analgesics.
__label__noRel	There is a paucity of high-level evidence on potentially useful interventions and a continued need for new and innovative research, incorporating quality-of-life measurements, in patients experiencing radiation-induced mucositis.	However, this difference did not translate into a worse feeling of general well-being as measured by a simple visual analogue scale (5.8 vs 5.2; P = 0.3).
__label__noRel	There is a paucity of high-level evidence on potentially useful interventions and a continued need for new and innovative research, incorporating quality-of-life measurements, in patients experiencing radiation-induced mucositis.	In conclusion, we were unable to identify a reduction in radiation-induced mucositis in patients receiving misoprostol.
__label__noRel	Major toxicity was similar across all three groups.	With a median follow-up time of 12 months and 382 deaths, there was no clear survival benefit when comparing PCV with TMZ (hazard ratio [HR], 0.91; 95% CI, 0.74 to 1.11; P = .350).
__label__noRel	Major toxicity was similar across all three groups.	For TMZ-5 versus TMZ-21, 12-week PFS rates were similar (63.6% and 65.7%, respectively; P = .745),
__label__noRel	Major toxicity was similar across all three groups.	but TMZ-5 improved overall PFS (HR, 1.38; 95% CI, 1.05 to 1.82; P = .023), survival (HR, 1.32; 95% CI, 0.99 to 1.75; P = .056), and global quality of life (49% v 19% improved > 10 points at 6 months, respectively; P = .005).
__label__Support	Major toxicity was similar across all three groups.	Although TMZ (both arms combined) did not show a clear benefit compared with PCV, comparison of the TMZ schedules demonstrated that the 21-day schedule was inferior to the 5-day schedule in this setting.
__label__noRel	Major toxicity was similar across all three groups.	This challenges the current understanding of increasing TMZ dose-intensity by prolonged scheduling.
__label__noRel	With a median follow-up time of 12 months and 382 deaths, there was no clear survival benefit when comparing PCV with TMZ (hazard ratio [HR], 0.91; 95% CI, 0.74 to 1.11; P = .350).	Major toxicity was similar across all three groups.
__label__noRel	With a median follow-up time of 12 months and 382 deaths, there was no clear survival benefit when comparing PCV with TMZ (hazard ratio [HR], 0.91; 95% CI, 0.74 to 1.11; P = .350).	For TMZ-5 versus TMZ-21, 12-week PFS rates were similar (63.6% and 65.7%, respectively; P = .745),
__label__noRel	With a median follow-up time of 12 months and 382 deaths, there was no clear survival benefit when comparing PCV with TMZ (hazard ratio [HR], 0.91; 95% CI, 0.74 to 1.11; P = .350).	but TMZ-5 improved overall PFS (HR, 1.38; 95% CI, 1.05 to 1.82; P = .023), survival (HR, 1.32; 95% CI, 0.99 to 1.75; P = .056), and global quality of life (49% v 19% improved > 10 points at 6 months, respectively; P = .005).
__label__Support	With a median follow-up time of 12 months and 382 deaths, there was no clear survival benefit when comparing PCV with TMZ (hazard ratio [HR], 0.91; 95% CI, 0.74 to 1.11; P = .350).	Although TMZ (both arms combined) did not show a clear benefit compared with PCV, comparison of the TMZ schedules demonstrated that the 21-day schedule was inferior to the 5-day schedule in this setting.
__label__noRel	With a median follow-up time of 12 months and 382 deaths, there was no clear survival benefit when comparing PCV with TMZ (hazard ratio [HR], 0.91; 95% CI, 0.74 to 1.11; P = .350).	This challenges the current understanding of increasing TMZ dose-intensity by prolonged scheduling.
__label__noRel	For TMZ-5 versus TMZ-21, 12-week PFS rates were similar (63.6% and 65.7%, respectively; P = .745),	Major toxicity was similar across all three groups.
__label__noRel	For TMZ-5 versus TMZ-21, 12-week PFS rates were similar (63.6% and 65.7%, respectively; P = .745),	With a median follow-up time of 12 months and 382 deaths, there was no clear survival benefit when comparing PCV with TMZ (hazard ratio [HR], 0.91; 95% CI, 0.74 to 1.11; P = .350).
__label__noRel	For TMZ-5 versus TMZ-21, 12-week PFS rates were similar (63.6% and 65.7%, respectively; P = .745),	but TMZ-5 improved overall PFS (HR, 1.38; 95% CI, 1.05 to 1.82; P = .023), survival (HR, 1.32; 95% CI, 0.99 to 1.75; P = .056), and global quality of life (49% v 19% improved > 10 points at 6 months, respectively; P = .005).
__label__Support	For TMZ-5 versus TMZ-21, 12-week PFS rates were similar (63.6% and 65.7%, respectively; P = .745),	Although TMZ (both arms combined) did not show a clear benefit compared with PCV, comparison of the TMZ schedules demonstrated that the 21-day schedule was inferior to the 5-day schedule in this setting.
__label__noRel	For TMZ-5 versus TMZ-21, 12-week PFS rates were similar (63.6% and 65.7%, respectively; P = .745),	This challenges the current understanding of increasing TMZ dose-intensity by prolonged scheduling.
__label__noRel	but TMZ-5 improved overall PFS (HR, 1.38; 95% CI, 1.05 to 1.82; P = .023), survival (HR, 1.32; 95% CI, 0.99 to 1.75; P = .056), and global quality of life (49% v 19% improved > 10 points at 6 months, respectively; P = .005).	Major toxicity was similar across all three groups.
__label__noRel	but TMZ-5 improved overall PFS (HR, 1.38; 95% CI, 1.05 to 1.82; P = .023), survival (HR, 1.32; 95% CI, 0.99 to 1.75; P = .056), and global quality of life (49% v 19% improved > 10 points at 6 months, respectively; P = .005).	With a median follow-up time of 12 months and 382 deaths, there was no clear survival benefit when comparing PCV with TMZ (hazard ratio [HR], 0.91; 95% CI, 0.74 to 1.11; P = .350).
__label__Attack	but TMZ-5 improved overall PFS (HR, 1.38; 95% CI, 1.05 to 1.82; P = .023), survival (HR, 1.32; 95% CI, 0.99 to 1.75; P = .056), and global quality of life (49% v 19% improved > 10 points at 6 months, respectively; P = .005).	For TMZ-5 versus TMZ-21, 12-week PFS rates were similar (63.6% and 65.7%, respectively; P = .745),
__label__noRel	but TMZ-5 improved overall PFS (HR, 1.38; 95% CI, 1.05 to 1.82; P = .023), survival (HR, 1.32; 95% CI, 0.99 to 1.75; P = .056), and global quality of life (49% v 19% improved > 10 points at 6 months, respectively; P = .005).	Although TMZ (both arms combined) did not show a clear benefit compared with PCV, comparison of the TMZ schedules demonstrated that the 21-day schedule was inferior to the 5-day schedule in this setting.
__label__noRel	but TMZ-5 improved overall PFS (HR, 1.38; 95% CI, 1.05 to 1.82; P = .023), survival (HR, 1.32; 95% CI, 0.99 to 1.75; P = .056), and global quality of life (49% v 19% improved > 10 points at 6 months, respectively; P = .005).	This challenges the current understanding of increasing TMZ dose-intensity by prolonged scheduling.
__label__noRel	Although TMZ (both arms combined) did not show a clear benefit compared with PCV, comparison of the TMZ schedules demonstrated that the 21-day schedule was inferior to the 5-day schedule in this setting.	Major toxicity was similar across all three groups.
__label__noRel	Although TMZ (both arms combined) did not show a clear benefit compared with PCV, comparison of the TMZ schedules demonstrated that the 21-day schedule was inferior to the 5-day schedule in this setting.	With a median follow-up time of 12 months and 382 deaths, there was no clear survival benefit when comparing PCV with TMZ (hazard ratio [HR], 0.91; 95% CI, 0.74 to 1.11; P = .350).
__label__noRel	Although TMZ (both arms combined) did not show a clear benefit compared with PCV, comparison of the TMZ schedules demonstrated that the 21-day schedule was inferior to the 5-day schedule in this setting.	For TMZ-5 versus TMZ-21, 12-week PFS rates were similar (63.6% and 65.7%, respectively; P = .745),
__label__noRel	Although TMZ (both arms combined) did not show a clear benefit compared with PCV, comparison of the TMZ schedules demonstrated that the 21-day schedule was inferior to the 5-day schedule in this setting.	but TMZ-5 improved overall PFS (HR, 1.38; 95% CI, 1.05 to 1.82; P = .023), survival (HR, 1.32; 95% CI, 0.99 to 1.75; P = .056), and global quality of life (49% v 19% improved > 10 points at 6 months, respectively; P = .005).
__label__Support	Although TMZ (both arms combined) did not show a clear benefit compared with PCV, comparison of the TMZ schedules demonstrated that the 21-day schedule was inferior to the 5-day schedule in this setting.	This challenges the current understanding of increasing TMZ dose-intensity by prolonged scheduling.
__label__noRel	This challenges the current understanding of increasing TMZ dose-intensity by prolonged scheduling.	Major toxicity was similar across all three groups.
__label__noRel	This challenges the current understanding of increasing TMZ dose-intensity by prolonged scheduling.	With a median follow-up time of 12 months and 382 deaths, there was no clear survival benefit when comparing PCV with TMZ (hazard ratio [HR], 0.91; 95% CI, 0.74 to 1.11; P = .350).
__label__noRel	This challenges the current understanding of increasing TMZ dose-intensity by prolonged scheduling.	For TMZ-5 versus TMZ-21, 12-week PFS rates were similar (63.6% and 65.7%, respectively; P = .745),
__label__noRel	This challenges the current understanding of increasing TMZ dose-intensity by prolonged scheduling.	but TMZ-5 improved overall PFS (HR, 1.38; 95% CI, 1.05 to 1.82; P = .023), survival (HR, 1.32; 95% CI, 0.99 to 1.75; P = .056), and global quality of life (49% v 19% improved > 10 points at 6 months, respectively; P = .005).
__label__noRel	This challenges the current understanding of increasing TMZ dose-intensity by prolonged scheduling.	Although TMZ (both arms combined) did not show a clear benefit compared with PCV, comparison of the TMZ schedules demonstrated that the 21-day schedule was inferior to the 5-day schedule in this setting.
__label__noRel	No significant effect was seen on global health status/quality of life.	A supervised multimodal exercise intervention including high and low intensity components was feasible and could safely be used in patients with various cancers who were receiving adjuvant chemotherapy or treatment for advanced disease.
__label__noRel	No significant effect was seen on global health status/quality of life.	The intervention reduced fatigue and improved vitality, aerobic capacity, muscular strength, and physical and functional activity, and emotional wellbeing,
__label__Support	No significant effect was seen on global health status/quality of life.	but not quality of life.
__label__noRel	No significant effect was seen on global health status/quality of life.	Improvement was noted in physical capacity: estimated mean difference between groups for maximum oxygen consumption was 0.16 l/min (95% CI 0.1 to 0.2, P<0.0001) and for muscular strength (leg press) was 29.7 kg (23.4 to 34.9, P<0.0001).
__label__noRel	No significant effect was seen on global health status/quality of life.	Significant effects were seen on vitality (effect size 0.55, 95% CI 0.27 to 0.82), physical functioning (0.37, 0.09 to 0.65), role physical (0.37, 0.10 to 0.64), role emotional (0.32, 0.05 to 0.59), and mental health (0.28, 0.02 to 0.56) scores.
__label__noRel	No significant effect was seen on global health status/quality of life.	Adjusted for baseline score, disease, and demographic covariates, the intervention group showed an estimated improvement at six weeks for the primary outcome, fatigue, of -6.6 points (95% confidence interval -12.3 to -0.9, P=0.02; effect size=0.33, 0.04 to 0.61).
__label__noRel	A supervised multimodal exercise intervention including high and low intensity components was feasible and could safely be used in patients with various cancers who were receiving adjuvant chemotherapy or treatment for advanced disease.	No significant effect was seen on global health status/quality of life.
__label__noRel	A supervised multimodal exercise intervention including high and low intensity components was feasible and could safely be used in patients with various cancers who were receiving adjuvant chemotherapy or treatment for advanced disease.	The intervention reduced fatigue and improved vitality, aerobic capacity, muscular strength, and physical and functional activity, and emotional wellbeing,
__label__noRel	A supervised multimodal exercise intervention including high and low intensity components was feasible and could safely be used in patients with various cancers who were receiving adjuvant chemotherapy or treatment for advanced disease.	but not quality of life.
__label__noRel	A supervised multimodal exercise intervention including high and low intensity components was feasible and could safely be used in patients with various cancers who were receiving adjuvant chemotherapy or treatment for advanced disease.	Improvement was noted in physical capacity: estimated mean difference between groups for maximum oxygen consumption was 0.16 l/min (95% CI 0.1 to 0.2, P<0.0001) and for muscular strength (leg press) was 29.7 kg (23.4 to 34.9, P<0.0001).
__label__noRel	A supervised multimodal exercise intervention including high and low intensity components was feasible and could safely be used in patients with various cancers who were receiving adjuvant chemotherapy or treatment for advanced disease.	Significant effects were seen on vitality (effect size 0.55, 95% CI 0.27 to 0.82), physical functioning (0.37, 0.09 to 0.65), role physical (0.37, 0.10 to 0.64), role emotional (0.32, 0.05 to 0.59), and mental health (0.28, 0.02 to 0.56) scores.
__label__noRel	A supervised multimodal exercise intervention including high and low intensity components was feasible and could safely be used in patients with various cancers who were receiving adjuvant chemotherapy or treatment for advanced disease.	Adjusted for baseline score, disease, and demographic covariates, the intervention group showed an estimated improvement at six weeks for the primary outcome, fatigue, of -6.6 points (95% confidence interval -12.3 to -0.9, P=0.02; effect size=0.33, 0.04 to 0.61).
__label__noRel	The intervention reduced fatigue and improved vitality, aerobic capacity, muscular strength, and physical and functional activity, and emotional wellbeing,	No significant effect was seen on global health status/quality of life.
__label__Support	The intervention reduced fatigue and improved vitality, aerobic capacity, muscular strength, and physical and functional activity, and emotional wellbeing,	A supervised multimodal exercise intervention including high and low intensity components was feasible and could safely be used in patients with various cancers who were receiving adjuvant chemotherapy or treatment for advanced disease.
__label__noRel	The intervention reduced fatigue and improved vitality, aerobic capacity, muscular strength, and physical and functional activity, and emotional wellbeing,	but not quality of life.
__label__noRel	The intervention reduced fatigue and improved vitality, aerobic capacity, muscular strength, and physical and functional activity, and emotional wellbeing,	Improvement was noted in physical capacity: estimated mean difference between groups for maximum oxygen consumption was 0.16 l/min (95% CI 0.1 to 0.2, P<0.0001) and for muscular strength (leg press) was 29.7 kg (23.4 to 34.9, P<0.0001).
__label__noRel	The intervention reduced fatigue and improved vitality, aerobic capacity, muscular strength, and physical and functional activity, and emotional wellbeing,	Significant effects were seen on vitality (effect size 0.55, 95% CI 0.27 to 0.82), physical functioning (0.37, 0.09 to 0.65), role physical (0.37, 0.10 to 0.64), role emotional (0.32, 0.05 to 0.59), and mental health (0.28, 0.02 to 0.56) scores.
__label__noRel	The intervention reduced fatigue and improved vitality, aerobic capacity, muscular strength, and physical and functional activity, and emotional wellbeing,	Adjusted for baseline score, disease, and demographic covariates, the intervention group showed an estimated improvement at six weeks for the primary outcome, fatigue, of -6.6 points (95% confidence interval -12.3 to -0.9, P=0.02; effect size=0.33, 0.04 to 0.61).
__label__noRel	but not quality of life.	No significant effect was seen on global health status/quality of life.
__label__noRel	but not quality of life.	A supervised multimodal exercise intervention including high and low intensity components was feasible and could safely be used in patients with various cancers who were receiving adjuvant chemotherapy or treatment for advanced disease.
__label__Attack	but not quality of life.	The intervention reduced fatigue and improved vitality, aerobic capacity, muscular strength, and physical and functional activity, and emotional wellbeing,
__label__noRel	but not quality of life.	Improvement was noted in physical capacity: estimated mean difference between groups for maximum oxygen consumption was 0.16 l/min (95% CI 0.1 to 0.2, P<0.0001) and for muscular strength (leg press) was 29.7 kg (23.4 to 34.9, P<0.0001).
__label__noRel	but not quality of life.	Significant effects were seen on vitality (effect size 0.55, 95% CI 0.27 to 0.82), physical functioning (0.37, 0.09 to 0.65), role physical (0.37, 0.10 to 0.64), role emotional (0.32, 0.05 to 0.59), and mental health (0.28, 0.02 to 0.56) scores.
__label__noRel	but not quality of life.	Adjusted for baseline score, disease, and demographic covariates, the intervention group showed an estimated improvement at six weeks for the primary outcome, fatigue, of -6.6 points (95% confidence interval -12.3 to -0.9, P=0.02; effect size=0.33, 0.04 to 0.61).
__label__noRel	Improvement was noted in physical capacity: estimated mean difference between groups for maximum oxygen consumption was 0.16 l/min (95% CI 0.1 to 0.2, P<0.0001) and for muscular strength (leg press) was 29.7 kg (23.4 to 34.9, P<0.0001).	No significant effect was seen on global health status/quality of life.
__label__noRel	Improvement was noted in physical capacity: estimated mean difference between groups for maximum oxygen consumption was 0.16 l/min (95% CI 0.1 to 0.2, P<0.0001) and for muscular strength (leg press) was 29.7 kg (23.4 to 34.9, P<0.0001).	A supervised multimodal exercise intervention including high and low intensity components was feasible and could safely be used in patients with various cancers who were receiving adjuvant chemotherapy or treatment for advanced disease.
__label__Support	Improvement was noted in physical capacity: estimated mean difference between groups for maximum oxygen consumption was 0.16 l/min (95% CI 0.1 to 0.2, P<0.0001) and for muscular strength (leg press) was 29.7 kg (23.4 to 34.9, P<0.0001).	The intervention reduced fatigue and improved vitality, aerobic capacity, muscular strength, and physical and functional activity, and emotional wellbeing,
__label__noRel	Improvement was noted in physical capacity: estimated mean difference between groups for maximum oxygen consumption was 0.16 l/min (95% CI 0.1 to 0.2, P<0.0001) and for muscular strength (leg press) was 29.7 kg (23.4 to 34.9, P<0.0001).	but not quality of life.
__label__noRel	Improvement was noted in physical capacity: estimated mean difference between groups for maximum oxygen consumption was 0.16 l/min (95% CI 0.1 to 0.2, P<0.0001) and for muscular strength (leg press) was 29.7 kg (23.4 to 34.9, P<0.0001).	Significant effects were seen on vitality (effect size 0.55, 95% CI 0.27 to 0.82), physical functioning (0.37, 0.09 to 0.65), role physical (0.37, 0.10 to 0.64), role emotional (0.32, 0.05 to 0.59), and mental health (0.28, 0.02 to 0.56) scores.
__label__noRel	Improvement was noted in physical capacity: estimated mean difference between groups for maximum oxygen consumption was 0.16 l/min (95% CI 0.1 to 0.2, P<0.0001) and for muscular strength (leg press) was 29.7 kg (23.4 to 34.9, P<0.0001).	Adjusted for baseline score, disease, and demographic covariates, the intervention group showed an estimated improvement at six weeks for the primary outcome, fatigue, of -6.6 points (95% confidence interval -12.3 to -0.9, P=0.02; effect size=0.33, 0.04 to 0.61).
__label__noRel	Significant effects were seen on vitality (effect size 0.55, 95% CI 0.27 to 0.82), physical functioning (0.37, 0.09 to 0.65), role physical (0.37, 0.10 to 0.64), role emotional (0.32, 0.05 to 0.59), and mental health (0.28, 0.02 to 0.56) scores.	No significant effect was seen on global health status/quality of life.
__label__noRel	Significant effects were seen on vitality (effect size 0.55, 95% CI 0.27 to 0.82), physical functioning (0.37, 0.09 to 0.65), role physical (0.37, 0.10 to 0.64), role emotional (0.32, 0.05 to 0.59), and mental health (0.28, 0.02 to 0.56) scores.	A supervised multimodal exercise intervention including high and low intensity components was feasible and could safely be used in patients with various cancers who were receiving adjuvant chemotherapy or treatment for advanced disease.
__label__Support	Significant effects were seen on vitality (effect size 0.55, 95% CI 0.27 to 0.82), physical functioning (0.37, 0.09 to 0.65), role physical (0.37, 0.10 to 0.64), role emotional (0.32, 0.05 to 0.59), and mental health (0.28, 0.02 to 0.56) scores.	The intervention reduced fatigue and improved vitality, aerobic capacity, muscular strength, and physical and functional activity, and emotional wellbeing,
__label__noRel	Significant effects were seen on vitality (effect size 0.55, 95% CI 0.27 to 0.82), physical functioning (0.37, 0.09 to 0.65), role physical (0.37, 0.10 to 0.64), role emotional (0.32, 0.05 to 0.59), and mental health (0.28, 0.02 to 0.56) scores.	but not quality of life.
__label__noRel	Significant effects were seen on vitality (effect size 0.55, 95% CI 0.27 to 0.82), physical functioning (0.37, 0.09 to 0.65), role physical (0.37, 0.10 to 0.64), role emotional (0.32, 0.05 to 0.59), and mental health (0.28, 0.02 to 0.56) scores.	Improvement was noted in physical capacity: estimated mean difference between groups for maximum oxygen consumption was 0.16 l/min (95% CI 0.1 to 0.2, P<0.0001) and for muscular strength (leg press) was 29.7 kg (23.4 to 34.9, P<0.0001).
__label__noRel	Significant effects were seen on vitality (effect size 0.55, 95% CI 0.27 to 0.82), physical functioning (0.37, 0.09 to 0.65), role physical (0.37, 0.10 to 0.64), role emotional (0.32, 0.05 to 0.59), and mental health (0.28, 0.02 to 0.56) scores.	Adjusted for baseline score, disease, and demographic covariates, the intervention group showed an estimated improvement at six weeks for the primary outcome, fatigue, of -6.6 points (95% confidence interval -12.3 to -0.9, P=0.02; effect size=0.33, 0.04 to 0.61).
__label__noRel	Adjusted for baseline score, disease, and demographic covariates, the intervention group showed an estimated improvement at six weeks for the primary outcome, fatigue, of -6.6 points (95% confidence interval -12.3 to -0.9, P=0.02; effect size=0.33, 0.04 to 0.61).	No significant effect was seen on global health status/quality of life.
__label__noRel	Adjusted for baseline score, disease, and demographic covariates, the intervention group showed an estimated improvement at six weeks for the primary outcome, fatigue, of -6.6 points (95% confidence interval -12.3 to -0.9, P=0.02; effect size=0.33, 0.04 to 0.61).	A supervised multimodal exercise intervention including high and low intensity components was feasible and could safely be used in patients with various cancers who were receiving adjuvant chemotherapy or treatment for advanced disease.
__label__Support	Adjusted for baseline score, disease, and demographic covariates, the intervention group showed an estimated improvement at six weeks for the primary outcome, fatigue, of -6.6 points (95% confidence interval -12.3 to -0.9, P=0.02; effect size=0.33, 0.04 to 0.61).	The intervention reduced fatigue and improved vitality, aerobic capacity, muscular strength, and physical and functional activity, and emotional wellbeing,
__label__noRel	Adjusted for baseline score, disease, and demographic covariates, the intervention group showed an estimated improvement at six weeks for the primary outcome, fatigue, of -6.6 points (95% confidence interval -12.3 to -0.9, P=0.02; effect size=0.33, 0.04 to 0.61).	but not quality of life.
__label__noRel	Adjusted for baseline score, disease, and demographic covariates, the intervention group showed an estimated improvement at six weeks for the primary outcome, fatigue, of -6.6 points (95% confidence interval -12.3 to -0.9, P=0.02; effect size=0.33, 0.04 to 0.61).	Improvement was noted in physical capacity: estimated mean difference between groups for maximum oxygen consumption was 0.16 l/min (95% CI 0.1 to 0.2, P<0.0001) and for muscular strength (leg press) was 29.7 kg (23.4 to 34.9, P<0.0001).
__label__noRel	Adjusted for baseline score, disease, and demographic covariates, the intervention group showed an estimated improvement at six weeks for the primary outcome, fatigue, of -6.6 points (95% confidence interval -12.3 to -0.9, P=0.02; effect size=0.33, 0.04 to 0.61).	Significant effects were seen on vitality (effect size 0.55, 95% CI 0.27 to 0.82), physical functioning (0.37, 0.09 to 0.65), role physical (0.37, 0.10 to 0.64), role emotional (0.32, 0.05 to 0.59), and mental health (0.28, 0.02 to 0.56) scores.
__label__Support	A significant improvement in symptoms after treatment was found on day 5 (p < 0.001) and on day 10 (p = 0.0002).	"Laying on of hands" resulted in a significant improvement of cancer- or cancer-therapy-associated symptoms.
__label__noRel	A significant improvement in symptoms after treatment was found on day 5 (p < 0.001) and on day 10 (p = 0.0002).	The magnitude of improvement obtained was similar whether on a self-declared-healer- or an actor-provided "treatment".
__label__noRel	A significant improvement in symptoms after treatment was found on day 5 (p < 0.001) and on day 10 (p = 0.0002).	There was no significant difference in average score values between the "healer" and the actor with regard to the primary (p = 0.34) or the secondary endpoint (p = 0.94),
__label__noRel	A significant improvement in symptoms after treatment was found on day 5 (p < 0.001) and on day 10 (p = 0.0002).	but the comparison was limited due to major protocol violations by the "healer" who unblinded his status after the first run and quit the study.
__label__noRel	"Laying on of hands" resulted in a significant improvement of cancer- or cancer-therapy-associated symptoms.	A significant improvement in symptoms after treatment was found on day 5 (p < 0.001) and on day 10 (p = 0.0002).
__label__noRel	"Laying on of hands" resulted in a significant improvement of cancer- or cancer-therapy-associated symptoms.	The magnitude of improvement obtained was similar whether on a self-declared-healer- or an actor-provided "treatment".
__label__noRel	"Laying on of hands" resulted in a significant improvement of cancer- or cancer-therapy-associated symptoms.	There was no significant difference in average score values between the "healer" and the actor with regard to the primary (p = 0.34) or the secondary endpoint (p = 0.94),
__label__noRel	"Laying on of hands" resulted in a significant improvement of cancer- or cancer-therapy-associated symptoms.	but the comparison was limited due to major protocol violations by the "healer" who unblinded his status after the first run and quit the study.
__label__noRel	The magnitude of improvement obtained was similar whether on a self-declared-healer- or an actor-provided "treatment".	A significant improvement in symptoms after treatment was found on day 5 (p < 0.001) and on day 10 (p = 0.0002).
__label__noRel	The magnitude of improvement obtained was similar whether on a self-declared-healer- or an actor-provided "treatment".	"Laying on of hands" resulted in a significant improvement of cancer- or cancer-therapy-associated symptoms.
__label__noRel	The magnitude of improvement obtained was similar whether on a self-declared-healer- or an actor-provided "treatment".	There was no significant difference in average score values between the "healer" and the actor with regard to the primary (p = 0.34) or the secondary endpoint (p = 0.94),
__label__noRel	The magnitude of improvement obtained was similar whether on a self-declared-healer- or an actor-provided "treatment".	but the comparison was limited due to major protocol violations by the "healer" who unblinded his status after the first run and quit the study.
__label__noRel	There was no significant difference in average score values between the "healer" and the actor with regard to the primary (p = 0.34) or the secondary endpoint (p = 0.94),	A significant improvement in symptoms after treatment was found on day 5 (p < 0.001) and on day 10 (p = 0.0002).
__label__noRel	There was no significant difference in average score values between the "healer" and the actor with regard to the primary (p = 0.34) or the secondary endpoint (p = 0.94),	"Laying on of hands" resulted in a significant improvement of cancer- or cancer-therapy-associated symptoms.
__label__Support	There was no significant difference in average score values between the "healer" and the actor with regard to the primary (p = 0.34) or the secondary endpoint (p = 0.94),	The magnitude of improvement obtained was similar whether on a self-declared-healer- or an actor-provided "treatment".
__label__noRel	There was no significant difference in average score values between the "healer" and the actor with regard to the primary (p = 0.34) or the secondary endpoint (p = 0.94),	but the comparison was limited due to major protocol violations by the "healer" who unblinded his status after the first run and quit the study.
__label__noRel	but the comparison was limited due to major protocol violations by the "healer" who unblinded his status after the first run and quit the study.	A significant improvement in symptoms after treatment was found on day 5 (p < 0.001) and on day 10 (p = 0.0002).
__label__noRel	but the comparison was limited due to major protocol violations by the "healer" who unblinded his status after the first run and quit the study.	"Laying on of hands" resulted in a significant improvement of cancer- or cancer-therapy-associated symptoms.
__label__noRel	but the comparison was limited due to major protocol violations by the "healer" who unblinded his status after the first run and quit the study.	The magnitude of improvement obtained was similar whether on a self-declared-healer- or an actor-provided "treatment".
__label__Attack	but the comparison was limited due to major protocol violations by the "healer" who unblinded his status after the first run and quit the study.	There was no significant difference in average score values between the "healer" and the actor with regard to the primary (p = 0.34) or the secondary endpoint (p = 0.94),
__label__noRel	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).
__label__noRel	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.
__label__noRel	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).	The incidence of toxicity in the groups was similar.
__label__noRel	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).
__label__noRel	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).
__label__Support	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.
__label__noRel	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.
__label__noRel	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).
__label__noRel	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.
__label__noRel	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).	The incidence of toxicity in the groups was similar.
__label__noRel	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).
__label__noRel	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).
__label__Support	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.
__label__noRel	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.
__label__noRel	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).
__label__noRel	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).
__label__noRel	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.	The incidence of toxicity in the groups was similar.
__label__noRel	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).
__label__noRel	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).
__label__Support	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.
__label__noRel	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.
__label__noRel	The incidence of toxicity in the groups was similar.	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).
__label__noRel	The incidence of toxicity in the groups was similar.	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).
__label__noRel	The incidence of toxicity in the groups was similar.	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.
__label__noRel	The incidence of toxicity in the groups was similar.	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).
__label__noRel	The incidence of toxicity in the groups was similar.	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).
__label__noRel	The incidence of toxicity in the groups was similar.	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.
__label__Support	The incidence of toxicity in the groups was similar.	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.
__label__noRel	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).
__label__noRel	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).
__label__noRel	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.
__label__noRel	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).	The incidence of toxicity in the groups was similar.
__label__noRel	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).
__label__noRel	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.
__label__Support	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.
__label__noRel	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).
__label__noRel	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).
__label__noRel	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.
__label__noRel	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).	The incidence of toxicity in the groups was similar.
__label__noRel	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).
__label__noRel	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.
__label__Support	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.
__label__noRel	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).
__label__noRel	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).
__label__noRel	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.
__label__noRel	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.	The incidence of toxicity in the groups was similar.
__label__noRel	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).
__label__noRel	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).
__label__Support	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.
__label__noRel	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).
__label__noRel	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).
__label__noRel	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.
__label__noRel	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.	The incidence of toxicity in the groups was similar.
__label__noRel	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).
__label__noRel	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).
__label__noRel	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.
__label__noRel	Nine CR and twenty-seven PR were obtained on one hundred eleven evaluable patients treated in experimental arm (RR = 32%, 95% confidence interval (95% CI): 24%-42%), while two CR and eleven PR were observed among one hundred three evaluable patients in control arm (RR = 13%, 95% CI: 7%-21%).	WHO grade 3-4 toxicity occurred in 13% of cycles of experimental arm and in 8% of cycles in control arm.
__label__noRel	Nine CR and twenty-seven PR were obtained on one hundred eleven evaluable patients treated in experimental arm (RR = 32%, 95% confidence interval (95% CI): 24%-42%), while two CR and eleven PR were observed among one hundred three evaluable patients in control arm (RR = 13%, 95% CI: 7%-21%).	The PFS was significantly longer in experimental arm (6.2 vs. 4.3 months, odds ratio 0.66, P = 0.003),
__label__noRel	Nine CR and twenty-seven PR were obtained on one hundred eleven evaluable patients treated in experimental arm (RR = 32%, 95% confidence interval (95% CI): 24%-42%), while two CR and eleven PR were observed among one hundred three evaluable patients in control arm (RR = 13%, 95% CI: 7%-21%).	the overall survival was similar in both arms (14.8 months in experimental arm vs. 14.1 months in control arm);
__label__noRel	Nine CR and twenty-seven PR were obtained on one hundred eleven evaluable patients treated in experimental arm (RR = 32%, 95% confidence interval (95% CI): 24%-42%), while two CR and eleven PR were observed among one hundred three evaluable patients in control arm (RR = 13%, 95% CI: 7%-21%).	quality of life was similar as well.
__label__noRel	Nine CR and twenty-seven PR were obtained on one hundred eleven evaluable patients treated in experimental arm (RR = 32%, 95% confidence interval (95% CI): 24%-42%), while two CR and eleven PR were observed among one hundred three evaluable patients in control arm (RR = 13%, 95% CI: 7%-21%).	Eighty percent of patients receiving second-line chemotherapy in control arm were treated with continuous infusion 5-FU.
__label__Support	Nine CR and twenty-seven PR were obtained on one hundred eleven evaluable patients treated in experimental arm (RR = 32%, 95% confidence interval (95% CI): 24%-42%), while two CR and eleven PR were observed among one hundred three evaluable patients in control arm (RR = 13%, 95% CI: 7%-21%).	schedule-specific biochemical modulation of FU is more active than MTX --> 5-FU as first-line treatment of advanced colorectal cancer.
__label__noRel	Nine CR and twenty-seven PR were obtained on one hundred eleven evaluable patients treated in experimental arm (RR = 32%, 95% confidence interval (95% CI): 24%-42%), while two CR and eleven PR were observed among one hundred three evaluable patients in control arm (RR = 13%, 95% CI: 7%-21%).	However, the overall survival was similar suggesting that alternating bolus and infusional 5-FU upfront may be as effective as giving them in sequence as first- and second-line treatment.
__label__noRel	WHO grade 3-4 toxicity occurred in 13% of cycles of experimental arm and in 8% of cycles in control arm.	Nine CR and twenty-seven PR were obtained on one hundred eleven evaluable patients treated in experimental arm (RR = 32%, 95% confidence interval (95% CI): 24%-42%), while two CR and eleven PR were observed among one hundred three evaluable patients in control arm (RR = 13%, 95% CI: 7%-21%).
__label__noRel	WHO grade 3-4 toxicity occurred in 13% of cycles of experimental arm and in 8% of cycles in control arm.	The PFS was significantly longer in experimental arm (6.2 vs. 4.3 months, odds ratio 0.66, P = 0.003),
__label__noRel	WHO grade 3-4 toxicity occurred in 13% of cycles of experimental arm and in 8% of cycles in control arm.	the overall survival was similar in both arms (14.8 months in experimental arm vs. 14.1 months in control arm);
__label__Support	WHO grade 3-4 toxicity occurred in 13% of cycles of experimental arm and in 8% of cycles in control arm.	quality of life was similar as well.
__label__noRel	WHO grade 3-4 toxicity occurred in 13% of cycles of experimental arm and in 8% of cycles in control arm.	Eighty percent of patients receiving second-line chemotherapy in control arm were treated with continuous infusion 5-FU.
__label__noRel	WHO grade 3-4 toxicity occurred in 13% of cycles of experimental arm and in 8% of cycles in control arm.	schedule-specific biochemical modulation of FU is more active than MTX --> 5-FU as first-line treatment of advanced colorectal cancer.
__label__noRel	WHO grade 3-4 toxicity occurred in 13% of cycles of experimental arm and in 8% of cycles in control arm.	However, the overall survival was similar suggesting that alternating bolus and infusional 5-FU upfront may be as effective as giving them in sequence as first- and second-line treatment.
__label__noRel	The PFS was significantly longer in experimental arm (6.2 vs. 4.3 months, odds ratio 0.66, P = 0.003),	Nine CR and twenty-seven PR were obtained on one hundred eleven evaluable patients treated in experimental arm (RR = 32%, 95% confidence interval (95% CI): 24%-42%), while two CR and eleven PR were observed among one hundred three evaluable patients in control arm (RR = 13%, 95% CI: 7%-21%).
__label__noRel	The PFS was significantly longer in experimental arm (6.2 vs. 4.3 months, odds ratio 0.66, P = 0.003),	WHO grade 3-4 toxicity occurred in 13% of cycles of experimental arm and in 8% of cycles in control arm.
__label__noRel	The PFS was significantly longer in experimental arm (6.2 vs. 4.3 months, odds ratio 0.66, P = 0.003),	the overall survival was similar in both arms (14.8 months in experimental arm vs. 14.1 months in control arm);
__label__noRel	The PFS was significantly longer in experimental arm (6.2 vs. 4.3 months, odds ratio 0.66, P = 0.003),	quality of life was similar as well.
__label__noRel	The PFS was significantly longer in experimental arm (6.2 vs. 4.3 months, odds ratio 0.66, P = 0.003),	Eighty percent of patients receiving second-line chemotherapy in control arm were treated with continuous infusion 5-FU.
__label__noRel	The PFS was significantly longer in experimental arm (6.2 vs. 4.3 months, odds ratio 0.66, P = 0.003),	schedule-specific biochemical modulation of FU is more active than MTX --> 5-FU as first-line treatment of advanced colorectal cancer.
__label__Support	The PFS was significantly longer in experimental arm (6.2 vs. 4.3 months, odds ratio 0.66, P = 0.003),	However, the overall survival was similar suggesting that alternating bolus and infusional 5-FU upfront may be as effective as giving them in sequence as first- and second-line treatment.
__label__noRel	the overall survival was similar in both arms (14.8 months in experimental arm vs. 14.1 months in control arm);	Nine CR and twenty-seven PR were obtained on one hundred eleven evaluable patients treated in experimental arm (RR = 32%, 95% confidence interval (95% CI): 24%-42%), while two CR and eleven PR were observed among one hundred three evaluable patients in control arm (RR = 13%, 95% CI: 7%-21%).
__label__noRel	the overall survival was similar in both arms (14.8 months in experimental arm vs. 14.1 months in control arm);	WHO grade 3-4 toxicity occurred in 13% of cycles of experimental arm and in 8% of cycles in control arm.
__label__noRel	the overall survival was similar in both arms (14.8 months in experimental arm vs. 14.1 months in control arm);	The PFS was significantly longer in experimental arm (6.2 vs. 4.3 months, odds ratio 0.66, P = 0.003),
__label__noRel	the overall survival was similar in both arms (14.8 months in experimental arm vs. 14.1 months in control arm);	quality of life was similar as well.
__label__noRel	the overall survival was similar in both arms (14.8 months in experimental arm vs. 14.1 months in control arm);	Eighty percent of patients receiving second-line chemotherapy in control arm were treated with continuous infusion 5-FU.
__label__noRel	the overall survival was similar in both arms (14.8 months in experimental arm vs. 14.1 months in control arm);	schedule-specific biochemical modulation of FU is more active than MTX --> 5-FU as first-line treatment of advanced colorectal cancer.
__label__Support	the overall survival was similar in both arms (14.8 months in experimental arm vs. 14.1 months in control arm);	However, the overall survival was similar suggesting that alternating bolus and infusional 5-FU upfront may be as effective as giving them in sequence as first- and second-line treatment.
__label__noRel	quality of life was similar as well.	Nine CR and twenty-seven PR were obtained on one hundred eleven evaluable patients treated in experimental arm (RR = 32%, 95% confidence interval (95% CI): 24%-42%), while two CR and eleven PR were observed among one hundred three evaluable patients in control arm (RR = 13%, 95% CI: 7%-21%).
__label__noRel	quality of life was similar as well.	WHO grade 3-4 toxicity occurred in 13% of cycles of experimental arm and in 8% of cycles in control arm.
__label__noRel	quality of life was similar as well.	The PFS was significantly longer in experimental arm (6.2 vs. 4.3 months, odds ratio 0.66, P = 0.003),
__label__noRel	quality of life was similar as well.	the overall survival was similar in both arms (14.8 months in experimental arm vs. 14.1 months in control arm);
__label__noRel	quality of life was similar as well.	Eighty percent of patients receiving second-line chemotherapy in control arm were treated with continuous infusion 5-FU.
__label__noRel	quality of life was similar as well.	schedule-specific biochemical modulation of FU is more active than MTX --> 5-FU as first-line treatment of advanced colorectal cancer.
__label__noRel	quality of life was similar as well.	However, the overall survival was similar suggesting that alternating bolus and infusional 5-FU upfront may be as effective as giving them in sequence as first- and second-line treatment.
__label__noRel	Eighty percent of patients receiving second-line chemotherapy in control arm were treated with continuous infusion 5-FU.	Nine CR and twenty-seven PR were obtained on one hundred eleven evaluable patients treated in experimental arm (RR = 32%, 95% confidence interval (95% CI): 24%-42%), while two CR and eleven PR were observed among one hundred three evaluable patients in control arm (RR = 13%, 95% CI: 7%-21%).
__label__noRel	Eighty percent of patients receiving second-line chemotherapy in control arm were treated with continuous infusion 5-FU.	WHO grade 3-4 toxicity occurred in 13% of cycles of experimental arm and in 8% of cycles in control arm.
__label__noRel	Eighty percent of patients receiving second-line chemotherapy in control arm were treated with continuous infusion 5-FU.	The PFS was significantly longer in experimental arm (6.2 vs. 4.3 months, odds ratio 0.66, P = 0.003),
__label__noRel	Eighty percent of patients receiving second-line chemotherapy in control arm were treated with continuous infusion 5-FU.	the overall survival was similar in both arms (14.8 months in experimental arm vs. 14.1 months in control arm);
__label__noRel	Eighty percent of patients receiving second-line chemotherapy in control arm were treated with continuous infusion 5-FU.	quality of life was similar as well.
__label__noRel	Eighty percent of patients receiving second-line chemotherapy in control arm were treated with continuous infusion 5-FU.	schedule-specific biochemical modulation of FU is more active than MTX --> 5-FU as first-line treatment of advanced colorectal cancer.
__label__noRel	Eighty percent of patients receiving second-line chemotherapy in control arm were treated with continuous infusion 5-FU.	However, the overall survival was similar suggesting that alternating bolus and infusional 5-FU upfront may be as effective as giving them in sequence as first- and second-line treatment.
__label__noRel	schedule-specific biochemical modulation of FU is more active than MTX --> 5-FU as first-line treatment of advanced colorectal cancer.	Nine CR and twenty-seven PR were obtained on one hundred eleven evaluable patients treated in experimental arm (RR = 32%, 95% confidence interval (95% CI): 24%-42%), while two CR and eleven PR were observed among one hundred three evaluable patients in control arm (RR = 13%, 95% CI: 7%-21%).
__label__noRel	schedule-specific biochemical modulation of FU is more active than MTX --> 5-FU as first-line treatment of advanced colorectal cancer.	WHO grade 3-4 toxicity occurred in 13% of cycles of experimental arm and in 8% of cycles in control arm.
__label__noRel	schedule-specific biochemical modulation of FU is more active than MTX --> 5-FU as first-line treatment of advanced colorectal cancer.	The PFS was significantly longer in experimental arm (6.2 vs. 4.3 months, odds ratio 0.66, P = 0.003),
__label__noRel	schedule-specific biochemical modulation of FU is more active than MTX --> 5-FU as first-line treatment of advanced colorectal cancer.	the overall survival was similar in both arms (14.8 months in experimental arm vs. 14.1 months in control arm);
__label__noRel	schedule-specific biochemical modulation of FU is more active than MTX --> 5-FU as first-line treatment of advanced colorectal cancer.	quality of life was similar as well.
__label__noRel	schedule-specific biochemical modulation of FU is more active than MTX --> 5-FU as first-line treatment of advanced colorectal cancer.	Eighty percent of patients receiving second-line chemotherapy in control arm were treated with continuous infusion 5-FU.
__label__noRel	schedule-specific biochemical modulation of FU is more active than MTX --> 5-FU as first-line treatment of advanced colorectal cancer.	However, the overall survival was similar suggesting that alternating bolus and infusional 5-FU upfront may be as effective as giving them in sequence as first- and second-line treatment.
__label__noRel	However, the overall survival was similar suggesting that alternating bolus and infusional 5-FU upfront may be as effective as giving them in sequence as first- and second-line treatment.	Nine CR and twenty-seven PR were obtained on one hundred eleven evaluable patients treated in experimental arm (RR = 32%, 95% confidence interval (95% CI): 24%-42%), while two CR and eleven PR were observed among one hundred three evaluable patients in control arm (RR = 13%, 95% CI: 7%-21%).
__label__noRel	However, the overall survival was similar suggesting that alternating bolus and infusional 5-FU upfront may be as effective as giving them in sequence as first- and second-line treatment.	WHO grade 3-4 toxicity occurred in 13% of cycles of experimental arm and in 8% of cycles in control arm.
__label__noRel	However, the overall survival was similar suggesting that alternating bolus and infusional 5-FU upfront may be as effective as giving them in sequence as first- and second-line treatment.	The PFS was significantly longer in experimental arm (6.2 vs. 4.3 months, odds ratio 0.66, P = 0.003),
__label__noRel	However, the overall survival was similar suggesting that alternating bolus and infusional 5-FU upfront may be as effective as giving them in sequence as first- and second-line treatment.	the overall survival was similar in both arms (14.8 months in experimental arm vs. 14.1 months in control arm);
__label__noRel	However, the overall survival was similar suggesting that alternating bolus and infusional 5-FU upfront may be as effective as giving them in sequence as first- and second-line treatment.	quality of life was similar as well.
__label__noRel	However, the overall survival was similar suggesting that alternating bolus and infusional 5-FU upfront may be as effective as giving them in sequence as first- and second-line treatment.	Eighty percent of patients receiving second-line chemotherapy in control arm were treated with continuous infusion 5-FU.
__label__noRel	However, the overall survival was similar suggesting that alternating bolus and infusional 5-FU upfront may be as effective as giving them in sequence as first- and second-line treatment.	schedule-specific biochemical modulation of FU is more active than MTX --> 5-FU as first-line treatment of advanced colorectal cancer.
__label__noRel	Gefitinib did not show better OS compared with GP (hazard ratio [HR], 0.932; 95% CI, 0.716 to 1.213; P = .604; median OS, 22.3 v 22.9 months, respectively).	The 1-year PFS rates were 16.7% with gefitinib and 2.8% with GP (HR, 1.198; 95% CI, 0.944 to 1.520).
__label__noRel	Gefitinib did not show better OS compared with GP (hazard ratio [HR], 0.932; 95% CI, 0.716 to 1.213; P = .604; median OS, 22.3 v 22.9 months, respectively).	Response rates were 55% with gefitinib and 46% with GP (P = .101).
__label__noRel	Gefitinib did not show better OS compared with GP (hazard ratio [HR], 0.932; 95% CI, 0.716 to 1.213; P = .604; median OS, 22.3 v 22.9 months, respectively).	Myelosuppression, renal insufficiency, and fatigue were more common in the GP arm,
__label__noRel	Gefitinib did not show better OS compared with GP (hazard ratio [HR], 0.932; 95% CI, 0.716 to 1.213; P = .604; median OS, 22.3 v 22.9 months, respectively).	skin toxicities and liver dysfunction were more common in the gefitinib arm.
__label__noRel	Gefitinib did not show better OS compared with GP (hazard ratio [HR], 0.932; 95% CI, 0.716 to 1.213; P = .604; median OS, 22.3 v 22.9 months, respectively).	Two patients (1.3%) in the gefitinib arm developed interstitial lung disease and died.
__label__Support	Gefitinib did not show better OS compared with GP (hazard ratio [HR], 0.932; 95% CI, 0.716 to 1.213; P = .604; median OS, 22.3 v 22.9 months, respectively).	Gefitinib failed to demonstrate superior OS compared with GP as first-line therapy for NSLAs.
__label__noRel	The 1-year PFS rates were 16.7% with gefitinib and 2.8% with GP (HR, 1.198; 95% CI, 0.944 to 1.520).	Gefitinib did not show better OS compared with GP (hazard ratio [HR], 0.932; 95% CI, 0.716 to 1.213; P = .604; median OS, 22.3 v 22.9 months, respectively).
__label__noRel	The 1-year PFS rates were 16.7% with gefitinib and 2.8% with GP (HR, 1.198; 95% CI, 0.944 to 1.520).	Response rates were 55% with gefitinib and 46% with GP (P = .101).
__label__noRel	The 1-year PFS rates were 16.7% with gefitinib and 2.8% with GP (HR, 1.198; 95% CI, 0.944 to 1.520).	Myelosuppression, renal insufficiency, and fatigue were more common in the GP arm,
__label__noRel	The 1-year PFS rates were 16.7% with gefitinib and 2.8% with GP (HR, 1.198; 95% CI, 0.944 to 1.520).	skin toxicities and liver dysfunction were more common in the gefitinib arm.
__label__noRel	The 1-year PFS rates were 16.7% with gefitinib and 2.8% with GP (HR, 1.198; 95% CI, 0.944 to 1.520).	Two patients (1.3%) in the gefitinib arm developed interstitial lung disease and died.
__label__Support	The 1-year PFS rates were 16.7% with gefitinib and 2.8% with GP (HR, 1.198; 95% CI, 0.944 to 1.520).	Gefitinib failed to demonstrate superior OS compared with GP as first-line therapy for NSLAs.
__label__noRel	Response rates were 55% with gefitinib and 46% with GP (P = .101).	Gefitinib did not show better OS compared with GP (hazard ratio [HR], 0.932; 95% CI, 0.716 to 1.213; P = .604; median OS, 22.3 v 22.9 months, respectively).
__label__noRel	Response rates were 55% with gefitinib and 46% with GP (P = .101).	The 1-year PFS rates were 16.7% with gefitinib and 2.8% with GP (HR, 1.198; 95% CI, 0.944 to 1.520).
__label__noRel	Response rates were 55% with gefitinib and 46% with GP (P = .101).	Myelosuppression, renal insufficiency, and fatigue were more common in the GP arm,
__label__noRel	Response rates were 55% with gefitinib and 46% with GP (P = .101).	skin toxicities and liver dysfunction were more common in the gefitinib arm.
__label__noRel	Response rates were 55% with gefitinib and 46% with GP (P = .101).	Two patients (1.3%) in the gefitinib arm developed interstitial lung disease and died.
__label__noRel	Response rates were 55% with gefitinib and 46% with GP (P = .101).	Gefitinib failed to demonstrate superior OS compared with GP as first-line therapy for NSLAs.
__label__noRel	Myelosuppression, renal insufficiency, and fatigue were more common in the GP arm,	Gefitinib did not show better OS compared with GP (hazard ratio [HR], 0.932; 95% CI, 0.716 to 1.213; P = .604; median OS, 22.3 v 22.9 months, respectively).
__label__noRel	Myelosuppression, renal insufficiency, and fatigue were more common in the GP arm,	The 1-year PFS rates were 16.7% with gefitinib and 2.8% with GP (HR, 1.198; 95% CI, 0.944 to 1.520).
__label__noRel	Myelosuppression, renal insufficiency, and fatigue were more common in the GP arm,	Response rates were 55% with gefitinib and 46% with GP (P = .101).
__label__noRel	Myelosuppression, renal insufficiency, and fatigue were more common in the GP arm,	skin toxicities and liver dysfunction were more common in the gefitinib arm.
__label__noRel	Myelosuppression, renal insufficiency, and fatigue were more common in the GP arm,	Two patients (1.3%) in the gefitinib arm developed interstitial lung disease and died.
__label__Attack	Myelosuppression, renal insufficiency, and fatigue were more common in the GP arm,	Gefitinib failed to demonstrate superior OS compared with GP as first-line therapy for NSLAs.
__label__noRel	skin toxicities and liver dysfunction were more common in the gefitinib arm.	Gefitinib did not show better OS compared with GP (hazard ratio [HR], 0.932; 95% CI, 0.716 to 1.213; P = .604; median OS, 22.3 v 22.9 months, respectively).
__label__noRel	skin toxicities and liver dysfunction were more common in the gefitinib arm.	The 1-year PFS rates were 16.7% with gefitinib and 2.8% with GP (HR, 1.198; 95% CI, 0.944 to 1.520).
__label__noRel	skin toxicities and liver dysfunction were more common in the gefitinib arm.	Response rates were 55% with gefitinib and 46% with GP (P = .101).
__label__noRel	skin toxicities and liver dysfunction were more common in the gefitinib arm.	Myelosuppression, renal insufficiency, and fatigue were more common in the GP arm,
__label__noRel	skin toxicities and liver dysfunction were more common in the gefitinib arm.	Two patients (1.3%) in the gefitinib arm developed interstitial lung disease and died.
__label__Support	skin toxicities and liver dysfunction were more common in the gefitinib arm.	Gefitinib failed to demonstrate superior OS compared with GP as first-line therapy for NSLAs.
__label__noRel	Two patients (1.3%) in the gefitinib arm developed interstitial lung disease and died.	Gefitinib did not show better OS compared with GP (hazard ratio [HR], 0.932; 95% CI, 0.716 to 1.213; P = .604; median OS, 22.3 v 22.9 months, respectively).
__label__noRel	Two patients (1.3%) in the gefitinib arm developed interstitial lung disease and died.	The 1-year PFS rates were 16.7% with gefitinib and 2.8% with GP (HR, 1.198; 95% CI, 0.944 to 1.520).
__label__noRel	Two patients (1.3%) in the gefitinib arm developed interstitial lung disease and died.	Response rates were 55% with gefitinib and 46% with GP (P = .101).
__label__noRel	Two patients (1.3%) in the gefitinib arm developed interstitial lung disease and died.	Myelosuppression, renal insufficiency, and fatigue were more common in the GP arm,
__label__noRel	Two patients (1.3%) in the gefitinib arm developed interstitial lung disease and died.	skin toxicities and liver dysfunction were more common in the gefitinib arm.
__label__Support	Two patients (1.3%) in the gefitinib arm developed interstitial lung disease and died.	Gefitinib failed to demonstrate superior OS compared with GP as first-line therapy for NSLAs.
__label__noRel	Gefitinib failed to demonstrate superior OS compared with GP as first-line therapy for NSLAs.	Gefitinib did not show better OS compared with GP (hazard ratio [HR], 0.932; 95% CI, 0.716 to 1.213; P = .604; median OS, 22.3 v 22.9 months, respectively).
__label__noRel	Gefitinib failed to demonstrate superior OS compared with GP as first-line therapy for NSLAs.	The 1-year PFS rates were 16.7% with gefitinib and 2.8% with GP (HR, 1.198; 95% CI, 0.944 to 1.520).
__label__noRel	Gefitinib failed to demonstrate superior OS compared with GP as first-line therapy for NSLAs.	Response rates were 55% with gefitinib and 46% with GP (P = .101).
__label__noRel	Gefitinib failed to demonstrate superior OS compared with GP as first-line therapy for NSLAs.	Myelosuppression, renal insufficiency, and fatigue were more common in the GP arm,
__label__noRel	Gefitinib failed to demonstrate superior OS compared with GP as first-line therapy for NSLAs.	skin toxicities and liver dysfunction were more common in the gefitinib arm.
__label__noRel	Gefitinib failed to demonstrate superior OS compared with GP as first-line therapy for NSLAs.	Two patients (1.3%) in the gefitinib arm developed interstitial lung disease and died.
__label__noRel	No QOL differences were noted between arms.	GE/G Grade 3-4 toxicities included: neutropenia (18.3%/28.2%); thrombocytopenia (14.6%/25.6%); and fatigue (11.0%/7.7%).
__label__noRel	No QOL differences were noted between arms.	No statistically significant relationships between biomarker expression and outcomes were observed.
__label__noRel	No QOL differences were noted between arms.	patients with low expression of cytoplasmic pGSK-3 trended toward greater OS with GE treatment.
__label__noRel	No QOL differences were noted between arms.	OS, PFS, QOL, and RR were comparable between arms.
__label__noRel	No QOL differences were noted between arms.	Adding E to G did not increase hematologic toxicities.
__label__Support	No QOL differences were noted between arms.	Data suggest that the GE combination may improve clinical outcomes.
__label__noRel	GE/G Grade 3-4 toxicities included: neutropenia (18.3%/28.2%); thrombocytopenia (14.6%/25.6%); and fatigue (11.0%/7.7%).	No QOL differences were noted between arms.
__label__noRel	GE/G Grade 3-4 toxicities included: neutropenia (18.3%/28.2%); thrombocytopenia (14.6%/25.6%); and fatigue (11.0%/7.7%).	No statistically significant relationships between biomarker expression and outcomes were observed.
__label__noRel	GE/G Grade 3-4 toxicities included: neutropenia (18.3%/28.2%); thrombocytopenia (14.6%/25.6%); and fatigue (11.0%/7.7%).	patients with low expression of cytoplasmic pGSK-3 trended toward greater OS with GE treatment.
__label__noRel	GE/G Grade 3-4 toxicities included: neutropenia (18.3%/28.2%); thrombocytopenia (14.6%/25.6%); and fatigue (11.0%/7.7%).	OS, PFS, QOL, and RR were comparable between arms.
__label__Support	GE/G Grade 3-4 toxicities included: neutropenia (18.3%/28.2%); thrombocytopenia (14.6%/25.6%); and fatigue (11.0%/7.7%).	Adding E to G did not increase hematologic toxicities.
__label__noRel	GE/G Grade 3-4 toxicities included: neutropenia (18.3%/28.2%); thrombocytopenia (14.6%/25.6%); and fatigue (11.0%/7.7%).	Data suggest that the GE combination may improve clinical outcomes.
__label__noRel	No statistically significant relationships between biomarker expression and outcomes were observed.	No QOL differences were noted between arms.
__label__noRel	No statistically significant relationships between biomarker expression and outcomes were observed.	GE/G Grade 3-4 toxicities included: neutropenia (18.3%/28.2%); thrombocytopenia (14.6%/25.6%); and fatigue (11.0%/7.7%).
__label__noRel	No statistically significant relationships between biomarker expression and outcomes were observed.	patients with low expression of cytoplasmic pGSK-3 trended toward greater OS with GE treatment.
__label__noRel	No statistically significant relationships between biomarker expression and outcomes were observed.	OS, PFS, QOL, and RR were comparable between arms.
__label__noRel	No statistically significant relationships between biomarker expression and outcomes were observed.	Adding E to G did not increase hematologic toxicities.
__label__noRel	No statistically significant relationships between biomarker expression and outcomes were observed.	Data suggest that the GE combination may improve clinical outcomes.
__label__noRel	patients with low expression of cytoplasmic pGSK-3 trended toward greater OS with GE treatment.	No QOL differences were noted between arms.
__label__noRel	patients with low expression of cytoplasmic pGSK-3 trended toward greater OS with GE treatment.	GE/G Grade 3-4 toxicities included: neutropenia (18.3%/28.2%); thrombocytopenia (14.6%/25.6%); and fatigue (11.0%/7.7%).
__label__noRel	patients with low expression of cytoplasmic pGSK-3 trended toward greater OS with GE treatment.	No statistically significant relationships between biomarker expression and outcomes were observed.
__label__noRel	patients with low expression of cytoplasmic pGSK-3 trended toward greater OS with GE treatment.	OS, PFS, QOL, and RR were comparable between arms.
__label__noRel	patients with low expression of cytoplasmic pGSK-3 trended toward greater OS with GE treatment.	Adding E to G did not increase hematologic toxicities.
__label__Support	patients with low expression of cytoplasmic pGSK-3 trended toward greater OS with GE treatment.	Data suggest that the GE combination may improve clinical outcomes.
__label__noRel	OS, PFS, QOL, and RR were comparable between arms.	No QOL differences were noted between arms.
__label__noRel	OS, PFS, QOL, and RR were comparable between arms.	GE/G Grade 3-4 toxicities included: neutropenia (18.3%/28.2%); thrombocytopenia (14.6%/25.6%); and fatigue (11.0%/7.7%).
__label__noRel	OS, PFS, QOL, and RR were comparable between arms.	No statistically significant relationships between biomarker expression and outcomes were observed.
__label__noRel	OS, PFS, QOL, and RR were comparable between arms.	patients with low expression of cytoplasmic pGSK-3 trended toward greater OS with GE treatment.
__label__noRel	OS, PFS, QOL, and RR were comparable between arms.	Adding E to G did not increase hematologic toxicities.
__label__Support	OS, PFS, QOL, and RR were comparable between arms.	Data suggest that the GE combination may improve clinical outcomes.
__label__noRel	Adding E to G did not increase hematologic toxicities.	No QOL differences were noted between arms.
__label__noRel	Adding E to G did not increase hematologic toxicities.	GE/G Grade 3-4 toxicities included: neutropenia (18.3%/28.2%); thrombocytopenia (14.6%/25.6%); and fatigue (11.0%/7.7%).
__label__noRel	Adding E to G did not increase hematologic toxicities.	No statistically significant relationships between biomarker expression and outcomes were observed.
__label__noRel	Adding E to G did not increase hematologic toxicities.	patients with low expression of cytoplasmic pGSK-3 trended toward greater OS with GE treatment.
__label__noRel	Adding E to G did not increase hematologic toxicities.	OS, PFS, QOL, and RR were comparable between arms.
__label__Support	Adding E to G did not increase hematologic toxicities.	Data suggest that the GE combination may improve clinical outcomes.
__label__noRel	Data suggest that the GE combination may improve clinical outcomes.	No QOL differences were noted between arms.
__label__noRel	Data suggest that the GE combination may improve clinical outcomes.	GE/G Grade 3-4 toxicities included: neutropenia (18.3%/28.2%); thrombocytopenia (14.6%/25.6%); and fatigue (11.0%/7.7%).
__label__noRel	Data suggest that the GE combination may improve clinical outcomes.	No statistically significant relationships between biomarker expression and outcomes were observed.
__label__noRel	Data suggest that the GE combination may improve clinical outcomes.	patients with low expression of cytoplasmic pGSK-3 trended toward greater OS with GE treatment.
__label__noRel	Data suggest that the GE combination may improve clinical outcomes.	OS, PFS, QOL, and RR were comparable between arms.
__label__noRel	Data suggest that the GE combination may improve clinical outcomes.	Adding E to G did not increase hematologic toxicities.
__label__noRel	Neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate (hazard ratio [HR], 1.22; 95% CI, 0.95 to 1.57; P = .12; and HR, 1.12; 95% CI, 0.87 to 1.43; P = .39, respectively).	In the gefitinib 250 mg/day, 500 mg/day, and methotrexate groups, respectively, median overall survival was 5.6, 6.0, and 6.7 months; ORRs (Response Evaluation Criteria in Solid Tumors) were 2.7%, 7.6% and 3.9%, with no statistically significant difference between either gefitinib arm and methotrexate.
__label__noRel	Neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate (hazard ratio [HR], 1.22; 95% CI, 0.95 to 1.57; P = .12; and HR, 1.12; 95% CI, 0.87 to 1.43; P = .39, respectively).	No unexpected adverse events were observed,
__label__noRel	Neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate (hazard ratio [HR], 1.22; 95% CI, 0.95 to 1.57; P = .12; and HR, 1.12; 95% CI, 0.87 to 1.43; P = .39, respectively).	QOL improvement rates (Functional Assessment of Cancer Therapy-Head &amp; Neck total score) were 13.4%, 18.0%, and 6.0% for gefitinib 250 mg/day, 500 mg/day, and methotrexate, respectively.
__label__Support	Neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate (hazard ratio [HR], 1.22; 95% CI, 0.95 to 1.57; P = .12; and HR, 1.12; 95% CI, 0.87 to 1.43; P = .39, respectively).	In patients with recurrent or metastatic SCCHN, while responses with gefitinib were seen, neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate.
__label__noRel	Neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate (hazard ratio [HR], 1.22; 95% CI, 0.95 to 1.57; P = .12; and HR, 1.12; 95% CI, 0.87 to 1.43; P = .39, respectively).	With the exception of tumor hemorrhage-type events with gefitinib, the adverse event profiles were generally consistent with those previously observed.
__label__noRel	Neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate (hazard ratio [HR], 1.22; 95% CI, 0.95 to 1.57; P = .12; and HR, 1.12; 95% CI, 0.87 to 1.43; P = .39, respectively).	except for tumor hemorrhage-type events with gefitinib (8.9%, gefitinib 250 mg/day; 11.4%, gefitinib 500 mg/day; 1.9%, methotrexate).
__label__noRel	In the gefitinib 250 mg/day, 500 mg/day, and methotrexate groups, respectively, median overall survival was 5.6, 6.0, and 6.7 months; ORRs (Response Evaluation Criteria in Solid Tumors) were 2.7%, 7.6% and 3.9%, with no statistically significant difference between either gefitinib arm and methotrexate.	Neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate (hazard ratio [HR], 1.22; 95% CI, 0.95 to 1.57; P = .12; and HR, 1.12; 95% CI, 0.87 to 1.43; P = .39, respectively).
__label__noRel	In the gefitinib 250 mg/day, 500 mg/day, and methotrexate groups, respectively, median overall survival was 5.6, 6.0, and 6.7 months; ORRs (Response Evaluation Criteria in Solid Tumors) were 2.7%, 7.6% and 3.9%, with no statistically significant difference between either gefitinib arm and methotrexate.	No unexpected adverse events were observed,
__label__noRel	In the gefitinib 250 mg/day, 500 mg/day, and methotrexate groups, respectively, median overall survival was 5.6, 6.0, and 6.7 months; ORRs (Response Evaluation Criteria in Solid Tumors) were 2.7%, 7.6% and 3.9%, with no statistically significant difference between either gefitinib arm and methotrexate.	QOL improvement rates (Functional Assessment of Cancer Therapy-Head &amp; Neck total score) were 13.4%, 18.0%, and 6.0% for gefitinib 250 mg/day, 500 mg/day, and methotrexate, respectively.
__label__Support	In the gefitinib 250 mg/day, 500 mg/day, and methotrexate groups, respectively, median overall survival was 5.6, 6.0, and 6.7 months; ORRs (Response Evaluation Criteria in Solid Tumors) were 2.7%, 7.6% and 3.9%, with no statistically significant difference between either gefitinib arm and methotrexate.	In patients with recurrent or metastatic SCCHN, while responses with gefitinib were seen, neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate.
__label__noRel	In the gefitinib 250 mg/day, 500 mg/day, and methotrexate groups, respectively, median overall survival was 5.6, 6.0, and 6.7 months; ORRs (Response Evaluation Criteria in Solid Tumors) were 2.7%, 7.6% and 3.9%, with no statistically significant difference between either gefitinib arm and methotrexate.	With the exception of tumor hemorrhage-type events with gefitinib, the adverse event profiles were generally consistent with those previously observed.
__label__noRel	In the gefitinib 250 mg/day, 500 mg/day, and methotrexate groups, respectively, median overall survival was 5.6, 6.0, and 6.7 months; ORRs (Response Evaluation Criteria in Solid Tumors) were 2.7%, 7.6% and 3.9%, with no statistically significant difference between either gefitinib arm and methotrexate.	except for tumor hemorrhage-type events with gefitinib (8.9%, gefitinib 250 mg/day; 11.4%, gefitinib 500 mg/day; 1.9%, methotrexate).
__label__noRel	No unexpected adverse events were observed,	Neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate (hazard ratio [HR], 1.22; 95% CI, 0.95 to 1.57; P = .12; and HR, 1.12; 95% CI, 0.87 to 1.43; P = .39, respectively).
__label__noRel	No unexpected adverse events were observed,	In the gefitinib 250 mg/day, 500 mg/day, and methotrexate groups, respectively, median overall survival was 5.6, 6.0, and 6.7 months; ORRs (Response Evaluation Criteria in Solid Tumors) were 2.7%, 7.6% and 3.9%, with no statistically significant difference between either gefitinib arm and methotrexate.
__label__noRel	No unexpected adverse events were observed,	QOL improvement rates (Functional Assessment of Cancer Therapy-Head &amp; Neck total score) were 13.4%, 18.0%, and 6.0% for gefitinib 250 mg/day, 500 mg/day, and methotrexate, respectively.
__label__noRel	No unexpected adverse events were observed,	In patients with recurrent or metastatic SCCHN, while responses with gefitinib were seen, neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate.
__label__Support	No unexpected adverse events were observed,	With the exception of tumor hemorrhage-type events with gefitinib, the adverse event profiles were generally consistent with those previously observed.
__label__noRel	No unexpected adverse events were observed,	except for tumor hemorrhage-type events with gefitinib (8.9%, gefitinib 250 mg/day; 11.4%, gefitinib 500 mg/day; 1.9%, methotrexate).
__label__noRel	QOL improvement rates (Functional Assessment of Cancer Therapy-Head &amp; Neck total score) were 13.4%, 18.0%, and 6.0% for gefitinib 250 mg/day, 500 mg/day, and methotrexate, respectively.	Neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate (hazard ratio [HR], 1.22; 95% CI, 0.95 to 1.57; P = .12; and HR, 1.12; 95% CI, 0.87 to 1.43; P = .39, respectively).
__label__noRel	QOL improvement rates (Functional Assessment of Cancer Therapy-Head &amp; Neck total score) were 13.4%, 18.0%, and 6.0% for gefitinib 250 mg/day, 500 mg/day, and methotrexate, respectively.	In the gefitinib 250 mg/day, 500 mg/day, and methotrexate groups, respectively, median overall survival was 5.6, 6.0, and 6.7 months; ORRs (Response Evaluation Criteria in Solid Tumors) were 2.7%, 7.6% and 3.9%, with no statistically significant difference between either gefitinib arm and methotrexate.
__label__noRel	QOL improvement rates (Functional Assessment of Cancer Therapy-Head &amp; Neck total score) were 13.4%, 18.0%, and 6.0% for gefitinib 250 mg/day, 500 mg/day, and methotrexate, respectively.	No unexpected adverse events were observed,
__label__noRel	QOL improvement rates (Functional Assessment of Cancer Therapy-Head &amp; Neck total score) were 13.4%, 18.0%, and 6.0% for gefitinib 250 mg/day, 500 mg/day, and methotrexate, respectively.	In patients with recurrent or metastatic SCCHN, while responses with gefitinib were seen, neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate.
__label__Support	QOL improvement rates (Functional Assessment of Cancer Therapy-Head &amp; Neck total score) were 13.4%, 18.0%, and 6.0% for gefitinib 250 mg/day, 500 mg/day, and methotrexate, respectively.	With the exception of tumor hemorrhage-type events with gefitinib, the adverse event profiles were generally consistent with those previously observed.
__label__noRel	QOL improvement rates (Functional Assessment of Cancer Therapy-Head &amp; Neck total score) were 13.4%, 18.0%, and 6.0% for gefitinib 250 mg/day, 500 mg/day, and methotrexate, respectively.	except for tumor hemorrhage-type events with gefitinib (8.9%, gefitinib 250 mg/day; 11.4%, gefitinib 500 mg/day; 1.9%, methotrexate).
__label__noRel	In patients with recurrent or metastatic SCCHN, while responses with gefitinib were seen, neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate.	Neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate (hazard ratio [HR], 1.22; 95% CI, 0.95 to 1.57; P = .12; and HR, 1.12; 95% CI, 0.87 to 1.43; P = .39, respectively).
__label__noRel	In patients with recurrent or metastatic SCCHN, while responses with gefitinib were seen, neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate.	In the gefitinib 250 mg/day, 500 mg/day, and methotrexate groups, respectively, median overall survival was 5.6, 6.0, and 6.7 months; ORRs (Response Evaluation Criteria in Solid Tumors) were 2.7%, 7.6% and 3.9%, with no statistically significant difference between either gefitinib arm and methotrexate.
__label__noRel	In patients with recurrent or metastatic SCCHN, while responses with gefitinib were seen, neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate.	No unexpected adverse events were observed,
__label__noRel	In patients with recurrent or metastatic SCCHN, while responses with gefitinib were seen, neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate.	QOL improvement rates (Functional Assessment of Cancer Therapy-Head &amp; Neck total score) were 13.4%, 18.0%, and 6.0% for gefitinib 250 mg/day, 500 mg/day, and methotrexate, respectively.
__label__noRel	In patients with recurrent or metastatic SCCHN, while responses with gefitinib were seen, neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate.	With the exception of tumor hemorrhage-type events with gefitinib, the adverse event profiles were generally consistent with those previously observed.
__label__noRel	In patients with recurrent or metastatic SCCHN, while responses with gefitinib were seen, neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate.	except for tumor hemorrhage-type events with gefitinib (8.9%, gefitinib 250 mg/day; 11.4%, gefitinib 500 mg/day; 1.9%, methotrexate).
__label__noRel	With the exception of tumor hemorrhage-type events with gefitinib, the adverse event profiles were generally consistent with those previously observed.	Neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate (hazard ratio [HR], 1.22; 95% CI, 0.95 to 1.57; P = .12; and HR, 1.12; 95% CI, 0.87 to 1.43; P = .39, respectively).
__label__noRel	With the exception of tumor hemorrhage-type events with gefitinib, the adverse event profiles were generally consistent with those previously observed.	In the gefitinib 250 mg/day, 500 mg/day, and methotrexate groups, respectively, median overall survival was 5.6, 6.0, and 6.7 months; ORRs (Response Evaluation Criteria in Solid Tumors) were 2.7%, 7.6% and 3.9%, with no statistically significant difference between either gefitinib arm and methotrexate.
__label__noRel	With the exception of tumor hemorrhage-type events with gefitinib, the adverse event profiles were generally consistent with those previously observed.	No unexpected adverse events were observed,
__label__noRel	With the exception of tumor hemorrhage-type events with gefitinib, the adverse event profiles were generally consistent with those previously observed.	QOL improvement rates (Functional Assessment of Cancer Therapy-Head &amp; Neck total score) were 13.4%, 18.0%, and 6.0% for gefitinib 250 mg/day, 500 mg/day, and methotrexate, respectively.
__label__noRel	With the exception of tumor hemorrhage-type events with gefitinib, the adverse event profiles were generally consistent with those previously observed.	In patients with recurrent or metastatic SCCHN, while responses with gefitinib were seen, neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate.
__label__noRel	With the exception of tumor hemorrhage-type events with gefitinib, the adverse event profiles were generally consistent with those previously observed.	except for tumor hemorrhage-type events with gefitinib (8.9%, gefitinib 250 mg/day; 11.4%, gefitinib 500 mg/day; 1.9%, methotrexate).
__label__noRel	except for tumor hemorrhage-type events with gefitinib (8.9%, gefitinib 250 mg/day; 11.4%, gefitinib 500 mg/day; 1.9%, methotrexate).	Neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate (hazard ratio [HR], 1.22; 95% CI, 0.95 to 1.57; P = .12; and HR, 1.12; 95% CI, 0.87 to 1.43; P = .39, respectively).
__label__noRel	except for tumor hemorrhage-type events with gefitinib (8.9%, gefitinib 250 mg/day; 11.4%, gefitinib 500 mg/day; 1.9%, methotrexate).	In the gefitinib 250 mg/day, 500 mg/day, and methotrexate groups, respectively, median overall survival was 5.6, 6.0, and 6.7 months; ORRs (Response Evaluation Criteria in Solid Tumors) were 2.7%, 7.6% and 3.9%, with no statistically significant difference between either gefitinib arm and methotrexate.
__label__Attack	except for tumor hemorrhage-type events with gefitinib (8.9%, gefitinib 250 mg/day; 11.4%, gefitinib 500 mg/day; 1.9%, methotrexate).	No unexpected adverse events were observed,
__label__noRel	except for tumor hemorrhage-type events with gefitinib (8.9%, gefitinib 250 mg/day; 11.4%, gefitinib 500 mg/day; 1.9%, methotrexate).	QOL improvement rates (Functional Assessment of Cancer Therapy-Head &amp; Neck total score) were 13.4%, 18.0%, and 6.0% for gefitinib 250 mg/day, 500 mg/day, and methotrexate, respectively.
__label__noRel	except for tumor hemorrhage-type events with gefitinib (8.9%, gefitinib 250 mg/day; 11.4%, gefitinib 500 mg/day; 1.9%, methotrexate).	In patients with recurrent or metastatic SCCHN, while responses with gefitinib were seen, neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate.
__label__noRel	except for tumor hemorrhage-type events with gefitinib (8.9%, gefitinib 250 mg/day; 11.4%, gefitinib 500 mg/day; 1.9%, methotrexate).	With the exception of tumor hemorrhage-type events with gefitinib, the adverse event profiles were generally consistent with those previously observed.
__label__noRel	Body image, anxiety, and cancer-specific posttraumatic distress were notable in their association with subscales of sexual functioning, while a global QOL measure was largely unrelated.	For sexually active female rectal and anal cancer survivors enrolled in a sexual health intervention, sexual dysfunction was significantly and consistently associated with specific measures of psychological well-being, most notably Sexual/Relationship Satisfaction.
__label__noRel	Body image, anxiety, and cancer-specific posttraumatic distress were notable in their association with subscales of sexual functioning, while a global QOL measure was largely unrelated.	These results suggest that sexual functioning may require focused assessment by providers, beyond broad QOL assessments,
__label__noRel	Body image, anxiety, and cancer-specific posttraumatic distress were notable in their association with subscales of sexual functioning, while a global QOL measure was largely unrelated.	attention to Sexual/Relationship Satisfaction may be critical in the development and implementation of interventions for this cohort of patients.
__label__noRel	Body image, anxiety, and cancer-specific posttraumatic distress were notable in their association with subscales of sexual functioning, while a global QOL measure was largely unrelated.	The Sexual/Relationship Satisfaction subscale was associated with all measures of psychological well-being (r=-0.45 to -0.70, all P<0.01).
__label__noRel	For sexually active female rectal and anal cancer survivors enrolled in a sexual health intervention, sexual dysfunction was significantly and consistently associated with specific measures of psychological well-being, most notably Sexual/Relationship Satisfaction.	Body image, anxiety, and cancer-specific posttraumatic distress were notable in their association with subscales of sexual functioning, while a global QOL measure was largely unrelated.
__label__noRel	For sexually active female rectal and anal cancer survivors enrolled in a sexual health intervention, sexual dysfunction was significantly and consistently associated with specific measures of psychological well-being, most notably Sexual/Relationship Satisfaction.	These results suggest that sexual functioning may require focused assessment by providers, beyond broad QOL assessments,
__label__noRel	For sexually active female rectal and anal cancer survivors enrolled in a sexual health intervention, sexual dysfunction was significantly and consistently associated with specific measures of psychological well-being, most notably Sexual/Relationship Satisfaction.	attention to Sexual/Relationship Satisfaction may be critical in the development and implementation of interventions for this cohort of patients.
__label__noRel	For sexually active female rectal and anal cancer survivors enrolled in a sexual health intervention, sexual dysfunction was significantly and consistently associated with specific measures of psychological well-being, most notably Sexual/Relationship Satisfaction.	The Sexual/Relationship Satisfaction subscale was associated with all measures of psychological well-being (r=-0.45 to -0.70, all P<0.01).
__label__noRel	These results suggest that sexual functioning may require focused assessment by providers, beyond broad QOL assessments,	Body image, anxiety, and cancer-specific posttraumatic distress were notable in their association with subscales of sexual functioning, while a global QOL measure was largely unrelated.
__label__noRel	These results suggest that sexual functioning may require focused assessment by providers, beyond broad QOL assessments,	For sexually active female rectal and anal cancer survivors enrolled in a sexual health intervention, sexual dysfunction was significantly and consistently associated with specific measures of psychological well-being, most notably Sexual/Relationship Satisfaction.
__label__noRel	These results suggest that sexual functioning may require focused assessment by providers, beyond broad QOL assessments,	attention to Sexual/Relationship Satisfaction may be critical in the development and implementation of interventions for this cohort of patients.
__label__noRel	These results suggest that sexual functioning may require focused assessment by providers, beyond broad QOL assessments,	The Sexual/Relationship Satisfaction subscale was associated with all measures of psychological well-being (r=-0.45 to -0.70, all P<0.01).
__label__noRel	attention to Sexual/Relationship Satisfaction may be critical in the development and implementation of interventions for this cohort of patients.	Body image, anxiety, and cancer-specific posttraumatic distress were notable in their association with subscales of sexual functioning, while a global QOL measure was largely unrelated.
__label__noRel	attention to Sexual/Relationship Satisfaction may be critical in the development and implementation of interventions for this cohort of patients.	For sexually active female rectal and anal cancer survivors enrolled in a sexual health intervention, sexual dysfunction was significantly and consistently associated with specific measures of psychological well-being, most notably Sexual/Relationship Satisfaction.
__label__noRel	attention to Sexual/Relationship Satisfaction may be critical in the development and implementation of interventions for this cohort of patients.	These results suggest that sexual functioning may require focused assessment by providers, beyond broad QOL assessments,
__label__noRel	attention to Sexual/Relationship Satisfaction may be critical in the development and implementation of interventions for this cohort of patients.	The Sexual/Relationship Satisfaction subscale was associated with all measures of psychological well-being (r=-0.45 to -0.70, all P<0.01).
__label__noRel	The Sexual/Relationship Satisfaction subscale was associated with all measures of psychological well-being (r=-0.45 to -0.70, all P<0.01).	Body image, anxiety, and cancer-specific posttraumatic distress were notable in their association with subscales of sexual functioning, while a global QOL measure was largely unrelated.
__label__noRel	The Sexual/Relationship Satisfaction subscale was associated with all measures of psychological well-being (r=-0.45 to -0.70, all P<0.01).	For sexually active female rectal and anal cancer survivors enrolled in a sexual health intervention, sexual dysfunction was significantly and consistently associated with specific measures of psychological well-being, most notably Sexual/Relationship Satisfaction.
__label__noRel	The Sexual/Relationship Satisfaction subscale was associated with all measures of psychological well-being (r=-0.45 to -0.70, all P<0.01).	These results suggest that sexual functioning may require focused assessment by providers, beyond broad QOL assessments,
__label__noRel	The Sexual/Relationship Satisfaction subscale was associated with all measures of psychological well-being (r=-0.45 to -0.70, all P<0.01).	attention to Sexual/Relationship Satisfaction may be critical in the development and implementation of interventions for this cohort of patients.
__label__noRel	Methods are needed to reduce professional time required while achieving sustained intervention effectiveness.	Trained versus control patients reported reduced barriers to pain relief (P<.001), lower usual pain (P=.03), and greater opioid use (P<.001).
__label__noRel	Methods are needed to reduce professional time required while achieving sustained intervention effectiveness.	No pain training patients reported severe pain (>6 on a 0-10 scale) at 1-month outcomes (P=.03).
__label__noRel	Methods are needed to reduce professional time required while achieving sustained intervention effectiveness.	Using video and print materials, with brief individualized training, effectively improved pain management over time for cancer patients of varying diagnostic and demographic groups.
__label__noRel	Trained versus control patients reported reduced barriers to pain relief (P<.001), lower usual pain (P=.03), and greater opioid use (P<.001).	Methods are needed to reduce professional time required while achieving sustained intervention effectiveness.
__label__noRel	Trained versus control patients reported reduced barriers to pain relief (P<.001), lower usual pain (P=.03), and greater opioid use (P<.001).	No pain training patients reported severe pain (>6 on a 0-10 scale) at 1-month outcomes (P=.03).
__label__Support	Trained versus control patients reported reduced barriers to pain relief (P<.001), lower usual pain (P=.03), and greater opioid use (P<.001).	Using video and print materials, with brief individualized training, effectively improved pain management over time for cancer patients of varying diagnostic and demographic groups.
__label__noRel	No pain training patients reported severe pain (>6 on a 0-10 scale) at 1-month outcomes (P=.03).	Methods are needed to reduce professional time required while achieving sustained intervention effectiveness.
__label__noRel	No pain training patients reported severe pain (>6 on a 0-10 scale) at 1-month outcomes (P=.03).	Trained versus control patients reported reduced barriers to pain relief (P<.001), lower usual pain (P=.03), and greater opioid use (P<.001).
__label__Support	No pain training patients reported severe pain (>6 on a 0-10 scale) at 1-month outcomes (P=.03).	Using video and print materials, with brief individualized training, effectively improved pain management over time for cancer patients of varying diagnostic and demographic groups.
__label__noRel	Using video and print materials, with brief individualized training, effectively improved pain management over time for cancer patients of varying diagnostic and demographic groups.	Methods are needed to reduce professional time required while achieving sustained intervention effectiveness.
__label__noRel	Using video and print materials, with brief individualized training, effectively improved pain management over time for cancer patients of varying diagnostic and demographic groups.	Trained versus control patients reported reduced barriers to pain relief (P<.001), lower usual pain (P=.03), and greater opioid use (P<.001).
__label__noRel	Using video and print materials, with brief individualized training, effectively improved pain management over time for cancer patients of varying diagnostic and demographic groups.	No pain training patients reported severe pain (>6 on a 0-10 scale) at 1-month outcomes (P=.03).
__label__noRel	The role of high-dose chemotherapy (HDCT) in metastatic breast cancer remains controversial.	Trials with late intensification HDCT have failed to show an advantage in overall survival.
__label__noRel	The role of high-dose chemotherapy (HDCT) in metastatic breast cancer remains controversial.	Intent-to-treat CR rates for patients randomized to HDCT and AT were 12.5% and 11.1%, respectively (P = .84).
__label__noRel	The role of high-dose chemotherapy (HDCT) in metastatic breast cancer remains controversial.	Objective response rates were 66.7% for patients in the high-dose group and 64.4% for patients in the AT arm (P = .82).
__label__noRel	The role of high-dose chemotherapy (HDCT) in metastatic breast cancer remains controversial.	In an intent-to-treat analysis, there were no significant differences between the two treatments in median time to progression (HDCT, 11.1 months; AT, 10.6 months; P = .67), duration of response (HDCT, 13.9 months; AT, 14.3 months; P = .98), and overall survival (HDCT, 26.9 months; AT, 23.4 months; P = .60).
__label__noRel	The role of high-dose chemotherapy (HDCT) in metastatic breast cancer remains controversial.	HDCT was associated with significantly more myelosuppression, infection, diarrhea, stomatitis, and nausea and vomiting, whereas patients treated with AT developed more neurotoxicity.
__label__noRel	The role of high-dose chemotherapy (HDCT) in metastatic breast cancer remains controversial.	This trial failed to show a benefit for up-front tandem HDCT compared with standard combination therapy.
__label__noRel	The role of high-dose chemotherapy (HDCT) in metastatic breast cancer remains controversial.	HDCT was associated with more acute adverse effects.
__label__noRel	Trials with late intensification HDCT have failed to show an advantage in overall survival.	The role of high-dose chemotherapy (HDCT) in metastatic breast cancer remains controversial.
__label__noRel	Trials with late intensification HDCT have failed to show an advantage in overall survival.	Intent-to-treat CR rates for patients randomized to HDCT and AT were 12.5% and 11.1%, respectively (P = .84).
__label__noRel	Trials with late intensification HDCT have failed to show an advantage in overall survival.	Objective response rates were 66.7% for patients in the high-dose group and 64.4% for patients in the AT arm (P = .82).
__label__noRel	Trials with late intensification HDCT have failed to show an advantage in overall survival.	In an intent-to-treat analysis, there were no significant differences between the two treatments in median time to progression (HDCT, 11.1 months; AT, 10.6 months; P = .67), duration of response (HDCT, 13.9 months; AT, 14.3 months; P = .98), and overall survival (HDCT, 26.9 months; AT, 23.4 months; P = .60).
__label__noRel	Trials with late intensification HDCT have failed to show an advantage in overall survival.	HDCT was associated with significantly more myelosuppression, infection, diarrhea, stomatitis, and nausea and vomiting, whereas patients treated with AT developed more neurotoxicity.
__label__noRel	Trials with late intensification HDCT have failed to show an advantage in overall survival.	This trial failed to show a benefit for up-front tandem HDCT compared with standard combination therapy.
__label__noRel	Trials with late intensification HDCT have failed to show an advantage in overall survival.	HDCT was associated with more acute adverse effects.
__label__noRel	Intent-to-treat CR rates for patients randomized to HDCT and AT were 12.5% and 11.1%, respectively (P = .84).	The role of high-dose chemotherapy (HDCT) in metastatic breast cancer remains controversial.
__label__noRel	Intent-to-treat CR rates for patients randomized to HDCT and AT were 12.5% and 11.1%, respectively (P = .84).	Trials with late intensification HDCT have failed to show an advantage in overall survival.
__label__noRel	Intent-to-treat CR rates for patients randomized to HDCT and AT were 12.5% and 11.1%, respectively (P = .84).	Objective response rates were 66.7% for patients in the high-dose group and 64.4% for patients in the AT arm (P = .82).
__label__noRel	Intent-to-treat CR rates for patients randomized to HDCT and AT were 12.5% and 11.1%, respectively (P = .84).	In an intent-to-treat analysis, there were no significant differences between the two treatments in median time to progression (HDCT, 11.1 months; AT, 10.6 months; P = .67), duration of response (HDCT, 13.9 months; AT, 14.3 months; P = .98), and overall survival (HDCT, 26.9 months; AT, 23.4 months; P = .60).
__label__noRel	Intent-to-treat CR rates for patients randomized to HDCT and AT were 12.5% and 11.1%, respectively (P = .84).	HDCT was associated with significantly more myelosuppression, infection, diarrhea, stomatitis, and nausea and vomiting, whereas patients treated with AT developed more neurotoxicity.
__label__Support	Intent-to-treat CR rates for patients randomized to HDCT and AT were 12.5% and 11.1%, respectively (P = .84).	This trial failed to show a benefit for up-front tandem HDCT compared with standard combination therapy.
__label__noRel	Intent-to-treat CR rates for patients randomized to HDCT and AT were 12.5% and 11.1%, respectively (P = .84).	HDCT was associated with more acute adverse effects.
__label__noRel	Objective response rates were 66.7% for patients in the high-dose group and 64.4% for patients in the AT arm (P = .82).	The role of high-dose chemotherapy (HDCT) in metastatic breast cancer remains controversial.
__label__noRel	Objective response rates were 66.7% for patients in the high-dose group and 64.4% for patients in the AT arm (P = .82).	Trials with late intensification HDCT have failed to show an advantage in overall survival.
__label__noRel	Objective response rates were 66.7% for patients in the high-dose group and 64.4% for patients in the AT arm (P = .82).	Intent-to-treat CR rates for patients randomized to HDCT and AT were 12.5% and 11.1%, respectively (P = .84).
__label__noRel	Objective response rates were 66.7% for patients in the high-dose group and 64.4% for patients in the AT arm (P = .82).	In an intent-to-treat analysis, there were no significant differences between the two treatments in median time to progression (HDCT, 11.1 months; AT, 10.6 months; P = .67), duration of response (HDCT, 13.9 months; AT, 14.3 months; P = .98), and overall survival (HDCT, 26.9 months; AT, 23.4 months; P = .60).
__label__noRel	Objective response rates were 66.7% for patients in the high-dose group and 64.4% for patients in the AT arm (P = .82).	HDCT was associated with significantly more myelosuppression, infection, diarrhea, stomatitis, and nausea and vomiting, whereas patients treated with AT developed more neurotoxicity.
__label__Support	Objective response rates were 66.7% for patients in the high-dose group and 64.4% for patients in the AT arm (P = .82).	This trial failed to show a benefit for up-front tandem HDCT compared with standard combination therapy.
__label__noRel	Objective response rates were 66.7% for patients in the high-dose group and 64.4% for patients in the AT arm (P = .82).	HDCT was associated with more acute adverse effects.
__label__noRel	In an intent-to-treat analysis, there were no significant differences between the two treatments in median time to progression (HDCT, 11.1 months; AT, 10.6 months; P = .67), duration of response (HDCT, 13.9 months; AT, 14.3 months; P = .98), and overall survival (HDCT, 26.9 months; AT, 23.4 months; P = .60).	The role of high-dose chemotherapy (HDCT) in metastatic breast cancer remains controversial.
__label__noRel	In an intent-to-treat analysis, there were no significant differences between the two treatments in median time to progression (HDCT, 11.1 months; AT, 10.6 months; P = .67), duration of response (HDCT, 13.9 months; AT, 14.3 months; P = .98), and overall survival (HDCT, 26.9 months; AT, 23.4 months; P = .60).	Trials with late intensification HDCT have failed to show an advantage in overall survival.
__label__noRel	In an intent-to-treat analysis, there were no significant differences between the two treatments in median time to progression (HDCT, 11.1 months; AT, 10.6 months; P = .67), duration of response (HDCT, 13.9 months; AT, 14.3 months; P = .98), and overall survival (HDCT, 26.9 months; AT, 23.4 months; P = .60).	Intent-to-treat CR rates for patients randomized to HDCT and AT were 12.5% and 11.1%, respectively (P = .84).
__label__noRel	In an intent-to-treat analysis, there were no significant differences between the two treatments in median time to progression (HDCT, 11.1 months; AT, 10.6 months; P = .67), duration of response (HDCT, 13.9 months; AT, 14.3 months; P = .98), and overall survival (HDCT, 26.9 months; AT, 23.4 months; P = .60).	Objective response rates were 66.7% for patients in the high-dose group and 64.4% for patients in the AT arm (P = .82).
__label__noRel	In an intent-to-treat analysis, there were no significant differences between the two treatments in median time to progression (HDCT, 11.1 months; AT, 10.6 months; P = .67), duration of response (HDCT, 13.9 months; AT, 14.3 months; P = .98), and overall survival (HDCT, 26.9 months; AT, 23.4 months; P = .60).	HDCT was associated with significantly more myelosuppression, infection, diarrhea, stomatitis, and nausea and vomiting, whereas patients treated with AT developed more neurotoxicity.
__label__Support	In an intent-to-treat analysis, there were no significant differences between the two treatments in median time to progression (HDCT, 11.1 months; AT, 10.6 months; P = .67), duration of response (HDCT, 13.9 months; AT, 14.3 months; P = .98), and overall survival (HDCT, 26.9 months; AT, 23.4 months; P = .60).	This trial failed to show a benefit for up-front tandem HDCT compared with standard combination therapy.
__label__noRel	In an intent-to-treat analysis, there were no significant differences between the two treatments in median time to progression (HDCT, 11.1 months; AT, 10.6 months; P = .67), duration of response (HDCT, 13.9 months; AT, 14.3 months; P = .98), and overall survival (HDCT, 26.9 months; AT, 23.4 months; P = .60).	HDCT was associated with more acute adverse effects.
__label__noRel	HDCT was associated with significantly more myelosuppression, infection, diarrhea, stomatitis, and nausea and vomiting, whereas patients treated with AT developed more neurotoxicity.	The role of high-dose chemotherapy (HDCT) in metastatic breast cancer remains controversial.
__label__noRel	HDCT was associated with significantly more myelosuppression, infection, diarrhea, stomatitis, and nausea and vomiting, whereas patients treated with AT developed more neurotoxicity.	Trials with late intensification HDCT have failed to show an advantage in overall survival.
__label__noRel	HDCT was associated with significantly more myelosuppression, infection, diarrhea, stomatitis, and nausea and vomiting, whereas patients treated with AT developed more neurotoxicity.	Intent-to-treat CR rates for patients randomized to HDCT and AT were 12.5% and 11.1%, respectively (P = .84).
__label__noRel	HDCT was associated with significantly more myelosuppression, infection, diarrhea, stomatitis, and nausea and vomiting, whereas patients treated with AT developed more neurotoxicity.	Objective response rates were 66.7% for patients in the high-dose group and 64.4% for patients in the AT arm (P = .82).
__label__noRel	HDCT was associated with significantly more myelosuppression, infection, diarrhea, stomatitis, and nausea and vomiting, whereas patients treated with AT developed more neurotoxicity.	In an intent-to-treat analysis, there were no significant differences between the two treatments in median time to progression (HDCT, 11.1 months; AT, 10.6 months; P = .67), duration of response (HDCT, 13.9 months; AT, 14.3 months; P = .98), and overall survival (HDCT, 26.9 months; AT, 23.4 months; P = .60).
__label__noRel	HDCT was associated with significantly more myelosuppression, infection, diarrhea, stomatitis, and nausea and vomiting, whereas patients treated with AT developed more neurotoxicity.	This trial failed to show a benefit for up-front tandem HDCT compared with standard combination therapy.
__label__Support	HDCT was associated with significantly more myelosuppression, infection, diarrhea, stomatitis, and nausea and vomiting, whereas patients treated with AT developed more neurotoxicity.	HDCT was associated with more acute adverse effects.
__label__noRel	This trial failed to show a benefit for up-front tandem HDCT compared with standard combination therapy.	The role of high-dose chemotherapy (HDCT) in metastatic breast cancer remains controversial.
__label__noRel	This trial failed to show a benefit for up-front tandem HDCT compared with standard combination therapy.	Trials with late intensification HDCT have failed to show an advantage in overall survival.
__label__noRel	This trial failed to show a benefit for up-front tandem HDCT compared with standard combination therapy.	Intent-to-treat CR rates for patients randomized to HDCT and AT were 12.5% and 11.1%, respectively (P = .84).
__label__noRel	This trial failed to show a benefit for up-front tandem HDCT compared with standard combination therapy.	Objective response rates were 66.7% for patients in the high-dose group and 64.4% for patients in the AT arm (P = .82).
__label__noRel	This trial failed to show a benefit for up-front tandem HDCT compared with standard combination therapy.	In an intent-to-treat analysis, there were no significant differences between the two treatments in median time to progression (HDCT, 11.1 months; AT, 10.6 months; P = .67), duration of response (HDCT, 13.9 months; AT, 14.3 months; P = .98), and overall survival (HDCT, 26.9 months; AT, 23.4 months; P = .60).
__label__noRel	This trial failed to show a benefit for up-front tandem HDCT compared with standard combination therapy.	HDCT was associated with significantly more myelosuppression, infection, diarrhea, stomatitis, and nausea and vomiting, whereas patients treated with AT developed more neurotoxicity.
__label__noRel	This trial failed to show a benefit for up-front tandem HDCT compared with standard combination therapy.	HDCT was associated with more acute adverse effects.
__label__noRel	HDCT was associated with more acute adverse effects.	The role of high-dose chemotherapy (HDCT) in metastatic breast cancer remains controversial.
__label__noRel	HDCT was associated with more acute adverse effects.	Trials with late intensification HDCT have failed to show an advantage in overall survival.
__label__noRel	HDCT was associated with more acute adverse effects.	Intent-to-treat CR rates for patients randomized to HDCT and AT were 12.5% and 11.1%, respectively (P = .84).
__label__noRel	HDCT was associated with more acute adverse effects.	Objective response rates were 66.7% for patients in the high-dose group and 64.4% for patients in the AT arm (P = .82).
__label__noRel	HDCT was associated with more acute adverse effects.	In an intent-to-treat analysis, there were no significant differences between the two treatments in median time to progression (HDCT, 11.1 months; AT, 10.6 months; P = .67), duration of response (HDCT, 13.9 months; AT, 14.3 months; P = .98), and overall survival (HDCT, 26.9 months; AT, 23.4 months; P = .60).
__label__noRel	HDCT was associated with more acute adverse effects.	HDCT was associated with significantly more myelosuppression, infection, diarrhea, stomatitis, and nausea and vomiting, whereas patients treated with AT developed more neurotoxicity.
__label__noRel	HDCT was associated with more acute adverse effects.	This trial failed to show a benefit for up-front tandem HDCT compared with standard combination therapy.
__label__noRel	Longer time to worsening was recorded for pain (hazard ratio [HR] 076, 95% CI 059-099; p=0041) and haemoptysis (HR 058, 95% CI 034-097; p=0038) with pemetrexed than with placebo;	no other significant differences in analyses of time to worsening were noted.
__label__noRel	Longer time to worsening was recorded for pain (hazard ratio [HR] 076, 95% CI 059-099; p=0041) and haemoptysis (HR 058, 95% CI 034-097; p=0038) with pemetrexed than with placebo;	Additional longitudinal analyses showed a greater increase in loss of appetite in the pemetrexed group than in the placebo group (43 mm vs 02 mm; p=0028).
__label__noRel	Longer time to worsening was recorded for pain (hazard ratio [HR] 076, 95% CI 059-099; p=0041) and haemoptysis (HR 058, 95% CI 034-097; p=0038) with pemetrexed than with placebo;	Rates of resource use were statistically higher for pemetrexed than for placebo: admissions to hospital for drug-related adverse events (19 [4%] vs none; p=0001), transfusions (42 [10%] vs seven [3%]; p=0003), and erythropoiesis-stimulating agents (26 [6%] vs four [2%]; p=0017).
__label__noRel	Longer time to worsening was recorded for pain (hazard ratio [HR] 076, 95% CI 059-099; p=0041) and haemoptysis (HR 058, 95% CI 034-097; p=0038) with pemetrexed than with placebo;	Quality of life during maintenance therapy with pemetrexed is similar to placebo,
__label__Support	Longer time to worsening was recorded for pain (hazard ratio [HR] 076, 95% CI 059-099; p=0041) and haemoptysis (HR 058, 95% CI 034-097; p=0038) with pemetrexed than with placebo;	except for a small increase in loss of appetite, and significantly delayed worsening of pain and haemoptysis.
__label__noRel	Longer time to worsening was recorded for pain (hazard ratio [HR] 076, 95% CI 059-099; p=0041) and haemoptysis (HR 058, 95% CI 034-097; p=0038) with pemetrexed than with placebo;	such treatment is an option for patients with advanced non-squamous NSCLC who have not progressed after platinum-based induction therapy.
__label__noRel	no other significant differences in analyses of time to worsening were noted.	Longer time to worsening was recorded for pain (hazard ratio [HR] 076, 95% CI 059-099; p=0041) and haemoptysis (HR 058, 95% CI 034-097; p=0038) with pemetrexed than with placebo;
__label__noRel	no other significant differences in analyses of time to worsening were noted.	Additional longitudinal analyses showed a greater increase in loss of appetite in the pemetrexed group than in the placebo group (43 mm vs 02 mm; p=0028).
__label__noRel	no other significant differences in analyses of time to worsening were noted.	Rates of resource use were statistically higher for pemetrexed than for placebo: admissions to hospital for drug-related adverse events (19 [4%] vs none; p=0001), transfusions (42 [10%] vs seven [3%]; p=0003), and erythropoiesis-stimulating agents (26 [6%] vs four [2%]; p=0017).
__label__Support	no other significant differences in analyses of time to worsening were noted.	Quality of life during maintenance therapy with pemetrexed is similar to placebo,
__label__noRel	no other significant differences in analyses of time to worsening were noted.	except for a small increase in loss of appetite, and significantly delayed worsening of pain and haemoptysis.
__label__noRel	no other significant differences in analyses of time to worsening were noted.	such treatment is an option for patients with advanced non-squamous NSCLC who have not progressed after platinum-based induction therapy.
__label__noRel	Additional longitudinal analyses showed a greater increase in loss of appetite in the pemetrexed group than in the placebo group (43 mm vs 02 mm; p=0028).	Longer time to worsening was recorded for pain (hazard ratio [HR] 076, 95% CI 059-099; p=0041) and haemoptysis (HR 058, 95% CI 034-097; p=0038) with pemetrexed than with placebo;
__label__noRel	Additional longitudinal analyses showed a greater increase in loss of appetite in the pemetrexed group than in the placebo group (43 mm vs 02 mm; p=0028).	no other significant differences in analyses of time to worsening were noted.
__label__noRel	Additional longitudinal analyses showed a greater increase in loss of appetite in the pemetrexed group than in the placebo group (43 mm vs 02 mm; p=0028).	Rates of resource use were statistically higher for pemetrexed than for placebo: admissions to hospital for drug-related adverse events (19 [4%] vs none; p=0001), transfusions (42 [10%] vs seven [3%]; p=0003), and erythropoiesis-stimulating agents (26 [6%] vs four [2%]; p=0017).
__label__noRel	Additional longitudinal analyses showed a greater increase in loss of appetite in the pemetrexed group than in the placebo group (43 mm vs 02 mm; p=0028).	Quality of life during maintenance therapy with pemetrexed is similar to placebo,
__label__Support	Additional longitudinal analyses showed a greater increase in loss of appetite in the pemetrexed group than in the placebo group (43 mm vs 02 mm; p=0028).	except for a small increase in loss of appetite, and significantly delayed worsening of pain and haemoptysis.
__label__noRel	Additional longitudinal analyses showed a greater increase in loss of appetite in the pemetrexed group than in the placebo group (43 mm vs 02 mm; p=0028).	such treatment is an option for patients with advanced non-squamous NSCLC who have not progressed after platinum-based induction therapy.
__label__noRel	Rates of resource use were statistically higher for pemetrexed than for placebo: admissions to hospital for drug-related adverse events (19 [4%] vs none; p=0001), transfusions (42 [10%] vs seven [3%]; p=0003), and erythropoiesis-stimulating agents (26 [6%] vs four [2%]; p=0017).	Longer time to worsening was recorded for pain (hazard ratio [HR] 076, 95% CI 059-099; p=0041) and haemoptysis (HR 058, 95% CI 034-097; p=0038) with pemetrexed than with placebo;
__label__noRel	Rates of resource use were statistically higher for pemetrexed than for placebo: admissions to hospital for drug-related adverse events (19 [4%] vs none; p=0001), transfusions (42 [10%] vs seven [3%]; p=0003), and erythropoiesis-stimulating agents (26 [6%] vs four [2%]; p=0017).	no other significant differences in analyses of time to worsening were noted.
__label__noRel	Rates of resource use were statistically higher for pemetrexed than for placebo: admissions to hospital for drug-related adverse events (19 [4%] vs none; p=0001), transfusions (42 [10%] vs seven [3%]; p=0003), and erythropoiesis-stimulating agents (26 [6%] vs four [2%]; p=0017).	Additional longitudinal analyses showed a greater increase in loss of appetite in the pemetrexed group than in the placebo group (43 mm vs 02 mm; p=0028).
__label__noRel	Rates of resource use were statistically higher for pemetrexed than for placebo: admissions to hospital for drug-related adverse events (19 [4%] vs none; p=0001), transfusions (42 [10%] vs seven [3%]; p=0003), and erythropoiesis-stimulating agents (26 [6%] vs four [2%]; p=0017).	Quality of life during maintenance therapy with pemetrexed is similar to placebo,
__label__noRel	Rates of resource use were statistically higher for pemetrexed than for placebo: admissions to hospital for drug-related adverse events (19 [4%] vs none; p=0001), transfusions (42 [10%] vs seven [3%]; p=0003), and erythropoiesis-stimulating agents (26 [6%] vs four [2%]; p=0017).	except for a small increase in loss of appetite, and significantly delayed worsening of pain and haemoptysis.
__label__noRel	Rates of resource use were statistically higher for pemetrexed than for placebo: admissions to hospital for drug-related adverse events (19 [4%] vs none; p=0001), transfusions (42 [10%] vs seven [3%]; p=0003), and erythropoiesis-stimulating agents (26 [6%] vs four [2%]; p=0017).	such treatment is an option for patients with advanced non-squamous NSCLC who have not progressed after platinum-based induction therapy.
__label__noRel	Quality of life during maintenance therapy with pemetrexed is similar to placebo,	Longer time to worsening was recorded for pain (hazard ratio [HR] 076, 95% CI 059-099; p=0041) and haemoptysis (HR 058, 95% CI 034-097; p=0038) with pemetrexed than with placebo;
__label__noRel	Quality of life during maintenance therapy with pemetrexed is similar to placebo,	no other significant differences in analyses of time to worsening were noted.
__label__noRel	Quality of life during maintenance therapy with pemetrexed is similar to placebo,	Additional longitudinal analyses showed a greater increase in loss of appetite in the pemetrexed group than in the placebo group (43 mm vs 02 mm; p=0028).
__label__noRel	Quality of life during maintenance therapy with pemetrexed is similar to placebo,	Rates of resource use were statistically higher for pemetrexed than for placebo: admissions to hospital for drug-related adverse events (19 [4%] vs none; p=0001), transfusions (42 [10%] vs seven [3%]; p=0003), and erythropoiesis-stimulating agents (26 [6%] vs four [2%]; p=0017).
__label__noRel	Quality of life during maintenance therapy with pemetrexed is similar to placebo,	except for a small increase in loss of appetite, and significantly delayed worsening of pain and haemoptysis.
__label__Support	Quality of life during maintenance therapy with pemetrexed is similar to placebo,	such treatment is an option for patients with advanced non-squamous NSCLC who have not progressed after platinum-based induction therapy.
__label__noRel	except for a small increase in loss of appetite, and significantly delayed worsening of pain and haemoptysis.	Longer time to worsening was recorded for pain (hazard ratio [HR] 076, 95% CI 059-099; p=0041) and haemoptysis (HR 058, 95% CI 034-097; p=0038) with pemetrexed than with placebo;
__label__noRel	except for a small increase in loss of appetite, and significantly delayed worsening of pain and haemoptysis.	no other significant differences in analyses of time to worsening were noted.
__label__noRel	except for a small increase in loss of appetite, and significantly delayed worsening of pain and haemoptysis.	Additional longitudinal analyses showed a greater increase in loss of appetite in the pemetrexed group than in the placebo group (43 mm vs 02 mm; p=0028).
__label__noRel	except for a small increase in loss of appetite, and significantly delayed worsening of pain and haemoptysis.	Rates of resource use were statistically higher for pemetrexed than for placebo: admissions to hospital for drug-related adverse events (19 [4%] vs none; p=0001), transfusions (42 [10%] vs seven [3%]; p=0003), and erythropoiesis-stimulating agents (26 [6%] vs four [2%]; p=0017).
__label__Attack	except for a small increase in loss of appetite, and significantly delayed worsening of pain and haemoptysis.	Quality of life during maintenance therapy with pemetrexed is similar to placebo,
__label__noRel	except for a small increase in loss of appetite, and significantly delayed worsening of pain and haemoptysis.	such treatment is an option for patients with advanced non-squamous NSCLC who have not progressed after platinum-based induction therapy.
__label__noRel	such treatment is an option for patients with advanced non-squamous NSCLC who have not progressed after platinum-based induction therapy.	Longer time to worsening was recorded for pain (hazard ratio [HR] 076, 95% CI 059-099; p=0041) and haemoptysis (HR 058, 95% CI 034-097; p=0038) with pemetrexed than with placebo;
__label__noRel	such treatment is an option for patients with advanced non-squamous NSCLC who have not progressed after platinum-based induction therapy.	no other significant differences in analyses of time to worsening were noted.
__label__noRel	such treatment is an option for patients with advanced non-squamous NSCLC who have not progressed after platinum-based induction therapy.	Additional longitudinal analyses showed a greater increase in loss of appetite in the pemetrexed group than in the placebo group (43 mm vs 02 mm; p=0028).
__label__noRel	such treatment is an option for patients with advanced non-squamous NSCLC who have not progressed after platinum-based induction therapy.	Rates of resource use were statistically higher for pemetrexed than for placebo: admissions to hospital for drug-related adverse events (19 [4%] vs none; p=0001), transfusions (42 [10%] vs seven [3%]; p=0003), and erythropoiesis-stimulating agents (26 [6%] vs four [2%]; p=0017).
__label__noRel	such treatment is an option for patients with advanced non-squamous NSCLC who have not progressed after platinum-based induction therapy.	Quality of life during maintenance therapy with pemetrexed is similar to placebo,
__label__noRel	such treatment is an option for patients with advanced non-squamous NSCLC who have not progressed after platinum-based induction therapy.	except for a small increase in loss of appetite, and significantly delayed worsening of pain and haemoptysis.
__label__noRel	Energy intake after RT increased in both groups 1 and 2 (p < or = .05).	Protein intake also increased in both groups 1 and 2 (p < or = .006).
__label__noRel	Energy intake after RT increased in both groups 1 and 2 (p < or = .05).	Both energy and protein intake decreased significantly in group 3 (p < .01).
__label__noRel	Energy intake after RT increased in both groups 1 and 2 (p < or = .05).	At 3 months, group 1 maintained intakes, whereas groups 2 and 3 returned to or below baseline levels.
__label__noRel	Energy intake after RT increased in both groups 1 and 2 (p < or = .05).	After RT, >90% of patients experienced RT toxicity;
__label__noRel	Energy intake after RT increased in both groups 1 and 2 (p < or = .05).	this was not significantly different between groups, with a trend for reduced symptomatology in group 1 versus group 2/group 3 (p < .07).
__label__noRel	Energy intake after RT increased in both groups 1 and 2 (p < or = .05).	At 3 months, the reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, xerostomia, and dysgeusia was different: 90% of the patients improved in group 1 versus 67% in group 2 versus 51% in group 3 (p < .0001).
__label__noRel	Energy intake after RT increased in both groups 1 and 2 (p < or = .05).	After RT, QOL function scores improved (p < .003) proportionally with improved nutritional intake and status in group 1/group 2 (p < .05) and worsened in group 3 (p < .05);
__label__noRel	Energy intake after RT increased in both groups 1 and 2 (p < or = .05).	at 3 months, patients in group 1 maintained or improved overall QOL, whereas patients in groups 2 and 3 maintained or worsened overall QOL.
__label__Support	Energy intake after RT increased in both groups 1 and 2 (p < or = .05).	During RT, nutritional interventions positively influenced outcomes, and counseling was of similar/higher benefit;
__label__noRel	Energy intake after RT increased in both groups 1 and 2 (p < or = .05).	in the medium term, only counseling exerted a significant impact on patient outcomes.
__label__noRel	Protein intake also increased in both groups 1 and 2 (p < or = .006).	Energy intake after RT increased in both groups 1 and 2 (p < or = .05).
__label__noRel	Protein intake also increased in both groups 1 and 2 (p < or = .006).	Both energy and protein intake decreased significantly in group 3 (p < .01).
__label__noRel	Protein intake also increased in both groups 1 and 2 (p < or = .006).	At 3 months, group 1 maintained intakes, whereas groups 2 and 3 returned to or below baseline levels.
__label__noRel	Protein intake also increased in both groups 1 and 2 (p < or = .006).	After RT, >90% of patients experienced RT toxicity;
__label__noRel	Protein intake also increased in both groups 1 and 2 (p < or = .006).	this was not significantly different between groups, with a trend for reduced symptomatology in group 1 versus group 2/group 3 (p < .07).
__label__noRel	Protein intake also increased in both groups 1 and 2 (p < or = .006).	At 3 months, the reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, xerostomia, and dysgeusia was different: 90% of the patients improved in group 1 versus 67% in group 2 versus 51% in group 3 (p < .0001).
__label__noRel	Protein intake also increased in both groups 1 and 2 (p < or = .006).	After RT, QOL function scores improved (p < .003) proportionally with improved nutritional intake and status in group 1/group 2 (p < .05) and worsened in group 3 (p < .05);
__label__noRel	Protein intake also increased in both groups 1 and 2 (p < or = .006).	at 3 months, patients in group 1 maintained or improved overall QOL, whereas patients in groups 2 and 3 maintained or worsened overall QOL.
__label__Support	Protein intake also increased in both groups 1 and 2 (p < or = .006).	During RT, nutritional interventions positively influenced outcomes, and counseling was of similar/higher benefit;
__label__noRel	Protein intake also increased in both groups 1 and 2 (p < or = .006).	in the medium term, only counseling exerted a significant impact on patient outcomes.
__label__noRel	Both energy and protein intake decreased significantly in group 3 (p < .01).	Energy intake after RT increased in both groups 1 and 2 (p < or = .05).
__label__noRel	Both energy and protein intake decreased significantly in group 3 (p < .01).	Protein intake also increased in both groups 1 and 2 (p < or = .006).
__label__noRel	Both energy and protein intake decreased significantly in group 3 (p < .01).	At 3 months, group 1 maintained intakes, whereas groups 2 and 3 returned to or below baseline levels.
__label__noRel	Both energy and protein intake decreased significantly in group 3 (p < .01).	After RT, >90% of patients experienced RT toxicity;
__label__noRel	Both energy and protein intake decreased significantly in group 3 (p < .01).	this was not significantly different between groups, with a trend for reduced symptomatology in group 1 versus group 2/group 3 (p < .07).
__label__noRel	Both energy and protein intake decreased significantly in group 3 (p < .01).	At 3 months, the reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, xerostomia, and dysgeusia was different: 90% of the patients improved in group 1 versus 67% in group 2 versus 51% in group 3 (p < .0001).
__label__noRel	Both energy and protein intake decreased significantly in group 3 (p < .01).	After RT, QOL function scores improved (p < .003) proportionally with improved nutritional intake and status in group 1/group 2 (p < .05) and worsened in group 3 (p < .05);
__label__noRel	Both energy and protein intake decreased significantly in group 3 (p < .01).	at 3 months, patients in group 1 maintained or improved overall QOL, whereas patients in groups 2 and 3 maintained or worsened overall QOL.
__label__noRel	Both energy and protein intake decreased significantly in group 3 (p < .01).	During RT, nutritional interventions positively influenced outcomes, and counseling was of similar/higher benefit;
__label__noRel	Both energy and protein intake decreased significantly in group 3 (p < .01).	in the medium term, only counseling exerted a significant impact on patient outcomes.
__label__noRel	At 3 months, group 1 maintained intakes, whereas groups 2 and 3 returned to or below baseline levels.	Energy intake after RT increased in both groups 1 and 2 (p < or = .05).
__label__noRel	At 3 months, group 1 maintained intakes, whereas groups 2 and 3 returned to or below baseline levels.	Protein intake also increased in both groups 1 and 2 (p < or = .006).
__label__noRel	At 3 months, group 1 maintained intakes, whereas groups 2 and 3 returned to or below baseline levels.	Both energy and protein intake decreased significantly in group 3 (p < .01).
__label__noRel	At 3 months, group 1 maintained intakes, whereas groups 2 and 3 returned to or below baseline levels.	After RT, >90% of patients experienced RT toxicity;
__label__noRel	At 3 months, group 1 maintained intakes, whereas groups 2 and 3 returned to or below baseline levels.	this was not significantly different between groups, with a trend for reduced symptomatology in group 1 versus group 2/group 3 (p < .07).
__label__noRel	At 3 months, group 1 maintained intakes, whereas groups 2 and 3 returned to or below baseline levels.	At 3 months, the reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, xerostomia, and dysgeusia was different: 90% of the patients improved in group 1 versus 67% in group 2 versus 51% in group 3 (p < .0001).
__label__noRel	At 3 months, group 1 maintained intakes, whereas groups 2 and 3 returned to or below baseline levels.	After RT, QOL function scores improved (p < .003) proportionally with improved nutritional intake and status in group 1/group 2 (p < .05) and worsened in group 3 (p < .05);
__label__noRel	At 3 months, group 1 maintained intakes, whereas groups 2 and 3 returned to or below baseline levels.	at 3 months, patients in group 1 maintained or improved overall QOL, whereas patients in groups 2 and 3 maintained or worsened overall QOL.
__label__noRel	At 3 months, group 1 maintained intakes, whereas groups 2 and 3 returned to or below baseline levels.	During RT, nutritional interventions positively influenced outcomes, and counseling was of similar/higher benefit;
__label__Support	At 3 months, group 1 maintained intakes, whereas groups 2 and 3 returned to or below baseline levels.	in the medium term, only counseling exerted a significant impact on patient outcomes.
__label__noRel	After RT, >90% of patients experienced RT toxicity;	Energy intake after RT increased in both groups 1 and 2 (p < or = .05).
__label__noRel	After RT, >90% of patients experienced RT toxicity;	Protein intake also increased in both groups 1 and 2 (p < or = .006).
__label__noRel	After RT, >90% of patients experienced RT toxicity;	Both energy and protein intake decreased significantly in group 3 (p < .01).
__label__noRel	After RT, >90% of patients experienced RT toxicity;	At 3 months, group 1 maintained intakes, whereas groups 2 and 3 returned to or below baseline levels.
__label__noRel	After RT, >90% of patients experienced RT toxicity;	this was not significantly different between groups, with a trend for reduced symptomatology in group 1 versus group 2/group 3 (p < .07).
__label__noRel	After RT, >90% of patients experienced RT toxicity;	At 3 months, the reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, xerostomia, and dysgeusia was different: 90% of the patients improved in group 1 versus 67% in group 2 versus 51% in group 3 (p < .0001).
__label__noRel	After RT, >90% of patients experienced RT toxicity;	After RT, QOL function scores improved (p < .003) proportionally with improved nutritional intake and status in group 1/group 2 (p < .05) and worsened in group 3 (p < .05);
__label__noRel	After RT, >90% of patients experienced RT toxicity;	at 3 months, patients in group 1 maintained or improved overall QOL, whereas patients in groups 2 and 3 maintained or worsened overall QOL.
__label__noRel	After RT, >90% of patients experienced RT toxicity;	During RT, nutritional interventions positively influenced outcomes, and counseling was of similar/higher benefit;
__label__noRel	After RT, >90% of patients experienced RT toxicity;	in the medium term, only counseling exerted a significant impact on patient outcomes.
__label__noRel	this was not significantly different between groups, with a trend for reduced symptomatology in group 1 versus group 2/group 3 (p < .07).	Energy intake after RT increased in both groups 1 and 2 (p < or = .05).
__label__noRel	this was not significantly different between groups, with a trend for reduced symptomatology in group 1 versus group 2/group 3 (p < .07).	Protein intake also increased in both groups 1 and 2 (p < or = .006).
__label__noRel	this was not significantly different between groups, with a trend for reduced symptomatology in group 1 versus group 2/group 3 (p < .07).	Both energy and protein intake decreased significantly in group 3 (p < .01).
__label__noRel	this was not significantly different between groups, with a trend for reduced symptomatology in group 1 versus group 2/group 3 (p < .07).	At 3 months, group 1 maintained intakes, whereas groups 2 and 3 returned to or below baseline levels.
__label__Support	this was not significantly different between groups, with a trend for reduced symptomatology in group 1 versus group 2/group 3 (p < .07).	After RT, >90% of patients experienced RT toxicity;
__label__noRel	this was not significantly different between groups, with a trend for reduced symptomatology in group 1 versus group 2/group 3 (p < .07).	At 3 months, the reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, xerostomia, and dysgeusia was different: 90% of the patients improved in group 1 versus 67% in group 2 versus 51% in group 3 (p < .0001).
__label__noRel	this was not significantly different between groups, with a trend for reduced symptomatology in group 1 versus group 2/group 3 (p < .07).	After RT, QOL function scores improved (p < .003) proportionally with improved nutritional intake and status in group 1/group 2 (p < .05) and worsened in group 3 (p < .05);
__label__noRel	this was not significantly different between groups, with a trend for reduced symptomatology in group 1 versus group 2/group 3 (p < .07).	at 3 months, patients in group 1 maintained or improved overall QOL, whereas patients in groups 2 and 3 maintained or worsened overall QOL.
__label__noRel	this was not significantly different between groups, with a trend for reduced symptomatology in group 1 versus group 2/group 3 (p < .07).	During RT, nutritional interventions positively influenced outcomes, and counseling was of similar/higher benefit;
__label__noRel	this was not significantly different between groups, with a trend for reduced symptomatology in group 1 versus group 2/group 3 (p < .07).	in the medium term, only counseling exerted a significant impact on patient outcomes.
__label__noRel	At 3 months, the reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, xerostomia, and dysgeusia was different: 90% of the patients improved in group 1 versus 67% in group 2 versus 51% in group 3 (p < .0001).	Energy intake after RT increased in both groups 1 and 2 (p < or = .05).
__label__noRel	At 3 months, the reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, xerostomia, and dysgeusia was different: 90% of the patients improved in group 1 versus 67% in group 2 versus 51% in group 3 (p < .0001).	Protein intake also increased in both groups 1 and 2 (p < or = .006).
__label__noRel	At 3 months, the reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, xerostomia, and dysgeusia was different: 90% of the patients improved in group 1 versus 67% in group 2 versus 51% in group 3 (p < .0001).	Both energy and protein intake decreased significantly in group 3 (p < .01).
__label__noRel	At 3 months, the reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, xerostomia, and dysgeusia was different: 90% of the patients improved in group 1 versus 67% in group 2 versus 51% in group 3 (p < .0001).	At 3 months, group 1 maintained intakes, whereas groups 2 and 3 returned to or below baseline levels.
__label__noRel	At 3 months, the reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, xerostomia, and dysgeusia was different: 90% of the patients improved in group 1 versus 67% in group 2 versus 51% in group 3 (p < .0001).	After RT, >90% of patients experienced RT toxicity;
__label__noRel	At 3 months, the reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, xerostomia, and dysgeusia was different: 90% of the patients improved in group 1 versus 67% in group 2 versus 51% in group 3 (p < .0001).	this was not significantly different between groups, with a trend for reduced symptomatology in group 1 versus group 2/group 3 (p < .07).
__label__noRel	At 3 months, the reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, xerostomia, and dysgeusia was different: 90% of the patients improved in group 1 versus 67% in group 2 versus 51% in group 3 (p < .0001).	After RT, QOL function scores improved (p < .003) proportionally with improved nutritional intake and status in group 1/group 2 (p < .05) and worsened in group 3 (p < .05);
__label__noRel	At 3 months, the reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, xerostomia, and dysgeusia was different: 90% of the patients improved in group 1 versus 67% in group 2 versus 51% in group 3 (p < .0001).	at 3 months, patients in group 1 maintained or improved overall QOL, whereas patients in groups 2 and 3 maintained or worsened overall QOL.
__label__noRel	At 3 months, the reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, xerostomia, and dysgeusia was different: 90% of the patients improved in group 1 versus 67% in group 2 versus 51% in group 3 (p < .0001).	During RT, nutritional interventions positively influenced outcomes, and counseling was of similar/higher benefit;
__label__Support	At 3 months, the reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, xerostomia, and dysgeusia was different: 90% of the patients improved in group 1 versus 67% in group 2 versus 51% in group 3 (p < .0001).	in the medium term, only counseling exerted a significant impact on patient outcomes.
__label__noRel	After RT, QOL function scores improved (p < .003) proportionally with improved nutritional intake and status in group 1/group 2 (p < .05) and worsened in group 3 (p < .05);	Energy intake after RT increased in both groups 1 and 2 (p < or = .05).
__label__noRel	After RT, QOL function scores improved (p < .003) proportionally with improved nutritional intake and status in group 1/group 2 (p < .05) and worsened in group 3 (p < .05);	Protein intake also increased in both groups 1 and 2 (p < or = .006).
__label__noRel	After RT, QOL function scores improved (p < .003) proportionally with improved nutritional intake and status in group 1/group 2 (p < .05) and worsened in group 3 (p < .05);	Both energy and protein intake decreased significantly in group 3 (p < .01).
__label__noRel	After RT, QOL function scores improved (p < .003) proportionally with improved nutritional intake and status in group 1/group 2 (p < .05) and worsened in group 3 (p < .05);	At 3 months, group 1 maintained intakes, whereas groups 2 and 3 returned to or below baseline levels.
__label__noRel	After RT, QOL function scores improved (p < .003) proportionally with improved nutritional intake and status in group 1/group 2 (p < .05) and worsened in group 3 (p < .05);	After RT, >90% of patients experienced RT toxicity;
__label__noRel	After RT, QOL function scores improved (p < .003) proportionally with improved nutritional intake and status in group 1/group 2 (p < .05) and worsened in group 3 (p < .05);	this was not significantly different between groups, with a trend for reduced symptomatology in group 1 versus group 2/group 3 (p < .07).
__label__noRel	After RT, QOL function scores improved (p < .003) proportionally with improved nutritional intake and status in group 1/group 2 (p < .05) and worsened in group 3 (p < .05);	At 3 months, the reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, xerostomia, and dysgeusia was different: 90% of the patients improved in group 1 versus 67% in group 2 versus 51% in group 3 (p < .0001).
__label__noRel	After RT, QOL function scores improved (p < .003) proportionally with improved nutritional intake and status in group 1/group 2 (p < .05) and worsened in group 3 (p < .05);	at 3 months, patients in group 1 maintained or improved overall QOL, whereas patients in groups 2 and 3 maintained or worsened overall QOL.
__label__Support	After RT, QOL function scores improved (p < .003) proportionally with improved nutritional intake and status in group 1/group 2 (p < .05) and worsened in group 3 (p < .05);	During RT, nutritional interventions positively influenced outcomes, and counseling was of similar/higher benefit;
__label__noRel	After RT, QOL function scores improved (p < .003) proportionally with improved nutritional intake and status in group 1/group 2 (p < .05) and worsened in group 3 (p < .05);	in the medium term, only counseling exerted a significant impact on patient outcomes.
__label__noRel	at 3 months, patients in group 1 maintained or improved overall QOL, whereas patients in groups 2 and 3 maintained or worsened overall QOL.	Energy intake after RT increased in both groups 1 and 2 (p < or = .05).
__label__noRel	at 3 months, patients in group 1 maintained or improved overall QOL, whereas patients in groups 2 and 3 maintained or worsened overall QOL.	Protein intake also increased in both groups 1 and 2 (p < or = .006).
__label__noRel	at 3 months, patients in group 1 maintained or improved overall QOL, whereas patients in groups 2 and 3 maintained or worsened overall QOL.	Both energy and protein intake decreased significantly in group 3 (p < .01).
__label__noRel	at 3 months, patients in group 1 maintained or improved overall QOL, whereas patients in groups 2 and 3 maintained or worsened overall QOL.	At 3 months, group 1 maintained intakes, whereas groups 2 and 3 returned to or below baseline levels.
__label__noRel	at 3 months, patients in group 1 maintained or improved overall QOL, whereas patients in groups 2 and 3 maintained or worsened overall QOL.	After RT, >90% of patients experienced RT toxicity;
__label__noRel	at 3 months, patients in group 1 maintained or improved overall QOL, whereas patients in groups 2 and 3 maintained or worsened overall QOL.	this was not significantly different between groups, with a trend for reduced symptomatology in group 1 versus group 2/group 3 (p < .07).
__label__noRel	at 3 months, patients in group 1 maintained or improved overall QOL, whereas patients in groups 2 and 3 maintained or worsened overall QOL.	At 3 months, the reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, xerostomia, and dysgeusia was different: 90% of the patients improved in group 1 versus 67% in group 2 versus 51% in group 3 (p < .0001).
__label__noRel	at 3 months, patients in group 1 maintained or improved overall QOL, whereas patients in groups 2 and 3 maintained or worsened overall QOL.	After RT, QOL function scores improved (p < .003) proportionally with improved nutritional intake and status in group 1/group 2 (p < .05) and worsened in group 3 (p < .05);
__label__noRel	at 3 months, patients in group 1 maintained or improved overall QOL, whereas patients in groups 2 and 3 maintained or worsened overall QOL.	During RT, nutritional interventions positively influenced outcomes, and counseling was of similar/higher benefit;
__label__noRel	at 3 months, patients in group 1 maintained or improved overall QOL, whereas patients in groups 2 and 3 maintained or worsened overall QOL.	in the medium term, only counseling exerted a significant impact on patient outcomes.
__label__noRel	During RT, nutritional interventions positively influenced outcomes, and counseling was of similar/higher benefit;	Energy intake after RT increased in both groups 1 and 2 (p < or = .05).
__label__noRel	During RT, nutritional interventions positively influenced outcomes, and counseling was of similar/higher benefit;	Protein intake also increased in both groups 1 and 2 (p < or = .006).
__label__noRel	During RT, nutritional interventions positively influenced outcomes, and counseling was of similar/higher benefit;	Both energy and protein intake decreased significantly in group 3 (p < .01).
__label__noRel	During RT, nutritional interventions positively influenced outcomes, and counseling was of similar/higher benefit;	At 3 months, group 1 maintained intakes, whereas groups 2 and 3 returned to or below baseline levels.
__label__noRel	During RT, nutritional interventions positively influenced outcomes, and counseling was of similar/higher benefit;	After RT, >90% of patients experienced RT toxicity;
__label__noRel	During RT, nutritional interventions positively influenced outcomes, and counseling was of similar/higher benefit;	this was not significantly different between groups, with a trend for reduced symptomatology in group 1 versus group 2/group 3 (p < .07).
__label__noRel	During RT, nutritional interventions positively influenced outcomes, and counseling was of similar/higher benefit;	At 3 months, the reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, xerostomia, and dysgeusia was different: 90% of the patients improved in group 1 versus 67% in group 2 versus 51% in group 3 (p < .0001).
__label__noRel	During RT, nutritional interventions positively influenced outcomes, and counseling was of similar/higher benefit;	After RT, QOL function scores improved (p < .003) proportionally with improved nutritional intake and status in group 1/group 2 (p < .05) and worsened in group 3 (p < .05);
__label__noRel	During RT, nutritional interventions positively influenced outcomes, and counseling was of similar/higher benefit;	at 3 months, patients in group 1 maintained or improved overall QOL, whereas patients in groups 2 and 3 maintained or worsened overall QOL.
__label__noRel	During RT, nutritional interventions positively influenced outcomes, and counseling was of similar/higher benefit;	in the medium term, only counseling exerted a significant impact on patient outcomes.
__label__noRel	in the medium term, only counseling exerted a significant impact on patient outcomes.	Energy intake after RT increased in both groups 1 and 2 (p < or = .05).
__label__noRel	in the medium term, only counseling exerted a significant impact on patient outcomes.	Protein intake also increased in both groups 1 and 2 (p < or = .006).
__label__noRel	in the medium term, only counseling exerted a significant impact on patient outcomes.	Both energy and protein intake decreased significantly in group 3 (p < .01).
__label__noRel	in the medium term, only counseling exerted a significant impact on patient outcomes.	At 3 months, group 1 maintained intakes, whereas groups 2 and 3 returned to or below baseline levels.
__label__noRel	in the medium term, only counseling exerted a significant impact on patient outcomes.	After RT, >90% of patients experienced RT toxicity;
__label__noRel	in the medium term, only counseling exerted a significant impact on patient outcomes.	this was not significantly different between groups, with a trend for reduced symptomatology in group 1 versus group 2/group 3 (p < .07).
__label__noRel	in the medium term, only counseling exerted a significant impact on patient outcomes.	At 3 months, the reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, xerostomia, and dysgeusia was different: 90% of the patients improved in group 1 versus 67% in group 2 versus 51% in group 3 (p < .0001).
__label__noRel	in the medium term, only counseling exerted a significant impact on patient outcomes.	After RT, QOL function scores improved (p < .003) proportionally with improved nutritional intake and status in group 1/group 2 (p < .05) and worsened in group 3 (p < .05);
__label__noRel	in the medium term, only counseling exerted a significant impact on patient outcomes.	at 3 months, patients in group 1 maintained or improved overall QOL, whereas patients in groups 2 and 3 maintained or worsened overall QOL.
__label__noRel	in the medium term, only counseling exerted a significant impact on patient outcomes.	During RT, nutritional interventions positively influenced outcomes, and counseling was of similar/higher benefit;
